<SEC-DOCUMENT>0000950170-25-040279.txt : 20250317
<SEC-HEADER>0000950170-25-040279.hdr.sgml : 20250317
<ACCEPTANCE-DATETIME>20250317161536
ACCESSION NUMBER:		0000950170-25-040279
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250317
DATE AS OF CHANGE:		20250317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GYRE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562020050
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		25744620

	BUSINESS ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(619) 949-3681

	MAIL ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20150820

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gyre-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-17T15:58:02.7900+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:gyre="http://www.gyretx.com/20241231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4293ce05-fd4b-46d8-a238-462aef780712" name="dei:AmendmentFlag" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95">false</ix:nonNumeric><ix:nonNumeric id="F_047c914f-8763-40d0-b33f-f0cb7afa03e2" name="dei:DocumentFiscalPeriodFocus" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95">FY</ix:nonNumeric><ix:nonNumeric id="F_36aeb3ff-d827-4e70-8e7c-5e38a92e3ff4" name="dei:EntityCentralIndexKey" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95">0001124105</ix:nonNumeric><ix:nonFraction id="F_e5069514-7ffc-45f8-813c-6fba7eae2521" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3448db62-d53f-481f-8d69-743602ddb884" name="us-gaap:CommitmentsAndContingencies" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_df845163-9662-4f0f-9d15-2572001b1a8c" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_67cc03b4-d2c1-416e-b1f7-03b4721d045e">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric id="F_e144250a-53d1-44d0-abc4-0e596d38ecb8" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_1dbb5718-381d-43cd-a699-edd659f1f0ad">P2Y</ix:nonNumeric><ix:nonNumeric id="F_a5e3a326-17c6-4924-b500-780170a688d9" name="gyre:LeaseExpirationMonthAndYear" contextRef="C_2b54e9bb-fda5-4585-863a-b3bcf1e6972a" format="ixt:date-monthname-year-en">March 2027</ix:nonNumeric><ix:nonNumeric id="F_89458a30-1f4b-4bab-95ce-8c2641b3664a" name="gyre:StatuteOfLimitationDueToTaxEvasion" contextRef="C_ab0e6ad3-77e4-40d2-a914-3a959c431d3b" format="ixt-sec:duryear">0</ix:nonNumeric><ix:nonFraction id="F_64b29595-72b7-4d1e-a2ef-bcc1f661c31b" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_7ff33148-e75c-4492-acae-7ea4bfe94b76" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="gyre-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_8004e979-5c0a-4003-aa51-99ebad904782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80b233b8-8d6b-4b3a-b077-9d160ffc37ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_838330c8-c71e-4fe2-a49f-e6fc75cb5071"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8437179e-663a-4744-b86d-fca26b0fe052"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_845d0f12-d806-4911-8fda-490329d00ecd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84e691d1-e698-40d8-a277-167dedf7a361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_855a18a4-8d8c-46bf-aa53-59975edfdf20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gyre:PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_865d32c0-6f1c-4e0d-9ca2-0c9a24caf2cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86b63a2c-389d-4950-a678-157a2397918e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_893c5230-daf1-4851-a6bd-a1088e652270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8af0977b-b1f9-48ee-9940-3554e079223c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b6f77fc-9f62-4a56-a8a3-60296e884fd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d6b27d0-681a-4b5e-86bf-4e37f3785874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8dc9cab1-3dbb-40a8-840c-8dd98ff4680f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAdministrationOfTaxationChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e5cc978-0a42-4ec0-af0d-d74c36ee2dfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e78646b-8c6e-48a2-bf10-a036ec1e9f6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f07b256-5b55-40cd-a1f0-534daf47f47f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ff20dd2-fe0c-4bf5-810a-2ce783d0f15b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9059de58-0342-483c-bb12-68f46c8efdab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90682bfe-2026-4fd0-87b6-43c6bb28213c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90704b89-2d95-4695-898f-ba265baa62ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94da0217-feba-4fbb-a5dc-d987be18247a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96a600bd-711e-4434-a24c-a2180e74b33f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97a869fa-0596-4ada-9896-83385642b0be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_981aaa53-b42e-4ad1-b13e-8a794b24f312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98731e29-6638-4818-bfa3-de1d42eaf704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_990c44c7-915a-4a78-9e70-be8742ec4a8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a91ad18-5e8c-4f49-bb3b-55e76625715d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e3328d4-ba00-4ce5-8265-2253f006ba54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f12cb44-8040-49a1-9b9e-a0f0137410fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a03ee1e8-f246-42c3-b72d-81a753170a1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:SubmissionOfTheNewDrugApplicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a06a4417-252f-4ba9-b828-689df30eb019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0d10ade-3d48-49d5-bdd7-851689590754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a29cbd02-6a5c-4fdb-aff1-44deb722af3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:GCBiopharmaCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a34646ab-b257-4cc5-aaa5-c6130d624d7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4960a5d-b308-445f-8714-9498ff7443b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a56d2451-275e-4c7f-95db-b89dd45a7915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityNonCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a614a706-e7b1-4b3a-a6dd-8a447fd08d76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6c79814-e564-4a3d-b0f2-8073710a53e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6f4023f-6af1-478e-8828-c64f6e19e231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a75bd85a-71ec-47ee-b069-04337603dd4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8369019-ac43-4387-8220-f7bb3505e614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8d02e48-8b97-4471-b7d2-9b754e3a60ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a90606c8-9443-4792-8781-57608b6e4e3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aaa537e5-aadd-401c-b660-aedaa53b9b03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab0e6ad3-77e4-40d2-a914-3a959c431d3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAdministrationOfTaxationChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad2aff12-25e7-4121-b6bd-e885663b2263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad700354-24cd-4e94-bf85-24453ba4377c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:GCBiopharmaCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adc4bb81-abd5-4674-adb5-54f33ef3d80c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae06bf9f-4849-4d7c-b764-bdd92fb5df72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afb0500b-16d2-4911-ab34-f347a18f0103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b069b7f9-1d2e-4765-80cb-c51aa4c12c6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-26</xbrli:startDate><xbrli:endDate>2022-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0da0539-7026-4894-ad23-631ed2889b06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2bd78e9-9849-479f-8eb7-41ba287f57e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b35aebfe-1f39-4446-b3d0-8ed57d7c18ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b489322b-84cd-4fef-81ee-6ac40fe1d795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4a86beb-1787-4bb4-bd49-dbe2b1f05f54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5f0da22-de98-4ff9-8f08-36e85ba3bc7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6236476-6e75-4438-a794-f025b4ae1817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7908f32-a52a-47b5-a0f7-73f8bc7e1786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8550c29-f99b-4014-8343-c78232d39a0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b931a2e4-4754-474d-9b6e-f1c8f4585e49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAdministrationOfTaxationChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd730111-0947-4496-be1e-82bb97c3ba65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfd51d7b-b349-4540-8451-b38e1a4adc25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0f50cf0-d705-4547-8bb2-292161d2dc8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c26605c5-09bd-4994-af5d-7d427048d643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gyre:PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2f5674d-e5bd-447a-8b4d-85feed272f13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3036813-c367-4137-83bc-d3111a243c9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c44dd11e-3d19-4a70-8872-8c9259134b11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4c9bfee-5e03-4161-8738-c6867fc7060c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c554efd0-8c25-49d5-887a-c4fae5255da6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c56613f3-6432-437c-9bab-9101a3786a66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c664e54d-79f7-479e-871b-a1086f9e1e55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c66f706c-79f5-4c3c-a4d4-6383b9abf3ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c72b6ba0-b44d-464c-8103-3b7702656381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7af3ec1-7037-4691-9c1c-8e9ff94d139a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc77e3d6-0b6d-4809-98bc-ba50dc57d0e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce07c61e-a68b-4a21-856c-80d6f63dc861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cef73343-7eb4-4d39-88e9-9171f4dd709f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf4603e2-2534-444f-a961-287cb64533d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1aaf22a-2bdd-4556-a9b8-d529d34aef04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d274c80b-8c06-41ed-bb58-3a6d5311414f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4414f45-2440-4efe-b9f6-4316754c428f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d65a54be-e60b-44d6-9d6e-c5423744feb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-26</xbrli:startDate><xbrli:endDate>2024-08-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8c5083e-baaa-4ff7-ae97-3c6730697288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9641dc2-ce11-4da3-92da-82b11fbc53ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_daacc8f9-d9a7-49ef-b6a0-b9c3726581cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbedf524-e39b-431f-b9b5-51f72b11b2b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc02e0a2-17b6-4879-92cf-e5b95666c954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e345ba39-3b04-455d-ae09-666d8d8b33bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3f9ca20-fe6e-464e-88fe-e2cdb2bbeb47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4d869fa-260f-4c9f-9cf3-79a75bfecf47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e528bfc1-0b49-4dd0-ae39-ee76c0228232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5513b2b-c8d0-4816-81a6-d83601aee525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7855790-0097-47bb-9146-f38e022e4521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e852315e-c976-4feb-af38-ee2ba333da3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e87f13d9-462c-4972-9cd3-8231e00d9d31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9706bd6-a8ea-4e15-9d5b-2d51ea3a4538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9ca2ac7-674d-4810-a3f7-5cf959925a7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9d4eda1-e8b4-4878-b3ba-046acdcd7131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea5bb34e-9257-4104-825f-20adf13f8344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb61462d-1632-48d9-a73a-8eefdbf9c020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb7ac400-9cc8-4292-a3f3-4243436fc055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eca554e0-e672-4d9d-8689-890225dec430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecfde2db-6b97-4952-8c3e-f7202cd08598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed398fbe-2209-4cef-89f5-4af5eb6bb183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeacae0c-b05c-49e6-aa94-3ba172e663e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ChinaResourcesPharmaceuticalGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0a09c76-9e8a-4c61-b540-701ad6b7648e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0bc705e-b8c5-4374-a7bb-91203f55f706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1739194-98a6-4fa5-9476-50a472bbd7b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f461bd8b-ec0e-46ff-8dbd-7d23531e4b91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ChinaResourcesPharmaceuticalGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5133705-2d68-4e8e-84cd-45bc68a7fcf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5361373-7c92-419e-8bf7-87b01cbf8a00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5823b3d-6762-4329-9b17-efe63bdb21f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5d8eb54-6979-4f3e-9be6-d8a1a8ec48fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:NMPAsApprovalOfTheNDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6130ae2-a2e5-45e6-a4ed-5c019bfa760e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:CPIContributionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f655bd73-1357-4906-aaa2-0388e4dae1b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f74c758a-d9fd-40e2-85f1-d6a87ddcc5dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:NDAPassesTheNMPAsReviewAndInspectionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f824d5e7-e950-4dec-bbd8-25ddc7864eac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9d872ab-6ad9-4e1a-9bab-df2b883d5c99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fabc4de6-f3ea-4c14-8ab7-d36a14e5c91d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb2f86f7-6be0-48e5-a0e5-ce77738921cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fce1ab14-263e-4f06-8e6c-95e2226660e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe14599d-907f-447e-be99-9689d7f34472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff4a65f5-6aee-43bc-ae21-205a10de9f61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:CPIContributionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_003c57ab-d9dd-422e-bacb-9a242555faac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:VertexAssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02538a53-cecd-41e8-aa82-e8efb664750a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_062c6dd6-59a4-4c32-8566-83e073df4f7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0694c0b0-9199-4cf1-86b8-378fc929e7fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_081e2763-6f98-4757-9d8d-5f31041f2742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_094d85c6-e458-4cfd-ad37-15cb54dd53db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10dfd633-6fab-4fb0-bb22-6722bb1f66cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1152de71-ba52-48e2-80b9-f500c5502e72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11e97b2b-d131-4b0d-a65f-f76a30c9fe74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12c92d66-d545-47dd-8492-bf82d190b61c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1388f67a-7e9b-4efe-996e-61341927c0bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_151e32fc-1c63-4e3f-9240-08cf605db0d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1550867e-92d1-4406-a92b-c15392d1f1b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18a964f8-b880-42dd-8893-8c908e72943e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18bc2358-95e4-46d2-9214-ce5de90d7258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18ff54a5-54d5-42f4-81e9-6aa9f1a79af5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-26</xbrli:startDate><xbrli:endDate>2022-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_196fe3c5-bc8a-4a5f-a84e-6cbf8da6bc14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gyre:LongTermCertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1999c1fd-3379-456f-aa61-90fe81f796d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19def526-bb67-4646-b79c-ffcf90c9dc23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c9a63af-c293-421c-835a-b808c5bda6ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1da1795e-730c-42e1-9de0-0fedc96400d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1dbb5718-381d-43cd-a699-edd659f1f0ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e426f09-37bb-440e-a20a-2c6caa2e0a48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2105308e-fcfa-4236-bc88-d64b4d792f06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21ad98a8-a7b0-4600-a53d-9f79dd8b3cbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:CPIContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21d9722b-ebb3-4d75-9c08-5b1c34dda6b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22f0fc96-1e38-40b1-9a23-4191cce058e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_254f82e6-b517-47d8-aa5e-0e78e7d7e7fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2552ff66-c519-4434-b8ac-87bd1b2941d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25e32d74-d3e2-425b-866e-4b5bc29838fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27a7a081-3cd9-44fb-b829-bbe0a51e1049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27c77b10-4086-4da2-b416-c9b80579f835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28b79e15-5ce4-4bf9-8af0-0a1821e83289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29261f54-503a-4613-b9da-f1c82b1b0e73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29facfe6-6ed6-43d0-af3e-0188d8bb96fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b54e9bb-fda5-4585-863a-b3bcf1e6972a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c09cdda-c1e5-435a-b940-ce423bcf6515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d08f24c-1345-467d-96a2-4553b687c2fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f70b255-6cf8-4fea-a0c2-53d777ed397c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3196cc03-d5f3-4937-bff3-52b2ec055f70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33998465-47eb-4f6f-9f5b-ae8cb85bcc79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33eee6f7-6eb9-4629-b3ef-0ea7887030bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34a9e2bf-ec9e-4a2f-8f4f-2c7daaad7f85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37337290-c4f6-4ef2-a6f7-8313d2a10b7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a618d1d-ac50-42d9-955f-3512c0439863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b4e1000-5f70-49f3-a666-01af6c7cbdd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bcf2b7f-ee59-442c-b6bd-34c12861eac8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c2ac92b-d05c-4dcb-8edc-d7dc05708e32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cc0872f-8c3c-4dc7-ae6b-0b2043d6351e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e003906-a6c6-4531-9eea-29f5b509e2c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:PatentsAndTechnologicalKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ea2f2ca-4eb5-48e9-9b14-30c3e9e2d1ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40f2813c-6dc2-4685-8c1e-588ca60a93fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40f3484c-5a7d-4fad-9c74-3ddeb2ee3ca3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47d1b610-ca09-4556-921e-9413b69cf697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49141630-2e23-47e6-b10b-c4c4722c6d0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49f4dab9-8bd1-4577-b767-6356a5621a2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b697f59-a7d2-4358-9a63-af70187de963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cb4b16d-4b5f-4f2a-9fb0-59f281280fc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:FCContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cf85ce7-378e-4422-9fd7-e7d329e19a16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-26</xbrli:startDate><xbrli:endDate>2022-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_502e4c1c-95d6-4ae7-893a-2eda77e87309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">gyre:MainlandChinaContributionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5037ba80-7341-4533-b5cb-88a46c19f3b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51a6c503-e72b-48c6-951e-f9d61b0aaa75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_524073ba-1001-4b0c-892e-803d6f0180eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_526db762-c121-4c94-bd8f-2957c39426c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_534c0221-d2f9-4713-8a7c-b850a4689dc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54965d21-2615-4d08-a3c4-08ca451112ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55596a3f-d3e4-4c79-87e1-e28ba063d3f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:CPIContributionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55971d12-0611-489b-9033-d8d1ebf17458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55af4e33-6cc0-4324-9605-d23cf73d489e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56859774-ba75-4d74-b1b3-78de98856e4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56cfb1ae-ec72-4d17-82fc-1198e04d1a30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_583140f7-2f5b-432a-a839-befb410b9e87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:ContinentPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-26</xbrli:startDate><xbrli:endDate>2022-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59171fe1-a910-4f9d-acea-66214546eade"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b26b6c7-7509-44ec-b688-6724fcb64480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:PatentsAndTechnologicalKnowHowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b526872-b885-43be-82fd-47148cef1b95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c3e3497-8c9f-4117-820b-ed5757b69655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e5fdd9a-b6de-418c-9820-744eb3b5f73c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e716a13-8908-4a45-90e4-2cfac3c1eeaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e72f9e3-7599-472f-92ab-fa429b264f71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_625ba7b4-bbf9-4cd1-b581-60e547a6e52a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gyre:ShortTermBankDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62f49f26-9563-408b-b7c2-7c3b1be23119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62f92e1d-e5a8-4fa2-9000-93f2a1b15be5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_637be181-9ac9-483b-8aeb-4f4857ea30c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63ac599f-e0eb-4b2e-8ae3-eadeb59bf215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_641c5278-93b2-409e-a72b-833546eaec22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_650b198d-ed03-434f-8873-424e5a2b6569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_661aab60-409f-4f43-a899-d4da1611a236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6644aae0-eb2b-4676-83a9-ae38663b37d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67cc03b4-d2c1-416e-b1f7-03b4721d045e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6846f876-7997-4227-a1ac-8419c302881e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68a0f639-5b32-411d-b8ae-3d27cfa51531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b620358-0d22-4e17-b10f-f5fdca4687e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c54312b-5d11-479d-8137-af33dda8c109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cec0878-7860-4728-9cc5-0c28173f20eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d30a83a-d0f3-4ca4-b55e-76c959f4075c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d9205fa-fd4f-4d6d-be1a-9d6b1b8e9900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e3414eb-e1eb-461f-b6f5-48348df952e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e5dc256-5a04-41b0-a879-49f3fee0883f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e8538d1-cf76-4d30-a57e-b5a4624ea831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_707b6aef-326f-458f-9f18-b11e1ee9ee78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72587811-89ac-4abd-97ba-a8887f54ccab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gyre:LongTermCertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75e8697e-8557-4795-a758-27f2b4bd196b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_761f52b8-1b53-40ce-8a99-390c026c9793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77b7dffb-7a31-4205-a9eb-98bee99e2a4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78e3aca5-80d5-40ae-9cf1-a3aa92d7c78c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a06ddc6-8a57-4cf2-a967-1f3297552aa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c56d128-f56c-40e8-9eed-aee500526cb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cf186e1-972c-4665-8d9c-1bfd52550fc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ddd47da-42c9-45c5-8866-0c39c6994ea9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">gyre:MainlandChinaContributionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_sqm"><xbrli:measure>utr:sqm</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>gyre:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_CNY"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_61d264df-69d6-495e-8eeb-41acb2cd480b" fromRefs="F_dff57515-4ec1-4c6d-a74d-b8260899ca74 F_14a49538-f42e-4f2b-b92e-6ef1dbdfc000 F_0cd5dd56-b36a-4418-98f9-f68c6f07ae41 F_663fdca3-38c0-48b4-8ee3-3c286855998b"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878" fromRefs="F_481558c6-a609-452f-b345-dd372cf841c3"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9" fromRefs="F_5c3010dd-bd13-4c9a-85c6-7eba53b7f240"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9" fromRefs="F_0a8e41ac-d9eb-4a0a-9c5a-a87ff2956e73"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_775f804e-b10d-499a-afe9-f05a8b8a2ac7" fromRefs="F_7bc06cc7-be2c-4203-b87b-21235f95744e"/></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.75in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form </span><span style="font-size:16pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_64cfc3bc-e6d1-4ed7-89c8-10257ca7a0d5" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_5b3aa47b-ba5b-4aae-9222-b1550983770a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For the year ended </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_4d334793-ce3c-462b-87fb-55d4f20e42b6" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_5991a5ed-a303-4b97-9640-17383190b789" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_c9e2b185-8d10-45b9-a57b-dbb85414f656" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">OR</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_5bffcfea-1268-433f-bfa5-04eae65b366e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">                     </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">                    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Commission file number: </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_2950d5fc-cc1a-49c4-a5c8-37662c9a51c4" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_ae3ada45-10cb-4e77-8df2-0b5de899a827" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_730fac0c-62d5-494d-ab73-269b07a0db4e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_5c21b1e9-5975-4d54-aa74-ec8e8f9ca71b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">56-2020050</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Incorporation or Organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_015f7805-f74e-4307-88c1-a88dedd76bd4" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12770 High Bluff Drive</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_60dea690-fa84-4b85-9ce4-0198dc0464cc" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 150</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_e0a8ae6e-d3ab-4674-a93f-5f3b6c17936c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:7.5pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_74207a89-ecac-470c-ab7e-d9c439c84663" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_939089ad-3ed2-4f96-9dc1-fe0dc3ee289d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92130</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_c3d111f1-1f44-4994-bd17-d9a877696466" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">619</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_a351a5c5-988a-4314-83c0-533a51fe5a05" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">949-3681</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:33.24%;box-sizing:content-box;"/>
    <td style="width:33.38%;box-sizing:content-box;"/>
    <td style="width:33.38%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_1c5f14b0-f96c-4b47-8952-881b5d93ba3c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_186aa108-2f64-45b6-a3bb-00dff863a0d2" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">GYRE</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The </span><span style="font-size:7pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d57066ca-db1e-40f1-ae6d-f44c54975e63" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  &#9744;    </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_6f23f133-df61-49af-87b3-35be3521994e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act.    Yes  &#9744;    </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_737b0aa6-b3a0-4703-87af-64301c7be3d2" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_32679977-66da-4092-b0ee-23ffbc68e7e5" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_9ce4b3aa-49b5-4632-81d0-ebc58d9741a2" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.04%;box-sizing:content-box;"/>
    <td style="width:44.8%;box-sizing:content-box;"/>
    <td style="width:25.04%;box-sizing:content-box;"/>
    <td style="width:5.12%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_ae0f78a3-0009-431a-a2f5-226636d823fd" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_9ea26764-a940-43de-a7c4-4322c5d2940a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_2ce8fa1e-3ebf-48ab-a4d4-ec861402c8a7" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_64cae1fb-7994-45fa-a19b-fc854ce50401" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_8949bdf9-9ce9-4853-80a6-28b2b609afdf" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  &#9744;    No  </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_146ff0a7-29a9-4c16-9f0d-2bb7d99db9c6" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The aggregate market value of the voting common stock held by non-affiliates of the registrant (based on the closing price of such stock on The Nasdaq Capital Market on June 30, 2024, the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebc4e969-1b63-46d1-a6bc-566f99d38dfd" contextRef="C_78e3aca5-80d5-40ae-9cf1-a3aa92d7c78c" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">83.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded because such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.75in;position:relative;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of March 7, 2025, the number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_301ea622-feb7-44f6-9597-56db3673a1e1" contextRef="C_f9d872ab-6ad9-4e1a-9bab-df2b883d5c99" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">93,612,442</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">which includes 7,280,230 shares of common stock issued in the name of the registrant to a stock plan administrator of the registrant (see Note 8&#8212;Stockholders&#8217; Equity).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:8pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_e3e5a98d-dff2-4ae3-9167-5eef0b7c748e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2025 (the &#8220;Proxy Statement&#8221;), which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Annual Report on Form 10-K</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.02%;box-sizing:content-box;"/>
    <td style="width:83.56%;box-sizing:content-box;"/>
    <td style="width:6.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Page</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PART I</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">60</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PART II</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">133</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">148</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">149</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">150</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">150</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">152</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_foreign_jurisdiction"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">152</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PART III</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PART IV</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">154</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">155</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#list_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">LIST OF EXHIBITS</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">156</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">160</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> I</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements and Market Data</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) and the documents incorporated by reference herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements, other than statements of historical facts, included or incorporated by reference in this Annual Report regarding our strategy, future results of operations, future financial condition, future revenues, projected costs, prospects, plans, intentions and objectives of management, as well as the assumptions that underlie these statements, are forward-looking statements. These forward-looking statements should not be relied upon as predictions of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. Forward-looking statements are identified by words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro forma,&#8221; &#8220;estimates,&#8221; or &#8220;anticipates&#8221; or the negative of these words and phrases or other variations of these words and phrases or comparable terminology, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on our management&#8217;s assumptions and assessments in light of information currently available to our management, its experience and its perception of historical trends, current conditions, expected future developments and other factors our management believes to be appropriate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. For example, forward-looking statements include any statements regarding:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to conduct extensive clinical trials to demonstrate safety and efficacy of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to develop a pipeline of product candidates to address unmet needs in the treatment of organ fibrosis and other inflammatory diseases;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the timing, progress and results of clinical trials for: (i) F351 (Hydronidone) from the Phase 3 clinical trial in the People&#8217;s Republic of China (the &#8220;PRC&#8221;) for the treatment of liver fibrosis associated with chronic hepatitis B (&#8220;CHB&#8221;) and Phase 2 trial in the United States for the treatment of metabolic dysfunction-associated steatohepatitis- (&#8220;MASH&#8221;) associated liver fibrosis; (ii) ETUARY from the Phase 3 clinical trial for pneumoconiosis; (iii) F573 from the Phase 2 clinical trial in the PRC for the treatment of on-chronic liver failure; and (iv) other product candidates we may develop, including F230 and F528, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available and research and development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the timing, scope and likelihood of U.S., PRC and comparable foreign regulatory filings and approvals, including timing of investigational new drug applications (&#8220;INDs&#8221;) and final FDA and National Medical Products Administration ("NMPA") approval of F351 for the treatment of liver fibrosis associated with MASH and CHB, respectively, ETUARY for the treatment of pneumoconiosis, F528 for the treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;), F230 for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;), and any other future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our expectations regarding the future pursuit of product development efforts, including whether we will pursue such efforts, estimates regarding the expenses, future revenue, timing of any future revenue, capital requirements and need for additional financing related to such efforts, the timing </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">of and our ability to pursue such efforts and our plans to develop and, if approved, subsequently commercialize any product candidates resulting from such efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash and investments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to develop and advance current product candidates and programs into, and successfully complete, clinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our manufacturing, commercialization and marketing capabilities and strategy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">plans relating to commercializing nintedanib and avatrombopag, and our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the need to hire additional personnel and our ability to attract and retain such personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the size of the market opportunity for our product candidates, including estimates of the number of patients who suffer from the diseases we are targeting;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">expectations regarding the approval and use of our product candidates in combination with other drugs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">expectations regarding the potential for accelerated approval or other expedited regulatory designation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our competitive position and the success of competing therapies that are or may become available;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">estimates of the number of patients that we will enroll in our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the beneficial characteristics and the potential safety, efficacy and therapeutic effects of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates and our expectations regarding particular lines of therapy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">plans relating to the further development of our product candidates, including additional indications we may pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">existing regulations and regulatory developments in the PRC, the United States, Europe, and other jurisdictions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ETUARY, nintedanib, avatrombopag, F351, F573, F528, and F230, and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our continued reliance on third parties to conduct additional clinical trials of our product candidates and for the manufacture of our product candidates for clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our relationships with patient advocacy groups, key opinion leaders, regulators, the research community and payors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to obtain and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the pricing and reimbursement of ETUARY, nintedanib, avatrombopag, F351, F573, F528, and F230, and other product candidates we may develop, if approved;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of F351, and other product candidates we may develop;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our financial performance;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the period over which we estimate our existing cash will be sufficient to fund our planned operating expenses and capital expenditure requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">expectations about the continued listing of our common stock on The Nasdaq Capital Market; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the impact of laws and regulations. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any such forward-looking statements are not guarantees of future performance and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in or contemplated by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, the risks and uncertainties described in this Annual Report, including those risks described in Part I, Item 1A, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">,&#8221; and Part II, Item 7, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">,&#8221; as well as others that we may consider immaterial or do not anticipate at this time. The risks and uncertainties described in this Annual Report, including in Part I, Item 1A, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">,&#8221; and Part II, Item 7, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">,&#8221; are not exclusive and further information concerning our company and our businesses, including factors that potentially could materially affect our operating results or financial condition, may emerge from time to time. All forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this Annual Report, speak only as of their date, and we undertake no obligation to update or revise these statements considering future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties, and you should carefully consider the factors set forth in other reports or documents that we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This Annual Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in such information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 1. BUSINESS.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">In this section, unless otherwise specified, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;our company&#8221; refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (&#8220;Gyre Pharmaceuticals&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are a commercial-stage pharmaceutical company with a proven track record of financial success developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs and involve complex, multi-stage processes with multiple pathways. While there are numerous potential targets for anti-fibrotic therapy, both established and emerging, addressing a single molecular pathway may not be sufficient to prevent, halt, or reverse fibrosis. Our strategy is to build on our success in the development and commercialization of ETUARY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(pirfenidone) to expand into new indications and advance our pipeline of innovative drug candidates. By leveraging clinically validated compounds, our goal is to drive a de-risked pipeline through late-stage clinical development and commercialization to provide effective treatments for patients in the United States and globally.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img99844967_0.jpg" alt="img99844967_0.jpg" style="width:624px;height:301px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">ETUARY (pirfenidone)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pirfenidone, the first anti-fibrotic drug approved for idiopathic pulmonary fibrosis (&#8220;IPF&#8221;) in Japan, the European Union (&#8220;EU&#8221;), the United States, and the PRC, is a small molecule drug that inhibits the synthesis of Tumor Growth Transforming (&#8220;TGF&#8221;)-&#223;1, Tumor Necrosis Factor (&#8220;TNF&#8221;)-&#945;, and other fibrosis and inflammation modulators.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We successfully advanced pirfenidone from research and development (&#8220;R&amp;D&#8221;) to commercialization in the PRC for the treatment of IPF. In 2024, ETUARY&#8217;s annual sales reached $105.0 million. In addition to IPF, pirfenidone is undergoing one additional Phase 3 trial in the PRC for the treatment of pneumoconiosis (&#8220;PD&#8221;) and was undergoing two Phase 3 trials in the PRC for the treatment of dermatomyositis-related interstitial lung disease ("DM-ILD") and sclerosis-related interstitial lung disease ("SSc-ILD") to broaden its indications and market. We are prioritizing the development of our product candidates for other targeted indications and, as a result, have paused our two Phase 3 trials in the PRC for the treatment of DM-ILD and SSc-ILD. We may decide to continue such Phase 3 trials in the future.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">F351 (hydronidone)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 (hydronidone), our lead development candidate, is a structural derivative of ETUARY. It is a new oral chemical entity with an anti-fibrotic, TGF-&#223;1-targeting mechanism of action, for which we hold patents in major markets. Our Phase 2 trial of F351 in the PRC for Chronic Hepatitis B (&#8220;CHB&#8221;)-associated liver fibrosis showed that F351 was well-tolerated without notable toxicity and patients treated showed statistically-significant improvement of liver fibrosis.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our most significant near-term catalyst is the anticipated topline results of F351 for our ongoing Phase 3 trial in the PRC expected in the second quarter of 2025. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our confirmatory 52-week Phase 3 trial enrolled 248 patients and the last patient completed the trial in October 2024. Topline results from our Phase 3 trial will be a critical milestone in our clinical development and commercial strategy. A positive outcome has the potential to enhance our commercial sales, strengthen our market position and drive overall company growth.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are preparing a U.S. IND application and expect to submit it in the first half of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> In the United States, we have completed a Phase 1 clinical trial of F351 in healthy volunteers. Following results from the PRC Phase 3 trial in CHB-associated liver fibrosis and pending approval of our IND, we expect to initiate a Phase 2 trial to evaluate F351 for the treatment of liver fibrosis associated with MASH in 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Generic Drugs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Nintedanib and avatrombopag are our two commercial-ready drugs that have planned commercial launches in the PRC in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Nintedanib is approved as a standard-of-care drug for IPF, SSc-ILD, and Progressive Fibrosing Interstitial Lung Disease (&#8220;PF-ILD&#8221;). Avatrombopag has received approval for two indications, the treatment of thrombocytopenia (&#8220;TP&#8221;) associated with chronic liver disease (&#8220;CLD&#8221;) and chronic idiopathic thrombocytopenia (&#8220;ITP&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Other Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F573 is our clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (&#8220;ALF/ACLF&#8221;) currently in Phase 2 clinical trials in the PRC. F230 is our clinical-stage product candidate for the treatment of PAH, and we expect to initiate a Phase 1 trial in the PRC in 2025. F528 is our preclinical-stage product candidate for the treatment of COPD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img99844967_1.jpg" alt="img99844967_1.jpg" style="width:624px;height:225px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Commercialization and Development Strategies in Targeted Indications</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Products and Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Pulmonary Fibrosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are focused on commercializing therapies for the treatment of pulmonary fibrosis and working to solidify our position as a leader in this space.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are uniquely positioned as the only company with both standard-of-care approved therapies for IPF. Our portfolio includes:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ETUARY&#174; (pirfenidone)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; an antifibrotic agent with anti-inflammatory and antioxidant properties, and one of the first three drugs approved for the treatment of IPF globally. In 2024 and 2023, our revenue from sales of ETUARY was $105.0 million and $112.1 million, respectively</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Nintedanib</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8211; a small molecule kinase inhibitor that inhibits lung fibroblast proliferation and migration. In May 2024, Gyre Pharmaceuticals executed a comprehensive agreement with Jiangsu Wangao Pharmaceuticals Co., Ltd. to obtain the drug registration certificate for and become the marketing authorization holder of nintedanib. Gyre Pharmaceuticals is planning to initiate commercialization of the nintedanib product in the PRC in 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pirfenidone is undergoing one additional Phase 3 trial in the PRC for the treatment of PD and two Phase 3 trials in the PRC for the treatment of DM-ILD and SSc-ILD. We have paused our Phase 3 trials of pirfenidone for the treatment of DM-ILD and SSc-ILD in the PRC to prioritize development of our product candidates in other targeted indications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Liver Fibrosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are also committed to developing effective therapies for the treatment of CHB-associated and MASH-associated liver fibrosis through our lead product candidate, F351 (hydronidone).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 is currently in a Phase 3 clinical trial in the PRC for the treatment of CHB-associated liver fibrosis. We commenced patient enrollment for our Phase 3 clinical trial in January 2022 and had our last patient out in October 2024. The topline results of F351 for our Phase 3 trial in the PRC are expected in the second quarter of 2025. In the United States, we are advancing F351 for the treatment of MASH-associated liver fibrosis. We are actively preparing to file an IND application in the first half of 2025. Following results from the PRC Phase 3 trial in CHB-associated liver fibrosis and pending approval of our IND, we expect to initiate a Phase 2 trial to evaluate F351 for the treatment of liver fibrosis associated with MASH in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 has demonstrated a favorable profile for the treatment of CHB-associated liver fibrosis in clinical trials. Due to the severity of the disease and the clinical trial progress of F351, in March 2021, the Center for Drug Evaluation (&#8220;CDE&#8221;) of the NMPA in the PRC granted F351 a Breakthrough Therapy designation, which helps to accelerate the review of drugs that have early evidence to suggest that the drug may demonstrate a substantial improvement over currently available therapies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Kidney Fibrosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are seeking to advance pirfenidone for the treatment of chronic kidney disease ("DKD"). We completed a Phase 1 trial for DKD in March 2022 and are discussing next steps for this program in 2025 with Chinese authorities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Other Indications: ALF/ACLF, PAH, COPD, TP with CLD, ITP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have also expanded our pipeline to address additional fibrotic and inflammatory diseases with significant unmet medical needs:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F573 (ALF/ACLF)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; A clinical-stage compound for acute and acute-on-chronic liver failure. F573 is currently in a Phase 2 trial in the PRC, initiated in March 2023, to evaluate its safety and efficacy in these severe liver conditions.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F230 (PAH)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; A clinical-stage compound for the treatment of pulmonary arterial hypertension. The NMPA approved the IND application for F230 in May 2024. We expect to initiate a Phase 1 trial in PAH in 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F528 (COPD) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8211; A preclinical-stage candidate targeting chronic obstructive pulmonary disease. F528 is designed to provide a first-line therapy to reduce long-term lung function decline and improve patient outcomes.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Avatrombopag </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; A commercial stage product targeting TP with CLD and ITP disease indications. We expect to begin commercialization in 2025. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Products for Pulmonary Fibrosis: ETUARY and Nintedanib</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are focused on commercializing therapies for the treatment of pulmonary fibrosis through our two therapeutic products: ETUARY&#174; (pirfenidone) and nintedanib. These two drugs represent the only approved therapeutics as the current standards of care for IPF, and we are uniquely positioned as the only company offering both treatment options.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Commercialized Product: ETUARY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ETUARY (pirfenidone capsule) was approved in the PRC as a National Category 1.1 New Drug in 2011 for the treatment of IPF, a rare disease. Given the absence of an approved IPF treatment in the PRC, ETUARY was included in the National Reimbursement Drug List ("NRDL") in 2017 and has since held a dominant market share. Clinical trials have shown that ETUARY can effectively slow down the decline in lung function and IPF disease progression. Moreover, given that different organ fibroses have similar pathogenic mechanisms and fibrosis processes, we are currently working to expand the therapeutic indications of ETUARY to another pulmonary fibrosis disease, PD, as well as diseases causing renal fibrosis, such as DKD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ETUARY Mechanism of Action</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pulmonary fibrosis is caused by activation of alveolar cells after epithelial damage, which secretes a series of pro-inflammatory cytokines, activating fibroblast proliferation and myofibroblast differentiation and reducing the rate of apoptosis. ETUARY reduces Type I Collagen expression by inhibiting the expression of pro-fibrogenic mediators, including TGF-&#223;1, platelet-derived growth factor (&#8220;PDGF&#8221;) and fibroblast growth factor, which ultimately reduces fibroblast proliferation and collagen fiber synthesis and decreases extracellular matrix accumulation. It also inhibits TNF-&#945;, IL-1 and other inflammatory mediators, thus reducing the inflammatory response.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The diagram below illustrates the mechanism of action of pirfenidone.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img99844967_2.jpg" alt="img99844967_2.jpg" style="width:499px;height:244px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Additional IPF Product: Nintedanib</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In May 2024, Gyre Pharmaceuticals executed a comprehensive agreement with Jiangsu Wangao Pharmaceuticals Co., Ltd. to obtain the drug registration certificate for and became the marketing authorization holder of nintedanib, a small-molecule drug  for the treatment of idiopathic pulmonary fibrosis, within the PRC. Nintedanib is expected to provide patients with more choices and benefits, and further enhance Gyre Pharmaceuticals&#8217; leading position in the pulmonary fibrosis market. Gyre Pharmaceutical is planning to initiate commercialization of nintedanib in the PRC in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We anticipate that this launch will drive meaningful revenue growth, expand our market penetration, and enhance brand recognition within the respiratory disease space. Additionally, the commercialization of nintedanib aligns with our broader strategy of building a comprehensive pulmonary care portfolio, potentially creating opportunities for synergies with our existing and future product offerings. We will continue to invest in commercialization efforts, including market access, physician education, and patient support programs, to optimize uptake and maximize the long-term value of this product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">IPF Disease Overview and PRC Market Opportunities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">IPF is a rare disease, defined as a chronic, progressive fibrotic interstitial pneumonia of unknown cause to the lungs, occurring primarily in the elderly. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis. The average five-year survival rate for patients with IPF is 32%, with the average 10-year survival rate dropping to 16%. According to Frost &amp; Sullivan, the prevalence of IPF in the PRC increased from 89,002 patients in 2018 to 145,776 patients in 2023 at a CAGR of 10.29%, and it is expected to increase to 322,000 patients by 2031 at a CAGR of 10.38% from 2023 to 2031. The total market size of IPF in the PRC increased from $23.9 million in 2018 to $156.8 million in 2023 at a CAGR of 22%, and is expected to reach $344.9 million by 2027 and $698.6 million by 2031 at a CAGR of 20.5% from 2027 to 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The scarring of lung tissues is irreversible. However, proper treatment may slow the rate of fibrosis, increase the patient&#8217;s survival rate, alleviate the patient&#8217;s symptoms and improve the patient&#8217;s quality of life. There are currently two types of IPF drugs approved in the PRC: pirfenidone and nintedanib. They are both clinically shown to slow down the formation of scar tissue in the lungs of IPF patients and are the only drugs that are considered effective for the treatment of organ fibrosis in the PRC. According to the latest guideline for the treatment of IPF issued by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Latin American Thoracic Association, pirfenidone and nintedanib are the only two types of IPF drug conditionally recommended with moderate-quality evidence.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ETUARY Competition in the PRC (IPF)</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sales of ETUARY reached $105.0 million in 2024. Although still a dominant player in the IPF drug market, the market share of ETUARY declined recently primarily due to the rising market share of new drugs, including avatrombopag, marketed as &#23433;&#21338;&#21496;, which had $20.4 million of sales in 2023, and OFEV (nintedanib), which had $72.1 million of sales in 2023. In 2023, the annual expenditures per patient in the PRC before NRDL reimbursement for ETUARY, avatrombopag marketed as &#23433;&#21338;&#21496;, and OFEV were $13,106 to $13,378, $10,553, and $15,132, respectively. Despite the recent decrease of market share of ETUARY in the IPF market, we continue to expect a strong sales performance due to sustained increases in the prevalence of IPF and future indication expansion of ETUARY for the potential treatment of PD and other diseases. In addition, there are various barriers to entry for the potential market entrants. For example, it is difficult for new entrants to build an experienced and specialized sales and marketing team in the short term given that sales and marketing strategies of organ fibrosis drugs significantly differ from that of etiological treatment drugs. In addition, long-term and stable collaboration with KOLs and hospitals is critical to developing and optimizing a product portfolio, including effectively educating and penetrating the market and recruiting patients for clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">PD Disease Overview and PRC Market Opportunities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PD refers to a spectrum of pulmonary diseases caused by inhalation of mineral dust, usually as the result of certain occupations. The main pathological features include chronic pulmonary inflammation and progressive pulmonary fibrosis, which can eventually lead to death caused by respiratory and/or heart failure. PD is widespread and a serious global public health concern. Its high incidence and mortality result from improper occupational protection and the lack of early diagnostic methods and effective treatments.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Frost &amp; Sullivan, in the PRC, the prevalence of PD increased from 873,299 patients in 2018 to 938,163 patients in 2023, and it is expected to increase to 970,000 patients by 2028 and 985,000 patients by 2031. The market size of anti-fibrosis drugs for PD is expected to reach $12.1 million by 2027 and $64.1 million by 2031 a CAGR of 58.1% from 2027 to 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To date, there are two pirfenidone product candidates for the treatment of PD in various clinical stages in the PRC. We enrolled the first patient in our Phase 3 clinical trial of ETUARY for the treatment of PD in June 2022, making ETUARY the most clinically advanced anti-fibrosis drug for the treatment of PD in the PRC. As of December 31, 2024, no small molecule or biologic anti-fibrosis product for the treatment of PD had been approved in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 ETUARY Clinical Trial (PD)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are conducting a randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical trial to evaluate the efficacy and safety of pirfenidone in the treatment of pneumoconiosis. The primary endpoint is the change in force vital capacity at 52 weeks of treatment compared to baseline. 272 patients will be enrolled in the trial, with 136 in the treatment group and 136 in the control group.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We obtained ethics committee approval as of January 2022 and enrolled the first patient in June 2022. Currently, we have enrolled 172 patients in our Phase 3 clinical trial of ETUARY for the treatment of PD as of December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Product Candidate For Liver Fibrosis: F351 (Hydronidone)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are strategically focused on addressing liver fibrosis through the development of our lead product candidate, F351 (Hydronidone) for two key indications: CHB-associated liver fibrosis in the PRC and MASH-associated liver fibrosis in the United States. F351 is advancing through critical stages of development and currently in a Phase 3 clinical trial in the PRC for the treatment of CHB-associated liver fibrosis. In October 2024, the last patient completed such trial, and topline data from the Phase 3 clinical trial in the PRC is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">expected by the second quarter of 2025. Additionally, we completed a Phase 1 trial in the United States for MASH-associated liver fibrosis and are actively preparing to file an IND application in the first half of 2025. We are committed to advancing F351 as a potential first-in-class treatment for these significant unmet needs in liver fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">CHB Disease Overview and PRC Market Opportunities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CHB is a major cause of liver morbidity and mortality in Asia. Patients chronically infected with the hepatitis B virus tend to experience liver fibrosis and may develop end-stage liver disease, such as decompensated cirrhosis and hepatocellular carcinoma ("HCC"), without intervention. In the PRC, about 70% of cirrhoses were developed from HBV infection, which reflects the significant demand for the treatment of CHB-associated liver fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of CHB-associated liver fibrosis globally increased from 228.9 million patients in 2018 to 265.0 million patients in 2023. The prevalence of CHB-associated liver fibrosis in the PRC from 2018 to 2023 ranges from 63.6 million to 66.4 million patients and is expected to remain stable in the next 10 years. The anti-liver fibrosis drug market in the PRC has increased from $144.8 million in 2018 to $167.8 million in 2023 with a CAGR of 2.99%. We expect the market to grow to $801.2 million in 2031, at a CAGR of 21.58%.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Etiological treatment is currently the most common treatment of liver fibrosis. For CHB-associated liver fibrosis, antiviral therapy is only able to suppress the viral infection, but is unable to prevent, slow or reverse the progress of fibrosis, suggesting a significant unmet need for effective antifibrotic therapy. Anti-fibrotic treatment is recommended for the treatment of intermediate and advanced liver fibrosis, as well as early-stage cirrhosis. As of December 31, 2024, no chemical or biological drugs treating CHB-associated liver fibrosis have been approved globally. Globally, there are currently a series of drugs that are in late-stage (Phase 2 or later) clinical trials for the treatment of liver fibrosis. Of these clinical-stage drugs, F351 is the most clinically advanced product candidate in the PRC that has the potential to effectively reverse the fibrosis process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our CHB-Associated Liver Fibrosis Clinical-Stage Product Candidate: F351 (Hydronidone)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351, our Phase 3 clinical-stage product candidate in the PRC, has the potential to become the first approved drug to treat CHB-associated liver fibrosis. Of the late clinical-stage drugs for the treatment of liver fibrosis, F351 is the most clinically advanced product candidate in the PRC that has the potential to effectively reverse the fibrosis process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 demonstrated positive results of the reversal of the fibrosis process in our Phase 2 clinical trial in the PRC. Due to the results of the Phase 2 clinical trial and as one of the first drugs in development to treat liver fibrosis, F351 was granted a Breakthrough Therapy designation by the CDE in March 2021 and we commenced patient enrollment for the Phase 3 clinical trial in January 2022. In October 2023, we fully enrolled our 248-patient Phase 3 clinical trial of F351 in the PRC for the treatment of CHB-associated liver fibrosis. In October 2024, the last patient completed this 52-week trial and we expect to report topline data from this trial by the second quarter of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 Mechanism of Action in CHB</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">When injuries occur and epithelial and/or endothelial cells are damaged, pro-inflammatory cytokines are released by the coagulation cascade for immune cell recruitment, mainly neutrophils and macrophages. These recruited immune cells function as the scavenger to remove tissue debris and dead cells, resulting in acute inflammation. Meanwhile, immune cells themselves release factors like chemokines and cytokines to amplify inflammatory reactions. Next, the released factors, such as TGF-&#223;1, PDGF, interleukin-13 and interleukin-4, induce the limited activation and proliferation of myofibroblasts. F351 is expected to treat and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">reverse liver fibrosis in chronic viral hepatitis B by inhibiting the proliferation of HSCs and the TGF-&#223;1 signaling pathway.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The diagram below illustrates the mechanism of action of F351:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img99844967_3.jpg" alt="img99844967_3.jpg" style="width:368px;height:256px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of F351 Clinical Results in CHB</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, more than five clinical trials sponsored by us or SG were carried out to explore the clinical risk/benefit of F351. Summarized below are the results of selected key clinical trials of F351 for CHB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Phase 2 PRC Clinical Trial of F351 for CHB-Associated Liver Fibrosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We conducted a Phase 2 randomized, double-blind, placebo-controlled, Entecavir-based (the first-line drug for the treatment of CHB virus infection), multi-center, dose-escalation trial assessing the safety and efficacy of F351 for treatment of patients in the PRC with CHB-associated liver fibrosis. The Phase 2 trial was randomized in 240 patients divided into four dose-escalating groups (placebo; 180 mg/day; 270 mg/day; and 360 mg/day) with a primary endpoint of the reduction of the liver fibrosis score (Ishak Scoring System) by greater than or equal to one stage after taking F351 in combination with Entecavir.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The trial met its primary endpoint of a statistically-significant improvement in the liver fibrosis score over the 52-week treatment versus placebo (p=0.0245). The percentages of patients who achieved a fibrosis regression of &gt; 1 were 25.58% (placebo), 40.48% (180 mg/day), 56.10% (270 mg/day) and 43.90% (360 mg/day). Accordingly, the 270 mg/day treatment group showed the highest percentage of patients who were able to reach the primary endpoint.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 showed better safety results when compared to the placebo in this trial. In the placebo group, 180 mg treatment group, 270 mg treatment group and 360 mg treatment group, rates of SAEs were 4.65%, 2.38%, 2.38% and 7.32%, respectively, with no statistical significance. A total of seven (4.17%) subjects experienced seven SAEs throughout the trial: two (4.6%) in the placebo group, one (2.38%) in the 180 mg group, one (2.38%) in the 270 mg group and three (7.32%) in 360 mg group, with no statistical significance. The SAEs were laboratory abnormalities, elevation of transaminases, embolic infarction, comminuted fracture, osteoporosis, unplanned pregnancy and hypertension. No deaths occurred.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Topline Phase 3 Results of F351 for CHB-Associated Liver Fibrosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are conducting a Phase 3 randomized, double-blind, placebo-controlled, Entecavir-based, multi-center trial assessing the safety and efficacy of F351 for treatment of patients in the PRC with CHB-associated liver fibrosis. The Phase 3 clinical trial was designed to be randomized in 248 patients with a primary endpoint of the reduction of the liver fibrosis score (Ishak Scoring System) by at least one stage after taking F351 in combination with Entecavir.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We commenced patient enrollment for the Phase 3 clinical trials of F351 in January 2022 and completed enrollment in October 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We expect to announce topline results in the second quarter of 2025. Topline results from our Phase 3 trial will be a critical milestone in our clinical development and commercial strategy. A positive outcome has the potential to enhance our commercial sales, strengthen our market position and drive overall company growth.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">MASH Disease Overview and U.S. Market Opportunities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">MASH, a severe form of metabolic dysfunction-associated steatotic liver disease (&#8220;MASLD&#8221;), an umbrella of conditions caused by the build-up of extra fat in the liver that is not caused by alcohol intake, is characterized histologically by the additional presence of inflammation and hepatocellular injury, such as visible ballooning, and has a significantly worse prognosis, with the potential to progress to liver fibrosis, cirrhosis or HCC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">MASH represents a large and rapidly growing problem in the U.S. and worldwide. Diagnoses have been on the rise and are expected to increase dramatically in the next decade. The prevalence of MASLD, which affects approximately 25% of the global population, and MASH, which develops in approximately 20% to 30% of MASLD patients, is driven primarily by the worldwide obesity epidemic. As a result, the prevalence of MASH has increased significantly in recent decades, paralleling similar trends in the prevalence of obesity, insulin resistance and Type 2 diabetes. The prevalence of these conditions is expected to increase further due to unhealthy nutrition habits, such as consumption of a diet high in fructose, sucrose and saturated fats, and sedentary behavior.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The critical pathophysiologic mechanisms underlying the development and progression of MASH include reduced ability to metabolize clear lipids, increased insulin resistance, injury to hepatocytes and liver fibrosis in response to hepatocyte injury. MASH patients have an excessive accumulation of fat in the liver resulting primarily from a caloric intake above and beyond energy needs. A healthy liver contains less than 5% fat, but a liver in someone with MASH can contain more than 20% fat. This abnormal liver fat contributes to the progression to MASH, a liver necro-inflammatory state, that can lead to scarring, also known as fibrosis, and, for some, can progress to cirrhosis and liver failure&#8212;cirrhosis develops in approximately 20% to 45% of patients. In some cases, cirrhosis progresses to decompensated cirrhosis, which results in permanent liver damage that can lead to liver failure. In addition, it is estimated that 8% of patients with advanced fibrosis will develop HCC. MASH is a complex, multifaceted disease that does not just affect the liver. Patients with MASH frequently have other significant metabolic co-morbidities such as obesity, hyperglycemia, dyslipidemia and systemic hypertension (a constellation of which is commonly referred to as metabolic syndrome) and these further contribute to the risk of cardiovascular disease.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our MASH-Associated Liver Fibrosis Clinical-Stage Product Candidate: F351 (Hydronidone)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351, our Phase 1 clinical-stage drug candidate in the United States, has the potential to treat MASH-associated liver fibrosis. We are actively preparing to file an IND application in the first half of 2025. Following IND clearance, we plan to initiate a Phase 2, proof-of-concept clinical trial in 2025 in the United States, subject to positive trends in the Phase 3 clinical trial of F351 in the PRC, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of F351 for patients with advanced liver fibrosis associated with noncirrhotic MASH.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 is a structural analogue of ETUARY, but with medicinal chemistry that has been modified to potentially reduce the safety liabilities associated with Phase 1 metabolism.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 Mechanism of Action in MASH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 is designed to treat liver fibrosis by inhibiting the activation of hepatic stellate cells (&#8220;HSCs&#8221;) through Smad7-mediated TGF-&#223; degradation, as well as decreasing the expression of fibrosis-related genes. The TGF-&#223; is a</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">central mediator of fibrogenesis in tissues. Activation of the HSCs is recognized as a central event in the progression of liver fibrogenesis, with the TGF-&#223; as one of the key mediators.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 has been shown to inhibit </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> both p38&#947; kinase activity and TGF-&#223;1-induced excessive collagen synthesis in HSCs. This is further supported by its anti-proliferative effects on the HSCs in the liver. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">In vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> anti-fibrotic effects of F351 were also confirmed in several established </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">rodent models of liver fibrosis, such as carbon tetrachloride (&#8220;CCl</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;)-induced liver fibrosis mouse model, DMN-induced liver fibrosis rat model, and HSA-induced liver fibrosis rat model, as well as mouse model of MASH fibrosis (CCl</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> +Western [High Fat] Diet). In the MASH mouse model, F351 significantly reduced the severity of fibrosis, as well as demonstrated improvements in the functional, biochemical and histopathological attributes of the affected liver tissue, including a significant reduction of hydroxyproline content and liver enzymes (ALT), aspartate (AST), a decrease in liver fat degeneration, and decreases in the levels of several of inflammatory cytokines at doses of 3-10 mg/kg/day, as well as a decrease in the NAS score in the CCl</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and WD-induced fibrosis and cell ballooning MASH models at doses of 15-50 mg/kg bid (HEDs of 144 &#8211; 480 mg) which are relevant to human exposure. Thus, the key attributes of F351&#8217;s molecular mechanisms of action in animal models of liver fibrosis support its efficacy potential in liver fibrosis of various etiologies including those associated with MASH.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of F351 Clinical Results in MASH</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Phase 1 U.S. Clinical Trial of F351 for MASH-Associated Liver Fibrosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have completed a Phase 1 clinical trial that evaluated the safety, tolerability, and PK of single and multiple doses of F351 in U.S. healthy volunteers, and collected bridging data to the data obtained in healthy volunteers in the PRC. This Phase 1 clinical trial of F351 was conducted on the basis of an IND that was filed in 2016 for F351 as an anti-fibrotic agent with a focus on liver fibrosis associated with a spectrum of chronic liver diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Following single oral doses of F351 (30 mg or 120 mg) in Part I of the trial, F351 was rapidly absorbed, showing a linear PK pattern of exposure with mean elimination half-life of five to six hours, and five to seven hours for M3 and M4 metabolites. Following repeated oral doses of F351 (30 mg or 120 mg TID) for seven days in Part II of the trial, F351 capsules were rapidly absorbed with a similar PK pattern of exposure and similar half-life as seen following single doses of F351. Modest accumulation (less than a 1.5-fold increase) was observed for F351, M3 and M4 with repeated 30 mg or 120 mg TID. Dose-normalized F351 C</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">max</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and AUC values were similar in males and females.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Overall, F351 was well tolerated when administered as a single oral dose of 30 mg or 120 mg and when administered as repeated oral doses of 30 mg or 120 mg TID for seven consecutive days. There were no premature discontinuations due to adverse events (&#8220;AEs&#8221;), no serious adverse events (&#8220;SAEs&#8221;), and no deaths reported in this trial. Treatment-emergent AEs reported following single dose administration in Part I of the trial included a single AE of rhinorrhea and scattered, isolated, reversible laboratory abnormalities. Treatment-emergent AEs reported following repeated dose administration in Part II of the trial included headache (25.0%), constipation (16.7%) and somnolence (12.5%). Abdominal discomfort and flatulence were also reported as gastrointestinal AEs in one subject each. There were no clinically significant overall changes in safety laboratory tests that were attributable to trial drug product, including no evidence of any significant drug-induced liver injury or clinically significant overall changes in vital signs, ECG parameters or physical examinations that were attributable to trial drug product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Anticipated Phase 2 U.S. Clinical Trial of F351 for MASH-Associated Liver Fibrosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Following IND clearance, we plan to initiate Phase 2 clinical development of F351 in MASH-associated liver fibrosis. We expect to file the IND in the first half of 2025. The goal of the proposed Phase 2 clinical trial is to obtain early proof-of-concept for F351 in subjects with MASH-associated liver fibrosis as a basis of expansion into a more comprehensive Phase 2/3 clinical program. This trial will be conducted under a new IND, reflecting the distinct risk-benefit profile that the drug may have in a MASH patient population. To support the IND filing and initiation of the proposed Phase 2 clinical trial, we plan to cross-reference all nonclinical and clinical data obtained in trials completed under the currently-active IND in the United States, as well as those previously completed in the PRC. We believe that the results obtained in these nonclinical and clinical studies provide adequate information on the current clinical risk/benefit profile of the drug and allow for safe initiation of the proposed Phase 2 clinical trial of F351 in MASH-associated liver fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 Competition in the U.S. (MASH)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The biopharmaceutical industry is intensely competitive and subject to rapid innovation and significant technological advancements. We believe the key competitive factors that will affect the development and commercial success of F351 and any future product candidates are efficacy, safety and tolerability profile, reliability, convenience of dosing, price, the level of generic competition and reimbursement. Our competitors include multinational pharmaceutical companies, specialized biotechnology companies, universities and other research institutions. A number of biotechnology and pharmaceutical companies are pursuing the development or marketing of pharmaceuticals that target the same diseases that we are targeting. Smaller or earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Given the high incidence of MASH, it is likely that the number of companies seeking to develop products and therapies for the treatment of liver and cardio-metabolic diseases, such as MASH, will increase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If F351 is approved for the treatment of MASH-associated liver fibrosis, future competition could arise from five main classes of drugs aiming to reach the market in the current MASH landscape: Farnesoid X receptor agonists, fibroblast grow factor 21, thyroid hormone receptor-&#946; agonists, glucagon-like peptide 1 (&#8220;GLP-1&#8221;) agonists, and PPAR agonists, but there are others as well. Resmetirom, a beta-thyroid hormone receptor agonist from Madrigal Pharmaceuticals, Inc. became the first drug to be approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis, to be used along with diet and exercise; other candidates include VK2809 a beta-thyroid hormone receptor agonist from Viking Therapeutics, Inc.; Aldafermin, an FGF19 analog from NGM Biopharmaceuticals, Inc.; denifanstat, a novel fatty acid synthase (FASN) inhibitor from Sagimet Biosciences; MK-3655, an FGFR1c/KLB agonist antibody from Merck &amp; Co., Inc.; Efruxifermin, a FGF21 fusion protein from Akero Therapeutics, Inc.; Pegozafermin, a FGF21 fusion protein from 89bio, Inc.; Belapectin, a Galectin-3 inhibitor from Galectin Therapeutics Inc.; Aramchol, a synthetic conjugate of cholic acid and arachidic acid from Galmed Pharmaceuticals Ltd.; Semaglutide, a GLP-1 receptor agonist from Novo Nordisk A/S; Pemvidutide/ALT-801, a dual GLP-1/glucagon agonist from Altimmune; Tirzepatide, a dual GIP/GLP-1 receptor agonist from Eli Lilly and Company; Lanifibranor, a PPAR alpha/delta/gamma agonist from Inventiva; NNC0194-0499, an FGF21 analog from Novo Nordisk; BOS-580, an FGF21 analog from Boston Pharmaceuticals; and BFKB8488A, and an FGFR1/KLB agonist antibody from Genentech.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">F351 Manufacturing and Supply</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The manufacturing of F351 active pharmaceutical ingredients (&#8220;API&#8221;) and drug product supplies required for supporting the Phase 2 clinical trial in MASH-associated liver fibrosis was completed at WuXi STA, based in the PRC. The API and drug product are of current Good Manufacturing Practice (&#8220;cGMP&#8221;) grade quality, and batch release and stability studies comply with applicable regulatory requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In light of the legislation known as the BIOSECURE Act, which was proposed in the 118</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Congress, we have taken several measures to strengthen our supply chain in the event that Wuxi Biologics, Inc. (&#8220;Wuxi Biologics&#8221;) or one of our other manufacturers is impacted. The version of the BIOSECURE Act introduced in the U.S. House of Representatives during the 118</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Congress would prohibit federal agencies from entering into procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a biotechnology company of concern, and includes a grandfathering provision allowing biotechnology equipment and services provided or produced by named &#8220;biotechnology companies of concern&#8221; under a contract or agreement entered into before the effective date until January 1, 2032. The pathway and timing for the BIOSECURE Act or its provisions to become law are uncertain. We are carefully monitoring and assessing the situation surrounding Wuxi Biologics and deliberating various options, including switching to a different CDMO for F351 clinical trials in the U.S. We will also continue to closely monitor geopolitical risk and implement additional mitigations and supply chain redundancies, as needed. See the risk factor entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing pharmaceutical products on a large commercial scale is highly exacting and complex, and we and our third-party manufacturers may encounter problems during the process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Product Candidate For Kidney Fibrosis: Pirfenidone</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">DKD Disease Overview and PRC Market Opportunities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">DKD is a chronic kidney disease (&#8220;CKD&#8221;) caused by diabetes mellitus.  DKD is clinically manifested as specific pathological structural and functional changes in the kidney of diabetes patients. In addition, DKD has become the primary cause of progression from CKD to the end-stage renal disease and one of the main diseases causing renal fibrosis. As one of the serious complications of diabetes, DKD in the PRC is characterized by high prevalence, low awareness rate, low treatment rate and low control rate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of DKD in the PRC increased from 47 million patients in 2018 to 53.6 million patients in 2023, and it is expected to increase to 61.6 million patients by 2031. The DKD market in the PRC increased from $26.4 billion in 2018 to $40.2 billion in 2023 and it is predicted to expand to $54.0 billion by 2028 and $60.5 billion by 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The standard of care for DKD has been blood glucose control, blood pressure control and blood liquid control. However, current therapeutic strategies are far from being completely effective because no available therapy successfully prevents DKD and many patients still progress to end-stage renal disease. The current available drugs for the treatment of DKD include hypoglycemic drugs, antihypertensive drugs and lipid-lowering drugs. As of December 31, 2024, there was one approved treatment for DKD in many parts of the world, finerenone (marketed under the name KERENDIA).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pirfenidone has demonstrated positive therapeutic effects on DKD due to its unique mechanism of action. Several growth factors or cytokines that are locally produced in the kidney appear to contribute to the extracellular matrix accumulation, inflammation and scarring in progressive DKD. The TGF-&#223;1 system is activated and plays a pathogenetic role in DKD in animal models of type 1 and type 2 diabetes. In addition, several studies in patients with type 1 and type 2 diabetes indicate increased renal production of TGF-&#223;1. The TNF-&#945;&#8217; system has also recently been linked with human DKD on the basis of circulating blood levels and gene expression in kidneys from patients with DKD. Pirfenidone has been found to inhibit TGF-&#223;1 production and consequent matrix deposition in experimental animal models of kidney disease. In animal models and cell culture studies, pirfenidone also reduces TNF-&#945;&#8217; production. Previous studies also showed that oral pirfenidone administered to db/db mice after the onset of established DKD was effective in reducing glomerulosclerosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">DKD Phase 1 Clinical Trial of Pirfenidone in the PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We conducted an open-label, parallel-controlled, single-center clinical trial to evaluate the safety and PK of a single dose of pirfenidone capsules in patients with CKD stages G2 and G3a. 24 subjects were enrolled, consisting of 12 patients with renal insufficiency and 12 healthy volunteers.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Phase 1 clinical trial was completed in March 2022. In this trial, pirfenidone was tolerated when used in patients with CKD G2 and G3a, there were no significant changes in the main pharmacokinetic parameters compared with healthy controls, and no dose adjustment was required.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are currently discussing further steps with Chinese authorities for 2025 plans in DKD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Product Candidate for ALF/ACLF: F573</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">ALF/ACLF Disease Overview and  PRC Market Opportunities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ALF/ACLF is severe liver damage caused by a variety of factors, resulting in severe impairment or loss of synthesis of detoxification, metabolism and biotransformation functions. ALF/ACLF can follow with symptoms of jaundice, coagulation dysfunction, hepatorenal syndrome, hepatic encephalopathy and ascites. The causes of ALF/ACLF are complex and include the hepatitis viruses (especially HBV) and other viruses, drugs, hepatotoxic substances (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, alcohol and chemical agents), bacteria and parasites. In the PRC, HBV, drugs and hepatotoxic substances are the most common causes of ALF/ACLF.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of ALF/ACLF in the PRC was 42,440 patients in 2018 and 38,130 patients in 2023 and is expected to be 32,940 patients in 2028 and 29,720 patients in 2031. The market size of ALF/ACLF in the PRC was $274.2 million in 2018 and $254.0 million in 2023 and it is expected to be $219.8 million in 2028 and $198.5 million in 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The main treatment options for liver failure include comprehensive medical therapy, non-biological artificial liver support treatment and liver transplantation. Medical treatment mainly includes general supportive therapy, symptomatic treatment, etiological treatment and treatment for complications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our ALF/ACLF Clinical-Stage Product Candidate: F573</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F573 is a caspase inhibitor and a potential Category 1 new drug for the treatment of ALF/ACLF. We enrolled the first subject for the Phase 1 clinical trial in January 2022 and initiated a Phase 2 clinical trial in March 2023 in the PRC. Our Phase 2 clinical trial of F573 as a treatment for ALF/ACLF is expected to be completed by the end of 2026.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F573 Mechanism of Action in ALF/ACLF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inflammatory response and immune dysfunction can lead to massive liver cell death, which causes ALF/ACLF. Therefore, inhibiting the apoptosis process of normal hepatocytes helps to delay the progression of ALF/ACLF. The main mediating pathways of hepatocyte apoptosis include the mitochondrial pathway and the death receptors pathway, where the caspase family plays an important role as the main executive molecules. The main mechanism of F573 is to inhibit the activity of the caspase family, including caspases 1, 3, 6, 7, 8 and 9 and to reduce the cleavage effects on poly-ADP-ribose polymerase, thus blocking the cell apoptosis process mediated by endogenous or exogenous signals. As a result, hepatic failure is expected to be alleviated by F573.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The diagram below illustrates the mechanism of action of F573:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img99844967_4.jpg" alt="img99844967_4.jpg" style="width:515px;height:232px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preclinical Data of F573 for ALF/ACLF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The efficacy profile of F573 has been demonstrated in four preclinical studies. In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> studies, F573 had a significant inhibitory effect on apoptosis in a variety of cells. Specifically, F573 had a protective effect on HeLa cells, human normal hepatocytes L02 and Jurkat cells, while inhibiting Caspase-3 enzyme activity and reducing its ability to cleave the substrate AC-DEVD-AMC. F573 improved liver function and alleviated the liver injury caused by D-GalN/LPS-induced fulminant liver failure in rats, which significantly inhibited hepatocyte necrosis and apoptosis and showed a preventive and therapeutic effect on acute and severe liver injury. In a pharmacodynamic acute liver injury experiment on D-Gal/LPS mortality in mice, F573 had a protective effect against acute liver injury caused by D-Gal and LPS in km mice and prolonged the survival time of km mice. F573 has been shown to improve liver function and reduce liver injury in ConA-induced acute liver failure in BALB/c mice. F573 significantly inhibits hepatocyte necrosis and apoptosis and has a preventive and therapeutic effect on acute and severe liver injury.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Phase 1 PRC Clinical Trial of F573 for the treatment of ALF/ACLF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We enrolled the first subject for our Phase 1 clinical trial to assess the tolerance and PK of single and multiple doses of F573 in January 2022. We recruited 100 healthy subjects for this trial and completed the Phase 1 clinical observations of tolerability and PK in July 2022. The Cmax of F573 was not dose-dependent at the dose range from 0.5 mg/kg to 2.0 mg/kg, and AUC0-t and AUC0-&#8734; of F573 showed linear pharmacokinetics. The rate of absorption of F573 showed sex differences. F573 was administered once a day for seven days without accumulation in the human body.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Phase 2 PRC Clinical Trial of F573 for the treatment of ALF/ACLF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We initiated our Phase 2 clinical trial in March 2023. The main objective of this trial is to assess the efficacy and safety of F573 for injection in the treatment of liver injury/failure. The Phase 2 trial is divided into three stages:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">First Stage</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">: 16 patients with 1/2 grade drug-induced liver injury (&#8220;DILI&#8221;) or other liver injury patients and 9 patients with CHB were enrolled. First, DILI or other liver injury patients were treated with the trial drug at either 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or placebo in a 1:1:1:1 ratio. CHB patients received the trial drug. The first stage was completed in December 2024.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Second Stage</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">: 24 patients with liver injury (DILI patients and patients with intrahepatic cholestatic liver injury) are expected to be enrolled. Qualified subjects will be screened and randomly assigned in a 3:1 ratio to receive the investigational drug or placebo, once daily for 14 consecutive days. The dosage is expected to be 0.5 mg/kg and 2.0 mg/kg based on a comprehensive consideration of the </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">efficacy and safety test results from the first stage. The 0.5 mg/kg dose group trial will be conducted first, enrolling 12 subjects. After the 0.5 mg/kg dose group trial is completed, the 2.0 mg/kg dose group trial will be conducted, also enrolling 12 subjects.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Third Stage</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">: The third stage is expected to employ a randomized, double-blind, placebo-controlled design. The trial is divided into a screening period (14 days), a treatment period (28 days), and a follow-up period (90 days). Qualified subjects will be randomly assigned in a 3:1 ratio to receive the investigational drug or placebo, once daily for 28 consecutive days. The dosage will be determined based on a comprehensive consideration of the efficacy and safety test results from the first and second stages. Subjects will also receive concomitant administration of the drug acetylcysteine injection. After discontinuation of treatment, subjects will undergo a 90-day safety follow-up.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Product Candidate for PAH: F230</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F230 is a selective endothelin-receptor A antagonist to treat PAH. PAH is a rare disease and a progressive, life-threatening disorder characterized by increased pressure in the pulmonary arteries that carry blood from the heart to the lungs. A common pathological hallmark of PAH is vascular remodeling, including increased stiffening and thickening of pulmonary arteries. This restricts blood flow through the lungs, causing pulmonary hypertension and making the heart work harder to pump blood to the lungs. The exact cause of PAH is unknown and there is no known cure for PAH. PAH is a serious disease that has a short life expectancy if left untreated. The prognosis for the treatment of PAH is poor, with a high mortality rate and survival of less than three years in the absence of standard therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of PAH in the PRC increased from 50,600 patients in 2018 to 60,600 patients in 2023 and it is expected to increase to 68,600 patients by 2028 and 70,600 patients by 2031. The market size of PAH in the PRC increased from $0.31 billion in 2018 to $0.37 billion in 2023 and it is expected to increase to $0.44 billion by 2028 and $0.48 billion by 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the study of hypoxia-induced PAH in rats, F230 resulted in significant decreases of, or exhibited a decrease trend based on different dose groups in, mean pulmonary arterial pressure, right ventricular systolic pressure, right ventricular/left ventricular plus septum and pulmonary artery wall thickness. Even at minimum effective dosage, the differences of those indexes between treatment group and PAH group are statistically significant. In March 2024, we submitted an IND application for F230 to the PRC Center for NMPA. In May 2024, we obtained the approval from the NMPA for the IND to launch a new clinical trial in the PRC of F230. We expect to launch the Phase 1 clinical trial in the PRC in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Product Candidate for COPD: F528</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F528 is an anti-inflammatory small molecule drug candidate developed for the treatment of COPD. F528 is a novel anti-inflammation agent that targets inhibition of multiple inflammatory cytokines and could modify the progression of COPD with extreme low toxicity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. COPD is a chronic inflammatory lung disease which causes obstructed air flow from the lungs. It consists of three separate illnesses: emphysema, chronic bronchitis and chronic obstructive asthma. COPD causes the destruction of barriers between alveoli inside the lungs, causing airways to get swollen and clogged with mucus. In most cases, COPD develops very slowly and symptoms may emerge for years before being diagnosed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Frost &amp; Sullivan, prevalence of COPD in the PRC increased from 103.5 million patients in 2018 to 107.3 million patients in 2023 and is expected to increase to 113.1 million patients in 2028 and 116.4 million patients in 2031. The COPD market in the PRC was $0.88 billion in 2018 to $1.06 billion in 2023. The market is predicted to expand to $1.29 billion by 2028 and $1.46 billion by 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The drug treatment of COPD is mainly used to relieve symptoms, reduce the frequency and severity of disease deterioration and improve cardio endurance and health. Currently, there is no conclusive clinical trial evidence</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">showing that existing drugs can slow down the long-term decline in lung function. For late-stage COPD patients, currently-available treatment options achieve limited therapeutic effects. As clinical research results from external parties indicated, 2% of patients were reported to gain improvement in exercise capability after 24 months of standard medical treatment and none were reported to gain improved health-related quality of life. Thus, there are significant unmet clinical needs for COPD patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We believe F528 could become first-line therapy for COPD. In a preclinical study of the effect of F528 in rats with COPD induced by smoke exposure and LPS tracheal injection, the lung index, the alveolar space and the lung injury score were significantly decreased after the treatment of F528. Preclinical validation of F528 is expected to be completed in 2025, including non-Good Laboratory Practices ("GLP") toxicology studies, GLP toxicology studies, and large animal safety studies. IND submission is expected in 2026.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Commercialization Plans in TP with CLD and ITP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Commercial-Stage Product Candidate: Avatrombopag</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals acquired avatrombopag under a transfer agreement with Nanjing Healthnice Pharmaceutical Technology, Co., Ltd. (&#8220;Nanjing Healthnice&#8221;) in June 2021. In June 2024, Gyre Pharmaceuticals received approval from the NMPA for avatrombopag maleate tablets for the treatment of TP associated with CLD in adult patients undergoing elective diagnostics procedures or therapy. TP is the most common hematologic complication in patients with CLD and can be life threatening in severe cases. Avatrombopag is an oral thrombopoietin receptor agonist. In January 2025, Gyre Pharmaceuticals received approval from the NMPA for avatrombopag maleate tablets to expand the treatment indications of avatrombopag maleate tablets to include ITP. Gyre Pharmaceuticals plans to start commercializing the avatrombopag product in the PRC in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Product Candidate for DM-ILD and SSc-ILD: Pirfenidone</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We were previously conducting two Phase 3 clinical trials of pirfenidone for the treatment of DM-ILD and SSc-ILD. We are prioritizing the development of our product candidates for other targeted indications and, as a result, have paused our two Phase 3 trials in the PRC for the treatment of DM-ILD and SSc-ILD. We may decide to continue such Phase 3 trials in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our success depends in part upon our ability to protect our core technology and intellectual property. Our intellectual property is critical to our business and we strive to protect it through a variety of approaches, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, new targets, indications and applications and other inventions important to our business. For our product candidates, we generally pursue patent protection covering compositions of matter, methods of manufacture and methods of use. As we further develop our product candidates, we plan to identify additional novel candidates for patent protection that may potentially enhance commercial success, including pursuit of claims directed to new therapeutic indications. We enter into collaboration agreements and other relationships with pharmaceutical companies and other industry participants to leverage our intellectual property or gain access to the intellectual property of others.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Patents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of the date of this Annual Report, Gyre owns 26 granted patents globally, 20 pending patent applications in the PRC and nine Patent Cooperation Treaty (&#8220;PCT&#8221;) patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of the date of this Annual Report, we are the owner of all the patents and patent applications that are material to our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The term of individual patents depends on the legal term for patents in the jurisdictions in which they are granted. In most jurisdictions, the patent term for inventions is 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable jurisdiction. The actual protection afforded by a patent varies on a claim-by-claim and country-by-country basis and depends upon many factors, including the type of patent, the scope of its coverage, the availability of any patent term extensions or adjustments, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Although ETUARY&#8217;s (Pirfenidone) substance patent expired in August 1993, Gyre currently holds one process patent that expires in 2038. In addition, Gyre holds a family of patents for methods using Pirfenidone compositions to treat certain cytotoxic- or radiation-induced injuries, such as pneumonitis, consisting of granted patents in Canada, Europe, Japan, the PRC, and the U.S.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our F351 patent portfolio currently consists of ten patent families, including patents and/or patent applications in various countries and under the PCT. The first patent family is for a method of preparing F351 and consists of one granted patent in the PRC that expires in 2028, two granted pants in Japan, both of which expire in 2037, and 2 PCT patent applications and 6 pending patent applications in the PRC. The second patent family is for a method of preparing a crystal form of F351 and consists of one granted patent in the PRC that expires in 2041. The third patent family relates to methods for using F351 to treat and/or prevent chronic hepatitis B with hepatic fibrosis and consists of one PCT patent application and one pending patent application in each of Australia, Canada, Europe, the PRC, India, Japan and Mexico, and the U.S. The fourth patent family pertains to the use of pharmaceutical compositions or drug kits in the preparation of drugs to treat or relieve pulmonary fibrosis or to improve the symptoms of pulmonary fibrosis and consists of one pending patent application in the PRC and one PCT patent application. The fifth patent family is for F351 compositions and methods of using F351 for treating liver fibrosis, liver cirrhosis, advanced hepatitis B and NASH and consists of one PCT patent application and one pending patent application in each of the PRC, Australia, Canada, Europe, Israel, Japan, Mexico, New Zealand, Singapore, South Korea and the U.S. The sixth patent family pertains to the use of pharmaceutical compositions or drug kits in the preparation of drugs to treat or prevent chronic renal failure and consists of one pending patent application in the PRC. The seventh patent family pertains to the use of pharmaceutical compositions or drug kits in the preparation of drugs to treat or prevent chronic kidney disease and consists of one pending patent application in the PRC. The eighth patent family pertains to the use of pharmaceutical compositions or drug kits in the preparation of drugs to treat or prevent radiation induced pulmonary fibrosis and consists of one pending patent application in the PRC. The ninth patent family pertains to the use of pharmaceutical compositions or drug kits in the preparation of drugs to treat or prevent fibrotic diseases and consists of one pending patent application in the PRC. The tenth patent family pertains to the use of pharmaceutical compositions or drug kits in the preparation of drugs to treat fatty liver disease associated with metabolic dysfunction and consists of one pending patent application in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For F573, Gyre owns two granted patents in the PRC, which both expire in 2031, one patent application in the PRC, one PCT patent application, and one patent application in each of Europe, Japan, South Korea, the PRC and the U.S. For F528, Gyre owns one PCT patent application, one patent in each of the PRC and Japan, and pending patent applications in Europe and the U.S.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We expect to continue to file patent applications to cover methods of treating additional indications, as well as new forms, formulations, and methods of manufacturing F351 and other drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Gyre Patent Family Tree</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img99844967_5.jpg" alt="img99844967_5.jpg" style="width:624px;height:351px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Trade Secrets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may rely, in some circumstances, on trade secret and/or confidential information to protect aspects of our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with consultants, scientific advisers and contractors. We have entered into confidentiality agreements and non-competition agreements with our senior management and key members of our R&amp;D team and other employees who have access to trade secrets or confidential information about our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. For details of risks related thereto, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Trademarks and Domain Names</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We conduct our business under the brand name of &#8220;Continent&#8221; or &#8220;</span><img src="img99844967_6.jpg" alt="img99844967_6.jpg" style="width:31px;height:13px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;. As of December 31, 2024, we own four registered artwork copyrights, 24 registered software copyrights and 55 registered trademarks in the PRC. We also own seven registered trademarks in Hong Kong, one international trademark of &#8220;ETUARY&#8221; and the trademark application of &#8220;ETUARY&#8221; in seven countries and regions including the United States, EU and Japan. As of the same date, we also hold 15 active domain names.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our Business Operations in the United States: Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">In this section, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;our company&#8221; refer to Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our U.S. operations are headquartered in San Diego, CA, and primarily focus on the development and commercialization of F351 for the treatment MASH-associated liver fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Employees in the United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We consider our ability to recruit, retain and motivate our employees to be critical to our success. We are an equal opportunity employer and are fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. We strive to administer all human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination in accordance with the principal of equal employment opportunity, meaning on the basis of individual skills, knowledge, abilities, job performance and other legitimate criteria and without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had five full-time employees in the United States. We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages. We consider our relations with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We aim to provide our employees with competitive salary and benefits that enable them to achieve a good quality of life and plan for the future. Our benefits are based on local norms and market preferences, but include all salary and social benefits required by local law (including paid time off for vacation and sick leave) and many additional benefits that go beyond legal requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Business Organization</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We commenced operations in 2002 and are a Delaware corporation. On August 20, 2015, we merged with Targacept, Inc. and on October 30, 2023, we completed the Contributions and became Gyre Therapeutics, Inc. Our corporate headquarters are in San Diego, California. We conduct general and administrative functions primarily from our San Diego, California location.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, are available for free at www.gyretx.com as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. They are also available for free on the SEC&#8217;s website at www.sec.gov. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combination</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">On December 26, 2022, Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;) entered into an Asset Purchase Agreement with GNI Group Ltd. (&#8220;GNI Japan&#8221;) and GNI Hong Kong Limited (&#8220;GNI Hong Kong&#8221;) (collectively, the &#8220;Sellers&#8221;) to acquire all assets and intellectual property rights primarily related to the proprietary F351 compound, excluding those in the PRC. Under the agreement, Catalyst paid $35 million in consideration, consisting of 6,266,521 shares of Catalyst common stock and 12,340 shares of Series X Convertible Preferred Stock. Concurrently, Catalyst entered into a Business Combination Agreement with GNI USA, Inc. (&#8220;GNI USA&#8221;), GNI Japan, GNI Hong Kong, Shanghai Genomics, Inc., and certain minority shareholders to acquire an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (now Gyre Pharmaceuticals Co., Ltd.) through equity contributions by GNI USA and the minority shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">On October 27, 2023, Catalyst entered into a Securities Purchase Agreement with GNI USA for a private placement of 8,110,000 units, comprising Convertible Preferred Stock and warrants, for an aggregate purchase price of approximately $5 million. Effective October 30, 2023, Catalyst increased its authorized shares of common stock, effected a 1-for-15 reverse stock split, and changed its name to Gyre Therapeutics, Inc. On the same date, the business combination was completed, with GNI USA and the minority shareholders contributing their respective equity interests in exchange for shares of Gyre common stock. Following these transactions, GNI USA owned approximately 85.3% of Gyre&#8217;s outstanding shares, the</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">minority shareholders owned approximately 12.3%, and pre-combination Catalyst stockholders held approximately 2.5%, assuming full conversion of the Convertible Preferred Stock. As a result, Gyre became primarily engaged in the research, development, manufacturing, and commercialization of innovative therapies for organ fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government Regulation in the United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government authorities in the United States, at the federal, state and local levels, and in other countries and jurisdictions, including the EU, extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs. Our current product candidates are expected to be regulated as pharmaceutical drugs. The processes for obtaining regulatory approval in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of our products and our R&amp;D activities and require the expenditure of substantial time, human capital and financial resources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Review and Approval of Drugs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the United States, the FDA and other government entities regulate drugs under the Federal Food, Drug, and Cosmetic Act ("FDCA") and the regulations promulgated thereunder, as well as other federal and state statutes and regulations. Failure to comply with applicable legal and regulatory requirements in the United States at any time during the product development process, approval process, or after approval, may subject us to a variety of administrative or judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, withdrawal of approvals, delay or suspension of clinical trials, issuance of warning letters and other types of regulatory letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil monetary penalties, refusals of or debarment from government contracts, exclusion from the federal healthcare programs, restitution, disgorgement of profits, civil or criminal investigations by the FDA, U.S. Department of Justice, State Attorneys General, and/or other agencies, False Claims Act suits and/or other litigation, and/or criminal prosecutions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">An applicant seeking approval to market and distribute a new drug in the United States must typically undertake the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">completion of pre-clinical laboratory tests, animal studies, chemical synthesis and manufacturing and formulation studies in compliance with the FDA&#8217;s GLP, regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND for human clinical testing, which must become effective without FDA objection before human clinical trials may begin;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s good clinical practice (&#8220;GCP&#8221;), regulations, to establish the safety and effectiveness of the proposed drug product for each indication for which approval is sought;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">preparation and submission to the FDA of an NDA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">review of the NDA by an FDA advisory committee, where applicable;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active pharmaceutical ingredient or ingredients thereof, are produced to assess compliance with cGMP, regulations and to assure that the facilities, methods, and controls are adequate to ensure the product&#8217;s identity, strength, quality, and purity;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">payment of user fees, as applicable, and securing FDA approval of the NDA; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">compliance with any post-approval requirements, such as any risk evaluation and mitigation strategy (&#8220;REMS&#8221;), or post-approval studies required by the FDA.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies and an IND</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To file an IND, an organization must produce batches of the actual material of drug substance and drug product to be used in the clinical trial. The batches of drug substance and drug product need to be characterized analytically before release and placed on stability. At least one month of stability data must be included in the IND upon submission.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preclinical studies can include </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and animal studies to assess the potential for adverse events and, in some cases, to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Other studies include laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or API and the physical properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND to justify that the proposed clinical study may safely proceed. Some preclinical testing, such as longer-term toxicity testing, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Following commencement of a clinical trial under an IND, the FDA may place a clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Human Clinical Studies in Support of an NDA</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites in late-stage clinical trials to assure compliance with GCP and the integrity of the clinical data submitted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. In the United States, when a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived, and some of the requirements may be waived upon the FDA&#8217;s decision. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with applicable FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Submission of an NDA to the FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under certain circumstances, the FDA will waive the application fee for the first human drug application that a small business, defined as a company with less than 500 employees, including employees of affiliates, submits for review. An affiliate is defined as a business entity that has a relationship with a second business entity if one business entity controls, or has the power to control, the other business entity, or a third-party controls, or has the power to control, both entities. In addition, an application to market a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a disease or condition that affects fewer than 200,000 individuals in the United States, or for which there is no reasonable expectation that U.S. sales will be sufficient to recoup the development and production costs.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The FDA also may require submission of a REMS plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA&#8217;s Decision on an NDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information for the FDA to reconsider the application. If those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. After approval, the FDA may seek to prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track Designation, Accelerated Approval, Priority Review, Orphan Drug Designation and Breakthrough Therapy Programs</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There are several FDA programs intended to help facilitate the development of new drugs that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and data demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug may request the FDA to designate the drug as a Fast Track product at any time during the clinical development of the product. Under a Fast Track designation, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Priority Review</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A product is eligible for priority review if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review to facilitate the review.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated Approval</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A product that is being studied for safety and effectiveness in treating serious or life-threatening illnesses and provides meaningful advantage over existing treatments may receive accelerated approval, which means that it may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint that can be measured earlier than, and is reasonably likely to predict an effect on, irreversible morbidity or mortality. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. The FDA also has increased authority for expedited procedures to withdraw approval of a product or indication approved under accelerated approval if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, for seven years. These circumstances are an inability to supply the drug in sufficient quantities or a situation in which a new formulation of the drug has shown superior safety or efficacy or a major contribution to patient care. This exclusivity, however, could also block the approval of its product for seven years if a competitor obtains earlier approval of the same drug for the same indication.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The FDA&#8217;s interpretation of the scope of orphan drug exclusivity may change. The FDA&#8217;s longstanding interpretation of the Orphan Drug Act is that exclusivity is specific to the orphan indication for which the drug was actually approved. As a result, the scope of exclusivity has been narrow and protected only against competition from the same &#8220;use or indication&#8221; rather than the broader &#8220;disease or condition.&#8221; In the September 2021 case </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst Pharmaceuticals, Inc. v. FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, a federal circuit court set aside the FDA&#8217;s narrow interpretation and ruled that orphan drug exclusivity covers the full scope of the orphan-designated disease or condition regardless of whether the drug obtains approval only for a narrower use. The decision concerned amifampridine, a drug used to treat Lambert-Eaton myasthenic syndrome (LEMS). Depending on how the FDA applies the decision beyond this case, it may limit the drugs that can receive exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Breakthrough Therapy Designation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A product may also be eligible for receipt of a Breakthrough Therapy designation. The Breakthrough Therapy designation is intended to expedite the FDA&#8217;s review of a potential new drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease where &#8220;preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.&#8221; The designation of a drug as a Breakthrough Therapy provides the same benefits as are available under the Fast Track program, as well as intensive FDA guidance on the product&#8217;s development program. Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for approval, but they may expedite the development or approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant criminal and civil liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Abbreviated New Drug Applications for Generic Drugs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the &#8220;Hatch-Waxman Amendments&#8221;) amending the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (&#8220;ANDA&#8221;) to the agency. Upon approval of an ANDA, the FDA indicates that the generic product is &#8220;therapeutically equivalent&#8221; to the drug product previously approved under an NDA, known as the reference listed drug (&#8220;RLD&#8221;), and it assigns a therapeutic equivalence rating to the approved generic drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider the therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of a therapeutic equivalence rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of nonpatent exclusivity for the RLD has expired. The FDCA provides a period of five years of data exclusivity for NDAs containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification (discussed further below), in which case the applicant may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Hatch-Waxman Patent Certification and the 30 Month Stay</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">505(b)(2) New Drug Applications</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA pursuant to an NDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant, and for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous findings of safety and effectiveness is scientifically and legally appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional bridging studies or measurements, including clinical trials, to support the change from the previously approved reference drug. The FDA may then approve the new drug candidate for all, or some, of the label indications for which the reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To the extent that a Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Extension</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the U.S., after an NDA is approved, owners of relevant drug patents may apply for up to a five-year patent extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory process. The allowable patent term extension is typically calculated as one-half the time between, the latter of the effective date of an IND and issue date of the patent for which extension is sought, and the submission date of an NDA, plus the time between NDA submission date and the NDA approval date up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue licensure with due diligence. The total patent term after the extension may not exceed 14 years from the date of product licensure. Only one patent applicable to a licensed biological product is eligible for extension and only those claims covering the product, a method for using it, or a method for manufacturing it may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">extended and the application for the extension must be submitted prior to the expiration of the patent in question. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Some, but not all, foreign jurisdictions possess patent term extension or other additional patent exclusivity mechanisms that may be more or less stringent and comprehensive than those of the U.S.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure of Clinical Trial Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sponsors of clinical trials of FDA-regulated products, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Other U.S. Healthcare Laws and Compliance Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, the Office of Inspector General), the U.S. Department of Justice (&#8220;DOJ&#8221;) and individual U.S. Attorney offices within the DOJ and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy provisions of the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) and similar state laws, each as amended.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. There are statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Our practices may not in all cases meet all the criteria for protection under a statutory exception or regulatory safe harbor.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act (&#8220;ACA&#8221;) to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved and thus non-reimbursable, uses. HIPAA created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for healthcare benefits, items or services.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additionally, the federal Physician Payments Sunshine Act within the ACA and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.  To distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing and to prohibit certain other sales and marketing practices. All our activities are potentially subject to federal and state consumer protection and unfair competition laws.  If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Data Privacy and Security</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, state health information privacy laws, such as California&#8217;s Confidentiality of Medical Information Act and Washington&#8217;s My Health My Data Act, govern the privacy and security of health-related information, specifically, may apply even when HIPAA does not and impose additional requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Even when HIPAA and state health information privacy laws do not apply, according to the FTC and state Attorneys General, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act and state consumer protection laws.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There are also a number of U.S. state privacy laws, such as the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (&#8220;CCPA&#8221;), that govern the privacy and security of personal information in certain circumstances, some of which are more stringent than HIPAA and in various ways. Numerous other states have passed similar laws, but many differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, and affords rights to California residents in relation to their personal information. Health information falls under the CCPA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked, directly or indirectly, with a particular consumer or household&#8212;unless it is subject to HIPAA&#8212;and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Some of these laws and regulations impose different, and in certain instances, more stringent requirements than HIPAA. Failing to comply with these laws and regulations can result in significant civil and/or criminal penalties, as well as exposure to private litigation, all of which can result in financial and reputational risks. The numerous other comprehensive privacy laws that have passed or are being considered in other states, as well as at the federal and local levels, also exempt some data processed in the context of clinical trials; but others exempt covered entities and business associates subject to HIPAA altogether, further complicating compliance efforts, and increasing legal risk and compliance costs for us and the third parties upon whom we rely.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage, Pricing and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, privately managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">specific products on an approved list, also known as a formulary, which might not include all the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. This is also true of Medicare reimbursement, where different vendors process payments, so that coverage by one vendor does not assure that all other vendors will provide coverage. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, the United States federal government position on matters related to drug pricing is evolving and uncertain and any changes could have a material impact on drug pricing generally in the United States, including for our product candidates if approved. Recently, the U.S. government passed the Inflation Reduction Act, which authorizes the U.S. Department of Health and Human service to negotiate prices of certain drugs with participating manufacturers in federal healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The National Institute for Health and Care Excellence (NICE) in the United Kingdom also requires consideration of cost-benefit analysis. The downward pressure on healthcare costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The Foreign Corrupt Practices Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries and to devise and maintain an adequate system of internal accounting controls for international operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biological, chemical and radioactive substances used in and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our Operations in the PRC: Gyre Pharmaceuticals</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">In this section, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;our company&#8221; refer to Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (&#8220;Gyre Pharmaceuticals&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals was founded in 2002 and is an innovative drug development enterprise in the PRC committed to the treatment of organ fibrosis diseases, integrated R&amp;D, production and commercialization. Gyre Pharmaceuticals is an indirect, majority-owned subsidiary of Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of our PRC Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. We initially focused on the treatment of IPF and have gradually broadened our therapeutic field and R&amp;D efforts to other areas of organ fibrosis. Our flagship product, ETUARY, was approved in the PRC in 2011 and is among the first three approved drugs for IPF worldwide.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As the PRC&#8217;s first approved treatment for IPF, ETUARY has been included in the NRDL of the PRC since 2017. Filling a vacuum in the PRC as the first approved IPF treatment, ETUARY has developed rapidly and maintained a dominant market share in the PRC. The total estimated market size for IPF treatments in the PRC was $156.8 million in 2023 and is expected to grow to $698.6 million by 2031, according to Frost &amp; Sullivan. Moreover, as different organ fibrosis diseases share a similar pathogenic mechanism and fibrosis process, we are seeking to expand the use of ETUARY to include other pulmonary fibrosis diseases, such as PD, as well as diseases causing renal fibrosis, such as DKD. The success of ETUARY in the IPF drug market lays the foundation for our R&amp;D and registration strategy to further expand the use of such drugs to indications with large patient populations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are one of a limited number of biopharmaceutical companies in the PRC that has grown from a development-stage company to achieving sustained profitability. This growth was primarily attributable to the increased market demand for ETUARY, which is the first IPF drug marketed in the PRC. We face limited competition in the IPF drug market and we direct our marketing resources to encourage physician adoption of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Through in-house R&amp;D efforts and collaborative arrangements with GNI Japan, we have developed, in addition to ETUARY, a pipeline of pharmaceutical product candidates at various phases of clinical development, including F351, F528, F230 and F573.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on our years of research into organ fibrosis, we have also expanded our R&amp;D to include potential treatments for COPD, PAH and ALF/ACLF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">While advancing the R&amp;D of our pipeline products, we are one of only a few biopharmaceutical companies focusing on organ fibrosis drugs in the PRC with manufacturing and commercialization capabilities and an established track record. For further details about our two manufacturing centers, manufacturing capabilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and processes, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Properties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals&#8217; Properties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; and &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Production and Quality Control&#8212;In-House Manufacturing Facilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; For further details about our professional sales team and a comprehensive sales network, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Sales, Marketing and Distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Employees in the PRC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 574 total employees, including 165 employees in Beijing, 41 employees in Cangzhou and 368 employees in other regions, which were primarily our sales and marketing employees located across the nation. We recruit our employees based on a number of factors, including work experience, educational background and the requirements of a relevant vacancy. We provide internal and external training for our management staff and other employees in various areas, such as product knowledge, project development and team building. We provide our employees with regular feedback and assess our employees based on their performance to determine their salary, promotion and career development.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In compliance with the relevant PRC labor laws, we enter into individual employment contracts with our employees covering matters such as terms, wages, bonuses, employee benefits, workplace safety and grounds for termination. The remuneration package of our employees includes salary and bonus, which are generally based on their qualifications, industry experience, position and performance. We consider the remuneration package of our employees to be competitive among our domestic competitors. The social insurance and housing provident funds for our employees have been paid in full during the years ended December 31, 2024 and 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are also subject to safety laws and regulations of the PRC. We have implemented various internal occupational health and safety procedures to maintain a safe work environment, including adopting protective measures at our production centers, inspecting our equipment and facilities regularly to identify and address safety hazards and providing regular training to our employees on safety awareness.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we have formed a labor union to represent our employees. We believe that we have maintained good working relationships with our employees. During the year ended December 31, 2024, we were not subject to any material claims, lawsuits, penalties or administrative actions relating to non-compliance with occupational health and safety laws or regulations and had not experienced any strikes, labor disputes or industrial actions which have had a material effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Occupational, Health, Safety and Environmental Matters</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are subject to various health, safety, social and environmental laws and regulations and our operations are regularly inspected by local government authorities. We are committed to social responsibility and consider environmental, social and governance essential to our continuous development and we believe we have adequate policies to promote compliance with applicable health, safety, social and environmental protection regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the oversight of the senior management, we actively identify and monitor the actual and potential impact of environmental, social and climate-related risks on our business, strategy and financial performance and incorporate considerations for these issues into our business, strategic and financial planning with a particular focus on areas such as employee responsibility, environment responsibility and public responsibility. Corporate social responsibility is viewed as part of our core growth philosophy and pivotal to our ability to create sustainable value for our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, we monitor and enforce the compliance of our operations with environment, health and safety laws and regulations. This responsibility is executed through training, formulation and implementation of strategies, policies, standards and metrics, communication of environmental, health and safety policies and procedures through a team of coordinators, environmental, health and safety audits and incident response</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">planning and implementation. With the oversight of our management, our quality control team assesses the likelihood of such risks occurring and the estimated magnitude of any potential impact.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Permits and Other Approvals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we have received all material permissions and approvals required for our business operations. As of December 31, 2024, our wholly-owned subsidiary (Beijing Continent Biomedical Technology Co., Ltd., a company organized under the laws of the PRC) has obtained a business license but has no business operations. The following table sets forth the details of material licenses, permits and approvals:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.947%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:31.947%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:31.947%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:1pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">License/Permit</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:1pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Validity Period</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:1pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Authority</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Drug Production License</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 2024 &#8211; September 2025</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Information Service Qualification Certificate</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">January 2021 &#8211; January 2026</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Zhongguancun High- tech Enterprise</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 2022 &#8211; December 2024</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Administrative Commission of Zhongguancun Science Park</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">High-tech Enterprise Certificate</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">November 2022 &#8211; November 2025</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing Municipal Science &amp; Technology Commission,</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing Municipal Finance Bureau, Beijing Municipal Administration of Taxation</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Drug Registration Approval (pirfenidone)</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Valid until August 2028</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Drug Registration Approval (pirfenidone capsule)</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Valid until August 2028</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GMP Certificate for Pharmaceutical Products (pirfenidone APIs)</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Valid until August 2028</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign Trade Operators Registration Form</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">From February 2022</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing Municipal Commission of Commerce</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Research and Development</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We consistently devote resources to R&amp;D to achieve long-term growth. We believe the diversification and expansion of our product pipeline through both in-house R&amp;D and external collaboration are critical to our long-term competitiveness and success.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have a dedicated in-house R&amp;D team of 69 employees in the PRC as of December 31, 2024. Our R&amp;D department is comprised of the following departments: drug discovery, chemistry, manufacturing and control (&#8220;CMC&#8221;), clinical development, medical affairs and regulatory affairs. Our R&amp;D employees possess significant expertise in molecular biology, chemistry regulatory affairs and clinical development. Through cross-functional collaboration, our R&amp;D organization has enabled us to develop new drug products to address unmet clinical needs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We employ a clinical-demand-oriented and market-driven approach to our R&amp;D efforts. We first identify suitable drug development targets and carry out project evaluation and overall project design based on our development strategies and then explore and establish experimental methodology by coordinating across</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">different experimental platforms. We carefully select drug development programs by balancing the commercial potential of each drug candidate and its likelihood of successful development, its potential competition, and the ultimate market size.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Discovery</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our molecule screening and design capabilities increase the possibility of success of advancing molecules from preclinical studies to market, enable innovative therapeutic approaches and support rich pipeline assets built around key pathways and targets. We have built an efficient system to conduct target identification and validation, compound design and screen and lead compound optimization. During the discovery stage, drug candidates are tested for their absorption, distribution, metabolism, excretion and toxicological properties, and promising compounds are optimized through structure modification to achieve maximum efficacy and minimum toxicity. Our R&amp;D centers support a targeted drug discovery and screening platform, which can efficiently complete target identification and validation, compound design and lead optimization.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">During the drug discovery stage, we explore new R&amp;D opportunities, conduct feasibility research and provide evaluation for the opportunities. We also design and prepare new chemical compounds, conduct systematic research related to the manufacturing process and quality management of the new drugs and develop technology platforms to support, manage and supervise the related technologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Chemistry, Manufacturing and Controls</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CMC Group</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The CMC group is a critical link between discovery and clinical study. It is responsible for developing chemical and pharmaceutical processes, so that drug substances can be made with the desired physical and chemical properties and formulated to achieve maximum bio availability and stability. During the CMC stage, the synthesis of each API molecule is investigated thoroughly to ensure that the drug substance can reach pre-determined quality standards, the manufacturing processes are safe, robust, economical and environmentally friendly and the drug products have good stability and suitable storage conditions and shelf life.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Clinical Development Group</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our clinical development team oversees clinical trials for drug development, sets up the procedural standard of clinical affairs and handles clinical medicine matters. Our clinical development team also focuses on clinical development strategy, clinical trial protocol design, clinical trial operation coordination, pharmacovigilance and clinical trial quality control. Our clinical development team members specialize in management of all stages of our clinical trials, including clinical trial design, implementation, drug supply and the collection and analysis of trial data. We collaborate with top clinical experts in various areas as our principal investigators, leverage the operational capabilities of industry leading clinical research organizations and rely on well-known academic medical institutions and clinical trial centers in the PRC and abroad to promote the high quality and efficient implementation of our clinical trials in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Design and Implementation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our clinical development group manages all stages of clinical trials, including protocol design, operation and the collection and analysis of clinical data. Our rapid trial advancements are driven by (i) our strategic decision to initiate clinical phase trials with our outstanding preclinical results, (ii) rigorous trial design, (iii) long-term partnership with numerous hospitals and principal investigators from different regions and (iv) high-quality execution. Leveraging our extensive knowledge and experience in clinical trials, our clinical development experts identify unique therapeutic opportunities for our drug candidates based on the differentiating properties observed in clinical trials and improve clinical plans accordingly.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The organ fibrosis market is subject to rapid change. While we believe that our robust pipeline of innovative products and drug candidates, strong sales and marketing capability and experienced leadership team provide us with competitive advantages, we face potential competition from many different sources working to develop therapies targeting the same indications which our marketed drug or our drug candidates target. These include major pharmaceutical companies, specialty pharmaceutical and biotechnology companies of various sizes, academic institutions, government agencies and research institutions. Any drug candidates that we successfully develop and commercialize will compete both with existing drugs and with any new drugs that may become available in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our products primarily compete with products that are indicated for similar conditions on the basis of efficacy, price and general market acceptance by medical professionals and hospitals. The identities of our key competitors vary by product or drug candidate, and in certain cases, our competitors may have greater financial resources and expertise in R&amp;D, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We believe our continued success will primarily depend on our ability to develop innovative products and advanced technologies, apply technologies to all production lines, continuously develop an extensive product portfolio and pipeline, effectively commercialize and market our existing and future products, expand our distribution network and maintain customer relationships, attract and retain seasoned and talented technology development personnel, maintain high quality standards, maintain a highly efficient operational model and obtain and maintain regulatory approvals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Production and Quality Control</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">In-House Manufacturing Facilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our manufacturing facilities are situated in Beijing and Cangzhou, Hebei province, in the PRC. During the years ended December 31, 2023 and 2024, 100% of pirfenidone we sold was manufactured at our Beijing and Cangzhou facilities. Our manufacturing facilities are designed and operated in compliance with cGMP regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Quality Management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We believe that the product quality is fundamental to ensure the safety of patients and achieve our long-term development. Our quality management team monitors every stage of our operations in accordance with NMPA&#8217;s regulations. We implement quality management measures throughout our production process, including supplier examination, raw material inspection and testing and process control, and all products are thoroughly inspected and tested before release.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Procurement Quality Control</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have established internal procedures governing the selection for raw material suppliers and quality control to meet the requirements of relevant cGMP and pharmaceutical registration regulations. We select our raw material suppliers based on a variety of factors, including their economic status, capital, reputation, quality control management, production scale and technological strengths and evaluate them based on their qualification, feedback to our questionnaire and our on-site examination.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Logistics and Delivery Management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have entered into logistics service agreements with third parties. Pursuant to the arrangement, logistics service providers provide delivery services in a safe and timely manner pursuant to our requirements, while we are responsible for the quality of goods. Our logistics service providers are responsible for any loss caused by their negligence during their provision of the logistics service, including transfer, loading, unloading, transportation and delivery. Our logistics service providers also liaise and handle the insurance aspects, while we arrange the payment of insurance premiums together with the freight charges.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Inventory Management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our inventory principally consists of raw materials, work-in-progress, semi-finished goods (representing APIs) and finished products. We endeavor to maintain our inventory at a reasonable level that is sufficient to sustain our production without interruption. We enter into supply agreements with reference to our annual sales plan, manufacturing plan and procurement plan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Sales, Marketing and Distribution</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our In-House Sales and Marketing Team</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our in-house sales and marketing team had market coverage of 30 provinces, autonomous regions and municipalities in the PRC. Our sales and marketing team is primarily responsible for establishing and maintaining relationships with outlets in their covered regions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We believe the relatively high level of medical knowledge and skill of our sales and marketing team are important to the implementation of our academic marketing approach and maintenance of our reputation as a leading pharmaceuticals company. As of December 31, 2024, our in-house sales and marketing team included 368 employees, with an average of more than ten years of experience in pharmaceutical sales. Our more experienced staff also share their academic promotion networking experience on a regular basis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For more details regarding the qualifications of our employees, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Employees in the PRC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Academic Promotion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We emphasize academic promotion and patient service in our sales and marketing efforts. We strive to promote and strengthen our academic recognition and brand awareness among medical experts by educating doctors and other medical professionals on ETUARY, our other product candidates and their respective indications. We believe that our working relationships with medical experts help to raise our profile, enhance awareness of ETUARY in the medical community and among patients, increase the clinical capabilities of healthcare providers and provide us with valuable clinical data to improve ETUARY, all of which help us more effectively market and sell ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Distribution</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Distributors are our direct customers and they resell our products to the outlets, including hospitals, other medical institutions and pharmacies. Distributors are primarily responsible for the delivery of products and their payments, while our in-house sales and marketing team is responsible for conducting academic marketing activities and other promotional efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">From time to time, we have terminated or opted to not renew our collaboration relationships with certain distributors due to consolidation of distribution channels and unstable business management of the distributors. At the same time, we add new distributors primarily as a result of the continued expansion and optimization of our sales network. In general, our relationships with our major distributors have remained stable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Product Pricing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We take into account a number of factors in determining our prices, which primarily includes our R&amp;D, production and marketing costs and expenses, the perceived value of products, our market share and the competitive landscape. In addition, our pricing strategies are also affected by the regulations and policies imposed on the pharmaceutical industry, including medical insurance reimbursement standards and regulation of medical and pricing practices. Our commercialization team closely monitors new policies affecting the pricing of pharmaceutical products in the PRC and keeps updating our pricing strategies to navigate in the evolving regulatory environment and cope with local policies and competition in different provinces, with the goal of maintaining the price levels of our products and maximizing our overall sales in the PRC. For details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Operations in the PRC: Gyre Pharmaceuticals&#8212;Regulatory Requirements in the PRC&#8212;Other PRC Regulations in Relation to the Pharmaceutical Industry&#8212;Price Controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">National Reimbursement Drug List</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Participants in the national public medical insurance program are eligible for full or partial reimbursement of the purchase price of drugs included in the NRDL, which sets forth the payment standard for drugs under the basic medical insurance, work-related injury insurance and maternity insurance funds. The PRC government started to regularly adjust the NRDL since 2017 and ETUARY successfully entered into the NRDL within the same year. The latest version of the NRDL has been implemented from January 1, 2025. For further details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Operations in the PRC: Gyre Pharmaceuticals&#8212;Regulatory Requirements in the PRC&#8212;Regulations Relating to the Development, Manufacture and Sale of Pharmaceuticals&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">National Medical Insurance, its Reimbursement Standards and the NRDL</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">."</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Two-Invoice System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On December 26, 2016, the Healthcare Reform Committee of the State Council of the PRC, the former National Health and Family Planning Commission (the &#8220;NHFC&#8221;), the National Development and Reform Commission of the PRC and other relevant PRC government authorities jointly issued the Circular on Issuing the Implementing Opinions on Carrying out the Two-Invoice System for Drug Procurement among Public Medical Institutions (for trial implementation), which provides detailed rules regarding the implementation of the Two-Invoice System at a national level. For details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our Operations in the PRC: Gyre Pharmaceuticals&#8212;Regulatory Requirements in the PRC&#8212;Regulations Relating to the Development, Manufacture and Sale of Pharmaceuticals&#8212;Drug Distribution and Two-Invoice System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;. To comply with these relevant regulations, we primarily adopt the single-layer distribution model with distributors who directly on-sell our products to hospitals and public medical institutions. Certain distributors may engage sub-distributors for the sales to pharmacies, which were not subject to the regime of the Two-Invoice System.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Centralized Tender Process and Centralized Volume-Based Procurement System</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Prices of most pharmaceutical products in the PRC sold to public hospitals and public medical institutions are determined through a competitive centralized tender process at the provincial or municipal level with varying terms and procedures. In the centralized tender process, the winning pharmaceutical production companies will be allowed to sell their products to public hospitals and other public medical institutions at the bid prices. The centralized tender process can create pricing pressure among substitute products or products that are perceived by the market to be substitute products and resulted in significant change in how drugs are priced and procured in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Raw Materials and Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition to the suppliers in our &#8220;Qualified Supplier Directory,&#8221; each of our significant raw material suppliers have backup suppliers. In addition, each material has more than one manufacturer, and each manufacturer has multiple distributors. These distributors have reasonable inventory reserves. If we need to find a new</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">supplier, we conduct comparative research and, after confirming, the supplier is added to our Qualified Supplier Directory to ensure product supply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government Regulations in the PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government authorities in the PRC extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products. Our current product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the PRC, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of our products and our R&amp;D activities and require the expenditure of substantial time and financial resources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Regulatory Authorities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The primary drug regulatory bodies in the PRC include the Standing Committee of the National People&#8217;s Congress, the State Council and several ministries and agencies under the State Council&#8217;s authority including, among others, the NMPA, the predecessor of which is the China Food and Drug Administration (&#8220;CFDA&#8221;), the National Health Commission (the &#8220;NHC&#8221;), the predecessor of which is the NHFC, and the National Healthcare Security Administration (the &#8220;NHSA&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The NMPA is a regulatory authority responsible for registration and supervision of pharmaceutical products, cosmetics and medical equipment under the supervision of State Administration for Market Regulation (&#8220;SAMR&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The NHC is the chief healthcare regulator of the PRC, and is primarily responsible for drafting national healthcare policy, regulating public health, medical services and the health contingency system of the PRC, coordinating healthcare reform in the PRC and overseeing the operation of medical institutions and practicing of medical personnel in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The NHSA is responsible for drafting and implementing policies, plans and standards of medical insurance, maternity insurance and medical assistance, administering the PRC&#8217;s healthcare fund, formulating a uniform medical insurance catalogue and payment standards for drugs, regulating medical disposables and healthcare services, and formulating and administering the bidding and tendering policies for drugs and medical disposables.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to the Development, Manufacture and Sale of Pharmaceuticals</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Pharmaceutical Product Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the PRC, the NMPA monitors and supervises the administration of pharmaceutical products, as well as medical devices and equipment. The local provincial medical products administrative authorities in the PRC are responsible for the supervision and administration of drugs within their respective administrative regions. According to the PRC Drug Administration Law (the &#8220;Drug Administration Law&#8221;), drugs refer to articles which are used in the prevention, treatment and diagnosis of human diseases and intended for the regulation of the physiological functions of human beings, for which indications or functions, usage and dosage are specified, including traditional Chinese drugs, chemical drugs and biological products. The Drug Administration Law and the Implementing Regulations of the PRC Drug Administration Law have established the legal framework for the administration of pharmaceutical products and applies to entities and individuals engaged in the research, production, trade, application, supervision and administration of pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Clinical Research and Animal Testing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The State Administration for Market Regulation requires preclinical data to support registration applications for imported and domestic drugs. Pursuant to the Administrative Measures for Certification of Good Laboratory Practice for Non-clinical Laboratory Studies, the NMPA is responsible for the certification of non-clinical research institutions across the PRC and the provincial counterparts of the NMPA are in charge of the daily supervision of non-clinical research institutions in the PRC. The NMPA decides whether an institution is qualified for undertaking pharmaceutical non-clinical research by evaluating such institution&#8217;s organizational administration, research personnel, equipment and facilities and operation and management of non-clinical pharmaceutical projects</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> A GLP Certification will be issued by the NMPA if all the relevant requirements are satisfied, which will also be published on the NMPA&#8217;s website, and the validity of such certification is five years.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Administrative Regulations on Laboratory Animals, the Administrative Measures on Good Practice of Experimental Animals and the Administrative Measures on the Certificate for Laboratory Animals (for Trial Implementation) stipulate that permits shall be obtained for the use and breeding of laboratory animals and performing experimentation on animals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Approval and Reform for Clinical Trials of New Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the Administrative Measures for Drug Registration, the Drug Administration Law and the Implementing Regulations of the PRC Drug Administration Law, new drug applications are subject to clinical trials. The NMPA has taken a number of steps to increase efficiency for approving clinical trial applications and has also significantly increased monitoring and enforcement of the Good Clinical Practice for Drug Trials (the &#8220;PRC&#8217;s GCP&#8221;), to ensure data integrity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Administrative Measures for Drug Registration confirms a number of reform actions, including but not limited to: (i) the full implementation of marketing authorization holder system and implied approval of the commencement of clinical trials; (ii) implementing associated review of drugs, excipients and packaging materials; and (iii) introducing procedures for expedited registration of drugs. Upon completion of nonclinical research, clinical trials must be conducted for the application of a new drug registration and applicants must apply for approval of IND from the NMPA, or the CDE before conducting clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Opinions of the State Council on the Reform of Evaluation and Approval System for Drugs and Medical Devices, established a framework for reforming the evaluation and approval system for drugs and medical devices.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Announcement on Several Policies on the Evaluation and Approval of Drug Registration further simplifies the evaluation and approval process of drug registrations and provides that the application process of an IND is subject to a one-off umbrella approval procedure, rather than a by-stage approval procedure. According to the Announcement on Adjusting Evaluation and Approval Procedures for Clinical Trials for Drugs, within 60 days after the acceptance of the application of the IND and the payment of the associated fees, the applicant may conduct clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any negative or questioning opinion from the CDE.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Priority Review and Approval Procedures for Drug Marketing Authorizations (for Trial Implementation) further clarifies that a fast-track mechanism for the review and approval during the drug registration process can be available to innovative drugs that meet certain criteria.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regarding International Multi-Center Clinical Trials</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the International Multi-Center Clinical Trial Guidelines (for Trial Implementation), promulgated by the NMPA, international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicants plan to implement international multi-center clinical trials in the PRC, the applicants must comply with the Drug Administration Law, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Implementing Regulations of the PRC Drug Administration Law and the Administrative Measures for Drug Registration. Additionally, applicants must abide by the GCP, make reference to universal international principles such as the ICH-GCP and comply with the laws and regulations of the countries involved in the international multi-center clinical trials. Where the applicants plan to use the data derived from the international multi-center clinical trials for approval of a drug registration in the PRC, the application must involve at least two countries, including the PRC, and must satisfy the requirements for clinical trials set forth in the International Multi-Center Clinical Trial Guidelines (for Trial Implementation) and the Administrative Measures for Drug Registration and other related laws and regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Clinical Trial Registration</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Administrative Measures for Drug Registration, upon obtaining the approval of the relevant IND, the applicant must, prior to conducting the clinical trial of drugs, register on the registration and information announcement platform for clinical trials of drugs, information regarding the scheme of the clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Announcement on Drug Clinical Trial Information Platform, all clinical trials approved by the NMPA and conducted in the PRC must complete a clinical trial registration and publish trial information through the Drug Clinical Trial Information Platform. The applicant must complete the trial pre-registration within one month after obtaining the approval of the IND in order to obtain the trial&#8217;s unique registration number and complete registration of certain follow-up information before the first subject&#8217;s enrolment in the trial. If the registration is not completed within one year after the approval of the IND, the applicant must submit an explanation and if applicant&#8217;s first submission is not completed within three years, the approval of the IND will automatically expire.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Phases of Clinical Trials and Communication with the CDE</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Administrative Measures for Drug Registration, a clinical trial consists of Phase 1, 2, 3 and 4 trials and a bioequivalence trial. In addition to the characteristics of a drug and the research purpose, the research contents must also include clinical pharmacological research, exploratory clinical trial, confirmatory clinical trial and post-marketing research under the Administrative Measures for Drug Registration.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Administrative Measures for Communication on Drug Research, Development and Technical Reviews, during the R&amp;D periods and in the registration applications of the innovative new drugs (among others), the applicants may propose to conduct communication meetings with the CDE. The communication meetings can be classified into three types. Type I meetings are convened to address key safety issues in clinical trials of drugs and key technical issues in the R&amp;D of breakthrough therapeutic drugs. Type II meetings are held during the key R&amp;D periods of drugs, and mainly include meetings before the IND application, meetings upon the completion of phase 2 trials and before the commencement of phase 3 trials, meetings before submitting a marketing application for a new drug and meetings for risk evaluation and control. Type III meetings refer to meetings not classified as Type I or Type II.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Sampling and Collecting Human Genetic Resources</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Administrative Regulations on Human Genetic Resources of the PRC stipulates that, in order to obtain marketing authorization for relevant drugs and medical devices in the PRC, no approval is required in international clinical trial cooperation using the PRC&#8217;s human genetic resources at clinical institutions without export of human genetic resource materials. However, the participating entities must file the type, quantity and usage of the human genetic resource to be used with the NHC before clinical trials commence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On June 1, 2023, The Ministry of Science and Technology of the PRC promulgated the Implementation Rules for the Administrative Regulation on Human Genetic Resources (the &#8220;HGR Implementation Rules&#8221;), which came into effect on July 1, 2023. The HGR Implementation Rules have refined the Administrative Regulations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">on Human Genetic Resources, including, but not limited to, refining the definition of &#8220;human genetic resources information&#8221;, clarifying the identification standard of &#8220;foreign entities&#8221;, adjusting the scope of collection approval, and adjusting and improving the approval procedures for international cooperative scientific research and administrative supervision rules.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Registration of Drug Marketing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Administrative Measures for Drug Registration, an applicant must complete studies in pharmacy, pharmacology and toxicology, as well as all phases of clinical trials before submitting the application for registration for marketing authorization. The applicant must submit an application for drug marketing authorization and the relevant research materials in accordance with the submission requirements after determining quality standards, verifying commercial scale manufacturing process and preparing to undergo examination and inspection for drug registration. Once an application is submitted, the CDE will form a group of pharmacists, medical professionals and other technical specialists to analyze the drug&#8217;s safety, effectiveness and quality control. After the comprehensive review, if the drug is approved for marketing, a drug registration certificate shall be issued.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Authorization Holder System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Drug Administration Law, a drug marketing authorization holder system is implemented for drug management. The drug marketing authorization holder is an enterprise or a drug development institution that has obtained the drug registration certificate and is responsible for non-clinical research, clinical trials, production and operation, post-marketing research, adverse reaction monitoring, reporting and processing of drugs in accordance with the provisions of the Drug Administration Law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the Circular on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System (the &#8220;Circular on Drug Marketing Authorization Holder System&#8221;), the drug marketing authorization holder must establish a drug quality assurance system and be equipped with special personnel to take charge of quality management on drugs independently. Additionally, the drug marketing authorization holder must regularly review the quality management system of the drug manufacturer and the drug distributor and supervise its continuous quality assurance and control capabilities. A drug marketing authorization holder who manufactures drugs on its own shall obtain a drug production license in accordance with the Circular on Drug Marketing Authorization Holder System and entrust a qualified drug manufacturer. The drug regulatory authority of the State Council has formulated guidelines for the quality of pharmaceuticals entrusted manufacturing, to guide and supervise the drug marketing authorization holder and the entrusted manufacturer to fulfill their drug quality assurance obligations. The Announcement of the State Drug Administration on Strengthening the Supervision and Administration on Entrusted Manufacturing by the Drug Marketing Authorization Holder, which came into effect on October 17, 2023, reiterates the importance of supervision over entrusted manufacturing and stipulates more stringent and detailed requirements on aspects of license, quality and supervision of the entrusted manufacturing of the drug marketing authorization holder.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Drugs&#8217; Registration Classification</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the Administrative Measures for Drug Registration, drugs are classified into traditional Chinese drugs, chemical drugs, biological products and others. According to the Announcement on the Issuance of the Reform Plan for the Registration Classification of Chemical Drugs, the registration classification of the chemical drugs are adjusted to five categories. Category 1 drugs refer to innovative chemical drugs that have not been marketed anywhere in the world. Improved new chemical drugs that are not marketed anywhere in the world fall into Category 2 drugs. Generic chemical drugs that have equivalent quality and efficacy to the originator&#8217;s drugs that have been marketed abroad but not yet in the PRC are classified as Category 3 drugs. Generic drugs that have equivalent quality and efficacy to the originator&#8217;s drugs and have been marketed in the PRC fall into Category 4 drugs. Category 5 drugs are drugs which have already been marketed abroad, but are not yet approved in the PRC. Category 1 and 2 drugs must follow the registration application procedure for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">new drugs according to the Administrative Measures for Drug Registration; Category 3 and 4 drugs must follow the procedure for generic drugs; and Category 5 drugs must follow the application and regulation requirements for importing drugs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Chemical Drug Registration Classification and Application Data Requirements, innovative chemical drugs and improved new chemical drugs are categorized as Category 5.1 drugs, while generic chemical drugs, all of which shall have been already marketed abroad but not yet approved in the PRC are categorized as Category 5.2 drugs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Special Examination and Fast Track Approval for Drugs Targeting Rare Diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Circular on Publishing the Procedures of Developing the Rare Disease List, the following four criteria must be met at the same time for rare disease designation: (i) the disease has a low incidence or prevalence in PRC and abroad; (ii) the disease significantly impacts the patient and his or her family; (iii) there is a clear diagnosis method; and (iv) the disease can be treated or intervened in an economically feasible way, or it has been included in a national scientific research project if there is no effective treatment or intervention for such disease. With certain drugs targeting rare diseases being listed in National Rare Disease List, a company may be eligible for the priority review and approval of new drugs for these diseases from the NMPA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Administrative Provisions on Special Examination and Approval of the Registration of New Drugs, special examination and approval for new drugs registration applications applies when (i) the effective constituent of a drug extracted from plants, animals and minerals, as well as the preparations thereof, have never been marketed in the PRC and the material medicines and the preparations thereof are newly discovered; (ii) the chemical raw materials for medicines as well as the preparations thereof and the biological product have not been approved for marketing, either in the PRC or aboard; (iii) new drugs with distinctive clinical treatment advantages for diseases such as AIDS, malignant tumor or other rare diseases; or (iv) new drugs for diseases that currently lacking effective treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Opinions of the State Council on the Reform of Evaluation and Approval System of Drugs and Medical Devices, a special evaluation and approval system shall be adopted for innovative drugs to accelerate the evaluation and approval process for innovative drugs for prevention and treatment of AIDS, cancer, major infectious diseases, rare diseases and other diseases.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Announcement of the State Drug Administration and the NHC on Optimizing the Evaluation and Approval of Drug Registration, the CDE will prioritize the allocation of resources for review, inspection, examination and approval of registration applications that have been included in the scope of priority evaluation and approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Good Manufacturing Practices</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Drug Administration Law, drug manufacturers  shall comply with the GMP and establish a sound GMP management system, to ensure that the entire process of drug manufacturing is maintained to meet the statutory requirements and the GMP requirements enacted by the NMPA and in accordance with the Drug Administration Law. The legal representative of and principal person in charge of a drug manufacturer are fully responsible for the drug manufacturing activities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Good Manufacturing Practice for Drugs provided guidance for, among others, the quality management, organization and staffing, production premises and facilities, equipment, material and products, recognition and inspection, documentation maintenance, manufacture management, quality control and quality assurance, contractual manufacture and contractual inspection for the products, product delivery and recalls of a manufacturer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Manufacturing Permit</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the Administrative Measures for the Supervision of Drug Manufacturing promulgated by SAMR, persons engaging in drug manufacturing activities shall be subject to approval by the provincial counterparts of the NMPA where the persons engaging in pharmaceutical manufacturing activities are located, obtain a drug manufacturing permit pursuant to these measures, comply strictly with the pharmaceutical manufacturing quality control rules and ensure that the manufacturing process complies with statutory requirements at all times. The period of validity of a drug manufacturing permit is five years. In the event the permit holder needs to continue to manufacture drugs upon the expiration of the permit, the holder shall apply to the original issuing authorities for reissuance six months before the expiration date of the permit.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Business Permit and Good Supply Practice Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Drug Administration Law and the Implementing Regulations of the PRC Drug Administration Law, before engaging in the wholesale distribution and/or retailing of drugs, the relevant entity must obtain a drug business permit with an appropriate scope of distribution from the local counterpart of the NMPA and comply with the Good Supply Practice for Drugs. Under the Measures for the Supervision and Administration of Drug Quality in Trading and Usage, which became effective on January 1, 2024, a drug business permit is valid for five years. Each holder of the drug business permit must apply for an extension of its permit during the period from two months to six months prior to expiration. Otherwise, the holder shall cease its trading activities upon expiration until another drug business permit is granted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Recall</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Administrative Measures for Drug Recalls, the term &#8220;drug recalls&#8221; refers to the activities of a drug marketing authorization holder to recall drugs that have been marketed, but have quality problems or other potential safety hazards under the prescribed procedures and take corresponding measures to timely control risks and eliminate potential hazards. The term &#8220;quality problems or other potential safety hazards&#8221; refers to non-compliance of drugs with statutory requirements, or other unreasonable risks that may endanger human health and life safety caused by drugs due to R&amp;D, production, storage and transportation, labeling and other reasons.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Administrative Protection and Monitoring Periods for New Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Implementing Regulations of the PRC Drug Administration Law, based on the needs for protection of public health, the NMPA may set an observation period of not more than five years for new drugs produced by drug manufacturers; and no approval shall be given to any other manufacturers to produce or import the said drugs during the observation period.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Packaging of Pharmaceutical Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Drug Administration Law, the packaging of drugs must include a label and an instruction. According to the Administrative Measures for the Packaging of Drugs, the packaging of drugs must comply with national and professional standards. Drugs with packaging that does not meet the relevant standards cannot be sold or marketed in the PRC (except for drugs for the military). According to the PRC&#8217;s GCP, the packaging labels of the investigational drugs must indicate that the drug is for clinical trial use only, and must provide information related to the clinical trial and the drug used in the trial. The packaging shall also ensure the maintenance of blind states in blind trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Insert Sheet and Labels of Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to Administrative Provisions for Drug Insert Sheets and Labels, the insert sheets and labels of drugs should be reviewed and approved by the NMPA. A drug insert sheet should include the important scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and reasonable use of drugs. The inner label of a drug should bear such information as the drug&#8217;s name, indication</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">or function, strength, dose and usage, production date, batch number, expiry date and drug manufacturer, and the outer label of a drug should indicate such information as the drug&#8217;s name, ingredients, description, indication or function, strength, dose and usage, adverse reaction, contraindications, precautions, storage, production date, batch number, expiry date, approval number and drug manufacturer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising for Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Interim Administrative Measures for the Review of Advertisements for Drugs, Medical Devices, Dietary Supplements and Foods for Special Medical Purpose, the contents of a drug advertisement must be based on the drug instructions approved by the NMPA. Where a drug advertisement involves drug name, indications or major functions and pharmacological effects, the drug advertisement shall not go beyond the scope of instructions and must state contraindications and adverse reactions in a prominent position. Prescription drug advertisements must also state that &#8220;the advertisement is meant to be read only by medical and pharmaceutical professionals&#8221; in a prominent position and OTC drug advertisements must also add the non-prescription drug label (OTC) in a prominent place and state that &#8220;please purchase and use the drugs in accordance with the drug instructions or under the guidance of a pharmacist&#8221; in a prominent position.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Technology Transfer</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Drug technology transfer refers to the transfer of drug production technology by its owner to a drug manufacturer and the application for drug registration by the drug manufacturer pursuant to the Administrative Provisions for Registration of Drug Technology Transfer. The NMPA promulgated the Administrative Provisions for Registration of Drug Technology Transfer, to standardize the registration process of drug technology transfer, which includes application for, evaluation, review, approval and supervision of drug technology transfer registration. An application for drug technology transfer must be submitted to the provincial counterparts of the NMPA for review and approval. Eligible applications will receive a letter of approval and a drug approval number for the supplementary application.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Online Drug Information Services</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Administrative Measures for Internet-based Drug Information Service, the operational internet drug information service refers to the activities of providing information on drugs (including medical devices) through the internet. Where any website intends to provide internet drug information services, the website must file an application with the local provincial counterparts of NMPA and will be subject to the examination and approval thereof for obtaining the qualifications for providing internet drug information services. The validity term for a Qualification Certificate for Internet Drug Information Services is five years and may be renewed at least six months prior to its expiration date upon a re-examination by the relevant authority.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">National Medical Insurance, its Reimbursement Standards and the NRDL</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Decision of the State Council on Establishing the Urban Employees&#8217; Basic Medical Insurance System, Opinions on the Establishment of the New Rural Cooperative Medical Insurance System, the Guiding Opinions of the State Council about the Pilot Urban Resident Basic Medical Insurance and the Opinions of the State Council on Integrating the Basic Medical Insurance Systems for Urban and Rural Residents, medical insurance would be available to all employees and residents in both rural and urban areas in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Notice of Opinion on the Diagnosis and Treatment Management, Scope and Payment Standards of Medical Service Facilities Covered by the National Urban Employees Basic Medical Insurance Scheme, the basic medical insurance scheme would cover a portion of the costs of diagnostic and treatment devices, as well as diagnostic testing. The scope and rate of reimbursement are determined by provincial policies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The major aim of the Guidance on Further Deepening the Reform of the Payment Method of Basic Medical Insurance released by the General Office of the State Council is to develop a diverse reimbursement mechanism that includes diagnosis-related groups, per-capita caps and per-bed-day caps. These new reimbursement systems have been implemented across the country, replacing the previous reimbursement method, which is based on service category and product price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Interim Measures for the Scope of Basic Medical Insurance Coverage for Drugs for Urban Employees, which set the standard for the drugs to be included in the NRDL, a drug must be clinically necessary, safe, effective, reasonably priced, easy to use, available in sufficient quantity to be included in the NRDL, and must meet one of the following requirements: (i) be set forth in the pharmacopoeia of the PRC, (ii) satisfy the standards promulgated by the NMPA and (iii) be approved by the NMPA as imported drugs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Ministry of Labor and Social Security of the PRC, together with other government authorities, has the power to determine the drugs included in the NRDL. The Western medicine and Chinese patent medicine included in the National Medical Insurance Catalog are divided into two parts, Part A and Part B. Provincial governments are required to include all Part A and Part B medicines listed on the National Medical Insurance Catalog in their provincial Medical Insurance Catalog in the National Medical Insurance Catalog. Fees incurred for the use of Part A medicines are entitled to reimbursement in accordance with the regulations in respect of basic medical insurance. Fees incurred by the use of Part B are shared by the patient and basic medical insurance. The percentage of reimbursement by basic medical insurance for Part B medicines is stipulated by local authorities and in result may differs from region to region in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Price Controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Drug Administration Law requires that, for drugs subject to market-determined prices, the relevant marketing authorization holders, manufacturers and distributors of drugs and medical institutions shall determine the price applying the principles of fairness, reasonableness, good faith and consistency between quality and prices. Marketing authorization holders, manufacturers and distributors of drugs and medical institutions must comply with the price management rules for drugs of the relevant competent authorities to determine the prices of drugs and are prohibited from making exorbitant profits, conducting price monopoly and price fraud, among others.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to PRC Price Law, prices of most commodities and services are market-adjusted prices and prices of a very small number of commodities and services are government- guided prices or government-set prices. The prices of drugs are mainly determined by market competition. Instead of direct governmental price controls, the government primarily regulates prices by establishing a centralized procurement mechanism, revising medical insurance reimbursement standards and strengthening regulation of medical and pricing practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Opinions on Effectively Implementing Current Drug Price Administration issued by the NHSA seek to further improve the drug pricing formation mechanism and emphasizes the market-oriented drug pricing mechanism. Although narcotic drugs and category I psychotropic drugs are subject to government-guided prices, other drugs are subject to market-determined prices. Meanwhile, the national and provincial medical security departments may implement or delegate third parties to implement price cost investigation on drug suppliers and the results can be used as the basis for determining whether the drugs were sold at unfair prices.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Distribution and Two-Invoice System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Implementation Opinions on Promoting the &#8220;Two-Invoice System&#8221; for Drug Procurement by Public Medical Institutions (For Trial Implementation) (the &#8220;Two-Invoice System Notice&#8221;) establishes a system requiring the issuance of only two invoices during the distribution of drugs in other words, in the whole drug procurement process, there should be only one layer of pharmaceutical distributor between the drug manufacturer and the procuring public medical institution. The Two-Invoice System prohibits the sale of drugs through a chain of distributors which will, as a result, increase the price of drugs paid by the public medical institutions. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Two-Invoice System was firstly promoted in pilot areas, and has been implemented nationwide by 2018. Drug manufacturers and distributors must comply with the Two-Invoice System in order to engage in procurement processes with public hospitals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to Work Safety</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC Work Safety Law applies to all entities engaged in production and business activities in the PRC. Such entities shall, according to the PRC Work Safety Law, strengthen work safety management, establish and improve an all-staff work safety responsibility system and internal rules and regulations in relation to work safety, increase investment in funds, materials, technologies and staff for work safety, improve working conditions, strengthen the development of a standardized, information technology- enabled work safety system, establish a dual prevention mechanism for managing safety risks and addressing hidden dangers, and improve risk prevention and resolution mechanism to ensure work safety. Violations of the PRC Work Safety Law may result in administrative penalties such as fine, suspension of operation and revocation of license.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to Intellectual Property Rights</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Patents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the PRC Patent Law and the Implementation Regulations of the PRC Patent Law, an invention-creation shall mean an invention, utility model or design. Inventions and utility models for which patent rights are granted and an invention-creation must possess novelty, creativity and practicality. The Patent Office under the China National Intellectual Property Administration is responsible for receiving, examining and approving patent applications. The protection period is 20 years for an invention patent, 10 years for a utility model patent and 15 years for a design patent, commencing from such patent&#8217;s application date. Any patentee or interested party may file a lawsuit with a people&#8217;s court against any individual or entity that utilizes a patent or conducts any other activity that infringes a patent without the patent holder&#8217;s authorization, and may request regulatory authorities to order the infringer to stop the infringement act forthwith or impose a fine on the infringer. If the patent infringement is found to constitute a crime, the patent infringer shall be held criminally liable in accordance with applicable laws. According to the PRC Patent Law, for public health purposes, the China National Intellectual Property Administration may grant a compulsory license for manufacturing patented drugs and exporting them to countries or regions covered under relevant international treaties to which PRC has acceded. In addition, according to the PRC Patent Law, any organization or individual that applies for a patent in a foreign country for an invention or utility model patent established in the PRC is required to report to China National Intellectual Property Administration for confidentiality examination.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Trademarks</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the PRC Trademark Law and the Implementation Regulations of the PRC Trademark Law, the validity period of registered trademarks is 10 years, calculated from the date of approval of the registration. A trademark registrant intending to continue to use the registered trademark upon expiry of the period of validity must undergo the renewal formalities within 12 months before expiry according to the relevant provisions. If it fails to do so, the trademark registrant may be granted a six-month grace period. The period of validity of each renewal is 10 years, commencing from the day after the expiry date of the last period of validity. If the renewal formalities are not satisfied within the grace period, the registration of the trademark is canceled.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Copyright</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the PRC Copyright Law, works protected by copyright refer to original intellectual achievements in the fields of literature, art and science which can be expressed in a certain form, including: (i) written works; (ii) oral works; (iii) musical, dramatic, opera, dance, and acrobatic artistic works; (iv) fine arts and architectural works; (v) photographic works; (vi) audio-visual works; (vii) graphic works and model works, such as engineering design plans, product design plans, maps, and schematic diagrams; (viii) computer software; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(ix) any other intellectual achievements which share the same characteristics of the aforementioned works. Copyright is a collection of personal and property rights, which, among others, includes the right of publication, the right of authorship, the right of modification, the right of distribution, the right of reproduction, and the right of internet information transmission.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Measures for the Registration of Computer Software Copyright, and the Regulations on Computer Software Protection, the National Copyright Administration of the PRC shall be the competent authority for the nationwide administration of software copyright registration, and the Copyright Protection Centre of China is designated as the authority responsible for the whole registration process of computer software. The Copyright Protection Centre of China issues registration certificates to applicants for computer software copyrights that comply with the aforementioned measures and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Domain Names</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Domain names are protected under the Administrative Measures on Internet Domain Names promulgated by the Ministry of Industry and Information Technology (the &#8220;MIIT&#8221;) and Implementing Rules on Registration of China Country Code Top-level Domain Names issued by China Internet Network Information Center. The MIIT is the regulatory body responsible for the administration of PRC internet domain names. Prior to the establishment of domain name root servers, domain name root server operation institutions, domain name registration management institutions and domain name registration service institutions within the PRC, the corresponding permits shall be obtained from the MIIT or its local counterparts. The China Internet Network Information Center is responsible for the administration of registration of China country code top-level domain names.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Trade Secrets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the PRC Anti-Unfair Competition Law and Provisions of the Supreme People&#8217;s Court on Several Issues Concerning the Application of Law in the Trial of Civil Cases Involving Trade Secret Infringement, the term &#8220;trade secrets&#8221; refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for its legal owners or holders and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business operators are prohibited from infringing others&#8217; trade secrets by: (i) acquiring a trade secret from its holder by theft, bribery, fraud, coercion, electronic intrusion or any other illicit means; (ii) disclosing, using or allowing another person to use a trade secret acquired from the right holder by any means as specified in clause (i); (iii) disclosing, using or allowing another person to use a trade secret in its possession, in violation of its confidentiality obligation or the requirements of the right holder for keeping the trade secret confidential; and (4) abetting a person, or tempting or aiding a person into or in acquiring, disclosing, using or allowing another person to use the trade secret of its holder in violation of his or her non-disclosure obligation or the requirements of the right holder for keeping the trade secret confidential.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to Environmental Protection</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the PRC Environmental Protection Law, the Administrative Regulations on the Environmental Protection of Construction Project, the PRC Environmental Impact Assessment Law and PRC Law on the Prevention and Control of Environment Pollution Caused by Solid Wastes, an enterprise, which causes environmental pollution and discharges other materials that endanger the public, must implement environmental protection methods and procedures into its business operations. Where effects may be exerted on the environment after the completion of construction projects, the construction enterprise must submit an environmental impact report (form) or environmental impact registration form to the relevant environmental protection authority. Any project that is required to prepare the environmental impact report (form) in accordance with the law must obtain the approval from the relevant environmental protection department for its environmental impact assessment documents; otherwise, construction on the project may not begin. Pursuant to the Administrative Measures for Pollutant Discharge Permit and the Regulations on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Administration of Pollutant Discharge Permit, a pollutant-discharging entity must legally obtain a pollutant discharge permit prior to discharging any pollutants, and shall discharge pollutants in compliance within the scope specified in the pollutant discharge permit.  A pollutant discharge permit is valid for five years from the date of issuance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Notice of the General Office of the State Council on Issuing the Implementation Plan for the Permit System for Controlling the Discharge of Pollutant Emission and the Classification Administration List of Pollutant Discharge Permitting for Fixed Pollution Sources (2019 Version), the state implements a focused management, a simplification management and a registration management of emission permits based on the pollutant discharging enterprises and other manufacturing businesses&#8217; amount of pollutants, emissions and the extent of environmental damage. The manufacturing of chemical drug substance is strictly regulated under the current regulatory framework, and the manufacturer shall obtain a pollutant discharge permit in accordance with the prescribed time limit.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Hazardous Chemicals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Regulations on Safety Administration of Hazardous Chemicals, provides regulatory requirements on the safe production, storage, use, operation and transportation of hazardous chemicals. The PRC government exerts strict control over implementing overall planning and rational layout for the production and storage of hazardous chemicals and exam safety conditions of construction project concerning manufacturing or storing hazardous chemicals. An enterprise that manufactures and stores hazardous chemicals is required to appoint a qualified institution to conduct safety evaluations of its safety production conditions once every three years and to prepare a safety evaluation report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Administrative Measures for the Registration of Hazardous Chemicals, the state adopts a registration system for hazardous chemicals. The registration of hazardous chemicals is subject to the principles of application by enterprises, two-level review, unified issuance of certificates and hierarchical administration. Where any registering enterprise fails to go through the registration formalities for hazardous chemicals or fails to go through the formalities for altering the registration contents of hazardous chemicals when the type of registration changes or the hazardous chemicals it manufactures or imports have new hazardous characteristics, the registering enterprise must make corrections and may be subject to a fine of not more than 50,000 yuan. If the registering enterprise refuses to make corrections, it shall be given a fine of not less than 50,000 yuan but not more than 100,000 yuan. If the circumstance is serious, the registering enterprise will be ordered to suspend production and business for rectification.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Product Quality</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the PRC Product Quality Law of the PRC, manufacturers shall be liable for the quality of products they produce and guarantee that the product quality meets the requirements stipulated by laws and shall not mix impurities or imitations into products, pass fake goods off as genuine ones or shoddy products as good ones or sub-standard products as standard ones. Sellers are required to take measures to ensure the quality of the products sold by them. The manufacturer shall be liable to compensate for any bodily injuries or damage to property other than the defective product itself resulting from the defects in the product, unless the manufacturer is able to prove that: (1) the product has never been circulated; (2) the defects causing injuries or damage did not exist at the time when the product was circulated; or (3) the science and technology at the time when the product was circulated were at a level incapable of detecting the defects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the PRC Civil Code, where a defect of a product endangers the personal or property safety of another person, the manufacturer or the seller shall assume civil liabilities in accordance with the law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to Labor Protection, Social Insurance and Housing Provident Fund</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Labor Protection</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the PRC Labor Law, employers must develop and improve their rules and regulations in accordance with the law to ensure that workers enjoy their labor rights and perform their labor obligations. Employers must develop and improve the system of labor safety and sanitation and strictly implement the national protocols and procedures on labor safety. Employers must guard against labor safety accidents and reduce occupational hazards and labor safety and sanitation facilities must meet the relevant national standards. Employers must provide workers with the necessary labor protection equipment that meets the safety and hygiene conditions stipulated under national regulations by the State and conduct regular health checks for workers who engage in operations with occupational hazards. Laborers engaged in special operations must have received specialized training and obtained the pertinent qualifications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to PRC Labor Contract Law and the Implementation Regulations of the PRC Labor Contract Law of the PRC, employers and employees must enter into written labor contracts to establish their employment relationships. With respect to a circumstance where a labor relationship has already been established but no formal contract has been made, a written labor contracts must be entered into within one month from the date when the employee begins to work. In addition, wages shall not be lower than the local minimum wage standard.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Interim Provisions on Labor Dispatch, employers may employ dispatched workers only for temporary, auxiliary or substitutable positions and must strictly control the number of dispatched workers which may not exceed 10% of the total number of its workers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Social Insurance and Housing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Provident Fund</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the PRC Social Insurance Law (the &#8220;Social Insurance Law&#8221;), the Interim Regulations on the Collection and Payment of Social Insurance Premiums, the Regulations on Work-Related Injury Insurance, the Regulations on Unemployment Insurance, the Trial Measures for Maternity Insurance of Enterprises Employees, and the Administrative Regulations on Housing Provident Fund, an enterprise established within the PRC shall pay a premium for basic pensions insurance, basic medical insurance, maternity insurance, work-related injury insurance and unemployment insurance, and contribute to the housing provident fund for its employees at a rate stipulated by the relevant authorities. Basic pension, medical and unemployment insurance contributions shall be paid by both employers and employees, while work-related injury insurance and maternity insurance contributions shall only be paid by employers. Employers who fail to promptly contribute social security premiums in full shall be ordered by the social security premium collection agency to make or supplement contributions within a prescribed time limit and shall be subject to a late payment fine computed from the due date at the rate of 0.05% per day; where payment is not made within prescribed time limit, the relevant administrative authorities shall impose a fine ranging from one to three times the outstanding amount.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Administrative Regulations on Housing Provident Fund, employers must register with the competent managing center for housing provident funds and complete procedures for opening an account at a bank for the deposit of employees&#8217; housing provident funds. Employers are also required to pay and deposit housing funds on behalf of their employees in full and in a timely manner. Employers that violate the Regulation on Housing Provident Fund and fail to open housing provident fund accounts for their employees with the housing fund administration center within a designated period or fail to go through the formalities of opening housing provident fund accounts for their employees shall be subject to fines.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations on Foreign Investment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC Foreign Investment Law and the Implementing Regulations for the PRC Foreign Investment Law, apply to any investment activities directly or indirectly conducted by a foreign natural person, enterprise or other organization and a foreign-invested enterprise established prior to the effective date of the Foreign Investment Law shall adjust its legal form or governance structure to comply with the provisions of the Company Law of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the PRC or the Partnership Enterprises Law of the PRC, as applicable and complete amendment registration before January 1, 2025. According to the PRC Foreign Investment Law, the state applies the administrative system of pre-establishment national treatment plus negative list to foreign investment and accords national treatment to foreign investment outside of the negative list. Furthermore, the Implementing Regulations for the Foreign Investment Law provides implementing measures and detailed rules to ensure the effective implementation of the Foreign Investment Law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On December 30, 2019, the Ministry of Commerce of the PRC (the &#8220;MOFCOM&#8221;) and the SAMR jointly promulgated the Measure for Reporting of Information on Foreign Investment, which came into effect on January 1, 2020 and pursuant to which, the establishment of the foreign-invested enterprises, including establishment through purchasing the equities of a domestic non-foreign-invested enterprise or subscribe to the increased capital of a domestic non-foreign funded enterprise and its subsequent changes are required to submit an initial or change report through a dedicated registration system.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Investment activities in the PRC by foreign investors are principally governed by the Special Administrative Measures (Negative List) for Foreign Investment Access (2024 Version) (the "Negative List 2024"). The Negative List 2024, which became effective on November 1, 2024, sets out the special administrative measures in respect of foreign investment access on a unified basis. The Negative List 2024 prohibits foreign investors from investing in certain specified sectors and requires them to meet investment conditions for certain other sectors. Sectors not covered in the Negative List 2024 shall be subject to administration under the principle of equal treatment for both domestic and foreign investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to Overseas Investment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Administrative Measures on Overseas Investments, the MOFCOM and its counterparts at provincial level are one of the regulatory bodies of overseas investment of PRC enterprises. According to these measures, overseas investment refers to the acquisition of ownership in an overseas non-financial enterprise by means of incorporation, merger, acquisition or any other method by an enterprise incorporated in the PRC. Any overseas investments involving sensitive countries, regions or industries shall be subject to the approval of the MOFCOM or its provincial counterparts. Overseas investments that do not fall into the aforementioned category shall be subject to filing with the relevant provincial counterparts of the MOFCOM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Administrative Measures for the Overseas Investment of Enterprises, an enterprise in the territory of the PRC (&#8220;the PRC Investor&#8221;) shall, in overseas investment, undergo the formalities for the confirmation or recordation, among others, of an overseas investment project (the &#8220;Investment Project&#8221;), report the relevant information and cooperate in supervisory inspection. Sensitive Investment Projects conducted by PRC Investors directly or through overseas enterprises controlled by them shall be subject to approval, and non-sensitive Investment Project directly conducted by PRC Investors, namely, non-sensitive Investment Projects involving PRC Investors&#8217; direct contribution of assets or rights and interests or provision of financing or security, shall be subject to filing. The aforementioned sensitive Investment Project means an Investment Project involving a sensitive country or region or a sensitive industry. The NDRC promulgated the Catalogue of Sensitive Sectors for Overseas Investment (2018 Edition) to list the sensitive industries in detail.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to Overseas Listing</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The China Securities Regulatory Commission (the &#8220;CSRC&#8221;) promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies in 2023, and issued several corresponding guidelines thereof (together, the &#8220;Overseas Listing Trial Measures&#8221;), requiring PRC companies&#8217; overseas offerings and listings of equity securities be filed with the CSRC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Overseas Listing Trial Measures clarify the scope of overseas offerings and listings by PRC companies that are subject to the filing and reporting requirements thereunder. According to the Overseas Listing Trial Measures, if an issuer of securities meets both of the following criteria, the relevant offering and/or listing shall</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">be considered as indirect overseas offering and/or listing of a PRC company: (i) 50% or more of the issuer's operating revenue, total profit, total assets or net assets, as documented in its audited consolidated financial statements for the most recent accounting year, is accounted for by PRC companies; and (ii) the primary business activities of the issuer are conducted in the PRC, or its main places of business are located in the PRC, or most members of the issuer&#8217;s management team are citizens or long-term residents of the PRC. The Overseas Listing Trial Measures further provide that the determination on whether an offering and/or listing constitutes an indirect offering and/or listing of a PRC company shall follow the principle of &#8220;substance over form,&#8221; making it possible for an offering and/or listing that does not meet the above criteria to still be considered an indirect overseas offering and/or listing of a PRC company, thus subject to the CSRC filing obligation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Overseas Listing Trial Measures further stipulate that PRC companies that have already directly or indirectly offered or listed securities in overseas markets shall fulfil their filing obligations and report relevant information to the CSRC within three working days after conducting a follow-on offering of equity securities on the same overseas market. They must also comply with relevant reporting requirements within three working days upon the occurrence of any specified circumstances. Failure to comply with the filing procedures may result in warnings and fines imposed by the CSRC or other competent PRC authorities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to PRC Taxation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Enterprise Income Tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the PRC Enterprise Income Tax Law (the &#8220;EIT Law&#8221;) and its implementation rules, a PRC resident enterprise is subject to Enterprise Income Tax (&#8220;EIT&#8221;) at the current uniform rate of 25% commencing from January 1, 2008 unless reduced under certain specific qualifying criteria. The term &#8220;resident enterprise&#8221; refers to any enterprise established in the PRC and any enterprise established outside the PRC with a &#8220;place of effective management&#8221; within the PRC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In 2018, we obtained a certificate from the Beijing government for a High and New Technology Enterprise (&#8220;HNTE&#8221;) qualification and the certificate was most recently renewed in 2022. This renewed certificate entitled the us to enjoy a preferential income tax rate of 15% for a period of three years from 2022 to 2025 if all the criteria for HNTE status could be satisfied in the relevant year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Non-resident Enterprises Taxation Arrangement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dividends (if any) paid by our subsidiaries in the PRC to their direct offshore parent companies are subject to PRC withholding income tax at the rate of 10%, provided that such dividends are not effectively connected with any establishment or place of the offshore parent company in the PRC. The 10% withholding income tax rate may be reduced or exempted pursuant to the provisions of any applicable tax treaties or tax arrangements. Hong Kong has a tax arrangement with mainland PRC that provides for a 5% withholding tax on dividends upon meeting certain conditions and requirements, including, among others, that the Hong Kong resident enterprise directly owns at least 25% equity interests of the PRC enterprise and is a &#8220;beneficial owner&#8221; of the dividends. Under the EIT Law and its implementation rules, gains derived by non-resident enterprises from the sale of equity interests in a PRC resident enterprise are subject to PRC withholding income tax at the rate of 10%. The 10% withholding income tax rate may be reduced or exempted pursuant to applicable tax treaties or tax arrangements. The gains are computed based on the difference between the sales proceeds and the basis price of the original investment. Stamp duty is also payable upon a direct transfer of equity interest in a PRC resident enterprise. The stamp duty is calculated at 0.05% on the transfer value, payable by each of the transferor and transferee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Announcement of the State Taxation Administration on Issues Relating to Withholding at Source of Income Tax of Non-resident Enterprises (&#8220;Circular 37&#8221;) purports to clarify certain issues in the implementation of the above regime, by providing, among others, the definitions of equity transfer income and tax basis, the foreign</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">exchange rate to be used in the calculation of withholding amounts and the date of occurrence of the withholding obligation. Specifically, Circular 37 provides that where the transfer income subject to withholding at its source is derived by a non-PRC resident enterprise by way of installments, the installments may first be treated as recovery of costs of previous investments; upon recovery of all costs, the tax amount to be withheld shall then be computed and withheld.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Value-added Tax (&#8220;VAT&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Interim Regulations on VAT of the PRC and its implementation rules, unless otherwise specified by relevant laws and regulations, any enterprise or individual engaged in the sale of goods, provision of processing, repair and replacement services, sales of service, intangible assets and real estate and the importation of goods in the PRC are generally required to pay VAT.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Circular of the Ministry of Finance and the State Taxation Administration on Adjustment to Value-Added Tax Rates (&#8220;Circular 32&#8221;) for VAT taxable sales acts or importation of goods originally subject to VAT rates of 17% and 11%, respectively, such tax rate shall be adjusted to 16% and 10%, respectively. For exported goods originally subject to a tax rate of 17% and an export tax refund rate of 17%, the export tax refund rate shall be adjusted to 16%. For exported goods and cross-border taxable acts originally subject to a tax rate of 11% and an export tax refund rate of 11%, the export tax refund rate shall be adjusted to 10%. Circular 32 became effective on May 1, 2018 and supersedes existing provisions which are inconsistent with Circular 32.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Announcement on Policies for Deepening the VAT Reform (&#8220;Circular 39&#8221;) for VAT taxable sales acts or importation of goods originally subject to VAT rates of 16% and 10%, respectively, such tax rate shall be adjusted to 13% and 9%, respectively. For exported goods originally subject to a tax rate of 16% and an export tax refund rate of 16%, the export tax refund rate shall be adjusted to 13%. For exported goods and cross-border taxable acts originally subject to a tax rate of 10% and an export tax refund rate of 10%, the export tax refund rate shall be adjusted to 9%. Circular 39 became effective on April 1, 2019 and supersedes existing provisions which are inconsistent with Circular 39. According to the Circular on the Value-added Tax Policies for Rare Disease Drugs, for the production and sale of drugs for rare diseases, VAT shall be calculated and paid at the rate of 3% under the simplified method.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to Foreign Exchange</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Regulations on Foreign Exchange Administration of the PRC apply to the receipt and payment of foreign currency or foreign exchange business activities conducted by PRC organizations and individuals or conducted by foreign organizations and individuals within the territory of the PRC. Renminbi is freely convertible for payments of current account items such as trade and service-related foreign exchange transactions and dividend payments, but is not freely convertible for capital expenditure items such as direct investments, loans or investments in securities outside of the PRC unless approval from the SAFE or its local counterpart is obtained in advance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Administrative Regulation regarding Foreign Exchange Settlement, Sales and Payment, foreign exchange receipts under the current account of foreign-invested enterprises may be retained to the fullest extent specified by the SAFE or its local counterparts. Any portion in excess of such amount shall be sold to a designated foreign exchange bank or through a foreign exchange swap center.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Circular on Further Simplifying and Improving Policies on Foreign Exchange Administration for Direct Investment, banks shall directly examine and handle foreign exchange registration under overseas direct investment. The State Administration of Foreign Exchange and its branches shall indirectly regulate the foreign exchange registration of direct investment through banks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the Circular on Reforming and Regulating Policies on the Control over Foreign Exchange Settlement of Capital Accounts, foreign currency earnings in capital accounts that maintain relevant policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">of willingness to exchange settlement and have been clearly implemented on (including the recalling of raised capital by overseas listing) may undertake foreign exchange settlement in the banks according to actual business needs of the domestic institutions. The tentative percentage of foreign exchange settlement for foreign currency earnings in capital account of domestic institutions is 100%, subject to adjust of the SAFE in due time in accordance with international revenue and expenditure situations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Circular of the State Administration of Foreign Exchange on Issues Relating to Foreign Exchange Administration for Overseas Investment and Round-trip Investment by Chinese Residents through Special Purpose Vehicles requires PRC residents to register their legally owned assets or equity interests in domestic enterprises or offshore assets or interests with local branches of SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The SAFE issued the Circular on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Listed Companies (the "Stock Option Rules"), which prescribed that PRC citizens or non-PRC citizens residing in the PRC for a continuous period of no less than one year (except for foreign diplomatic personnel in the PRC and representatives of international organizations in the PRC) who participate in any stock incentive plan of an overseas listed company shall, through itself (if its securities are listed overseas) or a domestic company which is affiliated with the overseas listed company (the &#8220;PRC Entity&#8221;), collectively entrust a domestic agency (the agency can be the PRC Entity or a qualified PRC organization as appointed by the PRC Entity) to handle foreign exchange registration and entrust an overseas institution to handle issues such as the exercise of options, the purchase and sale of corresponding stocks or equity and transfer of corresponding funds. In addition, the domestic agency is required to amend the SAFE registration with respect to the stock incentive plan if there is any material change to the stock incentive plan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Failure to comply with the abovementioned foreign exchange regulations and requirements may result in warnings, fines, confiscation of illegal gains and even criminal liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Relating to Dividend Distribution</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The principal laws, rules and regulations governing dividend distributions by foreign-invested enterprises in the PRC are the PRC Company Law and the PRC Foreign Investment Law and its Implementation Regulations. Under these requirements, foreign-invested enterprises may only pay dividends out of their accumulated profits, if any, as determined in accordance with PRC accounting standards and regulations. A PRC company is required to set aside at least 10% of its after-tax profits each year, after making up previous years&#8217; accumulated losses, if any, as such company&#8217;s mandatory capital reserve funds until the aggregate amount of these reserve funds have reached 50% of its registered capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The EIT Law and its implementation rules provide that since January 1, 2008, a withholding income tax rate of 10% will be applicable to dividends declared to non-PRC resident enterprises, unless otherwise reduced according to treaties or arrangements between the PRC central government and the governments of other countries or regions where the non-PRC resident enterprises are incorporated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Hong Kong has a tax arrangement with mainland China that provides for a 5% withholding tax on dividends distributed to a Hong Kong resident enterprise, upon meeting certain conditions and requirements, including, among others, that the Hong Kong resident enterprise directly owns at least 25% equity interests of the Chinese enterprise and is a &#8220;beneficial owner&#8221; of the dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PRC Taxation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under Article 2 of the EIT Law, a resident enterprise is an enterprise that is established in the PRC under the PRC laws, or an enterprise that is established under the laws of foreign countries (regions) but whose place of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">effective management is located in the PRC. We are a PRC resident enterprise for PRC tax purposes because we are a legal entity registered in Beijing, PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Because we are a PRC resident enterprise for PRC Enterprise Income Tax purposes, dividends (if any) paid by us to our direct offshore institutional shareholders which are not PRC resident enterprises for PRC tax purposes are subject to PRC withholding income tax at the rate of 10%, provided that such dividends are not effectively connected with any establishment or place in the PRC of such offshore shareholders. In addition, gains derived by non-resident enterprises from the sale of equity interests in a PRC resident enterprise are subject to PRC withholding income tax at the rate of 10%. The 10% withholding income tax rate may be reduced or exempted pursuant to the provisions of any applicable tax treaties or tax arrangements. See the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Business Operations in the PRC&#8212;Since Gyre Pharmaceuticals is a legal entity registered in Beijing, PRC, it is classified as a PRC tax resident for PRC income tax purposes by default, and such classification results in unfavorable tax consequences to Gyre Pharmaceuticals and its non-PRC shareholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">With respect to gains realized from the sale or other disposition of the shares, there is a possibility that a PRC tax authority may impose an income tax under the indirect transfer rules set out under the Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise Income Tax on Indirect Property Transfer by Non-Resident Enterprises, or SAT Circular 7, except that such transaction could fall under the safe harbor thereunder. See the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Business Operations in the PRC&#8212;Gyre Pharmaceuticals and its shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company, or other assets attributable to a PRC establishment of a non-PRC company. Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential offshore restructuring transactions or sales of the shares of Gyre Pharmaceuticals&#8217; offshore holding companies or investments where PRC taxable assets are involved</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government Regulation Outside of the United States and PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To obtain regulatory approval of an investigational drug under EU regulatory systems, we must submit a marketing authorization application.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 1A. RISK FACTORS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The following section includes the most significant factors that may adversely affect our business and operations. You should carefully consider the risks and uncertainties described below and all information contained in this Annual Report on Form 10-K before deciding to invest in our common stock. If any of the following risks actually occur, our business, financial condition, results of operations and growth prospects may be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose all or part of your investment. Moreover, some of the factors, events and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events or contingencies have occurred in the past and instead reflect our beliefs and opinions as to the factors, events, or contingencies that could materially and adversely affect us in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our securities involves a high degree of risk. Below please find a summary of the principal risks we face. These risks are discussed more fully below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our business is significantly dependent on the sales of ETUARY&#174;, our marketed product in the PRC, amid a competitive landscape, and there is a possibility that we may not be able to sustain or boost the sales volume, pricing, and profitability of ETUARY.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There is a risk that our marketed product in the PRC, ETUARY, along with any other products that we may commercialize in the future, including nintedanib and avatrombopag, and may receive approval in the future, may not attain sufficient market acceptance among physicians, healthcare facilities, pharmacies, patients, third-party payers, and the broader medical community, which is crucial for their commercial viability.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The future of our business and financial outcomes is largely contingent on the progress and success of our product candidates in clinical and pre-clinical stages, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC. We face the risk of not being able to finalize their clinical development, secure necessary regulatory approvals, or accomplish their market launch successfully, or we may encounter substantial setbacks in these processes.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To support the growth of our research and development activities and operations, we require further funding, which might not be obtainable on favorable terms or could be entirely unavailable. If we fail to secure the needed capital at the critical time, we might have to postpone, scale down, or halt some of our development projects, market introduction initiatives, or other operational aspects.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The true market potential for our product and product candidates may be less than expected. Our expansion could be constrained by the current and emerging number of IPF patients in the PRC, pending the approval and profitable launch of expanded applications for ETUARY for future indications in the PRC, and our other product candidates.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The approval procedures of the NMPA, FDA, and comparable foreign regulatory authorities are extensive, protracted, and inherently uncertain. Failure to secure necessary approvals, or encountering delays in the approval process, will prevent us from marketing our product candidates, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, which may significantly affect our revenue generation.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Should we or our licensors fail to secure, uphold, defend, or extend adequate patent and other intellectual property rights for our products, ETUARY, nintedanib and avatrombopag, which are approved in the PRC, and any product candidates globally, or if the breadth of these intellectual property rights is insufficient, our ability to effectively compete in our markets could be compromised.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have established, and may continue to establish, collaborative agreements and strategic partnerships. However, there is no guarantee we will fully achieve the anticipated benefits from these collaborations, alliances, or licensing agreements, and conflicts could emerge with our present or prospective partners.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process and outcomes are uncertain, and we may not successfully complete clinical trials for drugs under development, including ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, or demonstrate the safety and efficacy of our product candidates to the satisfaction of regulatory authorities.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our ongoing success is reliant on our capacity to retain key executives and to recruit, maintain, and inspire skilled professionals.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If our intangible assets are impaired, our results of operations and financial condition may be adversely affected. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Modifications to laws, regulations, and rules by the PRC government could lead to alterations in our operational processes and business approaches.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The market price of our common stock has been, and may continue to be, volatile.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance with regulations related to operating as a public company.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Condition and Capital Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is significantly dependent on the sales of ETUARY, our marketed product in the PRC, amid a competitive landscape, and there is a possibility that we may not be able to sustain or boost the sales volume, pricing, and profitability of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are a biotechnology company and have only generated revenues from the commercial sale of ETUARY, which is approved in the PRC, and certain generic drugs. We only have one product and certain generic drugs for commercial sale and are still in the early stages of development of our other product candidates. We are largely dependent on sales of ETUARY, but we may not be able to maintain ETUARY&#8217;s sales volumes, pricing levels or profit margins. Sales of ETUARY accounted for 99.3% and 98.9% of our total revenue in 2024 and 2023, respectively, and we expect that sales of ETUARY will continue to comprise a substantial portion of our total revenue in the near future. As a result, any reduction in sales or profit margins of ETUARY will have a material negative impact on our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, the pharmaceutical industries are characterized by rapid changes in technology, constant enhancement of industrial know-how and frequent emergence of new products, which renders our targeted markets highly competitive. Notably, the IPF drug market in the PRC is characterized by increasingly fierce competition, with several pirfenidone and nintedanib products approved and commercialized, in addition to our products ETUARY and nintedanib, which Gyre Pharmaceuticals acquired the commercial rights to in May 2024. There are also several drug candidates that have entered into Phase 2 or more advanced clinical trial stage. With the increase in the penetration rate of IPF drugs and the expansion of the overall market, including past new market participants, we expect that more market players will join the IPF market, and, consequently, the sales of our product ETUARY may decrease. For details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Business&#8212;Our Products and Product Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">ETUARY: National Category 1.1 New Drug for IPF Approved in 2011</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunities and Competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Annual Report. New entrants to the IPF market in the PRC may exert downward pressure on our average selling price of ETUARY, which may negatively impact sales and/or profit of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Many of our competitors, including foreign pharmaceutical companies, may have substantially greater clinical, research, regulatory, manufacturing, marketing, financial and human resources compared to us. Certain of our competitors may be actively engaged in research and development in areas where we have products or where we are developing product candidates or new indications for our existing products. Other companies may discover, develop, acquire or commercialize products more quickly or more successfully than we do. Moreover, there may also be significant consolidation in the pharmaceutical industry among our competitors or ventures among competitors that may increase their market share. Furthermore, our competitors may apply for and obtain marketing approvals in the PRC, United States or other countries for products with the same intended use as our generic products, ETUARY and product candidates more rapidly than we do. The capacity of the relevant authorities, such as the NMPA, FDA or other comparable foreign regulatory authorities, to concurrently review multiple marketing applications for the same type of innovative drug may be limited. Therefore, such authorities&#8217; review of our product candidates may be delayed when there is concurrent review of our product candidates with our competitors&#8217; products, and the registration process of our products may be prolonged.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition to market competition from generic drugs and other products or therapies indicated for the same disease, many of the factors discussed in this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> section could adversely affect sales of ETUARY, including but not limited to, pricing pressures caused by government policies and inclusion or removal from the governmental medical insurance coverage, market acceptance among the medical community, disruptions in manufacturing or distribution, issues with product quality or side effects and disputes over intellectual property. Moreover, despite our efforts, we may be unable to develop or acquire new products that would diversify our business and reduce our dependence on ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The future of our business and financial outcomes is largely contingent on the progress and success of our product candidates in clinical and pre-clinical stages, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC. We face the risk of not being able to finalize their clinical development, secure necessary regulatory approvals, or accomplish their market launch successfully, or we may encounter substantial setbacks in these processes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have devoted most of our financial resources to research and development, including our preclinical and clinical development activities. Our ability to generate revenue and realize profitability depends on the successful completion of the development of our product candidates, obtaining necessary regulatory approvals, and manufacturing and commercializing our product candidates, which is contingent upon various factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the clinical development of ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">enhancing our commercial manufacturing capabilities;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to attract, hire and retain skilled personnel&#894;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the successful enrollment in, and completion of, clinical trials, as well as completion of pre-clinical studies and favorable safety and efficacy data therefrom&#894;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">receipt of regulatory approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the performance by contract research organizations (&#8220;CROs&#8221;), or other third parties, of their duties to us in a manner that complies with our trial protocols and applicable laws and protects the integrity of the resulting data;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to acquire or in-license other product candidates and technologies;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">obtaining, maintaining, protecting and enforcing patent, trade secret and other intellectual property and proprietary protection and regulatory exclusivity, and ensuring we do not infringe, misappropriate or otherwise violate the patent, trade secret or other intellectual property and proprietary rights of third parties&#894;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">successfully launching commercial sales, including our plan to commercially launch nintedanib and avatrombopag; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">obtaining and/or maintaining favorable governmental and private medical reimbursement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">efficiently and cost-effectively enhancing our marketing platform and distribution capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">competition with other products and product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">continued acceptable safety profile following regulatory approval, including of ETUARY; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">creating additional infrastructure to support operations as a public company and our product development and planned future commercialization efforts&#894; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">delays or other issues with any of the above.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may not be able to achieve one or more of the foregoing factors in a timely manner or at all. As a result, we could experience significant delays in or obtaining or not be able to obtain approval for and/or successful commercialization of our product, ETUARY, and product candidates, which would render us unable to achieve our planned milestones and materially harm our drug development prospects. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to sustain or increase profitability on a quarterly or annual basis. Failure to sustain or increase profitability would depress the value of our common stock and could impair our ability to raise capital, expand our business, maintain research and development efforts, diversify product offerings or even continue operations. A decline in the value of our common stock could also cause you to lose all or part of your investment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">To support the growth of our research and development activities and operations, we require further funding, which might not be obtainable on favorable terms or could be entirely unavailable. If we fail to secure the needed capital at the critical time, we might have to postpone, scale down, or halt some of our development projects, market introduction initiatives, or other operational aspects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The development, commercialization, manufacturing, marketing, sales and distribution of biopharmaceutical products and product candidates is capital-intensive. We have only generated revenues from the commercial sale of ETUARY and certain generic drugs in the PRC and will not be able to generate any product revenues in addition to those generated by ETUARY and certain generic drugs until we receive approval to sell our other product candidates from the NMPA, FDA or other regulatory authorities. As we have only generated revenue from commercial sales of ETUARY and certain generic drugs to date and do not expect to generate any revenue from our other product candidates until they obtain regulatory approval, if ever, we will need to raise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">substantial additional capital in order to fund our future research and development, including any new clinical trials, product development, partnerships with third parties and strategic collaborations. However, we expect to need to raise substantial additional capital to continue the clinical development of ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, and depending on the availability of capital, may need to delay or cease development of some or all of our product candidates. Even if we raise additional capital, we may elect to focus our efforts on one or more development programs and delay or cease other development programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">While we expect that the implementation of our strategies and business plans will require us to rely in part on external financing sources, including our ATM Program with Jefferies LLC, our ability to obtain additional capital on commercially reasonable terms is subject to a variety of factors, many of which are outside of our control, including our future financial condition, results of operations and cash flows, the global economic conditions, industry and competitive conditions, interest rates, prevailing conditions in the credit markets and government policies on lending. Additional funds may not be available when we need them on terms that are acceptable, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate some or all of our research or development programs, and we may not be able to execute our strategies and business plans as currently contemplated, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and commercialize our products under development. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the costs and results of preclinical studies or clinical trials of ETUARY, F351, F573, F528 and F230 or other product candidates, and expenses related to potential clinical development of such candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the expenses associated with promoting academic marketing and expanding our sales and distribution network; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the number and characteristics of product candidates that we pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the terms and timing of any future collaboration, licensing or other arrangements that we may establish;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our need and ability to retain key management and hire scientific, technical, business and medical personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the outcome, timing and cost of regulatory approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our efforts to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the costs and timing associated with manufacturing our products, including ETUARY and generic products and product candidates for which we may receive regulatory approval, and establishing commercial supplies and sales, marketing and distribution capabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">market acceptance of any product candidates for which we may receive regulatory approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the capital expenditure required to increase our production capacity and to expand and upgrade our facilities;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the costs of continuing to operate our business, including costs associated with being a public company; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the extent to which we acquire, license or invest in businesses, products or technologies.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Further, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from public health crises, the conflict between Russia and Ukraine or the conflicts in the Middle East. For details regarding the risks related to the relations between the PRC and the United States, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Business Operations in the PRC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our strategy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional funds by issuing securities or through licensing arrangements may cause dilution to stockholders, restrict our operations or require us to relinquish proprietary rights.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of common stockholders. We currently have in place an Open Market Sale Agreement</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> with Jefferies LLC that permits us, subject to applicable SEC regulations, to issue up to $50.0 million of shares of our common stock in &#8220;at the market&#8221; transactions at prevailing market prices.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We may also seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. There can be no assurance that we will be able to obtain additional funding if, and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, curtail or eliminate one or more, or all, of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may grow our business in part through acquisitions, which may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and have material adverse effect on our ability to manage our business, and we may fail to successfully complete such acquisitions or enhance post-acquisition performances in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To enhance our growth and benefit our product development, technology advancement and distribution network, we have in the past and may continue to acquire businesses, products, technologies or know-how or enter into strategic partnerships. Any completed, in-process or potential acquisition or strategic partnership may entail numerous risks, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">inability to identify suitable acquisition targets and reach agreement on acceptable terms;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">lack of access to financing for acquisitions on acceptable terms or at all, or otherwise on assumption of additional indebtedness or contingents and issuance of our equity securities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">failure to obtain or secure the governmental approvals and third-party consents necessary to consummate any proposed acquisition;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">increased operating expenses, including research and development expenses due to an increased number of product candidates, administrative expenses and selling expenses;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">difficulty in retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products and product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs; and/or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">deficiencies in internal controls, data adequacy and integrity, product quality and regulatory compliance and product liabilities in the acquired business we discover after such acquisition. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our plan to grow our business through such acquisitions may not materialize as expected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our high gross margin during the years ended December 31, 2024 and 2023 may not be sustainable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, we maintained a high level of gross margin. Our profit margins were 96.3% and 95.9% for the years ended December 31, 2024 and 2023, respectively, due to our mature technology and significant cost reduction due to the scale effect. However, there can be no assurance that we will sustain a similarly high gross margin in the future. Various factors may affect our gross margin, many of which are beyond our control. For example, changes in the competitive landscape of the relevant markets may decrease the average selling prices of ETUARY, which may have a negative effect on our gross margin. Moreover, our gross margin will be influenced by various components of our costs, such as the cost of raw materials. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;Risks Relating to Manufacture and Supply of Our Product&#8212;Fluctuations in prices of our raw materials and energy supply, as well as other costs associated with our production processes, may have a material adverse effect on us if we are not able to pass the cost increases on to our customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Risk Factors section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our five largest customers accounted for a substantial amount of our revenue during the years ended December 31, 2024 and 2023, which subjects us to concentration risks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our five largest customers accounted for a substantial amount of our revenue for the years ended December 31, 2024 and 2023. As such, we may be exposed to credit risks, and there can be no assurance that we can properly assess and respond in a timely manner to changes in our customers&#8217; credit profile. As of each of December 31, 2024 and 2023, we had certain concentrations of credit risk of 10%. In addition, as of December 31, 2024, 54.3% and 84.9%, and as of December 31, 2023, 50.5% and 85.5%, of our trade receivables were due from our largest customer and our five largest customers, respectively. If such customers&#8217; cash flows, working capital, financial condition or results of operations decrease, they may be unable, or they may otherwise be unwilling, to pay trade receivables owed to us promptly or at all. Any substantial defaults or delays could materially and adversely affect our cash flows, and if we terminate our relationships with our customers as a result of such customers&#8217; default or payment delay, then that may adversely and materially affect our cash flows and operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If any of our major customers stop purchasing ETUARY or substantially reduce order size in the future, whether due to the termination or amendment of our contractual relationship with such customer, or due to any other reason unrelated to us, we may not be able to identify and sell ETUARY to an alternative customer in a timely manner, or at all. As a result, our business and financial performance may be materially and adversely affected.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may face risk regarding the obsolescence of our inventories.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our inventories consist of raw materials, works in progress, semi-finished goods and finished goods. As of December 31, 2024 and 2023, our inventories were valued at $6.3 million and $4.3 million, respectively. During the years ended December 31, 2024 and 2023, we did not identify material inventory items requiring impairment provisioning, and we believe that maintaining appropriate levels of inventory helps us meet market demands in a timely manner. We generally purchase supplies based on our estimated demand and manufacturing capacity, and our management system covers each stage of the warehousing process. The storage and distribution of our inventories are closely monitored in order to keep our inventories and logbook consistent. However, as our business expands, our inventory levels may increase and the risk of obsolescence may increase accordingly. Furthermore, any unexpected material fluctuations in the supplies or changes in customers&#8217; preferences may lead to decreased demand and overstocking of supplies and increase the risk of obsolescence.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">If our intangible assets are impaired, our results of operations and financial condition may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have intangible assets primarily consisting of product development in progress, patents, technological know-how, and computer software, which accounted for a considerable portion of our total assets as of December 31, 2024 and 2023. The value of our intangible assets is based on a number of assumptions made by our management. If any of these assumptions do not materialize, or if the performance of our business is not consistent with such assumptions, we may have to write off a significant portion of our intangible assets and record a significant impairment loss. In addition, our determination on whether intangible assets are impaired requires an estimation of the carrying amount and recoverable amount of an intangible asset. If the carrying amount exceeds its recoverable amount, our intangible assets may be impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to credit risk in collecting trade receivables due from our customers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, our trade receivables amounted to $19.6 million and $15.2 million, respectively, which primarily represented the balances due from our distributors. Our liquidity and cash flow are directly affected by our customers&#8217; ability to pay us in a timely manner, but there can be no assurance that our customers will not default on us in the future, despite our efforts to conduct credit assessments. During the years ended December 31, 2024 and 2023, our trade receivables turnover days were 60 days and 50 days, respectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If any of our customers&#8217; business, cash flow, conditions or results of operations decrease, such customers may be unable or unwilling to pay trade receivables owed to us promptly or at all. Bankruptcy or deterioration of the credit condition of our major customers could also materially and adversely affect our collection of trade receivables. For details of the risk associated with concentrations of credit risk that we are exposed to, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our five largest customers accounted for a substantial amount of our revenue during the years ended December 31, 2024 and 2023, which subjects us to concentration risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Risk Factors section. If significant amounts due to us is not settled in a timely manner, we may incur significant write-offs and our liquidity and cash flow may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We have historically received government grants and have been entitled to preferential tax treatment, but we may not continue to receive government financial incentives in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have historically received government grants in connection with certain of our research and development and manufacturing activities, and recognized government grants under other income and gains of $0.1 million and $1.0 million for the years ended December 31, 2024 and 2023, respectively. For details of the amounts of our other recognized income, see Note 4 to the Audited Financial Statements of Gyre Therapeutics, Inc. in this</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Annual Report. We were also entitled to a preferential corporate income tax rate of 15% for each of the years ended December 31, 2024 and 2023 as a High and New Technology Enterprise. In addition, our product ETUARY, which is approved in the PRC, has been entitled to a preferential VAT treatment at the tax rate of 3%. However, there can be no assurance of the continued availability of such preferential treatment. Our eligibility for government grants and preferential tax rates depends on a variety of factors, including, but not limited to, the assessment of our improvement on existing technologies, relevant government policies and the availability of funding at different granting authorities. In addition, the timing, amount and criteria of government financial incentives are determined within the sole discretion of the PRC government authorities. Government financial incentives are non-recurring in nature, and there can be no guarantee that we will continue to receive government incentives. In addition, some government financial incentives may be subject to the satisfaction of certain conditions, including compliance with the applicable financial incentive agreements and completion of the specific projects therein, which we may not satisfy. Any reduction or elimination of the government financial incentives we currently receive could have an adverse effect on our financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to Our Business Operations and Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">There is a risk that our marketed product in the PRC, ETUARY, along with any other products that we may commercialize in the future, including nintedanib and avatrombopag, and may receive approval in the future, may not attain sufficient market acceptance among physicians, healthcare facilities, pharmacies, patients, third-party payers, and the broader medical community, which is crucial for their commercial viability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The commercial success of our existing marketed product, ETUARY, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and future approved products, if any, depends upon the degree of market acceptance such products can achieve, particularly among physicians, hospitals, pharmacies and other medical institutions, which is contingent upon a number of factors. Such factors affecting the market acceptance of a current or future approved product, if any, may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the clinical indications for which the product is approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the safety and efficacy of the product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the potential and perceived advantages and disadvantages of the product, relative to competing or alternative products or treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the affordability of the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the cost of treatment in relation to alternative treatments and therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the strength of our relationships with patient communities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the current diagnostic conditions of the disease for which the product is indicated, which may be influenced by the number of physicians from the relevant department and their respective experiences, available diagnostic methods and equipment therefor; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the effectiveness of our sales and marketing efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If our existing and future approved products, if any, fail to achieve or maintain widespread market acceptance, or if new products introduced by our competitors are perceived more favorably by healthcare practitioners and patients, are more cost-effective or otherwise render our products obsolete, the demand for our products may decline and our business and profitability may be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If any of our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Doctors may not accept or use ETUARY as a treatment for pneumoconiosis even if ETUARY receives marketing approval for such indication. Doctors may not accept or use F351 as a treatment for liver fibrosis even if F351 receives marketing approval. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues from or receive any return on our investment in any such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process and outcomes are uncertain, and we may not successfully complete clinical trials for drugs under development, including ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, or demonstrate the safety and efficacy of our product candidates to the satisfaction of regulatory authorities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approval for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate their safety and efficacy, but there can be no assurance that such trials will be completed in a timely or cost-effective manner, due to the inherently unpredictable nature of clinical drug development. We have only obtained regulatory approval for one product that we developed, ETUARY for the treatment of IPF in the PRC, and it is possible that none of our existing product candidates in development or any product candidates we may seek to develop in the future will ever obtain regulatory approval. Events that may prevent successful or timely completion of clinical development may include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">regulators, institutional review boards or ethics committees not authorizing us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our inability to reach agreements on acceptable terms with prospective CROs, SMOs and hospitals as trial centers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">manufacturing issues, including problems with manufacturing, supply quality, compliance with GMP, or obtaining sufficient quantities of a product candidate for use in a clinical trial in a timely manner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">clinical trials producing negative or inconclusive results, resulting in additional clinical trials or abandoning drug development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">changes to the clinical trial protocol;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our third-party contractors&#8217; failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our suspending or terminating clinical trials for various reasons, including negative or inconclusive clinical response or a finding that participants are being exposed to unacceptable health risks or experiencing adverse effects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the cost of clinical trials being greater than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials being insufficient or inadequate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">participants choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">occurrence of adverse effects or serious adverse effects associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the occurrence of serious adverse events in clinical trials of competing products or conducted by competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol or other regulatory requirements or committing fraud; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the results of pre-clinical studies or early clinical trials not being predictive of the results of later-stage clinical trials, and initial or interim results of a trial not being predicative of final results.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If we are required to conduct additional preclinical studies or clinical trials of our product candidates, including of ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC or other testing, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">be delayed in obtaining regulatory approval from the NMPA, FDA, EMA or other regulatory authorities for our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">not obtain regulatory approval at all and lose our ability to further develop and commercialize our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">be required to conduct additional clinical trials or other testing beyond those that we currently contemplate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">continue to be subject to post-marketing testing requirements from the NMPA, FDA, EMA or other regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">be unable to be listed in the NRDL in the PRC; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">experience having the product removed from the market after obtaining regulatory approval.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consequentially, any delays in completing our clinical trials may increase our costs, delay our product candidate development and approval process, and jeopardize our ability to commercialize our approved products and generate revenues.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Liver fibrosis is an area of our focus, and our key product candidate in this area is F351. Our future clinical trials for F351 may not be successful.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We expect to invest a substantial amount of our efforts and financial resources into the research and development of F351. F351 is currently in its Phase 3 clinical trial in the PRC and has the potential to be the world&#8217;s first approved drug to treat liver fibrosis associated with CHB. F351 was granted a Breakthrough Therapy designation by the NMPA&#8217;s CDE in March 2021 and the patient enrollment for our Phase 3 clinical trial was commenced in January 2022. As of October 2023, the 248 patient Phase 3 clinical trial in the PRC was fully enrolled. However, F351&#8217;s Breakthrough Therapy designation does not increase the likelihood that F351 will</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ultimately receive approval from the NMPA or other comparable regulatory authorities. In October 2024, the last patient completed the 52-week pivotal Phase 3 trial, and we expect to report top-line data by the second quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, we are actively preparing an IND application in the United States that we expect to file by the first half of 2025 for a Phase 2 clinical trial to evaluate F351 for the treatment of advanced liver fibrosis associated with noncirrhotic MASH. Following IND clearance, we plan to initiate a Phase 2, PoC clinical trial in 2025 in the United States, subject to positive trends in the Phase 3 trial of F351 in the PRC, to evaluate the safety, tolerability, PK, and PD of F351 for patients with advanced liver fibrosis associated with noncirrhotic MASH. The FDA has provided pre-IND advice on the design of the planned Phase 2 trial of F351 and provided guidance on the contents of the IND filing. Our clinical trials may be adversely affected by the March 2024 marketing approval for Rezdiffra or the potential regulatory approvals for one or more investigational MASH products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote F351, or any other product candidates, before we receive marketing approval from the NMPA, FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The success of F351 will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of F351, even if approved. If we are not successful in commercializing F351, or are significantly delayed in doing so, our business will be materially harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">If we experience delays or difficulties in the commencement of clinical trials or patient enrollment in clinical trials, our regulatory approvals could be delayed or prevented.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We or our collaborators may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate, enroll and maintain enrollment of a sufficient number of eligible patients to participate in these trials as required by the NMPA, FDA or similar regulatory authorities outside the PRC or the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, there are inherent difficulties in enrolling MASH patients, which can currently only be definitively diagnosed through a liver biopsy. Specifically, identifying patients most likely to meet MASH enrollment criteria on biopsy is an on-going challenge, with existing clinical indicators lacking both sensitivity and specificity. As a result, MASH trials often suffer from high levels of screen failure following central review of the baseline liver biopsy, which can lead to lower enrollment. As a result of such difficulties and the significant competition for recruiting MASH patients in clinical trials, we or our future collaborators may be unable to enroll the patients we need to complete clinical trials on a timely basis, or at all. In addition, our competitors, some of whom have significantly greater resources than we do, are conducting clinical trials for the same indications and seek to enroll patients in their studies that may otherwise be eligible for our clinical studies or trials. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which could further reduce the number of patients who are available for our clinical trials in these sites. The availability of other approved products and other products in clinical trials have and may limit the number of patients willing to participate in our clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Patient enrollment is affected by other factors including:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the severity of the disease under investigation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the eligibility criteria for the study in question;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the perceived risks and benefits of the product candidate under study;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">clinical trials of other product candidates in the same indication;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">laboratory testing and turnaround time for samples needed for eligibility assessments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the patient referral practices of physicians;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our inability to enroll a sufficient number of patients for our clinical trials will result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in clinical trials conducted by us may also result in increased development costs for our product candidates, which would cause the value of the Company to decline and limit our ability to obtain additional financing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our commercialized product, ETUARY, which is approved in the PRC, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025 and any other future product, if approved, may be excluded or removed from national, provincial or other government-sponsored medical insurance programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under medical insurance programs in the PRC, patients are entitled to reimbursement of all or a portion of the cost of pharmaceutical products listed in the NRDL, the relevant provincial reimbursement drug lists, or other medical insurance reimbursement lists. However, such inclusion is based on a variety of factors, including clinical needs, use frequency, efficacy, safety and price, which may be outside of our control. Moreover, the relevant PRC government authorities may, from time to time, review and revise, or change the scope of reimbursement for, the products that are included in the medical insurance reimbursement lists.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">While our product ETUARY, which is approved in the PRC, has been included in the NRDL as a Category B drug for its IPF indication since 2017, there can be no assurance that it will remain so listed, or unimpacted negatively by changes in the scope of reimbursement. To the extent that our future approved product candidates are not included in any medical insurance reimbursement list, or if any such insurance schemes are changed or canceled, which results in the removal of such product candidates from the relevant medical insurance reimbursement lists, patients may choose, and hospitals, pharmacies and other medical institutions may recommend, alternative treatment methods, which may reduce demand for our product, ETUARY, and future products, if approved, and adversely impact our sales.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may face pressure to lower the prices of our commercialized product, ETUARY, which is approved in the PRC, and any other future product, if approved, in order for such products to qualify for medical insurance reimbursement or due to market competition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may face pressure to lower the prices of our commercialized product, ETUARY, which is approved in the PRC, and any other future product, if approved, in order to have such product candidates included in the medical insurance reimbursement lists, while such low price and reimbursement may not necessarily lead to increased sales. It is difficult to estimate the net effect of decreased prices and the potential of increased sales on our profitability, and our profits from the sales of our future products may decrease if we significantly lower prices without a greater increase in sales.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, it is typical that the prices of pharmaceutical products will decline over the life of the product as a result of, among other things, increased competition from substitute products, the tender process by the hospitals or the government authorities, pricing policies of the relevant government authorities, or voluntary price adjustments by pharmaceutical companies. Any strategic downward price adjustments of our existing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">or future approved products due to market competition could have a materially adverse effect on our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Moreover, our marketed product ETUARY is subject to the risk of being included in the PRC&#8217;s centralized volume-based procurement scheme. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;In the future, the policies of centralized volume-based procurement set by the PRC government may cover our commercialized product, ETUARY, and any other future products, if approved, and the prices of such product may decrease, which in turn may have a material adverse impact on our revenue, financial condition and results of operation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Risk Factors section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may fail to win bids to sell our commercialized product, ETUARY, and any other future products, if approved, to PRC public hospitals through the centralized tender process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Because a considerable portion of pharmaceutical products we sell to our distributors are sold to public hospitals and other medical institutions in the PRC, we must submit bids in a centralized tender process to supply our commercialized product, ETUARY, and any other future products, if approved, to these institutions at specified prices. Each public medical institution in the PRC must generally procure drugs through a provincial centralized drug purchase platform and make substantially all of its purchases of pharmaceutical products through a centralized tender process. Our bids submitted in the centralized tender process are generally considered on the basis of price relative to substitute products and the clinical effectiveness of such substitute products, as well as the quality of our product and services, among other things. As a result, our sales volumes and profitability of ETUARY depend on our ability to successfully differentiate our product and price our bids in a manner that enables us to succeed in the centralized tender process at profitable levels.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">However, we may fail to win bids in a centralized tender process due to various factors, including reduced demand for the relevant product, noncompetitive bidding price, failure to meet certain quality requirements, or the relevant products being perceived to be less clinically effective than competing products. If our commercialized product, ETUARY, and any other future products, if approved, are not selected in the centralized tender process in one or more regions, our sales of the relevant product to the public hospitals in those regions may encounter difficulties, and our market share, revenues and profitability could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">In the future, the policies of centralized volume-based procurement set by the PRC government may cover our commercialized product, ETUARY, and any other future products, if approved, and the prices of such product may decrease, which in turn may have a material adverse impact on our revenue, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PRC government authorities have implemented policies that aim to further increase the affordability of pharmaceutical products, including the centralized volume-based drug procurement system. For further details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Business&#8212;Product Pricing&#8212;Centralized Tender Process and Centralized Volume-based Procurement System&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Business&#8212;Regulatory Requirements in the PRC&#8212;Other PRC Regulations in Relation to the Pharmaceutical Industry&#8212;Centralized Drug Procurement and Use</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Future procurement by the PRC government is expected to include drugs listed in the NRDL that have great market demand and high purchase price, and such future procurement is expected to gradually cover all types of domestically marketed drugs in the PRC necessary for clinical use and of reliable quality to the extent possible. As a result, all appropriate drugs may be procured thereunder in the PRC. Appropriate procurement methods for &#8220;orphan drugs&#8221; and drugs in shortage may be actively explored to ensure stable supply.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our marketed product, ETUARY, is currently not subject to the centralized volume-based procurement process. However, it is uncertain whether the centralized volume-based procurement scope would be expanded in the future and result in the inclusion of our product ETUARY, which is approved in the PRC, or other product candidates if commercialized, which may cause their retail prices to decrease. Moreover, if any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">products comparable or similar to our product, generic drugs or product candidates if commercialized are included in the centralized volume-based procurement, patients&#8217; willingness to use such products may be materially and adversely affected and we may need to change our pricing strategy. If any or all of the foregoing were to occur, our sales revenue may decrease, which in turn would have a material adverse impact on our financial condition, profitability and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The true market potential for our product and product candidates may be less than expected. Our expansion could be constrained by the current and emerging number of IPF patients in the PRC, pending the approval and profitable launch of expanded applications for ETUARY for future indications in the PRC, and our other product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products, since the market opportunities for our product candidates may be smaller than we anticipate. Similarly, the actual market size of our product ETUARY, which is approved in the PRC, may not be as large as we anticipate. The total addressable market opportunity will depend on, among other things, acceptance of the product by the medical community and patient access, product pricing and reimbursement. Moreover, the number of patients in the addressable markets may be lower than expected, patients may not be amenable to treatment with our product, or new patients may become increasingly difficult to identify or access. Further, new studies may change the estimated incidence or prevalence of the diseases that our product candidates target. Any of the above unfavorable developments could have a material adverse effect on our business, financial condition and results of operations. In particular, if the existing and newly identified cases of IPF patients in the PRC are fewer than we expect, our growth and financial position may be negatively impacted until and if the expanded indications of ETUARY and our other product candidates such as F351 are approved and become profitable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of IPF in the PRC has increased from 89,002 patients in 2018 to 145,776 patients in 2023, and is expected to increase to 238,000 patients by 2028 and 322,000 patients by 2031. Notwithstanding the short term increase in the prevalence of IPF, with strengthening of the public health system as well as medical and technological advancement in the PRC, the potential risks that cause IPF may be lowered or eliminated in the future which in turn may lead to corresponding decrease in the prevalence of IPF in the PRC. The shrinking prevalence of IPF in the PRC, as a result, may have a negative impact on the market size of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to conduct effective academic marketing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Effective marketing and successful sales are crucial for us to increase the market penetration of ETUARY in the PRC, expand our coverage of hospitals, pharmacies and other medical institutions and promote new products, if any, in the future. In particular, we place a strong emphasis on academic marketing, through which we promote ETUARY to medical professionals, hospitals, pharmacies and other medical institutions. While our sales and marketing force actively works with medical professionals, hospitals, pharmacies and other medical institutions and we endeavor to inform them of the distinctive characteristics, advantages, safety and efficacy of ETUARY as compared to our competitors&#8217; products, we may not be able to successfully enhance our product awareness.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may fail to maintain a qualified sales and marketing force.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In order to successfully market and sell our commercialized product, ETUARY, which is approved in the PRC, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, our sales and marketing teams are expected to possess a relatively high level of technical knowledge, up-to-date understanding of industry trends, necessary expertise in the relevant therapeutic areas and products, as well as sufficient promotion and communication abilities. However, there can be no assurance that there will be a sufficient amount of competent sales professionals with the relevant rare disease knowledge and/or academic KOLs or doctor networks available for hire. As a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">result, if we are unable to effectively train our in-house sales representatives or monitor and evaluate their academic marketing performances, our sales and marketing may be less successful than desired.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Moreover, our ability to attract, motivate and retain a sufficient number of qualified sales professionals is especially important because we primarily rely on our in-house sales force to market our product. As competition for experienced marketing, promotion and sales personnel is intense, we may be unable to attract, motivate and retain a sufficient number of marketing, promotion and sales professionals. If we fail to maintain a qualified sales and marketing force, sales volume of our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, may be adversely affected and we may be unable to expand our coverage of hospitals, pharmacies and other medical institutions or increase our market penetration.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may fail to maintain or expand an effective distribution network for our commercialized product, ETUARY, which is approved in the PRC, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, or further expand our distribution channel.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As we primarily rely on our network of distributors to distribute commercialized product, ETUARY, in the PRC, and intend to continue engaging distributors to sell our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, in the foreseeable future, our ability to maintain and grow our business depends on our ability to maintain and manage a sufficient number of distributors with an extensive sales network, which we could fail to achieve for several reasons. Our distributors may be unable to maintain or expand their sales network, or may encounter difficulties in selling our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, and any other future products, if approved. Our distributors might elect not to renew their agreements with us or otherwise terminate their business relationships with us for various reasons, such as price controls or other factors that substantially reduce the margins they can obtain through the resale of our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, and any other future products, if approved. Further, we may fail to find an appropriate group of distributors suitable for our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, and any other future products, if approved, or the costs of doing so may become prohibitively high. Any disruption to our distribution network, including our failure to maintain relationships, form new relationships or renew our existing distribution agreements, could negatively affect our ability to sell our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, and any other future products, if approved, and may materially and adversely affect our business, results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may fail to sufficiently and promptly respond to clinical demand and market changes in the pharmaceutical industry.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Clinical demand and market conditions for pharmaceutical products may change rapidly and significantly, and our success in part depends on our ability to anticipate product offering lead-times and demand, identify customer preferences and adapt our products to these preferences. We may need to adjust our research and development plan, production scale and schedule, product portfolio and inventory levels based on customer demand, sales trends and other market conditions. However, there can be no assurance that we will be able to sufficiently and promptly respond to changes in clinical demand and purchasing patterns in a timely manner or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Geopolitical events and global economic conditions, such as public health crises, the conflicts between Russia and Ukraine and in the Middle East may impact our third-party supply of the raw materials and components needed for our product, ETUARY, and product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">beyond the PRC, which increases the risk that we will not have sufficient quantities of such product, generic drugs or product candidates or will not have such quantities at an acceptable cost, which will delay, prevent or impair our commercialization, marketing or development efforts, as applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If supplies of the raw materials for our product, ETUARY, or product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, are significantly delayed, or if the third parties that we engage to supply any materials or to manufacture any products for our preclinical tests and clinical trials should cease to continue to do so for any reason, including due to the effects of global economic conditions, including new or increased tariffs and other barriers to trade, trade and other international disputes, inflation and fluctuating interest rates, slower growth or recession, tighter credit, volatility in financial markets, high unemployment, labor availability constraints, public health crises, significant natural disasters, including as a result of climate change, changes to fiscal and monetary policy or government budget dynamics, particularly in the pharmaceutical and biotech areas, political and military conflict, including the conflicts between Russia and Ukraine and in the Middle East, we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For example, trade policies and geopolitical disputes (including as a result of China-Taiwan relations) and other international conflicts can result in tariffs, sanctions and other measures that restrict international trade, and can materially adversely affect our business, particularly if these measures occur in regions where we source our components or raw materials. In addition, tensions between the United States and the PRC have led to a series of tariffs being imposed by the United States on imports from China mainland, as well as other business restrictions. Tariffs increase the costs of the components and raw materials we source. Countries may also adopt other measures, such as controls on imports or exports of goods, technology or data, that could adversely impact the Company&#8217;s operations and supply chain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, if we are not able to obtain adequate supplies of our product, generic drugs or product candidates or the substances used to manufacture them, it will be more difficult for us to commercialize, market or develop our product, generic drugs or product candidates, as applicable, and compete effectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our current and anticipated dependence upon third-party suppliers may adversely affect our ability to develop our product, generic drugs, and product candidates and could delay our clinical trials and development programs as well as marketing and commercialization efforts, and otherwise harm our operations and financial condition and increase our costs and expenses. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;Risks Related to Our Reliance on Third Parties&#8212;Because we rely on a limited number of suppliers for certain of our raw materials, we may experience supply interruptions that could harm our ability to manufacture products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For details regarding the risks related to the relations between the PRC and the United States, see</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> &#8220;&#8212;Risks Related to Our Business Operations in the PRC&#8212;Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our operations, and those of our distributors, suppliers, research institution collaborators and other business partners, could be subject to natural or man-made disasters, health epidemics or business interruptions, for which we are predominantly self-insured. Damage or extended periods of interruption to our and our partners&#8217; administration, development, research, manufacturing or storage facilities due to fire, natural disaster, health epidemic, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development or commercialization of some or all of ETUARY, our generic products or product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">candidates, seriously harm our and our partners&#8217; operations and financial condition and increase our and our partners&#8217; costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited insurance coverage, and any claims beyond our insurance coverage may result in substantial costs and a diversion of resources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We operate in the pharmaceutical industry, which involves numerous operating risks and occupational hazards. The insurance policies we maintain are required under the applicable laws and regulations as well as based on our assessment of our operational needs and industry practice. However, there can be no assurance that the existing insurance coverage is sufficient to compensate for actual losses suffered or incurred. In addition, there are certain types of losses, such as losses from war, acts of terrorism, health or public security hazards, earthquakes, typhoons, flooding and other natural disasters, for which we cannot obtain insurance at a reasonable cost or at all. If an uninsured loss or a loss in excess of insured limits were to occur, our business, results of operations and financial condition may be materially and adversely affected. For details of the specific risks of inadequate insurance coverage in the event of product liability claims and environmental liabilities, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;We may be subject to product liability claims that could expose us to costs and liabilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; and &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">,&#8221; respectively, in this section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications for these product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to identify, discover, or develop new product candidates, or to identify additional therapeutic opportunities for our product candidates, in order to expand or maintain our product pipeline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may not be able to continue to identify and develop new product candidates to enrich our current pipeline. Research programs to pursue the development of our product candidates for additional indications and to identify new product candidates and product targets require substantial technical, financial and human resources. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development. For example, product candidates may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be successfully developed, much less receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will materially and adversely affect our future growth and prospects, which likely would result in significant harm to our financial position and adversely affect our stock price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Results from preclinical or early stage clinical trials, including the results of our preclinical testing and early clinical trials of ETUARY, F351 and F573, may not be confirmed in later trials or be predictive of the success of later clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later-stage clinical trials. Trials of our product candidates in larger numbers of patients may not have similar efficacy results and could result in adverse effects that were not observed in the earlier trials with smaller numbers of patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We will be required to demonstrate substantial evidence through well-controlled clinical trials that our product candidates are safe and effective before we can seek marketing approvals for their commercial sale. Demonstrations of efficacy or an acceptable safety profile in our prior preclinical studies does not mean that future clinical trials will yield the same results. For instance, while ETUARY is approved in the PRC for the treatment of IPF, it may not be approved for the treatment of other indications, such as PD or DKD, or in other markets. In addition, we do not know whether F351 will perform in future clinical trials as F351 has performed in preclinical studies and early clinical trials conducted by us in the PRC, and, despite F351&#8217;s Phase 1 trial in the United States showing promising evidence of tolerability and PK and our Phase 2 clinical trial in the PRC demonstrating results in the reversal of CHB-associated fibrosis. To date, there are no approved therapies for CHB-associated liver fibrosis. We also do not know whether F573 will perform in its Phase 2 clinical trial for ALF/ACLF as it has performed in its Phase 1 clinical observation of tolerability and PK. Product candidates, including ETUARY, F351 and F573, may fail to demonstrate in later-stage clinical trials sufficient safety and efficacy to the satisfaction of the NMPA, FDA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and earlier stage clinical trials. Regulatory authorities may also limit the scope of later-stage trials until we have demonstrated satisfactory safety or efficacy results in earlier-stage trials. In particular, although ETUARY is approved in the PRC for the treatment of IPF, it may not perform in the Phase 3 clinical trial for the treatment of pneumoconiosis or Phase 1 clinical trial of ETUARY for the DKD Program. In addition, we are actively preparing an IND application that we expect to file in the first half of 2025 for a Phase 2 clinical trial to evaluate F351 for the treatment of advanced liver fibrosis associated with noncirrhotic MASH. Following IND clearance, we plan to initiate a Phase 2, PoC clinical trial in 2025 in the United States, subject to positive trends in the Phase 3 trial of F351 in the PRC, to evaluate the safety, tolerability, PK, and PD of F351 for patients with advanced liver fibrosis associated with noncirrhotic MASH. The FDA has reviewed the planned Phase 2 trial of F351 in the United States and provided comments on the design, trial assessment, and the contents of the IND filing. Although data from liver fibrosis associated with CHB patients in our Phase 2 clinical trial in the PRC demonstrated F351 has the potential to improve liver fibrosis, the efficacy of F351 in prior preclinical studies in a MASH model does not mean that future clinical trials will yield the same results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition to the pre-IND guidance provided, at the time of review of the IND application, the NMPA, FDA or other comparable foreign regulatory authorities may require additional investigations (nonclinical) and analyses (both nonclinical and clinical, including the analysis of the supportive clinical trials conducted in the PRC) before it accepts the IND file to ensure that there is sufficient and adequate information on the risks to human subjects. Such additional requests may delay the timelines for the IND filing and initiation of the planned Phase 2 trial in MASH-associated liver fibrosis. Furthermore, if the NMPA or FDA believes that additional data is necessary to supplement our clinical study data and Phase 2 clinical trial data, then the NMPA or the FDA may require us to conduct additional trials before expanding into a broader Phase 2 clinical trial. There is no guarantee that the NMPA, FDA and other comparable foreign regulatory authorities will consider the data that is expected to be obtained in the planned Phase 2 trial in the United States sufficient to allow us to expand the development of F351 in a larger Phase 2 or confirmatory Phase 3 clinical trial. There is no guarantee that we will be able to complete such trials on the timelines we anticipate or that such trials will produce positive results. Any limitation on our ability to conduct clinical trials could delay or prevent regulatory approval or limit the size of the patient population to which we may market our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage MASH clinical trials after achieving positive results in earlier development, and we may face similar setbacks. Many companies that believed their product candidates performed satisfactorily in preclinical studies and early clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the results of clinical trials for our product candidates warrant marketing approval, the NMPA, FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Any Phase 2, Phase 3 or other clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Preliminary, &#8220;top-line&#8221; or interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have publicly disclosed and may in the future publicly disclose preliminary or top-line data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any preliminary or top-line data should be viewed with caution until the final data are available. From time to time, we have also disclosed and may in the future disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the likelihood of approval or commercialization of the particular product candidate and our company in general. In addition, from time to time we may disclose top line or summary information regarding a particular preclinical study or clinical trial. Such summary information is necessarily based on more fulsome and extensive information, and investors or regulators may not agree with what we determine is material or otherwise determine is appropriate information to include in our disclosure. If the preliminary, top-line or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our product, ETUARY, which is approved in the PRC, and product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, may cause or be perceived to cause significant adverse events, toxicities or other undesirable side effects that may result in a safety profile that could interrupt, delay or halt clinical trials, delay or prevent regulatory approval, marketing approval or market acceptance, limit their commercial potential and profile of an approved label, adversely affect our reputation and results of operations or result in significant negative consequences following any regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If our product candidates, including ETUARY, F351, F573, F528 and F230, are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or INDs, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Many times, side effects are only detectable after investigational product candidates are tested in large-scale, Phase 3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our current product candidates and any future product candidates has serious or life-threatening side effects or other side effects that outweigh the potential therapeutic benefit, the development of the product candidate may fail or be delayed, or, if the product candidate has received marketing approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any adverse events or serious adverse events reported in our clinical trials caused by our product candidates could give rise to significant negative consequences. Such consequences may include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">regulatory authorities may order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">regulatory authorities may seek an injunction against our product candidates manufacture or distribution;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw approvals or revoke licenses of an approved product candidate, or we may determine to do so even if not required; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, of an approved product candidate or impose other limitations on an approved product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">regulatory authorities may issue safety alerts, require press releases or other communications containing warnings or other safety information about the product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">regulatory authorities may require us to change the way such product is administered;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">we may be required to develop a REMS for the product candidate, which could include a medication guide outlining the risks of such side effects for distribution to patients, or to incorporate additional requirements under REMS; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">we may be required to conduct additional clinical trials or post-market studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">we could be subject to litigation proceedings and held liable for harm caused to patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">we could be found in breach of contract with our major customers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">patient enrollment may be insufficient or slower than we anticipate or patients may drop out or fail to return for post-treatment follow-up at a higher rate than anticipated;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our commercialized products could be removed from medical insurance reimbursement lists or be rendered unable to participate in the centralized tender process in the PRC;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">regulatory authorities may impose fines, injunctions or criminal penalties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">we may fail to achieve or maintain market acceptance of a particular product candidate, if approved, which may cause serious harm to our business; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Undesirable or unintended side effects may be a result of a number of factors that are outside of our control, including potential side effects not revealed in clinical testing, unusual but severe side effects in isolated cases, defective products not detected by our quality management system, and misuse of our products by end-users.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Further, our product, generic drugs and future products, if approved, may be perceived to cause severe side effects if other pharmaceutical companies&#8217; products containing the same or similar active pharmaceutical ingredients, raw materials or delivery technologies as our product, generic drugs and future products, if approved, cause or are perceived to have caused severe side effects, or if regulators or international institutions determine that products containing the same or similar pharmaceutical ingredients as our product, generic drugs and future products, if approved, cause severe side effects. Our product, generic drugs and future products, if approved, may also be perceived to cause severe side effects when a conclusive determination as to the cause of the severe side effects is not obtained or is unobtainable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In general, the anticipated clinical trials of F351 will include patients with advanced liver fibrosis who are at risk of further progression to cirrhosis and deterioration, but are not critically ill. A certain percentage of patients with HBV-induced liver fibrosis treated with F351 have experienced adverse events, including gastrointestinal diseases, ear and labyrinth diseases, systemic diseases, metabolic and nutritional diseases, skin and subcutaneous tissue diseases, heart organ diseases, and hepatobiliary system diseases. However, the risk/benefit of F351 in MASH may differ from that shown in HBV liver fibrosis patients and there is always a risk that the severity and frequency of the adverse events may worsen. See the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;Business&#8212;Our Product Candidate For Liver Fibrosis: F351 (Hydronidone)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, the patient populations treated with our product candidates in our various Phase 3 clinical trials have serious diseases that make them susceptible to significant health risks. Therefore, these patients may experience adverse events, including serious adverse events.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">In conducting drug research and development, we face potential liabilities; in particular, product liability claims or lawsuits that could cause us to incur substantial liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability as a result of clinical trials if our product candidates cause, or are perceived to cause, injury, or are found to be otherwise unsuitable during clinical testing. Regardless of the merits or eventual outcome, such liability claims may, among others, result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">decreased demand for our product candidates after commercialization; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants and inability to continue clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">a diversion of management&#8217;s time and our resources; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To cover such liability claims arising from clinical trials, we have clinical trial insurance for all of our trials, which are necessary for the approval of commercialization of our pipeline products. However, it is possible that our liabilities could exceed our insurance coverage or that our insurance will not cover all situations in which a claim against us could be made. We may also not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse drug reactions and negative results from off-label use of our commercialized product, ETUARY, which is approved in the PRC, future commercialized products, including nintedanib and avatrombopag,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">which we expect to commercialize in 2025, and any other future products, if approved, could materially harm our business reputation, product brand name, and financial condition and expose us to liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Products distributed or sold in the pharmaceutical market may be subject to off-label drug use, and may be prescribed for an indication, dosage or in a dosage form that is not in accordance with regulatory approved usage and labeling. As such, our product, ETUARY, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and future products, if approved, may be subject to off-label drug use and may be prescribed to a patient population, or in a dosage or dosage form that has not been approved by competent authorities, which may render our product, generic drugs and future products, if approved, less effective or entirely ineffective and cause adverse drug reactions. Any of these occurrences can create negative publicity and significantly harm our business reputation, product brand name, commercial operations and financial condition, including our share price. These occurrences may also expose us to liability and cause, or lead to, a delay in the progress of our clinical trials and may ultimately result in failure to obtain regulatory approval for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Breakthrough Therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 was granted a Breakthrough Therapy designation by the PRC&#8217;s NMPA&#8217;s CDE in March 2021 and the patient enrollment for its Phase 3 clinical trial was commenced in January 2022. However, F351&#8217;s Breakthrough Therapy designation does not increase the likelihood that F351 will ultimately receive approval from the NMPA or other comparable regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may, in the future, apply for Breakthrough Therapy designation in the United States, or the equivalent thereof in other foreign jurisdictions (where available), for our product candidates, depending on robustness of the clinical benefit in clinical trials. In the United States, Breakthrough Therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the NDA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Relating to Manufacture and Supply of Our Product and Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing pharmaceutical products on a large commercial scale is highly exacting and complex, and we and our third-party manufacturers may encounter problems during the process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The manufacturing of pharmaceutical products is highly complex, and problems may arise during manufacturing for a variety of reasons, including, but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">equipment malfunction;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">failure to follow specific protocols and procedures;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">changes in product specification;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">low quality or insufficient supply of raw materials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">delays in the construction of new facilities or the expansion of our existing manufacturing facilities and limits to manufacturing capacity due to regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">changes in the types of products produced;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">advances in manufacturing techniques;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">physical limitations that may inhibit continuous supply;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">man-made or natural damages, other disasters and environmental factors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">shortage of qualified personnel or key contractors. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Despite our quality control and assurance system and procedures, we may not be able to eliminate such risks, which may delay or suspend our manufacturing activities, and we may not be able to secure temporary, alternative manufacturers for our product, generic drugs or product candidates with the terms, quality and costs acceptable to us, or at all. If we encounter any manufacturing problems, including those listed above, our clinical trials and/or the availability of our product, ETUARY, which is approved in the PRC, generic drugs and future products, if approved, for commercial sale may be delayed, and we may spend significant time and costs in order to rectify such problems and maintain production at our manufacturing facilities. Moreover, products with quality issues may have to be discarded, resulting in product shortages or additional expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, manufacturing methods and formulation are sometimes altered through the development of product candidates from clinical trials to approval, and further to commercialization, in an effort to optimize manufacturing processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause the product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay the commercialization of product candidates and require bridging studies or the repetition of one or more clinical trials, which may result in increases in clinical trial costs, delays in product approvals and jeopardize our ability to commence product sales and generate revenue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We plan to use F351 capsules manufactured by Wuxi Biologics, and may continue to use foreign CROs and CMOs in the future. Wuxi Biologics has completed manufacturing one lot of the F351 capsules for our planned Phase 2 clinical trial in the U.S. WuXi Biologics is identified in the U.S. legislation known as the BIOSECURE Act, which was proposed in the 118th Congress, as a &#8220;biotechnology company of concern.&#8221; The version of the BIOSECURE Act introduced in the U.S. House of Representatives during the 118th Congress would prohibit federal agencies from entering into procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a biotechnology company of concern, and includes a grandfathering provision allowing biotechnology equipment and services provided or produced by named &#8220;biotechnology companies of concern&#8221; under a contract or agreement entered into before the effective date until January 1, 2032. The pathway and timing for the BIOSECURE Act or its provisions to become law are uncertain. Foreign CMOs may be subject to U.S. legislation, including the proposed BIOSECURE Act, sanctions and trade restrictions and requirements by foreign regulators, which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For example, the biopharmaceutical industry in the PRC is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in the PRC which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in the PRC&#8217;s public health, economic, political, and social conditions and the uncertainty around the PRC&#8217;s relationship with other governments, such as the United States and the U.K., could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical development programs. For more details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Business Operations in the PRC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, we plan to enter into various development, manufacturing and clinical supply services agreements with third-party manufacturers for drug substance and drug product manufacturing of our other product candidates. If our third-party manufacturers are not able to provide sufficient quantities or quality of our product candidates on a timely basis, or at all, whether due to production shortages or other supply delays or interruptions resulting from public health crises or otherwise, our preclinical trials, clinical trials or regulatory approvals, as applicable, may be delayed. Significant portions of our research and development resources are focused on manufacturing. If any of our third-party manufacturers experiences difficulties in scaling production or experiences product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error or improper storage conditions, the potential trials of the affected product candidate would be delayed, perhaps substantially, which could materially and adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We and our contract manufacturers will be subject to significant regulation with respect to manufacturing our product, ETUARY, which is approved in the PRC, and our product candidates. Delays in completing and receiving regulatory approvals for our and our third-party manufacturing facilities could delay our development plans or commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including us and any contract manufacturers for ETUARY and our other product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product, generic drugs or product candidates that may not be detectable in final product testing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our existing and planned manufacturing facilities, as well as our manufacturing process, and our third-party manufacturing facilities and process, will be subject to ongoing, periodic inspection by the NMPA, the FDA or other comparable regulatory agencies to ensure compliance with GMP, which is usually the prerequisite to obtain marketing approval. Moreover, we and our third-party manufacturers must obtain various permits, certificates and other approvals for our manufacturing facilities and other premises from the relevant administrative authorities at various stages of property development, including, planning permits, construction permits, land use rights certificates, environmental assessments, fire control assessments, construction completion inspections and ownership certificates. Failure to comply with applicable regulations could lead to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">increased expense and result in sanctions being imposed on us (including fines, injunctions, civil penalties, requirements to suspend or pause one or more of our clinical trials); </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">failure to obtain marketing approval of our product candidates; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">delays, suspension or withdrawal of approvals; supply disruptions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">license revocation; seizures or recalls of product, generic drugs or product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">operating restrictions and criminal prosecutions, any of which could materially and adversely harm our business.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may experience substantial disruption to our production sites and problems in manufacturing our product, ETUARY, which is approved in the PRC, and future products, if approved.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are dependent on our manufacturing facilities in Beijing, PRC and Cangzhou, PRC. The continued operation of our manufacturing facilities and our production safety may be substantially interrupted due to a number of factors, many of which are outside of our control. These factors may include fire, flood, earthquakes, power outages, fuel shortages, mechanical breakdowns, terrorist attacks and wars, or other natural disasters, as well as loss of licenses, certifications and permits, changes in governmental planning for the land underlying these facilities or their vicinity and regulatory changes. Moreover, the production activities on our manufacturing facilities may be suspended on a temporary basis due to governmental policies or regulations, including that on environmental protection or organizing public events. If the operation of any of our manufacturing facilities is substantially disrupted, we may not be able to replace the equipment or inventories at such facilities, or use different sites or a third-party contractor to continue our production in a legal, timely and cost-effective manner or at all. Although we maintain property insurance for certain properties, machinery and equipment and other assets owned, operated or deemed important for us, in line with industry practice in the PRC, we do not have certain types of insurance, such as business interruption insurance. The amount and nature of our insurance coverage may not be sufficient to cover any substantial losses in the event of a significant disruption to any of our manufacturing facilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Since September 2021, as a result of the shortage of coal supply combined with high electricity demand from manufacturers, the PRC has experienced widespread power outages. The PRC government has imposed power curbs, including imposing power restrictions on factories in a number of provinces in the PRC to deal with an imbalance in energy supply and demand. As of December 31, 2024, we have not received any notice from relevant government authorities ordering us to temporarily suspend or limit production, and our Beijing and Cangzhou production centers were not subject to any power restrictions. The PRC government imposed power restrictions did not have a material adverse impact on our business operations or financial performance during the years ended December 31, 2024 and 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to meet the increasing demand for our commercialized product, ETUARY, which is approved in the PRC, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, maintain adequate manufacturing capacity or successfully manage our anticipated growth.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To produce ETUARY, nintedanib, avatrombopag and our increasing number of product candidates, if approved, in the quantities that we believe will be required to meet anticipated market demand, we may need to increase our production capacity over the initial level of production by constructing new manufacturing facilities and production lines. However, our ability to successfully implement our expansion plan for increasing production capacities is subject to a number of risks and uncertainties, including, but not limited to, the risk of construction delays and delays in equipment procurement, and our ability to timely recruit sufficient qualified staff to support the increase in our production capacity. If we are unable to do so, are delayed, face costs that are not economically feasible or cannot find a third-party manufacturer, we may not be able to produce ETUARY and our future approved product candidates, if any, in sufficient quantities to meet future demand. Moreover, our plans to increase our production capacities require significant capital investment and the actual costs of our expansion plan may exceed our original estimates, which could adversely affect the return on our expenditure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, given the size of our existing and planned manufacturing facilities, we may not be able to fully utilize within a reasonable period of time after we commence operation. During the construction and ramp-up period, there may be significant changes in the macroeconomics of the pharmaceutical industry, including, among other things, market demand, product and supply pricing trends and customer preferences. Any adverse trends in this area could result in operational inefficiency and unused capacity in our facilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fluctuations in prices of our raw materials and energy supply, as well as other costs associated with our production processes, may have a material adverse effect on us if we are not able to pass the cost increases on to our customers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In order to manufacture our commercialized product, ETUARY, which is approved in the PRC, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, we must obtain sufficient quantities of high-quality raw materials and stable supply of energy and power at commercially acceptable prices and in a timely manner, which exposes us to risks associated with fluctuations in prices of raw materials. The prices of such materials may be affected by a number of factors, including market supply and demand, the PRC, the United States or international environmental and regulatory requirements, natural disasters and the global and local economic conditions. In addition, we may be subject to fluctuations in other costs associated with our production processes, such as costs of waste disposal, which are beyond our control. We may have limited capability to increase our revenue in a timely manner, and a significant increase in such costs may increase our cost of sales and negatively affect our profit margins.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to maintain optimal inventory levels could increase our operating costs or lead to unfulfilled customer orders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are required to maintain optimal inventory levels in order to satisfy demand coming from our distribution network and successfully meet our customers&#8217; demand. However, we may not be able to maintain proper inventory levels of our commercialized product, ETUARY, which is approved in the PRC, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, generic drugs and any other future products, if approved, as a result of rapid changes in product life cycles, changing clinical demands and uncertainty of product developments and launches, as well as the volatile economic environment in the PRC. There can be no assurance that we can accurately predict these trends and events and avoid over-stocking or under-stocking our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, generic drugs and any other future products, if approved. Further, demand for our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, generic drugs and any other future products, if approved, could change significantly between the time when the products are ordered and the time they are ready for delivery.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventory levels in excess of demand may result in inventory write-downs, expiration of our product or an increase in inventory holding costs and a potential negative effect on our liquidity. On the other hand, if we underestimate demand, we may experience inventory shortages which may, in turn, result in unfulfilled customer orders, leading to a negative impact on our customer relationships.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We have established, and may continue to establish, collaborative agreements and strategic partnerships. However, there is no guarantee we will fully achieve the anticipated benefits from these collaborations, alliances, or licensing agreements, and conflicts could emerge with our present or prospective partners.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have in the past formed, and may in the future seek and form, strategic alliances, joint ventures or other collaborations, including entering into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our existing commercialized products, ETUARY, nintedanib and avatrombopag, which are approved in the PRC, generic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">drugs and product candidates, including ETUARY, F351, F573, F528, F230, and any future product candidates that we may develop. Our strategic collaboration with partners involves numerous risks. We may not achieve the revenue and cost synergies expected from the transactions, as such synergies are inherently uncertain and subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and are beyond our control. In addition, the synergies from our collaboration with our partners may be offset by other costs incurred during the collaboration, including increases in other expenses, operating losses or problems in the business unrelated to our collaboration.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Moreover, disputes may arise between us and our current or future collaboration partners. Such disputes or our partners&#8217; failure to fully perform their obligations may cause delay or termination of the research, development or commercialization of our product, generic drugs or product candidates, or result in costly litigation or arbitration that may divert management attention and resources. In particular, international business relationships subject us to additional risks that may materially and adversely affect our ability to attain or sustain profitable operations, including, difficulty of effective enforcement of contractual provisions in local jurisdictions, and third-party collaborators may not properly obtain, maintain, protect or enforce our patent, trade secret and other intellectual property rights and regulatory exclusivity for our product, generic drugs or product candidates or may use our intellectual property that exposes us to potential litigation or other intellectual property-related proceedings that could jeopardize or invalidate our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we can reach a definitive agreement with a collaborator will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of preclinical trials, the likelihood of approval by the NMPA, FDA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative products, product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us. There can also be no assurance that we will enter into any collaboration agreements, or that any such agreements will be on favorable terms.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Collaborations are complex and time consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, and increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our rights to develop and commercialize some of our product candidates, are subject, in part, to the terms and conditions of licenses granted to us by others.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The success of our collaborations with our partners depends on each party&#8217;s performing its respective obligations under the relevant collaboration agreement. Such agreements may impose on us diligence obligations in product development or commercialization, payment obligations when certain development or regulatory milestones and sales are achieved and other obligations. If we fail to comply with our obligations under our current or future agreements, our counterparties may have the right to terminate these agreements, in which event we may not be able to develop, manufacture or market the product candidate that is covered</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">under the agreements. Termination of the licenses or assignments provided for under these agreements or reduction or elimination of our rights under these agreements may result in us having to negotiate new or amended agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, we may not have the exclusive right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the product or product candidates that we are licensed or assigned from third parties. In the event that these patents and patent applications are not prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business, our rights to the relevant intellectual property may be reduced or eliminated, and our right to develop and commercialize the product, generic drugs or product candidates covered under the agreement could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Moreover, the third parties on whom we rely with respect to licenses to certain patent rights and other intellectual property rights that are important or necessary to the development, manufacture or commercialization of our product, generic drugs or product candidates may themselves rely on upstream licenses from other third parties. Such sub-licenses may not provide exclusive rights to use the covered intellectual property in all relevant fields of use or in all territories in which we may wish to develop or commercialize our product candidates, and add further uncertainties and complications as to the scope of our rights under the relevant agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Further, the license or assignment agreements we have entered into, or will enter into in the future, are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our advancement through our collaboration relationship with its partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct certain aspects of our preclinical studies and any clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such tasks or trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We rely on third parties such as CROs, medical institutions and clinical investigators to conduct certain aspects of preclinical development, including assay development and testing, and to enroll qualified patients and conduct, supervise and monitor clinical trials. For more details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;Business&#8212;Our Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Annual Report. Our reliance on these third parties for preclinical and clinical development activities reduces our control over these activities. Our reliance on these third parties, however, will not relieve us of our regulatory responsibilities, including ensuring that our clinical studies are conducted in accordance with good clinical practices, and the investigational plan and protocols contained in the relevant regulatory application, such as an IND. In addition, the CROs with whom we contracts may not complete activities on schedule or may not conduct our preclinical studies or clinical studies in accordance with regulatory requirements or our clinical study design. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, compromise the quality or accuracy of the clinical data obtained by CROs or our investigators due to failure to adhere to our clinical protocols or regulatory requirements, or the quality of the products manufactured fails to comply with GMP, our efforts to complete development and obtain regulatory approvals for, and to commercialize, our product, generic drugs and product candidates may be delayed or prevented.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, we, our CROs for clinical programs and our investigators are required to comply with GCP for all of our product candidates in clinical development. If we or any of our CROs or investigators fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the NMPA, FDA or comparable regulatory authorities may require us to perform additional clinical trials before considering whether to approve our marketing applications, which would delay the regulatory approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">If our distributors act in violation of the relevant agreements, or if sub-distributors with whom we have not entered into distribution agreements do not comply with policies and measures that our distributors agree to comply with, our business, prospects and reputation could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">While we rely on the distribution agreements and the policies and measures we have in place to manage our distributors, we cannot guarantee that these agreements, policies and measures will be able to effectively manage our distributors, or that our distributors will comply with our agreements and policies. If our distributors take one or more of the following actions, our business, results of operations, prospects and reputation may be adversely affected:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">failing to distribute our product, generic drugs and future products, if approved, in the manner we contemplate, impairing the effectiveness of our distribution network;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">breaching the distribution agreements or our policies and measures;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">failing to maintain the requisite licenses, permits or approvals or failure to comply with applicable regulatory requirements; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">violating any applicable anti-corruption, anti-bribery, competition or other laws and regulations. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any such actual or alleged violation or non-compliance by our distributors of the distribution agreements, our policies or any applicable laws and regulations could result in the erosion of our goodwill, expose us to liabilities, disrupt our distribution network and create an unfavorable public perception about the quality of our product, ETUARY, generic drugs and future products, if approved.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Moreover, some of our distributors engage sub-distributors to distribute our product, and we do not engage these sub-distributors directly or maintain contractual relationships with them. Instead, we mainly rely on our distributors to manage and control their sub-distributors in accordance with regulatory requirements, the terms of the distribution agreements between us and our distributors and our policies for our distributors. Since our control is limited over these sub-distributors, there is no assurance that the sub-distributors will comply with the geographical restrictions agreed to with our distributors or other distribution requirements under our distribution agreements and policies. As a result, there can be no assurance that we will be able to identify or remediate any practices by any sub-distributors&#8217; that may be detrimental to our business in a timely manner or at all, which may adversely affect our results of operations and reputation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Because we rely on a limited number of suppliers for certain of our raw materials, we may experience supply interruptions that could harm our ability to manufacture products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, we had a small number of suppliers, with whom we believe we have stable relationships. However, the stability of operations and business strategies of our suppliers are beyond our control, and there can be no assurance that we will be able to maintain a stable relationship and high-quality outsourced raw materials or services with our large suppliers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to Employee Matters, Managing Growth and Our Business Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our ongoing success is reliant on our capacity to retain key executives and to recruit, maintain, and inspire skilled professionals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our executive management and scientific personnel. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. In addition, we will need to add personnel to achieve our business objectives. The loss of the services of any of our executive officers,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">other key employees, and our inability to find suitable replacements, or our inability to hire new clinical development and manufacturing personnel, could result in delays in product development and harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We conduct our U.S. operations at our facility in San Diego, California. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. In the PRC, we compete for qualified personnel with other pharmaceutical and biotechnology companies, universities and research institutions. The pool of suitable candidates is limited, and we may not be able to hire and retain enough skilled and experienced scientists or other technical personnel at the current level of wages, and may need to offer higher compensation and other benefits, which could materially and adversely affect our financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">To induce valuable employees to remain with us, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of management and scientific and development teams have terminated and may terminate their employment with us on short notice. Our employees are under at-will employment arrangements, which means that any of our employees can leave employment with us at any time, with or without notice. Failure to retain, replace or recruit personnel could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product, generic drugs and product candidates, harming future marketing approvals, sales of our product, generic drugs and product candidates and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the NMPA, FDA, SEC and non-PRC and non-U.S. regulators, to provide accurate information to the NMPA, FDA and non-PRC and non-U.S. regulators, to comply with healthcare fraud and abuse laws and regulations in the PRC, United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained during clinical studies that could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance with regulations related to operating as a public company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As a public company, we have and will continue to incur significant legal, accounting and other expenses, including costs associated with public company reporting and corporate governance requirements, in order to comply with the rules and regulations imposed by the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection, as well as rules implemented by the SEC and Nasdaq. Stockholder activism, the political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways that are not currently anticipated. Our management and other personnel need to devote a substantial amount of time to compliance with regulations related to operating as a public company. In addition, these rules and regulations make it difficult and expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain our current levels of such coverage. We expect that we will annually incur significant expenses to comply with the requirements imposed on us as a public company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our management team has not previously managed and operated a U.S. public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that we comply with all of these requirements. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Increased labor costs negatively affect our operations and have an adverse impact on our profitability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our strategies and business growth may require us to hire additional employees, and we may also hire additional employees as a result of acquisitions. The average cost of labor in the PRC has been steadily increasing in recent years as a result of inflation, government-mandated wage increases and other changes in PRC labor laws, as well as competition for talent and qualified employees among pharmaceutical companies. As a result, increased labor costs could have negative effects on our growth and decrease our profitability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Should we or our licensors fail to secure, uphold, defend, or extend adequate patent and other intellectual property rights for our products, ETUARY, nintedanib and avatrombopag, which are approved in the PRC, and any product candidates globally, or if the breadth of these intellectual property rights is insufficient, our ability to effectively compete in our markets could be compromised.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our products, ETUARY, nintedanib and avatrombopag, which are approved in the PRC, and product candidates. In order to protect the technologies, products and product candidates that we consider commercially important, we have filed and continue to file patent applications in the PRC, United States and other countries. However, applying for patent protection is an expensive and time-consuming process, and we may not be able to successfully file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may not be able to prevent competitors from developing and commercializing competitive products in all such fields and territories.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. For example, there can be no assurance that we were the first to make the inventions claimed in our patents or pending patent applications because of the delay between publications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">of discoveries in scientific or patent literature and actual discoveries and patent applications. Under the &#8220;first-to-file&#8221; system adopted by the PRC, and the United States, even after reasonable investigation, we may be unable to determine with certainty whether our product, product candidates, processes, technologies, improvement and other related matters are or may become unpatentable because a third party filed or may file a patent application earlier than we have or do for inventions thereunder that are the same or substantially similar to our inventions. Additionally, the USPTO and patent offices in other jurisdictions have often required that patent applications directed to pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. Accordingly, even if we or our licensors are able to obtain patents, the patents might be substantially narrower than anticipated. Thus, there is no assurance as to the degree and range of protections any of our patents, if issued, may afford us or whether patents will be issues. Third parties may challenge the validity, enforceability or scope of our patents, which may result in those patents being narrowed or invalidated. The patent applications that we own may fail to result in issued patents with claims that cover our product and product candidates in the PRC, United States or in other foreign countries. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product or product candidates or prevent others from designing around our claims. Certain of our patents also cover processes, for which enforcement can be difficult. Any of these outcomes could impair our ability to prevent competition from third parties that may have an adverse impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If the patents or patent applications we hold or have in-licensed for ETUARY, our programs or product candidates are invalidated or fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product or product candidates, it could threaten our ability to commercialize future products. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. In the PRC, the amendment to the PRC Patent Law (the &#8220;Amended PRC Patent Law&#8221;) provides for patent term extension and patent linkage. The Amended PRC Patent Law and relevant implementing regulations provide a cause of action to allow a patent holder to initiate a declarative action during the regulatory review process of a drug to determine whether the drug in review falls within the relevant scope of the patent of such patent holder, which may be comparable to the patent linkage system in the United States. The system requires that the NMPA continue to review the potentially infringing follow-on application during any lawsuit by the innovator. However, the NMPA may not approve the follow-on application pending resolution of the patent litigation in favor of the follow-on application or for a specified period of time, whichever is shorter. The Amended PRC Patent Law and relevant implementing regulations also provide patent term extension, similar to the United States, for the patent term lost during the regulatory review process of a new drug upon the patent holder&#8217;s request. The extended term shall not exceed five years, and the total patent term of the new drug from the date of its market approval shall not exceed 14 years. However, subject to the decision of relevant authorities, the patents we have in-licensed or own in the PRC may not be eligible to be extended for any patent term lost during the regulatory review process. Various extensions may be available; however the life of a patent, and the protection it affords, is limited. Once the patent life has expired for a product, we may be subject to competition from generic medications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent and other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining the physical security of our premises and physical and electronic security of our information technology systems. Enforcing a claim that a party illegally obtained and is using our trade secrets is challenging and the outcome is unpredictable. In addition, courts outside of the United States may be less willing to protect trade secrets. While we have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Although we expect all of our employees and consultants to assign their applicable inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide guarantee that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. Moreover, some of our employees, including senior management, may have been employed at other pharmaceutical companies, including our competitors or potential competitors. Such employees may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. We may be subject to claims these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. In the event that litigation is necessary to defend against such claims, we may be subject to monetary damages and lose valuable intellectual property rights or personnel.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Further, filing, prosecuting and defending patents on our product, ETUARY, and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the PRC and United States are less extensive than those in the PRC and United States. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the PRC or United States. As a result, we may encounter significant problems in protecting and defending our intellectual property in the PRC, United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. In addition, we may be involved in claims and disputes of intellectual property infringement in other jurisdictions, and the defense of these claims or disputes, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The China National Intellectual Property Administration (the &#8220;CNIPA&#8221;) and other governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. For example, in several stages over the lifetime of a patent, periodic maintenance fees are due to be paid to the CNIPA and other patent agencies. Although an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, non-compliance could result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Such non-compliance events may include failure to respond to official actions in a timely manner, non-payment of fees, and failure to properly submit formal documents. In addition, under PRC patent law, any applicant that applies for a patent in a foreign country for an invention or utility model accomplished in the PRC must report to the CNIPA for confidentiality examination. If the applicant fails to report to the CNIPA for confidentiality examination, the patent right may not be granted if an application is later filed in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The scope of our patent protection may be uncertain, and third-party claims of intellectual property infringement or challenging the inventorship or ownership of our patents may prevent or delay our development and commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future are to be issued as patents, they may not be issued in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. In addition, the patent position of medical device companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the PRC and United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, third-party submissions of prior art to the CNIPA, USPTO or other related intellectual property offices, oppositions, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reexamination proceedings before the CNIPA, USPTO, and corresponding foreign patent offices and post-grant proceedings such as opposition, derivation, revocation, invalidation, re-examination or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> review, or interference proceedings or similar proceedings in foreign jurisdictions challenging the priority of our invention or other features of patentability of our patents and patent applications. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product, ETUARY, and product candidates may be subject to claims of infringement of the patent rights of third parties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Third parties may assert that the manufacture, use or sale of our product, ETUARY, and our product candidates infringes patents held by such third parties, or that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product, generic drugs and product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or current product may infringe.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief that could effectively block our ability to further develop and commercialize one or more of our product, ETUARY, and our product candidates unless we redesigned infringing products (which may be impossible) or obtained a license under the applicable patents (which may not be available on commercially reasonable terms or at all), or until such patents expire.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents. To counter infringement or unauthorized use, we or our collaborators may be required to file infringement claims that can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one of our patents is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse determination or outcome of a third-party submission, proceeding or litigation may result in loss of patent rights or exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to prevent competitors from using or commercializing similar or identical technologies and products, or limit the duration of the patent protection of our technologies, product, ETUARY, and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the PRC or United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims, regardless of their merit, would cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, in addition to paying royalties, redesign infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law could diminish the value of patents generally, which may impair our ability to protect ETUARY and our product candidate pipeline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Decisions made by the National People&#8217;s Congress of the PRC and the CNIPA could change the laws and regulations governing patents in unpredictable ways that may affect our ability to obtain new patents or to enforce our existing patents and/or future patents. The United States has enacted and is currently implementing wide-ranging patent reform legislation. In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. Similar changes in the laws of other jurisdictions may impact the value of our patent rights or our other intellectual property rights. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, there is uncertainty with respect to the value of patents once obtained, if any. As the laws and regulations governing patents evolve in the PRC and other jurisdictions, such changes may have a negative impact on our intellectual property protection.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A third-party may hold intellectual property, including patent rights, that is important to or necessary for the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may fail to protect our trademarks and trade names, which may negatively affect our ability to build brand recognition in our markets of interest.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We currently own issued trademark registrations and have trademark applications pending in order to build name recognition among potential partners and customers in our markets of interest. However, such trademark registrations and applications subject us to risks of trademark invalidity, dilution and infringement. Our trademark registrations and applications may be subject to a governmental or third-party objection, and may be challenged, infringed, circumvented or declared generic. If an issued trademark registration or trademark application is successfully challenged, then we may not be able to register or maintain such trademark registration or application. Moreover, as our product, ETUARY, continues to be marketed, such product&#8217;s reliance on our trademarks to differentiate us from our competitors may increase. We may not be able to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our trademark rights, or from engaging in conduct that constitutes unfair competition, defamation or other violations of our trademark rights. In addition, owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names may pursue trade name or trademark infringement claims against us. If we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively in our markets of interest, and our business may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights may not address all potential threats to our business or competitive advantage.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The degree of protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. The limitations of currently available intellectual property protection regimes include that:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">others may be able to make products that are similar to ETUARY or our product candidates or utilize similar technologies that are not covered by our owned and licensed patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the proprietary technologies on which we rely may not be patentable; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">we may choose not to file a patent for certain trade secrets or know-how, yet a third party may subsequently file a patent covering such intellectual property. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to Regulatory Approval of Our Product Candidates and Other Compliance Matters</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">All material aspects of research, development, manufacturing and commercialization of our product, ETUARY, which is approved in the PRC, and product candidates are heavily regulated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Obtaining regulatory approvals and maintaining compliance with applicable laws and regulations is a lengthy, expensive and uncertain process which requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the drug development process or approval process, or after approval, may subject us to administrative or judicial sanctions. These sanctions could include, but are not limited to, a regulator&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, warning or untitled letters, voluntary or mandatory product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">recalls, product seizures, total or partial suspension of production or distribution, import alerts, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The approval procedures of the NMPA, FDA, and comparable foreign regulatory authorities are extensive, protracted, and inherently uncertain. Failure to secure necessary approvals, or encountering delays in the approval process, will prevent us from marketing our product candidates, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, which may significantly affect our revenue generation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The process of obtaining regulatory approvals, in the PRC, United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other than certain generic drugs, we have only three successfully approved products: (i) ETUARY, which is approved in the PRC for the treatment of IPF; (ii) nintedanib, which is approved in the PRC for the treatment of IPF; and (iii) avatrombopag maleate tablets for the treatment of thrombocytopenia (&#8220;TP&#8221;) associated with chronic liver disease (&#8220;CLD&#8221;) in adult patients undergoing elective diagnostics procedures or therapy. We also received approval to expand the indication for avatrombopag maleate tables to include chronic idiopathic thrombocytopenia ("ITP") in January 2025. However, only ETUARY is currently commercialized. We expect to commercially launch nintedanib and avatrombopag in 2025. ETUARY is currently in its Phase 3 clinical trial for the treatment of pneumoconiosis and Phase 1 clinical trial of ETUARY for the DKD Program. Although ETUARY is approved in the PRC for the treatment of one indication, we may be unable to successfully commercialize ETUARY in the PRC for the treatment of other indications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, F351 is currently in its Phase 3 clinical trial in the PRC for liver fibrosis associated with CHB. In addition, F351 currently has one active IND application with the FDA in the United States for the treatment of liver fibrosis associated with a broad spectrum of chronic liver diseases. In the future, it is expected that an additional IND will be filed for F351 specifically for liver fibrosis associated with MASH, and we may file additional IND applications for future indications or future product candidates. If any such future IND is not timely cleared by the FDA, our clinical development timeline may be negatively impacted and any future clinical programs may be delayed or terminated. As a result, we may be unable to obtain regulatory approvals or successfully commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We also have an early clinical-stage product pipeline that includes F573 for ALF/ACLF treatment. F573 has entered into Phase 2 clinical trials in the PRC. We completed our Phase 1 clinical observations of tolerability and PK in July 2022 and initiated our Phase 2 clinical study of F573 in March 2023. We have also established a tiered preclinical product pipeline. For instance, we are researching and developing F528 for the treatment of COPD. In addition, our product candidate F230 is currently in its preclinical phase and has demonstrated the potential to significantly alleviate PAH in animal studies. In March 2024, we submitted an IND application for F230 in the PRC, and in May 2024, the NMPA approved such IND.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure at any stage of drug development, including failure to demonstrate efficacy in a clinical trial or across a suitable population of patients, the occurrence of severe or medically or commercially unacceptable adverse events, failure to comply with protocols or applicable regulatory requirements and determination by the NMPA, FDA or any comparable foreign regulatory authority that a drug product is not approvable. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We cannot commercialize product candidates in the PRC or United States without first obtaining regulatory approval from the NMPA or the FDA, respectively. Similarly, we cannot commercialize product candidates outside of the PRC or United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The NMPA, FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the NMPA, FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may be unable to demonstrate to the satisfaction of the NMPA, FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the NMPA, FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the NMPA, FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the PRC, United States or elsewhere, and we may be required to conduct additional clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the NMPA, FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the NMPA, FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contracts for clinical and commercial supplies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the NMPA, FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The approval requirements for our product candidates are likely to vary by jurisdiction such that success in one jurisdiction is not necessarily predicative of success elsewhere.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the availability of financial resources to commence and complete the planned trials;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">obtaining approval at each clinical trial site by an IRB;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">recruiting suitable patients to participate in trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">having patients complete a trial or return for post-treatment follow-up;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">adding new clinical trial sites&#894; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">manufacturing sufficient quantities of qualified materials under Current Good Manufacturing Practice (&#8220;cGMPs&#8221;) regulations and applying them on a subject-by-subject basis for use in clinical trials.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We could also experience delays in obtaining approval if physicians encounter unresolved ethical issues, including but not limited to those associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles given the serious nature of the diseases for the core indications for our product candidates. Additionally, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which the trials are being conducted, the Data Monitoring Committee for the trial, or by the NMPA, FDA or other regulatory authorities for a number of reasons, including failure to conduct the clinical trial in accordance with regulatory requirements or its clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues, or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, the FDA review and approval process could be delayed by any future shutdown of the U.S. government, and our development activities could be harmed or delayed as a result. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, our ability to commercialize our product candidates will be harmed and our ability to generate revenue will be materially impaired. Additionally, delays in completing trials will increase costs, delay our product development and approval process, and impair our ability to commence product sales and generate revenue. Many of the factors that could create or lead to a delay in the commencement or completion of clinical trials may lead to the denial of regulatory approval for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the NMPA,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, which would significantly harm our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If we were to obtain approval, regulatory authorities may approve any of our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be materially impaired.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We are developing F351 for the treatment of liver fibrosis associated with MASH. The requirements for approval of F351 by the NMPA,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">FDA and comparable foreign regulatory authorities are unknown, may be difficult to predict, and may change over time, which makes it difficult to predict the timing and costs of clinical development and the likelihood of marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are developing F351 for the treatment of liver fibrosis associated with MASH. Although there are guidelines issued by the FDA for the development of drugs for the treatment of MASH, the development of a novel product candidate such as F351 may be more expensive and take longer in the United States than for other, better known or extensively studied product candidates. As other companies are in later stages of clinical trials for their potential MASH therapies, we expect that the path for regulatory approval for MASH therapies may continue to evolve in the near term as these other companies refine their regulatory approval strategies and interact with regulatory authorities. Such evolution may impact our future clinical trial designs, including trial size and endpoints, in ways that we cannot predict today. In particular, regulatory authority expectations about liver biopsy data may evolve especially as more information is published about the inherent variability in liver biopsy data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certain of our competitors have experienced regulatory setbacks for MASH therapies following communications from the FDA. We currently do not know the impact, if any, that these setbacks could have on the path for regulatory approval for MASH therapies generally or for F351.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our anticipated development costs would likely increase if development of F351 or any future product candidate is delayed because we are required by the NMPA, FDA or other comparable regulatory authorities to perform studies or trials in addition to, or different from, those that we currently anticipate, or make changes to ongoing or future clinical trial designs. In addition, if we are unable to leverage our safety database for MASH indications, we may be required to perform additional trials, which would result in increased costs and may affect the timing or outcome of our clinical trials. In addition, F351 may not be developed as a monotherapy, but as a part of a combination therapy, which will add to the complexity of clinical development and may cause further delays in F351&#8217;s development and affect our costs and divert management&#8217;s resources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our failure to obtain or renew certain approvals, licenses, permits and certificates required for our business may materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to relevant laws and regulations, we are required to obtain and maintain various approvals, licenses, permits and certificates from relevant authorities to operate our business. Some of these approvals, permits, licenses and certificates are subject to periodic renewal and/or reassessment by the relevant authorities, and the standards of such renewal and/or reassessment may change from time to time. Any failure to obtain or renew any approvals, licenses, permits and certificates necessary for our operations may result in enforcement actions thereunder, including orders issued by the relevant regulatory authorities ceasing our operations, and may include corrective measures requiring capital expenditure or remedial actions. If the interpretation or implementation of existing laws and regulations changes, or new regulations come into effect requiring us to obtain any additional approvals, permits, licenses or certificates that were previously not required to operate our existing businesses, there can be no assurance that it will successfully obtain such approvals, permits, licenses or certificates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our product, ETUARY, and future products, if approved. As a pharmaceutical company, even though we do not and may not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. These regulations include:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the Federal Healthcare Anti-Kickback Statute that prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid, and which will constrain our marketing practices and the marketing practices of our licensees, educational programs, pricing policies, and relationships with healthcare providers or other entities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients to providers of &#8220;designated health services&#8221; with whom the physician or a member of the physician&#8217;s immediate family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">federal false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent, and which may expose entities that provide coding and billing advice to customers to potential criminal and civil penalties, including through civil whistleblower or qui tam actions, and including as a result of claims presented in violation of the Federal Healthcare Anti-Kickback Statute, the Stark Law or other healthcare-related laws, including laws enforced by the FDA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services that, as amended by HITECH, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">federal physician sunshine requirements under the ACA, which requires manufacturers of approved drugs, devices, biologics and medical supplies to report annually to the U.S. Department of Health and Human Services, information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the Federal Food, Drug, and Cosmetic Act, which, among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#8217;s </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and which may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws such as HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our operations are subject to various fraud and abuse laws, including, but not limited to, the PRC Anti-Unfair Competition Law, the PRC Criminal Law and the physician payment sunshine laws and regulations. There are ambiguities as to what is required to comply with any of these requirements, and violations of such fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension from governmental healthcare programs and debarment from contracting with the relevant jurisdiction. As law enforcement authorities increase their focus on enforcing these laws, efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-corruption and anti-bribery laws of the PRC and other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in certain markets, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our operations are subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of the PRC and other countries in which we operate. The FCPA and these other laws generally prohibit us, our officers and our employees and intermediaries from, directly or indirectly, offering, authorizing or making improper payments to non-U.S. government officials for the purpose of obtaining or retaining business or other advantage. We may engage third parties for clinical trials outside of the PRC and United States, to sell our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, abroad and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. As our business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. If our procedures and controls to monitor anti-bribery compliance fail to protect us from reckless or criminal acts committed by our employees or agents or if we, or our employees, agents, contractors or other collaborators, fail to comply with applicable anti-bribery laws, our reputation could be harmed and we could incur criminal or civil penalties, be required to disgorge profits, and incur other sanctions and/or significant expenses, which could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our product, ETUARY, and future products, if approved, or our failure to obtain any required import or export authorization for such products, when applicable, could harm our international or domestic sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our product, ETUARY, and future products, if approved, may create delays in the introduction of such products in international markets or, in some cases, prevent the export of such products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons or products targeted by such regulations, could result in decreased use of our product, ETUARY, and future products, if approved, or in our decreased ability to export such products to, existing or potential customers with international operations. Any decreased use of our product, ETUARY, and future products, if approved, or limitation on our ability to export or sell such products would likely adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All jurisdictions in which we conduct our research, development, manufacturing and commercialization activities regulate these activities in great depth and detail. Obtaining regulatory approvals is a lengthy, expensive and uncertain process. We intend to focus our activities in the major markets of the PRC and the United States. These geopolitical areas all have strict regulation on medical devices, and, in doing so, they employ broadly similar regulatory strategies, including regulation of product development, approval, manufacturing, sales and marketing and distribution of medical devices. However, regulatory regimes vary in different regions, which makes regulatory compliance more complex and costly for companies like us that plan to operate in each of these regions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The price of pharmaceuticals has been a topic of considerable public discussion that could lead to price controls or other price-limiting strategies by payors that have the effect of lowering payment and reimbursement rates for drugs or otherwise making the commercialization of pharmaceuticals less profitable. Many federal and state legislatures have considered, and adopted, healthcare policies intended to curb rising healthcare costs, such as the Inflation Reduction Act of 2022. These cost-containment measures may include, among other measures: requirements for pharmaceutical companies to negotiate prescription drug prices with government healthcare programs; controls on government-funded reimbursement for drugs; new or increased requirements to pay prescription drug rebates to government healthcare programs, including if drug prices increase at a higher rate than inflation; controls on healthcare providers; challenges to or limits on the pricing of drugs, including pricing controls or limits or prohibitions on reimbursement for specific products through other means; requirements to try less expensive products or generics before a more expensive branded product; and public funding for cost effectiveness research, which may be used by government and private third-party payors to make coverage and payment decisions. Political, economic and regulatory developments may further complicate developments in healthcare systems and pharmaceutical drug pricing. These developments could, for example, impact our potential licensing agreements as commercial and collaborative partners may also consider the impact of these pressures on their licensing strategies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any new laws or regulations that have the effect of imposing additional costs or regulatory burden on pharmaceutical manufacturers, or otherwise negatively affect the industry, could adversely affect our ability to successfully commercialize our product candidates. The implementation of any price controls, caps on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">prescription drugs or price transparency requirements could adversely affect our business, operating results and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The policies of the NMPA may change, or additional government regulations may be enacted, that could prevent, limit or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our profitability. We cannot predict the likelihood, nature or extent of governmental policies or regulations that may arise from future legislation or administrative actions in the PRC, where the regulatory environment is constantly evolving. For example, if changes to regulatory requirements and guidance require us to substantially amend clinical trial protocols, we may experience increased costs or inability to complete clinical trials in a timely manner or at all. Changes in government regulations relating to pharmaceutical product registrations and approvals, such as a relaxation in regulatory requirements, or the introduction of simplified approval procedures, could lower the barriers to entry for potential competitors, or increased regulatory requirements could increase the difficulty to satisfy such requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In recent years in the PRC, there have been, and will likely continue to be, efforts to enact administrative or legislative measures that include more rigorous coverage criteria and may result in downward pressure on prices on our product, ETUARY, and future products, if approved. For details of the risks associated with such downward pricing pressure, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Business Operations and Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may face pressure to lower the prices of our commercialized product, ETUARY, which is approved in the PRC, and any other future product, if approved, in order for such products to qualify for medical insurance reimbursement or due to market competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Risk Factors section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, any changes in laws and regulations on collection and transfer of personal data in the PRC, including the Personal Information Protection Law of the PRC and the Administrative Regulations on Human Genetic Resources of the PRC, could affect our ability to use medical data and subject us to liability for the use of such data for previously permitted purposes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC government or other government authorities in countries where we plan to sell our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved in the PRC, could adopt new or different regulations with respect to sales of pharmaceutical products to address bribery, corruption or other concerns. New or different regulations could result in increased costs incurred by us, our employees or distributors in selling our product, ETUARY, and future products, if approved, or impose restrictions on sales and marketing activities, which could, in turn, increase our costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to evolving privacy and data protection laws, including HIPAA and the EU General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;). If we fail to protect personal information or comply with existing or future data protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of personal information. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA) (&#8220;PHI&#8221;) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. HIPAA requires covered entities and business associates, such as us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the GDPR, which came into force in May 2018, related data protection laws in individual EU Member States as well as implementations of the GDPR in the European Economic Area. The GDPR establishes a number of strict requirements and restrictions applicable to the processing (processing includes collecting, analyzing and transferring) of personal data (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, data which identifies an individual or from which an individual is identifiable) in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the personal data breaches which may have to be notified to the national data protection authorities and data subjects, the measures to be taken when engaging processors, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation. Furthermore, it affords various rights to individuals (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, the right to access or erasure of personal data), and imposes potential penalties for breaches of up to 4% of the annual worldwide turnover or &#8364;20 million, whichever is greater. In case of a breach of the GDPR, individuals (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, study subjects) may also have a right to compensation for financial or non-financial losses (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, distress).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There may be circumstances under which a failure to comply with the GDPR, or the exercise of individual rights under the GDPR, would limit our ability to utilize clinical trial data collected on study subjects. Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation (EU CTR), EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with these obligations could lead to government enforcement actions and significant penalties, harm to reputation, and adversely impact the business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, we are subject to various U.S. state laws which may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Because our operations involve the use of hazardous chemical materials and may produce hazardous waste, we are subject to numerous environmental, health and safety laws and regulations, including those governing air emissions, discharge of water and the handling, use, storage, treatment and disposal of hazardous materials and wastes. While we have entered into hazardous waste disposal agreements with third parties for the disposal of these materials and wastes, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. Further, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage, use or disposal of hazardous materials and waste.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to extensive ongoing regulatory obligations and continued regulatory review related to our commercialized product, ETUARY, which is approved in the PRC, and we may be subject to such obligations and review related to our future product candidates, if approved, which may result in</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our product, ETUARY, which is approved in the PRC, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any product candidates that are approved in the future remain subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, distribution, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including requirements in the PRC, federal and state requirements in the United States and requirements of comparable foreign regulatory authorities, as described in &#8220;Business&#8212;Government Regulation&#8221; of this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, regulatory approvals may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, our commercialized product, ETUARY, which is approved in the PRC, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and our product candidates, if approved, and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the NMPA, FDA and other regulatory agencies in the PRC, United States and by comparable foreign regulatory authorities, respectively. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCPs for any clinical trials that we conduct following approval. Manufacturers of drug products and their facilities are also subject to continual review and periodic, unannounced inspections by the NMPA, FDA and other regulatory authorities for compliance with cGMPs. In addition, following an approval for commercial sale of any product candidates, certain changes to the product, such as changes in manufacturing processes and additional labeling claims, may be subject to additional review and approval by the NMPA, the FDA, and/or comparable regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If we fail to comply with applicable regulatory requirements, or there are safety or efficacy problems with a product, a regulatory agency or enforcement authority may, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">issue warning or notice of violation letters; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">impose civil or criminal penalties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">suspend or withdraw regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">suspend any of our ongoing clinical studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">refuse to approve pending applications or supplements to approved applications submitted by us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">seize or detain products, or require a product recall; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">require entry into a consent decree.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to Our Business Operations in the PRC</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The PRC government may intervene in, influence or exert control over Gyre Pharmaceuticals&#8217; operations, which could result in an adverse change in our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC government has some oversight and discretion over the conduct of our business in the PRC and may intervene in, influence or exert control over our operations. The PRC government has recently published new policies that significantly affected certain industries, and we cannot rule out the possibility that it will in the future do the same regarding our industry, including policies that could require us to seek permission from the PRC authorities to continue to operate our business in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The central or local governments may impose new, stricter regulations or interpretations of existing regulations that would require additional expenditures and efforts on our part to ensure our compliance with such regulations or interpretations. For instance, regulations introduced by the NMPA concerning drug inspection, investigation, evidence collection and disposal are relatively new, and because of the limited volume of published judicial and administrative decisions, which are non-binding in nature, the interpretation and enforcement of these laws and regulations are uncertain. In addition, the implementation of laws and regulations may be in part based on government policies and internal rules that are subject to the interpretation and discretion of different government agencies (some of which are not published on a timely basis or at all) that may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until sometime after the violation. The imposition of new regulations or interpretations of existing regulations can occur quickly with little advance notice. We may incur penalties for any failure to comply with PRC laws and regulations. In addition, any litigation in the PRC, regardless of outcome, may be protracted and result in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have discretion in interpreting and implementing statutory and contractual terms, it may be difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy. If we were to become subject to the direct intervention or influence of the PRC government due to changes in laws or other unforeseeable reasons, it may require a material and potentially adverse change in our operations in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, the PRC government has indicated an intent to increase oversight and control over offerings of companies with significant operations in the PRC that are to be conducted in foreign markets. For example, in July 2021, the relevant PRC government authorities made public the Opinions on Strictly Scrutinizing Illegal Securities Activities in Accordance with the Law. These opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision of overseas listings by China-based companies and proposed to take effective measures, such as promoting the construction of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas-listed companies. In February 2023, the China Securities Regulatory Commission (the &#8220;CSRC&#8221;) released the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises (the &#8220;Trial Measures&#8221;), which came into effect on March 31, 2023. The Trial Measures comprehensively improve and reform the existing regulatory regime for overseas offering and listing of PRC domestic companies&#8217; securities and regulate both direct and indirect overseas offering and listing of PRC domestic companies&#8217; securities by adopting a filing-based regulatory regime.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In February 2023, the CSRC and other PRC governmental authorities jointly issued the Provisions on Strengthening the Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Confidentiality Provisions&#8221;), which came into effect on March 31, 2023. According to the Confidentiality Provisions, PRC domestic companies that directly or indirectly conduct overseas offerings and listings shall strictly abide by the laws and regulations on confidentiality when providing or publicly disclosing, whether directly or through their overseas listed entities, materials to securities services providers. In the event such materials contain state secrets or working secrets of government agencies, PRC domestic companies shall first obtain approval from authorities, and file with the secrecy administrative department at the same level with the approving authority; in the event that such materials, if divulged, will jeopardize national security or public interest, PRC domestic companies shall comply with procedures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">stipulated by national regulations. Given the recent nature of the introduction of the Trial Measures and the Confidentiality Provisions, there remains uncertainty as to the interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If (i) we mistakenly conclude that certain regulatory filings, permissions and approvals are not required, (ii) applicable laws, regulations, or interpretations change, or (iii) we are required to obtain such filings, permissions or approvals in the future, we may be unable to obtain them in a timely manner, or at all, and such filings, permissions or approvals may be denied or rescinded even if obtained. We may face adverse actions or sanctions by the CSRC or other PRC regulatory agencies if we are unable to comply with such requirements, which may result in fines and penalties, restrictions on our operations, having to delist from a stock exchange outside of China, the halting of securities offerings to foreign investors and other actions that could materially and adversely affect our operations and the interest of our investors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, the risks that the PRC government may intervene or influence our operations in the PRC could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The pharmaceutical industry in the PRC is highly regulated and such regulations are subject to change, which may affect approval and commercialization of our product, ETUARY, and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The pharmaceutical industry in the PRC is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. For details of a discussion of regulatory requirements that are applicable to our current and planned business in the PRC, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;Business&#8212;Regulatory Requirements in the PRC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Annual Report. We believe our strategy and approach are consistent with the PRC government&#8217;s policies, but we cannot ensure that our strategy and approach will continue to be consistent. In recent years, the regulatory framework for the pharmaceutical industry in the PRC has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">increased compliance costs on our business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">delays in or prevention of successful development or commercialization of our product candidates; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">reduction of the current benefits we experience and believe are available to us from developing and manufacturing drugs in the PRC. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC authorities have also become increasingly vigilant in enforcing laws in the pharmaceutical industry, and any failure by us to maintain compliance with applicable laws and regulations may result in the suspension or termination of our business activities in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse changes in political, economic and other policies of the PRC government could have a material adverse effect on the overall economic growth of the PRC, which could reduce the demand for our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, or otherwise materially and adversely affect our business, operations or competitive position.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our business, results of operations, financial condition and prospects may be influenced to a significant degree by economic, political, legal and social conditions in the PRC. The PRC&#8217;s economy differs from the economies of developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate, control of foreign exchange, allocation of resources and an evolving regulatory system. The PRC government has implemented various measures to encourage economic development and guide the allocation of resources, but some of these measures may have a negative effect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">on us. For example, our financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations that are currently applicable to us. Growth of the PRC economy has been uneven across different regions and among various economic sectors of the PRC, and there can be no assurance that future growth will be sustained at similar rates or at all. If the business environment or economic conditions in the PRC deteriorates from the perspective of domestic or international investment, our business may also be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC legal system is a civil law system based on written codes and statutes. Unlike the common law system, prior court decisions may be cited as persuasive authority, but have limited precedential value. Since the late 1970s, the PRC government has promulgated a comprehensive system of laws, rules and regulations governing economic matters in general. However, as these laws and regulations are relatively recent and the number of published decisions is limited, their interpretation and enforcement involve significant and certainties, and can be inconsistent and unpredictable. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we may experience compared to developed legal systems. These uncertainties may impede our ability to enforce the contracts we have entered into and could materially and adversely affect our business, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, PRC laws and regulations afford significant protection to state-owned assets. Contributions that may lead to losses of state-owned assets are subject to heightened scrutiny by the competent authorities, and the competent authorities have significant discretion in interpreting and implementing the relevant laws and regulations. In the event we or our affiliates conduct transactions with state-owned enterprises or their affiliates, we are exposed to risks and uncertainties involving the potential of loss of state-owned assets, which may subject us to liabilities and could materially and adversely affect our business, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Implementation of the labor laws and regulations in the PRC may adversely affect our business and results of operations, and failure to fully comply with PRC labor-related laws may expose us to potential liabilities and penalties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the PRC Labor Contract Law, employers are subject to stricter requirements in terms of signing labor contracts, minimum wages, paying remuneration, determining the term of employees&#8217; probation and unilaterally terminating labor contracts. Due to lack of detailed interpretative rules and broad discretion of the local competent authorities, it is uncertain as to how the labor contract law and its implementation rules will affect our current employment policies and practices. Our employment policies and practices may violate the labor contract law or its implementation rules, and we may thus be subject to related penalties, fines or legal fees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Compliance with the labor contract law and its implementation rules may increase our operating expenses, in particular, our personnel expenses. In the event that we decide to terminate some of our employees or otherwise change our employment or labor practices, the labor contract law and its implementation rules may also limit our ability to effect those changes in a desirable or cost-effective manner, which could adversely affect our business and results of operations. According to the Social Insurance Law, employees must participate in pension insurance, work-related injury insurance, medical insurance, unemployment insurance and maternity insurance, and the employers must, together with their employees or separately, pay the social</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">insurance premiums for such employees. Recently, the PRC government enhanced its measures relating to social insurance collection, which may lead to stricter enforcement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We expect our labor costs to increase due to the implementation of these laws and regulations. Compliance with the Social Insurance Law and its implementation rules may increase our operating expenses, in particular, our personnel expenses. As the interpretation and implementation of these laws and regulations are still evolving, there can be no assurance that our employment practice policy will at all times be deemed to be in full compliance with labor-related laws and regulations in the PRC, which may subject us to labor disputes or government investigations. If we are deemed to have violated relevant labor laws and regulations, we could be required to provide additional compensation to our employees and our business, financial condition and results of operations could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fluctuations in exchange rates may result in foreign currency exchange losses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The change in the value of the Renminbi against other currencies may fluctuate and is affected by, among other things, changes in the PRC&#8217;s political and economic conditions and the PRC&#8217;s foreign exchange policies, as well as supply and demand in the local market. We are exposed to the risks of market forces or government policies and their impact on the exchange rate between Renminbi or other currencies in the future. Substantially all of our revenue and costs are denominated in Renminbi and most of our financial assets are also denominated in Renminbi. Any significant fluctuations in the value of the Renminbi may materially and adversely affect our liquidity and cash flows and the value of our financial assets.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our operations are subject to and may be affected by changes in PRC tax laws and regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC government from time to time adjusts or changes its tax laws and regulations, and future adjustments or changes to PRC tax laws and regulations, together with any uncertainty resulting therefrom, could have an adverse effect on our results of operations. Our product ETUARY, which is approved in the PRC, has been subject to a preferential VAT treatment at the tax rate of 3%, applicable to a number of drugs for rare diseases, since March 2019. However, there can be no assurance that our applicable VAT rate will stay the same or decrease, and any future changes to the VAT policies may negatively impact the selling price of ETUARY and future approved product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, under the amended Individual Income Tax Law, foreign nationals who have no domicile in the PRC, but have resided in the PRC for a total of 183 days or more in a tax year, are subject to PRC individual income tax on their income gained within or outside the PRC. The amended Individual Income Tax Law may materially affect our ability to attract and retain highly skilled foreign scientists and research technicians to work in the PRC. We are also subject to periodic examinations on fulfillment of our tax obligation under the PRC tax laws and regulations by PRC tax authorities, and there can be no assurance that any such examinations by PRC tax authorities would not result in fines, other penalties or actions that could adversely affect our business, financial condition and results of operations, as well as our reputation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may be restricted from transferring our scientific data abroad or using human genetic resources collected in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On March 17, 2018, the General Office of the State Council promulgated the Measures for the Management of Scientific Data (the &#8220;Scientific Data Measures&#8221;), which provides a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in the PRC must seek governmental approval before any scientific data involving a state secret may be transferred abroad or to foreign parties. Upon approval by the competent authorities, the enterprise shall undergo the required procedures, and enter into the confidentiality agreements with the users of the scientific data. Further, any researcher conducting research funded at least in part by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before such data may be published in any foreign academic journal. Given that the term &#8220;state secret&#8221; is not clearly</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">defined, if and to the extent any data collected or generated in connection with our R&amp;D of medical drug candidates are subject to the Scientific Data Measures and any subsequent laws as required by the relevant government authorities, there can be no assurance that we can always obtain relevant approvals for sending scientific data (such as the results of our pre-clinical studies or clinical trials conducted within the PRC) abroad or to our foreign partners in the PRC. As a result, we may be subject to fines and other administrative penalties imposed by those government authorities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, pursuant to the Service Guide, the sampling, collection or research activities of human genetic resources through clinical trials is required to be filed online with the China Human Genetic Resources Management Office. Furthermore, the Administrative Regulations on Human Genetic Resources of the PRC stipulates that collecting human genetic resources of the PRC&#8217;s important genetic families and specific regions, or collecting those human genetic resources in such categories and quantities as prescribed by the administrative department for science and technology under the State Council, preserving the PRC&#8217;s human genetic resources and providing the basic platform for scientific research, utilization of the PRC&#8217;s human genetic resources for international cooperation in scientific research, as well as transporting the PRC&#8217;s materials of human genetic resources abroad shall be subject to the approval of the administrative department for science and technology under the State Council.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If we are unable to obtain necessary approvals or comply with the regulatory requirements in a timely manner, or at all, our R&amp;D of drug candidates may be hindered. If the relevant government authorities consider the transmission of our scientific data or collection and usage of human genetic resources to be in violation of the requirements under applicable PRC laws and regulations, we may be subject to fines and other administrative penalties imposed by those government authorities. Furthermore, it is possible that the regulation may be interpreted and applied in a manner that is inconsistent with our clinical trial practices, potentially resulting in the confiscation of human genetic resources samples and associated data and administrative fines.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due to our operations in the PRC, our business, results of operations and financial condition may be influenced to a certain degree by economic, political, legal and social conditions in the PRC or changes in government relations between the PRC and the United States or other governments. There is significant uncertainty about the future relationship between the United States and the PRC with respect to trade policies, treaties, government regulations and tariffs. The PRC&#8217;s economy differs from the economies of developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. While the PRC&#8217;s economy has experienced significant growth over the past four decades, growth has been uneven across different regions and among various economic sectors. The PRC government has implemented various measures to encourage economic development and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may have a negative effect on us. In addition, in the past, the PRC government implemented certain measures, including interest rate increases, to control the pace of economic growth. These measures may cause a decrease in economic activity in the PRC, which may affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, we directly and indirectly relied on certain overseas suppliers to obtain raw materials, and we have directly and indirectly relied on collaboration with entities in foreign countries and regions in connection with our business operations. We may also pursue partnerships with entities in foreign countries and regions in the future. our business is therefore subject to changing international economic, regulatory, social and political conditions, and local conditions in foreign countries and regions. As a result, the PRC&#8217;s political relationships with those foreign countries and regions may affect development and commercialization of our product, ETUARY, and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additionally, the PRC&#8217;s political relationships with those foreign countries and regions may also affect our current and future relationships with third parties. There can be no assurance that our existing or potential</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">collaborators will not alter their perception of us or their preferences as a result of adverse changes to the state of political relationships between the PRC and the relevant foreign countries or regions, and such alteration may cause a decline in the demand for our product, ETUARY, and future products, if approved, and adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In July 2021, the PRC government provided new guidance on the PRC-based companies raising capital outside of the PRC, including through arrangements called variable interest entities (&#8220;VIEs&#8221;). In light of such developments, the SEC has imposed enhanced disclosure requirements on the PRC-based companies seeking to register securities with the SEC. Although we do not have a VIE structure, due to our operations in the PRC, any future PRC, U.S. or other rules and regulations that place restrictions on capital raising or other activities by companies with operations in the PRC could affect our business and results of operations. If the business environment in the PRC deteriorates from the perspective of domestic or international investment, or if relations between the PRC and the United States or other governments deteriorate, the PRC government may intervene with our operations and our business in the PRC and United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. and PRC regulations may impact our business, our operating results and our ability to raise capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The U.S. government, including the SEC, has made statements and taken certain actions that led to changes to United States and international relations, and will impact companies with connections to the United States or the PRC, including imposing several rounds of tariffs affecting certain products manufactured in the PRC, imposing certain sanctions and restrictions in relation to the PRC and issuing statements indicating enhanced review of companies with certain operations based in the PRC. It is unknown whether and to what extent new legislation, executive orders, tariffs, laws or regulations will be adopted, or the effect that any such actions would have on companies with significant connections to the United States or to the PRC, our industry or on us. We conduct research activities and has business operations both in the United States and the PRC. Any unfavorable government policies on cross-border relations and/or international trade, including increased scrutiny on companies with certain operations based in the PRC, capital controls or tariffs, may affect the competitive position of our drug product, generic drugs and product candidates, the hiring of scientists and other research and development personnel, the demand for our drug product, the import or export of raw materials in relation to drug development or our ability to raise capital, or prevent us from selling our drug product in certain countries. Furthermore, the SEC has issued statements primarily focused on companies with certain operations based in the PRC, such as us. For example, on July 30, 2021, Gary Gensler, Chairman of the SEC, issued a Statement on Investor Protection Related to Recent Developments in the PRC, pursuant to which Chairman Gensler stated that he has asked the SEC staff to engage in targeted additional reviews of filings for companies with certain operations based in the PRC. The statement also addressed risks inherent in companies with VIE structures. We do not have a VIE structure and are not in an industry that is subject to foreign ownership limitations by the PRC. However, it is possible that our periodic reports and other filings with the SEC may be subject to enhanced review by the SEC and this additional scrutiny could affect our ability to effectively raise capital in the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In response to the SEC&#8217;s July 30, 2021 statement, the China Securities Regulatory Commission (&#8220;CSRC&#8221;) announced on August 1, 2021 that &#8220;[i]t is our belief that Chinese and U.S. regulators shall continue to enhance communication with the principle of mutual respect and cooperation, and properly address the issues related to the supervision of the PRC-based companies listed in the U.S. so as to form stable policy expectations and create benign rules framework for the market.&#8221; While the CSRC will continue to collaborate &#8220;closely with different stakeholders including investors, companies, and relevant authorities to further promote transparency and certainty of policies and implementing measures,&#8221; it emphasized that it &#8220;has always been open to companies&#8217; choices to list their securities on international or domestic markets in compliance with relevant laws and regulations.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If any new legislation, executive orders, tariffs, laws and/or regulations are implemented, if existing trade agreements are renegotiated, if the U.S. or the PRC governments take retaliatory actions due to the recent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">U.S.-PRC tension or if the PRC government exerts more oversight and control over securities offerings that are conducted in the United States, such changes could have an adverse effect on our business, financial condition and results of operations, and our ability to raise capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance with the PRC&#8217;s new Data Security Law, Cyber Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme on cyber security and any other future laws and regulations may entail significant expenses and could affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC has implemented or will implement rules and is considering a number of additional proposals relating to data protection. The Data Security Law provides that the data processing activities must be conducted based on &#8220;data classification and hierarchical protection system&#8221; for the purpose of data protection and prohibits entities in the PRC from transferring data stored in the PRC to foreign law enforcement agencies or judicial authorities without prior approval by the PRC government.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additionally, the PRC&#8217;s Cyber Security Law and the Administrative Measures for the Hierarchical Protection of Information Security requires companies to take certain organizational, technical and administrative measures and other necessary measures to ensure the security of their networks and data stored on their networks. Under the multi-level protection scheme (&#8220;MLPS&#8221;), entities operating information systems must have a thorough assessment of the risks and the conditions of their information and network systems to determine the level of the entity&#8217;s information and network systems. These levels range from the lowest Level 1 to the highest Level 5 pursuant to a series of national standards on the grading and implementation of the classified protection of cyber security. The grading result will determine the set of security protection obligations that entities must comply with. Entities classified as Level 2 or above should report the grade to the relevant government authority for examination and approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Recently, the Cybersecurity Administration of China (&#8220;CAC&#8221;) has taken action against several PRC internet companies in connection with their initial public offerings on U.S. securities exchanges for alleged national security risks and improper collection and use of the personal information of PRC data subjects. According to the official announcement, the action was initiated based on the National Security Law, the Cyber Security Law and the Cybersecurity Review Measures, which are aimed at &#8220;preventing national data security risks, maintaining national security and safeguarding public interests.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Revised CAC Measures, critical information infrastructure operators procuring network products and services, and online platform operators (as opposed to &#8220;data processors&#8221; in the Revised Draft CAC Measures) carrying out data processing activities which affect or may affect national security, shall conduct a cybersecurity review pursuant to the provisions therein. In addition, online platform operators possessing personal information of more than one million users seeking to be listed on foreign stock markets must apply for a cybersecurity review. On November 14, 2021, the CAC further published the Regulations on Network Data Security Management (Draft for Comment), or the Draft Management Regulations, under which data processors refer to individuals and organizations who determine the data processing activities in terms of the purpose and methods at their discretion. The Draft Management Regulations reiterate that data processors shall be subject to cybersecurity review if&#8201; (i) they process personal information of more than one million persons and they are aiming to list on foreign stock markets or (ii) their data processing activities affect or may affect PRC national security. The Draft Management Regulations also request data processors seeking to list on foreign stock markets to annually assess their data security by themselves or through data security service organizations, and submit the assessment reports to relevant competent authorities. As the Draft Management Regulations are released only for public comment, the final version and the effective date thereof is subject to change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of the date of this Annual Report, we have not received any notice from any PRC regulatory authority identifying us as a &#8220;critical information infrastructure operator,&#8221; &#8220;online platform operator&#8221; or &#8220;data processor,&#8221; or requiring us to go through the cybersecurity review procedures pursuant to the Revised CAC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Measures and the Draft Management Regulations. Based on our understanding of the Revised CAC Measures, and the Draft Management Regulations if enacted as currently proposed, we do not expect to become subject to cybersecurity review by the CAC for issuing securities to foreign investors because: (i) the clinical and preclinical data we handle in our business operations, either by its nature or in scale, do not normally trigger significant concerns over PRC national security and (ii) we have not processed, and does not anticipate to process in the foreseeable future, personal information for more than one million users or persons. However, there remains uncertainty as to how the Revised CAC Measures, and the Draft Management Regulations, if enacted as currently proposed, will be interpreted or implemented. Furthermore, there remains uncertainty as to whether the PRC regulatory authorities may adopt new laws, regulations, rules, or detailed implementation and interpretation in relation, or in addition, to the Revised CAC Measures and the Draft Management Regulations. While we intend to closely monitor the evolving laws and regulations in this area and take all reasonable measures to mitigate compliance risks, we cannot guarantee that our business and operations will not be adversely affected by the potential impact of the Revised CAC Measures, the Draft Management Regulations or other laws and regulations related to privacy, data protection and information security.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, the Personal Information Protection Law provides a comprehensive set of data privacy and protection requirements that apply to the processing of personal information and expands data protection compliance obligations to cover the processing of personal information of persons by organizations and individuals in the PRC, and the processing of personal information of persons in the PRC outside of the PRC if such processing is for purposes of providing products and services to, or analyzing and evaluating the behavior of, persons in the PRC. The Personal Information Protection Law also provides that critical information infrastructure operators and personal information processing entities who process personal information meeting a volume threshold to be set by PRC cyberspace regulators are also required to store in the PRC personal information generated or collected in the PRC, and to pass a security assessment administered by PRC cyberspace regulators for any export of such personal information. Lastly, the Personal Information Protection Law contains proposals for significant fines for serious violations of up to approximately $7.2 million or 5% of annual revenues from the prior year and may also be ordered to suspend any related activity by competent authorities. We do not maintain, nor do we intend to maintain in the future, personally identifiable health information of patients in the PRC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interpretation, application and enforcement of these laws, rules and regulations evolve from time to time and their scope may continually change, through new legislation, amendments to existing legislation or changes in enforcement. Compliance with the PRC&#8217;s new Cyber Security Law and Data Security Law could significantly increase the cost to us of providing our service offerings, require significant changes to our operations or even prevent us from providing certain service offerings in jurisdictions in which we currently operate or in which we may operate in the future. Despite our efforts to comply with applicable laws, regulations and other obligations relating to privacy, data protection and information security, it is possible that our practices, offerings or platform could fail to meet all of the requirements imposed on us by the Cyber Security Law, the Data Security Law and/or related implementing regulations. Any failure on our part to comply with such law or regulations or any other obligations relating to privacy, data protection or information security, or any compromise of security that results in unauthorized access, use or release of personally identifiable information or other data, or the perception or allegation that any of the foregoing types of failure or compromise has occurred, could damage our reputation, discourage new and existing counterparties from contracting with us or result in investigations, fines, suspension or other penalties by PRC government authorities and private claims or litigation, any of which could adversely affect our business, financial condition and results of operations. Even if our practices are not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm our reputation and brand and adversely affect our business, financial condition and results of operations. Moreover, the legal uncertainty created by the Data Security Law, the Revised CAC Measures and the recent PRC government actions could adversely affect our ability, on favorable terms, to raise capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Restrictions on currency exchange, including the risks of transferring cash outside of the PRC, may limit Gyre Pharmaceuticals&#8217; ability to receive and use effectively financing in foreign currencies or Gyre Therapeutics&#8217; ability to transfer cash from Gyre Pharmaceuticals or other potential investors in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals&#8217; ability to obtain currency exchange is subject to significant foreign exchange controls and, in the case of transactions under the capital account, requires the approval of and/or registration with PRC government authorities, including the State Administration of Foreign Exchange, or SAFE. In particular, if Gyre Pharmaceuticals finances by means of foreign debt from BJContinent Pharmaceuticals Limited or other foreign lenders, the amount is not allowed to, among other things, exceed the statutory limits and such loans must be registered with the local branch of SAFE. If Gyre Pharmaceuticals finances by means of additional capital contributions, these capital contributions are subject to registration with the State Administration for Market Regulation or its local branch, reporting of foreign investment information with the MOFCOM, or its local branch or registration with other governmental authorities in the PRC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In light of the various requirements imposed by PRC regulations on loans to, and direct investment in, PRC-based entities by offshore holding companies, there can be no assurance that Gyre Pharmaceuticals will be able to complete the necessary government requirements or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans or capital contributions by Gyre Pharmaceuticals. If Gyre Pharmaceuticals fails to adhere to such requirements or obtain such approval, Gyre Pharmaceuticals&#8217; ability to capitalize or otherwise fund Gyre Pharmaceuticals&#8217; PRC operations, including Gyre Pharmaceuticals&#8217; technology development may be negatively affected, which could materially and adversely affect Gyre Pharmaceuticals&#8217; ability to fund and expand Gyre Pharmaceuticals&#8217; business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics may not be able to transfer funds out of Gyre Pharmaceuticals, or Gyre Therapeutics might face difficulties in transferring funds from investors in the PRC should Gyre Therapeutics decide to solicit investments from investors in the PRC, in a timely manner due to restrictions imposed by the PRC authorities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">PRC regulations relating to the establishment of offshore special purpose companies by residents in the PRC may subject our PRC resident beneficial owners in the PRC to liability or penalties, or may otherwise adversely affect us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37 requires residents of the PRC to register with local branches of SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with such residents&#8217; legally owned assets or equity interests in domestic enterprises or offshore assets or interests, referred to in SAFE Circular 37 as a &#8220;special purpose vehicle.&#8221; The term &#8220;control&#8221; under SAFE Circular 37 is broadly defined as the operation rights, beneficiary rights or decision-making rights acquired by residents of the PRC in the offshore special purpose vehicles or PRC companies by such means as acquisition, trust, proxy, voting rights, repurchase, convertible bonds or other arrangements. SAFE Circular 37 further requires amendment to the registration in the event of any changes with respect to the basic information of or any significant changes with respect to the special purpose vehicle, such as an increase or decrease of capital contributed by PRC residents, share transfer or exchange, merger, division or other material events. If the shareholders of the offshore holding company who are residents of the PRC do not complete their registration with the local SAFE branches, the PRC subsidiaries may be prohibited from making distributions of profits and proceeds from any reduction in capital, share transfer or liquidation to the offshore parent company and from carrying out subsequent cross-border foreign exchange activities, and the offshore parent company may be restricted in its ability to contribute additional capital into its PRC subsidiaries. Moreover, failure to comply with the SAFE registration and amendment requirements described above could result in liability under PRC law for evasion of applicable foreign exchange restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certain residents of the PRC may hold direct or indirect interests in our company, and we will request residents of the PRC who we know hold direct or indirect interests in our company, if any, to make the necessary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">applications, filings and amendments as required under SAFE Circular 37 and other related rules. However, we may not at all times be fully aware or informed of the identities of our stockholders or beneficial owners that are required to make such registrations, and we cannot provide any assurance that these residents will comply with our requests to make or obtain any applicable registrations or comply with other requirements under SAFE Circular 37 or other related rules. The failure or inability of our PRC resident stockholders to comply with the registration procedures set forth in these regulations may subject us to fines or legal sanctions, restrictions on our cross-border investment activities. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to make distributions to you could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Any failure to comply with PRC regulations regarding the registration requirements for our employee equity incentive plans may subject us to fines and other legal or administrative sanctions, which could adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies, or the Stock Option Rules and other relevant rules and regulations, PRC citizens or non-PRC citizens residing in the PRC for a continuous period of not less than one year who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain procedures. Our employees who are PRC citizens or who reside in the PRC for a continuous period of not less than one year and who participate in our stock incentive plans will be subject to such regulation. We plan to assist our employees to register their equity awards. However, any failure of PRC individual beneficial owners and holders of equity awards under our stock incentive plans to comply with the SAFE registration requirements may subject them to fines and legal sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Since Gyre Pharmaceuticals is a legal entity registered in Beijing, PRC, it is classified as a PRC tax resident for PRC income tax purposes by default, and such classification results in unfavorable tax consequences to Gyre Pharmaceuticals and its non-PRC shareholders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under Article 2 of the PRC Enterprise Income Tax Law, a resident enterprise is an enterprise that is established within the territory of the PRC or an enterprise established with a &#8220;de facto management body&#8221; within the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals is a PRC tax resident for PRC tax purposes by default because it is a legal entity registered in Beijing, PRC. Because Gyre Pharmaceuticals is a PRC tax resident for PRC enterprise income tax purposes, Gyre Pharmaceuticals is subject to PRC tax at a rate of 25% on its world-wide income, which materially reduces Gyre Pharmaceuticals&#8217; net income. In addition, Gyre Pharmaceuticals is also subject to PRC tax resident income tax reporting obligations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, because Gyre Pharmaceuticals is a PRC tax resident for enterprise income tax purposes, gains realized on the Contributions may be subject to PRC tax, at a rate of 10% in the case of non-PRC enterprises or 20% in the case of non-PRC individuals (in each case, subject to the provisions of any applicable tax treaty), if such gains are deemed to be from PRC sources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals and its shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company, or other assets attributable to a PRC establishment of a non-PRC company. Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential offshore restructuring transactions or sales of the shares of Gyre Pharmaceuticals&#8217; offshore holding companies or investments where PRC taxable assets are involved.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC tax authorities have enhanced their scrutiny over the direct or indirect transfer of certain taxable assets, including, in particular, equity interests in a PRC resident enterprise, by a non-resident enterprise by promulgating and implementing Notice of Ministry of Finance and State Administration of Taxation (&#8220;SAT&#8221;) on Several Issues relating to Treatment of Corporate Income Tax Pertaining to Restructured Business Operations of Enterprises (&#8220;Circular 59&#8221;) and the Notice on Strengthening Administration of Enterprise Income Tax for Share Transfers by Non-PRC Resident Enterprises (&#8220;Circular 698&#8221;). Pursuant to the Bulletin on Issues of Enterprise Income Tax and Indirect Transfers of Assets by Non-PRC Resident Enterprises (&#8220;Bulletin 7&#8221;) an &#8220;indirect transfer&#8221; of assets, including equity interests in a PRC resident enterprise, by non-PRC resident enterprises may be recharacterized and treated as a direct transfer of PRC taxable assets, if such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to Bulletin 7, &#8220;PRC taxable assets&#8221; include assets attributed to an establishment in the PRC, immoveable properties located in the PRC, and equity investments in PRC resident enterprises, in respect of which gains from their transfer by a direct holder, being a non-PRC resident enterprise, would be subject to PRC enterprise income taxes. When determining whether there is a &#8220;reasonable commercial purpose&#8221; of the transaction arrangement, factors to be taken into consideration include: whether the main value of the equity interest of the relevant offshore enterprise derives from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consists of direct or indirect investment in the PRC or if its income mainly derives from the PRC; whether the offshore enterprise and its subsidiaries directly or indirectly holding PRC taxable assets have real commercial nature which is evidenced by their actual function and risk exposure; the duration of existence of the business model and organizational structure; the replicability of the transaction by direct transfer of PRC taxable assets; and the tax situation of such indirect transfer and applicable tax treaties or similar arrangements. In respect of an indirect offshore transfer of assets of a PRC establishment, the resulting gain is to be included with the enterprise income tax filing of the PRC establishment or place of business being transferred, and would consequently be subject to PRC enterprise income tax at a rate of 25%. Where the underlying transfer relates to the immoveable properties located in the PRC or to equity investments in a PRC resident enterprise, which is not related to a PRC establishment or place of business of a non-resident enterprise, a PRC enterprise income tax at 10% would apply, subject to available preferential tax treatment under applicable tax treaties or similar arrangements, and the party who is obligated to make the transfer payments has the withholding obligation. Where the payor fails to withhold any or sufficient tax, the transferor shall declare and pay such tax to the tax authority by itself within the statutory time limit. Late payment of applicable tax will subject the transferor to default interest. Bulletin 7 does not apply to transactions of sale of shares by investors through a public stock exchange where such shares were acquired from a transaction through a public stock exchange.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Bulletin 7 may be determined by the tax authorities to be applicable to some of Gyre Pharmaceuticals&#8217; offshore restructuring transactions or sales of the shares of Gyre Pharmaceuticals&#8217; offshore holding companies or investments where PRC taxable assets are involved. The transferors and the transferees may be subject to tax filing or withholding and tax payment obligations, while Gyre Pharmaceuticals may be requested to assist in such filings. Furthermore, the transferors or the transferees (as withholding agent) may be required to spend valuable resources to comply with Bulletin 7 or to establish that the transferors should not be taxed under Bulletin 7, for Gyre Pharmaceuticals&#8217; previous and future restructuring or disposal of shares of Gyre Pharmaceuticals&#8217; offshore subsidiaries. The PRC tax authorities have the discretion under Bulletin 7 to adjust the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. If the PRC tax authorities adjust the taxable income of the transactions under Bulletin 7, income tax costs on the transferor side associated with such potential acquisitions or disposals will increase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals faces uncertainties on the reporting and consequences on future private equity financing transactions, share exchange or other transactions involving the transfer of shares in Gyre Pharmaceuticals by investors that are non-PRC resident enterprises. The PRC tax authorities may pursue such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">non-resident enterprises with respect to a filing or the transferees with respect to withholding obligation, and request Gyre Pharmaceuticals to assist in the filing. As a result, non-resident enterprises in such transactions may become at risk of being subject to filing obligations or being taxed, under Circular 59 or Bulletin 7 and Bulletin 37, and may be required to expend valuable resources to comply with Circular 59, Bulletin 7 and Bulletin 37 or to establish that its non-resident enterprises should not be taxed under these circulars.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The PRC tax authorities have the discretion under SAT Circular 59, Bulletin 7 and Bulletin 37 to adjust the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. Although Gyre Pharmaceuticals currently has no plans to pursue any acquisitions in the PRC or elsewhere in the world, Gyre Pharmaceuticals may pursue acquisitions in the future that may involve complex corporate structures. Because Gyre Pharmaceuticals is a PRC tax resident by default, and if the PRC tax authorities adjust the taxable income of the transactions under SAT Circular 59 or Bulletin 7 and Bulletin 37, Gyre Pharmaceuticals&#8217; income tax costs associated with such potential acquisitions will be increased, which may have an adverse effect on Gyre Pharmaceuticals&#8217; financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The enacted &#8220;Holding Foreign Companies Accountable Act&#8221; and the &#8220;Accelerating Holding Foreign Companies Accountable Act&#8221; call for additional and more stringent criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are not inspected by the Public Company Accounting Oversight Board. These developments could add uncertainties to the market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Holding Foreign Companies Accountable Act(the &#8220;HFCAA&#8221;) requires certain issuers of securities to establish that they are not owned or controlled by a foreign government. Specifically, an issuer must make this certification if the Public Company Accounting Oversight Board (the &#8220;PCAOB&#8221;) is unable to audit specified reports because the issuer has retained a foreign public accounting firm not subject to inspection by the PCAOB. Furthermore, if the PCAOB is unable to inspect the issuer&#8217;s public accounting firm for three consecutive years, the issuer&#8217;s securities are banned from trading on a national exchange or through other methods. In December 2022, the Accelerating Holding Foreign Companies Accountable Act amended the HFCAA by decreasing the number of non-inspection years from three to two, thus reducing the time period before our common stock may be prohibited from trading or delisted if the PCAOB were to determine that it could not inspect our auditor.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In March 2021, the SEC adopted interim final amendments to implement congressionally mandated submission and disclosure requirements of the HFCAA. The interim final amendments will apply to registrants that the SEC identifies as having filed an annual report on Forms 10-K, 20-F, 40-F or N-CSR with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that the PCAOB has determined it is unable to inspect or investigate completely because of a position taken by an authority in that jurisdiction. In December 2021, the SEC adopted amendments finalizing such rules to require that any such identified registrant is required to submit documentation to the SEC establishing that it is not owned or controlled by a governmental entity in that foreign jurisdiction, and is also required to disclose in the registrant&#8217;s annual report the audit arrangements of, and governmental influence on, such a registrant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In December 2021, the PCAOB issued a Determination Report which found that the PCAOB was then unable to inspect or investigate completely registered public accounting firms headquartered in: (1) mainland China of the PRC, because of a position taken by one or more authorities in mainland China; and (2) Hong Kong, a Special Administrative Region and dependency of the PRC, because of a position taken by one or more authorities in Hong Kong. The PCAOB has made such designations as mandated under the HFCAA. Pursuant to each annual determination by the PCAOB, the SEC will, on an annual basis, identify issuers that have used non-inspected audit firms and thus are at risk of such suspensions in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In August 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol (the &#8220;Protocol&#8221;), governing inspections and investigations of audit firms based in the PRC and Hong Kong. Pursuant to the Protocol, the PCAOB shall have independent discretion to select any issuer audits for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">inspection or investigation and has the unfettered ability to transfer information to the SEC. In December 2022, the PCAOB determined that the PCAOB was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB&#8217;s access in the future, the PCAOB will consider the need to issue a new determination. Notwithstanding the foregoing, if the PCAOB is not able to inspect and investigate completely our auditor&#8217;s work papers in China, you may be deprived of the benefits of such inspection which could result in limitation or restriction to our access to the U.S. capital markets and trading of our securities may be prohibited under the HFCAA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our auditor, Grant Thornton Zhitong Certified Public Accountants LLP, an independent public accounting firm registered with the PCAOB, and an auditor of publicly traded companies in the U.S., is subject to laws in the U.S. pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. Our auditor is headquartered in mainland China and was inspected by the PCAOB for the first time in July 2024 and was identified as a firm subject to the determinations announced by the PCAOB in December 2021. Should the PCAOB be unable to fully conduct inspection of our auditor&#8217;s work papers in mainland China, it will make it difficult to evaluate the effectiveness of our auditor&#8217;s audit procedures or equity control procedures. Investors may consequently lose confidence in our reported financial information and procedures or quality of the financial statements, which would adversely affect us and our securities. Moreover, if trading in our securities is prohibited under the HFCAA in the future because the PCAOB determines that it cannot inspect or fully investigate our auditor at such future time, if our securities were then traded on an exchange, that exchange may determine to delist our securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to Commercialization of Our Product and Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Many of our product candidates are years away from regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our development candidates are not expected to be commercially available for several years, if at all. Further, the commercial success of product candidates will depend upon its acceptance by physicians, individuals, third-party payors and other key decision-makers as a therapeutic and cost-effective alternative to products available at the time, which may include competing products currently under development by others. See the risk factor titled &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.&#8221; If we are unable to successfully develop, obtain regulatory approval in a timely manner (including due to reasons that are beyond our control, such as changes in regulations or a shutdown of the federal government, including the FDA) and commercialize our development candidates, our ability to generate revenue from product sales with respect to any product candidates that ultimately obtain approval may be delayed and our business, growth and financial prospectus may be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For instance, no anti-fibrosis product for the treatment of pneumoconiosis has been approved in the PRC. Although ETUARY is approved in the PRC for the treatment of IPF, we cannot be certain that the NMPA, FDA or other comparable regulatory authority will approve ETUARY for the treatment of other indications, such as pneumoconiosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, the regulatory authorities in the PRC, United States and the EU have not approved any products for the treatment of MASH, and while there are guidelines issued by the NMPA and FDA for the development of drugs for the treatment of MASH and an NMPA and FDA surrogate endpoint table for drug approval, respectively, it is unclear whether the requirements for approval will change in the future or whether the NMPA or FDA will rely on regulatory precedent for future regulatory approvals. Any such changes may require us to conduct new trials that could delay our timeframe and increase the costs of our programs related to F351 or any future product candidate for the treatment of MASH. In addition, we cannot be certain which efficacy endpoints or presentation thereof clinical or regulatory agencies may require in a Phase 3 clinical trial of MASH or for approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Even if the NMPA, FDA or other regulatory agency approves our product candidates, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing commitments or requirements for post-approval studies, including additional research and development and clinical trials. The NMPA, FDA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Regulatory approval from authorities in foreign countries will be needed to market our product candidates in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. For example, ETUARY is approved for the treatment of pulmonary fibrosis in the PRC but may not be approved in any other jurisdiction, such as the United States, for such indication. If we fail to obtain approvals from foreign jurisdictions, the geographic market for our product candidates would be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We face substantial competition that may result in others discovering, developing, commercializing or marketing products, including our commercialized product, ETUARY, which is approved in the PRC, before or more successfully than we do.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Although there is one approved therapeutic drug treatment for liver fibrosis in the United States, several companies are developing product candidates in clinical studies. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;Business&#8212;Competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We face competition with respect to our current product, generic drugs and product candidates and will face competition with respect to any future product candidates from segments of the pharmaceutical, biotechnology and other related industries that pursue targeted therapies for patients with organ fibrosis, such as IPF, MASH, PD, DKD, ALF/ACLF or COPD. If ETUARY, F351, F573, F528, F230, or our future product candidates do not offer sustainable advantages over competing products, we may not be able to successfully compete against current and future competitors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our product, ETUARY, which is approved in the PRC, and future products, if approved, and these competitors may also be more successful than us in manufacturing and marketing their products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our commercial opportunity in different indications could be reduced or eliminated if competitors develop and market products or therapies that are more convenient to use, more effective, less expensive, and safer to use than our product, ETUARY, and future products, if approved. Furthermore, if competitors gain NMPA, FDA or other foreign regulatory authority approval earlier than we do, we may be unable to establish a strong market presence or to gain market share. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors. Our product candidates, if any are approved, may compete with these existing drug and other therapies but may not be competitive with them in price. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and individual registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our commercialized product, ETUARY, which is approved in the PRC, and any other future product, if approved, including nintedanib and avatrombopag, which we expect to commercialize in 2025, may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives that would harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we or our collaborators commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate that receives marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmaco-economic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the NMPA, FDA or similar regulatory authorities outside the PRC and United States. Moreover, eligibility for reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers its costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover its costs and may not be made permanent.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the PRC or United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that it develops could have a material adverse effect on our operating results, ability to raise capital needed to commercialize products and overall financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Moreover, our marketed ETUARY is subject to the risk of being included in the PRC&#8217;s centralized volume-based procurement scheme. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;In the future, the policies of centralized volume-based procurement set by the PRC government may cover our commercialized product, ETUARY, future commercialized products, including nintedanib and avatrombopag, which we expect to commercialize in 2025, and any other future products, if approved, and the prices of such product may decrease, which in turn may have a material adverse impact on our revenue, financial condition and results of operation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Risk Factors section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products in the United States and decrease our ability to generate revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments in the United States. Sales of our product candidates will depend substantially, both domestically in the United States and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common stock has been, and may continue to be, volatile.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The market price of our common stock could be subject to significant fluctuations. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">timing and results of INDs, preclinical studies and clinical trials of our product candidates, or those of our competitors or our existing or future collaborators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the success of competitive products or announcements by potential competitors of their product development efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">failure to meet or exceed financial and development projections we may provide to the public; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">failure to meet or exceed the financial and development projections of the investment community; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">if we do not achieve the perceived benefits of the Contributions as rapidly or to the extent anticipated by financial or industry analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">actions taken by regulatory agencies with respect to our product, product candidates, clinical studies, manufacturing process or sales and marketing terms; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">additions or departures of key personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">lawsuits, including patent or stockholder litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">geo-political developments, general market or macroeconomic conditions including inflation and interest rates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">announcement of expectation of additional financing efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">sales of securities by us or our securityholders in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">if we fail to raise an adequate amount of capital to fund our operations and continued development of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">publicity or announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the impact of any natural disasters or public health emergencies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the introduction of technological innovations or new products or product candidates that compete with our product, ETUARY, and product candidates and our services; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">period-to-period fluctuations in our financial results.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, macroeconomic conditions, a recession, depression</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">or other sustained adverse market event or otherwise could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fluctuations in operating results could adversely affect the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our operating results are likely to fluctuate significantly from quarter to quarter and year to year. These fluctuations could cause our stock price to decline. Some of the factors that may cause operating results to fluctuate on a period-to-period basis include the scope, progress, duration results and costs of preclinical and clinical development programs, as well as non-clinical studies and assessments of product candidates and programs, restructuring costs, implementation or termination of collaboration, licensing, manufacturing or other material agreements with third parties, non-recurring revenue or expenses under any such agreement, the cost, timing and outcomes of regulatory compliance, approvals or other regulatory actions, the likelihood of regulatory approval, failure of regulators to grant regulatory approval and general and industry-specific economic conditions, particularly as it affects the pharmaceutical, biopharmaceutical or biotechnology industries in the PRC or United States. Period-to-period comparisons of our historical and future financial results may not be meaningful, and investors should not rely on them as an indication of future performance. Fluctuating losses may fail to meet the expectations of securities analysts or investors. Failure to meet these expectations may cause the price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our current trading volumes are modest, and sales of a substantial number of shares of our common stock in the public market, or the perception that these sales could occur, could cause the market price to decline. Any additional sales in the public market of our common stock or other securities under these shelf registration statements could adversely affect prevailing market prices for our common stock. In addition, we have outstanding options to purchase 18,077,869 shares of common stock at a weighted average exercise price of $1.75 as of December 31, 2024. If such options are exercised and the shares are sold into the open market, such sales also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Conversion or exercise of these securities into shares of our common stock will cause dilution to the other holders of our common stock, and all such stock may be sold in the public market after conversion or exercise, subject to restrictions under the securities laws, which may lead to a decline in the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provisions that will be included in our certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the Company that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors will be responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions will:</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">continue the use of a classified board of directors such that not all members of our board of directors are elected at one time; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">limit the manner in which stockholders can remove directors from our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">provide for advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and for nominations to our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">limit who may call stockholder meetings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">limit actions by our stockholders by written consent; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">require the approval of the holders of at least two-thirds of the votes that all stockholders would be entitled to cast to amend or repeal certain provisions of our certificate of incorporation or bylaws.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which generally prohibits a person who, together with their affiliates and associates, owns 15% or more of the company&#8217;s outstanding voting stock from, among other things, merging or combining with the company for a period of three years after the date of the transaction in which the person acquired ownership of 15% or more of the company&#8217;s outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our certificate of incorporation and bylaws generally provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our certificate of incorporation and bylaws provide that, unless the company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the sole and exclusive forum for the following types of proceedings: (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to the company or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or our bylaws (in each case, as they may be amended from time to time) or that is governed by the internal affairs doctrine. This choice of forum provision will not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This exclusive forum provision may make it more expensive for stockholders to bring a claim than if the stockholders were permitted to select another jurisdiction and may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees or stockholders, which may discourage such lawsuits against us and our directors, officers and other employees and stockholders. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation and bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The current expectation is that we will retain our future earnings, if any, to fund the growth of our business as opposed to paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and tax credit carryforwards may be subject to limitations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, after consideration of certain limitations (see below), we had approximately $193.4 million federal and $13.9 million state net operating loss carryforwards. Under Section 382 and Section 383 of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 &#8220;ownership change&#8221; is generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. We have experienced several ownership changes. Approximately $156.5 million and $75.2 million of the NOLs will expire unutilized for federal and California state income tax purposes, respectively. The Contributions resulted in an additional ownership change and we may experience additional ownership changes in the future due to subsequent shifts in our stock ownership (some of which are outside of our control).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, our ability to use our NOLs to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our NOLs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Even if we achieve profitability, we may not be able to utilize a material portion of our NOLs and other tax attributes, which could have a material adverse effect on cash flow and results of operations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or in their implementation may adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. Changes in tax law may adversely affect our business or financial condition or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be predicted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. Prospective investors should consult their tax advisors regarding the potential consequences of changes in tax law on our business and on the ownership and disposition of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We are a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards and, as a result, qualify for, and rely on, exemptions from certain corporate governance requirements. Our stockholders do not have the same protections afforded to stockholders of companies that are subject to such requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The GNI Parties control a majority of the voting power of our outstanding common stock. As a result, we qualify as a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of Nasdaq. Under these rules, a listed company of which more than 50% of the voting power with respect to the election of directors is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including the requirements that (i) a majority of our board of directors consist of independent directors, (ii) director nominees be selected or recommended to our board of directors entirely by independent directors and (iii) our compensation committee be composed entirely of independent directors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We rely on these exemptions. As a result, we do not have a majority of independent directors, director nominees are not selected or recommended to our board of directors by entirely independent directors and our compensation committee does not consist entirely of independent directors. Accordingly, you may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. In the event we cease to be a "controlled company" and our shares continue to be listed on Nasdaq, we will be required to comply with these provisions within the applicable transition periods.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our executive officers, directors and principal stockholders, in the aggregate, beneficially owned a majority of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may be exposed to increased litigation, including stockholder litigation, which could have an adverse effect on our business and operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may from time to time become subject to various litigation, legal or contractual disputes, investigations or administrative proceedings arising in the ordinary course of our business, including, but not limited to, various disputes with or claims from our suppliers, customers, contractors, licensors, business partners and other third parties that we engage for our business operation. In addition, we may be exposed to increased litigation due to the combination of Catalyst&#8217;s business and Gyre Pharmaceuticals&#8217; business as a result of the consummation of the Contributions. Such litigation may have an adverse impact on our business and results of operations or may cause disruptions to our operations. In addition, in the past, stockholders have initiated class action lawsuits against biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If any verdict or award is rendered against us or if we agree to settle with an adverse party, we could be required to pay significant monetary damages, assume other liabilities and/or suspend or terminate the related business projects. Negative publicity arising from litigation, legal disputes, investigations or administrative proceedings may damage our reputation and adversely affect the image of our brands and products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to product liability claims that could expose us to costs and liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are exposed to product liability risks as a result of developing, producing, marketing, promoting and selling pharmaceutical products in the PRC, United States and other jurisdictions. Such claims may arise if our product, ETUARY, and future products, if approved, are deemed or proven to be unsafe, ineffective, defective or contaminated, or if we are alleged to have engaged in practices such as insufficient or improper labeling of products or providing inadequate, insufficient or misleading warnings or disclosures regarding side effects. A product liability claim brought against us may, regardless of merit or outcome, result in reputational harm and strain on financial resources and may consume the time and attention of our management. If we are unable to successfully defend itself against such claims, we may, among others, be subject to product recalls, civil liability for physical injury, death or other losses caused by our product, ETUARY, and future products, if approved, criminal liability and the revocation of our business licenses. PRC laws and regulations currently do not require us to, and we do not, maintain liability insurance to cover product liability claims. As a result, we may not be able to recover our losses resulting from future product liability claims.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Breach, failure or disruption in or to our information system could compromise sensitive information related to our business and expose us to liability or reputational harm, and our ability to effectively manage our business operations could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our information systems may fail and are subject to risks of breakdown, breach, interruption or damage from computer viruses, ransomware and other cyber-attacks, computer hackers, malicious code, employee error or malfeasance, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures or other compromise. Any system damage or failure that interrupts data input, retrieval or transmission or increases service time could disrupt our normal operations, including the loss of clinical trial data from completed or future clinical trials. Loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. There can be no assurance that we will be able to effectively handle a failure of our information systems, or that we will be able to restore our operational capacity in a timely manner or at all to avoid disruption to our business. Further, cybersecurity breaches or other cybersecurity incidents may allow hackers access to our preclinical compounds, strategies, discoveries, trade secrets, and/or other confidential information. Additionally, sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, vendors&#8217; or partners&#8217; use of generative AI technologies. To the extent that any disruption or cybersecurity incident were to result in a loss of, or damage to, our data or applications, or inappropriate use, disclosure of or access to confidential or proprietary information, we could incur liability, including under laws and regulations governing the protection of protected health information and other personal data, our competitive position could be harmed and the further development and commercialization of our product, ETUARY, and product candidates could be hindered or delayed. The risk of a cybersecurity incident or other informational technology disruption, particularly through cyber-attacks, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We may collect and store sensitive personal data in the ordinary course of our business. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#8212;Risks Related to Our Business Operations in the PRC&#8212;Compliance with the PRC&#8217;s new Data Security Law, Cyber Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme on cyber security and any other future laws and regulations may entail significant expenses and could affect our business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221; in this Risk Factors section. If personal data are compromised due to a material breach of our information, the market perception of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">You may have difficulty enforcing judgments obtained against us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Substantially all of our assets are located outside of the United States. Most of our operations and administrative and corporate functions are conducted in the PRC. In addition, several of our directors and officers are nationals and residents of countries other than the United States. A substantial portion of the assets of these persons are located outside the United States. As a result, due to the lack of reciprocity and treaties between the United States and some of these foreign jurisdictions, together with cost and time constraints, it may be difficult for you to effect service of process within the United States upon these persons. In particular, several of our officers and directors are generally located in the PRC, and it will be more difficult to enforce liabilities and enforce judgments on those individuals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to Section 404(a) of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), our management is required to report upon the effectiveness of our internal control over financial reporting. Beginning with our annual report for our fiscal year ending December 31, 2024, we have become an &#8220;accelerated filer.&#8221; By becoming an &#8220;accelerated filer,&#8221; Section 404(b) of the Sarbanes-Oxley Act will require our independent auditors to express an opinion on our internal control over financial reporting. Ensuring that we have adequate internal controls in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that will need to be evaluated frequently. If we are unable to maintain effective internal control over financial reporting, we may not have adequate, accurate or timely financial information, our independent registered public accounting firm may issue a report that is adverse, and we may be unable to meet our reporting obligations as a public company or comply with the requirements of the SEC or the Sarbanes-Oxley Act. This could result in a restatement of our financial statements, the imposition of sanctions, including the inability of registered broker dealers to make a market in our common stock, or investigation by regulatory authorities. Any such action or other negative results caused by our inability to meet our reporting requirements or comply with legal and regulatory requirements or by disclosure of an accounting, reporting or control issue could adversely affect the trading price of our securities and our business. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. This process will be time-consuming, costly and complicated.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">We may identify material weaknesses or significant deficiencies in our internal control over financial reporting in the future or fail to maintain effective internal control over financial reporting, which may</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">result in material misstatements of our consolidated financial statements or cause us to fail to meet our periodic reporting obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of the registrant&#8217;s financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Remediation measures to remediate a material weakness or significant deficiency may be time consuming, may result in us incurring significant costs, and may place significant demands on our financial and operational resources.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our failure to identify and address any material weaknesses or significant deficiencies that may be identified in the future could result in material misstatements to our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis, which could cause investors to lose confidence in our reported financial information, which may result in volatility in and a decline in the market price of our securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 1B. UNRESOL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">VED STAFF COMMENTS.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_cf8ba115-c09c-436b-ab5a-1dc9a803e903" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_cf8ba115-c09c-436b-ab5a-1dc9a803e903_1"><p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 1C. CYBERSECURITY.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We strive to safeguard our important data, hardware, and internal network from digital attacks, theft and damage. In the ordinary course of our business, we collect, use, store, and digitally transmit confidential, sensitive, proprietary, and personal information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy. To this end, we have implemented processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_06aaba23-264c-4869-9e41-28cd6d72c174" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">At Gyre Therapeutics, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d4c4976f-973a-451b-9d67-17a0f68d5a44" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">these processes are managed and monitored by a third-party information technology</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (&#8220;IT&#8221;) consulting company (the &#8220;Managed Service Provider&#8221;) and are overseen by our Chief Financial Officer.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> At Gyre Pharmaceuticals, these processes are managed and monitored by a dedicated Information Security team, which is led by the General Manager. Gyre Therapeutics&#8217; and Gyre Pharmaceuticals&#8217; processes include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data. In the process of advancing the systematic development of information security, we seek to maintain a robust approach that encompasses policy formulation, organizational structuring, technological application enhancement, process optimization, and personnel training. For example, Gyre Therapeutics and Gyre Pharmaceuticals maintain software and hardware inventories, perform security monitoring and alerting, and complete ongoing risk assessments. Gyre Therapeutics and Gyre Pharmaceuticals also conduct regular employee trainings on cyber and information security, among other topics. In addition, both companies consult with outside advisors and experts on a regular basis to assist with assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the Company&#8217;s risk environment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our Chief Financial Officer, who reports directly to our Chief Executive Officer, is responsible for assessing and managing Gyre Therapeutics&#8217; cybersecurity risks with support from the Managed Service Provider, which employs IT consultants with over 20 years of experience managing information technology and cybersecurity matters and are certified as Microsoft Certified Systems Engineers. Our Gyre Pharmaceuticals information security team, who reports to the Secretary of the General Manager at Gyre Pharmaceuticals, comprises of three employees with an average of 20 years of experience managing information technology and cyber</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_cf8ba115-c09c-436b-ab5a-1dc9a803e903_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">security matters. The Secretary of the General Manager reports to the General Manager at Gyre Pharmaceuticals, and the General Manager reports to the Board of Directors and is responsible for assessing and managing Gyre Pharmaceuticals&#8217; cybersecurity risks. We consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework. Since the beginning of the last fiscal year, we have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the heading &#8220;Breach, failure or disruption in or to our information system could compromise sensitive information related to our business and expose us to liability or reputational harm, and our ability to effectively manage our business operations could be adversely affected.&#8221;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_da47ff88-edc4-43de-b196-1476f5ac9bfe" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_7b9a469c-1f4a-4ff6-add7-43541c823586" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_16783702-ffa6-4a1f-8559-8387686436b2" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our management team.</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_feb3d64b-4a5a-45cb-836e-e8f319a3f8de" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true" continuedAt="F_feb3d64b-4a5a-45cb-836e-e8f319a3f8de_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_feb3d64b-4a5a-45cb-836e-e8f319a3f8de_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></ix:continuation></span></p></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 2. PROPERTIES.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics&#8217; Properties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our corporate headquarters are in San Diego, California, where we lease approximately 1,643 rentable square feet of office space. The lease commenced on November 11, 2023 and expires on the last day of the 38th full calendar month beginning on or after November 11, 2023. Gyre expects to be able to renew this lease or obtain alternative facilities on commercially reasonable terms.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals&#8217; Properties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Owned Properties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals has land use right certificates for two parcels of land in Shunyi District, Beijing, PRC and Cangzhou, Hebei province, PRC with an aggregate site area of 66,559 square meters and building ownership certificates for eight properties with an aggregate gross floor area of 22,169 square meters. Gyre Pharmaceuticals&#8217; two production centers are in Beijing, PRC and Cangzhou, PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Leased Properties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals leases 22 properties in the PRC. Among Gyre Pharmaceuticals&#8217; 22 leased properties, 10 are used as offices, and 12 are used as employee dormitories.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 3. LEGAL PROCEEDINGS.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are currently not a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 4. MINE SAFETY DISCLOSURES.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">131</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item  5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PUR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CHASES OF EQUITY SECURITIES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc. is listed on the Nasdaq Capital Market under the symbol &#8220;GYRE.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Holders of Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of March 7, 2025, there were approximately 44 stockholders of record of our common stock. Since many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On January 12, 2023, we paid a  cash dividend of approximately $7.6 million (or $0.24 per share) to our common stockholders of record as of the close of business on January 5, 2023. In June 2023, we distributed $3.5 million, which reflected, in connection with the Vertex Transaction, the hold-back amount received from Vertex less expenses and a reserve for potential tax liabilities, to the holders of Catalyst Common Stock as of January 5, 2023 (the &#8220;CVR Holders&#8221;). On August 26, 2024, we distributed approximately $12.6 million (or $0.40 per contingent value right) to the CVR Holders. We currently intend to retain all future earnings, if any, for use in our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors our board of directors may deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item  6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">[RESERVED].</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">132</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; You should carefully read the &#8220;Cautionary Note About Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; sections of this Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from the results described below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are a commercial-stage biotechnology company with a proven track record of financial success developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs and involves a complex, multi-stage process with multiple pathways. While there are numerous potential targets for anti-fibrotic therapy, both established and emerging, addressing a single molecular pathway may not be sufficient to prevent, halt, or reverse fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our strategy is to build on our success in the development and commercialization of ETUARY&#174; (pirfenidone) to expand into new indications and advance our pipeline of innovative drug candidates. Pirfenidone, the first anti-fibrotic drug approved for IPF in Japan, the EU, the United States, and the PRC, is a small molecule drug that inhibits the synthesis of TGF-&#223;1, Tumor Necrosis Factor-&#945;, and other fibrosis and inflammation modulators. We have obtained approval for ETUARY (pirfenidone) in the PRC for IPF.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals successfully advanced pirfenidone from research and development to commercialization in the PRC for the treatment of IPF. In addition to IPF, pirfenidone is undergoing one additional Phase 3 trial in the PRC for the treatment of pneumoconiosis (&#8220;PD&#8221;) to broaden its indications and market. In May 2024, Gyre Pharmaceuticals executed a comprehensive agreement with Jiangsu Wangao Pharmaceuticals Co., Ltd. to acquire the commercial rights to nintedanib, a small-molecule drug for the treatment of IPF. With this acquisition, we acquired the other product approved for the treatment of IPF, which is currently approved globally for the treatment of IPF. Nintedanib is expected to provide patients with more choices and benefits, and further enhance Gyre Pharmaceuticals&#8217; leading position in the pulmonary fibrosis market. Gyre Pharmaceutical is planning to initiate commercialization of the nintedanib product in the PRC in 2025, which is to help offset declines in ETUARY sales as a result of the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">fluctuations in the Chinese economy significantly affecting demand for anti-fibrosis drugs and decreasing healthcare spending generally. We believe that this launch can drive meaningful revenue growth, expand our market penetration, and enhance brand recognition within the respiratory disease space. Additionally, the commercialization of nintedanib aligns with our broader strategy of building a comprehensive pulmonary care portfolio, potentially creating opportunities for synergies with our existing and future product offerings. We expect to continue to invest in commercialization efforts, including market access, physician education, and patient support programs, to optimize uptake and maximize the long-term value of this product.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351, our lead development candidate in both the United States and the PRC, is a structural derivative of ETUARY (pirfenidone). It is a new oral chemical entity with an anti-fibrotic, TGF-&#223;1-targeting mechanism of action. Studies suggest that F351 and its major metabolites have minimal drug-drug interaction risks. We are prioritizing F351 for the treatment of liver fibrosis due to the large potential addressable market and significant unmet need.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">133</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals has completed a Phase 2 trial of F351 in the PRC for CHB-associated liver fibrosis. The Phase 2 trial showed that F351 was well-tolerated without notable toxicity and patients treated showed statistically-significant improvement of liver fibrosis, with the best efficacy results achieved at 270 mg/day dosing. Based on these results, a confirmatory Phase 3 trial is ongoing in the PRC with a primary endpoint of the reduction of the liver fibrosis score (Ishak Scoring System) by at least one stage after taking F351 in combination with Entecavir. In October 2024, the last patient completed the 52-week pivotal Phase 3 trial. Gyre Pharmaceuticals expects to report top-line data from this trial by the second quarter of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the United States, we have completed a Phase 1 clinical trial of F351 in healthy volunteers. Following results from the PRC Phase 3 trial in CHB-associated liver fibrosis and pending approval of an IND submission, we expect to initiate a Phase 2 trial to evaluate F351 for the treatment of MASH-associated liver fibrosis in 2025. We cannot guarantee that a Phase 2 trial will be initiated or estimate the funding needed for such trial at this time, but may need to raise additional capital to fund this program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In parallel, we are also conducting a randomized, double-blind, placebo-controlled Phase 2 clinical trial in the PRC to assess the safety and efficacy of F573, a caspase inhibitor for the treatment of acute/acute on-chronic liver failure. In addition, in May 2024, we obtained the approval from the NMPA for the IND to launch a new clinical trial in the PRC of another new drug candidate, F230, a selective endothelin receptor agonist for the treatment of pulmonary arterial hypertension. We are preparing for the anticipated launch of the clinical trial in the PRC. We are also evaluating F528, a novel anti-inflammation agent that targets the inhibition of multiple inflammatory cytokines, in preclinical studies as a potential first-line therapy for the treatment of chronic obstructive pulmonary disease.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In June 2024, Gyre Pharmaceuticals received approval from the NMPA for avatrombopag maleate tablets for the treatment of TP with CLD and ITP disease indications. TP is the most common hematologic complication in patients with CLD and can be life threatening in severe cases. Avatrombopag is an oral thrombopoietin receptor agonist. Avatrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with CLD-associated TP in May 2018, and its indication was subsequently expanded to include the treatment of immune thrombocytopenia in June 2019. Gyre Pharmaceuticals acquired avatrombopag under a transfer agreement with Nanjing Healthnice Pharmaceutical Technology, Co., Ltd. (&#8220;Nanjing Healthnice&#8221;) in June 2021 and is planning to start commercializing the avatrombopag product by 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F351 Asset Acquisition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On December 26, 2022, we purchased the F351 Assets from GNI Japan and GNI Hong Kong, other than such assets and intellectual property rights located in the PRC, pursuant to the F351 Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Business Combination Agreement</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On December 26, 2022, Catalyst entered into a Business Combination Agreement, as amended on March 29, 2023 and August 30, 2023 (the &#8220;Business Combination Agreement&#8221;) with GNI USA, GNI Japan, GNI Hong Kong, SG (collectively with GNI USA, GNI Japan and GNI Hong Kong, the &#8220;Contributors,&#8221; and each a &#8220;Contributor&#8221;), certain individuals and CPI. On October 30, 2023 (the &#8220;Effective Time&#8221;), the Contributions (as defined below) became effective and Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (doing business as Gyre Pharmaceuticals Co., Ltd.).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Business Combination Agreement, at the Effective Time of the Contributions, and after giving effect to the 1-for-15 reverse stock split:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GNI USA contributed all of its ordinary shares in the capital of CPI to Catalyst in exchange for 45,923,340 shares of Common Stock (the &#8220;CPI Contribution&#8221;), </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">134</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GNI USA contributed its interest in Further Challenger International Limited (&#8220;Further Challenger&#8221;) for 17,664,779 shares of Common Stock (the &#8220;FC Contribution&#8221; and together with the CPI Contribution, the &#8220;GNI USA Contributions&#8221;), and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">each Minority Holder contributed 100% of the interest he or she held in his or her respective entity in exchange for an aggregate of 10,463,627 shares of Common Stock (the &#8220;Minority Holder Contributions&#8221; and together with the GNI USA Contributions, the &#8220;Contributions&#8221;).</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As a result of the GNI USA Contributions, Gyre directly and indirectly holds 100% of CPI&#8217;s shares. Through Gyre&#8217;s ownership of CPI, prior to the Minority Holder Contributions, Gyre held a 56.0% indirect interest in Gyre Pharmaceuticals. Upon completion of the Minority Holder Contributions, Gyre obtained additional indirect interests in Gyre Pharmaceuticals and holds, in aggregate, a 65.2% indirect interest in Gyre Pharmaceuticals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">At the Effective Time, Gyre Pharmaceuticals terminated its 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;) and the options (the &#8220;Gyre Pharmaceuticals Options&#8221;) outstanding under the 2021 Plan were terminated and replaced with options granted under a subplan for Chinese participants under the Gyre 2023 Omnibus Incentive Plan (the &#8220;2023 Omnibus Incentive Plan&#8221;) that are substantially similar in all material respects to the Gyre Pharmaceuticals Options previously outstanding under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The majority shareholder of Gyre Pharmaceuticals is BJContinent Pharmaceuticals Limited (&#8220;BJC&#8221;). The immediate holding company of BJC is CPI. Immediately following the GNI USA Contributions, the immediate holding company of CPI is Gyre. The majority stockholder of Gyre is GNI USA, which is indirectly wholly owned by GNI Japan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The GNI USA Contributions were treated as an asset acquisition under U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), with CPI treated as the accounting acquirer and presented as the predecessor for post-acquisition reporting purposes. Since Catalyst is the legal acquirer, the GNI USA Contributions were accounted for as a reverse asset acquisition. This determination was based upon the terms of the Business Combination Agreement and other factors including that, immediately following the GNI USA Contributions: (i) GNI USA (as the parent company of CPI immediately prior to the GNI USA Contributions) owns a substantial majority of the voting power of the combined company; (ii) GNI USA has the ability to control the board of directors of the combined company; and (iii) senior management of Gyre Pharmaceuticals and GNI USA hold a majority of the key positions in senior management of the combined company. Immediately prior to the closing of the GNI USA Contributions, Catalyst did not meet the definition of a business because Catalyst did not have an organized workforce that significantly contributed to its ability to create output, and substantially all of its fair value was concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of the closing date of the GNI USA Contributions, the net assets of Catalyst were recorded at their acquisition-date relative fair values in the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K and the reported operating results prior to the GNI USA Contributions are those of CPI.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where we obtained additional indirect interests in and maintained our control over Gyre Pharmaceuticals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contingent Value Rights Agreement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Concurrent with the signing of the Business Combination Agreement on December 26, 2022, Catalyst and the Rights Agent (as defined in the CVR Agreement) executed a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), as amended on March 29, 2023, pursuant to which each CVR Holder, excluding GNI Japan and GNI Hong Kong, received one contractual contingent value right (a &#8220;CVR&#8221;) issued by the Company for each share of Catalyst common stock held by such holders. Each CVR entitles the CVR Holder thereof to receive certain cash payments in the future. For additional information, see Note 13 &#8212; Commitments and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">135</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contingencies to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On October 30, 2023, we effected a 1-for-15 reverse stock split immediately prior to the Effective Time of the Contributions. The par value of the Catalyst Common Stock following the Reverse Stock Split was not adjusted and remains at $0.001 per share. All of the Catalyst&#8217;s issued and outstanding common stock and options have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding, which resulted in a proportional decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options, warrants, and in the case of stock options and warrants, a proportional decrease in the exercise price of such stock options and warrants.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Stock Split and stockholders who would otherwise be entitled to a fraction of one share received a proportional cash payment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Private Placement and Securities Purchase Agreement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On October 27, 2023, we entered into the Securities Purchase Agreement for a private placement with GNI USA (the &#8220;Private Placement&#8221;). Pursuant to the Securities Purchase Agreement, GNI USA agreed to purchase (i) 811 shares of our Convertible Preferred Stock, par value $0.001 per share (the &#8220;Convertible Preferred Stock&#8221;) and (ii) warrants to purchase up to 811 shares of Convertible Preferred Stock (the &#8220;Preferred Stock Warrants&#8221;) for an aggregate purchase price of $5.0 million. The Private Placement closed immediately after the closing of the Contributions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Preferred Stock Warrants are exercisable at an exercise price of $4,915.00 per share of Convertible Preferred Stock and expire on October 30, 2033.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Jiangsu Wangao Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In May 2024, Gyre Pharmaceuticals entered into an agreement with Jiangsu Wangao Pharmaceuticals Co., Ltd. (the &#8220;Jiangsu Wangao Agreement&#8221;), effective from May 7, 2024 to May 6, 2035. Pursuant to the Jiangsu Wangao Agreement, Gyre Pharmaceuticals obtained the drug registration certificate for and became the marketing authorization holder of nintedanib, a small-molecule drug for the treatment of idiopathic pulmonary fibrosis, within the PRC. The total minimum payments under the Jiangsu Wangao Agreement are RMB 35.0 million, or approximately $4.8 million, based on the May 7, 2024 spot exchange rate. This includes an upfront transfer fee of RMB 15.0 million, or approximately $2.1 million, payable in three installments, and subsequent low- to mid-single-digit royalty payments over eight years following the commencement of sales. Additionally, Gyre Pharmaceuticals will bear the costs associated with relocating the production site to a designated location and will cover all expenses related to the manufacturing process. As of December 31, 2024, we had paid RMB 5.0 million, or approximately $0.7 million, based on the May 13, 2024 spot exchange rate of the first installment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-Term Investment Measured Under Equity Method</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On June 28, 2024, Gyre Pharmaceuticals entered into a partnership agreement as a limited partner and is obligated to pay $4.2 million for an 18.93% equity interest in the partnership. Pursuant to the partnership agreement, Gyre Pharmaceuticals, as a limited partner, shall not participate in any activities related to the management of the investment business. However, Gyre Pharmaceuticals may appoint a member to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">136</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">advisory committee of the partnership. As of December 31, 2024, our total investment into the partnership and the carrying value of the Company&#8217;s long-term investment in this affiliate was $1.7 million and $1.6 million, respectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, we had a net income of $17.9 million and a net income attributable to common stockholders of $12.1 million. For the year ended December 31, 2023, our net loss was $85.5 million and net loss attributable to common stockholders was $92.9 million. As of December 31, 2024, we had accumulated deficit of $73.5 million and cash and cash equivalents of $11.8 million. As of December 31, 2023, we had an accumulated deficit of $85.5 million and cash and cash equivalents of $33.5 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Components of Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sales of Pharmaceutical Products</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We generate revenue primarily through sales of ETUARY and certain generic drugs in the PRC. Distributors are our direct customers, and sales to distributors accounted for 100.0% of the revenue from ETUARY. Such distributors sell ETUARY to certain outlets, including hospitals and other medical institutions, as well as pharmacies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and Marketing Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing expenses primarily relate to selling and marketing our product ETUARY in the PRC and consist of expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development costs consist primarily of costs related to the pre-clinical and clinical development of our product candidates, which include payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services for pre-clinical research and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">clinical trials, materials, and consulting costs, as well as allocations of facilities, depreciation and other overhead costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">137</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We manage our research and development expenses by identifying the research and development activities we expect to be performed during a given period and then prioritizing efforts based on anticipated probability of successful technical development and regulatory approval, market potential, available human and capital resources, scientific data and other considerations. We regularly review our research and development activities based on unmet medical need and, as necessary, reallocate resources among our research and development portfolio that we believe will best support the long-term growth of our business. We do not track research and development expenses by product candidate or development phase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to our functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D expenses represent costs incurred for acquisitions of IPR&amp;D with no alternative future use, which are expensed immediately upon acquisition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture Losses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Prior to the GNI USA Contributions, we recorded a loss from the divestiture of almost all our assets other than our 56.0% indirect ownership interest in Gyre Pharmaceuticals. This expense was reflected in our consolidated statements of operations and comprehensive income (loss). The loss is presented net of the direct costs incurred with the transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on Disposal of Property and Equipment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The net loss on the sale and disposal of property and equipment is reflected in our consolidated statements of operations and comprehensive income (loss).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other Income (Expense), Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest Income, Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income consists primarily of interest earned on our long-term certificates of deposit. Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other (Expense) Income, Net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other income consists mostly of government grants. Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying amount of the asset and released to profit or loss by way of a reduced depreciation charge.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expenses consist of any non-operating costs, such as loss from equity method investments.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in Fair Value of Warrant Liability</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">138</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In connection with the Private Placement, we issued the Preferred Stock Warrants, which are freestanding financial instruments classified as warrant liability since the underlying securities are contingently redeemable upon the occurrence of events which are outside of our control. The Preferred Stock Warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period, with any change in fair value recognized in our statements of operations as other (income) expense.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for income taxes are comprised primarily of current income tax provision, mainly attributable to the profitable Gyre Pharmaceuticals operations in the PRC, and deferred income tax provision, mainly including deferred tax recognized for temporary differences in relation to research and development tax credit and net operating loss carryforwards for U.S. tax purposes, deemed income inclusions from controlled foreign corporations for U.S. tax purposes, and fixed and intangible assets, net of valuation allowances.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2024 and 2023 (in thousands, except percentage change):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.83%;box-sizing:content-box;"/>
    <td style="width:1.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.398000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.398000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.818%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.998000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change (%)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">105,757</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">113,450</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(7,693</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(6.8</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3,884</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4,636</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(752</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(16.2</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Profit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">101,873</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">108,814</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(6,941</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(6.4</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">57,511</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">61,159</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(3,648</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(6.0</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">12,024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">13,780</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1,756</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(12.7</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">16,109</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">14,662</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1,447</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">9.9</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">83,104</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(83,104</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,711</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(2,711</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">66</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">628</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(562</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(89.5</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">85,710</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">176,044</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(90,334</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(51.3</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (loss) from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">16,163</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(67,230</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">83,393</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1,547</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1,044</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">503</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">48.2</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1,659</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1,518</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(141</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">9.3</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">7,167</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(9,261</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">16,428</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (loss) before income taxes</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">23,218</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(76,965</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">100,183</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(5,320</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(8,515</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3,195</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(37.5</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">17,898</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(85,480</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">103,378</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income attributable to noncontrolling interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">5,813</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1,640</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(22.0</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) attributable to common stockholders</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">12,085</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(92,933</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">105,018</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">** Not meaningful.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024 and 2023</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues for the years ended December 31, 2024 and 2023 were $105.8 million and $113.5 million, respectively. The $7.7 million decrease was primarily driven by a $7.1 million decrease in ETUARY's revenue and a $0.6 million decrease in generic drug revenue as a result of decreased sales volumes. The decrease in</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">139</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ETUARY and generic drug sales volumes was due to fluctuations in the Chinese economy that significantly affected demand for anti-fibrosis drugs and decreasing healthcare spending generally. To support future revenue growth, we plan to commercially launch new products, such as nintedanib and avatrombopag, in 2025, which will be supported by our extensive sales and marketing platform across the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of Revenues</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues for the years en</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ded December 31, 2024 and 2023 was $3.9 million and $4.6 million, respectively. The decrease was primarily driven by a $0.5 million factory stoppage loss due to factory renovation in 2023, which did not occur in 2024, and a $0.2 million decrease due to decreased sales volumes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and Marketing Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing expenses decreased by $3.6 million, or 6.0%, for the year ended December 31, 2024 compared to the year ended December 31, 2023. The decrease was primarily driven by a $2.4 million decrease in conference costs and promotion expense due to decreased sales activities, a $0.9 million decrease in selling and marketing payroll costs due to the decrease of sales of ETUARY in 2024, a $0.3 million decrease in share base compensation expense, and a $0.1 million decrease in miscellaneous expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The table below details our costs for research and development for the years ended December 31, 2024 and 2023 (in thousands, except percentage change):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change ($)</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change (%)</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Direct program expenses:</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Clinical trials</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4,328</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4,228</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">100</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.4</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Materials and utilities</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,294</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,607</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(313</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(12.0</span></p></td>
    <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pre-clinical research</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">766</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,038</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1,272</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(62.4</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Indirect expenses:</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Personnel-related costs including stock-based compensation</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3,253</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4,092</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(839</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(20.5</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Facilities, depreciation and other</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1,383</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">815</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">568</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">69.7</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">12,024</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">13,780</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1,756</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(12.7</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development expenses decreased by $1.8 million, or 12.7%, for the year ended December 31, 2024 compared to the year ended December 31, 2023. The decrease was primarily from Gyre Pharmaceuticals, and was driven by a $0.3 million decrease in materials and utilities, a $1.3 million decrease in pre-clinical research expense  due to several research and development projects advancing to the clinical trials stage or reaching the application phase in 2024, a $0.4 million decrease in staff cost due to reduced headcount, and a $0.5 million decrease in stock-based compensation related to options being fully vested in 2023, which did not occur in 2024. This overall decrease was partially offset by a $0.7 million increase in research and development expense from Gyre Therapeutics due to increased consulting fees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative expenses increased by $1.4 million, or 9.9%, for the year ended December 31, 2024 compared to the year ended December 31, 2023. The increase was primarily driven by costs associated with being a public company, including a $1.9 million increase in professional expense, a $2.1 million increase in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">140</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">miscellaneous expenses, and a $3.0 million increase in functional and administrative department's personnel cost, offset by a $5.6 million decrease in stock-based compensation cost.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There was no acquired IPR&amp;D expense for the year ended December 31, 2024 compared to $83.1 million for the year ended December 31, 2023. The acquired IPR&amp;D represents costs incurred for acquisitions of IPR&amp;D with no alternative future use, which were expensed immediately upon the closing of GNI USA Contributions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture Losses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There was no divestiture loss for the year ended December 31, 2024 compared to $2.7 million for the year ended December 31, 2023. The divestiture losses are related to sales of almost all our assets other than our 56.0% indirect ownership interest in Gyre Pharmaceuticals. The loss is presented net of the direct costs incurred with the transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on Disposal of Property and Equipment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We recorded a net loss on the sale and disposal of property and equipment of $66.0 thousand and $628.0 thousand for the years ended December 31, 2024 and 2023, respectively, in our consolidated statements of operations and comprehensive income (loss).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other Income (Expense), Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income increased by $0.5 million, or 48.2%, for the year ended December 31, 2024 compared to the year ended December 31, 2023, primarily due to additional investments in long-term certificates of deposit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expenses, net increased by $0.1 million, or 9.3%, for the year ended December 31, 2024 compared to the year ended December 31, 2023. The increase was primarily due to a $1.0 million increase in loss from equity method investment, partially offset by a $0.9 million decrease in government grants.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability was a decrease of $7.2 million and an increase of $9.3 million for the years ended December 31, 2024 and 2023, respectively. The decrease is related to the remeasurement of the Preferred Stock Warrants liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for income taxes was $5.3 million and $8.5 million for the years ended December 31, 2024 and 2023, respectively. The decrease was primarily attributable to a lower profit from Gyre Pharmaceuticals' operations for the year ended December 31, 2024 compared to the year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had cash and cash equivalents of $11.8 million, short-term bank deposit of $14.9 million and long-term certificates of deposit of $24.6 million, which are available to fund operations, and an accumulated deficit of $73.5 million. Our net income during the year ended December 31, 2024 was $17.9 million, while cash used in operating activities was $3.6 million. We believe that our existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund our operating activities and obligations for at least 12 months following the filing date of this Annual Report.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">141</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Future Funding Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We expect to use cash flows from operations to meet our current and future financial obligations, including funding our operations, and capital expenditures. Our ability to make these payments depends on our future performance, which will be affected by financial, business, economic, regulatory, and other factors, many of which we cannot control. In particular, following results from the PRC Phase 3 trial in CHB-associated liver fibrosis and pending approval of an IND submission, we expect to initiate a Phase 2 trial to evaluate F351 for the treatment of MASH-associated liver fibrosis in 2025. We cannot guarantee that a Phase 2 trial will be initiated or estimate the funding needed for such trial at this time, but may need to raise additional capital to fund this program. Factors that may affect financing requirements include, but are not limited to:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the timing, progress, cost and results of our clinical trials, preclinical studies and other discovery and research and development activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the timing and outcome of, and costs involved in, seeking and obtaining marketing approvals for our products, and in maintaining quality systems standards for our products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the timing of, and costs involved in, commercial activities, including product marketing, sales and distribution;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to successfully commercialize and to obtain regulatory approval for, and successfully commercialize our other or future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">increases or decreases in revenue from our marketed products, including decreases in revenue resulting from generic entrants or health epidemics or pandemics;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the number and development requirements of other product candidates that we pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to manufacture sufficient quantities of our products to meet expected demand;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the costs of preparing, filing, prosecuting, maintaining and enforcing any patent claims and other intellectual property rights, litigation costs and the results of litigation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">our ability to enter into collaboration, licensing or distribution arrangements and the terms and timing of these arrangements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the potential need to expand our business, resulting in additional payroll and other overhead expenses;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the potential in-licensing of other products or technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the emergence of competing technologies or other adverse market or technological developments; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the impacts of inflation and resulting cost increases.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary businesses, products and technologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the periods presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash Flow Data:</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net cash (used) provided by operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(3,641</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">25,892</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(19,884</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(19,760</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,102</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,500</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(273</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(298</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(21,696</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8,334</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash Flows from Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">142</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash used in operating activities for the year ended December 31, 2024 was $3.6 million, reflecting our net income of $17.9 million, offset by non-cash items of $5.9 million primarily related to the $7.2 million cash used in change in fair value of warrant liability, depreciation and amortization of $1.5 million, stock-based compensation of $0.8 million. Additionally, cash used in operating activities reflected changes in net operating assets and liabilities of $15.7 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2023 was $25.9 million, reflecting our net loss of $85.5 million, offset by non-cash items of $103.9 million primarily related to the acquired IPR&amp;D of $83.1 million in connection with the GNI USA Contributions, $9.3 million related to the change in fair value of warrant liability, stock-based compensation of $7.3 million, divestiture losses of $2.7 million, and equity loss of unconsolidated affiliates of $1.3 million. Additionally, cash provided by operating activities reflected changes in net operating assets and liabilities of $7.5 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash Flows from Investing Activities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash used in investing activities for the year ended December 31, 2024 was $19.9 million, which consisted of $15.5 million in purchases of certificates of deposit, $2.3 million in purchases of property and equipment, $0.8 million in acquisition of intangible assets and $1.7 million paid for equity method investment, partially offset by $0.4 million of cash acquired in connection with the sale of equipment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash used in investing activities for the year ended December 31, 2023 was $19.8 million, which consisted of $15.7 million in purchases of certificates of deposit, $8.5 million in purchases of property and equipment and $1.0 million paid for equity method investment, partially offset by $5.6 million of cash acquired in connection with the GNI USA Contributions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash Flows from Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2024 was $2.1 million due to $1.9 million in proceeds from the exercise of stock options and $0.8 million in proceeds from the issuance of common stock under our ATM Program with Jefferies LLC, partially offset by $0.5 million of cash used in connection with deferred financing costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2023 was $2.5 million due to the portion of proceeds from the issuance of Convertible Preferred Stock and Preferred Stock Warrants in the Private Placement received after the GNI USA Contributions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Restricted Net Assets</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under PRC laws and regulations, Gyre Pharmaceuticals is subject to restrictions on foreign exchange and cross-border cash transfers, including to parent companies and U.S. stockholders. The ability to distribute earnings to the parent companies and U.S. stockholders is also limited. Current PRC regulations permit Gyre Pharmaceuticals to pay dividends to BJC only out of its accumulated profits as determined in accordance with PRC accounting standards and regulations. Amounts restricted include paid-in capital and the statutory reserves of Gyre Pharmaceuticals. The aggregate amounts of restricted capital and statutory reserves of the relevant subsidiaries not available for distribution were $64.3 million as of December 31, 2024 and December 31, 2023. We do not expect the restrictions described above to have a material impact on our ability to meet our cash obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contractual Obligations and Other Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Leases</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">143</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have entered into lease arrangements in (1) San Diego, California for our headquarters, which expires on the last day of the 38th full calendar month beginning on or after November 11, 2023, and (2) the PRC, for office and laboratory spaces through May 2027. As of December 31, 2024, our fixed lease payment obligations were $1.7 million, with $0.8 million payable within 12 months.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other Contractual Obligations and Commitments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In June 2021, we entered into a transfer agreement with Nanjing Healthnice Pharmaceutical Technology Co., Ltd. (&#8220;Nanjing Healthnice&#8221;), an independent third party, pursuant to which Nanjing Healthnice agreed to transfer to us the avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia and all relevant technologies, complete any research or trials and transfer to us all materials necessary for the application of marketing approval by the NMPA. We were approved by the NMPA as the marketing authorization holder of the avatrombopag maleate tablets on June 25, 2024. In exchange, we paid a total of approximately $2.3 million upon certain milestones (e.g., the completion of bioequivalence study, or the registration application to the NMPA) being met. We have completed the bioequivalence study and received NMPA acceptance on August 1, 2022, and as of December 31, 2024, we have made total payments of approximately $2.3 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In September 2022, we entered into a transfer agreement with New Jiyuan (Beijing) Pharmaceutical Technology Co., Ltd. (&#8220;New Jiyuan&#8221;), an independent third party, pursuant to which New Jiyuan agreed to transfer to us the minocycline hydrochloride foam for the treatment of moderate to severe acne and all relevant technologies, complete product development and transfer to us all materials necessary for the application of marketing approval of NMPA. Upon the completion of the transfer, we expect that we will be approved by NMPA as the marketing authorization holder of the minocycline hydrochloride foam. In exchange, we will pay a total amount of $1.0 million and the payments will be made by installments conditioned upon certain milestones (e.g., the completion of bioequivalence study, or the registration application to NMPA) being met. Process verification has been completed. As of December 31, 2024, we have made total payments of approximately $0.7 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and Development Programs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we have committed to allocate $33.0 million toward future research and development activities for various programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our commitments related to the purchase of property and equipment contracted but not yet reflected in the consolidated financial statements were $1.4 million as of December 31, 2024 and are expected to be incurred within one year.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We expect to satisfy these contractual obligations and commitments through a combination of cash on hand and cash provided by operating activities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP and our discussion and analysis of our financial condition and operating results require our management to make judgments, assumptions and estimates that affect the amounts reported in our consolidated financial statements and accompanying notes. Our significant accounting policies and methods used in preparation of the consolidated financial statements are described in Note 2 &#8212; Summary of Significant Accounting Policies to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">144</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Management believes our critical accounting policies and estimates discussed below are critical to understanding its historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We recognize revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#8217;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For the sale of pharmaceutical products, revenue is recognized at a point in time when control of the asset is transferred to the customer, generally on completion of delivery of the pharmaceutical products. For the sales of pharmaceutical products, most of our customers are distributors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenue from product sales is recognized net of estimated sales discounts. These discounts are estimated based on sales volumes from the preceding months and applying the discount percentages specified in each contract. The estimation process requires management judgment, particularly in determining the amount of sales discounts based on historical sales volumes and contractually agreed-upon discount percentages. Additionally, variable consideration related to sales rebates is recorded as deductions from revenue based on historical experience and contract terms. Depending on the contract structure, we apply either the expected value method or the most likely amount method to estimate future rebates, selecting the approach that best predicts the amount of variable consideration. The estimates for these rebates are reviewed regularly, and adjustments are made as necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Accruals</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred when the expenditures relate to ongoing research activities without alternative future use. A significant portion of our research and development expenses consists of pre-clinical and clinical trial costs, which involve contracts with third-party service providers such as contract research organizations. These costs are accrued based on management&#8217;s estimates of the services performed during the respective period.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We estimate the amount of work completed through discussion with internal personnel and external service providers in conjunction with reporting information obtained directly from the external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. Accruals are based on progress reports, contractual terms, and management&#8217;s judgment regarding the stage of completion of various projects. Since there is often a timing difference between service delivery and invoicing, we make adjustments as more information becomes available. We also assess the likelihood of milestone-based payments under contract terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">145</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">performed may vary and may result in us reporting expenses that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We record income taxes using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We account for uncertain tax positions in accordance with the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 740, Income Taxes. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits are recorded as a component of income tax expense, if any.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We measure the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value-based measurement of the award on the date of grant and recognize the related expense over the period during which an employee, non-employee or director is required to provide services in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once we have determined that it is probable that performance conditions will be satisfied.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Determining the fair value of stock-based awards at the grant date requires judgment. We use the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by our assumptions regarding a number of variables including the fair value of our common stock, its expected common stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. We record stock-based compensation as a compensation expense, net of the forfeited awards. We elected to account for forfeitures when they occur. As such, we recognize stock-based compensation expense over their requisite service period based on the vesting provisions of the individual grants. Such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different. We will continue to use judgment in evaluating the assumptions utilized for our stock-based compensation expense calculations on a prospective basis. See Note 12 &#8212; Stock Based Compensation to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K for more information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Liability</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In connection with the Private Placement, we issued the Preferred Stock Warrants (see Note 3 &#8212; Fair Value Measurements and Financial Instruments to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K) which are freestanding financial instruments classified as warrant liability since the underlying securities are contingently redeemable upon the occurrence of events which are outside of our control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">146</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">remeasurement at the end of each reporting period. We use the Black-Scholes option-pricing model to determine the fair value of the Preferred Stock Warrants which is affected by our assumptions regarding a number of variables, including the fair value of our Convertible Preferred Stock, the expected share price volatility over the expected life of the options, expected term of the warrant, risk-free interest rates and expected dividends. Such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our estimated fair value of warrant liability could be materially different. We will continue to use judgment in evaluating the assumptions utilized for our warrant liability fair value calculations on a prospective basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Smaller Reporting Company and Accelerated Filer Status</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on the aggregate market value of our common stock held by non-affiliates as of June 30, 2024, we believe we remain a smaller reporting company, but have become an &#8220;accelerated filer&#8221; as of December 31, 2024. Because we believe our non-accelerated filer status expired on December 31, 2024, we are required, pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, to include in our Annual Report on Form 10-K for the year ending December 31, 2024 an attestation report as to the effectiveness of our internal control over financial reporting that is issued by our independent registered public accounting firm. However, we expect to continue to take advantage of the reduced reporting requirements applicable to smaller reporting companies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Refer to Note 2 &#8212; Summary of Significant Accounting Policies to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K for a discussion of recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">147</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 7A.	QUANTITATIVE AND QUALITAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">IVE DISCLOSURES ABOUT MARKET RISK.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Market risk represents the risk of loss that may impact on our financial position because of adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure resulting from potential changes in exchange rates, interest rates, or inflation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Exchange Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our expenses are generally denominated in the currencies of the jurisdictions in which we conduct our operations, which are primarily in the United States and the PRC. Our results of current and future operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates. A hypothetical 10% increase or decrease in the relative value of the U.S. dollar to other currencies would not have a material effect on our operating results. As the impact of foreign currency exchange rates has not been material to our historical operating results, we have not entered into derivative or hedging transactions, but we may do so in the future if our exposure to foreign currency becomes more significant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Inflation Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We do not believe that inflation has had a material effect on our business, financial condition, or results of operations, other than its impact on the general economy. Nonetheless, if our costs were to become subject to inflationary pressures, we might not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">148</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 8. FINANCIAL STATEMEN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">TS AND SUPPLEMENTARY DATA</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">See Index to Consolidated Financial Statements and Schedules on page F-1 of this Form 10-K.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">149</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 9A. CONTROLS AND PROCEDURES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Evaluation of disclosure controls and procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our management, with the participation and supervision of our principal executive officer and our principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2024 to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework. Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2024,.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The effectiveness of our internal control over financial reporting as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, has been audited by </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_bc60d274-70f9-4153-a90a-7d0fe6cb7d2a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Grant Thornton Zhitong Certified Public Accountants LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, an independent registered public accounting firm, as stated in their report that is included herein.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">150</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Board of Directors and Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on internal control over financial reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have audited the internal control over financial reporting of Gyre Therapeutics, Inc. (a Delaware corporation) and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024, based on criteria established in the 2013 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in the 2013 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">issued by COSO.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated financial statements of the Company as of and for the year ended December 31, 2024, and our report dated March 17, 2025 expressed an unqualified opinion on those financial statements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Definition and limitations of internal control over financial reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">151</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Grant Thornton Zhitong Certified Public Accountants LLP</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing, China</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 9B. OTHER IN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">FORMATION.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Trading Arrangements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">None of our directors or executive officers </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_8c6da38b-171e-442f-bb85-32b77793ca0c" contextRef="C_56859774-ba75-4d74-b1b3-78de98856e4c" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_06d47d55-cbe9-4f1d-8970-8bb2b8d52d3e" contextRef="C_56859774-ba75-4d74-b1b3-78de98856e4c" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_73f2a3d4-6485-40d3-83a5-5daa15c2d98e" contextRef="C_56859774-ba75-4d74-b1b3-78de98856e4c" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_b7df9b72-ba7a-4e69-88ca-b0371b6e4c4a" contextRef="C_56859774-ba75-4d74-b1b3-78de98856e4c" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the three months ended December 31, 2024, as such terms are defined under Item 408(a) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_foreign_jurisdiction"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 9C. DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">152</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">T III</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 10. DIRECTORS, EXECUTIVE OFF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ICERS AND CORPORATE GOVERNANCE.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The information required by this Item 10 is incorporated herein by reference to the information in our proxy statement for our 2025 Annual Meeting of Stockholders (the &#8220;2025 Proxy Statement&#8221;), which we expect to be filed with the SEC within 120 days of the end of our fiscal year ended December 31, 2024, including under the heading &#8220;Corporate Governance,&#8221; "</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_9c405263-42c3-4ae0-a8a0-494d7cfaa1d0" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">," and, as applicable, &#8220;Delinquent Section 16(a) Reports&#8221; per Item 405 of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is available on our website located at www.gyretx.com, under &#8220;Corporate Governance.&#8221; We intend to disclose on our website any amendments to, or waivers from, the code of business conduct and ethics that are required to be disclosed within four business days following the date of the amendment or waiver.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 11. EXECUTI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">VE COMPENSATION.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The information required by this Item 11 is incorporated herein by reference to the information in our 2025 Proxy Statement, including under headings &#8220;Executive Compensation&#8221; and &#8220;Corporate Governance&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 12. SECURITY OWNERSHIP OF CERTA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">IN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The information required by this Item 12 is incorporated herein by reference to information in our 2025 Proxy Statement, including under headings &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 13. CERTAIN RELATIONSHIPS, RELATED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">TRANSACTIONS AND DIRECTOR INDEPENDENCE.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The information required by this Item 13 is incorporated herein by reference to information in our 2025 Proxy Statement, including under headings </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Corporate Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Party Transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 14. PRINCIPAL ACCOU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">NTANT FEES AND SERVICES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The information required by this Item 14 is incorporated herein by reference to information in our 2025 Proxy Statement, including under the heading &#8220;Ratification of Independent Auditor Appointment.&#8221;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">153</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 15. EXHIBIT AND FINA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">NCIAL STATEMENT SCHEDULES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following documents are filed as part of this Annual Report on Form 10-K:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Financial Statements</span></div></div>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">See Index to Consolidated Financial Statements at Part II, Item 8 Financial Statements and Supplementary Data, herein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Financial Statement Schedules</span></div></div>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All schedules are omitted because they are not applicable or the required information is shown under Item 8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</span></p>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">See LIST OF EXHIBITS</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">See LIST OF EXHIBITS</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">154</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 16.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">FORM </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10-K SUMMARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">155</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="list_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">LIST OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">EXHIBITS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.025%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:45.086%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:6.719%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:11.031%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:8.063%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:14.039%;box-sizing:content-box;"/>
    <td style="width:1.023%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Incorporated by reference</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.1(a)&#134;#</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Asset Purchase Agreement, dated as of December 26, 2022, by and among Catalyst Biosciences, Inc., GNI Group Ltd., and GNI Hong Kong Limited.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dec. 27, 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.1(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agreement and Amendment to Asset Purchase Agreement, dated as of March 29, 2023, by and among Catalyst Biosciences, Inc., GNI Group Ltd., and GNI Hong Kong Limited.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Mar. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.2(a)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex2-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Business Combination Agreement, dated as of December 26, 2022, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the individuals listed on Annex A thereto and Continent Pharmaceuticals Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dec. 27, 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.2(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amendment to Business Combination Agreement, dated as of March 29, 2023, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders and Continent Pharmaceuticals Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Mar. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.2(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/brhc20058284_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Second Amendment to Business Combination Agreement, dated as of August 30, 2023, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc. and Continent Pharmaceuticals Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Aug. 31, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000095017024126306/gyre-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Restated Certificate of Incorporation of the Company.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Nov. 13, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex3-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Company.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.3(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312517121994/d375894dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed with the Delaware Secretary of State on April 10, 2017.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Apr. 13, 2017</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.3(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000095017024037242/gyre-ex3_6b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certificate of Elimination of Series A Preferred Stock, filed with the Delaware Secretary of State on March 25, 2024.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.6(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Mar. 27, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.4(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Delaware Secretary of State on December 27, 2022.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dec. 27, 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">156</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.025%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:45.086%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:6.719%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:11.031%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:8.063%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:14.039%;box-sizing:content-box;"/>
    <td style="width:1.023%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Incorporated by reference</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.4(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex3-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Delaware Secretary of State on October 30, 2023.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.5(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123030517/brhc20054638_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series Y Preferred Stock, filed with the Delaware Secretary of State on June 20, 2023, with respect to the Series Y Preferred Stock.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">June 20, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.5(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/brhc20058284_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certificate of Elimination of Series Y Preferred Stock, filed with the Delaware Secretary of State on August 31, 2023.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Aug. 31, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Description of Securities.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex4-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form of Warrant to Purchase Series X Convertible Preferred Stock.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.1(a)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123035866/ny20009756x1_ex2-5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contingent Value Rights Agreement, dated as of December 26, 2022, by and between Catalyst Biosciences, Inc. and American Stock Transfer &amp; Trust Company, LLC.</span><span style="color:#0000ff;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">S-3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">333-273395</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">July 24, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.2(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amendment to Contingent Value Rights Agreement, dated as of March 29, 2023, by and between Catalyst Biosciences, Inc. and American Stock Transfer &amp; Trust Company, LLC.</span><span style="color:#0000ff;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Mar. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/brhc10049211_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Asset Purchase Agreement, dated as of February 27, 2023, by and between Catalyst Biosciences, Inc. and GC Biopharma Corp.</span><span style="color:#0000ff;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Mar. 2, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement, dated as of October 27, 2023, by and between Catalyst Biosciences, Inc. and GNI USA, Inc.</span><span style="color:#0000ff;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.5+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312516554394/d165946ddef14a.htm#toc165946_34"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Catalyst Biosciences, Inc. (formerly Targacept, Inc.) 2015 Stock Incentive Plan (as Amended and Restated Effective June 9, 2016).</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Appendix A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Apr. 25, 2016</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.6+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000156459017013442/cbio-ex101_24.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form of Incentive Stock Option Award Notice.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">July 14, 2017</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.7+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000156459017013442/cbio-ex102_25.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form of Non-qualified Stock Option Award Notice.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">July 14, 2017</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.8+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000156459020020531/cbio-def14a_20200611.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Appendix A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">May 1, 2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.9+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312518160813/d581034ddef14a.htm#toc581034_35"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Appendix B</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">May 11, 2018</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.10+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000156459022012877/cbio-ex108_9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form of Stock Option Award Agreement.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Mar. 31, 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">157</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.025%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:45.086%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:6.719%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:11.031%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:8.063%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:14.039%;box-sizing:content-box;"/>
    <td style="width:1.023%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Incorporated by reference</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.11+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.12+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.13+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Employment Agreement, dated as of October 30, 2023, by and between the Company and Ruoyu Chen.</span><span style="color:#0000ff;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.14+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/ef20019132_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Employment Agreement, dated as of January 15, 2024, by and between the Company and Dr. Han Ying.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Jan. 19, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036124047980/ny20036484x4_8k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Open Market Sale AgreementSM, dated November 27, 2024, by and between the Company and Jefferies LLC.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8-K</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Nov. 27, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">19.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Insider Trading Policy of the Company.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">21.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">List of subsidiaries of the Company.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consent of Grant Thornton Zhitong Certified Public Accountants LLP, Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">24.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Power of Attorney (included as part of the signature page hereto).</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">32.1**</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">32.2**</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certification of the Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000095017024037242/gyre-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Clawback Policy of the Company</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">000-51173</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Mar. 27, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">158</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.025%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:45.086%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:6.719%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:11.031%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:8.063%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:14.039%;box-sizing:content-box;"/>
    <td style="width:1.023%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Incorporated by reference</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">101.INS*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">101.CAL*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">101.DEF*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">101.LAB*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">101.PRE*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:70%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">** Furnished.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#134; The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"># Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) the Company customarily and actually treats that information as private or confidential and (ii) the information was not material.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">+ Denotes management contract, compensatory plan or arrangement.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">159</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">URES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.64%;box-sizing:content-box;"/>
    <td style="width:42.3%;box-sizing:content-box;"/>
    <td style="width:4.64%;box-sizing:content-box;"/>
    <td style="width:48.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GYRE THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Date: March 17, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Han Ying, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Han Ying, Ph.D.</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Date: March 17, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Ruoyu Chen</span></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ruoyu Chen</span></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">POWER OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ATTORNEY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Each person whose individual signature appears below hereby authorizes and appoints Han Ying, Ph.D. and Ruoyu Chen, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:38.96%;box-sizing:content-box;"/>
    <td style="width:1.7%;box-sizing:content-box;"/>
    <td style="width:19.24%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Han Ying, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Han Ying, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Ruoyu Chen</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Chief Financial Officer (Principal Financial and Accounting Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ruoyu Chen</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Songjiang Ma</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">President and Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Songjiang Ma</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Thomas Eastling</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Thomas Eastling</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Gordon Carmichael, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gordon Carmichael, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Ping Zhang</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ping Zhang</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Rodney L. Nussbaum</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rodney L. Nussbaum</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">160</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:38.96%;box-sizing:content-box;"/>
    <td style="width:1.7%;box-sizing:content-box;"/>
    <td style="width:19.24%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Renate Parry, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Renate Parry, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ David M. Epstein, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">David M. Epstein, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">161</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Index to Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.8%;box-sizing:content-box;"/>
    <td style="width:6.2%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID #</span><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d3c5f891-b2d5-4c84-860f-f7b83bb471ce" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">1487</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Financial Statements</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Income</span></a><a href="#consolidated_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (Loss)</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#sose"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Equity</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#schedulei"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Schedule I - Condensed Financial Information of Parent Company</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">45</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">EPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Board of Directors and Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_54d7311d-5e89-43cc-ae40-0fb5248db7f4" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the financial statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Gyre Therapeutics, Inc. (a Delaware corporation) and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of comprehensive income (loss), consolidated statements of convertible preferred stock and equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes and the financial statements schedule included in Schedule I (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in the 2013 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated March 17, 2025 expressed an unqualified opinion.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Critical audit matter</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred stock warrants</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As described in Note 3 and 11 to the consolidated financial statements, in October 2023, the Company completed a private placement whereby the Company issued shares of convertible preferred stock and warrants to purchase shares of convertible preferred stock. The warrants were classified as a liability instrument and are subject to fair value remeasurement at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value of warrant liabilities was estimated by management using the Black-Scholes option pricing model. As the Company's warrant liabilities are not traded in an active market with readily observable prices, the use of this model includes significant unobservable inputs to measure the fair value of the warrant liabilities. We identified the warrant liabilities to be a critical audit matter.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The principal considerations for our determination that warrant liabilities is a critical audit matter is the significant judgment by management when assessing the volatility and expected term assumptions, which in turn led to a high degree of auditor judgment and effort in performing procedures and evaluating audit evidence relating to those assumptions. The audit effort also involved the use of professionals with specialized skills and knowledge.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our related audit procedures included the following, among others:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Reading and evaluating the </span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">convertible preferred shares and warrants agreement</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Evaluating, with the assistance of specialists, management&#8217;s assessment of the fair value of the warrant liabilities, specifically the reasonableness of the expected volatility used by management in determining the fair value</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Evaluating the competence, capability and objectivity of the independent valuation firm engaged by the Company</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Grant Thornton Zhitong Certified Public Accountants LLP</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_bc727a24-3d30-45ed-b466-319b8ade9a7b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beijing, China</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 17, 2025</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets">&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_589a5522-9336-429f-9bf9-31a8f75bf61b" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,813</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d31a212c-5df7-4139-9fec-1eb916e44cea" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,509</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Short-term bank deposits</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49e356f4-c866-4860-9144-f18da6c13407" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,858</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Notes receivable</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4e7974c-432b-415a-9291-1eaf131b5e54" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:NotesAndLoansReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,373</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edde70ac-7d40-4f93-b611-ec5a08b3840e" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:NotesAndLoansReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ac6b665-e029-49cd-9d5c-1db802b6cb15" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,589</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b6c6b04-74e2-4bbc-be69-a407f7c681f5" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,163</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other receivables from GNI</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59275fda-78b2-42fc-946c-b2c1ca5e088e" contextRef="C_081e2763-6f98-4757-9d8d-5f31041f2742" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9c94083-5943-42ce-807e-68c2e7476e2e" contextRef="C_c2f5674d-e5bd-447a-8b4d-85feed272f13" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,287</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, net</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3a838e5-5d8d-4e95-bf79-21f278b2ec13" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,337</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e838e0a-e046-41a9-aaeb-b29e9afae333" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,281</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Prepaid assets</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6be2f987-4139-4a15-a228-7785d4ddc134" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:PrepaidAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,189</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9eecefa-4f2e-4abb-8e1d-e45788843fad" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:PrepaidAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,547</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Receivable from GCBP</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc8d4865-35c7-49af-9501-db3f99799d08" contextRef="C_ad700354-24cd-4e94-bf85-24453ba4377c" name="us-gaap:NontradeReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78f9ae34-841c-4a7e-a50b-342a58a5cfaa" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,436</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15d5502e-fa94-424f-8505-98e54128ddaf" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,045</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total current assets:</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2103dc33-d796-4481-b3f5-807181c1242e" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,786</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2de8997-cad6-42be-a374-09feb63490f4" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,221</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c238c5a-2ca6-4fd3-b88e-30993d333cb0" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,880</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53beb134-3406-41f0-9531-d0e87023100f" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,288</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9e6eed7-5bff-42ac-be7a-092dc951a2f0" contextRef="C_a29cbd02-6a5c-4fdb-aff1-44deb722af3d" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03aa718-51b9-4ebf-b95a-92285fb4b34c" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_facb4a47-c6ce-45d9-b971-360547b4111c" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f463d2e6-e563-4617-acda-04c2359b883d" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,818</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b32e139d-13b0-4721-8a4a-97d80eb0b594" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Land use rights, net</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf69dcd4-e563-4a43-96d0-80f1971fac83" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:LandUseRightsNetNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,432</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abf36086-062d-41a0-9d38-6adcef6d9e00" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:LandUseRightsNetNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,493</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_421c7242-454d-43d7-bf1c-a8fca081b290" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,619</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_223c37b0-b04f-4ee6-ae22-bb2e54a5a8d8" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,695</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5928e424-d348-463b-8d81-7d771717e9af" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,568</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94497a9f-5e0d-4fbd-ac55-d6d8996b5cd4" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,431</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other assets, noncurrent</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25f0ee93-cba8-48f1-b8a9-69b103cad8e3" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,030</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7461734b-da04-4ddf-930d-e768e858a750" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">995</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5cad52c-de75-4dd5-b9ac-34413279ed3f" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,406</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3229480b-4ea7-4dcc-9c53-f31f7f666416" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,539</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Liabilities, convertible preferred stock, and equity</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_869ddb53-9449-4301-b55c-d79e5292b1d7" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd090a2f-6333-4c12-b9ac-beaea98f3dcc" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79a33ecb-6e43-4ae3-a4b8-e26b61d75b91" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4573a1f9-9231-4455-853e-2197f0252b5b" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due to related parties</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e5bd08b-4309-4e75-ae36-dd1467424810" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3659ade7-5d0e-4a96-9bed-561c1b6e743e" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,369</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR excess closing cash payable</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afae975d-396b-4264-9c40-a7ae636ac4eb" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:CvrExcessClosingCashPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,085</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0475f11-e0fe-4a71-a695-511947691e75" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,615</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7fbabc6-a687-4e44-9f61-98c0960e86b7" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,935</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c442e40-36c5-43e7-99d5-5562adc65e3b" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,831</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ced0b897-a172-491a-8bfa-0af58a046151" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,054</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_288d6f31-472c-49bc-b27d-7e10bb7567be" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">713</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4cd6cb3-ff5e-4adb-ae6d-efdf862ebf27" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bd73ef3-be3b-4d0a-9775-db9fa0a8738c" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:CVRDerivativeLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total current liabilities:</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af44a45c-4f32-4d26-8d28-f25992c492a0" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,516</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b707806-9f76-475c-a2e5-af020d76516b" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,047</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating lease liabilities, noncurrent</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f7e4ccf-5da7-4a8a-89bf-24badb28fca4" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">885</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bf551d5-e2eb-4d6e-b3e3-c308a797919f" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred government grants</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e50996a3-41d4-437c-a338-5da90a8541f4" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">928</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e63df01c-c959-4883-b9e3-3d489cbdaabd" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability, noncurrent</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdf1410a-69bc-4ca1-8a5a-fb3fabdbabe5" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:CVRDerivativeLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d9fa434-6544-4fee-958e-a18e4227f3ca" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,668</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e8ab186-5b42-4db5-978f-8e1affe35bfd" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,835</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other noncurrent liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d63fd580-960c-4af3-b767-7c9cf3fa9faf" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cb74eca-de7c-453c-b9d5-a30db5622be9" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5304823-a826-4d53-b59b-31331d279a4b" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,004</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03690da9-ff34-480c-83f7-ed4974a12735" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,065</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_e5069514-7ffc-45f8-813c-6fba7eae2521;"><span style="-sec-ix-hidden:F_3448db62-d53f-481f-8d69-743602ddb884;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and Contingencies (Note 13)</span></span></span></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock, $</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f683379-95b2-478b-a878-2205b120de3d" contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8d636a94-5cca-4fd8-92dd-a23fcd9bb9b9" contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_441dc8bc-0866-4099-847c-36dbea3f04dd" contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_749950dd-43ba-4397-b9f0-9632d664005c" contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc55fe80-4b21-4aff-8c7f-3386870a5162" contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_11e614c5-bca9-4088-96b2-978b850d524a" contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_151928ae-6b15-4b99-865b-6463141953cb" contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2bd2fbb7-6da3-43a2-a1ca-7fa8fc7183c8" contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and 2023, respectively</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b62a0001-bca7-456f-b5e7-9d8c426a6a1a" contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Equity:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24209542-b945-4616-b9ce-ab91b85c03b6" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_39333e5d-340e-42c5-b4c7-c188e2da0071" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c7b6e95-b2e4-4d15-85b1-cffadda11f2a" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8a6b1aac-db64-4d11-8245-eef600b514f5" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5cff3e0-4f9d-482e-b18f-ded9a92bcc93" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6afeac9f-dbd1-41d6-9f42-0775d35feab9" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,307,544</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b103a05-49c4-4fe6-94aa-fa848e51f310" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_af9597b5-6f09-495c-90de-69165a1429d9" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,595,616</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and 2023, respectively</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6cd9edd-351a-4952-905b-555cc3c6f579" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca655226-9e40-4ebf-a023-5248e8ad1c5f" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3cf2f5d-e422-47a4-a4de-1c4d18ec6056" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,185</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e6aba98-dffd-4039-8af4-738065f84053" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,179</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Statutory reserve</span></p></td>
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f909335e-5cda-49a8-946d-5edcd0538ec7" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:StatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,098</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ba2dcf2-b130-49c1-8a36-d0c2e78bb2a6" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:StatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,098</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc21ec7f-cd27-4a82-be76-d14f068409a0" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,453</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe912cb6-4ea6-4f90-8beb-ea850c5dcea7" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,538</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0b861cb-e69f-48d5-ad75-60d2d9b1a393" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,597</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e853340-8ace-4575-8e80-f2045344481c" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,644</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total Gyre stockholders&#8217; equity (deficit)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f75a31f-4fd4-4312-ae31-ba227cfe01c7" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,319</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afde1cd3-a4c6-407b-b7ce-1340b718ec99" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,828</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Noncontrolling interest</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cf07c15-aac5-4538-81ac-148c981e5f59" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,083</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eec4cab1-afbe-4a43-bc59-93a248aa6eac" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,777</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total equity</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34884ad5-27d5-4002-be96-e36c64bdbac9" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,402</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9db5a80-3509-45c1-8011-baa8b65a3cea" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total liabilities, convertible preferred stock, and equity</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fbc786f-c14c-4191-9fbd-02bebdf78cb3" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,406</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8efa17cd-580f-4072-a1b8-72fde09e7353" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,539</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ents of Operations and Comprehensive Income (Loss)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.96%;box-sizing:content-box;"/>
    <td style="width:1.52%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.52%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a482f91-cf2a-4f09-bad1-c8d51996d24a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,757</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9e03913-a068-45bb-9186-0d66a86fb03b" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5122719-d6df-4bea-8ed9-4c4294f96e90" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,884</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79f94d59-fb69-499c-85bc-dc93c4a1b617" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,636</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83e56e80-8db0-4d4f-8765-51597b271283" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,511</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87da24a1-7929-41bd-8c25-69e0f0f563ac" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,159</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a838e5a0-0420-4f5a-9594-78a74cf147be" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,024</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eba6e293-047b-473e-a3ce-b1ec72e5c1fd" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,780</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6f2b18a-0356-424b-8e4d-f72600297e98" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,109</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0bf2c38-4c67-40d2-9dfb-db7dfe1925b3" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,662</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d87d0b6-2666-4c52-9a63-296ffe2db06b" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37cd8c73-c63a-4880-9a9d-77cdbe9d8ba8" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f826cf5-d8ff-4a36-b781-0b85e24256e8" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39027330-9221-4e83-a59b-e1be67ab7187" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0300f231-868d-4727-b07f-19e6b08efa97" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,594</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_261c4efa-2c7f-4548-af0f-d080c68299fe" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,680</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (loss) from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1360edd2-c3e6-4ef4-8158-75abd5c59d63" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,163</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43930c47-c738-4cfb-a487-f038e1bb30db" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,230</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b897ba8-c207-40b0-8ca5-7f6cc03cec40" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,547</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_255a3eec-4bba-4ffe-a624-cea59c00dbf5" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,044</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7923be3f-f891-4fe9-ae3b-7872e3598fe2" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,659</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_269cf636-e37f-4ceb-8afc-b788e8adc757" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,518</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_674f2681-6e6d-4841-b2b6-016b4b5b1d04" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,167</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_260a39cb-ae3d-4e59-8fcf-585705848ca7" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (loss) before income taxes</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7df95b8c-49bb-46c7-91a3-19c6b3f01381" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,218</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_401343f9-d751-43ab-bfc8-43e5eda87a67" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76,965</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3591768-d17d-4572-a0f7-9634309905c0" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,320</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27ff8dd5-8f68-4ce1-b677-04ae0a1a110d" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,515</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c308a6d-7091-4962-aa34-35e9af0f626c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,898</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e78ce140-4811-4767-a5ab-c182bd48e90f" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income attributable to noncontrolling interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8982faf0-2728-49d2-9b61-83b533875768" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,813</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f863750-54ee-4fc0-ba9b-28df46d895dd" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) attributable to common stockholders</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e08efddb-e459-4010-8bf3-1fd12925932b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,085</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f8189ac-f56d-4e63-86fc-53594dbb9f78" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) per share attributable to common stockholders:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4983a70-00c7-4283-863f-154bfdfc60b5" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9671cbff-afb8-41ac-98dc-a16ca82aa836" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49af914e-8cdf-4793-a43f-fa829a6c96a7" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.05</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9730931-a21d-41c8-8442-f0d03b9b5ac7" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e8cdb51-4c18-4304-ad60-9e300eb16d1f" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,094,948</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d63278c1-128a-4145-aa96-20f81a66656c" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f304801-75d1-42b4-8400-7ae6ad20c854" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">102,293,526</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bac29d6-3ad3-47f8-a79f-24bbc598cbf8" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e86e3f05-571e-4080-819b-4a900da1cb8d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,898</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7686994d-abb4-4552-9213-f9977aac12be" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da81b943-b8e9-4d29-902a-83d09ab87477" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,460</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a2d7f20-c0b0-4b19-9013-9cf1f0a13b71" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,484</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Comprehensive income (loss) from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dd80aea-dcd3-4ed7-a06b-720877940661" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,438</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22735d29-7be0-4124-b2ff-e7d5de8edcd9" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,964</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income attributable to noncontrolling interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70c60514-0717-42f6-8c71-479406b1985b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,813</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60d7f994-f5ab-43fa-adf7-37efd913d4bc" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments attributable to noncontrolling interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2baf38b1-7475-4b80-9d59-8147a73fdb27" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">507</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d365304d-91b8-4cc2-a656-7db41d7c8cbb" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">647</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Comprehensive income attributable to noncontrolling interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89f22e60-fd17-42be-8577-dd346175f4e6" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,306</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74438ab4-d998-4f61-8dfb-25fd200bdb18" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,806</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Comprehensive income (loss) attributable to common stockholders</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e3c975f-6b51-499c-a8ff-3debb2a63a55" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,132</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3970d897-b759-48de-950a-ac57218f6be0" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,770</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="sose"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#1d1c1d;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.84%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.4%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.4%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.24%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Statutory</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Retained Earnings</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total Gyre Stockholders&#8217; Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-controlling</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total<br/>Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Reserve</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Accumulated Deficit)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Deficit)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#caf0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe41e59f-fbf6-47e3-889e-e074653c6212" contextRef="C_62f49f26-9563-408b-b7c2-7c3b1be23119" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,588,119</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da09cb4f-118c-4601-b8a7-70218a91d08d" contextRef="C_62f49f26-9563-408b-b7c2-7c3b1be23119" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee662f43-c48b-4a73-8d64-8be7c641bd5f" contextRef="C_641c5278-93b2-409e-a72b-833546eaec22" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,795</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff2f8d7a-f454-4e4e-b6f0-a92f0792cea4" contextRef="C_29261f54-503a-4613-b9da-f1c82b1b0e73" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,660</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13412589-7691-4489-8c0b-db0c931f2fcd" contextRef="C_29facfe6-6ed6-43d0-af3e-0188d8bb96fe" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,395</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f26accb-6a60-4628-8808-4d1f71c4de80" contextRef="C_59171fe1-a910-4f9d-acea-66214546eade" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90d29daa-a533-4752-b3ee-7f208504e402" contextRef="C_afb0500b-16d2-4911-ab34-f347a18f0103" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,522</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d857bc29-e7a8-48ee-a6f7-4f80b2b9c5ea" contextRef="C_c66f706c-79f5-4c3c-a4d4-6383b9abf3ef" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,695</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_189a3f75-a7f8-4d3a-b930-66aa8a0efeb2" contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,217</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d035b0c6-8a61-43c6-a11a-1f765c49a003" contextRef="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23" name="gyre:TemporaryEquityIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,340</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf408c83-94aa-4d00-a7f4-65fd2c126493" contextRef="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23" name="gyre:TemporaryEquityIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,099</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba3990a8-1c9b-4147-8e28-ae1e1d35eda8" contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,531,851</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_078eb0b7-b2fa-490f-ab88-ef2c5be5f606" contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e24db3dc-4c76-4bb7-8482-774cffbc6987" contextRef="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,246</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44dd2bad-388c-4673-ac41-0b25e971d291" contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,249</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a17ee9e4-6ae2-4da0-9688-9f9f48230a7f" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,249</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#caf0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquisition of minority interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa0d9264-c402-4027-a206-dfc139f88064" contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706" name="gyre:MinorityInterestDecreaseFromRedemptionsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,463,627</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdec5e13-73a8-48dd-beab-8c50c66b7eb9" contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_529f10db-f6d6-4c2b-a3f7-a8aacf74c723" contextRef="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,845</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c19ba779-bb1f-43f6-81c0-69736108f5f5" contextRef="C_a75bd85a-71ec-47ee-b069-04337603dd4a" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">438</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddaec7bb-f458-415a-b4b2-2f67a4227b13" contextRef="C_1da1795e-730c-42e1-9de0-0fedc96400d9" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">415</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e91fed4-cf01-459c-b665-ed2416980aaf" contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,878</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efa57573-2b6a-4c66-9d2f-7cb81f5fe751" contextRef="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,878</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Issuance of Preferred Stock upon Private Placement</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_818c1858-2c5a-4679-8afe-d0401aab7eb5" contextRef="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23" name="gyre:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">811</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3fb1f93-876a-49b7-8590-879e462d9e22" contextRef="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,426</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#caf0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5b2093c-8242-4ad6-b3c6-d2af797e55db" contextRef="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d776285-7ab8-414f-9dd5-55433c765383" contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7f66202-7386-42c8-8fa6-1a073acda3bf" contextRef="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,154</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9344d66d-1b2f-4a8b-8e0e-0e9658360020" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07a07032-cf3e-4c1d-9fa7-a385cde7dd3f" contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,019</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56252254-35f7-4dd2-bcaf-99c690446276" contextRef="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80347059-bed3-41bf-8f10-3c47895396bb" contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de58b3d3-5a9f-425d-8710-0abf601ca583" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#caf0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_605eb16f-85f6-46af-8343-c79494e33523" contextRef="C_1da1795e-730c-42e1-9de0-0fedc96400d9" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f11ee3a-cd6a-492e-a720-37828938c655" contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf65909d-65d8-4b34-aa9b-6da6dcbda1a4" contextRef="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">647</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad4979ac-252d-44d3-a2a2-f73ab2bcb486" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,484</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_468de409-2c11-44cb-9f85-1673f2e5477e" contextRef="C_47d1b610-ca09-4556-921e-9413b69cf697" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed9a7a45-59fe-4450-bb5f-3966954bf1e4" contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc06887-edf9-4539-893f-0bfe52fc8d27" contextRef="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab0dafbe-e4bc-40d3-899a-b085022d9dec" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#caf0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03beecbe-be89-4ba2-90bb-1c5cc52862a8" contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_135cd1cd-dbbb-44ed-997d-e08e8feefefc" contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfa4da1e-d828-439e-87d8-19b339fdec04" contextRef="C_a6c79814-e564-4a3d-b0f2-8073710a53e4" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,595,616</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3015c29a-0831-4aa7-ba0f-f793fb6d429d" contextRef="C_a6c79814-e564-4a3d-b0f2-8073710a53e4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f9bd68-ff15-4576-8069-5bb3612d8e3d" contextRef="C_56cfb1ae-ec72-4d17-82fc-1198e04d1a30" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,179</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac46dadc-299a-4b25-aa03-ed7857e11c23" contextRef="C_1e426f09-37bb-440e-a20a-2c6caa2e0a48" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,098</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09672b9d-ec62-4c5d-b9cc-3388eb4fdc7b" contextRef="C_d1aaf22a-2bdd-4556-a9b8-d529d34aef04" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,538</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab998662-1d31-4221-bc40-0fff54feaf8c" contextRef="C_54965d21-2615-4d08-a3c4-08ca451112ae" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,644</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7439f823-0134-4fbd-9fbf-d7bb7ab3db71" contextRef="C_8e5cc978-0a42-4ec0-af0d-d74c36ee2dfd" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,828</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6af6e60f-5270-4e92-b2b2-8d4f08d54971" contextRef="C_1550867e-92d1-4406-a92b-c15392d1f1b0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,777</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac5e0c79-be58-4945-a7d1-022a980219d7" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93e9cf81-cfda-48a5-91ff-123f6a965891" contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8c2ac0a-ea58-4b45-af66-d1e0cffb4eaf" contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3915dd6-058c-4af2-866f-7935377ad41c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#caf0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49d2defe-58d1-410e-a05b-8484de87bc32" contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">874,328</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eba93654-24c5-4b47-a7c0-484ff1b22c10" contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dfefde5-41fd-4586-aa1c-c9fe7b780119" contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,864</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0797a1f3-aa92-4789-9edf-b7bc950635b8" contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6dc1cc4-68fb-4ec4-a1a5-1c4eee9d1910" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible preferred stock conversion</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfd0f1c5-8449-4aa2-97a2-c4311beae953" contextRef="C_34a9e2bf-ec9e-4a2f-8f4f-2c7daaad7f85" name="gyre:TemporaryEquityConvertiblePreferredStockConversionShares" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">13,151</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8f18499-58d2-4c33-bdd9-43a783451eea" contextRef="C_34a9e2bf-ec9e-4a2f-8f4f-2c7daaad7f85" name="gyre:TemporaryEquityConvertiblePreferredStockConversionValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a06bff46-bcc0-4acf-92b8-1280a014d31a" contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e" name="gyre:TemporaryEquityConvertiblePreferredStockConversionShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,767,333</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec4e5183-2772-44d0-ad9a-2710362f6118" contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e" name="gyre:TemporaryEquityConvertiblePreferredStockConversionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_024463b6-3d41-47a4-ae37-a152158e9b83" contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055" name="gyre:TemporaryEquityConvertiblePreferredStockConversionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,517</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0a1e064-0db5-47df-a2ca-92c38023994a" contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621" name="gyre:TemporaryEquityConvertiblePreferredStockConversionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13045f89-6577-4835-b81a-80e5a939e680" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:TemporaryEquityConvertiblePreferredStockConversionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#caf0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Issuance of Common Stock upon ATM program</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38b7a0c5-89f7-4596-93d1-fab392fbcfaf" contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">70,267</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a876715-6b11-449f-8202-bee02240e9fa" contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">773</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9e82b51-a692-46f8-9034-bcc845b148c8" contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">773</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a02cfd8-1e9f-4e2b-b5f7-69925a53dc7d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">773</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR Liability settlement</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22f193cb-7830-4e85-ba47-cd0999e10fd6" contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055" name="gyre:CvrLiabilitySettlement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3533c90-12d3-4951-940d-332c550168fe" contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621" name="gyre:CvrLiabilitySettlement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ddcf795-2074-4d42-8a52-9f98788809a7" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:CvrLiabilitySettlement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#caf0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred Financing Costs Amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ea55d88-93de-4707-9952-630ba7c16da9" contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d68c54b-2ed6-4dc4-8f23-4273a9be3dbb" contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68f929df-acff-4ef2-9221-3aa82c90d451" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c2fd7ae-aff7-4b76-bd19-35a115c9ba65" contextRef="C_94da0217-feba-4fbb-a5dc-d987be18247a" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">953</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ef4699d-bfa0-4455-891e-443ec799050b" contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">953</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_941a7995-47d7-48e6-875e-94814e7ce00d" contextRef="C_3b4e1000-5f70-49f3-a666-01af6c7cbdd7" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">507</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8385a38-c349-4666-9353-df19beed6fd9" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,460</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#caf0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c28307e-840e-4780-96c6-fe40df954788" contextRef="C_8f07b256-5b55-40cd-a1f0-534daf47f47f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,085</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d33bc77-1d79-4eb8-a26d-6c419d07db86" contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,085</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1c2e5be-19ed-4b73-8e01-5c82fbe08330" contextRef="C_3b4e1000-5f70-49f3-a666-01af6c7cbdd7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,813</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f4a848c-797c-4395-b538-b7c445fdd3fb" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,898</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07c118bf-0e48-49dc-af3a-0b3384c08436" contextRef="C_1999c1fd-3379-456f-aa61-90fe81f796d6" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,307,544</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec953cf6-bde1-41db-9111-f6732b7a4ab6" contextRef="C_1999c1fd-3379-456f-aa61-90fe81f796d6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ba2a0e4-3f4e-474a-a8cc-32caca3c277d" contextRef="C_adc4bb81-abd5-4674-adb5-54f33ef3d80c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,185</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62f8cedc-e83d-45d0-97a0-0f6f3f0bc70d" contextRef="C_84e691d1-e698-40d8-a277-167dedf7a361" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,098</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97f99dfa-938f-4274-b858-2e489753a632" contextRef="C_e528bfc1-0b49-4dd0-ae39-ee76c0228232" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,453</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d20260c-4313-4ecc-86a0-3c57456580d1" contextRef="C_55af4e33-6cc0-4324-9605-d23cf73d489e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,597</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_459c8638-8a2f-4549-9fe1-3c8117857cc3" contextRef="C_eca554e0-e672-4d9d-8689-890225dec430" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,319</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a4b4bbd-02b8-4677-8363-2099bfa2532a" contextRef="C_40f2813c-6dc2-4685-8c1e-588ca60a93fa" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,083</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6732b48b-7582-48d6-b4e7-3146b79c0734" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,402</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.56%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.56%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating Activities</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d5ddc6b-061e-4cee-875e-6ab0163a8aff" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,898</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7425b275-6c25-4160-8918-b89480204351" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1243883-2fbc-45c4-a58e-52ac4530dbb9" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1a0ec51-90db-439e-b442-7a7c69ec8aec" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ef9a054-477b-43ee-94e8-1cdb504a0d4b" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b625d2b2-1dfe-46c6-b5e9-b686acbe13a0" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,549</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7972c778-410b-4bdb-80df-b4c4776e2612" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,074</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Noncash lease expense</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c1f0898-e787-4211-ab74-7ff1f1514f12" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">672</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebad3b30-bc81-4b19-83c4-ce17544db7c0" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortization of land use rights</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44b5269-a985-4872-9689-99d20c4f045e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:AmortizationOfLandUseRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ef126d4-a2f6-4296-84ab-873046171b55" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AmortizationOfLandUseRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred income taxes, net</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2705b94-166a-4cd0-a4c2-ee27b898a5e4" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:DeferredIncomeTaxExpenseBenefitNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffca3d86-f6f8-4ac4-90fc-705ac4c29a51" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:DeferredIncomeTaxExpenseBenefitNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,160</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Bad debt expense and other non-cash items</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a40d4a28-f0ef-44e9-9289-34c705969d19" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:BadDebtExpenseAndOtherNonCashItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3c3c9ca-6517-4eeb-91d7-8e3d6878f624" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:BadDebtExpenseAndOtherNonCashItems" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued interest on bank deposit</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df6176f7-0a68-4dce-a461-63d58814fffd" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:AccruedInterestOnBankDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,046</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcf4b10f-c0bf-4e07-80f7-3076c9108e54" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AccruedInterestOnBankDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">633</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of receivables from GCBP</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7d9136b-8271-4ad5-80f5-fee19d481343" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ChangeInFairValueOfLongTermReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01268efa-1b62-4bdb-8a9e-600edd95fc21" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:ChangeInFairValueOfLongTermReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69d95ea9-f4c7-4041-a632-09f14fce39b8" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ChangeInFairValueOfDerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d86c8b7-6500-4510-8cf1-c49934d6a34f" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:ChangeInFairValueOfDerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c698895-316e-4317-b459-f08ae84c462f" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,167</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1f698d7-9458-4a07-843b-0aafce67a4bf" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Equity loss of unconsolidated affiliates</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_877b91f1-e02c-437a-a1fa-79ddf04fba83" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:EquityGainLossOfUnconsolidatedAffiliates" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a50537c-4665-4bf6-9a98-5e51c532207a" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:EquityGainLossOfUnconsolidatedAffiliates" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,314</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc734f53-f382-4bc0-ba84-b851da0e7f1b" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f55d4f8-680b-4b8a-bbe9-ce00ce57f40a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76c2e75d-cf40-46c1-9d10-7b8bebd0eed9" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:20pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Notes receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66b8af29-145f-4c24-aa90-bcb1a5252732" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInNotesReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,028</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d892d265-563b-4148-a561-8a5cccaa924d" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInNotesReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,113</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db21d03d-dfd5-40bb-bf81-8d024acbfb7d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,257</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d27abe46-c8ae-4801-a081-eb64586cdf9b" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">285</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other receivables from GNI</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b12f5a21-8f2f-483f-b7d3-65664eae158c" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4a00c82-23fa-4944-bb5e-28cb00b1d601" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,139</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95a5d0b6-d9ee-4be4-b3ef-cc2512ea4fb1" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,747</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Prepaid and other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f802b516-7c8c-49e0-bb19-3f46a2b51ec0" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">520</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32ea3674-9935-49ba-a7a7-38423a953274" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b849ca8-68fe-451c-a61f-35829178a2e3" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1bde380-35f4-4a21-87fc-4b1abd2bea77" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,003</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e97e25ea-31b3-4365-8f8a-c14f990d8a1d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f849bca2-036b-42b6-8da6-91e315dd351c" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other noncurrent liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b0e7c4a-3b52-4219-bb24-b74bb520d89c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6d1107d-926a-4e2b-9004-4799c07b06ed" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due to related parties</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f4dc31e-ea62-4944-90bb-39eba2e754f0" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcd3b6f3-4c20-4185-8fc5-0a9ff5b87736" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea86c3c5-57a5-4a51-860c-204db42ae4b8" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,497</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e577e1a-0c2d-49c6-9094-7bfe5e28956a" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,446</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a90d1cf-9959-4605-8554-dee11e64554e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">816</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96ad4359-68cb-4dcd-93ea-728b6a502331" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">473</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net cash (used) provided by operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_972fb665-433d-4d00-a140-61064ca098d1" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,641</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_034d3983-172a-4018-b82b-e22619393b79" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,892</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Investing Activities</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquisition of intangible assets</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9541388-9b88-46b9-bf14-a7829f86696c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">813</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7384830-4bf6-4854-b09d-c343db83f234" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase of certificates of deposit</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9f7420d-eaf3-4997-b169-5e4a441a7ca3" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,471</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d013c55-ec8a-43b9-8775-92afad3d3e1d" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,735</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_256e7b7d-a6e9-4093-a338-253827eb0496" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,315</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7c58cf1-7b11-4642-8df7-88f22e3f06a6" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,517</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Proceeds from sale of equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a89bc96e-de75-4379-94ed-f738e222ba06" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4759baa3-ba72-4fce-88bc-bc6942b9b44b" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">664</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase of equity method investment</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ded52038-42a0-4e51-9cc6-3d57377642ad" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,686</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1ec078b-8da6-4624-868b-3e7931a049a6" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents acquired in connection with the GNI USA Contributions</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_210c7b70-6e85-4e05-a78f-8da6f82db664" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,587</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Payments made for acquisition costs</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ae42da8-0a42-4bd0-8b12-547f6d4a4498" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:CashPaidForAcquisitionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash balance in a disposed subsidiary</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_994b53c2-7240-4e44-be88-3249ac9e1209" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:PaymentOfDisposalOfSubsidiary" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">566</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5123d3dd-261f-424b-b8a8-0dd92af53380" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19,884</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f16f510-ccf5-4b8c-93fa-274f1dedf0ce" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19,760</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financing Activities</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred offering costs</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c168bd7b-f988-480d-a209-8eb2e60a3719" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:PaymentOfDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">536</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock in ATM program</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42e3d390-01ed-42b4-be30-75ed0751138d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">773</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Proceeds from the exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deab8d91-ac20-4871-86c5-f0064fd9083f" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Proceeds from issuance of Convertible Preferred Stock and Preferred Stock Warrants under the Private Placement</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2109caae-8e0d-4c71-9215-197bc6ce1e82" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_648ff37d-b9c6-4bc5-93dd-11b924a65533" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,102</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_585260ac-1846-4965-88cc-3d5330c49a3c" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09472ecc-23d6-48f6-ba24-33496bad608c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e326bb4-8cae-4366-a387-414d563765cb" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_072b113b-14d3-471d-852a-158926b81a43" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,696</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07de216b-5729-418a-9cdf-2ff7863324ed" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,334</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of the period</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ef3506a-dc70-4e6b-a9c1-4e8569fcf986" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,509</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b3b04a6-7d28-4993-afea-0ed150b0cefd" contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,175</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b371b179-8d8b-4add-8183-bd24086ba50b" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,813</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33f221ec-fcf5-4462-bc10-fa551f6f0a17" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,509</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of Non-Cash Financing and Investing Activities:</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b55a94e-d8a1-4dc1-9700-ab084972ecb3" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,348</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Advance payment for Convertible Preferred Stock and Preferred Stock Warrants acquired upon the GNI USA Contributions</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea97a878-d32b-4ad3-8c7b-bb441389f9cc" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Disposal consideration in other receivables from GNI</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88ea521a-aba2-4f56-9d06-f8897062286e" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:DisposalConsiderationInOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquisition costs in due to related parties</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abd88644-a5e0-482c-8822-52b3a09edcc9" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AcquisitionCostsInDueToRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">535</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Right-of-use asset obtained in exchange for operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e41a54d1-c8c1-4f04-968b-e3469b4f59fe" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84778b81-dc3e-421f-a02c-bb137c61e3e3" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Proceeds from the exercise of stock options included in other receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03fd29cd-71ed-4e15-be48-aba9e919d686" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible preferred stock conversion</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab3b48c2-d8fc-4b6a-97fe-41721c79e73b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ConvertiblePreferredStockConversion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of Cash Flow Information:</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash paid for income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da019e26-581c-4c15-846a-30ffc663fa49" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,518</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6.5pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82d00b16-4ab4-4714-9fd5-65f9ca2084e4" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,346</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Notes to the Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p>
  <div><ix:nonNumeric id="F_94f47330-9c08-429d-884d-7420ebf064fe" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NatureOfOperations" escape="true" continuedAt="F_94f47330-9c08-429d-884d-7420ebf064fe_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Organization and Nature of Operations</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Gyre,&#8221; or the &#8220;combined company&#8221;), formerly known as Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;), is a biopharmaceutical company originally incorporated in Delaware on March 7, 1997 under the name Targacept, Inc. Catalyst was a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, Catalyst had several protease assets that were designed to address unmet medical needs in disorders of the complement or coagulation systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">After completion of the transactions under the Business Combination Agreement as described below, Gyre became a commercial-stage pharmaceutical company with a proven track record of financial success developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs and involves a complex, multi-stage process with multiple pathways.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">F351 Asset Acquisition</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On December 26, 2022, Catalyst executed and closed an Asset Purchase Agreement, which was amended on March 29, 2023 (the &#8220;F351 Agreement&#8221;), with GNI Group Ltd. (&#8220;GNI Japan&#8221;) and GNI Hong Kong Limited (&#8220;GNI HK&#8221;) to purchase all of the assets and intellectual property rights primarily related to a clinical-stage proprietary Hydronidone compound for the treatment of metabolic dysfunction-associated steatohepatitis (&#8220;MASH&#8221;), a severe form of nonalcoholic fatty liver disease (collectively, the &#8220;F351 Assets&#8221;), other than such assets and intellectual property rights located in the People&#8217;s Republic of China (&#8220;PRC&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combination Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On December 26, 2022, Catalyst entered into a Business Combination Agreement, as amended on March 29, 2023 and August 30, 2023 (the &#8220;Business Combination Agreement&#8221;) with GNI USA, Inc. (&#8220;GNI USA&#8221;), GNI Japan, GNI HK, Shanghai Genomics, Inc. (&#8220;SG&#8221; and collectively with GNI USA, GNI Japan and GNI HK, the &#8220;Contributors,&#8221; and each a &#8220;Contributor&#8221;), certain individuals (each, a &#8220;Minority Holder&#8221; and collectively, the &#8220;Minority Holders&#8221;) and Continent Pharmaceuticals Inc. (&#8220;CPI&#8221;). On October 30, 2023 (the &#8220;Effective Time&#8221;), the Contributions (as defined below) became effective and Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (doing business as Gyre Pharmaceuticals Co,, Ltd.) (&#8220;Gyre Pharmaceuticals&#8221;). In connection with the Contributions, and immediately prior to the Effective Time of the Contributions, Catalyst amended its certificate of incorporation, increased the number of authorized shares of its common stock, par value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8ce3751-2d32-45f6-a6cb-cfa9637d5228" contextRef="C_8af0977b-b1f9-48ee-9940-3554e079223c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share (the &#8220;Common Stock&#8221;) from </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_800c4c17-1269-464d-9a1b-2cf6e0714a6a" contextRef="C_a4960a5d-b308-445f-8714-9498ff7443b8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_884161c4-97b4-4923-ae05-4d7f5f950bc2" contextRef="C_3a618d1d-ac50-42d9-955f-3512c0439863" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, effected a</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_f64db999-38c9-4e20-995a-508f0a343dac" contextRef="C_661aab60-409f-4f43-a899-d4da1611a236" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1-for-15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reverse stock split</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (the &#8220;Reverse Stock Split&#8221;) and changed its name to Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Shares of Catalyst Common Stock were previously listed on The Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221; Catalyst had filed a listing application for the combined company with the Nasdaq Stock Market Inc. (&#8220;Nasdaq&#8221;). On October 31, 2023, Gyre&#8217;s Common Stock commenced trading on the Nasdaq Capital Market under the symbol &#8220;GYRE&#8221;, on a post-reverse stock split adjusted basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Business Combination Agreement, at the Effective Time of the Contributions, and after giving effect to the </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_da33e611-41df-4c16-979f-6b57fafd3148" contextRef="C_18ff54a5-54d5-42f4-81e9-6aa9f1a79af5" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1-for-15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reverse stock spli</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t,</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_94f47330-9c08-429d-884d-7420ebf064fe_1" continuedAt="F_94f47330-9c08-429d-884d-7420ebf064fe_2"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GNI USA contributed all of its ordinary shares in the capital of CPI to Catalyst in exchange for </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c043b80-9b58-4103-b7ca-ac65640a854b" contextRef="C_f6130ae2-a2e5-45e6-a4ed-5c019bfa760e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">45,923,340</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;CPI Contribution&#8221;), </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GNI USA contributed its interest in Further Challenger International Limited (&#8220;Further Challenger&#8221;) for </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4576dade-bfd0-4e00-8a52-38dcbbd4216f" contextRef="C_4cb4b16d-4b5f-4f2a-9fb0-59f281280fc0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,664,779</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;FC Contribution&#8221; and together with the CPI Contribution, the &#8220;GNI USA Contributions&#8221;), and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">each Minority Holder contributed </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51ee594f-735f-4268-bdb4-7d953e66ed93" contextRef="C_25e32d74-d3e2-425b-866e-4b5bc29838fb" name="us-gaap:MinorityInterestOwnershipPercentageByParent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the interest he or she held in his or her respective entity in exchange for an aggregate of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4ed83a5-5ea8-4c3f-9dcc-112cd54eeadb" contextRef="C_25e32d74-d3e2-425b-866e-4b5bc29838fb" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,463,627</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;Minority Holder Contributions&#8221; and together with the GNI USA Contributions, the &#8220;Contributions&#8221;). </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As a result of the GNI USA Contributions, Gyre directly and indirectly holds </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_661b1400-ab85-4548-97ff-6ab42b9301c6" contextRef="C_4cf85ce7-378e-4422-9fd7-e7d329e19a16" name="gyre:PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of CPI&#8217;s shares. Through Gyre&#8217;s ownership of CPI, prior to the Minority Holder Contributions, Gyre held a </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f625e9c3-8fb9-49d6-8284-e89cb6f63b89" contextRef="C_583140f7-2f5b-432a-a839-befb410b9e87" name="gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">56.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> indirect interest in Gyre Pharmaceuticals. Upon completion of the Minority Holder Contributions, Gyre obtained additional indirect interests in Gyre Pharmaceuticals and holds, in aggregate, a </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfdc8296-e4b6-49d1-82ef-fb636a935028" contextRef="C_b069b7f9-1d2e-4765-80cb-c51aa4c12c6f" name="gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">65.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> indirect interest in Gyre Pharmaceuticals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Immediately after the closing of the Contributions, excluding potentially dilutive securities, GNI USA owned approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a26c41d-8a73-48ba-8fd6-b6235f06b296" contextRef="C_8437179e-663a-4744-b86d-fca26b0fe052" name="gyre:PercentageOfOutstandingSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">83.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the outstanding shares of Gyre Common Stock, Catalyst&#8217;s existing stockholders, excluding GNI USA, owned approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79051165-9989-418b-aa5b-12f5ea607890" contextRef="C_6e8538d1-cf76-4d30-a57e-b5a4624ea831" name="gyre:PercentageOfOutstandingSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the outstanding Gyre Common Stock, and the Minority Holders owned approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_497a5351-d036-4a58-96e7-4d85ddc22d97" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the outstanding shares of Gyre Common Stock. The Convertible Preferred Stock remained outstanding after the closing of the Contributions and is not included in the above ownership percentages.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">At the Effective Time, Gyre Pharmaceuticals terminated its 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;) and the options (the &#8220;Gyre Pharmaceuticals Options&#8221;) outstanding under the 2021 Plan were terminated and replaced with options granted under a subplan for Chinese participants under the Gyre 2023 Omnibus Incentive Plan (the &#8220;2023 Omnibus Incentive Plan&#8221;) that are substantially similar in all material respects to the Gyre Pharmaceuticals Options previously outstanding under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remained issued and outstanding, and such shares and options were unaffected by the Contributions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company registered and established in the PRC in 2002. Gyre Pharmaceuticals is committed to the research and development of new drugs as well as manufacturing and commercialization of ETUARY (pirfenidone capsule) for the treatment of idiopathic pulmonary fibrosis and other pharmaceutical products. The registered office of Gyre Pharmaceuticals is located at 60 Shunkang Road, Shunyi District, Beijing, PRC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The immediate holding company of Gyre Pharmaceuticals is BJContinent Pharmaceuticals Limited (&#8220;BJC&#8221;). The intermediate holding company of Gyre Pharmaceuticals is CPI. Immediately following the Contributions, the immediate holding company of CPI is Gyre. The immediate holding Company of Gyre is GNI USA and the ultimate holding company of Gyre is GNI Japan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The GNI USA Contributions were treated as an asset acquisition under U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), with CPI treated as the accounting acquirer and presented as the predecessor for the post-acquisition SEC reporting purposes. Since Catalyst is the legal acquirer, the GNI USA Contributions were accounted for as a reverse asset acquisition. This determination was based upon the terms of the Business Combination Agreement and other factors including that, immediately following the GNI USA Contributions: (i) GNI USA (as the parent company of CPI immediately prior to the GNI USA Contributions) owns a substantial majority of the voting power of the combined company; (ii) CPI, through GNI USA, has the ability to control the board of directors of the combined company; and (iii) senior management of Gyre Pharmaceuticals and GNI USA holds a majority of the key positions in senior management of the combined company. Immediately prior to the closing of the Contributions, Catalyst did not meet the definition of a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_94f47330-9c08-429d-884d-7420ebf064fe_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">business because Catalyst did not have an organized workforce that significantly contributed to its ability to create output, and substantially all of its fair value was concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of the closing date of the GNI USA Contributions, the net assets of Catalyst were recorded at their acquisition-date relative fair values in the accompanying consolidated financial statements of the Company and the reported operating results prior to the GNI USA Contributions are those of CPI.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in Gyre Pharmaceuticals.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Value Rights Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Concurrent with the signing of the Business Combination Agreement on December 26, 2022, Catalyst and the Rights Agent (as defined in the CVR Agreement) executed a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), as amended on March 29, 2023, pursuant to which each holder of Catalyst Common Stock as of January 5, 2023 (the &#8220;CVR Holder&#8221;), excluding GNI, received one contractual contingent value right (a &#8220;CVR&#8221;) for each share of Catalyst Common Stock held by such holder. Each CVR entitles the holder thereof to receive certain cash payments in the future. For additional information, see Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On October 30, 2023, the Company effected a </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d6d909ae-c091-4e0a-bfca-3b3c0f7f5fd7" contextRef="C_661aab60-409f-4f43-a899-d4da1611a236" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1-for-15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reverse stock split</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> immediately prior to the Effective Time of the Contributions. The par value of the Catalyst Common Stock following the Reverse Stock Split was not adjusted and remains at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c5029b7-f6ee-4b6e-bd54-fe7b70309369" contextRef="C_1999c1fd-3379-456f-aa61-90fe81f796d6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share. All of the Catalyst&#8217;s issued and outstanding common stock and options have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding, which resulted in a proportional decrease in the number of shares of the Company&#8217;s Common Stock reserved for issuance upon exercise or vesting of such stock options, warrants, and in the case of stock options and warrants, a proportional decrease in the exercise price of such stock options and warrants.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Stock Split and stockholders who would otherwise be entitled to a fraction of one share received a proportional cash payment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company had a net income of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff27ff39-a4a5-48aa-ba35-6df808d1ed24" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, while net cash used in operating activities was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bc2c1fb-50cf-4d97-b848-0ee24156bf1e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cddb08b-27a4-4dd8-a679-1a2a5ef3cc8b" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">73.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e2aada6-c32d-44c4-94fa-e41ea0cd875e" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Based on the Company&#8217;s current operating plan, management believes that existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund the Company&#8217;s operating activities and obligations for at least 12 months following the issuance of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_1" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_2"><div><ix:nonNumeric id="F_030db12f-17da-4915-a59a-c0f596ab7ccb" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" continuedAt="F_030db12f-17da-4915-a59a-c0f596ab7ccb_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_2" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_3"><div><ix:continuation id="F_030db12f-17da-4915-a59a-c0f596ab7ccb_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_e04f6feb-4a99-4af7-b8b5-84ab484c72a6" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_3351fc13-a6aa-41a0-b1ef-35efe92a058c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:NoncontrollingInterestPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Noncontrolling Interest</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company reports noncontrolling interest (&#8220;NCI&#8221;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_f9bd2e32-35ec-4f6e-adba-baea0acbde77" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The measure of segment profit or loss is reported on the income statement as consolidated net income (loss). The CODM uses net income (loss) to evaluate income generated from segment assets in deciding whether to reinvest profits and monitor budget versus actual results in assessing performance of the segment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM, as a group, includes Gyre&#8217;s Chief of Executive Officer (&#8220;CEO&#8221;), Gyre Pharmaceuticals&#8217;  General Manager, Gyre's Chief Operating Officer, and the Chairman of Gyre&#8217;s Board of Directors (&#8220;Gyre&#8217;s Board&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company has determined that it operates in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8e1a674-a162-4298-886d-7899f5a598dc" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> distinct operating segments and has </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9d1ac29-51fc-4ff3-98c2-c5fb65703489" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reportable segments.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_b203af37-0b9a-4e2d-b07c-2ff125f30315" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:RisksAndUncertainitiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_2863e381-0ee8-4cb7-a68b-fb0156121bd3" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_2863e381-0ee8-4cb7-a68b-fb0156121bd3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">f Credit Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, note receivable, long-term certificates of deposits, and short-term bank deposits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_3" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_4"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_2863e381-0ee8-4cb7-a68b-fb0156121bd3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In May 2015, a new Deposit Insurance System (&#8220;DIS&#8221;) managed by the People&#8217;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#8220;RMB&#8221;) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1926a929-9950-465f-94a9-7c49cb654d04" contextRef="C_3c2ac92b-d05c-4dcb-8edc-d7dc05708e32" name="gyre:DepositsInLicensedBanksProtectedByDepositInsuranceSystem" unitRef="U_CNY" decimals="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daabf9a2-d031-407f-97cb-490f9af585aa" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22d43133-6dc6-403f-b4a5-c8b8dcc3eab5" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> millio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">n, and long-term certificates of deposit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_677f13e6-9703-4fdf-9768-d6c427a9d2a7" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b1b4250-5a80-41f9-b028-386f7fc8854e" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> millio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">n, respectively. In addition, the Company had short-term bank deposits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d76a5f2-a366-41c8-b3f5-d1ab3d550766" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2024. For the years ended December</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> 31, 2024 and 2023, cash and cash equivalents, short-term bank deposits and long-term certificates of deposits exceeded the PRC DIS coverage by $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f67df5a9-82a0-4fa7-8a79-4c6676b4118e" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:ValueOfAssetsExceedingDepositInsuranceSystemLimit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2970d9b7-0f0b-4417-b095-0ea943fb58e0" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:ValueOfAssetsExceedingDepositInsuranceSystemLimit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">49.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ac</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_52b7d5e6-2c72-4cad-b46e-de99dce9f35d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ConcentrationOfCustomerRiskPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Customer Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, one customer, Sinopharm Group Co., Ltd., accounted for approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_919c4626-b660-491a-b41f-f996d8c0e853" contextRef="C_33eee6f7-6eb9-4629-b3ef-0ea7887030bf" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">54.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfbf1723-1313-4e28-a92c-c19c36a1b0fb" contextRef="C_9f12cb44-8040-49a1-9b9e-a0f0137410fb" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">50.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of accounts receivable, respectively. For the year ended December 31, 2024, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34e98bf7-83a1-4056-8cda-d5af973f848f" contextRef="C_a8369019-ac43-4387-8220-f7bb3505e614" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">48.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1955eaa6-6f5d-436a-be0c-8aa306f6c69d" contextRef="C_eeacae0c-b05c-49e6-aa94-3ba172e663e7" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69b9b503-32f5-4003-ae3f-f9c7718d33a0" contextRef="C_5e5fdd9a-b6de-418c-9820-744eb3b5f73c" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of total revenue respectively. For the year ended December 31, 2023, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> accounted for approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59cc14c0-c92d-4b19-8acd-c35d94f0d147" contextRef="C_b35aebfe-1f39-4446-b3d0-8ed57d7c18ed" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">50.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d09dd4f-d0da-41be-a006-8efb3d10822f" contextRef="C_f461bd8b-ec0e-46ff-8dbd-7d23531e4b91" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af9faea2-7da8-488f-b89b-86b496abd1e5" contextRef="C_534c0221-d2f9-4713-8a7c-b850a4689dc4" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of total revenue respectively. All customers are located in the PRC.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_14745b4e-6568-4337-8fd7-ba7b507540df" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and Cash equivalents includes cash on hand, demand deposits and money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_bab91892-5c57-4668-93aa-1130901360d1" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" continuedAt="F_bab91892-5c57-4668-93aa-1130901360d1_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> Value Measurements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_4" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_5"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_bab91892-5c57-4668-93aa-1130901360d1_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_a720e31c-8f38-4976-b78b-3411e77e7d91" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for additional information regarding the CVR derivative liability.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_4c795b02-a29c-4b40-8004-63735e09ba06" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:PreferredStockWarrantsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Stock Warrants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrants to purchase shares of the Convertible Preferred Stock (&#8220;Preferred Stock Warrants&#8221;) are freestanding financial instruments classified as warrant liability on the Company&#8217;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#8217;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_dc406a2f-27d8-4d93-a7bb-0e9355ef2fdb" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ConvertiblePreferredStockPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, to account for the Convertible Preferred Stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_37839fee-ef40-4ac9-865a-ef18aa96c2b9" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:LongTermCertificatesOfDepositPolicyTextBlock" escape="true" continuedAt="F_37839fee-ef40-4ac9-865a-ef18aa96c2b9_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-term Certificates of Deposit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The long-term certificates of deposit will mature between </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_ccf9684e-a6e4-4213-b55f-9f18f4778c41" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:Long-TermCertificatesOfDepositMaturityDateRangeStart" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">J</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">anuary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_ba75ac6b-26b1-4b04-b947-027516df8c44" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:Long-TermCertificatesOfDepositMaturityDateRangeEnd" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">April 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_5" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_6"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_37839fee-ef40-4ac9-865a-ef18aa96c2b9_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">effective interest method. The Company recorded </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_146839d9-6d85-4f84-bac6-f299e7024730" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AllowanceForCreditLossesCertificatesOfDeposit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9782ac43-6dbc-4f78-ba63-48dcdf12fb43" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AllowanceForCreditLossesCertificatesOfDeposit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> allowance for credit losses associated with the certificates of deposit as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and 2023.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_c43f1780-9f65-4abe-a399-21fb7ad086e5" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ShortTermBankDepositsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Short-term Bank Deposits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The short-term bank deposits will mature between </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_fa450738-7a1d-4b7e-bc5b-64fc138d762c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:Short-TermBankDepositsMaturityDateRangeStart" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">January 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_58facf9d-4b54-4386-960b-986e539eb80d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:Short-TermBankDepositsMaturityPeriodEnd" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Short-term bank deposits consist of bank deposits with original maturities of one year or less, and long-term deposits that have a remaining maturity of less than one year. These deposits are recorded at amortized cost. Interest income from these deposits is recognized and reported within interest income. The Company recorded </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3c0bac2-ceef-4fc4-b15c-37f508484ed5" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AllowanceForCreditLossesShort-TermCertificatesOfDeposit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c7f3ba5d-a5e1-45d0-bc58-d447fe53376d" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AllowanceForCreditLossesShort-TermCertificatesOfDeposit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> allowance for credit losses associated with the short-term certificates of deposit as of December 31, 2024 and 2023.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_3bbe23ea-c6ca-4801-8b38-0f8af4d49438" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ReceivablesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-Term Receivable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#8220;GCBP&#8221;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for additional information regarding the long-term receivable.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_ef181d53-1b2c-4545-908a-ac556fb7c948" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:LongTermInvestmentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-term Investments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise more than minor influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC Topic 323, Investments&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Method and Joint Ventures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 323&#8221;). Under the equity method, the Company initially records its investments at fair value. The Company subsequently adjusts the carrying amount of the investment to recognize the Company&#8217;s proportionate share of the equity investee&#8217;s net income or loss after the date of investment. The Company evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80046989-beb5-45c4-92e0-374745270a57" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_199ad78c-ffea-4069-ae20-887f473e2d27" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> impairment charge was recognized for the years ended December 31, 2024 and 2023.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_b877b63d-b045-4e22-a582-9778de7bdb95" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true" continuedAt="F_b877b63d-b045-4e22-a582-9778de7bdb95_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts and Note Receivables, Net</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#8217;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#8217;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_ff2b2e02-3955-4ef9-b537-2b2f6782d537" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true" continuedAt="F_ff2b2e02-3955-4ef9-b537-2b2f6782d537_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_6" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b877b63d-b045-4e22-a582-9778de7bdb95_1"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_ff2b2e02-3955-4ef9-b537-2b2f6782d537_1">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.012%;box-sizing:content-box;"/>
          <td style="width:2.04%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:17.463%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:2.28%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.203%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91aa1224-94bf-4d9e-a5f7-9163488d84ec" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,798</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a858bf4-0209-4a40-942f-b3e39ee93211" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,204</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Note receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abb4f2cc-8ef3-41f0-baaf-65e89abf4416" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:NotesAndLoansReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,373</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28ab2262-aad9-4184-971a-c6e90f0cfd41" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:NotesAndLoansReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Allowance for credit losses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f10e3457-55bb-483c-8d8c-67c73194ec7a" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b59df5af-7678-4866-bd40-a20f7b9aac96" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts and note receivables, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eae3b02-e470-4632-8c06-929c29d8e4f1" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,962</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96cea72a-b05a-4f4d-bf1d-eae7ad0ae482" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,552</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_61536b80-58ef-48cb-ade7-b3184586d632" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in the allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.012%;box-sizing:content-box;"/>
          <td style="width:2.04%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:18.462999999999997%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.28%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.203000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance, beginning of year</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b902f76-74b9-4960-bf60-9a6e909718fe" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8932fd5d-0eeb-41b8-8346-89b9968bd8e2" contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for allowance for credit losses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5603cb3c-4f4a-480b-b816-8a27193c52e1" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Recoveries collected and write-off</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfc53bf8-575e-48f8-8887-653759a0d32a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be49fbf3-46e3-4a6a-88c8-ecaed20a6d9e" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_868a8d55-a0df-48f0-ae50-63ff89bf2afc" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaa9e725-2586-4546-ad01-5a150ba84e0a" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance, end of year</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f284843-b305-4718-b7ab-f39070b0ada1" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5703e978-7faf-4b51-83b6-99ee2be1583d" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d71b6ad2-e633-45ca-9300-7cfe89c8de21" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Inventories, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_360861cf-69fd-4c36-8f7b-7c20ba3fae4c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_360861cf-69fd-4c36-8f7b-7c20ba3fae4c_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_1fe4d6c7-08d0-4e6e-a7f7-8be9d5e87fcb" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" escape="true" continuedAt="F_1fe4d6c7-08d0-4e6e-a7f7-8be9d5e87fcb_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;box-sizing:content-box;"/>
          <td style="width:58.58%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Buildings</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_19072842-fdd0-40c0-9160-19e2f3dfcd65" contextRef="C_bd730111-0947-4496-be1e-82bb97c3ba65" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_82006d65-a365-4fc9-bd46-c4635f567efa" contextRef="C_8004e979-5c0a-4003-aa51-99ebad904782" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Leasehold improvement</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_df845163-9662-4f0f-9d15-2572001b1a8c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of the estimated useful life or the term of the lease</span></span></span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_7" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_8"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_360861cf-69fd-4c36-8f7b-7c20ba3fae4c_1"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_1fe4d6c7-08d0-4e6e-a7f7-8be9d5e87fcb_1">
        <table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;box-sizing:content-box;"/>
          <td style="width:58.58%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Machinery and electronic devices</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_61b7bd86-535c-4f71-9d43-7e2d5263b7db" contextRef="C_6b620358-0d22-4e17-b10f-f5fdca4687e7" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d33af5a4-3af3-4591-a49e-5a1195b15b09" contextRef="C_f824d5e7-e950-4dec-bbd8-25ddc7864eac" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_e91b36bf-124c-48f9-b724-81113272bda7" contextRef="C_845d0f12-d806-4911-8fda-490329d00ecd" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_684bbdb1-617a-4eee-bd3b-d07cc40755f2" contextRef="C_3cc0872f-8c3c-4dc7-ae6b-0b2043d6351e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_fd749efc-4973-4193-b1dd-5603eb9545a1" contextRef="C_75e8697e-8557-4795-a758-27f2b4bd196b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_a74413ed-53b6-46fe-8019-ae9d22631635" contextRef="C_f5133705-2d68-4e8e-84cd-45bc68a7fcf0" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_30397301-6cf0-445b-a407-78a6f158aa72" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents, technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Nonrefundable advance payments for intangible assets are capitalized in &#8220;other assets, noncurrent&#8221; and will be recognized as intangible assets when the Company obtains the control of the underlying asset. As of December 31, 2024, the Company had paid $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_633ddd1f-a039-4123-9114-cccec8ff95e8" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million to obtain the drug registration certificate for nintedanib and the advance payment was included in &#8220;other assets, noncurrent&#8221;.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Patents and Technological Know-How</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_5163b8ea-25ec-4372-aee0-a30c4ad4680f" contextRef="C_5b26b6c7-7509-44ec-b688-6724fcb64480" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_321a6041-97b1-4167-b7fb-766c1885690d" contextRef="C_3e003906-a6c6-4531-9eea-29f5b509e2c5" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Computer Software</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_e144250a-53d1-44d0-abc4-0e596d38ecb8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_5caa1626-a280-4726-87c0-46ea2b5fcc77" contextRef="C_981aaa53-b42e-4ad1-b13e-8a794b24f312" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_01e5312a-15f5-4c24-adef-1da4d9d4a0f3" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_01e5312a-15f5-4c24-adef-1da4d9d4a0f3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_8" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_9"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_01e5312a-15f5-4c24-adef-1da4d9d4a0f3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#8217;s leases do not contain any residual value guarantees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_524d3452-da8d-4ad7-99e5-4bd6fd2d6186" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:LandUseRightsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Land Use Rights, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d2874ed6-a912-426b-850d-79661073e2f5" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair valu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63759f48-2605-456b-ae96-00ba486c0ed6" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_24612923-57a6-4df1-8556-18b6cc9b6ffd" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t record any impairment of long-lived assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_59bb2782-f2cb-458f-bead-c93aa8f507a9" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_59bb2782-f2cb-458f-bead-c93aa8f507a9_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Expense</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_9" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_10"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_59bb2782-f2cb-458f-bead-c93aa8f507a9_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_3f6e4247-d87d-4f8c-89bb-ebe32de996eb" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company records revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#8217;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Sale of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer upon delivery of the underlying products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#8217;s estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04d9e374-4180-45f5-a59d-cc569aacaec2" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4cb725cd-ecad-4460-8954-a79107d0ad71" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t recognize any contract assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_d4a5e62b-15aa-456f-903f-4213dd81b462" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true" continuedAt="F_d4a5e62b-15aa-456f-903f-4213dd81b462_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contract liabilities are recognized when the payments are received from customers before the Company transfers the related goods or services. Contract liabilities are recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_10" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_11"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_d4a5e62b-15aa-456f-903f-4213dd81b462_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024, the Company&#8217;s Contract liability balance was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f05d883-5bcd-47c8-bede-7cc79514a821" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Contract liability balance was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcc86c59-081c-43ce-b89e-066c4fddb992" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">39,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2023 which has been recognized as revenue during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d244fde1-7ade-41d1-99d6-3ddf1c4cdf76" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CostOfSalesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_8c2b188e-ebdb-45f3-acb8-27abc3c70301" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#8217;s assumptions regarding a number of variables including the fair value of its Common Stock, its expected Common Stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_9f06b436-a54e-448b-9251-281a04c8f5ab" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:InProcessResearchAndDevelopmentPolicy" escape="true" continuedAt="F_9f06b436-a54e-448b-9251-281a04c8f5ab_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;D with no alternative future use is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_11" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_12"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_9f06b436-a54e-448b-9251-281a04c8f5ab_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">charged to expense at the acquisition date. Refer to Note 7 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for a more detailed description.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_19613377-14f2-449d-80dc-20dba9606b2d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_8c82a61c-d096-4ae4-9e5a-a46d5865e4ac" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:SellingAndMarketingExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Selling and Marketing Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_7256902b-fc28-4758-a032-0632882198bf" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:GeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_c5d25d99-b08a-46b2-adbe-56128bf889e7" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:AdvertisingCostsPolicyTextBlock" escape="true" continuedAt="F_c5d25d99-b08a-46b2-adbe-56128bf889e7_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising Cost</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_c5d25d99-b08a-46b2-adbe-56128bf889e7_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Advertising costs are expensed when incurred. Such costs approximated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_229efdee-ce2e-4330-a246-b89520dc8452" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f75d96d-c1e9-4440-8c6b-c8f993f32675" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for the 2024 and 2023 fiscal years, respectively. Advertising costs are included in selling expenses on the consolidated statements of operations and comprehensive income (loss).</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_d0c121ff-3c16-42f9-8681-37f6191468b4" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:GovernmentAssistancePolicyTextBlock" escape="true" continuedAt="F_d0c121ff-3c16-42f9-8681-37f6191468b4_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Government Grants</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_d0c121ff-3c16-42f9-8681-37f6191468b4_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying amount of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive income (loss).</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_e28e8471-41ce-4d93-b0dc-ef7888e1d527" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:InterestIncomePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_679215b5-aedc-470c-8ec6-4eed44175686" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true" continuedAt="F_679215b5-aedc-470c-8ec6-4eed44175686_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Income (Loss)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_12" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_13"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_679215b5-aedc-470c-8ec6-4eed44175686_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_541be587-e6c9-409d-a41d-3403c86671af" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Net Income (Loss) </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Per Share (&#8220;EPS&#8221;) Attributable to Common Stockholders</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 260&#8221;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#8217;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">EPS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for more information.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_07cd173b-40e6-4825-877f-48193e6d91bf" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Translation and Remeasurement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of Gyre Pharmaceuticals is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company uses the U.S. Dollar as its reporting currency.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive income (loss). During the years ended December 31, 2024 and December 31, 2023, the Company had translation loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b93c6b5-759e-43c7-8f27-435e036edb7e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a44826b-8b15-4358-812b-7d7f8a8f3100" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of operations and comprehensive income (loss). The foreign currency transaction gains or losses for the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">were immaterial.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_94c89ae7-0bb2-45d5-acd4-95379e2d12db" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ForeignCurrencyRiskPolicyTextBlock" escape="true" continuedAt="F_94c89ae7-0bb2-45d5-acd4-95379e2d12db_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_13" continuedAt="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_14"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_94c89ae7-0bb2-45d5-acd4-95379e2d12db_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#8217;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47d9df1d-0a7e-4ddc-a06f-19caeee4bcff" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">62.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s cash and cash equivalents, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65dd12a9-3199-40aa-b9c0-3e3b81a10efc" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s short-term bank deposits and long-term certificates of deposit as of December 31, 2024 in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd2f11b2-1e69-45da-927b-e2ce6b6c4a6e" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:CashAndCashEquivalentsReportingCurrencyDenominatedValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aefe8fa-1936-4e04-9a6f-69354bd85a37" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38c0a103-7d26-465e-8e72-01ae863ed954" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively, were denominated in RMB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_2766eb95-7edd-4ec8-bacb-3b92e4ab4d87" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Recently Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_861ba113-7ddc-46c9-8565-833c94e573a4" contextRef="C_650b198d-ed03-434f-8873-424e5a2b6569" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> this standard as of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_03a71367-7883-47d1-aa9c-f13a4e980f0c" contextRef="C_650b198d-ed03-434f-8873-424e5a2b6569" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">January 1, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The adoption of this ASU did </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_4f702f53-9561-4893-b1f9-051d59a63503" contextRef="C_650b198d-ed03-434f-8873-424e5a2b6569" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">not </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">have any material impact on the Company&#8217;s consolidated financial statements.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_fcf2b118-e921-4be5-b269-14bb43b41c39" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" escape="true" continuedAt="F_fcf2b118-e921-4be5-b269-14bb43b41c39_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#8217;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. ASU 2023-06 modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. Because of the variety of Topics amended, a broad range of entities may be affected by one or more of those amendments. Many of the amendments allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not previously subject to the SEC&#8217;s requirements. Also, the amendments align the requirements in the Codification with the SEC&#8217;s regulations. For entities subject to the SEC&#8217;s existing disclosure requirements and for entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. The amendments in this update should be applied prospectively. For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is currently evaluating the potential impact this standard will have on its consolidated financial statements and related disclosures.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The ASU requires the disaggregated disclosure of specific expense categories, including purchases of inventory, employee compensation, depreciation, and amortization, within relevant income</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d_14"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_fcf2b118-e921-4be5-b269-14bb43b41c39_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">statement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">captions. This ASU also requires disclosure of the total amount of selling expenses along with the definition of selling expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU can either be applied prospectively to consolidated financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the consolidated financial statements. Early adoption is also permitted. This ASU will likely result in the required additional disclosures being included in our consolidated financial statements, once adopted. The Company is currently evaluating the provisions of this ASU.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"></span></p></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_1b13f7e5-42a7-45a3-89f1-5f25cf679d1a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_1b13f7e5-42a7-45a3-89f1-5f25cf679d1a_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For a description of the fair value hierarchy and fair value methodology, see Note 2 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company&#8217;s highly liquid money market funds are included within cash equivalents.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_e8e50f0e-0dfb-46f5-abb5-1ab8233f7a91" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dff57515-4ec1-4c6d-a74d-b8260899ca74" contextRef="C_8b6f77fc-9f62-4a56-a8a3-60296e884fd5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cd5dd56-b36a-4418-98f9-f68c6f07ae41" contextRef="C_a90606c8-9443-4792-8781-57608b6e4e3e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Receivable from GCBP</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_928d0d09-a913-44f3-b5b9-b82f42ece371" contextRef="C_b4a86beb-1787-4bb4-bd49-dbe2b1f05f54" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0c068a4-1a80-40e9-be02-eb106d35d7f9" contextRef="C_6d30a83a-d0f3-4ca4-b55e-76c959f4075c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_381e9a79-f9de-4145-9b77-4421b09fe309" contextRef="C_e9706bd6-a8ea-4e15-9d5b-2d51ea3a4538" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f741d829-9914-4635-bfc5-62c9af5b1cc0" contextRef="C_b0da0539-7026-4894-ad23-631ed2889b06" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fd378d0-8c64-4b11-a672-03e92ce0f898" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,261</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b984e886-2e9c-4155-9c8f-46e93ed8fc8b" contextRef="C_ae06bf9f-4849-4d7c-b764-bdd92fb5df72" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f12b0598-35bf-49a5-9281-6bf2ec846a6e" contextRef="C_6d9205fa-fd4f-4d6d-be1a-9d6b1b8e9900" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06026020-a383-4d14-9c89-ccb9f09d0aa3" contextRef="C_68a0f639-5b32-411d-b8ae-3d27cfa51531" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,668</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afe9dff5-a14f-4d94-b05d-8a6a25116fe1" contextRef="C_3bcf2b7f-ee59-442c-b6bd-34c12861eac8" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,668</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_131d89ac-5a3b-433f-b9eb-0fc796b3a740" contextRef="C_b0da0539-7026-4894-ad23-631ed2889b06" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,629</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e90b621a-10e4-4343-9f3c-a7e4a52d4662" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,629</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_663fdca3-38c0-48b4-8ee3-3c286855998b" contextRef="C_a34646ab-b257-4cc5-aaa5-c6130d624d7f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14a49538-f42e-4f2b-b92e-6ef1dbdfc000" contextRef="C_90704b89-2d95-4695-898f-ba265baa62ee" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_215fd13c-3c2d-4785-aa5a-ff296a4c62cd" contextRef="C_f1739194-98a6-4fa5-9476-50a472bbd7b0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78561435-641b-45ee-aca0-d2df3fdc29b4" contextRef="C_d4414f45-2440-4efe-b9f6-4316754c428f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_723bfe9f-e311-4240-95a2-d5600e71f8ae" contextRef="C_5e72f9e3-7599-472f-92ab-fa429b264f71" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5193e3eb-c2f4-403d-ba76-84e6bcfce396" contextRef="C_77b7dffb-7a31-4205-a9eb-98bee99e2a4b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd5f8916-aa25-41f1-9525-188212146ae8" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,582</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f50acf29-4ed5-4df0-be52-30ef0433f35e" contextRef="C_e9d4eda1-e8b4-4878-b3ba-046acdcd7131" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46e10bbf-4aba-494a-8d5a-37dc2ac24661" contextRef="C_8d6b27d0-681a-4b5e-86bf-4e37f3785874" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cf0d455-b9d9-40a3-9002-3b29f9c02232" contextRef="C_d274c80b-8c06-41ed-bb58-3a6d5311414f" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,835</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7fa37ef-dfe8-4ca5-976c-49baef604f2f" contextRef="C_ecfde2db-6b97-4952-8c3e-f7202cd08598" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,835</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e305647c-e796-4ad5-8e98-c567796d0ad9" contextRef="C_77b7dffb-7a31-4205-a9eb-98bee99e2a4b" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,557</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6553ac65-6017-4ddc-9e61-61894a2ca1d6" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,557</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1)  </span><ix:footnote id="FNT_61d264df-69d6-495e-8eeb-41acb2cd480b" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</span></ix:footnote></p></ix:nonNumeric></div><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The carrying amounts of cash, accounts and note receivables, net, other receivables, accounts payable, due to related parties, CVR excess closing cash payable, and accrued liabilities approximate their fair values due to their short maturities.</span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, there were </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cd1d25f-3914-465b-b512-661493fee8ee" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> transfers of fair value measurement between Level 1 and Level 2 and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6e2c04c-6c0a-462d-90e1-8be2a691c5fd" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:FairValueAssetsAndLiabilitiesLevel3TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> transfers into or out of Level 3 for both financial assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_1b13f7e5-42a7-45a3-89f1-5f25cf679d1a_1" continuedAt="F_1b13f7e5-42a7-45a3-89f1-5f25cf679d1a_2"><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Receivable from GCBP and CVR Derivative Liability</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The receivable from GCBP and the corresponding CVR derivative liability relate to the asset purchase agreement with GCBP. The fair value of this receivable and derivative liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">These unobservable inputs include the probability of GCBP meeting its contractual payment obligations, the timing of cash flows, and the expected recovery rate of the receivable. The estimation process incorporates GCBP&#8217;s financial condition and market conditions that could impact its ability to fulfill obligations. Additionally, the selection of the discount rate (currently estimated at </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e50b37aa-59d8-4116-8c6f-1f4488511241" contextRef="C_c72b6ba0-b44d-464c-8103-3b7702656381" name="us-gaap:DerivativeAssetMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%) may fluctuate over time</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The estimated fair value of the receivable from GCBP and CVR derivative liability was determined based on the anticipated amount and timing of projected cash flows to be received from GCBP pursuant to the GCBP asset purchase agreement discounted to their present values using an estimated discount rate of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc9f3f6b-a178-4f9c-b7bf-2545313072a3" contextRef="C_c72b6ba0-b44d-464c-8103-3b7702656381" name="us-gaap:DerivativeAssetMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a863672b-a8f5-4e55-9411-e6c8ef6bf9e5" contextRef="C_a56d2451-275e-4c7f-95db-b89dd45a7915" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.05</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company expects to receive a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9b2e25d-1d11-4e86-9001-05c71f10caeb" contextRef="C_a8d02e48-8b97-4471-b7d2-9b754e3a60ee" name="gyre:AmountToBeReceivedUnderAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> hold-back payment from GCBP in the first quarter of 2025, which will be distributed, net of expenses, to the CVR Holders. The change in fair value of the receivable from GCBP and the corresponding CVR derivative liability was recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Liability</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In October 2023, Catalyst entered into a Securities Purchase Agreement for a private placement with GNI USA (the &#8220;Private Placement&#8221;). The Private Placement closed immediately following the Contributions on October 30, 2023. Upon closing of the Private Placement, the Company issued </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daebdc22-0116-4113-8bbe-ebe700319eac" contextRef="C_f0a09c76-9e8a-4c61-b540-701ad6b7648e" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_d7afc566-4507-47e4-bd5a-34a380b2f4b1" contextRef="C_12c92d66-d545-47dd-8492-bf82d190b61c" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Preferred Stock Warrants to purchase shares of Convertible Preferred Stock t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">o GNI for an aggregate purchase price of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40550603-ecdb-433e-8d34-41927f3fa056" contextRef="C_ea5bb34e-9257-4104-825f-20adf13f8344" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Preferred Stock Warrants are immediately exercisable at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35619202-6534-4bba-ba9a-67fb62e0d15c" contextRef="C_12c92d66-d545-47dd-8492-bf82d190b61c" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4,915.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share of Convertible Preferred Stock and expire on </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_dc85b8f5-bb6a-488f-9858-6372befb145a" contextRef="C_12c92d66-d545-47dd-8492-bf82d190b61c" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">October 30, 2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">he number of shares of Common Stock issuable upon exercise and conversion of the Preferred Stock Warrants is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d17a89b4-7f0d-45c8-80ba-325594d18af5" contextRef="C_12c92d66-d545-47dd-8492-bf82d190b61c" name="gyre:NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">540,666</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company accounted for the Private Placement as a non-arm's length transaction. The Preferred Stock Warrants were initially recognized at fair value upon issuance and the remaining proceeds from the Private Placement were allocated to the Convertible Preferred Stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Preferred Stock Warrants are freestanding financial instruments classified as a warrant liability on the Company&#8217;s consolidated balance sheet. The fair value of the Preferred Stock Warrants is subject to uncertainty due to unobservable inputs, including the expected volatility of the Company&#8217;s stock price, the likelihood of warrant exercise, and the estimated term of the warrants. Since there is limited market activity for the Preferred Stock Warrants, their fair value is determined using an option pricing model, which incorporates subjective inputs such as the Company&#8217;s stock price volatility, derived from historical and peer company data, as well as management&#8217;s expectations regarding future performance. As these assumptions evolve due to market conditions or company specific factors, the warrant liability may experience fluctuations. The Preferred Stock Warrants are revalued each reporting period with the change in fair value recorded as change in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_192f5052-5bbe-4f8e-9fee-788ff093daeb" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value of the warrant liability is estimated based on th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">e Black-Scholes option pricing model using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81%;box-sizing:content-box;"/>
        <td style="width:1.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.620000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Share price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b9c83dd-9942-4e76-8e87-54db97ab66c0" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:WarrantsSharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="1" format="ixt:num-dot-decimal">12.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c018188-25de-4bab-bd5b-bd074f688015" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4,915.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk-free interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a286995-1ef3-443f-ab4d-9f8da0c9ad8e" contextRef="C_02538a53-cecd-41e8-aa82-e8efb664750a" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.54</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Term (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_a18cb9f2-2385-49dd-a12e-d72ef729f3cd" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.83</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3864886-c38c-4e20-950e-a21b47fd3e9a" contextRef="C_ed398fbe-2209-4cef-89f5-4af5eb6bb183" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">83.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_1b13f7e5-42a7-45a3-89f1-5f25cf679d1a_2" continuedAt="F_1b13f7e5-42a7-45a3-89f1-5f25cf679d1a_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_72de72cf-487f-499a-8700-4ebe8c8aed85" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level 3 financial assets and liabilities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.2%;box-sizing:content-box;"/>
        <td style="width:1.481%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.625%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.481%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.365%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.481%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.365%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additions in the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a086b1d-0666-4b79-8f51-284c28c50ac1" contextRef="C_3ea2f2ca-4eb5-48e9-9b14-30c3e9e2d1ef" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebd868d3-d928-4220-a3d4-cc8182caebe6" contextRef="C_254f82e6-b517-47d8-aa5e-0e78e7d7e7fe" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e5f2e03-193e-4e7b-8869-e828a02c9168" contextRef="C_5037ba80-7341-4533-b5cb-88a46c19f3b0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,574</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a8323a9-5c21-4fcf-8a32-b000c85691c2" contextRef="C_3ea2f2ca-4eb5-48e9-9b14-30c3e9e2d1ef" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_289372f0-7c7e-4618-bd80-cb8292af369c" contextRef="C_254f82e6-b517-47d8-aa5e-0e78e7d7e7fe" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fed4ca6b-0250-4c08-a786-9a39fd706bb0" contextRef="C_5037ba80-7341-4533-b5cb-88a46c19f3b0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4a4352b-4ad1-47f5-baef-a1c8da8bce43" contextRef="C_d4414f45-2440-4efe-b9f6-4316754c428f" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c250b83f-7b03-450d-b08f-f5f444a1dd2a" contextRef="C_8d6b27d0-681a-4b5e-86bf-4e37f3785874" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a97a15f-9291-4feb-8abc-4dfea89e519f" contextRef="C_ecfde2db-6b97-4952-8c3e-f7202cd08598" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,835</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efff157a-ec7b-48d3-8a3c-5b821ed99af0" contextRef="C_6c54312b-5d11-479d-8137-af33dda8c109" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dd9fbb1-2bf8-45f3-a793-591ccb4b26a9" contextRef="C_c44dd11e-3d19-4a70-8872-8c9259134b11" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_830944d5-c8b6-46fa-95d6-db3c2e20987b" contextRef="C_6e3414eb-e1eb-461f-b6f5-48348df952e9" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20d5ea71-e115-4cb7-b2b8-1e2515172178" contextRef="C_6d30a83a-d0f3-4ca4-b55e-76c959f4075c" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35e7f0f6-76ed-4c5a-83ef-764225303423" contextRef="C_6d9205fa-fd4f-4d6d-be1a-9d6b1b8e9900" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_923213ba-536d-4c04-be3a-b834fc2afdc0" contextRef="C_3bcf2b7f-ee59-442c-b6bd-34c12861eac8" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,668</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial Instruments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_051312fa-60c3-4cde-b8e8-db758a0763c8" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash equivalents and held-to-maturity debt securities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.06%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds  (cash equivalents)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbe451da-c42d-4876-b12b-686e3e6db255" contextRef="C_c664e54d-79f7-479e-871b-a1086f9e1e55" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d514dd2-c944-4a2c-8cad-d19e67afa32c" contextRef="C_c664e54d-79f7-479e-871b-a1086f9e1e55" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Short-term bank deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28e6ea82-35fd-4856-bb21-05d2b526f747" contextRef="C_625ba7b4-bbf9-4cd1-b581-60e547a6e52a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,858</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57e394ee-dc6e-4d07-8830-0c088f9fcf9f" contextRef="C_625ba7b4-bbf9-4cd1-b581-60e547a6e52a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,858</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b0cd26b-1a1b-4ca6-9ad0-268e7c3cef5d" contextRef="C_196fe3c5-bc8a-4a5f-a84e-6cbf8da6bc14" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,568</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e655cf9-196d-47b0-93f7-af5ab2be2017" contextRef="C_196fe3c5-bc8a-4a5f-a84e-6cbf8da6bc14" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,568</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0699a27-0572-4dbe-8ee5-bfd4b234383c" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,726</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_973f9e78-3ba3-440a-8626-fc0dea14bd26" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,726</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Classified as:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02acb80e-44bf-4758-a9b0-3f37e789ebab" contextRef="C_8ff20dd2-fe0c-4bf5-810a-2ce783d0f15b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Short-term bank deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c72bfa44-d2d3-4877-82ef-d5db269ccc41" contextRef="C_625ba7b4-bbf9-4cd1-b581-60e547a6e52a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,858</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27b5c5d0-e374-4fd7-bbd6-fba7c574f1fb" contextRef="C_196fe3c5-bc8a-4a5f-a84e-6cbf8da6bc14" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,568</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe651238-f246-436c-ad27-a9e664c59f25" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,726</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.951%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.318%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.438%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.778%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.118%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds  (cash equivalents)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f6de45f-2178-49bb-8f44-c2f8b0c3b796" contextRef="C_dbedf524-e39b-431f-b9b5-51f72b11b2b3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d1a51d0-e2b8-4256-bb13-9d7160a22781" contextRef="C_dbedf524-e39b-431f-b9b5-51f72b11b2b3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_650e7e84-eae6-4abb-a408-db06f98e41db" contextRef="C_72587811-89ac-4abd-97ba-a8887f54ccab" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,431</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f9b5c1-626d-4442-8fd9-fca6ba79c921" contextRef="C_72587811-89ac-4abd-97ba-a8887f54ccab" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,431</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72610c01-f8f8-47d4-9abd-3a2c697c7624" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,291</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0194d45-3378-4b09-8ac0-f1a1ba3bd1d2" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,291</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Classified as:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f30a127-dc9b-46e9-bd18-c4cae8b0620f" contextRef="C_90682bfe-2026-4fd0-87b6-43c6bb28213c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cc7465f-9a53-4f23-a71d-4cafce46c894" contextRef="C_72587811-89ac-4abd-97ba-a8887f54ccab" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,431</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adec12d4-11b7-4684-8916-1d01d0c3d950" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,291</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_f92a98f5-4aa0-49c2-97f0-20fb2f8d9921" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value and amortized cost of the Company's held-to-maturity debt securities and redemption date were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.06%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due in one year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_489443db-15fb-4f6f-a27c-54baa96c908a" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,858</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc63a0e3-746f-41f3-8050-7830c507923f" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,858</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due in one to five years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f0e7c77-fa85-47c4-b3cc-d737aa5dace7" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,568</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47fc98d5-cf98-4f98-806b-011decdeb6e9" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,568</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bbe9ba9-568d-4152-8fae-cd032d4a4b69" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4a0a67f-a0aa-4747-86af-ec28010ea01b" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1b13f7e5-42a7-45a3-89f1-5f25cf679d1a_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income from the short-term bank deposits is recognized on an accrual basis over the term of the deposits. The accrued interest income for the periods ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_947db538-8e15-4c81-ab7c-72e95c4cd833" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AccruedInterestIncomeOnShortTermBankDeposits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df5b95f8-7d5a-4623-b10f-3f499030f326" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AccruedInterestIncomeOnShortTermBankDeposits" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income from the long-term certificates of deposit is recognized on an accrual basis over the term of the deposits. The accrued interest income for the periods ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8f0141a-3b1e-443d-9617-73d5cfbfca33" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AccruedInterestIncomeOnLongTermCertificatesOfDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f111e8c1-f278-4fe3-ba75-56089af0c00c" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AccruedInterestIncomeOnLongTermCertificatesOfDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div><ix:nonNumeric id="F_84de264d-52e9-4a74-8ea7-f4d6a5b54d95" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true" continuedAt="F_84de264d-52e9-4a74-8ea7-f4d6a5b54d95_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance Sheet Components</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_f4a7d302-5e44-45ad-a98f-fbf1f40a738e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, net of reserves of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb5a9493-d72e-4e31-a923-c70a0a1a9230" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1960ef30-d1ee-4243-a643-61e9bf2ab2cb" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">46,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2024 and 2023, respectively, consisted of the following components (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcd396d1-d4c4-4b08-bd0e-feffc756b6d9" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:InventoryRawMaterials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">794</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c270704f-f728-4ed7-91be-6036e23cdc09" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:InventoryRawMaterials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">919</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Work in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ead9634-9c39-4d2f-9185-99ea3026f031" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:InventoryWorkInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,929</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a012755-feb1-485a-8cf1-2f3eb081783c" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:InventoryWorkInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,997</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e49eb53-2a9f-4f09-b657-4b190219560e" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:InventoryFinishedGoods" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,614</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcf2f766-e2a3-49a3-989f-cd79ead2b419" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:InventoryFinishedGoods" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,365</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35fd2f82-1365-40c4-98d4-bd77b9452738" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,337</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_314eb9a0-4533-4bb5-bf57-b0af94ae0f87" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The provision for inventory and write-downs for the years ended December 31, 2024 and 2023 were immaterial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d3405402-544c-4725-b931-3b023683e948" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.280000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued payroll and welfare</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3615bf5-2844-49a9-b8e8-c7877dd0465b" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AccruedPayrollAndWelfare" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,765</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_390f7190-ab26-4ab2-9389-5ecd06802e7a" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AccruedPayrollAndWelfare" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,790</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Payable to PPE suppliers</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1702929-b1bc-440e-9f0b-92a4bac8b162" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:PayableToPropertyPlantAndEquipmentSuppliers" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,219</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f876fdb7-6cab-4f36-a633-3dcede6df453" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:PayableToPropertyPlantAndEquipmentSuppliers" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,336</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses - general and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d238287-78ae-4a9c-a8ff-100c98acdf92" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AccruedExpensesGeneralAndAdministrative" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,005</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a9dfc40-e8c1-442a-a6a6-1d671022e673" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AccruedExpensesGeneralAndAdministrative" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,190</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued sales discount</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_700d4d14-125a-4690-a828-e051cf410f2f" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AccruedSalesDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">908</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36525e1b-3ffb-4cc5-82d5-1a452189d25f" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AccruedSalesDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">903</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Payable to selling expense suppliers</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_082594c0-972e-4d5a-a00b-0e308cea20a2" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:PayableToSellingExpenseSuppliers" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">900</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00805867-67f3-43c8-a437-6cb2add4b6fc" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:PayableToSellingExpenseSuppliers" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">820</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Employee reimbursement</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6360f68-cfdb-4ac3-9bda-7c250e8eda7e" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">737</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56e656bd-90ef-4264-8675-0bf183a6ab99" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">648</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd91dcb0-f569-41ac-8ece-b5e59f9c4df9" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">667</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32892775-ce13-4ad2-a8e0-3a20d1a9e466" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b55699c-b678-47a0-a353-df621ebda4a6" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredGovernmentGrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e5eacaf-bd8d-43bc-8b29-fdb8b47c16b4" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredGovernmentGrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses - research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bedad5a-a56f-42f0-9a37-a4d82399d4f7" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AccruedExpensesResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87762dd6-6c5d-4801-8121-b144315af7d0" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AccruedExpensesResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a3b2453-eaa8-4073-ba41-958d4705dcdc" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22afb842-1055-4dfe-be34-42fdc2feb7cc" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_994f862c-bcb5-4200-bab7-f1b5a1238fd3" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,615</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_debc9069-12e7-4303-9687-c0233a41c081" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,935</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred government grants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred government grants represent funds provided by the government for research and development, construction of new facilities, or improvement of existing production facilities. The amount of deferred government grants as of December 31, 2024 and 2023, is net of the amount recognized as government grant income. During the years ended December 31, 2024 and 2023, the Company received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_819ef035-e2e6-49b8-bb19-80c494fa57fc" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ProceedsFromGovernmentGrantsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8983f1e9-f86f-487e-94eb-4b79dca90c65" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:ProceedsFromGovernmentGrantsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million government grants, respectively. During the years ended December 31, 2024 and 2023, the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_84de264d-52e9-4a74-8ea7-f4d6a5b54d95_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8d440a1-bc19-423a-8e1e-6b2b69348e10" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:GovernmentGrantIncomeWithinOtherIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8047fff1-46c8-4b61-a2cd-8ba91b6a4108" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:GovernmentGrantIncomeWithinOtherIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million of government grant income within other income in the consolidated statements of operations and comprehensive income (loss), respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_f4eb0f58-3b97-4b9c-acaf-a6ddaac59333" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Summarized below are deferred government grants as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government grants for property and equipment, included in accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ca1b6c4-220e-4832-9afa-b19f2b6b4a3b" contextRef="C_855a18a4-8d8c-46bf-aa53-59975edfdf20" name="gyre:DeferredGovernmentGrantsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc1c8878-584c-4ef7-94db-eca725457855" contextRef="C_c26605c5-09bd-4994-af5d-7d427048d643" name="gyre:DeferredGovernmentGrantsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d1382e2-ae92-4760-a37c-5b7f04c82a52" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredGovernmentGrantsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85ba76bf-cf11-4c49-b234-e62ff178e471" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredGovernmentGrantsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government grants for property and equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33fe4be3-ca62-47ca-9e39-08f592875bf2" contextRef="C_865d32c0-6f1c-4e0d-9ca2-0c9a24caf2cd" name="gyre:DeferredGovernmentGrantsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">928</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c78c82a-3e33-4f2e-ab45-dd84ab2cde68" contextRef="C_6cec0878-7860-4728-9cc5-0c28173f20eb" name="gyre:DeferredGovernmentGrantsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-current deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10d26ab7-3a13-41da-8974-30dc45393cf2" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredGovernmentGrantsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">928</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_904d0655-f5e9-4397-8330-a93043e8d978" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredGovernmentGrantsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae469746-dbcb-408e-939a-1ab074dbb9cb" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredGovernmentGrantsCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,023</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7071ee10-880a-41f0-a0ba-6dfa23eda7da" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredGovernmentGrantsCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_8e580160-3986-4167-b7b0-031b899eda38" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.92%;box-sizing:content-box;"/>
        <td style="width:1.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Buildings</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f32884f-d7ac-4d7e-a643-c98999140cb1" contextRef="C_97a869fa-0596-4ada-9896-83385642b0be" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,980</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c6abc5d-034f-44c7-a65f-a81a422c518b" contextRef="C_fabc4de6-f3ea-4c14-8ab7-d36a14e5c91d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdfb13ab-31e9-4cf6-a036-773d53772bd5" contextRef="C_9e3328d4-ba00-4ce5-8265-2253f006ba54" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b895bc2-7f69-45b7-acd3-82a23cfebec2" contextRef="C_ad2aff12-25e7-4121-b6bd-e885663b2263" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,875</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Machinery and electronic devices</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8721de4-5284-4e2f-bfc4-bd2da19b460f" contextRef="C_5e716a13-8908-4a45-90e4-2cfac3c1eeaf" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,442</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7092846-087a-44e7-886a-f8a184ef0327" contextRef="C_33998465-47eb-4f6f-9f5b-ae8cb85bcc79" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,598</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1265c4db-6411-4d6a-90cd-563f365a598d" contextRef="C_094d85c6-e458-4cfd-ad37-15cb54dd53db" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">653</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92ced667-a6a1-4521-8cfa-dcab7cce9692" contextRef="C_990c44c7-915a-4a78-9e70-be8742ec4a8b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3960465-4508-43e3-81e0-0b1b4d38e083" contextRef="C_eb61462d-1632-48d9-a73a-8eefdbf9c020" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37af26b8-73dd-4c13-9f82-bcfd0a76115c" contextRef="C_526db762-c121-4c94-bd8f-2957c39426c5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba2cd80f-590d-421f-9896-94b40960f1c7" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,479</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c706560b-14c6-414f-8cf7-cc49d84c0c54" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,553</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1354745-b247-426e-b282-e9c08d7337e4" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,599</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_567fddac-ad55-4020-af8b-ffc4cf6d1769" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,265</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10f87cf7-3db3-4ace-bead-26bcbf104708" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,880</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56cea492-10e5-4242-890e-bfeb9b717d2e" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,288</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_199f3dea-5ebd-47c6-9c05-8ea0bc5e44f8" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02782614-b596-4d2b-b797-ac1049e822c6" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for each of the years ended December 31, 2024 and 2023, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-Term Investment Measured Under Equity Method</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On June 28, 2024, Gyre Pharmaceuticals entered into a partnership agreement as a limited partner with other investors and is obligated to pay $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b07f616f-8be2-453d-96ec-9dcc199b62ad" contextRef="C_a6f4023f-6af1-478e-8828-c64f6e19e231" name="gyre:InvestmentSubscriptionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for an </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_445cac5e-43bf-441d-8463-bf673b0c4ecb" contextRef="C_a6f4023f-6af1-478e-8828-c64f6e19e231" name="gyre:PercentageOfEquityInterest" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">18.93</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> equity interest in the partnership. Pursuant to the partnership agreement, Gyre Pharmaceuticals, as a limited partner, shall not participate in any activities related to the management of the investment business. However, Gyre Pharmaceuticals may appoint a member to the advisory committee of the partnership. As of December 31, 2024, the Company's total investment into the partnership and the carrying value of the Company&#8217;s long-term investment in this affiliate, which was included in &#8220;Other assets, noncurrent&#8221; in the balance sheet, was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_476b1123-263a-4ea1-8a95-9110b54db104" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:EquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63cac92f-735f-4a73-bca9-8da844aa4749" contextRef="C_b8550c29-f99b-4014-8343-c78232d39a0a" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_bf86e90b-5836-4dff-9f33-a71ad841fd7d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true" continuedAt="F_bf86e90b-5836-4dff-9f33-a71ad841fd7d_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">5.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_9cb1e692-2db7-415d-bb65-2b96c63b7d7a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true" continuedAt="F_9cb1e692-2db7-415d-bb65-2b96c63b7d7a_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The gross carrying amounts and accumulated amortization of the Company&#8217;s intangible assets with determinable lives as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_bf86e90b-5836-4dff-9f33-a71ad841fd7d_1"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_9cb1e692-2db7-415d-bb65-2b96c63b7d7a_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.99%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.197000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.077%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.157%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e7cf955-9029-464c-b9ac-99460e11ef58" contextRef="C_d9641dc2-ce11-4da3-92da-82b11fbc53ff" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">423</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0de35761-1211-49cc-a39d-ea2ac6b7679e" contextRef="C_d9641dc2-ce11-4da3-92da-82b11fbc53ff" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">303</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c86fc29d-efb7-4a1c-ba6f-0b0636104658" contextRef="C_d9641dc2-ce11-4da3-92da-82b11fbc53ff" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2b486dd-afdb-4bbb-be30-1d40e4762a89" contextRef="C_f5823b3d-6762-4329-9b17-efe63bdb21f4" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa4a0372-4c50-4720-b06d-4086bba645aa" contextRef="C_f5823b3d-6762-4329-9b17-efe63bdb21f4" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b782b56-99e5-4548-bf6b-a68a4b226540" contextRef="C_f5823b3d-6762-4329-9b17-efe63bdb21f4" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">153</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_356e31a8-4840-493a-9ebf-39be1979a434" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">701</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_305b783c-be1d-42c9-ad8e-bd2840db6a86" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">428</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bc0c5e1-55dd-4456-bfc5-c4d377b77b62" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7082301-4011-4693-bccf-8544e1b33f86" contextRef="C_2c09cdda-c1e5-435a-b940-ce423bcf6515" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">430</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f1b9521-80bb-491f-814f-9bd354ab7652" contextRef="C_2c09cdda-c1e5-435a-b940-ce423bcf6515" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20f9d621-566b-4183-821a-1e2abb9d804f" contextRef="C_2c09cdda-c1e5-435a-b940-ce423bcf6515" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0bb3513-090b-4cf4-8fae-e03378a0b688" contextRef="C_37337290-c4f6-4ef2-a6f7-8313d2a10b7a" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06fc8bae-3c56-4adf-94e6-eeb5d5bd852f" contextRef="C_37337290-c4f6-4ef2-a6f7-8313d2a10b7a" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8a38f8e-b196-4d57-b94c-de1282aeca1d" contextRef="C_37337290-c4f6-4ef2-a6f7-8313d2a10b7a" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffcde63a-30be-4d73-aa8b-32000baec85f" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">601</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9edb1f2-637b-4f35-977c-f5049871a624" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cacf404a-5621-4595-a8f9-4f365800638a" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets are carried at cost less accumulated amortization and impairment, if applicable, and the amortization expense is recorded in operating expenses. The weighted average amortization period for the intangible assets as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_5176e29f-705b-4c02-a665-da9782b81d28" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4.04</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortization expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a78e972a-afec-4d4e-9ba9-845f6cb047fd" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">38,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bac1a1b3-c809-435b-ab4a-2d340fedaa5c" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for each of the years ended December 31, 2024, and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively. </span><span><ix:nonNumeric id="F_65bba05f-eccb-4359-8e58-06f2b23ab68d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true" continuedAt="F_65bba05f-eccb-4359-8e58-06f2b23ab68d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on finite-lived intangible assets recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024, the estimated future amortization expense is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_65bba05f-eccb-4359-8e58-06f2b23ab68d_1" continuedAt="F_65bba05f-eccb-4359-8e58-06f2b23ab68d_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:85.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated Amortization Expense</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aab4c38-fc02-4534-b40e-920efcade45f" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6ec1ca4-102f-4264-bb6a-2fd6c8f85c46" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_266ad79d-6e40-4381-8052-1e5af24a2206" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d42d506e-3be8-489d-8133-f19aa923c477" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4af6e0a8-072e-475d-9c81-6755d496277a" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a3d5891-65aa-4be2-8529-1e0777be3dde" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07af8e26-d676-4b1e-af9a-5f368b1be388" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:continuation></div>
  <div><ix:continuation id="F_65bba05f-eccb-4359-8e58-06f2b23ab68d_2"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_6310e3bc-276b-472f-94a1-07f4967f4b99" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true" continuedAt="F_6310e3bc-276b-472f-94a1-07f4967f4b99_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">6.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s product revenues were mainly generated from the sale of ETUARY. Sales of ETUARY accounted for </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73db2876-9b08-4af8-b75e-eda2ce8d7e12" contextRef="C_c0f50cf0-d705-4547-8bb2-292161d2dc8e" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">99.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bef25dea-a0fe-480e-b80b-176e5bbd5639" contextRef="C_51a6c503-e72b-48c6-951e-f9d61b0aaa75" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">98.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of total revenue for the years ended on December 31, 2024 and 2023, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company generates revenue mostly through sales of ETUARY and certain generic drugs. The distributors were the Company&#8217;s direct customers, and sales to distributors accounted for </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8617e88c-d6c7-451e-8f00-4a5cd04f6650" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:PercentageOfRevenueAccountedSalesToDistributors" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of revenue from ETUARY. The distributors sell ETUARY to outlets, including hospitals and other medical institutions, as well as pharmacies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Product </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">returns to date have not been significant and the Company has not considered it necessary to record a reserve for product returns. The Company&#8217;s product revenues were recognized at a point in time when the underlying product was delivered to the customer, which was when the customer obtained control of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_6310e3bc-276b-472f-94a1-07f4967f4b99_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">product. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenue from sales of pharmaceutical products was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f65a25e-7a97-4ca9-8bb8-2302b54e7d0f" contextRef="C_e4d869fa-260f-4c9f-9cf3-79a75bfecf47" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ef19e5b-eec3-4b44-9925-205dcd4c967b" contextRef="C_1152de71-ba52-48e2-80b9-f500c5502e72" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">113.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively. All sales are generated in the PRC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_de6e5ab2-4080-45db-896e-ffa6234a0118" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s sales by product categories for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.008%;box-sizing:content-box;"/>
        <td style="width:1.06%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:27.705%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:27.225%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sales of Pharmaceutical Products</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1488b479-cf03-40b9-8055-99f88bbe41d3" contextRef="C_e4d869fa-260f-4c9f-9cf3-79a75bfecf47" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,757</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49d613b8-4550-4711-bd59-1d98806dea54" contextRef="C_1152de71-ba52-48e2-80b9-f500c5502e72" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11d4f5ae-a000-431e-aec8-5f1325352a78" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,757</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1b309da-b63e-4833-b3d2-b5789eaae21b" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div><ix:nonNumeric id="F_b384e3e3-6ea7-4b69-8f43-40d90d957dcb" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true" continuedAt="F_b384e3e3-6ea7-4b69-8f43-40d90d957dcb_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">7.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The GNI USA Contributions under the Business Combination Agreement (see Note 1) was treated as a reverse asset acquisition, with CPI as the accounting acquirer and Catalyst as the legal acquirer. Under U.S. GAAP, a company must evaluate if an integrated set of assets and activities qualifies as a business acquisition or an asset acquisition by assessing if the gross assets&#8217; fair value is primarily concentrated in a single asset or a group of similar assets. If this criterion is met, the acquired operations are not considered a business. Catalyst did not meet the business definition as its fair value was concentrated in one IPR&amp;D asset, it lacked an organized workforce contributing significantly to output creation, and no substantive processes were acquired. As such, the GNI USA Contributions was treated as an asset acquisition. In an asset acquisition, goodwill is not recognized, and the cost allocated to the acquired IPR&amp;D with no alternative future use is expensed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_584f911e-1088-4345-80e2-624d7e9057c0" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" escape="true" continuedAt="F_584f911e-1088-4345-80e2-624d7e9057c0_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:84%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Catalyst Common Stock outstanding</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70ca9fae-9d69-46d1-a1b2-6e2f1ee83069" contextRef="C_e7855790-0097-47bb-9146-f38e022e4521" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,532</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Multiplied by the fair value per share of Catalyst stock (1)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_481558c6-a609-452f-b345-dd372cf841c3" contextRef="C_e7855790-0097-47bb-9146-f38e022e4521" name="us-gaap:BusinessAcquisitionSharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.67</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of common shares to be owned by Catalyst&#8217;s stockholders</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97d12e1b-a27e-481f-add4-89111f801799" contextRef="C_e7855790-0097-47bb-9146-f38e022e4521" name="gyre:BusinessCombinationFairValueOfCommonShares" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,420</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of preferred shares to be owned by Catalyst&#8217;s stockholders (2)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c3010dd-bd13-4c9a-85c6-7eba53b7f240" contextRef="C_e7855790-0097-47bb-9146-f38e022e4521" name="gyre:BusinessCombinationFairValueOfPreferredShares" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,099</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of Catalyst</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_347f5d2b-afd9-4a13-bb61-0cf306e23d67" contextRef="C_e7855790-0097-47bb-9146-f38e022e4521" name="gyre:BusinessCombinationFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,519</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a8e41ac-d9eb-4a0a-9c5a-a87ff2956e73" contextRef="C_e7855790-0097-47bb-9146-f38e022e4521" name="gyre:PreMergerStockOptionsAssumed" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,829</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of consideration issued</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fe8c611-9573-4ec7-bcd1-aae2fd1eb3ab" contextRef="C_e7855790-0097-47bb-9146-f38e022e4521" name="us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,348</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7442f9ea-2a40-4595-8e84-9eb66252a950" contextRef="C_e7855790-0097-47bb-9146-f38e022e4521" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">659</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase price</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b010ebc3-0fe5-4724-ba35-18adf118ce4e" contextRef="C_2d08f24c-1345-467d-96a2-4553b687c2fb" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,007</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</span></ix:footnote></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This amount is calculated based on </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39d4b8d7-f324-44e5-ae23-0a0e2fc368bf" contextRef="C_daacc8f9-d9a7-49ef-b6a0-b9c3726581cc" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,340</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_8edcaf29-df9e-4a4d-b687-72b121ba5794" contextRef="C_daacc8f9-d9a7-49ef-b6a0-b9c3726581cc" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">666.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</span></ix:footnote></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </span><span><ix:nonNumeric id="F_ec175c4c-56e4-436f-84d5-b5ba30f7f13e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true" continuedAt="F_ec175c4c-56e4-436f-84d5-b5ba30f7f13e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span></ix:nonNumeric></span></ix:footnote><span><ix:continuation id="F_ec175c4c-56e4-436f-84d5-b5ba30f7f13e_1" continuedAt="F_ec175c4c-56e4-436f-84d5-b5ba30f7f13e_2"></ix:continuation></span></div></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_b384e3e3-6ea7-4b69-8f43-40d90d957dcb_1"><div><ix:continuation id="F_584f911e-1088-4345-80e2-624d7e9057c0_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ec175c4c-56e4-436f-84d5-b5ba30f7f13e_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:84%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:14%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_47abff85-a3ea-4232-9ee3-57283680d7ea" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38a776db-bb7d-4601-88ba-94f26e9c6816" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.30</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk free interest rate</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25d0acc4-8f5d-465c-bcd3-eeaf51aebcf6" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.65</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_7fec32f8-5a13-4cc2-9178-468fe1671d48" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:84.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.04%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f411facd-6d5a-427d-8fa4-fb2d964ffa50" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,587</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other receivables from GNI</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbaf9e7b-cd0e-45dd-ad14-6d85deddb747" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">423</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Prepaid assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f7c31b2-6aa9-4ae9-bad9-de662b6d0846" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,097</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dc37157-d931-4dd3-93ff-25e39e0c646c" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_908781ad-e0f0-4461-914b-29156f258dfe" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other assets, noncurrent</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19b30c2b-2fb3-4cc0-ad43-e19ec26914f7" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">IPR&amp;D</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1627c7cb-22ac-4cdf-adcb-18229d087975" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6f1a3dd-0962-4e03-87b1-0091c9025c90" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Advance payment received from GNI</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b947fd4-133a-400e-8f07-cee2530c883f" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c362e0e6-2f3c-4001-b009-81d05f290417" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,784</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR excess closing cash payable</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a175cfc-f4ca-4adf-94e8-4925a30ff75e" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="gyre:BusinessCombinationExcessClosingCashPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,085</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability, noncurrent</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34bc20f8-46d8-4226-99b9-2b980586a677" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net assets acquired</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e96c3e63-d09d-43ba-b35c-434503748e11" contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,007</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in Gyre Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_3408262f-9279-4eb9-b906-3cba309f4ca2" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true" continuedAt="F_3408262f-9279-4eb9-b906-3cba309f4ca2_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Restructuring</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_3408262f-9279-4eb9-b906-3cba309f4ca2_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Prior to the Contributions, CPI entered into a CP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> U.S. Share Purchase Agreement with GNI USA and divested almost all of its assets other than its </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16823d9b-9382-4375-860a-a4b24d70a920" contextRef="C_96a600bd-711e-4434-a24c-a2180e74b33f" name="gyre:PercentageOfIndirectOwnershipInterest" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">56.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> indirect ownership interest in Gyre Pharmaceuticals. GNI USA is the parent company of Gyre. In connection with the transaction, the Company recorded a receivable in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_431d1948-d6f0-4a60-892d-a1bb4b1188dd" contextRef="C_49141630-2e23-47e6-b10b-c4c4722c6d0e" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million included in other receivables from GNI on the consolidated balance sheet as of December 31, 2023 and recognized a loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_074e2eb1-c3b1-470e-b757-86dbbdb864ba" contextRef="C_b5f0da22-de98-4ff9-8f08-36e85ba3bc7e" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2023, included in divestiture losses of the consolidated statements of operations and comprehensive income (loss).</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div><ix:nonNumeric id="F_ae2d7493-3012-4ce3-b659-1c755d832cdd" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_ae2d7493-3012-4ce3-b659-1c755d832cdd_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">9.</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Leases</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Operating leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In April 2024, Gyre Pharmaceuticals entered into a lease arrangement for its new corporate headquarters, an approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b99528d-50dc-4d50-b150-f87983b03241" contextRef="C_7a06ddc6-8a57-4cf2-a967-1f3297552aa6" name="gyre:SquareMeterAreaForOfficeSpaceUnderLease" unitRef="U_sqm" decimals="INF" format="ixt:num-dot-decimal">2,130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> square meter office space in Beijing, PRC, which lease is set to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_24997a32-4a5b-4930-86f7-f9c5700a1c7a" contextRef="C_761f52b8-1b53-40ce-8a99-390c026c9793" name="gyre:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">June 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. In 2022, Gyre Pharmaceuticals secured a lease for an office space of approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56f64288-7207-4f28-b230-1158a3fda502" contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf" name="gyre:SquareMeterAreaForLaboratoryCenterUnderLease" unitRef="U_sqm" decimals="INF" format="ixt:num-dot-decimal">180</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> square meters in Zhengzhou, PRC, which was renewed in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_c46f1833-ee01-4c87-bc4e-2413b411d516" contextRef="C_2552ff66-c519-4434-b8ac-87bd1b2941d2" name="gyre:LeaseRenewedMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">July 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and is set to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_0f0ca66c-782e-4e68-ba86-70a1102b5dab" contextRef="C_2552ff66-c519-4434-b8ac-87bd1b2941d2" name="gyre:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">August 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. In November 2024, Gyre Pharmaceuticals secured a new lease for an office space of approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89e07186-922d-4e83-8f59-c9aaa1ee9177" contextRef="C_fce1ab14-263e-4f06-8e6c-95e2226660e4" name="gyre:SquareMeterAreaForLaboratoryCenterUnderLease" unitRef="U_sqm" decimals="INF" format="ixt:num-dot-decimal">224</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> square meters in Shanghai, China, with the lease set to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_b72d39e1-35ad-4d92-967b-49394541bd5a" contextRef="C_1c9a63af-c293-421c-835a-b808c5bda6ff" name="gyre:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. In November 2023, the Company secured a lease for its U</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.S. headquarters in San Diego, California, with the lease set to expire in the </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_a5e3a326-17c6-4924-b500-780170a688d9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">first quarter of 2027</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_ae2d7493-3012-4ce3-b659-1c755d832cdd_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company also has multiple short-term leased properties used as offices and employee dormitories. The Company recorded a total of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd997bb-2e60-40f7-b8e0-87efcdb37e44" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">68,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_701d8a77-7d44-45ff-b2d7-9955314e2b5e" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">89,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> short-term rent expenses during the years ended December 31, 2024 and 2023, respectively. The short-term rent expense amounts are recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company recorded an aggregate ROU asset of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d0c77df-0f4d-4a9d-a53a-f332ee187760" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and an aggregate lease liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_875762c9-5c36-4e84-a8dd-717ec86f4f97" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rent expense related to operating leases was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4382d10-7908-4912-83ae-c41f2e874f90" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_789bec90-9477-4e54-a09a-dc35d7142a22" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, and 2023, respectively. Variable lease payments for the years ended December 31, 2024 and 2023 were immaterial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_9a635ec8-88b2-44d2-a3fa-b15cb58d74cc" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.04%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cc3dacd-b522-4d26-8b79-3ca58ae3e4cf" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">872</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f0edd95-4597-42ea-88c0-a1bc51fb12a7" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">573</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_1920f69c-e437-4798-86e7-593144caa927" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The present value assumptions used in calculating the present value of the lease payments were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.687%;box-sizing:content-box;"/>
        <td style="width:14.141%;box-sizing:content-box;"/>
        <td style="width:2.02%;box-sizing:content-box;"/>
        <td style="width:14.141%;box-sizing:content-box;"/>
        <td style="width:1.01%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_42206722-e60f-4e5f-b103-222b77be99b3" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_36b331d6-3af1-458d-8221-8f2e53dc2a0e" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#ffffff;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1740976-b6c7-44e4-a717-d01ed1f7023e" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_438a1794-e702-4472-95c6-a99572a0f608" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_404557b4-ccfb-4f4f-aa34-276deada1169" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, undiscounted future minimum payments under the Company&#8217;s operating leases were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:83%;box-sizing:content-box;"/>
        <td style="width:1.84%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29cd39e5-8ee2-4351-a147-b9767b6787e7" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">782</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf0f0788-398c-465e-b238-f2cecabf9aca" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3f5d538-0711-4e93-84a4-08d855df49e4" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">279</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba9d29dc-4269-44bf-b227-3c42c4343779" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,692</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934fc1ff-0b56-4279-a8b7-0a93f3878ed9" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f93cd17a-c651-4a60-a29a-bc10b09d6b72" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,598</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: current portion of lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0bed329-1c28-4da8-9aec-50cded469884" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">713</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Lease liabilities, net of current portion</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c3730de-5554-4c6b-95cb-7126a7b26b60" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">885</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is required to maintain security deposits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_beddf837-d156-4851-824b-530da5bf02df" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> in connection with various leases, which amounts are included in other assets, noncurrent on the Company&#8217;s consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Land use rights</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company held land use rights for two land parcels in Beijing&#8217;s Shunyi District, expiring in 2053, and in Cangzhou, Hebei Province, expiring from 2067 to 2071. These parcels, with a combined area of approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a3afba3-eb62-4ea7-a6a8-9fb386b84d4a" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" unitRef="U_sqm" decimals="0" format="ixt:num-dot-decimal">66,559</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> square meters, are utilized as manufacturing facilities. As of December 31, 2024, the aggregate recorded land use rights, net assets for these parcels was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9afa38b1-5f1a-4b20-a8f9-b92d3b5f186a" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:LandUseRightsNetAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div><ix:nonNumeric id="F_e6c064d9-8369-43fd-872d-e5d1312bd3f7" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_e6c064d9-8369-43fd-872d-e5d1312bd3f7_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the Company&#8217;s amended and restated certificate of incorporation, the Company has </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d83cd10-61d6-421b-b645-d4a48ac94c3c" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_33ac202e-54e0-4b89-9e82-646534a1a4fd" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">400,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Common Stock authorized for issuance with a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_159673c0-d4ac-409f-8a6d-a2c43b9f8415" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_aa2ba5ed-1c60-458e-b5d6-48b7916e54c3" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> par value per share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. The holders of Common Stock have voting rights equal to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_ad8c8b58-2dd2-4ff8-b51a-3ae2b87f22ec" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">one vote</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share of Common Stock held. The holders of Common Stock are entitled to receive dividends when and as declared or paid by the Company&#8217;s board of directors.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_e604aa26-ba81-41c6-b688-a1bd578c4b1a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.38%;box-sizing:content-box;"/>
        <td style="width:1.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:20.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ba7e61f-e0c9-453f-b1eb-4d582812e893" contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,767,332</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preferred Stock Warrants issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eeaeac0-861b-4818-bfaa-f4faa85ff36f" contextRef="C_fe14599d-907f-447e-be99-9689d7f34472" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">540,666</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a42831-1aef-4278-a58e-d9f2ebedea08" contextRef="C_40f3484c-5a7d-4fad-9c74-3ddeb2ee3ca3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">540,666</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bc06cc7-be2c-4203-b87b-21235f95744e" contextRef="C_0694c0b0-9199-4cf1-86b8-378fc929e7fa" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,077,869</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">[1]</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d4afb78-6534-445b-b894-aef5ac38b7ff" contextRef="C_ce07c61e-a68b-4a21-856c-80d6f63dc861" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,280,548</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total Common Stock reserved</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f127fd1-11a7-4cc8-9204-ab5b2b428a47" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,618,535</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4af882da-a2ad-43ee-b723-3c6f7242067e" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,588,546</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">[1]</span><ix:footnote id="FNT_775f804e-b10d-499a-afe9-f05a8b8a2ac7" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Includes </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3951a9cb-95a3-4402-8a2d-463c51b29c74" contextRef="C_86b63a2c-389d-4950-a678-157a2397918e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,304,898</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> options exercisable for shares of common stock, which underlying shares of common stock were transferred in the name of the Company to Futu Network Technology Limited, the stock plan administrator of the 2023 Omnibus Incentive Sub-Plan for Chinese Participants.</span></ix:footnote></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">2024 ATM Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On November 27, 2024, Gyre Therapeutics, Inc. entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;) with Jefferies LLC (the &#8220;Sales Agent&#8221;) as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of Common Stock with aggregate gross sales proceeds of up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20623e8a-00ef-439f-9fe6-d02cb8129afc" contextRef="C_e852315e-c976-4feb-af38-ee2ba333da3a" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> through an at-the-market offering program (the &#8220;ATM Program&#8221;). The Company will pay the Sales Agent a commission of up to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb20fda6-a35b-41a9-9749-5e05fd2d5e89" contextRef="C_c4c9bfee-5e03-4161-8738-c6867fc7060c" name="gyre:PercentageOfCommissionForSharesSold" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the gross proceeds of any shares sold. The Company also agreed to reimburse </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the Sales Agent for certain expenses incurred in connection with its services under the ATM Agreement, including up to $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c463db7d-0535-4d7e-a79d-3d31b806cb6b" contextRef="C_e852315e-c976-4feb-af38-ee2ba333da3a" name="gyre:LegalExpensesIncurred" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">135,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for legal expenses in connection with the establishment of the ATM Program. During the year ended and as of December 31, 2024, the Company sold </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0012445-ac51-49df-834f-5091dbda930d" contextRef="C_63ac599f-e0eb-4b2e-8ae3-eadeb59bf215" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">70,267</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Common Stock under ATM Program and received net proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92832966-3a0c-49fc-b62f-953b3b055338" contextRef="C_63ac599f-e0eb-4b2e-8ae3-eadeb59bf215" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, after deducting commissions and offering costs of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01a7a84f-de30-4ad8-b49b-639ec3c3e393" contextRef="C_63ac599f-e0eb-4b2e-8ae3-eadeb59bf215" name="gyre:CommissionsAndOfferingCosts" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.02</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sales of shares of Common Stock under the ATM Program may be made pursuant to the registration statement on Form S-3 (File No. 333-283237), which was declared effective by the SEC on November 22, 2024, and a related prospectus supplement filed with the SEC on November 27, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Net Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under PRC laws and regulations, Gyre Pharmaceuticals is subject to restrictions on foreign exchange and cross-border cash transfers, including to parent companies and U.S. stockholders. The ability to distribute earnings to the parent companies and U.S. stockholders is also limited. Current PRC regulations permit Gyre Pharmaceuticals to pay dividends to BJC only out of its accumulated profits as determined in accordance with PRC accounting standards and regulations. Amounts restricted include paid-in capital and the statutory reserves of Gyre Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The aggregate amounts of restricted capital and statutory reserves, which represented the amount of net assets of the relevant subsidiaries not available for distribution were $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58f65311-8af1-4f5b-b17a-5cc396c50134" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">64.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b98c809-b18e-4de1-84e7-f7d6f240cec3" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">64.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_e6c064d9-8369-43fd-872d-e5d1312bd3f7_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As a result of the above restrictions, parent-only financial statements are presented in Schedule I.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Statutory Reserve</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals is required to set aside at least </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56dbda11-c684-4c19-a1d7-d4626f5b73b8" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:StatutoryReserveFund" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% of its after-tax profits as the statutory reserve fund until the cumulative amount of the statutory reserve fund reaches </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaf4cfbe-2f82-40a7-9c47-97ad93fff68d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:CumulativeAmountOfStatutoryReserveFund" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% or more of its registered capital, if any, to fund its statutory reserves, which are not available for distribution as cash dividends. At the Company&#8217;s discretion, the Company may allocate a portion of after-tax profits based on PRC accounting standards to a discretionary reserve fund.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76707d0e-51aa-46ef-9a93-b799a4af6a5c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:AppropriationsToStatutoryReserve" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_736168c1-47e5-4f3e-96f8-6069d0e407d7" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AppropriationsToStatutoryReserve" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> appropriations to these reserves during the years ended December 31, 2024 and 2023.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_f75203e3-bc2a-48c2-b355-84614fa5a283" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:PreferredStockTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">11.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In December 2022, Catalyst issued an aggregate of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7730094b-b911-4d78-95b4-00ed325723b9" contextRef="C_21d9722b-ebb3-4d75-9c08-5b1c34dda6b9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,340</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock to GNI Japan and GNI HK in connection with the F351 Asset Acquisition (see Note 1 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Organization and Nature of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">), which were subsequently transferred to GNI USA in October 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In October 2023, immediately following the closing of the Contributions, the Company issued </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e0fb8ba-4370-41e0-8e76-394add5630ec" contextRef="C_637be181-9ac9-483b-8aeb-4f4857ea30c6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7ffebba-5361-47ed-8052-598c0f1cafc8" contextRef="C_e345ba39-3b04-455d-ae09-666d8d8b33bd" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Preferred Stock Warrants to GNI USA under the Private Placement. For additional information, see Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In November 2023, GNI USA provided notice to the Company to convert its </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d618e590-e1eb-496b-a4c8-87eff78a9c89" contextRef="C_7c56d128-f56c-40e8-9eed-aee500526cb8" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock. Each share of Convertible Preferred Stock was convertible into approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_709e78a9-7820-4ce0-988c-4a45733233bc" contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">666.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock. On January 22, 2024, subject to the terms and conditions of the Convertible Preferred Stock Certificate of Designation, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75a5ffcd-5732-4c43-a716-14747106ec76" contextRef="C_fb2f86f7-6be0-48e5-a0e5-ce77738921cb" name="gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,767,332</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Common Stock were issued to GNI USA upon such conversion.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div><ix:nonNumeric id="F_0ef81c40-f1e1-4331-b1b3-4d9cf58a1d64" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_0ef81c40-f1e1-4331-b1b3-4d9cf58a1d64_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">12.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock Based Compensation</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Omnibus Incentive Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The 2023 Omnibus Incentive Plan was approved by Catalyst&#8217;s stockholders in August 2023 and ratified by Gyre&#8217;s board of directors (the &#8220;Board&#8221;) in October 2023. The 2023 Omnibus Incentive Plan became effective on October 30, 2023. The 2023 Omnibus Incentive Plan permits the Company to issue up to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b093db1e-a747-456b-9fe1-9671e72ca9d4" contextRef="C_707b6aef-326f-458f-9f18-b11e1ee9ee78" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,845,496</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock and will automatically increase by the lesser of (i) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9738190d-09cf-4904-b602-e4ee6d3e53c2" contextRef="C_4b697f59-a7d2-4358-9a63-af70187de963" name="gyre:PercentageOfOutstandingSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% of the total number of outstanding shares of common stock on December 31st of the preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board on the first day of each fiscal year beginning on January 1, 2024. On January 1, 2024, pursuant to the automatic increase in the number of shares reserved, an additional </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5367ccce-4b37-42df-833a-6e39ef977f7b" contextRef="C_9059de58-0342-483c-bb12-68f46c8efdab" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,829,780</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved and made available for issuance under the 2023 Omnibus Incentive Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0ef81c40-f1e1-4331-b1b3-4d9cf58a1d64_1" continuedAt="F_0ef81c40-f1e1-4331-b1b3-4d9cf58a1d64_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity considering the conversion of Gyre Pharmaceuticals options to Gyre options to purchase shares of Gyre common stock upon completion of the Contributions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_8d3db45b-3fdc-472a-b1c1-0eb8caf0e40e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.521%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:20.759%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.67%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.151%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.031%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.738%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.031%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Number of Shares Underlying Outstanding Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-Average Remaining Contractual Term (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value (thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Outstanding &#8212; December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9535ff1a-0557-45ad-840a-e85c65f618f6" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,280,548</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc815794-8a73-46e6-9b1e-c603d760bbec" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.49</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_8b5fe38b-25f4-445a-83e6-8a284bc19617" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c39a4bc7-31f2-4815-9b22-f63ddf2ad997" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,197</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_023e5e09-15d7-4f53-b39a-7b30c4d8a147" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">680,732</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff30c48f-1eff-4d69-a031-028eb4f788fe" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a957b097-3573-4dff-bed5-8d8f678436d5" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">874,328</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f201565-3603-42a5-b65e-253b9f17d67f" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.13</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options forfeited and cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db4fd7fc-3f95-4254-a380-c6ecae622ae1" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,083</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9317257d-9cb3-4b4c-8cec-15d0ed7b7ecb" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.24</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Outstanding &#8212; December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf98a530-53ff-4736-a522-a35389656437" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,077,869</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32930c21-a38b-491e-9bf2-51bd740e55bc" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.75</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_128702f7-b6e6-4fe7-98fa-d5787cf994ca" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06997f2b-ce15-469d-b73b-b39008168ac9" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Vested and exercisable &#8212; December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b39b018e-d54b-4088-92aa-88949792422d" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,458,607</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_943e7835-86f9-470e-a8b5-49b241fe1136" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.48</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_f57503af-e38c-4903-ab9d-857a0dea69a2" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_915e3a6f-2323-4da1-86f8-547d9e7d7024" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189,054</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_c1ce74d7-411e-4cdd-99dc-a9916db9a939" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0211fd4-116a-4057-a0db-e912389922f0" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share for the years ended December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a67b4c91-27ff-4b71-8850-8ba03f7eb84b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a1483a8-0c5a-431e-84a8-aa3ce4f99986" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value of all equity awards that vested during the periods ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_214e7071-0502-423e-afa6-79b8129280ee" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_777ddfe5-3ab6-4dcd-ad15-0a70fd4c7356" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash received from the exercise of options was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18b33b6d-ae29-4a6a-ae83-72459cb8737a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14b38b97-544b-478d-b7a3-d712181e5511" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and 2023, respectively.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0ef81c40-f1e1-4331-b1b3-4d9cf58a1d64_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation Assumptions</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited relevant historical data, the Company estimated its volatility considering a number of factors, including the use of the volatility of comparable public companies. The expected term of options granted under the 2023 Omnibus Incentive Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited relevant history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_12688adc-6717-4d25-8756-4bb9cc2e52f5" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value of employee stock options granted was estimated using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.151%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:19.904%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:19.284%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected volatility (%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a51c1bea-73e8-4c3e-9fd8-2340f3b7fc44" contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_129ff156-24e8-4467-9ea7-d3284060f99f" contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.30</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc86fc3-964b-4e21-861d-35b8651b7b06" contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a264aa4e-15d8-4410-afa9-78f0699e0d86" contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.30</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk-free interest rate (%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11cd20bd-76a5-4994-8c9a-6a9c9f757d70" contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_629c11ab-1f8f-46aa-b5b0-25103d0401f9" contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.22</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00b17808-1363-4cff-ab63-b32be7124db9" contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5329bdf4-09cb-49fe-bf03-f0493ac757ed" contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.77</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected option life (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_0d078081-87d1-474d-84b0-a22654021b51" contextRef="C_19def526-bb67-4646-b79c-ffcf90c9dc23" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_f367b770-8a07-48a6-a0de-222f4dfd333c" contextRef="C_c56613f3-6432-437c-9bab-9101a3786a66" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_b2877ba7-7a78-4195-ae8a-49da19a575ae" contextRef="C_893c5230-daf1-4851-a6bd-a1088e652270" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_0e4cb2cc-77ea-4f8b-89e1-10a906966dcc" contextRef="C_b6236476-6e75-4438-a794-f025b4ae1817" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.8</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected dividend yield (%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average share price of the Company (USD per share)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f1d7b76-7a61-4900-a99f-c7d18a4c52c9" contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16" name="gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a770a051-5a62-4bf4-b5aa-5b6b06e5c47c" contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690" name="gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.93</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_c4254ba8-3ffa-445c-b614-ae686447539d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total stock-based compensation recognized was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.42%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b667b7d7-7c03-443b-a473-fcc56d9a0272" contextRef="C_e5513b2b-c8d0-4816-81a6-d83601aee525" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a59b5f84-b15f-4fd8-a812-6f4faffacabc" contextRef="C_c3036813-c367-4137-83bc-d3111a243c9e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aefbca92-1eaa-4530-9e68-2858176f0693" contextRef="C_49f4dab9-8bd1-4577-b767-6356a5621a2b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1098d157-d10c-4dca-a6d1-b3a030147347" contextRef="C_cc77e3d6-0b6d-4809-98bc-ba50dc57d0e8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4694084-8504-4df9-970e-e258c9c96b6f" contextRef="C_28b79e15-5ce4-4bf9-8af0-0a1821e83289" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,404</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_465710c7-8529-4c45-aba0-695b69af3585" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_564dbf4b-bad9-4343-ae31-89493baaed0f" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had an unrecognized stock-based compensation expense of $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28760abc-8b9c-41db-99c2-887240964609" contextRef="C_27c77b10-4086-4da2-b416-c9b80579f835" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_889f6ba6-94d2-4120-b82c-332bd3c190fa" contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">years.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div><ix:nonNumeric id="F_69411f87-1fd0-4d3b-b6ac-ff22a180d76d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CommitmentsDisclosureTextBlock" escape="true" continuedAt="F_69411f87-1fd0-4d3b-b6ac-ff22a180d76d_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">13.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Value Rights Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Each CVR under the CVR Agreement (see Note 1 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Organization and Nature of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) entitles the holder to receive (i) certain cash payments from the net proceeds related to the disposition of Catalyst&#8217;s legacy assets, (ii) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_983de2ce-22c3-4198-ad48-d12e6adefc73" contextRef="C_b7908f32-a52a-47b5-a0f7-73f8bc7e1786" name="gyre:PercentageOfExcessCashOnDispositionsNet" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by the Company in excess of $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed5ec1ff-baa8-4595-9ce8-8d5d801d2f2f" contextRef="C_b7908f32-a52a-47b5-a0f7-73f8bc7e1786" name="gyre:ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million as of the closing date of the transactions under the Business Combination Agreement, (iii) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d240cf6e-116a-48b0-bd5a-be0b113b9357" contextRef="C_003c57ab-d9dd-422e-bacb-9a242555faac" name="gyre:PercentageOfAmountReceivedOnAgreement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% of the amount actually received by the Company, net of expenses, pursuant to an asset purchase agreement Catalyst entered into with Vertex Pharmaceuticals Inc. (&#8220;Vertex&#8221;) in May 2022 and (iv) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b72160ac-4339-4972-8c1a-6682281ae6b7" contextRef="C_b7908f32-a52a-47b5-a0f7-73f8bc7e1786" name="gyre:PercentageOfExcessPreapprovedCosts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">of the excess amount, by which the preapproved costs to manage, negotiate, settle and finalize certain third party claims exceed the costs actually incurred with respect to such claims. The CVRs are not transferable, except in certain limited circumstances as provided for in the CVR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_69411f87-1fd0-4d3b-b6ac-ff22a180d76d_1" continuedAt="F_69411f87-1fd0-4d3b-b6ac-ff22a180d76d_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agreement, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In June 2023, Catalyst fully settled the CVR payments related to the Vertex asset purchase agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In February 2023, Catalyst sold its legacy rare bleeding disorder program to GCBP. As a result, the Company distributed the net cash proceeds received from the GCBP asset sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc668d6f-9ca5-4aff-96cb-73620d031cf8" contextRef="C_55971d12-0611-489b-9033-d8d1ebf17458" name="gyre:DistributionFromAssetSaleProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to the CVR Holders as well as recorded a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_332039b0-be7b-4b06-a9e1-50dbfde1b571" contextRef="C_838330c8-c71e-4fe2-a49f-e6fc75cb5071" name="gyre:ContingentValueRightsDerivativeLiabilityNonCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> long-term CVR derivative liability for the future distribution of the hold-back amount to be received in May 2025. As of December 31, 2024 and 2023, the carrying value of the CVR derivative liability was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f12fa9b4-a387-4dcd-b089-f6a3e98f13ee" contextRef="C_f5361373-7c92-419e-8bf7-87b01cbf8a00" name="gyre:CVRDerivativeLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95627c8d-c732-440b-8e0d-07ce4c7412c6" contextRef="C_10dfd633-6fab-4fb0-bb22-6722bb1f66cb" name="gyre:CVRDerivativeLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> on the consolidated balance sheet, respectively. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for additional information regarding the CVR derivative liability and GCBP asset sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On October 30, 2023, pursuant to the CVR Agreement, the Company recorded a $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e18b447e-67c9-40ab-9d64-b0a5e16b6af6" contextRef="C_cef73343-7eb4-4d39-88e9-9171f4dd709f" name="gyre:ContributionsClosingPayableAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> CVR excess closing cash payable upon closing of the Contributions. During the first quarter of 2024, the Company received a settlement related to the CVR litigation, and on August 26, 2024, it distributed approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49b3569e-3d26-4a03-bff7-a9b218111a44" contextRef="C_d65a54be-e60b-44d6-9d6e-c5423744feb5" name="gyre:DistributionsToHolders" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d434a98e-9130-46c9-ae03-59ab6969573d" contextRef="C_d65a54be-e60b-44d6-9d6e-c5423744feb5" name="gyre:DistributionsToHoldersPerCVR" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per contingent value right) to the CVR Holders. Subsequent to the payment, the CVR Holders have received all requisite cash payable under the CVR Agreement and there are </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ed00197-6038-4675-a68f-a302d49690a7" contextRef="C_f5361373-7c92-419e-8bf7-87b01cbf8a00" name="gyre:RemainingOutstandingBalanceOfAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> outstanding distributions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation and Legal Matters</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company&#8217;s consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Purchasing Commitments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s commitments related to purchase of property and equipment contracted but not yet reflected in the consolidated financial statements were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b19227e1-c447-4769-a3a6-a7a01130e722" contextRef="C_5c3e3497-8c9f-4117-820b-ed5757b69655" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2024 and were expected to be incurred within one year.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">F351</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In September 2020, Gyre Pharmaceuticals entered into an intellectual property (&#8220;IP&#8221;) transfer agreement (the &#8220;F351 Transfer Agreement&#8221;) with GNI Japan and certain of its wholly owned subsidiaries (the &#8220;GNI Group&#8221;). According to the F351 Transfer Agreement, Gyre Pharmaceuticals acquired the exclusive right to use Hydronidone IP rights in mainland China and the right of first offer for the global IP rights (the &#8220;F351 IP Rights&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the F351 Transfer Agreement, in exchange for the F351 IP Rights, Gyre Pharmaceuticals is obligated to pay GNI Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5dd1391-e3c8-4248-bfdc-d58d72730d0c" contextRef="C_a03ee1e8-f246-42c3-b72d-81a753170a1d" name="gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> upon submission of the F351 New Drug Application (the &#8220;NDA&#8221;) to Center for Drug Evaluation of the National Medical Products Administration (the &#8220;NMPA&#8221;) of the PRC, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd7e0b56-2a47-41ee-89cb-ca63ede7c07e" contextRef="C_f74c758a-d9fd-40e2-85f1-d6a87ddcc5dc" name="gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> after the NDA passes the NMPA&#8217;s Center for Food and Drug Review and Inspection&#8217;s on-site registration inspection for the F351 product, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7191048-87d4-48c0-85b9-0bae6dc6b076" contextRef="C_f5d8eb54-6979-4f3e-9be6-d8a1a8ec48fa" name="gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> upon NMPA&#8217;s approval of the NDA. As of December 31, 2024, the payment conditions have not been met, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b0f91b3-578c-4db7-89d4-f1a6fc04e7cd" contextRef="C_3196cc03-d5f3-4937-bff3-52b2ec055f70" name="gyre:PaymentsForExchangeForIntellectualPropertyRights" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> payments have been made.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Programs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition to the F351 program, as of December 31, 2024, the Company has committed to allocate </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4837564b-fd91-4ae5-910b-182e3cb701b2" contextRef="C_151e32fc-1c63-4e3f-9240-08cf605db0d4" name="gyre:CommittedToAllocate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> toward future research and development activities for various programs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_69411f87-1fd0-4d3b-b6ac-ff22a180d76d_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, the Company may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div><ix:nonNumeric id="F_9a1b71af-6c02-499d-bc52-6f7154868921" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_9a1b71af-6c02-499d-bc52-6f7154868921_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">14.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income Taxes</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_8c3643f6-a2bf-48c0-9233-78a42ccdaacf" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The components of the Company&#8217;s provision for income taxes for the years ended December 31, 2024 and 2023 consist of the following (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.094%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.123000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.123000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current income tax provision:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f485ca4-e5ef-46cd-80ea-707032987732" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d408b0b-990f-4a44-9839-df276040106a" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c039ff89-4142-4f6a-897c-b68cec7fc997" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc95f2ef-d6c5-4663-85b4-e56ba1b2548e" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,343</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total current income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51ad1700-4729-4c19-92f0-f162e13fc9d3" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,322</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b955e44-c38e-4923-ae26-eaf696b2b73b" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,349</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred income tax provision:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d3c8847-5d3c-4b33-b697-5df5c251ffe7" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f441237-f50d-43b7-9c25-9e3a6b9ee68d" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">834</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total deferred income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18ddc54b-cfb7-4346-a3c5-eb50e85f511d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c02bcf4-0d34-43c3-8dd7-dda7ecb05da4" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">834</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83b1e05b-6f1c-4d43-8426-1e090da7ca58" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e84bb7d-165a-4b70-b764-ab48e40c7790" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,515</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_ecc355fa-1daf-430f-80db-2e0a3e032780" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December 31, 2024 and 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.987%;box-sizing:content-box;"/>
        <td style="width:16.217%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:15.137%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d5085ff-deaa-46be-bad1-0d6654958a05" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b11fb370-4927-44e4-8251-9cc8d8186aeb" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rate difference due to different jurisdiction</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7742668-daec-4dc8-ac2c-67b3cd2b1e4c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8adf0f0-4d4e-40c3-9a17-88237b1bd7f7" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">2.43</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preferential income tax rate for HNTE</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01a4c09a-dea4-408c-9e42-4087c5d07bf1" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">9.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a9674a2-5388-4711-9140-11ba176da45f" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.19</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-deductible expense &#8211; Operating</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_553defcb-b9cc-43c2-9e72-ab0494127f2d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ad8c050-4e3b-45ae-b809-684d5657263e" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">6.28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-deductible expense &#8211; acquisition related</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_811bd764-35f6-4cd5-a929-6edcf9b1024c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a941b3a-e647-4d58-b161-03662d232063" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">22.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">R&amp;D Super-deduction</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b63500ea-2722-4e9f-a1b3-24cccf4a45d9" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92876279-34dc-4434-a426-ba617265de2a" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">1.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Valuation allowance change</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba9010f2-5800-4fca-8695-c26f4c21e278" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_894fc20e-2c38-4db2-b5fe-350ef475a0fc" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">4.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ESOP</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3edc42a-485a-437e-8227-45b0c35172de" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_572b69f5-c4f4-49d3-bedd-9a1f5a5ad804" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_195685f0-c685-4865-90b0-3cdf74a77eee" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.02</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4a3af06-d91c-47ed-b19d-6af276b714a9" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e693f30-f4d2-4fca-bda4-ec1b9e1972d3" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">22.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65e4e40c-a683-4441-bd89-f3eda026ace2" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">10.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_9a1b71af-6c02-499d-bc52-6f7154868921_1" continuedAt="F_9a1b71af-6c02-499d-bc52-6f7154868921_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_8fe242ac-db8d-4da7-985d-18d7f2e897f6" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> December 31, 2024 and 2023 consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.066%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.136999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.136999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7482204-c273-4016-b221-5a4b5dc72a19" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5487c13-e7b0-4ad7-9837-2232dbcd9c94" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,811</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb8221d5-c530-4e2b-97d7-72b90e788f97" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredTaxAssetsContractLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">153</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f724f1e-852d-47e5-9906-024bac2cae97" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredTaxAssetsContractLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a427d1f2-e00b-49ca-bc7a-b15c95da3230" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,714</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8be29188-39dc-4d8a-82f4-6f148aaa58cd" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,669</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Tax credit carry forwards</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c62be00-cec3-4c6a-8852-dd31a8e6ff4d" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,463</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de2d2d5a-e716-40cd-adc6-0b08297dea3c" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,463</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fixed and intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b7cb18f-fa0e-4c45-8408-46b36fbd5f92" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredTaxAssetsFixedAssetsAndIntangibles" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,385</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c89e7efb-bc59-43f8-9f6e-de769bb55c26" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredTaxAssetsFixedAssetsAndIntangibles" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,332</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Impact from foreign corporations</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f82cbf1-c25f-480b-8c90-a9afd6cb4075" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredTaxAssetsImpactFromForeignCorporations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,754</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd5ed119-7c30-4975-9e85-1f8f11d416de" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredTaxAssetsImpactFromForeignCorporations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,590</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Capitalized transaction costs</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8d6deb4-bdc4-4669-b935-b5d1f21e1c57" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredTaxAssetsCapitalizedTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">430</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92c66c6d-5227-4052-9dcc-5d32168f3286" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredTaxAssetsCapitalizedTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">658</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54fab19d-c4f5-43ed-852b-76eac32bd01d" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9b0208c-68a6-40db-914c-a338aebfca0d" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred income tax assets before valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3f260d9-1396-41fc-87cb-d86d8e15cbb6" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,594</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b16186d-be30-4de2-8c9a-a3d65bd9aeab" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,660</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax liability &#8211; ROU assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_924a56b3-bf49-4188-a0dc-0c52e894e814" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="gyre:DeferredTaxLiabilityRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc5ce49c-8381-4000-ac30-ab9a8820b5eb" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="gyre:DeferredTaxLiabilityRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax liability &#8211; Fixed assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_566291af-1fc3-4cae-8ff1-972987968faf" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_026efd20-feea-4f13-8a66-348f255bc578" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7495a019-918a-4d9e-bc15-3e0dfde0759f" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,605</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09996313-825b-4cdc-8553-77490b30de52" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,773</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_659e39a7-7e3f-464d-832c-fff6b68b7a53" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,619</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38825961-fc7a-43fa-bea6-91e771e39e6d" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,695</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_35bfcb11-c260-48f9-89f1-0fb0384bb61c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SummaryOfValuationAllowanceTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The movements of the valuation allowance are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.677%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.424%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.01%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.889%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8766e012-b035-403e-a6d8-4f379928c746" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,773</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes of valuation allowances</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52de0c9a-1a18-4897-93f8-16216c0a1327" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ChangesOfValuationAllowances" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,832</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fa23bc2-fea7-4d6a-b501-2381f465eedf" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:ChangesOfValuationAllowances" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,773</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46acf859-e6b6-425a-86c4-3f57ae8ea806" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,605</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19713498-9254-431c-9d78-aaeeb64cc074" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,773</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on the available objective evidence on December 31, 2024, the Company does not believe it is more likely than not that its net deferred tax assets will be realizable for US tax purposes. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets on December 31, 2024 for U.S. tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, after consideration of certain limitations (see below), the Company had approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0314a848-0198-4515-b4d4-5ba2a11ed047" contextRef="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">193.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million federal and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa37bc36-2618-4d19-ba8f-210478fe2d2a" contextRef="C_e3f9ca20-fe6e-464e-88fe-e2cdb2bbeb47" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, will begin to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_d56aa348-3ec3-40ca-82de-15bf277e373f" contextRef="C_18a964f8-b880-42dd-8893-8c908e72943e" name="gyre:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for federal and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_c3a0ab1c-d86f-48fa-b199-ede618c6ed78" contextRef="C_aaa537e5-aadd-401c-b660-aedaa53b9b03" name="gyre:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2034</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for state tax purposes. The federal net operating loss carryforward includes $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b06f4e4d-71b2-4c83-a2f6-9aa04fbb5945" contextRef="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c" name="gyre:OperatingLossCarryforwardsWithIndefiniteLife" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">191.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million that have an indefinite life.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_791a4a6e-157a-42b0-ba03-8fa3e3d7a660" contextRef="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">8,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for federal and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9d20303-a5b8-40da-9889-223e24ccbe5a" contextRef="C_e3f9ca20-fe6e-464e-88fe-e2cdb2bbeb47" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for state. If unused, the federal credit will begin to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_bbe667c5-33ce-4162-ae5f-45502060198d" contextRef="C_18a964f8-b880-42dd-8893-8c908e72943e" name="gyre:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and the state tax credit does not expire.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company&#8217;s stock immediately before such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes under Section 382 occurred on December 31, 2007, August 20, 2015, April 13, 2017, February 15, 2018, February 18, 2020, and December 26, 2022. Approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b20cada1-da38-4ed1-825d-197596dc0ff5" contextRef="C_2f70b255-6cf8-4fea-a0c2-53d777ed397c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">156.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa244039-102b-49a7-891d-98f569cd96ca" contextRef="C_c554efd0-8c25-49d5-887a-c4fae5255da6" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">75.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">of the NOLs will expire</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_9a1b71af-6c02-499d-bc52-6f7154868921_2" continuedAt="F_9a1b71af-6c02-499d-bc52-6f7154868921_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">unutilized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for federal and California state income tax purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e199c988-26bb-4968-9cec-e32009d16d69" contextRef="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c" name="gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards" unitRef="U_USD" scale="6" decimals="-5">32.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d09e81fe-d2bf-4da2-be68-83a271bd6354" contextRef="C_c554efd0-8c25-49d5-887a-c4fae5255da6" name="gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards" unitRef="U_USD" scale="6" decimals="-6">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for federal and California state income tax purposes, respectively through the year ended December 31, 2024.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All of the federal R&amp;D credits could expire unutilized, whereas none of the California R&amp;D credits are subject to expiration. Approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_753d5af9-5696-43da-b203-567acde83e21" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" unitRef="U_USD" scale="6" decimals="-5">26.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million of gross federal R&amp;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and credit carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Uncertainty in Income Taxes</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company had approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2a725c1-f6d8-4137-ad15-f6be8c7bee3f" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million of unrecognized tax benefits as of December 31, 2024. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_ea879f49-858b-4df2-a42f-c31ba391b779" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.18%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beginning Balance on January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f05be56-e786-4398-82b2-646eceedd5c9" contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase related to business combination on October 30, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cd2b021-a666-4f39-91a9-91080a50cb23" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,883</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbaefe36-349f-4942-ab42-fb1f79306ec4" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92e4ec09-ae13-4ed4-8018-3bc1ddfe1900" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ending Balance on December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ef6e9f1-0719-41a4-8364-ee79dc217422" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,883</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f88b742-642a-4cb2-ab28-098d64e1e15b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3045db3-620e-4f68-a6e2-c8cd39d2310e" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ending Balance on December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_406bc931-3862-43b1-9dff-f6abe00a46f3" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,883</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#8217;s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_472adb57-69f4-4a21-b723-67e3cef933f2" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_69ff38e2-205f-4f3e-978e-90b7714e0047" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t recognized any tax-related penalties or interest in its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the United States federal, California, and Florida for tax year 2023. The Company filed an initial return in 2022 in Florida and final returns in 2021 in Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2024 and 2023, the Company had </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2883e4ca-7969-499a-b23e-d2e830eaa9c2" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ba694843-3c9c-4b10-a4c7-1d8b094372df" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> uncertain tax positions which affected its financial position as its results of operations or its cash flow for US tax purposes, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the PRC Tax Administration and Collection Law, the statute of limitations is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_b9614409-3933-42b6-8032-7d7e5868a019" contextRef="C_ab0e6ad3-77e4-40d2-a914-3a959c431d3b" name="gyre:StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitations is extended to five years under special circumstances where the underpayment of taxes is more than RMB100 thousand. In the case of transfer pricing issues, the statute of limitations is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_342b65df-f41c-4ad2-9840-581e07a4f51e" contextRef="C_ab0e6ad3-77e4-40d2-a914-3a959c431d3b" name="gyre:StatuteOfLimitationDueToTransferPricingIssues" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> years. There is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_89458a30-1f4b-4bab-95ce-8c2641b3664a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">no</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> statute of limitations in the case of tax evasion. The income tax returns of the Company&#8217;s PRC subsidiaries for the years from </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_75917b88-e989-4b23-841e-ffaf304c0e01" contextRef="C_b931a2e4-4754-474d-9b6e-f1c8f4585e49" name="us-gaap:OpenTaxYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2019</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_7ef2aa57-1d1d-4f20-804e-856b23bd9b99" contextRef="C_8dc9cab1-3dbb-40a8-840c-8dd98ff4680f" name="us-gaap:OpenTaxYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> are open to examination by the PRC tax authorities.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_9a1b71af-6c02-499d-bc52-6f7154868921_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">APB 23</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Generally, a taxable outside basis difference associated with a foreign subsidiary may not be recognized if the indefinite reversal criterion of ASC paragraph 740-30-25-17 (APB Opinion No. 23, Accounting for Income Taxes &#8211; Special Areas (&#8220;APB 23&#8221;)) is met. A deferred tax liability is recognized when an entity no longer meets the indefinite reversal criterion. ASC paragraph 740-30-25-17 provides a presumption that all undistributed earnings will be transferred to the parent entity may be overcome, and no income taxes shall be accrued by the parent entity, if sufficient evidence shows that the subsidiary has invested or will invest the undistributed earnings indefinitely or that the earnings will be remitted in a tax-free liquidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company does not have a plan of repatriation of earnings from non-US subsidiaries to the Company. However, to the extent the Company will not permanently reinvest in its PRC business, a deferred tax liability of approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deff9164-4799-4ae4-aea2-3323b465ecd9" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 related to PRC withholding taxes on repatriation of Gyre Pharmaceuticals&#8217; earnings (i.e., the Company&#8217;s primary operating subsidiary in the PRC) would need to be recorded.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_de96861a-8acc-4cb8-b347-276a49a1b65f" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">15.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Related Party Transactions</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development with GNI Group</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development fees paid to GNI Group during the year ended December 31, 2024 were $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a51b66a0-53f5-41a8-8b7e-31ae31ccab94" contextRef="C_62f92e1d-e5a8-4fa2-9000-93f2a1b15be5" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c421633c-b717-4e4d-8a22-826eaba5a23f" contextRef="C_dc02e0a2-17b6-4879-92cf-e5b95666c954" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> research and development fees were paid to GNI Group d</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">uring the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had a $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e39659ce-3576-4724-8269-b83306b6a490" contextRef="C_c7af3ec1-7037-4691-9c1c-8e9ff94d139a" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e54a033-c6a1-4fdd-b49c-31f7b51cb0dd" contextRef="C_11e97b2b-d131-4b0d-a65f-f76a30c9fe74" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million related parties payable due to GNI Group, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Other receivables from GNI Group</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had recorded $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdc55e8b-758a-4aee-abd8-d71a89ad5e99" contextRef="C_a0d10ade-3d48-49d5-bdd7-851689590754" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million in other receivables from GNI Group, of which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_499d5d7f-8a60-4a8c-8be0-f9fb400b3518" contextRef="C_ff4a65f5-6aee-43bc-ae21-205a10de9f61" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> was from CPI&#8217;s restructuring transaction (see Note 8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">). As of December 31, 2023, the Company had recorded $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30964851-1eb9-4e2f-a22d-da53b54fcc5c" contextRef="C_2105308e-fcfa-4236-bc88-d64b4d792f06" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million in other receivables from GNI Group, of which $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92183bbc-6483-43a6-b979-bc9dbfb372e6" contextRef="C_55596a3f-d3e4-4c79-87e1-e28ba063d3f2" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million was from CPI&#8217;s restructuring transaction (see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Note 8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4c0d2cf-412c-4798-b8e8-ae698f70162a" contextRef="C_062c6dd6-59a4-4c32-8566-83e073df4f7e" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million was from Gyre&#8217;s cost sharing with GNI Group.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div><ix:nonNumeric id="F_b19a3580-d82d-4c00-98a0-f443120640a8" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_b19a3580-d82d-4c00-98a0-f443120640a8_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">16.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">EPS</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The dilutive effect of outstanding stock options and warrants is calculated using the treasury stock method. Stock options and warrants are anti-dilutive and excluded from the diluted net income per share attributable to common stock calculation if the exercise price exceeds the average market price of the common shares.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b19a3580-d82d-4c00-98a0-f443120640a8_1"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_f02a851f-60f7-45b6-9bb1-5c408f35e153" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.64%;box-sizing:content-box;"/>
        <td style="width:1.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.540000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.7%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70b6f8a1-0ec2-4bff-84bb-4c393898d5f7" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,898</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_649e7a4d-5ae2-4152-b25d-f59d1bd4f504" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f88cff84-f251-413a-822d-77e0cecbf1c3" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,813</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4f1f634-c473-4c8a-b1b4-41e204b0518a" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) attributable to common stockholders - basic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c224bf5-6859-4e61-aaeb-4e7504747994" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,085</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_513987a9-e2ff-4b19-988d-555f1d1c0793" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Less:   Change in fair value of warrant liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eae49253-60aa-4887-815c-260f0ad83aaa" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) attributable to common stockholders - diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_468667be-3f8b-4747-bdfd-392c48b4555b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,918</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_538f36cb-dcb9-4b83-b9bc-337f520663d8" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Basic common shares outstanding:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc064e9f-94e9-408f-877f-ac9a12333d42" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,094,948</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e600983a-e0a0-4b45-b7da-22ea8b05f86a" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, basic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc3c215a-076d-4513-ac65-24f2b096dc5d" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,094,948</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_903d9f3a-477f-43f4-9401-a778a4b2e689" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">            </span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dilutive potential common shares:</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a04d4e65-ad4e-4899-b700-95fc65812a18" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,407,847</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Convertible Preferred Stock (as converted)</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0e51b8e-fd05-4a49-8a5a-5a0941b1a0a4" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">528,442</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Preferred Stock Warrants (as converted)</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7a00484-f8cd-4238-aaf9-2d726ffd6fa6" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="gyre:WeightedAverageOfPreferredStockWarrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">262,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1cd1ad2-5578-4b26-a9fd-26c9c646ad30" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">102,293,526</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41472ea9-7bb3-4717-a5fd-a7d14b25a3e2" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) per share attributable to common stockholders:</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d9081c3-c53d-446f-8f3a-faf28fef7201" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6aa29583-12ee-4da2-9191-efea0bb924e5" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b67f08a6-6e55-4628-b547-ab2df81acb90" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.05</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_474dc95c-c3ce-40d7-a447-5dbf48799c2b" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:nonNumeric id="F_ef0e52a4-1d68-491f-b818-38faa4252ab2" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_ef0e52a4-1d68-491f-b818-38faa4252ab2_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.76%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.84%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c21a15c-1007-4547-97cc-aa98e0b02f38" contextRef="C_7cf186e1-972c-4665-8d9c-1bfd52550fc8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">896,960</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6436289e-fff8-495e-8592-f7727115a78d" contextRef="C_a06a4417-252f-4ba9-b828-689df30eb019" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,280,548</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred stock (as converted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e495e25-7f06-4af4-8b5b-a41bb0981974" contextRef="C_d8c5083e-baaa-4ff7-ae97-3c6730697288" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,767,332</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preferred Stock Warrants (as converted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d508f7b6-309f-47ba-9b90-7de851f3c88c" contextRef="C_9a91ad18-5e8c-4f49-bb3b-55e76625715d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">540,666</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dfd8ba2-32c1-49a0-a726-bb6d6ab5bb1a" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">896,960</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f35a58f4-075b-4d81-934b-2666241fad21" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">27,588,546</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_ef0e52a4-1d68-491f-b818-38faa4252ab2_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div><ix:nonNumeric id="F_f7043259-2723-42d9-9434-3c9db4cfee11" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:DefinedBenefitPlanTextBlock" escape="true" continuedAt="F_f7043259-2723-42d9-9434-3c9db4cfee11_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">17.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Employee Benefit Plans</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Mainland China Contribution Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to relevant PRC regulations, the Company is required to make contributions to various defined contribution plans organized by municipal and provincial PRC governments. The contribution for each employee is based on a percentage of the employee&#8217;s current compensation as required by the local</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_f7043259-2723-42d9-9434-3c9db4cfee11_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">government. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme. The total contributions for such employee benefits were $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5759a3a9-70e7-4f4d-a7ba-721693977c86" contextRef="C_7ddd47da-42c9-45c5-8866-0c39c6994ea9" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de1a1970-d1fd-4c17-a4a8-4b0d94948dd7" contextRef="C_502e4c1c-95d6-4ae7-893a-2eda77e87309" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Defined-Contribution Savings Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the U.S., the Company maintains a defined-contribution savings plan pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended. The plan is available to employees who meet the minimum age and length of service requirements. The contributions made during the year ended December 31, 2024 and 2023 were immaterial.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div><ix:nonNumeric id="F_168d8495-2362-4808-b149-fe3ad00671e5" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_168d8495-2362-4808-b149-fe3ad00671e5_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"/>
      <td style="width:93.82%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">18.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Segment Information</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is a consolidated entity comprised of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2240111a-500b-4282-b6d1-b48c47327c72" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> distinct operating segments: Gyre Pharmaceuticals </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and Gyre after the Contributions. The Company&#8217;s reportable segments are based upon internal organizational structure, the manner in which operations are managed, the criteria used by the CODM to evaluate segment performance, the availability of separate financial information, and overall materiality considerations. All Gyre&#8217;s operations are within the U.S., while all of Gyre Pharmaceuticals&#8217; operations are in mainland China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre Pharmaceuticals&#8217; product revenues are mainly generated from the sale of ETUARY and certain generic drugs. Gyre Pharmaceuticals primarily sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Gyre</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of MASH-associated liver fibrosis in the United States. Other than the IP associated with F351 in the U.S., Gyre has no other product candidates since the Company sold all of its legacy IP assets prior to the closing of the Contributions. Subsequent to the closing of the Contributions, Gyre has not generated any revenue.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Other</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other represents the financial information from other subsidiaries, consisting of mainly CPI, GNI HK, and Continent Pharmaceuticals U.S., Inc. During the year ended December 31, 2023, prior to the Contributions, CPI divested almost all of its assets other than its </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10d0da9d-9c43-467a-a3c3-e17a95ce2737" contextRef="C_21ad98a8-a7b0-4600-a53d-9f79dd8b3cbd" name="gyre:PercentageOfIndirectOwnershipInterest" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">56.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% indirect ownership interest in Gyre Pharmaceuticals (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Restructuring</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_77c19da4-5efe-4ea5-a696-d985688f8ec6" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_77c19da4-5efe-4ea5-a696-d985688f8ec6_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Segment inform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ation for the years ended December 31, 2024 and 2023 is as follows (in thousands):</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_168d8495-2362-4808-b149-fe3ad00671e5_1" continuedAt="F_168d8495-2362-4808-b149-fe3ad00671e5_2"><div><ix:continuation id="F_77c19da4-5efe-4ea5-a696-d985688f8ec6_1" continuedAt="F_77c19da4-5efe-4ea5-a696-d985688f8ec6_2">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.35%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.938%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.738000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.938%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.938%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0b8a713-798d-4979-b70f-52b2cd1dccbd" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,757</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5745eb3-75c3-4edc-953d-cb02f37a6095" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,757</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f0f8c78-cc4c-4e5c-b13e-b4c3d98679eb" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,884</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d10c6df9-e481-4261-a475-c00c293c20f4" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,884</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67235a47-8c78-4686-8e74-e2f40c06e2e2" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,873</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6da9b44-1e86-43ce-9510-2cea3e88701f" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,873</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_274e1dcc-1463-4fac-8f71-ce4715f12941" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,511</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff79ed2-2273-40b2-8bb6-0215204b58d3" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,511</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3df59929-853c-4c30-ac89-53814b6403e0" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,224</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_627f2d80-93ce-4c34-adaf-d4d24e53f280" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">800</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c0163d9-dff4-4509-b539-3bb81812219b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,024</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fbb8d23-0669-43c2-87f4-cf6194e5b6b8" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,051</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec4548fb-06f1-4ce7-887d-f9c399271130" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,056</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e6254d8-6099-4904-9a76-52c446dab696" contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e25b8c7-c531-4065-a078-cd9b25bd6de1" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,109</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66fbe23f-ac24-4059-b92b-e87399826734" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_215ee5cd-0253-4274-aaad-b34dd2f8504c" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee597467-027d-43a1-9af6-6f09ccc4c912" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,852</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e55e601-fcbf-41ce-8e6c-dfa517d54ee0" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,856</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa5c3dd3-683e-4167-894d-557af0c0c153" contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d20504e-9800-4d4b-a85d-fa81902af323" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,710</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (Loss) from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0489c76-ee7c-4293-be82-2114540fc56f" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,021</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ac38036-3f65-41bb-8b20-59bf5acf548a" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,856</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50ea9115-d9a9-4b6b-bb84-d3f14b70064a" contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05c65eb0-8e1c-4239-8939-247df6acbf61" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,163</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25255eeb-e0f2-4e35-9514-fc1a88c75091" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,321</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a0257f3-16d0-4bc3-96c9-616dbd96e546" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">232</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1fb2c63-3d1a-49d2-99cc-3553fdb3cc69" contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8b105cd-2b6a-4e27-9afa-0469242027f4" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,547</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c1110a8-6dd5-470f-93f8-69468be77555" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,329</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb441f4c-83e1-4a8d-aa90-46b934e46795" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">336</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f38450b8-f7cf-4587-bddb-db605352bcb6" contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5040d3c0-2bcf-4469-8949-b27da84c6123" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,659</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d797daf3-4e2e-4af4-8d6c-64f8b5c1863a" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e89c28e2-bca0-4e07-a96f-05a5ca888089" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c9e95c7-a2be-489f-9452-1175b7e39a5e" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,318</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1db12ea3-2bb8-42f1-9649-f53414143874" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_794cfacc-7af9-4b2b-89d1-156f7f6a1aef" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8fde14a-1191-4d06-83b9-5919a5ca1816" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,695</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c26c635-8baf-4ae2-b0dc-e7a66bc50147" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,205</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db30e4ec-401d-4409-89a3-e15571ee6cca" contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5271396-1bf6-4a5f-bf6d-3421410c7f27" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,898</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2316d2bd-fbb4-416e-90d4-dafa6f147735" contextRef="C_22f0fc96-1e38-40b1-9a23-4191cce058e8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c98e5f57-e986-4c76-bc20-957ee224bda2" contextRef="C_cc77e3d6-0b6d-4809-98bc-ba50dc57d0e8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_034925ea-6bfd-4cea-8f3f-e8dacb6bf61c" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c7db666-da67-47d1-9cfd-5af70416724b" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.35%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.938%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.738000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.938%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.938%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00336cc8-d657-4efe-b72c-841593f02e5f" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_592253d1-36af-4849-9a0e-7e4e0aee1c17" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_731589bc-bd0b-49d3-8db3-b3eb2030876a" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,636</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0adaa776-4b6e-461c-8a6e-50ad08c5af97" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,636</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f783604-c945-4060-a2a0-53f6c5f64ea6" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,814</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8834ad1d-165a-4488-bf50-9d0b5082af10" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,814</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33a55c4c-b23a-40e4-86f4-8e9c821c50af" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,159</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3994432f-7e7d-4903-84a7-d19320af99d1" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,159</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_140905c1-f4c1-4269-a165-dd6cb701b3d7" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,698</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb416ea8-d6f4-4b62-bcce-88d4142a4219" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1f6a80b-d8ec-4f0b-88f4-005c7967701c" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,780</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdf42420-64b9-4b7a-ae6a-9aaa682d73ef" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,872</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c52bcf7-72d3-434e-ac34-01cedd222596" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,214</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41a46ffc-d8be-4647-b4b8-9a54d44df13a" contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">576</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de8487ba-c446-485f-9240-607a84d47e62" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,662</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_255d3d3f-5972-4031-8b10-62df9895942a" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="gyre:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50d9539f-09dd-43fe-ab13-174463a33319" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="gyre:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_149a77f7-ffed-436a-81d7-99f191445001" contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbe96d6a-bd06-4120-bd08-5d232c6f2199" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69555945-c376-4435-ab10-c2a2ac7ca51a" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bca352e3-aa05-41e4-b92e-2c9fac7aba9a" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbf5358b-6c50-4e5d-8ddd-8d4e0a4dc2c6" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,357</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc205222-c793-4bf0-a6e9-c855f6c058af" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,400</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15be67dc-280f-444c-a2ed-9af1c0655119" contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,287</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b39cfc07-a68b-4a78-a538-6bacf3801554" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,044</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (Loss) from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8bdc2a7-c00a-4231-84b2-1feb82ed589f" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,457</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd53ea85-b79f-47b0-beff-b4e1313ccb73" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88,400</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8edf54ef-f93d-4adb-be58-5a6c7a27e29f" contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,287</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_471c2433-c48c-43b3-8ea9-429de3a5f92e" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,230</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c26c81cd-b321-4ee5-8a0e-daee52b1d698" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,044</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f71b78d1-aea0-4c45-b839-0d946b1b00cb" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,044</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a4cd8e4-4764-416e-aa11-171e954e1280" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,246</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_205c0a2f-faf3-4079-bc7d-e8d5aae9f0fe" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1249a10-2121-4832-9aad-ccb63e3df8ae" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,518</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e55fe255-3758-471f-b7f9-35d4e07bf87e" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01762126-2558-4bf1-88ef-add3fb056850" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11d0786b-7012-418f-ac99-89b3cd8dabf2" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,509</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c182280-3e1b-4c05-824d-f55ec769994d" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d7198fe-d66a-4d59-85bc-8c8178f646ae" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,515</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dcc9459-ca9d-410a-a3d9-1a843450624f" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,746</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_655f59d7-8471-4af3-9d39-23dfc0151c14" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,939</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52431f4d-f769-42a8-b972-954a61e916e7" contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,287</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6bdf3a9-126e-4c2d-bfeb-b4a4a79a9f77" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faf2cf50-5e78-4117-8248-29ab3dc1cc4a" contextRef="C_18bc2358-95e4-46d2-9214-ce5de90d7258" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd82c3c2-bf5b-4cec-888f-5335f205e262" contextRef="C_e5513b2b-c8d0-4816-81a6-d83601aee525" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0698a47b-b070-459d-a341-20ee3fe0afe1" contextRef="C_b2bd78e9-9849-479f-8eb7-41ba287f57e6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_699643b4-5ece-4ed4-af13-3756bcf61d36" contextRef="C_c3036813-c367-4137-83bc-d3111a243c9e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_211632da-a6b3-43ec-a3df-3505a61cca74" contextRef="C_6846f876-7997-4227-a1ac-8419c302881e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7959f6ac-d792-45d7-a169-143bc7842a17" contextRef="C_49f4dab9-8bd1-4577-b767-6356a5621a2b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d81132c6-e41c-43c8-87f9-bb357672f578" contextRef="C_f655bd73-1357-4906-aaa2-0388e4dae1b0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,916</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04411ced-d72a-4b02-a69e-e43a87e886e5" contextRef="C_80b233b8-8d6b-4b3a-b077-9d160ffc37ec" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,488</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16d08413-9d0d-4e59-b98b-576cbbe774ab" contextRef="C_28b79e15-5ce4-4bf9-8af0-0a1821e83289" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,404</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70027150-590f-4d44-a130-34aeae58aa80" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,793</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90637eef-7ed4-4037-a3ef-9b953032a26d" contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,488</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba37559b-cc86-46c6-88ea-78974f063ce1" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8743f915-a28f-4629-9d66-17cefbd55044" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:LegalFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million represents legal expense recorded in CPI during the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f53e62a1-41f9-4544-b5d3-0f4dd093d2cb" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million represents divestiture losses. See Note 8 for details.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_168d8495-2362-4808-b149-fe3ad00671e5_2"><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_77c19da4-5efe-4ea5-a696-d985688f8ec6_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The table below presents total assets as of December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.102%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.082%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a1cde87-fad0-4901-ba07-5c77f557dad1" contextRef="C_6e5dc256-5a04-41b0-a879-49f3fee0883f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,248</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a79a8a1-fbae-47da-adb5-2474b48941b0" contextRef="C_6644aae0-eb2b-4676-83a9-ae38663b37d8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,790</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e862cc8c-d1f5-4014-996c-c631a742278d" contextRef="C_e9ca2ac7-674d-4810-a3f7-5cf959925a7c" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bceba1b5-fc46-4864-bf3e-83c1b54f55a2" contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,406</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.102%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.082%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ef395ac-41fe-4b2c-8f98-234df4051ae4" contextRef="C_e87f13d9-462c-4972-9cd3-8231e00d9d31" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,761</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1573bea2-e4f8-4b6f-8e7b-2a97164df236" contextRef="C_a614a706-e7b1-4b3a-a6dd-8a447fd08d76" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,865</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5ad7750-bb0d-4490-8e86-2901c46dc73a" contextRef="C_27a7a081-3cd9-44fb-b829-bbe0a51e1049" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05311238-9471-42dd-b2f1-3014622589ed" contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,539</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.102%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.082%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7edfb146-a2f1-46f7-a550-549409760c2f" contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,301</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_660561dd-52cb-433a-83e7-94233fb4945f" contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0e0b58a-c344-4199-b9bb-0d56c09110d0" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,315</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.102%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.082%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f3e835e-49d7-4ad4-aef0-ee91cbaf51c7" contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,517</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a497632c-b55b-403e-af4f-48c62a55485f" contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,517</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additional Financial Information of Parent Company</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial Statements Schedule I</span></p>
  <div><ix:nonNumeric id="F_41ae00e0-1e15-40bc-8256-14e7804fc4f3" contextRef="C_5b526872-b885-43be-82fd-47148cef1b95" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" escape="true" continuedAt="F_41ae00e0-1e15-40bc-8256-14e7804fc4f3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="schedulei"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands, except shares and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Related party receivables</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfee539c-c471-4ec5-bca7-31ad05f3fba6" contextRef="C_cf4603e2-2534-444f-a961-287cb64533d2" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_458c6249-5c9b-439a-902e-25b95a438d85" contextRef="C_8e78646b-8c6e-48a2-bf10-a036ec1e9f6e" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f866a708-0ee9-4ff5-9f0e-f783ae7a3d32" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b438359d-75d2-48f4-b84c-31051753f15c" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Investment in subsidiaries</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95f67bf0-d67f-4a60-b7e4-c40ade986c4d" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,313</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbd01e8b-416f-4328-bd44-91f316bf13b6" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,709</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_793da66b-5818-49de-ab4b-df96b6a16214" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,081</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15881b22-20d2-4cfd-9dfd-317074dfe115" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,477</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Liabilities, convertible preferred stock, and stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due to related parties</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58aa036b-6048-4661-bc80-9931e489dd64" contextRef="C_cf4603e2-2534-444f-a961-287cb64533d2" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">538</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa7598ad-b958-4489-a482-1a656a20cee7" contextRef="C_8e78646b-8c6e-48a2-bf10-a036ec1e9f6e" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">538</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6aeca817-826b-483d-b492-2444481e3090" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,224</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_448a989e-705d-45ef-838d-5fff9a1157e0" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,242</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cceeff;padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total current liabilities:</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a60bd226-8b09-4506-94c5-04861d9cfce7" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,762</ix:nonFraction></span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05cc8573-3fd1-43ce-bc3b-a47c974a651f" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,780</ix:nonFraction></span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock, $</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9e24ae-d545-4855-b627-625b67b5c159" contextRef="C_98731e29-6638-4818-bfa3-de1d42eaf704" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f71cd05d-692d-4ed1-8e7a-c642db9a5618" contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5603e56a-e7ff-43e4-a0a4-3a4a78f0d5b8" contextRef="C_98731e29-6638-4818-bfa3-de1d42eaf704" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_266f0958-22a9-401f-9702-96ff2049cd90" contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6981c9e1-bf54-484f-bfe4-baa31017746a" contextRef="C_98731e29-6638-4818-bfa3-de1d42eaf704" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f9c28d35-3066-417e-9c9e-284d22d61905" contextRef="C_98731e29-6638-4818-bfa3-de1d42eaf704" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares and </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_606535b4-bf96-435e-878c-eff6f768783f" contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ce8f69a8-391f-4863-a28f-d03c9ad433ea" contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and 2023, respectively</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa23a4a1-373b-4bc2-a4c1-91c7a4d52583" contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity (deficit):</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1832e9de-9bd1-4b2f-9360-c0b7c9726fcf" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_329aca45-0732-47b1-8b48-5619307fe83c" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85d6fb31-8c5a-4e84-836b-87bf23e7b91a" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7aaadbcd-372c-4a70-9bb8-808987c89519" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa504c57-560c-4989-82c7-069401a32235" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a5100ac2-17f6-4085-bdcc-e72114b27869" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,307,544</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares and </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec86d371-9d6e-4819-b1c7-2869bb1b591b" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_016e1c2b-ed1d-4d8d-94a8-c419820f99b6" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,595,616</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and 2023, respectively</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c83b440-083d-496b-9500-a65259d6a71c" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_335e9c7d-5ccc-4216-9698-ec3f3602502c" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f542441c-8762-4b93-96e5-5a7626dd154f" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,185</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84f8a65a-a237-45b9-9681-4ec8734ccf05" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,179</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Statutory reserve</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a721fec1-7af4-4126-9b1a-3f3cd2488d18" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="gyre:StatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,098</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_982bba9e-5fbe-42cb-ac06-75275da9bdd2" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="gyre:StatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,098</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_403b71c6-d49c-4116-9762-b8fba627684e" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,453</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fab26b53-22bf-43ae-94dc-473a2c2abd6b" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,538</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47a3461a-4967-485d-856a-c4ce1a9991eb" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,597</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_caa39233-645a-40cf-a61b-d0bb7cfe0c3e" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,644</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity (deficit)</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4effec30-89dc-4340-8706-ce92dc5a09be" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,319</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53682284-9867-4931-9091-ccab5a653517" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,828</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80b2de8c-2fa1-4445-9d9d-df1233bdf86e" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,081</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a926197c-8b44-4dc4-a47f-c81b7788b6a0" contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,477</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_41ae00e0-1e15-40bc-8256-14e7804fc4f3_1" continuedAt="F_41ae00e0-1e15-40bc-8256-14e7804fc4f3_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_955606ef-bb88-4303-80e3-356b6fac1d73" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47549841-4b8b-4f0f-9877-3f4b3a5aae1c" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ae21d0e-201c-4c01-9ee5-6712277b44da" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss before equity in income of subsidiaries</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ccffa07-6a73-4333-86dd-8019b0a42c4a" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84295304-8987-4736-be0f-0bc7a3c1d460" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,316</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Equity in income (loss) of subsidiaries</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9d7ccaf-1b82-4d05-8da4-24f3213526e3" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,190</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_befcb390-09ce-4458-998e-33ecc83a4189" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,617</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
      <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bd66c0a-7541-4642-bda3-8518cc6c639b" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,085</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1d8912a-b2b4-4224-835b-0168b43c85e1" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other comprehensive loss, net of tax of </span><span style="font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_64b29595-72b7-4d1e-a2ef-bcc1f661c31b;"><span style="-sec-ix-hidden:F_7ff33148-e75c-4492-acae-7ea4bfe94b76;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">:</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
      <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f3712f9-00fa-4cbd-8324-f45e2d01b8fa" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">953</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54137a36-534a-4c97-9540-6da42fb42a40" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Comprehensive income (loss)</span></p></td>
      <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c2dd9ea-40d5-405d-8138-df22fb031f01" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,132</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3b0f4fd-ac41-4e88-9abf-3bb0a011240d" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,770</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_41ae00e0-1e15-40bc-8256-14e7804fc4f3_2" continuedAt="F_41ae00e0-1e15-40bc-8256-14e7804fc4f3_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:68.874%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.963000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.5%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.663%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating Activities</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b54466a-248f-47db-ab34-1271f10529a1" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,085</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cad4f2cf-5155-49cf-8dc4-a529dff245b0" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net income (loss) to net cash used for operating activities:</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Equity (income) loss of subsidiaries</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9633dbb1-516d-4c86-8f74-cc43b7753da3" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,190</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7831c33f-fa39-40b4-a292-5ce114b2e39f" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,617</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd8ec319-b7b2-4667-b1dd-d5b52e578192" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due to related parties</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01240fb9-d460-4333-923e-e23bbff1a6f5" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">533</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c5fbff1-1586-4d68-a050-1edd5e04e2bb" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7be8ff3a-0525-4601-988c-0ba961a3b0c1" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa55deca-103d-48ae-b1b3-4ce81c9f2c03" contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8ad263f-a8be-44b8-95f9-a3039857a208" contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of the period</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:'Aptos',sans-serif;"><ix:continuation id="F_41ae00e0-1e15-40bc-8256-14e7804fc4f3_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Notes</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a pa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">rent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40065c22-bccf-4704-8832-346d2cd551f2" contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3" name="gyre:PercentageOfRestrictedNetAssetsExceedNetAssets" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> percent of consolidated net assets as of the end of the most recently completed fiscal year.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries. CPI, the legal acquiree and accounting acquirer of the Contributions considered the &#8220;registrant&#8221; and presented as the parent company, Gyre Therapeutics, Inc. (&#8220;Gyre&#8221;) to supplement its condensed financial statement in Schedule I. The parent company records its investments in subsidiaries under the equity method of accounting as prescribed in ASC 323, Investments-Equity Method, and Joint Ventures. Such investments are presented on the Condensed Balance Sheets as &#8220;Investment in subsidiaries&#8221;. Ordinarily under the equity method, an investor in an equity method investee would cease to recognize its share of the losses of an investee once the carrying value of the investment has been reduced to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to reflect its share, based on its proportionate interest, of the losses of subsidiaries regardless of the carrying value of the investment even though the parent company is not obligated to provide continuing support or fund losses.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or redemption requirements of redeemable stocks or guarantees of the parent company.</span></div></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>gyre-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 4.1</font></p>
  <p style="font-size:10pt;margin-top:17pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES<br>REGISTERED PURSUANT TO SECTION 12 OF<br>THE SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc. (&#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; or the &#x201c;Company&#x201d;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (&#x201c;1934 Act&#x201d;): our common stock. The following summary of the terms of our common stock is based upon our Fourth Amended and Restated Certificate of Incorporation, as amended (our &#x201c;restated certificate of incorporation&#x201d;) and our bylaws. This summary does not purport to be complete and is subject to, and is qualified in its entirety by express reference to, the applicable provisions of our restated certificate of incorporation and our bylaws, which are filed as exhibits to our Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our restated certificate of incorporation, our bylaws and the applicable provisions of the Delaware General Corporation Law (&#x201c;DGCL&#x201d;) for more information.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Description of Common Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under our restated certificate of incorporation, we have authority to issue 400,000,000 shares of our common stock, par value $0.001 per share. As of December 31, 2024, 86,307,544 shares of our common stock were issued and outstanding. All shares of our common stock will, when issued, be duly authorized, fully paid and nonassessable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Subject to preferential dividend rights of any other class or series of stock, the holders of shares of our common stock are entitled to receive dividends, including dividends of our stock, as and when declared by our board of directors, subject to any limitations imposed by law and to the rights of the holders, if any, of our preferred stock. On September 20, 2022, we paid a special, one-time cash dividend of approximately $45.0 million (or $1.43 per share) to our common stockholders of record as of the close of business on September 6, 2022. On January 12, 2023, we paid a special, one-time cash dividend of approximately $7.6 million (or $0.24 per share) to our common stockholders of record as of the close of business on January 5, 2023. In June 2023, we distributed $3.5 million, which reflected, in connection with an asset purchase agreement with Vertex Pharmaceuticals Inc. (&#x201c;Vertex&#x201d;), the hold-back amount received from Vertex less expenses and a reserve for potential tax liabilities, to holders of the contingent value right issued to our stockholders of record on January 5, 2023. On August 26, 2024, we distributed approximately $12.6 million (or $0.40 per contingent value right) to the CVR Holders. We do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as the board of directors deems relevant.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate provision for all of our known debts and liabilities, each holder of our common stock will be entitled to share ratably in all assets that remain, subject to any rights that are granted to the holders of any class or series of preferred stock.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. For all matters submitted to a vote of stockholders, each holder of our common stock is entitled to one vote for each share registered in his or her name. Except as may be required by law and in connection with some significant actions, such as mergers, consolidations, or amendments to our restated certificate of incorporation that affect the rights of stockholders, holders of our common stock vote together as a single class. There is no cumulative voting in the election of our directors, which means that, subject to any rights to elect directors that are granted to the holders of any class or series of preferred stock, a plurality of the votes cast at a meeting of stockholders at which a quorum is present is sufficient to elect a director.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Other Rights and Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Subject to the preferential rights of any other class or series of stock, all shares of our common stock have equal dividend, distribution, liquidation and other rights, and have no preference, appraisal or exchange rights, except for any appraisal rights provided by Delaware law.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furthermore, holders of our common stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities. Our restated certificate of incorporation and our bylaws do not restrict the ability of a holder of our common stock to transfer his or her shares of our common stock.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The rights, powers, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any series of preferred stock which we may designate and issue in the future.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Listing</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Our common stock is listed on the Nasdaq Capital Market under the symbol &#x201c;GYRE.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Transfer Agent and Registrar</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The transfer agent for our common stock is Equiniti Trust Company, LLC. Its address is 6201 15th Avenue, Brooklyn, NY 11219.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Description of Preferred Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under our restated certificate of incorporation, we have authority, subject to any limitations prescribed by law and without further stockholder approval, to issue from time to time up to 5,000,000 shares of preferred stock, par value $0.001 per share, in one or more series. On December 22, 2022, we designated 123,418 shares of our preferred stock as &#x201c;Series X Convertible Preferred Stock&#x201d; (hereinafter referred to as, &#x201c;Convertible Preferred Stock&#x201d;). As of December 31, 2024, we had zero shares of preferred stock issued and outstanding.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to our restated certificate of incorporation, we are authorized to issue &#x201c;blank check&#x201d; preferred stock, which may be issued from time to time in one or more series upon authorization by our board of directors. Our board of directors, without further approval of the stockholders, is authorized to fix the designation, powers, preferences, relative, participating optional or other special rights, and any qualifications, limitations and restrictions applicable to each series of the preferred stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes could, among other things, adversely affect the voting power or rights of the holders of our common stock and, under certain circumstances, make it more difficult for a third party to gain control of us, discourage bids for our common stock at a premium or otherwise adversely affect the market price of the common stock.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Series X Convertible Preferred Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Conversion</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Under our restated certificate of incorporation, (i) effective as of 5:00 p.m. (New York City time) on the second business day after the date on which such stockholder approval is received, each share of Convertible Preferred Stock then outstanding automatically converts into approximately 10,000 of common stock, and (ii) at any time thereafter at the option of the holder thereof, into approximately 10,000 shares of common stock, in the case of each of (i) and (ii) subject to certain beneficial ownership limitations, including that a holder of Convertible Preferred Stock is prohibited from converting shares of Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be initially set at 9.9% and thereafter adjusted by the holder between to a number between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Except as otherwise provided in the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on December 27, 2022, as amended on October 30, 2023 (as amended, &#x201c;Certificate of Designation&#x201d;) or as otherwise required by the DGCL, Convertible Preferred Stock does not have voting rights. However, as long as any shares of Convertible Preferred Stock are outstanding, in addition to any other requirement of the DGCL or our restated certificate of incorporation, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of Convertible Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to Convertible Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of or add any provision to, our restated certificate of incorporation or our bylaws, or file any articles of amendment, certificate of designations, preferences,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of Convertible Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to our restated certificate of incorporation or by merger, consolidation or otherwise, (ii) issue further shares of Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Convertible Preferred Stock, (iii) at any time while at least 30% of the originally issued Convertible Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined in the Certificate of Designation) or (B) any merger or consolidation of the combined company with or into another entity or any stock sale to, or other business combination in which the combined company&#x2019;s stockholders immediately before such transaction do not hold at least a majority of the capital stock of the combined company immediately after such transaction, or (iv) enter into any agreement with respect to any of the foregoing.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Holders of Convertible Preferred Stock shall be entitled to receive when, as and if dividends are declared and paid on shares of common stock, an equivalent dividend (with the same dividend declaration date and payment date), calculated on an as-converted basis without regard to the Beneficial Ownership Limitation (as defined in the Certificate of Designation), provided, however, in no event shall holders of Convertible Preferred Stock be entitled to receive (a) the &#x201c;rights&#x201d; distributed pursuant to the Contingent Value Rights Agreement, dated December 26, 2022, as amended on March 29, 2023 (as amended, the &#x201c;CVR Agreement&#x201d;) or any amounts paid under the CVR Agreement, or (b) cash distributions declared by the combined company on or prior to the closing of the transactions contemplated by the Business Combination Agreement, dated as of December 26, 2022, as amended on March 29, 2023 and August 30, 2023, by and among us, GNI USA, Inc., a Delaware corporation, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability, GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People&#x2019;s Republic of China, the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Convertible Preferred Stock ranks (i) senior to any class or series of capital stock of the combined company hereafter created specifically ranking by its terms junior to any Convertible Preferred Stock; (ii) on parity with common stock and any class or series of capital stock of the combined company hereafter created specifically ranking by its terms on parity with Convertible Preferred Stock; and (iii) junior to (A) any class or series of capital stock of the combined company hereafter created specifically ranking by its terms senior to any Convertible Preferred Stock or (B) any &#x201c;rights&#x201d; distributed pursuant to the CVR Agreement or any amounts paid under the CVR Agreement, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the combined company, whether voluntarily or involuntarily.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certain Effects of Authorized but Unissued Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing requirements of The Nasdaq Capital Market. We may issue these additional shares for a variety of corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved preferred stock may enable our board of directors to issue shares of preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of common stock and the likelihood that holders of common stock will receive dividend payments or payments upon liquidation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Anti-Takeover Effects of Provisions of Our Charter Documents</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our restated certificate of incorporation provides for our board of directors to be divided into three classes serving staggered terms. Approximately one-third of our board of directors will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of the outstanding voting stock from obtaining control of the board of directors until the second annual stockholders meeting</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company and could increase the likelihood that incumbent directors will retain their positions. Our restated certificate of incorporation provides that directors may be removed with or without cause only by the affirmative vote of the holders of at least 66 2/3% of the voting power of all outstanding stock entitled to vote in the election of directors, voting together as a single class.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our restated certificate of incorporation requires that certain amendments to the restated certificate of incorporation and amendments by the stockholders of our bylaws require the affirmative vote of holders of at least 66 2/3% of the then outstanding stock entitled to vote generally in the election of directors, voting together as a single class. These provisions could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company and could delay changes in management.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual stockholders meeting, including proposed nominations of persons for election to our board of directors. At an annual stockholders meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors. Stockholders may also consider a proposal or nomination by a person who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to the Secretary of the Company timely written notice, in proper form, of his or her intention to bring that business before the annual stockholders meeting. Our bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of the stockholders. However, our bylaws may have the effect of precluding the conduct of business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our bylaws provide that only our board of directors, the chairperson of the board, the President or the Chief Executive Officer may call a special meeting of stockholders. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of our board of directors by calling a special meeting of stockholders prior to such time as a majority of our board of directors, the chairperson of the board, the President or the Chief Executive Officer believed the matter should be considered or until the next annual meeting provided that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace the board also could be delayed until the next annual stockholders meeting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our restated certificate of incorporation does not allow stockholders to act by written consent without a meeting. Without the availability of stockholder&#x2019;s actions by written consent, a holder controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a stockholders&#x2019; meeting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our restated certificate of incorporation and bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery (the &#x201c;Court of Chancery&#x201d;) of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the sole and exclusive forum for the following types of proceedings (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery or (iv) any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or our bylaws (in each case, as they may be amended from time to time) or that is governed by the internal affairs doctrine. This choice of forum provision will not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the 1934 Act or any other claim for which the federal courts have exclusive jurisdiction. Our bylaws also provide that, unless we consent in writing to the selection of an alternative forum, federal district courts of the United States will be the exclusive forum for any complaint asserting a</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">cause of action arising under the Securities Act. There is uncertainty as to whether a court would enforce such a provision. In addition, our bylaws provide that any person or entity purchasing or otherwise acquiring or holding any interest in shares of our capital stock are deemed to have notice of and consented to the foregoing choice of forum provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Anti-Takeover Effects of Provisions of Delaware Law</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We are subject to the provisions of Section 203 of the DGCL, or Section 203. Under Section 203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">prior to this time, our board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers, and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">at or subsequent to such time, the business combination is approved by our board of directors and authorized at a special or annual stockholders meeting, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under Section 203, a &#x201c;business combination&#x201d; includes:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder, subject to limited exceptions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In general, Section 203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>gyre-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GYRE THERAPEUTICS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INSIDER TRADING POLICY<br><br>(dated October 30, 2023)</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">I.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INTRODUCTION</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal and state laws prohibit buying, selling, gifting or making other transfers of securities by persons who have material information that is not generally known or available to the public.  These laws also prohibit persons with such material nonpublic information (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">MNPI</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from disclosing this information to others who trade.  Trading while in possession of MNPI is often referred to as &#x201c;insider trading.&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Who Is Subject to this Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Gyre Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has adopted the following policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) regarding trading in securities by directors, officers, employees and consultants (together, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Personnel</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as well as their family members who reside with them, anyone else who lives in their household and any family members who do not live in their household but whose transactions in Company securities (as defined below) are directed by them or are subject to their influence or control (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Family Members</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and corporations or other business entities controlled, influenced or managed by them or their Family Members, and trusts for which such persons are a trustee or in which they have a beneficial or pecuniary interest (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlled Entities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; and together with &#x201c;Company Personnel&#x201d; and &#x201c;Family Members,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Unless otherwise indicated, all references to &#x201c;you&#x201d; in this Policy should be read to include all of your Family Members and Controlled Entities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Which Securities Are Subject to this Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Policy applies to transactions, whether direct or indirect, in the Company&#x2019;s securities, including its common stock, options to purchase common stock, restricted stock or restricted stock units or any other type of securities that Company may issue from time to time, including but not limited to preferred stock and convertible debentures, as well as derivative securities relating to the Company but that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company&#x2019;s securities.  Similarly, this Policy applies to all securities issued by a Company Counterparty, as well as any derivative securities, such as puts, calls or swaps.  When this Policy refers to another entity&#x2019;s &#x201c;securities,&#x201d; it refers to its common stock, options to purchase common stock or any other type of securities that the entity may issue, as well as derivative securities relating to that entity but that are not issued by that entity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Application of this Policy to Company Counterparties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The principles discussed in this Policy also apply to nonpublic information that you obtain in the course of your employment or other involvement with the Company about another public company with whom the Company has a preexisting or prospective relationship, such as the Company&#x2019;s customers, suppliers or a firm with which the Company is negotiating a major transaction, such as a joint venture, licensing transaction or other collaboration, or material acquisition or disposition (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Counterparty</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Counterparties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Exceptions.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The prohibition against trading while in possession of MNPI is absolute and unconditional.  The securities laws do not recognize any mitigating circumstances, and, in any event, even the appearance of an improper transaction must be avoided to preserve the Company&#x2019;s reputation for adhering to high standards of conduct.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Individual Responsibility.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You are responsible for ensuring that you (as well as your Family Members and Controlled Entities) do not violate federal or state securities laws or this Policy.  We designed this Policy to promote compliance with the federal securities laws and to protect the Company and you from the serious liabilities and penalties that can result from violations of these laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consequences for Violating Insider Trading Laws.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If you violate insider trading laws, you may have to pay civil fines for up to three times the profit gained or loss avoided by such trading, as well as criminal fines of up to $5 million.  You also may have to serve a jail sentence of up to 20 years.  In addition, the Company may face civil penalties up to the greater of $1 million, or three times the profit gained or loss avoided as a result of your insider trading violations, as well as criminal fines of up to $25 million.  Both the Securities and Exchange Commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and The Nasdaq Stock Market (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) are very effective at detecting and pursuing insider trading cases.  The SEC has successfully prosecuted cases against employees trading through foreign accounts, trading by family members and friends and trading involving only a small number of shares.  Therefore, it is important that you understand the breadth of activities that constitute illegal insider trading.  This Policy sets out the Company&#x2019;s policy in the area of insider trading and should be read carefully and complied with fully.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Administrative Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All Company Personnel will be required to certify their understanding of and intent to comply with this Policy by signing the Receipt and Acknowledgement attached hereto periodically.  This Policy will be reviewed, evaluated and revised by the Company from time to time in light of regulatory changes, developments in the Company&#x2019;s business and other factors.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">II.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POLICIES AND PROCEDURES</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Policy</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Prohibition.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You may not buy, sell or gift securities of the Company or a Company Counterparty when you are in possession of MNPI about that company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Tipping.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You may not convey MNPI about the Company or a Company Counterparty to others.  You also may not suggest that anyone purchase or sell any company&#x2019;s securities while you are aware of MNPI about that company.  These practices, known as &#x201c;tipping,&#x201d; also violate U.S. securities laws and can result in the same civil and criminal penalties that apply if you engage in insider trading directly, even if you do not receive any money or derive any benefit from trades made by persons to whom you passed MNPI.  This Policy against &#x201c;tipping&#x201d; applies to information about the Company and its securities, as well as to information about Company Counterparties.  Persons with whom you have a history, pattern or practice of sharing confidences&#x2014;such as family members, close friends and financial and personal counselors&#x2014;may be presumed to act on the basis of information known to you; therefore, special care should be </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taken so that MNPI is not disclosed to such persons.  This Policy does not restrict legitimate business communications on a &#x201c;need to know&#x201d; basis.  MNPI, however, should not be disclosed to persons outside the Company unless you are specifically authorized to disclose such information and such disclosure is made in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of information regarding the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Short-Term or Speculative Trading.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  It is against Company policy for you to engage in short-term or speculative transactions in Company securities.  As such, you may not engage in:  (a) short-term trading (generally defined as selling Company securities within six months following a purchase); (b) short sales (selling Company securities you do not own); (c) transactions involving publicly traded options or other derivatives, such as trading in puts or calls with respect to Company securities; and (d) hedging transactions (such as &#x201c;cashless&#x201d; collars, forward sales, equity swaps and other similar arrangements).  Additionally, because securities held in a margin account or pledged as collateral may be sold without your consent, if you fail to meet a margin call or if you default on a loan, a margin or foreclosure sale may result in unlawful insider trading.  Because of this danger, you should exercise caution when including Company securities in a margin account or pledging Company securities as collateral for a loan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applying the Trading Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  As stated above, these restrictions also apply to your Family Members and Controlled Entities.  The SEC and federal prosecutors may presume that trading by Family Members or Controlled Entities is based on information you supplied and may treat any such transactions as if you had traded yourself.  There is no exception for small transactions or transactions that may seem necessary or justifiable for independent reasons, such as the need to raise money for an emergency expenditure.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, references to &#x201c;trading&#x201d; and &#x201c;transactions&#x201d; include, among other things:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases and/or sales of Company securities in public markets;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of Company securities obtained through the exercise of employee stock options granted by the Company;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making gifts of Company securities; and</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">using Company securities to secure a loan.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors, officers, employees and consultants should consult the Chief Financial Officer (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CFO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) if they have any questions.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Transactions.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  From time to time, the Company may engage in transactions in its own securities.  It is the Company&#x2019;s policy to comply with all applicable securities and state laws (including appropriate approvals by the Board of Directors or appropriate committee, if required) when engaging in transactions in Company securities.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What is</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Nonpublic Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">?  When is Information &#x201c;Public&#x201d;?</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Information</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information is generally considered &#x201c;material&#x201d; if there is a likelihood a reasonable investor would consider such information important in making an investment decision to buy, hold or sell securities.  Either positive or negative information may be material.  There is no bright&#x2010;line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances.  The CFO or attorneys designated by the CFO should be consulted and shall determine whether information is material, but in general, any information that could reasonably be expected to affect the Company&#x2019;s stock price should be considered material.  Depending on the circumstances, common examples of information that may be material include:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant new product developments, innovations or discoveries;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pending U.S. Food and Drug Administration, European Medicines Agency or other regulatory action;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical data or significant interactions, approval or rulings by a regulatory agency relating to the Company or a Company product;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">status of pre-clinical or clinical studies;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">earnings, revenue or similar financial information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected financial results;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unpublished financial reports or projections;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extraordinary borrowing or liquidity problems;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in control or sale of all or part of the Company&#x2019;s business;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in directors, senior management or auditors;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information about current, proposed or contemplated transactions, business plans, financial restructurings, acquisition targets or significant expansions or contractions of operations;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in dividend policies, the declaration of a stock split or the proposed or contemplated issuance, redemption or repurchase of securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiations regarding an important license, distribution agreement, joint venture or collaboration agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material defaults under agreements or actions by creditors, clients or suppliers relating to the Company&#x2019;s credit rating;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information about major contracts;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gain or loss of a significant customer or supplier;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant cybersecurity incidents, events or risks that affect the Company or third&#x2010;party providers that support the Company&#x2019;s business operations, including computer system or network compromises, viruses or other destructive software, and data breach incidents that may disclose personal, business or other confidential information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impending financial problems;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the interruption of production or other aspects of the Company&#x2019;s business as a result of an accident, fire, natural disaster, public health emergency or breakdown of labor negotiations;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">major environmental incidents;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">institution of, or developments in, major litigation, investigations or regulatory actions or proceedings;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information about Company affiliates and Company Counterparties; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the imposition of a trading &#x201c;blackout&#x201d; by the Company on transactions in Company securities or the securities of a Company Counterparty.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal and Nasdaq investigators will scrutinize a questionable trade after the fact with the benefit of hindsight, so you should always err on the side of deciding that the information is material and not trade.  The mere fact that a person is aware of MNPI is a bar to trading.  It is no excuse that such person&#x2019;s reasons for trading were not based on the MNPI.  If you have questions regarding specific transactions, please contact the CFO.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonpublic Information</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonpublic information is information that is not generally known by or available to the public.  We consider information to be available to the public only when:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it has been released to the public by the Company through appropriate channels (e.g., by means of a press release, a filing with the SEC or a widely disseminated statement from a senior officer); and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enough time has elapsed to permit the investment market to absorb and evaluate the information.  As a general rule, you should consider information to be nonpublic until two full trading days have lapsed following the time of public disclosure.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fact that rumors, speculation or statements attributed to unidentified sources are public is insufficient to be considered &#x201c;generally available to the public&#x201d; even when the information is accurate.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unauthorized Disclosure; Prohibition on Certain Public Speaking</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Company Personnel must maintain the confidentiality of Company information for competitive, security and other business reasons, as well as to comply with securities laws.  All information you learn about the Company or its business plans is potentially nonpublic information until it is publicly disclosed.  You should treat this information as confidential and proprietary to the Company.  You may not disclose it to others, such as Family Members, other relatives or business or social acquaintances.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, you are prohibited from participating as an &#x201c;expert,&#x201d; consultant, advisor and/or in any capacity for an &#x201c;expert network&#x201d; and/or any other outside firm which compensates individuals for speaking with investors and other investment professionals.  This prohibition is designed to protect the Company, its stockholders and you.  Indeed, United States criminal authorities and the SEC have prosecuted numerous public company employees who received monetary compensation by expert networks to speak with investors and disclose confidential company information which investors then used for trading purposes.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal rules govern the timing and nature of our disclosure of material information to outsiders or the public.  Violation of these rules could result in substantial liability for you, the Company and its management.  For this reason, we permit only specifically designated representatives of the Company to discuss the Company with the news media, securities analysts and investors and only in accordance with the Company&#x2019;s Guidelines For Public Disclosures And Communications With The Investment Community.  If you receive inquiries of this nature, refer them to the CFO.  At any time when the Company does not have an active CFO, the duties and responsibilities assigned to the CFO under this policy shall be performed by the principal financial officer.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When and How to Trade Company Stock</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Quarterly Blackout Periods and Trading Windows</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company imposes a blackout period in connection with its quarterly release of financial information, during which time Insiders are not permitted to purchase, sell or enter into any other transaction with respect to the Company&#x2019;s securities (subject to the exceptions set forth in Section II.D.4 or pursuant to an approved Rule 10b5-1 Trading Plan pursuant to Section II.E).  A quarterly blackout period will typically </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">begin</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> two weeks prior to the end of each quarter (two weeks prior to the end of each December, March, June and September) and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">end</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> two full business days after the public release of the Company&#x2019;s quarterly or annual earnings results.  For example, if the Company publicly releases earnings results at the open of market on a Friday, then trading in the Company&#x2019;s securities may commence at the open of market on the following Tuesday.  The exact date of the public release of the Company&#x2019;s earnings results is announced in advance via press release.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, Insiders may trade in Company securities only from the date that is two full trading days after an earnings release to the close of business on the date that is two weeks prior to the end of each quarter (such period, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trading</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Window</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  However, even if a Trading Window is open, you may not trade in Company securities if you are aware of MNPI about the Company.  In addition, if you are subject to the Company&#x2019;s pre-clearance policy (described below), you must pre-clear transactions even if you initiate them when the Trading Window is open.  Generally, all pending purchase and sale orders regarding Company securities that could be executed while the Trading Window is open must be cancelled before it closes.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Special Blackout Periods</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regularly scheduled quarterly blackout periods, the Company may, from time to time, close trading during a Trading Window due to developments (such as a significant event or transaction) during which there may exist MNPI about the Company or a Company Counterparty.  This is referred to as a special blackout period.  In such cases, the Company may notify particular individuals that they should not engage in any transactions involving the purchase, sale or other transaction in Company securities or the securities of a Company Counterparty, as applicable (subject to the exceptions set forth in Section II.D.4 or pursuant to an approved Rule 10b5-1 Trading Plan pursuant to Section II.E).  If you are subject to a special blackout period, you should not trade in the applicable company&#x2019;s securities during such time and you should not disclose to others the fact that you are prohibited from trading, as the existence of a special blackout period may, itself, be deemed MNPI.  These special blackout periods will vary in length, be determined by the CFO and be communicated to the appropriate personnel via e-mail.  Termination of a special blackout period will also be communicated to the appropriate personnel via e-mail.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, it is not the Company&#x2019;s policy to impose special blackout periods every time that MNPI exists or every time that Insiders may be in the possession of MNPI.  Thus, the absence of a special blackout period should not be interpreted as permission to trade.  In addition, if you are subject to the Company&#x2019;s pre-clearance policy (described below), you must pre-clear transactions even if you initiate them while a blackout period is not in place.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In light of these restrictions, if you expect a need to sell Company stock at a specific time in the future, including executing sales to satisfy tax withholding obligations in connection with the exercise of stock options, vesting of restricted stock or settlement of restricted stock units in the future, you may wish to consider entering into a prearranged Rule 10b5-1 trading plan (as discussed below).</font></p>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-clearance</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company requires its directors, officers, C-level employees and certain other employees and consultants who are so designated from time to time (such officers and designated employees and consultants, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to contact the CFO in advance of effecting any purchase, sale, gift or other trading of Company securities and to obtain prior approval of the transaction.  All requests must be submitted to the CFO at least two business days in advance of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proposed transaction.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The pre-clearance policy applies to directors and Restricted Employees, including their Family Members and Controlled Entities, even if they are initiating a transaction while a blackout period is not in place.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a transaction is approved under the pre-clearance policy, the transaction must be executed by the end of the second full trading day after the approval is obtained, but regardless may not be executed if you acquire MNPI concerning the Company during that time.  If a transaction is not completed within the period described above, the transaction must be approved again before it may be executed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a proposed transaction is not approved under the pre-clearance policy, you may not transact in Company stock, and you should not inform anyone within or outside of the Company of the restriction.  For the avoidance of doubt, there should be no presumption that the CFO will grant any or all pre-clearance requests and there shall be no obligation to inform directors or Restricted Employees of the reasons for any request approval or denial.  Any transaction under a Rule 10b5-1 trading plan will not require pre-clearance at the time of the transaction, but the adoption, amendment, modification or termination of any such Rule 10b5-1 trading plan is subject to pre-clearance.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exceptions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The restrictions contained in this Policy shall not apply to:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exercise of Company stock options if (a) no shares are to be sold to third parties or (b) there is only a &#x201c;net exercise&#x201d; (defined as the Company withholding shares to satisfy your tax obligations or to cover the exercise price or equivalent);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;sell to cover&#x201d; transactions involving a sale of shares of common stock directed by the Company in its sole discretion in order to cover the Company&#x2019;s or such individual&#x2019;s or entity&#x2019;s withholding tax obligations in connection with the grant, vesting or settlement of equity awards pursuant to the Company&#x2019;s equity incentive plans and agreements, for example, from the vesting or settlement of restricted stock units under such plans;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the vesting of Company stock options, restricted stock, restricted stock units or other equity incentive awards according to their terms; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the withholding of shares to satisfy the exercise price or a tax withholding obligation upon the grant, vesting or settlement of equity awards pursuant to the Company&#x2019;s equity incentive plans and agreements, for example, from the vesting or settlement of restricted stock units under such plans;</font></div></div>
  <div class="page-border-spacing">
   <hr style="border-top: 2px solid black; width: 192px; margin-left:0px"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Transactions by the CFO (or the CFO&#x2019;s Family Members and Controlled Entities) are required to be approved in advance by the Chief Executive Officer.</font></p><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">transferring shares to an entity that does not involve a change in the beneficial ownership of the shares (for example, transferring shares from one brokerage account to another brokerage that you control);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of Company securities as a selling stockholder in a registered public offering, including a &#x201c;synthetic secondary&#x201d; offering, in accordance with applicable securities laws; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other purchase of Company securities from the Company or sale of Company securities to the Company in accordance with applicable securities and state laws.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent applicable and such elections are permitted, your elections regarding participation in &#x201c;net exercise,&#x201d; or &#x201c;sell to cover&#x201d; transactions, including changes from any defaults established by the Company, may only be made during a Trading Window and while not in possession of MNPI.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 provides an affirmative defense from insider trading liability if trades occur pursuant to a pre-arranged trading plan that meets specified conditions (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">10b5-1 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  It is possible to pre&#x1f;arrange trades in Company securities by entering into a 10b5-1 Plan.  A 10b5-1 Plan must either specify the number of securities to be bought or sold, along with the price and the date, or provide a written formula for determining this information.  Alternatively, a 10b5-1 Plan can delegate investment discretion to a third party, such as a broker, who then makes trading decisions without further input from the person implementing the 10b5-1 Plan.  A 10b5-1 Plan must be established during a Trading Window and at a time when you are not aware of any MNPI.  A 10b5&#x2011;1 Plan must not permit you to exercise any subsequent control or influence over how, when or whether the purchases or sales are made.  Because the SEC rules on 10b5-1 Plans are complex, you should consult with your broker and be sure you fully understand the limitations and conditions of the rules before you establish a trading plan.  All 10b5-1 Plans must comply with the Company&#x2019;s &#x201c;Guidelines for Rule 10b5-1 Trading Plans&#x201d; set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and be reviewed and approved in advance by the CFO.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">F.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Noncompliance</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anyone subject to this Policy who fails to comply with this Policy will be subject to appropriate disciplinary action, up to and including termination of employment.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">G.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Termination Transactions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy will continue to apply to your transactions in Company securities after your employment or service with the Company has terminated until such time as you are no longer aware of MNPI or until that information has been publicly disclosed or is no longer material.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Questions about this Policy should be directed to </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">the</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> CFO.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECEIPT AND ACKNOWLEDGMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, ________________________________, hereby acknowledge that I have received and read a copy of the Gyre Therapeutics, Inc. Insider Trading Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  I agree to comply with this Policy and certify that I will communicate with all members of my household to inform them of the obligations in this Policy that apply to them.  I understand that violation of this Policy may subject me to discipline by Gyre Therapeutics, Inc. up to and including termination for cause.</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">__________________________________<br>Signature</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">_______________________________<br>Date</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">APPENDIX A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Gyre Therapeutics, Inc. Guidelines for Rule 10b5-1 Trading Plans</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed above, Rule 10b5-1 provides an affirmative defense from insider trading liability.  In order to be eligible to rely on this defense, you must enter into a Rule 10b5-1 Trading Plan for transactions in Company securities that meets certain conditions specified in Rule 10b5&#x2011;1.  Capitalized terms used in these guidelines without definition have the meaning set forth in the Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These guidelines are in addition to, and not in lieu of, the requirements and conditions of Rule 10b5-1.  The CFO will interpret and administer these guidelines for compliance with Rule 10b5-1, the Policy and the requirements below.  No personal legal or financial advice is being provided by the CFO or other members of the Company regarding any Rule 10b5-1 Trading Plan or proposed trades.  You remain ultimately responsible for ensuring that your Rule 10b5-1 Trading Plan and contemplated transactions fully comply with applicable securities laws.  It is recommended that you consult with your own attorney or other advisor about any contemplated Rule 10b5-1 Trading Plan.  Note that for any director or officer, as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 16 Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Company is required to disclose the material terms of his or her Rule 10b5-1 Trading Plan (and may be required to disclose the material terms of Rule 10b5-1 Trading Plans of Family Members and Controlled Entities of such persons), other than with respect to price, in its periodic report for the quarter in which the Rule 10b5-1 Trading Plan is adopted or terminated or modified (as described below).</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance Requirement.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Rule 10b5-1 Trading Plan must be reviewed and approved in advance by the CFO (or, in the case of the CFO, by the CEO) at least five trading days prior to the entry into the plan in accordance with the procedures set forth in the Policy and these guidelines.  The Company may require that you use a standardized form of Rule 10b5-1 Trading Plan. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Time of Adoption.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to pre-clearance requirements described above, the Rule 10b5&#x2011;1 Trading Plan must be adopted at a time:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">when you are not aware of any MNPI; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Trading Window is open.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan Instructions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Rule 10b5-1 Trading Plan must be in writing, signed and either:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify the amount, price and date of the sales (or purchases) of Company securities to be effected;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide a formula, algorithm or computer program for determining when to sell (or purchase) the Company&#x2019;s securities, the quantity to sell (or purchase) and the price; or </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delegate decision-making authority with regard to these transactions to a broker or other agent without any MNPI about the Company or its securities.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, you may not subsequently influence how, when or whether to effect purchases or sales with respect to the securities subject to an approved and adopted Rule 10b5-1 Trading Plan.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Hedging.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You may not have entered into or alter a corresponding or hedging transaction or position with respect to the securities subject to the Rule 10b5-1 Trading Plan and must agree not to enter into any such transaction while the Rule 10b5-1 Trading Plan is in effect.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Faith Requirements.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You must enter into the Rule 10b5-1 Trading Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rules 10b-5 and 10b5&#x2011;1.  You must act in good faith with respect to the Rule 10b5-1 Trading Plan for the entirety of its duration.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certifications for Section 16 Persons.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Section 16 Persons and their Family Members and Controlled Entities that enter into Rule 10b5-1 Trading Plans must certify that they are: (1) not aware of any MNPI about the Company or the Company securities; and (2) adopting the Rule 10b5-1 Trading Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rules 10b-5 and 10b5-1 under the Securities Exchange Act of 1934, as amended. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooling Off Periods.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The first trade under the Rule 10b5-1 Trading Plan may not occur until the expiration of a cooling-off period as follows:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For Section 16 Persons (as well as their Family Members and Controlled Entities), the later of (1) two business days following the filing of the Company&#x2019;s Form 10-Q or Form 10-K for the completed fiscal quarter in which the Rule 10b5-1 Trading Plan was adopted and (2) 90 calendar days after adoption of the Rule 10b5-1 Trading Plan; provided, however, that the required cooling-off period shall in no event exceed 120 days.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For others, 30 days after adoption of the Rule 10b5-1 Trading Plan. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Overlapping Rule 10b5-1 Trading Plans.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You may not enter into overlapping Rule 10b5-1 Trading Plans (subject to certain exceptions).  Please consult with the CFO for any questions regarding overlapping Rule 10b5-1 Trading Plans.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Single Transaction Plans.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You may not enter into more than one Rule 10b5-1 Trading Plan designed to effect the open-market purchase or sale of the total amount of securities as a single transaction during any rolling 12-month period (subject to certain exceptions).  A single-transaction plan is &#x201c;designed to effect&#x201d; the purchase or sale of securities as a single transaction when the terms of the plan would, for practical purposes, directly or indirectly require execution in a single transaction.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modifications and Terminations.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Modifications/amendments and terminations of an existing Rule 10b5-1 Trading Plan are strongly discouraged due to legal risks, and can affect the validity of trades that have taken place under the plan prior to such modification/amendment or termination.  Under Rule 10b5-1 and these guidelines, any modification/amendment to the amount, price or timing of the purchase or sale of the securities underlying the Rule 10b5-1 Trading Plan (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Modification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will be deemed to be a termination of the current Rule 10b5-1 Trading Plan and creation of a new Rule 10b5-1 Trading Plan.  As such, the modification/amendment of an existing Rule 10b5-1 Trading Plan must be reviewed and approved in advance by the CFO in accordance with </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pre-clearance procedures set forth in the Policy and these guidelines, and any Material Modification will be subject to all the other requirements set forth in these guidelines regarding the adoption of a new Rule 10b5-1 Trading Plan.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The termination (other than through an amendment or modification) of an existing Rule 10b5-1 Trading Plan must be reviewed and approved in advance by the CFO in accordance with the pre-clearance procedures set forth in the Policy and these guidelines.  Except in limited circumstances, the CFO will not approve the termination of a Rule 10b5-1 Trading Plan unless:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">you are not aware of any MNPI; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Trading Window is open.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>gyre-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUBSIDIARIES OF GYRE THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note: Gyre Therapeutics, Inc. or one of its Subsidiaries has 100% ownership of the Subsidiaries listed below, except for Beijing Continent Pharmaceuticals Co., Ltd. (65.2%) and Beijing Continent Biomedical Technology Co., Ltd (65.2%).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:72.1%;box-sizing:content-box;"></td>
    <td style="width:27.9%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:13.7pt;background-color:#e4e5e3;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subsidiaries</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jurisdiction</font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Further Challenger International Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">British Virgin Islands</font></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nepenthe Holdings Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hong Kong</font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ratel Holdings Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">British Virgin Islands</font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aaring Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hong Kong</font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rosefinch Holdings Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">British Virgin Islands</font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Continent Pharmaceuticals Inc.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cayman Islands</font></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BJContinent Pharmaceuticals Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hong Kong</font></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beijing Continent Pharmaceuticals Co., Ltd.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">People&#x2019;s Republic of China</font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beijing Continent Biomedical Technology Co., Ltd.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">People&#x2019;s Republic of China</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>gyre-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br> <br> <br> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> <br> <br> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have issued our reports dated March 17, 2025, with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of Gyre Therapeutics, Inc. on Form 10-K for the years ended December 31, 2024 and 2023. We consent to the incorporation by reference of the aforementioned reports in the Registration Statements of Gyre Therapeutics Inc. on Forms S-8 (Nos. 333-206523, 333-206526, 333-212345, 333-219301, 333-225902, 333-239712, 333-264027, 333-275222 and 333-278291), and Form S-3 (Nos. 333-273395 and 333-283237).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Grant Thornton Zhitong Certified Public Accountants LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beijing, China</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 17, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>gyre-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rule 13</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-14(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) AND 15</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">d</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-14(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) of the Securities Exchange Act of 1934</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">I, Han Ying, certify that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Gyre Therapeutics, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Date: March 17, 2025</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Han Ying, Ph.D.</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Han Ying, Ph.D.</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>gyre-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rule 13</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-14(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) AND 15</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">d</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-14(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) of the Securities Exchange Act of 1934</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">I, Ruoyu Chen, certify that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Gyre Therapeutics, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Date: March 17, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Ruoyu Chen</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ruoyu Chen</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>gyre-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Gyre Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Han Ying, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.53%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.53%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Date: March 17, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Han Ying, Ph.D.</font></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Han Ying, Ph.D.</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Note: A signed original of this written statement required by &#167; 906 has been provided to Gyre Therapeutics, Inc. and will be retained by Gyre Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>gyre-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Gyre Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Ruoyu Chen, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.53%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.53%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Date: March 17, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Ruoyu Chen</font></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;Ruoyu Chen</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Note: A signed original of this written statement required by &#167; 906 has been provided to Gyre Therapeutics, Inc. and will be retained by Gyre Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img99844967_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img99844967_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )/!,8# 2(  A$! Q$!_\0
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M5*<Z;DIKE/1?^'S_ /P4K_Z.2_\ ,/? /_YUE'_#Y_\ X*5_]')?^8>^ ?\
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MZ&$JOVM.,H*7*G))N2\B_P"'S_\ P4K_ .CDO_,/? /_ .=91_P^?_X*5_\
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MPE+&+,.)/98C$4,-A8O&YHJV+GB:5:M2EA:7M.;$4Y4Z%1^TI*4;V2;N:/\
MP^?_ ."E?_1R7_F'O@'_ /.LH_X?/_\ !2O_ *.2_P#,/? /_P"=97CFI_\
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MJ:JYKG[K59X.G#"T\?FL\2ZF.H5<10I.E&3Y:W)1FIT)25:,TTJ<DI./:?\
M#Y__ (*5_P#1R7_F'O@'_P#.LH_X?/\ _!2O_HY+_P P]\ __G65\V?%O]A?
M]K3X&>// 7PR^)WP1\4Z%XV^*5\-+^'>CZ=<Z#XNB\8ZG]HLK:73-!UCP9J_
MB#0[[4K674;#[=81ZE]KT^.]MI[Z&W@FCD;I_C-_P3I_;-_9^\!ZE\3OBO\
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MW_R\_43_ (?/_P#!2O\ Z.2_\P]\ _\ YUE'_#Y__@I7_P!')?\ F'O@'_\
M.LK\NZ*/]5>&/^B<R'_PSY?_ /,X?ZR<1?\ 0_SK_P .F._^7GZB?\/G_P#@
MI7_T<E_YA[X!_P#SK*/^'S__  4K_P"CDO\ S#WP#_\ G65^7=%'^JO#'_1.
M9#_X9\O_ /F</]9.(O\ H?YU_P"'3'?_ "\_43_A\_\ \%*_^CDO_,/? /\
M^=91_P /G_\ @I7_ -')?^8>^ ?_ ,ZROR[HH_U5X8_Z)S(?_#/E_P#\SA_K
M)Q%_T/\ .O\ PZ8[_P"7GZB?\/G_ /@I7_T<E_YA[X!__.LH_P"'S_\ P4K_
M .CDO_,/? /_ .=97Y=T4?ZJ\,?]$YD/_AGR_P#^9P_UDXB_Z'^=?^'3'?\
MR\_;[]EW_@K7_P %!OB+^T/\'? OC+]H#^V/"OBKQYH6BZ]I?_"JO@EI_P!O
MTR\N1'<VWV[2OAO8ZC:^8G'G65Y;W"=8Y5/->"_\/G_^"E?_ $<E_P"8>^ ?
M_P ZROEW]B?_ ).T_9\_[*AX9_\ 2P5\NUQPX8X:>88J#X>R-PC@\#*,'E.
MY8RG7S%3DH_5[*4E""DTKR4(IMJ*MV3XBX@67X6:SW.%.6,Q\9369XWFE&%#
M+G"+E[>[C%SFXINT7.;23D[_ *B?\/G_ /@I7_T<E_YA[X!__.LH_P"'S_\
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MMY&U?Q=X8#PZC>7%C)IU[J-Y=:OI5SI:Z??_ !W\4/\ @GQ^V3\&E\/GXB?
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M/?&?BS4O-U+X;WDT7]K>)=<U34OL<,D>GV/VK['IMK9V$%O:P_B#7U%^UO\
M\E"^'G_9KO['_P#ZR_\ ">BIPQPTL?A8+A[(U"6$QTI064X#EE*%7 *$I1^K
MV<HJ<U%M7BIR2MS.Y3XBX@>!Q4WGN<.<<1@XQD\SQKE&,H8MR2E[>Z4G&+DD
M[/EC>]E;ZB_X?/\ _!2O_HY+_P P]\ __G64?\/G_P#@I7_T<E_YA[X!_P#S
MK*_+NBNS_57AC_HG,A_\,^7_ /S.<G^LG$7_ $/\Z_\ #ICO_EY^HG_#Y_\
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M_%G[0']JZ78_ 7]JGQI:VO\ PJKX)6/E>)?AO^S!\8/B)X+U+S]-^&]G</\
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M\9+#O$TZL,#G>-Q52.(PE3#4ZV%]E2K.H\3%XNC*-)0O.,FXM\K2\K_X?/\
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MC*]6E4IX26-5"=*%;VBK5</"4Z,%!^U<7"+YK(^?O^'S_P#P4K_Z.2_\P]\
M_P#YUE'_  ^?_P""E?\ T<E_YA[X!_\ SK*^7_BS^Q3^U+\#_B=X)^#?Q+^#
M?B31/B3\2#9KX"\-:==Z#XN;Q=+>WRZ;#;:#JO@W5_$&AZA>17KQPWUE!J;7
M>F^=!+J,-K#/#))V?QG_ ."=7[9G[/O@+4_B?\6/@I?>'O FAW]CIFOZ_IGC
M+X<^-(O#M[J4EM#8Q^(['P-XP\2ZGX>CN+B]L;5;G6;*QMDO+ZQM))DN;VUB
ME]U9;P#)X1+ <(-X_7 I87)6\:G/V:>$M3_VB]3W/W//[_N_%H>,\?QLEB6\
M;Q2E@O\ ?&\3FR6$M#VC^LWG^XM#W_WO)[GO;:GMO_#Y_P#X*5_]')?^8>^
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M$6TW%6^HO^'S_P#P4K_Z.2_\P]\ _P#YUE'_  ^?_P""E?\ T<E_YA[X!_\
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M/A?K?$%?"RQF(IQC*I1PL:V*BZLH*I3BY>[3YZD*?/SRY3PG_A\__P %*_\
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M<,Z-&C7]GB,5G%*I5I5\12PM.5*,G:495JT(J4G&$F^6$I3<82]%_P"'S_\
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M/]9.(O\ H?YU_P"'3'?_ "\_43_A\_\ \%*_^CDO_,/? /\ ^=91_P /G_\
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ME@U7A7^KRA]8K3IQYO:^[[-I5KW3IIJ27@__  ^?_P""E?\ T<E_YA[X!_\
MSK*/^'S_ /P4K_Z.2_\ ,/? /_YUE>-^-_\ @FY^V[\-_#O@/Q7XY^ 'B3PW
MH?Q)\3^%?!GA:XU#7/!8NAXG\;7<&G^%](\3:5#XFEU;P)/JFH7-OIZR>.K'
MPW;VFH3)8W\UK=L(:]W_ &V/^"4GQJ_9%\+_  G\96<6K?$+P_XYTCP5H?BN
M>VM/"]IJ/A;XU^+3>(GPNTC0-'\9>(]?\72&6U:&PUS1=,GTN\G"P1W;S3P(
MV_L/#IU\'AHX+A&I5Q\Z]+"*C@<IK0JU<,H^VI*K2HSIQJ1<XQ4)SC*4WR04
MI^Z8^VX\5'%8B6+XHITL%"C4Q+JXS,Z4J=/$-JE/V=2K&I*$K.3E",HQ@N>3
M4=3,_P"'S_\ P4K_ .CDO_,/? /_ .=91_P^?_X*5_\ 1R7_ )A[X!__ #K*
M\:^*W_!-_P#;6^"7P^UCXH_$OX%ZMH7@GP[#IUQXDU.R\6?#[Q1?>&K;5!"U
ME=>)?#OA+Q;KOB7P]:N+B SW.LZ/8P68D7[;);YX^(*]#"9)P5F%.5; 91PO
MC:49NG*KA,ORG$TXU$E)PE.C1G%3491DXMJ24D[6:.'%9QQ=@9QI8W-.(\'5
ME!5(T\5C<SP\Y0;:4XPJU82<&XR2DE9M-7NF?J)_P^?_ ."E?_1R7_F'O@'_
M /.LH_X?/_\ !2O_ *.2_P#,/? /_P"=97Y=T5U?ZJ\,?]$YD/\ X9\O_P#F
M<YO]9.(O^A_G7_ATQW_R\_;[]I+_ (*U_P#!0;P#\3;/P]X2_: _LG1Y?A'^
MSOXGDL_^%5?!*_W:YXZ_9\^%_CCQ5??:-3^&]Y=#^U/%'B+6=4^S+.+.Q^V?
M8M.M[/3K>UM(/!?^'S__  4K_P"CDO\ S#WP#_\ G65\N_MA_P#)9]/_ .R"
M_LE?^LH?!6OEVN++>&.&JF79?.?#V1SG/!86<YSRG 2G.<J%-RE*3P[<I2;;
ME)MMMMMW.O,.(N((8_&PAGN<0A#%XF,(1S/&QC&,:TU&,8JNE&,4DDDDDE9*
MQ^HG_#Y__@I7_P!')?\ F'O@'_\ .LH_X?/_ /!2O_HY+_S#WP#_ /G65^7=
M%=O^JO#'_1.9#_X9\O\ _F<Y/]9.(O\ H?YU_P"'3'?_ "\_43_A\_\ \%*_
M^CDO_,/? /\ ^=91_P /G_\ @I7_ -')?^8>^ ?_ ,ZROR\&,C=G;D;L8SC/
M.,\9QTSQGK7[\?"K]C+_ ()1?%/]G#XN?M+:7XX_;N@\%_ D^'+/XB6US>_
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M4@'[5'_94;__ --NF5\&5]Y_\%0/^4@'[5'_ &5&_P#_ $VZ97P97]?\/_\
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MD/\ U4_[*U?+M?47B+_DROX/_P#9T7[2'_JI_P!E:OEVN#+OX-;_ +#\R_\
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M<-?]"[B#_P ),!_\\SG_ .(4\0_]!V2?^%.._P#G<?PNT5_=%_PZ6_X)6_\
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MN(/_  DP'_SS#_B%/$/_ $'9)_X4X[_YW'\+M%?W1?\ #I;_ ()6_P#1 /\
MS*O[1G_SR*/^'2W_  2M_P"B ?\ F5?VC/\ YY%'_$8N&O\ H7<0?^$F _\
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M6IX2$5%_V?=R3H3YDTDDXV;;:C_$717]NG_#M'_@D%_T17_S(_[3W_S>4?\
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M?\1BX:_Z%W$'_A)@/_GF'_$*>(?^@[)/_"G'?_.X_A=HK^Z+_ATM_P $K?\
MH@'_ )E7]HS_ .>11_PZ6_X)6_\ 1 /_ #*O[1G_ ,\BC_B,7#7_ $+N(/\
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M<#_\\P_XA9GW_0PR+_PKQO\ \[C^(NBO[=/^':/_  2"_P"B*_\ F1_VGO\
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MM%?W1?\ #I;_ ()6_P#1 /\ S*O[1G_SR*/^'2W_  2M_P"B ?\ F5?VC/\
MYY%'_$8N&O\ H7<0?^$F _\ GF'_ !"GB'_H.R3_ ,*<=_\ .X_A=HK^Z+_A
MTM_P2M_Z(!_YE7]HS_YY%'_#I;_@E;_T0#_S*O[1G_SR*/\ B,7#7_0NX@_\
M),!_\\P_XA3Q#_T'9)_X4X[_ .=Q_"[17]T7_#I;_@E;_P!$ _\ ,J_M&?\
MSR*/^'2W_!*W_H@'_F5?VC/_ )Y%'_$8N&O^A=Q!_P"$F _^>8?\0IXA_P"@
M[)/_  IQW_SN/X7:*_NB_P"'2W_!*W_H@'_F5?VC/_GD4?\ #I;_ ()6_P#1
M /\ S*O[1G_SR*/^(Q<-?]"[B#_PDP'_ ,\P_P"(4\0_]!V2?^%.._\ G<?Q
M_P#[8?\ R6?3_P#L@O[)7_K*'P5KY=K^ZWXB_P#!/#_@EOXE\3G4/B!\(/MO
MB2S\.^"O#AF_X6!^T1;>7H'@_P %>'_"7@ZS\O1?&T%@_P#9W@[1-!T_[1L:
M]N_LWVO5)[K5)KRYEX;_ (=H_P#!(+_HBO\ YD?]I[_YO*PP/BQD&'P6#H3R
MSB&4J&%P]&4H8+!.$I4Z4(.4&\RBW%N+<6XIM6;2V-L9X8YY7Q>*KPQ^21C6
MQ%>K%3Q6,4U&I5E-*267M*232DDVD[V;W/XBZ*_MT_X=H_\ !(+_ *(K_P"9
M'_:>_P#F\H_X=H_\$@O^B*_^9'_:>_\ F\KJ_P"(O</?]"KB/_PAP/\ \\SG
M_P"(69]_T,,B_P#"O&__ #N/XBZ*_MT_X=H_\$@O^B*_^9'_ &GO_F\H_P"'
M:/\ P2"_Z(K_ .9'_:>_^;RC_B+W#W_0JXC_ /"' _\ SS#_ (A9GW_0PR+_
M ,*\;_\ .X_B+HK^W3_AVC_P2"_Z(K_YD?\ :>_^;RC_ (=H_P#!(+_HBO\
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M (;?\B*/^QLUG_TS^&Z["O+J_P 6?^)G=#X(_P"&/Y(****S*"BBB@ HHHH
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M/_#GXFVCV['Q?X5TO4]0CM6+6]IKBP_8_$6G1,0I*Z9KUMJ6G$E5.ZU.54Y
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M2O\ P3(T"X\*_%C_ (*;>&;GQ[K?Q-E\/_MK:9HP\:>)KG3+[Q+J<.F_LS?
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M;N],^Q:/X(^)'AF*;2[FT>X+_6OQ(_X)KP_$S4/VK+'7/B[9R_#K]L/]I_\
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M?B#?>-[G4[6#1O$^CW+W?B6TM%T+5M%E:6V\/VMCI6C6,,39GP/_ &#/B/\
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M(?\ H291_P"&W!?_ "D/]<>+O^BJXD_\/F9__-7DON/7/^&@/CQ_T6SXN?\
MAR/&7_RYH_X: ^/'_1;/BY_X<CQE_P#+FO(Z*/\ 5_(?^A)E'_AMP7_RD/\
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M-&N?%7@OQ<%U27PKJR>'_$E]X8U..YU[T7Q[^P-X!\6^*#\0_"_Q:^-OP?\
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MF=1AD.L:L;[F?B#_ ,$P? _Q#\"1^#[[]I3]IG2M9U_XL?\ "Z_C9\1+:/\
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M4 %%%% !1110 4444 >#_%'_ )'?5/\ KS\/_P#J-Z17G]>@?%'_ )'?5/\
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MA5X4\>7-@UQ#IX6;5Y8]/;Z&\/\ [7'[/GB?P3^SI\0M&^($-YX4_:OU;1M
M^!&HPZ#XFG/C+7]<\(Z_XXL]%N8+71IYO"FH0>'O"WB*;4X_&":#%I&HZ1=:
M'J4UKK9AT^7-.DW*RA=Z-V2YKNV]O>7,[:-KF=MRGSZ7YM+6U;MI=>CMJMM#
ML?%'P%^$_C/XBP_%CQ+X4_M+Q_;_  H\:_!"'7_[=\2V>SX7_$35M USQCX8
M_LJPUBUT5O[8U3POH5U_;3::WB'3_L/D:7JUC;W-Y#<>?>*OV,_V</&7P.^&
M/[.6N> +S_A4WP63P&/A+I>B^/?B1X6\5_#FY^&.E#0O VJ^#_BAX7\7Z/\
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M%<W*>$]56>XCM?.N/LT<TH:1+?SY_)5A'YTFW>WRC7UM/_R#/$/_ &*?B_\
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M7?\ 86D_]%15Y[7H7Q7_ .2C>+O^PM)_Z*BKSVO?H_PJ7_7N'_I*/,G\<O\
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M5CKGB:U^+]A?WA^#EOXSU31KS2V-._6V[W^_R_/NP/T__M.'_H#Z5_WQ??\
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M_$_A?5OM]Z=0309#33?7S?EY]=/Q[L#]Q_[3A_Z ^E?]\7W_ ,GT?VG#_P!
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M#_T!]*_[XOO_ )/K\G]/_;;^/-GX]_X)]^!OBO\ !GPU\#?$'[27C?\ ::\
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MX8&K:-JME9EUWV\_3S_KYL#[H_M.'_H#Z5_WQ??_ "?1_:</_0'TK_OB^_\
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MK/\ A)[/_H3O"?\ WYUW_P"7U'_"3V?_ $)WA/\ [\Z[_P#+ZN3HHY(_WO\
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M?J*.6.CLKJ[6BT;=VUVN]7YA=]V>'_$/]F/]FSXN^+M \?\ Q8_9[^!_Q/\
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M%6"_^8@_X@YX8?\ 1%Y-_P""JW_RX]"_X65KO_/II/\ WXO/_D^C_A96N_\
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M  JP?_S%Y?GW8?\ $(/#/_HC<G_\%U?_ )<?0_\ PTOX[_Z!/A+_ , -8_\
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MK!]/^Y(3\'O#*5K\&9,[;7I5O_EQZ%_PLK7?^?32?^_%Y_\ )]'_  LK7?\
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MXE\,>(M(NUWVFJ:%K^BW5[I6K:==)\]O?6%W<6TR_-'*PYKHZ>^P@K[$O_\
MCZ?_ *YV_P#Z3Q5\=U]B7_\ Q]/_ -<[?_TGBKBQ>]+TJ?G3.BA]O_MW_P!N
M*=%%%<AT!1110 4444 %%%% !1110 4444 >#_%'_D=]4_Z\_#__ *C>D5Y_
M7H'Q1_Y'?5/^O/P__P"HWI%>?UZE'^%2_P"O</\ TE'#/XY?XI?FPHHHK0D*
M*** "BBB@ HHHH **** "BBB@#]"/@=_R2[PO_W&_P#U(M7HH^!W_)+O"_\
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MX-O=4MM<O/"4'BEK0ZY#X8N]:L[/6+G08[]=*GU2TMM0EM'NX(ID35_P_!W
M_)_XWZU\9-*\>_'WX;?%#XG6_CB[L?\ @DK\5?$GBE/!NA>(OAS\+]=\>_\
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M:6T:#VR&030Q2JVY98HY%;RWBW!T#!O*D_>1Y!SY<GSI]U_F!J6BBJ ****
M"BBB@ HHHH **** "BBB@"_I?_(0M/\ KJ/Y&OSV_P"%:Z%_S]ZM_P!_[/\
M^0*_0G2_^0A:?]=1_(U\<5^;^(/@AX3^,G]D?\10X%R/C7_5SZ__ &'_ &S2
MK5?[,_M?ZE_:?U;V->CR_7/[+R_VW-S7^J4K6L[^[DG&/$_"7UG_ %;SK&Y/
M_:'L?KOU2<(_6/JOM?J_M.>$[^Q^LU^2UK>UEO<\]_X5KH7_ #]ZM_W_ +/_
M .0*/^%:Z%_S]ZM_W_L__D"O0J*_-_\ B2+Z)W_1B^!__"7&_P#S:>]_Q&/Q
M/_Z+3.?_  ;1_P#E)Y[_ ,*UT+_G[U;_ +_V?_R!1_PK70O^?O5O^_\ 9_\
MR!7H5%'_ !)%]$[_ *,7P/\ ^$N-_P#FT/\ B,?B?_T6F<_^#:/_ ,I//?\
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M)_\ T6F<_P#@VC_\I//?^%:Z%_S]ZM_W_L__ ) H_P"%:Z%_S]ZM_P!_[/\
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M!'_A+C/_ )M\OS[L/^(O^)G_ $66<?\ @RE_\I/GC_AFCP)_T%O%O_@?H_\
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M -G_ /(%'_"M="_Y^]6_[_V?_P @5Z%173_Q)%]$[_HQ? __ (2XW_YM,/\
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M_P!%EG'_ (,I?_*3YX_X9H\"?]!;Q;_X'Z/_ /*&C_AFCP)_T%O%O_@?H_\
M\H:^AZ*/^)*/HI_]&.X(_P#"7&?_ #;Y?GW8?\1?\3/^BRSC_P &4O\ Y2?/
M'_#-'@3_ *"WBW_P/T?_ .4-.3]FKP&KJQU/Q7(%96*/?Z3L< @E&V:&C[6
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M)?\ _'T__7.W_P#2>*N+%[TO2I^=,Z*'V_\ MW_VXIT445R'0%%%% !1110
M4444 %%%% !1110!X/\ %'_D=]4_Z\_#_P#ZC>D5Y_7H'Q1_Y'?5/^O/P_\
M^HWI%>?UZE'^%2_Z]P_])1PS^.7^*7YL****T)"BBB@ HHHH **** "BBB@
MHHHH _0CX'?\DN\+_P#<;_\ 4BU>BCX'?\DN\+_]QO\ ]2+5Z*^<K_QZW_7V
MI_Z7(]6G_#I_X(_^DH^7?B9X@M;7Q[XHMW\+^&[QHM3=&NKN+5VN9B(HOGF,
M&LP0ESG!,<,:X ^6N%_X2>S_ .A.\)_]^==_^7U:WQ7_ .2C>+O^PM)_Z*BK
MSVO=I03I4WK_  X/XI?RKS\E]R/-FWS2V^)]%W?D=9_PD]G_ -"=X3_[\Z[_
M /+ZC_A)[/\ Z$[PG_WYUW_Y?5R=%:<D?[W_ (%+_/R7W$W?E]R_R.L_X2>S
M_P"A.\)_]^==_P#E]1_PD]G_ -"=X3_[\Z[_ /+ZN3HHY(_WO_ I?Y^2^X+O
MR^Y?Y'6?\)/9_P#0G>$_^_.N_P#R^H_X2>S_ .A.\)_]^==_^7U<G11R1_O?
M^!2_S\E]P7?E]R_R.L_X2>S_ .A.\)_]^==_^7U'_"3V?_0G>$_^_.N__+ZN
M3HHY(_WO_ I?Y^2^X+OR^Y?Y'6?\)/9_]"=X3_[\Z[_\OJ/^$GL_^A.\)_\
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MZ%[XB?\ @I\-?_-;1_PW)\)O^A>^(G_@I\-?_-;1_P 18\-?^BPRG_P?B/\
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MR_Z=>GX^8?ZU</?]#;"?^!2_^0\_S[,_2;^TX?\ H#Z5_P!\7W_R?1_:</\
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M^'F/P(_Z%/XM_P#@A\'?_-[1_P /,?@1_P!"G\6__!#X._\ F]H_XBIX=_\
M16Y5_P"#:WE_TZ]/Q\P_UJX>_P"AMA/_  *7_P AY_GV9^DDVIPC3]=;^Q]*
M(C\,>*92A2^VRK%X<U25H9!]O!,,X0PS!&20Q.XCDC?;(OS!_P )/9_]"=X3
M_P"_.N__ "^KYYE_X*8? A[/5;<>$_BV'OM#U[38B=!\';5GU31K[3K=Y"/'
MI(A2>ZC:9E5W6(.R1R.%1O#?^&Y/A-_T+WQ$_P#!3X:_^:VNG#^*WAO%2Y^+
MLJ3;C;]]76B7E3]/GYF-7BC('R\N:X5[WUD][6WA_778^^/^$GL_^A.\)_\
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M_"3V?_0G>$_^_.N__+ZC_A)[/_H3O"?_ 'YUW_Y?5\#_ /#<GPF_Z%[XB?\
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M_P# I?\ R'G^?9GZ3?VG#_T!]*_[XOO_ )/H_M.'_H#Z5_WQ??\ R?7YL_\
M#S'X$?\ 0I_%O_P0^#O_ )O:/^'F/P(_Z%/XM_\ @A\'?_-[1_Q%3P[_ .BM
MRK_P;6\O^G7I^/F'^M7#W_0VPG_@4O\ Y#S_ #[,_2;^TX?^@/I7_?%]_P#)
M]']IP_\ 0'TK_OB^_P#D^OS9_P"'F/P(_P"A3^+?_@A\'?\ S>T?\/,?@1_T
M*?Q;_P#!#X._^;VC_B*GAW_T5N5?^#:WE_TZ]/Q\P_UJX>_Z&V$_\"E_\AY_
MGV9^DW]IP_\ 0'TK_OB^_P#D^C^TX?\ H#Z5_P!\7W_R?7YL_P##S'X$?]"G
M\6__  0^#O\ YO:/^'F/P(_Z%/XM_P#@A\'?_-[1_P 14\._^BMRK_P;6\O^
MG7I^/F'^M7#W_0VPG_@4O_D//\^S/TF_M.'_ * ^E?\ ?%]_\GT?VG#_ - ?
M2O\ OB^_^3Z_-G_AYC\"/^A3^+?_ ((?!W_S>T?\/,?@1_T*?Q;_ /!#X._^
M;VC_ (BIX=_]%;E7_@VMY?\ 3KT_'S#_ %JX>_Z&V$_\"E_\AY_GV9^DW]IP
M_P#0'TK_ +XOO_D^C^TX?^@/I7_?%]_\GU^;/_#S'X$?]"G\6_\ P0^#O_F]
MH_X>8_ C_H4_BW_X(?!W_P WM'_$5/#O_HK<J_\ !M;R_P"G7I^/F'^M7#W_
M $-L)_X%+_Y#S_/LS])O[3A_Z ^E?]\7W_R?7A_Q \0VMOXQUZ%_"WAJZ:.[
M0&XN8M8,\O\ HT!W2&'68(BPSM^2)!@#C.2?DG_AYC\"/^A3^+?_ ((?!W_S
M>UY?XN_;[^#NO^(]5UBS\-?$N*VOKA984N='\+).JK#%&1(L7C*:,-N0D!97
M&".<Y VH>*WAS&;<^+LJ2Y79^VK+6\6MJ?E?UOUN9U>*.'W%<N:X1OF763TL
M^\/-?CV9]J_\)/9_]"=X3_[\Z[_\OJ/^$GL_^A.\)_\ ?G7?_E]7P/\ \-R?
M";_H7OB)_P""GPU_\UM'_#<GPF_Z%[XB?^"GPU_\UM=?_$6/#7_HL,I_\'XC
M_P"5^2^XY_\ 6?(O^AIA/Q_^0\_S[,^^/^$GL_\ H3O"?_?G7?\ Y?4?\)/9
M_P#0G>$_^_.N_P#R^KX'_P"&Y/A-_P!"]\1/_!3X:_\ FMH_X;D^$W_0O?$3
M_P %/AK_ .:VC_B+'AK_ -%AE/\ X/Q'_P K\E]P?ZSY%_T-,)^/_P AY_GV
M9]\?\)/9_P#0G>$_^_.N_P#R^H_X2>S_ .A.\)_]^==_^7U? _\ PW)\)O\
MH7OB)_X*?#7_ ,UM'_#<GPF_Z%[XB?\ @I\-?_-;1_Q%CPU_Z+#*?_!^(_\
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MIA/Q_P#D//\ /LS[X_X2>S_Z$[PG_P!^==_^7U'_  D]G_T)WA/_ +\Z[_\
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M=2;T/JG_ (2>S_Z$[PG_ -^==_\ E]7U9>ZC"MPP.DZ6W[N Y9;W/,$1QQ?
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MTX?^@/I7_?%]_P#)]95%%O7[W_73\^[ U?[3A_Z ^E?]\7W_ ,GT?VG#_P!
M?2O^^+[_ .3ZRJ*+>OWO^NGY]V!X7\5I!)XYU5Q%'$#9Z =D6\(,^'=)/ =W
M( !"@9^ZHSEMS-YW7H'Q1_Y'?5/^O/P__P"HWI%>?UZE'^%2_P"O</\ TE'#
M/XY?XI?FPHHHK0D**** "BBB@ HHHH **** "BBB@#]"/@=_R2[PO_W&_P#U
M(M7HH^!W_)+O"_\ W&__ %(M7HKYRO\ QZW_ %]J?^ER/5I_PZ?^"/\ Z2CX
MY^*__)1O%W_86D_]%15Y[7H7Q7_Y*-XN_P"PM)_Z*BKSVO?H_P *E_U[A_Z2
MCS)_'+_%+\V%%%%:$A1110 4444 %%%% !1110 4444 %%%% !1110!]$?#;
M_D11_P!C9K/_ *9_#=>7?M9_\FK?M,?]F_?&7_U7/B2O4?AM_P B*/\ L;-9
M_P#3/X;KL*\NK_%G_B9W0^"/^&/Y(_EV^%MQ^RE;ZQ^PE+_P46_X5X?@)'_P
M29_9/G_9-C^/<*W/P9?X]PQ:B?C<? ]KXACE\'7'[3X\*M\%!X$CTN*3XOOX
M:>\3X6HQ?Q8I]G_8;C@B\-_\$EXO"\^NW-M%=?\ !3F/P[<^.!XD7Q+<0)XT
M\:+I$_B]?%L-OXO7798Q;R>(!XFMX/$@U!KL:S#%JGVE%_HBHK%1M;7:W37=
M/5W\K+LBC^5WX(_\*-_X1S]B'_A77]@?\/G_ /AI'X6?\-=[/._X:Z_LO_A9
M,/\ PVW_ ,-,^3_Q6G_#/7_"M?\ A,/^%=?\+%_XLA]E_P"%/?\ "D/W?_"M
M:Y?X]?\ #'(^'7_!2B/6M1L;C_@HG)^V'^T'<_L2:<+GQ&?VEK#XT^=X)A^$
MS?L:V,HC\3KILWCZ#1I_BI>_!1)_"<IDUZ#XW7AT6WU2TM/ZRJ\C^$GP8\+_
M  97XE)X7O\ 7[\?%/XN>-_C/X@_M^ZTZZ-GXH\>S6,^L6&C?V=I6EBWT"V>
MPA&FVMZ-1U&%6E%UJMX60HN7TV:V]-;7W[OTT!:-/L?S,_\ !3;5/AGXW\9_
M\% (?B/9?LZ>&/VG?@]^SAHX^!TGQSM/&'QM_:7US7=&^ :_%"+XC_\ !/KX
M7>&]:\":_P# GPUHOCB\N['4_C3\-M4\>W5M\3/!FO\ BGXA6FC:5X(;2+CU
MRP\"_LS>$/VE?V^O$GBSP)\"O"G[1_QD_P""9GPI^+/PB\1ZMX.\ :!\6_B1
MJFM_!#]I*T_:/\;?#G6Y=,L_$_B36]4N;733\:=0\-7=UJUU:+H]WXV+V$NF
M3/\ TS44^75O35I[=K^>^NX'X&_!OX$_"7]GW]H+_@D#XH^#G@NP\"^+/CC\
M#OBYX<^-_C#3+O5;KQE\:M'TO]F/PSX]T.V^,'B[5;_4/$GQ0E\-^*]+L=4\
M*WWCK4]>O_"B0?V=X<NM,TJ6:QD\&\,CX1'X,?\ !, _MECP:?V"1H/[7I^)
MW_"X!I__  SD/V@?^$^M1\!3^T'_ ,)'_P 4"/#'_",GXSCP,?BA_P 4!_PL
M<Z")/^*^/P[K^FNBCE\_P_P^?6WX@?#_ /P3Z_X4_P#\* O/^&>_^%L_\*)_
MX6W\8?\ A4W_  M+^SO[*_X0[_A/=8^S?\**^Q?Z3_PS-]O_ +0_X4'_ &G^
M\_X5Y_9/]B?\4A_PC5?D7^P)^R#\=_VKOV#/AW\/?B-^TEX#TK]C_6?CK\6O
M%6N?!+P5^SOJ&E_&#Q)IWPY_;"^(/C:U\$Z]^T)KWQV\2^'7\,>)O&WABTNO
M%/\ 8OP$T+6;WPI/<>%-/U?2Y)9]=G_I4HIVV\E:VRZ?AIMJ!_*W\+?VB?@S
M>_LK_P#!,/\ 98L_'%G=?M%?"#_@HG\"O#'Q?^#EOIFO3>.OA#KGA3XZ_$NR
MU.S^+&C1Z4TWPS6[N4\OPS>>.#H-CXT62"7P=<Z]#<V\DOMWC*]\-ZC^Q/\
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M6-Q:6MS-^P](0&!5@"I!!! (((P00>""."#P10HVZ]+:;]-=_+L'2WK^-O\
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MU;V_]B>Q]O\ 5*-;V/MO8U?9>TY?:>RJ<E^25OS3Q#P6,QG]C_5,)BL5[/\
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M@O\ ^:.C_AE'X_?]"%_Y=/@O_P":.C_B'_'G_1$\7?\ B-YS_P#,0?V+G/\
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M?]0^./\ HC.*_P#Q'<W_ /F,?]A9W_T)LU_\-V+_ /E)\DT5];?\,+?M4?\
M1+?_ "]_AS_\UU'_  PM^U1_T2W_ ,O?X<__ #74?ZA\<?\ 1&<5_P#B.YO_
M /,8?V%G?_0FS7_PW8O_ .4GR317UM_PPM^U1_T2W_R]_AS_ /-=1_PPM^U1
M_P!$M_\ +W^'/_S74?ZA\<?]$9Q7_P"([F__ ,QA_86=_P#0FS7_ ,-V+_\
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M_P"&4?C]_P!"%_Y=/@O_ .:.C_B'_'G_ $1/%W_B-YS_ /,0?V+G/_0IS/\
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M_P"([F__ ,QA_86=_P#0FS7_ ,-V+_\ E)\DT5];?\,+?M4?]$M_\O?X<_\
MS74?\,+?M4?]$M_\O?X<_P#S74?ZA\<?]$9Q7_XCN;__ #&']A9W_P!";-?_
M  W8O_Y2?)-%?6W_  PM^U1_T2W_ ,O?X<__ #74?\,+?M4?]$M_\O?X<_\
MS74?ZA\<?]$9Q7_XCN;_ /S&']A9W_T)LU_\-V+_ /E)\DT5];?\,+?M4?\
M1+?_ "]_AS_\UU'_  PM^U1_T2W_ ,O?X<__ #74?ZA\<?\ 1&<5_P#B.YO_
M /,8?V%G?_0FS7_PW8O_ .4GR317UM_PPM^U1_T2W_R]_AS_ /-=1_PPM^U1
M_P!$M_\ +W^'/_S74?ZA\<?]$9Q7_P"([F__ ,QA_86=_P#0FS7_ ,-V+_\
ME)\DT5];?\,+?M4?]$M_\O?X<_\ S75S^I?L?_M%Z1?7.FZC\._L][:.([B'
M_A+? TWEN45P/,@\32Q/\KJ<I(PYQG((#7 7'4G:/!?%DGO9<.9PW;OI@Q/(
M\[6^3YHO7+\6OSHGS317T1_PRC\?O^A"_P#+I\%__-'1_P ,H_'[_H0O_+I\
M%_\ S1U7_$/^//\ HB>+O_$;SG_YB%_8N<_]"G,__"#%?_*CYWHKZ(_X91^/
MW_0A?^73X+_^:.C_ (91^/W_ $(7_ET^"_\ YHZ/^(?\>?\ 1$\7?^(WG/\
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M=Q8W]C<17=E>VDKP7-K<P.LD,\$T;+)%+%(JNCHP96 (->^_\,H_'[_H0O\
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MX1TKX[?$;X-^%?@O?:YJ?BO3[OPQH-E!X]>3Q%XBC31-!_M'4YX+64LN[_\
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M?<OZZ?GW9J^=HG_0.U7_ ,'-I_\ **CSM$_Z!VJ_^#FT_P#E%65119>?WO\
MS"_I]R_KI^?=G1:=+HQOK8)8:FK^8-K/J]JZ@X/)4:(A8>P=?K7RC]L\"_\
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MT<]/^;_R:7^86EV_!>7_  /Q\S[A\[1/^@=JO_@YM/\ Y14>=HG_ $#M5_\
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M%7P]_P -R?";_H7OB)_X*?#7_P UM'_#<GPF_P"A>^(G_@I\-?\ S6T<]/\
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M^A<\6?\ A::/_P#,%1]L\"_]"YXL_P#"TT?_ .8*ODS_ (:7\"?] GQ;_P"
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M[?C5=4NQ>7<,5S<>9-&CJ6>FNS_#3_)]KW>RT#O_ %U7]=?U7S/^T+]LU/\
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MZGG_ ,MG_P#"&CZEB?\ GU_Y/3_^3#ZQ1_G_ /)9?_(GR717UI_PRY_U//\
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M;^LD3*K3C;FE:][:2>WHGW/DNBOK3_AES_J>?_+9_P#PAH_X9<_ZGG_RV?\
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M[$O_ /CZ?_KG;_\ I/%7QW7V)?\ _'T__7.W_P#2>*N+%[TO2I^=,Z*'V_\
MMW_VXIT445R'0?E7_P %N_\ A,O^'5O[9/\ PA/]H?;/^%<:5_PD_P#9G]J_
M:_\ A5__  G7A/\ X7#_ ,@3_B9_9/\ A5/_  F7]I?9_D_LW[7]K_T/[17U
MGKDG[*\/[&VJ3>(1\-3^Q?%^SO=2:P+2*UG^%!_9W3X?NUX+.#1DDMYO!Q\
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MKRST>YUZ.P;2H-4N[;3Y;M+N>*%RS[O\/\@^2_'_ #_J[\K=]Y.B?]!'5?\
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M7R=$_P"@CJO_ ()K3_Y>T>3HG_01U7_P36G_ ,O:RJ*+/N_P_P @^2_'_/\
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M_P#I+;UTX9-U'[TE[CVY?YH]XLRK-<JT3]Y;W[/LU_3?E:G]C\"_]#'XL_\
M"+T?_P";VC['X%_Z&/Q9_P"$7H__ ,WM<G17=RO_ )^3^Z'_ ,A_5WY6Y;K^
M6/\ Y-_\E_5WY6ZS['X%_P"AC\6?^$7H_P#\WM'V/P+_ -#'XL_\(O1__F]K
MDZ*.5_\ /R?W0_\ D/ZN_*Q=?RQ_\F_^2_J[\K=9]C\"_P#0Q^+/_"+T?_YO
M:/L?@7_H8_%G_A%Z/_\ -[7)T4<K_P"?D_NA_P#(?U=^5BZ_EC_Y-_\ )?U=
M^5NL^Q^!?^AC\6?^$7H__P WM'V/P+_T,?BS_P (O1__ )O:Y.BCE?\ S\G]
MT/\ Y#^KORL77\L?_)O_ )+^KORMUGV/P+_T,?BS_P (O1__ )O:/L?@7_H8
M_%G_ (1>C_\ S>UR=%'*_P#GY/[H?_(?U=^5BZ_EC_Y-_P#)?U=^5NL^Q^!?
M^AC\6?\ A%Z/_P#-[1]C\"_]#'XL_P#"+T?_ .;VN3HHY7_S\G]T/_D/ZN_*
MQ=?RQ_\ )O\ Y+^KORMUGV/P+_T,?BS_ ,(O1_\ YO:/L?@7_H8_%G_A%Z/_
M /-[7)T4<K_Y^3^Z'_R']7?E8NOY8_\ DW_R7]7?E;K/L?@7_H8_%G_A%Z/_
M /-[7TYJ@B%[*(7DDB"6^QY8UBD8?9H>6C2694.<C E?C!SS@?&]?8E__P ?
M3_\ 7.W_ /2>*N/%)IT[R<M)[\NG\/\ EBM_/Y'10=^;1+X=K^?=O^GZ6IT4
M45RFX4444 %%%% !1110 4444 %%%% '@_Q1_P"1WU3_ *\_#_\ ZC>D5Y_7
MH'Q1_P"1WU3_ *\_#_\ ZC>D5Y_7J4?X5+_KW#_TE'#/XY?XI?FPHHHK0D**
M** "BBB@ HHHH **** "BBB@#]"/@=_R2[PO_P!QO_U(M7HH^!W_ "2[PO\
M]QO_ -2+5Z*^<K_QZW_7VI_Z7(]6G_#I_P""/_I*/CGXK_\ )1O%W_86D_\
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MPJTGC/Q!>7Y_4SX$_L4?LV?LX>+/$'Q"^&'@76G^)7BC0[;PMKGQ3^)WQ/\
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M]KGXA_\ !.K_ (*3?#_XX>*_C;\*]0^"%CX0U_X=>*O&VJ?L#WG[2OC?X?\
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M)M+%_8:CJ&HMIZ>2ZOSB]_D];"/CG]I?PSX-^&_[<G[3FE?!G2-#\-CXN?\
M!)']I'Q]^U3X?\*P6^CZ7J/BGP=XGT;PY^SI\1/%>C:5916%SXZUK2=>^.'A
M:T\0:@?[:UCPSX=:TFNS9^'+&"?R[_@C'(?%_B?P#J'[5-N--_:A^'?[&7[/
M%A^Q[X&N+UM0^'&A_L.:Y\(/A;;ZM\4?@==7-IIW_"1?$+QY\3UO-#_:<\2W
M&EVGBWP=>:=\./AN8K?X?'PGK?CG]COA9^Q/^S'\&/!OQ4\#_#_X:&RT_P".
M5C=Z;\9?$7B'QI\0?'OQ.^*=G=Z)>^&_*\??&3Q_XK\3_%OQ4]AH>I:AINB3
MZSXVN[CP_;WMT-"ETYYY7;<;]DK]GW^S/V;M*A\ &RC_ &1)-&/[.VHZ9XL\
M;Z5XC^'-GHGA ^ 8M#@\6:;XEM?%'B7PMK'@_P O0O&'A'QEK'B+POX\M+6Q
M;QMI'B"XT^QFMRSNGINW;IK;_*_J!^1'[)GPI_9Y^)/_  1+\767[1GASP;=
M?#2#2_VUO$/BSQ'XDT[3%G\)P>&OCU\=]1M?'&EZ[<6D][H'B7P:UE%K7AKQ
M'IS)J^A:II]E>Z5*EU;PBO2/V??%OQ7;QW_P1=^)?Q#AU!_BU\?_ -A_Q_\
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MHKK?^$!\=_\ 0E>+?_"<UC_Y#H_X0'QW_P!"5XM_\)S6/_D.CV<_Y)_^ O\
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MU_PZ^\\[HKT3_A4/Q9_Z)?\ $3_PBO$O_P K*/\ A4/Q9_Z)?\1/_"*\2_\
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M)8[:VCAMH8HD\!KVL$FH24G=^[=_)_?Z]=SAQ%FXV5E[W_MH4445V',%%%%
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MKS^O4H_PJ7_7N'_I*.&?QR_Q2_-A1116A(4444 %%%% !1110 4444 %%%%
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M .8NN3HHY7_S\G]T/_D/ZN_*Q=?RQ_\ )O\ Y+^KORMUG_".:/\ ]#[X3_\
M /QU_P#,71_PCFC_ /0^^$__  #\=?\ S%UR=%'*_P#GY/[H?_(?U=^5BZ_E
MC_Y-_P#)?U=^5NL_X1S1_P#H??"?_@'XZ_\ F+H_X1S1_P#H??"?_@'XZ_\
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M'_R;_P"2_J[\K=9_PCFC_P#0^^$__ /QU_\ ,71_PCFC_P#0^^$__ /QU_\
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M2P3)(<&'6\CYCP<:.1D=#@D>A(KY/\(_\C7X8_[&'1?_ $Y6U?3D_P#KYO\
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M_P#@'XZ_^8NN3HKNY7_S\G]T/_D/ZN_*W+=?RQ_\F_\ DOZN_*W6?\(YH_\
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M_5WY6U?[.M/^@[I7_?G7/_E-1_9UI_T'=*_[\ZY_\IJRJ*+/N_P_R#Y+\?\
M/^KORMJ_V=:?]!W2O^_.N?\ RFH_LZT_Z#NE?]^=<_\ E-65119]W^'^0?)?
MC_G_ %=^5M7^SK3_ *#NE?\ ?G7/_E-1_9UI_P!!W2O^_.N?_*:LJBBS[O\
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MJ.@ZOHZ>/)M#\!:GX>\9^(?#^KV?[3I\(OA/%H'A3PI'\,/AY'X6\">(]/\
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M*_%/P=)\';J[^)7BWQ!+>^.I-?V[[QQ\7O!/[3%E\;M?^+/Q-^(OPH\4?\%
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MNG"_Q)?X'_Z5$QK_  +_ !+\F</1117><H4444 %%%% !1110 4444 %%%%
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M_(BC_L;-9_\ 3/X;KL*X_P"&W_(BC_L;-9_],_ANNPKRZO\ %G_B9W0^"/\
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M6^&GQ-_:"^.EW^S)^SG!I,/A;0_%FA:?X@^-2_"GXPRZ?X_^(FG^(;%?A;X
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MS_L5O#/_ *8["N3%[0]9?DC>AO+T7YDM%%%<1TA1110 4444 %%%% !1110
M4444 -G_ .09XA_[%/Q?_P"HOJ]?)-?6T_\ R#/$/_8I^+__ %%]7KY)KMPF
MT_6/Y,YZ_P!C_M[_ -M"BBBNLYPHHHH **** "BBB@ HHHH **** .A\(_\
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MZ;:_!I?A]\/]%^(?B+0/B-H%Q\17UU_$WAW2]:AM?'VD>$;7Q+-\+YHFO_B
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M@;3S<6'B6S\)Z[JVI^"]=LYM&\6V6C7LUBEY\H?LH_'RQ_9D^,G[>7@+XL?
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M/[5'_14O_+(^'/\ \R-?)-%3_KYQQ_T6?%?_ (D6;_\ S8/^W<[_ .ASFO\
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M;I_:H_Z*E_Y9'PY_^9&ODFBC_7SCC_HL^*__ !(LW_\ FP/[=SO_ *'.:_\
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ML^*__$BS?_YL#^W<[_Z'.:_^''%__+CZV_X;I_:H_P"BI?\ ED?#G_YD:/\
MANG]JC_HJ7_ED?#G_P"9&ODFBC_7SCC_ *+/BO\ \2+-_P#YL#^W<[_Z'.:_
M^''%_P#RX^MO^&Z?VJ/^BI?^61\.?_F1H_X;I_:H_P"BI?\ ED?#G_YD:^2:
M*/\ 7SCC_HL^*_\ Q(LW_P#FP/[=SO\ Z'.:_P#AQQ?_ ,N/K;_ANG]JC_HJ
M7_ED?#G_ .9&C_ANG]JC_HJ7_ED?#G_YD:^2:*/]?../^BSXK_\ $BS?_P";
M _MW._\ H<YK_P"''%__ "X^MO\ ANG]JC_HJ7_ED?#G_P"9&C_ANG]JC_HJ
M7_ED?#G_ .9&ODFBC_7SCC_HL^*__$BS?_YL#^W<[_Z'.:_^''%__+CZV_X;
MI_:H_P"BI?\ ED?#G_YD:Y_4OVP/VB]7OKG4M1^(GVB]NW$EQ-_PB7@:'S'"
M*@/EP>&8HD^5%&$C4<9QDDGYIHIKCWCJ+O'C3BR+VNN(\X3MVTQ@GGF=O?.,
MT?KF&+?YUCZ(_P"&KOC]_P!#[_Y:W@O_ .9RC_AJ[X_?]#[_ .6MX+_^9ROG
M>BJ_XB!QY_T6W%W_ (DF<_\ S:+^VLY_Z&V9_P#A?BO_ ):?1'_#5WQ^_P"A
M]_\ +6\%_P#S.4?\-7?'[_H??_+6\%__ #.5\[T4?\1 X\_Z+;B[_P 23.?_
M )M#^VLY_P"AMF?_ (7XK_Y:?1'_  U=\?O^A]_\M;P7_P#,Y1_PU=\?O^A]
M_P#+6\%__,Y7SO11_P 1 X\_Z+;B[_Q),Y_^;0_MK.?^AMF?_A?BO_EI]$?\
M-7?'[_H??_+6\%__ #.4?\-7?'[_ *'W_P M;P7_ /,Y7SO11_Q$#CS_ *+;
MB[_Q),Y_^;0_MK.?^AMF?_A?BO\ Y:?1'_#5WQ^_Z'W_ ,M;P7_\SE'_  U=
M\?O^A]_\M;P7_P#,Y7SO11_Q$#CS_HMN+O\ Q),Y_P#FT/[:SG_H;9G_ .%^
M*_\ EI]$?\-7?'[_ *'W_P M;P7_ /,Y1_PU=\?O^A]_\M;P7_\ ,Y7SO11_
MQ$#CS_HMN+O_ !),Y_\ FT/[:SG_ *&V9_\ A?BO_EI]$?\ #5WQ^_Z'W_RU
MO!?_ ,SE>X_!#]KW7_[?_L3XNZK'J6EZK-''9>(QIVF:<^B7#81$O8-(LK&W
MFTR9N99V@:YM7/F&1[<&-/@:GQQR32)%$CRRRNJ1QHI9W=B JJH!+,Q(  !)
M)KU,F\4N/\HS/!YA#BG/LR>&JQE+ 9KFV8YC@,7!^[.AB,)B<34ISC4BW%2B
MHUJ4FJE&I3JQC-=&%XBSK"XBE768XRO[.2;HXG$UZ]&JMG"=*I4E%J2;5TE*
M+]Z$HR2:_H9BEBGBCG@DCFAFC26&:)UDBEBD4/')'(A*/&Z$,CJ2K*0RD@@U
M]D7_ /Q]/_USM_\ TGBK\M?V:/"/Q \'?#FTT_Q[J+R23NESHF@W,9:^\-:8
MZ%A8WETSES).S+,NFE/^)4H\EY!/+-:6?ZE7_P#Q]/\ ]<[?_P!)XJ_T*RO,
ML3G&3Y1FF+RW$Y/B<=@XXBOEF,<7B,'4J*FW2J.#_P"WX<\:=94Y15>C0K>T
MHP_>\KKU,5A*6(JX>IA:E:E3J3P]6WM*4I)WC*WWJZC*S7/"$^:$:=%%%=AZ
M04444 %%%% !1110 4444 %%%% '@_Q1_P"1WU3_ *\_#_\ ZC>D5Y_7H'Q1
M_P"1WU3_ *\_#_\ ZC>D5Y_7J4?X5+_KW#_TE'#/XY?XI?FPHHHK0D**** "
MBBB@ HHHH **** "BBB@#]"/@=_R2[PO_P!QO_U(M7HH^!W_ "2[PO\ ]QO_
M -2+5Z*^<K_QZW_7VI_Z7(]6G_#I_P""/_I*/CGXK_\ )1O%W_86D_\ 145>
M>UZ%\5_^2C>+O^PM)_Z*BKSVO?H_PJ7_ %[A_P"DH\R?QR_Q2_-A1116A(44
M44 %%%% !1110 4444 %%%% !1110 4444 ?1'PV_P"1%'_8V:S_ .F?PW78
M5Q_PV_Y$4?\ 8V:S_P"F?PW785Y=7^+/_$SNA\$?\,?R05\N:E^W'^Q3HWQ.
ME^">L?M@?LMZ5\9H/$4/A"?X1ZE^T#\)K'XG0^++F6*&W\+R^ KKQ;%XJC\1
M3S30Q0Z(^DC4I998HTMF:1 ?J.OY@])TKXQ?&3PG_P %DOV6_AK^P_K_ ,=C
M\<OVQ_VF?AWIOQO\2^./V=/#'P0^'_B#QU\*/AAX>L[[QQ;^*_BI:_'O[+\/
M;B>R\;75Q\//@]XIOI9?L<7A6>77$GFT[)NVWF]F]K::;7OOT*_K^NY_3Y17
MX>ZE\6OVH?V>Y?VS_$6J_';4?'7PU_X)P_LJ_#/Q1IOP;M_A_P" X9OC=X[T
MK]D[7?$&OW7Q#^*6H:%JOC:T\'ZOXKT:V\8M8>$X/#OBFQUN!II_&%YX2>\\
M$77IWA?Q_P#M0? 'XP?L56OQ0_:;U#]IGPY^V=;>-?"WC3PKXD^&_P 'OA_X
M8^$_CSP[\"/&'Q]L/'/P6U?X7^"?#/BO3/A*%\%:IX$U7PY\8O$7QK\11VGB
M#P=J\7Q$CU+3]6'B<YO)[VZ=[=^]_N _72BOP"_8V^+/[3W[47Q8_98\>^)O
MB?\ M;^,?#FIV'Q&^)7[1G@35OA'>?L]_L@_"[4+?3G_ .%23_LY_'3PC\#_
M (67O[77@+7-:N(=-\,Z9=?'[]IGX;_$+X>:E/\ %+Q&FE7ECX3)YP_M0?MP
MZ'^RK^S1\0Y?C!\2_C%\3OVV_P!I&S^".AZ3\(?A-^RAX5\3?!OP-X7@_:%\
M8:O>_"2'XU:KX)^%'B#XT^,O#OPRT[PY=^)?CIXUU3X96?V6/7_"WP@&KVEY
MX6\9KF79_P!6\^[2]=P_X'X^I_1!17X&Q?'K_@I WP\^*7PT72OBQ:>-?!G[
M0/PITS0;KQ'XK_X)F?\ #PKQ3^SOXJ^&FM^-?B%:>&?ASX!^)OCG]C.Z^/'A
MS7O#]UJ?@]/&WA?X>:'XO^"4VIZMIG@C5?&?AR2^U7HM+_:6_:O\>?LKZC9_
M"'XF?$7XC_%OP;^UU>_"'X@6MQ\-_@5\$/V^]%^$6C^#X?B-KOA#3?A5\?\
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M_P"9KB'_ .>QO_J3PQ_T+/\ R]S#_P":S\D_^'6O_5=/_,9?_C"H_P"'6O\
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M .&"/^JK_P#EB_\ X8T?\,$?]57_ /+%_P#PQK]$**/^($^%7_1+?^9SB/\
M^? ?ZG<.?]"[_P N\?\ _-1^=_\ PP1_U5?_ ,L7_P##&C_A@C_JJ_\ Y8O_
M .&-?HA11_Q GPJ_Z);_ ,SG$?\ \^ _U.X<_P"A=_Y=X_\ ^:C\[_\ A@C_
M *JO_P"6+_\ AC1_PP1_U5?_ ,L7_P##&OT0HH_X@3X5?]$M_P"9SB/_ .?
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MW9:/)-X&^%.@>"_"6H66@:#HM[I,NCZ-IEE9_9=%%EV0'X0?LY?\$O\ Q_\
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M7GAK1?$UQXET'0=:U'3&M[KPKXR/@7XG:(]MJ.C>+O"?@[7[:6S@-/+OT^3
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MODFNW";3]8_DSGK_ &/^WO\ VT****ZSG"BBB@ HHHH **** "BBB@ HHHH
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M\+/L_N9R=%=9_P ()XQ_Z%O5O_ 23_"C_A!/&/\ T+>K?^ DG^%'M(?SP_\
M E_GYK[PL^S^YG)T5UG_  @GC'_H6]6_\!)/\*/^$$\8_P#0MZM_X"2?X4>T
MA_/#_P "7^?FOO"S[/[F<G176?\ "">,?^A;U;_P$D_PH_X03QC_ -"WJW_@
M))_A1[2'\\/_  )?Y^:^\+/L_N9R=%=9_P ()XQ_Z%O5O_ 23_"C_A!/&/\
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MI(VDM99[2>>UFD@:-Y+::6!RT4CJQ9=][]NN]O/73U\P*M%:O]AZQ_T#KO\
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M,\BHKK/^$$\8_P#0MZM_X"2?X4?\()XQ_P"A;U;_ ,!)/\*[O:0_GA_X$O\
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MSOVMT7<H_86BOQ7\#?MO_ME^(_@I\"_&NKZ)^S):_$/]LSXY6OP%_9RT/2=
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MPZ3I?[&/@GXOZ=IT?P3^'BVEE\4F_:+\8VK_ !!M8?\ A']L/BY[>QLX7UU
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MB[0?BGK,6K^%+CQ</&MS\!;'P0U[I;ZE;_%G4/A]'XVT?0+S=KWB*UT>VO\
MPM 77R[]'Z??_5F!^J-%?SX:9_P4"_:P\>7TOPA7XD_LZZGK_P =?V0/V@OC
M=\-OBE\,?V7_ -J+PMX%^#7B;X/6_@*_U'PU8^/_ !Q\:[#PE^UCIFL^&_B#
M+;>'_BC\&_&/PG_X1O7]#TKQC?>#M2\.^*=&TP/\'?MS_M0_"3]F7_@G%\/O
M%7C[PY\0?CC^U)^SXWQEU'XV:1^Q+^V!^T[+X/\ AGX$^&_P=NGLO%?[/G[/
M'Q/\>_%KXM?%'Q-XF^)VE67B'XM3?$OX1?#V #5_$5]X:T[4Y= \&^(US+T]
M;>5EOUNO+7<#^@RBOQXL/V]_VE/$_P !?@C!I?P9T[X=?M-_'G]K;7?V3/!V
MI?'/X1_'_P"$WPP?3?#&A>._B'>?M,+\%?BAIOPU^.<O@CQ#\)_A_J'B+PS\
M)]3U_P /ZP_C74XO -U\5'L]'U+QJ_?_ +&:?&*W_;;_ &_]/^.-Y\.];\;Z
M7X+_ &,+(^+/A=HGB'PAX1\9:5_PBWQHNK7Q%:^ O%/BCQ[K?@"Y:YN;W2;K
MPK=_$3X@"%M*758?%5S#JR6&G-._1_Y:7U^7R"V_DK_BE^I^J^E_\A"T_P"N
MH_D:^.*^Q]+_ .0A:?\ 74?R-?'%=N$_Y>?]N?\ MQSU_L?]O?\ MH4445V'
M.%%%% !1110 4444 %%%% !1110 4444 %?6=G_R!_#G_8K>&?\ TQV%?)E?
M6=G_ ,@?PY_V*WAG_P!,=A7)B]H>LOR1O0WEZ+\R6BBBN(Z0HHHH **** "B
MBB@ HHHH **** &S_P#(,\0_]BGXO_\ 47U>ODFOK:?_ )!GB'_L4_%__J+Z
MO7R37;A-I^L?R9SU_L?]O?\ MH4445UG.%%%% !1110 4444 %%%% !1110!
MT/A'_D:_#'_8PZ+_ .G*VKZ<G_U\W_763_T-J^8_"/\ R-?AC_L8=%_].5M7
MTY/_ *^;_KK)_P"AM7#BOCC_ (?U9TT-I>J_(BHHHKE-PHHHH **** "BBB@
M HHHH **** "OG_XD_\ (\>(O^OR/_TEMZ^@*^?_ (D_\CQXB_Z_(_\ TEMZ
MZ<+_ !)?X'_Z5$QK_ O\2_)G#T445WG*%%%% !1110 4444 %%%% !1110 4
M444 %?8E_P#\?3_]<[?_ -)XJ^.Z^Q+_ /X^G_ZYV_\ Z3Q5Q8O>EZ5/SIG1
M0^W_ -N_^W%.BBBN0Z HHHH **** "BBB@ HHHH **** /!_BC_R.^J?]>?A
M_P#]1O2*\_KT#XH_\COJG_7GX?\ _4;TBO/Z]2C_  J7_7N'_I*.&?QR_P 4
MOS84445H2%%%% !1110 4444 %%%% !1110!^A'P._Y)=X7_ .XW_P"I%J]%
M'P._Y)=X7_[C?_J1:O17SE?^/6_Z^U/_ $N1ZM/^'3_P1_\ 24?'/Q7_ .2C
M>+O^PM)_Z*BKSVO0OBO_ ,E&\7?]A:3_ -%15Y[7OT?X5+_KW#_TE'F3^.7^
M*7YL****T)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z(^&W_(BC_L;
M-9_],_ANNPKC_AM_R(H_[&S6?_3/X;KL*\NK_%G_ (F=T/@C_AC^2/F3PM^R
ME\._"/PT_:%^%FFZSXTG\/?M*>-_C=X^\=7E]J.ARZSI.L?'J.YB\86WA.XM
M_#MM8V.FZ:MW(?#4.L:=KUU9LJ'5+S6 &#._X95^'G_"3_LI>*_[9\9_VC^Q
M[X?\3^&_AG#_ &CH?V+7+'Q9\,K?X5:C+XZC_P"$=\_4[N'P];1WEE)H%SX8
MACUHO<3P7-B5TY;OC#]K/]GSX?C]HQO&GQ"C\-I^R;X#T7XG?'Z74_#7C&&#
MP-X#\0^&]?\ %FB^([:<>'FA\9V>H:+X6\0M#%X!?Q1>#5-*NO#\ELGB )I;
M\EXE_;.^!_\ P@_AC7O /Q$\,:_KOQ7_ &9/B-^U1\%!J>E_$(^%?%'PE^'_
M (9\)Z]>^/\ Q-JGA?P5XDU?PEX.MV^(7@2.\^W:+_PEE\-=>Q\,>&=>UVPO
M-)@RT\OZ?^:7ST*,6]_83^$=S^SS\-OV>;7Q+\3-%M/@SXPM_B/\'_BOHGB#
M0[#XO_#7XCV&O>(M=TSQQX;UM?"TGA.?4[1?%GB'P]>:/X@\%:WX.\3^#M9U
M;PCXS\,^)- UC6+"_P 'PM_P3\^&NC:C:^+O%WQ0^-GQ;^+4OQR^&_QY\4_&
MCXCZS\/&\?>-]?\ A#I>O:+\./!FL:=X'^&G@CX;>'/AAX4TSQ+K4.F^"_AK
M\/\ P':K>ZEJNO2W,GB+7?$&KZMR7[,__!1?P;^T'\?_ !?^S</A]\2-,\7^
M"_A=\&O'D_CW3?@]^T@OPA\2W_Q)\*>)?$6N1:7X[\<? GP)X>\.>$=/D\-.
MGPY\7^-=9T6W^,EI?C_A"+.YU;1];TFRP/V2?^"F_P %OCAX5^#.B?$3QAI^
MA?&CXK>(?%W@:WB\-_#/XNV?P5NOB3X;U[Q? OPLTGXTZGH6N?""'XKCPWX7
MDU.Z^%=Y\5I_B&\L5V\/AN-#%:QKW=-O+M=67W]GO;J!]*:S^R%\-=<N?VO[
MJ[USQQ')^VKX6TOPC\4UM]2T!$T#3=(^%4WP@MI_A^)?#,S:5?/X:G>^GD\1
MMXK@;70MS';16 .F'SCQ7^P7X>U3Q-\//'?P]_:'_:5^!7C[X9? #0?V;/#O
MB[X5^(?A1<277PWT/4[?5"?$?A'XI?![XF_#?Q)XDU*>UMTDUS5_!5U+H(22
MY\%P^%M0NKR]N+W[6_[2?Q-^&OC;X!_L[?L[>%?!?BK]HW]I?6O&<?A6^^)=
MUK"?#/X4_#?X9:';:[\3/C)X_P!*\,3V?BGQ5IGAPZMX8\-^'_!&B:MX6G\9
M>,/%NAZ/-XU\)V;76K0^9R_&O]NOX)M\9=$_:!\&?!3XG:3X=_9K^*7QP^&?
M[1/P/\"?$;X=?#6U\;_#>P2:3X.?%OX5^-/B?\4]=T;4]8BO+7Q%X6\4>'_B
M[<V?BK1](\5Z7<Z5X1U33--N-8':]K/U2V;UW6O9NWE<#M$_X)U_!SP_\./@
M=X+^%?CGXS?!CQI^SO?^/M6^&GQ\\#^*_#GB#XU1ZM\8-1O-;^-U_P"--2^+
MO@SXG^ OB8/C1XCO[CQ7\0],^(GP]\3Z'?>+8=(\4:+I>AZ[X;\,W^C6E_X)
MZ?!I?@S:_"P>,/B^?&5G\9(_VD8OVE&\6Z*_[1+?M'(7A;XV2^)W\*-X'D\2
MSZ-+-X-G\)M\._\ A4LOPXFE^%Y^'/\ PKESX6I_[+W_  4!^ /[1T?PH\'Z
M5XXW_%KXB_"+2OB786*_#GXJ>$OAUX]%EHGAZZ^(,WP.^)?C/PO:?#CXQ:7X
M*U?7H+/7XOAAX^\?7?AB*2-=?GA:*><7]"_X*.?L:>)_ /C/XHZ!\7Y]5\ >
M!-:\/>%=8\46GPT^+CZ?JOCOQ5XEU;P=H?PQ\! ^ EN/BC\6[OQ7HUUX=F^$
MGPS@\6_$K3]8N=%L-2\*V=QXC\/)JA[KUTV[V[/Y-67FK(#YD_:=_8H\5Z)^
MR3^TS\)_@YIGQE_:<_:*_;+U73;#Q?\ 'WXA_$'X1>"_%'@WQMI_AS2M ^&_
MQP\6ZGX=B^"OAOPAX/\ @(GA+PUJWA;PO^SO\+Y_$R>(["SO](\$W&J:SXE\
M66_T?=_L"_#.+X3_ +(OPR\#>.?B9\&K_P#8JE\.S_!;X@?"Z[\$R^++(:7\
M-M:^%7B+3->MOBIX&^*/A+Q-H_C[PIXBUF'Q='KOA>_U6ZU*YAU[3M7TS7[2
MWU--$?\ !17]CF#X>WGQ/UKXN3^#?#.E?%/1O@EXBL/B+\-OBU\-/'O@_P"*
MWB2R.I>&? _COX4_$#P)X:^*7@+6O%&GFWOO#">,O!VAV_B.SU'1[G1;B^AU
MK27O<G7OV\?A/XD^!GQD^*?P4\4:-+K_ ,%/%'A#P?X\\+?'[P/^T!\#M5\"
M:_XKUCPDFGV/Q%^'FN_!NX^.OA9?$'ASQ59ZMX,U$_">\TOQ&M[INH6MV?#K
M:AK-B>[W6W=:6U]?-OOJ!A^,?^";_P *_&'B/QO&WQ8^/GAWX'?%;XEM\8/C
M!^R?X;\3> K;X ?%+X@WNH6FM>)-4\1?VG\--6^,^AZ#X[\0Z?9>(_B)\/?A
M[\8_!7PU\>ZY_:]]XK\'ZJWBWQFGB+SCQ#^P[\0_BE^TM^V7XSU#XU?M%?L[
M_#WXSZ5\#/"EAJ7P*\>_#"QC^*G@OPW\+K[PWXUT*^TKQMX*^*6H_#F^T_5;
MV?3X?B#X TWX4?%KR)T&@>/VTRRL#9_37QF_;I_9>^ 'C+4O 7Q1^(>KZ5XA
M\.^&M*\:>.W\._"_XM_$3PY\)?!>NW&HVVB^,_CCXV^''@3Q9X+^!7@_5GT?
M69=-\4_&'Q!X(T&]L]&UB_M]0DL=*U"XM\O]OG]HWQ9^R]^QE\;?VC_AA9^$
M?$?BGX=^%-'\0^%[7Q7;ZEK'@_5&U3Q-X>T@2:A#X>USP_J-[8R6&KS7%L^G
M:[9%Y1;RB>2$-%*6CWVU=GMOIIJEOH@.?\4_L _#4GX:7WP)^)?QF_9$\2?"
MOX*:-^S?H'BK]GC5/ATVI:E\!?#*QMX4^&7B;1_CC\,_C9X+UNP\'WB3ZEX-
M\5S>%8_B-X2OM5\1/X=\9Z;#XI\30:OZ%X(_8Z^$/PYD_9D'@^7QCIEC^RCX
M>\?>'/AQIUUXC;75UF#XDZ'::+XIU/Q[JWB&SU;Q)XEUV\>VEUHZK'KFFSSZ
M[?W]YJ'VZ*9+6+L/VC?BUJ'P6^!_BKXIZ=-X'MK_ ,/CPGY<OQ$O?&VF^#$;
MQ#XM\/>'95U6\^'G@KXB^,8#(FLO%IATKP?K"G57L5U,V.E&^U.SR]:_:W_9
M[\/?#CXX?%G6?B"MAX$_9O\ %?B;P-\9]4D\+>-7U'P;XN\)QZ1-JN@#PO#X
M<D\5^(M0N8?$.@3>'(O"FB:ZOC&'7=&F\(-KD>JV#7#LOR?I;;TV_ #S^W_8
M8^$5N^KL==^(%PFM_MB3_MM7T%SJGAJ2!OBE<:/;:'-X:1%\))_Q;E[.U0G1
MY&D\1F9Y"?%AC98E\I^'_P#P3*^&O@*;]GZQ?X\?M,^,? G[*/Q#TSQ_^S=\
M*_%/BSX8V_@#X41Z/X3\:>!],\&V]OX-^$7A'Q)\0?#5AX7\<:AI.G:G\8/$
MWQ%^(.DVUC8+I/CFQ^TZ]_;?LNJ_MY?LL:)\3;KX3ZI\1=8M=?T[QMHWPQUG
MQ2?A9\7YO@MX<^*7B)M,BT3X5>*_VB;?P%+\ ?"?Q4U.\US0M+M?AKXD^)>E
M^.)-;U[0=#_L :QK6EV-WV?PY_:S^ 7Q<^+/Q!^"'PW\:WWBWXD?"?4/$>C_
M !,TK3/ WQ"_L7P)KOA;4-&T[5/#WBGQO<^%+?P+HWB2XDU[3KWP]X=O?$L6
MM^+M#^W^(_"=AK7A_1]7U.Q/=TV[;]=-/R]- ,7X]?![QAXL^*G[+WQI^'+Z
M0?%7P.^)>MVWBG3-8NY+"+Q-\$OBQX6O/!?Q.T6PO$MKM(-<T744\#?$W18I
MXHXM7O?ATOAAKS3E\0/J%KWD/P(\(P?M%:A^TTFH^)#X\U+X+Z5\"Y]):\TP
M^$4\):1XWU;Q[;:C%8#1QK*^(WUC6;JVGNWU^33&TV."&/2(KI9+R7X0UWXW
M_MW?%/\ ;/\ VIOV?/V=O&O[)/P]\#_LW>#?V?-?MG^-/P%^,?Q/\5^--5^-
M'AGQ?KMU:S^)_ W[3GPHTCPYI^FW/A-K2WGC\"Z]<PP7ZW$D6H26IM[CIOA)
M^W1XX\;>"/#EI\0?!/PW^%?QR\(_MHV/[%WQ_P# ^K>*O'^M>$X/&(TT>(XM
M:^"WB+PW\-M8U3Q!%\0O >K^#/B)\-H/B/HOP^T1-&\1R:1XO\5:+?6$%[J1
M=?>^O5K33[M-O(#ZY^!W[.W@KX ZA\<M2\':IXIU*?X__'3Q9^T#XR3Q->Z3
M>0Z9XR\8Z)X7T'4],\,KI>B:,]GX8@L_"6FR6%EJLFLZK%<SWKW&M744D$-M
MQ?@+X,^+H_VM_CS^T?XW>PAL-9^'7PH^!'P8T:RU:ZU"6S^'O@N?Q/\ $'QM
MXMUBT,,%AH^N^./B/\0+G0Y-,MC?R_\ "-?##PEJMUJ*3ZQ+H^DPK^W)^S&W
MQ=C^"3>/=;A\83>/9?A/;:]<_"OXO6GP<O/BU#;R7$GPDL?VA[GP%%\ +[XL
M*8)[(?#*S^)D_CIM6M[C14T!M7@FL4K^!OV[_P!EGXC_ !&TSX8>$OB-JMYK
MWB/Q!XE\)>"/$6I_"_XN>&?A)\4/%G@Y=6?Q5X5^#OQW\4>!-&^"/QE\3:!'
MX?\ $<VJ>'_A9\0O%^KVL'AGQ-/)9B+PYK;V!IIJM'IKUVM^.P'F/QB_X)S?
M#SXQ:[^T9<3_ !O_ &C/AWX"_:U\/RZ1^T-\(/AAXG^&WA_P/\1=7?X8V7PA
MC\8RZ_JGPIU_XP>%]>7P+H_AS2K[2O!/Q2\->!/$@\/67_"6^#?$$.H>(X-<
MK_$+_@F]\/OB!:>,?"C?';]I#PI\'OBOX>\(>&?CK\!O#WB+X5ZA\+_C9IOA
M+PAH/P_/_"2OXY^$'C+XA?#Z;Q5X(\,Z)X<\;'X ^/O@Y#XD@LSJEU"GB&XN
MM8G])\0?M_\ [)_A?XJW'P<UGXD:U%XGT_Q]X>^%.M^)+/X3?&75_@QX7^*?
MBN6SM?#GPQ\9?M%:/\/K_P#9_P#!?Q%U>_U+2M)L_ _BOXF:-XH?6]9T30VT
MI=7UK2[*[U5_;D_9C;XNQ_!)O'NMP^,)O'LOPGMM>N?A7\7K3X.7GQ:AMY+B
M3X26/[0]SX"B^ %]\6%,$]D/AE9_$R?QTVK6]QHJ: VKP36*'N^6_?KV_/3K
MKW8'G?QG_P""?G@?XTZQ\4([_P"-_P"T+X*^%7QZAT:V_:!_9]\':_\ #&[^
M$'QDMM)\/:3X/N;?5U^(/PG\>?$KX=1>)?!N@Z/X8\6K\"/B/\)/^$ALK%-2
MOR_B2>\URYM_%[]@?P7\3_&OQ$\9>%_C=^T1\ (_C=H/ASPQ^T'X5^!/BKP%
MH/ASXYZ/X5T@>%](;Q3-XV^&?C[Q5X&\2+X)"^!+WX@? OQ/\(_B+J?A&UT;
M2]0\6W+>%_"=SH78ZS^W?^RSH'Q1O?A'JWQ&U6V\0Z7XYTCX7:WXJ3X7_%RZ
M^"?ASXIZ^^F0:+\*_%'[1MGX$N/V?/"_Q1U.]UO0M+L_AQX@^)VF^-9M9U_0
M=$70CJVMZ597?0_M7_''7/@;\.?#MWX)T_0]8^*/Q3^*WPO^!OPGTGQ+]JDT
M"7QS\4_%VG^'DUS7++3[_2M2U70/ 7AM_$?Q(\1Z-IFJZ3J.K^'O!^J:;8ZO
MI5U=1:A;%EK^-M[_ "U^2[ON!P'CW]A;X?ZWKG@+Q7\'OB5\7OV3_%WP^^$F
MG_ "P\1?L[7GPULVUKX&:+<)>>'/A=XC\._%[X8_%_P5>Z-X1OOM5YX)\0V?
MA?3O'_@B;5_$*>$O&&C6_B7Q!!J>;IW_  3H_9JTOP?=_#FTTKQ9_P *ZO\
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M_P#(0M/^NH_D:^.*[<)_R\_[<_\ ;CGK_8_[>_\ ;0HHHKL.<**** "BBB@
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M*7,<,\,KQ!)49OYCM TOP3\-? ?_  3(UC]H/P)JV@_LTK_P4+_;@^)/PF\
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MWP\,UIJ>N_!7X#>" /CP8/'%[\6M;T)KO59/V=\!?$_P-\3E\9-X'US^VU\
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M_P"7-9]S\:/C%>SR75Y\6/B7=W,S!IKBY\=^*9YY6 "AI)I=5>1V"@*"S$X
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M']0M]4T?5+=;FRO;9BT<L;$JRLK!9(9H9%>&XMYDCGMIXY()XXYHW1?MV_\
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M*** "BBB@#]"/@=_R2[PO_W&_P#U(M7HH^!W_)+O"_\ W&__ %(M7HKYRO\
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M>FZEJ7QKU.ZE\7>*+>+P<U[>R^#_  3T:3]I+QI_P38UOXU_%/XM>)[WP?\
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MMJ*/]0^!_P#HC.%/_$=RC_YC#^PLD_Z$V5?^&["?_*3Y)_X86_97_P"B6_\
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M!_8N3?\ 0IRS_P (,+_\J/G?_AE'X _]"%_Y=/C3_P":.C_AE'X _P#0A?\
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MG"G_ (CN4?\ S&']A9)_T)LJ_P##=A/_ )2?)/\ PPM^RO\ ]$M_\O?XC?\
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M_H0O_+I\:?\ S1U]$44?\0_X#_Z(GA'_ ,1O)O\ YB#^Q<F_Z%.6?^$&%_\
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MOPI^R[^UCHW[+/[47B*7P[JEYX>TZ+7-9^'VE?LYZ%XZ^'&H:)K'BWPY\6?
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M\&=:\,?$?P]K7@S41X@\&ZGX&DLAHFJ>&]>T;Q-K%MJLT-APOQ'^*7CWQ?\
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M%]-<;'[6NL_LZ_!?]O'X!? 3]I?]M?XY_L[_ +->C?L*^,M<\-W?B+_@H?\
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M<5\<?\/ZLZ:&TO5?D14445RFX4444 %%%% !1110 4444 %%%% !7S_\2?\
MD>/$7_7Y'_Z2V]?0%?/_ ,2?^1X\1?\ 7Y'_ .DMO73A?XDO\#_]*B8U_@7^
M)?DSAZ***[SE"BBB@ HHHH **** "BBB@ HHHH **** "OL2_P#^/I_^N=O_
M .D\5?'=?8E__P ?3_\ 7.W_ /2>*N+%[TO2I^=,Z*'V_P#MW_VXIT445R'0
M%%%% !1110 4444 %%%% !1110!X/\4?^1WU3_KS\/\ _J-Z17G]>@?%'_D=
M]4_Z\_#_ /ZC>D5Y_7J4?X5+_KW#_P!)1PS^.7^*7YL****T)"BBB@ HHHH
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M?_@'XZ_^8NN3HHY7_P _)_=#_P"0_J[\K%U_+'_R;_Y+^KORMUG_  CFC_\
M0^^$_P#P#\=?_,71_P (YH__ $/OA/\ \ _'7_S%UR=%'*_^?D_NA_\ (?U=
M^5BZ_EC_ .3?_)?U=^5NL_X1S1_^A]\)_P#@'XZ_^8NC_A'-'_Z'WPG_ . ?
MCK_YBZY.BCE?_/R?W0_^0_J[\K%U_+'_ ,F_^2_J[\K=9_PCFC_]#[X3_P#
M/QU_\Q='_".:/_T/OA/_ , _'7_S%UR=%'*_^?D_NA_\A_5WY6+K^6/_ )-_
M\E_5WY6^H_A_I5A!X-\F+Q-HE['_ ,)/JTGVJVM_$:0;WTKP^K6^V\\/VESY
MT:QI([?9O(*31".>2031Q=5_9UI_T'=*_P"_.N?_ "FKSKX;?\B*/^QLUG_T
MS^&Z["O,JI^TG[S?O/5\OZ12_ [8?#'1?"N_9>9J_P!G6G_0=TK_ +\ZY_\
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M>2G*=KWY8SE:]K7Y7I>SW\[;:>]?\(YH_P#T/OA/_P  _'7_ ,Q='_".:/\
M]#[X3_\  /QU_P#,77@O_"Y/AO\ ]#'_ .4?7O\ Y5T?\+D^&_\ T,?_ )1]
M>_\ E773[:A_T%T__!E#_+^KORME[&M_T#U/_!=7^O\ AWY6]Z_X1S1_^A]\
M)_\ @'XZ_P#F+H_X1S1_^A]\)_\ @'XZ_P#F+KP7_A<GPW_Z&/\ \H^O?_*N
MC_A<GPW_ .AC_P#*/KW_ ,JZ/;4/^@NG_P"#*'^7]7?E8]C6_P"@>I_X+J_U
M_P ._*WO7_".:/\ ]#[X3_\  /QU_P#,71_PCFC_ /0^^$__  #\=?\ S%UX
M+_PN3X;_ /0Q_P#E'U[_ .5='_"Y/AO_ -#'_P"4?7O_ )5T>VH?]!=/_P &
M4/\ +^KORL>QK?\ 0/4_\%U?Z_X=^5O>O^$<T?\ Z'WPG_X!^.O_ )BZ/^$<
MT?\ Z'WPG_X!^.O_ )BZ\%_X7)\-_P#H8_\ RCZ]_P#*NC_A<GPW_P"AC_\
M*/KW_P JZ/;4/^@NG_X,H?Y?U=^5CV-;_H'J?^"ZO]?\._*WO7_".:/_ -#[
MX3_\ _'7_P Q='_".:/_ -#[X3_\ _'7_P Q=>"_\+D^&_\ T,?_ )1]>_\
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M?_*NNGVU#_H+I_\ @RA_E_5WY6P]C6_Z!ZG_ (+J_P!?\._*WO7_  CFC_\
M0^^$_P#P#\=?_,71_P (YH__ $/OA/\ \ _'7_S%UX+_ ,+D^&__ $,?_E'U
M[_Y5T?\ "Y/AO_T,?_E'U[_Y5T>VH?\ 073_ /!E#_+^KORL>QK?] ]3_P %
MU?Z_X=^5O>O^$<T?_H??"?\ X!^.O_F+H_X1S1_^A]\)_P#@'XZ_^8NO!?\
MA<GPW_Z&/_RCZ]_\JZ]!T[4K'5[&VU+3;J*\L;N,2V]Q"24D0Y!X(#(ZL"DD
M<BK)%(K1R(KJRBH3A4;4,0IM*[4)4I-+35J,79?Y^EIE"<$G.BXIZ)RC4BF^
MVK7]-^5NY_X1S1_^A]\)_P#@'XZ_^8NC_A'-'_Z'WPG_ . ?CK_YBZY.BM.5
M_P#/R?W0_P#D/ZN_*T77\L?_ ";_ .2_J[\K=9_PCFC_ /0^^$__  #\=?\
MS%T?\(YH_P#T/OA/_P  _'7_ ,Q=<G11RO\ Y^3^Z'_R']7?E8NOY8_^3?\
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M[\ZY_P#*:C^SK3_H.Z5_WYUS_P"4U95%%GW?X?Y!\E^/^?\ 5WY6U?[.M/\
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M_P#D/ZN_*Q=?RQ_\F_\ DOZN_*W6?\(YH_\ T/OA/_P#\=?_ #%T?\(YH_\
MT/OA/_P#\=?_ #%UR=%'*_\ GY/[H?\ R']7?E8NOY8_^3?_ "7]7?E;K/\
MA'-'_P"A]\)_^ ?CK_YBZ/\ A'-'_P"A]\)_^ ?CK_YBZY.BCE?_ #\G]T/_
M )#^KORL77\L?_)O_DOZN_*W6?\ ".:/_P!#[X3_ / /QU_\Q='_  CFC_\
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MI6,]G]H\CS8?.\GSO,\KSHO,V[/-CW;AX5^R%^S]_P ,I_LP_ W]G#_A+?\
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M??5%%%;F84444 %%%% 'T1\-O^1%'_8V:S_Z9_#==A7'_#;_ )$4?]C9K/\
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M)O%G@WPQ"NOZ1XXTVR\;W=U<V'A:6U[GX1?\H7/AY_VC+\._^LOVU>H>$/\
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M6\?I5-*RM_7Y+\=0"BBBF 4444 %%%% !1110 4444 7]+_Y"%I_UU'\C7X
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MV?+SRTE\3^TN_P#A]?Z6O6?\(7K'_/YX3_\ "]\"_P#S1T?\(7K'_/YX3_\
M"]\"_P#S1UR=%:6G_-#_ , ?_P L]?Z6L^[VE_X$O_D?7^EKUG_"%ZQ_S^>$
M_P#PO? O_P T='_"%ZQ_S^>$_P#PO? O_P T=<G11:?\T/\ P!__ "SU_I:G
MN]I?^!+_ .1]?Z6O6?\ "%ZQ_P _GA/_ ,+WP+_\T='_  A>L?\ /YX3_P#"
M]\"__-'7)T46G_-#_P  ?_RSU_I:GN]I?^!+_P"1]?Z6O6?\(7K'_/YX3_\
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M7J->Z^Y_YAIY_?\ \#U_I:ZO]C7?_/;2O_![H?\ \L:/[&N_^>VE?^#W0_\
MY8UE44:]U]S_ ,PT\_O_ .!Z_P!+7HM.TBZ2^MF,NF$+("0FMZ,[=#T1+]G8
M^RJ3[5\H_P#"%ZQ_S^>$_P#PO? O_P T=?3>E_\ (0M/^NH_D:^.*Z\*I?O+
M.*^'>+?\W]Y>?]+7"O;W;I_:V:7\OD_/^M^L_P"$+UC_ )_/"?\ X7O@7_YH
MZ/\ A"]8_P"?SPG_ .%[X%_^:.N3HKLM/^:'_@#_ /EGK_2UY_=[2_\  E_\
MCZ_TM>L_X0O6/^?SPG_X7O@7_P":.C_A"]8_Y_/"?_A>^!?_ )HZY.BBT_YH
M?^ /_P"6>O\ 2U/=[2_\"7_R/K_2UZS_ (0O6/\ G\\)_P#A>^!?_FCH_P"$
M+UC_ )_/"?\ X7O@7_YHZY.BBT_YH?\ @#_^6>O]+4]WM+_P)?\ R/K_ $M>
ML_X0O6/^?SPG_P"%[X%_^:.C_A"]8_Y_/"?_ (7O@7_YHZY.BBT_YH?^ /\
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M_P L:RJ*->Z^Y_YAIY_?_P #U_I:ZO\ 8UW_ ,]M*_\ ![H?_P L:/[&N_\
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MT+2-3T'P?IG@?P_HMMXT\:M$VK L]->U]7:UE?YWVZZ_<'AW_!6?XK>'=/\
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M GCSX1>)O&$GPY\(^$&^*OPJ\-:Q^U?\(/VKKSQ(UIX;O[SXW>*_"WP9L_C
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M\2_@U^TCX_\ AC\+?^$LM=)_:7^(_B'P?=>!OBGX-^'7A?X=?"?QAJW@JX\
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M^:3CR6M9)WYM]_\ #^)$ZKI6LD^:^_E;_-GYB?\ " ^._P#H2O%O_A.:Q_\
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MCNOL2_\ ^/I_^N=O_P"D\5<6+WI>E3\Z9T4/M_\ ;O\ [<4Z***Y#H"BBB@
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M:'_@#_\ EGK_ $M3W>TO_ E_\CZ_TM>L_P"$+UC_ )_/"?\ X7O@7_YHZ/\
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MRJ\=^,G[1'[/_P"SKI&E^(/V@OCG\'?@5H.N7[Z5HFM_&3XF^"OACI&L:G%
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ML_X0O6/^?SPG_P"%[X%_^:.C_A"]8_Y_/"?_ (7O@7_YHZY.BBT_YH?^ /\
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MMI7_ (/=#_\ EC6511KW7W/_ ##3S^__ ('K_2UU?[&N_P#GMI7_ (/=#_\
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MU_I:GN]I?^!+_P"1]?Z6O6?\(7K'_/YX3_\ "]\"_P#S1T?\(7K'_/YX3_\
M"]\"_P#S1UR=%%I_S0_\ ?\ \L]?Z6I[O:7_ ($O_D?7^EKUG_"%ZQ_S^>$_
M_"]\"_\ S1T?\(7K'_/YX3_\+WP+_P#-'7)T46G_ #0_\ ?_ ,L]?Z6I[O:7
M_@2_^1]?Z6O6?\(7K'_/YX3_ /"]\"__ #1T?\(7K'_/YX3_ /"]\"__ #1U
MR=%%I_S0_P# '_\ +/7^EJ>[VE_X$O\ Y'U_I:]9_P (7K'_ #^>$_\ PO?
MO_S1T?\ "%ZQ_P _GA/_ ,+WP+_\T=<G11:?\T/_  !__+/7^EJ>[VE_X$O_
M )'U_I:^D^%_"&K0>)O#LSW?A=DAUW2)76'QOX+N)2L>H6[L(K>WU^6>>0@$
M)##')+*V$C1W95/T1-H]V9I2)M+P9)#SKFB \L>H.H @^H(!'0C-?)_A'_D:
M_#'_ &,.B_\ IRMJ^G)_]?-_UUD_]#:N'%*7-&[B_=Z1:Z_XF=-"UI63W75?
MY+S_ *6NA_8UW_SVTK_P>Z'_ /+&C^QKO_GMI7_@]T/_ .6-95%<VO=?<_\
M,VT\_O\ ^!Z_TM=7^QKO_GMI7_@]T/\ ^6-']C7?_/;2O_![H?\ \L:RJ*->
MZ^Y_YAIY_?\ \#U_I:ZO]C7?_/;2O_![H?\ \L:/[&N_^>VE?^#W0_\ Y8UE
M44:]U]S_ ,PT\_O_ .!Z_P!+75_L:[_Y[:5_X/=#_P#EC1_8UW_SVTK_ ,'N
MA_\ RQK*HHU[K[G_ )AIY_?_ ,#U_I:ZO]C7?_/;2O\ P>Z'_P#+&C^QKO\
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M_P#2Y'JT_P"'3_P1_P#24?'/Q7_Y*-XN_P"PM)_Z*BKSVO0OBO\ \E&\7?\
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M[5\+V^M?%6'5-"\0:WXY\D\ ?M,_M6_M(:-^PCX6T;XSV/P2\0_%7QG^V_\
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M_9R_:.\9^#OB)\6/!&LZCXY\"Z'K7A/1/%7A#XF?%7X5:U?>"?$>I:1K&O\
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MZZR?^AM7#BOCC_A_5G30VEZK\B*BBBN4W"BBB@ HHHH **** "BBB@ HHHH
M*^?_ (D_\CQXB_Z_(_\ TEMZ^@*^?_B3_P CQXB_Z_(__26WKIPO\27^!_\
MI43&O\"_Q+\F</1117><H4444 %%%% !1110 4444 %%%% !1110 5]B7_\
MQ]/_ -<[?_TGBKX[K[$O_P#CZ?\ ZYV__I/%7%B]Z7I4_.F=%#[?_;O_ +<4
MZ***Y#H"BBB@ HHHH **** "BBB@ HHHH \'^*/_ ".^J?\ 7GX?_P#4;TBO
M/Z] ^*/_ ".^J?\ 7GX?_P#4;TBO/Z]2C_"I?]>X?^DHX9_'+_%+\V%%%%:$
MA1110 4444 %%%% !1110 4444 ?H1\#O^27>%_^XW_ZD6KT4? [_DEWA?\
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MT/X>^"]*?X@_#3X[7.FW/@;QAKOPYUK1?$?PVLOB3X=GTWQ[X*\8VNG^&I?
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MYLX_$NJ>+= ?5'U30-6TZP2OIOTWOO9WWUM;Y7^8?U_7]>I]]44458!1110
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MCI"BBB@ HHHH **** "BBB@ HHHH ;/_ ,@SQ#_V*?B__P!1?5Z^2:^MI_\
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M/%7%B]Z7I4_.F=%#[?\ V[_[<4Z***Y#H"BBB@ HHHH **** "BBB@ HHHH
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MOP[_ /+:OT(HH_M&O_+2_P# 9_\ R8?5:?\ -/[X_P#R)^>__"COBC_T*_\
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M\/\ (\!_X0GQ/_T#/_)W3_\ Y+H_X0GQ/_T#/_)W3_\ Y+KWZBCV\^T?N?\
MF'(N[_#_ "/ ?^$)\3_] S_R=T__ .2Z/^$)\3_] S_R=T__ .2Z]^HH]O/M
M'[G_ )AR+N_P_P CP'_A"?$__0,_\G=/_P#DNC_A"?$__0,_\G=/_P#DNO?J
M*/;S[1^Y_P"8<B[O\/\ (\!_X0GQ/_T#/_)W3_\ Y+H_X0GQ/_T#/_)W3_\
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M/_T#/_)W3_\ Y+H_X0GQ/_T#/_)W3_\ Y+KWZBCV\^T?N?\ F'(N[_#_ "/
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M@J*SJ8RK424HTU:]K*77UDRX4(0;:<M>[7Z)'@/_  A/B?\ Z!G_ ).Z?_\
M)='_  A/B?\ Z!G_ ).Z?_\ )=>_45E[>?:/W/\ S+Y%W?X?Y'@/_"$^)_\
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M1WQ1_P"A7_\ *WX=_P#EM1_PH[XH_P#0K_\ E;\._P#RVK]"**/[1K_RTO\
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M "77OU%'MY]H_<_\PY%W?X?Y'@/_  A/B?\ Z!G_ ).Z?_\ )='_  A/B?\
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M "71_P (3XG_ .@9_P"3NG__ "77OU%'MY]H_<_\PY%W?X?Y'@/_  A/B?\
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M0K/0XO&*VWCOXE> /VG?V?)/"NJ:[?\ A%=3\$_#C4M'M[#6M=U1K[W7P?\
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M]1L=4_8+L[N7PA*;GQYJ/@[XIW^GZI<7&LW0^E/'_P#P3-L?'?PM_:N\'O\
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MWRS7/^"Q'PCT77KJTB_9=_;4U[P7;?M5_$?]B&+XK^'/A?\ #;5?!&I_M1>
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MQ1^$EU?>'[:WOOL"6_A7Q'>^)1K6JZ-<)H=WHL&MW=AR?QQ_X)[?\+G^&/\
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MWOQ?_L'5_@YJGQ!_X3F\\)6/A'X+_#WXC>%;_6_"$_B'XD?$#0/"?B?PG\2
M#[(_;-^*NO\ PHB_99N=#^)WBCX:1>/_ -L[X!_"G74\+_#'P/\ $QOB%H7C
MS4-;TRZ^&>OGQOXD\-CX?^%_$]PEH^M?$SPD=<\;^%(=/C;P_P"&]6>]N(X_
M%Q_P5+^%J?$:3PG=_ ']J33?AO8?M42?L8>(OVD]4\&?#/3O@9X<_:"N?'5U
M\-_#'A>>2[^+T7Q:\2>'_&?C)O#N@:+\0O /PF\8> -)USQEH/ASQOXE\(^)
M[+Q;HGACZ:_:>_9P_P"&C[;X"V__  F7_"&_\*0_:>^#/[1^_P#X1W_A(O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img99844967_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img99844967_1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '.!0 # 2(  A$! Q$!_\0
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MZ]X:T^[U^[TWPS+J6DZ1XN&AZ]K.CQ^+;7PYI%Q=ZS8 ']2%%?Y\_P#P7/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$;'3[[X0^$=<\6> O&.AP^']'\,^,M%\86/A6ZAUG1;R<:G<)J5PEE\U_\
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MT+\,/'-[IFKHJC.I>$-"U/P_X#E+;F$/A6!"S;-QZK]I7_@F5_P6$_X+(_\
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M-S9W<$UO/$[1RQNC$'Y5TO\ X)Z_L":'\//%/PBT7]AW]C_2/A/XXU?1-?\
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M#7?A_;^#H_">KZYI4JB73=6U#2+B_L9 'M;B)@#0!_#/_P %3[;Q5^SO??\
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M[J"*XDLFECAN;B-'"32*VK\.?AI\.?@]X)T#X:_"3P!X)^%OPY\)VLMCX6\
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M_P %U_\ I75_\ZY?L>?_ #$T?\/#_P#@NO\ ]*ZO_G7+]CS_ .8F@#]_J*_
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MY_\ ,30!^_U%?@#_ ,/#_P#@NO\ ]*ZO_G7+]CS_ .8FC_AX?_P77_Z5U?\
MSKE^QY_\Q- '[_45^ /_  \/_P""Z_\ TKJ_^=<OV//_ )B:0_\ !2+_ (+9
M:01>>+?^#=_Q39Z(IV3W'@[_ (*??LF>/]<21P?)$'AO2_"EC=7,3,,33BYC
M2W4AFW$A2 ?O_17\^UW_ ,%\[7X/FWOOVV_^"8__  4J_8\\#$L-7^,OB+X$
M0_%GX+>%<'SED\4>,_A=K.L:K81/8O%.OV3PKJ-P;A+^S6W8Z?+,WZK_ +)W
M[=G['W[='A*\\:_LE?M"_#;XXZ+I8M3KMMX0UHIXH\+F^5GLD\8>!M9@TOQM
MX/EO520V</BCP]I,MUY4WD)(8I-@!]94444 %%%% !1110 45\N?M4?ML_LF
M?L1>"[?Q_P#M8?'_ .&OP,\-:@UU'HK^-]?AMM<\47%C$LU[9>#?"-BE]XN\
M9ZA:0NDUSIWA30]8OH(G622W5&#'\FK?_@OQHOQA>6[_ &&?^";7_!2']M7P
M2T:/I?QH\'? 27X5? [Q&SNTH7P_XY^+&I>']3O,:9#-?G[3X4LI-\^D6?E^
M;J@>V /Z"**_  ?\%)/^"UVLDWO@[_@W@\6WNAL=D%QXV_X*<_LG?#K7FD4!
MI!/X9U7PM?W=O$ R>7.;J1)6\Q1M:)A2_P##P_\ X+K_ /2NK_YUR_8\_P#F
M)H _?ZBOP!_X>'_\%U_^E=7_ ,ZY?L>?_,31_P /#_\ @NO_ -*ZO_G7+]CS
M_P"8F@#]_J*_ '_AX?\ \%U_^E=7_P ZY?L>?_,31_P\/_X+K_\ 2NK_ .=<
MOV//_F)H _?ZBOP!_P"'A_\ P77_ .E=7_SKE^QY_P#,31_P\/\ ^"Z__2NK
M_P"=<OV//_F)H _?ZBOP!_X>'_\ !=?_ *5U?_.N7['G_P Q-'_#P_\ X+K_
M /2NK_YUR_8\_P#F)H _?ZBOP!_X>'_\%U_^E=7_ ,ZY?L>?_,31_P /#_\
M@NO_ -*ZO_G7+]CS_P"8F@#]_J*_ '_AX?\ \%U_^E=7_P ZY?L>?_,32?\
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MI\:-0N]556T.R;X:_#C2_$WB;19-?9XX]%O/%%GH.DW[2*T>HB+=(OQ%;_\
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M .E=7_SKE^QY_P#,31_P\/\ ^"Z__2NK_P"=<OV//_F)H _?ZBOP!_X>'_\
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ME=7_ ,ZY?L>?_,31_P /#_\ @NO_ -*ZO_G7+]CS_P"8F@#]_J*_ '_AX?\
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M^E=7_P ZY?L>?_,30!^_U%?@#_P\/_X+K_\ 2NK_ .=<OV//_F)H_P"'A_\
MP77_ .E=7_SKE^QY_P#,30!^_P!17X _\/#_ /@NO_TKJ_\ G7+]CS_YB:/^
M'A__  77_P"E=7_SKE^QY_\ ,30!^_U%?@#_ ,/#_P#@NO\ ]*ZO_G7+]CS_
M .8FC_AX?_P77_Z5U?\ SKE^QY_\Q- '[_45^ /_  \/_P""Z_\ TKJ_^=<O
MV//_ )B:/^'A_P#P77_Z5U?_ #KE^QY_\Q- '[_45^ '_#S_ /X*[^$R;CXM
M_P#!O?\ &G1M-(#I-\'?V[/V9?C]J9C<F!"^C^&='T&:.7[8]NDD!G9XK)[C
M47_<VK))8T?_ (.(/V3O OB*S\(_MR? #]MC_@FYK>JW,-KH&K_M>?LX>+-%
M^'/B>:Z_X]QX?^(GP[;Q[H\D0^9+V^UF#1-*L)HYXKC4!Y$KH ?OO17G7PH^
M+WPJ^.W@+0/BE\%?B/X(^+'PW\4VQN_#OCKX>>)]'\7^%=8A5C'+]AUS0KR^
MT^:6VF5[>\MUG^T65U'+:W<4-Q%)$OHM !1110 4444 %%%?FQ^V-_P5Y_X)
MW?L(:V/!7[17[2GA'1OBK.MFNG_!+P/9:[\5/C1J%WJJJVAV3?#7X<:7XF\3
M:+)K[/''HMYXHL]!TF_:16CU$1;I% /TGHK^?NW_ ."UG[3'Q-B%_P#LR_\
M!$3_ (*4_$K0;V24^'O$WQD\/?#[]F#0_$>GEO\ B7ZWI\_CWQ!K5U%H^JV]
MOJ%Y97=W9PL;7^QGDA236XXK64?\%%/^"Y\X$UI_P;KW+VLP$MLU[_P5G_9
MT^\:WD&^%KNPF\%M-8W)C*F>SE9I+:4O"[%D)H _?^BOP!_X>'_\%U_^E=7_
M ,ZY?L>?_,31_P /#_\ @NO_ -*ZO_G7+]CS_P"8F@#]_J*_ '_AX?\ \%U_
M^E=7_P ZY?L>?_,31_P\/_X+K_\ 2NK_ .=<OV//_F)H _?ZBOP!_P"'A_\
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M#G2M3M&^)OB>RT3P3#X@N)5L_"LGB!->U6TN;/3KBUD /W,HK^4:W_X+^?\
M!3.Z_:KOOV(K?_@@QJ\O[4FF_"R/XUWWPH7_ (*1?!@7UO\ #";4[;1H_%+^
M)&^!P\%F)M2N[:W&EIXD;7 )EG.F"WS*/U-_X)]_\%/M=_;;_:A_;U_9>\4?
MLYGX%>)OV$_$'P@\+>(M3;XN6GQ+;QCKOQ-TKQG>ZO8M86'P_P#"5CX</@[4
M/!UQI9N++7_%UIKYNOMEO<:?# B70!^ME%?ES^PK_P %*!^VI^T]_P %%/V<
M#\&!\-!^P)\:]#^#Y\9GXC?\)B/BN-9G\;PGQ&?#W_"">%/^$$%M_P (;O\
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M_:]^#_\ P1(^!GCK6?!G@?QGX(N/VA/^"F7Q*\#WXMO$_@K]E;3]0LM.\,_
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MW3_P4Q_:8^(/P\3X^_\ !(3_ (90_9V^('@NX\:0?M#_ /#?WP ^.OV"TO\
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MC#PQ\0O"'A7Q]X)US3_$W@SQQX;T/QAX1\2:3.+G2O$/ACQ-IEKK6@:YIER
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M_;?B&3PE;>+-0)DR9=?RT=NY:VA_6"OP!_X-^&.D^ ?^"I'PYLU\WPU\)?\
M@M1^W[X"\'7\ 0:?=^'(-<\!Z]#%9@;65K/4-=U"*Y6-9+-9& M;RY'FB']_
MJ /PE_X.&_B#XN'[!VB?LE_"^]FL/BY_P4=_:*^"/["G@2\MT>5]-LOC#XJ2
M]^(FJ7L(V1_V&?AOX9\4:!K4]S<6EK:VOB%9IKF,*H;]G/A5\,_!WP7^&/P[
M^#_P\TBWT#P%\+/ _A7X>>"]$M8XXK?2?"W@S0['P]H.GQ)$B(%M=,TZVARJ
M+N*%B,L:_#[_ (*L$^(?^"H?_!O[\.=1!3PWJG[4/[4GQ+NKF0C[(GB?X/\
M[/4&N>#K9PQ*_:[R^U>\6Q/ELP>.78\;$;OW_H **** /*/%?QY^!O@/XB^
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M'[-T-G\3/A'XY\2&/RUD\3:]\/5B^%'AF:5KK=IEAJ$*6UN(Y[P?T,5^ /\
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M16.A7\'W[*__  5R_:8\&_\ !%+]CC]I_P"#?QJTW5?"G_!-?]K[X>?LL_\
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M:?I<%GJ]IXON+[Q#>>@Z7^U=_P %<?\ @GY\5?\ @EG\0/VS_P!M/X6_MO\
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MRBLM5\/G2($^)FD^+9X[NPO_ !5#H6B^+M+UK1?B?2/^"Y?[9GQ&_P""=?\
MP2H^,GQ)^/7@[]C?1_VH_P!HSXX_ ;]KW]O73_@)X?\ B##\+G^#NK7R_#:#
M1/A9XB@\5_#SPSXB^.>G:;?:9XE\2ZYX7U7PEX-O]'\0^*-/\/Z)X=L)+*T
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MKMY:Z980S7NH7%O82165I%+<W+Q0QLX_%C_@[5_Y0Q?%G""0_P#"YOV?L(2
M'_XN+I_R$G( ;H21CGGBJ/\ P3J_9:\3>.]8\4^'/B5_P0/^"?\ P2@L/$_[
M,/C?PKX8_;D_9^_:'_8\^(OQOAUOQ]H&C^!KBQ\"6?PK^%T'B[P)XHU[PGXF
M\2>+;+QAJZZMHNE7GA]-'US2M4.KI;R '[R>!OVNOV3_ (G_ !-UWX*_#7]I
M[]GGXA_&3PO]O'B;X2^!OC5\-O%OQ-\.G2FVZH-=\!Z!XEU#Q5I']FL0M_\
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M6VNK_P!=E% 'X]?'#_@BC^S-\:?VL?'O[7VG?&G]LWX!^./C1X5\+>"_VAO
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M2Q:@YD41N2@("-G:>_HH _#;_@W-^(UQXO\ ^"3OP!^''B&WGTSXF?LLZ_\
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MF*P@U"*]M#:1W4=?B'X6^#_[6O[,_P#P2Y_;3_X(H:]_P2D_:W^-W[5/QO\
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M (*5W'PM^'?_  3(^$G[*WQ;C_X)S:!X>U/]N#]G;XO6?A*:_N;S4/A5\0_
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M0:#X;\&II7_"%+X9U#29[6_T+4/!USH6B7WAV^LITDLKO2[0NL\'G02_G/\
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M?_!0[]G#2FUW]H__ ():_%2\_:;\.^%H_EF^)'P*O=&CT/\ :A^%,<T<$MW
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MEL+>YET?0QJ_B*YA&G:-?31 'YG?L9WB_'W_ (+U_P#!5+X^Z)$MUX)_9D^
M'[,G["NF^(]Q>#5O&]U<:M\;/B=HNEN(R%;P9X@>VT3Q% \L;PZD]FZQS1W
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MPS\-OVP- AO(62W8>'_$/@[Q9X+3Q'9R7<L0CN[6RA1K(SWT7VB"TF-2R?\
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M:I)/%^<W_!/W_@IK\4/AY\2_#'_!,W_@K'IT?P8_;R\/:>VC?"GXSZL]K9?
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M":5XS6&*.&WL;KXJVNDZ#H.E1KI>C>'(#$EW+UEI_P %G?VM?A_:K;_M*_\
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MI_UA7_X+_?\ BN3_ /')0!^_U%?@#_P_T_ZPK_\ !?[_ ,5R?_CDH_X?Z?\
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MGN83XA\+?$O2XEC9Y;:#3[I[)8+V62<.UJ+*YV '[[45^ /_  _T_P"L*_\
MP7^_\5R?_CDH_P"'^G_6%?\ X+_?^*Y/_P <E '[_45^ /\ P_T_ZPK_ /!?
M[_Q7)_\ CDH_X?Z?]85_^"_W_BN3_P#')0!^_P!17X _\/\ 3_K"O_P7^_\
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M)-2^+,VEZ7:S+YL<,K&XG>YA\C[)NGMC-CWG[;O_  7%_:@NI]!_9(_X):^
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M\NH-H.@6F@>%DU*6?58]"75;N]OKG]!: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ:%>:QX/\7:;K'A[4[K1=3BBU'2;B]TZ>73;Z..[LWAN$60> ?MT_P#!//\
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M_)HFD?\ 9?\ ]M?_ -;7_:%H_97_ .3N_P#@IW_V7_\ 9_\ _6*/V=Z /O\
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M;.UGO$FEMXF0L?V2_P!E;]EW_@I%^QU<?LS?LS_L^_LZS^.?V=OVW;'QM/\
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MHH **** "BBB@ HHHH ***\W^+OQ>^&OP%^''BGXN_&#Q?I?@/X;>";.VO\
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MHECK-QX4^.WA2XUG2_"V@_$7]GG0T.N>*O%5QXJ\5:YX<\&ZE\$],/BCXI^
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M9[3^VO'&M?9-1M/A?\&I+K3=>\6Z_INH7GB9O#7@?PUXLU_3OH/X/?![P?\
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MOM>N7\,>"/!?@G_A(?\ A#/"'A?PC_PEWBC5O&_BO_A&- TG0/\ A)_&FO\
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M,4\UK^Q'\ Q\<?#<<LEJ?VA_BQXXN_@3^S%>2JYB>X^'OBR/P3\1/B9\<;*
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MHK_Z;%7W_10!\ ?\*Y_X*F_]'D?L ?\ BM/]HK_Z;%1_PKG_ (*F_P#1Y'[
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M_P /2?$7]D_:,>5_:/\ 8&L_8]WG_P!F7VS[/)]_T4 ? '_"Q/\ @HK\+/\
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MGW?-\B#S,;_)CSL7[_HH ^ /^%<_\%3?^CR/V /_ !6G^T5_]-BH_P"%<_\
M!4W_ */(_8 _\5I_M%?_ $V*OO\ HH ^ /\ A7/_  5-_P"CR/V /_%:?[17
M_P!-BH_X5S_P5-_Z/(_8 _\ %:?[17_TV*OO^B@#X _X5S_P5-_Z/(_8 _\
M%:?[17_TV*C_ (5S_P %3?\ H\C]@#_Q6G^T5_\ 38J^_P"B@#X _P"%<_\
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M_P#38J/^%<_\%3?^CR/V /\ Q6G^T5_]-BK[_HH ^ /^%<_\%3?^CR/V /\
MQ6G^T5_]-BH_X5S_ ,%3?^CR/V /_%:?[17_ --BK[_HH ^ /^%<_P#!4W_H
M\C]@#_Q6G^T5_P#38J/^%<_\%3?^CR/V /\ Q6G^T5_]-BK[_HH ^ /^%<_\
M%3?^CR/V /\ Q6G^T5_]-BH_X5S_ ,%3?^CR/V /_%:?[17_ --BK[_HH ^
M/^%<_P#!4W_H\C]@#_Q6G^T5_P#38J/^%<_\%3?^CR/V /\ Q6G^T5_]-BK[
M_HH ^ /^%<_\%3?^CR/V /\ Q6G^T5_]-BH_X5S_ ,%3?^CR/V /_%:?[17_
M --BK[_HH ^ /^%<_P#!4W_H\C]@#_Q6G^T5_P#38J/^%<_\%3?^CR/V /\
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M-ACO+3Q#\;2+?3]0UG[]IKHDB-'(JNCJR.CJ&1T8%65E8$,K D,I!!!((P:
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M"IO_ $>1^P!_XK3_ &BO_IL5'_"N?^"IO_1Y'[ '_BM/]HK_ .FQ5]_T4 ?
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MV /_ !6G^T5_]-BK[_HH ^ /^%<_\%3?^CR/V /_ !6G^T5_]-BH_P"%<_\
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M_!)W_E%E_P $T_\ LP#]C?\ ]9U^'- 'W_1110 4444 %%%% !1110 4444
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M+Z^L[)]0O$T_3UN[F&V:^OY8IIXK&S69T-S>20V]Q,EM"'F>*":14*1.5N4
M%%%% !1110 5\ ?\%2O^)1^P-^TE\4+?]UK?[./@F#]K7PI?+Q+IGBW]DK7M
M(_:.\.WL>W$DL(U+X90VVI6$3#^V='N=1T.82VNISPR??]? '_!6+_E%E_P4
ML_[, _;(_P#6=?B-0!]_T444 ? '_!+O_B<_L,_ OXJW/[_7/VD=+\1_M7^)
M]4;YI=:U_P#:C\8:_P#'>YU'S#ECIZ6GCVRT[P[:AFMM(\+:?H>AZ=Y>EZ78
MPQ??]? '_!)W_E%E_P $T_\ LP#]C?\ ]9U^'-??Y (((!!&"#R"#U!'<&@
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M\&_CGJGB'X'?L?-\4['X/_LX?%_]GZ;7?C;^RQ\,XM<M/CY\5M#^'UOX>O\
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M+Q+IGBW]DK7M(_:.\.WL>W$DL(U+X90VVI6$3#^V='N=1T.82VNISPR??]?
M'_!6+_E%E_P4L_[, _;(_P#6=?B-7W_0 5\ 2?\ %<_\%0_L.H?Z59_LV?L-
M:1XCT"UZ0:;K_P"UY\<O%_A[4]9N8FW)/J4NA?L>'2-"O (Y]*TZ]\86D;R0
M^(;I%^_Z^ /AS_RE-_;(_P"S /\ @FG_ .M%?\%8J /O^BBB@ HHHH ****
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MT6U>1X/#EM'!]_U\ ?$;_E*;^QO_ -F ?\%+/_6BO^"3M??] !1110 4444
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M^(+73-8AL[VXT35]+U6&![#4+2XFZ:@ HHHH **:[K&C.YPJ*SL<$X502QP
M2< $X )/85P_PO\ B7X)^,_PW\!?%WX:ZU_PDGP\^)W@_P .>/O WB'^S=6T
M?^W/"?BS2;37/#^K?V3K]AI>N:;_ &AI=]:W7V'5],T_4K7S?(O;.VN$DA0
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MQ&_Y2F_L;_\ 9@'_  4L_P#6BO\ @D[7W_7P!\1O^4IO[&__ &8!_P %+/\
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MB!-([?'ES^NWP?\ VB?@A\?-'T;6?A'\2O#/C&/7O!6@_$>PTBVNI=+\71^
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M7P!_P5B_Y19?\%+/^S /VR/_ %G7XC5]_P!? '_!6+_E%E_P4L_[, _;(_\
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M4UWJU_-<?@C_ ,%SO /ASXG?\% ?^".W@KQ7^R'_ ,-TZ-J]C_P4&\_]F?\
MMCX5>'_^$ZFL_A)\);VUN_[<^,_C#P)X"TO_ (16X@C\4?:]0\26E^O]D^7H
MT-[J<EM:2_F/\4?V-OB[\(]6_P""%W[-/[7O[(A_;6\2?VQ_P53UW2_V)Q\8
M_ /Q$/A'X;Z_H7@3Q=\)/@T/C+\?O&'@CP1K!_9]\(7&AVG]L?\ "6/9P?\
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MI=>$M9T7Q3>_X* ?\%*OVDO@;^T)^T!\%/@'<_LA_#VQ_92_8<M/VW_'>O\
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MO_R<5_P5B_[/_P#AQ_ZZR_X)IU]_U\ ?L;_\G%?\%8O^S_\ X<?^NLO^":=
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M< _<RBOQ;^"'[?'[6'Q4^.6D+X@^!OA;PY^S'X]_:D_:4_9?T#5]?O\ X*^
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MU_PSJFEZQ>?47C_XL> /A?>?#S3_ !UK_P#8=W\5OB#I_P +/ ,/]E:UJ?\
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M* /@#]C?_DXK_@K%_P!G_P#PX_\ 767_  33K[_KX _8W_Y.*_X*Q?\ 9_\
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M\&?@O:^-?%NL>-O$_B+QU\"O&OP]'[,>CZ?>?#_4O"WQ%^(/[/5GH,5_>Z:
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M.A 'UK7P!_P4L_Y-U^'/_9__ /P2=_\ 7IO[&]??]? '_!2S_DW7X<_]G_\
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MG_L__P#X)._^O3?V-Z^_Z^ /^"EG_)NOPY_[/_\ ^"3O_KTW]C>@#[_HHHH
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MCPWH?PX\(>.[/X)^ HO%-EXG^#?Q3\0V27OCL^#?$_A6YU[PS<^!@#>^&?\
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MQ3<7>JZA:WNJV_B/XK>)K2WNM)M-%L4\.V.B6LFGS:C;7VK:E\K_  &^./\
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M[11\;6]C'=?%W3O$?Q(ALOBW>_7NJ_L1?'KQ]X4O_$VD?$GX1_LP_$+]HO\
M9(^$O[-/[6GP[\/_  BU+XT^!/#^C> ])\?6*+^S+JO_  M#X41?#;Q)X?TS
MXO?$#PUHFK>-M"^,G@-(;#P)>S?#K4T\/:Y'XV /IS4/V]/V6M-^,;_ >7Q[
MXDN_B%;>/_!GPMU631_@]\:]?^'GAOQ]\2/!_A/QW\./#?B_XS:%\.]1^#?@
MVZ^(GASQSX6?P#<>*O'NCV'C36M3/A7PS=ZIXJL-2T6S]OTGXKZ!XVT3XH7G
MPL#?$#7/A=XC\6> =3T.,7OAJTO_ (E^$])LM0OO!EGXD\0:=:Z-<B*]U.PT
M/4O$>E2ZOX?T?6_[5T>\O/[9\/:YIEA^>OQ@_8IO/AQ^S'^V9X&^$?A/Q;\;
M=<^//B7X6>*?@SX$\.7'P[\*>(/A-XU^$GP&_9V^"/P<\33^-OBQX]T7PUJD
M7PQ\:?L]^$OC7J?BX"#Q-8Q1RV/A?P)XQ\1:+I\'B+[D_9D^#<WP"^!'PX^%
M>HZQ'XE\3:!HT^H^/_%D<?DKXT^*/B[5+_QC\4_&WDF&!H?^$Q^(FO\ B;Q*
M(7B1X%U18&&8Z /,OV+_ (U?&OXU>$?B_<?'[PG\,_!/Q"^&W[07Q$^%<WAO
MX3:YXF\5>%-+T7P[9>&=6T:S;Q?XLTSP[J?C#6;*U\0_8-8\4Q>#O VG:W=V
MAO;#P;H$$BV@^Q:\.^"?P9_X4[<?&:?_ (23_A(O^%N_''QE\9MG]C_V1_PC
MW_"7:7X:TW_A&]W]J:I_:W]G_P#"/>=_;&W3?M?VSR_[+MOL_F3^XT ? '_!
M6+_E%E_P4L_[, _;(_\ 6=?B-7W_ %\ ?\%8O^467_!2S_LP#]LC_P!9U^(U
M??\ 0 5\ ?#G_E*;^V1_V8!_P33_ /6BO^"L5??]? 'PY_Y2F_MD?]F ?\$T
M_P#UHK_@K%0!]N^*O"'A/QUHLWAOQOX7\.^,?#MS>:3J%QH'BK1--\0Z+/?Z
M!J]CK^A7TVE:O;7EC+>:+KNF:;K6DW+P--IVKZ?8ZE9O#>6EO-&:EX0\)ZQX
M@\-^+-7\+^'=5\4^#5UE?"'B74M%TV^\0>%5\1VD.G^(5\-ZS<VTNHZ&NO6%
MO!9:R-+N;4:I:00VU\)X8T1?D[XV?%SX[:9^UC^S/^SU\(KWX2Z#X<^*'PO^
M/_Q:^)?B;XC^#/&/C;6[/1?@=X]_9CT*/0? VG>&/B+\/;"#5/%>E_&?Q%I3
MZGK]UJ%IX?O_ .Q?%:V&NV_AV^\$^,?B7X.?\%"?VL/'OQFL]3\0? '0],_9
MC\5?M-_M-_LWZ!/>W/P5\%>/-(O?V?+GXU:'IM[HNOZQ^VIXA^(GQK^(_C37
M/@;J=Y>?!'0?V//AMXA\,Z!XNOM3B\1^(- ^%6J^*?'(!^IE]^SS\ =3^*=G
M\<]2^!OP>U#XV:<L"Z?\8;[X9^"[OXIV*VNFOHUJMG\09]$D\6VRVVD2R:5
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MO&UIX9^(GA>7S=!\?^#/"'BRPU;P]I_L-?*/[$?A;XK>"/V9?AKX0^,_P_\
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MWA7QAK-OH$/A"RT'4M?]<_X*-_"?XD_&"']B_P /_#+Q%\5_ FJ:1^VU\/\
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M_A_X.1?"CP''\*]"UW2/% \;Z3K6C?#U- 'A'3-6TSQH!XOT[4;+2(+RR\4
M:_;31:L!=U_-@_\ P6H_X*)^%/@9\7_&7C7X%_LIR>.M.\'?L;_$SX-7-YXX
M^$FC:?JGAS]IS]H?P1\'KC1?&?P>^ O[>G[9_P 48_"-[X>\5W&N?#[]H:[U
M7P'H]_J>FZC9ZE\&Y[K3K?1M;^X_^"W4W[3&F_\ !%?]H:/Q!X[^$^B?%74/
M"/@[PU\;M5\#>"O'X\$^(?!_C7XAZ!X1\6^%/AW8WGQ/TOQ3X;36M/\ $&GZ
M1J&L>(M?\217_AT>)[!] MYM?LI]" /TPTW]A/\ 8AT;XNR?M Z/^QO^RKI7
MQZE\4ZEXYE^-NF_L\_".Q^+LGC769[JZUCQA)\2;7PA%XR?Q3JMS>WMQJ7B!
MM:.K7T]W=375W+)<2L_TGX@\/Z#XLT+6O"WBG1-(\2^&?$FDZCH/B+PYX@TV
MSUG0M?T/5[2;3]6T76M(U&&YT_5=)U2PN+BRU'3KZWGL[VTGFMKF&6&5T;^+
M_P#X*RZO+\$--^*WP"E\'? /PW-\ _V$_P#@E-KL/BCP-=_&'X&_!RS^Q?\
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M]DZ/:?8H;B>*V\M)9%;5^)/[,?[-GQE^'F@_"+XO_L]_ [XK?"CPJ=*;PO\
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M":= 'W_7P!_P4L_Y-U^'/_9__P#P2=_]>F_L;U]_U\ ?\%+/^3=?AS_V?_\
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M5>$[FYU[]FK]H;3=>\6_$GXAV?A2^ANO#GQAOHD^'OCJ?Q'J_CCPY\._A?\
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M)[J4>((=?860!R7[9W[>/B[X(?M@:;^STW[:?_!/;]B/P1-^SGX7^,%AXO\
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M=]4TS1O$E_X2\*WVOZ7974%CK%YX9\/7.HP7,VBZ:]MYW9?L\?L_Z9\7;_\
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M_!2S_P!:*_X).U]_U\ ?$;_E*;^QO_V8!_P4L_\ 6BO^"3M??] !7P!\.?\
ME*;^V1_V8!_P33_]:*_X*Q5]_P!? 'PY_P"4IO[9'_9@'_!-/_UHK_@K%0!]
M3_&#XX?#3X#^'](\1_$O6M3TZW\1^)++P=X4T3PUX0\9_$7QQXT\6W]CJ>K0
M>&? OPX^''A_Q9\0/'&OIH>B:[XBN](\)>&=9O\ 3_#/A_Q!XEOX+;0=!U?4
M;/PF_P#^"@7[+5GX#^'_ ,1+/Q9\1/%6D?$ZW^(USX3\.?#S]G?]H[XG?%;R
M?@]J@\/_ !;/BCX'_#OX3>*/C/X!?X7>*I+3P5\18O'O@+PU+X)\>ZGHO@/Q
M*FF>,=<T?1+[L?VD/V?=9^,U]\%?'/@3QYIGPW^+O[//Q*U#XF?#'Q-XE\%W
M7Q(\#RW_ (A^'/CCX3>*M!\=> =/\9_#G5O$>@:OX*^(6O-:?V#\0/!FMZ1X
MFLO#^L1:U<Z79ZOX>U[YG^*O[#OQZ^,ME\%I_B/^U7X2^(.L>#=#^*NA?%_P
M[\0/V=;O6/@3\2O^%F>)]#\2Z3XB\&_ ?PU\=/!GAKPAXR^#5OH4?@WX,^(_
MB_JO[24N@>"]0UF'Q9:^-_%^N:YXSU, ]9^('_!1?]D#X:6XO?$7Q+\0ZEIZ
M?!SX??M#7VI_#_X,_'/XLZ3H?P'^*%QXQMO!_P 8_$^J_"OX:^,M.\*_#.8^
M ?%EQX@\:^)+G2O#_@C3M+35/&]_X=TW4M)N[[EOVT?^"@WPA_99^'OQ933_
M !!<^)/C1X3_ &=/'OQU\,>'M"^%'QB^+?@GP_I>D>%?%>I>!/%7QQ\4_"+P
MOK'AGX.?#/QAX@\+ZEIVC^*_BEXU^&NB>*HM$\30^&?$DDVA:M<:;YK\+?\
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M"?AW4O&?C/7+/0](LI/$?C'Q7XBGU7Q!J(!XC\1O^4IO[&__ &8!_P %+/\
MUHK_ ().U]_U\ ?$;_E*;^QO_P!F ?\ !2S_ -:*_P""3M??] !1110 4444
M %? '_!)W_E%E_P33_[, _8W_P#6=?AS7W_7P!_P2=_Y19?\$T_^S /V-_\
MUG7X<T ??]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? '
M[&__ "<5_P %8O\ L_\ ^''_ *ZR_P"":=??]? '[&__ "<5_P %8O\ L_\
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M<_AUO"WP<\(?%<:!IO@WP?J_Q=U3P]9>-;3X@<5\,_\ @D?JFB:[/KWQ=_:
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MS6EI:V%K;6-E;PVEG96\-I:6MO&L4%M:VT:PV]O!$@"1PPQ(D<<:@*B*JJ
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MJ]M/:W_BRU\;ZGI]S\5?VG+S3;E(FL=-^(VG^&_"G@KX&)=6W]L6_P +-/\
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M6TG4[&>"\T_4;"YN+.]M9HKBVFDAD1R ;5%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %? '[ __%4M^V;\=;;YM"_:%_;C^+GB;PM<GKJ7
MAWX%^!OA/^Q7::W"P^2?2_$%Q^RS>:[X<O82]OJ?AC4=%U2WDD@O8W;J?VAO
MBGXG^(6JZY^R7^SCXBN[+XT^)](33_B?\5/#Z/<V/[)7P\\3Z9<F?XBZSJHB
METB'XSZII3E?@-\-;N>77=:\2WNE_$'6]!D^%7A7Q9JB?4/PW^'?@WX1_#_P
M5\+?AYH=IX9\"?#SPMH?@SPAX?L0PM=(\.^'--M]*TFQC:1GEF,%G:Q+)<3R
M27-S+ON+F66>621@#M:^"/\ @IS:7:?L4?%7QG:6UQ=_\*0\2? []J"^BLH9
M+K48]%_9._: ^%O[3&OW>E6D"O<7NL6&A_"?4+[2+&U1[N]U.WM+6T1[B:)3
M][U1U/3--UO3=1T;6+"SU72-7L;O3-5TO4;:&\T_4M-O[>2UOK"^L[A)+>ZL
M[RUEEM[JVGC>&>"1XI49&92 36EW:7]K;7]A<V][8WMO#=V=Y:31W-K=VES&
MLUO<VUQ"SPSV\\+I+#-$[QRQNKHS*P)L5\"_LO:_/^SGK&D_L,_%/6)4NO"=
MEJD7[(WC;7KYY$^,_P"S[H+7,WAOP%'K&H2&YUCXU_L[>$XM/\#_ !&TJZN+
M_7_&'@S1O"OQN6ZOF\6>--,\$??5 !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ? '_  5-_P")I_P3[_:D^'%O^\UO]H+X:W7[*GA*Q7_6ZKXV
M_:PU/3?V</!NDPXR\;:AXD^*&F6\ETBN=/MFGU%E\JTD(^_Z_/NSGA_;-^/?
MP]\;Z!-%J7[*O[+?BW7?%/AOQ+%(EUH7[0G[2\&CZAX.TG6_"-Q"6LM>^$O[
M/&EZYXQC7Q"'U'2/&/QXU/2[SPY)IUW\ SJ?B/\ 02@ KX C_P"**_X*CZC<
MW_\ HMO^T;^PAX7TGPY/TAU;5?V0/CWX[U7Q#IEQ*<(NH6&F?MHZ1J.BV3M]
MIO["3Q5>6<;V^B:I)!]_U\K_ +5GP<\7?$;P[X%^(/PC;2K7]H']GSQW9?%?
MX-S:U>2:9HGB2[CT[4/#/Q!^$OBG4X;>\>Q\)?&?X9:[XK^'M]JDUCJUOX-\
M0:MX6^)UOHNJZ[X T.WH ^J**\@^"'QO\#?'[P-#XV\$SWUI+::A=^&_&O@O
MQ#!!IGCSX7>/]'6!?%'PT^)/AR.ZNY/#/CKPI=3QVVKZ5)/<6T\,MGK.B7^K
M^'-5T?6=0]?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO*OC-\9
MO _P)\#W?CKQU=WAMS>6FA>&?#.A6G]K^-?B'XUU?S8_#/PZ^'7AF.6*]\6^
M/O%M[$=/\.>'-//VB]N/,FFDM=/M;Z^M0#Y5U+_BLO\ @J5X(DTW_2(_V=?V
M"/BU:>+I$X32[O\ ;$_:#^!]UX$M9&7*S7&JVO[$'CZY,+%9+&WTV"8J8]6C
M:OO^OE']E7X0>,O VF_$KXK?&"+3H_CW^T;X[?XF?$VPTN_76-+\ Z59:/I_
MA3X6_!30-;6.*/5M$^$/P[T;1?#^HZS8P6&D>,OB+=?$3XEV&CZ._CVZT^'Z
MNH *^ (_^**_X*CZC<W_ /HMO^T;^PAX7TGPY/TAU;5?V0/CWX[U7Q#IEQ*<
M(NH6&F?MHZ1J.BV3M]IO["3Q5>6<;V^B:I)!]_U\K_M6?!SQ=\1O#O@7X@_"
M-M*M?V@?V?/'=E\5_@W-K5Y)IFB>)+N/3M0\,_$'X2^*=3AM[Q['PE\9_AEK
MOBOX>WVJ36.K6_@WQ!JWA;XG6^BZKKO@#0[>@#ZHHKR#X(?&_P #?'[P-#XV
M\$SWUI+::A=^&_&O@OQ#!!IGCSX7>/\ 1U@7Q1\-/B3X<CNKN3PSXZ\*74\=
MMJ^E23W%M/#+9ZSHE_J_AS5='UG4/7Z "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHKRKXS?&;P/\  GP/=^.O'5W>&W-Y::%X9\,Z%:?VOXU^(?C7
M5_-C\,_#KX=>&8Y8KWQ;X^\6WL1T_P .>'-//VB]N/,FFDM=/M;Z^M0#Y5U+
M_BLO^"I7@B33?](C_9U_8(^+5IXND3A-+N_VQ/V@_@?=>!+61ERLUQJMK^Q!
MX^N3"Q62QM]-@F*F/5HVK[_KY1_95^$'C+P-IOQ*^*WQ@BTZ/X]_M&^.W^)G
MQ-L-+OUUC2_ .E66CZ?X4^%OP4T#6UCBCU;1/A#\.]&T7P_J.LV,%AI'C+XB
MW7Q$^)=AH^COX]NM/A^KJ "BBB@ HHHH *J7]A8ZK8WNEZI96FI:9J5I<V&H
MZ=?VT-Y8W]C>0O;W=E>VEPDEO=6EU;R207-M/')#/#(\4J,C,IMT4 ? +?LK
M?'+X'$_\,5_'W3/!O@2(E[;]FK]HSPGX@^-7P3T&WC.Y-%^#WBK2?&W@KXP_
M W2&39I^E^'$\5_%#X0>!-(MK'2OA]\%?#NF6AL9T_X3_P#X*FVW[C_ADO\
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M^E.T?\+&_P""IO\ T9O^P!_XLL_:*_\ I3M??]% 'P!_PL;_ (*F_P#1F_[
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MO^"IO_1F_P"P!_XLL_:*_P#I3M'_  L;_@J;_P!&;_L ?^++/VBO_I3M??\
M10!\ ?\ "QO^"IO_ $9O^P!_XLL_:*_^E.T?\+&_X*F_]&;_ + '_BRS]HK_
M .E.U]_T4 ? '_"QO^"IO_1F_P"P!_XLL_:*_P#I3M'_  L;_@J;_P!&;_L
M?^++/VBO_I3M??\ 10!\ ?\ "QO^"IO_ $9O^P!_XLL_:*_^E.T?\+&_X*F_
M]&;_ + '_BRS]HK_ .E.U]_T4 ? '_"QO^"IO_1F_P"P!_XLL_:*_P#I3M'_
M  L;_@J;_P!&;_L ?^++/VBO_I3M??\ 10!\ ?\ "QO^"IO_ $9O^P!_XLL_
M:*_^E.T?\+&_X*F_]&;_ + '_BRS]HK_ .E.U]_T4 ? '_"QO^"IO_1F_P"P
M!_XLL_:*_P#I3M'_  L;_@J;_P!&;_L ?^++/VBO_I3M??\ 10!\ ?\ "QO^
M"IO_ $9O^P!_XLL_:*_^E.T?\+ _X*FW/[C_ (9)_8 T;S?E_M3_ (>(?M%>
M)?L7?SO[!_X=?^$_[4QC'V;_ (2/2-V[=]K7;L?[_HH ^ /^&7/C]\<_E_;+
M_:"T_6O 5Q\UW^S;^S%X;\1?!CX3Z]:2_P"NT'XO_$;5O%_BOXT_&?1]F^QU
M+1-)U_X+?#'QMH]WJ&B?$'X2>*-)NC9I]X:5I6EZ%I>FZ)HFFV&C:+HUA9Z5
MI&D:59V^GZ7I6EZ?;QVEAINFV%I'#:6-A8VD,5K9V=K%%;VUO%'##&D:*HOT
M4 %%%% !7PUXD_8ATW0?$&N>-OV5OC-\2OV/O%'B75M0\1^+/#GPPL_!7BOX
M#^/O$VJ74M_J6N^,O@#\2O#7BGP3I6M:WJ-S=ZGXL\7?!E_@W\1_&VHW N_%
M_CK6GM[40_<M% 'P!_PK/_@J+;_N;3]L_P#86N;:/Y()]=_X)N_':]UB6,?=
M?4;O1/\ @J-X9TFXNC_RTET_0-)MF/\ J[*$<4?\*Y_X*F_]'D?L ?\ BM/]
MHK_Z;%7W_10!\ ?\*Y_X*F_]'D?L ?\ BM/]HK_Z;%1_PKG_ (*F_P#1Y'[
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M[0?[&5W>(>5FNOAY:_ ;]NFUMKB)5$4PMOB1);WLDC7D,6EQQKITGW_10!\
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MJ;_T9O\ L ?^++/VBO\ Z4[1_P +&_X*F_\ 1F_[ '_BRS]HK_Z4[7W_ $4
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M>OI5E=Q_5U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ?\ #9'[17_2)W]O_P#\.-_P2R_^F64?\-D?M%?](G?V_P#_ ,.-_P $LO\
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M5_TB=_;_ /\ PXW_  2R_P#IEE'_  V1^T5_TB=_;_\ _#C?\$LO_IEE??\
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M5_TB=_;_ /\ PXW_  2R_P#IEE'_  V1^T5_TB=_;_\ _#C?\$LO_IEE??\
M10!\ ?\ #9'[17_2)W]O_P#\.-_P2R_^F64?\-D?M%?](G?V_P#_ ,.-_P $
MLO\ Z997W_10!\ ?\-D?M%?](G?V_P#_ ,.-_P $LO\ Z991_P -D?M%?](G
M?V__ /PXW_!++_Z997W_ $4 ? '_  V1^T5_TB=_;_\ _#C?\$LO_IEE'_#9
M'[17_2)W]O\ _P##C?\ !++_ .F65]_T4 ? '_#9'[17_2)W]O\ _P##C?\
M!++_ .F64?\ #9'[17_2)W]O_P#\.-_P2R_^F65]_P!% 'P!_P -D?M%?](G
M?V__ /PXW_!++_Z991_PVU\6=-_>^,/^"9_[?_@ZS^\+SR_V)_B5F).)Y?[,
M^!?[:GQ7UU?(9H5^SOI*WMWYV[3K6\CMKY[3[_HH ^7O@S^V1^S_ /'/Q-<_
M#[PKXKUKPO\ %K3]-FU?4_@E\8? ?CSX'?&JSTNTDC@U#6(/A;\7?#G@WQCK
MOAFPNI8K>7QIX7TK7?!-R;BRN=-\1WUAJ6FW=W]0UY#\9O@+\(OV@O#-MX4^
M+W@?2?%^GZ7J4.O>&=1F-UI?BOP+XIM(Y(].\:?#GQMHMQIWC#X<^.M'\QY-
M$\;>"-<T'Q3HTS&;3-6M9"6/B7P;^(WCOX;?%1?V4?COXENO&GB6^\+ZSXY_
M9]^-6IV>EZ=??'#X<>%;K1=.\8>'_'%MH=CI6@:;\=OA1=^(O#__  ET.C:3
MHN@?$;P=K^A?$;P9IEM<V7Q/\*_#H ^RZ*** "OF;XU?M@_L_? +7]-\$^.O
M&>H:I\3M;TW^V-!^#7PN\%>.OC5\;-;T<SO:1ZWI_P (/A#X;\;?$3_A&WOD
M-@_BN[\.VOA6TN\Q7^M6@21DY/XU_$WQ[XU^)UK^RG\ /$'_  BGQ F\*Z1X
M_P#C=\8(],TS6G_9]^$?B74=?T3PO>>&])UVUO\ 0-=^-GQ8U?PKXLTCX4:9
MK^F:UX1\*6/A+QC\2_'VCZ[8>'?"_P ._BAZ_P#!7]G[X1?L]Z!J6@_"GP=8
M^'Y?$6I?V_XX\4W4UUKOQ ^)GBQX$M[KQM\4_B%KD^H>,OB3XVOHD2*\\5^-
M-:UK6YH(X;07B65M;6T(!\S?\-N?%74OWG@W_@FI^W_XSM/O?:_LG[&7PR_=
M'Y1+_9_QY_;,^$FL\S++#]G_ +,^VKY7VE[5;&>TNK@_X;(_:*_Z1._M_P#_
M (<;_@EE_P#3+*^_Z* /@#_ALC]HK_I$[^W_ /\ AQO^"67_ -,LH_X;(_:*
M_P"D3O[?_P#X<;_@EE_],LK[_HH ^ /^&R/VBO\ I$[^W_\ ^'&_X)9?_3+*
M/^&R/VBO^D3O[?\ _P"'&_X)9?\ TRROO^B@#X _X;(_:*_Z1._M_P#_ (<;
M_@EE_P#3+*/^&R/VBO\ I$[^W_\ ^'&_X)9?_3+*^_Z* /@#_ALC]HK_ *1.
M_M__ /AQO^"67_TRRC_ALC]HK_I$[^W_ /\ AQO^"67_ -,LK[_HH ^ /^&R
M/VBO^D3O[?\ _P"'&_X)9?\ TRRC_ALC]HK_ *1._M__ /AQO^"67_TRROO^
MB@#X _X;(_:*_P"D3O[?_P#X<;_@EE_],LH_X;(_:*_Z1._M_P#_ (<;_@EE
M_P#3+*^_Z* /@#_ALC]HK_I$[^W_ /\ AQO^"67_ -,LH_X;(_:*_P"D3O[?
M_P#X<;_@EE_],LK[_HH ^ /^&S/C_%^]O_\ @E1^W_864?S75[_PFW_!,S5O
MLL YDG_LSPY_P48UK7K_ ,M<M]ETC2-1U";&RVLYY2J&Q:?\%%O@EH5W;6/Q
M\\%?'S]D=[RXAM+;7?VFO@[XB\$_"X7,\BVZ6VH?M >&F\:_L[:%>273I:VF
MG^(?BSI.H:JY,VC6NHVBO<K][U7N[2TO[6YL+^VM[VQO;>:TO+.[ACN;6[M+
MF-H;BVN;>97AGMYX7>*:&5'CEC=D=65B" .M[BWO+>"[M)X;JUNH8KBVN;>5
M)[>XMYT66&>":)FCFAFC99(I8V9)$971BI!,U?G1XM\$VG_!/VPU'XN_!;2I
MM._9%TAKK6OCU^SKX?L]_AOX+>%DBN+SQ%\>_P!G3PU90LWA32_"BI_;WQ?^
M!7A>&#PCXE\+0^(/B'\,O#FE_%JPUS0/C5^AMC?66IV5GJ6FWEKJ&G:A:V]]
M87]C<17=E?65W$EQ:WEG=6[R07-K<P21S6]Q#(\4T3I)&[(RL0"U1110 5\3
M>,_V_O@!H7BK7OA_\/8_BA^TE\1/"VI7&C>*?!_[,'PI\:_&N/PAK5BVW4]"
M\=_$#POI;?"'X=^)-,!#7?A?X@?$7POXE+-'!:Z3<W,L4#\G='4OVZO%'C'P
M]!K>L:%^Q?\ #[Q5XD^'7B9O#>HWFA:]^UA\2/!&NZAX7^(WA.3Q'IMQ;:UH
M/[.'PX\6:3JO@3Q9:Z)<Z7KGQU\>Z'XG\,W^HV?P/\.ZEI_QV^W_  ;X*\&_
M#GPKH/@7X>^$O#/@3P1X5TVWT;PQX.\&Z#I7A?PKX<TBT79::5H/A[1+2QTC
M1]-M4^6WL=/L[>UA7Y8XE'% 'Q-_PVA\=;G][HW_  2R_;_UFQ/"7_\ PD__
M  3C\,[W7B1/[)\>?\%!_"7B*+RVRGFW&BPV\^/,M9KB$K(3_ALC]HK_ *1.
M_M__ /AQO^"67_TRROO^B@#X _X;(_:*_P"D3O[?_P#X<;_@EE_],LH_X;(_
M:*_Z1._M_P#_ (<;_@EE_P#3+*^_Z* /@#_ALC]HK_I$[^W_ /\ AQO^"67_
M -,LH_X;(_:*_P"D3O[?_P#X<;_@EE_],LK[_HH ^ /^&R/VBO\ I$[^W_\
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M_IEE'_#9'[17_2)W]O\ _P##C?\ !++_ .F65]_T4 ? '_#9'[17_2)W]O\
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M2==M;_0-=^-GQ8U?PKXLTCX4:9K^F:UX1\*6/A+QC\2_'VCZ[8>'?"_P[^*
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M[/4_@#Q-\<?&N@:)HVF+/HWP7^!WP^\6KX!TFT\3^*OA[IUEX<LHOK#X@_\
M!3&'PM=^,?&7A?X-?\)=^SU\-/V(/A-^W?X\^)][\1'\,>.3\-OC':?'B7P?
MX*\#?"9_ 6LP^)/B+J-U\'=+CMK;Q+\0? 7A*&S\3ZS=Z[XMT"Y\*:9IWC4
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M"OPWUI;3X[>'[:<;6M_^%A?LW>(/C'\-IIFD2W@B\7FZNUEM[9X7^_Z^ /\
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M\.?#GXR)XT^%%Q9_&_6KK2/V?/$'BKX416K>"-(TR;XK^5XON]1\'=G\8OV
M?'WC/P[^V5H/AKQ/X,U:]^.O_!+;X=?L'?#7Q;X]O]:'B=/''@ZQ_:LL]8\2
M_$6_L/"VL2V'A#Q%+\:/A_J>H7N@3^(]7OM0T?Q%-=>&5;3-$?5_>[3_ (*(
M_LLZWX[^*_PF\'?$GPAXU^,'P/\ &_P@\!?%'X5:/\3/@QI'C'PKK'QF\0>!
M?#&@SS?\)O\ $WPGX>U*TT37OB#H6@Z[!HVO:CK%[XM$OP]\&:3XN^(]YH?A
M#5_97_:M_9<C^(/BWX22?M)? -/BMX T?7?$7COX8M\8?AX/B'X+\/\ A?2M
M,UWQ+KGBSP4?$7_"2^'=(\/:)K>C:QKFI:OIEG9Z3I>KZ7J%_-;VFH6DTP!^
M5W[:'[%_QBEB\4>+_ OACP5X[\-^(? ?_!(3X#Z)\++'1_%/B2T_M?\ 9F_X
M*'/\2?'NM>+_  9H_A22PA^#6B_#_P"(-O>ZAK-I+>76C>%M#\;7^LZ#H^B:
M2ESJ'I<?['7[5>O?'W2/VM/$NE?L^^'/B0O[7/PF^*FK?!'PQ\9/B/KWPUA^
M$WP]_9@^.?[+NI>)H?BU?_L\>&->UOXWZQI'QUNO&=QI-S\&-%\-:CIGPW\!
M?"BX\<V-K#)\1K+Z^^#/[=O[.7[1O@#X'_%+X >.?#_Q>\ _'CQ]J'PW\.>(
M/"?CKX66_P#8'BC2O!'B_P ?:GI7B/1O$OQ \/\ B&\U_3M"\&:C/J'@/P-I
M'C3XEZ?9SQ^)+[P5;^"]+\3>)] ](TG]J[]EO7]1^*ND:%^TG\ M:U;X$Z3J
M>O?'#2])^,7P[U'4?@WH>B2:I%K.M?%6RL_$<US\/-)TF71-:BU/4?%T6CV=
MA)I&J)=31-878B /S:^"O_!.#XD?"S]HCP;XCU6#PEXT^'/P^_:=_:3_ &F_
M#WQ<\6?M;_MH^(O'*:C^T#J?QIUJ3PMH'[&PU;0?V7? _BW3!\=-?\)ZS\7W
M\:>-]*\0>&]&U75!\$K#Q5\0QJGP]\VL_P#@FM^T?X?\&_LO&*W\ >,O$?[*
M?PM_:$_9OT'P)HG[<7[6G[+GAOXD_"_XI^,OA?XN\+_%?6OB[^S[\(;7QIX/
M\< ?"RQT;QQ\$KOP#\3_  )?6^M6]_8?$Z:\\(:?_;/[)_#/X]? SXTWWC72
M_@Y\9_A/\6=3^&VLP>'/B+IWPS^(O@_QW?> ?$-U%-/;:#XUM/"VL:K<>%=9
MN(+>XF@TO78["^EB@FDC@9(G*^9WG[9G[-_A3PIJ/C+XO?&#X3_ 31-/\1_%
MW0!=?&'XV_ K0+2]M?@E\1E^%GCSQ);ZUHOQ/\1^'(-&T?Q==Z+IFMV>IZUI
M_BKP/JOB/1/"GQ,\->"/'-Q<>%;0 [/]F;X2'X!_L\?!+X)&'PU:_P#"I_A=
MX)^'ZV?@Q_'4OA&R3PIH%CHR6'A>7XG^-?B-\1)?#]BEHMII$OC7QUXJ\226
M$,#ZMK-W=M(]?./[&_\ R<5_P5B_[/\ _AQ_ZZR_X)IU]UZ)K>B^)M%TCQ)X
M;U?2_$'AWQ!I=AK>@Z]HE_::KHNMZ+JMI%?Z7J^D:I82W%CJ6EZE8W$%[87]
ME/-:7EI-%<6\LD,B.WPI^QO_ ,G%?\%8O^S_ /X<?^NLO^":= 'W_7P!_P %
M+/\ DW7X<_\ 9_\ _P $G?\ UZ;^QO7W_7P!_P %+/\ DW7X<_\ 9_\ _P $
MG?\ UZ;^QO0!]_T444 %%?*'A_XZ^+M6_;A^+'[-%QIWAQ/ G@3]EKX"_&_2
M-6AM-37Q;<^*_BE\5OVB/ WB#3]2OY-7DT>;P]9Z3\)/#=QH]I:Z#9ZE;ZC>
MZW->ZMJ%M<V%IIOSS\&_^"CW@&Y^%7A7Q!\?IM4T[XH>.?&_[9]GX-^'WP.^
M"'QY^,'B'Q3X!_9/_::UOX(ZMK.@>!/A5X6^+OC35=8TK0[_ .'.I>*;2SAF
MNK^]UO6==T/1;7P[I6JP:" ?IK17YE_M)?\ !4/]G/X6? 7Q9\1OACX[;XC^
M,K[]E/Q/^T_\+X_#/PC^-OQ2\"6?@Z7P1XE\1?#/QK\<M>^&7A"]TKX'?#GQ
MGJ_AV^TZPUKXR>*?A3;:U)H?BO3-*UB'4_#6N_V3['JO[<WP+^'&@_#Y?C'X
MIU70/%?B'X->"_C-XX;PG\*_B]XX\%?"_P '>*K9H4\<?%CQEX'\'>,O"?P-
M^'M[J^F^*8M$\5_&3Q3X2T._T_P=XTU"VUF]L? _BZ_T@ ^T:*^0_$O[=O[,
M/A/QK\3OA[JWCCQ1/XJ^#FH>&-%^(MIX>^#?QM\7Z;H/B7QUI?PYUGX?^#8/
M$GA+X=:WX:U_QY\1K'XL>!A\./ ?AO5]7\8_$*^U'5-*\&:'KFJ>%?%MGH>1
MHG[?/P U;P+KOQ)O4^*OAGPMI_Q=OO@9X;T_Q!\&OB4GQ7^(_P 3-)TJ;5]:
M\*^!?V;])\.:O^TQ=:]H]EIVOZA=>&_$/P=\.>*KCPMX:UKXDZ9H.H?"M+#Q
MSJ !]IT5\+7O_!03]GZ"RT+QS!XVT"'X.R? []I_XZ>-_$OB#2OC+X;^)O@7
M0/V3==\ :!\8=/U?X+WGP6FUS2-;^'FI^-GTCXE>"?'^N_#WXO>$O$=G9^'M
M'^%GC*]D\4-X,[SPE^VY^S1XRC^,,MEX\UGP['\!_!NF?$GXEO\ $KX7_%KX
M0KIWPSUJW\27.B_$_P -GXK>!?!@^(GPQUE?!WBF#2/B+\.?^$L\%ZI?Z#J6
MF6.N7&HVSVM 'U;17S3\$_VJ/A[^T#XI^)/ACX>^'/BQIY^%EOX6'BC4_BC\
M*?&OP3G75O%VG76LZ7I%EX!^,6E^!OB_/$=%AM]4C\73?#BV^'6L"[FTGPSX
MSUWQ%X>\8:-X<_)#]AG_ (*D?%[]HGXA?LTZ#JWQY_87_:'O_CS%\1Q\5_@#
M^RYX(\6^'?CE^Q9:^#_!7C+Q9IOB_P".>K7?[5G[05M?>&'\1>&-$^$VJ6_B
MCX9_ ^_G\:^/_#5QH]S<2PW/AN8 _H%HK\QOV2/^"FWP3^-7P(^$'C#XM^+K
M?X<_%#Q#^R+HW[4_Q);4_A;\8_AO\&1X<T/P?X3USXTZY\*?B?\ $;P[_P *
M^^(?AKX5ZKXJL;7QA8^!OB7\0=;\"VU_IJ>+IH)9UN)O;;#]OW]F*^\%_$'Q
MS/K_ ,5/#UC\,9/AU%XJ\*^-OV9OVG/A_P#%J23XO:BFB?"R/PC\#O''P>\/
M?&?XC/\ $/Q";CPOX-7X=^ O%)\1>+=-UOPII?VGQ'H.M:98 'V917RU?_MG
M?L]:=\.-%^*,_B7QG-HGB+X@3_"C1?"NF_!;XW:O\9K_ .)MI#JM_J/@&/\
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MZ^ /AS_RE-_;(_[, _X)I_\ K17_  5BH ^_Z**0D*"S$*J@EF)   &223P
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M;Q)X[^)%QK/[+OA/]GKPI\-_$OBSX4^*_#'A+6/"/[4?Q+\13:CKGPXM=?\
M"?A_5_$GBG1O 0!^M-%?BK\(OVL?VB?VA/VKO^">_C;Q)\-[;X)_ ?\ :%_9
M[_:@^,'P[\.^%/V@=:^(=UX]\$WOAW]GSQ#\-;_X^> /^%:_#?PQX-^)NC:)
MXK?4;'P[X;U_XY>&_#-SJWB.ST_XE&8J^L^#_M4>(OVIO'?[1?QM^%?P'_:0
M\>_"/QM:?\%"?V5]&^%%]/XE\1W_ ,/M(;3_ /@GUXI^,L7PZ\7>#H=0%KJ7
MP1^(GQ'\,Z;+\7O!&F16:^)=-U'6=2MGM_%!L-7M@#^B*BOP3U;]K_QC\9]*
M_P""E?C/PQXC^(OPPUOX:_\ !*_P)J>J?"J3Q;JNGZY^SE^TWX=\2?\ !0WP
M]\4["T@TC4EL= ^(6B:]X!\,6?\ PGOAEH'\9>'O"_@'Q;H6LZIX8;PEJ)]'
M\%^#M5_92\=?\$X?$7PP^,'[2?C+3OVLO%$/PA^-WPN^.7[3'QW_ &G-#U^T
MU3]E[XH?'%/BWX8G_:)\?_%?QA\.?$O@3Q7\+=-L;E/AYKGAGP/JGAGQGKEC
MXJ\/7E^GA?5]# /VEHK\7OVIOB?^TQ\)/^"@=W\6_A*_QD^,7PL^#/[)WPDN
M_BY^Q]\._M'B0_$GPK\6OC+\;_#FN?$_X<^!'E$5U\;?A?J7@OP-KEG-I*+J
M_BOX967C_P $QP:CJVH^&!8>,? 3]J;]IG]GS6_VV(?C;K>C?&GXS^)OVW_A
M3X6\,_#GXC_'74?!/PV^$47Q$_8=^#OQ_P#$WPF^#\.C^ OBO\2/$WAKX<Q-
MXDT'PKX)^!OP+^(?C[X@^(VE^(?BOPWH>AZE\2_B/X4 /Z"**_)'P)_P59\/
MZI\.=$^)?Q*^$&H?#[0M9^$_[4GB&WDT_7_%^N_;?CC^QY\7=7^$?Q=^ FD6
M7B[X1_#+Q(VJ:_>V-MXA^#NI^)_#GA+QAX_TB'Q3#JGPM\&:EX1O+2[_ %,\
M(:AXBU;PEX7U7Q?X>M?"/BS4_#NB:AXH\*66MCQ-9>&/$5[IEM<ZWX>M/$8T
MW11X@M=%U*6YTVWUL:/I(U6*V2_&FV(N/LL0!T5%%% 'P!\1O^4IO[&__9@'
M_!2S_P!:*_X).U]_U\ ?$;_E*;^QO_V8!_P4L_\ 6BO^"3M??] !7P!_P2=_
MY19?\$T_^S /V-__ %G7X<U]_P!? '_!)W_E%E_P33_[, _8W_\ 6=?AS0!]
M_P!%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? '_!-/_DW
M7XC?]G__ /!6+_UZ;^V17W_7P!_P33_Y-U^(W_9__P#P5B_]>F_MD5]_T %%
M%% !1110 5\ ?\$G?^467_!-/_LP#]C?_P!9U^'-??\ 7P!_P2=_Y19?\$T_
M^S /V-__ %G7X<T ??\ 7S7IO[(GP"TCX@GXGV/A+7E\6+\9;O\ :#LDN/B;
M\5;[PGHGQBU/X<^-OA1K7C?PS\/+[QM<_#WPK>^(_!'Q%\9V7BG3_#?A?2M$
M\5:UK<GC'Q%IFI^,[/3O$%G]*5^-7_!2N^\6:E^TW^PY\.],\$_ME_%SPAXM
M\+?M7:SXJ^$'[%G[4^I?LH>//$U_X2TOX+MX:\2^(?&=O^U?^QUIFM:#X.?6
M]7"Z+J7Q4N9OM&O&;3_#.I'[3-9@'Z!>)/V1/V?_ !5X,N/ FI>"]4L]'D^+
M/BOX[6&J>&/B%\2_!7CKPO\ %_QSJ_B36?%GC_P'\3O!OC#0?B3\//$&MS^,
MO%VG75QX%\6>'8E\,^*/$'@^"&'PIK&H:+<+\/?V1/V>/A;+X'N?!GP^-K?_
M  ]\)?%_P7H.JZYXM\<^,M9U'1_C_P"*_!WCKXU7OCG6O&?B;Q!JWQ/\7?$[
MQCX"\+^)?&/C_P")5YXM\=ZSK%G?WMSXD:;7_$#:I^)?Q-T/]J+PXW_!-WX,
M_'SPQ^W1\:O$'B#1/VZO$'BSX+_LL?MJW'P3^.;^$-#\7^ M5_9]T_XQ?'31
M_P!KG]DS0?BQXG^"OPJ\3Z%X.\=ZW<_&SQ9)XI\;/K/B#3W\>R7EWXIN>T_9
M^UGXG_M"VW[#'[,/Q(_:0^.,WPR\?_#O]O?XU^.-=\$_%SXB?#/X[>+8_@)^
MTK\/_AK\'_V9/'W[07@V3P-\<+;Q%\ O"WQ5;0/CCX@\)>+_  IXX^(WQ#^&
M%B^L^/\ QMX0NO&9\:@'W/XQ_P""5O[,-W\'_BI\.?AEIGBOP'XH\<?LL?'O
M]DCP-X^\8?%#XX?'.+X/_"KX^Z#H>F:[X2\%>#OBI\6]8TG3/A[H6H^$/!>J
M>'?AKX=N_"_AKP]:^'$T+P?_ ,(IINIZDMQ[IX-_9"\!_!G3OB=KOP'>31/C
M'\0?!.F>#;7XA?'/Q/\ &W]IG0?#VG>&X-3/A/PQI_@OXA_&VVU+P[\(M%U/
M6-2U5_@Y\*_'7PL\(W5U>W4\'V#4)1J":W[.?@NT^$<?Q:^%VD_M >)?COI/
M@GQC87/AWP;X\\<7/Q/^,/P-T/7O _AK6+/X7>//B=XO\7^)?B7X^DU:_;4_
M'O@_Q%\8]4F\<+X;\8V&C77B'7?#^D:)J2_GUI__  4H^(WCGP/.GC/X1:A^
MSI\08_B;^R-9Q>!-"^*/V?XTZ#X5^.G[7?PR^ E]8?%+X8?M-_LF^!O%7AF.
M.R\:12ZWJ_P_^&?Q.^&/BVQ7Q-X<^&/[2GAWQ"/"7Q$E /T2_9'_ &9/!O[(
M?[.OPX_9X\&7 U32O ^D7D>JZ\=,M=$D\4^*-?U*^U_Q=XD;2;&6>#1X-9\0
MZKJ5SIFB0W=Y#X>T=M.\/VE[<VFEV\K:7@O]ECX#?#R;X$7'@_P)_8\W[,_P
MB\0_ CX(O_PD_C+4/^$)^%/BJU^'EEKWA7;JGB&]7Q)]OMOA3X!B_MSQ<NO>
M)+7^P=]EK%O)JFM/J/R9X%_;R^*?BOXA?#:WU7]G#POH/P1^)7[7'[27[&^G
M?$.U^/-SK?Q)LOB!\!/%?Q_\/:7XRG^$;_!K2/#TGPX\;P_ '6#>WH^,<7C/
MPEKNNV.EQ>"/%.A6DOBZ?NOA3^U]\5_BYK\OC?PY^SOHS_LDP_$+X^?#>]^-
MJ_&RV'Q5\.WG[/\ X@\<^"==\=>*/V?]1^'&E:='\,_$WCSX;>)O#7AN[\'?
M&?QM\35BU;P+KFM_"C2-+U?Q?)X  (-:_P""7'[#^O>#K'X>7GPF\2VG@&U^
M!.D_LT:CX)T#X[?M"^%?"GC+X)>'K/7+#PQX*^)WA[PQ\5M(TKXL_P#")6WB
M7Q!_PA_B/XFVGBWQ;X1N-8U"\\-Z]I=Y<RSM]$ZO^S)\#]>\*?M#^"-6\$?:
M_"_[5D&HV_Q\TS_A)/%T'_">PZM\(O"OP(U!/MMMK\.H>%_M'PI\$^&/"N[P
M7=^'7B_LS^W(&C\27NH:Q=_&7[#_ /P49\5?MB>(O",5[^RO\5_AA\/OBE\(
M[SXV?#'XGW?@O]HT^$$\*M>^%)?#OA?XH>*?BQ^R_P# OX;^'OB9XM\+^-=)
M\1>']"^$'Q%^/W@[4CX?\?V^G?$*^TOP_H.O^,/*=4MO'_@;]M+0+'X8_'+X
MW?'GXO>%=9^.'Q>_;)MKOQ]\1H?V;_AK^S9XG\"?%S4/V;/@4WP1E\6^(O@;
MX#^,<?B[4_@K;>!;OP#X8T+XW_$'P#\-_'GQ3^(^JG1/%C1>(0#[U\6_L5_L
MV>-+KQ;J&J^ ]5TW5?&GB_PK\1-4UOP5\2?BI\.-?TKXD>#?#&H>"-(^)?@?
M7_AYXV\+ZS\-/B7>>!]4OO _BKXA_#J^\+>,_'?@J9?"/C?7/$/AV"WTV)V@
M?L7_ +.OA73O@[IWAOPAXFT.3X$^,/%/C[P!KNF?%OXQ6?C*X\7>/+N[U'XA
MZS\1_'D/CY?&OQKE^)6K7T^N?$VU^,^O^/['XD>(!;^(/'%KK^M6=G?0?F5^
MP_XH^(>A?$7_ ()S^,;OXY_%CXJW7[??[#?Q(^.W[0>C^/?BG\0/B'X%G^*?
MA_1/V</'FC_$3X0^"O&NO:MHGP*\.Z5<_%KQ7X(F\"_";2?!/P^OM'UOPNNJ
M:!+K^AZ;J-U['X&^,=U^QMXO_P""E?Q)_:G_ &E/B3\5_AU\$?"OP0^+>L>(
M?'\OAC2M)\'V>N>!_&%U?^$OAAX'\-:?X6\$^"]$O+C3=#T+1--2)M7U[5?L
MFJ>._&'B7Q)?:IXFN@#[^\<_LR? _P")/BO7?&_C3P1_;7BCQ+!\ ;?6]3_X
M23Q=IWVV']EWXNZU\=_@4GV+2=?L-/MO^$&^*WB+6/%6ZTM+=_$WVS^P_&#>
M(/#=O:Z/!Z!X8^&W@KP=XH^(WC3PWHO]G>)?BUKVB^)_B#J7]HZM>?\ "0:Y
MX=\(:!X"T>^^QW]_=6&E?8_"?AC0]*^S:):Z;9W'V'[==6\^I7-Y>7'XZ?\
M!*7]JO3_ -H7]HS]O:WNOVR?AK^TUK.H:A^SQ\3]*\%?"KX[^#/B]\,/@II7
MBOX7_9?$7P[^#=KX-UO4M,M_ W@;6K73?"?B;Q99VL$_CGXA6FM>,/$7V+6_
M$9T?3_>/#G_!2+4-6_:G\&? K4OA-X,3X=?$SXS_ !J^ W@/XH>"OC!XG^)F
MNCQ[\&O"/Q+\77$/CW3/"?P*G_9^\&KXALO@Q\25;PGI_P"U7XM^+G@MX?"F
MF?$#X8^&?%=_XZ\+?#8 ^N/!O[(OP"\ V/P]TSPUX2UZ+3/A+\6_%'QP^&&F
MZQ\3?BIXJT_P!\0O&'@_QWX!UJ;PC9>*O&VM6V@^#U\(_$SQQHVB?##3HK?X
M8>%H]>ENO"_@[1[ZRTVZLL#Q=^P_^S9XSL(+2\\)^,O#.H6GC#XK^.K'QC\+
MOC9\<_@S\3-,U[XY^(1XL^+T.D_%?X1_$CP1\3-)\,_$'Q+%8:WXC\#Z;XLM
M?!-YJ.A^&;@>'HW\+>'/[+^%M$_X*P>,=%^#_@3]H3XV?LN6/@;X1?%?]ASQ
M[^VE\.6^'?QVB^*7Q(G@^&7AOX7>)/$WPU\:>#]=^$WPJ\+^&;W7+7XJ:/\
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M7A[XT?#BT\':'JME\!;"Q\&?$+5+7QI?^"[K4;O4-<\#?$2*]AT[1>T^+_\
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MAGX+USXF^#DMH]4AMD\*^/=3T2Z\5>'DMXM<UN*!=(U6S$4>L:HD85=0NQ,
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MR^!?P<^'7Q"^)K^9\2?'G@3X8^"O"/C/X@R?VC>ZOO\ ''BCP_HFGZYXL?\
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M?#KX2:GX(^ _PM^/7BO]MF;]F'5M;^(&F^%_&6F:9X"O_P!C#XD_M3:5X_\
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MSX2_!SX;:E;_  ^M]3TS2M!UGXD6D:R:7^D7_!)W_E%E_P $T_\ LP#]C?\
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MM'M;73KVZU:_^&T&MR>,K/3;:RUC2;N>_N-%CM8;75-.N))5BO;9Y60?M%?
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M??.6M_\ !-+]J+QM^S]X6_9U\07/[-_A/1_V=?\ @GS^TS^Q;\$O'OA#QO\
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M?%NAQ?"BPBLV\;>,/L#]E7X!_P##,O[-WPG_ &>_^$L_X3;_ (5?X.A\)_\
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M]^&'Q$^'#^"[&]TG5-8\)>%_$=Y\7?$GQ7T(7D7CGQ!\3O&WQ)@E\77? ?\
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M_P"467_!2S_LP#]LC_UG7XC5]_T %? 'PY_Y2F_MD?\ 9@'_  33_P#6BO\
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M_#FOO^O@#_@D[_RBR_X)I_\ 9@'[&_\ ZSK\.: /O^BBB@".;_52_P#7-_\
MT$U_+C\,/A%\0OBI\'_^",6J?!?Q5<>$/CM\&_V8?VI_C/\ !:\EU>ZTGPMX
MB\;^$M?^ %A=?#3XC?9X+V.Y^&OQ>\':[XJ^%7C6>73-4O/#FC>,9O&?AVS_
M .$L\,Z!<6_]21 (((!!&"#R"#U!'<&N!\/?"GX7>$D\'1^%/AMX!\,1_#O1
M=8\-?#]/#W@[P[HJ>!?#GB*73)_$&@>#ETW3K9?#.BZ[/HNCS:QI6B"QL=3E
MTG3)+V"=["U:( _F@7Q3\#_V[?%VM:GXK^''AOQY\+OB;_P6_P#@'X?^(WP8
M^,/A/PWXQL-&\6>#O^"5_P .- \?_"GXG>#-;MM;\-7OB7X:_$;PSJWA?Q)I
MES#J6G6_B7PW-<6$]U!%9WLGZD_L;^%/AU\'OVU_VR/@#^S)IGAWPO\ LO\
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MKS0#\V/B1^VU^UM\"M;/PSU2X_9B^*/B?QIX6_8S\>_"GQ%X*\#?$OP[X(\
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MF^&=M8^!)O _BF[?]GC1M;TGQ39^,H?#FD>-#X9T:W\9WO!O_!2#6M=_:C\
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MK%_V?_\ #C_UUE_P33K[_H ^ /VR/^3BO^"3O_9__P 1_P#UUE_P4LK[_KX
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M?V.?V1?A)H4OA?X4_LL?LX_#'PU/J/AG6)_#OP]^!_PR\%Z%-JW@KQ;#X_\
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M_P""//[,WB3]G[XP>(H[F36? ?QST/0?VFM+\<?M'? ;Q5K\]YXM\/\ Q?\
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M7P!_P5B_Y19?\%+/^S /VR/_ %G7XC5]_P!? '_!6+_E%E_P4L_[, _;(_\
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M9XR^'.JZ;XH\ W_ANXNKCPKJ7@'3=,U?]2]<_:?_ &:?#'PH\-_'CQ)^T/\
M SP]\#O&;Z''X/\ C-KGQ:\ Z3\*/%<GB=VC\-1^&_B)?^(+?PAKK^(9$>/0
MTTO6+IM6=&6P%PRD!?$7[3W[-7A"]^&NF^+/VAO@;X8U'XS6-MJGP?L/$7Q:
M\ Z+>_%?3+V;1[:SU'X:VNI>(+:?QU8W=QXAT"WMKOPO'JEO/-KFCQ12/)J=
MDLX!\N_LB?L6ZQ^S?\2].\5W\/PO30?#_P"PK^R1^R?X8M/!#_$2ZN?#NI?
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MOA;PUJ5S=:'8 'T-7P!^QO\ \G%?\%8O^S__ (<?^NLO^":=??\ 7P!^QO\
M\G%?\%8O^S__ (<?^NLO^":= 'W_ %\ ?\%+/^3=?AS_ -G_ /\ P2=_]>F_
ML;U]_P!? '_!2S_DW7X<_P#9_P#_ ,$G?_7IO[&] 'W_ $A 8%2,A@01Z@C!
M''/3TI:* /SL_9I_85U_X ^)OV?-4U3XOZ#XQ\/_ +,_PG_:5^!WPXT+1_A9
MJG@[4+SX<?'/X@_ 7QMX5'B[7M2^*_CF/5O&'P^M?@D^BZWX@TK1O#^D^/9/
M$\>JV?A;P)_83Z=K?F'BG_@FKXQU6+PQINC_ +07AR\\(6OQ/_;)\=^-_AE\
M4O@OK_Q(^$WBRT_:U_:'UGX_6&IVWPWTWX[> _#"_%_X*3:M-X-\!?$OXB67
MQ5\,?V5J7BF_C^%&E7'B::WLOUBHH _*KX1_\$V_$GP:\"Z/\.O#/Q[\/7OA
MX?\ !./X*?L#>+)?$?P \.^*+O7;[]GZT^(]G\/_ (JZ=HOBCQOKGP[MO#FK
M0?%SQU;?$CX,^,_ /Q#TOQ=82>'K#3/&GA6WTO5QXD^A?V1?V5?$'[,\/Q*A
MU3Q]X-U71_'-WX5;PU\+?@[\-O%?P9^ /PGL?#&E7^FS1_#'X2>*?C-\<(_!
M-UXI:^BF\4VGA'Q-X=\%WG]B:#-IO@G2=737M8\0_:%% 'Y=^"/^"?7Q$^"O
M@W]E^;X#_M ^#?#WQL_9J^!?Q#_9WB\=_%'X$:U\2OAGX]^'GQ)\2^!_&FL2
MZM\)O#/QW^%/B;1/$VD>*?AQX6O/#FK:3\9#90:=/XFTS7-'\0'5-'O/#7K7
M[)O[#NA?LF^)9=8\._$'5O%^FR?LU_ CX R6>O:%9V>L7FK_  A^(O[1?Q+\
M1?$C4=7TV_CTQ[GXB>(/VAM4E?PKI?AK2-,\*?V&(].O;^RU*"PT;[JKPW]I
MWXF:]\%OV;/V@OC%X6M-(O\ Q-\*/@E\5/B3X=L?$$%Y=:%>ZYX'\#:[XFTF
MTUJUTZ_TK4+G2;B_TRWAU&"QU33KR:T>:.VO[29DN(P#XM^(W_!*C]GOXS3_
M +3/Q ^,?A7X2?$?]IGXX^)_%.O_  R_:B\2? +X=ZW\6OV8+6#P5H/@CX'Z
M;\&O$/B9/$7B#09/@=%X6T3QCI-YHWB/P]!K_P 2IO$WC?\ L[0;_P 3WD$/
M3^'/V6/VO_AW^T#\4_C#\-_VI?V=H?#'QWUCX+>(?B[X0^(G[''Q%\8>*[[6
M?AC\+_!_PN\2S^ _'?A/]MCX9:#X/MO&FG^%I]7TJTUKX9^./^$/U+4UCGF\
M66=CY%W\-?!__@J/\7?%'A'XV:QH/QZ_88_;8B\"_L%_%O\ :NE^(/[(G@CQ
M;X=\"? 'XK_#S2-!O?#'P)^/MK#^U9^TO9ZSJGQ(.N:UJGA^&Q\?_"SQ?'I?
MPO\ &Z2>%98+JUUK2K_P4_X*J^/%\,_%'XH>+OC)^QW^W)\%OAA^Q=\1/VHO
MB%\1/V%/"^O>"(/@G\2? 47@^]T/]F?X@_VK^TO^U;X7UOX@?%S3/$7B6Z\&
M-)XR^'?B+1C\.==EU7P'J6EZG!JFF@'ZI?!7]GG6_@?X"^.7A?PU\1+:[\1_
M%KXT_M!?&O0/%-[X-(L_!&M_&WQ9K/B[2M.N_#H\4N?%=MX)OM3@BGG&M>'3
MXHBLW(@\/&ZVV_S;;?\ !+7]GCQ!'^SMX/\ CAX3^&?[1WP/_9E_9WD^#_P\
M^"WQL^#7@SXA^&;KXG:_JWA:^^('[1GB=?&;^)='UKXE>+++P;I=C:7<OAJ/
M5?#]QXA^)6HIXEU*3X@ZI!;>A_"?5/\ @HMI?BKX9ZU\<[3]EOQ_\/?B3/+;
M^._!/P/\'_$'X=^,?V8A>>&-8\1Z9J=U\3OB;\:?&6D_M0Z#IVO6.E_#?6KC
MP_\ !W]G?Q)=7.NVWQ#T[PBFEV>I^#[+[PH _+O3O^">'C#X9Z?\+]6_9U^/
M7A?X4?$7]GSQ1^T+I/[/\^M? +3?%OP<\+?LS?M#^-=%\;:I^ROXV^#_ (7^
M(_POU'Q+X"^'=_X7\&1?"WQ!\/?B7\'?$/A6#X?^"M-!O/"\'BOPUXPL?$#]
MA_\ :/\ '/A/P/X@N?VP= U/]I/PC^T_X3_:<7QQXZ^!/C#Q;^SIH]]X2^&/
MB7X4V/PO^&/[,^E?M+>#O$'PX^'#Z)XBG\03H/V@?$WBW5/&]QK7B/Q-XI\1
M?VM;6.D_IY10!\6^'_V</C%KGQ:_9P^.?QV^,WPT\:?$7X#>&_V@_"^I1_"7
MX%>*?A#X*\:6/QL;X>Q:5-9>'_&/[0'QSUWPI=^#K+P#'%J#S^,/%4/BNZU-
M[JV@\*16BV=QZS^T?\$?^&@OAUI'@#_A)_\ A$?[*^,G[.OQ;_M;^Q?[>\__
M (4%^T!\,_CI_P (_P#8/[6T7RO^$L_X5U_PBW]J_;9/["_MC^V_[-UG^S_[
M(OO>:* /A3PO^Q5_PC>D?"?2O^%E_;?^%7_MP?M!?ME^?_PAOV?^W/\ A>WC
M#]I/Q7_PKCRO^$KG_LS_ (1;_AH7[!_PF'F:A_;G_"(?:O\ A%]'_M_[-HGW
M7110!\ ?\%8O^467_!2S_LP#]LC_ -9U^(U??]? '_!6+_E%E_P4L_[, _;(
M_P#6=?B-7W_0 5^?'@2UBO?^"H?[:5E.TZPW?_!/C_@FS:S-:W5U8W*Q3_M#
M?\%9(I&M[VRFM[VSG".3#=6EQ!=6\FV6WFBE1'7]!Z^ /AS_ ,I3?VR/^S /
M^":?_K17_!6*@#1^!O\ P39_9-_9UT6\\)?#'1/C>?A[?^#O%G@&[^$?Q'_;
M _;"^-_P1F\)^.7N)?%NE'X'_&WX\?$/X1JVMR7NH/=Z@G@M=45M4U<P7L)U
M;4OM5*__ ."8G[&.K?"/XG_!#6/A]\0M9\"_&6\\!77Q(NM9_:4_:=U?XD>(
M[/X6:K!K7PT\,CXU:E\8[KXS:/X#^'^I0>?X-^'6@>/M+\!>&TNM2M=(\.6E
MIJNIP7?WW7PW_P %%?CK\<?V</V7M=^*W[/?AGX<^*OB'IWQ%^"/AF/3_BCX
MJUWPEX9CT7XA?&/P/X U>87WA_P+X_O9[^:'Q*FG0(VD01:9!?W/B-9M1NM$
MMO#FN@'O/P1^ 7@7]G[1-8\/^!-=^->O6&N:JFLWMQ\;OVE/VB_VF-;@NTM(
M;(0Z/XF_:0^*GQ6\2>'=*,,".^A>']5TS1)+MIM0?3VO[BXN9<5/V5_@;#M^
MQ^%-8TW'[0D_[4\O]D?$+XDZ/]M^.-T93=^*]3_LOQ=9_P!JZ1>^<XOOA_J7
MVKX<7J%4NO",R1QJOQ9\4/VUOCE8_#__ (**7\OP9T7P'HG[#OPE\:3^)OB5
MX%^/NF:OXTUCXL:?^R5\+OVEK/1OA1X=\>_LP>)O"7]FZ0GQ'O\ P]-X[^)_
MAV[TZUN=$\+ZZ/A-XVM_$WB7PEX(;\4O^"D6J?"/XXZ/\,9_A;X3\8?#6Q^,
M?[.?P"\;_$73?C!KWB+XIZ#XU_:%N/ASH.@:UK/PN^%?P!\<_#/P3I%CXH^+
MGP^L;C3OCC\=?@!XYU_3IO%/BSPI\.+OPM%\-[OXG@'U%\:OV'_@%\>_B39?
M%_QLWQU\._$FR\$67PX_X2OX'?M;?M9?LRWVH^"--UW5O$NG>'O$$/[-_P ;
M?A18>)[33]=UW6-1L9/$5IJEW9S:A<+;W$<+"->E\1?LC? /Q;>:GJWB7PAJ
MVO\ B+4T^$"_\);KGQ"^)>K^,=+D^ VJ2:]\*I_#GB^_\8S>)_"UQX=U^XU#
M7M0N/#.KZ1/XOUK6O$>J^-)?$-_XEU^YU+X8TWXT?'#PW_P32_;I^+_@[79/
M%_Q=^&7Q)_X*G7/@+5/B'XVUZUBT:Q^%?[4?[2FE>#+2#Q$^@>.M1L].^'?A
M+PYIMCX(\.0Z)-I,-GX=T+PC;OX?T,)?Z9ROPX_:_P#C?\&_@?I'P^\,? +1
MOBQXP_9H_8_^&/[3/[4%UX\_;2^+'BW5[;PE\1T^)FN:5I/PI^+'Q;^"/C+Q
M_P#'_P"*^K>'OA5XX\1W.E_%J7X*>"="U"_\'^"+;XG?V/+?:OX5 /JK]C[_
M ()W_!3]D?PI\%8=/N/%?Q!^)GP=^!?A[X'V/CKQ1X^^+>J>$+6PL]'\.V'C
M/7?AC\#_ !E\3O'?PM^!EU\1]1\-6&J^+8_ACHVD:CK"16^FZYKFMVMLI?L_
M!W[ '[)/@>\U^?2?A3+JVEZ]\.O%GP@B\$^//B#\4/BA\+?!OPF\>-:CQO\
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MM6NO%FC?%C2?CE:>)->^(7Q+\4:W/\6-$_9X3]E.P\:ZQJ?B;QAJ]WX@U/\
MX4,@\$WT.O2ZEI^K7+2^,]6L[WQY-+XG?\F/VN_VO/%'@W_@H)X"OM)\:?M,
M:?\ #;]CB;X.>&OBWX7^%WP5_:6\8_LV?$C4/VFI;VT^/4_[17Q$^&GPJ\6_
M!#P5<?LO?!+6/@M^T#X(F^+?CSPE/H">)=:NT-GI^LB\O?,/B+^V9^U%X4_8
MS_X*L6>@?LZ_MJ_$.;P-\0O^"DFD>!OVKO!7Q:_9;T_P?\)]-\-WOQ#B\*WW
MAZX^('[8?@/]HWPYI'P5C@MI+6U\%?"&XU'1(M$"_#;2M>DATR*Y /TZ_:,_
M8(TWXI>'_A_IGP8\>#X&:GX'^.WQ*_:!GOR_QNU$ZYXX^+NF>.+7QY?1>*?@
MW^T7^SE\;/"<NK:EX^U[4FT_P;\:-#\%W5I>W?A[6_!>M:"=.LM*],^''[(N
MC:=^S)H?[-?Q\\>^-/VE-,L/$-KXHU3Q-X[\4_$5]:O+_0_BA!\5_!&DVGB?
MQ#\1/&OQ<O/#GP\UW3/#VE^%V^(OQ=^)?CC4= \.Z?9>/O'GCB>XU2\O[W[4
M7Q4UCX2_ SP=XSTS4?%%GJ&J_&K]D?X=SWGA;4?!]AK+VOQH_:2^#_PBU1KB
M\\>?#[XGZ+-I+67CJYE\164?AJV\0ZMHJZAIGA?Q?X"\27NE^./#_P ]^!?V
M\OBGXK^(7PVM]5_9P\+Z#\$?B5^UQ^TE^QOIWQ#M?CS<ZW\2;+X@? 3Q7\?_
M  ]I?C*?X1O\&M(\/2?#CQO#\ =8-[>CXQQ>,_"6NZ[8Z7%X(\4Z%:2^+IP#
M[Y^)'PQ\#_%SPY:>$_B%HG_"0>'[#QE\.OB!::?_ &EJ^D^5XN^$WQ \,_%+
MX?ZO]JT2_P!-O7_L#QWX.\.:[]@DN7TS5?[._LS6[+4M&O+_ $^Z\5^(_P"Q
M=^SK\5-9U?Q-XJ\(^*++Q=K7Q*T'XO3^./ /Q>^,OPG\?:?\0O#?PXMOA!I^
MO>&_'?PK^('@SQ?X0BNOAC:KX(\0:'X4UK1O#WBSP_/J%EXJTK65U34C=_E]
M^W#'\2/''[?^K_#;P[\-OV^_C5I6E_L/>"_%OA+PE^QO^VS=_LE^'/AY\1]<
M^,GQ?T*+XB?$BPO/VR?V5O#WC&+4K?2-$TU)'\/_ !GN[2QT"6&]\'2V30V6
MJ_!7Q,U7]K#P[=?M@#XO>+_VU[G]H+X!?#7]D;P[)^V1\(/VN?$G@;]B']F+
MXOWO[+/PCU'Q[\1_BM^R]I?[1OA2#XD^!/\ A:&I:W\2?&UII/[#OQJT'7/#
M6IW2>(+32K :D/#P!_0/'_P3S_9-L?"WAWP?X>\!^,O ^D>%KKXNW&DW/PT^
M._[0'PO\2O!\>?'\_P 4OB[HVM>-?AW\4?#'C+Q-X6\;_$*XD\6:EX0\2Z]J
MWA:VU5;>33-'L8[6UBAV/B1^P=^RO\5;7P_8>*?AQJ>G:7X>^'.@_!PZ+\._
MB=\6OA!H/BOX-^%WN3X>^#GQ/T'X2^._!.C_ !@^$6D1:CK5E9?"_P"*UCXR
M\"1:9XF\7Z5_PCYTSQAXHM-7^3?"OPRU#]LS]HS]M-/BY\</VD_">E?LR_%_
MP)\"_@QX&^!'[17Q@_9OT/PO8W'[./P3^-.J_%OQ3IOP.\8>!H_BUXI\>>+/
MBM?/9V/QAN?B1\.=(\(^$O#NAZ)X)TJ>]^(#>*OT6^ ^H3ZG\&?AC=W?QC\/
M?M"WI\%Z%;:A\<O"EEX;TW0/BOJ-A916.H>.[#3O!NI:MX3L/^$BO;:?4;JR
M\-7\NAVE[-<6^EQVMG'#:0 &U\0/A;X"^*/P_P!7^%GC?P]!JW@'7;&QTS4O
M#EM>:EH5M+I^F7=G?6%I;W7AZ]TK4-/@M;G3[-HDT^\M0L<"P'-NSQ-W]%%
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MZ5!=RW\.F7)\&Z#HQGT^&^GFO(K*7?;1W<TMPD8FD=SV.C?"KX7^'-7LM?\
M#WPW\!:%KVF/\0Y--UO1O!_A[2]7T^3XN^*K#QU\5WLM2L=.@O+1_B=XWTK3
M/&7Q#:":-O&GBK3K#Q#XD.I:O9V]Y& ?"UW\3_AO^TM_P39^'OQP_:Z\16WP
M=^'7C?X:?![XM?'*W\&Z[>6OA?4DTS7/"GBOQ!\+ NHZ7J^O>*OAU\5]<TT?
M#?6?AO%8ZAXE^)7@[Q9>?#.W.IZEXEVWGYXZ+^SWIUC:?LL_#+XI_ ?0?@I^
MQA^US_P43\<>*]$_89U[P=X93X<> ?A)8?L/_$"/X/\ P9^+7POLY+CX:>%[
M3XF_&/X4R?M%Z]\%].T^[\+^'?BEXOTKPCJ]EJ/B^TUC[3^Z/C+]G7]GWXB_
M"F+X#_$'X%?!SQW\#H(-&M8/@SXR^&/@GQ/\*8;;P[>6^H>'[>+X=ZWHE]X0
MC@T+4+2TOM&A31Q'IEY:V]S9+!-#&Z^>>'?V&/V)?!_PO\8_!'PE^QW^RQX7
M^"_Q%U&UUCX@_"'P[^SY\)=$^%_CK5K)+2.SU3QCX TSPC:^%/$^HVD=A8):
MWNMZ3?7-NEE:+%*BVT(0 _*;X;Z;^S-<?L-75A^T-'K_ ,3?V9?A#^WG^U?X
M _9W_9TTRRT[XD^'?VG_  YH/QB^.'PJ^!G[,6G_  MUVQU:U^.W@O0-0U.Y
MMOA!\.Y98/"FC7/PM\ ^*]2U*V\$_#>76+3D-=_8/O\ QUX0_8V^ 7Q?F_8C
MTKXH^#/ /[;WQI\&_LM?MA?LM:_^VO\  _P+X&^(/QP^&?BK0? '@6QM_C%\
M%? ;7_[(7@#Q?X6^!-IK>F^*M1CTWPYK8O? OA4>![;S%_:?XA?LB?LG_%SX
M=>#/@_\ %;]F#]GCXG?"7X<26$OP]^%WQ"^"OPV\:?#KP'+I>EW&AZ9)X,\$
M^)/#6I>&O"\FG:)=W6CV#Z'IEBUGI=S<:?;F.TFDA;%D_8@_8ME^%.A_ >7]
MD+]EZ3X'>&/$DGC/PW\&I/@#\*'^%/A[QA-<W%Y+XKT/X=MX3/A#2?$DMW=W
M5U)KMAH]OJCW-S<3M=&6:1F (OV'_B9I7QE_8\_9E^*.A_#WP]\)]%\;_!+X
M=:YI/PW\'6MM9>"/!FFS^&M/CLM"\ V]G8Z9:#X?VEO%&/ <UMING07/A!M%
MN8M/LDF6VB^IJ@MK:VLK:WL[.W@M+.T@BMK6UMHHX+:VMH(UB@M[>")4BA@A
MB1(XHHU6..-51%55 $] !1110!\ ?\$T_P#DW7XC?]G_ /\ P5B_]>F_MD5]
M_P!? '_!-/\ Y-U^(W_9_P#_ ,%8O_7IO[9%??\ 0 4444 %%%% !7P!_P $
MG?\ E%E_P33_ .S /V-__6=?AS7W_7P!_P $G?\ E%E_P33_ .S /V-__6=?
MAS0!]_T5'-)Y44LN-WEQO)MSC=L4MC.#C.,9P<=<&OS _9I_X*!_$OXQW'[)
M.K_%/]G'PU\'? /[;GP<O/B/\"=7T'X[W/Q5\8P>*=%^'=A\5=8\$_$WP>OP
M;\!Z'X2TW4O KZUK_@CQAX=\>^.GUB#0VT_QCX9^'?B#4;+17 /U#HK\0M/_
M ."M'Q=U+P-^RYKEO^QS;S>-_P!K#X+ZS^TGX$\"^'?B#^T;\7QX=^!OA_0?
MA.MUJ_C?4?V<_P!ACXV>(-$\=:[XY^+>CZ/X0\-+X)N?!=UX-TZ]\4^,?BAX
M%\8W.G?"V[?^TY^W]\<_'_P _:'TO]GG]G/Q9X,UWP9_P3Q/[37Q@U?XR_%#
MQ)^S5\=?@)+\:_AK\8+KX=^%?A_\/+3X7>,M5\1?&_P3J'PN\4WOBW3?&'C7
MX#Z3X2U&S\/#1O&VL:C?7T>@@'[=5^6'P,_X)V?$?X,_'32/B9'^UAXRNOA]
MHWQ'^,GQ"D^%/AB;]H+PYH?C)/B_JWC/7+WPGX\\!^)?VKOB'^RC%H&G:[XP
M7Q,US\)?V3/A!XA;Q3H&GZKX>UOPG;:SXVTSQ7!KO[</Q0\#>%[SP[\,/@MI
M'QSU/]G;]C_X,_M,?M):]X^^-VH?"S63X1\>>'O'%]9:3\*XQ\*OBDGQ3^+.
MHZ3\(?'^N76F>.]<^$'@IM1N_!^GWWQ/ADU_Q!?^#^<\:_\ !3OQWIEM\3?'
M_P //V:-"\>_ CX4_'/]F/X+:SXRU+X\3^"OB5XKD_:R^'_[,7BGX9Z[X!^%
MMQ\&=<T"\FTOQ'^U#X4T+QOH_CGXK?#VWTGP_I5YXIT/7?$VJSR^#-/ /IO3
MO^"<W['NF:=XXT.'X8:[>>'/'GPF\=_ BX\):W\8OC?XC\&>!?@W\3K:*R\?
M_#7X&>#?$'Q(U/PO^SEX1\56-KI6GZKI'P TCX:6\NG^'?"=@BQV?A'PQ!I/
ML/Q _9=^!'Q3N_%E_P"/? ,'B"^\;>!/ OPXUZ\DU[Q5877_  C'PP\8ZO\
M$/X<2:'<:5KEC-X3\4^!/'FMWOC+PEX_\*/HOCWP_P")H=)UO2_$MMJ&@:%<
M:=\6:1^VS\1/$?Q;\ ?!_P >^"(OA3\3O"W[<]Q^S'\3O#OPC^+.D_$[X:Z[
MI6I_L)>/_P!L3P=K<WC+XE?LT^#O&'B#P_JGAR#PWIVM^&O#'AKX/>*_#OQ
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M "<5_P %8O\ L_\ ^''_ *ZR_P"":= 'W_7P!_P4L_Y-U^'/_9__ /P2=_\
M7IO[&]??]? '_!2S_DW7X<_]G_\ _!)W_P!>F_L;T ??]%%% !1110 4444
M%>2?'[X6?\+R^!7QH^"O]N_\(O\ \+>^%'Q#^&'_  DO]F?VW_PCW_">^$=7
M\+?VY_8W]H:1_:W]E?VK]O\ [,_M73/MWD?9?[0L_-^T1^MT4 ?/'Q!^ O\
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MJ>&/AA\(OV?/!7B'XBV&E>)=0\,KH&FV?@N'[THHH **** "BBB@ HHHH ^
M/^"L7_*++_@I9_V8!^V1_P"LZ_$:OO\ KX _X*Q?\HLO^"EG_9@'[9'_ *SK
M\1J^_P"@ KX ^'/_ "E-_;(_[, _X)I_^M%?\%8J^_Z^ /AS_P I3?VR/^S
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MWX*?LD^$_@M!87/BSX@_$SX/_ KP_P# ZQ\=>)_'_P 7-2\)6NGVFC>'=/\
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MI>&/B!X7EU#PCXLT#5+X ]WHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* _VYM_OX_X7)X=W8_U>4SGS1C[_ *^ OVN4?X*_%G]G[]MJ)67PG\)U\8?
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M]G?]FNX8&2VUOX$_!'7/&FIZ[\7='9_E33OCC\8_''C:\T#5-/:?2O'/P?\
MAW\$?'%A>W5CK-DMM]_4 %? '_!*7_1_^"9O[ VAO_Q\^"_V1O@'\-]2]1K'
MPQ^&WA[X>:T"/X&&K>&;T-&>8V!0Y*U]_P!? '[*/_%AOB]\>?V.M;_T'3$\
M:>.OVH_V;;FX_<6WBCX,?';QYJOC;XG>%-$\S;%<:A\!?C]XK\7>'-7T'2C+
M;>#/A9X^_9]:X2QB\5:=9H ??]%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 445\U?M9?&K6?@?\'-7U?P+IEGXF^-/CC4+#X6_L]^!KN1PGC?XX
M>.?/TSP+I=Y' DUXGA70KA;KQU\2]8M;:Y'A#X5>$O''C:_B&D^&]0EC /%?
M^"9_[W]F?Q9J*<VOB#]MO_@IWXLTR3_GOHGC#_@I9^UKXIT*Z]!]JT;5[&YP
M"RCS<*[KAC]_UXK^SA\%=&_9Q^ ?P>^ ^@ZG>:]I_P )_AWX5\$/XEU.-(]8
M\7:GH>DVUKKGC37MCR"7Q%XSUM=0\4^(;DR2O=ZWJ]_=22R23,[>U4 %%%%
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M=?\ YXU'_#V+_@EE_P!)+/V /_$R/V=?_GC5]_T4 ? '_#V+_@EE_P!)+/V
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M7X_+I<:@RQ'XF_LY?"[6+L$0V.CWDV%8_P"'EG[.O_1.?V__ /Q4[_P5-_\
MH-Z^_P"B@#X _P"'EG[.O_1.?V__ /Q4[_P5-_\ H-Z/^'EG[.O_ $3G]O\
M_P#%3O\ P5-_^@WK[_HH ^ /^'EG[.O_ $3G]O\ _P#%3O\ P5-_^@WH_P"'
MEG[.O_1.?V__ /Q4[_P5-_\ H-Z^_P"B@#X _P"'EG[.O_1.?V__ /Q4[_P5
M-_\ H-Z/^'EG[.O_ $3G]O\ _P#%3O\ P5-_^@WK[_HH ^ /^'EG[.O_ $3G
M]O\ _P#%3O\ P5-_^@WH_P"'EG[.O_1.?V__ /Q4[_P5-_\ H-Z^_P"B@#X
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M /\ Q4[_ ,%3?_H-Z^_Z* /@#_AY9^SK_P!$Y_;_ /\ Q4[_ ,%3?_H-Z/\
MAY9^SK_T3G]O_P#\5._\%3?_ *#>OO\ HH ^ /\ AY9^SK_T3G]O_P#\5._\
M%3?_ *#>C_AY9^SK_P!$Y_;_ /\ Q4[_ ,%3?_H-Z^_Z* /@#_AY9^SK_P!$
MY_;_ /\ Q4[_ ,%3?_H-Z/\ AY9^SK_T3G]O_P#\5._\%3?_ *#>OO\ HH ^
M /\ AY9^SK_T3G]O_P#\5._\%3?_ *#>C_AY9^SK_P!$Y_;_ /\ Q4[_ ,%3
M?_H-Z^_Z* /@#_AY9^SK_P!$Y_;_ /\ Q4[_ ,%3?_H-Z/\ AY9^SK_T3G]O
M_P#\5._\%3?_ *#>OO\ HH ^ /\ AY9^SK_T3G]O_P#\5._\%3?_ *#>C_AY
M9^SK_P!$Y_;_ /\ Q4[_ ,%3?_H-Z^_Z* /@#_AY9^SK_P!$Y_;_ /\ Q4[_
M ,%3?_H-Z/\ AY9^SK_T3G]O_P#\5._\%3?_ *#>OO\ HH ^ /\ AY9^SK_T
M3G]O_P#\5._\%3?_ *#>C_AY/\ IOW6G?"O]O_4KY_EMK'_AUC_P4NT7[3)V
MB_M7Q3^R=H'AZQR,GS]6UG3[08VM<*S(K??]% 'P!_PM7]LO]H7_ (E/P?\
M@EJ'[(G@"]_=:A\<?VG5\(:_\6)M*G^5KWX0?LU^!/%?BJUM-8N+5ISIVO\
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MLO\ I)9^P!_XF1^SK_\ /&H_X>Q?\$LO^DEG[ '_ (F1^SK_ //&K[_HH ^
M/^'L7_!++_I)9^P!_P")D?LZ_P#SQJ/^'L7_  2R_P"DEG[ '_B9'[.O_P \
M:OO^B@#X _X>Q?\ !++_ *26?L ?^)D?LZ__ #QJ/^'L7_!++_I)9^P!_P")
MD?LZ_P#SQJ^_Z* /@#_A[%_P2R_Z26?L ?\ B9'[.O\ \\:C_A[%_P $LO\
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M1^SK_P#/&H_X>Q?\$LO^DEG[ '_B9'[.O_SQJ^_Z* /@#_A[%_P2R_Z26?L
M?^)D?LZ__/&H_P"'L7_!++_I)9^P!_XF1^SK_P#/&K[_ ** /@#_ (>Q?\$L
MO^DEG[ '_B9'[.O_ ,\:C_A[%_P2R_Z26?L ?^)D?LZ__/&K[_HH ^ /^'L7
M_!++_I)9^P!_XF1^SK_\\:C_ (>Q?\$LO^DEG[ '_B9'[.O_ ,\:OO\ HH ^
M /\ A[%_P2R_Z26?L ?^)D?LZ_\ SQJ/^'L7_!++_I)9^P!_XF1^SK_\\:OO
M^B@#X _X>Q?\$LO^DEG[ '_B9'[.O_SQJ/\ A[%_P2R_Z26?L ?^)D?LZ_\
MSQJ^_P"B@#X _P"'B7PE^(?_ !*/V2?"?Q&_;+\57G[G3+SX+>%=6A^!]I._
MR_:_%O[4GBZQT/\ 9_T+3=/)^TZQIVC^.?%?Q$.GQ7+^&/AWXKU1+?2+OU#X
M/? _QS-XVC_:!_:2UGP[XI^.DFBZGH'A#PMX-FO;WX2_L[^$/$$UA<Z[X)^%
M5YK.D:%K_BW7/$#Z5HZ_$/XR^*]%T7Q+X^GTBTAT;PI\-?!45E\/]/\ J^B@
+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img99844967_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img99844967_2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )B!. # 2(  A$! Q$!_\0
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M'P&_91^*'PKU[Q!?>)_CUXA\=VNHZ)<:9;6FH2716SN)'C*72^9<N-Z!& P
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M5M>U*^M?VI_%MA:W-S)-%:1RWVV%&<E4&+P#"@@< =*]'^+O[+GQ+^('P_\
MAMH6@_'/7_"6J>&;![35=7LY+D2ZW*R0*)I=EPK$@Q.?G9S^]//7/T[10!\N
M_ 3]E?XG?"K5/$MSXH^.WB#QY#J>CS:=:0:A)=$64[LI6Y3S+A_F4*0,8/S=
M17EW_# ?QU_Z.R\8?]_K_P#^3:^\Z* /ECX\_LH_%#XJ:]X?OO#'QZ\0^!+7
M3M$M],N;33Y+H+>7$;R%[IO+N4&]PZ@Y!/R#)/:+P/\ LF_%/PS\)?'_ (5U
M+X_>(M;UWQ#]C_LWQ#/)=&?2/*D+2>46N2P\P':=K+TYS7U910!\2^"OV'?C
M3X;\9:#J^H_M0>*]:T_3[^"[N=-GEO3'=Q)(K/"VZ[(PX!4Y!&#T-=)\=/V0
MOBQ\4/BIK?B?PU^T+XD\#:)?>1]GT"PDNQ#:[((XVVB.Z1?F9&<X4<N>IY/U
MM10!\NV?[*_Q.M_V=[[P!)\=_$$WBR?6!J,?C)I+K[5% %0?9@?M&_;E6/#X
M^8\5C?!/]CWXM?#3XH:%XE\1_M$^)?&NBV#R-<:%?2W9AN@T3H P>Z=>&96Y
M4\J/K7UW10!\5>/_ -B/XS>+/'GB37-+_:<\5:!IFI:E<WMKI-O+>B.RADE9
MT@3;=JNU%8*,*!A> .E=3XX_9-^*?B;X2^ /"NF_'[Q%HFN^'OMG]I>(8)+H
M3ZOYL@:/S2MR&/E@;1N9N#QBOJRB@#YB_9M_9<^)?P9^(%QKOB_XYZ_\2-+D
ML)+1=(U.2Y:))6>-A,/-N)%R C#[N?G/->4_\,!_'7_H[+QA_P!_K_\ ^3:^
M\Z* /F?]H#]F'XD_%C_A$_\ A%OC?KW@'^R--%E>_P!G27*_VA*,?OW\NX3Y
MC@_>W'GK57X2?LK_ !.\ >"?B+HVN_'?Q!XLU'Q)IHLM+U2\DNC)HTP64>?%
MON&(;,B'Y2A_=CGICZBHH ^$;3]@GXY6]U#*_P"U=XOE1'5FC::^PP!R1_Q^
M=Z[WX]_LC_%7XJ_%#5/$OAC]H'Q'X#T6Z2%8="T^2[$,!2)48@1W*+\S*6.%
M'+'KUKZQHH ^8O#/[+GQ+T7]GGQ=X!O/CGK^I>*]8OXKNR\8RR7/VK3HT>!F
MA0FX+X812#Y74?O6XZYY;X2_L9?%_P  _$C0/$.N_M(^)_%FD:?<B:YT6\EO
M#%=H 1L8/=,N.>ZGI7V-10!\<_%K]C+XO^/OB1K_ (AT+]I'Q/X3TC4+DS6V
MBV<MX(K1" -BA+I5QQV4=:Z3Q!^RO\3M6_9]\,> [7X[^(-/\4Z7J4M[=^,(
MY+K[5?0L9BL#D7 ?:OF)U<C]V..F/J*B@#Y.^ G[(_Q5^%7Q0TOQ+XG_ &@O
M$?CS1;5)EFT+4)+LPSEXF121)<NORLP894\J.G6N"N_V"?CE<74TL?[5WB^)
M'=F6-9K["@G('_'YVK[NHH ^9_C-^S#\2?B-X#^&FB>'OC?KW@W4_#&FFRU7
M5K&2Y$FMS>5;IY\NRX1BVZ&1OG9SF9N>I-7X*?LK_$[X:Z7XXMO$7QW\0>-)
MM=T>33M/GOI+HMI<[*P%S'ON'PRD@_+M/'6OJ*B@#X,_X8#^.O\ T=EXP_[_
M %__ /)M>H_M$?LK_$[XO>-K'6?"?QW\0?#W3H--ALI-+TV2Z6.69&<M.?+N
M(QN8,H/&?E')KZBHH ^4_ _[)OQ3\,_"7Q_X5U+X_>(M;UWQ#]C_ +-\0SR7
M1GTCRI"TGE%KDL/,!VG:R].<URW@#]B/XS>$_'GAO7-4_:<\5:_IFFZE;7MU
MI-Q+>F.]ACE5W@?==LNUU4J<J1AN0>E?:M% 'R3\=/V0OBQ\4/BIK?B?PU^T
M+XD\#:)?>1]GT"PDNQ#:[((XVVB.Z1?F9&<X4<N>IY.I>?LK_$ZX_9WL? $?
MQW\00^+(-8.HR>,EDNOM4L!5Q]F)^T;]N64\OCY1Q7U%10!\B?!/]CWXM?#3
MXH:%XE\1_M$^)?&NBV#R-<:%?2W9AN@T3H P>Z=>&96Y4\J/K6!XU_8=^-/B
M3QEKVKZ=^U!XKT73]0OY[NVTV"6]$=I$\C,D*[;L#" A1@ 8'05]M44 ?+OQ
M)_97^)WC+X6_#WPSH_QV\0>&]:\.PS1ZGKUK)=";6&?9M:4K<*Q*[3C<S?>/
M2I?V<?V7/B7\'?&6JZOXN^.>O_$73[O2I;"'3=3DN6C@F:2)EN!YEQ(-RB-E
MX .)#SUS].T4 ?!G_# ?QU_Z.R\8?]_K_P#^3:]1^/?[*_Q.^*NJ>&KGPO\
M';Q!X#ATS1X=.NX-/DN@+V=&8M<OY=PGS,& .<GY>IKZBHH ^7?A)^RO\3O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HKJU@OK6:VN88[BWF0QR0RJ&1U(P58'@@CL:EHH ^8M-_8'\
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M^%?[07[45O\ $;P_X9^)GP.LX].U6Z2"36]$F80V,>?GFE=)+A.%!(4E-QP
M1FO?/ G[27PW^)/CK7_!F@>*;2Z\4:'<RVMWI<FZ*4M&Q5S%N $JJ5()0L!W
MQD9 /3**** "BBB@ HHHH **** "BO!OV@_VVOA3^S?'-;>(]>74?$*#Y?#V
MC[;B]SP1O7(6+@@_O&7(Z9Z5\J? W_@K!:>//C=JA^(,FG?#SX<0Z/,;"W$4
MUY/+>>=;A/-E1"2?+\\@*B+SSN(4T ?I)17S;_P\:_9S_P"BEVO_ (+KW_XS
M1_P\:_9S_P"BEVO_ (+KW_XS0!])45\V_P##QK]G/_HI=K_X+KW_ .,T?\/&
MOV<_^BEVO_@NO?\ XS0!])45\V_\/&OV<_\ HI=K_P""Z]_^,T?\/&OV<_\
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M"_\ HG.O?^!D/^% S]%Z*_.C_A]!X+_Z)SKW_@9#_A1_P^@\%_\ 1.=>_P#
MR'_"@#]%Z*^/_P!F7_@H]X;_ &FOBE!X(TSP?JNBW4UI-=BZN[F-T C )&%Y
MR<U]@4P"JVHZE::/9RWE_=0V5I%@R7%Q((XTR<#+$X') _&K-?.?_!0__DS7
MXD_]>]K_ .ED% 'MVG>/O#&L7D=I8>(])O;J3A(+>^BD=OHH;)J_/KVF6NJ0
M:9-J-I#J5PN^&SDG59I%YY5"<D<'H.QK\5_$*?LX:?\ LG>']1\.7]Y8_'ZW
M6UFW:=-?!S<B8>9OWYA0"/+ Q[3N5<'J#]9^%O%<O_#2_P"RW8^//"BZE\1+
M[P7'-+XBN[ZY2ZM28+LE7AR$>0@'>7!.YV]!2 _02LYO$>DQZPND-JEFNJLG
MF"Q-P@G*_P![R\[L>^*^%?A5^WA\<?CI_:2> O@MINMC2[N6WO;IM5\B 9C8
MPH#(5PQ9'R<D?,@.W.X^(?LBZIJ5O^T=\6_BQX\\ P7@\+WVHZIKNN?VD'F\
M/S"*\+000B4+<;RK1 [7"[%P5ZT ?K517P9IO_!1KQKIOA_2_B1XH^$36/P8
MUK46T^QURSU))+R+#R+ODASEN8W&,(,J0&.5SW'CK]LKQSIO[3'B;X0^"_AO
M#XUU"UTJ&\TV2*_6V#.\4$K/<22$)'$J2/R.6;RU&-V0P/K+4=2M-'LY;R_N
MH;*TBP9+BXD$<:9.!EB<#D@?C3[.\@U"UBN;6:.YMIE#QS0N'1U(R&!'!!'<
M5\#>(/VN?^%W?LF_&^T^('P^@A\1>"+BTL-=\/K>R1VT[O>!%"R1MYB%9(9,
M@,>4'S$,0.T\0?M6I\#?V:?@7:>#?!\>H^+?&VG6-EX=\-FY<P1#RX1M:5SN
M8*9HD&Y@6+Y)P#0!]>3:]IEOJT&E2ZC:1ZI.GF163SJ)I%&?F5,[B/E;D#^$
M^E7Z_-+0?&'CWQC_ ,%-O@U-\2O!L?@GQ7:>'+NUFLK>Z2XM[A!;ZFZSQ,K,
M-A#[<;B0R,,UZ;=?M^?$#QPWB7Q)\)?@W+XS^&GAFYD@OM>N-1$$MV$0.YAA
MQN7 8-@"0["I94)P$!]P45\7_$#_ (**6^D^"?@WXN\)^%9M>TWQSJ$]E=Z:
MS9O[9H98HY(HE4[7E)D;:"0&^0\!JW?A7^U]X\O/VE;;X0_%/X;0>!]5UJR?
M4=&^QZBEYB)8Y'Q*ZDJ^1#,-R8PR8V\Y# ^LZ*^*O&'[=WCG4O'WC^R^%OPM
M7QIX5^'AD7Q'J%UJ*VLQ9#*'\A<G(_<R$85V8(?E&1GZ7^!/QCTCX^_"O0O'
M6B07%I8ZHC_Z-= >9#)'(T<B''!PZ-@CJ,'O0!WU%%% !1110 4444 %%%%
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M=^-O^"@WA#X7^!O$-QH_A[PWIWV_Q0L,*2)*KA97217!!!0VL:N!N1KAR.]
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MQ#&JK.\4B\I)(WELJR?*#@ '/[(44A'PA_PYO^"__0S^//\ P867_P B4?\
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ME[@0&EB(PQ4?=://S9)_3RJVFZ;::/8PV5A:PV-G"NV*WMHQ'&@]%4  #Z4
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MM_="C=GTKX*_9H%_^T%\4O%O[17B.&2--3DDT;PE8S+_ ,>6F1.5WCDX9F#
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M^WU^TMK;\_V+IMCJ$*'E6G%BD<>1]93]*^<Q4O:IL]+#ITTD>L?#?PC;Z_\
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M'XD^%[+Q'X8U2#6M#O=_V>^MB3')L=HVQD=G1A]16[0 4444 %%%% !1110
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M@9ET?P)/>.4_A9Y+F'YL]L2KT[D5]PUZ5#^&CCK.\V%%%%=!B%%%% !1110
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M\+Z1XAT:Y%YI.JVD5[:3@$;XI$#*<'D'!'!Y%:U?/GU@4444 %%%% !1110
M4444 %%%% !7S5^Q?H?PGT7_ (63_P *M\1:SK_GZ\\FM?VO'L^SW?S92/\
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M$4(*@[ 0HV@G<06*$<#_ ,$[OV6?&_[,?P[U:W\9:^DT^MRQ7B^'+8B2'3)
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MF0@&9E R6(P,'8BDD']=OVEOV8?!_P"U-X-LO#_BQ+BW-C=I=VFI6&U;JWY
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M,2ZG!#J)=DEAO<R)):0 A/NJ\@#@@/G O_'3]K[XC^&=0\)ZIH=_:6/@:_\
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M$\Q0F64#NH!ZYYVJ1D9QZCX\^.%EKU]+I-I=OXGO;AV0^'_"I:17S@[+B].
M%QG*Q#) (W5\W_M??#WQ(_PYT+3-7-H?''CO6K/PWHNC6;[(=.@9P[;<<'YE
MC0]L2DG))KD:]I4]2W+W++H?3/\ P3+\ 'P+^R#X4FF@>"^U^:YUJX5_XO,D
M*1,/8P1PG\:^J*R/!_A>Q\$>$]$\.:8ACTW2+&#3[5#U6**-8T'_ 'RHK7KV
MCA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OF7_@H#\5O#OP?^#>C:SX
MF^'VD_$FPGU^&S32=891%%(UO<N)QNC<;@(V7ITD//K]-5\R_P#!0#X-6?QQ
M^#>C:%?>-=#\"16^OPWPU+Q!.L4$C+;W*>4I+#YR)"P'HC4 4OVROCIXR^$/
MQ(^!.D^%M3CL+#Q3XB_L_58WMHI3/#YUJNT%U)3B5^5P>?85]3U\S?M<VGPJ
MN?B%\$V^(M[KEIK,>OY\-II"J8I+OSK;B?*GY-WD],<%J^F: "O+_P!J/5+S
M1?V;_B=?Z==SV%_:^';Z:"ZM9&CEB=8'*LK*05(/((YKU"N _: U32=#^!OC
MW4->TC^W]$M=$NYKW2O/:#[7"L3%XO,7E-PR-PY&: /-/^">_B+5?%7[(/@'
M5=;U.\UC4[C^T/.O=0N'GFDVZA<JNYW)8X50!D\  =J^BJ\2_8O\1^&?%O[-
M/@[5O!WA?_A#/#EQ]L^RZ']L>[^S;;R=7_>O\S;G5WYZ;\=J]MH **** . ^
M+WP1\,_&K2;:VUR&6VU&Q9I--UJP81WMA(PPS12$$8.!N1@R-@!E.!7RQK/[
M&?Q.TN_G%I=>$?&%CC]W<W$]SH]V?]^-(YXV/^T&3Z=J^YJ*]#"X_$X/^!-H
M\G'95@LQ_P!YIJ7GU^\^ M/_ &/_ (LZU;J9=%\*:"SN QU'7[FZ:)<]1%#;
MJ'X&=IE7KU])_BO^S'>_L^:/X8^)\>MWGBJ[\/W,BZZ8;,0VUI8R@?OK>V0D
MI'%(B-(27<HSLS;8P!][4UT6165E#*PP589!'I734S?&5I1E5G>W3H<-'A[+
ML/"4*%/E;5K[OY7/B'7/CX?$FFQK8W%OIT+HK>?#-\TBXX*G X/7(SGUKR#Q
MI>:A\8M8L/ >F7$VHZMXC\S3(I)69S&DD;)+.<G(CAC9Y&/^RJ]77/V!KO[#
M/PEU:ZFGL=*U3PP+B<SS6_A[6+JRMG8]0(%?RD!_V%4_K7>_"[X ^ O@W+=7
M'A70$L]1NUV7.J74\MY>S+Q\C7$S/)LR =F[:#R!7L3SRC'#NG0I<LFK7/G:
M?"^(GBXUL5B.:,7>VU[;'?0PK;PQQ(,)&H51G/ &!4E%%?''Z,%%%% !6?HO
MA[2O#<$\.D:99Z7#<7$EW-'96Z0K)-(VZ25@H&79B26/)/)K0HH **** "BB
MB@ KYA_8B_9_\6_ G_A9O_"50VD/]O\ B!M1LOLMP)<PG=@M@?*>1Q7T]7PS
M_P $OO\ FN/_ &-TG_L] 'W-1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 445\W?M/_MY?#?]F6"YT^\O!XE\9JO[OPWID@,J$C(^
MT28*P#D'YLO@@A&% 'T1J6I6FCZ?<W^H74-C8VL;33W5S((XHHU&6=F) 50
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MBV*[BF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M..Q:0>]>:Z?J)_;,_:0U;Q3K-VR^%89S;Z8K JD&G++L@7K\AEP9G/4EB 0
MNW[=U3X.^&OAOH=I<&=SIMN/*-C;HD>\D' C QC!^8CG@&NV-.%-+GU;/TC#
MY7EN54Z4LSBZE6HKJ"NDD]KM:MOU5CYOTW]MC]H'PBYO?%/@#0]>TE 3)'96
MMSI\PX_YZ^9.J@8[Q_B*^G_V=_VL?!?[1EO/;:4T^B^)[.(2WGAW5-BW*)D
MRQE25EBW'&]3QE=P4L!7D-?,?[2%O:^ _'7ACQ/X4DCT;QG:S/J$=U .4D5E
MV.R]"KG>K#&'7<#FJ]E&II%69[%;AS!9HG# T_9U$FUJW%V5[.]VO6Y^LE%<
M/\$?B=;?&7X2^%?&EJB0C6+&.>:"-MP@G'RS19[[)%=,_P"S7<5P'Y#*+BW%
M[H****"0HJA:^(-+OOLGV;4K2X^UAVM_*G5O."'#E,'Y@I(!QTSS5^@ HJ*.
MZAEN)8$FC>:( R1JP+(#G!([9P?R-2T %%%% !1110 5\U?L8?%_P_\ %C_A
M9/\ 87P\T;P#_9&O-97/]D+&/[0D&[]_)LB3YN#UW'GK7TK7S-^Q3\&K/X0_
M\++^R>-="\9?VSK[7LG]B3K)]B8[OW4N&.'YZ<=* /IFBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***@O;VWTVSGN[N>*UM8$:6:>9PB1HHRS,
MQX  !))H GKB_BQ\9?!?P/\ "\GB'QOX@M- TU3M0SMF6=_[D4:Y>1O]E03C
M)Z FOB_]J+_@J]X:\"M=^'/A);P^,=?&8FUR;/\ 9MNV<?NP,-<-P>1A.5(9
MQD5XE\)/V"_C)^V#XJC^(/QU\0:IH>D7(#J+[']I7$1;/EP0$;+6/EL;E&,@
MB-@<TA%OXQ?\%#/BQ^U-XH/P\^ .@:KHUG=G8+FT4'5KE.A=I =EI'DC+!LC
M )D )6O5OV7_ /@E#HWAJ:W\4?&>ZC\5:ZY$X\/V\C-90N3NS/)PT[9QE>$S
MN!\P'-?:?P=^!?@;X!^&1H7@;P_:Z)9M@SRQ@O/=,,X>:5LM(>3C)P,X  XK
MO: *VFZ;::-I]M8:?:PV-C:QK#!:VT8CBBC485$4 !5    X&*LT44QA1110
M!P_QR\#W_P 3/@WXV\):7+;P:CK>CW6GV\MVS+"DDL3(I<JK$+D\X!/M7A_P
MH_95\5^!?B=X(\1:AJ&BSV&A_"V#P1<QV\TK2/>I,9#(@:( PX/WB0V?X:^J
M** /C?X0_L;^-/ $/[-2:AJF@S'X:2^(7U?[+<3MYXOW9H?L^Z$;MH(W;]F.
MVZJ__#%_C;^P/L/]J:!YO_"ZO^%C[OM$^W^SMF/*_P!3_P ?&?X?N?[=?:%%
M 'P1K?[&OQLO/"OQ5^']MJ?@9/!7Q!\6R:_/?R3W3WUC"URDQ"IY(1G(BB&W
M. 5;YOFW+U'Q4_8C\4>,(_V@[;2-4T>TL/'5AX=MM"6XFF:2$Z:D.Y;C]W\H
M<PX#*7/.2.U?9]% '/\ @!?$">#=*3Q3;:?9Z^D6VZ@TJ=Y[9""0H1W1&;Y0
MN<J.<XXYKH*** "BBB@ HHHH **** "O%9?V5_"LO[4T/QP*C^W8](.GFU\O
MY#<X\L7>[/W_ ",PXQC;@]17M5% !1110 4444 %%%% !1110 4444 %%%%
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M,'P]^)$[7,&T'RM/U@8\V/KA1-D,.F2< !8J]$N;674OAS\+H#ME3Q#XEO\
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MHGPS_9V\)>&_#OBZS\=Z-9?:_(\0:>BI#=;[N:1MH620#:SLA^8\H>G0>QT
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MCC&!@5W/@GP-I?P^T=],TAM1>U:9IR=3U6ZU&7<0 <2W,DC@84?*&P.2!R:
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M_P $^=%N?"'CSXC^&-23R+K2EA%NF[[\+RRDX]=K*!G_ &OI7T)K7_(9O_\
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MXV\36/AN/4#(MJUZQ F*;=X& >FY?SH [>BO#/\ AN/X#?\ 14-"_P"_C_\
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M;\/6>O0V?@[3_P"TM16^M(HW:+9*^(@LK;FQ"_!([<UY=_P]Q^"G_0,\8?\
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M:\W_ .'N/P4_Z!GC#_P70?\ R17VA!IMI:N7AM887(P6CC"G'IP*C_L73_\
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M%SC((SVKOJ\V_:4\/:EXM_9]^(^BZ/9R:AJNH:!>VUK:PCYYI7A951?<D@4
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M_!*/Q<;);^4D&2Y+K;A<B(L2P3S"F[GTXH ^W:*\#_9\^+_Q9^)$VC:CXO\
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M7!/LK#O^( KXK^%>EQ_LZ_M?_$[X3RM]DT#Q41XN\,0_*L>'W?:(HU'3!5E
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M-&D<MS ^Y&64)A6E1XR69%12LL7R@YH [&BBB@ HHHH **** "BBB@ HHHH
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MFE&'DB$:[&88&"5P>@H POB=\;? OP9BT^3QMXFL?#<>H&1;5KUB!,4V[P,
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M*"6'S"O#KC_@I);Z79ZS=ZI\)O$^GVGAG6%TCQ3<&XMY(](9W*1D%6_>DLK
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M55U+M&ORC)Z#-?68.X _TI@>$_!7]D'PW\%O%=EXAB\2^)O%>H:;I T'2_\
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M>THH **** "BBN/^*WPG\-?&OP;<>%?%MI/?:)<2QS2007<MLS,C!E^>)E;
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M'@GQ]X<^)&B_VMX8UFSUO3Q(87EM) QBD !:*1?O1R+D91@&&>0*FEB*-?\
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M[K?X5\&^%/A1X8^ W[>7@*[\3PR0> ]6U&>ZT:!MHM-/UEU"JKKC 7S!$R$
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MX'X^^'(/&'P1\>:'=:O9Z!;:CHMW:R:KJ+A+:T5XF4RR,2 $7.22>@H Y/\
M8U\>6?Q._9M\(>)=/\,:3X-L[[[9LT30X5AM+;9>3QGRT4 #<4+GC[SDU[57
MBO[&O@.S^&/[-OA#PUI_B?2?&=G8_;-FMZ',LUI<[[R>0^6ZD@[2Y0\_>0BO
M:J "FNZQHSNP55&2S'  ]:=7G'[2<UU;_LZ_%.6Q9TO4\*ZJT#1G#"06<I4C
MWSBD]%<#R/PSI8_:@UZQ\>:_;RW/A=)O/\*:!=%OL\<"[A'J,T)PKW$H)D3>
M#Y49CVX?>Q]W3PVEGM\T1HN/]8WS<^E<G\,OL-GX;TJ+23Y=A':0"U(_YXA
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M^(GBCXF?L_\ B#5/%OB#4O$FI0^)[BVCNM4N7GD2(6EHP0,Q)"AG8X]6/K3
M^Q:*** "BBB@ HHHH **** "BBB@#QS]KOXV#]G[]GSQ=XOAD5-6BMOLFE*=
MI+7DQ\N$A3PVPMYA'=8VKY&\ _$*R_90_9YT+PCI">?XMG1KW6+N106.H2X:
M51G.\I\L>\\8C7[Q-7?^"AWC)_B)\?OAE\)[60OINB*?%>LJI#*7!*6Z,.Q
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ML>37'[+/PUFT;POI<>C7]A:>&%NTT@Z;KNH6<MJMTZR7 \V&=78.RJ<,QQC
MP*[GP3X&TOX?:.^F:0VHO:M,TY.IZK=:C+N( .);F21P,*/E#8') Y-=!10!
MA1^!]$B\<7'C!;+'B.?3H])DO?-?YK6.5Y4CV;M@P\KG<%W?-@G  KB_^&:/
MA_\ \)8=?_LR^\\ZG_;?V#^V+S^SOM^_?]J^Q^;Y'F;_ )L[/O?-][FO4:*
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ML&DV<5G"TARS*BA=S>YQD^Y-?&OPK\;:'X4UJ^^+?B&QOM8M1=2>&/!^FZ7
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MMZ_EWME.!^\4*P4R(#TD48QC.ULJ/;*S/YVE%Q=I+4*^1/\ @IS\*?%OQ@^
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MW4<0J4>5HXZM!U)<R9YQXF\50Z5;/%;R+)>L, *<[/<_X54^!'/QFT(GD_\
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M9OI.CLIBED6WMG,YVQH-Q$BKTZ1CGT /IJBBB@ HHHH **** "BBB@ KP_\
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M,9(X1!FO"_V0?@QH>K?&CQ=XST:[N=3\!^&-2N],\)RWAR95:1R)>WW8G!Y
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MN[J5IKB9B\DC=237A'AYYO!/A=XK&[6RMYYFN-0\2ZY*(Y+ZX<DM(6<GDG/
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MOC'*G'"Q^9\):IKWCK]EKXS:!\18D>YU/26$5TN[RUU2Q^[)#(0"#\G1B#C
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MP\;79.3G<[.B]/EBYSD5]/U!^(XB$*=:<(.Z3"BBB@Y@HHHH **** "BBB@
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ML7X+?]%%T;_OXW_Q-<EIOP]\+_"KX4Z(M]I'VJ^:-8K6U:XDCV1A1@':1T4
MDD9W-7'7VJV=SN$&C6EH#T9))F8?BTA'Z4['EX;)/K5W"3M>U[*W_I5_P/JC
MP?XTT+X@:!;ZWX<U6UUG2;@L([NTD#HQ!PP]B",$'FMJOD#X"^-!\,?C%+X>
MNI%A\-^-F,UL6X2#5XT *YX \^)1UR2\/'+5]?U)X.,PL\'6E1GT"BBB@XPH
MHHH **** "BBB@ HHHH **** "FLV*'SM..M>,_%CXHZXWB'_A"O!#1Q:[Y0
MFU#6)T$L.E1,/ERG\4S?PJ>,<FLZE2-*/-+83=E<]GS3-V1@\?YZU\WZ9\,8
MK6W\_4=6US7;]QF6\O\ 5)MSMZA%<(OT K*O/#?B#PGJ,>I^#?$^H:9=QMO;
M3-3NI;O3[KU216+%,] R$$<UX<LXH0E:::0N8G\6:1-X!^,&L6,[;=+\4R?V
MGILG11<A%6XA_P!XX#@=\FM!;J1>'.UNF!77:)J/A[]ICX?WFFZW9/I^KV<H
MCO;,28N=-NARLD;CMQN1QPP_$5QEU\/?B;X1A%L=+LOB!;1_+'?VMXEC>,@_
MYZQR#RRWNA&>M?/YEDT\1/ZUA'=,0^23S.ARW;/%9.I:/_PFWB;0_!$6Z1KR
M>._U4(.(+"-PYW^GF,JH >H+&M33_"GQ0U]3';>%-.\' _\ +_J^H)>.H/\
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M.2^*/#L]M:7#66J0NEWI]ZAPUM=1L'AE4]L.!T[9KZS^ /Q//QD^#_AGQ<\
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M.2+/[26K>9XU^/MK\6/%VM:?XTL= T]?!VG:;=W,5G<Q2VV+ORHEPCHYXE#
M  RG!VG;^J;0QR2)(T:M)'G8Q4$KGK@]J&B1I%D**9%!"L1R,]<&D!^</P]^
M)6E_!GXM?"[6_%=U<:?HFK? 33;#3W$;NMU> Q/Y$04'=*0F O7+*/XAGS_P
M+X@B_P"%&_LIZ?\ $'7M2T7X/:E-XA77;JTO9[=)KI;NY-M'<2188)N"[>>A
MD/&W(_5YXDD*%T5RAW*6&<'U%5-5U#3K&*%=2N;6WCN)E@C6ZD51+*>51=W5
MCC@#GB@#\N/B=XR>_P!#^!J+XE\6-\$]335&AN/B!KDVFRW-PCML%S<V44KB
M-3M,&]68X?D)@U]K_L+S^(;K]FOPS<>(M>D\2/.T\MCJ$[W#RO9F1C"KO<11
MR.5&0&*X*A2I*X->]S0QW$9CEC66-NJNH(/X&GTP"BBN-UKXC/9ZI)8:+X8U
MKQ7+!D74VEBVC@MVZ!#+<31*[D@@K&7*D#?LW+D [*BL#PMXP@\3>?!)87VB
MZK;!3<Z7J<:I/$&SM;*,T<B'!P\;NN0RYW*P&_0 4444 %%%% 'S_8_LH_8?
MVP-1^.G_  E._P"V6 L?[!_L_&S%O'#O\_S>?]7NQY??&>]=U^T1\(/^%]_!
MKQ)X"_M;^PO[9CBC_M#[-]H\G9-'+GR]Z;L^7C[PZY]J]&HH ^2/C%^P%%\7
MOAE\'O!L_CN;2H/ %J+22\M],#2WZ^7 A9,S?N&Q#D']Y@MWQSI_#+]CGQ)I
M?QZTWXK_ !,^*$WQ(\0:-8M8:2@T>/3T@4JZ[V".RL=LLO&!\S[BQP*^I**
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW@OQ5^U7<_"KQY=>)?!OA:T\>6_V3_A&;*VFC-O<YD(N/.(N2!M3!&67GUH
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M\4O%$C7&L7LDWGO C.7$ EYW,6.^1APSD#+!%8_4=%% !1110 4444 %%%%
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MU KBE[VC/OZF"5?#^SA\4=5^J^9^CL,S6\JR(<,IR*\._:6^'#?%2U\'Z_H
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MOPQV]GH\YAE2Z-O<E9"1+'E0@E&,GEAQW'TU7RO_ ,%&?@7XR_:"^".B>'?
M^F1ZKJUKXB@U"6&2ZBMP(5MKF,MND90?FE08SGGVH O_ +7/QTO/A#\0O@GI
M-KX<T/7(_%.O_P!GRW&KVS2RV:^=;+YD!##:_P"])R<\JOI7TS7S-^US\*?#
MOQ&^(7P3U'6_B#I/@JZT'7_MEC8ZBJF35Y/.MF\B',B_-F-5X#?ZP<>OTS0
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M]6\P$2?:;@!MK@\ATC$49]XS7=C7R)0ZG)AJ:3<CZ$HHHKR#T0HHHH ****
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M"NBZ'_PEWAOP9]G\0P7OV_Q1>_9+:3;;7*>4KX.7/F;@/1&/:OJ.OAG_ (+
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M (22\\-Z@F@^,]+N_#7BF*/=-97$#>7, 0K2P2#*21%NC*Q]#S5CPKX9U/\
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MD+'8S 83+7A<--2[*]^MS$_9^^--KX'^&-A8_86O+>2SBGLVA(4<Q+A3GHO
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MKRDI1UV:VOZD8[.L+6QT9<O-32:?G<\*\7>+M0\:ZP^I:DZ&<H(U6,$(BCH
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M#/A.L.L?\(3IUY%'=VCW^LV\MO.H>.2)[. E64\%3DY!X/-<I\%_$=_^Q/\
MM&I\(-8N'/P>\<7$EUX/O+J0LNEWC$%[/>W(5G8+@D\O$W!DD-5O@WXP6'XN
M>'].=\6>FVU[?3@$81GBV[B>@^5><] H-9'QJ\76O[=WQ'\-?!SX>I#JWA[1
M]3AUOQ/XNMI T%A#&73RH)<8:1@[8:,D$D $J)"NN'E+GTV.2<5[.[W/T7HH
MHKUCC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF7_@H!^T#XB_9O^#>
MC>)?#-EI-]?W6OPZ<\>L6S3Q"-K>YD)"JZD-F)><]">.:^FJ^9O^"@'PZ\%_
M$WX-Z-I?CKQ]!\.=(AU^&YBU2XM?M"RS"WN56';N7!*N[9S_ ,L_>@#E/V[O
MB)XH\#_%7]G2R\/>(-2T6SUCQ1]FU&"QN7B2[B\^S&R4*0'7#N,'^\?6OL2O
MFO\ :T\2?"O0OB!\%H/B)X3U+Q'K%[KWE>&[JQN'B2PN_-MAYDH6:/<NYHC@
MA_N'CGGZ4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0
MG R>!7R)K7QNTC4_VA;#QE;6-]<^'-%M&T^:[@B+94^:!-CC:NZ4<'G ]3BO
MJCQ4Q7POK#*2&%G,01U^X:\/T?38]%_9_P#B#9;418-2U&%]JA0=LVWD?08^
M@H ]\T_4+?5M/MKZTE6>TN8EFAE3HZ, 58>Q!!KRO]I3XC:=X.^'][I,RM<Z
MGKD$MG;6T?4!EVM(WL-PXZDD =R.K^#G_))_"'_8*MO_ $6M<1X_TLW7[0G@
M6]95>*W58L, <,\=XP/_ )"_0>@H E_9I\=6.L>";#PT\-Q8:WI%JOG6MU'L
M,D98[94SU4Y'T)]P3ZSJFJ6NBZ9=ZA>RBWL[2)YYI6!(1%!9C@<\ 'I7EEIM
M_P"&JKS;C/\ PB0W8]?M2=:[OX@6)U3PG=V(_P"7J2& Y&1AYD4@CN.>E 'S
M'\/OC/I,'QU\1>,KVSO;/P_K"+81WC1[D@;]T%,A' !$9/&2,]^37U]7S!XN
MVI^QUH@^55,4/'0$[V/\_P!:^GZ /FC]L+QM8WFF:?X+LUEO-:-RE[+'"I81
M($< 'U9MV<#H!D]1GVWX<_$33OB5H4FHV$-Q:O!.UK<VEW'LE@F4 LC#\1S_
M ".0.&TFQ:/]JC6+LJ-DOAXQ@\?>62V)_1Q6E\(UB7QI\1!"$""^M!A,8S]E
MCST]\T >AZYK5IX<T6^U6^D\JSLX7GF;&2%4$G [GC@=Z^6?AS\6YK#XE:[X
M^U?PY?Z?X9\0>5;B^ +QV^TK&'+$#>H888K]TD#DD ^]_&K3CK'PXU"P!VFZ
MN+.#=Z;KJ)<_K7D/BB3R_P!C&P.,_P"BVP_.<#^M 'TO7SE^U9XODUJ.V^'F
MC:7=:OK-SLO91:J7,2J3@;0"22 2>F!@]^/HVO$-)LVC_:OUB[S\LND-$![H
MMJ3_ .AB@#N/A3\2+7XAZ'*4M9M.U+3V6WO;&<AFC?:""K#[R,,X;C.#Q6K\
M0?&UG\._"&HZ_?*9(K1,K"IPTLA(5$![98@9QP,GM7$_"F3S/BI\3CMV_/IB
MX^EKC/Z55_:FTXZI\.(H0VW;<R3]?^>=G<R8_P#': . _9^^($_ASQ'J*^(-
M"OM(M?&.I_:;"\D0^5YDNYD0Y )5LX5P,$@]@2*OPE :Q^(9S\R^/M=X]C=O
M_A7=?%)A_8WP;7/S'Q!I9 _X#_\ 7KS[X/2K-<?&! 6_T?XAZD@4]!NPYQ^)
M)^I-=6&=JAS8CX#NJ***]L\@**** "N=\>,1X?< XS(H/YUT5<O\0F T./WG
M7'_?+5K2^-&57X&7OV%V#^"/B"^<NWC6_#'Z16ZC_P = 'X5Z;\=/B-:_#OP
M//));M>WFI;K&UM8VVEV=2"V<'@#VY.!WS7F7["2_P#%N/&K8^5_&FJLK=B-
MT?(_*NG_ &AK,7/B'X>2$@?9]5CE'&<YN+9/_9J^:J_Q)>I]!2_AQ]#*_9E\
M9-H.DV/P_P!=TJ\T76HUFN+;[6NT7"EC(RX.&5P&SM(^Z-W>OH"O'/&S+_PT
M5\-1QNQJ6?7'V08_K7KE]_QXW'_7-OY&LC4^3K[XK3>(?C=%\0M.\-ZA?>%_
M#UM+I\]U;KD/&/-)E!8  XEW;"<X')&>/JO1=9L_$6D6>IZ?,+BRO(EFAD'\
M2L,CCL?8]*\)\!PPZ?\ "/XB0ML2WA\17B'( 4*)(A^6!7HGP#_Y([X4_P"O
M,?\ H1H S?VA/'Q\(^#3I=MI\NI:IXA$FF6D,?3<Z[22?7YAA>Y/UKE_V>_$
MFJ^"X=+^&_BC1'TC4$BGGL;@3+(MP-[2NC!2=K*')Z\C'3C.O\?HA)X@^&+'
MK'XEM2/^_B#^M2>+ID;]HCP!$&_>+#J+%?0&W0 _H?RH ]>KY(U#X@>(?%'Q
M8;XF:-X5EN_#_AV-],?S9UB+J!)DDD_?_?9V@'^$<DU];UX#X-CBTGX4_$8,
M0D$/B*\;/95#Q']!0![5X8\16GBWP]I^LV!8VE]"L\>\88 CH1ZCH?I7D/[3
M7BRZNM,MOAYH^ERZGKGB%0R!2%5(T<-G)ZD[#Z  $FNS^ ?_ "1WPI_UYC_T
M(US/CB$']I;X<2]UM+Q?S@G/]/UH N? OQO=S6,7@C7=);1M?T&PA3R_-61+
MB! (Q("O (( (R>?Q ]'\2:];>%_#^HZO=AVMK*!YW6, NP49VJ"1DGH/<BO
M,]#F27]IC5E5LM'X<"N/0_:R<?D1^==W\0K5;_PE=VS\)-)!&W&>#,@_K0!\
M+?'+6O%>L?#3X@^.Y_#7V30?$0LW2Y^T+^Y^SW<#H0#\SY,.#P,Y)& *[:M[
MXR(LG[!@1CC=IN!]</C]<5QGA/4/[6\+:-??\_-E#-R,?>0'^M-'WG"\OXL?
M0U:***H^_"N3^#/CJV\-?M?6QNX9)8+G2Y=.$D9QY4DUQ"B,1W&8<'IC=GM@
M]97E7PS>/4/C?J%[D[HM4T6W4]CYEQ<R']%%2SP,^ERY=/S:7XW_ $/TKKY3
M^,7B#Q+\0OBI$WAK1([BU\ W0G>ZG?:AERCL9,E<*&AQP>@)R >/JRO!/#<0
MCUCX\$?QIN_\@SC^E(_(SU3X;^.8?B)X1M-:BMGLI)"\4]I(<M#*C%73..>1
MP?0C@=*Y[X]>/)_ _@DQV-E_:.JZO+_9MK;Y/WI%(W8')QP,>K+6?^S3.EU\
M/;N:,[HY-7O'4XQD&3(J3XY6JW$OAB1NMOJ-M(O'<WMHO\F- '%_LYZIKOPZ
MN;/P!XIT;^S)+XSW.GS^:K,[JJO)&P!(^Z=P(^G7./HBO&_&TBG]HOX:IGY@
M-2)_&T'^!KV2@#Y7^(2^,?BQ\5I]0T2RM;/3_ MRCQ2:@Q"O(&63>0OS,&"*
MV!_"!W.#[]\+_''_  L;P/INO&U^PR7 =9;?=NV.CLC 'N,KD>QKC/!]NMOJ
M'Q5V])#$^/3-FN?Y?K4_[+\@F^#.D2+T:>Z89][B2@"_\=?'FH^"/"")HEI]
MKUO5)ELK48R(RY"^80>#@LJ@'NPSD9%><? ?_A(O@WXDT[X?>([.U\K7/.OK
M2:UD+O'(L8+JYZ$80CCD$'J"#7H/QILTN1H4C_>M[RUE3ZG4+)/Y,:Q_'?\
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M9/6NNKS/]G6Y%Y\+;2X52JRWM[(%/49N9#7IE !1110 4444 %%%% !1110
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M<UUE%$8J.B0@HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGP+^(C0VEPYU#4M3GMH_*(>2-[AMK;3SC'//89KW2HHKJ&>-I(Y8Y$4LK,K
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M/VC6^(_AL^++6"'3D^'JZYIYN'\++@-;F/S XORV;L+O)#@0[<_+7V!^QO\
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MKOVZTLM1V>9JK^;;MY,.Z1#NS$HX#?ZP<>OT?0 4444 %%%% !1110 4444
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MYXFC66ZF>)FQ\Z;MH(]LJ1SZ5)^TTPMO"?AV^EW+96.OVL]U-M9A#%LE0NP
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MI!KZ;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OC'_@JSXRU_
MP/\ L\^'K[PYKFI>'[Z3Q3;P/<Z7=R6TC1FTNV*%D()4E5..F5'I7V=7S?\
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M/J<J1V^UOEVN7.W!SC!ZYQ7P+KUK?Z+<+XK\,2'3_&&E1F6RNH<@S!2&-O*
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M =*/ /Q,3]FOQK87ZS26_@+6));?5M+CW-%!<F-GAN8(^B.S)Y;!<!@ZD@D
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MLPY26)ARKJ<$$?RK(C^*&M?M$ZOIESXICWV_@^VCTYK5MIAN=67(N+W:!C.
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M2JVVW!!-S\T94LN%'4,W2NG^ ?[26D,F@^ ?$NF7/A35TA2RTVZNY4>TU+8
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M$"Q*"69F/"[<'.<%2"#@@U\B?&K]H$?&NUL[+PWX7U ^';.Z6[M];OG$#7K
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MPI#2:==22$$=V?YCZGD\U^I-%%, HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^:OV^?V>?$'[2WP>T?PQX<U31M)OK37H=2>;7+B2&%HUM[B,J&
M2-SNS*IQC& >?7Z5KX9_X+ _\FT^&O\ L;K;_P!([VD!VW[:OP:\8_%+XF?
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M_:5[87,-T1W)A1RA/T< ^U?D6?\ "V*Q&<T\VPL(U%IS1D[;?\ ^TR_-Z5/
M2P5:3B];-''?MC?#.'QQXPL?A]X&MEEU>]AFU"2RMQE8_(@FD()Z(&;R$'09
MD [D5F^%]>@\3^'=.U6VQY-W LNT'[A(^93[J<@^X-?5_P "_P!GZP^#<-]?
MW6IR^)O%NI )>ZY<Q"(^4IRL$,8)$40))V@DDG+$X&. ^*'[)^KWGBC4_$?P
M\\0V.C2:DYN+O0=8M7DL7N&.7FC>-@\);EF #!F).!FHS[@VKF&!@L,HQJ*3
MERKX?>W2^Y#RW/(X7$/VK;BTE?KIU-[6_"O@>Q^"#:N5MX6BLQ.NH,V)/.V]
M&.>F[(*G@<],9KXV^$=O?Z3JVL'4[)K%/%!;Q1I7FKM>>SEFDC5ORC1O7$JG
MO7TCX8_8Y\2>(KZU?XD>)M-FT6%]T^@>';>5([T#HLUQ(V_9ZHJC(.,UZ_\
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M +.[ [8KY_.^"YXNK0Q6!FE4IVNI+W79W_/H>%@,]C1IU*.(3<9=MUI8Y/\
M:HUG0/C3-X1^'/AN7[?KGB&^CMYI[5/FM;$,KW$K9'W5C#'V.!U->/\ @6&Y
MT/3)/">J1_9M>\,.-(O[<Y!#1 *DBY RDB!75NA#<5]E?"/]GGPG\'9[G4--
MCNM5\17<?DW6O:O-Y]Y+'NW>6&P%C3./DC55.U<@D U7^*O[-OA'XK:HFM7
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M_5*\*F&3Y8WT?GN?,?P9^)-C\/K[4?[3C;['=QJ3-&N61DSC/L0Q_(5Y[<>
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M<G>3M:[LEMZ(\"O655I05HK9?B%%%%>D<P4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OAW]KK2M0^(7[<7[-
M?AJ&QNC9:-=-K<E[]G8P9$HF,>_INVZ><C/ 8'O7W%7R5^SG\>/&GQH_:\^-
M.F1ZPLWPP\)[=/M-.$$)VW@=8O,68)O96-O=-@L1\ZXZ4 ?6M? W@.TO_P!G
MG_@ISXF\/6UK<-X7^)VGMJR+"&=(YL/*9GP.,3QW2>@$ZD\5]\UX7^VIJ7Q"
M\/\ [._BC6_AE?+IWB+38A=3S+"DDYLER;@1%N%=4R^<$X1@HW$$ 'NE%>6_
MLS?&ZP_:$^"OAOQG:/']KNH!#J-O&1_HUX@"S1D9R!N^9<\E&0]Z]2H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKQ8=[$@!5+[0221P.: /8:*@OK^VTRQGO;RXBM+.WC:6:XG<)'&BC+,S'@
M$DG@5Y5H?[6_P:\2>+%\-:9\2?#UYK#E5CBCO%\N5FSA8Y?]6[''W58GIQR*
M /7**XCXG?&WP+\&8M/D\;>)K'PW'J!D6U:]8@3%-N\# /3<OYUS'A7]KGX.
M^./$5AH.@_$'1]4UB_D\FULX'8O*^,[1\O7@T >O4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBWC/!I]N\DKFW:2X+QW"/&JC*3@85F'WN?5 >(?LM_$+1?BQ_P %+OB=XO\
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M^[U379=3A?2)I9(UB:*) &,D:$-E#P 1TYKZ0I@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 ?'SX@ZK\*_@YXL\5:
M'HEUXBUG3;)I+/3[2!IF>4D*K,J\F-"V]\?P(U=AKVN6/AC0]0UC5+A;33=/
MMY+NZN&!(BB12SL0 3@*">/2OB7]FOQIX[_:U_:FU/XP6E_J/ASX1>&X)M%T
MK3O-=$U<D-S)'G:3EA*[?PE8$&[:6 !V?_!/?X :O\/?!.K_ !&\<I)+\1_'
MDYU*]ENE'GP6[DND;#^%W9FD=1C&Y%(!CKZVHHH **** "OF/]K_ /8_E^/%
MUX>\8^"M3M?"GQ1\.W,4UAK$R$1S1HX8)*55CE#\Z':W.Y2,/E?IRB@#Q_P#
M^TMX%\1?$J]^%)\76NJ_$+18$BOA' 8(KRX1,SB#YF7<A!+1AB4^8<[&(]@K
MY<_:Z_8GL_CU<67C'P=J$7@SXJ:7)'+::[&6B6Y*8V"=HP6#+@;90"RXQ@C&
M-IOVNO!7PI^)VB_![X@>)YO^$OCTBUEN_$]]:)9Z?=73+RI(PL9?&\$#RQG;
MNW#% 'T3124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %?4-/M=7T^YL;ZVAO;&ZB:"
M>VN(Q)'+&P*LCJ1AE()!!X(-4O#'A/1/!.BPZ1X=T;3]!TF L8K#2[5+:",L
MQ9BL: *,L23@<DDUJT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#%5O>,OCS\./AWJD6F^*/'7A_P_J$L"W,=KJ6HQ02-$Q(5PK,"5)5L'V-
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MP: .^HK@-+_: ^&>N>'M7U[3_'OAV]T31_+_ +1U"#4HG@M/,;;'YKAL)N/
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M\/\ B#4(H&N9+73=1BGD6)2 SE58D*"RY/N* .\HKR7_ (:V^"G_ $5?P?\
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MK?59] \=>']9ATJV:\OY+'48I1:P*"3)(58[5 !Y/'%8/_#6WP4_Z*OX/_\
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MVNW-G:O?7,6GZE%,T-NA4/*P5CA 64%CP,BL/_AK;X*?]%7\'_\ @ZM__BJ
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M@E#V<$+.)-CY4*64\*L85(\N%W!N/JR.-8HU1%"(HPJJ,  = !3J* "BBB@
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M_AQIWB2P\.>#8-,M/$>GR:7JL:W=R_VFU<%6C):0E00QY7!YZU[#10!\Y_\
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M)7PE^,VOV^M^,O!\&MZI;VB6,=Q)=W$16%"Q5,1R*."[<XSS1H/[)7PE\,^
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MG_"CX<^&_%6@>'?"$.F:1XIMEM-8M5N[AQ=Q*LBA26D)7B6094@_-]*];HH
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M(Z@@YS0!+1110 4444 %%%% !116+XJ\9:-X(T^.]UN^2PM9)!$DC*S98@G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPO\ K #QA@.QW G/4?"?P3XB^'S7^EW]SI^IZ5++)=IJ2&1;R>=RNXRJV0>
M>=Q/ Z]@!GQ>\)ZOJU[X9\0Z+:1:K=Z!=/.VES,$^TJP7.UCP'7:",^I(Y !
MD\+?$C1_%>G>)+O3K"31O$=G ?MUK>6ZQW*LB-L+?WU!+ 9Z<Y SSO\ B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img99844967_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img99844967_3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %_ B8# 2(  A$! Q$!_\0
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MT[?SQQ3ZDL***3(]1^8H 6BDX(Z_R/\ B*4 #..YS^- !1110 4444 %%%%
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M7ZU<F4GS]3\!ZO$]DT^]MT]S96\,TASF0'!K]OQ/A)G?$W#^3XK+\GQ> Q^
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MM.56GCX.I#GQ%3$2Q52>*K_5J*;MAEWO['W[7US8? ;]H_\ :7U[_@H-??\
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M?B)J/_'L/^OJP_\ 2^VK]N_V;?\ D2-._P"N$7_HN&OS/QH_Y*G ?]B#"_\
MJQS4^R\//^1+BO\ L:5__43!'TG1117Y$?>!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 (W0\9XQ^=?#/[2OQ4_:]^#WC;1-?\ @_\ L^6_[2OP
MDU;P]]AUWPGX9\4:1X0^)?A+QA;WDKQ:Q;R^(YXM(\0^&M5L)88+BVCE@O\
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M_:Z9\2OBM L<B:Y=Z;&GAWPQ<;%61/"VD7?FLMRN/FUB_:6^D(#PK;?**_7
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MMOJM@NI,K*99K&\ARH<BO[H)U9HR%.#E2?H""W4$=,]>/6ORP^.7PF@\ _\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I" PP0"/0TM%
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MJ=I9ZGIUQ:ZA9VMS%_&A\9?^"?/_  4+_P"#>#XF>,?VOO\ @DC>^*OVH?\
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MU'XR_:PTKXRMX%\-Z)XB@_:X\ _"SXO>)/B-XBT:;P--XCL=7UJV_9ZA\(_
M35-$\<VVA^,OA5KSQ?"R;P< ?L]\6/BCX$^!WPL^)?QJ^*.N_P#"+_#+X/\
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M_"'2?!<WA"Z\36.M?$:__9O\1^#/A-?^"OB?8-KGPWDBT;X7?V!^GW_!*/\
MY.*_X*??]E,_8*_]=9_L;T ?MA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!^ /\ P='?\H*/VYO^[9O_ %L/]GVOO_\ X)._\HLO^":?_9@'[&__
M *SK\.:^ /\ @Z._Y04?MS?]VS?^MA_L^U]__P#!)W_E%E_P33_[, _8W_\
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MBE^(?PWO_!=E\0?!%CH'C[4_$_AG2]-^&7Q&N_"WY4#X#_M0_LJ?M-_\$O\
MPKX M?@#\4OVBM>\.?\ !8'X_?%SP=XM\9^//A7\$M2\8?M-_&?X ?''XH>!
M/AM\5?#GPN^(_C'PCX8^&_C3XHO:^ /%VO? CQ;>^//"W@A-%USP/\.]2\>_
M\)%\.OLW]FC_ ()]?&#X._$K]C3XG^,/%OPSU36?AC:_\%(OB'^T+I_A>X\0
MVVDQ?&7_ (*%?&SX?_'_ %+PU\%K:[\*V3:W\+_ASXIL?&GA&PU_Q@_@OQ)J
MOAZQ\+:ZWA2TO=:U30/#@!]=Z7^WM^RQK/QQE_9ZTWQ_XBN/'R?$/5_@_!KA
M^$'QJ@^">J?&+P_X:O/%GB#X.Z!^TQ<_#N']G#Q'\7O#^CZ5KB:]\+=!^*VI
M>/=%UOPUXK\+ZGX>M?$_A3Q'H^EP:7^W[^ROJUS\<'MO&_C&V\)_LY:)\4M?
M^,'Q@UCX&_'KP_\ LZ^&[/X):TWASXLV.F?M,:]\,M-_9\\;^)/ .OV^J:-X
MC\'^ OB7XG\66.I>'?%UF=%:?P=XI31_S>^"W_!+'QU\(_CW;1>)? /A_P"-
MOP(\-_M?_$7]JGX=?$?Q#_P4U_;^^'^J>"-4^(?Q<\5_M!Z5*_\ P3IT7P-X
MJ_8MUKQ?\*OB-X[UWPUI6K:9X\\(:)\2M*TRR^)GBC0O#WCGQ'XGTJ?TK0OV
M)OVAM/\ C3^T9XTLO@?^S'X1^ 'Q<^''Q_T3QO\ L<M^U]\>OBS^SM^U[\2?
MBSXB\'7&A_$#XF?#/QY^R9IOPM_8XOYM%TCXAWOQBNO@'\,OC'<_&SQ1\8=<
MU7XCP^*-8\.IXF\3 'Z>_ [X[^!?VAO"%WXY^'NE?%O2=!M-;GT!HOC+^S]\
M>_V</$EU>0:7I.L&^TKP5^T1\-?A;XSUKPW/9ZW9+8^,-(T"^\)ZC?QZII-A
MK5SJNAZW9:?[)7P)_P $^OV?/CS^SK\/_B1X8^-'B:#^P]=^(]OK?P8^#MK^
MT-\9_P!KJS_9]^&UG\/O _AB?X?V/[3W[1/A#P%\:/BI8:YXWT#Q;\1;"U\8
M>%--MOAS9^,H?AQX8FU'P[X9T_4+C[[H ^<?CA^QU^R+^TWJ>A:W^TE^RQ^S
MC^T'K/A>PNM*\,ZO\</@?\,OBQJ?AW3+ZX2[O=.T*_\ 'GAC7[K2+"\NHTN;
MJST^6WM[BX1)I8WD4,.U\6_ /X%>/XOAA!X[^"WPE\:P?!+Q-X=\:?!B'Q;\
M.?!_B2+X1>,?""P)X3\6?#"/6=&O4\ ^)O"Z6MLOAW7O"@TG5-$6W@73;JV$
M,87UFB@#YZ\+_LC?LH^!_C!KW[0W@K]F+]GKPA\?O%4VMW'B?XX^%_@M\-_#
M_P 8/$=QXF=9?$<^O?$S2?#5IXTUB;Q!(B2:W+J&MW#ZJZJ]^UPR@AC_ +(7
M[)LOA2^\!R?LO_L[R>!M4^&7ASX*:GX,?X*?#5_"FH_!OP?KFK^)O"7PEOO#
MK>&3I%W\,O"WB3Q!KWB'PYX#N+.3PKHFN:WJ^K:9I5K?ZE>7$WT110!\8_"W
M]F#_ ()XZMX&\1>&?@I^SQ^QCJ?PUU#PEJ7P:\6>'_A;\)?@?>^!K[P)JNMW
M?C_6/A3XBTKPGX?DT"Y\):EXD\3WWC;4O NI6[Z/>:WXAN_$EUI<E_JTU[<=
M3XI_8:_8G\<W7POOO&W['G[+7C&^^"'AGPSX+^"UYXI_9]^$OB"Z^$/@[P5+
M%-X-\)_"^XU;PC=S> /#/A*:&&7PSH/A1])TO0988I-*M;1HT(_FG_X,P_W'
M_!.[]JG37YGLOV__ (E>:Z\Q-O\ @=^SW /+8[7/SVDA.Z-/E9#R2P7^OV@
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M%E_P33_[, _8W_\ 6=?AS7P!_P '1W_*"C]N;_NV;_UL/]GVOO\ _P""3O\
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MD^#_ !K/_<E4<T,5Q%+!/%'/!/&\,T,R+)%-%(I22*6-PR21R(Q1T=2KJ2K
M@D4 ?$'[ G_!1;]E#_@I;\%+;XX_LI_$./Q7HEO)::?XU\&:U;Q:'\2_A;XC
MN[=[@>%OB1X/-W>3Z%JA$-T+#4+.[U7POXCBL[K4/"7B'Q!I47V]ON.OY)/V
M_O\ @@I\8?V>OC9J'_!2?_@A-XS;]F_]J/0YGUOQW^R?HL^E>'_@;\==-,LE
MYK^B>&=#OIK#P;H4WB!EC^W_  N\3QI\+M:NTM-5\-W7PV\2:3:W^K?/L/\
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MN;^OV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI6O?MI10!_&]^Q__ ,%L?VL/^"97QG\._P#!.K_@X#T&X\,ZJ]O9Z/\  /\
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M5;4/"'C[PK>>5KG@WQ9IN]))]'UNSMI+NPGL=<TB34O#VJZ1JU_]3T %%%%
M!1110 4444 %%%% '\@7_!HS_HGPZ_X*A:-]W^S/V_\ Q9^[BXM4\S0EM?\
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M1W^WO#']I_:O[!^P>7_;NG^1]K^U;YO(^S3?/?Q!_P"">'_"=^%_^"M/AO\
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M;X#_ !4^)WA[P=\(/CQX<^*?C/P'\?O@?\8/$GP^M]<M_ OQ;U#P!X:^)/P
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MDLK^\\"?$32=/O\ P-XLU'PEK7AOQWX?T;7[KQ#X*\0Z7XDTO3IC\0G]FO\
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M/MY+T ^T[G_@HYX=\3^ _A;\3OV<OV6/VN?VNO 7Q2^ WAW]HZV\6_!'P?\
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MM[NXE6-(K*$EH-.L([;]3_\ @D[_ ,HLO^":?_9@'[&__K.OPYKX _X.CO\
ME!1^W-_W;-_ZV'^S[7W_ /\ !)W_ )19?\$T_P#LP#]C?_UG7X<T ??]%%%
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MCALO''A^RA2W%YIEGXOT7P;XCOAX=A /USHHHH **** /Y O^#8C_1_VO?\
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MW_\ ^#']HK_Z &C_ (B._P#@J;_TK'_M_P#_ (,?VBO_ * &@#^OVBOY O\
MB([_ ."IO_2L?^W_ /\ @Q_:*_\ H :/^(CO_@J;_P!*Q_[?_P#X,?VBO_H
M: /Z_:*_D"_XB._^"IO_ $K'_M__ /@Q_:*_^@!H_P"(CO\ X*F_]*Q_[?\
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M+OAI\1O$FF>-]6T74O#O@NY\)>%M>3Q;XLMU\(^'O[2\3W%KI,WY,:7\'?\
M@JSX(T[XM7'[*.F?MP_"#X+F/X1:UI/P1_;+_:%_8F_:H_:AT'Q'??&SX90_
M&VT_8?\ BSX_^(G[4GAK0].T_P#9C\.?$S1/#%I^V[^T%XM\(O\ $WQ[IK>'
M/!/A/2+/5-;?Y[B_X)M_MI>)?CA\<OC!X2^!G[0'A/PE9>"/^";GQ.^$GAK]
MM+]MS1_VC_C'\>_B/^P3^U[K'[0/COX3_&CQ.WQT^/WASX.ZU\7XFO9/AKHG
MPY\5^*_V</#L.I^'/%>HW?PQ\3^)?'GP]\% 'ZS_ +2O_!7KX#_"/]E_XZ?'
M;X9^'?BWX[\<?!+Q!\)/"?B3X+^._P!F[]JSX._$_P ,WGQM\26V@^!/&?C7
MX4^/O@5HOQ=T'X8ZM:P^*M0\*_$"_P# ^F_#WXC>)O!6M?"WPQX]A\=-):Z?
M[;#_ ,% _P!G_P -2_'?Q%X^^-$#^'_A[\2/@1\.M)^&.G_LR_M%^%_CUX3\
M:?'?X)?#3XJ> O@YJ'PZU*Q\3?$SX]?&?QWI7CJV\>:9X-^$_P '/#7BWP+X
M=U:3X>^-/ <GC'X<^.->D^:OVRM-_:]_;?\ V-/VH?AUI'[#_C7X*ZU':?!N
M^^$/A7XN_&K]FZ]^-'Q9UWP9\8? _P 3_'^B6.B?";XG?$_X(>!?#DVA>#=-
MTOP3X@\7_M)V&H^*_&4FHV/BSPA\/?#6B:/XQ\2_+VN_LC?M@']LSQ__ ,%!
M-"_9O\1ZDGAG]NKX ?M0>%/V:O$'Q'^!&F_%#XF?"SQ1_P $H_!/[%7QCTG0
M=8L?BMKGP;T7XU_ ?Q[XG\67NEZ'XV^)WAGX?>.M2^'6MP>%OBI_PC?B+PGX
MUU8 _3;4/^"H_P"PYI'PW\._%+5_B_KFD:'XH^/-Q^RUIGA;5O@G\?=,^,T'
M[2:>$?%/CK3?@-K_ .SW??"ZW^/7A/XM^+/"_A#4=1^'W@'Q5\-]&\3?$F;5
MO ^E^ -.\2ZO\2OAW8>*?H?]GW]IGX,_M0^&_$OB?X-^(]<U6#P3XRU+X>>.
M_#OC/X>?$CX0?$;P!XXTJPTO5[OPK\0/A1\8?"/@/XG>!=<?1-<T/Q!86'BW
MPCHT^J^'-<T7Q%I:WFB:OIU_<_BM?_L<?M9?&;]K+X:_MG^)_@'>_"BS\6_\
M%-/V<OC'K_P/\5?$+X/^(?'_ ,)?V>_V:?V'_P!K/]GZR^+?Q/U+P/X\\3_#
M34/'?CWXD_%3PU);> OA#XX^+&I>'O!LW@>]O-;N=1L_%VG>"_TE_97^"WQ4
M^''[7/\ P4Z^)?C7PY)H_P /_P!H3]H'X ^.O@UJYUW0-2B\6>'?!O[$_P"S
MK\(?%VKII&E:O?ZMX=DL/B!\/_$?AV2U\3Z=H>I:@NBQ:I8VMYH=UI>I70!]
M_4444 ?@#_P='?\ *"C]N;_NV;_UL/\ 9]K[_P#^"3O_ "BR_P"":?\ V8!^
MQO\ ^LZ_#FO@#_@Z._Y04?MS?]VS?^MA_L^U]_\ _!)W_E%E_P $T_\ LP#]
MC?\ ]9U^'- 'W_1110 4444 %%%% !6?JT&I7.E:G;Z-?V^E:O<:?>P:5JEW
M8'5;33=2EMI([&_N=+6\TYM2M[.Z:*XFL%U"Q-Y'&UN+RV,GGIH44 ?A#_P1
MT_X(V:C_ ,$[/%W[3G[1O[1?Q=T_]J']MG]I[XD>+K_QI^T&-.U.PD;X977B
M637-'T6PTW67GNM"UCQCJ26_B_XAV-G=WNEVNJ6_A[PII.HZMHO@O3-9U/\
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MH?$?2=)U)O$]E?ZIHWQ-\-^-].U*WN]"_I,HH _EC_X)J?\ !P!XCD^+K?\
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M\'+5K+\D\W[:NE74:?>W0'X]?MHR"3<NY!\EW;G:S!_WF-N4<+_7[0 4444
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M/?'W7O\ A,/^$@^P?\(=_P *.T3P+K/V3_A'_P"Q+W_A(?\ A*/^$U^S>?\
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MA_P<2V<G,L_QQ\/WJ,G,8B;XJ?&24*Q;:PDVW\(("%=RR#?@*7_K]H ****
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MT*>)I*=3#N%&]&JI1=ZEE[1)RI?'%2:L_K?1O@9X$_:*^(_QM^)NC6OBVX\
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M@[P_X7^.FM_LF?"S6X_#'BO4-)O_ -H_Q_HMK'I/A#QCJ;>)+[3O"7B.^TP
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M?>%/$M[=_"KPK\0[B.'4VTJWLKGQ!8ZAI%KK:K_P44L=5O\ XC77P#_9"_;
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MNJV^H^ =)7PM9>&Y_"WA;POI=S=^'])\-P:!9^'],T0 _.YO^"C/Q+L?VQ/
M_P -(?%GPE^)/P7\<?M+^)/V;[S0OA5^RI^V3J\/P^N[,>/]$T+6M;_X* W@
M'['OB/XDV7C/P=I^C_$W]GR'P?X6U[P)?ZGXB\,:3\0/&VM>#H;CQ5Q/ACXJ
M?M4>%?@I^V;XW_:(\;_L[?M*:+X;_P""@WPM^$W@/P/JO[//CWP_H?A>*?\
M:9^ G@&[U*2+Q?\ M+_%JPNM-\.V'B72?%7PKT'2-(\.3> OB3X>;QIJ&N>,
M9-333=-^O]*_X)I?#C3/''@SQ'+\>?VF=5\!_"[]HC6_VH/A)\!K[Q;\-;;X
M0_#3XI^*O%7C?QCXLGTM=%^$ND?$SQCX=U_6OB)XNDC\/_%CXE?$2S\)0ZM)
M'\/CX/>.*1>WU3]@SP1J\_QTT^[^,'QO/P]^/'QA^'/QZU;X3I>?"8^#/ _Q
M4^'WQ#^'GQ,N?$G@'6)?A'+\3K>#Q[XC^&?AY/&?A_Q=\0_&/AN"PN-73P-I
M'@J]OUOH #Y7\<_MH_M;:1\'/CA^W?H$'[.]A^QM^S_XI^.,WB#X,^(? 7Q(
MU3]HGQO\&/V8_B#XR^'_ ,8OBGI'QJTCXO:?\/O!_B348?ASXS\;?#GX57GP
M"\8OJ6B1>'="\1^/-"\0:S?IH.M^T3^UG^V;X9E_;]\3_ _3_P!G"/P9^P)
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M7]HWX*?$WQY^VW_P3H^+WA3PS_:OP\^!&N_M3WGQ6\0_VSX?L?\ A%;;XC_
MF?P9X,D_LG4M5L]<US^V?$CKINSPWIFL2:=G[9JJV-@#=#\IOAK^S+^V]^S5
M^U3\)/V@[#]C[Q/\;?!GA7]IC_@NIXJ\;>'? /Q;_9QTCXD6?PX_;9_:P^"7
MQ,_9M\7^ =.^*'Q?\ >"]?UGQMH7@FZUC6?#GB+Q_P"!;KP=X(M_%C^([RR\
M?6WA3X;>-_Z4Z* /P(_9I_8F_:<\.?MM?LW?M6_$?X5Z3X,TCQ5XF_X*H?&[
MXJ^#]/\ &'@;79/V==8_:TU+]C&T^"GPQUNZTS7I8O&GQ UGPI\$O%>L?$_Q
M!\+;?Q7X TGXB3^,;"S\7ZUX?O?#7BKQ9P>L_LD?MCP?LL?%C_@EU8?LX:IJ
MOA/XG?M=?$_X@Z7^W=%\4/@K;?!G1O@3\7OVLM7_ &Q=2\9^*O U[\08/VEV
M_:!\%#Q%J_PET?P%H/P5USP/K'C;1/"?BEOC/HW@_4=4U'PU_1G10!_/]X1_
M9O\ VLO 7[6GA+7/V9_@1^U%^Q_H-]^TMXPU_P#:-AD_;!^"WQT_X)F?%[X'
M^+?BQJWQ0^)?CGP+\#?B#XN\7_'[X7?'SXL6I\[1=/\ @M^S=^S%HWA7XF^.
M_%T?C+QSXP\'::_B+QC\B_"_]A+]K7X*?LK?LF^&M&_9#_;!^'7[8?PL_8T^
M GP[LOVCOV'/VY?V<O ]Q:?$KX1:MX^UO3_@O^U]\%_C9\4]#_9Q^*'PB\,>
M(/%1GT[Q+;_#S]LN?5?"GC3X@6&DZ!X+U#3-)L/%?]7=% 'G/P>T_P")ND_"
M3X7:5\:]>\/^*?C)IGPZ\%:?\6?$WA.U:Q\+>(OB79^&]-M_'6N^&K)]/TE[
M/0-6\41ZI?Z/:OI6F-;Z?<6\3:?9E#;1E>C44 %%%% !1110 4444 %%%% !
M7G?Q5^$_@#XU^"=4^'OQ+\/Q>(O"^JRV%VUN+S4=)U/3-6TB]@U/0O$?AOQ!
MHMWIVO\ A;Q5X=U:UM-7\.>*/#NIZ9K^@:O:6NIZ1J-G>V\4Z>B45G5I4J]*
MI1KTZ=:C5A*G5I581J4ZE.:<9PJ0DG&<)1;C*,DU)-IIHZ\!C\=E6.PF9Y9C
M,5EV8Y?B:.,P&/P.(JX3&X+%X:I&MA\5A,50G3K8?$4*L(5:-:E.%2G4C&<)
M1DDSX(_X=C?L3_\ 1'[C_CW\_P#Y*-\4?^1W_P"BU_\ (Y_\G%_]7&?\EN_Z
MGRC_ (=C?L3_ /1'[C_CW\__ )*-\4?^1W_Z+7_R.?\ R<7_ -7&?\EN_P"I
M\K[WHKR/]6N'/^A#DW_ALP7_ ,I/T/\ XC9XR?\ 1V/$G_Q..)O+_J9^2/@C
M_AV-^Q/_ -$?N/\ CW\__DHWQ1_Y'?\ Z+7_ ,CG_P G%_\ 5QG_ "6[_J?*
M]W^"7[+GP._9TFUZX^#G@ZY\'3>++;3$\7F/Q;XTUB'Q=J^F/>.?&GBFRU_Q
M#JEAX@^)6LO?3'Q9\4-4M;GXA^,TBL(O%GB;68=+TN.S^@**VP^1Y+A*T,1A
M,HRS#8BGS>SKX? 86C6I\T7"3A4ITHS@Y0E*+<9*\92B]&T_,SCQ2\3.(<NQ
M.3Y_XA\<9WE.,5-8O*\VXKSW,<NQ2HUJ6(HK$X+%X^MAJZI5Z-&O356G-0K4
MJ=6*52$9+Y^^%?[-_@?X0_%_]I_XU>&M5\5WWBG]K'Q_\/OB-\1;#7+[2+GP
M_HNM_#;X*?#SX#Z':^"K6PT+3-1T[2KOPA\-="U'5H-=U7Q'=S^)+O5KRSOK
M#3)[/1[#Z!HHKU3X0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M\?\ _@L=_P $B/A%_P %8_V?(O".K7EK\.OVC_A:NI>(OV:OCU;Q72:E\/\
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MORU_P[6_ZK1_YCG_ /#NOU(HKKI8[%481ITZO+"-^6/)3=KMR>LH-N[;>K_
M]_ \49[EN%IX/!8[V.&H\_LZ?U;!U.7VE256?OU</4J.\YRE[TG:]E9))?EO
M_P .UO\ JM'_ )CG_P##NC_AVM_U6C_S'/\ ^'=?J115_P!I8W_G]_Y3I?\
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M?@>%F&8XS-,0\7CJWM\1*$8.I[.E2O&"M%<E&%.&BZJ-WU;"BBBLSB"BBB@
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MB@ HHHH **** "BBB@ HHHH _G]_X+@?\$9U_P""@WA;PE^TQ^R]KW_"E/\
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M2T_PC'X"B\+IXOM+B\\0?"WQ3I]G>ZQI%GIT\NEV!ANV74-+-Q_H>4 %%%%
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MC^UM\0O'&N7$D=Q<W%MI;:L'G(S<HU]XPU769YDF;)\U(+=T8X5<<5TVL_\
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MZ5_'0_\ P7N_;2M&$-WX3^ ,,\:PB;[7X;\8V4AD=2BF19_$D4<;2,"0N
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M=7>UGI<[?ZUW^8M%!('4@?6DR..1STY'/T]:8"T4F1G'J<#\L_@<<X].:6@
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M\@_UNK7Z"[B#8MK7> R_T9:=HFFZ2!'IFG:?IL  _<:?96ME%D<<1VL,*8
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M/\0Y?!NFWVHP31ZV+'3KC1/"-SI]S+<AIGTW2=TLRR)YL?QB\/\ BGQ=\/\
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ML+J\B\5TG]O']AS7O'7C'X7:'^V9^REK7Q,^'=OXWO/B!\.])_:(^$.H^.O
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M;:KXODU77=&FL/"B>'/@_P");*>^T6#7]776[[0K:/0I+"YU#4M,/V5/VD/
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MPJ^)%KI5\_[-'@OXH^ =?UZ72?C=X&^',?Q>N$/]-E% 'Y'?\$7/ ?B+X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img99844967_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img99844967_4.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (R!. # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ"]L;B2TNX6#1S1,593G/:OO/]F+]II/B3#_ &!XA>.W\1PK\C#A;I1_$/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3?#CXY?$'QOHMO\ "FV\3ZMI.L3^*I=*_P"$CU.(&_ALPA?RV[+*,8KM=+\
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M-#;7L0F2.YCV2*#_ 'E/0USMG\7_  ]>?%Z\^'"27'_"2V>GIJ<J&,^5Y+'
M.[U]J^<)/%OC/XBZ#\$_A_IOBV]\-W/B+1WU/5M;MT!N94C4?NXVZ!B2<^U9
M?PU\,:O\/_VV?&EIJ?BF37KB#P6DEOJNI !XHP?E\W'7;@DF@#[?I&^Z:_-?
MXB?$W5/"WA%O&NA?$3QKXL\2:9>1R7FIVL6WP_)$9>81D<(1QD=:]5\/:1XX
M^.7QD^*%N?B%K?ASP_ID-I/I]KIDP5HYY(%<YXY0'M0!]6^.?'NA?#?03JOB
M"\6PL/-CMU9@<M(YPJ@#J2:Z!&$D:N#]X CBOSA^)'BG5/C=^QSX5UKQ#J]_
M_:NE^*X]&EGAEVBZVRE/.<8^_P 9![&OT*\*Z-_8.A:98"[N;];6!(Q<WK[Y
MI, ?,[=S0!E?$OXF:-\)_# U[7FE33_M$5KF%-[;Y&VIQ]37413B>*.1,['4
M,NX8ZC(KYY_;[CN9?V=[M+-TBNVU6P$+N,JK^>N":XK4;KQ5\ _CA\)+)/&.
ML>)M-\;,]EJ-AJ\PDCBD6-6\R+ &WKC% 'TYX/\ 'EEXTO-;M[.VO+=])O&L
MIC=PF,.Z]2F?O+[UTKYVG%? .M_&/X@:AX^U_P"&VA^(9],O?$/C:YT^+6Y%
M!_L^UC&3''Z,0.*[;0=.\<_";]L+P+X*O/B#J_BGPOJFD75XMMJ+@N&12/G/
M\7(R* /ICX7_ !,T7XKZ!-K.@O,]E#=S6;&>,H?,C;:V!Z9%=E7YS_#CPGXH
ML?V;/'WCZP\;ZOH=WH&JZC>:=8:?,%M66.4DB5,?,6Z$YK[=^"'C.Z^(OPF\
M)>)[^-(KW5-/BN9EC'RAV7G'M0!W=%%% !1110 4444 %%%% !1110 5\):/
M;_$J;]M/XU?\*YN=#MY_L]C]K_MM7((\L;=FT'G/K7W;7SEXL_8^@UWXH^(?
M'>D^/O$?A;5-=6)+N'3&01D(H"@9&>V: .W^&NB_%&]M-<L_B7?:');W,8BM
M&\/^8DB9!#EBP&.V,5\I^#_%'BK4_CD?@1J'CFXN?#_AV\EU7^V(+EA>ZHBG
M<E@7[LO\0'4"OI'P5^SOK'@^?4IG^*7BG5GN[-[6/[:T;"W9ACS4&/O#MGBL
M]?V.?"%M\/\ 0_#MC?:A9:II.I+JT/B2-A_:$EUDEW=R.0V<%>F* /(-)\$>
M)/CQ\-/$_P 3]2^(NNZ'J]G<7KZ596$WDVVG+;LP570'YB0OS$]C65IOQ8\<
M?M%0_!;P1<>(+GPM#XATV?4=9UG3B(WOO)8KY43]L[<G'7->SW?['\<3>(K/
M1_'^O:+X>\12--JFCVZQM',[_P"L*L1E-_.0OK7)_M%?#[PG\.O#?PST:U\/
M>(K'1_#\KK8^(O#*&6?1<+]YUP2Z,>O!H Y+PW>>(_@9^TEX^T1_%^L^*]%T
MCP<^J6-KJ,QE:)NRGU((ZGG%>::7X]\>W7P^LOB%93>.KOXB2.+Q;J1U_L2:
M)F_U)CSM"XZ'KFO5_P!EWX8S>*OCKXW\?^?KFI^%K_2ETS[=XD@,-SJ,C?ZQ
ME7 "ICC&!UKTBQ_8UBT[2(/#47Q!\0CP-!>B\C\._)Y8 <.(C)C<4R.F: /,
MO!_A'Q-\>?C)\48]>\8>(/#^FV%M9S6^EZ7>M%]FNWMU9CD=5!YV]S6;X,^-
MWC?QI^SUX"T5/$%QINLZSXJD\+W/B7 :98(V8&0D])& P#7U=X1^$.F>"O&W
MC'Q)9W-S)<^)FB,\$A'EP^6@0!,#/0=Z\_T_]CCPO8?!V?X>C5M4>U;5I-;M
MM3#A;FUN6?>&0@8X/3- 'G<>A:Y^S;^T?\/] TGQCJWB#0/&8GAO].UJ<S2)
M*B;O/C)Z9/4=JF^$?BW7;W]E[XPZE=ZQ>SZA9W.KK:W<LI,D.S?L"MVVD#'I
MBO4O"'[-%OI?Q!T[QMXJ\4ZGXV\0Z5 ;?39]01(DM%(P2JH!DD=2:YKQ-^QC
M8ZXGBO3-/\<Z]X?\*>);AKR_T*R$?E^:?O%'(W*">2.AH ^;=+\3>++GP+\/
M]>\7W'C3Q1X*D\.0$2^$;PBZMKS><O.BG<QZ8)%?9O[-7BK3_%WPFTV[T[Q7
M=>,(8I'@.H7\/E7*%3_JI1_?3H2>M<AIO[(T7A"+1SX,\<ZWX5N;#3!I4TUN
MD<@NX@20SHPQN&>"!7IGPA^$^D_!SP='H&D237*F:2ZN+JX(,EQ/(<O(W;D]
MAQ0!\_\ [6=YXCT_XC:5>WD/B?6?AW;V!-Y8>#KOR[R"YW?+)(BG<R_05S/@
M_P")9UG7O@I;^'_'&L^(-/?6[ZWO(]40PW<8$6Y;:X!Y=EX^8U]$?$3X&/XR
M\9V/B[1/%>J>#O$-M:M9O<Z<J2+<0DYVNC@J2#T/:L#PM^R3X=\,ZEX8U)=7
MU&ZU;1M4GU>6]E*;[ZYF7:QEP.@'0#% 'BG@SP_XO_:3@^(WCW4?B#K7A2?2
M;^[L-(TC3IO*CL%A!^:5?XBV,\UY_P#!V[\9?%VZ^"6AWWCC6K6SU+3]4DU>
M:UNV2:[6.<!0''0^_I71?$Y=!T?QW\2;8V'C_P &ZAK,KPOI>CVAFM-?;;\L
MD;@'R\G&>17K_P"R[^S#+X&\(_#76_$%S/!XCT'3KB$6* "-5N'WE7XSO7@<
M=Z .>^$OBW5O 7B_X[_#V]\87C:-X7M8[W3]?UJ0SRV*RQ9P2?O*IY'K7BGB
MSQI=^ +7P=XW\*ZM\0-6NDU>TM[[Q#K5PR:;JBR-@H(6.0#GY0!7V+>_LO>'
MM2\3_$W6[F_O96\>V4=E?6[$;(%1=JM'QU^M<3K7[$B^,-%\/Z-XD^)7B/5]
M(T!XY--LVCBC2,QD;2V!\Y & 30!YM\0?^$INOCA\<AX*O!9^(Y=&TW[.%D6
M.27."T<;L0 Q&<&MC]FCQUH</Q7M=#&M^./"^L36SQW'ACQB&GCOYE^9I()&
MZ$')XZU[%XH_98\.^+O$/C'5[_4M12Z\26=O:.86"_9##]R2,XR&R,^E2>$?
MV<6TCQWI'BOQ+XQU;QIJ6C0-;Z9_:$<<:6P88+?(!N8CN: /;**** "D/0TM
M(>E 'RU^W7XUFT7P/IN@VTLD4FJ3$2%3@-&O+*?K7PH!@ #H*^N?^"@FXWW@
M_P#NYF_/ KY'KY+,9.5:W8_GCBZM.IF,XO:-K?<%%%%>8?!BA<U[/\ _@#I_
MQAT#6=5U'7)M'ATV7:QB16&T+DL2>F*\7KZU_8U^PCX9>.3J@SI0E;[4!WC\
MKYOTKNP4(U*O+)71]1P]A:.)Q:C6CS1['$>)?@)\.M'\/7U_8?$G^T;FWA:2
M&WPG[QAT7KWJG\(?V<]+^(7@$>*=9\2GP_ ;A[=0ZH$.#UW,15?XFS?!*?P9
M<KX'MI(M<)7R"Z2# [_>XZ5W'ACXY>%/"7P=\,Z'KO@R]U&&.0,WF1!899<X
M,@)X;KTKTHPH.JU))*W2Y];2P> J8QPG&*23V;:;\SE-1_9]\)VGCK2]"A\<
MK/87EM)<2WP,>(V4X"\''/O79VG['7A;4X[B6Q\?-=I;KYDIC6-@B_[1!X%<
M#^U!\--!\%W6BZ[X?@%CI^MPFX:Q)YC<X.57L.>:VO%5D_P3_9XT_3+?$&N^
M*G$MW/&PWI%C(7/4J1QCWJ53I1E)2AHM3%X;"T:E:-6BK15[IOY6UZG-?#']
MG^/QU%JVKZCK\>D>%[&>2V%^<;I64X!&>,5E_&GX(W/PDN+&Y@O1JVAZ@N;:
M]4#\FQQSVYKG/"4T^G&TN-<L]3O/!$,P:\M8F86\GL0.,_6O=?VJ[=M:^'/@
M_7=$G1/!BQI%:V**0ZDCAF[<8Q62ITZF'<U&S7]?<<7U3"U\OG4C3M**OOK_
M ,,?,%%%%>,?GH4444#6Y]5?L'>,Y;/Q+K7AV:<_9;F,7$,)Z"0??/Y8K[A4
M@<U^<G[&HE/QTLMG^K^R2[_R%?HX *^MP$G.@K]&?T3PA6G6RU<W1M(DIK_=
M-.I#T->F?<GR7^VUK>NVU[X#T;2->O=!CU74#!/-8N48C Q]:;:_L8^)[BV1
MW^,_BE&8[MH<<_K3/VV<_P#"8_"D9R1K _I7U98[FMH2W78*X%"-2K/FUM;J
MSZ^IBZF#R_#^QLN:]W9-O7S1\M?\,6>*/^BS^*O^^EH_X8L\4?\ 19_%7_?2
MU]2ZCJ5OI5C<7EY,EM:6\;2S32'"QJ!DL3V %9_A/QCHOCG2(]5\/ZI;:OIL
MA(6YM) Z$CJ,BMO80[?B_P#,\O\ MG&?S+[E_D?-7_#%GBC_ *+/XJ_[Z6C_
M (8L\4?]%G\5?]]+7UB37/>'?''A_P 77>IVFBZQ::E<Z7-]GO8K:0.UO)_=
M8=C1["';\7_F']LXS^9?<O\ (^;_ /ABSQ1_T6?Q5_WTM'_#%OBC_HL_BK_O
MM:^C/%?C_P />!6L%\0ZU9Z.=0F^SV@NY0GGR?W5SU//2GZ-XWT'Q!KFJ:-I
MNJVE[JFF%1>VD,@:2#(^7>.HR#3]A#M^+_S#^V<9_,ON7^1\X?\ #%GBC_HL
M_BK_ +Z6C_ABSQ1_T6?Q5_WTM?3/B3Q+I7@[1+K5];OX-,TRU7?/=W+[(XQG
M&2?K3=.\6Z-JFF6.HVFK6EQ87V/LMPLJ[)\]-ISS2]A#M^+_ ,P_MG%_S+[E
M_D?-'_#%GBC_ *+/XJ_[Z6C_ (8L\4?]%G\5?]]+7U@S;026P!W/:N9U[XA^
M&O#.G0ZEJNO6%E82W M([B6==C3$X" YY.>,4>PAV_%_YA_;.,_F7W+_ "/G
M7_ABSQ1_T6?Q5_WTM'_#%GBC_HL_BK_OI:^K(Y 51@VY6&0W8CUS4NZCV$.W
MXO\ S#^V<7_,ON7^1\G?\,6>*/\ HL_BK_OI:/\ ABSQ1_T6?Q5_WTM?6.:,
MT>PI]OQ?^8?VSB_YE]R_R/D[_ABSQ1_T6?Q5_P!]+1_PQ9XH_P"BS^*O^^EK
MZQS2$\&CV%/M^+_S#^V<9_,ON7^1\G_\,6>*/^BS^*O^^UH_X8L\4?\ 19_%
M7_?2U](ZQXUT'P]IFI:EJ>K6=EI^F@->W$LP"6X)XWGH.35[0M=T_P 3Z3;Z
MGI5Y%?V%RN^*XMW#(X]011["GV_%_P"8?VSB_P"9?<O\CY@_X8L\4?\ 19_%
M7_?2T?\ #%GBC_HL_BK_ +Z6OJ#6-:LO#VF7>I:G=1V5A:QF6>XF;;'$@ZLQ
M["J&C^.O#VO:#!K>G:U9W>CW!Q%>QS*8Y#TP#GD^U'L*?;\7_F']LXO^9?<O
M\CYN_P"&+?%'_19_%7_?2T?\,6>*/^BS^*O^^EKZM4Y(/;UZU)FCV%/M^+_S
M#^V<7_,ON7^1\G?\,6>*/^BS^*O^^EH_X8L\4?\ 19_%7_?2U]8[J0L<&CV%
M/M^+_P P_MG&?S+[E_D?*'_#%?BC_HM'BK_OM:!^Q7XH!_Y+1XI'ON6O=_#O
MQF\#^+O%5QX<T?Q+I^HZY;$^;9V\H=UV]<_2NW?)4@'!H]A3[?B_\P_MC%_S
M+[E_D? /Q6^'?B_]G_Q/X.NH/B9XAUH7NIQ0M%=R80C<,YP>:^]-/=YK:%F.
M25!R>M?*'[<:O_:/P[#-G_B<Q?\ H0KZRT\@VT7LHJ:24:DXK;0ZLTJRQ&&H
M59VYG>[22V]"W11176?-!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12-
M]TU4AO;>XEDCBGBEDBX=4D!*^Q Z4 7**ISWMM;311S7,,,DIVHDCA2Y] .]
M227<$!8231QE1D[W P/4^U $[' ->5?&WX&6?QIG\&27FJW.F?\ "-:S'K$?
MD1A_/=!@(V>@/J*]21TE0,C!U/1@<@U7AOK>Y>1(9XI7C.UUC<,5/N!TH X'
MXZ?!30_C_P"!+GPWK+RV;[UGL]1MP/.LYU.5D3/H>W>O/V_9B\2:9XKB\3Z%
M\2[O3O$4^DPZ3J5[-IL4IO%CX64*3A'QZ5] O>0QSQP/-&LS_=0N S#V%++>
M00;_ #)HX]HRP9P,?6@#Y>T3]A>P\/\ A/5-/@\;:N^O7>LQZ]!X@:%//MKM
M!@G'\2MW!KH_"/[+NI6'QGL?B?XF\>7GB;Q#:V<ECY36:00"-AC"J#\OK7J_
MQ.^).D_"GP+JGBO6'8Z;81>:WE89G). J_4UH^&_%-CX@\.:;K"2I!;WUO'<
MH)9!E0X! )]><4 >!6_[&8T"V\,W'AOQG=Z9K^@7MW=P:E+9QS"19V):-HR<
M87/%:WP]_92D\)_$?Q+XYUKQQJ/B;7M?TU].O&N+=(HU5NA0*?E"] !Q7O=U
M>P6=LT\\\5O".3)(X50/7)KAOBU\9M!^#_A_3M5U9VGCU"]BL;5("#YDDAP#
MGT'7- 'E/@3]CEO".D>#]*NO&]YJ>G>$];?5],C-G&K!6!S"Y'49).:W=?\
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M4 %%%% !1110 4444 %%%% !43H)%*L RL,$$9!%2T4 11QK$@10J(HP%48
MJ6BB@ HHHH ^3/V]?VKO%'[+FB>&;OPU86%_)J<[QRB^5CM &<C!%8'[ _[9
M7C#]J3Q!XKL?$VFZ=81:5;1SPFQ5E+%GP0<D\8KS3_@L9_R*_@/_ *^WKD/^
M".'_ ".GQ%/_ $XP?^AT ?J91110 4AI:* *[1)(Z,Z*S)]TLH)7Z>E6***
M"BBB@ HHHH **** "D/0TM-;I0!\M_MU>"I=:\":=KT$3R2:7-\X49V1OP6/
ML*^% P*Y'0U^N7B[PW:^+_#VH:1>()+:\A:%U/H1U_.ORQ^(7@;4/AMXMO\
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M&;2)Y)$AU%4SJ#7&[YP[?W<$U]_-]TUX-^QW\$->^ GPL;PWXBN;*ZOS>R7
MDL68IM8Y Y[U[RWW30!\A_MR_P#(7^'W_8:A_P#0Q7UCIG_'I%_NU\G?MR_\
MA?X??]AJ'_T,5]8Z9_QZ1?[M<M/^)/Y'O8[_ '/#_,N4445U'@A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$\(PZMX)U"V@NK)_!\+0:7!;7+)"%*[3YB#A^.Y[T >FT5&G)SZU)0 4444
M%%%% !1110 4444 %%%% !1110 444AH _./_@L9_P BMX#_ .OMZY#_ ((X
M_P#([?$7_KQ@_P#1@K3_ ."O/C/0]1B\)^';748)M<L)C-=6"G]Y$C#Y6([
MX-<A_P $C_&VA^&?B-XOT[5=3ALK[5K6&&QMY6P]PP?)"CZ4 ?K11110 444
M4 %%%% !1110 4444 %%%% !2'I2TC=* (_3Z5X?^TM\!H_B[X:,UBJQ:_9
MO:S$??\ 5&]C7N/ %#(-I]*SG"-2+C+9G#B\)2QM&5&JKIGY ZSHVH>'-5N-
M-U2TDL[^W;9)#(,$>X]1[BJ-?IM\9?V??#OQBTYOM4/V/5XU_<7\( =#VSZC
MVKX4^*G[//C#X43RR7UDU_I2GY-0ME+(!ZL.H/UKY;$X&=)WCK$_!<ZX7Q.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%)FEH ***3- "T44E 'YY_\ !5O]G4>)?"5G\5=&M5_M#11Y
M&J!$^:6V)P'/J5/0>]<'_P $E?@)#JNL:S\5=6M-Z6>=/T@RI_$?]9(OJ,';
M[5^EOBWPS9>,_#6J:%J40ELM0MWMYE8!LJP(Z5D?"?X8:%\&? .D^#_#ENUO
MI.FQF.(,<L22268^I)- '9T444 %%(6 '6L+5?''A[0G*:CKNFV#]UN+I$(_
M,T[7%<W!FEZUR$?Q:\%38">+=%<G@;;^,_UKI;.\@OH5F@F2>%N5DC8,I^A%
M'*UN0IQ>Q;HHHI&@4444 %%%% !1110 F!2T44 -;BJ=Y917D;1RQ++$PPRN
M 0?J#5W@TA7 ZT$2@IJS/!O'_P"R%X&\<!YX+ Z->D'$UB=BECW*]Z^>_%7[
M#7B_2[MQHNH6NI6@&0T_[N0^VWFOOK)]:,9'/-<53"4:NKB?,XSAS 8Q\TX6
M?=:'Y6Z]\#/'WAM99+[PM?);QMM\Y%W ^XQ7)/H>J1.5?2KY&'4&V?\ PK]?
M&02<,JD>]1/IEM("&A7IW KAEED/LL^5J\"X>3O3FUZH_(-K"\1MK6=TK?W6
M@8-_*GC1]38_+IE\WM]F?_"OUG?PEI$\WGOIULTPY#M$I/'O5^'2K6,?)"GY
M"H65+K(Y(\"1O[U33T/RMT'X1>-O$T9DTWPQJ%S&#@L8]N/SQ7IWAG]BKX@:
MX;>:]^QZ7;R'$BR/F1!ZXQ7Z&);H.!&J_08J0+M' K>&748_%=GL8;@K!4W>
MHW+\#YN^'G[$W@_PP\=QK@F\0WB9R)_EA/\ P"O=;33]*\(:.Y@@@TO3K2(N
MX50B(BCJ3]!6Z#ZUQ'QB^&]O\7/ASKG@^YU"ZTJWU6W,#W=DV)$!_I7I4Z4*
M:M!6/LL)EN%P4>6C32\^OWGS?\+_ /@IK\,O'7Q$UCPSJK-X=ACO#;Z9JMRV
M;>\4':"3_ 2>E?7]M=0WD,4]O,D\$H!26-@RL#W!'6OPV_:1_81^(?[.KRWD
MMHWB?PF&VQZO81EC&O;S4'*G'?I[T?LT_MU?$+]GJ6VL8[UO$OA'>/,TF^D+
M&)>_E/U7Z5J>H?NGFEKPS]GC]KWX>?M':7&_A[4TM-94?O\ 1;U@ES$WL.C?
M45[G0 4AZ&C-#=#VH ^2/VV1CQG\*N/^8N/QZ5]5:>2;&#M\HKY,_;GO8-+\
M1_"^[NI1%;Q:MODD?HJC'->QV'[2?PV@M(E?Q58AL=Y.XK@A.$*L^9VV/JL1
M0JU\OPSI1<K7V5^IZUNHW5Y;_P --?#7_H:[#_OY2_\ #3'PU_Z&JP_[^C_&
MNGVU/^9?>>)]0Q?_ #[?W,]1R*PO&O@[2?'_ (5U/P]K=LMYI>H0M!/$1V(Z
MCW'4>]<7_P -,_#7_H:[#_OZ*/\ AIGX:_\ 0UV'_?T4>VI_S+[P^H8K_GW+
M[CYOG_X)[>+O^$3/@:V^->KQ_#WS"$T5K8$K$6SY6[.2*]8^+'['6@_$#X&>
M'OAKI%_)H%MX?FAGT^\$?FE7C.?F7(R":[C_ (:9^&O_ $-EA_W]%'_#3/PU
M_P"ALL/^_HI^VA_,OO%]0Q?_ #[E]QXIIO[#>L7?Q4TKQYXG^(L^L:O:VKV<
ML<-BL",GEE$V8(V%>N1UQ62?^"?VM:K9:+H'B#XER:WX/TS4?MPL9M-07$XW
M[C')+G)';.:^@?\ AIGX;?\ 0V6'_?T4']IGX;8_Y&RP_P"_HH]M3_F7WC^H
M8K_GW+[CY/\ VB/A-J7Q%_;M\':)H6JW_A)[;PQYMIK-E"7%LT;':N>G3L37
MH&C_ + $,WA+XBVOBOQC/XF\4^,(UC?7Y;<+);8P3M&><U[5_P -(_#!IQ-_
MPDVFF4# DW#=CZU-_P -,_#7_H:]/_[^C_&E[:G_ #+[P^H8O_GW+[CP.+]@
MGQ%?ZQX#U/6_B=)?S>#I85TZ!--1(A!&0=A /+''WJZCXE_LA>)/$_COQ5KW
MAWXCRZ)9>)+<6UWIMU8I=)"HZF$L<H<Y/'K7JO\ PTS\-?\ H:[#_OZ*/^&F
M?AK_ -#78?\ ?T4>VI_S+[P^H8O_ )]R^X\RU;]A_P .ZC^S;IGPKAU26TGT
M^X34(M;2$>8UV#N,I0\<GJ,^E:_PC_9N\3^"?B(GB[Q9\0I_%-Q'9K906<-D
MEM",<!VQU;'TKMO^&F?AK_T-=A_W]'^-'_#3/PU_Z&NP_P"_H_QH]M3_ )E]
MX?4,7_S[E]Q+^T+\'1\>?A9JW@QM4?1A?&-C=I&)"FU@<;21Z5Y9\3OV-YO&
MVF?#.;2/%AT?Q!X%CV6NH2V@F2X^4 %D)P._KUKTW_AIGX:_]#78?]_1_C2_
M\-,_#7_H:[#_ +^BCVU/^9?>+ZAB_P#GW+[CRKX7_L87O@/QWXV\5:AXZGUW
M4/%>E36%[YMDJ;99!@RK@\#_ &:0?L11_P##)9^"7_"72A3<>>-9^RC=_K-^
MW9G\.M>K?\-,_#;_ *&NP_[^BC_AIGX;?]#7I_\ W]%/VU/^9?>'U#%_\^Y?
M<<5\0/V4%\=^/_A/XF/B.2S/@0PD6RVX(O/+&.3GY<_C7.ZO^Q FJZQ\:M0'
MBZ6,_$B-D,?V4'[#D@\'/S=*]7_X:9^&O_0UV'_?T?XTG_#3/PU_Z&NP_"44
MO;4_YE]X?4,5_P ^W]Q\??MB^&_#WPR_9N\,?!MCJ?B/QI9M'+HDMM:D"5\X
M+';G'4CZU]9_LI_"I_@[\"_"_AVY0#4U@%Q?/MPSS/\ ,=WN,@?A1<_M _">
M[O8+R?7])FNX!B*>3:SH/]DGI5W_ (::^&P./^$KL!_VU%'MJ?\ ,OO']0Q7
M_/M_<>ITF17E_P#PTS\-?^AKL/\ OZ/\:3_AIKX:_P#0UV'_ ']%'MJ?\R^\
M7U#%?\^Y?<>I4AZ&O+?^&F_AM_T--A_W]H;]IOX;8/\ Q55A_P!_:7MJ?\R^
M\/J&*_Y]2^X\7_;C'_$U^'N6S_Q.8>/^!BOK.P 6SA _NBOB#]K+XI>%O'^M
M> 8M U>VU&>+5X6=(&W'!85]NZ<NVS@'^P*SI24IS<7?8]7,:<Z6$P\:B:>N
MC+M%%%=9\X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%,D&4([T $G*'^E>1?M&?M+^$?V:_!D^L^([M9+^
M1"+#28F'GW<F.%4=0/4FN'_:[_;3\,?LP^'Y;.)X]9\;W49^Q:/&V2F>DDI_
MA4?F:_'#QOXZ\<?M#_$=-0UB>Z\3>*=2D\NVM8%) S_RSC0?= H _:O]D[]J
M[0/VI?!PU*R1-*UZT.W4-%:3<\'H0<?,I]:]\KXG_8&_89N/V?P?&?BJ]E;Q
MC?0[#8VTA6"VB89V./XV'OTK[8H **** "BBB@ HHHH **** "BBB@ HHHH
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M +2<.I7:6OA/1WM%E80.6.2@/!/-%2JH6NGKV16'P,L3.4%**:[NR^1]9_\
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MZ>4*4?LU?#8=?"FG9_ZY"NWUR;4XO#-Y<:? DNK+:NT$+_=:;;PI]LU\L?\
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MJSV,EFZLX:Z#AH\_>&WDD4 >W^(_VRM&\*>+-7\(:?X2\1^)]7T"VAGO?L$
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M"(.I8X K\W;?X?\ B#]F+Q1=ZUX3UV_DN--_X^M+O[AYX)X_XCDG@XR:]/\
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MDEMGCR9]P'0]J]C4<COSBO/_ !GX]\2>'_'GA;1]*\)RZSH^INZW^JK+M6P
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M&?UKH++X]?#K4RHMO&FD3%N@%RO->677@;P#J;D3^'-(WGM $6LF^^ 'PUU
MDR^'7@8]#%+@?I5_6GV*]M);H^C[#Q9HFK /9:O8W0]8[A3_ %K4BN(Y?]7*
MDG^X0:^/+W]E+P%<'-M<7NGOU!5G./R853'[-6K:0V[PU\0]1T]E^[B[:/\
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M[>.!UH ^J::Y^4U\RZK^U+J.J?"SX8:GX8L8IO%'C2^BL!;SHQCMG4XNB1U
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M344F<,5:*3'4445H6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\9_CIXY\-S?%:WL-$\ Z+,MXNB03"1[Z1?N"4#I@\\\8K[+R200>*.>:Z*6
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MI&H7/KQR?Q->00_"3]I6\.R[\1Z1!'_>2Y9L_ABM&#]FCXOZNN-4^(UM9?\
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MN:W22T1LE;86BBBJ&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=#L? ?QG^*;^/?&7C/P'>7^I?:K2YT: R0:A:LN557 )+#ICI0!]E^,/VEO
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M]0#BN-\>_ 2_\5_M7>'[O3Y=:\,Z+H_A46EGK.D,$$3B0CR22"#\N.*^M**
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MR17P?_V'%_\ 0#7CW_!'#_DJ_P 1_P#L#V__ *.KV'_@L-_R17P?_P!AQ?\
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MQY]SR$) ^4=3VKZLB)8+GKBL82;E)=F=^(H4Z5&E4B]9*[\F3CI2T@Z4M;'
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\!_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%8W@\C_A$]%Y_P"7*'_T 5LT %%%% !1110 4444 %%%% !2,,J12TC'"DT
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MC4O*/VI+K[3Y0'/F!\X_.OZ49$62-D=0R,"&4C((K\Q-2_8#DE_;YB1;%O\
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MJ>^S//Y5MKA<8'3BL84[.3ONSNQ&(]K1I4[6Y=/4D'2EHHK8X0HHHH ****
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MQE+EO)/T^;&:].@E2>-)(V5T<!E93D,.Q%?@=:W<B2(-Y*9Y!K]@/V+O%O\
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M6H>-O[2AGT.QM'NWF1Q@A5SM^I/&/>I_B1K/A70?!^HW7C2[LK3P^(R)WOV
MC*XZ8/4_3FOQK^.?QKB\::EXB\+^ M4OK#X/R7 EN9YL@3[3G"#ZC@?3-:RE
M3Q4.:W+)=MF8TJ=7!U.5/F@^[U1YQ+;:C\5?&MJUGN;4_&_B3?;6[##/"9=T
M;'V/(_"OWX\.Z=_9.B:;8XVFVMHX<8_NJ!_2OS;_ ."<'[,UYXL\9Q_&+Q%I
MAL- L8OL_AFRG'+ <>=CL!C(/J37Z9)]X=>*X)N[]#VX+2Y-1114&@4444 %
M%%% !1110 4444 ,V]*_.+_@H=9/IW[6?P6UO4X&DT!XQ:*P/ N/.+#]"*_1
MXGI7R'_P4M^$-_\ $3X%1>(M'5FUGP==#5H47C,8&)#^"Y-:4Y<LTS*I'F@U
MW/9[)E,T!4Y!48.?:L;Q=J;:7H-]=*?WFTJON3Q7!_LQ_%FR^+OP@T#7;20&
M98$BN4W9*N!@[JW?BS<"/1((5;'F39^HKZ3#1YJJ7<^;Q-3DHR\CRC.>3DDG
M))[T445]4?#!1113$%%%% !1110 4444 (P!1MPR,'(]L5\SPZO?^%_VK_A!
MXFLY/)2YU+^QY2GWF0N=P/U!Q7TE?R>38W4G]R)F_(5\K?$"XEL?$?PEU& ^
M5=#Q2SH_Y8-<68TU/"2D^ECMRNJX8^,5UN?LKD>M+5:T<RVL$C<NT:D_7 )J
MS7YR?JPAY%<C\4/$MYX+^'7B'6[#3+K5[ZRLI);>QLT+RS2!3M55'4YKKZ3H
M* /COX!?LEW6J_!'?XNUW6;#6O%0FO\ 5;0?)AYLD+(IZLHP.:X/2_!7CZ?]
MFO5_!EQX>UBZU;X;^)(Y]/292/[:LHI=RM&3PV%S@>U?H!D>M% 'R%\5_C)K
MWQS\)ZEX>\%^!M1>VFT*ZEU*]UK3Y('MI/+^6W@S]Z0G/MQ7,F/5?&7[.'P-
MATWP_K*7^A^(;&WOK6>R:.6W,>=[E3_",CYNE?;_ -./7%*!@\<>U 'P_P#&
M/X+^*YOC\/!.BZ5(WP\\?:E#KNLWL4!:"W>WP7C<]!YA /O74_M!ZIJ]I\9;
M+0M:?Q)I'PS&D*T,OA.Q9WFG#8\F21!N48' %?76:8<CH./K0!^=7PI\"Z_-
M\-OVE?LOA'Q#IEOK< DT>TU6-VNKB,*0/F/+,<9QUYJ+4O"BZY+\(?'&J:+X
MKMO#UMH0T34WTZW>*]TRZC& _ECYBIY&X5^C(;'4FOD[X@ZE>V_[;W@FVCO+
MB.UDLW#6RRD1OP>J]#6%6:A:ZOJ>C@L.\3*:4K-1;^2Z?,M?LC^ ;&'XB>./
M&5EH^OVMK.L6G6VJ>)"ZW=^B_,6*MSM!Z&OJRHP<J,'(_E3ZW/.%I#T-!KG_
M !]JKZ'X(U_4(FV26MC-*K>A"$TF[*X'ROX)B3XO?M0^+/&%P3=:1H+?8-/;
MJJE!\X(^M>D>/M6:\O%ASC/S,!V'85QG[(EF(/A!_;)4"XU61YIVQU=G))K7
M\0S&;6+C/(4[1^%?S#QSF$Y0E&]N9O\ R/NLEPZ]K=]%^9G4445^ GWP445P
MOC7XN:7X0UF+0H;2XU?Q%. 8--MUYD)Z#<:]7 8"OF-94,/%RD<U>O##QYZC
MLBC\9;>XT)M#\=:=;BXO?#UTDDL10-YL!.'0^V*^S?!.HZ)XF\-Z?K>CP6OV
M34($G5H$7!R.G ['-?*&B? ;XK?&. MXFO(? ?AN93FP@4274J$\H_\ =..]
M?57PW\ Z;\,/!NE^&-',K:?IZ>7$T[;G/?DU_8?!F68K*\O5'&;WNEY,_*\U
MQ%/$UN:E\SJ40*H4* !T &*EHHK]%/$$/(/>OD[]H/P9XA^.?[1W@7P.+74]
M/\&Z%"VMW^JI"?L\TW2.,/TWCKCWKZRI.E 'QM\:_@YKGPA^)/@/XE>%I=?\
M5W,5V=)U6V0&5Q9S#:9#CG"9S5/X8?%+5_@'\-O$GP^NO FNZOXIL[^Y;2(E
ML'EMM429RT;M(!@#YOFSZ5]JDX%,!R>] 'QIX@?7] _:B\+ZMKOAN^"ZIX-D
MTR672;5Y;."[92?+SV';GOBK?@3X+:GXN_8IM- OM,N-.\2:=/+J=C#=PE98
M[B*8R)A>HW 8'UK[ QG&1_7%/)H ^0?@!HOC]O@]\1OBGJNB-:?$WQ/'+);Z
M=>6Q66%(4*11E#USC<!WS7SS\3-.U3X@?#?P^EOIWQ"\4^/IKZTN=36^M)8+
M/3PC@R!8AA#Z#'85^HA-,9BH)H ^-/AMHFIW/Q6^//A&\TS5]+NO$MJDFFZB
M;9E@D40;2!+T!R0,?6O%-%^'UJWPGMO ^I>&O'\_C'SETRY\/ 2_V8P\S!EW
MCY?+Q\V:_3.25(T+RLL:]-SL /SIX^7D]?6@#)\(:%'X9\+Z1I$2>7%8VL5N
MJYW;0J@8SWK:I,CUI: "FM@J03@8YIU<_P".]2?2?!.O7J [[>QFE7'7(0T#
M1\C>$]:_X3/XI?%/XC'S)+6W<:'I$Y_@'W95'T(_6O+_ (GZF]SK,5F&S#;I
MD@'^(]<UW7P>@:R^!.D3[F']IZG=7SJ?XB3W]:\@UJ[-_J]Y.26WR$\]N:_/
MLZK.551/W#@O!QC3=1[E*BBBOFS]:"BBE"EC@ L3V R?RH0F[*Y;T=[2+5K1
M]0B,]DLJ^?&#]Y<\BO0?AEX"\5?$OQ)XHTO09_#_ (>O=*D4-9W,)FV1-S&R
MGN,=?>N"FTF/3;5;O6[V+1[1E#*)#NGD7UCC'+'VKV3]G;0_%7B#XQ:'XJ\/
M:)=:;X7L[#[#>ZCJ2^7_ &DF?]8J'G=TZ],5]?E&%;;=2'N]S\>XPS*.BPU6
MTENDSUCX*?L]>-/ OQ9NO&?BKQ1I^LO/IBZ<(;&T, "JP*Y'3C%?1B_>-'7Z
M4#K7V<8I*RV/Q>4W)N4G=L<>AKS[X[_#J?XL_"+Q3X2MYDM[G4[,Q03N.%D!
M#*?S%>A54EU:QB9D>]MT=>"&E4$'\ZL1\H^'_P!J/7/AY\,(/#FL?#?Q3<^/
M](MQIL5G:V#2VUY(B[%E64<;"0":R9?"_P 3]1\5_ 35O',$^J:\=4NKO4FL
MK?\ <:9&Z?+&Q7H ,<GO7V NL6!QF^M@?^NRG^M..LZ?C_C^MO\ O\O^- 'Y
M_:AX M_AS\3?B=:^*[7QW&VH7\FH:3=^'$DDAU-'7A'*?Q@\<]JL6.@:_P##
M/PWX \/76G^)?!_@+5;:ZU'4O[!M6N;V.YD?<L4KC+1Y'4#O7WM_;%@/^7ZV
M_P"_R\?K2_VQ8'C[=:X_Z[*?ZT ?%?[(O@>6]^-WQ8N9O#'B#3?!VMZ;';6<
MGB-',MW']QRS-SR.=IZ U9_9X^$_B^+XZQZ'XFTZ6/PC\,89X- NIH"(KMKA
MB1)&QZE%./PK[,_MFP_Y_P"V/_;9?\:1]8T\J?\ 3K;I_P ]E_QH _.J]\.:
M1\)?&OQ$T'QG+XQL]8U#4I[S0TT:1V37(W&5&%ZL. <]C7V)^ROX!7X;?!/P
M_I/]ER:+)(K7<EC-(6>%I#O(8GOSR*\F_:-N89?VGO@H\=U&T:W%QEED4A?E
M'4YXKZ9U7Q?HV@:5=ZEJ&I6L%G:1M--*\RX1 ,L3SV K"$FY279GIXJC&G1I
M3B]9*[\C?S2USW@[QKH?C[2+?5O#NJ6FLZ7.N^*YM)0ZD?T/UKH,BMSS!:1O
MNFEILC;(V;T!-)@?$O[4_BV;QM\4[;PW#(?L.DC#1CO,>N?PQ5CQLG_"+>%M
M%\-PJ8W>-;RZ[$NPX4_[M<9X-63XA?'"\N[WEKC4F\TCLH8C_P!EK<^(^J+K
M'C75+A&)C\PH@)Z!>.*_)>*<3+G<4]M#RL5/1G-4445^7GCA1110 4444; 5
MM1LUO[*6!@"&4X^M?0W[&'C:;5/#6H^&+N3?-I,F^ $Y(B8]S]:\"!P:ZS]E
MG59M!^.\FG1$&'4;>19?^ C</UK]3X.Q3C*>';TW1ZV!GO$^Y*0]*6BOU@]<
M^0OAM\*M>U_X(_'#P^=.N](U/6M;U)[0RQ^2USDDH0>ZM@#/H:\.TCX?Z=XE
M\ >%?!\WAOQ_=>)Y+FWL]0T*]65=-M/+;YY-_P!W8,9!'K7Z23:G9PLT<MW!
M&XZJTH!'ZU$=8L,'%_;9/?SE_P : /D_3XM0_9M_:0\6ZO)X:U;Q%X9\5V5N
MT5]I4)NIK.XB7:(&4<JIP.3Q7C?P]T37?BW\#/VB1IFASQ:U/XL74!I!XE!C
M<.T7^]A3P.YKZL^(_P #+?Q=XWF\7^'OB3K'@O6[FV2SN/[.O4:"2)3G_5MP
M&_VJ['X1_#SPO\&_"HT31]06YWS/<W-]=W"M/=3.<M)(V>2: /DGXO\ CK4?
MC;XM^"EIX<\$^)_LFAW:W.I7MWIKQ);R>5L,9SUQZ]*T=(3X@?#_ /9.TN+2
M=+U;2[M_$\PU/R+#S;ZWLWF8M+%&>^#UK[<&L6&1_IUMCU$R_P"-..LV&/\
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MX?K=A-$TA#<ZC*C95#U<,/8 #\:^6?C[XR_MC5?LL*_9X&.$MT/RPPKPB?3
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MNW28Z_+CGK7J'_!4#Q18ZW\?/ /AZ1\KI.G7%S<H#]TR+F,G\0*Z[]B'3X?
M7[#?BKQ7=R8?Q)-<2DL>K#]T.OO6V'OS)+JS#%VC3E)OH?7O[,^N#7O@QX8F
M$<,7E6H@\J!0J)M. ,#IQC\Z]41LM7D/[*FCG1O@CX>21#%++$974\<DG^F*
M]>0#(XK'$)*M)+NS3 RF\/!R[$M%%%8'H!1110 4444 %%%% !1110 51U'3
M;?5[&ZL;V%;BSN8VBEB<95D(P5/J"":O44 ?F!\$H[O]DK]K;Q/\)=2=D\,:
M\YOM&E<X7:YR,>YY7'^S7T[\7W*S:;'DX*L<?C7E/_!4_P )3:#H7@'XKZ84
MAU#PUJJ02N%^>1)"-N3Z @_G7=:YX@B\;^!O"?B.!_,BO+17+CU8"OI,LGSR
M2>Z/ELUAR0DULSEZ***^O/A0HHHH **#Q10 449HH **** *FM_\@6_]?(?^
M1KY&^.<[Z=X2^'NJ(QB>RUX,)>H7.WK7UWJD9GTN\C'5H7'Z&OESXSZ;/K7P
M%\0VMM!YUUI-W%?J>ZHI^;^51BX.I@YI$X.HJ694V]GH?K_X?F\_0]-E)W%[
M:-BWU0&M%J\J_9>^("_%/X!>"/$9E22>YTV-9Q&>$D4;2I]Q@5ZJU?EY^R+8
M=2'I2T4#/D[_ (*(?M ^,?V=_A9H&M^"KJVM=0O-46UE>Y@\T&,J3C'K7P!_
MP\]^/W_08TC_ ,%XK]9OC3^S]X*_:$T"ST7QQICZIIUI.+F&))WBVR8QG*FO
M'O\ AV)^SU_T)TW_ (,)O_BJ /SZ_P"'GOQ^_P"@QI'_ (+Q1_P\]^/W_08T
MC_P7BOT%_P"'8G[/7_0G3?\ @PF_^*H_X=B?L]?]"=-_X,)O_BJ /SZ_X>>_
M'[_H,:1_X+Q1_P //?C]_P!!C2/_  7K7Z"_\.Q/V>O^A.F_\&$W_P 51_P[
M%_9Z_P"A.F_\&$W_ ,50!^?7_#SWX^D?\AC2#_W#Q7G7C;]L/XI>/?%EAXHO
M]8BLO$%B MO?:?"(FC'IQUS7ZD#_ ()D?L]8_P"1-E&/^HA-_P#%5Y1\1/\
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MTLUNK.?3)(]*B_X5YX8_Z%[3/_ 5/\* /YX?[9\7_P#/]K__ 'W-1_;/B_\
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MX, PFN:V3;W94=<#&7/U KZ-TO\ 9 ^%FF_$S5?'DGA6UOO$-^X??<H'B@P
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M:>R)'*L>U@YZC/IBOT3#8NE7]V#NS^=,QRC$X#]Y6A9-GU+1117HGA!1110
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M;#(.FYC@C\J\J\1:C_9FFN1DRR?(@'4GO7V%^S%\.&^'WPYMGND*ZEJC"[N
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M6J[(H(QP!Z^^:^XRK 3PZ<JG4_"^*L]HYFXT:'PQ>YT-%(.E+7T9^=!1110
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MZT9'K7F'PW_:*\!?%C59=)\/ZUYNKQ)YIL+N%X)BG]Y5<#(]Q73^&/B)X?\
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M!]OO;:RDF("I/,J$D_PC)H TLCUI:\W^,7QJT3X+Z3H][JI:X.JW\5A;11L
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M#P[)(EW''; B_MV',3$$4_\ :3^!>J?'#2O"\6D:['X?O=!U>/5HYY8#('*
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M*)NS]F,(.-O8^]/\'>&?$?[2/Q6\<3ZMXTUW0-'M]&L+Z+3M,N6A"7;VZL9
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M=1$ZS;WIEQ\K9W[P<;?:O??&=])%XO\ A=X4;2=(UWQ]!X:$Z>(?%,H2UB3
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M= _DD_PY/&*]P\6_!'P+IGQV^ UG9^'K.UA>RN/,2)0HN!'"K()!_'SD\]:
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MWVCGV%'E@$X4>O2I:* (@O/*\?2D\I2X)0%AT8C)%344 1/'GL"#U!&:0+M
M55VCT Q4U% $2J<8Q@>E(\08C**V#P2.E344 1!3Z8]OYTBH(QA$"C_9%344
M 0F,-D%01Z'D4H7@ # '3 XJ6B@"%854G"*N?110R!G!*C/KMZ5-10!$T>\%
M64$9S\PS2A!E1C '3CBI** "BBB@ HHHH :^=IQUK@[OX2:=>?%^Q^(CW5TN
MJ6FFMIB6RD>28RV[<1C.:[ZB@#Q[3_V9O#%OKOQ.U&ZFO+]/B!M&IVDS#RXP
MJ;1Y>!D=<_A7G\_[#=EJ_P#PB\.N_$'Q+K.G^%[B.;2+.9HUCA"$%5;"Y?&
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MOW(W<!G^@[TZ_P!1MM.MFGNIX[>%>LDC!5'XFBZ(Y7IIN6<_2DR:PE\<:"2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5QOQAUC^P_ACXCO5\00^%VBM&VZQ,NY;4GC?CN1V'K78MTKD/BI\.+#XL^ -
M8\*:H\D-GJ4/E-+%C?$<@AU[9! /- 'P;J7CV^^'/BCX=>)_"VK^/]3CO-8M
M]/U+4_$,Q&GZJL@P=L;'<#SD#&*]9E\">(/C7^TK\5="N/B#K^@:%I26CVVG
MZ7<;-DKQ##Y] ><=#75ZO^Q=<^+Y_#)\5?$G7=;M_#<T4VFVWDQ11QM&1@L
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MY8N@1]_;V)]*Z>L#P-X0T_P!X2TCPYI,!@TW3+=;:!&.2%4=2?>M^@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C**Y964%?0CBEP
M< 8 ' HHH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img99844967_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img99844967_5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +0!0 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^0+]A_\
M8?\ BG_P4H^*?_!53XI?%+_@JI_P5_\ @O\ \*7_ ."O_P"W'^S1\.OAU^S1
M^W'XC^'/PL\-?"SX<^(_"7B+PCI.D^$?$7A+QW_8_P#8_P#PG>H:%86&A:AI
M7AS3_#FE:#IFF:#8_89Y[S^OVOP!_P""!?\ SFH_[3_?\%&__>-T '_#@O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX$\"^'/"NIZ?)X.\3:%\/O$/Q+\2^)]1U^S\8>)+31[/1+I/WD_9B_X)#?M
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M[3/@;]@CP5^Q]^S_ /#;XK?&+X_ZO\!? /[2'CSXH^-_BQX=\)>(?#/A'0/
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MA_RG7_X.*O\ O$;_ .L>>-J_?ZOP!_X)X?\ *=?_ (.*O^\1O_K'GC:OW^H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M05'_ !"X_P#!"C_HQG_S9G]L/_Z(*@#]_J*_ '_B%Q_X(4?]&,_^;,_MA_\
MT05'_$+C_P $*/\ HQG_ ,V9_;#_ /H@J /W^HK\ ?\ B%Q_X(4?]&,_^;,_
MMA__ $05'_$+C_P0H_Z,9_\ -F?VP_\ Z(*@#]_J*_ '_B%Q_P""%'_1C/\
MYLS^V'_]$%1_Q"X_\$*/^C&?_-F?VP__ *(*@#]_J*_ '_B%Q_X(4?\ 1C/_
M )LS^V'_ /1!4?\ $+C_ ,$*/^C&?_-F?VP__H@J /W^HK\ ?^(7'_@A1_T8
MS_YLS^V'_P#1!5^=O_!1C_@WZ_X)#_LZ>'_V1]0^#W[(-GX7N_BY^WA^S?\
M CX@2WGQL_:/\7#6_A9\2+WQ-!XR\.6\7C7XP>(H=!N]5BTRR6'Q1X<CTCQ=
MHYA9M$U[37FG:4 _L0HK\ ?^(7'_ ((4?]&,_P#FS/[8?_T05'_$+C_P0H_Z
M,9_\V9_;#_\ H@J /W^HK\ ?^(7'_@A1_P!&,_\ FS/[8?\ ]$%1_P 0N/\
MP0H_Z,9_\V9_;#_^B"H _?ZBOP!_XA<?^"%'_1C/_FS/[8?_ -$%1_Q"X_\
M!"C_ *,9_P#-F?VP_P#Z(*@#]_J*_ '_ (A<?^"%'_1C/_FS/[8?_P!$%1_Q
M"X_\$*/^C&?_ #9G]L/_ .B"H _?ZBOP!_XA<?\ @A1_T8S_ .;,_MA__1!4
M?\0N/_!"C_HQG_S9G]L/_P"B"H _?ZBOP!_XA<?^"%'_ $8S_P";,_MA_P#T
M05'_ !"X_P#!"C_HQG_S9G]L/_Z(*@#]_J*_ '_B%Q_X(4?]&,_^;,_MA_\
MT05'_$+C_P $*/\ HQG_ ,V9_;#_ /H@J #_ ()X?\IU_P#@XJ_[Q&_^L>>-
MJ_?ZO@#]AC_@EQ^PG_P37_X6C_PQ3\#/^%+_ /"Z/^$)_P"%E_\ %S?C%\1O
M^$E_X5S_ ,)=_P (;_R5GX@^._['_L?_ (3OQ7_R /[*_M#^U?\ B:_;OL.F
M_8_O^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)_8%_P"CX?V0/_$EO@Q_\VM'_#O;]@7_ *,>_9 _\1I^#'_S%4?\.]OV!?\
MHQ[]D#_Q&GX,?_,50 ?\/"?V!?\ H^']D#_Q);X,?_-K1_P\)_8%_P"CX?V0
M/_$EO@Q_\VM'_#O;]@7_ *,>_9 _\1I^#'_S%4?\.]OV!?\ HQ[]D#_Q&GX,
M?_,50 ?\/"?V!?\ H^']D#_Q);X,?_-K1_P\)_8%_P"CX?V0/_$EO@Q_\VM'
M_#O;]@7_ *,>_9 _\1I^#'_S%4?\.]OV!?\ HQ[]D#_Q&GX,?_,50 ?\/"?V
M!?\ H^']D#_Q);X,?_-K1_P\)_8%_P"CX?V0/_$EO@Q_\VM'_#O;]@7_ *,>
M_9 _\1I^#'_S%4?\.]OV!?\ HQ[]D#_Q&GX,?_,50 ?\/"?V!?\ H^']D#_Q
M);X,?_-K1_P\)_8%_P"CX?V0/_$EO@Q_\VM'_#O;]@7_ *,>_9 _\1I^#'_S
M%5^6/_!53]CC]D3X=^&/V'[CX?\ [*W[.'@:?Q9_P4D_90\"^*I_!WP.^&/A
MF;Q-X(\1ZAXN3Q#X.\02:+X7LGUGPKKJ6ULFL^'M1:YTC5%MX%OK.<11A0#]
M3O\ AX3^P+_T?#^R!_XDM\&/_FUH_P"'A/[ O_1\/[('_B2WP8_^;6C_ (=[
M?L"_]&/?L@?^(T_!C_YBJ/\ AWM^P+_T8]^R!_XC3\&/_F*H /\ AX3^P+_T
M?#^R!_XDM\&/_FUH_P"'A/[ O_1\/[('_B2WP8_^;6C_ (=[?L"_]&/?L@?^
M(T_!C_YBJ/\ AWM^P+_T8]^R!_XC3\&/_F*H /\ AX3^P+_T?#^R!_XDM\&/
M_FUH_P"'A/[ O_1\/[('_B2WP8_^;6C_ (=[?L"_]&/?L@?^(T_!C_YBJ/\
MAWM^P+_T8]^R!_XC3\&/_F*H /\ AX3^P+_T?#^R!_XDM\&/_FUH_P"'A/[
MO_1\/[('_B2WP8_^;6C_ (=[?L"_]&/?L@?^(T_!C_YBJ/\ AWM^P+_T8]^R
M!_XC3\&/_F*H /\ AX3^P+_T?#^R!_XDM\&/_FUH_P"'A/[ O_1\/[('_B2W
MP8_^;6C_ (=[?L"_]&/?L@?^(T_!C_YBJ/\ AWM^P+_T8]^R!_XC3\&/_F*H
M /\ AX3^P+_T?#^R!_XDM\&/_FUH_P"'A/[ O_1\/[('_B2WP8_^;6C_ (=[
M?L"_]&/?L@?^(T_!C_YBJ/\ AWM^P+_T8]^R!_XC3\&/_F*H /\ AX3^P+_T
M?#^R!_XDM\&/_FUH_P"'A/[ O_1\/[('_B2WP8_^;6C_ (=[?L"_]&/?L@?^
M(T_!C_YBJ/\ AWM^P+_T8]^R!_XC3\&/_F*H /\ AX3^P+_T?#^R!_XDM\&/
M_FUH_P"'A/[ O_1\/[('_B2WP8_^;6C_ (=[?L"_]&/?L@?^(T_!C_YBJ_+'
M_@BG^QQ^R)\5?^"97[-'CWXH?LK?LX?$CQUKW_"Y/[<\:>/?@=\,?&'BS6?[
M+_: ^*NC:9_:WB/Q#X7U'6-1_L[1].T_2;'[9>3?9--L;.QM_+M;6") #]3O
M^'A/[ O_ $?#^R!_XDM\&/\ YM:/^'A/[ O_ $?#^R!_XDM\&/\ YM:/^'>W
M[ O_ $8]^R!_XC3\&/\ YBJ/^'>W[ O_ $8]^R!_XC3\&/\ YBJ #_AX3^P+
M_P!'P_L@?^)+?!C_ .;6C_AX3^P+_P!'P_L@?^)+?!C_ .;6C_AWM^P+_P!&
M/?L@?^(T_!C_ .8JC_AWM^P+_P!&/?L@?^(T_!C_ .8J@ _X>$_L"_\ 1\/[
M('_B2WP8_P#FUH_X>$_L"_\ 1\/[('_B2WP8_P#FUH_X=[?L"_\ 1CW[('_B
M-/P8_P#F*H_X=[?L"_\ 1CW[('_B-/P8_P#F*H /^'A/[ O_ $?#^R!_XDM\
M&/\ YM:/^'A/[ O_ $?#^R!_XDM\&/\ YM:/^'>W[ O_ $8]^R!_XC3\&/\
MYBJ/^'>W[ O_ $8]^R!_XC3\&/\ YBJ #_AX3^P+_P!'P_L@?^)+?!C_ .;6
MC_AX3^P+_P!'P_L@?^)+?!C_ .;6C_AWM^P+_P!&/?L@?^(T_!C_ .8JC_AW
MM^P+_P!&/?L@?^(T_!C_ .8J@ _X>$_L"_\ 1\/[('_B2WP8_P#FUH_X>$_L
M"_\ 1\/[('_B2WP8_P#FUH_X=[?L"_\ 1CW[('_B-/P8_P#F*H_X=[?L"_\
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M_-K1_P /"?V!?^CX?V0/_$EO@Q_\VM'_  [V_8%_Z,>_9 _\1I^#'_S%4?\
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M_-K1_P /"?V!?^CX?V0/_$EO@Q_\VM'_  [V_8%_Z,>_9 _\1I^#'_S%4?\
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MQ_\ -K1_P[V_8%_Z,>_9 _\ $:?@Q_\ ,51_P[V_8%_Z,>_9 _\ $:?@Q_\
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M_P 1I^#'_P Q5 !_P\)_8%_Z/A_9 _\ $EO@Q_\ -K1_P\)_8%_Z/A_9 _\
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M0/\ Q);X,?\ S:T?\.]OV!?^C'OV0/\ Q&GX,?\ S%4?\.]OV!?^C'OV0/\
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M]D#_ ,1I^#'_ ,Q5'_#O;]@7_HQ[]D#_ ,1I^#'_ ,Q5 !_P\)_8%_Z/A_9
M_P#$EO@Q_P#-K1_P\)_8%_Z/A_9 _P#$EO@Q_P#-K1_P[V_8%_Z,>_9 _P#$
M:?@Q_P#,51_P[V_8%_Z,>_9 _P#$:?@Q_P#,50 ?\/"?V!?^CX?V0/\ Q);X
M,?\ S:T?\/"?V!?^CX?V0/\ Q);X,?\ S:U^6/\ P6L_8X_9$^%7_!,K]I?Q
M[\+_ -E;]G#X;^.M!_X4W_8?C3P%\#OACX/\6:-_:G[0'PJT;4_[)\1^'O"^
MG:QIW]HZ/J.H:3??8[R'[7IM]>6-QYEK=3Q/^IW_  [V_8%_Z,>_9 _\1I^#
M'_S%4 '_  \)_8%_Z/A_9 _\26^#'_S:T?\ #PG]@7_H^']D#_Q);X,?_-K1
M_P .]OV!?^C'OV0/_$:?@Q_\Q5'_  [V_8%_Z,>_9 _\1I^#'_S%4 '_  \)
M_8%_Z/A_9 _\26^#'_S:T?\ #PG]@7_H^']D#_Q);X,?_-K1_P .]OV!?^C'
MOV0/_$:?@Q_\Q5'_  [V_8%_Z,>_9 _\1I^#'_S%4 '_  \)_8%_Z/A_9 _\
M26^#'_S:T?\ #PG]@7_H^']D#_Q);X,?_-K1_P .]OV!?^C'OV0/_$:?@Q_\
MQ5'_  [V_8%_Z,>_9 _\1I^#'_S%4 '_  \)_8%_Z/A_9 _\26^#'_S:T?\
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M>&M-OK\F]O+'1;>RM;F[/VF:)YOGK]3O^'>W[ O_ $8]^R!_XC3\&/\ YBJ
M#_AX3^P+_P!'P_L@?^)+?!C_ .;6C_AX3^P+_P!'P_L@?^)+?!C_ .;6C_AW
MM^P+_P!&/?L@?^(T_!C_ .8JC_AWM^P+_P!&/?L@?^(T_!C_ .8J@ _X>$_L
M"_\ 1\/[('_B2WP8_P#FUH_X>$_L"_\ 1\/[('_B2WP8_P#FUH_X=[?L"_\
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MC_YM:/\ AWM^P+_T8]^R!_XC3\&/_F*H_P"'>W[ O_1CW[('_B-/P8_^8J@
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MK_E$]^U9_P!T,_\ 6DO@]7Z_5^0/_!>K_E$]^U9_W0S_ -:2^#U 'Z_4444
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M /Q-U^_U% 'X _\ #@O_ *S4?\%_O_%C?_XFZ/\ AP7_ -9J/^"_W_BQO_\
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MHHH **** /Y OV'_ -A_XI_\%*/BG_P54^*7Q2_X*J?\%?\ X+_\*7_X*_\
M[<?[-'PZ^'7[-'[<?B/X<_"SPU\+/ASXC\)>(O".DZ3X1\1>$O'?]C_V/_PG
M>H:%86&A:AI7AS3_  YI6@Z9IF@V/V&>>\^__P#AP7_UFH_X+_?^+&__ ,3=
M'_! O_G-1_VG^_X*-_\ O&Z_?Z@#\ ?^'!?_ %FH_P""_P!_XL;_ /Q-T?\
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M7^_\6-__ (FZ/^'!?_6:C_@O]_XL;_\ Q-U^_P!10!^ /_#@O_K-1_P7^_\
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M .)NOW^HH _ '_AP7_UFH_X+_?\ BQO_ /$W6/XA_P"#>K0/%V@:YX4\5_\
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M_P#E.=\%_P#M'#\1O_5[6M?K]7Y ^,_^4YWP7_[1P_$;_P!7M:T ?K]1110
M4444 ?RA0_LN_%/_ (*)?\%G/^"RGPM\6?\ !1__ (*?_LS_  R_9/\ ^'>/
M_"I/AU^QU^V!XC^#/@2Q_P"%Z_LJ'Q%X]^V>$=2\/^-O#]M]I\0>";;7;?\
MX1G3_#GG:QKWB?4]9_M>]U2.>T^O_P#AP7_UFH_X+_?^+&__ ,3='_!/#_E.
MO_P<5?\ >(W_ -8\\;5^_P!0!^ /_#@O_K-1_P %_O\ Q8W_ /B;H_X<%_\
M6:C_ (+_ '_BQO\ _$W7[_44 ?@#_P ."_\ K-1_P7^_\6-__B;H_P"'!?\
MUFH_X+_?^+&__P 3=?O]10!^ /\ PX+_ .LU'_!?[_Q8W_\ B;H_X<%_]9J/
M^"_W_BQO_P#$W7[_ %% 'X _\."_^LU'_!?[_P 6-_\ XFZ/^'!?_6:C_@O]
M_P"+&_\ \3=?O]10!_.CX]_X-R/ /Q5\)ZMX"^*'_!7#_@N=\2/ NO?8?[<\
M%^/?V]M%\8>$]9_LO4K/6=,_M;PYXA^!VHZ/J/\ 9VL:=I^K6/VRSF^R:E8V
M=];^7=6L$J=A_P ."_\ K-1_P7^_\6-__B;K]_J* /P!_P"'!?\ UFH_X+_?
M^+&__P 3='_#@O\ ZS4?\%_O_%C?_P")NOW^HH _ '_AP7_UFH_X+_?^+&__
M ,3='_#@O_K-1_P7^_\ %C?_ .)NOW^HH _ '_AP7_UFH_X+_?\ BQO_ /$W
M1_PX+_ZS4?\ !?[_ ,6-_P#XFZ_?ZB@#\ ?^'!?_ %FH_P""_P!_XL;_ /Q-
MT?\ #@O_ *S4?\%_O_%C?_XFZ_?ZB@#\ ?\ AP7_ -9J/^"_W_BQO_\ $W7G
M_P#P1O\ #7Q3^!W_  4G_P""U?['7BS]K7]K_P#:P^&7[,__  [A_P"%2:[^
MV+\>?$?QU\=^'?\ A<WP%^*'Q2\>_8]3U*#2/#^D?VOX@U>VL[C_ (1GPQH/
MV_1_#GABWUG^U+W2(]0E_H^K\ ?^">'_ "G7_P"#BK_O$;_ZQYXVH _?ZBBB
M@ HHHH _('_@GG_R>Y_P5Z_[.0^$7_JI$K]?J_('_@GG_P GN?\ !7K_ +.0
M^$7_ *J1*_7Z@ HHHH *_D"_8?\ V'_BG_P4H^*?_!53XI?%+_@JI_P5_P#@
MO_PI?_@K_P#MQ_LT?#KX=?LT?MQ^(_AS\+/#7PL^'/B/PEXB\(Z3I/A'Q%X2
M\=_V/_8__"=ZAH5A8:%J&E>'-/\ #FE:#IFF:#8_89Y[S^OVOP!_X(%_\YJ/
M^T_W_!1O_P!XW0 ?\."_^LU'_!?[_P 6-_\ XFZ/^'!?_6:C_@O]_P"+&_\
M\3=?O]10!^ /_#@O_K-1_P %_O\ Q8W_ /B;H_X<%_\ 6:C_ (+_ '_BQO\
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MI92J(ID<LQ55!.% 'Z_5^0/_  1K_P"23?MA_P#:1[]KS_U)= H _7ZBBB@
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MG5O#&F67BC7/!EW8J!HK>&9[/Q->W]Y;:%JX!5T'_@N_^WQ\2_@I^R<_PD^
MW[,^I?M%?\%-?VP_C[\.?V"K;Q]I?Q<\(_"/PO\ LE_!G6[708OC+^T''I/C
MKQ7XR\1^*K^^>[FNK/P/<^#+2?P[:7?B?2?#]PD.G:1KGD7[,'Q0_:^\ _\
M!=O_ (*8?$K]JSP1\!/#_P"TU\)/^"05IXEOHO@AXC\;>+_@'XXO_!+?#KQ/
MX;\4>&[;QC:>%OB/H7AW6YX([#6/!WB&Z.OZ5=6&IPVGB?4K*XTS6IOV/_:E
M_P""+?@[XP?L\?L$_#+]G3X^>*?V2?C;_P $U)?!DW[)_P"T+HG@3PW\59O#
M)\/^&O#WA?Q+;>-/AIXDO_#_ (?\=V?CBV\,Z5J^N07>J:9%<^(;.*YU*/5M
M#N];\.ZSYK\ O^")?Q0^&O[2W[4?[5WQM_X*#^/?VH_B]^UG^Q1K'[)_Q%U[
MQY\"O!'@H:3XDUN'1[27XA>#-(^'?BS0_"GAOP'I5EH=E!H/P:L/#,<UE++?
MWE[\3-4N[Z::@#\ZO!?_  7S_P""E.F_\$\OAA^W]\5_V6?V3-4T/]J+4/"7
M[.'[('PQ^'7BSXD:7X^^)_[7/BOXC^*_#G_"7^--/USQ+XCT#P'^SYIWASP=
MXDM[/PI_PEVK?$G7/%ND:5]N\3^%-!\8_:O"?Z#_ +.'_!1G_@HE\)/^"@_P
M/_X)Z?\ !5'X3_L@V/B[]K7X5_$#XB_LY_%S]B#6OB[=^"X=?^%^FWFO^+?A
MO\2O#/QFO+_Q-:ZE%X<T?6=23Q9I,T'A^.^;0-&T^+7QJ>KZIX:ZFU_X(3?#
M75O^"2'P6_X)<_$#X[^*M9U?]GSQ$OQ'^$G[3O@CP=;^ _%'@[XP:1X_\:>.
MO!_C[3OA_?>+/&NG/#H\?C74_#&K^'[[Q7>?VUHMSJ,^GZOX;UFXTS4]%ZS]
ME_\ X)(_%_PG^V3X(_;Q_;V_;V\7?M^_M!?!CX;:_P#"[]GQY/@%\._V:OAM
M\)-'\86$NF>,?$EK\/?A]KOB>QUSQ]XBL+[6[&[\3O?Z6C6&N7-K=:7>+I/A
M9_#X!^/=I_P7,_X+*>-?V*/VKOVZ_AM^S;_P3Q;X*?L4_M)_$[X9?%&X\8>(
M_CY9_$'XH>!/!_BGP9HT-O\ "_X<:3XEN]%\-^(_"VF>)TU#Q;XS\:_%>XLO
M$1N6'A'X8Q3Z(-/\1_8OCG]J3X=_%#_@M'_P1D^),?[/OPLEU+]HW_@GO\6_
MC)I'Q?\ $MY\6K_XP?"7PMX@^&/BSQ\_@OPFFA?$;PS\)=3L9(;NYT[5-4\9
M?!GQ3XE6&_UC_A&M4\._V@$B^@?AS_P0W_X0#_@F?^W+_P $[/\ AJ#^UO\
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M!-E'X@UL:%IMIXRUA/#KZM=6UI'<:%::%H>B_II\8?\ @G(OQ9_X*7_L??\
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MW^K\ ?\ @@7_ ,YJ/^T_W_!1O_WC=?O]0 4444 %%%% !1110 4444 %%%%
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M_P '%7_>(W_UCSQM7[_4 %%%?R>:?^TW_P %8O\ @H?^T#_P4R\0_LJ?M]?
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MB'QOXA\#^%'U$7VF>'K<Z=;RP@']2=%?Q%:C_P %#O\ @L[^SO\ L#?L^?\
M!;?XQ_MD?!#XQ_L__&#XC_#S5O'W_!/'0?V9/ /A#P_X0^#'Q2\=WOAZPL/A
MQ^T;I-Q<_%&]\?:7I4%@+6Q\;2WUCX<U/4[XZ_K7CA_#O]F:][++^U9_P6+_
M &I?CU_P7 \%_L]?M[_#C]G+X9_\$_/&<?BCX21^(/V3/A3\6/B#=Z;9_#SX
M@^++#X066O:K!I?AG0/!6O?\(KN\2^._&GA#XR_$&QU#^S3X=^RZ=;ZI8ZR
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M_P#P<5?]XC?_ %CSQM7[_4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8=?CU'6+SQ3?6?B--7\/0P:KK*Z-%H7@#O/^"9?[>W_!03]E;]GW_@AG\/\
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M--\-ZQJ?BF\^+NH:UJ@U/Q79>#- T..RT6Y_6+]C_P#;V_;XOO\ @IM\3?\
M@G;^WE\,/V3]!U1_V2K3]L;X3>+?V5]>^*VK6.A>#9?B9IOPWOOAS\1M2^*K
M6<GBOQ7I^IZE.I\5>&_#/@G0[J'15U&+1577QIWA\ _=.BOY$]5_X+__ +4G
MA;XS?#CQ+?:3^QO\3?V8OB)^W+HO[*I\%? KP;^U/\0_'/AGP'XN\7KX-\/?
M$=OVY-&&J?L,^+?&=E<75EK.I?#'0I(+G58S=Z#H^MK?:=K6H:-]66'_  4;
M_P""M'[4OQ3_ &R/%G_!/']F;]CCXA?LX?L3?M,^)/V5]6^%GQO\>?$+PC^T
M]^TI\0?A9/I+_%2\^%_CRWU[0?@?\)-)ELO$.EGP8_Q-TW6XY%@N;S5+MIYQ
MHMD ?T@45_.G_P %(?\ @KE^U9\"?VJO@S^Q3^R9\!=+O/C5XG_9K3]J7XO:
MMX[_ &?OVF_VOX? ?A;4/%$O@72_A_I/PJ_8F:\\:7VMVOBBVNO^$F^)=[KT
M?PVTBW&E:=9W&K:KXATY4ROAE_P5_P#VRO%'B?\ X).^"_BU^R=:?LW>,_VR
M_P!H[]HWX!_M$^"_C!\,OCEX,\16NG?!/P+;>*?"_P 3O@1I/Q)/PP\6>'O"
MOQ'%Y9ZQ9)\1?!GBZ73K.>]\,--<:OHEYK$X!_2#2,RJ,LP4$JH+$ ;F8*JY
M/=F(51U+$ 9) K^3/_@H'_P49_;W^)/[.G_!>_X?_ O6?@U\'[C_ ()Z^,_A
MSX1\+?$O0YOC-X)^+<?P7\7_  MUCQ?\0-=\->-/!_Q!F>R^.^G:S#HR?#[7
MM.L?"?A2QT_^U8=:TV\NI;6]A@_:H^)/Q_@_X)"?\$M?%O[>/P__ &8_VE?B
M/\0_VSO^"?%MIK6NJ?M,?\(S'X4\<6%E<>!?B1XGU*#XO>!?'7B7X_Z187-Q
M?^+KWQ%X@\1_"WQ%XHNKZ_U+P-K5A<I86X!_6I17\W]A_P %&_\ @K1^U+\4
M_P!LCQ9_P3Q_9F_8X^(7[.'[$W[3/B3]E?5OA9\;_'GQ"\(_M/?M*?$'X63Z
M2_Q4O/A?X\M]>T'X'_"329;+Q#I9\&/\3=-UN.18+F\U2[:><:+9>U_\%'O^
M"D/[1W[.WQ8_9U^!_P #+K]E?X:>._BA\)_$WQ9^(>D_'SPO\=OVJ/BQX>33
M;?R='\)>#_V7OV)M2OOC'K]E+K5CKVEZI\7-]S\.)+[2;G1_#LVN:S"UI( ?
MNK17\8>F?MW>)O\ @HY\9/\ @VT_:;\=> ](^''Q U/]L/\ ;>^'_C[PSX;?
M7CX5'B[X8_#Z_P#!>J:QX6MO%EM9^+M*T+7QI4&LVF@>*[9/$7AN2]GT#5+C
M4;C33JE[_9Y0 4444 ?@#_P:X_\ *"C]AG_NYG_UL/\ :"K]_J_ '_@UQ_Y0
M4?L,_P#=S/\ ZV'^T%7[_4 %%%% 'Y _MP?\I-?^"-G_ &.'[;'_ *S_ *+7
MZ_5^0/[<'_*37_@C9_V.'[;'_K/^BU^OU !1110 5^ /_!0__E.O_P &ZO\
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M>_OIUM/AS!\4=7U_X@1:!Y-Q%*D?BK6M3U1+N2Z5[R:(1-0!]2T444 %%%%
M'X _\%#_ /E.O_P;J_\ >7+_ -8\\$U^_P!7X _\%#_^4Z__  ;J_P#>7+_U
MCSP37[_4 %%%% !7Y ^,_P#E.=\%_P#M'#\1O_5[6M?K]7Y ^,_^4YWP7_[1
MP_$;_P!7M:T ?K]1110 4444 ?@#_P $\/\ E.O_ ,'%7_>(W_UCSQM7[_5^
M /\ P3P_Y3K_ /!Q5_WB-_\ 6//&U?O]0 4444 %%%% !1110 4444 %%%%
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M#_P0+_YS4?\ :?[_ (*-_P#O&Z_?ZOP!_P""!?\ SFH_[3_?\%&__>-U^_U
M!1110 5^0/\ P1=_Y-Z_:%_[/N_:P_\ 4WM:_7ZOR!_X(N_\F]?M"_\ 9]W[
M6'_J;VM 'Z_4444 %%%% !1110 4444 %%%% 'X _P#!/#_E.O\ \'%7_>(W
M_P!8\\;5^_U?@#_P3P_Y3K_\'%7_ 'B-_P#6//&U?O\ 4 ?YP/\ P4M\;?LH
M_M0?%[_@M!\8=<T7X*W7Q1_9Y\6>+?@UX(\=_M^_\%"/%GA3XZ^#_'?PHT;4
MK#1],_X)V_L;_!KX5>%Y=.T%O&OA9E\/6OQ!^(WB*7Q7K20:OK&J+'<_$CPD
M?HSP;X%@_;X_;(_X-M_!_P"TKXR^*OB?3/C%_P $I?B5%\8-3\-?%KXC> /&
MOQ2TO3? 'C8:KH7C7XD>#/$NB_$34=+\;II,$'Q %OXILK_Q?;7&HVVJW\MO
MJ-['-_;!XG_8T_9 \;_$'Q+\6O&G[*?[-OB[XJ^-/#.H^"_&/Q,\3_ SX8:_
M\0?%G@[6-&/AS5_"?B7QGJOA>[\1Z[X9U3P\S:#J.@ZIJ5UI=]HS'2[FUEL2
M8*V_#_[+7[,?A/7OA;XJ\+?LY_ CPUXH^!WA.\\!_!3Q)X?^$/P^T;7O@_X&
MU&WN;34/!GPMUC3O#UMJ'P_\)W]K>WEM>>'?"=QI&CW5O=W,,]F\<\JN ?PN
M^';GXP?L/_L:?\'1W[,W[#GB'X@^#/AS^RI\;_AHOP0\-6'B[QGXAUOX+_#/
MXEZ]JFG?&^Z\!:]?:M>Z_HTNF?#*PN[B?Q7+J$GB*RT_P\/$NJZ]?Z]8OK$G
ME_BGX9?\$G?A5^T?_P &\=E_P3J^..B^./B7X\_:M^!/Q!_:6\%^#_VD?&/Q
MCM]1\6:G;?"L7?Q*^+GP\U7QUXX\-_"3XR7'B*?6-(O-(L[3P+K*VUYK.AW'
MAVYTS0+%-$_T%/"_P)^"'@?7_B?XK\%?!OX5>$/%/QMOH=3^,_B7PO\ #SPC
MX?U_XNZE;VU[9V^H?$_6=)T>TU'Q]?06>I:C:PW?BNYU:XBMK^]@218KJ=)/
M)?"/[!G[#7P_A\/6W@/]C']E#P3;^$?B%9?%OPG;^$?V=?A!X;A\,?%;3;1+
M#3OB;X>BT;P?9)HOQ"L+&..RLO&FFK;>)+6TC2V@U*.%50 'XF?\'8<$MU_P
M2JL+:"_U#2IKC]K;]FR"'4](NFL=5TZ6;Q#K$<=_IEZ@9[/4+-V%Q972JS6]
MS'%*H)0"OS?^*G_!+S]F/X9?\%_/V7_V4/ &L_M(^%O@E^VC^Q5\4/'O[86A
M:?\ M6_M#2>*/VF_$/@^_P#'NN._Q;^)M]\1+OXFZKI_BO6?"V@:EXNTO1_%
M^AV-_/I[1Z?#I5KJ6KV^H?V;_%?X+_!WX\^%D\#?'+X3_#3XS>"8]8TSQ#'X
M/^*_@3PM\1/"T>OZ)*\^C:XGA_Q?I6L:2NL:1-))-IFIK:"]L)7>2UGB=F)9
MJ7P3^#.L_%'PQ\<=7^$GPQU7XU>"?#VH>$?!GQ@U+P%X5OOBCX1\*:N+P:KX
M8\,?$"ZTF7Q9H/A[4QJ%^-0T72M6M--O1?7@N;:7[3-O /X3?AAK/QU_8Q_8
M%_X.<_V?_P!A[Q-\4O#'A+]C[]IO1-$_9V\.:%XN\6:_X@^!7PP\4>,=0LOC
M)JGP_P!>O+G5?%6E/I/PSTC4M9O]>&K1ZEI::-=^-)]6&OQ:AJU[XA^PG\ ?
MAAX7_:G_ ."==G\(OVAO^"8?@[3?VL?#NN?"C]H[X0_LE?MB_P#!1']I3XV_
MML_!7XI> I[3XIZ'^T=\.'^%/B7P]\(O'NC6]_XO\3VWB7QEXA^!.@^"/'=M
MX@\W6K ?#K3X/"7^@_X*^"'P6^&VN?$?Q/\ #KX0_"_P#XE^,>N#Q/\ %WQ#
MX*\ >%/"NN?%3Q*J7<:^(?B/JVA:387_ (XUP1ZA?QC5O$]QJE^$O;M1<;;F
M8/YW\(_V,OV/OV?_ !=K/Q ^ W[*/[-?P2\>>(K6ZL?$'C;X1_ OX7_#;Q=K
MME>W:W][9ZSXD\&^%M%UG4[6[OE6]NK>]O9XKB[5;F5'F >@#^+'_@B9^S;^
MPI\'[7_@NI9Z+IO@[P=^V7\&/&O_  4,^ _PL\!:M\6/%J_%+0OV.O#WANVM
MK2RM/A/XB\<3R^)/"FE>*-(L-/OOB7J_A36_$EOJ20:;J?B\/?+;W/PA??LA
M_"GX0_\ !OY_P3:_X*?^"=9^,-G^VQX(_:4^'^D^"?BY>_'+XL:E;^"/ US^
MT!\6=%/PS\"^ ;KQ:_P[\#>!D>PM]::T\'^%M#UN[UN34;K4-=O+?6M;M-1_
MT66_99_9B;XD^,?C*W[.7P';XO\ Q$\*ZCX%^('Q6;X0_#X_$GQUX)UBVM+/
M5_!WC'QR?#W_  E'B?PKJEI86-KJ/A[6]4OM(OK:RM(+FSEBMH52C>?LB_LH
M:A\'_#_[/5_^S%^SS?? 'PGJ=MK7A7X'7GP6^&US\'_#6LV6IWNMV>K>'_AG
M-X:?P7HVIVFLZEJ.KVU_IVB6UU!J=_>W\4J7=U/+( ?R7_M?^"OV-_VM?^"Z
MW[57P;_X+3_%2Q\(?LM_!?\ 9,^$?C7]AWX:_%OX_P#B']G/X)ZR?$^B:#??
M%KXE^%]>TOQE\-#XE^(&F>)X/&&FRI::WJ-UJ.G:3K>FZO!K>F?#K3(]%_(S
MP3\8/'?QB_9>_P""9WP*_;,^-_Q)NO\ @COXO_X*L?M6?!N;XN_$CQYXM\#V
MWQ4_9D^'UAX O/V??#WQ>^,1U;P9K)^&<OB/5OC%I,>I:W?^'E\,V'AG56LO
M[#@^%N@KX?\ ]$[XV_LJ_LO_ +3%OX>M?VC_ -F_X"?M VOA&6[G\*6WQM^#
MWP]^*UOX8FOTACOIO#T/COP[KT>BRWL=M;QW<FFK;/<I!"DQ=8D"[?C3]GKX
M _$CX6Q? WXB? [X/^/?@G;V^DVD'P>\:?#/P7XI^%L-IH$T-SH5K%\/M<T2
M^\)1V^BW%O!/I,*:0L>FS00RV:PO&C* ?Q0?L(Z3^Q+\/_\ @L;_ ,%4O#'[
M"W[36I:#^RAX#_X)(ZUHOA7XX?#GXG^,_P!I/2_V>(]*B^&TGB/4?@MXQU;6
M/'FO>*]"^%%V]QXN\-:!X?\ $?BNQL->2_T#PY<0QP0:/IOR+_P39T;X=_L<
M_MO?\$SM3N;G]G3]HN^_:$^+?B#P-X _;2_X)O\ [:7Q,;XQ_&4>-;B[DU23
M]OC]ESX\#Q-XL\8Z5:7=T9?B)9:5X:^$6F?#>.^N$CU[4O$7AO1M%U7_ $!_
MAY^S!^S5\(_$=EXP^%'[//P-^&/B[3?A_IOPFT[Q3\//A+X!\%^([#X5Z->1
MZAH_PTLM;\-^']-U.U^'^DW\45]IO@V"ZC\.6-Y''<VNFQ3(KCFOAM^Q;^QS
M\&?B!J/Q9^#_ .R;^S/\*?BGJYU$ZM\2_AM\"/A;X%^(&J'6#*VKG4?&7A?P
MKI?B.].JM/.=1^TZE+]N,TIN?-,CY /QL_X.=_B#\6? 7_!.CPM;>!O&WC[X
M9?"?XA?M4? OX9?M;?$GX:7%Y8>*/!O[,'C&]UZQ\=7G]KV-K+-HVCZIKJ>$
M] U6Z>YM;358]4A\(ZE'J.D^)M0TVY_#^\_97_X)N:-_P4S^&'["?_!,;Q1I
M_P :/V$_VE_V'?C[XB_X*+?!3X2_M.?$GXW?!1+#P+X>O?'7P1^*&M^-]*^)
MFNW/@SXA7?Q*\/\ PX@%WX<\>6FH0:5=:+H,6A:/X<^(>IVOBW^\_P 2>&O#
MGC+P_K7A/Q?H&B>*_"OB33+W1/$7AGQ)I5CKGA_7]&U*WDM-1TC6M&U2"ZT[
M5=,O[666VO;"^MI[2ZMY)(9XI(W93XU\&_V3?V6/V=--\1Z+^SY^S1^S_P#
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M* "OR!_X+*?\DF_8\_[2/?LA_P#J2Z_7Z_5^0/\ P64_Y)-^QY_VD>_9#_\
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M5HUYIM]'I6L7]S\4D\06WB:XTG2-5F@T^YN-/^'][<74]Q:R:3::C:7=K<S
M'4_%W_@WE_9,^+D?[5GAR;]H[]O/X??"#]L3XD>)/C/\6?V?/AE^T+HOASX*
M#XQ>+M0\.ZIXA^)&F^&;WX::UK&MZKJ-]X;M;AO#GQ'\1^/OA];S3)-:^#8)
M]"\(R^'/T$^!G_!/WX-?L_?M/?&G]K'P;XF^)NI_$7XZ_"#X&?!7Q=HOB;6?
M"M[X*T[PM^S_ .'3X9\&W_AS3M*\&:+KMIX@U.P/G>)KK4_$>KZ=>WG[S2M*
MT6'_ $>OKOP%X[\'?%'P/X/^)7P[\2:3XQ\ _$#PQH7C3P5XMT&[CO\ 1/$W
MA7Q-IEMK.@:]I-[$3'=:=JVEWEK?6<ZX$D$Z-@$D#K* /QV/_!$C]E1OV$(/
M^">I^('[0?\ PI>#]H'_ (:03Q./%?PX_P"%H'QQ_P +7D^,/]E-K7_"J/\
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M>*I[GPEXHU_1]"LK^U9+75_AEKWP\\8P13K/%XF74=+T"_TC]5** /PUL/\
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M38Z'X8TD:9X;T>$:7X9\/Z!X<T/0=#LY;H6.G1S7MY-/\:?M1_\ !"O]F?\
M:/\ C]\3/VEO!?[0_P"W5^Q?\5/CIHVEZ+^T#??L0_M)7/P2T/X\PZ)I<>A:
M5<_%#P[J7A'QOI>JW%KHD0TZ6#2(-#TS4S+>ZIJ^GZAKNJ:IJM[^U=<EX_\
M%O\ P@/@3QIXZ_X1GQ=XT_X0SPGXB\5_\(=X T;_ (2/QWXK_P"$>TB\U;_A
M&_!?A[[39_V[XLUS[)_9GAW1_MEK_:>KW5G9?:8/.\U0#\X6_P""0/[)FA_L
M7?"+]A[X2:C\:_V>OA]\!_&.D?$OX4?$OX&_%34_!WQP\+?%'3-0U35;WXBS
M^-KRQUS2?%.N>)-0UW6[CQ%I'C/PMXB\$WG]H106GA.QMM$\-0Z+@> _^"+W
M['OA_P"$G[8_PL^*=[\8/VH-1_;YO=$OOVI_B[^T-XUT?7?BW\1G\'6HM_AQ
M##K/P^\(_#;PMX3A^%\X&I^ /^$1\'Z)/HFIQVMS+->C3].CM/T/^ WQ8E^.
MGP<^'?Q?F^&'Q9^"\GQ"\-67B5OA7\=?"<'@7XO^!Q>F3;H7Q!\'6^K:Y'X;
M\1P*BR7>DMJEW-:++''<F*X$L$7B?P%_;>^%'[1'[2/[8G[+O@KP_P#$+2_'
M_P"Q)XF^%WA7XK:QXITGPW9>#_$&H?%OP7/XZ\.3?#[4-)\6:WK6JV5EI$#V
M^MR>(_#_ (3GMM1*PV%OJ5L3>* ?-W[*7_!(OX)?LN_'+PY^T9J_Q[_:^_:L
M^+/P[^&.H_!OX,>(?VO/C+I7Q6C^!GPYUF6W.NZ%\+;#0_ O@:UTR\UVSL[3
M2-8\4:_'XD\77^BVXTN;7C:374=QV7[9O_!+SX)_ME?%+X=?M 2_%;]I;]F#
M]I+X8>$]7^'?AS]HK]D3XL1?"/XL77PQUV]FU75/AGXCO]5\,^-?#/B3P5-K
M-Q/K-MI^K^%[F\TS5)I[O2M0L7N+@2_I-10!^0^L?\$3OV-K_P#8=L_V!]*O
M_C-X7^%LGQF\+?M">,?B#IGCO2M<^.'Q0^,_AWQ?I?CC4?B#\2O'OCSPGXQL
M_$>O^-M=TBS/BZX3P[8))81IIWAZ/P[:V]G';?KQ17)>/_%O_" ^!/&GCK_A
M&?%WC3_A#/"?B+Q7_P (=X T;_A(_'?BO_A'M(O-6_X1OP7X>^TV?]N^+-<^
MR?V9X=T?[9:_VGJ]U9V7VF#SO-4 ZVBO)/@-\6)?CI\'/AW\7YOAA\6?@O)\
M0O#5EXE;X5_'7PG!X%^+_@<7IDVZ%\0?!UOJVN1^&_$<"HLEWI+:I=S6BRQQ
MW)BN!+!%ZW0 4444 ?@#_P %#_\ E.O_ ,&ZO_>7+_UCSP37[_5^ /\ P4/_
M .4Z_P#P;J_]Y<O_ %CSP37[_4 %%%% !7Y ^,_^4YWP7_[1P_$;_P!7M:U^
MOU?D#XS_ .4YWP7_ .T</Q&_]7M:T ?K]1110 4444 ?@#_P3P_Y3K_\'%7_
M 'B-_P#6//&U?O\ 5^ /_!/#_E.O_P '%7_>(W_UCSQM7[_4 %%%% !7B7[1
MW@7XR_$OX*>/? W[/GQW_P"&9?C'XATVTM? WQT_X5AX5^,__"O-1AU;3[R[
MU3_A6/C:\L/"WBW[9I5M?Z/]BUB[@@M_[2_M"-C<V<*M[;10!_*'_P $I/$O
M_!8#]HC]L?\ :[\-?'/_ (*T_P#"P/A'_P $^/VM+CX$^//AG_PP=^S!X4_X
M:7T*PT;4+R6^_P"$S\'P:)XF^#7VJ>.!_LVC3^-+R#R=JZPZ2.IPO^"=_P#P
M<.VFF?LY>!M2_;O\.?M;?%+7]?\ VJ_B=\#?'/[77@K]E?2M(_9:^#ESJGQ@
MU7PM\'/!WQ,^(_AFP^'/A0ZB?#<WA];A_ASX5^(&JV<=[IX\87$&OZA';S_K
MK_P3I_81^+O[(OQ\_P""G?Q3^)/B/X<:WX?_ &T_VNM0^/GPML_ ^K^)]2UG
M0/!UWI-W81Z;X_M]>\(>&K+2O$JS3HSV?AW4?%6EB(,RZRS (WYIM_P1(_:K
M;_@CC:?\$]1\0/V?/^%T0?MK?\-(/XG/BOXC_P#"KSX'_P"&D9_C#_92ZU_P
MJC_A*SXK_P"$9E6Q^PGP4ND?VZ#:_P!N_P!G@:F0#]%_VN/^"T'[-?[)?QQ\
M7?L\-\)OVG_VC?B3\+?!6A?$#XXV?[,GPW\(^-],^!'AGQ39RZOX8D^)>H^,
MOB3\.@FL>(?#MM=^)]*\,>#8?&'B:;P_;?;Y-(A^V:;%>_2OQ#_:N\,_$G_@
MG3\4OVR_V6_'<6J^']9_9/\ B?\ &_X*?$"+1!E+G3?AGXB\2>%M8N/#/B_2
M6$5]I.KV$']H^'O$^AO]GO[*YTO6M+?R[FU/X\?MG_\ !%SXZ>,?VY?VE?VQ
M?V<OAG_P3"_:.@_:W^'WPZT+QAX*_P""E_P5U;XE3? 'XD?#+PD? VC?$CX#
MZGI/PX^)D%_8:UHD6GZAXL\#:[9^'+37M8TZRCN]<?3[+3H;']FOV?/V1+7X
M9_L*^$/V,?B7KOA7QE"GP4UWX4?$G7_AK\)_AC\!O!VNS^.=,UFV\<W?@GX2
M?"?PEX5^&O@#1)[OQ'JRZ%HVA^%K>.*V%O=ZS_:VM3ZIJ-\ ?B-+_P %%OVR
M%_X-?HO^"B2_&+'[8S? Q?&+?&#_ (5]\+#GQ&?VAV\"G4?^%?GP1_PJT?\
M%*@:7]C'@C[!_P OWV7^T?\ 3*^Q[S_@LEX!^"'A/]BWX/\ C;X3_M0_M9_M
M?_'K]B+X;?M6^)OA]^S!\+? &N^)1X-O/!FF2>*OB+J=MXN\>?!SP7Y>L>+;
M7Q'%9^$?A_=:SKUO+:.L7A/3=,N-'-W^7LW_  1>_P""SI_8KMO^"0:_M6_\
M$_)?^"<T>L0^&)OCE_PK;XW6G[:LGP:'Q(/Q*FT)? 9BO_@:NJ_VLQM8[?\
MX2L:F;(+&WQ!67=,WV[_ ,%-/^"0?Q-_:FC^#/@SX6_"#_@G]\?O@?\ "_\
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MV5%%% !1110 5^ /_!/#_E.O_P '%7_>(W_UCSQM7[_5^ /_  3P_P"4Z_\
MP<5?]XC?_6//&U '[_4444 %%%% 'Y ?\$W?^3L?^"M__9W_ (>_]5OI]?K_
M %^0'_!-W_D['_@K?_V=_P"'O_5;Z?7Z_P! !1110 5^ /\ P0+_ .<U'_:?
M[_@HW_[QNOW^K\ ?^"!?_.:C_M/]_P %&_\ WC= '[_4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?@#_ ,$"_P#G-1_VG^_X*-_^
M\;K]_J_ '_@@7_SFH_[3_?\ !1O_ -XW7[_4 %%%% !7Y _\$7?^3>OVA?\
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MX+L=$M=)T>WU>SUB"WU2VU?3X+ :=JL-[$LZ:C:W(9I!B1P#Z-HHHH ****
M"BBB@#\ ?^"!?_.:C_M/]_P4;_\ >-U^_P!7X _\$"_^<U'_ &G^_P""C?\
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MK6E:C>>']2U33H;^U^V-*OZU_P#!";X;>$?V<_VL/^"U/[)GP<L]4\(_LY_
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MI#^PW_PT#_9@TS_AG[6?^$P/Q%_X7X#=?V@+O_A'O^$:_P"$:!MOL_\ ;/\
M:@,GV*NY^)/_  4T_P""@?P^C_:6_P"";/\ PO*"Z_X*5S?\%/O@_P#L^?LQ
M?%2[^&WP<N/%,_[&7Q^N8/BSX4^,<GPTTWX=1?##Q"G@/X->$_&VB>/M=O?
MTUCH$E_;WNK3Q^(+>SE8 _K4\:^-_!?PU\(^(_'_ ,1?%WACP#X#\':/?^(O
M%WC;QKK^E>%?"/A7P_I<#W6IZ[XC\2:[=V&C:'H^G6L<ES?ZGJ=[:V5G CS7
M$\<:LPN>&O$OASQGX=T'Q?X/\0:)XL\)>*='TWQ%X8\4>&M5L-=\.^(_#^M6
M<.HZ/KN@ZWI<]UIFKZ/JVGW-O?:;J>GW-Q97]G/#=6L\L$J.W\5/[7O[1?\
MP4(_;0_9-_X+S_%)OVQ?AA\+/V9_V//%_P"TE^Q5%^QUXE_9_P# NMS_ !&\
M(?#SP='H/B/XC^)_C!;ZSX7^*'@SXM_$:7Q):WGP\BTF]U+X=Q>,-)NM!F\
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M>6-.[K^&K_@GY^U7^U5X-_X)N?\ ! 7]@O\ 9,^+/A#]F3QI^WI>_MA66O\
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MQ_X]LM9-PVCWDWQ'UN\%RTMWJ-AI6BFZL=-T?\U?@#_P57_X+5?&GP7\/?\
M@HCIEUH6G_LK>.OVF)/!FJ_"3XG:U_P3.^#O[).@?"Y/BQ??#'4? FE?&CXG
M_M(_#K]L.'XUV-A8&Z\.W7BS3;:V\4^/9$M],\$:KX/U'1DO #^T;XG_ !C^
M$7P2T72?$GQF^*?PZ^$GAW7O$^B>"=#U[XF>-O#7@31M9\9>)9I+?P[X3TK4
M_%&IZ79:AXDUV:&:+2-#M)YM3U%X9A:6TWE2;?2*_#3_ (+V?$[Q+\*_V>_V
M0=7\,:=\/M2N_$'_  4J_8V\&7\7Q&^$OPJ^,.F0:/XC\7ZS:ZC=Z)HOQ<\&
M>-]&\->*H(D!T/QWX<L-*\;^&)FDN?#7B'2;F665_D7]H#X]?\%1/C-_P4I_
MX*:?LN_LU?MT>%_V5_@Q^RA^S!\"/CAX8GO?V6?A)\=/&NG^)/$7P_U+Q'J&
M@>$[KQ>FAV,6D^,]4T^_F\9:G\0&^(=SIEG:Z7IW@+3/#,MY?ZI  ?U"T5^<
M?_!(O]J7XE?MJ_\ !-S]DG]I_P",0T5OBA\5OAI)J/CBY\.Z<ND:1J>OZ!XH
M\0^$+O6K72HF:WTQ]=_X1Y-9N["R$>GV=[?7%OIUO;6,=O;Q?HY0 5^ /_!/
M#_E.O_P<5?\ >(W_ -8\\;5^_P!7X _\$\/^4Z__  <5?]XC?_6//&U '[_4
M444 %%%% 'Y ?\$W?^3L?^"M_P#V=_X>_P#5;Z?7Z_U^0'_!-W_D['_@K?\
M]G?^'O\ U6^GU^O] !1110 5^ /_  0+_P"<U'_:?[_@HW_[QNOW^K\ ?^"!
M?_.:C_M/]_P4;_\ >-T ?O\ 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?@#_P $"_\ G-1_VG^_X*-_^\;K]_J_ '_@@7_SFH_[
M3_?\%&__ 'C=?O\ 4 %%%% !7Y _\$7?^3>OVA?^S[OVL/\ U-[6OU^K\@?^
M"+?S_LZ?'ZX3YH+K]NC]JZXM9E^:&YMV\<P(L]O(,I-"SQNBRQLR%D=0V5(
M!^OU%%% !1110 4444 %%%% !1110!^ /_!/#_E.O_P<5?\ >(W_ -8\\;5^
M_P!7X _\$\/^4Z__  <5?]XC?_6//&U?MK\9M?U?PG\'_BOXIT"[^P:]X:^&
MOCK7]$OO(MKK[%J^C>%]4U'3;O[+>PW-G<_9KRVAF\B[MY[:;9Y<\,L3.C '
MI-%?RZ_\$>?^"ZWP-^*/_!-KX;^/?^"@G_!1']F/3/VPK^Y^+X\7V/Q$\?\
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M^/ESXO\  _P]_;3^+_PJ^%^N:;\-O"WAOQ=XF\%)8^";SX1_#'P9X!\$^$_
MLGB#Q7J2:W>R6K^(M.M]:MK1M0U;QQKVF:)H6IZEI0!^D_Q+_P""$_\ P2G^
M+?Q$\=?%#QG^RE:+XF^)_B.X\7?$>P\'?&/]H/X9^ /'GB6]O'O]4UKQ?\)O
MAK\6/"7PK\17VN7LDMSXBEU;P9=?\)'+-.VNC4//EW_J)X$\">"_A?X,\+?#
MGX<>%/#W@7P#X'T'3/"_@[P;X3TFQT'PUX8\.:+:16&DZ)H>C:;#;V&F:9IU
MG#%;6EG:010PQ1JJ( *_(']GG_@NK^RW\=?&/Q#^%GBWX'?MH?LF?&SP-\#/
M&/[1^C? _P#;'^ </P-^)GQ;^$7@32;W6/$7B;X0V%WXTUWP_P"+?)MM-U'[
M)877B+1KW4(M,UK4[2&71/#WB#5=+^=O"/\ P<[_ +!'BWP]^SO\0_\ A27[
M>WAKX(?M#^-]+^&-G^T;XL_9=N]'_9\^&7Q.U;Q!K.@P?#SX@_%4>,KKPYK/
MBNW31+K6[^Q^#,WQ;M['13+)<W<>HZ3XATW1@#^C*BOR;_:X_P""P?P'_96^
M/,O[+OAOX#?MD_ME?M#:+X'B^)?Q#^$O[$'P$D^./BCX1^ KZ))-#\3?$M[[
MQ3X*T;0[?Q)YD<>AZ98:KJ^O74MUI:3Z3:_V_P"'CJOU!\ ?VY?@=^U1^R';
M_MH_L['QM\7/AC>^"_&/BNP\)^$_"5W+\7+_ %OP%%JL7B;X7VOP_OY[&[?X
MI6FNZ->^%;3PR][':ZMKILCI6K7FCZEI^KW0!]B45_&M_P $P?\ @N-^T/\
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M7P?K%E8:W>Z5^Q5 'X _\$"_^<U'_:?[_@HW_P"\;K]_J_ '_@@7_P YJ/\
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M2=7^+/PK^'^E/-%Y6I7FF2/$DGH7CW]B#XL^*?\ @KW\%OV_M,\3> ++X/\
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MQIOQ(UW2M=A^%^A7%W9/IGQ$UVW-W/:?FU\(O^"%?[6OAS]H3QE\<]8\)_\
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M@JXBC\2V\%]9S2Z8D=S"S@'D"?\ !*[]@Q/A=%\&%^!&/AI#^U0/VV(_#?\
MPL_XRG;^TV-;'B(?$S^V#\0SKY_XG*B\_P"$,;53\/\ C[/_ ,(I]ES!53]I
M/_@DU_P3M_:^^-.B_M"_M'?LN^"?B=\7-&\/VOA.7Q-J.L>-]%L_%?ABPO+>
M_P!.T#XF>$O"WBG0O!GQ:TC2[NSLIM*L/BAX>\7VVE_8;)+".WCL[9(OL+XM
M_&_X+? 'P;)\1?CO\7OA?\%/A]#>V>FS>.OBWX_\*?#CP;%J.HB0Z?82>)_&
M.K:-HB7M\(939VK7PGN1%(8(WV-CC+;]K;]E2]^&_A#XR6?[37[/EW\(?B%X
MKTSP'X!^*MM\9_AQ/\-_''CC6K^XTK1O!GA#QS%XD?PQXE\5ZMJ=I=:=IGAW
M1=4O=7O[^VN+.ULY;B&2-0#YFU[_ ()(?\$[/%'[)_PU_8B\1?LS^'=;_9J^
M#>J76N?"?P3J7C'XFW?B/X<:Y?:WJOB*\UOP5\6Y?&S?&3PYK-SJNMZK+-JN
ME_$"VU![2\?2S<?V4D5E'<\-?\$G_P#@GOX._9/^)/[$/A;]FWP]H/[-/QCN
MVU'XL>"=-\7?$JW\1_$C56UFPU[^V?&OQ;7QI_PN3Q)K::CI>G&'6M5^(%UJ
ML%C9P:1#>1Z0@L:]N\7?MP_L5_#_ ,">'/BEX]_:_P#V7?!'PR\8:WXC\,^$
MOB-XN^/_ ,)_#?@3Q3XD\':K>:#XN\/^'/%^L^+;+P_K>M^%=<T[4-&\1Z3I
MFH75_H>JV-YIVIV]K>6L\*?,W[5O_!8#]A#]COQ%^RIH/Q5^-7@R^M/VO?%6
MC:/\//%WA/XC_!RY\&>&/!.NP7DEC\=OB)K_ (C^)GAB+1?@']HL9]-D^)^A
MP^)M)_M,"SABF<.4 /J&_P#V.OV<=3^-WP*_:-OOAUY_QF_9I^'GBGX5?!/Q
ME_PEWCN/_A"O 7C72K;1/$V@_P#"/0^)X_"OB/\ M+2[.WM?[4\6Z'KVM6?E
M^=I^HVMP\DK?*UK_ ,$7/^"85E^T!!^TY:?LE^#[;XMVOQ,7XT6TT'BSXGQ?
M#>W^+B3R74?Q,A^!:>.1\#(_',-[(]_!XG3X<#5X-1(U"&[2]59Q[3?_ +6^
MK/\ MJ_"+]F#POX.^$WBCX:_%+]G3Q!\?$^,L'[4GPEM/'L::=KBZ5HFF^#O
MV8M]W\5OB/X'URTFM-2E^,GAV1?A]I/VQ=.N;^348XK>[]7^'_[6W[*GQ8^)
M'B3X.?"S]IK]GSXE_%WP:E_)XO\ A7\/_C/\./&7Q(\*QZ5=1V6IOXD\#^'?
M$FI>)]#33;R:*TOVU/2[5;.ZECM[@QRNJ$ /VC?V5_@-^UIX9\$^#OV@O G_
M  G_ (<^'/Q5\"_&WP;IW_"4>,O"O]C_ !/^&M]/J7@KQ-]K\$^(O#=_J']B
MWMS--_8NJW5]X>U'?Y>K:3?Q*D:XUC^QO^S?IOQH^/G[0ME\.?)^,'[3WP^\
M+?"SXY>+_P#A+_'DG_"<> _!>CWN@^&="_L"7Q1)X7\-?V;I.HWEI_:GA#1?
M#^LWGG>?J&HW5S'%,E3Q1^W1^Q+X'O\ 4=*\:?MB?LL>$-4TCXBW'P@U;3?%
M'[0?PE\/W^E_%JTM[:\N_A=J-GJWBZTN++XBVMI>V=U<>";F.+Q+#;W=M/)I
MBQ3Q,_U,K*RJRL&5@&5E(*LI&0RD9!!!!!!P1R* /%?V<_V=?@Y^R9\%/ '[
M.W[/W@__ (0#X.?"[2[O1? O@_\ X2#Q3XJ_L/3+[5]1UVZMO^$@\;:WXD\4
MZGYNJZMJ%UYVL:WJ%PGVCR(Y4MHH88_:Z^>_ '[6_P"RG\5_B/XE^#OPM_:;
M_9[^)7Q=\&)?R^,/A9X ^,_PX\8_$?PI'I5S'9:I)XE\#^'?$FH^)M"33;R:
M*TOWU32[5;.YEC@N#'*ZH?S6_9C_ ."SWPX_:]_X*1?&_P#8:^!OA?X0>*OA
MI\#--2#4OVB(/VM/A7<^)OB-XNC\-1Z]K%C\&_V==)TK5/%/Q*\#>%;\S>&_
M&'Q)T'QH^F>%]8MVAUG2K0S6J3@'[6U^ /\ P3P_Y3K_ /!Q5_WB-_\ 6//&
MU?O]7X _\$\/^4Z__!Q5_P!XC?\ UCSQM0!^_P!1110 4444 ?D#_P $T/\
M2/VE/^"L^HR<7$O[;T^F,%XC^SZ/X"T6"T(4Y(E*3.9FW$.V"JH!@_K]7Y _
M\$R?^3A?^"L7_9]VN?\ J$:!7Z_4 %%%% !7X _\$"_^<U'_ &G^_P""C?\
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M.OAK7KC[+<WNF^'?%&H>!_%=W;:M:VFIVT/A/QWH_B&&RO9H1 WI?CC]G/\
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MP+GUCP]=1>./^$H?XFKX,LMUO8W4G_",ZCXBM/&"^5L;P^'>-7_N-) !)(
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M^_X*-_\ O&Z_?ZOP!_X(%_\ .:C_ +3_ '_!1O\ ]XW7[_4 %%%% !7Y _\
M!:'C]GW]G:0<21?MX_LGR1..'BD'C:[421L/F1PK, RD, Q&<$U^OU?D#_P6
MB_Y-Z_9Z_P"S[OV3_P#U-[J@#]?J*** "BBB@#\ ?^"!?_.:C_M/]_P4;_\
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MGPWT/POX;\+_  =ABU*8P36WAFVDO+[3(Q;ZOJFJ7EWJVHZF ?T1?LP?M6_
M;]LKX8O\9/V<?&\_Q!^&Z>+_ !?X$'B2;PCXW\%K+XG\":S/H'BFPM]*\?\
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MMCX,?MG?'W47_:!_X*7^'/!=AX&^-W[?WAMM3\:? SQ'\6[GX?\ BCX<R_\
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MI>L^)-=\):!9>(+*]\ _#72O$WAOX>^#/%6BQ>,;7P[>Z_=&[MOE_P#X*C_
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M^\-MX@DL[#5;RZ^'?C*-9?"/Q%T@:3KL%QH&H_VO'X?UG6-!T:V !_2Y=?\
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M[PIXWL?B9\+M*\)I>?&74?%-Q>ZKJUQJ7Q$\3:O%I,<VGZ+H.GZ9I=A<1ZD
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M_P YJ/\ M/\ ?\%&_P#WC=?O]0 4444 %?D!_P $3O\ DT[XD_\ 9W_[4?\
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M_P#M&7GA&+X4?"WQ'%I^L3:Z?BGK4>M>%M&\/W&IZJ]MJ6KVOARQ^+_V>?\
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MXQ\/^*QJ&E>*=/;2H;":SNI9/R*^$7_!U7\9M0\7_ ;XI?%JY_X)U:K^S_\
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M_*37_@C9_P!CA^VQ_P"L_P"BU^OU?D#^W!_RDU_X(V?]CA^VQ_ZS_HM?K]0
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M\6^%OBCX4^(G@;PWX3TS1?'WA?5/$^KQ:/J>G^$[?3CIMP^GZGI&I6\]XMT
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MX2U?QS?:1J?C#4=$\/6PM;*Z\1ZAH&A>&=%N]5EC&;J?3/#^D6COS%8P+\M
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M[?2M&T?3;6,".VL-,TVTMK*SMXP$AMX(XU 510!NT444 %?@#_P3P_Y3K_\
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M\?KWP-;_  $U?QM)J8;1+;PSIGQ+N]8N_$22>';6TFUV.33U /M[2?@)\"]
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M[;6WVO4+RTL;?S/.N[F"!))4_&O_ ((%_P#.:C_M/]_P4;_]XW7[_4 ?Q4_
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M6W]AX926 8$J=K $$JQ56"L!T.UE;!P=K*>A!I: /Y??#7[%W[?W[47[3?\
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MT_PTB^.]]\=%\4O^S\-/D^.H^+TEM<KX%@L/L#:-&T=K')XI72(GU0?VV44
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MJ.GW%A'IUI8VVLW,IU?Q'!J%IIU_?V/?:I_PU'_PR'_P=(_\,<?\+ _X7O\
M\/'?%']C_P#"I_[0_P"%G_\ "&[_ (7_ /"U/^$#_LC_ (G/_"1?\*Q_X2WR
M/[#_ .)_]E^U_P#"/_\ $[_L^@#^W*BOXF?^";G_  QM;?\ !5C]CV/_ ((<
M?\+-;]F>[_9S^,G_  ],,G_#1-WX&377\*?:?@3_ ,+;D^./G:'9?'D?$R'4
M%7_A'&@\1I:G7;6/;H,^KPR?F!X8_97^$G@O_@B[X!_X**Z /B'9_M@_#C_@
MJ'/H'PH^+$?Q>^*D*?"/PW?_ +8EUX8UKP]\-/ UKXOMOAYX6TSQ);27^I^)
MVM?"CZAXAUW5+O5-6OKJ6'35L #_ $I:*_ K_@XW^*FC?#G]@KPKX>\9>#M;
M\0_#+XQ_M-?!'X4_%3Q1)XW^(G@+X3_"[P-KFL7^I7?C[]H?4OA5X>UGQUKO
MP0LM6T?1]*\7^"-!U3P7?>+3JUEIUKXNMKP6VCZU^'7_  37\1>&-$UK_@O_
M /"?X&>+/ -W^S!-_P $_?#_ ,6?A[X4^!OPJ^._P/\ V=5U_P 4?!3XJZ?J
M7CCX2?#+]H7QQ\0/%UM:>*-,M[*'5_B%X?UBS\'_ !6DTZS\4:!8#0H]!%N
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M=^PC_P!F>?LV?^J=\'5]KT %?@#_ ,$\/^4Z_P#P<5?]XC?_ %CSQM7[_5^
M/_!/#_E.O_P<5?\ >(W_ -8\\;4 ?O\ 4444 %%%% 'Y _\ !,G_ ).%_P""
ML7_9]VN?^H1H%?K]7Y _\$R?^3A?^"L7_9]VN?\ J$:!7Z_4 %%%% !7X _\
M$"_^<U'_ &G^_P""C?\ [QNOW^K\ ?\ @@7_ ,YJ/^T_W_!1O_WC= '[_444
M4 %?A3_P6&_8.^)O[;GQ\_X)0W&@_ WPK\=/@;\"_P!L.;Q]^U)H/CBZ^&5W
MX0T[X07NC:/8:A/XC\$_$G6;*/XA:3>&VN;>[\,:#H?BK4+F-")=&DB="W[K
M44 ?SJ?%G_@D_I'PX_X+"_\ !*W]IW]BS]C'X#_!C]G?X(:#^UM#^U!XP^!O
M@SX#_!&UL-5\>?""]\)_"E_$?@_PW)X.\7?$&XN=7U'4--TVZT+PUXI'AR._
MO9M0ETFQNIYY/RZ\;_ 73?C-_P %^_&'[ WP1\<_#3XC_L7?$SX_?#+_ (*P
M_M>>%OAYXDT[QA??!SX_?L]Z3XW\$>+?A5\0%TNYU/3O"6K_ !;^-]O\-O$O
MC[P=K:VOB(6>KZ2\46FV_FP3?VX5Y%\/OV?O@-\)/%7Q#\=?"KX)?"+X9>-_
MB[K<OB;XL>,?A]\-O!O@SQ5\3_$D]Y>ZA-X@^(?B'PYHNFZOXUUN:_U+4;Z7
M5O$EYJ=_)>:A>W+W!FNIWD /Y0OB]^P5_P %3?A?\,_^"U/[&/P6_8B^%?[2
M'PT_X*,?&CX]_M(_#3]JG7?VE?AAX _L>V^,F@V]P_PL\0?#;Q9:OXXUKXK>
M#M1T#3;3X<:CJ!\*_#"'Q;K5QXAU?XB>'])T]IKK[C_9L_8!_:;\%?\ !0;_
M ()<?'7Q[\';.S^&_P"S)_P1YT?]F3XF>+;KQ=\,M8E^'W[1EM_8%G<^$;#2
M;#Q9J'B34[Q=+77;(^,O!^EZMX2DLKB\M$\3/%?&*?\ HWHH _D$^*O[!'_!
M3OX0^#_^"MW[$WP3_8Z^&G[2GPD_X*G?M!_&3XQ^$_VQ[_\ :2^'/PP@^!NF
M_M%V6D:+KFD?&KX8>+]-N?B9XLN?A"MC/K.@S_#6P\3)K$\T]S80VEY>-86_
MW%\%O^";?QX^"W_!2[_@FY\1[WPU:?$?X%?L??\ !)@_LC>)OCO>:WX,24?&
MW0=0TG1K*33?".K>(!\1DN/$7ARWU6ZCU_3?#=SI=IIVIW.E:AK4,]S/:2?T
M,T4 ?QTV_P#P2N_;S3]@VQ^##? C'Q+A_P""_*_ML2>&_P#A9_P:.W]F0?%"
M/Q$?B9_; ^(9T _\293>?\(8NJGX@<?9_P#A%/M6(*^N_BO^RW_P42_9\_X*
M3_\ !1'XX_LX?L?_  K_ &POA'_P4O\ @G\%_!,7CKQW^T#X(^$-G^SCXF^%
M/PXO/A=J6@_%+0?%&BZ_XT\:_#CQ-9ZK?>)'TOX7^&/$UQ?IIFA:%J TR26Y
MU'3_ .ENB@#^.+X'?\$O?^"B?[./[)O_  0[^,WAW]G/PG\5/VE?^"8>M?M6
M#XL?L6>*?C1\,O"E_P",]#_:0UOQ1IEGK?@#XP1:OXK^#=GXV\%Z5/I7BBR7
M5/$::?=-<VD0U:QU72)=/N-3XC_\$O?^"A'QQ_9%_P""Z/Q@\4_ 30?AK^TM
M_P %2]6^ =S\)_V+=$^-?PU\9WW@#2O@3J>DZ3]L\9_%YM3\*?!N3QCXWTXZ
MCXDU :5XDGTJVMK&VMYM:N-7NSIUO_8310!^#?BK]A_X_7/_  4O_P""3WQL
M\.?#*'2?@-^S'^Q)\?/@G\7/%.C>)_A[I4'PT\8^,_AKHOACPAX<TOPLGB.W
M\1:LDM]9S6EG?^"_#VMZ!I8MXY;R^L[3RI&_$KX$_P#!%']L/X3>#OAQ^QEX
ML_X)_>'/C%#X"_:@3Q8O[=_Q!_X*2?M)6'[*=S\((/BQJ/Q'L/B##^P?\)_V
MJ/A1XKL?C;H.GW4-CX?T+2/"&D^&9O%EM;^)?$?B'59Y]7O=1_N9HH ****
M"BBB@#\ ?^"!?_.:C_M/]_P4;_\ >-U^_P!7X _\$"_^<U'_ &G^_P""C?\
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MA6WO+74]0;QY/I,]UK>LW_\ 8JW5U#);>:_M&_\ !"']F'X]_&CXT_&SP?\
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MKNJ>(+:PL(9=+NM \2>&-,ANGE>\TF^A98$ /Y#?^"C?[>'_  4*_P""AO\
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M?K]0 4444 %?@#_P4/\ ^4Z__!NK_P!Y<O\ UCSP37[_ %?@#_P4/_Y3K_\
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MX7L+74X]7\'_ /"O/B9J6E>'(_[<N+G3KG_A(%N3J.F_V7Y-K$Z7LY7^9/\
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MQS\#_BCX@AU&'51I/B+XG^(-5\2^'K[5WUCPOX5@T7P[+J_REIOPNT+XU?\
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M/7T=0!^ /_!KC_R@H_89_P"[F?\ UL/]H*OW^K\ ?^#7'_E!1^PS_P!W,_\
MK8?[05?O]0 4444 ?D#^W5_HO_!2'_@CEJ;?-'%\1?VO=*,0X<R:W\!]+MXI
M03\NR!H2TB_>8, O(-?K]7Y _M[?\I"/^"/'_98/VFO_ %2-G7Z_4 %%%% !
M7X _\%#_ /E.O_P;J_\ >7+_ -8\\$U^_P!7X _\%#_^4Z__  ;J_P#>7+_U
MCSP30!^_U%%% ' _%/XI?#SX(_#CQO\ %[XM>+]$\ _#/X;^&M6\8>./&7B*
MZ%GHWAWPYH=I)>ZEJ5[-M>1EA@B80VUM%/>7MPT-G8V]S>3P02?ACX7_ .#D
MG]B/5M3\%Z[XV^!'[?GP._9K^)7B.T\,_#C]N3XW?LHZ[X&_8V\<76KWTFG^
M'=0T3XKCQ)JFK0Z)XBGAN'L=6UKP;I-KI]K:WM[XC;0[2QO)H/IW_@NO^S/\
M9/VO/^"4_P"UU\"?@#9:EK?Q6\1^#O#FO^&?">D2M%J?CE? 'CWPKX]U?P/I
MX%]8+<ZAXJT7PWJ&D:;823.FI:C<6NG^1,]TB'\HY?\ @O;^Q#\3_P!EKX(_
MLC_!G]C/QE^V/^V/=Z9\%_A1XG_X)<>.?@9\1_!</PRUSPI-X>T3Q+%\1_$_
MCCX$?$'X7:'X5^$%UI*:O9ZI;6'B0V4=CHEUJ</A41ZGJ&@ '] GPT_;?^$W
MQ5_;(_:+_8A\-Z%X_@^*G[,G@#X1_$?QUXEU33/#47PXUO0?C/IUSJ?A6#P9
MK-AXMU'Q'J6I6=M:N-<BUCPGH%G;R-&-.OM5C8R+]CU_&?\ %[]AW]GC]LW_
M (*_?\%GO#7[2G@O7/%/@_X7_L(?LI^+-!^%^@_%#XD>"/ATGC2S^#^MRZ#K
M>O:-\.O$/@>#QM=> I])<>!/^$DM[C2] EU#4-4L=%MM3FM;BQ^1O!GA$?M@
M_LR?\&G?@+X\>+OB1XETOXE^+_VH_!WC?6]'^)'C7P=X\USP=X=\*:YH<'A<
M_$7PGK6C^.-,TS4/"7AZR\$ZI+HNOZ=JEQX1EO-(AU&V6X,R@']]-%?PG_MK
M?"K_ ()Y?!;]O;]K#X.?\%:-!^*?A/\ 9/\ A-^R=^SGX"_X(S^&)]4_:?O?
M@_X?T#P;\([KP]\1]#^$.H?"S4;_ /M3XUZ9X]L_#-F9?&VH:EXMNI8//GGN
M=.&D3%FH_"7]H#]H+X5?\&MOP@_X*)77QEL_BEX]^)_[4OA_XIKJ/C'QS\,?
MC7J/PXA\$WTO@/0_&/C'PYJ?A[XDZ+KGB7X0V/A30?'-TVL:7XVU32]3UBUU
MW4HM;U'4;J@#^T7]H[XUM^SK\$_'WQH3X1_&OX[OX#TRTU%?A+^SIX%_X67\
M:/&C7FK:?I*Z?X$\#G5-%_M_4+8Z@-2O;?\ M.T^SZ19:C?;G^R^5)ZGX:UI
M_$?ASP_XADT;6_#DFO:)I6M/X>\36D%AXCT%]4L(+YM&\06-M=7UM9:WI;3F
MQU6TM[V\@MK^"XABNKB-%F?^!KXN_#;PC^SG^P)_P=/?LF?!RSU3PC^SG\ _
MC-^SC%\&_A3)XG\4^)O#OP[C\=?\(5K?BZ/PY)XNUK7M5M4U_5;2TO-01]1E
M622UME4)%!$B?9__  4FA_9NE_;4_8/?_@KG%X]D_P""2UO_ ,$YM,F^';R)
M\:'^ $'[<3:G9V]Q+\3&^"@.KQ>-C\')[F#P4^OE;0F:WC\/G[7)KJD _LQK
M\8(?^"['[&#?L=>.OVT;OP[\=[#P;X4_::\1?L@^%OA0W@KPAJGQX^-/Q[T#
M6=.T6#P5\&? WA[XB:SI/BN[\1RW\E[H"ZEXJ\/W#:9IFJ7NL6VCI;(LWJW_
M  1N_P"%7?\ #!WPW_X47_PVI_PHS_A(_'W_  IG_AO+^RO^%T_\*T_X2B]_
MX1?_ (1S[%_Q./\ A2/V//\ PI3_ (3'_BJ_^%?_ -D?;?\ 0/[,K^+S]B/P
M?X^_9;\,?#O_ (+':EX3UC]I3]F;]CG_ (*-_MR_#KX__ 6XTV;Q)>_L^^$O
MB?XF\)6E[^V5\$/#5JUC83>._"+266F^/[_7WU66#0-+\*7.GC0K/3+WQAX,
M /[YK#]IS4KGX\?"OX"W_P"S)^U)H5[\3/@G=?&75/BIJ'P^\,:A\"_A-=V=
MS':3?!SXI_%;PSX\\0>&].^-/VAG6#PIX3F\8Z3?P)_:6F>)+[2#_:"\]^UC
M^V]\*/V.?$?[+'ACXF^'_B%KM_\ M=_M)>#/V7/AM-X$TGPWJ=GHGQ \<V.K
M:AI.L>.)/$'BSPQ-IO@ZWAT>Z74=0T&W\2ZU#+) MMX>NT:1XOYYOV]/B%XL
M^+/_  5A\'?$[]BSQ4OCCQOX_P#^#?G]L/Q?^S/XP^&]_P#VG/XE\3:_K^J:
ME\,M:\!W^GLQN=8O]2N-*N/"\D)$G]KO8JRHZNB_A_\ !+_AW=G_ (((#]E<
M?''_ (:Z_P"'@'[,/_#PP^(_^&E/^$//[1)'B/\ X3L?&;_A8A_X4[_POP?$
M,>-_^$$_X1\#Q_\ \*O/B/[03X2_LW !_I045_&]\<_V)/V=_P!M;_@LC_P6
MOT+]I/PUXH\?>#OAO^P_^R_XST'P%9?$WXE>!/!5_P",X/A/K]SH'BKQ9H?P
M\\5^%(O&6K>#I]+>?P:GB:75--\/7FJ:IJ5EIXU.6VO;3\\OBWKOQC^+W_!(
M_P#X-^-1_: ^+FMZ'^POK$'QHT;]LGXL_$7X<?%']H?X5:%KOAF[UGP]^S!=
M?M&^ ?AM\2OA=XX\6?#S1I=$U#1= EN_B!I7AKP]JEK9:YXD35_[%TC2+\ _
MT+J*_@"^'?P$DTK_ ()Z?'']L#]D;XN_$[]H;P9_P3!_;R^'_P"V1^RGXF7]
MFCQ1^S[\#=0\ ?#[1X+?]KGX7_LA6/C_ /:7_:(^)VK?LZ>(?!UU+XG\2/JE
MIX#\+'QCX3OHO#-AXAL[S4K_ $C^@'_@A5ILG[0<'[;'_!5W6M,U6QN_^"D'
M[1VJZU\(8/$L(A\3Z/\ LK?L^)>?!KX(Z5J]L%\K3+N[.B>*-5ELK&:ZLY;"
M?1KH7M](YN7 /W\HHHH _ '_ (*'_P#*=?\ X-U?^\N7_K'G@FOW^K\ ?^"A
M_P#RG7_X-U?^\N7_ *QYX)K]_J "BBB@ K\@=:_Y3P^"_P#M%CXC_P#6HHJ_
M7ZOR!UK_ )3P^"_^T6/B/_UJ**@#]?J*** "BBB@#\ ?^">'_*=?_@XJ_P"\
M1O\ ZQYXVK]_J_ '_@GA_P IU_\ @XJ_[Q&_^L>>-J_?Z@ HKYN^-_[9/[(/
M[,NKZ)X?_:1_:K_9N_9]U[Q+ILVL^'-$^-_QR^&'PHU?7](MKIK*XU71--\>
M>*- O=5TVWO5:TFOK"&>UBNE:WDE64%*I^#_ -MK]C+XAV_P]N_A_P#M;_LR
M>.K3XM^,-:^'GPJN_!OQY^%GBBV^)?C[PW8V6I^(?!'@&XT/Q5?0^,/%V@Z=
MJ>FWVL^'/#[ZAK&F6FI:?<7MG!%?6K2@'TW(I9'48RR,HSTR00,]>*_F1\&?
M\$7?VH_#O_!#C]K'_@F=>^/?@%+\=_CO\4_BGXW\(^++7Q3\1'^$FG:3XX^,
M?A?XAZ3;^)->F^%D'C&SU&WT71+NUU&+3/ 6L6T6J26\%M=W=H\E[%_1=X(^
M+?PI^)FI^.M%^&_Q-^'OQ!UGX7>*[GP)\3-)\$>-/#?BO4_AUXXLX(KJ[\&^
M.K#0=2O[KPCXKM;:>&XN?#OB"+3]7@@FBEELUCD1CZ%0!^"__!2;_@DQ\0/V
MNM+_ ."?_P 2_AU!^RQX]^-7["EMK6D2?!;]L3P-J?Q(_9+^.WA7Q[X \-^#
M/''ASQYIUIX9\0Z[IUSI=YX8T_7O ?B2#P9J\NF:HJ:C<Z*E_::;-8^/Z5_P
M2._;1B_X)Y_MV_ WP?\ %+]C7]CC]IS]K/Q5X:UWX?:=^P1\$-+_ &;?@!\%
M_"'@;4]'N],^%T_Q+^%/PU^&7[0/Q'3Q[I=OXC\/^.OB5X^M/$>L:5H_BO4-
M*\,^$CH#:KH6O?TD44 ?RW_LA?\ !$W]I+X7_MNZ'^T[\2?"G_!/;X#_  _O
M/V)_C#^RYXN^'W[&5G\:YO$;^)_'=YINGZ'X[\0>+OBUX8M;_P",^K2>'M/6
M75/%/B:[\"ZGH:1:9X3M-!\3Q:?<^,-4Y?P'_P $:?\ @HU!_P $Y/V7OV!?
MB;\2/V+]4M?V-OVZ/@%\;/A%XX\&:Y\;=*N?%O[/_P ,OB)XV\?^++?XAPZQ
M\-=1AM/BW>7'BF"T\+:!X=T__A$1:0/;ZUXU:YC&J77].'@;XQ_"+XGZU\0/
M#?PU^*?PZ^(7B+X3>)W\$_%+0?!'C;PUXKUGX;>,HX3<2>$_'NF:%J=_>^$/
M$D<(:5]#\00:?J:(DA:V'EOM](H _*#P]^PI\7-)_P""LO[2O[=]SXB^'+_"
M+XQ_L-^ _P!F;PQX<@U?Q,WQ(L/'GA?QL_B34-6U[2)/"$?ABU\(S6+"*SO]
M/\8:IK,EWF.?0;>']_7YCVG_  03^-&N?\$8_P!DW]@GQM\0/V>;G]I7]D']
MH_4_VF_!]YK>A^)/BU^RM\1/$,/QE^+'C?3_ (:_%3P_XH\'^%/$GB3X;>+/
M!'Q+DT'QM:MX.\V/489K6&QUW13.NI_T#?&_]LG]D']F75]$\/\ [2/[5?[-
MW[/NO>)=-FUGPYHGQO\ CE\,/A1J^OZ1;7365QJNB:;X\\4:!>ZKIMO>JUI-
M?6$,]K%=*UO)*LH*5W'@[X]_ OXB?#"Y^-OP_P#C1\)O'/P8LM+U;6[SXN>#
MOB-X/\3?#"TT70+62^UW5[GQ]HNLWWA2#2]%L89;S5K^75DM--M8I+B\EAA1
MG !_,[XK_P""(7[7?Q1_9;_X*#> =2\&_P#!*/\ 9<^(O[4?P;^''P;^#7P@
M_8H_9]T?X4?!?PE#X7^(WA3X@>,/&_Q9_:$L_P!G+1/VDO&.J>*[CPW#;Z;X
M*CTK4/A[X<%M:SIH5_K$J:[IOZ=>)?\ @G[\9=9_X**?\$VOVN;7Q-\,H_AO
M^QU^RS\9O@A\3=$GUGQ4OC?7?%GQ%\%:1X;T34/ FFQ^#)=!U/P]:WUA-+JM
MWX@\2^&-2@M&BDM-)OIF>!/U0^'WQ$\ ?%KP7X<^)'PL\<>$/B5\//&&G1ZQ
MX3\=^ O$FC^+_!WB?2I7DCCU+P_XE\/WFH:-K%@\D4L2W>GWMQ 9(I(]^^-U
M'8T ?C'_ ,$I_P!AK]K[]@7QM^V)\,_B1XT_9U\>_LE_%;]H_P"+W[2/P%UK
MP8?B/:_M"V'B#XQ^*+'5M9\.?%32-9T.Q^'5AH>C:58Q06$GA;6_$6HWFK-/
M=SW=K83PZ;9>-?'K_@GK_P %$OA=^VA^V)^U?_P3E^)?['=WIG_!0#X;_"_P
M?\?/ '[8MA\8[&3X<>+/A!X*U/X>^%/'GPDU_P"#^FZZ_B*&[\/:SJ%WJO@[
MQ?9Z/:'6&WQ:V]D\%O8?T T4 ?SC^'?^"(?C[X-? K_@BW\ /@_\4_ _BG0/
M^";'[64'[0_QE\6?$!_$?A/5?B%8ZS?^,?$_C5?AMX?T+0/&UJFJ3^+/&5^/
M#^@>)=?T:PMM$AMX[SQ1)=H[2_T<444 %%%% !7X _\ !/#_ )3K_P#!Q5_W
MB-_]8\\;5^_U?@#_ ,$\/^4Z_P#P<5?]XC?_ %CSQM0!^_U%%% !1110!^0/
M_!+/_DK/_!5;_M(]\6?_ %&O"-?K]7Y _P#!+/\ Y*S_ ,%5O^TCWQ9_]1KP
MC7Z_4 %%%% !7X _\$"_^<U'_:?[_@HW_P"\;K]_J_ '_@@7_P YJ/\ M/\
M?\%&_P#WC= '[_4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?@#_P0+_YS4?]I_O^"C?_ +QNOW^K\ ?^"!?_ #FH_P"T_P!_P4;_
M />-U^_U !1110 5^0/_  1!_P"3([W_ +.0_:8_]6WXAK]?J_('_@AY^]_8
M5@U%/^/;5_V@?VE-2LR>':UE^,/B>!3(G6-_,MY 4.2  <\T ?K]1110 444
M4 %%%% !1110 4444 ?@#_P3P_Y3K_\ !Q5_WB-_]8\\;5^_U?@#_P $\/\
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M^"FGQI_X)Y_M@?L_^-_V+O\ @ISX7_:'N_C_ 'WCOQ+^SC^S!^QK^S7\#_\
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M^+/BG]HSQ_\ L]?%6W^%^HS1:)INM^)M1\90^(=4\.ZWI?A)]0A\*W)U?3?
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M3OAM_P!G?_LN?^K(M*_7^OR _P""V/\ R:=\-O\ L[_]ES_U9%I0!^O]%%%
M!1110!^ /_! O_G-1_VG^_X*-_\ O&Z_?ZOP!_X(%_\ .:C_ +3_ '_!1O\
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M/&WAS5K)_/LM<\">._$UG"RM;:HVG7I6V;ZZH _ '_@UQ_Y04?L,_P#=S/\
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MU#2KR_\ "OC'2]9T*\NM,OX8;W3[BXL));*[BBN;9XIHU<?%UCX9^&/[)?\
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MD#_P2S_Y*S_P56_[2/?%G_U&O"-?K]7Y _\ !+/_ )*S_P %5O\ M(]\6?\
MU&O"-?K]0 4444 %?@#_ ,$"_P#G-1_VG^_X*-_^\;K]_J_ '_@@7_SFH_[3
M_?\ !1O_ -XW0!^_U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'X _P#! O\ YS4?]I_O^"C?_O&Z_?ZOP!_X(%_\YJ/^T_W_  4;
M_P#>-U^_U !1110 5^0/_!#+_E'OX._[+!^T7_ZN[QM7Z_5^0/\ P0R_Y1[^
M#O\ LL'[1?\ ZN[QM0!^OU%%% !1110 4444 %%%% !1110!^ /_  3P_P"4
MZ_\ P<5?]XC?_6//&U?O]7X _P#!/#_E.O\ \'%7_>(W_P!8\\;5^_U !17X
M'_\ !:?_ (*$_%/]@/XQ?\$L;_PQ\2-8\!_!GXT_M>R^ OVE=)\._"S3OBQX
M@\>_#"#2M#F_X170M M_ GCKX@_VQ?7U^UMID/PMM+'QEJ5[=P65C/-(T4:_
M0?['?_!9G]E[]K[Q_P#M*_"B?X=_M-?LH_%']D_P9;?$WXO?#O\ ;/\ @\OP
M+\8:5\*[FP35?^%E)HC^)O$UWIWA6'2[G3-4F'BM?#.O#2M9TG58]#DTV\6Z
M4 _6VBOPC^%__!PG^QO\3?'GPITN7X*?MP_#7X#_ ![^*"?!SX$?MM_%K]FG
M4O!/['7Q?\?ZC?7.E^%-(\'_ !/N/$]WXDAC\<:I9:AI_AB]\3^ O#EI)<:5
MKC:S+HT'A_79M-3XH?\ !P3^RQ\.OBI^UI\$M!_9H_;^^.7Q1_8P\;P>%/C)
MX7_9Z_9I@^*ZVF@?V7JVJ:I\5;?Q#HOCZ+PIX>^&6@KI$MGJ.J?$K7? 'B*Z
MO)X_[!\+ZS:VNJW6G '[NT5^2OQ)_P""U'[%7@?]E+]FK]K;PA<_%KX_^%_V
MP_%%GX$_9H^%?P!^&]WXY^.GQ:\?R3:A9ZUX&T'P#J&I>'+>P\1^#]3TC5-&
M\60>(=?T:QTS6K/^RXK^[O;W3(;[XK_:%_X.$/!FC_L@?MR_$7X&_LK_ +8?
MA_\ :Q_8^M=-\/\ C?\ 9U^.G[.,D7BSX.:QX_\ "/BWQ#\-OC1\:]"\&_$^
MZT:W_9O4>%+O4/%?C7PY\0[O4=(T:?1]2N-*ATWQ%H-[J(!_1]17\G7Q&_X+
M)?$_XQ_\$9/@]^VCXJOOVP_^"??Q#G^-/[,_@+Q]\0_"'['_ ,,_%$7QDU#Q
M=I>D:_X@UC]G?P3\>?C5H^C^(/V;?']Y?M8Z-\5_^$X3Q%9?V7<VT?AOQ!8'
M4]+O_5]=_P""['QI\/\ _!;*Y_X)Z?\ #%_[3GB+X!6_P[TG1$N_#7[,^N:K
M\9[CXB:G\4[3P<?VE%U1/BI;^&W_ &'+72+L27WQ6C\*)>6]S;7EP-/=(1"P
M!_3=17\^_P $_P#@IS\./@[\4O\ @ME\0?VE/VI_C;XY^$/[#'Q@\ P:KX5\
M=_ +X5^!?"OP-TGQ+9:[H^@_#7X':]\,?'?BSQG\<&\7>(+;2M%MM<^(WASX
M<:H=7DT1)=+GN-3\1>(G^H_V/?\ @L!\%/VN_C/X?^ 4_P"SK^VC^RY\3/'?
MPJB^-?PITO\ :T^!EA\-=,^+WPV>-+F77_A_X@\*^.?B'HEU):V+G4)])\07
MWA[6#:0W;P6$\EC>QVX!^LM%?RO?\%S/VY_VP?@'^W[_ ,$\?V7?@)_P4%^'
MO_!.SX2?M(>!OC1J7Q:^.7Q4^&'[//CSP!X6U#P2L%_X<UGQ%?\ QYT=++28
M+N6#_A%[2&U\:>&+.XU#7;1Y5O[Q+:VE]]_X(1?MQ_MC_M5>*_VY?A5^T3\6
M_A]^V/\ "?\ 9B^*?A?P+\$/V_\ X6?#S0_AIX'_ &B)]3L=;N_&&D:;IG@N
M./X<ZU-X0@MO#=Y-?>!P]IIJZ_'%>ZCKMGJ>@:M. ?T245^</[:__!3GX,?L
M3_$GX,? S5/A7^T?^TA^T-\?;3Q+K7PV_9__ &4_AA8?$[XHZCX2\'+&WB?Q
MQJEKK_BSP+X6T'PGHS2%+C4=7\56L\HM]0N+2SN+32M4N++Y/UK_ (.#/V'_
M  [^Q)XP_;HU[P5^TYH7@7X7_M&67[*OQF^$7B#X4:+X<_: ^#'QEN'A-_X?
M^(/@3Q!X\TO0XHM L[FUO]<F\,>,?$\]N)9=*M;2\\1:?JNBV !^YU%?D#^S
M+_P6J_9@_:=_; D_8HL/A)^V!\#/BSK?P^U?XK_"+4OVGOV=?$'P,\*_M ?#
M;1KB[6;QM\(8/%>ICQ[=^';RPTW5M9TO4?'/@3P+#J6GZ/JT-J7U>PN-+3\T
M/^"A?_!QA\-[#]ES]MZX_8C\(_MA6OB?X(VVO_#GP+^WOI?[*B>./V*-/^/6
M@>*O#FB3>"(?BCK=OXS\.OK%[-J;:5I-YXZ^'-KX'U*?4M'N+?7&M]>\-7NI
M@']5M%?+W[$/Q%\9?%_]C+]DSXL?$36/^$A\?_$S]FWX(^/_ !OK_P#9^E:3
M_;?BWQ?\-O#6O^(M6_LK0['3-%TW^T=7U"[N_L&D:=8:9:>=Y%C9VUM'%"GU
M#0!^ /\ P0+_ .<U'_:?[_@HW_[QNOW^K\ ?^"!?_.:C_M/]_P %&_\ WC=?
MO]0 4444 %?D!_P6Q_Y-.^&W_9W_ .RY_P"K(M*_7^OR _X+8_\ )IWPV_[.
M_P#V7/\ U9%I0!^O]%%% !1110!^ /\ P0+_ .<U'_:?[_@HW_[QNOT'_P""
MHO[+/Q!_;:_X)_\ [4?[*GPJUCP;X?\ B'\;?AP_@_PIK/Q!U#6]*\&:?J;:
M[HVIB?Q#J/ASP]XKURTL?L^G3H9=-\.ZM<><\2_9=C/(GY\?\$"_^<U'_:?[
M_@HW_P"\;K]_J /@G]A__@GS^S5^QK\+?A1:>!OV:_V8_AM\=]"^"?P^^'/Q
M7^+'P6^#G@'P=XC\=^(-"\*Z'I_C&_OO'>C^"_"_C'Q1INO^)M.N];:Z\2+#
M>ZK-+'J6J6,.H22HG\Z_B+_@AG_P5@;]DGQ9_P $]_#/QT_X)^-^RCH'[8<7
M[2GPS\1:KI'[0]C\?_'FBW/QTD^*USH?Q(UF#2M8^'OPYN]'AN;B[M;'PAX1
M^(@U_4;?3] G\3>'M/2^\07_ /8]10!^!GQN_P"":?[7VJ_M[_MT?M"_!?QQ
M^S;=? 7]O_\ 8EF_9S^*.@_%"Z^)^D?%WP#\0O!WPB\;^!?AEJ?@&3PIX:U[
MP;J'@S4_$>MZ-?>.[_Q%,VN6.BR:HGA_0;V^L+0:KR5A_P $DOVCK7]GS_@A
M/\)Y/&OP2;Q%_P $P_C/\*OB+\>[U/$?CLZ+XNT3P-X0U#0-6M?A#<M\-EOM
M?U6XO+N.73H/&>F^ +2:V5WN;ZTE"PM_1!10!^(>@_\ !*WQSXB_:6_X+:^-
M/BQXT\&VOP1_X*F?"CX(?"?P*/ FJ:_?_$_P+IO@GX#^-_A'XWUCQ=I&N>$M
M'\+V&H)J/BJWU;PC!HOB7Q9:ZE;VC_VX-)8_8YOCGX8?\$B/^"C'CJ[_ ."<
M'P'_ &R/C5^QI>_L@_\ !+;XG_#+XJ?!KQ+^S_X?^-%M^T7\<]7^ &D1^&/@
MII7Q2T3QO%:?#?X<Z?:Z''#-XSG\(:[XTN-5O+7[-:1QB\;4K3^H*B@#^=K4
M_P#@D?\ M'WG[-G_  7/^#L7C7X(KXF_X*;?'/XJ?$WX#7TGB3QV-"\):#XX
M\+:%HFDVGQ=NE^&SZAH.KV]WIEQ)J-OX-TOQ]90V[PO;7]W(SQ1^=?M'?\$A
M?VU_B1\1_P!BG7-$\2_L;?'OX-? S]ACX>?LJ_$/]F/]K_5_VA=<_9\\(?%K
MPW:Z3I7B+]I3X>?"WX?6%GX<^,_B74?#W]J^&(M&^(T?PNN=2\.66G:7>^(;
M%KRQN_"']-5% '\KG['O_!#C]JS]GC1_^"36E^+/'W[-=]_PP9^UO^V-\=_B
MPO@;5_B+I^DZ_P""_P!H*UU*W\$:5\*-%O\ X8VJ#5])^UPC7?#WB*\\.Z/H
M5LGV31O$GB,0)+-Y1_P<E01_$S]I3]A#X!?LB_$C5O#O_!3+XKP^/_@,G@OP
MQX \4:O?:O\ L.?M7>&_&7PT^,'C?Q=XTM]$/A#1_"?P\UCPK=:M;1:EXABU
MO0C=>(?%VEV5E'IMQJL?]?5% 'RS?_LS>'_"/[%FK_L@?!6TTOPSX=T;]FC6
M?V?/AC;:M/=Q:3I-E'\-+OP!X7DUJ\M+74M0^S0EK2XUB^ALM1OY!]JNUMKR
MZ?RY?%O^"4O[)/Q'_87_ .">'[,O[)7Q;UKP3XB^(_P8\%:[X<\4:U\.M2UW
M5_!-_?:GXW\5^)8)= U+Q-X;\(Z[=6B6&NVD4SZCX;TJ9;N.YC2"2%(IYOT/
MHH _E1O/^"'?[9J?\$K/@G^Q-X8^+_[.7A?X]?"[_@HY_P -C+\1;C4/B)XG
M^&VD^#H?B[XX^(>E_P!G:?/\-]%UWQ3XUTFT\2:3,_A#4]+\,^&M7U"RO-)E
M\<V%E)'J[>[>'/\ @F+_ ,%#OCG^T/\ M:_M>_MS?$[]CB/XR^/O^"=_Q-_X
M)^?LY^ OV7++XSZ?\*M-T/X@W6L>([CXE_%+6OBCIM_XRTC5YO%6HSPR^'=!
MM_'5EIN@ZI)]FU*_O]#@.L_T<44 ?SV>-_\ @D!\<_%G_!*O_@GG^RIHGQ=^
M%W@C]K__ ()U^+OV=?CC\,/',MAXH\;? 3Q%\:OV?8M32RT#Q3#-I7A'QM>_
M#;Q(-6N(KG5K30--\1Z?)#9WD>C7,:7.FW>U\"?^";'[;_C']J#]J3]O?]M+
MXI_LG^&/VIOB]^QM?_L3?![P7^S;X(\??%+]G[X>>!+C4O\ A+?^$X^(FG?'
MF'PWK'Q5U34_&8@.L> KG1=$\/3^%H;S1FURY?5O.TS]^:* /Y?/^"=O_!%G
M]I[]E_\ ;K^'W[5WB2W_ &,?V5?"/A7X5>-O!WQJ^'?[ OBG]H!/!_[9_C'7
MM.O=$\*^(OBC\%OB/X7\&?!_X)>'_!!O/^$VT3PU\*M.UY;7Q@DT$-XNG36-
MSI'5?#G_ ((^?M6_#S_@E)IO[$MQ>?L,_%3XG:;^U5\2_CCXA\"?'KP3XJ^+
MG[,WQ4^'/C?XF>+O%MOX#U+Q%J7P_P!'^(_PJ\;1:5XBL;JS^*/@;P3J^O>$
M-:TR[L-"6]@U4:]8?TLT4 ?B7_P1E_X)J?&;_@G3HW[3EI\1?%7PZ\+> OC5
M\3=#\5_![]D;X$?$/XR_%;]G_P#9BT#1M-U2#6U\!>._CY8Z/\1=6U_XG:MJ
MPUOQO"_A[0M"MK[1M/\ [*MY+:2&UTK]M*** /P!_P"#7'_E!1^PS_W<S_ZV
M'^T%7[_5^ /_  :X_P#*"C]AG_NYG_UL/]H*OW^H **** /R!_;V_P"4A'_!
M'C_LL'[37_JD;.OU^K\@?V]O^4A'_!'C_LL'[37_ *I&SK]?J "BBB@ K\ ?
M^"A__*=?_@W5_P"\N7_K'G@FOW^K\ ?^"A__ "G7_P"#=7_O+E_ZQYX)H _?
MZBBB@ HHHH **** /YQOVB?V$/\ @KEX(_X*J_'/_@H7_P $]O$G_!.6?0OC
M;^SM\+_@-J?AG]LK5_VF)M7TZU\$3:9JFI:E8:+\$O!]K96MQ<:OI%JEC>7/
MC35HIM.>X6XT:TN6CDC\WU__ ((5_M%>)?V#O^"G7A7Q[^T!\+/B]_P49_X*
M@:GX'\1_%7XM:QHVO_#GX$>#QX \3:%J/A#X:>$ET7P[XS\;P>!?"&AVNL:=
MIFKS^&Y-1U0/H5I=:!IR:9)?3_U T4 ?SI_\%+?^"3/QY_;$M?@GI&E_"K_@
MG?\ M&>"/!'[-EI\'M8\'?M76GQA^%?C_P"'/Q*TNU7[!\3_ (.?M0_L_>#]
M=^,,_A6YNQ:KJ_PBU2U\*:#>G3'U?^UQJ.M"+0O)_C#_ ,$*_P!H3QA^R_\
M\$O]+U/XQ_L__M@?M4?\$[(OB19>(=)_;R\$Z]\3?V8OVCO"GQD@,7B;P!XY
MM9]'\:>,8+'X9VEKH&B_"/Q??^'/$.K6MMX:TS6-2T:TU&WTV#2/ZA** /YM
M]*_X)'?MHQ?\$\_V[?@;X/\ BE^QK^QQ^TY^UGXJ\-:[\/M._8(^"&E_LV_
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M** "BBB@ HHHH _ '_@H?_RG7_X-U?\ O+E_ZQYX)K]_J_ '_@H?_P IU_\
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M@#_P0+_YS4?]I_O^"C?_ +QN@#]_J*** "BBB@ HHHH **** "BBB@ HHHH
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MX;>&M \1:3_:NAWVIZ+J7]G:OI]W:?;](U&_TR[\GS[&\N;:2*9_J&BB@#\
M?^"!?_.:C_M/]_P4;_\ >-U^_P!7X _\$"_^<U'_ &G^_P""C?\ [QNOW^H
M**** "OR _X+8_\ )IWPV_[._P#V7/\ U9%I7Z_U^0'_  6Q_P"33OAM_P!G
M?_LN?^K(M* /U_HHHH **** /P!_X(%_\YJ/^T_W_!1O_P!XW7[_ %?@#_P0
M+_YS4?\ :?[_ (*-_P#O&Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _ '_ (-<?^4%'[#/_=S/_K8?[05?O]7X _\ !KC_
M ,H*/V&?^[F?_6P_V@J_?Z@ HHHH _(']O;_ )2$?\$>/^RP?M-?^J1LZ_7Z
MOR!_;V_Y2$?\$>/^RP?M-?\ JD;.OU^H **** "OP!_X*'_\IU_^#=7_ +RY
M?^L>>":_?ZOP!_X*'_\ *=?_ (-U?^\N7_K'G@F@#]_J*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /P!_X*'_ /*=?_@W5_[RY?\
MK'G@FOW^K\ ?^"A__*=?_@W5_P"\N7_K'G@FOW^H **** "OR!UK_E/#X+_[
M18^(_P#UJ**OU^K\@=:_Y3P^"_\ M%CXC_\ 6HHJ /U^HHHH **** /P!_X)
MX?\ *=?_ (.*O^\1O_K'GC:OW^K\ ?\ @GA_RG7_ .#BK_O$;_ZQYXVK]_J
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M_5^ /_!/#_E.O_P<5?\ >(W_ -8\\;5^_P!0 4444 %%%% !7\%O_!5/X?\
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M^ /_  4/_P"4Z_\ P;J_]Y<O_6//!-?O]7X _P#!0_\ Y3K_ /!NK_WER_\
M6//!-?O]0 4444 %?D#K7_*>'P7_ -HL?$?_ *U%%7Z_5^0.M?\ *>'P7_VB
MQ\1_^M114 ?K]1110 4444 ?@#_P3P_Y3K_\'%7_ 'B-_P#6//&U?O\ 5^ /
M_!/#_E.O_P '%7_>(W_UCSQM7[_4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?@#_P3P_Y3K_\ !Q5_WB-_]8\\;5^_U?@#_P $\/\
ME.O_ ,'%7_>(W_UCSQM0!^_U%%% !1110!^0/_!)[_D;/^"I7_:4[]I?_P!-
MO@.OU^K\@?\ @D]_R-G_  5*_P"TIW[2_P#Z;? =?K]0 4444 %?@#_P0+_Y
MS4?]I_O^"C?_ +QNOW^K\ ?^"!?_ #FH_P"T_P!_P4;_ />-T ?O]1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^ /_! O_G-1_VG
M^_X*-_\ O&Z_?ZOP!_X(%_\ .:C_ +3_ '_!1O\ ]XW7[_4 %%%% !7Y _\
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MY _\%OO^3([+_LY#]F?_ -6WX>H _7ZBBB@ HHHH _ '_@@7_P YJ/\ M/\
M?\%&_P#WC=?O]7X ZU_P;X_"S_A:?[0'Q2^%O_!2C_@K_P#LV?\ #2?[0'Q6
M_:7^(OPZ_9H_;&\.?!WX6?\ "T_C%XCE\1>+M6TGPCX=^"W_ &#]"L+_ %W4
M-=\1_P#".:%H.F:GKVJ?V7!/1_PX+_ZS4?\ !?[_ ,6-_P#XFZ /W^HK\ ?^
M'!?_ %FH_P""_P!_XL;_ /Q-T?\ #@O_ *S4?\%_O_%C?_XFZ /W^HK\ ?\
MAP7_ -9J/^"_W_BQO_\ $W1_PX+_ .LU'_!?[_Q8W_\ B;H _?ZBOP!_X<%_
M]9J/^"_W_BQO_P#$W1_PX+_ZS4?\%_O_ !8W_P#B;H _?ZBOP!_X<%_]9J/^
M"_W_ (L;_P#Q-T?\."_^LU'_  7^_P#%C?\ ^)N@#]_J*_ '_AP7_P!9J/\
M@O\ ?^+&_P#\3='_  X+_P"LU'_!?[_Q8W_^)N@#]_J*_ '_ (<%_P#6:C_@
MO]_XL;__ !-T?\."_P#K-1_P7^_\6-__ (FZ /W^HK\ ?^'!?_6:C_@O]_XL
M;_\ Q-T?\."_^LU'_!?[_P 6-_\ XFZ /W^HK\ ?^'!?_6:C_@O]_P"+&_\
M\3='_#@O_K-1_P %_O\ Q8W_ /B;H _?ZBOP!_X<%_\ 6:C_ (+_ '_BQO\
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M_P#B;H _?ZBOP!_X<%_]9J/^"_W_ (L;_P#Q-T?\."_^LU'_  7^_P#%C?\
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M[RY?^L>>":_?ZOQ!_9]_X(7_  L^!W[6/P _;%\6?MY_\%/_ -K#XF_LS_\
M"U?^%2:%^V+^U%X<^.O@3P[_ ,+F^&VM?"WQ[]CTS4OA'I'B#2/[7\/ZO;7E
MQ_PC/B?0?M^L>'/#%QK/]J66D1Z?+^WU !1110 5^0.M?\IX?!?_ &BQ\1_^
MM115^OU?D#K7_*>'P7_VBQ\1_P#K445 'Z_4444 %%%% 'X _P#!/#_E.O\
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M^_U%?@#_ ,."_P#K-1_P7^_\6-__ (FZ/^'!?_6:C_@O]_XL;_\ Q-T ?O\
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M:^'? 7V/Q=IOP\\$^(+G[-X?\;7.A7'_  DVH>(_)T?0?#&F:-_9%EI<D%V
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M6-__ (FZ /W^HK\ ?^'!?_6:C_@O]_XL;_\ Q-T?\."_^LU'_!?[_P 6-_\
MXFZ /W^HK\ ?^'!?_6:C_@O]_P"+&_\ \3='_#@O_K-1_P %_O\ Q8W_ /B;
MH _?ZBOP!_X<%_\ 6:C_ (+_ '_BQO\ _$W1_P ."_\ K-1_P7^_\6-__B;H
M _?ZBOP!_P"'!?\ UFH_X+_?^+&__P 3='_#@O\ ZS4?\%_O_%C?_P")N@#]
M_J*_ '_AP7_UFH_X+_?^+&__ ,3='_#@O_K-1_P7^_\ %C?_ .)N@#]_J*_
M'_AP7_UFH_X+_?\ BQO_ /$W1_PX+_ZS4?\ !?[_ ,6-_P#XFZ /W^HK\ ?^
M'!?_ %FH_P""_P!_XL;_ /Q-T?\ #@O_ *S4?\%_O_%C?_XFZ /W^HK\ ?\
MAP7_ -9J/^"_W_BQO_\ $W1_PX+_ .LU'_!?[_Q8W_\ B;H /^"!?_.:C_M/
M]_P4;_\ >-U^_P!7P!_P3K_X)U_"S_@FO\+/BI\+?A;\5/V@/C1_PNC]H#QQ
M^TO\1?B+^TOXX\.?$;XI^)?BG\1O#G@CP[XNU;5O%WAWP1X$_MC^V/\ A!-/
MUV_O]=T_5?$>H>(]5U[4]3UZ^^W006?W_0 4444 %?D#_P $)/\ E&5\$/\
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MX?\ !=?_ *6*O_.1O['G_P VU'_#O#_@NO\ ]+%7_G(W]CS_ .;:@#]_J*_
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MU%?@#_P[P_X+K_\ 2Q5_YR-_8\_^;:C_ (=X?\%U_P#I8J_\Y&_L>?\ S;4
M?O\ 45^ /_#O#_@NO_TL5?\ G(W]CS_YMJ/^'>'_  77_P"EBK_SD;^QY_\
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M8\_^;:C_ (=X?\%U_P#I8J_\Y&_L>?\ S;4 ?O\ 45^ /_#O#_@NO_TL5?\
MG(W]CS_YMJ/^'>'_  77_P"EBK_SD;^QY_\ -M0!^_U%?@#_ ,.\/^"Z_P#T
ML5?^<C?V//\ YMJ/^'>'_!=?_I8J_P#.1O['G_S;4 ?O]7Y ZU_RGA\%_P#:
M+'Q'_P"M115\_P#_  [P_P""Z_\ TL5?^<C?V//_ )MJ\@F_X([?\%?[CX\6
M7[34W_!?_?\ &_3OA7<_!2S\;?\ #JG]F!?)^&5WXI'C2X\,_P#"-I\3E\(R
M>9XF4:E_;,N@/X@3'V--573\VM ']+M%?@#_ ,.\/^"Z_P#TL5?^<C?V//\
MYMJ/^'>'_!=?_I8J_P#.1O['G_S;4 ?O]17X _\ #O#_ (+K_P#2Q5_YR-_8
M\_\ FVH_X=X?\%U_^EBK_P Y&_L>?_-M0!^_U%?@#_P[P_X+K_\ 2Q5_YR-_
M8\_^;:C_ (=X?\%U_P#I8J_\Y&_L>?\ S;4 ?O\ 45^ /_#O#_@NO_TL5?\
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MW_PDOQ-\816$/B/Q-L\1?$[5X]&_M&/3+%?[&\/II7A^T\C-CI5JTLQD]?\
M^'>'_!=?_I8J_P#.1O['G_S;4 ?O]17X _\ #O#_ (+K_P#2Q5_YR-_8\_\
MFVH_X=X?\%U_^EBK_P Y&_L>?_-M0!^_U%?@#_P[P_X+K_\ 2Q5_YR-_8\_^
M;:C_ (=X?\%U_P#I8J_\Y&_L>?\ S;4 ?O\ 45^ /_#O#_@NO_TL5?\ G(W]
MCS_YMJ/^'>'_  77_P"EBK_SD;^QY_\ -M0!^_U%?@#_ ,.\/^"Z_P#TL5?^
M<C?V//\ YMJ/^'>'_!=?_I8J_P#.1O['G_S;4 ?O]17\H7[44/\ P6<_X)V_
M%/\ X)P>+/BE_P %E/\ AK#X9?M,?\%/_P!C_P#8Z^(OPD_X=X_LJ? K[=X$
M^,WB/Q!J7BZ\_P"$]\.GQMX@MOM/A_P3J'AG[/H5MH.L0_\ "1_VSIGB?2[W
M2(([O^KV@ HHHH **** "BBB@ HHHH **_$'_@J;^VM^WU\#OVL?^";W['7_
M  3]T#]D#4?B;^W1_P -@_VAKO[8NE?&B[\">'?^&9/AM\/?BE:_8]3^"GBO
M2/$&D?VOX?U?QG9W'G>&/%WV_6$\,6\?]@62ZKJ$OG__ !U-?]8 ?_.BE '[
M_45^ /\ QU-?]8 ?_.BE'_'4U_U@!_\ .BE '[_45^ /_'4U_P!8 ?\ SHI1
M_P =37_6 '_SHI0!^_U%?@#_ ,=37_6 '_SHI1_QU-?]8 ?_ #HI0!^_U%?@
M#_QU-?\ 6 '_ ,Z*4?\ '4U_U@!_\Z*4 ?O]7Y _\$)/^497P0_['#X__P#K
M0'Q,KY__ ..IK_K #_YT4KYP_9-_9?\ ^#ES]CCX%^%OV?OACJ__  0QUWP;
MX1U+QAJFFZGX[U#]OK4_$\]QXU\8:YXVU5+Z]\/^'_"^E2PV^J^(+RWT];?1
M;9XM/BM8KF2[N4ENY@#^HVBOP!_XZFO^L /_ )T4H_XZFO\ K #_ .=%* /W
M^HK\ ?\ CJ:_ZP _^=%*/^.IK_K #_YT4H _?ZBOP!_XZFO^L /_ )T4H_XZ
MFO\ K #_ .=%* /W^HK\ ?\ CJ:_ZP _^=%*/^.IK_K #_YT4H _?ZBOP!_X
MZFO^L /_ )T4KS_P#^VM_P %H?@=_P %)_\ @GM^QU_P4"T#_@F!J/PR_;H_
MX:Q_L_7?V.M*_:MN_'?AW_AF3X"WGQ2NOMFI_&OQ7I'A_2/[7\0:OX,L[?R?
M#'B[[?HZ>)[>3^P+U=*U"4 _H^HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *_ '_ ()X?\IU_P#@XJ_[Q&_^L>>-J_?ZOP!_X)X?\IU_^#BK_O$;_P"L
M>>-J /W^HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M _ '_@@7_P YJ/\ M/\ ?\%&_P#WC=?O]7X _P#! O\ YS4?]I_O^"C?_O&Z
M_?Z@ HHHH **** "BBB@ HHHH _ '_@UQ_Y04?L,_P#=S/\ ZV'^T%7[_5^
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M@'[&_P#ZSK\.:^_Z^ /^"3O_ "BR_P"":?\ V8!^QO\ ^LZ_#FOO^@ HHHH
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M !1110!^ /\ P7T_YPK_ /:?[_@G)_[V2OW^K\ ?^"^G_.%?_M/]_P $Y/\
MWLE?O]0 4444 %%%% !1110 4444 ?@#_P %#_\ E.O_ ,&ZO_>7+_UCSP37
M[_5^ /\ P4/_ .4Z_P#P;J_]Y<O_ %CSP37[_4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?@#_ ,%#_P#E.O\ \&ZO_>7+_P!8\\$U
M^_U?@#_P4/\ ^4Z__!NK_P!Y<O\ UCSP30!^_P!1110 4444 %%%% !1110
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M_5?$MCIUNK*FG:=+X,32M0U"[,.G:;<:_IM[JMY8:7#>WL'PE^TK^W9\&?\
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M*** "OP!_P"">'_*=?\ X.*O^\1O_K'GC:OW^K\ ?^">'_*=?_@XJ_[Q&_\
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MIKWQ%H%CJ7G7_!QE^V;^TI^P?_P3BU#X]?LI?$C_ (57\6(/CE\(_!T7BO\
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M/#^J?:=/L)3;PQ@?2% !1110 5^ /_!KC_R@H_89_P"[F?\ UL/]H*OW^K\
M?^#7'_E!1^PS_P!W,_\ K8?[05 '[_4444 %%%% !1110 4444 ? '_!6+_E
M%E_P4L_[, _;(_\ 6=?B-1_P2=_Y19?\$T_^S /V-_\ UG7X<T?\%8O^467_
M  4L_P"S /VR/_6=?B-1_P $G?\ E%E_P33_ .S /V-__6=?AS0!]_T45^,7
M_!7C_@HO\9_V /$7_!/+2_A)X;^%6OZ?^UC^VS\./V</B9<_$_1_%>JOH'@'
MQ=<6L>KZSX,F\,^./!D.E>*;6*:1[/4?$$?B/18-H:YT.Y4," ?L[17XT_\
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MT3P_]C_X2_\ X3?P]_P@W]@_V/\ :_M'_"+^,?[4^T_9_(T[R?/E /RPU_\
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MB_H]OXI\07B:*LNL_$B#7/#T.HZC>7-]%X#L4*VE??7[=G_!+;Q1^TM^T/\
M 7]M3]F#]J_Q+^Q3^VC\ _!FM_"C2/C)8?";PA\>_!WC+X.^)9=0N]7\ >./
MA!XZUC0=%U007VKZU=Z!K5KKUC/I$NNZG<SV>IZE;>&M0\. 'Y[Z?_P6Z_:I
M\/?L6_\ !6>Z^,7P6^!/@W_@H7_P2BN/#FG>/=!\)W'CGQK^RU\2K;QU/$?
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MV?\ "I_[5_X7O_PJKPCX,\*_V;]G_P"%EZ;_ ,*O_M[_ (1#[?\ ;//^(?\
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M%]HWB;3[W4/"OAG3ENM CL[_ $74K.^G2/YST#_@@E^U!XA\=?L$>.OVF?\
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MM1IVKV.I3:PNI:)^O/[>_P#P3J_X;@^,?[ 'Q:_X7#_PK#_AAC]IO2_VC/\
MA'_^%??\)K_PM'^S7T1_^$._M7_A-_"7_"$^=_8V/^$A_LWQ=Y?VG/\ 8<GD
MXE\X^!__  2J_P"%,_$__@K)\2/^%\?\))_P]"U1]2_L;_A5_P#8_P#PH[?X
M(\>>#O)_M'_A8FJ?\+,Q_P )O_:/F?8?A_G^S/L?EC[;]JM #Z)_X)D?MDW/
M_!0+]A#]F[]KW4?"=CX&UOXR^!Y]4\2^$]+O;O4-(T7Q7X=\1:WX-\40Z-=W
M\,-Z^BW&O>'-0OM'BNS<W5KIMU:VES?:A/!)?7'W?7PI_P $TOV*O^'=W[$G
MP,_8X_X67_PN#_A2^E^*=-_X6-_PAO\ PK__ (27_A)?'7BCQKYW_"(?\)5X
MV_L?[%_PDG]F>7_PE&J_:?L7VSS(/M'V2#[KH _ '_@OI_SA7_[3_?\ !.3_
M -[)7[_5^ /_  7T_P"<*_\ VG^_X)R?^]DK]_J "BBB@ HHHH **** "BBB
M@#\ ?^"A_P#RG7_X-U?^\N7_ *QYX)K]_J_ '_@H?_RG7_X-U?\ O+E_ZQYX
M)K]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OP!_X
M*'_\IU_^#=7_ +RY?^L>>":_?ZOP!_X*'_\ *=?_ (-U?^\N7_K'G@F@#]_J
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OP!_P"">'_*=?\ X.*O^\1O
M_K'GC:OW^K\ ?^">'_*=?_@XJ_[Q&_\ K'GC:@#]_J*** "OS"_X*A?\%9/V
M;_\ @DK\.OA9\3_VE?"?QF\5>&?BU\09_AQH0^#7AKP;XFU+2=6M="N_$-QJ
M7B&T\8?$'P D.BQ:?93@RZ1<:SJ;S[(X]+<-O'Z>U_+S_P '(WAGP]XT^(__
M  1%\'^+M$TSQ+X4\5_\%8O@7X;\3>'=;LH-1T;7M UR]L-,UC1M6T^Z22VO
MM-U/3[JXLKZSN(Y(+FVGEAE1D=@0#]6?VVO^"LG['G["/[&W@[]N7XG^*=<\
M=?!CXG#X?-\(;+X26OAW7O&WQ=C^)>FP^(?#LWP_T?Q9XH\$:1J4,?A!KOQG
MJLNH^(-)33_#FF7\S&34!::==_7?[,WQ_P#!O[5?[/7P7_:4^'FF>)M&\"_'
M3X;>$OBEX2TGQG9Z5IWBS3O#_C/1[76]+L_$=CH>L^(M'M-8@M+N.._M],U[
M5[**X5TM]0NHPLK?QB_ME?\ !"WXA_LI?L@_\%$OB7\</CYIOQQ_9+_9(_9Q
M_:7M_P#@E+\![QM1UC4?V<=$^/\ JD?B/XC:AXWF\0>&;1YO%?A&V2W\$> K
MZT\6^-X[G2Y+SQ4LO@V_73?#FG_%'QZ_X3_XK:;_ ,$$/V:/B_K7[.-G^QKX
ME_X)7_#;Q_X3\$_MO_M _'/]FG]C;XG?M&Z'IMW8ZM#X[^(OP1L/[2O_ (B^
M$?#$G@BX\#^'=<OH=&:?6[?2Y+Y9O&P\.^(P#_0P^.'QI^'/[.7P>^)GQZ^+
M^NR^&/A=\(/!7B'XA>/_ !##I.L:]-HWA3POIT^JZSJ$6B^'[#5-;U26WL[>
M5X[+2]/O+VX<"."!W(%?%GCO_@JI^R]X-MO^">FKZ;!\3/B!X5_X*:>-_#?@
MC]F[Q=X.\):?::1!+XLT+2_$6B>(?B+I_CWQ%X'\5>%_#]QINKVC2+8>'-?\
M06\PEBGT!"@+_P FOPA_9Y\)_&/_ ((B?\%F/@CXQ^+OP'_:X^"W[)7B?XB?
M&G]DKPA^RS\4OVR/BQ\*?V6?B-X/^%'C'Q(OP]^'?QR^,?P^^%D?QD^'O@,S
M67B3PKI/A?Q7\:?!*6&N:EKGCC5=2N_$=E?:G\R:7\ _V*;_ /9#_P"#<'P;
M^ROXSCT'4?CM^W+\+[S]K_7O@)^T#XPG^)/AW]HCQ7\+_A!H?Q-M[[Q%I_CC
M6O$?P+^(;:+%80R^'/"S>!Y_#UK<VVJZ'I&ERWMOJ$@!_I%T5_%!\$?A!J'_
M  3>_P""K'_!9[]F+_@G)I'C7PKX8B_X)2W'[2GPD^#4OC/Q[\58$_:<L?#V
M@1^%O$FBI\0M8\;^(?$OB?4_$.L:A/#'XBO/$>H:E?ZY/HD5U!HCV.FV/X_#
M3?V*OA7_ ,$T_P!B7]O/]CK]ICQ+XN_X+W?$[]H;X6S^(;S2_P!I;QGX_P#V
MCOBK\5_$_P 3]1A^(GPK^+?P'E\::Y8R>!6MI=*L93XE\%>'CXWTT>$+?Q)X
MC\10^.&TSQ, ?Z<%?#7[!'_!0#X-_P#!13X:_$KXI_!/PU\3/"_A_P"%OQT^
M(7[/WB"S^*6C>%M$UF\\9_#9=&;7=3T:W\)>,_&]E<>&+L:Y:?V3>WNHZ?JL
MYCN/MFBV&R(S?S#?M0:;^QS\=_\ @O7^UKX*_P""SWQBTCX;?!;X _LL_ ?Q
MS^PEH'Q#_:,\;_LS_#O2=3UBQ\/ZKX[^(GPU\2>&_B5\.YM9^+.F^.6\4V&G
M#1]3U35M8N-,U&.WL=2?P#I#:5^<W[)_AKP%\3/^#>+]HWP-_P -MZ'^S=X2
M^(/_  5S\8:/X6^*?QZU7XL6?PL_:#L[K0O!>H:-\*_VE?B%\,M&?X@^"_ '
MQ3TJU/B7QGX_EM]%AL=8T.RDUN?3UO) @!_H[U^97[0W_!5/X&_L_P#[9GPA
M_8*M?A-^TW\>OVC/BQX;T+Q[>^'?V=_A/:>/M'^$7PNU[Q;)X-A^*OQAUO5?
M%GA6+PSX!T[5;>[EUO5-&@\37VDV-O'+=Z6D^IZ+;:G^%?\ P;PZ]X0^%7[<
MO[:/[)-A\'O WPF\;Z+\'?AQ\4/%EK^Q;^UK>?M(?\$Y]>#:KIVA6GB?P!X(
M\43>+/'/P/\ BCX@AU&'51I/B+XG^(-5\2^'K[5WUCPOX5@T7P[)J_ >(O\
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MMXT^(VA^%+GQ%<:KI47@#7';4='T*+R=3L-;\8:A8>%N3^(7_!%_]K+X3_\
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MO["DW[:UY_P43O?V?="U7]LB\M-/L_\ A<FM^*?B%KLMA_9/@_3? &F7^A^
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MVG:5X;^(/B'4/#S:-\.?B!::])%8Z?H_B.\T?Q%!J[QVUM;I>,J'[&_X)!?
MSXM_"3_@H]_P7=\4^-/@[\1OAE\-?B]^U;\-?&GPE\1^*/A]XF\%^!_BA:2Z
M;\3+GQ/XL^'6KZKI&FZ!XUMY-3U2"XU[7?#5QJ<;W^HPRZA=&XO$:3^AVB@
MKX _X*Q?\HLO^"EG_9@'[9'_ *SK\1J^_P"O@#_@K%_RBR_X*6?]F ?MD?\
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MDMM/LW^*7AO^R_"%K_87Q%>TTG2K5_&^E_9?$S6VF:? =3,5E;+']65^6?\
MP2G_ ."EO_#SCX5_M"?$S_A2O_"DO^%#_M3_ !-_9H_L3_A8_P#PLG_A*O\
MA7.B^#]8_P"$U_M+_A _ /\ 8?\ ;/\ PE?V?_A'/L&L?V?]@\[^WK[[5Y5L
M ?H!8?!7X-Z7\5=<^.VF?"7X9Z=\</$WABS\$^)/C)8> _"UG\5?$/@S3I[2
MYT_PEKGQ#M]*C\7:MX8L;BPL;BST&_UBXTJVGLK26&T22WA9/./#G[&?['_@
M[XMZC\?O"/[*7[-GA;X[:Q?:EJ>K_&KPY\"_A?H?Q;U34M8.[5]0U'XCZ9X6
MM?&-]?:J>=2N[G69;B^/-U)*:^'_ /@FS_P5G\!?MV_LJ?&K]K+XH>#_  A^
MR-X!^"'Q\^)/P5\3ZCX]^-6C:WX/M-/^'MOX5E_X3K7OB!XA\)?"[1?"]EJ\
M_BF&U_LS4+::#3Y8(Q_;EZ]XL</VGHO[77P*^*WP7^*OQB_9>^,GP!_:8T[X
M9^%O%6K2W/PV^/OPUU;P&WB/0/#FH:]8^&O%OQ1T#5O$WA;X>V^HM9)%J'B#
MQ!NM/#^G23ZW?6TEE9S @'7_ !4_9B_9K^.GB3P/XR^-O[/7P.^,7B_X97HU
M+X;>*OBI\)O 7Q"\2?#[41?66IB_\#ZYXMT#5]3\)WHU+3=.U 76@W5A.+ZP
MLKOS//M8)(XK']EO]F73/A]X]^$FF_LZ? G3_A3\5/$&M>+/B?\ #*Q^$7P_
MM/A]\1_%/B6>TNO$7B7Q[X,@\/1^'/&'B#7[JPL+G6M9\0Z;J.HZK/96DU]<
MSR6T+)\Y_LH_MW^"?BQ^S-^S#\8/VB_&?[,GP%^)O[3$NKZ'X/\ AYX8_:M^
M#7QB\'>+/&^D^(-8TB3P=\(?BOX2\1/X/^,FNI9Z=;WNIZ;\.K[Q))H]_<7>
MBRSW5QIL]P_T3\+?VJ/V8?CEI'CCQ!\$_P!H[X#?&'0?AE</:?$G6_A;\7_A
M]\0=(^'UU';7=Y);>.-2\)>(=7L_"=Q'::??W3PZ]-82+;65W.RB*VF9 #0^
M"G[-O[.W[->BZIX;_9S^ ?P6^ /A[7+V+4=:T'X*?"SP-\*]%U?4($EC@O\
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M9_"_X?3O:7EUH:>*/"W@WQ'XK\7ZS?VNE6^E/97][?V7T]X8_P"#B7X'W?\
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M&O\ P41_X)Y?"WQ-\*8_B?XUC\*?%3XJ:QXY^#>KZ]^RIK7A'XNZ%X$GT)?
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M9'_K.OQ&H /^"3O_ "BR_P"":?\ V8!^QO\ ^LZ_#FOO^O@#_@D[_P HLO\
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M&3X5>)]9^!U^-*^-6D^'OB'X1UK4_@_JALKK4AIOQ1L--U>YNOA_?G3K&]U
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MM8U;X'>++NXL=*T3XG?V'+IJSWD+/92R/#;3 '0_#K_@A'_P22^$_P >-/\
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MGA:94$J%@#G_ -EK]CO]G+]BSP;XQ^'_ .S/\.O^%:^$?'_Q-\6?&/Q=I/\
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MO_6//!- '[_4444 %%%% !1110 4444 %%%% !1110 4444 %?@#_P $\/\
ME.O_ ,'%7_>(W_UCSQM7[_5^ /\ P3P_Y3K_ /!Q5_WB-_\ 6//&U '[_444
M4 %%%% !1110 5_#-_P35_X*1? /_@A3K'_!1C]C#_@HUX?^-/PB^)6M?ML_
M&G]H/X'ZEI_P>\;^*O#_ .T9X&\<Z7X?T#P^/A5J.BZ7<V%Q<ZB_@K3[JRU/
M7;_2/"<W_"7Z592^)+:^TW7X-,_N9HH _P ^KX4?LBV>B_\ !N=XKN_V\_"_
M[3O[-/A/XQ?\%%-0_:M\&^)/ ?P&D^.NL?!+PSK2Z=I7@SXK?M.?L\ZW>^&Y
M/%7P 5M$UQ_$?A_58)9=6M-9\">(+#2KR/4],BG]\_X)2>-W\2^,/^"O-CX3
MT']F#]H[P#:_L&^)1??\%)_V3?@-\1_V6?!OQ8\0VG@G6K?1_A1\1_@[]C\,
M_L^7/Q(M=$>X\1S7_P (_ NF7'AF33?$-EJWBGQ5+XAO+?P__<S10!_G(>&O
MAQX&^+__  32_P"#4GX7_$WPQI?C7X>^//V\?''ACQGX1UR%KG1/$WAW5?CI
MK=MJFAZQ:*Z"\TO4K5Y+34+*4FWO;26:UN8Y;>:6-^@_X*??!+X&?L[?MH_\
M%W/@[\%_ L/[/'P:US_@E/\ LZ^,+WP)^S9\/M#\.^%+/QA#\>OV<X-.U:X^
M'OA@^'="T;P->7KX^+=UX;LHKBW\#:IX]\3Q:)XCUZXNM/UG_1/KY3_;4_8R
M^!W[?7[/7B_]F;]H73/$-_\ #KQ?=Z!J[7?A#Q'?^$O%OAWQ)X3UFT\0>%_%
M'ACQ!8;WL-:T+6+&VO+7[7:ZAIER%DL]4TW4+"XN+64 _DR_X([_ ![_ &5O
MCS_P4W^ ?Q7U?]H__@GA\(?C!X"_8SE_9I^$?[-G[$OP+_:S^"6E?M$66JB#
M7+[Q=XB\2?M0?L__ +.^DZI8^';/PO=3_#SX7^#[#Q[>VT5O]LC\42IHOEW_
M /;S7Y _"+_@C3\'/ OQ[^#G[1OQE_:G_;J_;5^(7[.LFKW_ , [?]K[XZ>&
M_'?A/X2^(M>TP:+J_B[PUX:^'_PR^%MEJ/BB]TM(;5]2\7GQ,L+VMC?VUO#J
MEC9WT'Z_4 %%%% !1110 4444 ?@#_P0+_YS4?\ :?[_ (*-_P#O&Z_?ZOP!
M_P""!?\ SFH_[3_?\%&__>-U^_U !1110 4444 %%%% !1110!^ /_!KC_R@
MH_89_P"[F?\ UL/]H*OW^K\ ?^#7'_E!1^PS_P!W,_\ K8?[05?O]0!6O+VS
MT^WDO+^[MK&TAV>;=7D\5M;Q>9(L4?F3S.D2;Y72--S#=(ZHN68 \#XX^,?P
MB^&6N_#_ ,+_ !)^*GPX^'WB7XL^)!X-^%?AWQQXX\,>$]=^)?B\QQRCPI\/
M])U[5+"_\9>)#%-%(-#\.6^I:H8Y8W%KM=2?YLO^#NGP9\6=<_X)2>)_%O@_
MXT?\(-\,O!7Q$^&9^+GPD_X5SX:\3?\ "[5\1_%#X?Z5X"7_ (3W5+J'Q!\-
MO^%;^)0WBO/AFVNSXPW_ -A:SY%@HDKY1_X*B^!/VP_A+IG_  ;M^#_$O[3G
M@G]HS]JQ/V\+:/PO\?\ XD? G2?AIX$^V^++?PP? \7BCX-?"+Q1I=O>Z3\/
M=!U73M%N(=$\5Z-J?C(Z&M]?ZGI=YJES-  ?VA45_*C\#O\ @H+^W]^QM^V7
M_P %3/V4_P!MC]H;PS^W;H_[)'[!%_\ MX?"GQ_HOP#\$_L[ZU)'H/AW3]:U
M+X9W/A3X:MJ%K::-=W6L2:;%>ZOJWCG68X-'M-<D\262:A?:-9?GC^S3_P %
M;/\ @M;XR'[,G[5MKI/[9?[3_@[XS_$[PSJ'Q9_9$\*_\$>O%'A/]F#PG\ _
M'>KR6E]KWP"_;4\)V^M>/?'&K^!-&6UU;P[K/C'4KKPOK<VHSMK>JZK8^&6'
MBT _MP^+?QI^#GP \%WGQ)^._P 6?AG\%/AWI]YI^G7_ (^^+?CSPM\-_!=C
MJ&K7"V>E6-YXI\8ZKHVAVUYJ=VZVNGVLU\D]Y<,L%LDDK!3YG\%?VT_V./VD
MM<U'PQ^SK^UG^S/\?/$ND6(U35O#WP5^/'PL^*>N:7IAD\H:CJ.D^!O%6NW]
ME8F7]V+NYMXK<R?()-W%?AW_ ,':N!_P1B^+)*EP/C-^S]E -Q<?\+%T_*A3
MPQ8< 'KG%?D]\&O@!?\ [6'_  4:_P""6/Q4_8 _X(Y_M)?\$O?#O[+'C*?Q
M]^U3^T;\8/V?K;]D3PU\1_AQ<Z)H\6H^$-&T;PX_V#XIS^-])L?%/A>.>#[=
MK%U!X]73=<L['P3>:[K-D ?W>T5_#K\(/^"KG_!6'0?V$/VY?^"G7Q&_:8^&
M?Q#^%'[&GQ\^/WP#\&_L[:A^SOX)CUGXO>+_ !!XU\!?#WX7:U\2_B+X'L/
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MY8G6M+4:?J7VFT AK^F2B@#^*#_@H!\&_P!CC]D?_@I!_P $Q_BO^VE^SO\
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M4/\ ^4Z__!NK_P!Y<O\ UCSP37[_ %?@#_P4/_Y3K_\ !NK_ -Y<O_6//!-
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M_:@_85\ _LF_!7X)?!3]H+X9>)/"7AW]JGX8_'[QOX#U'Q+X7\<:?I6J>/\
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ME^$,FO\ QK^%_B'X2R?&7P'%\+M"NM=\7_$KPN_AB7Q3I.E^"/"M^='U&_\
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M7_SFH_[3_?\ !1O_ -XW7[_5^ /_  0+_P"<U'_:?[_@HW_[QNOW^H ****
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M[\!>(]'\7^#O$^EM++ FI^'O$V@7FH:+K6G230RQQWVFWMS:R-&X25MIKLJ
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MI9_V8!^V1_ZSK\1J/^"3O_*++_@FG_V8!^QO_P"LZ_#FC_@K%_RBR_X*6?\
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MZ;I&FZCK&H:5X:GU74[+2+"\U2YLXK"UGN$_5F@#\ OC;_P;Q?L\_&']I_\
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M[XB^%/">C>"I8-01);GPSXHO]*\76VCW6G^(KC08_#VIZ?JEUQ'P _X+C?\
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MEJ>GZA>VEO87EM<R?S1_"3_@G+^UG'_P4=\ _P#!+7QG^SM\6(?^"7?[-_\
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MNGS:UHECI=]9Z+8Z5';^%M.?PU=]#^R]_P $POB-\%/V_?%/_!0;XO?M:?\
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M;X2:;K&C*;GX6:'+\-O[?TQ;*VU;Q9)J?_"0:UXE_HM_9K^#W_#//[.WP(^
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MI^GV%M/>7U]>W$5K9V5I;1M-<W5W=3O'!;VUO"CRSSS.D44:,\C*JDC^&/\
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M=XY$8,C%2#5JOY8)/^"DO_!3+XG_ !%_;,^'/_!*']FK]B*V_9!_X)6:A-\
M/%T_[4_B;XLVGQ$^,WBCX,^'+]?%7@OX"Q_##6M+\&>$(M!TKPL?#WA]_B.6
MT.XAN_#7B*[\2VZ:IJ?AKP[Q,7_!?3]L7]I_Q_\ \$TO!7_!/W]GO]GS6-8_
MX*$_LM_&KXA2>'/VC-8\>:3;_"GXV?!_Q'XV\&>*QJ/C[PEXBTP:U\)/!>N^
M ?$FHS6NE_#J[\;?$;1K338-'N?!=_K4C:* ?UJT5R?@+_A.?^$&\&?\+/\
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M_J*** "BBB@ HHHH **** /@#_@K%_RBR_X*6?\ 9@'[9'_K.OQ&H_X)._\
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MXI_M<ZM-\6OC1X/UCXH_$+]JO_@J=^P+X<_X)U_&SP/XV\3:KI7C/X0?#O\
M98\:_$/P)=_!KQ6UGI5SI'@[2M*(\?>%=;TGQ;%IGA.QUA](M_"7TK\?_P!N
MK]L']C3P3_P5G_X)3Q?M!_&GQY^V1XY_;'^ OA#_ ()W?$_QS\6/&NJ?%O\
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M/#NB>)Y='U[P1\13XL7^W-'MO%/C7PW?ZAKUR^H_U?\ [:'_  29_P"">?\
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M7^GZ3I?CC7[;P!<:'9V%CJ4_B#_A(=;U;\UCX\_;W^%/_!%[_@GQ_P %=_\
MAZ7^WMXT^-\7[07@?P3>?"'Q9\6[2_\ V?/$GPQU'XV_$SPQ/X=^(/@\Z$?$
M?Q=\5W+Z':RW_CSXS>+_ (B7%SHLTOABVT2QTZQ\/2:%_9[\ _\ @E%_P3W_
M &6[WXVWO[/?[-7ACX3-^T9\-M'^$GQEL_"/B?XAV6C^,O >AZ'>^';/33H,
MOC"?1/#^J7.G:EJ,FM^*_"VGZ)XN\2ZO?WOB+Q%KNJ>(+J?5)%U?_@E1^P1K
MW['_ ,/_ -@G5?@-]J_9.^%OB;3?&'@3X4?\+1^,\']A>(](\3ZSXRT[4?\
MA.K;XB0_$K4_L_B3Q!J^H_9-8\8ZA83?:_L<]K+86]K:P@'\T8U7]HK_ (*&
M_$#_ (+M_'#XO_\ !1K]J/\ 9,L_^"?_ (N^,WP5^"W[.?PF^*7A'PM^SGHO
MP^\,?#GX@:?8>(OV@_A9XP\)ZGX6^+^B_$^317)OM;O-'U*2[G\2C2/$-DL?
MA)_#W[)?\&TG_*$C]AG_ +%?XH_^KU^)]?1_QV_X(J?\$M?VFOV@Y_VIOCM^
MQO\ #;XC_'"^TZVTS6O%.L:GXYMM&\4Q6>BS^';.^\:?#S2/%FG?#;QOKUGH
MLL5A:>)O%WA#6O$5M'IVAO!JD<WA_0Y=/^TOV:/V:/@E^Q]\$? W[.7[.G@K
M_A7?P:^&MKJEEX*\'?\ "1^+?%O]BVVM:[JGB74XO^$A\=:]XF\5:C]IUO6=
M2O=^K:Y?R0_:?LUN\5I#;V\0![K7P!_P5B_Y19?\%+/^S /VR/\ UG7XC5]_
MU\ ?\%8O^467_!2S_LP#]LC_ -9U^(U !_P2=_Y19?\ !-/_ +, _8W_ /6=
M?AS7W_7P!_P2=_Y19?\ !-/_ +, _8W_ /6=?AS7W_0 4444 %%%% !1110
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MTZ]N+GP]I.I^(AJ-OIDF@2Z_\Z?M.?\ !P'\;OV6H/B7\8?B-_P2W^*'@_\
M8\^%OQJM/A+J?Q5^+_[1?P^^!G[1WC'1YM?7PX?BC\,?V,OB+X)T_P =^,_
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M#XF^,OVR_@)^S%KD/C/PO]INO'/A?X%?"#XD6FL^./CYJ/A+3-/U=9X/#O\
M8UYJGB/29O#&F6,]WJWA:Y\0@']+=%?@Y^TS_P %V/AY\(/@W_P30^/7P,_9
MT^(O[4_@3_@I5X_TGP/X#\.^#?%?AWP?\5?"MUK%CI?DZ7;>%-:LM2\)^*?'
M%AXCU&?PAK/AK4_B+X&\/Z5K.EZC)<^.1IT#7@_/G]J3_@O7^W/9_!__ (*.
M_ 72O^"<OB_]E+]NS]E3X$V_QB-I?_M1? 3XHZ7\/O@'XJ\.7<M[^TY9>(9/
M!DW@'QUK?PNNM5\&7\OP<\+6_CIO$LFM7VF1^)[36/#>J:40#^NFBOR8_P""
M*G[4'[7/[7'[ OP6^+_[8GP8E^&?CK6?!7@27PQ\0IOB9\-_'LW[2_@_4/ ?
MAO5X/V@9?#GPTT+P]IOPBE\:ZM?ZHLGPPU;3UUG07L3+.1!=P(OR)\:?^"Y?
MQK3X]?M7_"_]AK_@F7\5?VYOAC^P?J5QX=_:V^-^E?'GX?\ P0L/!GB_1;35
M=3\9>%?A;X%\8^%O$'B'XVZWX1L-"UNVO]'\,7.G^(;O7M,>QLM#DT;5/#GB
M/7 #^B*BOXJO^"T?_!6O]J/]H']DC_@FSXU_X)P^'_C-X1_9Z_;Z^+7PST"Z
M^.?PG_:*\"? 3X\:O\2-3USQKX3US]BG3KJ[TS7M<^$/C9=>T&<ZM\>;.^U7
MX=:1K.@'3)AXB\/W$W]K?UB_L>:%\0O#/[*_[/GA[XLZ%\1?"_Q-T;X2^"-/
M\>>&_BY\8]+_ &AOB?H7BFVT.TCUG2?'OQTT6QTS2?BWXJT^]$MKK/Q T_3[
M2V\47D<NK1PH+F@#Z0HHHH _ '_@OI_SA7_[3_?\$Y/_ 'LE?O\ 5^ /_!?3
M_G"O_P!I_O\ @G)_[V2OW^H **** "BBB@ HHHH **** /P!_P""A_\ RG7_
M .#=7_O+E_ZQYX)K]_J_ '_@H?\ \IU_^#=7_O+E_P"L>>":_?Z@#_/.UWQ;
M^SKX9_X+7?\ !;JU^/O_  2:^//_  5/;6_&GPEL_!FA_ _]EO3/VCI_@]?C
MP#>1ZA?>)-4N@^I_"V#QP;G3;33?$&APSZA=/X;O;B")[C1+=&]'_9_U+_@K
M5_P2I_8D_P""3O[-?@WQ/I/[,_Q(_;1_X*.?%SPQI7P1^,6CZ+\6-'^%OP6^
M)Q\)Q_#_ .'?CYM:T/7/$_ANUT[Q7?>(_B9JNA_#K7O"OBJZ'BA[?7=9T#Q5
MJOB&QT?^O3]G3_@G9\%/V9/VM/VR/VR? ?BCXI:O\3_VX-3\!:K\5]"\7:WX
M3O\ P'X>N/AUI^I:=HB?#S2]&\$:!XATF&Z@U2X?55\2>*/%KSRI"UI)8HKI
M)H_M<_\ !/\ ^#?[9_Q*_9 ^*?Q1\2_$S0?$'[%7QTL/V@?A99^ =9\+:7HV
MO^,].;2V@TSX@6_B'P9XIO=5\,.=(MO-LO#FH^%=58//LUI-T9B /Y[O^"@O
M[?'_  4M_9B_:#_8[_X)B>$/VC_C!XT^,=_^SCK7[1O[2W[:'[-'_!-_PY^T
MK\>?B#"?B%XW\.>'?#?P\_9&TB>^^&7A/PG9Q:);:/XQ\7BWU(Z>KZ+J\=W9
M:BNHZ#KWSY\9/^"MO_!7[X3?\$J/C7\0/'>E_%KX._M)_!/]N#X)?![X3?M,
M?'S]B@?LUW'[4GP$^)EWKDEGK_B3X!?%7PAKWA;POXI$VCS:5\0HOAM8O8>&
MK2^T&U\.ZR^K"[UW5?Z4_P!N3_@EO\ _VZO&_P (OC%XA\?_ +0?[.?[1?P+
M75M/^&7[37[)7Q13X/?'+0?"GB%95\1> [CQ-<^'O%FC:UX,ULSW'VO2-;\.
M:A);17VM6FE7>G67B3Q+;:Q^,W_!2C_@@[-I'_!,3QY^R_\ L)>#?BM^TU\<
MOC;^UQ\&_CI^T%\2_C_\<?"VM?';XW?\([?ZO!XE\9?$?XL?$;7/ASX?U"ZT
M/1-0DAL=+T/^Q)9);[4M2L-)O/$&K:UJ-\ >PZ;^U!_P4L_8K_X*Q?L4_LQ_
MM<_M4_"S]KOX)?\ !1WPU\:YM*\*^"OV<?#/P'D_9<\;_"OPR?&4=C\/[K0?
M$7C#QUX\\"3-?:5X>EUWXK^)=;U"?2S?:K.^C:CIKG4?R)_:O_X+*?\ !1CX
M?_#7]H_]M7X*_M[6_P 7/!WP>_:5;PKX8^"O[.W_  3=\9?$'_@GI%\,]/\
MB!I?@T>"OB/^W[\9/@_\*O$^I?$&6WUS2Y?$-W\,_&M_INIZG)IR?#W5KG1O
M%D&K^$_Z1OV8/^"(_P"RU^S?^TS9?M<:O\5/VNOVG/B]X4\'ZQX!^"Q_:^_:
M$UCX]:%^S9X&\16^LV&L>"_@C'K>D6.N:1H4FA:]J7A>W7QAXA\;WMEH<]TE
ME?P:AJFM:CJ?RKX@_P"#8G]AK7O@_P#$[]G-/VB_^"A^B_LV^/O%,_C7PO\
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M;QIX&\-?%+4]>^*%S,GB;5O%WA;P]XQ\6Q1>.Y9XKW17TVWUU)X3IB3)\E_
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M7P,E%M\4O%T^J?#[4=/U!M9T"ZU/P_K5SK5AH5WHD-QI4OB'1@#X0U']NO\
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M:!:Z?J5Q/K#_ "Z='<MQ0!_.1XH_X-O_ (JCX/?M/_L>_!__ (*I?&/X-?\
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M? KX7>&_VH+[]K+X=:_?_M"Z5X.T:U^,^HWC_M ?%?PZ+/4?B0MK_P );?\
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MLWB3P=IL5SK&K_VCIOAG4=*L->@U34;/7[;4[.^N8)?7_@IXS_9"^"G_  4
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MM[#PMXCTO4Y[K4M-U[P_:1Q:3J]AJ%S<7UGJ%I<6]W/-<1R2-_4E0 5^ /\
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M\&=,>UTRXOM1C\!P?%T:Y<(GANX%F^M>(/'5U_=710!_/E\2/^"9G[;G@O\
MX*9?LI_\%"OV3_B1^R[.OAC]D[X9?L9?M0_#G]H&'XJ%)/AAX;\9V7B#QGXM
M^!NI_#S1O,U'QOJ&E"6W\*VGCE_#VB:=J^F6MYK!U73M9N-,T?=^"W_!+/\
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MUY=_TQT44 %%%% 'X _\%]/^<*__ &G^_P""<G_O9*_?ZOP!_P""^G_.%?\
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M2V\3VEWI/AL:])XFNM5U:]UFZDU2^2;]6OBI_P $O/V8_AE_P7\_9?\ V4/
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M;V_L7?LD_P#!27X4_MK?MF_M^?"3P!^UA^V!\3?VO_BIX&^*C_';18O&E_\
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M HHHH **** /P!_X-<?^4%'[#/\ W<S_ .MA_M!5^_U?@#_P:X_\H*/V&?\
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MTFGR)XUM_"_QL\"_#K7-9\(0IJ^CM?>)]#L-2T331K.C#4;ZU.K:<+G\??\
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ML7_*++_@I9_V8!^V1_ZSK\1J #_@D[_RBR_X)I_]F ?L;_\ K.OPYK[_ *^
M/^"3O_*++_@FG_V8!^QO_P"LZ_#FOO\ H **** "BBB@ HHHH *_ '_@Z._Y
M04?MS?\ =LW_ *V'^S[7[_5^ /\ P='?\H*/VYO^[9O_ %L/]GV@#]_J***
M"BBB@ K_ "]_V-/@?_P3O^*/Q0_X* ZI^U__ ,$EO^"HO[?GCNT_;^_:$TOP
MY\4OV&_A9\6O'/PU\'>%#XF^T1>!_%VJ> /CC\,=+LO&-MJUQJFOW%G=Z+?W
MR:%K6DW#:D\$T%K;_P"H17Y;_P#!+S_@FM_P[:T']JO0_P#A='_"Y_\ AIO]
MK#XD?M0?:O\ A7/_  KK_A"/^%A6^DP?\(/Y'_"=^.O^$E_LC^R]_P#PDOG:
M!]O\_;_PC]EY6Z0 _.[]OC_@HQ^T-^PE\7O!'[(O[,_B+_@F3^RQ\$OA3^S+
MX0U+P;XN_;_^.GB/QAX_^(M]IFDS>'O!?PE^&O[._P %/BQ#^TAIMMI&G:!9
MZ5/\2?B#X:U;3?%6I6VLV>@SZSKNGV=IXB_&G]L__@J[_P %+OVW/V2/^"-O
M[6O[.6M?!;]G#1?C9^V]X.^$'B/PGH'Q%_:(\/ZAXI_:K\*_$7Q_X3TG0?B#
M<>$+O1K;7?V,?&7AG2-)\0^+?!MR^M_$+3]6U&31(;W7H-,&JW?]"OQ@_P""
M-_Q8US_@H)\<OV[?V:?^"@WC[]EBZ_:K^'G@GX:_M(>"]*_9Y^#/Q@\7:SX>
M\$>']&\+6<7P:^+/Q/749/@N+[1O#VE/>I_P@OCDG6?M6J)(%MO#5EX:^=].
M_P"#<VRTC_@FE^SS^PCHW[9WBC0OBO\ LJ?M67G[77P,_:ITCX+:29/#_P 1
MV\2>)=<TJW\1?!G6_B3KFD^*=.TR'Q+(L@F\=:>U_J^F:;J;QP::VI>']0 /
MA_\ X*)_%_\ X+F^$/\ @J__ ,$C?ACX7^*/[$WA;XC?$SX:_%1O"7P]\,>-
M?VO]%_99\?\ Q5T'X0Z%=?']OVC_  EI^J6FN^+/ .BZ^VH7/[.?]F6-]XCT
M^U:VE\:-!>M.]?5]Q_P7,_:,^#'[)_\ P5AC_:>\"_ VP_;X_P""=OQETGX2
M^ ?!7@'P7\2-(^$OQMM/C5=Z1H7[+7C>P\">(?BIXA^(]YIGQ!U>;5M;UO2M
M+\>VEP/"<>ESZ??VEY<SF+[,_;%_X)'_ !T_:J/[ GQIT7_@H+XB^$7[?'["
M6C^)-/TW]KK3_P!FOX:^+M ^*.I?$#PSHGA_XCZ]K?[.&H>)M(^'WAV[\12Z
M-)>:7ING:Q?Z#H%OK.KZ;)I6LI_95SI7Y._$W]BKQ[_P44_X. ?AG\4X?V7?
MVNO@I^SA^RY;^#[K]L/XM_'CX7CX0_![]L'XQ_LF>./%X_9_\4_!>%M2UO2_
MBMX1\0:Q/H%W%JUA)!#/\-["1KK1?#[-IUYK@!^NO_!6.]^+FI?\$%OVNM2^
M/MCX1TKXX:C^P_J&H?%W2? -GJ6G^"=(^(][X7TJZ\9:1X4M-8\0>*]4BT'2
MM>EOM/TPWWB36[F6UMHY9-1N6DWGZ%_X(S@'_@DY_P $Z@0"#^QW\!P0>00?
MA]HN01W!KW_]NO\ 9?\ ^&U?V/OVB/V4/^$X_P"%:?\ "_/AAX@^''_">_\
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MZAK]C>WVIZ/)IVK7NC, ?F=^PK_P<<_&3XI?M>_LF_ /]HKQ;_P3K^,'@_\
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M **** "BBB@#\ ?^"A__ "G7_P"#=7_O+E_ZQYX)K]_J_ '_ (*'_P#*=?\
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M_'L(N/"'CGQCX<LOA]=Z]\)O"VN6WFW-MK7Q;TWP/8QVUGJ-S<S00:9J,EJ
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MX=>)O$<D7AV6_74_@[KOB[PK:BQU:>YU6P34]&T&Q_/OXQ?\''7[.OQ!^/\
M_P $_/A+_P $Z/C'\#OV@]-_:)_;(\-_L\_M$67C7P+\9/#OCGP5X$\07.B6
MD'BSX<:+XGN?A+J$HN;J]U&RL?'4OA[Q[X#DU"U6P"2WD4L$@!_0AXT_9Z^
M/Q(^%D7P,^(GP.^#_CWX)00:+;0_!WQI\,_!?BGX60VWAN[MK_P[;Q?#[7-$
MOO"4<&@7]E9WNBQ)I CTJ[M+:YL5@F@B=/6;:VMK*VM[.SMX+2SM((K:UM;:
M*."VMK:"-8H+>W@B5(H8(8D2.**-5CCC541550!^6_[5'_!;/_@EM^Q3\9X_
MV>OVE_VO/!?P[^,0@TF?4O!=IX2^*/CZX\+KKB6T^DQ>.M6^&O@7QCX?^']W
M>V-Y9:O'9>-]6\/WBZ%>V6ORP1Z+=V]_+VGQU_X*Y?\ !-W]FC4OA9IWQQ_:
MU^&O@"/XW?!W4OC[\(]?OHO%&J>"?B'\)]-T]]3'B?PM\0/#_A[5_ VJ3ZS:
M*I\(^&H?$)\6>-[FXLK'P=H6NWU_96UP ?HW17PG^S-_P4U_8-_;!^!7Q _:
M7_9]_:7\ ^+O@?\ ">ZU6U^*/CS7X_$/POM/AQ_8NFIK%_>>.M'^*^B>!_$?
MA/21I3'4;/6]=T>PT?5+.&YGTR^O([2Y:'R[]E#_ (+-?\$R_P!M_P"+#_ S
M]F3]JOPO\0OBN^DZKKFD^#=2\%_%7X;WWBW2=#GOX-8O?A_=_%3P'X)TKXC1
MZ8-+U2[O5\!W_B.2#2],U'5Y$&E6-U>0@'Z>T444 %?@#_P4/_Y3K_\ !NK_
M -Y<O_6//!-?O]7X _\ !0__ )3K_P#!NK_WER_]8\\$T ?O]1110 4444 %
M%%% !1110 4444 %%%% !1110 5^ /\ P3P_Y3K_ /!Q5_WB-_\ 6//&U?O]
M7X _\$\/^4Z__!Q5_P!XC?\ UCSQM0!^_P!7P3^V_P#\%$_@I^P-J_[+FC?&
M'PO\4O$EU^UM^T)X3_9L^'$GPUT3PGK%OHGCKQC-#!IFJ^-W\4>-_!LFF^$X
M'G0W]]H,7B36(E#&WT*Z( /WM7\G'_!T_H'B[Q7:_P#!(KPO\/\ QR_PP\=^
M)/\ @I9\,M!\%_$F+P]I_BZ3X?>*]7M$T_P]XVC\*ZM<6FE^)7\+:M<6FN)H
M&I75M8ZPUB-/N[B&"XDD4 _>']NC_@H#\&_^"?F@_ ;Q%\9?#7Q-\367[0_[
M1GP[_9C\%1?#+1O"NLW6E^/?B6FK/H6K^*$\5>,_!<-EX0M!H]T-7O\ 29];
MUF R0?8] OPTAB^YJ_A(_P""PW['W_!1?]GP?\$WO%W[7G_!5S5OVZ_A[JG_
M  4]_98\/Z'\++_]CGX1_L]1>'/%MQJ>O:A:>.4\7^ ?&?B+5M4DL=*T[5]$
M'A^YLXK&===>_>Y6?3X(Y>/_ ."KOA[7OVE/^"W7[2OP3_:WUO\ 8@F^!WPI
M_9P^%WBG]E3X=_\ !2K]KS]I7]D;X #PSXF\(:2?BC\3O@MK?P/MM/TSQ7\3
MH_%T/C+2O$USKFJ07MAIFAW4NE_VN_@+[?X4 /[YZ*_S9_BGXU1_V'O^"$J?
MM(_MM:9\4/@]\/?^"HWQ0^'\7[67P=\:?M*>#AX6_9_T#4/!-C/9Z5\;/C5\
M)_@?\5;M/AG;WGB;P=!\4O"WAU?#>C>&-&L;+PSXM,GAF\DTK]"/V5/B5^R5
M^Q1_P5)_X*(:)_P3,^)WBKQM_P $WO O_!*?QS^TS^T5I_[.OQGU7X_>#O#/
M[1'@^Y%];^*OA=\3/&_B7XI^'-6^,U]X.C1;*\U?Q+J.G1ZMJ7B.WUXWEKX5
MU#2]% /[D*^6_A5^V=^SK\:_VA?VC?V6/AMXXNM?^.'[)[^ X_CGX1D\)^+]
M(M_"3_$K19O$'A!;7Q)K6AZ?X9\2G4-,@DEF/AK5]56PD AO3!(<5_F^Z-XE
M^#OPW;_@DK^U/^S6_P"SS\-/CY\6_P!N7X1:IXE\7:9_P4<^)O[6?_!3#Q_X
M$\?>.KVR\=V'[8^B^&_AY\&OA1X;\,:XUI8Z#XGTV+P[]IO([^R\(WFF:;J%
MW\0(=:_:7_@F)^QI_P $ZO@+_P '&W_!1KP!KGAGP=\,OB9\#_$OP7\4?L#>
M#/&/QF\?:+XJN-:^*/P5U_Q!\;KGX=^'_%/Q#2^^,T^I:1XEO=<U#3M=M/'B
M>&M'O&U/0K/1M.M(Y[< _I(E_P""I_P:^'?[)GQ2_;+_ &M/A)^TC^Q+\)OA
M7\8M1^$>IZ?^T7\'_$-A\0-;'_"6:)X.\*^._#_@;P&GC?7=2\#^-=7U^SAT
M'7;>VEL;@6^HW<-S<:/;P:M=_1'QM_:EO?A)XN_9?\->&/V=OVB/CQI/[2_Q
M#L_!4WC[X+^ XO$G@;X&Z'>Z=::C#\2/CIJU]JFE7/@;P.\=]"8]4N+&9&2T
MU6*1HM4@T[2]6_SPOB=^SQ\,OB=_P;M?M\?'#Q-X(NO$7Q*_9O\ ^"MOQGU+
MX8^*+75/%=NO@6R^)WQ-_9Y\$?$*^NM&T75;7P_J]KK/AY[?27G\5Z3J\.DR
M217.CMIVI2K<M^RG[6_PZ_8V^%FG_P#!LUX/_8*U#P)JG[-=O_P4ATK5/#%W
M\./BEJGQB\+-XFUW7?"VL?$**#QQK/B[QQJ5SJ,'CB]UZ'6='N?$$K^'-52[
MT(66EBP&GVP!_:U7SW^UA^TIX%_8[_9N^,W[47Q-TGQ9KO@#X&^!-8^(7BW1
M_ ECH^I^,-1T71(TDN[7P[I_B#7?#&BW>J2*X%O#J?B#2+1SGS+V(8)_@"_X
M*@?#[X;>&?VL_P#@I'^UQK/Q=_97_;P\/_#_ ..>F/XMTC7?VO?C-^QI_P %
M0/V*]6\(:S##8?#']FO_ (3"(?".[\">%-1%SX7\&:UX-^&?Q9U'X@1);QZ+
MIL^K:6T;_P!7'_!47QG;?$;_ (-]_P!IKX@V47CN"S\<?\$_[/Q=:1?%$V;?
M$M+;Q'X!\/:O /B"^G10:?)XV\J[0^*9+&""SDULWSVL,4#)&H!YU^SS_P '
M(W[%WQT^)/P%^'OBS]G_ /;Q_97TS]J'6-&\.?L^_%O]JC]G;2?A]\%?BSXB
M\2&Q3PUI'@WXA^%?B1X_L-4.ORZII4>GZPELOAL#5=/FO-:M+6ZCG/\ 0=7^
M7Y>?'"X^$/[+W_!'/X_^,?\ @IE^SQ_P4QN_V=/B%^SE=_"S_@D5#\./!7P_
M\;?!75M3\+10:?;77CCX$?$&Y\:^+?'GPAO],T70]'U7XY^%8](NM>>!=?T[
M67O+OP9XA_KH_P"#C3X>ZQIG[(/P2_;W\%:7(_Q3_P"":?[4'P2_:OTB".X-
MIJ%_X&L?&6A:!\3?"#W<+QR+I^IV&H:-JNLP1R;+RU\,FW=)DD,3@']#=?+G
M[0'[2FL_ SQ_^S?X$TK]G#]HCXWP_M!?%$?#C5?&WP7\#VOBKP-\!M/%K!/)
M\0OCIK<^KZ>W@OP.KW*+'K#6MU;2I9ZJ@E748=,TS5_X)M9_;+^(O[)OQI^*
M?_!?VUUSQO?_  N_X*FM_P %(?V</AA96NAW>D:;X7T?X2^%O#6B_L"ZCJ&E
MW>FW.JIXC\9>)_@]J,=Q?SV9M-/TS3IM2NAI,8\217?W7\:_V1&_8?\ @]_P
M:I?L\:K8M9>-M%_;F\#>,?BLLQ:2]D^+?Q1O/"7Q%^),5]=/B:\ETKQ5XFU'
MP_;7,Q\S^S=(L81M2%$4 _JYLO\ @H1^R]K7Q!_;+^$OA;QCK?BKXH_L%>#=
M,\;_ +1_@?2_!OB:PO\ PYI>N>"-4^(&AVN@:YXFT[0/!OBO4M6\/Z1=&"+1
M?$UQ:6MZT-MJE[8!VE3M_P!BW]K3X<_MU?LO_"']K/X2:+XV\._#GXTZ#J'B
M+PMHOQ&TW0M(\;6%EIOB+6?#,\7B#3O#/B3Q?H5K=/?Z'=S1)IWB358FM)+>
M1YXYGEMX?XDO@1^QI_P3J^ O_!7[_@N!X USPSX.^&7Q,^!_P7G\4?L#>#/&
M/QF\?:+XJN-:^*/[)/Q&\0?&ZY^'?A_Q3\0TOOC-/J6D>);W7-0T[7;3QXGA
MK1[QM3T*ST;3K1)[?X\OOV0_A3\(?^#?S_@FU_P4_P#!.L_&&S_;8\$?M*?#
M_2?!/Q<O?CE\6-2M_!'@:Y_: ^+.BGX9^!? -UXM?X=^!O R/86^M-:>#_"V
MAZW=ZW)J-UJ&NWEOK6MVFH@'^FC14-M(TUO!,P :6&*1@N0H9T5B%!)( ).,
MDG'4GK4U 'X _P#! O\ YS4?]I_O^"C?_O&Z_?ZOP!_X(%_\YJ/^T_W_  4;
M_P#>-U^_U !1110 4444 %%%% !1110!^ /_  :X_P#*"C]AG_NYG_UL/]H*
MOW^K\ ?^#7'_ )04?L,_]W,_^MA_M!5^_P!0 4444 ?@GHG[%O[3%G_P<6>,
M?V[;CX:^7^RIJO\ P3WL?@=8?%/_ (3'P _G_%&'QQX>UB7PO_P@\?BIOB/%
MMTZQNKC^VYO"$?AUO*\E=6,[QQ/Y5^S1_P $S_VB+[XU_P#!PYHOQH\,3_";
MX5?\%)->/AOX"?$VV\4>"?%,VN^%/$GPR^*_@?5_%Z>&O"/C&]\2:'_PC]SX
MPTNY;0_&EKX4O]51VMX89+?[6\7](-% '\$GP$_X(@_M<Z/H7[/7[+?Q$_X)
M#_!.?7/A7\2_#MO\2_V^_BG_ ,%/OVFO'O[-GC#P'X'U_P#M&#X@_#_]BOX4
M?M+?#3Q]HGC_ %C3#"?#.BWVC>&O"-EXATI9-8\+Z!HOBB>U\(?IU^W7^QY_
MP5"^*_\ P4B^-7B2^^!7C;]M#]A_XF?"?P)X3_9N\&:/_P %+/'?[$?P(_9I
M\86>@66G^.O$GQY^%'PRU;2O'WQ?O=;\0MXEU"Z?0_#/Q%@U;PKJMCH-]YL4
M]MI/@3^J&B@#^&WP9_P1Q_X*5>!?^"-7_!/GX6Z-\ O"^H?M<_L+_P#!2.3]
ML/4OV;-7^,GPNTJ/XD>"-(\;^--4T[1O#OQ:L/%WB#X;Z1J.JP:OHM[&NO>(
MHI+72)=2DO FN6%OH6I_KYXS_9C_ &T_CQ_P5[_X)/\ [>_B_P#9H_X5/X!^
M%?[(WQF\/_M+Z+_PN7X3^._^%$_%?XD^$?&45E\-O[2TO7]'UKXG_8M8URTT
MG_A,? '@[4?#=SG[?+-86HE,/]"U% '\UG[,'[ /[6_P[U?_ (.+KKQC\)O[
M'@_;N\>?$W6OV4W_ .$\^&>H?\+4TSQ#\-?C!X?T>YVZ7XSOG\#_ &S5_%.@
MVGD_$=?"%Q;_ &[[1=106MK>36_Y"VO_  0F_;-\#?"O_@EO\;?&/[&*?M9^
M+O@!^RIXS_99_:;_ &'M-_;4/[*_Q%\/O?\ QL^*_P 3/!'Q,^'/[1?PQ^*N
MC> ]473H?'[-XH\*KX\FTS4+>WL+%-,U/4]7O-9\$_WFT4 ?R'^"O^"4O[4M
MC_P22_X*I?#'PU^PM\'?V8/C[^VS#I3?"S]F'X?_ +47Q/\ V@?B1+IGA34+
M1-!A^/?[2?[1?[0'C3X4^(?B"]M=ZN(-1^',_P ._!W]DVL-UJR7.L:I#HWA
MOZ%_:5_X)[?M?^/_  /_ ,&YVC^$?A%_:VH_L'_%;]G+Q+^U;;?\)]\,+#_A
M5>B^ _AU\,M!\5WOG:GXULH/'']E:KX>UBU^S?#>7QA=WWV/S]-@O+:XM9I_
MZ:Z* /YW/^"0_P"RU^W3^PG^UO\ \%#?@Q\5OV<?#NJ_LI?M'_M5?'3]L+X9
M_MC>'OC=X#E2XOOB%K'AV/PY\)=2^ F;CXEVFKRZ']KO]6\4WG]GZ!H^J:-?
M:3;-KUK?:7K$NK_P4%_90_;8^'G_  4]_9H_X*N?L6_ ;PS^V/>^ _V=_%G[
M*?Q;_9AU;XQ^#O@3XP'AC7_$'B/Q/HGQ)^'7Q$^)R7'@.WET_4/$MU%XDTBY
METS4[BVTJST_38=1C\4ZQJ?AO^@ZB@#^3GX<?\$R/V]/%O[*G_!>#X[_ !M^
M$_@SP+^V%_P5C\":MIGPY_9(\"_%'PCXPL/AOI_A#X;>-?"OP[\*^)?B_J6H
M:)\/]2\;:]>>,IK+7=8M/$%MX+B32;76TO=(76;C0O#_ .\?_!,SX/?$;]GS
M_@GK^Q=\#?B_X=_X1'XI?";]FWX2> /B!X7_ +7T+7_[ \6^&/!^EZ5KFD_V
MWX8U/6O#NJ_8;^WF@^WZ)J^I:9<[/-L[RXA9)&^XZ* "BBB@ K\ ?^#7'_E!
M1^PS_P!W,_\ K8?[05?O]7X _P#!KC_R@H_89_[N9_\ 6P_V@J /W^HHHH *
M*** "BBB@ HHHH ^ /\ @K%_RBR_X*6?]F ?MD?^LZ_$:C_@D[_RBR_X)I_]
MF ?L;_\ K.OPYH_X*Q?\HLO^"EG_ &8!^V1_ZSK\1J/^"3O_ "BR_P"":?\
MV8!^QO\ ^LZ_#F@#[_HHHH **** /XP?AA_P1,^"/[>'_!83_@L[XS_X*"?L
MA_%[6/A7?^*_@]??LO\ Q6UZ7X]?!SPEK=UK7@W5-*\;Z]\+O%_A?6O!?A#X
MG3:5+I7A[[6ER_C31]'O+:VCNK"-+V[@O/"K#P__ ,%3?AW_ ,$8?%W[&D7[
M&OQ2^*?BO]B/_@HI8?!O1M=\;_L;^#/CSX[\1_L,>%-8UK6?#'QU_9;^$'QZ
M\ -X!^.7C?PYK8'AGP?XHT7PKXGGTOPQJ6F:QI\ND9G\4^%O[LZ* /X1? 7[
M*/[:'[4W_!2WXV>+K'X=?\%2_#WP^^/_ /P1Q_:0_9\\"?M&?\%%O!'@WP+X
ML7XA>,[G7-*\+:!K[_ GP;X9^'WP;TL:U=07FC_#7Q;IGAOXI7-I;:EXTU/P
MY'#K>G7]S\V_'?1?VQ_BG_P16_9<_P""9NA?\$</V]?#WQK_ &,?C/\ "*?X
MM?$?5/V?[1OA9!=>'_'_ (ZL-3\:_ /5='U;Q)X[^-MYXV?7IK[QOK_PX\('
MPSX>TS6M=U_4O%%WX1N-.OM8_P!$RB@#^6?QI\$?VL]+_P""V/\ P4\^.'PK
M_9L\2^.;'Q3_ ,$>[?P%\#==^)'P[UA?V>OBU\<[*Q\&R:'\(+_QKXCM=*^'
M'B.XU35;(Z?XD\(77BBT\S2UU*#69],T];V]MOPEUKX0_P#!0+XS_!#_ ()@
M^&KW]EK_ (*V1>-/V?OV\?V>O%/QP^'OB3]COX#_ +,W[$/P*FT_QCXCO=7U
M3]G#X#?LY?"GP1X_N_".G032:I?_ !>O]'N?AEX>LIM5U'5-8\.^)/' T6O]
M'*B@#^8_]I/PY\>_V:O^#B[X+_MFC]D_]I?X]_LX_'+]B3PW^R"/B%^S=\-)
M_BE:?"CXE:Q\<&U&XUWXRPV]_I:> /A[X=TJ;3]=\0^+M4N/LL6A7D]YH\.M
M7FDZOIME^.&A?\$W/VU_B)_P1R^-GA.R_9<^*&I^._A%_P %M?&G[8VJ_LO_
M !+\#Z]X \4?M(? #PS;Z;8:KIO@_P ->.M)T6;QIIWB*RUB?4]#M[1VL?&%
MGH>L:=X=&N^(QI&DW/\ ?_10!_*A\*+7XY_\%'?^"V'[&/[<W@7]A+]K']B'
M]GO]C#]GCXN>"_BAXW_;#^#MO^SS\0?C#KOQ*\)^(= \)?"7PQX#&K7VN^)O
M#'@B\\6_VU;:U+J&I^$K&YM/%4,-OI-T-#F\4_$/P*_8I_: T[_@WW_X+._"
M;7OV2OC%8_'/XP_M9?M ^+/ OPSU?X#>-;7XL?%+2;?Q=\(M5^'OB7PEX-O/
M"B>,/&^G03:9J.I>#-9T?3=3MHI=/O;S1+E7M)Y(_P"XVB@#\!?V,?\ @E)X
MJD\-?L5_M,^.?V\_^"L?PT\:>%/@M^R=X@\6?L=)^U%J/@W]F+1_$?PW^#OP
MXT+6OACXI_9[UCX='5M/\-ZKJ/ANX3XB^"]2U^VO[[6M0\1+=S6,]V\,'[]4
M44 %%%% !7P!_P %8O\ E%E_P4L_[, _;(_]9U^(U??]? '_  5B_P"467_!
M2S_LP#]LC_UG7XC4 '_!)W_E%E_P33_[, _8W_\ 6=?AS7W_ %\ ?\$G?^46
M7_!-/_LP#]C?_P!9U^'-??\ 0 4444 %%%% !1110 5^ /\ P='?\H*/VYO^
M[9O_ %L/]GVOW^K\ ?\ @Z._Y04?MS?]VS?^MA_L^T ?O]1110 4444 %%%%
M 'XT_M#?\'!/_!(?]E3XU>/_ -GCX^?M;CP%\8?A=K,7A_QWX0/P&_:;\3C0
MM7FT^QU6.T/B'P;\&/$7A;4@UAJ-G<&XTC6]0M5\[RFG6:.6./ZOE_X*4_L3
M3?L;^,/V^_#7QW\.?$']E;P)H5UKWB?XD_#;3]?\=2Z3'9W=CI]SI.H^$O#F
MDWWC'2O$=I?:IIUOJ7A_6=!T[5=#2\BOM>MM+TU)[V+\+?\ @EQ_PA/_  _4
M_P"#A7_A-_\ A%O[._X2W]F;'_"5?V3]B\C_ (1#Q?\ ;L?VO^X\KR,?:_X/
M*QYWR8K\A[;Q[:?"/7/^#JGXI?\ !./QGJWPQ_99\,> O@E>?#3XB_L\>(M;
M\%^"/#W[0=KJ6FQ^.;KX*^+O EYINDZ3);:OJ7Q%2:?P;J%O%#H^H:2NC,OA
M:ZTD2 ']_P#\.?'WAGXK?#[P+\4/!5U=WW@[XC^#_#7COPG?7^E:GH=]>>&O
M%VC66OZ'=WFBZU:6&L:3<W.F:A:S3:=JEC9ZA92.UO>6T$\<D:]E7\8?[7^I
M?\%)OB_\./\ @E#JOP,^+O[1'QS^'#_\$\OAE\4_VC?V8OV0?V^/"W[(O[??
MC/QCKG@+1DOOVD-8\3^*/[>^)OQP\#,]S%;67AK0K#4[K6/B+I&J1ZM<1-K=
MS?#R;XM_\%2OVE/"'_!!?X;>*?V=/VEOVG/'OQF\3?MXV/["_P 3/C-^T7X*
M^'/P9_:H^"6GWW_"1ZGXF\"^*O&&L^,?%'P^C^(.E0V6D>%M&^/^N>(+&;3]
M,\26VK>+)? OCG1+TZ4 ?W*T5_&-^R+\7?\ @H#^P'^USXW\+?M+_$;]I;X6
M?LG>)/V*OC7\7_%OA[_@I%_P41_8[_;Z_:/\ ^-/@SX0\2>*M/\ C]\$OAY\
M*_B7IWQV\:_#L6'A>\TKQ7\.?"7A$^&;W5Y=<U*]U^R2WT6W\,_GI'^U%^V[
M\#-._P""7'[:?A']HK_@JYXRT/\ :I_;6^%O@_Q+\5OVP?VA_@1X<_9W_:<^
M%OQ3\3WD>O:#X _X)X^ _B_\=[OX.Z.=!TV2WT/6+JYTZU\-:?>'7_#U^][X
MD\(MX4 /]$2BOXX/^"PX_P""C5U^W/\ ''Q;\-/BC^U_\6?V1/A9\ /"+I\-
M/^"8/[</@;X%?'S]CSQ=J&BQ:QJ/Q&^/W[,5O)+\0OVC)_$-[:W/BOPII5[+
MH/AR]^']^]E)X@TW^SXL_)/QC_;_ /VS/VU_B'_P2M_96_9D^-O[;?QO^%/Q
M>_8AUC]HKQ3XG_9Z^*WP&_X)M_M>?M,_$;P7X]^)/P]U73?$GQ)\=>+=<\(>
M&+CX:P_#V1OB-X&^'/C'6K;QY./$OBG19-4T3^PO$VA ']ZM%?@)_P $%?B3
M^V?J/@O]K?X ?MD>+KWQIJ7[.'QXC\-_">[^)7[5?[,W[5?[47A#X>>);'5+
MJ+X8?M0^+?V</'/B]4^)'@?4M$N5.O?$?3_"GBGQ6-6OQ9:'9:-H%MIFE?OW
M0 4444 %%%% 'X _\%]/^<*__:?[_@G)_P"]DK]_J_ '_@OI_P X5_\ M/\
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MBTC1/A=9:[IO@O0=.O/$7Q%B^ .F1>$9]5N?B[XQT;P+X&672-%TR^3_ (2
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M^'?%W@GQKH&E>*O"/BKP_JD#VNIZ%XC\-Z[:7^C:YH^HVLDEM?Z9J=E=65Y
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M?!FO:5XH\+>(=+G+"#4M#\0Z'=WVDZM83%6$5Y87=Q;R%6"2'!QTU 'X _\
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MOM+?PY\0[/PZP\3>&D:T6Z?5+WQCH0TV:YTR7PSX7\/WWAZ]N?%?YL?L&_\
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MFRZNVDZ]8ZAJD/PF\4^&+_2+=H-.N/%GA_Q(E]'W7[+G_!";Q_\ L@?M6_\
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M^":/[,/[8/[._P /_B]XD_;H_:DNOVE/VAOC[\8?$/Q9\0Z9X:U[Q]J'P#^
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M^*O@'6_!]Q\1?BA^T+\2/@I8_'OP)H^EMK-W;R>#/A-K TC7-(ET^'7(;_\
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M89_[N9_];#_:"H _?ZBBB@ HHHH **** "BBB@#X _X*Q?\ *++_ (*6?]F
M?MD?^LZ_$:C_ ()._P#*++_@FG_V8!^QO_ZSK\.:/^"L7_*++_@I9_V8!^V1
M_P"LZ_$:C_@D[_RBR_X)I_\ 9@'[&_\ ZSK\.: /O^BBB@ HHHH *_G!\/\
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M:2;9R(Z]QH _ '_@OI_SA7_[3_?\$Y/_ 'LE?O\ 5^ /_!?3_G"O_P!I_O\
M@G)_[V2OW^H **** "BBB@ HHHH **** /P!_P""A_\ RG7_ .#=7_O+E_ZQ
MYX)K]_J_ '_@H?\ \IU_^#=7_O+E_P"L>>":_?Z@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K\ ?^"A_P#RG7_X-U?^\N7_ *QYX)K]
M_J_ '_@H?_RG7_X-U?\ O+E_ZQYX)H _?ZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\ ?^">'_ "G7_P"#BK_O$;_ZQYXVK]_J_ '_ ()X?\IU_P#@
MXJ_[Q&_^L>>-J /W^K^+#]K7]C[3_P!MO_@Z&\:?!_4OVA_VI_V9K:Q_X)I^
M$_&@^(7[(7Q:@^#/Q2NY-&\<Z=IR^&KWQ9<>&?%D<_A'41K37FJZ-_9B-=W^
MF:1<"ZB^Q%)?[3Z* /XROV6OV,[7]B'_ (.9/ WPCT+]I#]JO]I=M;_X)=^/
M/&T/Q"_;&^+</QL^)&E7NJ_%*^T:/PYIOB6U\-^#!;^#=/.A1:C8Z&+/S(=2
MU/6;G[>?MRI!_.E9_"/X>^&O@K^TK^RE^V[^T./A/^WUK_[3GBN7Q)^S=H__
M  1W?]J#_@H'\5?'VL^/8-;\$_$;]GK]L"X^,7PSOM;TCQ>D5YJ_AJ2V^('@
MK0WT>?Q%IUD=?TKQ]IUSXZ_U8J* /X&_BG\0?V&?@1_P7>^(/CC_ (*T^!;C
MXI_#+P?_ ,$M/V7-/\2^,_CC^S1J?QST/PC\7[K1/A7H\OC#XR_"[X<Z9\<O
M#_A'Q-XBU"36="@U5(_&GAGP_P"-M<71='\92R7VFZQ?_//AK6-9^$/_  0I
M_:7\<:M^R#>>,OV&_P!H[_@KY-XZ_9P\'?'W1_VB+'X3_ C]D'Q#?:9XE\,?
MM >._ 7[/OC/P)\1O$/P6T;6O#>G:=H/@VTUG2_!6N>,[B'5+B'QC->Z-I?B
MC^X7PG_P3_\ @WX._P""@'Q3_P""CVF>)?B9/\</B[\"_#?[/WB3PK?ZSX6E
M^%5CX,\+ZGX?U;3]3T/0[?P9:^+K;Q/-<>&[%+R]O_'.I:5)#+=K#HMO))#)
M!]RT ?Y^7[$'AGX,?M%?\%N/$GA#PO)\ _VFO@=\<O\ @D]\1M&>;P+_ ,$[
M4_8I_9P^+\6A^/\ 27\/0^&?@K\3)/$L/Q/T+P_XA\)^%HK3XL:AJFLZ1>:_
MX:M]'T+4+?3O!5C;6'F/[%^O_LR:%_P;+?\ !3+]GS1? >@> ?V]_@?\-/%N
ME_MG:5??!35/ 'Q<M['5OVA/$4_PBT[XC_$'4?!NCMXZ72=&AU6PT30Y?%.O
MWW@N."ZT^ZTW0TN($N?]%NB@#^#KXY_\*(^#GQ^_X(9_M3?\%-?AO'X^_P""
M7NA_\$DOAU\,[/7?&WP@U_X\? OX>?M.ZM\.X-0$OQ)^&^B>%OB$EWJ?BKPU
M<^%+3PR][X0F;5-0TZQU'38;D> =7O\ 2_WM_P""$?B/]FGQ]\*OVJOB=^QG
M^P]XA_8R_99^(7[4OC'6OA)J^H>-_B3<>%/VH=/MM/L=-N_VA?AO\$_'>DZ)
MI'P"\$>(+>UTO0](\'> K"/PV(=$312EE=>$VTG3?W8HH _A\_9P_81_X;?_
M ."Z/_!=&P_X;*_;S_9"_P"%=^/O@!>?;?V'/VA_^% ZAXZ_X23P?JT/V7XB
MW/\ PB'BS_A)[/0?[&\WPU!LL?[+GU769-T_V[$7V]\<OA]_PJ;_ (.'?^"(
M'PN_X3?XA?$S_A77["7[1'@C_A8OQ;\2_P#"9?%/QU_PB_P\\?:+_P )=\1O
M%WV+3?\ A)_''B+[%_:WBG7_ .S['^U]:N[V_P#LEOY_E)_5+10!_EU?"/XB
M_P#!+?PA_P $X/\ @J)\,?VDOV=H?%O_  4 _: _:C_:K\)?L<>+]0_9=\8>
M//'/C_Q4][X:\/\ @'2?@/\ 'F#P#XD\.^%+[X>>/=8;4?&WAG3?%_A76)(=
M6B@?1O$5UXCTRSU#]@M1_9<;XG?\%*/^#<;]FW]O;X=67Q.UK3_^"7GBFP^-
M7PS^*EM-KMIJ/C+P'\--?UFUT#XD:1?7M[:^*K_PWX@T72QXAT[Q!)JVF:IX
M@T:2XU&UN@ @_N3HH _SZ/$<'_!-S]D/]I+_ (+9_#7_ (*[?LZZ/K'[0/QF
M\=^()?V +3Q7^SGXK^)K^.?V;;CP?KO@[]GSP1^QUK6A>%-<\-_"Z_\ !MO=
M>#/!&FS>%?%_@.?PO]@T#PP=;TN/X9:I%X;[+XP_L^2>#/\ @C9_P1%M_P#@
MHM\7/CY^R3\;O@CXG\=:M\.?CSXU_98TW]KW]GCX":=KFO75U\'O 7[97P6\
M<O'8:+))\,!\.O#?PPD\1>&?$5Q\.+CP[K^D:OI$-KI&IP6O]\M% '^?I\)?
M%^I>+/\ @AE_P7NFM?@S\!='\$PZSI\GAS]JS]EWP%\7?@]\!OVPM5GO]&'B
M7QQX1^$7Q,-CX>\,:GX7GAL;'7=5^$_A3P-X"U>'6M'TS3_#DL/AVT\0Z[VW
M[=/@_P#9UTWP3_P1B^-?Q"_:3U+]CSXR^&O^"8OPF\,?#OXM_M*?L6^'OVP?
M^">?Q&TNY^'.FWM_\&_$_P#PDUOXGM?A1\9KU+K5)]9\6Z?X%U?4IO >LZ):
M6%W:ZR^C;_[U:* /P2_X-O?$&L^)/^":FAWU_P#LW>!_V;=&3XT_%V'P;8_"
MW3?C#X:^%?Q?\+'6+*:T^.GPV\#?'+4]5\>>!/"GQ OI=0,/A]Y--T2?5-*U
M37]'\.>%8-:?PWI7[VT44 ?@#_P0+_YS4?\ :?[_ (*-_P#O&Z_?ZOP!_P""
M!?\ SFH_[3_?\%&__>-U^_U !1110 4444 %%%% !1110!^ /_!KC_R@H_89
M_P"[F?\ UL/]H*OW^K\ ?^#7'_E!1^PS_P!W,_\ K8?[05?O]0 4444 %%%%
M !7QI\0_^"C7_!/7X1>-/$'PV^+'[=_[&?PP^(GA*\73O%7@'XA_M0?!'P5X
MT\,Z@]O!>)8^(/"WB3QQIFN:->/:7-M=+:ZC8VT[6]Q!.$,4L;-]EU_GY67@
M3QSXX_X+D?\ !:F+P5_P1M^"W_!7A].^(OP4?4-%^,7QH_9V^#L/P,2Y\%W"
MVVJ:#<?'_P (^*[?7I?'IAFM-0A\,)936">%;1]5:=+NP$0!_>O\.?B7\.?C
M#X)T#XE?"3Q_X)^*7PY\66LM]X6\?_#GQ5H7C?P3XELH+NXT^>\T#Q5X9O\
M4]"UFUAO[.[LI;C3K^YBCN[6XMG=9H)47E_C7\?_ ('_ +-W@^W^('[0'Q;^
M'GP9\$7GB+1/"-GXJ^)7BS1?!^AWGBCQ'<-;:'H%IJ&MW=G;W6K:E)'/);V,
M#R7!M;6]O71+*QNYX?YT_P!LO]IKXZ_L[WG_  3O_8X_9R^(WP[_ ."6E[XX
M^!.J?%;XI_L??LG_ +)NL_\ !0?]K_P5?);B_O\ X<?!;X1?"CX!>.?V=Q\*
MO"OBP^,;'Q;\7]:N/"LGBS4--U_Q'X(TK5;?P_K=EJ'Y'_%G_@JM^V+\9O\
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M!_X.CO\ E!1^W-_W;-_ZV'^S[7[_ %?@#_P='?\ *"C]N;_NV;_UL/\ 9]H
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M^L>>":_?ZOP!_P""A_\ RG7_ .#=7_O+E_ZQYX)K]_J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OP!_P""A_\ RG7_ .#=7_O+E_ZQ
MYX)K]_J_ '_@H?\ \IU_^#=7_O+E_P"L>>": /W^HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *_ '_@GA_RG7_X.*O\ O$;_ .L>>-J_?ZOP!_X)X?\
M*=?_ (.*O^\1O_K'GC:@#]_J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /P!_X(%_\YJ/^T_W_!1O_P!XW7[_ %?@#_P0+_YS4?\
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M\>:5-X%G\1:IXB@L=5N);*[\/>*O"^FQW:0R3Z3<PJ\$GL?[)?[9/P!_;>\
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M** "BBB@ HHHH **** "BBB@ K\ ?^"A_P#RG7_X-U?^\N7_ *QYX)K]_J_
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M?@#_ ,&N/_*"C]AG_NYG_P!;#_:"K]_J "BBB@ HHHH **** "BBB@ HHHH
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MLO\ @I9_V8!^V1_ZSK\1J^_Z^ /^"L7_ "BR_P""EG_9@'[9'_K.OQ&H /\
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M>.?AOX+_ .2G_P!D_P#"C?\ A8/@'PMXX_M+_DGFI?\ "S/[(_X27^R_L?\
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MX%@UV-],L[R#Q!X?O(=+OK< _LVHK\,_VJO^"OOQ>\"?MB:]^P=^P9_P3_\
M'7_!03]H?X5_"S0?BY^T%86OQX\ _LV> _A!X7\66^E7?A+2I/B#\2] \0:9
MXK\::SIVM:3JX\.0PZ3)/INJV4FB7WB#4+3Q+I_AWYKUW_@Y+^'DWP6_8O\
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M_@I9_P!F ?MD?^LZ_$:C_@D[_P HLO\ @FG_ -F ?L;_ /K.OPYH ^_Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^ /^"L7_ "BR_P""
MEG_9@'[9'_K.OQ&K[_KX _X*Q?\ *++_ (*6?]F ?MD?^LZ_$:@ _P""3O\
MRBR_X)I_]F ?L;_^LZ_#FOO^O@#_ ()._P#*++_@FG_V8!^QO_ZSK\.:^_Z
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M?^L>>":_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#I8J_\Y&_L>?\ S;4?\.\/^"Z__2Q5_P"<C?V//_FVK]_J* /P!_X=X?\
M!=?_ *6*O_.1O['G_P VU'_#O#_@NO\ ]+%7_G(W]CS_ .;:OW^HH _ '_AW
MA_P77_Z6*O\ SD;^QY_\VU'_  [P_P""Z_\ TL5?^<C?V//_ )MJ_?ZB@#\
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M5E;^_P#_  [P_P""Z_\ TL5?^<C?V//_ )MJ_?ZB@#\ ?^'>'_!=?_I8J_\
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M^'>'_!=?_I8J_P#.1O['G_S;4?\ #O#_ (+K_P#2Q5_YR-_8\_\ FVK]_J*
M/P!_X=X?\%U_^EBK_P Y&_L>?_-M1_P[P_X+K_\ 2Q5_YR-_8\_^;:OW^HH
M_ '_ (=X?\%U_P#I8J_\Y&_L>?\ S;5]_P#_  2X_88_X=K_ +"?P,_8I_X6
MC_PNC_A2_P#PLW_BY?\ PA/_  KG_A)?^%B_&+X@_%G_ )$W_A+O'?\ 8_\
M8_\ PG?]@?\ (UZK_:']E?VK_H/V[^S;/[_HH **** "BBB@ HHHH **** /
M /VL?@7_ ,-0?LL?M+?LT?\ "4_\(/\ \-$?L_\ QD^!?_":_P!B?\)-_P (
M?_PMOX=>(_ '_"4_\(Y_:_A__A(/^$?_ .$@_M;^Q/[>T3^U?LGV#^U]-^T?
M;(?Q ^$__!)__@LY\#OA9\-/@I\+?^#@W_A%_AE\'_A_X-^%OPZ\,_\ #J#]
ME36_^$=\"?#_ ,.:;X3\(Z%_;/B+XC:OX@U?^R/#^D:?I_\ :>NZKJ>L7_V?
M[5J>H7M[+/<R_P!'U% 'X _\.\/^"Z__ $L5?^<C?V//_FVH_P"'>'_!=?\
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M -IZ%JNF:Q8?:/M6F:A97L4%S%_1]10!X!^R=\"_^&7_ -EC]FG]FC_A*?\
MA./^&=_V?_@W\"_^$U_L3_A&?^$P_P"%2?#KPYX _P"$I_X1S^U_$'_"/_\
M"0?\(_\ VM_8G]O:W_97VO[!_:^I?9_MDWO]%% !1110 4444 %%%% !7P!_
MP5'_ &&/^'E'["?QS_8I_P"%H_\ "E_^%T?\*R_XN7_PA/\ PL;_ (1K_A77
MQB^'WQ9_Y$W_ (2[P)_;']L?\()_8'_(UZ5_9_\ :O\ :O\ IWV'^S;S[_HH
M _ '_AWA_P %U_\ I8J_\Y&_L>?_ #;4?\.\/^"Z_P#TL5?^<C?V//\ YMJ_
M?ZB@#\ ?^'>'_!=?_I8J_P#.1O['G_S;4?\ #O#_ (+K_P#2Q5_YR-_8\_\
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M /2Q5_YR-_8\_P#FVK]_J* /P!_X=X?\%U_^EBK_ ,Y&_L>?_-M1_P .\/\
M@NO_ -+%7_G(W]CS_P";:OW^HH _G!\2_P#!&_\ X*3_ !Q^*?[)7BS]L7_@
MM7_PTQ\,OV3_ -K_ . W[8NA?"3_ (=P_ 7X,_\ "1>._@5XCGU+3+/_ (3W
MX6_%#2/$&D?VOX?U?Q/X9^T7EMXCT>P_M[^V;CPQJ][I>GQQ?T?444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img99844967_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img99844967_6.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  E %L# 2(  A$! Q$!_\0
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4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>gyre-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-17T15:58:05.4304+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.gyretx.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:gyre="http://www.gyretx.com/20241231" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" namespace="http://xbrl.sec.gov/stpr/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" id="DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity">
        <link:definition>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations" id="DisclosureOrganizationAndNatureOfOperations">
        <link:definition>995467 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidity" id="Role_DisclosureLiquidity">
        <link:definition>995477 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995487 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureF351AssetAcquisition" id="Role_DisclosureF351AssetAcquisition">
        <link:definition>995497 - Disclosure - F351 Asset Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments" id="DisclosureFairValueMeasurementsAndFinancialInstruments">
        <link:definition>995507 - Disclosure - Fair Value Measurements and Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>995517 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>995527 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>995537 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement">
        <link:definition>995547 - Disclosure - GNI USA Contributions under the Business Combination Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuring" id="Role_DisclosureRestructuring">
        <link:definition>995557 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>995567 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedLiabilities" id="Role_DisclosureOtherAccruedLiabilities">
        <link:definition>995577 - Disclosure - Other Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995587 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>995597 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>995607 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995617 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995627 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995637 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions1" id="DisclosureRelatedPartyTransactions1">
        <link:definition>995647 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEps" id="DisclosureEps">
        <link:definition>995657 - Disclosure - EPS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlans1" id="DisclosureEmployeeBenefitPlans1">
        <link:definition>995667 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995677 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany" id="DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany">
        <link:definition>995687 - Disclosure - Financial Statements Schedule I Financial Information of Parent Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995697 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995707 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsTables">
        <link:definition>995717 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>995727 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
        <link:definition>995737 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>995747 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables">
        <link:definition>995757 - Disclosure - GNI USA Contributions under the Business Combination Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995767 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>995777 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995787 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995797 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsTables" id="DisclosureEpsTables">
        <link:definition>995807 - Disclosure - EPS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995817 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail" id="DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail">
        <link:definition>995827 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail" id="Role_DisclosureLiquidityAdditionalInformationDetail">
        <link:definition>995837 - Disclosure - Liquidity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995847 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail">
        <link:definition>995857 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail">
        <link:definition>995867 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail">
        <link:definition>995877 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail">
        <link:definition>995887 - Disclosure - Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>995897 - Disclosure - Fair Value Measurements and Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo">
        <link:definition>995907 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail">
        <link:definition>995917 - Disclosure - Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail">
        <link:definition>995927 - Disclosure - Fair Value Measurements and Financial Instruments - Cash Equivalents and Held-to-maturity Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe">
        <link:definition>995937 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Fair Value and Amortized Cost of Held-to-maturity Debt Securities and Redemption Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" id="DisclosureBalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>995947 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail" id="DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail">
        <link:definition>995957 - Disclosure - Balance Sheet Components - Schedule of Inventories, Net of Reserves (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" id="DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>995967 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail" id="DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail">
        <link:definition>995977 - Disclosure - Balance Sheet Components - Schedule of Deferred Government Grants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" id="DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail">
        <link:definition>995987 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails" id="DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails">
        <link:definition>995997 - Disclosure - Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" id="DisclosureIntangibleAssetsAdditionalInformationDetails">
        <link:definition>996007 - Disclosure - Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" id="DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails">
        <link:definition>996017 - Disclosure - Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" id="DisclosureRevenueAdditionalInformationDetails">
        <link:definition>996027 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails" id="DisclosureRevenueSummaryOfSalesByProductCategoriesDetails">
        <link:definition>996037 - Disclosure - Revenue - Summary of Sales by Product Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail">
        <link:definition>996047 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails">
        <link:definition>996057 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails">
        <link:definition>996067 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail">
        <link:definition>996077 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue">
        <link:definition>996087 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail" id="Role_DisclosureRestructuringAdditionalInformationDetail">
        <link:definition>996097 - Disclosure - Restructuring - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>996107 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail" id="Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail">
        <link:definition>996117 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" id="Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail">
        <link:definition>996127 - Disclosure - Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" id="Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
        <link:definition>996137 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>996147 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" id="DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail">
        <link:definition>996157 - Disclosure - Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails" id="DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails">
        <link:definition>996167 - Disclosure - Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>996177 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>996187 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" id="DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>996197 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail" id="DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail">
        <link:definition>996207 - Disclosure - Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail">
        <link:definition>996217 - Disclosure - Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>996227 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>996237 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail" id="Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail">
        <link:definition>996247 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail">
        <link:definition>996257 - Disclosure - Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails" id="DisclosureIncomeTaxesMovementOfValuationAllowanceDetails">
        <link:definition>996267 - Disclosure - Income Taxes - Movement of Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>996277 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail">
        <link:definition>996287 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>996297 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails" id="DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails">
        <link:definition>996307 - Disclosure - EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" id="DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
        <link:definition>996317 - Disclosure - EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" id="Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail">
        <link:definition>996327 - Disclosure - Restructuring - Summary of Restructuring Charges Recorded in Component of Operating Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" id="DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
        <link:definition>996337 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" id="DisclosureSegmentInformationAdditionalInformationDetail">
        <link:definition>996347 - Disclosure - Segment Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail" id="DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail">
        <link:definition>996357 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails" id="DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails">
        <link:definition>996367 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>996377 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails">
        <link:definition>996387 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails">
        <link:definition>996397 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails">
        <link:definition>996407 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails">
        <link:definition>996417 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails">
        <link:definition>996427 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails">
        <link:definition>996437 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="gyre-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="gyre-20241231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="gyre-20241231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="gyre-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity" xlink:href="gyre-20241231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical" xlink:href="gyre-20241231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="gyre-20241231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="gyre-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations" xlink:href="gyre-20241231.xsd#DisclosureOrganizationAndNatureOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidity" xlink:href="gyre-20241231.xsd#Role_DisclosureLiquidity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="gyre-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureF351AssetAcquisition" xlink:href="gyre-20241231.xsd#Role_DisclosureF351AssetAcquisition" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments" xlink:href="gyre-20241231.xsd#DisclosureFairValueMeasurementsAndFinancialInstruments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="gyre-20241231.xsd#DisclosureBalanceSheetComponents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssets" xlink:href="gyre-20241231.xsd#DisclosureIntangibleAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenue" xlink:href="gyre-20241231.xsd#DisclosureRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement" xlink:href="gyre-20241231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuring" xlink:href="gyre-20241231.xsd#Role_DisclosureRestructuring" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureFinancialInstruments" xlink:href="gyre-20241231.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedLiabilities" xlink:href="gyre-20241231.xsd#Role_DisclosureOtherAccruedLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:href="gyre-20241231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="gyre-20241231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="gyre-20241231.xsd#DisclosureConvertiblePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="gyre-20241231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="gyre-20241231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="gyre-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions1" xlink:href="gyre-20241231.xsd#DisclosureRelatedPartyTransactions1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEps" xlink:href="gyre-20241231.xsd#DisclosureEps" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:href="gyre-20241231.xsd#DisclosureEmployeeBenefitPlans1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:href="gyre-20241231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany" xlink:href="gyre-20241231.xsd#DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gyre-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="gyre-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" xlink:href="gyre-20241231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="gyre-20241231.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="gyre-20241231.xsd#DisclosureIntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueTables" xlink:href="gyre-20241231.xsd#DisclosureRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables" xlink:href="gyre-20241231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="gyre-20241231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="gyre-20241231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="gyre-20241231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="gyre-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsTables" xlink:href="gyre-20241231.xsd#DisclosureEpsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="gyre-20241231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureLiquidityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail" xlink:href="gyre-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail" xlink:href="gyre-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail" xlink:href="gyre-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="gyre-20241231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo" xlink:href="gyre-20241231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" xlink:href="gyre-20241231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail" xlink:href="gyre-20241231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe" xlink:href="gyre-20241231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail" xlink:href="gyre-20241231.xsd#DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="gyre-20241231.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail" xlink:href="gyre-20241231.xsd#DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" xlink:href="gyre-20241231.xsd#DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails" xlink:href="gyre-20241231.xsd#DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:href="gyre-20241231.xsd#DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="gyre-20241231.xsd#DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:href="gyre-20241231.xsd#DisclosureRevenueAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails" xlink:href="gyre-20241231.xsd#DisclosureRevenueSummaryOfSalesByProductCategoriesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails" xlink:href="gyre-20241231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails" xlink:href="gyre-20241231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail" xlink:href="gyre-20241231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue" xlink:href="gyre-20241231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureRestructuringAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:href="gyre-20241231.xsd#DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails" xlink:href="gyre-20241231.xsd#DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="gyre-20241231.xsd#DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="gyre-20241231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail" xlink:href="gyre-20241231.xsd#DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:href="gyre-20241231.xsd#Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails" xlink:href="gyre-20241231.xsd#DisclosureIncomeTaxesMovementOfValuationAllowanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails" xlink:href="gyre-20241231.xsd#DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:href="gyre-20241231.xsd#DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#DisclosureSegmentInformationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail" xlink:href="gyre-20241231.xsd#DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails" xlink:href="gyre-20241231.xsd#DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="gyre-20241231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails" xlink:href="gyre-20241231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails" xlink:href="gyre-20241231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails" xlink:href="gyre-20241231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails" xlink:href="gyre-20241231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:href="gyre-20241231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails" xlink:href="gyre-20241231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:href="gyre-20241231.xsd#DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2" xlink:href="gyre-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_InterestIncomePolicyTextBlock" xlink:label="gyre_InterestIncomePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LeaseExpirationMonthAndYear" xlink:label="gyre_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsLeaseLiabilities" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ProceedsFromGovernmentGrantsReceived" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RequiredMinimumTaxableIncome" xlink:label="gyre_RequiredMinimumTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NassimUsmanPhdMember" xlink:label="gyre_NassimUsmanPhdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LeaseLabAndOfficeSpaceMember" xlink:label="gyre_LeaseLabAndOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Short-TermBankDepositsMaturityDateRangeStart" xlink:label="gyre_Short-TermBankDepositsMaturityDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MinorityHolderContributionsMember" xlink:label="gyre_MinorityHolderContributionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TaxCreditCarryforwardExpirationYear" xlink:label="gyre_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIGroupMember" xlink:label="gyre_GNIGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfExcessCashOnDispositionsNet" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_IncomeTaxTable" xlink:label="gyre_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedExpensesGeneralAndAdministrative" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue" xlink:label="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NDAPassesTheNMPAsReviewAndInspectionMember" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SoftwareMember" xlink:label="gyre_SoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DistributionsToHolders" xlink:label="gyre_DistributionsToHolders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MainlandChinaContributionPlanMember" xlink:label="gyre_MainlandChinaContributionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfRevenueAccountedSalesToDistributors" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MinorityInterestDecreaseFromRedemptionsShares" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityConvertiblePreferredStockConversionValue" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LandUseRightsNetAssets" xlink:label="gyre_LandUseRightsNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PostClosingIndemnificationObligation" xlink:label="gyre_PostClosingIndemnificationObligation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsLineItems" xlink:label="gyre_DeferredGovernmentGrantsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LiquidityAbstract" xlink:label="gyre_LiquidityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityNonCurrentMember" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StockholdersEquityDisclosureLineItems" xlink:label="gyre_StockholdersEquityDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_WeightedAverageOfPreferredStockWarrant" xlink:label="gyre_WeightedAverageOfPreferredStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfAmountReceivedOnAgreement" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SharesForAggregatePurchasePrice" xlink:label="gyre_SharesForAggregatePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PayableToPropertyPlantAndEquipmentSuppliers" xlink:label="gyre_PayableToPropertyPlantAndEquipmentSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SellingAndMarketingExpensesPolicyTextBlock" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NoncontrollingInterestPolicyPolicyTextBlock" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="us-gaap_PaymentsOfDividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatuteOfLimitationDueToTaxEvasion" xlink:label="gyre_StatuteOfLimitationDueToTaxEvasion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDepositPolicyTextBlock" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CvrLiabilitySettlement" xlink:label="gyre_CvrLiabilitySettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsTable" xlink:label="gyre_DeferredGovernmentGrantsTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_IncreaseDecreaseInAccountsAndNotesReceivables" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RestructuringLiability" xlink:label="gyre_RestructuringLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SquareMeterAreaForLaboratoryCenterUnderLease" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityConvertiblePreferredStockConversionShares" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OperatingLossCarryforwardsWithIndefiniteLife" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsPolicyTextBlock" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LandUseRightsNetNoncurrent" xlink:label="gyre_LandUseRightsNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestIncomeOnShortTermBankDeposits" xlink:label="gyre_AccruedInterestIncomeOnShortTermBankDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquisitionCostsInDueToRelatedParties" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAdministrationOfTaxationChinaMember" xlink:label="us-gaap_StateAdministrationOfTaxationChinaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsImpactFromForeignCorporations" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommittedToAllocate" xlink:label="gyre_CommittedToAllocate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatuteOfLimitationDueToTransferPricingIssues" xlink:label="gyre_StatuteOfLimitationDueToTransferPricingIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedSalesDiscount" xlink:label="gyre_AccruedSalesDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LiquidityTable" xlink:label="gyre_LiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AllowanceForCreditLossesCertificatesOfDeposit" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GCBiopharmaCorpMember" xlink:label="gyre_GCBiopharmaCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserveFund" xlink:label="gyre_StatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit" xlink:label="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NoncashLeaseExpense" xlink:label="gyre_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OrganizationAndNatureOfOperationsTable" xlink:label="gyre_OrganizationAndNatureOfOperationsTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Short-TermBankDepositsMaturityPeriodEnd" xlink:label="gyre_Short-TermBankDepositsMaturityPeriodEnd"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BadDebtExpenseAndOtherNonCashItems" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestOnBankDeposit" xlink:label="gyre_AccruedInterestOnBankDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CvrExcessClosingCashPayable" xlink:label="gyre_CvrExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SeveranceAndOtherCosts" xlink:label="gyre_SeveranceAndOtherCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LandUseRightsPolicyTextBlock" xlink:label="gyre_LandUseRightsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RemainingOutstandingBalanceOfAgreement" xlink:label="gyre_RemainingOutstandingBalanceOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ForeignCurrencyRiskPolicyTextBlock" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AppropriationOfStatutoryReserve" xlink:label="gyre_AppropriationOfStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_WarrantsSharePrice" xlink:label="gyre_WarrantsSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DistributionFromAssetSaleProceeds" xlink:label="gyre_DistributionFromAssetSaleProceeds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AffiliatesBeneficialOwnSharesPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsNonCurrent" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationExcessClosingCashPayable" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_VertexPharmaceuticalsIncorporatedMember" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommissionsAndOfferingCosts" xlink:label="gyre_CommissionsAndOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DrenBioIncAndCopiaScientificLLCMember" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentOfDeferredOfferingCosts" xlink:label="gyre_PaymentOfDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AppropriationsToStatutoryReserve" xlink:label="gyre_AppropriationsToStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CollaborationRevenueMember" xlink:label="gyre_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_InvestmentSubscriptionAmount" xlink:label="gyre_InvestmentSubscriptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CumulativeAmountOfStatutoryReserveFund" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SubleaseArrangementMember" xlink:label="gyre_SubleaseArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AmortizationOfLandUseRights" xlink:label="gyre_AmortizationOfLandUseRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContinentPharmaceuticalsIncMember" xlink:label="gyre_ContinentPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StockholdersEquityDisclosureTable" xlink:label="gyre_StockholdersEquityDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_UpfrontPaymentReceived" xlink:label="gyre_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember" xlink:label="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShortTermBankDepositsMember" xlink:label="gyre_ShortTermBankDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShortTermBankDepositsPolicyTextBlock" xlink:label="gyre_ShortTermBankDepositsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContributionsClosingPayableAmount" xlink:label="gyre_ContributionsClosingPayableAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetMeasurementInput" xlink:label="us-gaap_DerivativeAssetMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PatentsAndTechnologicalKnowHowMember" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfExcessPreapprovedCosts" xlink:label="gyre_PercentageOfExcessPreapprovedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedPayrollAndWelfare" xlink:label="gyre_AccruedPayrollAndWelfare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DivestitureLossesMember" xlink:label="gyre_DivestitureLossesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDepositMember" xlink:label="gyre_LongTermCertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SinopharmGroupCompanyLimitedMember" xlink:label="gyre_SinopharmGroupCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PrepaidAssetsCurrent" xlink:label="gyre_PrepaidAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneMember" xlink:label="gyre_FThreeFiveOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermInvestmentsPolicyTextBlock" xlink:label="gyre_LongTermInvestmentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated" xlink:label="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DisposalConsiderationInOtherReceivables" xlink:label="gyre_DisposalConsiderationInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredIncomeTaxExpenseBenefitNet" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIUSAMember" xlink:label="gyre_GNIUSAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LegalExpensesIncurred" xlink:label="gyre_LegalExpensesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LeaseRenewedMonthAndYear" xlink:label="gyre_LeaseRenewedMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangesOfValuationAllowances" xlink:label="gyre_ChangesOfValuationAllowances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OperatingLossCarryforwardsExpirationYear" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValueOfPreferredShares" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RisksAndUncertainitiesPolicyTextBlock" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyrePharmaceuticalsMember" xlink:label="gyre_GyrePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRMergerClosingPayable" xlink:label="gyre_CVRMergerClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangeInFairValueOfLongTermReceivables" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrants" xlink:label="gyre_DeferredGovernmentGrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommitmentsAndContingenciesDisclosureTable" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="us-gaap_AllOtherSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserveMember" xlink:label="gyre_StatutoryReserveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsCurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalAdditionsMember" xlink:label="us-gaap_CapitalAdditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent" xlink:label="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfEquityInterest" xlink:label="gyre_PercentageOfEquityInterest"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationAgreementMember" xlink:label="gyre_BusinessCombinationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GovernmentGrantIncomeWithinOtherIncome" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsCapitalizedTransactionCosts" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CashPaidForAcquisitionCosts" xlink:label="gyre_CashPaidForAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedExpensesResearchAndDevelopment" xlink:label="gyre_AccruedExpensesResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp" xlink:label="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CpUSSharePurchaseAgreementMember" xlink:label="gyre_CpUSSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FCContributionMember" xlink:label="gyre_FCContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValueOfCommonShares" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentOfDisposalOfSubsidiary" xlink:label="gyre_PaymentOfDisposalOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NMPAsApprovalOfTheNDAMember" xlink:label="gyre_NMPAsApprovalOfTheNDAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_IncomeTaxLineItems" xlink:label="gyre_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ConcentrationOfCustomerRiskPolicyTextBlock" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DistributionsToHoldersPerCVR" xlink:label="gyre_DistributionsToHoldersPerCVR"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SubmissionOfTheNewDrugApplicationMember" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentsForExchangeForIntellectualPropertyRights" xlink:label="gyre_PaymentsForExchangeForIntellectualPropertyRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxLiabilityRightOfUseAssets" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OrganizationAndNatureOfOperationsLineItems" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangeInFairValueOfDerivativeLiabilities" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MaximumAmountOfTaxOffsetPerYear" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreMergerStockOptionsAssumed" xlink:label="gyre_PreMergerStockOptionsAssumed"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PayableToSellingExpenseSuppliers" xlink:label="gyre_PayableToSellingExpenseSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsContractLiabilities" xlink:label="gyre_DeferredTaxAssetsContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit" xlink:label="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentForResearchAndDevelopmentFees" xlink:label="gyre_PaymentForResearchAndDevelopmentFees"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated" xlink:label="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OtherDirectorOrOfficerMember" xlink:label="gyre_OtherDirectorOrOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValue" xlink:label="gyre_BusinessCombinationFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_EquityGainLossOfUnconsolidatedAffiliates" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CostOfCollaborationMember" xlink:label="gyre_CostOfCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ConvertiblePreferredStockConversion" xlink:label="gyre_ConvertiblePreferredStockConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityCurrent" xlink:label="gyre_CVRDerivativeLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LiquidityLineItems" xlink:label="gyre_LiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyFourATMProgramMember" xlink:label="gyre_TwoThousandTwentyFourATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestOnLongTermCertificatesOfDeposit" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RemainingNumberOfFullTimeEmployees" xlink:label="gyre_RemainingNumberOfFullTimeEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SquareMeterAreaForOfficeSpaceUnderLease" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit" xlink:label="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AmountToBeReceivedUnderAgreement" xlink:label="gyre_AmountToBeReceivedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_InterestIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_InterestIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_InterestIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Held-to-maturity Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Movement of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Valuation Allowance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government grants received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Government Grants Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from government grants received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total restructuring charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of complement portfolio to Vertex</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RequiredMinimumTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum taxable income required to support realizing the company's.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RequiredMinimumTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Required Minimum Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RequiredMinimumTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required Minimum Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Statements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GNI USA Contributions under the Business Combination Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Vested and exercisable - December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Notes Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Notes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term receivable from GCBP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NassimUsmanPhdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nassim Usman PhD.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NassimUsmanPhdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nassim Usman PhD [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NassimUsmanPhdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nassim Usman, Ph.D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseLabAndOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease lab and office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseLabAndOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Lab And Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseLabAndOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Lab And Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Short-TermBankDepositsMaturityDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Bank Deposits Maturity Date Range Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Short-TermBankDepositsMaturityDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term bank deposits maturity date range start.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Short-TermBankDepositsMaturityDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term bank deposits maturity date range start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityHolderContributionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority Holder Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityHolderContributionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minority Holder Contributions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityHolderContributionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minority holder contributions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforward, expire year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax year remains open to examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GNI Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GNI group.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GNI Group</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of excess cash on dispositions net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Excess Cash On Dispositions Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of excess cash on dispositions net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restructuring And Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee reimbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses - general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses general and administrative.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents denominated in RMB</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents Reporting Currency Denominated Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents reporting currency denominated value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-Cash Financing and Investing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NDA Passes the NMPA's Review and Inspection</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">N D A Passes the N M P A's Review and Inspection [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">N D A Passes the N M P A's Review and Inspection.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of finite lived intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionsToHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Distributions To Holders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionsToHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Distributions to holders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionsToHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distributions to holders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax-related penalties or interest recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MainlandChinaContributionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mainland China Contribution Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MainlandChinaContributionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mainland China Contribution Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MainlandChinaContributionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mainland China Contribution Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options Forfeited and Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options Forfeited and Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions in the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Preferred Stock upon Private Placement (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of revenue accounted sales to distributors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue accounted sales to distributors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of minority interest (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Decrease From Redemptions Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minority interest decrease from redemptions shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Convertible Preferred Stock Conversion, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, convertible preferred stock conversion, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Convertible preferred stock conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement and Securities Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement and Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private placement and securities purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Land use rights, net assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Use Rights, Net Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Land use rights, net assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before equity in (loss) income of subsidinaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total Gyre Stockholders' Equity (Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PostClosingIndemnificationObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post closing indemnification obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PostClosingIndemnificationObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Closing Indemnification Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PostClosingIndemnificationObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post closing indemnification obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shanghai Pharmaceuticals Holding Co., Ltd</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shanghai Pharmaceuticals Holding Company Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shanghai Pharmaceuticals Holding Company Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority holders owned outstanding shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minority Holders Owned Outstanding Shares Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minority holders owned outstanding shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">C V R derivative liability non current member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C V R Derivative Liability Non Current [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Derivative Liability non current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable, Date of Record</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, dividend payable, date of record</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and exercisable - December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value and Amortized Cost of Held-to-maturity Debt Securities and Redemption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority interest ownership directly and indirectly holds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minority Interest Ownership Directly And Indirectly Holds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minority interest ownership directly and indirectly holds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liabilities estimated fair value increase decrease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities Estimated Fair Value Increase Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Financing Costs Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred Financing Costs Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income per share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Asset, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one ATM program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One A T M Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 ATM Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses excluding cost of revenues:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets acquisition, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_WeightedAverageOfPreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Of Preferred Stock Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_WeightedAverageOfPreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average of preferred stock warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_WeightedAverageOfPreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average of Preferred Stock Warrants (as converted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of amount received on agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Amount Received On Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of amount received on agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increase (decrease) resulting from tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(Decrease) of unrecognized tax benefits taken in prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling and Marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License of Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement transfer between Level 1 and Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets and Liabilities Level1 To Level2 Transfers Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets and liabilities level1 to level2 transfers amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SharesForAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares for aggregate purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SharesForAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares for Aggregate Purchase Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SharesForAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares for aggregate purchase price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Cost [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligation to pay in exchange for the intellectual property rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligation to pay in exchange for the intellectual property rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Purchase Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PayableToPropertyPlantAndEquipmentSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payable To Property, Plant, And Equipment Suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PayableToPropertyPlantAndEquipmentSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payable to property, plant, and equipment suppliers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PayableToPropertyPlantAndEquipmentSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable to PPE suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling and Marketing Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expenses [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Selling and marketing expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Outstanding Options, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Outstanding Options, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority interest ownership indirectly holds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minority Interest Ownership Indirectly Holds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minority interest ownership indirectly holds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncontrolling interest, policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Statements, Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets fixed assets and intangibles.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Fixed Assets And Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed and intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Common Stock reserved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Ordinary Dividends, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount of special dividend payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate amount of special dividend payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatuteOfLimitationDueToTaxEvasion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statute Of Limitation Due To Tax Evasion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatuteOfLimitationDueToTaxEvasion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statute of limitation due to tax evasion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatuteOfLimitationDueToTaxEvasion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statute of limitations due to tax evasion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used) provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Certificates of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Certificates of Deposit [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term certificates of deposit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CvrLiabilitySettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CVR Liability settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CvrLiabilitySettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR liability settlement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CvrLiabilitySettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Liability settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Issuance Of Options To Former Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options issuance of options to former stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Value Rights Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Value Rights Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts and note receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts And Notes Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accounts and notes receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China Resources Pharmaceutical Group Ltd</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">China Resources Pharmaceutical Group Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">China Resources Pharmaceutical Group Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts and Note Receivables, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Advance payment received from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Advance Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed advance payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">long-term certificates of deposit maturity period start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">long-term certificates of deposit Maturity Date Range Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">long-term certificates of deposit Maturity Date Range Start.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RestructuringLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RestructuringLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RestructuringLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of stock options included in other receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options included in other receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Stock Options Included In Other Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Square meter area for laboratory center under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Square Meter Area For Laboratory Center Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Square meter area for laboratory center under lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Convertible Preferred Stock Conversion, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, convertible preferred stock conversion, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Convertible preferred stock conversion (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted EPS Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property And Equipment, Included In Accrued Expenses And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment, Included In Accrued Expenses And Other Current Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment, included in accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards with indefinite life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards With Indefinite Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards having indefinite life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Land use rights, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Use Rights Net Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Land use rights net noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other receivables from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive Security not Included in Diluted per Share Calculations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of restricted net assets of consolidated subsidiaries of consolidated net assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Restricted Net Assets Exceed Net Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of restricted net assets exceed net assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Less: Allocation of undistributed earnings to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, CVR Derivative Liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed, CVR derivative liability, noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">CVR derivative liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR derivative liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance payment for convertible preferred stock and preferred stock warrants acquired upon contributions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payment for Convertible Preferred Stock and Preferred Stock Warrants acquired upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payment For Convertible Preferred Stock And Preferred Stock Warrants Acquired Upon Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liability - Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred Tax Liability - Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amounts of restricted capital and statutory reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Amounts Of Restricted Capital And Statutory Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate amounts of restricted capital and statutory reserves.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options exercisable for shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Vested and exercisable- December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen omnibus incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Omnibus Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Omnibus Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestIncomeOnShortTermBankDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Income On Short term Bank Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestIncomeOnShortTermBankDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest income on short-term bank deposits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestIncomeOnShortTermBankDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest income on short term bank deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit carry forwards derecognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Carry Forwards Derecognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross federal R&amp;D credit-related deferred tax assets derecognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MotorVehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Motor Vehicles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MotorVehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Motor Vehicles [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MotorVehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Motor vehicles.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Excess amount retained from net proceeds related to disposition of assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excess Amount Retained From Net Proceeds Related To Disposition Of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excess amount retained from net proceeds related to disposition of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Issued, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition costs in due to related parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition costs in due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Costs In Due To Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits in licensed banks protected by DIS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits In Licensed Banks Protected By Deposit Insurance System</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deposits in licensed banks protected by deposit insurance system.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Charges related to write off of prepaid manufacturing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Charges Related To Write Off Of Prepaid Manufacturing Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charges related to write off of prepaid manufacturing cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Option, Issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Issuance Of Options To Former Stockholders In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options issuance of options to former stockholders in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAdministrationOfTaxationChinaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State Administration of Taxation, China [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAdministrationOfTaxationChinaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PRC Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term bank deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term bank deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact from foreign corporations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Impact From Foreign Corporations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets impact from foreign corporations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommittedToAllocate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Committed to allocate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommittedToAllocate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Committed To Allocate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommittedToAllocate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Committed to allocate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatuteOfLimitationDueToTransferPricingIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statute Of Limitation Due To Transfer Pricing Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatuteOfLimitationDueToTransferPricingIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statute of limitation due to transfer pricing issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatuteOfLimitationDueToTransferPricingIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statute of limitations due to transfer pricing issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedSalesDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued sales discount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedSalesDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued sales discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedSalesDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Sales Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options Forfeited and Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance costs and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive (loss) income, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Product and Service Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Gross Carrying Amounts and Accumulated Amortization of intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income (loss) attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Catalyst common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allowance for Credit Losses Certificates of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Allowance for credit losses certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Warrants (as converted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Ownership Percentage, Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase as a result of the GNI USA Contributions on October 30, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of Convertible Preferred Stock and Preferred Stock Warrants under the Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeeds from issuance of aggregate gross sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign - PRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiopharmaCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GC Biopharma Corp.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiopharmaCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G C Biopharma Corp [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiopharmaCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GC Biopharma Corp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets with finite lives:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible assets, Weighted average amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents acquired in connection with the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of Pharmaceutical Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ETUARY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cost of Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Divestiture losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Loss on divestiture of subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Divestiture losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on divestiture of subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ETUARY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory reserve fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statutory Reserve Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statutory reserve fund.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses short-term certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allowance For Credit Losses Short-Term Certificates Of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Allowance for credit losses short-term certificates of deposit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Information Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial assets at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ParentCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Parent Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ParentCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Sales by Product Categories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling and marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling and Marketing Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturity of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Notes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Notes Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized employee stock based compensation expense, period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statutory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statutory reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Nature of Operations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Operations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Nature Of Operations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Short-TermBankDepositsMaturityPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term bank deposits maturity period end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Short-TermBankDepositsMaturityPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Bank Deposits Maturity Period End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Short-TermBankDepositsMaturityPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term bank deposits maturity period end.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issuable upon exercise and conversion of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Stock Shares Issuable Upon Exercise and Conversion Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock shares issuable upon exercise and conversion of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issued in Business Combination, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair value of consideration issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions for employee benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements - Issued But Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected option life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bad debt expense and other non-cash items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bad Debt Expense And Other Non-cash Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bad debt expense and other non-cash items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign - PRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statements, Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Pronouncements Recently Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity loss (income) of subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equity (income) loss of subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity in income (loss) of subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Allowance for Credit Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts and financing receivable, allowance for credit loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestOnBankDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest On Bank Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestOnBankDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest on bank deposit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestOnBankDeposit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued interest on bank deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value of Option Awards Based on Black-scholes Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Productive Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Productive Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Cost And Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average share price of the Company (USD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of all equity awards that vested during the periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CvrExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR excess closing cash payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CvrExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CVR Excess Closing Cash Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CvrExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR excess closing cash payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeveranceAndOtherCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance and other costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeveranceAndOtherCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance And Other Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeveranceAndOtherCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance and other charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Computer Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software, Intangible Asset [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Land Use Rights, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Use Rights [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Land use rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from GCBP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nontrade Receivables, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nontrade Receivables, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR derivative liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C V R Derivative Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RemainingOutstandingBalanceOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining outstanding balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RemainingOutstandingBalanceOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Outstanding Balance of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RemainingOutstandingBalanceOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining outstanding balance of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Risk [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Issuance Of Common Stock And Convertible Preferred Stock To Former Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed issuance of common stock and convertible preferred stock to former stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired In Process Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Outstanding Shares Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Common Stock upon ATM program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationOfStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Appropriation of statutory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationOfStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Appropriation of statutory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from option exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_WarrantsSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_WarrantsSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants share price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_WarrantsSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants share price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedCashFlowStatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Cash Flow Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">long-term certificates of deposit Maturity Date Range end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">long-term certificates of deposit Maturity Date Range end.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">long-term certificates of deposit maturity period end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionFromAssetSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Distribution from asset sale proceeds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionFromAssetSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Distribution From Asset Sale Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionFromAssetSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distribution to CVR holders from asset sale proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CPIContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CPI Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CPIContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C P I Contribution [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CPIContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CPI contribution.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed, accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Affiliates beneficial own shares percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliates Beneficial Own Shares Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliates beneficial own shares percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants Non current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">CVR excess closing cash payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Excess Closing Cash Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination excess closing cash payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance, end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Balance, beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Allowance for credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts and financing receivable, allowance for credit loss, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, Allowance for Credit Loss, Foreign Currency Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts and financing receivable, allowance for credit loss, foreign currency translation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants Current And Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants current and noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Valuation Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Other-than-Temporary Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex pharmaceuticals incorporated.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Pharmaceuticals Incorporated [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Pharmaceuticals Incorporated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BC 2021 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B C Two Thousand Twenty One Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">B C two thousand twenty one stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommissionsAndOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commissions And Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommissionsAndOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commissions and offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommissionsAndOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commissions and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dren Bio, Inc. and Copia Scientific, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dren Bio Inc And Copia Scientific L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dren Bio, Inc. and Copia Scientific, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCommissionForSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of Commission for shares sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCommissionForSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission For Shares Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCommissionForSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission for shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiplied by the fair value per share of Catalyst stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of deferred offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationsToStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Appropriations to statutory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationsToStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Appropriations To Statutory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationsToStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Appropriations to statutory reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_InvestmentSubscriptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Subscription Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_InvestmentSubscriptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment subscription amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_InvestmentSubscriptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment obligation amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative amount of statutory reserve fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Amount Of Statutory Reserve Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative amount of statutory reserve fund.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category of Item Purchased [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends declared, unpaid, per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, cash dividend declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubleaseArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubleaseArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubleaseArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmortizationOfLandUseRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of land use rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmortizationOfLandUseRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Land Use Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmortizationOfLandUseRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of&#160;land use rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2023-07</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContinentPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CPI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContinentPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Continent Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContinentPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Continent pharmaceuticals inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Option, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Deemed Issuance Of Options To Former Stockholders In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options deemed issuance of options to former stockholders in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, convertible preferred stock, and equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net cash flows (used in) provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currently Estimated Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Currently Estimated Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input, currently estimated discount rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of equity method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShortTermBankDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Bank Deposits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShortTermBankDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term bank deposits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShortTermBankDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Bank Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recoveries collected and write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShortTermBankDepositsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Bank Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShortTermBankDepositsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Bank Deposits [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShortTermBankDepositsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term bank deposits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Other expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CatalystMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Catalyst</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CatalystMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Catalyst [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CatalystMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Catalyst.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expenses [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Gyre stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GC Biophrarma Corp asset purchase agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G C Biophrarma Corp Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GCBP Asset Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContributionsClosingPayableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions closing payable amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContributionsClosingPayableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contributions Closing Payable Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContributionsClosingPayableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contributions closing payable amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeAssetMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative asset measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeAssetMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Asset, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PatentsAndTechnologicalKnowHowMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents and Technological Know How [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents and Technological Know-how</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred income tax assets before valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessPreapprovedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of excess preapproved costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessPreapprovedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Excess Preapproved Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessPreapprovedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of excess preapproved costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidation Basis of Accounting [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedPayrollAndWelfare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and welfare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedPayrollAndWelfare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll And Welfare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedPayrollAndWelfare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued payroll and welfare.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Supplemental Disclosure of stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of stock-based compensation expense included in General and administrative expenses above:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DivestitureLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Divestiture Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DivestitureLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Divestiture Losses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DivestitureLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Divestiture losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Certificates Of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term certificates of deposit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Certificates of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability for Uncertainty in Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SinopharmGroupCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sinopharm Group Co., Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SinopharmGroupCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sinopharm Group Company Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SinopharmGroupCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sinopharm Group Company Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts and Note Receivable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrepaidAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrepaidAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Assets Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrepaidAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid assets current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized employee stock based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technological know-how</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Technology-Based Intangible Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliated Entity [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MachineryAndElectronicDevicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and Electronic Devices</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MachineryAndElectronicDevicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Electronic Devices [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MachineryAndElectronicDevicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Machinery and electronic devices.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Concentration risk percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of customer risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">F three five one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">F Three Five One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">F351</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable, Amount Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends payable per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Short-Term Bank Deposits and Long-Term Certificates of Deposit Reporting Currency Denominated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of short-term bank deposits and long-term certificates of deposit reporting currency denominated.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of short-term bank deposits and long-term certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DisposalConsiderationInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal consideration in other receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DisposalConsiderationInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal consideration in other receivables from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DisposalConsiderationInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Consideration In Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for allowance for credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Notes Receivable, Provision for Allowance for Credit Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts and notes receivable, provision for allowance for credit losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred income tax expense benefit net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses excluding cost of revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-Free Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIUSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GNI USA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIUSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G N I U S A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIUSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GNI USA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">R&amp;D Super-deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D Super-deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series X Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements and Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, All Other Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LegalExpensesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal expenses incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LegalExpensesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Expenses Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LegalExpensesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal expenses incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock, and equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseRenewedMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Renewed Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseRenewedMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease renewed month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseRenewedMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewed month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income per share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Leasehold Improvement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock, policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Receivable from GCBP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financing Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period value acquisitions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Value Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangesOfValuationAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes of valuation allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangesOfValuationAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes of Valuation Allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangesOfValuationAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes of valuation allowances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangesOfValuationAllowances_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes of valuation allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of preferred shares to be owned by Catalyst's stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Fair Value of Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination fair value of preferred shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Common Stock upon ATM program (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible Expense - Operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR merger payable, amount distributed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Contingent Consideration Liability, Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainities [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks And Uncertainities [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GyrePharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gyre Pharmaceuticals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GyrePharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gyre Pharmaceuticals [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GyrePharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gyre Pharmaceuticals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRMergerClosingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C V R Merger Closing Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRMergerClosingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR merger closing payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRMergerClosingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR merger closing payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Receivables Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed, other receivables current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income attributable to common stockholders - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock, Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average of Convertible Preferred Stock (as converted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfIndirectOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indirect ownership interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfIndirectOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Indirect Ownership Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfIndirectOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of indirect ownership interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CVR derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR derivative liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C V R Derivative Liability Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR derivative liability noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Option Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">F351 asset purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">F Three Five One Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">F351 Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beijing Continent Pharmaceuticals Co., Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beijing continent pharmaceuticals Co., Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR merger payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of long-term receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Long Term Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of receivables from GCBP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, before Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EPS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to acquire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of employees terminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Due to Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Due to Related Parties, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Segment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statutory Reserve [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statutory Reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Preferred Stock upon Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment, Expenditure, Addition to Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock in ATM program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in one to five years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets state net operating loss carry forwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets State Net Operating Loss Carry Forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward, derecognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalAdditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalAdditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Addition Purchase Commitments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed in-process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Share ("EPS") Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statute Of Limitation Due To Computational Errors Made By Taxpayer Or Withholding Agent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statute of limitation due to computational errors made by taxpayer or withholding agent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statute of limitations due to errors made by taxpayer or withholding agent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfEquityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Equity Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfEquityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of equity interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfEquityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of equity interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon acquisition of F351 Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award weighted average share price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average share price of the Company (USD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferential income tax rate for HNTE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Preferential Income Tax Rate For HNTE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation preferential income tax rate for HNTE.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(Decrease) of unrecognized tax benefits related to current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders (deficit) equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Assistance [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government grant income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Grant Income Within Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grant income within other income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized transaction costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of outstanding preferred stock redeemed for cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Outstanding Preferred Stock Redeemed For Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of outstanding preferred stock redeemed for cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment Estimated Useful Life [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of property plant and equipment estimated useful life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net (decrease) increase in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CashPaidForAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments made for acquisition costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CashPaidForAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Acquisition Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CashPaidForAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for acquisition costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses - research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses, Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses, research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Statements Schedule I Financial Information of Parent Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Receivables From G C Biophrarma Corp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of receivables from GC biophrarma corp.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of receivables from GCBP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional and consulting services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income attributable to common stockholders - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss) attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Vested and exercisable - December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">F351 Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CpUSSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CP U.S. Share Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CpUSSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CP U.S. Share Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CpUSSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CP U.S. SHARE PURCHASE AGREEMENT [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FCContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FC contribution.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FCContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FC Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FCContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">F C Contribution [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common shares to be owned by Catalyst's stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Fair Value of Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination fair value of common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Certificates Of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long Term Certificates Of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Service [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards available to offset future federal tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group, Including Discontinued Operation, Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration for sales agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and rights outstanding, measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfDisposalOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash balance in a disposed subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfDisposalOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Disposal of Subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfDisposalOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of disposal of subsidiary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NMPAsApprovalOfTheNDAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NMPA's Approval of the NDA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NMPAsApprovalOfTheNDAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">N M P A's Approval of the N D A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NMPAsApprovalOfTheNDAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">N M P A's Approval of the N D A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax computed at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax computed at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights derivative liability non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Derivative Liability Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR derivative liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term CVR derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex Asset Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Asset Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Customer Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration of Customer Risk [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of customer risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionsToHoldersPerCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Distributions To Holders Per CVR</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionsToHoldersPerCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Distributions to holders per CVR.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionsToHoldersPerCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distributions to holders per CVR</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Submission of the New Drug Application</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Submission of the New Drug Application [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Submission of the New Drug Application.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends paid per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, cash dividend paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts and note receivables, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts and note receivables, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Receivable from GCBP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred stock (as converted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated gross unrealized gain before tax available for sale securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Gross Unrealized Gain Before Tax Available For Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentsForExchangeForIntellectualPropertyRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for exchange of intellectual property rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentsForExchangeForIntellectualPropertyRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Exchange For Intellectual Property Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentsForExchangeForIntellectualPropertyRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for exchange for intellectual property rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Components of the Company's Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less current portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign currency translation loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency translation adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued upon conversion of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Deemed Issuance Of Options To Former Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options deemed issuance of options to former stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GyreMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gyre</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GyreMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gyre [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GyreMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gyre.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liability - ROU assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Liability - ROU Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liability Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liability right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rate difference due to different jurisdiction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and nature of operations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Operations [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Operations [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term receivable from GCBP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Long-term Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed long-term receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Or Rights Warrants Issued During Period Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants or rights warrants issued during period shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation and Remeasurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Omnibus Incentive Plan [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three omnibus incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of derivative liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventories, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Inventory, Current [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions in the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of tax offset per year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Of Tax Offset Per Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of tax offset per year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issuable upon conversion of the outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Of Common Stock Issuable Upon Conversion Of The Outstanding Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of common stock issuable upon conversion of the outstanding shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Equity, Attributable to Noncontrolling Interest, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Equity, Attributable to Noncontrolling Interest, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity, Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of issuance of common stock for public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 400,000,000 shares authorized; 86,307,544 shares and 76,595,616 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Restricted Certificates of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Future Amortization Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Divestiture losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Net gain on disposal of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement transfer Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets and Liabilities Level3 Transfers Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets and liabilities level3 transfers amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreMergerStockOptionsAssumed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-GNI USA Contributions Catalyst stock options assumed by CPI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreMergerStockOptionsAssumed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Merger Stock Options Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreMergerStockOptionsAssumed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre merger stock options assumed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PayableToSellingExpenseSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable to selling expense suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PayableToSellingExpenseSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payable To Selling Expense Suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PayableToSellingExpenseSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payable to selling expense suppliers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Government Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Government Grants Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of deferred government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Contract Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, contract liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Income On Long Term Certificates Of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest income on long-term certificates of deposit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest income on long term certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Note 13)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined square meter area for manufacturing facilities under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Square Meter Area For Manufacturing Facilities Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined square meter area for manufacturing facilities under lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentForResearchAndDevelopmentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Research and Development Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentForResearchAndDevelopmentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for research and development fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Cash and Cash Equivalents Reporting Currency Denominated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of cash and cash equivalents reporting currency denominated.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total average shares used in net (loss) income per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OtherDirectorOrOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other director or officer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OtherDirectorOrOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Director or Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OtherDirectorOrOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Director or Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Segment Reporting Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of minority interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair value of Catalyst</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undiscounted future payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Gain Loss of Unconsolidated Affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity gain loss of unconsolidated affiliates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equity loss of unconsolidated affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CostOfCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of collaboration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CostOfCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Collaboration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CostOfCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConvertiblePreferredStockConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConvertiblePreferredStockConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock conversion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConvertiblePreferredStockConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income (loss) from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G N I [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C V R Derivative Liability Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">C V R derivative liability current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated acquisition-date fair value of Catalyst</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyFourATMProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four A T M Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyFourATMProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty four atm program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyFourATMProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 ATM Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Present Value Assumptions used in Calculating Present Value of Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of present value assumptions of lease payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in one to five years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued interest on long-term certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest On Long-term Certificates Of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest on long-term certificates of deposit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period shares acquisitions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Shares Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use asset obtained in exchange for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset and lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESOP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Deduction, Employee Stock Ownership Plan Dividend, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RemainingNumberOfFullTimeEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining number of full time employees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RemainingNumberOfFullTimeEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Number Of Full Time Employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RemainingNumberOfFullTimeEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining number of full time employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance at the end of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Balance at the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible expense - acquisition related</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Related To Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible expense related to acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial liabilities at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Liabilities, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Square meter area for office space under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Square Meter Area For Office Space Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Square meter area for office space under lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Affiliates beneficial own shares specified percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliates Beneficial Own Shares Specified Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliates beneficial own shares specified percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Buildings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Building [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Of Assets Exceeding Deposit Insurance System Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of assets exceeding deposit insurance system limit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, short-term bank deposits and long-term certificates of deposits exceeding China DIS coverage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmountToBeReceivedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount to be received under agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmountToBeReceivedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount To Be Received Under Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmountToBeReceivedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount to be received under agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_InterestIncomePolicyTextBlock" xlink:to="gyre_InterestIncomePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LeaseExpirationMonthAndYear" xlink:to="gyre_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsLeaseLiabilities" xlink:to="gyre_DeferredTaxAssetsLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ProceedsFromGovernmentGrantsReceived" xlink:to="gyre_ProceedsFromGovernmentGrantsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_RequiredMinimumTaxableIncome" xlink:to="gyre_RequiredMinimumTaxableIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:to="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NassimUsmanPhdMember" xlink:to="gyre_NassimUsmanPhdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LeaseLabAndOfficeSpaceMember" xlink:to="gyre_LeaseLabAndOfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_Short-TermBankDepositsMaturityDateRangeStart" xlink:to="gyre_Short-TermBankDepositsMaturityDateRangeStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MinorityHolderContributionsMember" xlink:to="gyre_MinorityHolderContributionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TaxCreditCarryforwardExpirationYear" xlink:to="gyre_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GNIGroupMember" xlink:to="gyre_GNIGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfExcessCashOnDispositionsNet" xlink:to="gyre_PercentageOfExcessCashOnDispositionsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IncomeTaxTable" xlink:to="gyre_IncomeTaxTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedExpensesGeneralAndAdministrative" xlink:to="gyre_AccruedExpensesGeneralAndAdministrative_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue" xlink:to="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NDAPassesTheNMPAsReviewAndInspectionMember" xlink:to="gyre_NDAPassesTheNMPAsReviewAndInspectionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SoftwareMember" xlink:to="gyre_SoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DistributionsToHolders" xlink:to="gyre_DistributionsToHolders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MainlandChinaContributionPlanMember" xlink:to="gyre_MainlandChinaContributionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfRevenueAccountedSalesToDistributors" xlink:to="gyre_PercentageOfRevenueAccountedSalesToDistributors_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MinorityInterestDecreaseFromRedemptionsShares" xlink:to="gyre_MinorityInterestDecreaseFromRedemptionsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TemporaryEquityConvertiblePreferredStockConversionValue" xlink:to="gyre_TemporaryEquityConvertiblePreferredStockConversionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:to="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LandUseRightsNetAssets" xlink:to="gyre_LandUseRightsNetAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PostClosingIndemnificationObligation" xlink:to="gyre_PostClosingIndemnificationObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OptionsToPurchaseCommonStockMember" xlink:to="gyre_OptionsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LiquidityAbstract" xlink:to="gyre_LiquidityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" xlink:to="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" xlink:to="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CVRDerivativeLiabilityNonCurrentMember" xlink:to="gyre_CVRDerivativeLiabilityNonCurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" xlink:to="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" xlink:to="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeMember" xlink:to="us-gaap_OtherIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TwoThousandTwentyOneATMProgramMember" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_StockholdersEquityDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_WeightedAverageOfPreferredStockWarrant" xlink:to="gyre_WeightedAverageOfPreferredStockWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfAmountReceivedOnAgreement" xlink:to="gyre_PercentageOfAmountReceivedOnAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SharesForAggregatePurchasePrice" xlink:to="gyre_SharesForAggregatePurchasePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" xlink:to="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PayableToPropertyPlantAndEquipmentSuppliers" xlink:to="gyre_PayableToPropertyPlantAndEquipmentSuppliers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SellingAndMarketingExpensesPolicyTextBlock" xlink:to="gyre_SellingAndMarketingExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" xlink:to="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NoncontrollingInterestPolicyPolicyTextBlock" xlink:to="gyre_NoncontrollingInterestPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:to="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsCommonStock" xlink:to="us-gaap_PaymentsOfDividendsCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StatuteOfLimitationDueToTaxEvasion" xlink:to="gyre_StatuteOfLimitationDueToTaxEvasion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LongTermCertificatesOfDepositPolicyTextBlock" xlink:to="gyre_LongTermCertificatesOfDepositPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CvrLiabilitySettlement" xlink:to="gyre_CvrLiabilitySettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsTable" xlink:to="gyre_DeferredGovernmentGrantsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContingentValueRightsAgreementMember" xlink:to="gyre_ContingentValueRightsAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IncreaseDecreaseInAccountsAndNotesReceivables" xlink:to="gyre_IncreaseDecreaseInAccountsAndNotesReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" xlink:to="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart" xlink:to="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_RestructuringLiability" xlink:to="gyre_RestructuringLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" xlink:to="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SquareMeterAreaForLaboratoryCenterUnderLease" xlink:to="gyre_SquareMeterAreaForLaboratoryCenterUnderLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TemporaryEquityConvertiblePreferredStockConversionShares" xlink:to="gyre_TemporaryEquityConvertiblePreferredStockConversionShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:to="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OperatingLossCarryforwardsWithIndefiniteLife" xlink:to="gyre_OperatingLossCarryforwardsWithIndefiniteLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PreferredStockWarrantsPolicyTextBlock" xlink:to="gyre_PreferredStockWarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LandUseRightsNetNoncurrent" xlink:to="gyre_LandUseRightsNetNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" xlink:to="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:to="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" xlink:to="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" xlink:to="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:to="gyre_TwoThousandEighteenOmnibusIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedInterestIncomeOnShortTermBankDeposits" xlink:to="gyre_AccruedInterestIncomeOnShortTermBankDeposits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:to="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MotorVehiclesMember" xlink:to="gyre_MotorVehiclesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" xlink:to="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AcquisitionCostsInDueToRelatedParties" xlink:to="gyre_AcquisitionCostsInDueToRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" xlink:to="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:to="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:to="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAdministrationOfTaxationChinaMember" xlink:to="us-gaap_StateAdministrationOfTaxationChinaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsImpactFromForeignCorporations" xlink:to="gyre_DeferredTaxAssetsImpactFromForeignCorporations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CommittedToAllocate" xlink:to="gyre_CommittedToAllocate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StatuteOfLimitationDueToTransferPricingIssues" xlink:to="gyre_StatuteOfLimitationDueToTransferPricingIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedSalesDiscount" xlink:to="gyre_AccruedSalesDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LiquidityTable" xlink:to="gyre_LiquidityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AllowanceForCreditLossesCertificatesOfDeposit" xlink:to="gyre_AllowanceForCreditLossesCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PreferredStockWarrantsMember" xlink:to="gyre_PreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GCBiopharmaCorpMember" xlink:to="gyre_GCBiopharmaCorpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StatutoryReserveFund" xlink:to="gyre_StatutoryReserveFund_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit" xlink:to="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NoncashLeaseExpense" xlink:to="gyre_NoncashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StatutoryReserve" xlink:to="gyre_StatutoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="gyre_OrganizationAndNatureOfOperationsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_Short-TermBankDepositsMaturityPeriodEnd" xlink:to="gyre_Short-TermBankDepositsMaturityPeriodEnd_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" xlink:to="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:to="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BadDebtExpenseAndOtherNonCashItems" xlink:to="gyre_BadDebtExpenseAndOtherNonCashItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedInterestOnBankDeposit" xlink:to="gyre_AccruedInterestOnBankDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CvrExcessClosingCashPayable" xlink:to="gyre_CvrExcessClosingCashPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SeveranceAndOtherCosts" xlink:to="gyre_SeveranceAndOtherCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LandUseRightsPolicyTextBlock" xlink:to="gyre_LandUseRightsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NontradeReceivablesCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CVRDerivativeLiabilityMember" xlink:to="gyre_CVRDerivativeLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_RemainingOutstandingBalanceOfAgreement" xlink:to="gyre_RemainingOutstandingBalanceOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ForeignCurrencyRiskPolicyTextBlock" xlink:to="gyre_ForeignCurrencyRiskPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" xlink:to="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AcquiredInProcessResearchAndDevelopment" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AppropriationOfStatutoryReserve" xlink:to="gyre_AppropriationOfStatutoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_WarrantsSharePrice" xlink:to="gyre_WarrantsSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd" xlink:to="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DistributionFromAssetSaleProceeds" xlink:to="gyre_DistributionFromAssetSaleProceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CPIContributionMember" xlink:to="gyre_CPIContributionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AffiliatesBeneficialOwnSharesPercentage" xlink:to="gyre_AffiliatesBeneficialOwnSharesPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsNonCurrent" xlink:to="gyre_DeferredGovernmentGrantsNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationExcessClosingCashPayable" xlink:to="gyre_BusinessCombinationExcessClosingCashPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:to="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_VertexPharmaceuticalsIncorporatedMember" xlink:to="gyre_VertexPharmaceuticalsIncorporatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" xlink:to="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CommissionsAndOfferingCosts" xlink:to="gyre_CommissionsAndOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DrenBioIncAndCopiaScientificLLCMember" xlink:to="gyre_DrenBioIncAndCopiaScientificLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfCommissionForSharesSold" xlink:to="gyre_PercentageOfCommissionForSharesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PaymentOfDeferredOfferingCosts" xlink:to="gyre_PaymentOfDeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AppropriationsToStatutoryReserve" xlink:to="gyre_AppropriationsToStatutoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CollaborationRevenueMember" xlink:to="gyre_CollaborationRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_InvestmentSubscriptionAmount" xlink:to="gyre_InvestmentSubscriptionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CumulativeAmountOfStatutoryReserveFund" xlink:to="gyre_CumulativeAmountOfStatutoryReserveFund_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SubleaseArrangementMember" xlink:to="gyre_SubleaseArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AmortizationOfLandUseRights" xlink:to="gyre_AmortizationOfLandUseRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContinentPharmaceuticalsIncMember" xlink:to="gyre_ContinentPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:to="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="gyre_StockholdersEquityDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_UpfrontPaymentReceived" xlink:to="gyre_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember" xlink:to="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShortTermBankDepositsMember" xlink:to="gyre_ShortTermBankDepositsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShortTermBankDepositsPolicyTextBlock" xlink:to="gyre_ShortTermBankDepositsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CatalystMember" xlink:to="gyre_CatalystMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" xlink:to="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContributionsClosingPayableAmount" xlink:to="gyre_ContributionsClosingPayableAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetMeasurementInput" xlink:to="us-gaap_DerivativeAssetMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PatentsAndTechnologicalKnowHowMember" xlink:to="gyre_PatentsAndTechnologicalKnowHowMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfExcessPreapprovedCosts" xlink:to="gyre_PercentageOfExcessPreapprovedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedPayrollAndWelfare" xlink:to="gyre_AccruedPayrollAndWelfare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:to="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DivestitureLossesMember" xlink:to="gyre_DivestitureLossesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LongTermCertificatesOfDepositMember" xlink:to="gyre_LongTermCertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SinopharmGroupCompanyLimitedMember" xlink:to="gyre_SinopharmGroupCompanyLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PrepaidAssetsCurrent" xlink:to="gyre_PrepaidAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MachineryAndElectronicDevicesMember" xlink:to="gyre_MachineryAndElectronicDevicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FThreeFiveOneMember" xlink:to="gyre_FThreeFiveOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LongTermInvestmentsPolicyTextBlock" xlink:to="gyre_LongTermInvestmentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated" xlink:to="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DisposalConsiderationInOtherReceivables" xlink:to="gyre_DisposalConsiderationInOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" xlink:to="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredIncomeTaxExpenseBenefitNet" xlink:to="gyre_DeferredIncomeTaxExpenseBenefitNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GNIUSAMember" xlink:to="gyre_GNIUSAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LegalExpensesIncurred" xlink:to="gyre_LegalExpensesIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LeaseRenewedMonthAndYear" xlink:to="gyre_LeaseRenewedMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceReceivablesMember" xlink:to="us-gaap_FinanceReceivablesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChangesOfValuationAllowances" xlink:to="gyre_ChangesOfValuationAllowances_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OperatingLossCarryforwardsExpirationYear" xlink:to="gyre_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationFairValueOfPreferredShares" xlink:to="gyre_BusinessCombinationFairValueOfPreferredShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_RisksAndUncertainitiesPolicyTextBlock" xlink:to="gyre_RisksAndUncertainitiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GyrePharmaceuticalsMember" xlink:to="gyre_GyrePharmaceuticalsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CVRMergerClosingPayable" xlink:to="gyre_CVRMergerClosingPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfIndirectOwnershipInterest" xlink:to="gyre_PercentageOfIndirectOwnershipInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CVRDerivativeLiabilityNoncurrent" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChangeInFairValueOfLongTermReceivables" xlink:to="gyre_ChangeInFairValueOfLongTermReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrants" xlink:to="gyre_DeferredGovernmentGrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="gyre_CommitmentsAndContingenciesDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StatutoryReserveMember" xlink:to="gyre_StatutoryReserveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsCurrent" xlink:to="gyre_DeferredGovernmentGrantsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:to="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalAdditionsMember" xlink:to="us-gaap_CapitalAdditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent" xlink:to="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfEquityInterest" xlink:to="gyre_PercentageOfEquityInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationAgreementMember" xlink:to="gyre_BusinessCombinationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GovernmentGrantIncomeWithinOtherIncome" xlink:to="gyre_GovernmentGrantIncomeWithinOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsCapitalizedTransactionCosts" xlink:to="gyre_DeferredTaxAssetsCapitalizedTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" xlink:to="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CashPaidForAcquisitionCosts" xlink:to="gyre_CashPaidForAcquisitionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedExpensesResearchAndDevelopment" xlink:to="gyre_AccruedExpensesResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp" xlink:to="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CpUSSharePurchaseAgreementMember" xlink:to="gyre_CpUSSharePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FCContributionMember" xlink:to="gyre_FCContributionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationFairValueOfCommonShares" xlink:to="gyre_BusinessCombinationFairValueOfCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LongTermCertificatesOfDeposit" xlink:to="gyre_LongTermCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PaymentOfDisposalOfSubsidiary" xlink:to="gyre_PaymentOfDisposalOfSubsidiary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NMPAsApprovalOfTheNDAMember" xlink:to="gyre_NMPAsApprovalOfTheNDAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" xlink:to="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_IncomeTaxLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_VertexAssetPurchaseAgreementMember" xlink:to="gyre_VertexAssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ConcentrationOfCustomerRiskPolicyTextBlock" xlink:to="gyre_ConcentrationOfCustomerRiskPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DistributionsToHoldersPerCVR" xlink:to="gyre_DistributionsToHoldersPerCVR_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SubmissionOfTheNewDrugApplicationMember" xlink:to="gyre_SubmissionOfTheNewDrugApplicationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:to="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PaymentsForExchangeForIntellectualPropertyRights" xlink:to="gyre_PaymentsForExchangeForIntellectualPropertyRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GyreMember" xlink:to="gyre_GyreMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxLiabilityRightOfUseAssets" xlink:to="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_OrganizationAndNatureOfOperationsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:to="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:to="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChangeInFairValueOfDerivativeLiabilities" xlink:to="gyre_ChangeInFairValueOfDerivativeLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MaximumAmountOfTaxOffsetPerYear" xlink:to="gyre_MaximumAmountOfTaxOffsetPerYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:to="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PreMergerStockOptionsAssumed" xlink:to="gyre_PreMergerStockOptionsAssumed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PayableToSellingExpenseSuppliers" xlink:to="gyre_PayableToSellingExpenseSuppliers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" xlink:to="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsContractLiabilities" xlink:to="gyre_DeferredTaxAssetsContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit" xlink:to="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" xlink:to="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PaymentForResearchAndDevelopmentFees" xlink:to="gyre_PaymentForResearchAndDevelopmentFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated" xlink:to="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OtherDirectorOrOfficerMember" xlink:to="gyre_OtherDirectorOrOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="us-gaap_MinorityInterestDecreaseFromRedemptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationFairValue" xlink:to="gyre_BusinessCombinationFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_EquityGainLossOfUnconsolidatedAffiliates" xlink:to="gyre_EquityGainLossOfUnconsolidatedAffiliates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CostOfCollaborationMember" xlink:to="gyre_CostOfCollaborationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ConvertiblePreferredStockConversion" xlink:to="gyre_ConvertiblePreferredStockConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GNIMember" xlink:to="gyre_GNIMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CVRDerivativeLiabilityCurrent" xlink:to="gyre_CVRDerivativeLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LiquidityLineItems" xlink:to="gyre_LiquidityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TwoThousandTwentyFourATMProgramMember" xlink:to="gyre_TwoThousandTwentyFourATMProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:to="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedInterestOnLongTermCertificatesOfDeposit" xlink:to="gyre_AccruedInterestOnLongTermCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_RemainingNumberOfFullTimeEmployees" xlink:to="gyre_RemainingNumberOfFullTimeEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SquareMeterAreaForOfficeSpaceUnderLease" xlink:to="gyre_SquareMeterAreaForOfficeSpaceUnderLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" xlink:to="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit" xlink:to="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AmountToBeReceivedUnderAgreement" xlink:to="gyre_AmountToBeReceivedUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GCBiopharmaCorpMember" xlink:label="gyre_GCBiopharmaCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRMergerClosingPayable" xlink:label="gyre_CVRMergerClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CvrExcessClosingCashPayable" xlink:label="gyre_CvrExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LandUseRightsNetNoncurrent" xlink:label="gyre_LandUseRightsNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PrepaidAssetsCurrent" xlink:label="gyre_PrepaidAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityCurrent" xlink:label="gyre_CVRDerivativeLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_GCBiopharmaCorpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="gyre_StatutoryReserve" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CVRMergerClosingPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CvrExcessClosingCashPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="gyre_LandUseRightsNetNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="gyre_PrepaidAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NontradeReceivablesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="gyre_LongTermCertificatesOfDeposit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CVRDerivativeLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CollaborationRevenueMember" xlink:label="gyre_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CostOfCollaborationMember" xlink:label="gyre_CostOfCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_CostOfCollaborationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserveMember" xlink:label="gyre_StatutoryReserveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AppropriationOfStatutoryReserve" xlink:label="gyre_AppropriationOfStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MinorityInterestDecreaseFromRedemptionsShares" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityConvertiblePreferredStockConversionValue" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityConvertiblePreferredStockConversionShares" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CvrLiabilitySettlement" xlink:label="gyre_CvrLiabilitySettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_24"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_25"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_27"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gyre_StatutoryReserveMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_AppropriationOfStatutoryReserve" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestDecreaseFromRedemptions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_MinorityInterestDecreaseFromRedemptionsShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityConvertiblePreferredStockConversionValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityConvertiblePreferredStockConversionShares" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_CvrLiabilitySettlement" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentOfDeferredOfferingCosts" xlink:label="gyre_PaymentOfDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DisposalConsiderationInOtherReceivables" xlink:label="gyre_DisposalConsiderationInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquisitionCostsInDueToRelatedParties" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_IncreaseDecreaseInAccountsAndNotesReceivables" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NoncashLeaseExpense" xlink:label="gyre_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AmortizationOfLandUseRights" xlink:label="gyre_AmortizationOfLandUseRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredIncomeTaxExpenseBenefitNet" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ConvertiblePreferredStockConversion" xlink:label="gyre_ConvertiblePreferredStockConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CashPaidForAcquisitionCosts" xlink:label="gyre_CashPaidForAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BadDebtExpenseAndOtherNonCashItems" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentOfDisposalOfSubsidiary" xlink:label="gyre_PaymentOfDisposalOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestOnBankDeposit" xlink:label="gyre_AccruedInterestOnBankDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp" xlink:label="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestOnLongTermCertificatesOfDeposit" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangeInFairValueOfLongTermReceivables" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangeInFairValueOfDerivativeLiabilities" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_EquityGainLossOfUnconsolidatedAffiliates" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="gyre_PaymentOfDeferredOfferingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_DisposalConsiderationInOtherReceivables" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_AcquisitionCostsInDueToRelatedParties" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gyre_IncreaseDecreaseInAccountsAndNotesReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_NoncashLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_AmortizationOfLandUseRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_DeferredIncomeTaxExpenseBenefitNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_ConvertiblePreferredStockConversion" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="gyre_CashPaidForAcquisitionCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_BadDebtExpenseAndOtherNonCashItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="gyre_PaymentOfDisposalOfSubsidiary" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_AccruedInterestOnBankDeposit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_AccruedInterestOnLongTermCertificatesOfDeposit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_ChangeInFairValueOfLongTermReceivables" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_ChangeInFairValueOfDerivativeLiabilities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_EquityGainLossOfUnconsolidatedAffiliates" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NassimUsmanPhdMember" xlink:label="gyre_NassimUsmanPhdMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OtherDirectorOrOfficerMember" xlink:label="gyre_OtherDirectorOrOfficerMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="gyre_NassimUsmanPhdMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="gyre_OtherDirectorOrOfficerMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureF351AssetAcquisition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuring" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEps" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NoncontrollingInterestPolicyPolicyTextBlock" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RisksAndUncertainitiesPolicyTextBlock" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ConcentrationOfCustomerRiskPolicyTextBlock" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsPolicyTextBlock" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDepositPolicyTextBlock" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShortTermBankDepositsPolicyTextBlock" xlink:label="gyre_ShortTermBankDepositsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermInvestmentsPolicyTextBlock" xlink:label="gyre_LongTermInvestmentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LandUseRightsPolicyTextBlock" xlink:label="gyre_LandUseRightsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SellingAndMarketingExpensesPolicyTextBlock" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_InterestIncomePolicyTextBlock" xlink:label="gyre_InterestIncomePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ForeignCurrencyRiskPolicyTextBlock" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_NoncontrollingInterestPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_RisksAndUncertainitiesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_ConcentrationOfCustomerRiskPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_PreferredStockWarrantsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_LongTermCertificatesOfDepositPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_ShortTermBankDepositsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_LongTermInvestmentsPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_LandUseRightsPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_SellingAndMarketingExpensesPolicyTextBlock" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_InterestIncomePolicyTextBlock" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_ForeignCurrencyRiskPolicyTextBlock" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContinentPharmaceuticalsIncMember" xlink:label="gyre_ContinentPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OrganizationAndNatureOfOperationsTable" xlink:label="gyre_OrganizationAndNatureOfOperationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OrganizationAndNatureOfOperationsLineItems" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FCContributionMember" xlink:label="gyre_FCContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIUSAMember" xlink:label="gyre_GNIUSAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationAgreementMember" xlink:label="gyre_BusinessCombinationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MinorityHolderContributionsMember" xlink:label="gyre_MinorityHolderContributionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyrePharmaceuticalsMember" xlink:label="gyre_GyrePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_CPIContributionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_ContinentPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_OrganizationAndNatureOfOperationsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_FCContributionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIUSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_BusinessCombinationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_MinorityHolderContributionsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_GyrePharmaceuticalsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_OwnershipAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="gyre_OrganizationAndNatureOfOperationsLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LiquidityAbstract" xlink:label="gyre_LiquidityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LiquidityTable" xlink:label="gyre_LiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LiquidityLineItems" xlink:label="gyre_LiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="us-gaap_PaymentsOfDividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityAbstract" xlink:to="gyre_LiquidityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="gyre_LiquidityLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_PaymentsOfDividendsCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SinopharmGroupCompanyLimitedMember" xlink:label="gyre_SinopharmGroupCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PatentsAndTechnologicalKnowHowMember" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AllowanceForCreditLossesCertificatesOfDeposit" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit" xlink:label="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Short-TermBankDepositsMaturityDateRangeStart" xlink:label="gyre_Short-TermBankDepositsMaturityDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Short-TermBankDepositsMaturityPeriodEnd" xlink:label="gyre_Short-TermBankDepositsMaturityPeriodEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit" xlink:label="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated" xlink:label="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated" xlink:label="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue" xlink:label="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_SinopharmGroupCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_PatentsAndTechnologicalKnowHowMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_AllowanceForCreditLossesCertificatesOfDeposit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_Short-TermBankDepositsMaturityDateRangeStart" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_Short-TermBankDepositsMaturityPeriodEnd" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Cash" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_LongTermCertificatesOfDeposit" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShortTermInvestments" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MachineryAndElectronicDevicesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MotorVehiclesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityNonCurrentMember" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember" xlink:label="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetMeasurementInput" xlink:label="us-gaap_DerivativeAssetMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AmountToBeReceivedUnderAgreement" xlink:label="gyre_AmountToBeReceivedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestIncomeOnShortTermBankDeposits" xlink:label="gyre_AccruedInterestIncomeOnShortTermBankDeposits"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit" xlink:label="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityNonCurrentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_ContingentValueRightsAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_VertexAssetPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_StatementScenarioAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeAssetMeasurementInput" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_AmountToBeReceivedUnderAgreement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_AccruedInterestIncomeOnShortTermBankDeposits" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_WarrantsSharePrice" xlink:label="gyre_WarrantsSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="gyre_WarrantsSharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShortTermBankDepositsMember" xlink:label="gyre_ShortTermBankDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDepositMember" xlink:label="gyre_LongTermCertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gyre_ShortTermBankDepositsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gyre_LongTermCertificatesOfDepositMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ProceedsFromGovernmentGrantsReceived" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GovernmentGrantIncomeWithinOtherIncome" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_InvestmentSubscriptionAmount" xlink:label="gyre_InvestmentSubscriptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfEquityInterest" xlink:label="gyre_PercentageOfEquityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_ProceedsFromGovernmentGrantsReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_GovernmentGrantIncomeWithinOtherIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_InvestmentSubscriptionAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_PercentageOfEquityInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedPayrollAndWelfare" xlink:label="gyre_AccruedPayrollAndWelfare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PayableToPropertyPlantAndEquipmentSuppliers" xlink:label="gyre_PayableToPropertyPlantAndEquipmentSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedExpensesGeneralAndAdministrative" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedSalesDiscount" xlink:label="gyre_AccruedSalesDiscount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PayableToSellingExpenseSuppliers" xlink:label="gyre_PayableToSellingExpenseSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrants" xlink:label="gyre_DeferredGovernmentGrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedExpensesResearchAndDevelopment" xlink:label="gyre_AccruedExpensesResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_AccruedPayrollAndWelfare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_PayableToPropertyPlantAndEquipmentSuppliers" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_AccruedExpensesGeneralAndAdministrative" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_AccruedSalesDiscount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_PayableToSellingExpenseSuppliers" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_DeferredGovernmentGrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_AccruedExpensesResearchAndDevelopment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsLineItems" xlink:label="gyre_DeferredGovernmentGrantsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsCurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsTable" xlink:label="gyre_DeferredGovernmentGrantsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsNonCurrent" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="gyre_DeferredGovernmentGrantsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsNonCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsTable" xlink:to="gyre_DeferredGovernmentGrantsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MachineryAndElectronicDevicesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MotorVehiclesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SoftwareMember" xlink:label="gyre_SoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_SoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfRevenueAccountedSalesToDistributors" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ProductConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="gyre_PercentageOfRevenueAccountedSalesToDistributors" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValueOfCommonShares" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValueOfPreferredShares" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValue" xlink:label="gyre_BusinessCombinationFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreMergerStockOptionsAssumed" xlink:label="gyre_PreMergerStockOptionsAssumed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CatalystMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValueOfCommonShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValueOfPreferredShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_PreMergerStockOptionsAssumed" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CatalystMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationExcessClosingCashPayable" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationExcessClosingCashPayable" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DrenBioIncAndCopiaScientificLLCMember" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SharesForAggregatePurchasePrice" xlink:label="gyre_SharesForAggregatePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_VertexPharmaceuticalsIncorporatedMember" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CpUSSharePurchaseAgreementMember" xlink:label="gyre_CpUSSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DivestitureLossesMember" xlink:label="gyre_DivestitureLossesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RestructuringLiability" xlink:label="gyre_RestructuringLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RemainingNumberOfFullTimeEmployees" xlink:label="gyre_RemainingNumberOfFullTimeEmployees"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SeveranceAndOtherCosts" xlink:label="gyre_SeveranceAndOtherCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_UpfrontPaymentReceived" xlink:label="gyre_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PostClosingIndemnificationObligation" xlink:label="gyre_PostClosingIndemnificationObligation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_PercentageOfIndirectOwnershipInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_DrenBioIncAndCopiaScientificLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_SharesForAggregatePurchasePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_VertexPharmaceuticalsIncorporatedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CpUSSharePurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="gyre_DivestitureLossesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_RestructuringLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_RemainingNumberOfFullTimeEmployees" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_SeveranceAndOtherCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_UpfrontPaymentReceived" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_PostClosingIndemnificationObligation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SubleaseArrangementMember" xlink:label="gyre_SubleaseArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LeaseLabAndOfficeSpaceMember" xlink:label="gyre_LeaseLabAndOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LeaseExpirationMonthAndYear" xlink:label="gyre_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LeaseRenewedMonthAndYear" xlink:label="gyre_LeaseRenewedMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SquareMeterAreaForOfficeSpaceUnderLease" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SquareMeterAreaForLaboratoryCenterUnderLease" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LandUseRightsNetAssets" xlink:label="gyre_LandUseRightsNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_SubleaseArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_LeaseLabAndOfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LeaseExpirationMonthAndYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LeaseRenewedMonthAndYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForOfficeSpaceUnderLease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForLaboratoryCenterUnderLease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LandUseRightsNetAssets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyFourATMProgramMember" xlink:label="gyre_TwoThousandTwentyFourATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StockholdersEquityDisclosureLineItems" xlink:label="gyre_StockholdersEquityDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StockholdersEquityDisclosureTable" xlink:label="gyre_StockholdersEquityDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LegalExpensesIncurred" xlink:label="gyre_LegalExpensesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserveFund" xlink:label="gyre_StatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CumulativeAmountOfStatutoryReserveFund" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AppropriationsToStatutoryReserve" xlink:label="gyre_AppropriationsToStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommissionsAndOfferingCosts" xlink:label="gyre_CommissionsAndOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AffiliatesBeneficialOwnSharesPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyFourATMProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="gyre_StockholdersEquityDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_LegalExpensesIncurred" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="gyre_StockholdersEquityDisclosureLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_StatutoryReserveFund" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_CumulativeAmountOfStatutoryReserveFund" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AppropriationsToStatutoryReserve" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_CommissionsAndOfferingCosts" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AffiliatesBeneficialOwnSharesPercentage" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gyre_OptionsToPurchaseCommonStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandEighteenOmnibusIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfExcessCashOnDispositionsNet" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyrePharmaceuticalsMember" xlink:label="gyre_GyrePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneMember" xlink:label="gyre_FThreeFiveOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommitmentsAndContingenciesDisclosureTable" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalAdditionsMember" xlink:label="us-gaap_CapitalAdditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SubmissionOfTheNewDrugApplicationMember" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NDAPassesTheNMPAsReviewAndInspectionMember" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfAmountReceivedOnAgreement" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NMPAsApprovalOfTheNDAMember" xlink:label="gyre_NMPAsApprovalOfTheNDAMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfExcessPreapprovedCosts" xlink:label="gyre_PercentageOfExcessPreapprovedCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DistributionFromAssetSaleProceeds" xlink:label="gyre_DistributionFromAssetSaleProceeds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContributionsClosingPayableAmount" xlink:label="gyre_ContributionsClosingPayableAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DistributionsToHolders" xlink:label="gyre_DistributionsToHolders"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DistributionsToHoldersPerCVR" xlink:label="gyre_DistributionsToHoldersPerCVR"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RemainingOutstandingBalanceOfAgreement" xlink:label="gyre_RemainingOutstandingBalanceOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentsForExchangeForIntellectualPropertyRights" xlink:label="gyre_PaymentsForExchangeForIntellectualPropertyRights"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommittedToAllocate" xlink:label="gyre_CommittedToAllocate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_VertexAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfExcessCashOnDispositionsNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_ContingentValueRightsAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_GyrePharmaceuticalsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gyre_FThreeFiveOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_CapitalAdditionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="gyre_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_SubmissionOfTheNewDrugApplicationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_NDAPassesTheNMPAsReviewAndInspectionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfAmountReceivedOnAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_NMPAsApprovalOfTheNDAMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfExcessPreapprovedCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_DistributionFromAssetSaleProceeds" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="gyre_CommitmentsAndContingenciesDisclosureLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContributionsClosingPayableAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_DistributionsToHolders" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_DistributionsToHoldersPerCVR" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_RemainingOutstandingBalanceOfAgreement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PaymentsForExchangeForIntellectualPropertyRights" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CommittedToAllocate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsContractLiabilities" xlink:label="gyre_DeferredTaxAssetsContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsImpactFromForeignCorporations" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsCapitalizedTransactionCosts" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsLeaseLiabilities" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxLiabilityRightOfUseAssets" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxAssetsContractLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxAssetsImpactFromForeignCorporations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxAssetsCapitalizedTransactionCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxAssetsLeaseLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxLiabilityRightOfUseAssets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangesOfValuationAllowances" xlink:label="gyre_ChangesOfValuationAllowances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_ChangesOfValuationAllowances" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAdministrationOfTaxationChinaMember" xlink:label="us-gaap_StateAdministrationOfTaxationChinaMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_IncomeTaxTable" xlink:label="gyre_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_IncomeTaxLineItems" xlink:label="gyre_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OperatingLossCarryforwardsExpirationYear" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OperatingLossCarryforwardsWithIndefiniteLife" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TaxCreditCarryforwardExpirationYear" xlink:label="gyre_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MaximumAmountOfTaxOffsetPerYear" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RequiredMinimumTaxableIncome" xlink:label="gyre_RequiredMinimumTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent" xlink:label="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatuteOfLimitationDueToTransferPricingIssues" xlink:label="gyre_StatuteOfLimitationDueToTransferPricingIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatuteOfLimitationDueToTaxEvasion" xlink:label="gyre_StatuteOfLimitationDueToTaxEvasion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAdministrationOfTaxationChinaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_IncomeTaxTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_OperatingLossCarryforwardsExpirationYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_OperatingLossCarryforwardsWithIndefiniteLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxTable" xlink:to="gyre_IncomeTaxLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_TaxCreditCarryforwardExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_MaximumAmountOfTaxOffsetPerYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_RequiredMinimumTaxableIncome" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_StatuteOfLimitationDueToTransferPricingIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_StatuteOfLimitationDueToTaxEvasion" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_OpenTaxYear" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentForResearchAndDevelopmentFees" xlink:label="gyre_PaymentForResearchAndDevelopmentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIGroupMember" xlink:label="gyre_GNIGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gyre_PaymentForResearchAndDevelopmentFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="gyre_CPIContributionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIGroupMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_WeightedAverageOfPreferredStockWarrant" xlink:label="gyre_WeightedAverageOfPreferredStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="gyre_WeightedAverageOfPreferredStockWarrant" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="gyre_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="gyre_PreferredStockWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MainlandChinaContributionPlanMember" xlink:label="gyre_MainlandChinaContributionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="gyre_MainlandChinaContributionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_CPIContributionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="gyre_PercentageOfIndirectOwnershipInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyrePharmaceuticalsMember" xlink:label="gyre_GyrePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="us-gaap_AllOtherSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_GyrePharmaceuticalsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_GyreMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestIncomeExpenseNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="gyre_StatutoryReserve" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedCashFlowStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GCBiopharmaCorpMember" xlink:label="gyre_GCBiopharmaCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRMergerClosingPayable" xlink:label="gyre_CVRMergerClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CvrExcessClosingCashPayable" xlink:label="gyre_CvrExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LandUseRightsNetNoncurrent" xlink:label="gyre_LandUseRightsNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PrepaidAssetsCurrent" xlink:label="gyre_PrepaidAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityCurrent" xlink:label="gyre_CVRDerivativeLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_GCBiopharmaCorpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="gyre_StatutoryReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CVRMergerClosingPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CvrExcessClosingCashPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="gyre_LandUseRightsNetNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="gyre_PrepaidAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NontradeReceivablesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="gyre_LongTermCertificatesOfDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CVRDerivativeLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CollaborationRevenueMember" xlink:label="gyre_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CostOfCollaborationMember" xlink:label="gyre_CostOfCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_CollaborationRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_CostOfCollaborationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserveMember" xlink:label="gyre_StatutoryReserveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AppropriationOfStatutoryReserve" xlink:label="gyre_AppropriationOfStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MinorityInterestDecreaseFromRedemptionsShares" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityConvertiblePreferredStockConversionValue" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TemporaryEquityConvertiblePreferredStockConversionShares" xlink:label="gyre_TemporaryEquityConvertiblePreferredStockConversionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CvrLiabilitySettlement" xlink:label="gyre_CvrLiabilitySettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gyre_StatutoryReserveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_AppropriationOfStatutoryReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestDecreaseFromRedemptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_MinorityInterestDecreaseFromRedemptionsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityConvertiblePreferredStockConversionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityConvertiblePreferredStockConversionShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_CvrLiabilitySettlement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NassimUsmanPhdMember" xlink:label="gyre_NassimUsmanPhdMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OtherDirectorOrOfficerMember" xlink:label="gyre_OtherDirectorOrOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="gyre_NassimUsmanPhdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="gyre_OtherDirectorOrOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OrganizationAndNatureOfOperationsLineItems" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OrganizationAndNatureOfOperationsTable" xlink:label="gyre_OrganizationAndNatureOfOperationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContinentPharmaceuticalsIncMember" xlink:label="gyre_ContinentPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FCContributionMember" xlink:label="gyre_FCContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIUSAMember" xlink:label="gyre_GNIUSAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationAgreementMember" xlink:label="gyre_BusinessCombinationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MinorityHolderContributionsMember" xlink:label="gyre_MinorityHolderContributionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyrePharmaceuticalsMember" xlink:label="gyre_GyrePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_OrganizationAndNatureOfOperationsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_CPIContributionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_ContinentPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_FCContributionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIUSAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_BusinessCombinationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_MinorityHolderContributionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_GyrePharmaceuticalsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LiquidityLineItems" xlink:label="gyre_LiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LiquidityTable" xlink:label="gyre_LiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="us-gaap_PaymentsOfDividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_LiquidityLineItems" xlink:to="gyre_LiquidityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_PaymentsOfDividendsCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SinopharmGroupCompanyLimitedMember" xlink:label="gyre_SinopharmGroupCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PatentsAndTechnologicalKnowHowMember" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AllowanceForCreditLossesCertificatesOfDeposit" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit" xlink:label="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd" xlink:label="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Short-TermBankDepositsMaturityDateRangeStart" xlink:label="gyre_Short-TermBankDepositsMaturityDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_Short-TermBankDepositsMaturityPeriodEnd" xlink:label="gyre_Short-TermBankDepositsMaturityPeriodEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit" xlink:label="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated" xlink:label="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated" xlink:label="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue" xlink:label="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_SinopharmGroupCompanyLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_PatentsAndTechnologicalKnowHowMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_AllowanceForCreditLossesCertificatesOfDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_Short-TermBankDepositsMaturityDateRangeStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_Short-TermBankDepositsMaturityPeriodEnd" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_LongTermCertificatesOfDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MachineryAndElectronicDevicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MotorVehiclesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityNonCurrentMember" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember" xlink:label="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetMeasurementInput" xlink:label="us-gaap_DerivativeAssetMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AmountToBeReceivedUnderAgreement" xlink:label="gyre_AmountToBeReceivedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestIncomeOnShortTermBankDeposits" xlink:label="gyre_AccruedInterestIncomeOnShortTermBankDeposits"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit" xlink:label="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityNonCurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_ContingentValueRightsAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_VertexAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeAssetMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_AmountToBeReceivedUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_AccruedInterestIncomeOnShortTermBankDeposits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_WarrantsSharePrice" xlink:label="gyre_WarrantsSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="gyre_WarrantsSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShortTermBankDepositsMember" xlink:label="gyre_ShortTermBankDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDepositMember" xlink:label="gyre_LongTermCertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gyre_ShortTermBankDepositsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gyre_LongTermCertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ProceedsFromGovernmentGrantsReceived" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GovernmentGrantIncomeWithinOtherIncome" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_InvestmentSubscriptionAmount" xlink:label="gyre_InvestmentSubscriptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfEquityInterest" xlink:label="gyre_PercentageOfEquityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_ProceedsFromGovernmentGrantsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_GovernmentGrantIncomeWithinOtherIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_InvestmentSubscriptionAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_PercentageOfEquityInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsLineItems" xlink:label="gyre_DeferredGovernmentGrantsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsTable" xlink:label="gyre_DeferredGovernmentGrantsTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsCurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsNonCurrent" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_DeferredGovernmentGrantsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsNonCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MachineryAndElectronicDevicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MotorVehiclesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SoftwareMember" xlink:label="gyre_SoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_SoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfRevenueAccountedSalesToDistributors" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ProductConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="gyre_PercentageOfRevenueAccountedSalesToDistributors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValueOfCommonShares" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValueOfPreferredShares" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValue" xlink:label="gyre_BusinessCombinationFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreMergerStockOptionsAssumed" xlink:label="gyre_PreMergerStockOptionsAssumed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CatalystMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValueOfCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValueOfPreferredShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_PreMergerStockOptionsAssumed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CatalystMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationExcessClosingCashPayable" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationExcessClosingCashPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DrenBioIncAndCopiaScientificLLCMember" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SharesForAggregatePurchasePrice" xlink:label="gyre_SharesForAggregatePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_VertexPharmaceuticalsIncorporatedMember" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CpUSSharePurchaseAgreementMember" xlink:label="gyre_CpUSSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DivestitureLossesMember" xlink:label="gyre_DivestitureLossesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RestructuringLiability" xlink:label="gyre_RestructuringLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RemainingNumberOfFullTimeEmployees" xlink:label="gyre_RemainingNumberOfFullTimeEmployees"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SeveranceAndOtherCosts" xlink:label="gyre_SeveranceAndOtherCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_UpfrontPaymentReceived" xlink:label="gyre_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PostClosingIndemnificationObligation" xlink:label="gyre_PostClosingIndemnificationObligation"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_PercentageOfIndirectOwnershipInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_DrenBioIncAndCopiaScientificLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_SharesForAggregatePurchasePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_VertexPharmaceuticalsIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CpUSSharePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="gyre_DivestitureLossesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_RestructuringLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_RemainingNumberOfFullTimeEmployees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_SeveranceAndOtherCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_PostClosingIndemnificationObligation" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SubleaseArrangementMember" xlink:label="gyre_SubleaseArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LeaseLabAndOfficeSpaceMember" xlink:label="gyre_LeaseLabAndOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LeaseExpirationMonthAndYear" xlink:label="gyre_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LeaseRenewedMonthAndYear" xlink:label="gyre_LeaseRenewedMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SquareMeterAreaForOfficeSpaceUnderLease" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SquareMeterAreaForLaboratoryCenterUnderLease" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LandUseRightsNetAssets" xlink:label="gyre_LandUseRightsNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_SubleaseArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_LeaseLabAndOfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LeaseRenewedMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForOfficeSpaceUnderLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForLaboratoryCenterUnderLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LandUseRightsNetAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StockholdersEquityDisclosureLineItems" xlink:label="gyre_StockholdersEquityDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StockholdersEquityDisclosureTable" xlink:label="gyre_StockholdersEquityDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyFourATMProgramMember" xlink:label="gyre_TwoThousandTwentyFourATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LegalExpensesIncurred" xlink:label="gyre_LegalExpensesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserveFund" xlink:label="gyre_StatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CumulativeAmountOfStatutoryReserveFund" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AppropriationsToStatutoryReserve" xlink:label="gyre_AppropriationsToStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommissionsAndOfferingCosts" xlink:label="gyre_CommissionsAndOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AffiliatesBeneficialOwnSharesPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_StockholdersEquityDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyFourATMProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_LegalExpensesIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_StatutoryReserveFund" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_CumulativeAmountOfStatutoryReserveFund" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AppropriationsToStatutoryReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_CommissionsAndOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AffiliatesBeneficialOwnSharesPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gyre_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandEighteenOmnibusIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommitmentsAndContingenciesDisclosureTable" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfExcessCashOnDispositionsNet" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyrePharmaceuticalsMember" xlink:label="gyre_GyrePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneMember" xlink:label="gyre_FThreeFiveOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalAdditionsMember" xlink:label="us-gaap_CapitalAdditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_SubmissionOfTheNewDrugApplicationMember" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NDAPassesTheNMPAsReviewAndInspectionMember" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfAmountReceivedOnAgreement" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NMPAsApprovalOfTheNDAMember" xlink:label="gyre_NMPAsApprovalOfTheNDAMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfExcessPreapprovedCosts" xlink:label="gyre_PercentageOfExcessPreapprovedCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DistributionFromAssetSaleProceeds" xlink:label="gyre_DistributionFromAssetSaleProceeds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ContributionsClosingPayableAmount" xlink:label="gyre_ContributionsClosingPayableAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DistributionsToHolders" xlink:label="gyre_DistributionsToHolders"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DistributionsToHoldersPerCVR" xlink:label="gyre_DistributionsToHoldersPerCVR"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RemainingOutstandingBalanceOfAgreement" xlink:label="gyre_RemainingOutstandingBalanceOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentsForExchangeForIntellectualPropertyRights" xlink:label="gyre_PaymentsForExchangeForIntellectualPropertyRights"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CommittedToAllocate" xlink:label="gyre_CommittedToAllocate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_VertexAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfExcessCashOnDispositionsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_ContingentValueRightsAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_GyrePharmaceuticalsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gyre_FThreeFiveOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_CapitalAdditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_SubmissionOfTheNewDrugApplicationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_NDAPassesTheNMPAsReviewAndInspectionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfAmountReceivedOnAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_NMPAsApprovalOfTheNDAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfExcessPreapprovedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_DistributionFromAssetSaleProceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContributionsClosingPayableAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_DistributionsToHolders" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_DistributionsToHoldersPerCVR" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_RemainingOutstandingBalanceOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PaymentsForExchangeForIntellectualPropertyRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CommittedToAllocate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_IncomeTaxLineItems" xlink:label="gyre_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_IncomeTaxTable" xlink:label="gyre_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAdministrationOfTaxationChinaMember" xlink:label="us-gaap_StateAdministrationOfTaxationChinaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OperatingLossCarryforwardsExpirationYear" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OperatingLossCarryforwardsWithIndefiniteLife" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_TaxCreditCarryforwardExpirationYear" xlink:label="gyre_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MaximumAmountOfTaxOffsetPerYear" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_RequiredMinimumTaxableIncome" xlink:label="gyre_RequiredMinimumTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent" xlink:label="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatuteOfLimitationDueToTransferPricingIssues" xlink:label="gyre_StatuteOfLimitationDueToTransferPricingIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatuteOfLimitationDueToTaxEvasion" xlink:label="gyre_StatuteOfLimitationDueToTaxEvasion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_IncomeTaxTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAdministrationOfTaxationChinaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_IncomeTaxTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_OperatingLossCarryforwardsWithIndefiniteLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_MaximumAmountOfTaxOffsetPerYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_RequiredMinimumTaxableIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_StatuteOfLimitationDueToTransferPricingIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_StatuteOfLimitationDueToTaxEvasion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentForResearchAndDevelopmentFees" xlink:label="gyre_PaymentForResearchAndDevelopmentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GNIGroupMember" xlink:label="gyre_GNIGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gyre_PaymentForResearchAndDevelopmentFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="gyre_CPIContributionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="gyre_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="gyre_PreferredStockWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_MainlandChinaContributionPlanMember" xlink:label="gyre_MainlandChinaContributionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="gyre_MainlandChinaContributionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_default" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_CPIContributionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="gyre_PercentageOfIndirectOwnershipInterest" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyrePharmaceuticalsMember" xlink:label="gyre_GyrePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="us-gaap_AllOtherSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_GyrePharmaceuticalsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_GyreMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestIncomeExpenseNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="gyre_StatutoryReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="gyre_StatutoryReserve" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="gyre_CvrExcessClosingCashPayable" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="gyre_LandUseRightsNetNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="gyre_CVRMergerClosingPayable" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="gyre_LongTermCertificatesOfDeposit" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="gyre_CVRDerivativeLiabilityCurrent" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="gyre_PrepaidAssetsCurrent" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CvrExcessClosingCashPayable" xlink:label="gyre_CvrExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LandUseRightsNetNoncurrent" xlink:label="gyre_LandUseRightsNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRMergerClosingPayable" xlink:label="gyre_CVRMergerClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CVRDerivativeLiabilityCurrent" xlink:label="gyre_CVRDerivativeLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PrepaidAssetsCurrent" xlink:label="gyre_PrepaidAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncome" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingExpense" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="6" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="gyre_PaymentOfDeferredOfferingCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_AccruedInterestOnLongTermCertificatesOfDeposit" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="gyre_CashPaidForAcquisitionCosts" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="gyre_PaymentOfDisposalOfSubsidiary" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_AccruedInterestOnBankDeposit" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_ChangeInFairValueOfLongTermReceivables" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="15" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_EquityGainLossOfUnconsolidatedAffiliates" order="16" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_BadDebtExpenseAndOtherNonCashItems" order="17" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="18" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="19" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="20" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="22" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_DeferredIncomeTaxExpenseBenefitNet" order="23" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_NoncashLeaseExpense" order="25" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivableCurrent" order="26" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="27" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_AmortizationOfLandUseRights" order="28" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_IncreaseDecreaseInAccountsAndNotesReceivables" order="29" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="31" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_ChangeInFairValueOfDerivativeLiabilities" order="32" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="36" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="37" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" order="38" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="39" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentOfDeferredOfferingCosts" xlink:label="gyre_PaymentOfDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestOnLongTermCertificatesOfDeposit" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp" xlink:label="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_CashPaidForAcquisitionCosts" xlink:label="gyre_CashPaidForAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PaymentOfDisposalOfSubsidiary" xlink:label="gyre_PaymentOfDisposalOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedInterestOnBankDeposit" xlink:label="gyre_AccruedInterestOnBankDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangeInFairValueOfLongTermReceivables" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_EquityGainLossOfUnconsolidatedAffiliates" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BadDebtExpenseAndOtherNonCashItems" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredIncomeTaxExpenseBenefitNet" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_NoncashLeaseExpense" xlink:label="gyre_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AmortizationOfLandUseRights" xlink:label="gyre_AmortizationOfLandUseRights"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_IncreaseDecreaseInAccountsAndNotesReceivables" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_ChangeInFairValueOfDerivativeLiabilities" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:label="us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_AccruedPayrollAndWelfare" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_PayableToPropertyPlantAndEquipmentSuppliers" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_AccruedExpensesGeneralAndAdministrative" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_PayableToSellingExpenseSuppliers" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_AccruedSalesDiscount" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_AccruedExpensesResearchAndDevelopment" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_DeferredGovernmentGrants" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedPayrollAndWelfare" xlink:label="gyre_AccruedPayrollAndWelfare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PayableToPropertyPlantAndEquipmentSuppliers" xlink:label="gyre_PayableToPropertyPlantAndEquipmentSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedExpensesGeneralAndAdministrative" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PayableToSellingExpenseSuppliers" xlink:label="gyre_PayableToSellingExpenseSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedSalesDiscount" xlink:label="gyre_AccruedSalesDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AccruedExpensesResearchAndDevelopment" xlink:label="gyre_AccruedExpensesResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrants" xlink:label="gyre_DeferredGovernmentGrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:to="gyre_DeferredGovernmentGrantsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:to="gyre_DeferredGovernmentGrantsNonCurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsCurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredGovernmentGrantsNonCurrent" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="gyre_BusinessCombinationFairValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gyre_BusinessCombinationFairValue" xlink:to="gyre_BusinessCombinationFairValueOfCommonShares" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="gyre_PreMergerStockOptionsAssumed" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gyre_BusinessCombinationFairValue" xlink:to="gyre_BusinessCombinationFairValueOfPreferredShares" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValue" xlink:label="gyre_BusinessCombinationFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValueOfCommonShares" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_PreMergerStockOptionsAssumed" xlink:label="gyre_PreMergerStockOptionsAssumed"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationFairValueOfPreferredShares" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationExcessClosingCashPayable" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" order="14" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationExcessClosingCashPayable" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="gyre_DeferredTaxLiabilityRightOfUseAssets" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gyre_DeferredTaxAssetsContractLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gyre_DeferredTaxAssetsImpactFromForeignCorporations" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gyre_DeferredTaxAssetsCapitalizedTransactionCosts" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gyre_DeferredTaxAssetsLeaseLiabilities" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxLiabilityRightOfUseAssets" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsContractLiabilities" xlink:label="gyre_DeferredTaxAssetsContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsImpactFromForeignCorporations" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsCapitalizedTransactionCosts" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_DeferredTaxAssetsLeaseLiabilities" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="gyre_WeightedAverageOfPreferredStockWarrant" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_WeightedAverageOfPreferredStockWarrant" xlink:label="gyre_WeightedAverageOfPreferredStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="gyre_StatutoryReserve" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20241231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent" name="StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_PercentageOfIndirectOwnershipInterest" name="PercentageOfIndirectOwnershipInterest" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_VertexAssetPurchaseAgreementMember" name="VertexAssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ShortTermBankDepositsPolicyTextBlock" name="ShortTermBankDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_SellingAndMarketingExpensesPolicyTextBlock" name="SellingAndMarketingExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" name="ConversionOfOutstandingPreferredStockRedeemedForCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AcquisitionCostsInDueToRelatedParties" name="AcquisitionCostsInDueToRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsTable" name="DeferredGovernmentGrantsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccruedInterestIncomeOnShortTermBankDeposits" name="AccruedInterestIncomeOnShortTermBankDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" name="AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" name="NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd" name="Long-TermCertificatesOfDepositMaturityDateRangeEnd" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" name="AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" name="PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_SinopharmGroupCompanyLimitedMember" name="SinopharmGroupCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue" name="CashAndCashEquivalentsReportingCurrencyDenominatedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" name="DeferredGovernmentGrantsCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_BeijingContinentPharmaceuticalsCoLtdMember" name="BeijingContinentPharmaceuticalsCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AppropriationsToStatutoryReserve" name="AppropriationsToStatutoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_StockholdersEquityDisclosureTable" name="StockholdersEquityDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccruedPayrollAndWelfare" name="AccruedPayrollAndWelfare" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CVRDerivativeLiabilityNoncurrent" name="CVRDerivativeLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeferredIncomeTaxExpenseBenefitNet" name="DeferredIncomeTaxExpenseBenefitNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DistributionsToHoldersPerCVR" name="DistributionsToHoldersPerCVR" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PaymentForResearchAndDevelopmentFees" name="PaymentForResearchAndDevelopmentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_StatuteOfLimitationDueToTaxEvasion" name="StatuteOfLimitationDueToTaxEvasion" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_NassimUsmanPhdMember" name="NassimUsmanPhdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PrepaidAssetsCurrent" name="PrepaidAssetsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_FCContributionMember" name="FCContributionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DisposalConsiderationInOtherReceivables" name="DisposalConsiderationInOtherReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" name="AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ChangesOfValuationAllowances" name="ChangesOfValuationAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_NoncontrollingInterestPolicyPolicyTextBlock" name="NoncontrollingInterestPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ShortTermBankDepositsMember" name="ShortTermBankDepositsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_InvestmentSubscriptionAmount" name="InvestmentSubscriptionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_LeaseRenewedMonthAndYear" name="LeaseRenewedMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_StockholdersEquityDisclosureLineItems" name="StockholdersEquityDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ChangeInFairValueOfDerivativeLiabilities" name="ChangeInFairValueOfDerivativeLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_CatalystMember" name="CatalystMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AmortizationOfLandUseRights" name="AmortizationOfLandUseRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" name="AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_RemainingOutstandingBalanceOfAgreement" name="RemainingOutstandingBalanceOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeferredTaxAssetsContractLiabilities" name="DeferredTaxAssetsContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_TemporaryEquityConvertiblePreferredStockConversionShares" name="TemporaryEquityConvertiblePreferredStockConversionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AllowanceForCreditLossesCertificatesOfDeposit" name="AllowanceForCreditLossesCertificatesOfDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_EquityGainLossOfUnconsolidatedAffiliates" name="EquityGainLossOfUnconsolidatedAffiliates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" name="NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" name="ScheduleOfDeferredGovernmentGrantsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AmountToBeReceivedUnderAgreement" name="AmountToBeReceivedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" name="TwoThousandTwentyThreeOmnibusIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsCurrent" name="DeferredGovernmentGrantsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_TwoThousandEighteenOmnibusIncentivePlanMember" name="TwoThousandEighteenOmnibusIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PreMergerStockOptionsAssumed" name="PreMergerStockOptionsAssumed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" name="ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_RequiredMinimumTaxableIncome" name="RequiredMinimumTaxableIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" name="AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CpUSSharePurchaseAgreementMember" name="CpUSSharePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CashPaidForAcquisitionCosts" name="CashPaidForAcquisitionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" name="TemporaryEquityIssuedDuringPeriodValueAcquisitions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_LandUseRightsPolicyTextBlock" name="LandUseRightsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_CommittedToAllocate" name="CommittedToAllocate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" name="DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp" name="ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" name="AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CvrExcessClosingCashPayable" name="CvrExcessClosingCashPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" name="AffiliatesBeneficialOwnSharesSpecifiedPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_StatutoryReserveFund" name="StatutoryReserveFund" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_OrganizationAndNatureOfOperationsTable" name="OrganizationAndNatureOfOperationsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PayableToSellingExpenseSuppliers" name="PayableToSellingExpenseSuppliers" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_PercentageOfExcessPreapprovedCosts" name="PercentageOfExcessPreapprovedCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" name="TemporaryEquityIssuedDuringPeriodSharesAcquisitions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PaymentsForExchangeForIntellectualPropertyRights" name="PaymentsForExchangeForIntellectualPropertyRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DivestitureLossesMember" name="DivestitureLossesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" name="ChargesRelatedToWriteOffOfPrepaidManufacturingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DrenBioIncAndCopiaScientificLLCMember" name="DrenBioIncAndCopiaScientificLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_VertexPharmaceuticalsIncorporatedMember" name="VertexPharmaceuticalsIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_TwoThousandTwentyOneATMProgramMember" name="TwoThousandTwentyOneATMProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" name="ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" name="ContingentValueRightsDerivativeLiabilityNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_MainlandChinaContributionPlanMember" name="MainlandChinaContributionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CVRDerivativeLiabilityNonCurrentMember" name="CVRDerivativeLiabilityNonCurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_BusinessCombinationFairValueOfCommonShares" name="BusinessCombinationFairValueOfCommonShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_TemporaryEquityConvertiblePreferredStockConversionValue" name="TemporaryEquityConvertiblePreferredStockConversionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CPIContributionMember" name="CPIContributionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LongTermInvestmentsPolicyTextBlock" name="LongTermInvestmentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" name="GeneralAndAdministrativeExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_NMPAsApprovalOfTheNDAMember" name="NMPAsApprovalOfTheNDAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_StatutoryReserve" name="StatutoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_RisksAndUncertainitiesPolicyTextBlock" name="RisksAndUncertainitiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AcquiredInProcessResearchAndDevelopment" name="AcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_FThreeFiveOneAssetPurchaseAgreementMember" name="FThreeFiveOneAssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PaymentOfDeferredOfferingCosts" name="PaymentOfDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsLineItems" name="DeferredGovernmentGrantsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ContinentPharmaceuticalsIncMember" name="ContinentPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" name="ChinaResourcesPharmaceuticalGroupLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" name="PrivatePlacementAndSecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" name="PercentageOfMinorityInterestOwnershipIndirectlyHolds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_RemainingNumberOfFullTimeEmployees" name="RemainingNumberOfFullTimeEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_CVRDerivativeLiabilityMember" name="CVRDerivativeLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LiquidityAbstract" name="LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LeaseLabAndOfficeSpaceMember" name="LeaseLabAndOfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PercentageOfRevenueAccountedSalesToDistributors" name="PercentageOfRevenueAccountedSalesToDistributors" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" name="PercentageOfRestrictedNetAssetsExceedNetAssets" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_SquareMeterAreaForLaboratoryCenterUnderLease" name="SquareMeterAreaForLaboratoryCenterUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfOutstandingSharesOfCommonStock" name="PercentageOfOutstandingSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AccruedInterestOnBankDeposit" name="AccruedInterestOnBankDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_LiquidityTable" name="LiquidityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" name="DepositsInLicensedBanksProtectedByDepositInsuranceSystem" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_MinorityHolderContributionsMember" name="MinorityHolderContributionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_SubleaseArrangementMember" name="SubleaseArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_OtherDirectorOrOfficerMember" name="OtherDirectorOrOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" name="DeferredTaxAssetsFixedAssetsAndIntangibles" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" name="EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_GNIMember" name="GNIMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LandUseRightsNetNoncurrent" name="LandUseRightsNetNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_GCBiopharmaCorpMember" name="GCBiopharmaCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DeferredTaxAssetsImpactFromForeignCorporations" name="DeferredTaxAssetsImpactFromForeignCorporations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_BusinessCombinationExcessClosingCashPayable" name="BusinessCombinationExcessClosingCashPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_BusinessCombinationAgreementMember" name="BusinessCombinationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccruedSalesDiscount" name="AccruedSalesDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeferredGovernmentGrants" name="DeferredGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AppropriationOfStatutoryReserve" name="AppropriationOfStatutoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_SharesForAggregatePurchasePrice" name="SharesForAggregatePurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_CostOfCollaborationMember" name="CostOfCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PercentageOfAmountReceivedOnAgreement" name="PercentageOfAmountReceivedOnAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_WeightedAverageOfPreferredStockWarrant" name="WeightedAverageOfPreferredStockWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfExcessCashOnDispositionsNet" name="PercentageOfExcessCashOnDispositionsNet" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_StatuteOfLimitationDueToTransferPricingIssues" name="StatuteOfLimitationDueToTransferPricingIssues" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_SoftwareMember" name="SoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_Short-TermBankDepositsMaturityDateRangeStart" name="Short-TermBankDepositsMaturityDateRangeStart" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_TwoThousandTwentyFourATMProgramMember" name="TwoThousandTwentyFourATMProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_GyrePharmaceuticalsMember" name="GyrePharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_LegalExpensesIncurred" name="LegalExpensesIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_PayableToPropertyPlantAndEquipmentSuppliers" name="PayableToPropertyPlantAndEquipmentSuppliers" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" name="ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AffiliatesBeneficialOwnSharesPercentage" name="AffiliatesBeneficialOwnSharesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" name="FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_PreferredStockWarrantsPolicyTextBlock" name="PreferredStockWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ContributionsClosingPayableAmount" name="ContributionsClosingPayableAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_CVRDerivativeLiabilityCurrent" name="CVRDerivativeLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ProceedsFromGovernmentGrantsReceived" name="ProceedsFromGovernmentGrantsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_SquareMeterAreaForOfficeSpaceUnderLease" name="SquareMeterAreaForOfficeSpaceUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ConvertiblePreferredStockConversion" name="ConvertiblePreferredStockConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit" name="ValueOfAssetsExceedingDepositInsuranceSystemLimit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" name="AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_RestructuringLiability" name="RestructuringLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeferredTaxLiabilityRightOfUseAssets" name="DeferredTaxLiabilityRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit" name="AllowanceForCreditLossesShort-TermCertificatesOfDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_OrganizationAndNatureOfOperationsLineItems" name="OrganizationAndNatureOfOperationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_SubmissionOfTheNewDrugApplicationMember" name="SubmissionOfTheNewDrugApplicationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" name="ObligationToPayInExchangeForTheIntellectualPropertyRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AccruedExpensesResearchAndDevelopment" name="AccruedExpensesResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" name="ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_MinorityInterestDecreaseFromRedemptionsShares" name="MinorityInterestDecreaseFromRedemptionsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LongTermCertificatesOfDepositMember" name="LongTermCertificatesOfDepositMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" name="SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" name="AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_MachineryAndElectronicDevicesMember" name="MachineryAndElectronicDevicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PostClosingIndemnificationObligation" name="PostClosingIndemnificationObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CumulativeAmountOfStatutoryReserveFund" name="CumulativeAmountOfStatutoryReserveFund" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DeferredTaxAssetsCapitalizedTransactionCosts" name="DeferredTaxAssetsCapitalizedTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_GyreMember" name="GyreMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_LandUseRightsNetAssets" name="LandUseRightsNetAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ContingentValueRightsAgreementMember" name="ContingentValueRightsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" name="DeferredTaxAssetsStateNetOperatingLossCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_MaximumAmountOfTaxOffsetPerYear" name="MaximumAmountOfTaxOffsetPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ChangeInFairValueOfLongTermReceivables" name="ChangeInFairValueOfLongTermReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsNonCurrent" name="DeferredGovernmentGrantsNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DistributionsToHolders" name="DistributionsToHolders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit" name="AccruedInterestIncomeOnLongTermCertificatesOfDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" name="PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" name="NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_MotorVehiclesMember" name="MotorVehiclesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccruedInterestOnLongTermCertificatesOfDeposit" name="AccruedInterestOnLongTermCertificatesOfDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" name="GCBiophrarmaCorpAssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PercentageOfEquityInterest" name="PercentageOfEquityInterest" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_StatutoryReserveMember" name="StatutoryReserveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" name="ConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_IncreaseDecreaseInAccountsAndNotesReceivables" name="IncreaseDecreaseInAccountsAndNotesReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CVRMergerClosingPayable" name="CVRMergerClosingPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_BusinessCombinationFairValueOfPreferredShares" name="BusinessCombinationFairValueOfPreferredShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_PercentageOfCommissionForSharesSold" name="PercentageOfCommissionForSharesSold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DistributionFromAssetSaleProceeds" name="DistributionFromAssetSaleProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_SeveranceAndOtherCosts" name="SeveranceAndOtherCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_Short-TermBankDepositsMaturityPeriodEnd" name="Short-TermBankDepositsMaturityPeriodEnd" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_BadDebtExpenseAndOtherNonCashItems" name="BadDebtExpenseAndOtherNonCashItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PaymentOfDisposalOfSubsidiary" name="PaymentOfDisposalOfSubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ForeignCurrencyRiskPolicyTextBlock" name="ForeignCurrencyRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" name="PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_InterestIncomePolicyTextBlock" name="InterestIncomePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" name="ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" name="FairValueAssetsAndLiabilitiesLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CommissionsAndOfferingCosts" name="CommissionsAndOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" name="CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated" name="PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_NDAPassesTheNMPAsReviewAndInspectionMember" name="NDAPassesTheNMPAsReviewAndInspectionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart" name="Long-TermCertificatesOfDepositMaturityDateRangeStart" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PatentsAndTechnologicalKnowHowMember" name="PatentsAndTechnologicalKnowHowMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember" name="MeasurementInputCurrentlyEstimatedDiscountRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LongTermCertificatesOfDepositPolicyTextBlock" name="LongTermCertificatesOfDepositPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_GovernmentGrantIncomeWithinOtherIncome" name="GovernmentGrantIncomeWithinOtherIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated" name="PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" name="DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_GNIUSAMember" name="GNIUSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_GNIGroupMember" name="GNIGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LiquidityLineItems" name="LiquidityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" name="BCTwoThousandTwentyOneStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_BusinessCombinationFairValue" name="BusinessCombinationFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_FThreeFiveOneMember" name="FThreeFiveOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CvrLiabilitySettlement" name="CvrLiabilitySettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_AccruedExpensesGeneralAndAdministrative" name="AccruedExpensesGeneralAndAdministrative" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_WarrantsSharePrice" name="WarrantsSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ConcentrationOfCustomerRiskPolicyTextBlock" name="ConcentrationOfCustomerRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_LongTermCertificatesOfDeposit" name="LongTermCertificatesOfDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_OperatingLossCarryforwardsWithIndefiniteLife" name="OperatingLossCarryforwardsWithIndefiniteLife" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GYRE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gyre Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,612,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12770 High Bluff Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">949-3681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Grant Thornton Zhitong Certified Public Accountants LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Beijing, China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2025 (the &#8220;Proxy Statement&#8221;), which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the financial statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Gyre Therapeutics, Inc. (a Delaware corporation) and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of comprehensive income (loss), consolidated statements of convertible preferred stock and equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes and the financial statements schedule included in Schedule I (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in the 2013 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated March 17, 2025 expressed an unqualified opinion.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,813<span></span>
</td>
<td class="nump">$ 33,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="nump">14,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Notes receivable</a></td>
<td class="nump">4,373<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">19,589<span></span>
</td>
<td class="nump">15,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">6,337<span></span>
</td>
<td class="nump">4,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PrepaidAssetsCurrent', window );">Prepaid assets</a></td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,436<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">64,786<span></span>
</td>
<td class="nump">57,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">23,880<span></span>
</td>
<td class="nump">23,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LandUseRightsNetNoncurrent', window );">Land use rights, net</a></td>
<td class="nump">1,432<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">5,619<span></span>
</td>
<td class="nump">4,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LongTermCertificatesOfDeposit', window );">Long-term certificates of deposit</a></td>
<td class="nump">24,568<span></span>
</td>
<td class="nump">23,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">125,406<span></span>
</td>
<td class="nump">116,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CvrExcessClosingCashPayable', window );">CVR excess closing cash payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,615<span></span>
</td>
<td class="nump">11,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">2,831<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">713<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CVRDerivativeLiabilityCurrent', window );">CVR derivative liability</a></td>
<td class="nump">4,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">19,516<span></span>
</td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred government grants</a></td>
<td class="nump">928<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CVRDerivativeLiabilityNoncurrent', window );">CVR derivative liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability, noncurrent</a></td>
<td class="nump">5,668<span></span>
</td>
<td class="nump">12,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">27,004<span></span>
</td>
<td class="nump">38,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 400,000,000 shares authorized; 86,307,544 shares and 76,595,616 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">136,185<span></span>
</td>
<td class="nump">68,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatutoryReserve', window );">Statutory reserve</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">3,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(73,453)<span></span>
</td>
<td class="num">(85,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,597)<span></span>
</td>
<td class="num">(1,644)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gyre stockholders' equity (deficit)</a></td>
<td class="nump">63,319<span></span>
</td>
<td class="num">(15,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">35,083<span></span>
</td>
<td class="nump">29,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">98,402<span></span>
</td>
<td class="nump">13,949<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and equity</a></td>
<td class="nump">125,406<span></span>
</td>
<td class="nump">116,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gyre_GCBiopharmaCorpMember', window );">GC Biopharma Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Receivable from GCBP</a></td>
<td class="nump">4,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent', window );">Long-term receivable from GCBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">GNI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables from GNI</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CVRDerivativeLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>C V R derivative liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CVRDerivativeLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CVRDerivativeLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CVR derivative liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CVRDerivativeLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CvrExcessClosingCashPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CVR excess closing cash payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CvrExcessClosingCashPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LandUseRightsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Land use rights net noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LandUseRightsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LongTermCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Certificates Of Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LongTermCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PrepaidAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid assets current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PrepaidAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gyre_GCBiopharmaCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gyre_GCBiopharmaCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">86,307,544<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">86,307,544<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 105,757<span></span>
</td>
<td class="nump">$ 113,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">4,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">57,511<span></span>
</td>
<td class="nump">61,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,024<span></span>
</td>
<td class="nump">13,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,109<span></span>
</td>
<td class="nump">14,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">89,594<span></span>
</td>
<td class="nump">180,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="nump">16,163<span></span>
</td>
<td class="num">(67,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1,659)<span></span>
</td>
<td class="num">(1,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">7,167<span></span>
</td>
<td class="num">(9,261)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">23,218<span></span>
</td>
<td class="num">(76,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(5,320)<span></span>
</td>
<td class="num">(8,515)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss)</a></td>
<td class="nump">17,898<span></span>
</td>
<td class="num">(85,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="nump">5,813<span></span>
</td>
<td class="nump">7,453<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="nump">$ 12,085<span></span>
</td>
<td class="num">$ (92,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to common stockholders, basic</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share attributable to common stockholders, diluted</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, basic</a></td>
<td class="nump">85,094,948<span></span>
</td>
<td class="nump">65,831,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, diluted</a></td>
<td class="nump">102,293,526<span></span>
</td>
<td class="nump">65,831,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from operations</a></td>
<td class="nump">$ 17,898<span></span>
</td>
<td class="num">$ (85,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,460)<span></span>
</td>
<td class="num">(1,484)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) from operations</a></td>
<td class="nump">16,438<span></span>
</td>
<td class="num">(86,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="nump">5,813<span></span>
</td>
<td class="nump">7,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation adjustments attributable to noncontrolling interest</a></td>
<td class="num">(507)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interest</a></td>
<td class="nump">5,306<span></span>
</td>
<td class="nump">6,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to common stockholders</a></td>
<td class="nump">$ 11,132<span></span>
</td>
<td class="num">$ (93,770)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Statutory Reserve</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Total Gyre Stockholders' Equity (Deficit)</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 72,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 32,795<span></span>
</td>
<td class="nump">$ 2,660<span></span>
</td>
<td class="nump">$ 7,395<span></span>
</td>
<td class="num">$ (392)<span></span>
</td>
<td class="nump">$ 42,522<span></span>
</td>
<td class="nump">$ 29,695<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</a></td>
<td class="nump">21,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">21,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,531,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Acquisition of minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">7,845<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415)<span></span>
</td>
<td class="nump">7,878<span></span>
</td>
<td class="num">(7,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_MinorityInterestDecreaseFromRedemptionsShares', window );">Acquisition of minority interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,463,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Preferred Stock upon Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Preferred Stock upon Private Placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,127<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(85,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,933)<span></span>
</td>
<td class="nump">7,453<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">13,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">68,179<span></span>
</td>
<td class="nump">3,098<span></span>
</td>
<td class="num">(85,538)<span></span>
</td>
<td class="num">(1,644)<span></span>
</td>
<td class="num">(15,828)<span></span>
</td>
<td class="nump">29,777<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">$ 1,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">874,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">874,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TemporaryEquityConvertiblePreferredStockConversionValue', window );">Temporary Equity, Convertible preferred stock conversion</a></td>
<td class="nump">$ 64,525<span></span>
</td>
<td class="num">$ (64,525)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">64,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TemporaryEquityConvertiblePreferredStockConversionShares', window );">Temporary Equity, Convertible preferred stock conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,151)<span></span>
</td>
<td class="nump">8,767,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock upon ATM program</a></td>
<td class="nump">773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock upon ATM program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CvrLiabilitySettlement', window );">CVR Liability settlement</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Deferred Financing Costs Amortization</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(953)<span></span>
</td>
<td class="num">(953)<span></span>
</td>
<td class="num">(507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">17,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,085<span></span>
</td>
<td class="nump">5,813<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 98,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 136,185<span></span>
</td>
<td class="nump">$ 3,098<span></span>
</td>
<td class="num">$ (73,453)<span></span>
</td>
<td class="num">$ (2,597)<span></span>
</td>
<td class="nump">$ 63,319<span></span>
</td>
<td class="nump">$ 35,083<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,307,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CvrLiabilitySettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CVR liability settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CvrLiabilitySettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_MinorityInterestDecreaseFromRedemptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minority interest decrease from redemptions shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_MinorityInterestDecreaseFromRedemptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TemporaryEquityConvertiblePreferredStockConversionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, convertible preferred stock conversion, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TemporaryEquityConvertiblePreferredStockConversionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TemporaryEquityConvertiblePreferredStockConversionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, convertible preferred stock conversion, value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TemporaryEquityConvertiblePreferredStockConversionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period shares acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period value acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss) from operations</a></td>
<td class="nump">$ 17,898<span></span>
</td>
<td class="num">$ (85,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">7,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NoncashLeaseExpense', window );">Noncash Lease Expense</a></td>
<td class="nump">672<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AmortizationOfLandUseRights', window );">Amortization of land use rights</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredIncomeTaxExpenseBenefitNet', window );">Deferred income taxes, net</a></td>
<td class="num">(1,002)<span></span>
</td>
<td class="num">(1,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BadDebtExpenseAndOtherNonCashItems', window );">Bad debt expense and other non-cash items</a></td>
<td class="nump">170<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedInterestOnBankDeposit', window );">Accrued interest on bank deposit</a></td>
<td class="num">(1,046)<span></span>
</td>
<td class="num">(633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ChangeInFairValueOfLongTermReceivables', window );">Change in fair value of receivables from GCBP</a></td>
<td class="num">(239)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ChangeInFairValueOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Less: Change in fair value of warrant liability</a></td>
<td class="num">(7,167)<span></span>
</td>
<td class="nump">9,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_EquityGainLossOfUnconsolidatedAffiliates', window );">Equity loss of unconsolidated affiliates</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesReceivables', window );">Notes receivable</a></td>
<td class="num">(4,028)<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,257)<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables from GNI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2,139)<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">520<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Income tax payable</a></td>
<td class="num">(2,166)<span></span>
</td>
<td class="nump">3,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(245)<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="num">(83)<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,497)<span></span>
</td>
<td class="nump">1,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(816)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used) provided by operating activities</a></td>
<td class="num">(3,641)<span></span>
</td>
<td class="nump">25,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="num">(813)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit', window );">Purchase of certificates of deposit</a></td>
<td class="num">(15,471)<span></span>
</td>
<td class="num">(15,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,315)<span></span>
</td>
<td class="num">(8,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of equipment</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of equity method investment</a></td>
<td class="num">(1,686)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash and cash equivalents acquired in connection with the GNI USA Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CashPaidForAcquisitionCosts', window );">Payments made for acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PaymentOfDisposalOfSubsidiary', window );">Cash balance in a disposed subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(566)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(19,884)<span></span>
</td>
<td class="num">(19,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PaymentOfDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="num">(536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock in ATM program</a></td>
<td class="nump">773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">1,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of Convertible Preferred Stock and Preferred Stock Warrants under the Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(298)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(21,696)<span></span>
</td>
<td class="nump">8,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">33,509<span></span>
</td>
<td class="nump">25,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">11,813<span></span>
</td>
<td class="nump">33,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Financing and Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions', window );">Advance payment for Convertible Preferred Stock and Preferred Stock Warrants acquired upon the GNI USA Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DisposalConsiderationInOtherReceivables', window );">Disposal consideration in other receivables from GNI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquisitionCostsInDueToRelatedParties', window );">Acquisition costs in due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liabilities</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable', window );">Proceeds from the exercise of stock options included in other receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ConvertiblePreferredStockConversion', window );">Convertible preferred stock conversion</a></td>
<td class="nump">64,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 8,518<span></span>
</td>
<td class="nump">$ 6,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedInterestOnBankDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on bank deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedInterestOnBankDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AcquisitionCostsInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition costs in due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AcquisitionCostsInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance payment for convertible preferred stock and preferred stock warrants acquired upon contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AmortizationOfLandUseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of&#160;land use rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AmortizationOfLandUseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BadDebtExpenseAndOtherNonCashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debt expense and other non-cash items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BadDebtExpenseAndOtherNonCashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CashPaidForAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CashPaidForAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ChangeInFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ChangeInFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ChangeInFairValueOfLongTermReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of long-term receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ChangeInFairValueOfLongTermReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ConvertiblePreferredStockConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ConvertiblePreferredStockConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed issuance of common stock and convertible preferred stock to former stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredIncomeTaxExpenseBenefitNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred income tax expense benefit net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredIncomeTaxExpenseBenefitNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DisposalConsiderationInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal consideration in other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DisposalConsiderationInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_EquityGainLossOfUnconsolidatedAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity gain loss of unconsolidated affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_EquityGainLossOfUnconsolidatedAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PaymentOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PaymentOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PaymentOfDisposalOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of disposal of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PaymentOfDisposalOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of stock options included in other receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 17,898<span></span>
</td>
<td class="num">$ (85,480)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Item 1C. CYBERSECURITY.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">We strive to safeguard our important data, hardware, and internal network from digital attacks, theft and damage. In the ordinary course of our business, we collect, use, store, and digitally transmit confidential, sensitive, proprietary, and personal information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy. To this end, we have implemented processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">At Gyre Therapeutics, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">these processes are managed and monitored by a third-party information technology</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (&#8220;IT&#8221;) consulting company (the &#8220;Managed Service Provider&#8221;) and are overseen by our Chief Financial Officer.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> At Gyre Pharmaceuticals, these processes are managed and monitored by a dedicated Information Security team, which is led by the General Manager. Gyre Therapeutics&#8217; and Gyre Pharmaceuticals&#8217; processes include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data. In the process of advancing the systematic development of information security, we seek to maintain a robust approach that encompasses policy formulation, organizational structuring, technological application enhancement, process optimization, and personnel training. For example, Gyre Therapeutics and Gyre Pharmaceuticals maintain software and hardware inventories, perform security monitoring and alerting, and complete ongoing risk assessments. Gyre Therapeutics and Gyre Pharmaceuticals also conduct regular employee trainings on cyber and information security, among other topics. In addition, both companies consult with outside advisors and experts on a regular basis to assist with assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the Company&#8217;s risk environment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Our Chief Financial Officer, who reports directly to our Chief Executive Officer, is responsible for assessing and managing Gyre Therapeutics&#8217; cybersecurity risks with support from the Managed Service Provider, which employs IT consultants with over 20 years of experience managing information technology and cybersecurity matters and are certified as Microsoft Certified Systems Engineers. Our Gyre Pharmaceuticals information security team, who reports to the Secretary of the General Manager at Gyre Pharmaceuticals, comprises of three employees with an average of 20 years of experience managing information technology and cyber</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">security matters. The Secretary of the General Manager reports to the General Manager at Gyre Pharmaceuticals, and the General Manager reports to the Board of Directors and is responsible for assessing and managing Gyre Pharmaceuticals&#8217; cybersecurity risks. We consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework. Since the beginning of the last fiscal year, we have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the heading &#8220;Breach, failure or disruption in or to our information system could compromise sensitive information related to our business and expose us to liability or reputational harm, and our ability to effectively manage our business operations could be adversely affected.&#8221;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our management team.</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.</span></span></span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our management team.</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.</span></span></span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our management team.</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Organization and Nature of Operations</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Gyre,&#8221; or the &#8220;combined company&#8221;), formerly known as Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;), is a biopharmaceutical company originally incorporated in Delaware on March 7, 1997 under the name Targacept, Inc. Catalyst was a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, Catalyst had several protease assets that were designed to address unmet medical needs in disorders of the complement or coagulation systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">After completion of the transactions under the Business Combination Agreement as described below, Gyre became a commercial-stage pharmaceutical company with a proven track record of financial success developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs and involves a complex, multi-stage process with multiple pathways.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">F351 Asset Acquisition</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On December 26, 2022, Catalyst executed and closed an Asset Purchase Agreement, which was amended on March 29, 2023 (the &#8220;F351 Agreement&#8221;), with GNI Group Ltd. (&#8220;GNI Japan&#8221;) and GNI Hong Kong Limited (&#8220;GNI HK&#8221;) to purchase all of the assets and intellectual property rights primarily related to a clinical-stage proprietary Hydronidone compound for the treatment of metabolic dysfunction-associated steatohepatitis (&#8220;MASH&#8221;), a severe form of nonalcoholic fatty liver disease (collectively, the &#8220;F351 Assets&#8221;), other than such assets and intellectual property rights located in the People&#8217;s Republic of China (&#8220;PRC&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combination Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On December 26, 2022, Catalyst entered into a Business Combination Agreement, as amended on March 29, 2023 and August 30, 2023 (the &#8220;Business Combination Agreement&#8221;) with GNI USA, Inc. (&#8220;GNI USA&#8221;), GNI Japan, GNI HK, Shanghai Genomics, Inc. (&#8220;SG&#8221; and collectively with GNI USA, GNI Japan and GNI HK, the &#8220;Contributors,&#8221; and each a &#8220;Contributor&#8221;), certain individuals (each, a &#8220;Minority Holder&#8221; and collectively, the &#8220;Minority Holders&#8221;) and Continent Pharmaceuticals Inc. (&#8220;CPI&#8221;). On October 30, 2023 (the &#8220;Effective Time&#8221;), the Contributions (as defined below) became effective and Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (doing business as Gyre Pharmaceuticals Co,, Ltd.) (&#8220;Gyre Pharmaceuticals&#8221;). In connection with the Contributions, and immediately prior to the Effective Time of the Contributions, Catalyst amended its certificate of incorporation, increased the number of authorized shares of its common stock, par value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share (the &#8220;Common Stock&#8221;) from </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, effected a</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1-for-15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reverse stock split</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (the &#8220;Reverse Stock Split&#8221;) and changed its name to Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Shares of Catalyst Common Stock were previously listed on The Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221; Catalyst had filed a listing application for the combined company with the Nasdaq Stock Market Inc. (&#8220;Nasdaq&#8221;). On October 31, 2023, Gyre&#8217;s Common Stock commenced trading on the Nasdaq Capital Market under the symbol &#8220;GYRE&#8221;, on a post-reverse stock split adjusted basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to the Business Combination Agreement, at the Effective Time of the Contributions, and after giving effect to the </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1-for-15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reverse stock spli</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t,</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GNI USA contributed all of its ordinary shares in the capital of CPI to Catalyst in exchange for </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,923,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;CPI Contribution&#8221;), </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GNI USA contributed its interest in Further Challenger International Limited (&#8220;Further Challenger&#8221;) for </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,664,779</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;FC Contribution&#8221; and together with the CPI Contribution, the &#8220;GNI USA Contributions&#8221;), and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">each Minority Holder contributed </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the interest he or she held in his or her respective entity in exchange for an aggregate of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,463,627</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;Minority Holder Contributions&#8221; and together with the GNI USA Contributions, the &#8220;Contributions&#8221;). </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As a result of the GNI USA Contributions, Gyre directly and indirectly holds </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of CPI&#8217;s shares. Through Gyre&#8217;s ownership of CPI, prior to the Minority Holder Contributions, Gyre held a </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> indirect interest in Gyre Pharmaceuticals. Upon completion of the Minority Holder Contributions, Gyre obtained additional indirect interests in Gyre Pharmaceuticals and holds, in aggregate, a </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> indirect interest in Gyre Pharmaceuticals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Immediately after the closing of the Contributions, excluding potentially dilutive securities, GNI USA owned approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the outstanding shares of Gyre Common Stock, Catalyst&#8217;s existing stockholders, excluding GNI USA, owned approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the outstanding Gyre Common Stock, and the Minority Holders owned approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the outstanding shares of Gyre Common Stock. The Convertible Preferred Stock remained outstanding after the closing of the Contributions and is not included in the above ownership percentages.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">At the Effective Time, Gyre Pharmaceuticals terminated its 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;) and the options (the &#8220;Gyre Pharmaceuticals Options&#8221;) outstanding under the 2021 Plan were terminated and replaced with options granted under a subplan for Chinese participants under the Gyre 2023 Omnibus Incentive Plan (the &#8220;2023 Omnibus Incentive Plan&#8221;) that are substantially similar in all material respects to the Gyre Pharmaceuticals Options previously outstanding under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remained issued and outstanding, and such shares and options were unaffected by the Contributions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company registered and established in the PRC in 2002. Gyre Pharmaceuticals is committed to the research and development of new drugs as well as manufacturing and commercialization of ETUARY (pirfenidone capsule) for the treatment of idiopathic pulmonary fibrosis and other pharmaceutical products. The registered office of Gyre Pharmaceuticals is located at 60 Shunkang Road, Shunyi District, Beijing, PRC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The immediate holding company of Gyre Pharmaceuticals is BJContinent Pharmaceuticals Limited (&#8220;BJC&#8221;). The intermediate holding company of Gyre Pharmaceuticals is CPI. Immediately following the Contributions, the immediate holding company of CPI is Gyre. The immediate holding Company of Gyre is GNI USA and the ultimate holding company of Gyre is GNI Japan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The GNI USA Contributions were treated as an asset acquisition under U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), with CPI treated as the accounting acquirer and presented as the predecessor for the post-acquisition SEC reporting purposes. Since Catalyst is the legal acquirer, the GNI USA Contributions were accounted for as a reverse asset acquisition. This determination was based upon the terms of the Business Combination Agreement and other factors including that, immediately following the GNI USA Contributions: (i) GNI USA (as the parent company of CPI immediately prior to the GNI USA Contributions) owns a substantial majority of the voting power of the combined company; (ii) CPI, through GNI USA, has the ability to control the board of directors of the combined company; and (iii) senior management of Gyre Pharmaceuticals and GNI USA holds a majority of the key positions in senior management of the combined company. Immediately prior to the closing of the Contributions, Catalyst did not meet the definition of a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">business because Catalyst did not have an organized workforce that significantly contributed to its ability to create output, and substantially all of its fair value was concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of the closing date of the GNI USA Contributions, the net assets of Catalyst were recorded at their acquisition-date relative fair values in the accompanying consolidated financial statements of the Company and the reported operating results prior to the GNI USA Contributions are those of CPI.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in Gyre Pharmaceuticals.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Value Rights Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Concurrent with the signing of the Business Combination Agreement on December 26, 2022, Catalyst and the Rights Agent (as defined in the CVR Agreement) executed a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), as amended on March 29, 2023, pursuant to which each holder of Catalyst Common Stock as of January 5, 2023 (the &#8220;CVR Holder&#8221;), excluding GNI, received one contractual contingent value right (a &#8220;CVR&#8221;) for each share of Catalyst Common Stock held by such holder. Each CVR entitles the holder thereof to receive certain cash payments in the future. For additional information, see Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On October 30, 2023, the Company effected a </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1-for-15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reverse stock split</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> immediately prior to the Effective Time of the Contributions. The par value of the Catalyst Common Stock following the Reverse Stock Split was not adjusted and remains at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share. All of the Catalyst&#8217;s issued and outstanding common stock and options have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding, which resulted in a proportional decrease in the number of shares of the Company&#8217;s Common Stock reserved for issuance upon exercise or vesting of such stock options, warrants, and in the case of stock options and warrants, a proportional decrease in the exercise price of such stock options and warrants.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Stock Split and stockholders who would otherwise be entitled to a fraction of one share received a proportional cash payment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company had a net income of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, while net cash used in operating activities was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Based on the Company&#8217;s current operating plan, management believes that existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund the Company&#8217;s operating activities and obligations for at least 12 months following the issuance of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span></p></td>
     </tr>
    </table><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Noncontrolling Interest</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company reports noncontrolling interest (&#8220;NCI&#8221;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The measure of segment profit or loss is reported on the income statement as consolidated net income (loss). The CODM uses net income (loss) to evaluate income generated from segment assets in deciding whether to reinvest profits and monitor budget versus actual results in assessing performance of the segment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM, as a group, includes Gyre&#8217;s Chief of Executive Officer (&#8220;CEO&#8221;), Gyre Pharmaceuticals&#8217;  General Manager, Gyre's Chief Operating Officer, and the Chairman of Gyre&#8217;s Board of Directors (&#8220;Gyre&#8217;s Board&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company has determined that it operates in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> distinct operating segments and has </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reportable segments.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">f Credit Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, note receivable, long-term certificates of deposits, and short-term bank deposits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In May 2015, a new Deposit Insurance System (&#8220;DIS&#8221;) managed by the People&#8217;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#8220;RMB&#8221;) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> millio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">n, and long-term certificates of deposit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> millio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">n, respectively. In addition, the Company had short-term bank deposits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2024. For the years ended December</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> 31, 2024 and 2023, cash and cash equivalents, short-term bank deposits and long-term certificates of deposits exceeded the PRC DIS coverage by $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ac</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Customer Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, one customer, Sinopharm Group Co., Ltd., accounted for approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of accounts receivable, respectively. For the year ended December 31, 2024, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of total revenue respectively. For the year ended December 31, 2023, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> accounted for approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of total revenue respectively. All customers are located in the PRC.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and Cash equivalents includes cash on hand, demand deposits and money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> Value Measurements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for additional information regarding the CVR derivative liability.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Stock Warrants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrants to purchase shares of the Convertible Preferred Stock (&#8220;Preferred Stock Warrants&#8221;) are freestanding financial instruments classified as warrant liability on the Company&#8217;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#8217;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, to account for the Convertible Preferred Stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-term Certificates of Deposit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The long-term certificates of deposit will mature between </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">J</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">anuary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">April 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">effective interest method. The Company recorded </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> allowance for credit losses associated with the certificates of deposit as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and 2023.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Short-term Bank Deposits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The short-term bank deposits will mature between </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">January 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Short-term bank deposits consist of bank deposits with original maturities of one year or less, and long-term deposits that have a remaining maturity of less than one year. These deposits are recorded at amortized cost. Interest income from these deposits is recognized and reported within interest income. The Company recorded </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> allowance for credit losses associated with the short-term certificates of deposit as of December 31, 2024 and 2023.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-Term Receivable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#8220;GCBP&#8221;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for additional information regarding the long-term receivable.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-term Investments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise more than minor influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC Topic 323, Investments&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Method and Joint Ventures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 323&#8221;). Under the equity method, the Company initially records its investments at fair value. The Company subsequently adjusts the carrying amount of the investment to recognize the Company&#8217;s proportionate share of the equity investee&#8217;s net income or loss after the date of investment. The Company evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> impairment charge was recognized for the years ended December 31, 2024 and 2023.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts and Note Receivables, Net</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#8217;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#8217;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div style="font-size:10pt;font-family:'Aptos',sans-serif;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.012%;box-sizing:content-box;"></td>
          <td style="width:2.04%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.463%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.203%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,798</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,204</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Note receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,373</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">389</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Allowance for credit losses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts and note receivables, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,962</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,552</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in the allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.012%;box-sizing:content-box;"></td>
          <td style="width:2.04%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:18.462999999999997%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.203000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance, beginning of year</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for allowance for credit losses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Recoveries collected and write-off</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance, end of year</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Inventories, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;box-sizing:content-box;"></td>
          <td style="width:58.58%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Buildings</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Leasehold improvement</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_df845163-9662-4f0f-9d15-2572001b1a8c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of the estimated useful life or the term of the lease</span></span></span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><div style="font-size:10pt;font-family:'Aptos',sans-serif;">
        <table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;box-sizing:content-box;"></td>
          <td style="width:58.58%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Machinery and electronic devices</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents, technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Nonrefundable advance payments for intangible assets are capitalized in &#8220;other assets, noncurrent&#8221; and will be recognized as intangible assets when the Company obtains the control of the underlying asset. As of December 31, 2024, the Company had paid $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million to obtain the drug registration certificate for nintedanib and the advance payment was included in &#8220;other assets, noncurrent&#8221;.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Patents and Technological Know-How</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Computer Software</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_e144250a-53d1-44d0-abc4-0e596d38ecb8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#8217;s leases do not contain any residual value guarantees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Land Use Rights, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair valu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t record any impairment of long-lived assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Expense</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company records revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#8217;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Sale of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer upon delivery of the underlying products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#8217;s estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t recognize any contract assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contract liabilities are recognized when the payments are received from customers before the Company transfers the related goods or services. Contract liabilities are recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024, the Company&#8217;s Contract liability balance was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Contract liability balance was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2023 which has been recognized as revenue during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#8217;s assumptions regarding a number of variables including the fair value of its Common Stock, its expected Common Stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;D with no alternative future use is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">charged to expense at the acquisition date. Refer to Note 7 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for a more detailed description.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Selling and Marketing Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising Cost</span></span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Advertising costs are expensed when incurred. Such costs approximated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for the 2024 and 2023 fiscal years, respectively. Advertising costs are included in selling expenses on the consolidated statements of operations and comprehensive income (loss).</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Government Grants</span></span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying amount of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive income (loss).</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Income (Loss)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Net Income (Loss) </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Per Share (&#8220;EPS&#8221;) Attributable to Common Stockholders</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 260&#8221;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#8217;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">EPS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for more information.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Translation and Remeasurement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of Gyre Pharmaceuticals is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company uses the U.S. Dollar as its reporting currency.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive income (loss). During the years ended December 31, 2024 and December 31, 2023, the Company had translation loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of operations and comprehensive income (loss). The foreign currency transaction gains or losses for the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">were immaterial.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#8217;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s cash and cash equivalents, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s short-term bank deposits and long-term certificates of deposit as of December 31, 2024 in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively, were denominated in RMB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Recently Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> this standard as of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The adoption of this ASU did </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">not </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">have any material impact on the Company&#8217;s consolidated financial statements.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#8217;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. ASU 2023-06 modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. Because of the variety of Topics amended, a broad range of entities may be affected by one or more of those amendments. Many of the amendments allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not previously subject to the SEC&#8217;s requirements. Also, the amendments align the requirements in the Codification with the SEC&#8217;s regulations. For entities subject to the SEC&#8217;s existing disclosure requirements and for entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. The amendments in this update should be applied prospectively. For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is currently evaluating the potential impact this standard will have on its consolidated financial statements and related disclosures.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The ASU requires the disaggregated disclosure of specific expense categories, including purchases of inventory, employee compensation, depreciation, and amortization, within relevant income</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">statement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">captions. This ASU also requires disclosure of the total amount of selling expenses along with the definition of selling expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU can either be applied prospectively to consolidated financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the consolidated financial statements. Early adoption is also permitted. This ASU will likely result in the required additional disclosures being included in our consolidated financial statements, once adopted. The Company is currently evaluating the provisions of this ASU.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Financial Instruments</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For a description of the fair value hierarchy and fair value methodology, see Note 2 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company&#8217;s highly liquid money market funds are included within cash equivalents.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Receivable from GCBP</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,261</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,668</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,668</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,629</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,629</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,582</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1)  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</span></p></div><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The carrying amounts of cash, accounts and note receivables, net, other receivables, accounts payable, due to related parties, CVR excess closing cash payable, and accrued liabilities approximate their fair values due to their short maturities.</span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, there were </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> transfers of fair value measurement between Level 1 and Level 2 and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> transfers into or out of Level 3 for both financial assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Receivable from GCBP and CVR Derivative Liability</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The receivable from GCBP and the corresponding CVR derivative liability relate to the asset purchase agreement with GCBP. The fair value of this receivable and derivative liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">These unobservable inputs include the probability of GCBP meeting its contractual payment obligations, the timing of cash flows, and the expected recovery rate of the receivable. The estimation process incorporates GCBP&#8217;s financial condition and market conditions that could impact its ability to fulfill obligations. Additionally, the selection of the discount rate (currently estimated at </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%) may fluctuate over time</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The estimated fair value of the receivable from GCBP and CVR derivative liability was determined based on the anticipated amount and timing of projected cash flows to be received from GCBP pursuant to the GCBP asset purchase agreement discounted to their present values using an estimated discount rate of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company expects to receive a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> hold-back payment from GCBP in the first quarter of 2025, which will be distributed, net of expenses, to the CVR Holders. The change in fair value of the receivable from GCBP and the corresponding CVR derivative liability was recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Liability</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In October 2023, Catalyst entered into a Securities Purchase Agreement for a private placement with GNI USA (the &#8220;Private Placement&#8221;). The Private Placement closed immediately following the Contributions on October 30, 2023. Upon closing of the Private Placement, the Company issued </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Preferred Stock Warrants to purchase shares of Convertible Preferred Stock t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">o GNI for an aggregate purchase price of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Preferred Stock Warrants are immediately exercisable at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,915.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share of Convertible Preferred Stock and expire on </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">October 30, 2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">he number of shares of Common Stock issuable upon exercise and conversion of the Preferred Stock Warrants is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540,666</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company accounted for the Private Placement as a non-arm's length transaction. The Preferred Stock Warrants were initially recognized at fair value upon issuance and the remaining proceeds from the Private Placement were allocated to the Convertible Preferred Stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Preferred Stock Warrants are freestanding financial instruments classified as a warrant liability on the Company&#8217;s consolidated balance sheet. The fair value of the Preferred Stock Warrants is subject to uncertainty due to unobservable inputs, including the expected volatility of the Company&#8217;s stock price, the likelihood of warrant exercise, and the estimated term of the warrants. Since there is limited market activity for the Preferred Stock Warrants, their fair value is determined using an option pricing model, which incorporates subjective inputs such as the Company&#8217;s stock price volatility, derived from historical and peer company data, as well as management&#8217;s expectations regarding future performance. As these assumptions evolve due to market conditions or company specific factors, the warrant liability may experience fluctuations. The Preferred Stock Warrants are revalued each reporting period with the change in fair value recorded as change in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value of the warrant liability is estimated based on th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">e Black-Scholes option pricing model using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.620000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Share price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,915.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk-free interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.54</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Term (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.83</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level 3 financial assets and liabilities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.2%;box-sizing:content-box;"></td>
        <td style="width:1.481%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.625%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.481%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.365%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.481%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.365%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additions in the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,683</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,683</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,574</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,668</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial Instruments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash equivalents and held-to-maturity debt securities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.06%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds  (cash equivalents)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Short-term bank deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Classified as:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Short-term bank deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.951%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.318%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.438%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.778%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.118%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds  (cash equivalents)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Classified as:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value and amortized cost of the Company's held-to-maturity debt securities and redemption date were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.06%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due in one year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due in one to five years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,426</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,426</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income from the short-term bank deposits is recognized on an accrual basis over the term of the deposits. The accrued interest income for the periods ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income from the long-term certificates of deposit is recognized on an accrual basis over the term of the deposits. The accrued interest income for the periods ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance Sheet Components</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, net of reserves of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2024 and 2023, respectively, consisted of the following components (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">919</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Work in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,929</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,614</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,365</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,337</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The provision for inventory and write-downs for the years ended December 31, 2024 and 2023 were immaterial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.280000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued payroll and welfare</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,765</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,790</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Payable to PPE suppliers</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,219</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,336</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses - general and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,005</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,190</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued sales discount</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">908</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">903</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Payable to selling expense suppliers</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">820</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Employee reimbursement</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">737</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">648</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">667</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses - research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,615</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred government grants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred government grants represent funds provided by the government for research and development, construction of new facilities, or improvement of existing production facilities. The amount of deferred government grants as of December 31, 2024 and 2023, is net of the amount recognized as government grant income. During the years ended December 31, 2024 and 2023, the Company received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million government grants, respectively. During the years ended December 31, 2024 and 2023, the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million of government grant income within other income in the consolidated statements of operations and comprehensive income (loss), respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Summarized below are deferred government grants as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government grants for property and equipment, included in accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government grants for property and equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">928</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-current deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">928</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,023</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">253</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.92%;box-sizing:content-box;"></td>
        <td style="width:1.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Buildings</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,980</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,875</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Machinery and electronic devices</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,442</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,598</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">653</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,553</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,599</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,265</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,880</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for each of the years ended December 31, 2024 and 2023, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-Term Investment Measured Under Equity Method</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On June 28, 2024, Gyre Pharmaceuticals entered into a partnership agreement as a limited partner with other investors and is obligated to pay $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for an </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.93</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> equity interest in the partnership. Pursuant to the partnership agreement, Gyre Pharmaceuticals, as a limited partner, shall not participate in any activities related to the management of the investment business. However, Gyre Pharmaceuticals may appoint a member to the advisory committee of the partnership. As of December 31, 2024, the Company's total investment into the partnership and the carrying value of the Company&#8217;s long-term investment in this affiliate, which was included in &#8220;Other assets, noncurrent&#8221; in the balance sheet, was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">5.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The gross carrying amounts and accumulated amortization of the Company&#8217;s intangible assets with determinable lives as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.99%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.197000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.077%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.157%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">423</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">278</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">701</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">428</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">430</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">601</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">396</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets are carried at cost less accumulated amortization and impairment, if applicable, and the amortization expense is recorded in operating expenses. The weighted average amortization period for the intangible assets as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">4.04</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortization expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for each of the years ended December 31, 2024, and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on finite-lived intangible assets recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024, the estimated future amortization expense is as follows (in thousands):</span></span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:85.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated Amortization Expense</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">6.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s product revenues were mainly generated from the sale of ETUARY. Sales of ETUARY accounted for </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of total revenue for the years ended on December 31, 2024 and 2023, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company generates revenue mostly through sales of ETUARY and certain generic drugs. The distributors were the Company&#8217;s direct customers, and sales to distributors accounted for </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of revenue from ETUARY. The distributors sell ETUARY to outlets, including hospitals and other medical institutions, as well as pharmacies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Product </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">returns to date have not been significant and the Company has not considered it necessary to record a reserve for product returns. The Company&#8217;s product revenues were recognized at a point in time when the underlying product was delivered to the customer, which was when the customer obtained control of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">product. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenue from sales of pharmaceutical products was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively. All sales are generated in the PRC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s sales by product categories for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.008%;box-sizing:content-box;"></td>
        <td style="width:1.06%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:27.705%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:27.225%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sales of Pharmaceutical Products</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,757</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,757</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">GNI USA Contributions under the Business Combination Agreement</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">7.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The GNI USA Contributions under the Business Combination Agreement (see Note 1) was treated as a reverse asset acquisition, with CPI as the accounting acquirer and Catalyst as the legal acquirer. Under U.S. GAAP, a company must evaluate if an integrated set of assets and activities qualifies as a business acquisition or an asset acquisition by assessing if the gross assets&#8217; fair value is primarily concentrated in a single asset or a group of similar assets. If this criterion is met, the acquired operations are not considered a business. Catalyst did not meet the business definition as its fair value was concentrated in one IPR&amp;D asset, it lacked an organized workforce contributing significantly to output creation, and no substantive processes were acquired. As such, the GNI USA Contributions was treated as an asset acquisition. In an asset acquisition, goodwill is not recognized, and the cost allocated to the acquired IPR&amp;D with no alternative future use is expensed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Catalyst Common Stock outstanding</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,532</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Multiplied by the fair value per share of Catalyst stock (1)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.67</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of common shares to be owned by Catalyst&#8217;s stockholders</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,420</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of preferred shares to be owned by Catalyst&#8217;s stockholders (2)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,099</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of Catalyst</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,519</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,829</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of consideration issued</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,348</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">659</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase price</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,007</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This amount is calculated based on </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">666.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span></span><span></span></div></div></div><div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:84%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:14%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.30</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk free interest rate</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.65</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:84.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,587</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other receivables from GNI</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">423</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Prepaid assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,097</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,683</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other assets, noncurrent</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">IPR&amp;D</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,104</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Advance payment received from GNI</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,784</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR excess closing cash payable</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,085</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability, noncurrent</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,683</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net assets acquired</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,007</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in Gyre Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">8.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Restructuring</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Prior to the Contributions, CPI entered into a CP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> U.S. Share Purchase Agreement with GNI USA and divested almost all of its assets other than its </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> indirect ownership interest in Gyre Pharmaceuticals. GNI USA is the parent company of Gyre. In connection with the transaction, the Company recorded a receivable in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million included in other receivables from GNI on the consolidated balance sheet as of December 31, 2023 and recognized a loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2023, included in divestiture losses of the consolidated statements of operations and comprehensive income (loss).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">9.</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Leases</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Operating leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In April 2024, Gyre Pharmaceuticals entered into a lease arrangement for its new corporate headquarters, an approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> square meter office space in Beijing, PRC, which lease is set to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">June 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. In 2022, Gyre Pharmaceuticals secured a lease for an office space of approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> square meters in Zhengzhou, PRC, which was renewed in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">July 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and is set to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">August 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. In November 2024, Gyre Pharmaceuticals secured a new lease for an office space of approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> square meters in Shanghai, China, with the lease set to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. In November 2023, the Company secured a lease for its U</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.S. headquarters in San Diego, California, with the lease set to expire in the </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_a5e3a326-17c6-4924-b500-780170a688d9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">first quarter of 2027</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company also has multiple short-term leased properties used as offices and employee dormitories. The Company recorded a total of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> short-term rent expenses during the years ended December 31, 2024 and 2023, respectively. The short-term rent expense amounts are recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company recorded an aggregate ROU asset of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and an aggregate lease liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rent expense related to operating leases was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, and 2023, respectively. Variable lease payments for the years ended December 31, 2024 and 2023 were immaterial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">872</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">573</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The present value assumptions used in calculating the present value of the lease payments were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.687%;box-sizing:content-box;"></td>
        <td style="width:14.141%;box-sizing:content-box;"></td>
        <td style="width:2.02%;box-sizing:content-box;"></td>
        <td style="width:14.141%;box-sizing:content-box;"></td>
        <td style="width:1.01%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#ffffff;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.76</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.78</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, undiscounted future minimum payments under the Company&#8217;s operating leases were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:83%;box-sizing:content-box;"></td>
        <td style="width:1.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">782</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">631</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">279</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,692</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,598</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: current portion of lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">713</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Lease liabilities, net of current portion</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">885</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is required to maintain security deposits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> in connection with various leases, which amounts are included in other assets, noncurrent on the Company&#8217;s consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Land use rights</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company held land use rights for two land parcels in Beijing&#8217;s Shunyi District, expiring in 2053, and in Cangzhou, Hebei Province, expiring from 2067 to 2071. These parcels, with a combined area of approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,559</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> square meters, are utilized as manufacturing facilities. As of December 31, 2024, the aggregate recorded land use rights, net assets for these parcels was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the Company&#8217;s amended and restated certificate of incorporation, the Company has </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Common Stock authorized for issuance with a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> par value per share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. The holders of Common Stock have voting rights equal to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">one vote</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share of Common Stock held. The holders of Common Stock are entitled to receive dividends when and as declared or paid by the Company&#8217;s board of directors.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.38%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,767,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preferred Stock Warrants issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,077,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">[1]</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,280,548</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total Common Stock reserved</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,618,535</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,588,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">[1]</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Includes </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,304,898</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> options exercisable for shares of common stock, which underlying shares of common stock were transferred in the name of the Company to Futu Network Technology Limited, the stock plan administrator of the 2023 Omnibus Incentive Sub-Plan for Chinese Participants.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">2024 ATM Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On November 27, 2024, Gyre Therapeutics, Inc. entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;) with Jefferies LLC (the &#8220;Sales Agent&#8221;) as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of Common Stock with aggregate gross sales proceeds of up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> through an at-the-market offering program (the &#8220;ATM Program&#8221;). The Company will pay the Sales Agent a commission of up to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the gross proceeds of any shares sold. The Company also agreed to reimburse </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the Sales Agent for certain expenses incurred in connection with its services under the ATM Agreement, including up to $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for legal expenses in connection with the establishment of the ATM Program. During the year ended and as of December 31, 2024, the Company sold </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,267</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Common Stock under ATM Program and received net proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, after deducting commissions and offering costs of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.02</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sales of shares of Common Stock under the ATM Program may be made pursuant to the registration statement on Form S-3 (File No. 333-283237), which was declared effective by the SEC on November 22, 2024, and a related prospectus supplement filed with the SEC on November 27, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Net Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under PRC laws and regulations, Gyre Pharmaceuticals is subject to restrictions on foreign exchange and cross-border cash transfers, including to parent companies and U.S. stockholders. The ability to distribute earnings to the parent companies and U.S. stockholders is also limited. Current PRC regulations permit Gyre Pharmaceuticals to pay dividends to BJC only out of its accumulated profits as determined in accordance with PRC accounting standards and regulations. Amounts restricted include paid-in capital and the statutory reserves of Gyre Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The aggregate amounts of restricted capital and statutory reserves, which represented the amount of net assets of the relevant subsidiaries not available for distribution were $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As a result of the above restrictions, parent-only financial statements are presented in Schedule I.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Statutory Reserve</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals is required to set aside at least </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% of its after-tax profits as the statutory reserve fund until the cumulative amount of the statutory reserve fund reaches </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% or more of its registered capital, if any, to fund its statutory reserves, which are not available for distribution as cash dividends. At the Company&#8217;s discretion, the Company may allocate a portion of after-tax profits based on PRC accounting standards to a discretionary reserve fund.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> appropriations to these reserves during the years ended December 31, 2024 and 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">11.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In December 2022, Catalyst issued an aggregate of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock to GNI Japan and GNI HK in connection with the F351 Asset Acquisition (see Note 1 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Organization and Nature of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">), which were subsequently transferred to GNI USA in October 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In October 2023, immediately following the closing of the Contributions, the Company issued </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Preferred Stock Warrants to GNI USA under the Private Placement. For additional information, see Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In November 2023, GNI USA provided notice to the Company to convert its </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,151</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock. Each share of Convertible Preferred Stock was convertible into approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">666.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock. On January 22, 2024, subject to the terms and conditions of the Convertible Preferred Stock Certificate of Designation, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,767,332</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Common Stock were issued to GNI USA upon such conversion.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">12.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock Based Compensation</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Omnibus Incentive Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The 2023 Omnibus Incentive Plan was approved by Catalyst&#8217;s stockholders in August 2023 and ratified by Gyre&#8217;s board of directors (the &#8220;Board&#8221;) in October 2023. The 2023 Omnibus Incentive Plan became effective on October 30, 2023. The 2023 Omnibus Incentive Plan permits the Company to issue up to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,845,496</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock and will automatically increase by the lesser of (i) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% of the total number of outstanding shares of common stock on December 31st of the preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board on the first day of each fiscal year beginning on January 1, 2024. On January 1, 2024, pursuant to the automatic increase in the number of shares reserved, an additional </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,829,780</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved and made available for issuance under the 2023 Omnibus Incentive Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity considering the conversion of Gyre Pharmaceuticals options to Gyre options to purchase shares of Gyre common stock upon completion of the Contributions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:'Aptos',sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.521%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.759%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.67%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.151%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.031%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.738%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.031%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Number of Shares Underlying Outstanding Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-Average Remaining Contractual Term (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value (thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Outstanding &#8212; December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,280,548</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444,197</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">680,732</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">874,328</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.13</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options forfeited and cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,083</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Outstanding &#8212; December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,077,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Vested and exercisable &#8212; December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,458,607</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.48</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189,054</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">7.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per share for the years ended December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value of all equity awards that vested during the periods ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash received from the exercise of options was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and 2023, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation Assumptions</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited relevant historical data, the Company estimated its volatility considering a number of factors, including the use of the volatility of comparable public companies. The expected term of options granted under the 2023 Omnibus Incentive Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited relevant history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value of employee stock options granted was estimated using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.151%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:19.904%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:19.284%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected volatility (%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.10</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.30</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.30</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.30</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk-free interest rate (%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.64</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.22</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.82</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.77</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected option life (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.8</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected dividend yield (%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average share price of the Company (USD per share)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.93</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total stock-based compensation recognized was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.42%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had an unrecognized stock-based compensation expense of $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3.12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">13.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Value Rights Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Each CVR under the CVR Agreement (see Note 1 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Organization and Nature of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) entitles the holder to receive (i) certain cash payments from the net proceeds related to the disposition of Catalyst&#8217;s legacy assets, (ii) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by the Company in excess of $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million as of the closing date of the transactions under the Business Combination Agreement, (iii) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% of the amount actually received by the Company, net of expenses, pursuant to an asset purchase agreement Catalyst entered into with Vertex Pharmaceuticals Inc. (&#8220;Vertex&#8221;) in May 2022 and (iv) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">of the excess amount, by which the preapproved costs to manage, negotiate, settle and finalize certain third party claims exceed the costs actually incurred with respect to such claims. The CVRs are not transferable, except in certain limited circumstances as provided for in the CVR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Agreement, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In June 2023, Catalyst fully settled the CVR payments related to the Vertex asset purchase agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In February 2023, Catalyst sold its legacy rare bleeding disorder program to GCBP. As a result, the Company distributed the net cash proceeds received from the GCBP asset sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to the CVR Holders as well as recorded a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> long-term CVR derivative liability for the future distribution of the hold-back amount to be received in May 2025. As of December 31, 2024 and 2023, the carrying value of the CVR derivative liability was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> on the consolidated balance sheet, respectively. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for additional information regarding the CVR derivative liability and GCBP asset sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On October 30, 2023, pursuant to the CVR Agreement, the Company recorded a $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> CVR excess closing cash payable upon closing of the Contributions. During the first quarter of 2024, the Company received a settlement related to the CVR litigation, and on August 26, 2024, it distributed approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> per contingent value right) to the CVR Holders. Subsequent to the payment, the CVR Holders have received all requisite cash payable under the CVR Agreement and there are </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> outstanding distributions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation and Legal Matters</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company&#8217;s consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Purchasing Commitments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s commitments related to purchase of property and equipment contracted but not yet reflected in the consolidated financial statements were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2024 and were expected to be incurred within one year.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">F351</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In September 2020, Gyre Pharmaceuticals entered into an intellectual property (&#8220;IP&#8221;) transfer agreement (the &#8220;F351 Transfer Agreement&#8221;) with GNI Japan and certain of its wholly owned subsidiaries (the &#8220;GNI Group&#8221;). According to the F351 Transfer Agreement, Gyre Pharmaceuticals acquired the exclusive right to use Hydronidone IP rights in mainland China and the right of first offer for the global IP rights (the &#8220;F351 IP Rights&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Under the F351 Transfer Agreement, in exchange for the F351 IP Rights, Gyre Pharmaceuticals is obligated to pay GNI Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> upon submission of the F351 New Drug Application (the &#8220;NDA&#8221;) to Center for Drug Evaluation of the National Medical Products Administration (the &#8220;NMPA&#8221;) of the PRC, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> after the NDA passes the NMPA&#8217;s Center for Food and Drug Review and Inspection&#8217;s on-site registration inspection for the F351 product, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> upon NMPA&#8217;s approval of the NDA. As of December 31, 2024, the payment conditions have not been met, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> payments have been made.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Programs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition to the F351 program, as of December 31, 2024, the Company has committed to allocate </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> toward future research and development activities for various programs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, the Company may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">14.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income Taxes</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The components of the Company&#8217;s provision for income taxes for the years ended December 31, 2024 and 2023 consist of the following (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.094%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current income tax provision:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,343</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total current income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,349</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred income tax provision:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">834</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total deferred income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">834</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December 31, 2024 and 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.987%;box-sizing:content-box;"></td>
        <td style="width:16.217%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:15.137%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rate difference due to different jurisdiction</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.87</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.43</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preferential income tax rate for HNTE</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.48</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.19</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-deductible expense &#8211; Operating</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.64</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.28</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-deductible expense &#8211; acquisition related</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.16</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">R&amp;D Super-deduction</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.40</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.45</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Valuation allowance change</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.13</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.37</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ESOP</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.13</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.55</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.02</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.76</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.91</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.91</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> December 31, 2024 and 2023 consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.066%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.136999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.136999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,669</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Tax credit carry forwards</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fixed and intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,385</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Impact from foreign corporations</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,754</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,590</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Capitalized transaction costs</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">430</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">658</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred income tax assets before valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,594</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax liability &#8211; ROU assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax liability &#8211; Fixed assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,605</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,773</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The movements of the valuation allowance are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.677%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.424%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.01%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.889%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes of valuation allowances</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,832</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,605</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on the available objective evidence on December 31, 2024, the Company does not believe it is more likely than not that its net deferred tax assets will be realizable for US tax purposes. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets on December 31, 2024 for U.S. tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, after consideration of certain limitations (see below), the Company had approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million federal and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, will begin to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for federal and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2034</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for state tax purposes. The federal net operating loss carryforward includes $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million that have an indefinite life.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for federal and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for state. If unused, the federal credit will begin to expire in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2042</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and the state tax credit does not expire.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">If the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company&#8217;s stock immediately before such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes under Section 382 occurred on December 31, 2007, August 20, 2015, April 13, 2017, February 15, 2018, February 18, 2020, and December 26, 2022. Approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">of the NOLs will expire</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">unutilized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for federal and California state income tax purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for federal and California state income tax purposes, respectively through the year ended December 31, 2024.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All of the federal R&amp;D credits could expire unutilized, whereas none of the California R&amp;D credits are subject to expiration. Approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million of gross federal R&amp;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and credit carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Uncertainty in Income Taxes</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company had approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million of unrecognized tax benefits as of December 31, 2024. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beginning Balance on January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase related to business combination on October 30, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ending Balance on December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ending Balance on December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#8217;s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t recognized any tax-related penalties or interest in its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the United States federal, California, and Florida for tax year 2023. The Company filed an initial return in 2022 in Florida and final returns in 2021 in Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2024 and 2023, the Company had </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> uncertain tax positions which affected its financial position as its results of operations or its cash flow for US tax purposes, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">According to the PRC Tax Administration and Collection Law, the statute of limitations is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitations is extended to five years under special circumstances where the underpayment of taxes is more than RMB100 thousand. In the case of transfer pricing issues, the statute of limitations is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> years. There is </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_89458a30-1f4b-4bab-95ce-8c2641b3664a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">no</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> statute of limitations in the case of tax evasion. The income tax returns of the Company&#8217;s PRC subsidiaries for the years from </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> are open to examination by the PRC tax authorities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">APB 23</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Generally, a taxable outside basis difference associated with a foreign subsidiary may not be recognized if the indefinite reversal criterion of ASC paragraph 740-30-25-17 (APB Opinion No. 23, Accounting for Income Taxes &#8211; Special Areas (&#8220;APB 23&#8221;)) is met. A deferred tax liability is recognized when an entity no longer meets the indefinite reversal criterion. ASC paragraph 740-30-25-17 provides a presumption that all undistributed earnings will be transferred to the parent entity may be overcome, and no income taxes shall be accrued by the parent entity, if sufficient evidence shows that the subsidiary has invested or will invest the undistributed earnings indefinitely or that the earnings will be remitted in a tax-free liquidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company does not have a plan of repatriation of earnings from non-US subsidiaries to the Company. However, to the extent the Company will not permanently reinvest in its PRC business, a deferred tax liability of approximately $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 related to PRC withholding taxes on repatriation of Gyre Pharmaceuticals&#8217; earnings (i.e., the Company&#8217;s primary operating subsidiary in the PRC) would need to be recorded.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">15.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Related Party Transactions</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development with GNI Group</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development fees paid to GNI Group during the year ended December 31, 2024 were $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> research and development fees were paid to GNI Group d</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">uring the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had a $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million related parties payable due to GNI Group, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Other receivables from GNI Group</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had recorded $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million in other receivables from GNI Group, of which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> was from CPI&#8217;s restructuring transaction (see Note 8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">). As of December 31, 2023, the Company had recorded $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million in other receivables from GNI Group, of which $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million was from CPI&#8217;s restructuring transaction (see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Note 8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million was from Gyre&#8217;s cost sharing with GNI Group.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EPS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EPS</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">16.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">EPS</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The dilutive effect of outstanding stock options and warrants is calculated using the treasury stock method. Stock options and warrants are anti-dilutive and excluded from the diluted net income per share attributable to common stock calculation if the exercise price exceeds the average market price of the common shares.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.64%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.540000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,898</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,813</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) attributable to common stockholders - basic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Less:   Change in fair value of warrant liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) attributable to common stockholders - diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,918</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Basic common shares outstanding:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,094,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,831,675</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, basic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,094,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,831,675</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">            </span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dilutive potential common shares:</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,407,847</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Convertible Preferred Stock (as converted)</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">528,442</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Preferred Stock Warrants (as converted)</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,293,526</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,831,675</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) per share attributable to common stockholders:</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.41</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.41</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.76%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">896,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,280,548</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred stock (as converted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,767,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preferred Stock Warrants (as converted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">896,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,588,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">17.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Employee Benefit Plans</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Mainland China Contribution Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to relevant PRC regulations, the Company is required to make contributions to various defined contribution plans organized by municipal and provincial PRC governments. The contribution for each employee is based on a percentage of the employee&#8217;s current compensation as required by the local</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">government. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme. The total contributions for such employee benefits were $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Defined-Contribution Savings Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the U.S., the Company maintains a defined-contribution savings plan pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended. The plan is available to employees who meet the minimum age and length of service requirements. The contributions made during the year ended December 31, 2024 and 2023 were immaterial.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 715<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477317/912-715-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;box-sizing:content-box;"></td>
      <td style="width:93.82%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">18.</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Segment Information</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is a consolidated entity comprised of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> distinct operating segments: Gyre Pharmaceuticals </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and Gyre after the Contributions. The Company&#8217;s reportable segments are based upon internal organizational structure, the manner in which operations are managed, the criteria used by the CODM to evaluate segment performance, the availability of separate financial information, and overall materiality considerations. All Gyre&#8217;s operations are within the U.S., while all of Gyre Pharmaceuticals&#8217; operations are in mainland China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre Pharmaceuticals&#8217; product revenues are mainly generated from the sale of ETUARY and certain generic drugs. Gyre Pharmaceuticals primarily sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Gyre</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of MASH-associated liver fibrosis in the United States. Other than the IP associated with F351 in the U.S., Gyre has no other product candidates since the Company sold all of its legacy IP assets prior to the closing of the Contributions. Subsequent to the closing of the Contributions, Gyre has not generated any revenue.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Other</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other represents the financial information from other subsidiaries, consisting of mainly CPI, GNI HK, and Continent Pharmaceuticals U.S., Inc. During the year ended December 31, 2023, prior to the Contributions, CPI divested almost all of its assets other than its </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">% indirect ownership interest in Gyre Pharmaceuticals (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Restructuring</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Segment inform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ation for the years ended December 31, 2024 and 2023 is as follows (in thousands):</span></p></div><div>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.35%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.738000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,757</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,757</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,884</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,884</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,873</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,873</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,511</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,511</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,051</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,056</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,109</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,856</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,710</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (Loss) from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,021</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,856</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,163</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">232</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,329</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">336</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,318</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,205</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,898</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.35%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.738000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,814</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,814</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,159</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,159</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,698</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">576</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (Loss) from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,246</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,509</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,746</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,939</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,916</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,488</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,404</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,793</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,488</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million represents legal expense recorded in CPI during the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million represents divestiture losses. See Note 8 for details.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The table below presents total assets as of December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.082%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">368</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,406</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.082%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,761</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,865</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,539</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.082%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,301</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,315</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.082%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">Financial Statements Schedule I Financial Information of Parent Company</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p><p id="schedulei" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands, except shares and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"></td>
      <td style="width:1.62%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:1.62%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Related party receivables</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Investment in subsidiaries</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,313</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,709</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,081</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,477</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Liabilities, convertible preferred stock, and stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due to related parties</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">538</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">538</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,224</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,242</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cceeff;padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total current liabilities:</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,762</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,780</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock, $</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares and </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,151</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and 2023, respectively</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,525</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity (deficit):</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000,000</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,307,544</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares and </span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,595,616</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and 2023, respectively</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,185</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,179</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Statutory reserve</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,098</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,098</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,453</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,538</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,597</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,644</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity (deficit)</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,319</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,828</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,081</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,477</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"></td>
      <td style="width:1.62%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:1.62%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">605</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,711</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss before equity in income of subsidiaries</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,316</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Equity in income (loss) of subsidiaries</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,190</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,617</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
      <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,085</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,933</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other comprehensive loss, net of tax of </span><span style="font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_64b29595-72b7-4d1e-a2ef-bcc1f661c31b;"><span style="-sec-ix-hidden:F_7ff33148-e75c-4492-acae-7ea4bfe94b76;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">:</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
      <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">953</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">837</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Comprehensive income (loss)</span></p></td>
      <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,132</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,770</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:68.874%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:12.963000000000001%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:1.5%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:12.663%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating Activities</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,085</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,933</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net income (loss) to net cash used for operating activities:</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Equity (income) loss of subsidiaries</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,190</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,617</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,711</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due to related parties</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">533</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of the period</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Notes</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a pa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">rent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> percent of consolidated net assets as of the end of the most recently completed fiscal year.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries. CPI, the legal acquiree and accounting acquirer of the Contributions considered the &#8220;registrant&#8221; and presented as the parent company, Gyre Therapeutics, Inc. (&#8220;Gyre&#8221;) to supplement its condensed financial statement in Schedule I. The parent company records its investments in subsidiaries under the equity method of accounting as prescribed in ASC 323, Investments-Equity Method, and Joint Ventures. Such investments are presented on the Condensed Balance Sheets as &#8220;Investment in subsidiaries&#8221;. Ordinarily under the equity method, an investor in an equity method investee would cease to recognize its share of the losses of an investee once the carrying value of the investment has been reduced to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to reflect its share, based on its proportionate interest, of the losses of subsidiaries regardless of the carrying value of the investment even though the parent company is not obligated to provide continuing support or fund losses.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or redemption requirements of redeemable stocks or guarantees of the parent company.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NoncontrollingInterestPolicyPolicyTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Noncontrolling Interest</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company reports noncontrolling interest (&#8220;NCI&#8221;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The measure of segment profit or loss is reported on the income statement as consolidated net income (loss). The CODM uses net income (loss) to evaluate income generated from segment assets in deciding whether to reinvest profits and monitor budget versus actual results in assessing performance of the segment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM, as a group, includes Gyre&#8217;s Chief of Executive Officer (&#8220;CEO&#8221;), Gyre Pharmaceuticals&#8217;  General Manager, Gyre's Chief Operating Officer, and the Chairman of Gyre&#8217;s Board of Directors (&#8220;Gyre&#8217;s Board&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company has determined that it operates in </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> distinct operating segments and has </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> reportable segments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_RisksAndUncertainitiesPolicyTextBlock', window );">Risks and Uncertainities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">f Credit Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, note receivable, long-term certificates of deposits, and short-term bank deposits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In May 2015, a new Deposit Insurance System (&#8220;DIS&#8221;) managed by the People&#8217;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#8220;RMB&#8221;) </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> millio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">n, and long-term certificates of deposit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> millio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">n, respectively. In addition, the Company had short-term bank deposits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2024. For the years ended December</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> 31, 2024 and 2023, cash and cash equivalents, short-term bank deposits and long-term certificates of deposits exceeded the PRC DIS coverage by $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ac</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ConcentrationOfCustomerRiskPolicyTextBlock', window );">Concentration of Customer Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Customer Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, one customer, Sinopharm Group Co., Ltd., accounted for approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of accounts receivable, respectively. For the year ended December 31, 2024, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of total revenue respectively. For the year ended December 31, 2023, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> accounted for approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of total revenue respectively. All customers are located in the PRC.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and Cash equivalents includes cash on hand, demand deposits and money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> Value Measurements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">and Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for additional information regarding the CVR derivative liability.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PreferredStockWarrantsPolicyTextBlock', window );">Preferred Stock Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Stock Warrants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrants to purchase shares of the Convertible Preferred Stock (&#8220;Preferred Stock Warrants&#8221;) are freestanding financial instruments classified as warrant liability on the Company&#8217;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#8217;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ConvertiblePreferredStockPolicyPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, to account for the Convertible Preferred Stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LongTermCertificatesOfDepositPolicyTextBlock', window );">Long-term Certificates of Deposit</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-term Certificates of Deposit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The long-term certificates of deposit will mature between </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">J</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">anuary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">April 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">effective interest method. The Company recorded </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> allowance for credit losses associated with the certificates of deposit as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and 2023.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ShortTermBankDepositsPolicyTextBlock', window );">Short-term Bank Deposits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Short-term Bank Deposits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The short-term bank deposits will mature between </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">January 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Short-term bank deposits consist of bank deposits with original maturities of one year or less, and long-term deposits that have a remaining maturity of less than one year. These deposits are recorded at amortized cost. Interest income from these deposits is recognized and reported within interest income. The Company recorded </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> allowance for credit losses associated with the short-term certificates of deposit as of December 31, 2024 and 2023.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Long-Term Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-Term Receivable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#8220;GCBP&#8221;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for additional information regarding the long-term receivable.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LongTermInvestmentsPolicyTextBlock', window );">Long-term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Long-term Investments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise more than minor influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC Topic 323, Investments&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Method and Joint Ventures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 323&#8221;). Under the equity method, the Company initially records its investments at fair value. The Company subsequently adjusts the carrying amount of the investment to recognize the Company&#8217;s proportionate share of the equity investee&#8217;s net income or loss after the date of investment. The Company evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> impairment charge was recognized for the years ended December 31, 2024 and 2023.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts and Note Receivables, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts and Note Receivables, Net</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#8217;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#8217;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.012%;box-sizing:content-box;"></td>
          <td style="width:2.04%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.463%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.203%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,798</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,204</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Note receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,373</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">389</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Allowance for credit losses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts and note receivables, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,962</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,552</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:'Aptos',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in the allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.012%;box-sizing:content-box;"></td>
          <td style="width:2.04%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:18.462999999999997%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.203000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance, beginning of year</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for allowance for credit losses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Recoveries collected and write-off</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance, end of year</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Inventories, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;box-sizing:content-box;"></td>
          <td style="width:58.58%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Buildings</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Leasehold improvement</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_df845163-9662-4f0f-9d15-2572001b1a8c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of the estimated useful life or the term of the lease</span></span></span></p></td>
         </tr>
        </table></div><div style="font-size:10pt;font-family:'Aptos',sans-serif;">
        <table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;box-sizing:content-box;"></td>
          <td style="width:58.58%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Machinery and electronic devices</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents, technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Nonrefundable advance payments for intangible assets are capitalized in &#8220;other assets, noncurrent&#8221; and will be recognized as intangible assets when the Company obtains the control of the underlying asset. As of December 31, 2024, the Company had paid $</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million to obtain the drug registration certificate for nintedanib and the advance payment was included in &#8220;other assets, noncurrent&#8221;.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Patents and Technological Know-How</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Computer Software</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_e144250a-53d1-44d0-abc4-0e596d38ecb8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#8217;s leases do not contain any residual value guarantees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LandUseRightsPolicyTextBlock', window );">Land Use Rights, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Land Use Rights, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair valu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t record any impairment of long-lived assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Expense</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company records revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#8217;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Sale of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer upon delivery of the underlying products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#8217;s estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">t recognize any contract assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Contract Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contract liabilities are recognized when the payments are received from customers before the Company transfers the related goods or services. Contract liabilities are recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024, the Company&#8217;s Contract liability balance was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Contract liability balance was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2023 which has been recognized as revenue during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#8217;s assumptions regarding a number of variables including the fair value of its Common Stock, its expected Common Stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired IPR&amp;D</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;D with no alternative future use is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">charged to expense at the acquisition date. Refer to Note 7 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for a more detailed description.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SellingAndMarketingExpensesPolicyTextBlock', window );">Selling and Marketing Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Selling and Marketing Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_GeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Cost</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising Cost</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Advertising costs are expensed when incurred. Such costs approximated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> for the 2024 and 2023 fiscal years, respectively. Advertising costs are included in selling expenses on the consolidated statements of operations and comprehensive income (loss).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Government Grants</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying amount of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive income (loss).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_InterestIncomePolicyTextBlock', window );">Interest Income</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Income (Loss)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share ("EPS") Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Net Income (Loss) </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Per Share (&#8220;EPS&#8221;) Attributable to Common Stockholders</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 260&#8221;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#8217;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">EPS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">for more information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Remeasurement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Translation and Remeasurement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of Gyre Pharmaceuticals is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The Company uses the U.S. Dollar as its reporting currency.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive income (loss). During the years ended December 31, 2024 and December 31, 2023, the Company had translation loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of operations and comprehensive income (loss). The foreign currency transaction gains or losses for the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">were immaterial.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ForeignCurrencyRiskPolicyTextBlock', window );">Foreign Currency Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#8217;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s cash and cash equivalents, and </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s short-term bank deposits and long-term certificates of deposit as of December 31, 2024 in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">, respectively, were denominated in RMB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Recently Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> this standard as of </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The adoption of this ASU did </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">not </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">have any material impact on the Company&#8217;s consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock', window );">New Accounting Pronouncements - Issued But Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#8217;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. ASU 2023-06 modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. Because of the variety of Topics amended, a broad range of entities may be affected by one or more of those amendments. Many of the amendments allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not previously subject to the SEC&#8217;s requirements. Also, the amendments align the requirements in the Codification with the SEC&#8217;s regulations. For entities subject to the SEC&#8217;s existing disclosure requirements and for entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. The amendments in this update should be applied prospectively. For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is currently evaluating the potential impact this standard will have on its consolidated financial statements and related disclosures.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The ASU requires the disaggregated disclosure of specific expense categories, including purchases of inventory, employee compensation, depreciation, and amortization, within relevant income</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">statement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">captions. This ASU also requires disclosure of the total amount of selling expenses along with the definition of selling expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU can either be applied prospectively to consolidated financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the consolidated financial statements. Early adoption is also permitted. This ASU will likely result in the required additional disclosures being included in our consolidated financial statements, once adopted. The Company is currently evaluating the provisions of this ASU.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ConcentrationOfCustomerRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of customer risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ConcentrationOfCustomerRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ConvertiblePreferredStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock, policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ConvertiblePreferredStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ForeignCurrencyRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ForeignCurrencyRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_GeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_GeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_InterestIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_InterestIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LandUseRightsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Land use rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LandUseRightsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LongTermCertificatesOfDepositPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term certificates of deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LongTermCertificatesOfDepositPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LongTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LongTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NoncontrollingInterestPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NoncontrollingInterestPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PreferredStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PreferredStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_RisksAndUncertainitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Uncertainities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_RisksAndUncertainitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SellingAndMarketingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SellingAndMarketingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ShortTermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term bank deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ShortTermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 25<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480270/815-25-40-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EEEE<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EEEE<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts and Note Receivable, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.012%;box-sizing:content-box;"></td>
          <td style="width:2.04%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.463%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.203%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,798</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,204</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Note receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,373</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">389</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Allowance for credit losses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts and note receivables, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,962</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,552</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Changes in Allowance for Credit Losses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in the allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.012%;box-sizing:content-box;"></td>
          <td style="width:2.04%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:18.462999999999997%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.203000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance, beginning of year</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Provision for allowance for credit losses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Recoveries collected and write-off</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance, end of year</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Estimated Useful Lives of Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;box-sizing:content-box;"></td>
          <td style="width:58.58%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Buildings</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Leasehold improvement</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="-sec-ix-hidden:F_df845163-9662-4f0f-9d15-2572001b1a8c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of the estimated useful life or the term of the lease</span></span></span></p></td>
         </tr>
        </table>
        <table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;box-sizing:content-box;"></td>
          <td style="width:58.58%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Machinery and electronic devices</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
          <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and financing receivable, allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Receivable from GCBP</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,261</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,668</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,668</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,629</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,629</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,582</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1)  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value of the warrant liability is estimated based on th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">e Black-Scholes option pricing model using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.620000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Share price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,915.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk-free interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.54</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Term (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.83</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level 3 financial assets and liabilities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.2%;box-sizing:content-box;"></td>
        <td style="width:1.481%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.625%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.481%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.365%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.481%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.365%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Additions in the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,683</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,683</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,574</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,668</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash Equivalents and Held-to-maturity Debt Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash equivalents and held-to-maturity debt securities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.06%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds  (cash equivalents)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Short-term bank deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Classified as:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Short-term bank deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.951%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.318%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.438%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.778%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.118%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Money market funds  (cash equivalents)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Classified as:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Fair Value and Amortized Cost of Held-to-maturity Debt Securities and Redemption Date</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value and amortized cost of the Company's held-to-maturity debt securities and redemption date were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.06%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due in one year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Due in one to five years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,426</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,426</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories, Net of Reserves</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, net of reserves of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> as of December 31, 2024 and 2023, respectively, consisted of the following components (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">919</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Work in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,929</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,614</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,365</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Inventories, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,337</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.280000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued payroll and welfare</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,765</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,790</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Payable to PPE suppliers</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,219</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,336</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses - general and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,005</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,190</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued sales discount</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">908</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">903</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Payable to selling expense suppliers</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">820</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Employee reimbursement</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">737</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">648</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">667</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses - research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,615</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock', window );">Schedule of Deferred Government Grants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Summarized below are deferred government grants as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government grants for property and equipment, included in accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Government grants for property and equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">928</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-current deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">928</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total deferred government grants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,023</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">253</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.92%;box-sizing:content-box;"></td>
        <td style="width:1.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Buildings</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,980</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,875</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Machinery and electronic devices</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,442</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,598</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">653</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,553</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,599</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,265</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,880</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of deferred government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Gross Carrying Amounts and Accumulated Amortization of intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The gross carrying amounts and accumulated amortization of the Company&#8217;s intangible assets with determinable lives as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.99%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.197000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.077%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.157%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">423</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">278</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">701</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">428</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">430</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">601</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">396</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on finite-lived intangible assets recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024, the estimated future amortization expense is as follows (in thousands):</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:85.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated Amortization Expense</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Sales by Product Categories</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Company&#8217;s sales by product categories for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.008%;box-sizing:content-box;"></td>
        <td style="width:1.06%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:27.705%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:27.225%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sales of Pharmaceutical Products</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,757</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,757</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Summary of Purchase Price</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Catalyst Common Stock outstanding</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,532</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Multiplied by the fair value per share of Catalyst stock (1)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.67</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of common shares to be owned by Catalyst&#8217;s stockholders</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,420</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of preferred shares to be owned by Catalyst&#8217;s stockholders (2)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,099</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of Catalyst</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,519</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,829</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fair value of consideration issued</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,348</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">659</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase price</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,007</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This amount is calculated based on </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">666.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span></span><span></span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:84%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:14%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.30</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk free interest rate</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.65</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Summary of Estimated Fair Value of Option Awards Based on Black-scholes Model</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:84%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:14%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.30</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk free interest rate</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.65</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:84.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,587</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other receivables from GNI</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">423</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Prepaid assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,097</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,683</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other assets, noncurrent</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">IPR&amp;D</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,104</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Advance payment received from GNI</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,784</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR excess closing cash payable</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,085</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CVR derivative liability, noncurrent</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,683</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net assets acquired</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,007</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.04%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">872</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">573</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock', window );">Schedule of Present Value Assumptions used in Calculating Present Value of Lease Payments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The present value assumptions used in calculating the present value of the lease payments were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.687%;box-sizing:content-box;"></td>
        <td style="width:14.141%;box-sizing:content-box;"></td>
        <td style="width:2.02%;box-sizing:content-box;"></td>
        <td style="width:14.141%;box-sizing:content-box;"></td>
        <td style="width:1.01%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#ffffff;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.76</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.78</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, undiscounted future minimum payments under the Company&#8217;s operating leases were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:83%;box-sizing:content-box;"></td>
        <td style="width:1.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">782</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">631</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">279</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,692</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,598</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: current portion of lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">713</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Lease liabilities, net of current portion</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">885</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of present value assumptions of lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock, Reserved for Future Issuance</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.38%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,767,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preferred Stock Warrants issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,077,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">[1]</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,280,548</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total Common Stock reserved</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,618,535</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,588,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">[1]</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Includes </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,304,898</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> options exercisable for shares of common stock, which underlying shares of common stock were transferred in the name of the Company to Futu Network Technology Limited, the stock plan administrator of the 2023 Omnibus Incentive Sub-Plan for Chinese Participants.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.521%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.759%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.67%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.151%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.031%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.738%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.031%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Number of Shares Underlying Outstanding Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-Average Remaining Contractual Term (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value (thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Outstanding &#8212; December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,280,548</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444,197</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">680,732</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">874,328</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.13</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options forfeited and cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,083</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Outstanding &#8212; December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,077,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Vested and exercisable &#8212; December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,458,607</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.48</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189,054</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options Granted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The fair value of employee stock options granted was estimated using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.151%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:19.904%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:19.284%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected volatility (%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.10</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.30</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.30</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.30</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Risk-free interest rate (%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.64</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.22</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.82</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.77</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected option life (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.8</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Expected dividend yield (%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average share price of the Company (USD per share)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.93</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Recognized</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total stock-based compensation recognized was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.42%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Provision for Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The components of the Company&#8217;s provision for income taxes for the years ended December 31, 2024 and 2023 consist of the following (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.094%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Current income tax provision:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,343</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total current income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,349</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred income tax provision:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">834</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total deferred income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">834</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December 31, 2024 and 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.987%;box-sizing:content-box;"></td>
        <td style="width:16.217%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:15.137%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Rate difference due to different jurisdiction</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.87</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.43</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preferential income tax rate for HNTE</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.48</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.19</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-deductible expense &#8211; Operating</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.64</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.28</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Non-deductible expense &#8211; acquisition related</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.16</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">R&amp;D Super-deduction</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.40</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.45</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Valuation allowance change</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.13</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.37</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ESOP</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.13</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.55</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.02</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.76</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.91</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">-</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.91</span><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of the Company's Deferred Tax Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> December 31, 2024 and 2023 consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.066%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.136999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.136999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,669</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Tax credit carry forwards</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Fixed and intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,385</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Impact from foreign corporations</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,754</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,590</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Capitalized transaction costs</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">430</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">658</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred income tax assets before valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,594</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax liability &#8211; ROU assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax liability &#8211; Fixed assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,605</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,773</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Movement of Valuation Allowance</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The movements of the valuation allowance are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.677%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.424%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.01%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.889%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Changes of valuation allowances</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,832</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,605</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Beginning Balance on January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase related to business combination on October 30, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ending Balance on December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Ending Balance on December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EPS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted EPS Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.64%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.540000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,898</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,813</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) attributable to common stockholders - basic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Less:   Change in fair value of warrant liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) attributable to common stockholders - diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,918</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Basic common shares outstanding:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,094,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,831,675</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, basic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,094,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,831,675</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">            </span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Dilutive potential common shares:</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,407,847</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Convertible Preferred Stock (as converted)</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">528,442</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Preferred Stock Warrants (as converted)</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,293,526</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,831,675</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) per share attributable to common stockholders:</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.41</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.41</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-dilutive Security not Included in Diluted per Share Calculations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.76%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">896,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,280,548</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Convertible Preferred stock (as converted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,767,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preferred Stock Warrants (as converted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">896,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,588,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Segment inform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ation for the years ended December 31, 2024 and 2023 is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.35%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.738000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,757</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,757</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,884</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,884</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,873</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,873</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,511</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,511</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,051</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,056</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,109</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,856</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,710</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (Loss) from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,021</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,856</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,163</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">232</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,329</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">336</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,318</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,205</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,898</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.35%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.738000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.938%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,814</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,814</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,159</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,159</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,698</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">576</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Divestiture losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income (Loss) from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,246</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,509</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,746</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,939</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,916</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,488</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,404</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,793</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,488</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million represents legal expense recorded in CPI during the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> million represents divestiture losses. See Note 8 for details.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The table below presents total assets as of December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.082%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">368</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,406</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.082%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,761</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,865</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,539</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.082%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,301</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,315</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.05%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.082%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre Pharmaceuticals</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Gyre</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 30, 2023</div></th>
<th class="th"><div>Dec. 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,307,544<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,898<span></span>
</td>
<td class="num">$ (85,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,453<span></span>
</td>
<td class="nump">85,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,813<span></span>
</td>
<td class="nump">33,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock', window );">Minority holders owned outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,641)<span></span>
</td>
<td class="nump">$ 25,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gyre_GyreMember', window );">Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfOutstandingSharesOfCommonStock', window );">Percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds', window );">Minority interest ownership directly and indirectly holds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gyre_GyreMember', window );">Gyre | CPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds', window );">Minority interest ownership indirectly holds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gyre_GyreMember', window );">Gyre | Gyre Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds', window );">Minority interest ownership indirectly holds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember', window );">Business Combination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio</a></td>
<td class="text"> 1-for-15 reverse stock split<span></span>
</td>
<td class="text">1-for-15 reverse stock spli<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember', window );">Business Combination Agreement | Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,463,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember', window );">Business Combination Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember', window );">Business Combination Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gyre_GNIUSAMember', window );">GNI USA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfOutstandingSharesOfCommonStock', window );">Percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gyre_CPIContributionMember', window );">CPI Contribution | Business Combination Agreement | Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,923,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gyre_FCContributionMember', window );">FC Contribution | Business Combination Agreement | Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,664,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_OrganizationAndNatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and nature of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_OrganizationAndNatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minority holders owned outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minority interest ownership directly and indirectly holds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minority interest ownership indirectly holds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gyre_GyreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gyre_GyreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_ContinentPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_ContinentPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_GyrePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_GyrePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gyre_GNIUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gyre_GNIUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gyre_CPIContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gyre_CPIContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gyre_FCContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gyre_FCContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 73,453<span></span>
</td>
<td class="nump">$ 85,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,898)<span></span>
</td>
<td class="nump">$ 85,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2015 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,813,000<span></span>
</td>
<td class="nump">$ 33,509,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AllowanceForCreditLossesCertificatesOfDeposit', window );">Allowance for credit losses certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit', window );">Allowance for credit losses short-term certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart', window );">long-term certificates of deposit maturity period start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd', window );">long-term certificates of deposit maturity period end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_Short-TermBankDepositsMaturityDateRangeStart', window );">Short-term bank deposits maturity date range start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_Short-TermBankDepositsMaturityPeriodEnd', window );">Short-term bank deposits maturity period end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LongTermCertificatesOfDeposit', window );">Long-term certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,568,000<span></span>
</td>
<td class="nump">23,431,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit', window );">Cash and cash equivalents, short-term bank deposits and long-term certificates of deposits exceeding China DIS coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,300,000<span></span>
</td>
<td class="nump">49,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,460,000<span></span>
</td>
<td class="nump">1,484,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated', window );">Percentage of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated', window );">Percentage of short-term bank deposits and long-term certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue', window );">Cash and cash equivalents denominated in RMB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Sinopharm Group Co., Ltd. | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of customer risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.50%<span></span>
</td>
<td class="nump">50.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Sinopharm Group Co., Ltd. | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of customer risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.30%<span></span>
</td>
<td class="nump">50.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | China Resources Pharmaceutical Group Ltd | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of customer risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Shanghai Pharmaceuticals Holding Co., Ltd | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of customer risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem', window );">Deposits in licensed banks protected by DIS | &#165;</a></td>
<td class="nump">&#165; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_PatentsAndTechnologicalKnowHowMember', window );">Patents and Technological Know How [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of finite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_PatentsAndTechnologicalKnowHowMember', window );">Patents and Technological Know How [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of finite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of finite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of finite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member', window );">ASU 2023-07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AllowanceForCreditLossesCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for credit losses certificates of deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AllowanceForCreditLossesCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for credit losses short-term certificates of deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents reporting currency denominated value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits in licensed banks protected by deposit insurance system.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>long-term certificates of deposit Maturity Date Range end.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>long-term certificates of deposit Maturity Date Range Start.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LongTermCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Certificates Of Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LongTermCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash and cash equivalents reporting currency denominated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of short-term bank deposits and long-term certificates of deposit reporting currency denominated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_Short-TermBankDepositsMaturityDateRangeStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term bank deposits maturity date range start.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_Short-TermBankDepositsMaturityDateRangeStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_Short-TermBankDepositsMaturityPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term bank deposits maturity period end.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_Short-TermBankDepositsMaturityPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of assets exceeding deposit insurance system limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gyre_SinopharmGroupCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gyre_SinopharmGroupCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gyre_ChinaResourcesPharmaceuticalGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gyre_ChinaResourcesPharmaceuticalGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_PatentsAndTechnologicalKnowHowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_PatentsAndTechnologicalKnowHowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 19,798<span></span>
</td>
<td class="nump">$ 15,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Note receivable</a></td>
<td class="nump">4,373<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent', window );">Allowance for credit losses</a></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and note receivables, net</a></td>
<td class="nump">$ 23,962<span></span>
</td>
<td class="nump">$ 15,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and financing receivable, allowance for credit loss, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent', window );">Balance, beginning of year</a></td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses', window );">Provision for allowance for credit losses</a></td>
<td class="num">(177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff', window );">Recoveries collected and write-off</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation', window );">Foreign currency translation adjustments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent', window );">Balance, end of year</a></td>
<td class="num">$ (209)<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and financing receivable, allowance for credit loss, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and financing receivable, allowance for credit loss, foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and notes receivable, provision for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember', window );">Machinery and Electronic Devices | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember', window );">Machinery and Electronic Devices | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember', window );">Motor Vehicles | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember', window );">Motor Vehicles | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,261<span></span>
</td>
<td class="nump">$ 10,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,629<span></span>
</td>
<td class="nump">17,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Long-term Receivable from GCBP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember', window );">CVR Derivative Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember', window );">Warrant Liability, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,668<span></span>
</td>
<td class="nump">12,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,629<span></span>
</td>
<td class="nump">17,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Long-term Receivable from GCBP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | CVR Derivative Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Warrant Liability, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,668<span></span>
</td>
<td class="nump">$ 12,835<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 27, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value measurement transfer between Level 1 and Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount', window );">Fair value measurement transfer Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,261,000<span></span>
</td>
<td class="nump">10,582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,629,000<span></span>
</td>
<td class="nump">17,557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedInterestIncomeOnShortTermBankDeposits', window );">Accrued interest income on short term bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit', window );">Accrued interest income on long term certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued | shares</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember', window );">Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares | shares</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price of warrants</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share | $ / shares</a></td>
<td class="nump">$ 4,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Oct. 30,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants', window );">Number of shares of common stock issuable upon exercise and conversion of warrants | shares</a></td>
<td class="nump">540,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Long-term Receivable from GCBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,961,000<span></span>
</td>
<td class="nump">$ 4,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement | GCBP Asset Purchase Agreement | CVR Derivative Liability non current | Estimated Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement | GCBP Asset Purchase Agreement | Long-term Receivable from GCBP | Estimated Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetMeasurementInput', window );">Derivative asset measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement | GCBP Asset Purchase Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AmountToBeReceivedUnderAgreement', window );">Amount to be received under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest income on long-term certificates of deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedInterestIncomeOnShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest income on short-term bank deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedInterestIncomeOnShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AmountToBeReceivedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be received under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AmountToBeReceivedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assets and liabilities level1 to level2 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assets and liabilities level3 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock shares issuable upon exercise and conversion of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_WarrantsSharePrice', window );">Warrants share price per share</a></td>
<td class="nump">$ 12.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="nump">$ 4,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">8 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">4.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_WarrantsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_WarrantsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Long-term Receivable from GCBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">$ 4,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Additions in the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Changes in fair value</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember', window );">CVR Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">4,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions in the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in fair value</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember', window );">Warrant Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">12,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions in the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in fair value</a></td>
<td class="num">(7,167)<span></span>
</td>
<td class="nump">9,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 5,668<span></span>
</td>
<td class="nump">$ 12,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Cash Equivalents and Held-to-maturity Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 42,726<span></span>
</td>
<td class="nump">$ 29,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">42,726<span></span>
</td>
<td class="nump">29,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gyre_ShortTermBankDepositsMember', window );">Short-term Bank Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">14,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gyre_LongTermCertificatesOfDepositMember', window );">Long-term Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">24,568<span></span>
</td>
<td class="nump">23,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">24,568<span></span>
</td>
<td class="nump">23,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 5,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gyre_ShortTermBankDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gyre_ShortTermBankDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gyre_LongTermCertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gyre_LongTermCertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Summary of Fair Value and Amortized Cost of Held-to-maturity Debt Securities and Redemption Date (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount', window );">Due in one year</a></td>
<td class="nump">$ 14,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount', window );">Due in one to five years</a></td>
<td class="nump">24,568<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total</a></td>
<td class="nump">39,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year</a></td>
<td class="nump">14,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due in one to five years</a></td>
<td class="nump">24,568<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue', window );">Total</a></td>
<td class="nump">$ 39,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ProceedsFromGovernmentGrantsReceived', window );">Government grants received</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_GovernmentGrantIncomeWithinOtherIncome', window );">Government grant income</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total investment</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_InvestmentSubscriptionAmount', window );">Investment obligation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfEquityInterest', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.93%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_GovernmentGrantIncomeWithinOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government grant income within other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_GovernmentGrantIncomeWithinOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_InvestmentSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment subscription amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_InvestmentSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ProceedsFromGovernmentGrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from government grants received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ProceedsFromGovernmentGrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Inventories, Net of Reserves (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">2,929<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">2,614<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 6,337<span></span>
</td>
<td class="nump">$ 4,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedPayrollAndWelfare', window );">Accrued payroll and welfare</a></td>
<td class="nump">$ 4,765<span></span>
</td>
<td class="nump">$ 5,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PayableToPropertyPlantAndEquipmentSuppliers', window );">Payable to PPE suppliers</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedExpensesGeneralAndAdministrative', window );">Accrued expenses - general and administrative</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedSalesDiscount', window );">Accrued sales discount</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PayableToSellingExpenseSuppliers', window );">Payable to selling expense suppliers</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Employee reimbursement</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">667<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrants', window );">Deferred government grants</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedExpensesResearchAndDevelopment', window );">Accrued expenses - research and development</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 10,615<span></span>
</td>
<td class="nump">$ 11,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedExpensesGeneralAndAdministrative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses general and administrative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedExpensesGeneralAndAdministrative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedExpensesResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses, research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedExpensesResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedPayrollAndWelfare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll and welfare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedPayrollAndWelfare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedSalesDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued sales discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedSalesDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PayableToPropertyPlantAndEquipmentSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable to property, plant, and equipment suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PayableToPropertyPlantAndEquipmentSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PayableToSellingExpenseSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable to selling expense suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PayableToSellingExpenseSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Deferred Government Grants (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsLineItems', window );"><strong>Deferred Government Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsCurrent', window );">Current deferred government grants</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsNonCurrent', window );">Non-current deferred government grants</a></td>
<td class="nump">928<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsCurrentAndNoncurrent', window );">Total deferred government grants</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember', window );">Property And Equipment, Included In Accrued Expenses And Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsLineItems', window );"><strong>Deferred Government Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsCurrent', window );">Current deferred government grants</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property Plant And Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsLineItems', window );"><strong>Deferred Government Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsNonCurrent', window );">Non-current deferred government grants</a></td>
<td class="nump">$ 928<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrantsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrantsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrantsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrantsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrantsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrantsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 29,479<span></span>
</td>
<td class="nump">$ 27,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(5,599)<span></span>
</td>
<td class="num">(4,265)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">23,880<span></span>
</td>
<td class="nump">23,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,980<span></span>
</td>
<td class="nump">12,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">7,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember', window );">Machinery and Electronic Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,442<span></span>
</td>
<td class="nump">6,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember', window );">Motor Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 701<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(428)<span></span>
</td>
<td class="num">(396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technological know-how</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(303)<span></span>
</td>
<td class="num">(290)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, Weighted average amortization period</a></td>
<td class="text">4 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets -Schedule of Estimated Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfRevenueAccountedSalesToDistributors', window );">Percentage of revenue accounted sales to distributors</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from sales</a></td>
<td class="nump">$ 105,757<span></span>
</td>
<td class="nump">$ 113,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">ETUARY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from sales</a></td>
<td class="nump">$ 105,757<span></span>
</td>
<td class="nump">$ 113,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">ETUARY | Sales | ETUARY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">99.30%<span></span>
</td>
<td class="nump">98.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfRevenueAccountedSalesToDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue accounted sales to distributors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfRevenueAccountedSalesToDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of Sales by Product Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 105,757<span></span>
</td>
<td class="nump">$ 113,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Sales of Pharmaceutical Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 105,757<span></span>
</td>
<td class="nump">$ 113,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Catalyst common stock outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,307,544<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember', window );">Catalyst</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Catalyst common stock outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Multiplied by the fair value per share of Catalyst stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 7.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationFairValueOfCommonShares', window );">Fair value of common shares to be owned by Catalyst's stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 19,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationFairValueOfPreferredShares', window );">Fair value of preferred shares to be owned by Catalyst's stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">63,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationFairValue', window );">Fair value of Catalyst</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PreMergerStockOptionsAssumed', window );">Pre-GNI USA Contributions Catalyst stock options assumed by CPI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure', window );">Fair value of consideration issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Acquisition costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total Purchase price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 85,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This amount is calculated based on </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </span><span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">666.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span></span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationFairValueOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination fair value of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationFairValueOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationFairValueOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination fair value of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationFairValueOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PreMergerStockOptionsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre merger stock options assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PreMergerStockOptionsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of equity issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details) - Convertible Preferred Stock - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 30, 2023</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, shares issued upon conversion of common stock</a></td>
<td class="nump">666.67<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember', window );">Catalyst</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, shares issued upon conversion of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">84.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.65%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details) - GNI USA Contributions<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent', window );">Other receivables from GNI</a></td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid assets</a></td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable', window );">Long-term receivable from GCBP</a></td>
<td class="nump">4,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets, noncurrent</a></td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="nump">83,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived', window );">Advance payment received from GNI</a></td>
<td class="num">(2,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationExcessClosingCashPayable', window );">CVR excess closing cash payable</a></td>
<td class="num">(1,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent', window );">CVR derivative liability, noncurrent</a></td>
<td class="num">(4,683)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 85,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationExcessClosingCashPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination excess closing cash payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationExcessClosingCashPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed, accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed advance payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed, CVR derivative liability, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed in-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed long-term receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed, other receivables current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gyre_CpUSSharePurchaseAgreementMember', window );">CP U.S. Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfIndirectOwnershipInterest', window );">Indirect ownership interest</a></td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables from GNI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfIndirectOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of indirect ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfIndirectOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gyre_CpUSSharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gyre_CpUSSharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>m&#178;</div>
</th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">2026-12<span></span>
</td>
<td class="text">2027-06<span></span>
</td>
<td class="text">2027-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026-08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LeaseRenewedMonthAndYear', window );">Lease renewed month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SquareMeterAreaForOfficeSpaceUnderLease', window );">Square meter area for office space under lease | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SquareMeterAreaForLaboratoryCenterUnderLease', window );">Square meter area for laboratory center under lease | m&#178;</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,000<span></span>
</td>
<td class="nump">489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,598,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease', window );">Combined square meter area for manufacturing facilities under lease | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LandUseRightsNetAssets', window );">Land use rights, net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined square meter area for manufacturing facilities under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LandUseRightsNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Land use rights, net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LandUseRightsNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LeaseRenewedMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease renewed month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LeaseRenewedMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SquareMeterAreaForLaboratoryCenterUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square meter area for laboratory center under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SquareMeterAreaForLaboratoryCenterUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SquareMeterAreaForOfficeSpaceUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square meter area for office space under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SquareMeterAreaForOfficeSpaceUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Cash Flow Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash Flow, Operating Activities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating lease</a></td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">$ 573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.76%<span></span>
</td>
<td class="nump">4.78%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liabilities</a></td>
<td class="num">(713)<span></span>
</td>
<td class="num">$ (210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">$ 885<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeeds from issuance of aggregate gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves', window );">Aggregate amounts of restricted capital and statutory reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,300,000<span></span>
</td>
<td class="nump">64,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatutoryReserveFund', window );">Statutory reserve fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CumulativeAmountOfStatutoryReserveFund', window );">Cumulative amount of statutory reserve fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AppropriationsToStatutoryReserve', window );">Appropriations to statutory reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock in ATM program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 773,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyFourATMProgramMember', window );">2024 ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeeds from issuance of aggregate gross sales</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfCommissionForSharesSold', window );">Percentage of commission for shares sold</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LegalExpensesIncurred', window );">Legal expenses incurred</a></td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock upon ATM program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock in ATM program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommissionsAndOfferingCosts', window );">Commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amounts of restricted capital and statutory reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AppropriationsToStatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Appropriations to statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AppropriationsToStatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CommissionsAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commissions and offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CommissionsAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CumulativeAmountOfStatutoryReserveFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of statutory reserve fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CumulativeAmountOfStatutoryReserveFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LegalExpensesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal expenses incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LegalExpensesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfCommissionForSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Commission for shares sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfCommissionForSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StatutoryReserveFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StatutoryReserveFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StockholdersEquityDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StockholdersEquityDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyFourATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyFourATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total Common Stock reserved</a></td>
<td class="nump">18,618,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27,588,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total Common Stock reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,767,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember', window );">Preferred Stock Warrants Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total Common Stock reserved</a></td>
<td class="nump">540,666<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">540,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gyre_OptionsToPurchaseCommonStockMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total Common Stock reserved</a></td>
<td class="nump">18,077,869<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18,280,548<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Includes </span><span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,304,898</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> options exercisable for shares of common stock, which underlying shares of common stock were transferred in the name of the Company to Futu Network Technology Limited, the stock plan administrator of the 2023 Omnibus Incentive Sub-Plan for Chinese Participants.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gyre_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gyre_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Parenthetical) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable for shares</a></td>
<td class="nump">17,458,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2023 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable for shares</a></td>
<td class="nump">7,304,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember', window );">Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, shares issued upon conversion</a></td>
<td class="nump">666.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares', window );">Number Of Shares Of Common Stock Issuable Upon Conversion Of The Outstanding Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,767,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issuable upon conversion of the outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Oct. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance</a></td>
<td class="nump">18,618,535<span></span>
</td>
<td class="nump">27,588,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options</a></td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="nump">$ 5.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of all equity awards that vested during the periods</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,865<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized employee stock based compensation expense</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized employee stock based compensation expense, period for recognition</a></td>
<td class="text">3 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember', window );">2023 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,829,780<span></span>
</td>
<td class="nump">17,845,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfOutstandingSharesOfCommonStock', window );">Percentage of outstanding shares of common stock</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares Underlying Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Beginning Balance</a></td>
<td class="nump">18,280,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Underlying Outstanding Options, Options granted</a></td>
<td class="nump">680,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Underlying Outstanding Options, Options Exercised</a></td>
<td class="num">(874,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Underlying Outstanding Options, Options Forfeited and Cancelled</a></td>
<td class="num">(9,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Ending Balance</a></td>
<td class="nump">18,077,869<span></span>
</td>
<td class="nump">18,280,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Underlying Outstanding Options, Vested and exercisable- December 31, 2024</a></td>
<td class="nump">17,458,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options granted</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options Exercised</a></td>
<td class="nump">2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options Forfeited and Cancelled</a></td>
<td class="nump">16.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Ending Balance</a></td>
<td class="nump">1.75<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and exercisable - December 31, 2024</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and exercisable - December 31, 2024</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 190,377<span></span>
</td>
<td class="nump">$ 444,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Vested and exercisable - December 31, 2024</a></td>
<td class="nump">$ 189,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">84.10%<span></span>
</td>
<td class="nump">84.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">84.30%<span></span>
</td>
<td class="nump">84.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">4.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice', window );">Weighted average share price of the Company (USD per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 6.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award weighted average share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 831<span></span>
</td>
<td class="nump">$ 7,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 831<span></span>
</td>
<td class="nump">$ 6,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 26, 2024</div></th>
<th class="th"><div>Oct. 30, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CVRDerivativeLiabilityNoncurrent', window );">CVR derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,722,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,315,000<span></span>
</td>
<td class="nump">8,517,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommittedToAllocate', window );">Committed to allocate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfExcessCashOnDispositionsNet', window );">Percentage of excess cash on dispositions net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets', window );">Excess amount retained from net proceeds related to disposition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfExcessPreapprovedCosts', window );">Percentage of excess preapproved costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DistributionFromAssetSaleProceeds', window );">Distribution to CVR holders from asset sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ContingentValueRightsDerivativeLiabilityNonCurrent', window );">Long-term CVR derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CVRDerivativeLiabilityNoncurrent', window );">CVR derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ContributionsClosingPayableAmount', window );">Contributions closing payable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DistributionsToHolders', window );">Distributions to holders</a></td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DistributionsToHoldersPerCVR', window );">Distributions to holders per CVR</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_RemainingOutstandingBalanceOfAgreement', window );">Remaining outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gyre_VertexAssetPurchaseAgreementMember', window );">Vertex Asset Purchase Agreement | Contingent Value Rights Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfAmountReceivedOnAgreement', window );">Percentage of amount received on agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember', window );">F351 | Gyre Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PaymentsForExchangeForIntellectualPropertyRights', window );">Payments for exchange of intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember', window );">F351 | Gyre Pharmaceuticals | Submission of the New Drug Application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights', window );">Obligation to pay in exchange for the intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember', window );">F351 | Gyre Pharmaceuticals | NDA Passes the NMPA's Review and Inspection</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights', window );">Obligation to pay in exchange for the intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember', window );">F351 | Gyre Pharmaceuticals | NMPA's Approval of the NDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights', window );">Obligation to pay in exchange for the intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CVRDerivativeLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CVR derivative liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CVRDerivativeLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CommittedToAllocate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Committed to allocate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CommittedToAllocate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ContingentValueRightsDerivativeLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights derivative liability non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ContingentValueRightsDerivativeLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ContributionsClosingPayableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contributions closing payable amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ContributionsClosingPayableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DistributionFromAssetSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distribution from asset sale proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DistributionFromAssetSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DistributionsToHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distributions to holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DistributionsToHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DistributionsToHoldersPerCVR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distributions to holders per CVR.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DistributionsToHoldersPerCVR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess amount retained from net proceeds related to disposition of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligation to pay in exchange for the intellectual property rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PaymentsForExchangeForIntellectualPropertyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for exchange for intellectual property rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PaymentsForExchangeForIntellectualPropertyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfAmountReceivedOnAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount received on agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfAmountReceivedOnAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfExcessCashOnDispositionsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of excess cash on dispositions net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfExcessCashOnDispositionsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfExcessPreapprovedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of excess preapproved costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfExcessPreapprovedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_RemainingOutstandingBalanceOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining outstanding balance of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_RemainingOutstandingBalanceOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gyre_VertexAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gyre_VertexAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_GyrePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_GyrePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gyre_SubmissionOfTheNewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gyre_SubmissionOfTheNewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gyre_NDAPassesTheNMPAsReviewAndInspectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gyre_NDAPassesTheNMPAsReviewAndInspectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gyre_NMPAsApprovalOfTheNDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gyre_NMPAsApprovalOfTheNDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign - PRC</a></td>
<td class="nump">6,320<span></span>
</td>
<td class="nump">9,343<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax provision:</a></td>
<td class="nump">6,322<span></span>
</td>
<td class="nump">9,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign - PRC</a></td>
<td class="num">(1,002)<span></span>
</td>
<td class="num">(834)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax provision:</a></td>
<td class="num">(1,002)<span></span>
</td>
<td class="num">(834)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision:</a></td>
<td class="nump">$ 5,320<span></span>
</td>
<td class="nump">$ 8,515<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax computed at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Rate difference due to different jurisdiction</a></td>
<td class="nump">3.87%<span></span>
</td>
<td class="num">(2.43%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte', window );">Preferential income tax rate for HNTE</a></td>
<td class="num">(9.48%)<span></span>
</td>
<td class="nump">3.19%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible Expense - Operating</a></td>
<td class="nump">6.64%<span></span>
</td>
<td class="num">(6.28%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition', window );">Non-deductible expense - acquisition related</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(22.16%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">R&amp;D Super-deduction</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="nump">1.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance change</a></td>
<td class="nump">3.13%<span></span>
</td>
<td class="num">(4.37%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends', window );">ESOP</a></td>
<td class="nump">1.13%<span></span>
</td>
<td class="num">(0.55%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">0.02%<span></span>
</td>
<td class="num">(0.76%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">22.91%<span></span>
</td>
<td class="num">(10.91%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible expense related to acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation preferential income tax rate for HNTE.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">$ 407<span></span>
</td>
<td class="nump">$ 2,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">41,714<span></span>
</td>
<td class="nump">40,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carry forwards</a></td>
<td class="nump">4,463<span></span>
</td>
<td class="nump">4,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsFixedAssetsAndIntangibles', window );">Fixed and intangible assets</a></td>
<td class="nump">15,385<span></span>
</td>
<td class="nump">15,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsImpactFromForeignCorporations', window );">Impact from foreign corporations</a></td>
<td class="nump">8,754<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsCapitalizedTransactionCosts', window );">Capitalized transaction costs</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred income tax assets before valuation allowance</a></td>
<td class="nump">71,594<span></span>
</td>
<td class="nump">68,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxLiabilityRightOfUseAssets', window );">Deferred tax liability - ROU assets</a></td>
<td class="num">(296)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Deferred tax liability - Fixed assets</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(65,605)<span></span>
</td>
<td class="num">(63,773)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 5,619<span></span>
</td>
<td class="nump">$ 4,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsCapitalizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsCapitalizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsFixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets fixed assets and intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsFixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsImpactFromForeignCorporations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets impact from foreign corporations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsImpactFromForeignCorporations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxLiabilityRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liability right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxLiabilityRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Movement of Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the beginning of the year</a></td>
<td class="num">$ (63,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ChangesOfValuationAllowances', window );">Changes of valuation allowances</a></td>
<td class="num">(1,832)<span></span>
</td>
<td class="num">$ (63,773)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the end of the year</a></td>
<td class="num">$ (65,605)<span></span>
</td>
<td class="num">$ (63,773)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ChangesOfValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes of valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ChangesOfValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized', window );">Gross federal R&amp;D credit-related deferred tax assets derecognized</a></td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit</a></td>
<td class="nump">1,883,000<span></span>
</td>
<td class="nump">$ 1,883,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Tax-related penalties or interest recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAdministrationOfTaxationChinaMember', window );">PRC Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent', window );">Statute of limitations due to errors made by taxpayer or withholding agent</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatuteOfLimitationDueToTransferPricingIssues', window );">Statute of limitations due to transfer pricing issues</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatuteOfLimitationDueToTaxEvasion', window );">Statute of limitations due to tax evasion</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAdministrationOfTaxationChinaMember', window );">PRC Tax | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year remains open to examination</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAdministrationOfTaxationChinaMember', window );">PRC Tax | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year remains open to examination</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 75,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards', window );">Net operating loss carryforward, derecognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 193,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OperatingLossCarryforwardsWithIndefiniteLife', window );">Net operating loss carryforwards having indefinite life</a></td>
<td class="nump">$ 191,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to offset future federal tax liabilities</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TaxCreditCarryforwardExpirationYear', window );">Credit carryforward, expire year</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards', window );">Net operating loss carryforward, derecognized</a></td>
<td class="nump">$ 32,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to offset future federal tax liabilities</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets state net operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_OperatingLossCarryforwardsWithIndefiniteLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards with indefinite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_OperatingLossCarryforwardsWithIndefiniteLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit carry forwards derecognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statute of limitation due to computational errors made by taxpayer or withholding agent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StatuteOfLimitationDueToTaxEvasion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statute of limitation due to tax evasion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StatuteOfLimitationDueToTaxEvasion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StatuteOfLimitationDueToTransferPricingIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statute of limitation due to transfer pricing issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StatuteOfLimitationDueToTransferPricingIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAdministrationOfTaxationChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAdministrationOfTaxationChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 1,883<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Increase as a result of the GNI USA Contributions on October 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Increase/(Decrease) of unrecognized tax benefits taken in prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase/(Decrease) of unrecognized tax benefits related to current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 1,883<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increase (decrease) resulting from tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development fees</a></td>
<td class="nump">$ 12,024,000<span></span>
</td>
<td class="nump">$ 13,780,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | GNI Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development fees</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other Receivables</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | GNI Group | CPI Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other Receivables</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | GNI Group | Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | F351 Agreement | GNI Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Due to related parties</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gyre_GNIGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gyre_GNIGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gyre_CPIContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gyre_CPIContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gyre_GyreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gyre_GyreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gyre_FThreeFiveOneAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gyre_FThreeFiveOneAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net (loss) income from operations</a></td>
<td class="nump">$ 17,898<span></span>
</td>
<td class="num">$ (85,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Allocation of undistributed earnings to noncontrolling interest</a></td>
<td class="nump">5,813<span></span>
</td>
<td class="nump">7,453<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="nump">12,085<span></span>
</td>
<td class="num">(92,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">7,167<span></span>
</td>
<td class="num">(9,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income attributable to common stockholders - diluted</a></td>
<td class="nump">$ 4,918<span></span>
</td>
<td class="num">$ (92,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares outstanding</a></td>
<td class="nump">85,094,948<span></span>
</td>
<td class="nump">65,831,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic</a></td>
<td class="nump">85,094,948<span></span>
</td>
<td class="nump">65,831,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average of common stock options</a></td>
<td class="nump">16,407,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Weighted average of Convertible Preferred Stock (as converted)</a></td>
<td class="nump">528,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_WeightedAverageOfPreferredStockWarrant', window );">Weighted average of Preferred Stock Warrants (as converted)</a></td>
<td class="nump">262,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted</a></td>
<td class="nump">102,293,526<span></span>
</td>
<td class="nump">65,831,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to common stockholders, basic</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share attributable to common stockholders, diluted</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_WeightedAverageOfPreferredStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average of preferred stock warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_WeightedAverageOfPreferredStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">896,960<span></span>
</td>
<td class="nump">27,588,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">896,960<span></span>
</td>
<td class="nump">18,280,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred stock (as converted)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,767,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_PreferredStockWarrantsMember', window );">Preferred Stock Warrants (as converted)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=gyre_MainlandChinaContributionPlanMember', window );">Mainland China Contribution Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions for employee benefits</a></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=gyre_MainlandChinaContributionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=gyre_MainlandChinaContributionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Detail) - Segment<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gyre_CPIContributionMember', window );">CPI Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfIndirectOwnershipInterest', window );">Indirect ownership interest</a></td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfIndirectOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of indirect ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfIndirectOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gyre_CPIContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gyre_CPIContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 105,757<span></span>
</td>
<td class="nump">$ 113,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">4,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">101,873<span></span>
</td>
<td class="nump">108,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses excluding cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">57,511<span></span>
</td>
<td class="nump">61,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">12,024<span></span>
</td>
<td class="nump">13,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,109<span></span>
</td>
<td class="nump">14,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses excluding cost of revenues</a></td>
<td class="nump">85,710<span></span>
</td>
<td class="nump">176,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="nump">16,163<span></span>
</td>
<td class="num">(67,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1,659)<span></span>
</td>
<td class="num">(1,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">7,167<span></span>
</td>
<td class="num">(9,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(5,320)<span></span>
</td>
<td class="num">(8,515)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss)</a></td>
<td class="nump">17,898<span></span>
</td>
<td class="num">(85,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">7,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">125,406<span></span>
</td>
<td class="nump">116,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Purchase of property and equipment</a></td>
<td class="num">(2,315)<span></span>
</td>
<td class="num">(8,517)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyrePharmaceuticalsMember', window );">Gyre Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">105,757<span></span>
</td>
<td class="nump">113,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">4,636<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">101,873<span></span>
</td>
<td class="nump">108,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses excluding cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">57,511<span></span>
</td>
<td class="nump">61,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">11,224<span></span>
</td>
<td class="nump">13,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,051<span></span>
</td>
<td class="nump">8,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses excluding cost of revenues</a></td>
<td class="nump">79,852<span></span>
</td>
<td class="nump">84,357<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="nump">22,021<span></span>
</td>
<td class="nump">24,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1,329)<span></span>
</td>
<td class="num">(1,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(5,318)<span></span>
</td>
<td class="num">(8,509)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss)</a></td>
<td class="nump">16,695<span></span>
</td>
<td class="nump">15,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">114,248<span></span>
</td>
<td class="nump">101,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Purchase of property and equipment</a></td>
<td class="num">(2,301)<span></span>
</td>
<td class="num">(8,517)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyrePharmaceuticalsMember', window );">Gyre Pharmaceuticals | Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyrePharmaceuticalsMember', window );">Gyre Pharmaceuticals | Selling and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyrePharmaceuticalsMember', window );">Gyre Pharmaceuticals | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyrePharmaceuticalsMember', window );">Gyre Pharmaceuticals | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyreMember', window );">Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses excluding cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,056<span></span>
</td>
<td class="nump">5,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses excluding cost of revenues</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="nump">88,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="num">(5,856)<span></span>
</td>
<td class="num">(88,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(336)<span></span>
</td>
<td class="num">(272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">7,167<span></span>
</td>
<td class="num">(9,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss)</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="num">(97,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">4,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,790<span></span>
</td>
<td class="nump">13,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Purchase of property and equipment</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyreMember', window );">Gyre | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">4,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses excluding cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses excluding cost of revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentExpenditureAdditionToLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyrePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=gyre_GyrePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=gyre_GyreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 16,109<span></span>
</td>
<td class="nump">$ 14,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">$ 64,786<span></span>
</td>
<td class="nump">$ 57,221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">125,406<span></span>
</td>
<td class="nump">116,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,615<span></span>
</td>
<td class="nump">11,935<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">27,004<span></span>
</td>
<td class="nump">38,065<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">19,516<span></span>
</td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 400,000,000 shares authorized; 86,307,544 shares and 76,595,616 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">136,185<span></span>
</td>
<td class="nump">68,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatutoryReserve', window );">Statutory Reserve</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">3,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(73,453)<span></span>
</td>
<td class="num">(85,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,597)<span></span>
</td>
<td class="num">(1,644)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gyre stockholders' equity (deficit)</a></td>
<td class="nump">63,319<span></span>
</td>
<td class="num">(15,828)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and equity</a></td>
<td class="nump">125,406<span></span>
</td>
<td class="nump">116,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in subsidiaries</a></td>
<td class="nump">64,313<span></span>
</td>
<td class="nump">49,709<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">65,081<span></span>
</td>
<td class="nump">50,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="nump">1,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 400,000,000 shares authorized; 86,307,544 shares and 76,595,616 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">136,185<span></span>
</td>
<td class="nump">68,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatutoryReserve', window );">Statutory Reserve</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">3,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(73,453)<span></span>
</td>
<td class="num">(85,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,597)<span></span>
</td>
<td class="num">(1,644)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gyre stockholders' equity (deficit)</a></td>
<td class="nump">63,319<span></span>
</td>
<td class="num">(15,828)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and equity</a></td>
<td class="nump">65,081<span></span>
</td>
<td class="nump">50,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Related party receivables</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">86,307,544<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">86,307,544<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">86,307,544<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">86,307,544<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 16,109<span></span>
</td>
<td class="nump">$ 14,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">23,218<span></span>
</td>
<td class="num">(76,965)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">17,898<span></span>
</td>
<td class="num">(85,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,460)<span></span>
</td>
<td class="num">(1,484)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to common stockholders</a></td>
<td class="nump">11,132<span></span>
</td>
<td class="num">(93,770)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">3,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in income (loss) of subsidiaries</a></td>
<td class="nump">12,190<span></span>
</td>
<td class="num">(89,617)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">12,085<span></span>
</td>
<td class="num">(92,933)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(953)<span></span>
</td>
<td class="num">(837)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to common stockholders</a></td>
<td class="nump">$ 11,132<span></span>
</td>
<td class="num">$ (93,770)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income, net of tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 17,898<span></span>
</td>
<td class="num">$ (85,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used) provided by operating activities</a></td>
<td class="num">(3,641)<span></span>
</td>
<td class="nump">25,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(298)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(21,696)<span></span>
</td>
<td class="nump">8,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">33,509<span></span>
</td>
<td class="nump">25,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">11,813<span></span>
</td>
<td class="nump">33,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">12,085<span></span>
</td>
<td class="num">(92,933)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity (income) loss of subsidiaries</a></td>
<td class="num">(12,190)<span></span>
</td>
<td class="nump">89,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used) provided by operating activities</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfRestrictedNetAssetsExceedNetAssets', window );">Percentage of restricted net assets of consolidated subsidiaries of consolidated net assets</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfRestrictedNetAssetsExceedNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of restricted net assets exceed net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfRestrictedNetAssetsExceedNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>120
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .R!<5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .R!<5IATN8F\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL].PS ,AU\%Y=ZZ:1E(49<+B!-(2$P"<8L2
M;XO6_%%BU.[M:<O6@> !.,;^Y?-GR:V.0H>$SRE$3&0Q7PVN\UGHN&9[HB@
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( .R!<5K>+VDE>@L  $P]   8
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M\J.[^1?%4W.8]9DKQ1?FXQPZAPA] _P^Y3!G%E]T =4!ZLO_ E!+ P04
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M$+^#(J&X.K9A]%WLZJ)SK#8LX:<36"R*RRV?G/W\$PZ]7VRA?R%G!WR#'=_
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M-6<0@-H ?E\*H1^^U"_8W6N>_0M02P,$%     @ [(%Q6IR&V;=V"@  FF$
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MM&'5FJNE##F"EQLVJ[CLR/B?-Q_OG?!C&Q>QE[3#JF>T#]ZP, [RE1=\P1O
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MW%,NJWCBV5/4,!8-,];=:\/M'13CQ?N#?3>G PXZHVD\;-$XS$B2^;8=[;6
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MVC4@4<IKIMH'U'O;33/3F\9.Y"N_WD W=O#P;YIV?=T1L:5,H@(VFM(=C/7
MBW8EM(;BE9VJ-5=Z1NTQUUL4A G0]QO.U=XP"?J]G/P"4$L#!!0    ( .R!
M<5HL=6B^0P(  (H&   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULG95;
M;YLP%(#_BL6D/;7AELN6 5+2;EH>.D5IMST[< "KQF:V">V_KVT(RZ:$2GD!
MVYSS^3M&'**6BV=9 BCT4E$F8Z=4JEZZKDQ+J+"<\!J8?I)S46&EIZ)P92T
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M"C6MAK2"EX+FN36F4!DCJ,OU'-E$ <UJI*J];!0-&U-QJ2EXY("9@AE$LWT
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M>-X!8_==YNNB&DJ7]?+J@!_"NOCW-2^4Y769>?@85NO;IJI@K6Y8=+[T>8O
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M@-Y9=I>W+=*Z^2AN 9>0%4!5'KYON@[A%=[NZ#OWI7 =4&V;-0M G.L=G >
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M"IG<GG(T' J@&LU0M$(*Q'0*3FE_@D?*!="U$V4@%:>Z[AA_$^C3"T!S"W1
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M?'(+ME&I79&7&'%,[+FI9>;#B(;!LX0[!OQO4;ZPC/]M;8L!C>LZU!K6'VK
M2D6D$&%(M?04;E6KS\/OA*4K3+D *OOPT6"2\XV#OSIL^).9S*'''&TK5MO,
MHL+6M(\Y)?V%&FTJMRW-=F3UOM-KNE$56TD9J-UMT-JMH(IUJ!UU:V*J0DDT
M)?94B)-5**6^ZI6H2-?&,LK8A$&J7+ E<4GSZU%+^O4H*:4V6VA8[:#&R9-
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MR*%I_:-OMKADMFAZ<'GIGS@AQ+7X 'R_;)I>_\ -<%P @??FOP!02P,$%
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MJH?2V\A9E,+K:,"5%2X^5BTU$(IZ#V0/58L_*JZV6GQ2Z=\10+Y_J^G/ ^E
MM4'$J_F>JU0O%=+MY0/[]NWGZ5<#?!ST2G3:@WJ?3H]P1T2"CI,\K\Y6[<.6
M9D]FU/^GR:-MD]=WMFS?]S.&L\8/47)E9OQS&^IQV+;[WZ34=^M?]%SY'[*L
MA_N? WV69D;XE:DIIG;:Y\,C8?Q/;/P7IQ?\LY:)=D[G?#E7$JR&!N#Y5&M7
M?:$%ZM\Y7?X;4$L#!!0    ( .R!<5K3,DI*1P<  +(2   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;*U86W/;QA5^YZ_88=34GH%) +P!LJ092;:3
M=**&8SO-0Z</2^"0W F 1787HMA?W^\L0(JR1%:9]H$$L)=OS_4[![C8:/.[
M71,Y\5 6E;WLKYVKSX=#FZVIE':@:ZHPL]2FE Z/9C6TM2&9^TUE,8S#<#HL
MI:KZ5Q=^;&ZN+G3C"E71W C;E*4TVQLJ].:R'_5W Y_5:NUX8'AU4<L5?2'W
M:STW>!KN47)54F65KH2AY67_.CJ_&?-ZO^ ?BC;VX%ZP)@NM?^>'G_++?L@"
M44&98P2)RSW=4E$P$,3XH\/L[X_DC8?W._1/7G?HLI"6;G7QF\K=^K*?]$5.
M2]D4[K/>_$B=/A/&RW1A_;_8M&O'D[[(&NMTV6V&!*6JVJM\Z.QPL"$)CVR(
MNPVQE[L]R$OY03IY=6'T1AA>#32^\:KZW1!.5>R4+\Y@5F&?N[J1A:PR$E]\
M!-SJLM855<Y>#!W0><TPZY!N6J3X"%(4BSM=N;45'ZN<\J< 0XBUERW>R783
MGT3\0-E C*) Q&$\/H$WVNLZ\GBC5^GZF0KI*!<?E,T*;1M#5OSS>F&=0:3\
MZR7]6_3QR^B</>>VEAE=]I$>ELP]]:^^_RZ:AN]/R#[>RSX^A?ZG_'0::3P0
MQ\#$3]4]KMHHLH&H,/=L0"]%IYSE^S,Q#L(P%++*^7[:/O@I>(_*!9F]!_TB
MW(P"AJC)YV.Q#42FD>.6?8%M;DUBJ0N0A:I6F-K+]D95F-2-!8Q]>]X[Q.]Y
M?,;N?98;Y(<CHV1A(=,L'>,_C=+>;Z ' 9#:Z!4$L"(.TC@549"FL]XG52ED
M42Y66N<\-8W&F!I-)[UG-C@3TV TFGGEXR027R$R0.^59RH0)4YIMVR]SANC
M'+W+]::R?I95W)(T5A!GR@E+B0T9$JK<*300UUEF&NRA!]"RA1-XJ0:B 5L8
M@U-%H>1"%<I!WE/+#Y=U'GAN_U<:?7=,+;<&>UNMJ5A*2,]6FDTGN$Z"61KV
MYG(K%P4)I\5\_A'5H*X+13!&%,01NV,TFO:>R?U.K*@B(UMLF9?L+Z0JQQ#V
MA.$$_Q'@=SNM++ M1W+K!D9)PP2_T>'I* T%Z]B=<2!)BB!.XK#WL:P+O25"
MO*IRT1A+)1MX!M]/Q\FCUD8O$4]P/L3CW% 9CIY.9R(9S6"R)<$Q'%GW9"J/
ML#*20SJ=B''XDJZ<8M)D:Z]L3D@37?N-DYF(IE'O%^]!V6T\]&0\C44<O0!Z
M.D[.1!0BY-E+$1)B-!$GQ#XQ9<AS'P:6#2*F30N.\<761];!#LZ$8WJVG.!,
MTY9NA&6%^KZ462=O(#C)2D9O78(5](" 8']B-.\V/NX8^"R5I0\&K,Z/Z_#?
MZ4O9'1>Z1U!#F5Y5ZM_ !,*WL* $<!D-Q(?&L)"OYX# KV62EM663R&$/+-M
M.$C1$2"&N;GQ_!L-HOW(,[V>LN[_0Y"=NBQ*]$R4<#\".QTQ!YH=MP;%M('9
MC7G*(1\!NE"Y+]+6X5+Z.@ TM*2<^5C@3^,B86C-G>(][5#>H*;;M]\J_<7W
MGE[J!3>D@AGJ?XB%UQ+D#\^0.?P1J=#$M56"_FA4%_Q0H6C8&:K:)_FK$SGE
M) :MW':S)[1K^>?/R";2. &_C'I_U]6[[!4G=,N_:@=N/+'PC$D<]CP3\60D
MYD<,PUEW:NY$)_%*1]TTJLBQWDN4!&D2\DV,.I_V;@\YZ4DC$<=B%B2S2>].
M9HAGZ@J_?_<PNE(9DYNO"FDP'L?H'R9ITOO4F$HY-)Y^\5(].-^$3F& :3CM
MW6ET$.*>UBKC4A8E,7Z3WC']5T:S*#A@EHIX%DPFH][/D.Z<FX"F;-IN-V>"
MSI3/'O$&)7F2IN(M[M#*H$B_/0K?-CY@@<2;!#=QDB S#N!VA70CO?4&HQ.<
MP"%&,-;.4:^EH*?I_+.N5N^^DBE]HVJ=CZ@[DMS-Y^)7H!GQ$3I G3N"]W/Q
M2R7^UE0DXJ2%#L0/6SA@OI9XQ<NH<2KCOA$X9'P"HE&0Z&N,@U?M6M5"PN=M
MT8&:$LE7*N=;'[_$,]J>SU@F;=J<1='0BT*MO!N BEZ)$W40/[&)K.#D03H2
M?_'&A^#*BV+=CA</9!F(.9J2AOD4@-],/@KZLH[!B_('PJXE.KA*.S^D,E5#
M8L]$8'W_$MTRC>G>G[J32UGA)7Y7C'E$/;IDT5ADA445_E%O4.;-$;.7L(FL
M:ZW8NJ)LHZ [0.9HL+FE!KU#9(>VK#OHB46N7V;L)\7KKQ:@3$@'(GI//S,A
M_.9KD31FRRQR+XMF?VZ']OUW21S-WEM1<#0ZCL8GN%@+W\OE$AP-BP5B@XQ>
M^RPY)'J&B</W76MG+7')KG35L:R?CM[OHF#1O<+Y-_]@GW*S9RDWW8U\DSLO
MO9,.#[XCE&16_FL)OQV@OVD_*>Q']Q]DKMOO$(_+VZ\Y=]*L%.IS04ML#0>S
M25^8]@M)^^!T[;]*++1SNO2W:Y)(6%Z ^:76;O? !^P_4UW]!U!+ P04
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M0'4OC6YBY,YU]XTT]%9PPY(>9ZBL .T74IKGB34P//=6_P)02P,$%     @
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M'0]4&.GV<@3PD-QZL[JL>_#9'CKA,G(KE*::^4%&/C!S7H)>#@9^\:%58\C
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MPC>F<.%TX;_K++1S.O<_4\$!'0G@^5+CA;>Z( /-A[ZK_P!02P,$%     @
M[(%Q6K]$OAU' P  ( <  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
MC55M;]- #/XK5G@12%.2IMV81ENI&S#V 52M&GQ ?+@F;G/B7L+=967\>NQ+
M%C9M*WS)W?GLQX_MLS/=6??#UX@!?FEE_"RI0VA.LLR7-6KA4]N@H9N-=5H$
M.KIMYAN'HHI&6F5%GA]E6DB3S*=1MG3SJ6V#D@:7#GRKM7 WIZCL;I:,DEO!
MI=S6@079?-J(+:XP7#5+1Z=L0*FD1N.E->!P,TL6HY/3">M'A2\2=_[.'CB2
MM;4_^'!1S9*<":'",C""H.4:SU I!B(:/WO,9'#)AG?WM^@?8NP4RUIX/+/J
MJZQ"/4N.$ZAP(UH5+NWN(_;Q'#)>:96/7]AUNA-2+EL?K.Z-B8&6IEO%KSX/
M=PR.\R<,BMZ@B+P[1Y'E.Q'$?.KL#AQK$QIO8JC1FLA)PT59!4>WDNS"_!)]
M<&T96B?-=IH%@N2+K.S-3SOSX@GS40&?K FUA_>FPNH^0$9<!D+%+:'38B_B
M.RQ3&(\.H,B+R1Z\\1#@..*-_R= $*:"2U0B8 4+?A R2/3P;;$F+7HAWQ]+
M0>=@\K@#[IH3WX@29PFUA4=WC<G\Y;/14?YV#_W)0'^R#_W?]=EO?IS"_00L
MG;0.@H50(YQ1Z9Q<M]P?_@#.EA> )J"CY$A#.H)$<)6N4EC5PB$L6U?6U *P
MV#I$:LU KS74</[Y JY6BYC=BIK,<WJ%TM8'6A38#<C@07B/M%AR311J8:+T
M\"C-X04YK*2C5@6[,^A\+1OF0%P(0QHXOV'_Q$)3IHEP*91/!\?2QW@:(DF<
M2JL;86[8+9NE<&%(9DP_"")E5J>*&R^B\*#/1V=(/*RK. ;>HKP6:X7,@I6$
MMBTY(?#GD*?'U)1*,:PTI6JKF+H^Q+^V'C;.ZDC7=BC$QULEJ_@2UT()4R)T
M8UAX!J<^0+TFE+X7QC&[S&QKY._(35GO.QY%^F;@476%9B<W*!Q5E$D]@#NX
M1[BKFJ1'@A$6(_ #HC[0PG6/U_1G<"*^G<B-T^ZPYH%]S=FB,\(K1GN=/M8)
MV9VII=%MXVSV!$/I[0;8(!W&_Z*;>G_5NW_')^&VDF@HW)!IGKXY3,!U\[@[
M!-O$&;BV@29JW-;T"T/'"G2_L3;<'MC!\%.<_P%02P,$%     @ [(%Q6J_P
M91^D!@  I!   !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULE5C;<B.W
M$7WG5Z#HC6NWBN9E*%XD2ZJ2M$[LU#I625Z[DE0>P)DF!S%F, M@Q*6_/J>!
MX? BB;MY$.>&;IR^G6[H<FWL'RXG\N)SH4MWU<V]KRX& Y?F5$C7-Q65^+(T
MMI >CW8U<)4EF06A0@^2X7 Z**0JN]>7X=V]O;XTM=>JI'LK7%T4TFYN29OU
M57?4W;YX4*O<\XO!]64E5_1(_F-U;_$T:+5DJJ#2*5,*2\NK[LWHXO:,UX<%
MORE:N[U[P98LC/F#'W[*KKI#!D2:4L\:)"Y/=$=:LR+ ^-3H[+9;LN#^_5;[
M7X/ML&4A'=T9_;O*?'[5G7=%1DM9:_]@UC]28\^$]:5&N_ KUG%M<MX5:>V\
M*1IA("A4&:_R<^.'/8'Y\!6!I!%( NZX44#Y7GIY?6G-6EA>#6U\$TP-T@"G
M2@[*H[?XJB#GKS\03'*7 P]=_&:0-G*W42YY16Z4B)]-Z7,G?B@SR@X5# "B
M19)LD=PF)S6^I[0OQJ.>2(;)V0E]X]:R<= W?M4RYXC$>^52;5QM2?S[9N&\
M11[\YR5[H[:SE[5Q;5RX2J9TU47R.[)/U+W^]IO1=/C]":QG+=:S4]I/1.&T
MW'E?1%'Q2T56>E6NA(XO?BK%3665#N[LB;]MX(#[7"*14ZJ]2J5V@DI/EC*A
M2F^$C))"6BO+%:'PO$#1"^6=*%%=J;&5P1XD<A3_IUI:"+N>D"BMJK+FLT*-
MD-Z(I#<:#U%>6$&B(*P29KE4*8G@0.PF;DG]%UA[XO[AKB?6N4KS9G?EA ,5
M 0]]KI0-J_]>E\1FS$2?S<)=\HI!CM*:#=K:POB![V![LSS".YH?HG6\Y[]R
M*E=_YJ8^P+B6#DP$;P2G 1B;"_]BD^Q%Z#?U"C7,:Z81_#_,$Q4+N.1$6'96
ML-__#TL2('EFR6..<.92]<1=KDH)4Y3/A<^IT?P,,PJQA?@"ZG$O"-^9HI+E
MYD67<\I\%/W'_D&J!#"PX;VBE0$:J146E^HK(/&GI;+P9*.,;6\RXM<],/">
M$3F"5("45:6A*C?6?P>)(NK.!!R&6O$*-5+S,U9'K[H012HJ;38@C@RDK[RQ
M6'BXB2640A9,]L9+S5C>B.F\-QP.@XHW8GX>'O8VMUQ., CM#!MEM>529;,V
M)"U7(BML/;^EP: N^ARD4U%H87H3\;RB7<C"U"4BP&G08H4334L1+8[&M3)-
MHVW\,36E,UIE2*E,.(\+4P$[::L!"P(P%K*4<X=^XC#AF<1;D*U[UQ<W0>*9
M18?)LW,E2&2ULK1B?GGXY2.BPDD0/#OJS]'YM Y-O#Q:&Q-&*[E06OG-5F+:
M2GS1Q(74LN2:XAZ*4#_L^]*2#HN0C>:889D,WHAA?W: CM],VC=<#5^,<N_5
M,/\F+2S36S,KN8FQ^"JUK5:Q)BZC@ED"^G1?/-85BH-U(7U3Z7*QQ'0&7\4I
M+PY<IRV7C$)#RHFWP<>F=MC0B7?BHO-/X(J#P0&L3H#%D#IWO&DE51:9K4E9
MY)"NFW1E^PKL!W8)O0B1/0PV"O.BL^M[K1D 9DUQC)JK<I;@=S(;A_();1QZ
MGZ2NB?.M+JJ8VX$6@ !DG-8ZZO#/)(!GQUAM9(*K=[[Y&E?\'B9'RKZ33T"\
MXJ3C:7J'/)1XTA\WX4[Z2;Q[+IEAV&%/BM"GS_JSJ?@+7^:XO%J0=;D5 \9E
M[7E4PJ2IBKK8V85%9/=K]]MOYLEH]KU[(3L.77"8'N\N.C<AV.R "<(QFR>=
MT&BFXU$G4'HR.^_\&HCU -F1HT>]Z7G2X2'O JE=U3[.,=@;7>*M.#\3[QHM
MS[(&LI/S>2.+[A78$[--R/N7T@SZ9J,Q%'XX_M)#BPZI>:P&V3:?'+0-Q:/#
MIUK96%0<8H^_V$"9NC*JC%.1:9E%QOL<!LHJFX-,:)9/8 :XM/'Y=C[9I_[]
M6C((G(V<RI!-N85KRA=C>I(@/S"OU$R.G'WNZY@^)XT0'DD&&EN;^+Z2-B7M
M]L;#%LYC7H.X>93W5J6^%R<#3CG%X^!D'!D4#W=R.[7]2 M2XMZ:)SB"]D0"
M.23#Z8RCD QGH]!-0VH% ,TT(KF]+3!O9^Q-^7S8FDY[D\GYX;S5"Y[''*?5
MGW&T*&19+W'DB T?=TWB?*%![AI<VR*/G!<S+X9TVP]V1C3-:=0_:Y.H_](Y
M9;!W<BS(KL+YF../-(J'R/9M>P2_B2?/W?)X?O]9VI4J.2.7$$5;G'0CU.V#
M-U4XARZ,QZDVW/)X2)87X/O2&+]]X W:?TQ<_P]02P,$%     @ [(%Q6@QU
M30"!"   E10  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULC5A;<]LV
M%G[WK\"H:;>=H26*DF4UOLPX3K*;3BX>.VD?.GV 2$A$ P(, %K1_OK]#D#2
M]$7>/B060> []^\<\'1K[%=7"N'9]TII=S8JO:]?3B8N+T7%W=C40N/-VMB*
M>SS:S<355O B'*K4)$O3Q:3B4H_.3\/:E3T_-8U74HLKRUQ35=SN7@EEMF>C
MZ:A;N):;TM/"Y/RTYAMQ(_R7^LKB:=*C%+(2VDFCF17KL]'%].6K.>T/&WZ7
M8NL&OQE9LC+F*SV\*\Y&*2DDE,@](7#\N1670BD"@AK?6LQ1+Y(.#G]WZ&^#
M[;!EQ9VX-.H/6?CR;+0<L4*L>:/\M=G^1[3V'!%>;I0+_[-MW)M!8MXX;ZKV
M,)XKJ>-?_KWUP^# ,MUS(&L/9$'O*"AH^9I[?GYJS999V@TT^A%,#:>AG-04
ME!MO\5;BG#^_\2;_6AI5".O^Q=Y\:Z3?G4X\D.G])&]17D64; _*-&,?C/:E
M8V]T(8K[ !.HU.N5=7J]RIY%?"WR,9M-$Y:EV?P9O%EOYRS@S?;@1<O8GQ<K
MYRU2X:^GC(P0\Z<AJ#Q>NIKGXFR$_'?"WHK1^4\_3!?IR3,*SGL%Y\^A_^-
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MV1"C;ZQQG5JU-;D013C3U"3B!3L"&6/^4(I&J4X61=8?0N)A%;T7]*0TJ]O
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MRZ1&+BN0']5 0Q>BX,,5'=MU^.&8&'_&G:70EK/_7W$O1<H+P<1J)6R!8.K
M(0Z\-W*IA"YD;1CA(I/R<L]JQ:0QC6!-1>MP[BV2J9><SIBA0#2D4JJ* @*M
M;:P5=C+/&6^0]C!'RO-\#Y52E%LCR##$/Q<&\4741_*83=G/M*2#6L'DK&R*
MI3M&#38UF,IR_9)(+)!EPE+$(=S1LD(,I\(2 H,H,Z[97N"'(!Y)B#5-NF&F
M $!0'D2^I)E!I:S)1J5S,,FX<GXM[<-*:DC/^)YH!0?SE320[<0NQ5J6)<'!
M]=]YV:!_L+8P^.SSDSV/58TV#4=2P_+$OS?IP9S227X"ODW?S(.VC&>9I-P
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M4$%TE%Y3?JBBB:(87>)EY (?WO%NRN&NY/1&YI!% =S0"#Y8$M;;YAHT_ZF
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M\?.F1-C4I?]_IN$@TNNOVCE36LV[/ZJ5^!F%%J4N +3FR'U';1W28G0_Y+B
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M1VD,:'\A*-IZ8APT?PN&OP!02P,$%     @ [(%Q6B4R 3G@!   70P  !D
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M4>]J[S$[A6F0N%$4'(5["?&M;UXOL((X<(-D?ACK_XQ"GWZ^1R3FH3L-XMU
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M -UO!.5"MS$/#/]1+/\!4$L#!!0    ( .R!<5K,9&@0WP,  )P(   9
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M @N2,&H8 <WI\%E^NVE',C_O%/&-N(C=AFMP5H$U\]L^WQZM?%V?"7WG_D/
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M/HE-W22;F]=_#]C]5J;;5L1 VUY!.3@4<-,NVO=7RK@=0M 1 9Y]VNT4P<X
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MLE85[G4K.(*6!J"?N-)^T +=OU7._PM02P,$%     @ [(%Q6AZ+"34T.@
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MD%>$8 #,K.J6[;HK/#[-D@+6< 28ML/77'[%6'3QSP\@$FKXB+(F*?)TF1<
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ME*Y@ P 1G8<"(*_R/8&,I^C9=HSM&R$1T#?+:I>OD$WQ+)-8]-QCT?/)L[\
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M<?)>+,P!"O\BX:W".@+=R(9YZ;89Z\'"L54=24B,:K'>.RDS0KW%8KK>@@R
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M$37=U^7Z,F:M$_:A5>X71GDD'"&.DDJBW)F0G2]:$UZ<"J,I#\]R3=*W,]D
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M6OER-4_U)X]5IY%:,'AAYU^3 [,!\UN'.ILS01B0XPJ!66%CI&4H8JX=R(C
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MVZ,?@+W@D,FR:MMJ1W]B@9>K\0'X?5T!-Y4/.,%U57^BY?WX_P!02P,$%
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M(%#6 /_/I32[A3V@>U<M_@=02P,$%     @ [(%Q6NK^MFF9 @  MP4  !D
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MTV1%:1SH/!-"=PL3H)_5T1]02P,$%     @ [(%Q6MY%*Y^W!@  RA$  !D
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M:WJ(WS7$/41<%>D%-I. QD$>4XT.EVKZ'GC@EJ%!%2)]9E)SZ(U04V7H?DQ
M:D[_J/>*!M%KVM6";Q "BZZ@8B -:)9)\<*AW[!X2T:C$>1CS90R%U&R:PBK
M93>257,H-T3]-]),-T2(-$_P.<B::1)O$6^G,KHF5V;IMD@E3.HJFLT*=42U
ML;K('E2V0Z@VNJ]6*V;&/7F #0*6!UQ/WA>"^SRE1N:U"3360)=<PR8!@!
M,)+6QT D-OC8(2LI$@"%MP%FC>$1CF?6),>@5^ZQ)(O%EK&=HB)T0V6H2$3!
MA25C*3:\B*9K, \6,<O?D<V_C&[-*"Y$@&_$K^DV1DHFNS"U B'1Y7B+5G"L
ME)BF 3)D&C=T4-N> 7VW]K&IFTXMI#&P4,.4-ID7UK.J?+?/LR(4$/&*B>)
MT;0,TV5NEFFY3]TN_DX+F,<T>#JZ#P :BB(1(8L=6*)2V#H-=3F>U3OS:F/6
M.18>000DG+-=SG:\D];52V9S13.9F-FT952J0S+LNF[K4:#),==;Z&U=WR6?
M6G=</4%> !E0LPRHU@3:("-^=S2$UY?\&1HCI.&6LS@DIHM[IY_(GC$_K,;\
M\&?'_%7%GNG+CR5[MY:YF65N7C)G65,%:S?(6M-JL%=]\VKP?V3W179417;T
M4Y&]7=EU% >$V4X5]%1S:<;R%TZ7:#('@N"H#>]MVI@-JBG >ZUX?_?3 NKZ
MGR]Z$<YO['@4 A88^Z!)F($">S>U_M'27VS=<<W!:A>I)0DX]YI3JGE$V,E8
MJ*SUMUWS'1S8"OH\6+<4V,IQ-5!%<KU94F$5O: J,B8&>,' 9K#!--F/9.@,
M)^/6+2B1T'T#!J_P2\H.#Z1FX/FXBQG&"K?[L,"5,D$.&T%:,3+HM[Z(='UD
MTO85KX"[F"_(P!E-_$+8"CDD%6F)TQ]-6M>+NP.:9*>79.([?7?0FMDIHG#(
M&+@.&0S(86L6/INQ4<X>JQ"+M[2^@\NUZ^+9()#8ZAE45JHP #A^=WRH1[ #
M7HXGJ.3B\<[L^? %5JXCAL=76X"/R; X"3,#7#8!+>&V.PYV+ -P_&M#(E5K
M95-A]FK?UPF3:_,K EB%W-A/[>II]4/%S'Z?OQZWOW+<4+G&521F*Q!UNV-H
MG]+^<F!OM,C,U_I2:/CV-Y<1H^ ='H#W*R%T>8,*JI]OIG\#4$L#!!0    (
M .R!<5IQS%.@Y0,  ,4)   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM
M;(U6;6_;-A#^[E]Q4+>B 3++EE_CV@8<9\4*)%C09"V&81]HZ6P3I42-I.+F
MW^^.DF4[48T AD51O.>>XW-WY'2GS7>[173P(U69G05;Y_))&-IXBZFP;9UC
M1E_6VJ3"T:O9A#8W*!)OE*HPZG2&82ID%LRG?N[>S*>Z<$IF>&_ %FDJS/,U
M*KV;!=U@/_%%;K:.)\+Y-!<;?$#W5WYOZ"VL41*98F:ESL#@>A8LNI/K(:_W
M"[Y*W-FC,7 D*ZV_\\OG9!9TF! JC!TC"'H\X1*58B"B\5^%&=0NV?!XO$?_
MY&.G6%;"XE*K;S)QVUDP#B#!M2B4^Z)W?V 5SX#Q8JVL_X==M;830%Q8I]/*
MF!BD,BN?XD>U#V\QB"J#R/,N'7F6-\*)^=3H'1A>36@\\*%Z:R(G,Q;EP1GZ
M*LG.S6^10K+PX5&L%-J+:>@(E#^%<05P70)$/P'H1G"G,[>U\'N68'(*$!*;
MFE*TIW0=G46\P;@-O>XE1)VH?P:O5X?8\WB]GX9H+2+<2!LK;0N#\,]B99VA
MA/BW*=X2K=^,QD4RL;F(<190%5@T3QC,W[_K#CL?SW#MUUS[Y]#G#U1T2:$0
M]!H>BCQ72 7@A(*EL%OX1"4$G[.R%"FGF]B?Q6]F?^(H9D=K=B0/CJC\E'"8
M@-- _<#09+8!5>;.3EB@WUHKLJ)4DAFXK2ZLR!(+%S!I_8W"E-D!I"VF*S2L
M;XOU99%[+1]=+F1"* 9$JHO,62(0JX*M/")"2OY(/B;*^^/=@Y)B)95T$NVD
M]6?-K0Z#B!F=OF0-O\!X%-'_8-2#,[H-:MT&;];MGC>6*'X5JD!86.IW.6^B
MA<*6P2R%B@M5TCE=3>:^(N%>/'.<MDGBLU2:)7ZD[<LK3T_>DVC@%1_Q<J\L
MB!M/EON75_Q@AP:/Y'^+VM]\J\3D-_%$HFR0LHN/CX,X#DT*4;L'SX1E:125
MH]>6"14U)PN0N C]]F@(O_)C3(\SL@YK68=OEO5.N,)(]\SC0YZ5:MT>DK!)
ML+-.F@5;6/9SO(&^'5Y"D>UCI@U>%X[[&9T+,BW2@RBTB(Q8K:5.<Y$]OW\W
MCKJCC[:A>D_U.RW?BTEKX8N1U1M0N8S&$0^',.QU>3"":'35>M3<.4Z8O<B2
M[N7P*FIQ)YZ 3//"^80CG=$Z^ !7?;BH4%Y5-=D.KL:5;5P8PQF9:^/[4E,;
M(+Q1MT> MR^_7$*&OG6\A*%N,!XT)DQX=+2F:#;^ F'!AUF>LO5L?4=9E$?S
M87EYP;D39B.IVA2NR;33'E$=F_+24+XXG?N#>J4='?M^N*5[%AI>0-_76KO]
M"SNH;V[S_P%02P,$%     @ [(%Q6L5"M:A6 P  #P<  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL?95=C]HZ$(;O^16C5.HYE7(V(4!(MX"T2UMU
MI7Z@9=M>5+TPR4"L=>S4=I;EWW?L!$J/@ N([<P\?L?CF4RV2C^:$M'"<R6D
MF0:EM?5U%)F\Q(J9*U6CI#=KI2MF::HWD:DULL([52)*XCB-*L9E,)OXM86>
M351C!9>XT&":JF)Z=XM";:=!/]@OW/--:=U"-)O4;(-+M%_KA:99=* 4O$)I
MN)*@<3T-;OK7MT-G[PV^<=R:HS&X2%9*/;K)73$-8B<(!>;6$1@]GG".0C@0
MR?C5,8/#EL[Q>+RGO_>Q4RPK9G"NQ'=>V'(:9 $4N&:-L/=J^P&[>$:.ERMA
M_#]L6]O1*("\,595G3,IJ+ALG^RY.X<CARP^XY!T#HG7W6[D5;YEELTF6FU!
M.VNBN8$/U7N3."Y=4I96TUM.?G:VM"I_+)4H4)M_X-VOAML=_/O 5@+-JTED
M:0MG&.4=[K;%)6=P_00^*6E+ ^]D@<7?@(BT'00F>X&WR47B6\RO8- /(8F3
MX07>X!#PP/,&9WA=B#]N5L9JNA,_3P79(H:G$:Y.KDW-<IP&5 @&]1,&LY<O
M^FG\YH+ X4'@\!)]MJ2Z*QJ!H-8P5U5%5]<G*83[=J\"J!;A?6,;C7!G3,-D
MCJ>BN+Q/QS:.#?H8O6[1O$/3 )BA-X(JV%SW*"-8K5"[K/1<5EQJ!KVYDD^H
M+:>; PLJ+=2:>%ZZ1]&$R0*H,1A+ RXW\/)%EO23-Y"%XW0<#@9)[_^.WYG6
M3%ISCC :QF&:IOMG[TOM:OVL>3\+X_$XS-+7\*/_TTV3+ Y'PZSWH"P3?YWW
MGS,ALY1^H\$(DG$XRF@X3#W@3N:B*=  J8^'8?8Z ]4IP&?4.3>ND/RAFI(1
MT"4U/SKX$+8ESTMHJ%JTV#F-IPUABY02NK'2= ?$)=@20;+*7Q4W)ODUDSNP
MRE\/^(S6]41XP+R42JC-#C[RBELL0F_?DFO!J#L6U%RX*PE+8CN>RRM\J21?
M-<;%BM*U4%@VJ_\6SLG%-2_I7AE*.:/<Y[QVV;HZ50;149.J4&]\*S849"-M
MVZ\.JX=N?],VN3_F[:?B$],;3F<L<$VN\=68FJMNVV\[L:KV+6^E+#50/RSI
MBX7:&=#[M5)V/W$;'+Z!L]]02P,$%     @ [(%Q6M\2*3[$!   +0L  !D
M  !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULE5;;;N,V$'WW5PRTZ2(!'%DW
MRTHV,>!<=KL/VPWL9!=%T0=:&MM$)%$E:3ONUW=(79*TCI&^2*0TES,SA\.Y
MV KYJ%:(&IZ*O%27SDKKZGPP4.D*"Z9<46%)?Q9"%DS35BX'JI+(,JM4Y(/
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MX7#\RPDDD>M[<&K>H=<\FUUORM7CZ4(2:DXH*3H-TF34Z(5N')%@Y 8!K9/
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M1FI0S7NT&1A9UF_ M33THJP_,WK"H[(;:'TC20OMP![0_U.P_!=02P,$%
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M_RQQ@OEO\!DL$U$0=L,,W!7U0RO-_Q@@#G'V2?1X? C Q_>?P'N@ Y9"BAC
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MNQ@O58S,8F'DTDV=N30XP]QCAE\9H*P!GJ=2FNW"OJ#Z;HG^ %!+ P04
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M;,V:76_;-A2&_PKA%4,+I+%$VK*3.0::&.D")$.0K.E%L0M&IFVADNB2E-T
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M+W=O<FMS:&5E=',O<VAE970U,BYX;6S-6&UOXC@0_BM6;G7:E;8-3B! #Y"
M;N\JM;M5>^U^.-T'0P:P-K$YVX'=?W]VDN8%@DM[G+1?2NS,/)YG/'D\]6#+
MQ3>Y E#H>QPQ.7162JTO7%?.5Q 3><[7P/2;!1<Q47HHEJY<"R!AZA1'KM=J
M!6Y,*'-&@W3N3HP&/%$197 GD$SBF(@?$XCX=NA@YWGBGBY7RDRXH\&:+.$!
MU./Z3NB16Z"$- 8F*6=(P&+HC/'%U&L9A]3BB<)65IZ1H3+C_)L97(=#IV4B
M@@CFRD 0_;.!*4210=)Q_).#.L6:QK'Z_(Q^E9+79&9$PI1'7VFH5D.GYZ 0
M%B2)U#W?_@$YH8[!F_-(IG_1-K=M.6B>2,7CW%E'$%.6_9+O>2(J#C@XX.#E
M#MZN0_N @Y\[^"G1++*4UB519#00?(N$L=9HYB'-3>JMV5!FMO%!"?V6:C\U
MNB)4H"<2)8!N@<A$@-XC)1%A(;JBC+ Y)1&Z9E*))'MSAJ8KPI8@$67HDU14
MYQ*T<0G$%^@&-A AOP(QEA)RW!M*9C2BBFJ,]Y>@"(T^:-C'ATOT_MT'],X
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M2I;DAVL@$7 =H*XO&9//"[T/4NU[3?X%4$L#!!0    ( .R!<5KZ=T+\I (
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ME?4]7T^T*-W=NA#:W-1NN#*_1I0VP*SG0NBWB;VNVY]M\@-02P,$%     @
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M+/5+!,($Z/TEYVH[,0FZMRW[ U!+ P04    " #L@7%:W9/&?\\"  "6"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6RMEM%NFS 4AE_%8M742FTA
M$$C2$:0V:;=>3*J:=KN8=N' (5@U.+--TNWI9QO*TH22*MH-V.;\O[]S -OA
MFO$GD0%(])S30HRM3,KEA6V+.(,<BW.VA$(]21G/L51=OK#%D@-.C"BGMNLX
M@9UC4EA1:,;N>!2R4E)2P!U'HLQSS']? 67KL=6S7@;NR2*3>L".PB5>P SD
MX_*.JY[=N"0DAT(05B .Z=BZ[%U,1CK>!'PCL!8;;:0SF3/VI#NWR=AR-!!0
MB*5VP.JV@@E0JHT4QJ_:TVJFU,+-]HO[C<E=Y3+' B:,?B>)S,;6T$()I+BD
M\IZMOT"=CZ_]8D:%N:)U'>M8*"Z%9'DM5@0Y*:H[?J[KL"'H]=\0N+7 ?:_
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MPNXT/A![V& /.[$?,E ;>2J!M\$/=^#[VS7OM#\0?M3 CSKA-]94;-;44U2
M;$MDM+/"N -O*Y.6&.??CU$!VAN[ICZQ?,5\00J!**1*Y9P/5*UX=0JH.I(M
MS48Z9U)MRZ:9J8,3<!V@GJ>,R9>.WIN;HUCT%U!+ P04    " #L@7%:"SEY
M.2D#  #:"P  &0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6RU5FMOVC 4
M_2M65DV=M)$7SPXB\>BT2JN$H-TT3?M@D@M836QF&^BD_OCY$5) (6HG^@5L
MY][C>TZNX]/=,OX@E@ 2/68I%3UG*>7JRG5%O(0,BQI; 55/YHQG6*HI7[AB
MQ0$G)BE+W<#SFFZ&"76BKED;\ZC+UC(E%,8<B7668?YW "G;]AS?V2U,R&(I
M]8(;=5=X 5.0]ZLQ5S.W0$E(!E001A&'><_I^U=#WR28B.\$MF)OC#25&6,/
M>G*3]!Q/5P0IQ%)#8/6W@2&DJ492=?S)09UB3YVX/]ZA?S'D%9D9%C!DZ0^2
MR&7/:3LH@3E>IW+"ME\A)]30>#%+A?E%6QO;5,'Q6DB6Y<FJ@HQ0^X\?<R'V
M$OSFB80@3PB.$^HG$L(\(31$;66&U@A+''4YVR*NHQ6:'AAM3+9B0ZA^C5/)
MU5.B\F0T@0W0-:!/J)\D1"N+4W1#;7]HG2]'(#%)Q0<5<C\=H<N+#^@"$8KN
MEFPM,$U$UY6J$ WGQOFF [MI<&)3/T"WC,JE0-<T@>00P%4,"AK!CL8@J$0<
M05Q#H?\1!5Y0+REH^/+TL**<L% U-'CA*3PB\&+!86$U9'.TT_G7-Q6*;B1D
MXG>9<!:W7HZKS_256.$8>HXZM +X!ISH_3N_Z7TN(WTFL ,)ZH4$]2KT: P\
M!BK5IT#3YSE]',=L324D2. 4!)(,)41(3F9KR7AI*]EM?-O ^JNTB?RNN]GG
M65G)?_)L%#P;E3QW+W;.669)E9&P&*U]#EZCU6@=$2D)\\-ZPRO"#DIL%B4V
M*TN\OKOO3WZ6E569]]IN.Q/8 <560;'U1@>N=4X)S@1V($&[D*!]AD9LOZP1
M2\(J&K%3E-AY02.B)S0UA_\)G>[,2J#7OI8S@1UP]KWG&]9[H][,@<^DPKG0
M#F78,QI^Y<L?,JHO!&Y5X$0\H%5Q1Y2RSYV+M]>%7JW3"8]Z]41<NW/4K.Z>
M2\J +XQY%,A<2-9I%*O6H ZT0=4NZVA=&=>^L6ON,XQUO;>8+P@5*(6Y@O1J
M+?5!Y]9(VHED*^/%9DPJ9V>&2V6^@>L ]7S.F-Q-] :%G8_^ 5!+ P04
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M#\($Z/T5YVH[,2_H_D@DOP%02P,$%     @ [(%Q6K<=\$XM!@  L!D  !D
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M%IM04'8#?E]+:5XFMB]JVMK9_U!+ P04    " #L@7%:5!>%]A #  !B"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6RUEEMOVC 4Q[^*E553*VWD
MPJUT$(G"+DCKALJZ/4Q[,,F!6$UL9CO0??L=.S2%-HW*Q'@@MG/.W^=WXLOI
M;X2\50F )G=9RM7 2;1>7;BNBA+(J&J(%7!\LQ RHQJ[<NFJE00:6Z<L=0//
MZ[@99=P)^W9L*L.^R'7*.$PE47F64?GG$E*Q&3B^<S]PS9:)-@-NV%_1)<Q
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MO1IWPR W#&O<]D9IH>NZ&RKF+).8OAFJG), DR/*4JGL*)Z;:F/"%=8NIKG
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MAP$0'[@.4->7C,G#B;Y!OH\T^0]02P,$%     @ [(%Q6O,CU!6J P  )!(
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M4CPWCPG0&(0VP/=;SM5C0P]070R%_P-02P,$%     @ [(%Q6N"XIQP:"
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MZ-(&5%M\3<6C.GI-[$]9E>7O]LVG]<U@9/=(9"+1%L'-OP=Q*[+,DLQ^_-%
M!X><-O#X]3,]KGZ\^3$KKL1MF?TK7>OMS>!R0-;BGN\S?5<^_E,T/VAB>4F9
MJ>HO>:RWG8T')-DK7>9-L-F#/"WJ__Q;TQ!' <&Y@+ )"%\;$#4!T<N R9F
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M^K$]]1M=[JK'S*Q*K<N\>KD5?"VDW<!\?U^6^OF-37!X>-+\?U!+ P04
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M<FMS:&5E=',O<VAE970X-2YX;6RMEVUOVS80Q[\*H15;"S21J&=EMH'41K$
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M"&;E^:3.\XDWSQ>7"_.DX$JL-[#KPP$D+(*$Q4 P*_O!H'GH'D ]K%4D($%
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MX,[&>9,:+NPM7AE%NYS\3'0F8IDC7+-[U/ >+C&6(N899^Z0Y1S&N.!"<+$
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M8#?/P9 2RY 2_J*Y'Y1$A=+6C8TE6PE.M@;E?M!&10*<D?"UI9*#,Q)'#DG
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M(N?8RZ@L5JL7/92B@JXJA-+6C8W%?A7N4(H"-E:XTX<KA$P?!^]BP G AJ.
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M IH[4,7]* ABOZ),>&GBQI8J361C.!.P5$0W5475KQEPN9UZH;<?N&=%:>R
MGR8U+6 %YJ%>*NSY/4O.*A":24$4K*?>37@]G]AX%_"=P58?M(EU\BCED^W<
MYE,OL(* 0V8L \7?!N; N25"&3\[3J]?T@(/VWOV3\X[>GFD&N:2_V"Y*:?>
M.X_DL*8--_=R^P4Z/TY@)KEV7[+M8@./9(TVLNK J*!BHOW37;</!X P/@*(
M.D#T$C ^ AAU@)$SVBISMA;4T#11<DN4C48VVW![X]#HA@E[BBNC<)8ASJ0K
M*/!,#+D5[8VP6_N6K/"RY T'(M=D'W$/M52&B>)9[/F2*IPMP;",\@MRO@!#
M&=<7R/*P6I#SLPMR1I@@WTK9:"IRG?@&==O5_:S3.&LU1D<TAA&YD[B&)A]%
M#OES A\-]ZZCO>M9=))Q =DE&85O2!1$XP%!\W^'CT[(&?6',')\XR-\7Z&@
MG, .4U/#T/Z<A-M$O]8US6#J829K4!OPTM>OPCCX,.2M);MR9#;)-VD<!(F_
M&3 P[@V,3QI88"IJPTRC@'"I-0R>\DF._W71DDT.7$1783AL8]+;F)RT\1D$
M*#P)O*:$YIAM3!M%;9T9LC/Y:Q_#. S>]Q):G0-1XSB.7@CU#S*X E6XPJ9)
M)AMAVFO=C[:U<X:UT]68%^-84V]<*?'_T+0%^8ZJ@@E-.*R1,KB\0F6J+7)M
MQ\C:U8E':;#JN&:)[P(H&X#S:RG-OF,7Z%^:]#=02P,$%     @ [(%Q6O.E
MI,7Z!@  @"<  !D   !X;"]W;W)K<VAE971S+W-H965T.38N>&ULU5I-;]LX
M$/TKA+?8;0$G%DE]V&EBH$W0;@X+!$F[>V8L)B8JB:Y(.<UB?_R2DB):$D7;
MK7KH(8EL#2=O2,Z\-Y3.GWC^1:PIE>!;FF3B8K*6<G,VFXG5FJ9$G/(-S=2=
M!YZG1*J/^>-,;')*XG)0FLR0YX6SE+!LLCPOO[O)E^>\D G+Z$T.1)&F)']^
M3Q/^=#&!DY<O;MGC6NHO9LOS#7FD=U1^WMSDZM.L\1*SE&:"\0SD].%B\@Z>
M7?J^'E!:_,WHD]BY!CJ4>\Z_Z _7\<7$TXAH0E=2NR#JSY9>TB31GA2.K[73
M2?,_]<#=ZQ?O'\K@53#W1-!+GOS#8KF^F,PG(*8/I$CD+7_ZD]8!!=K?BB>B
M_ V>:EMO E:%D#RM!RL$*<NJO^1;/1$[ Z _, #5 ]"A W ] )>!5LC*L*Z(
M),OSG#^!7%LK;_JBG)MRM(J&97H9[V2N[C(U3BX_L(QD*T82<">)I&J!I !W
M:K/$14+!-3#WK[-JT^C)YP_@AN3*%ESR=$.R9W"BKK)8+2^-]97@"8N5OQB\
M)XER0,&=ABC ZRLJ"4O$&S7B\]T5>/WJ#7@%6 8^K7DA2!:+\YE4<6ETLU4=
MP_LJ!C00PQ5=G0(,IP!YR+<,OSQ\.&X/GZG9;*84-5.*2G]XP-]ED9=30X10
M$9_9XJD<^'8'.G//Q(:LZ,5$I::@^99.EK__!D/OK2VZD9RU8L5-K-CE??F)
M2[4U5OLCKMQ$I1M=6K;+T(_FX?ELNQM*WRJ($(*-50NCWV#T#\!88;-!JT8'
M._\4HL#WNM@L9C ,\,(.+FC !0=MEH21>Y8PR:A]_H(Q=\Q(SEH!ATW H7,U
MK@H*)%<,D)3E84-R';,MY+ WX0A%G47IVT <#BQ)U"",G C?K59YH:#1;QM=
MSP1050EPN:9YL]%W5LN&/.JC\D(8=+!;K. "!W;P\P;\_(#-O@??O#^SD>?Y
M'7Q]*SSWP@%\BP;?XHB"L6_7+_I3M A@-S/[5DK$^)$=*/0,,WK.U+R3?/5E
MS9.8YHJWE#1@*R;? /JU8/+9"K=V.%*6CN6M'?Z.,(#.E5+,GBJJ%WH6IN"5
M=^IY4*<KV)*DH%/@>][4JWZ 6"LUH!*ED&N>LW]I_!;,PRGVHFG@^\U=E491
M. T6P32$X<NW3 B=;&6.%5)(=<&R1T D4+Q,TWN5=2_47AIIDIZJ\B$VM%2
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M@83 -4!=WS(F7P[TEF&U1;SZ!E!+ P04    " #L@7%:GX\ K6\$  "A$@
M&0   'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6R]6%USHS84_2L:NM-)9IJ
MP.;#M3V3.+MM'G8WL^FVSS+(MAI 7DG8R;_O%1"PC:";CK<O-HA[#^?<*W%
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M=0!5%M5^2'6B^+;<4EARI7A6'FXH@0+H +B^XER]GN@;-+M2\W\ 4$L#!!0
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M56\/T-NKWAZ@MU>]/4!O7SWL!NCM56\/T-NKWAZ@MU>]/4!OKWI[@-Y>]?8
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MI_M.P<?I<]^/MZ*O=17PG5Y/E\_VM^^_+K\NUK?A2G1[GS$^_0502P,$%
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M<?SR3/NJ'5[RQ?(ORIN?4$L! A0#%     @ [(%Q6D;'34B5    S0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #L
M@7%:8=+F)O(    K @  $0              @ '#    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #L@7%:F5R<(Q &  "<)P  $P
M@ 'D 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .R!<5K>+VDE
M>@L  $P]   8              " @24(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #L@7%:M]R;/\ (   ]+   &
M@('5$P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ [(%Q
M6OXSP1;3 @  W D  !@              ("!RQP  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( .R!<5KJ$%9JB08  .,<   8
M      " @=0?  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #L@7%:G(;9MW8*  ":80  &               @(&3)@  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ [(%Q6E4.Y@J["@  030  !@
M             ("!/S$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( .R!<5JJR.M33P(  *,%   8              " @3 \  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #L@7%:+'5HOD,"  "*
M!@  &               @(&U/@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ [(%Q6CRE,S@1 @  W00  !@              ("!+D$
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .R!<5I//!R9
MY0D  *\@   9              " @75#  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ [(%Q6E9X*\#]$   :3(  !D
M ("!D4T  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #L
M@7%:VQAC^QDJ   FA@  &0              @('%7@  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( .R!<5J?BG[L^@L  /,D   9
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M970Q-RYX;6Q02P$"% ,4    " #L@7%:OT2^'4<#   @!P  &0
M    @(&BK0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M .R!<5JO\&4?I 8  *00   9              " @2"Q  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ [(%Q6@QU30"!"   E10  !D
M             ("!^[<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #L@7%:#;?GA= #  "P"   &0              @(&SP   >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .R!<5II"]D:> @
M 'D4   9              " @;K$  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ [(%Q6H6Y- !("@  HAD  !D              ("!
M:<T  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #L@7%:
MB ;^_WX.  #>*   &0              @('HUP  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( .R!<5H/PYB1!P,  "((   9
M      " @9WF  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ [(%Q6B4R 3G@!   70P  !D              ("!V^D  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #L@7%:S&1H$-\#  "<"
M&0              @('R[@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( .R!<5H4$H:Y&0D  ,@9   9              " @0CS  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ [(%Q6K/_"39R
M"0  8AD  !D              ("!6/P  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #L@7%:'HL)-30Z  !FSP  &0
M@($!!@$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .R!
M<5H*W9I )@0   P*   9              " @6Q  0!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ [(%Q6HES$H"$!@  #!4  !D
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M=#,V+GAM;%!+ 0(4 Q0    ( .R!<5IQS%.@Y0,  ,4)   9
M  " @7E> 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M[(%Q6L5"M:A6 P  #P<  !D              ("!E6(! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #L@7%:WQ(I/L0$   M"P  &0
M            @($B9@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( .R!<5K('7[R>P8  /42   9              " @1UK 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ [(%Q6C-&O$>W!
M( P  !D              ("!SW$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #L@7%:8M/\+F,&  "T$@  &0              @(&]
M=@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .R!<5K9
M]@1G)0@  %!*   9              " @5=] 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ [(%Q6H@&\'7@ P  ?Q8  !D
M     ("!LX4! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .R!<5I4E1P8AP4  * E   9              "
M@4B> 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ [(%Q
M6K_%?/$""   ET<  !D              ("!!J0! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " #L@7%:P^Z$S2(#   *"@  &0
M        @($_K $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( .R!<5JTB7$O600  ,\3   9              " @9BO 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ [(%Q6G+&DD#A P   Q,
M !D              ("!*+0! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " #L@7%:^G="_*0"  !X!P  &0              @(% N $
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( .R!<5HF6_UF
MG0,  #T/   9              " @1N[ 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ [(%Q6M*C'%"< @  ]08  !D
M ("![[X! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #L
M@7%:+@'AH,$#   G#   &0              @('"P0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( .R!<5IH- -A'0,  #$,   9
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M970V,BYX;6Q02P$"% ,4    " #L@7%:"SEY.2D#  #:"P  &0
M    @(&MU@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M .R!<5HN(#\5L@(  %0(   9              " @0W: 0!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ [(%Q6K<=\$XM!@  L!D  !D
M             ("!]MP! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    " #L@7%::1S2SXH#  #Y$P  &0              @(%:XP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( .R!<5H)M45VP@(
M $P&   9              " @1OG 0!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ [(%Q6GACJ:JZ P  X@H  !D              ("!
M%.H! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " #L@7%:
M5!>%]A #  !B"@  &0              @($%[@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Y+GAM;%!+ 0(4 Q0    ( .R!<5IS>[-C[00  (@>   9
M      " @4SQ 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%
M  @ [(%Q6M^ID>^& @  [@4  !D              ("!</8! 'AL+W=O<FMS
M:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " #L@7%:K>^M5'8"   ]!@
M&0              @($M^0$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+
M 0(4 Q0    ( .R!<5KJL)'2+0,  +P*   9              " @=K[ 0!X
M;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ [(%Q6G*2-)C\
M!   IAD  !D              ("!/O\! 'AL+W=O<FMS:&5E=',O<VAE970W
M-"YX;6Q02P$"% ,4    " #L@7%:J&Y5!PL$  "W#P  &0
M@(%Q! ( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( .R!
M<5I!#6,2?0(  $\&   9              " @;,( @!X;"]W;W)K<VAE971S
M+W-H965T-S8N>&UL4$L! A0#%     @ [(%Q6J"B0H6H P  HA4  !D
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M=#@Q+GAM;%!+ 0(4 Q0    ( .R!<5K@N*<<&@@  $A)   9
M  " @;<A @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @
M[(%Q6J"I8BKW @  \0D  !D              ("!""H" 'AL+W=O<FMS:&5E
M=',O<VAE970X,RYX;6Q02P$"% ,4    " #L@7%:_#AO:^(#  "M#   &0
M            @($V+0( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4
M Q0    ( .R!<5K)E)BSYP,  $0-   9              " @4\Q @!X;"]W
M;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ [(%Q6AV<8M:U @
M60<  !D              ("!;34" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX
M;6Q02P$"% ,4    " #L@7%:R*_R%NX&  "!.   &0              @(%9
M. ( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( .R!<5I[
MGA6Z(P,  !8)   9              " @7X_ @!X;"]W;W)K<VAE971S+W-H
M965T.#@N>&UL4$L! A0#%     @ [(%Q6N([.*^; P  6Q$  !D
M     ("!V$(" 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .R!<5H'+;<&_@H  &12   9              "
M@<54 @!X;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @ [(%Q
M6KL8B'^6 @  =08  !D              ("!^E\" 'AL+W=O<FMS:&5E=',O
M<VAE970Y-2YX;6Q02P$"% ,4    " #L@7%:\Z6DQ?H&  " )P  &0
M        @(''8@( >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0
M   ( .R!<5K5\U1O* 0  "X6   9              " @?AI @!X;"]W;W)K
M<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ [(%Q6I^/ *UO!   H1(
M !D              ("!5VX" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q0
M2P$"% ,4    " #L@7%:(BW'^J4"  !<!P  &0              @(']<@(
M>&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0    ( .R!<5H8\0)L
MX@0  (,5   :              " @=EU @!X;"]W;W)K<VAE971S+W-H965T
M,3 P+GAM;%!+ 0(4 Q0    ( .R!<5KX$ASY4 (  $X%   :
M  " @?-Z @!X;"]W;W)K<VAE971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0    (
M .R!<5JJ_/MC6P,  ,P5   -              "  7M] @!X;"]S='EL97,N
M>&UL4$L! A0#%     @ [(%Q6I>*NQS     $P(   L              ( !
M 8$" %]R96QS+RYR96QS4$L! A0#%     @ [(%Q6NDLEA4@!P  9$(   \
M             ( !ZH$" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .R!
M<5ICQ!%*W0(  %P[   :              "  3>) @!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .R!<5I_X$/,6P(  $TY   3
M          "  4R, @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !M &T
*]!T  -B. @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>257</ContextCount>
  <ElementCount>561</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>92</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Fair Value Measurements and Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995547 - Disclosure - GNI USA Contributions under the Business Combination Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions1</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995657 - Disclosure - EPS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureEps</Role>
      <ShortName>EPS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlans1</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Financial Statements Schedule I Financial Information of Parent Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenue</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995757 - Disclosure - GNI USA Contributions under the Business Combination Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995807 - Disclosure - EPS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsTables</Role>
      <ShortName>EPS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/DisclosureEps</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail</Role>
      <ShortName>Organization and Nature of Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Liquidity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail</Role>
      <ShortName>Liquidity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Fair Value Measurements and Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Fair Value Measurements and Financial Instruments - Cash Equivalents and Held-to-maturity Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Cash Equivalents and Held-to-maturity Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995937 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Fair Value and Amortized Cost of Held-to-maturity Debt Securities and Redemption Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Summary of Fair Value and Amortized Cost of Held-to-maturity Debt Securities and Redemption Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995947 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Balance Sheet Components - Schedule of Inventories, Net of Reserves (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Inventories, Net of Reserves (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995967 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995977 - Disclosure - Balance Sheet Components - Schedule of Deferred Government Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Deferred Government Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995987 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995997 - Disclosure - Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Revenue - Summary of Sales by Product Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails</Role>
      <ShortName>Revenue - Summary of Sales by Product Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996057 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996067 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996077 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996087 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996097 - Disclosure - Restructuring - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail</Role>
      <ShortName>Restructuring - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996107 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996117 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail</Role>
      <ShortName>Leases - Schedule of Supplemental Cash Flow Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996127 - Disclosure - Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail</Role>
      <ShortName>Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996137 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996147 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996157 - Disclosure - Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996167 - Disclosure - Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996177 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996187 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996197 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996207 - Disclosure - Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail</Role>
      <ShortName>Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996217 - Disclosure - Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail</Role>
      <ShortName>Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996227 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996237 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996247 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996257 - Disclosure - Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996267 - Disclosure - Income Taxes - Movement of Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Movement of Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996277 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996287 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996297 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996307 - Disclosure - EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails</Role>
      <ShortName>EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996317 - Disclosure - EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail</Role>
      <ShortName>EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996337 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996347 - Disclosure - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996357 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996367 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>996387 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>996397 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>996407 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>996417 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>996427 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="gyre-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>996437 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="gyre-20241231.htm">gyre-20241231.htm</File>
    <File>gyre-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img99844967_0.jpg</File>
    <File>img99844967_1.jpg</File>
    <File>img99844967_2.jpg</File>
    <File>img99844967_3.jpg</File>
    <File>img99844967_4.jpg</File>
    <File>img99844967_5.jpg</File>
    <File>img99844967_6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="975">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>127
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gyre-20241231.htm": {
   "nsprefix": "gyre",
   "nsuri": "http://www.gyretx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "gyre-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "gyre-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 409,
   "keyCustom": 152,
   "axisStandard": 36,
   "axisCustom": 0,
   "memberStandard": 49,
   "memberCustom": 36,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2024": 6,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://www.gyretx.com/20241231": 2
   },
   "contextCount": 257,
   "entityCount": 1,
   "segmentCount": 92,
   "elementCount": 1042,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 975,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 7,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:NotesAndLoansReceivableNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:CostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity",
     "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Equity",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_1388f67a-7e9b-4efe-996e-61341927c0bf",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1388f67a-7e9b-4efe-996e-61341927c0bf",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_56859774-ba75-4d74-b1b3-78de98856e4c",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_56859774-ba75-4d74-b1b3-78de98856e4c",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations",
     "longName": "995467 - Disclosure - Organization and Nature of Operations",
     "shortName": "Organization and Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995487 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments",
     "longName": "995507 - Disclosure - Fair Value Measurements and Financial Instruments",
     "shortName": "Fair Value Measurements and Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponents",
     "longName": "995517 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssets",
     "longName": "995527 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenue",
     "longName": "995537 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement",
     "longName": "995547 - Disclosure - GNI USA Contributions under the Business Combination Agreement",
     "shortName": "GNI USA Contributions under the Business Combination Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuring",
     "longName": "995557 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995587 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "longName": "995597 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock",
     "longName": "995607 - Disclosure - Convertible Preferred Stock",
     "shortName": "Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995617 - Disclosure - Stock Based Compensation",
     "shortName": "Stock Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995627 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995637 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions1",
     "longName": "995647 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEps",
     "longName": "995657 - Disclosure - EPS",
     "shortName": "EPS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlans1",
     "longName": "995667 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995677 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany",
     "longName": "995687 - Disclosure - Financial Statements Schedule I Financial Information of Parent Company",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995697 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995707 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables",
     "longName": "995717 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)",
     "shortName": "Fair Value Measurements and Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "longName": "995727 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsTables",
     "longName": "995737 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueTables",
     "longName": "995747 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables",
     "longName": "995757 - Disclosure - GNI USA Contributions under the Business Combination Agreement (Tables)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995767 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityTables",
     "longName": "995777 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995787 - Disclosure - Stock Based Compensation (Tables)",
     "shortName": "Stock Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995797 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsTables",
     "longName": "995807 - Disclosure - EPS (Tables)",
     "shortName": "EPS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995817 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
     "longName": "995827 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)",
     "shortName": "Organization and Nature of Operations - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "gyre:PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
     "longName": "995837 - Disclosure - Liquidity - Additional Information (Detail)",
     "shortName": "Liquidity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995847 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a040f6f-bb6c-4771-9c85-7f74144c1343",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail",
     "longName": "995857 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail",
     "longName": "995867 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_7328c607-f5b4-4691-8c97-31b6f9ec5936",
      "name": "gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "gyre:AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
     "longName": "995877 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_bd730111-0947-4496-be1e-82bb97c3ba65",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bd730111-0947-4496-be1e-82bb97c3ba65",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
     "longName": "995887 - Disclosure - Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a90606c8-9443-4792-8781-57608b6e4e3e",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
     "longName": "995897 - Disclosure - Fair Value Measurements and Financial Instruments - Additional Information (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo",
     "longName": "995907 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "gyre:WarrantsSharePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "gyre:WarrantsSharePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
     "longName": "995917 - Disclosure - Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_d4414f45-2440-4efe-b9f6-4316754c428f",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ea2f2ca-4eb5-48e9-9b14-30c3e9e2d1ef",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail",
     "longName": "995927 - Disclosure - Fair Value Measurements and Financial Instruments - Cash Equivalents and Held-to-maturity Debt Securities (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Cash Equivalents and Held-to-maturity Debt Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe",
     "longName": "995937 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Fair Value and Amortized Cost of Held-to-maturity Debt Securities and Redemption Date (Details)",
     "shortName": "Fair Value Measurements and Financial Instruments - Summary of Fair Value and Amortized Cost of Held-to-maturity Debt Securities and Redemption Date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
     "longName": "995947 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail",
     "longName": "995957 - Disclosure - Balance Sheet Components - Schedule of Inventories, Net of Reserves (Detail)",
     "shortName": "Balance Sheet Components - Schedule of Inventories, Net of Reserves (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "longName": "995967 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "gyre:AccruedPayrollAndWelfare",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "gyre:AccruedPayrollAndWelfare",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail",
     "longName": "995977 - Disclosure - Balance Sheet Components - Schedule of Deferred Government Grants (Detail)",
     "shortName": "Balance Sheet Components - Schedule of Deferred Government Grants (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "gyre:DeferredGovernmentGrantsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "gyre:DeferredGovernmentGrantsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
     "longName": "995987 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
     "longName": "995997 - Disclosure - Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails",
     "longName": "996007 - Disclosure - Intangible Assets - Additional Information (Details)",
     "shortName": "Intangible Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails",
     "longName": "996017 - Disclosure - Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)",
     "shortName": "Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
     "longName": "996027 - Disclosure - Revenue - Additional Information (Details)",
     "shortName": "Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "gyre:PercentageOfRevenueAccountedSalesToDistributors",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "gyre:PercentageOfRevenueAccountedSalesToDistributors",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails",
     "longName": "996037 - Disclosure - Revenue - Summary of Sales by Product Categories (Details)",
     "shortName": "Revenue - Summary of Sales by Product Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
     "longName": "996057 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e7855790-0097-47bb-9146-f38e022e4521",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
     "longName": "996067 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_f0a09c76-9e8a-4c61-b540-701ad6b7648e",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_daacc8f9-d9a7-49ef-b6a0-b9c3726581cc",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail",
     "longName": "996077 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
     "longName": "996087 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_3c6a57d9-a896-48da-8a44-7f1b76f85732",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3c6a57d9-a896-48da-8a44-7f1b76f85732",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
     "longName": "996097 - Disclosure - Restructuring - Additional Information (Detail)",
     "shortName": "Restructuring - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_1a040f6f-bb6c-4771-9c85-7f74144c1343",
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_96a600bd-711e-4434-a24c-a2180e74b33f",
      "name": "gyre:PercentageOfIndirectOwnershipInterest",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
     "longName": "996107 - Disclosure - Leases - Additional Information (Detail)",
     "shortName": "Leases - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_1c9a63af-c293-421c-835a-b808c5bda6ff",
      "name": "gyre:LeaseExpirationMonthAndYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c9a63af-c293-421c-835a-b808c5bda6ff",
      "name": "gyre:LeaseExpirationMonthAndYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail",
     "longName": "996117 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail)",
     "shortName": "Leases - Schedule of Supplemental Cash Flow Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail",
     "longName": "996127 - Disclosure - Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "shortName": "Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail",
     "longName": "996137 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "shortName": "Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
     "longName": "996147 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
     "longName": "996157 - Disclosure - Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)",
     "shortName": "Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails",
     "longName": "996167 - Disclosure - Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Parenthetical) (Details)",
     "shortName": "Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_86b63a2c-389d-4950-a678-157a2397918e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "longName": "996177 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_12c92d66-d545-47dd-8492-bf82d190b61c",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb2f86f7-6be0-48e5-a0e5-ce77738921cb",
      "name": "gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "longName": "996187 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
     "longName": "996197 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity (Detail)",
     "shortName": "Stock Based Compensation - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_7328c607-f5b4-4691-8c97-31b6f9ec5936",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
     "longName": "996207 - Disclosure - Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)",
     "shortName": "Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail",
     "longName": "996217 - Disclosure - Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)",
     "shortName": "Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "996227 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_7328c607-f5b4-4691-8c97-31b6f9ec5936",
      "name": "gyre:CVRDerivativeLiabilityNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c3e3497-8c9f-4117-820b-ed5757b69655",
      "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
     "longName": "996237 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Components of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail",
     "longName": "996247 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)",
     "shortName": "Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail",
     "longName": "996257 - Disclosure - Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)",
     "shortName": "Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails",
     "longName": "996267 - Disclosure - Income Taxes - Movement of Valuation Allowance (Details)",
     "shortName": "Income Taxes - Movement of Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_7328c607-f5b4-4691-8c97-31b6f9ec5936",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "gyre:ChangesOfValuationAllowances",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "996277 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail",
     "longName": "996287 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_7328c607-f5b4-4691-8c97-31b6f9ec5936",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a040f6f-bb6c-4771-9c85-7f74144c1343",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
     "longName": "996297 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_62f92e1d-e5a8-4fa2-9000-93f2a1b15be5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
     "longName": "996307 - Disclosure - EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)",
     "shortName": "EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
     "longName": "996317 - Disclosure - EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "shortName": "EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail",
     "longName": "996337 - Disclosure - Employee Benefit Plans - Additional Information (Detail)",
     "shortName": "Employee Benefit Plans - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "C_7ddd47da-42c9-45c5-8866-0c39c6994ea9",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ddd47da-42c9-45c5-8866-0c39c6994ea9",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
     "longName": "996347 - Disclosure - Segment Information - Additional Information (Detail)",
     "shortName": "Segment Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_21ad98a8-a7b0-4600-a53d-9f79dd8b3cbd",
      "name": "gyre:PercentageOfIndirectOwnershipInterest",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
     "longName": "996357 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Detail)",
     "shortName": "Segment Information - Schedule of Segment Reporting Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:GrossProfit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
     "longName": "996367 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)",
     "shortName": "Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "C_1a040f6f-bb6c-4771-9c85-7f74144c1343",
      "name": "us-gaap:LegalFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a040f6f-bb6c-4771-9c85-7f74144c1343",
      "name": "us-gaap:LegalFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
     "longName": "996387 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a1ccaa34-a6d8-421c-aded-31248ab461e3",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
     "longName": "996397 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "C_3f38f4dc-c197-451a-9a92-1bfe597894f8",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a1ccaa34-a6d8-421c-aded-31248ab461e3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
     "longName": "996407 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_70a89060-d74f-4aad-a20a-b03e7164f4ee",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails",
     "longName": "996417 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R100": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
     "longName": "996427 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "C_5b526872-b885-43be-82fd-47148cef1b95",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_70a89060-d74f-4aad-a20a-b03e7164f4ee",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
     "longName": "996437 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "C_a1ccaa34-a6d8-421c-aded-31248ab461e3",
      "name": "gyre:PercentageOfRestrictedNetAssetsExceedNetAssets",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a1ccaa34-a6d8-421c-aded-31248ab461e3",
      "name": "gyre:PercentageOfRestrictedNetAssetsExceedNetAssets",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2023-07 [Member]",
        "terseLabel": "ASU 2023-07",
        "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349"
     ]
    },
    "gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLossCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail": {
       "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodEndLabel": "Balance, end of year",
        "negatedPeriodStartLabel": "Balance, beginning of year",
        "negatedLabel": "Allowance for credit losses",
        "label": "Accounts and Financing Receivable, Allowance for Credit Loss, Current",
        "documentation": "Accounts and financing receivable, allowance for credit loss, current."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Accounts and Financing Receivable, Allowance for Credit Loss, Foreign Currency Translation",
        "documentation": "Accounts and financing receivable, allowance for credit loss, foreign currency translation."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recoveries collected and write-off",
        "label": "Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off",
        "documentation": "Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Allowance for Credit Losses",
        "label": "Accounts and Financing Receivable, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Accounts and financing receivable, allowance for credit loss."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for allowance for credit losses",
        "label": "Accounts and Notes Receivable, Provision for Allowance for Credit Losses",
        "documentation": "Accounts and notes receivable, provision for allowance for credit losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts and note receivables, net",
        "totalLabel": "Accounts and note receivables, net",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Receivable from GCBP",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r1306"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r105"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Other Accrued Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued expenses and other current liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r1105"
     ]
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail": {
       "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r351",
      "r1043"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "terseLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1306"
     ]
    },
    "gyre_AccruedExpensesGeneralAndAdministrative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccruedExpensesGeneralAndAdministrative",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses - general and administrative",
        "documentation": "Accrued expenses general and administrative.",
        "label": "Accrued Expenses General and Administrative"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccruedExpensesResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccruedExpensesResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses - research and development",
        "label": "Accrued Expenses, Research And Development",
        "documentation": "Accrued expenses, research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r157"
     ]
    },
    "gyre_AccruedInterestIncomeOnLongTermCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccruedInterestIncomeOnLongTermCertificatesOfDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest Income On Long Term Certificates Of Deposit",
        "documentation": "Accrued interest income on long-term certificates of deposit.",
        "terseLabel": "Accrued interest income on long term certificates of deposit"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccruedInterestIncomeOnShortTermBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccruedInterestIncomeOnShortTermBankDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest Income On Short term Bank Deposits",
        "documentation": "Accrued interest income on short-term bank deposits.",
        "terseLabel": "Accrued interest income on short term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccruedInterestOnBankDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccruedInterestOnBankDeposit",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest On Bank Deposit",
        "documentation": "Accrued interest on bank deposit.",
        "negatedLabel": "Accrued interest on bank deposit"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccruedInterestOnLongTermCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccruedInterestOnLongTermCertificatesOfDeposit",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued interest on long-term certificates of deposit",
        "label": "Accrued Interest On Long-term Certificates Of Deposit",
        "documentation": "Accrued interest on long-term certificates of deposit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccruedPayrollAndWelfare": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccruedPayrollAndWelfare",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and welfare",
        "label": "Accrued Payroll And Welfare",
        "documentation": "Accrued payroll and welfare."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued professional services",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional and consulting services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee reimbursement",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1044"
     ]
    },
    "gyre_AccruedSalesDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccruedSalesDiscount",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued sales discount.",
        "terseLabel": "Accrued sales discount",
        "label": "Accrued Sales Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r213",
      "r859"
     ]
    },
    "gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated gross unrealized gain before tax available for sale securities.",
        "label": "Accumulated Gross Unrealized Gain Before Tax Available For Sale Securities",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r109",
      "r223",
      "r853",
      "r902",
      "r906"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16",
      "r28",
      "r665",
      "r668",
      "r744",
      "r897",
      "r898",
      "r1283",
      "r1284",
      "r1285",
      "r1293",
      "r1294",
      "r1295",
      "r1297"
     ]
    },
    "gyre_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development",
        "label": "Acquired In Process Research And Development",
        "documentation": "Acquired in process research and development."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AcquisitionCostsInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AcquisitionCostsInDueToRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition costs in due to related parties.",
        "terseLabel": "Acquisition costs in due to related parties",
        "label": "Acquisition Costs In Due To Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r1105",
      "r1513"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1293",
      "r1294",
      "r1295",
      "r1297",
      "r1447",
      "r1514"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r262",
      "r263",
      "r264",
      "r265",
      "r276",
      "r348",
      "r349",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r438",
      "r439",
      "r443",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r707",
      "r708",
      "r721",
      "r722",
      "r723",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r795",
      "r796",
      "r797",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r538"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs of issuance of common stock for public offering",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r142"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance payment for convertible preferred stock and preferred stock warrants acquired upon contributions.",
        "terseLabel": "Advance payment for Convertible Preferred Stock and Preferred Stock Warrants acquired upon the GNI USA Contributions",
        "label": "Advance Payment For Convertible Preferred Stock And Preferred Stock Warrants Acquired Upon Contributions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Cost",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expense",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r1088"
     ]
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliates"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1026",
      "r1127",
      "r1391",
      "r1463",
      "r1464",
      "r1465"
     ]
    },
    "gyre_AffiliatesBeneficialOwnSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AffiliatesBeneficialOwnSharesPercentage",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates beneficial own shares percentage.",
        "label": "Affiliates Beneficial Own Shares Percentage",
        "terseLabel": "Affiliates beneficial own shares percentage"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AffiliatesBeneficialOwnSharesSpecifiedPercentage",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates beneficial own shares specified percentage.",
        "label": "Affiliates Beneficial Own Shares Specified Percentage",
        "terseLabel": "Affiliates beneficial own shares specified percentage"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AggregateAmountsOfRestrictedCapitalAndStatutoryReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amounts of restricted capital and statutory reserves",
        "label": "Aggregate Amounts Of Restricted Capital And Statutory Reserves",
        "documentation": "Aggregate amounts of restricted capital and statutory reserves."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1243"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1156",
      "r1167",
      "r1177",
      "r1210"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1170",
      "r1180",
      "r1213"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1171",
      "r1181",
      "r1205",
      "r1214",
      "r1218",
      "r1226"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r1060",
      "r1061"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1224"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r581"
     ]
    },
    "gyre_AllowanceForCreditLossesCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AllowanceForCreditLossesCertificatesOfDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses certificates of deposit",
        "label": "Allowance for Credit Losses Certificates of Deposit",
        "documentation": "Allowance for credit losses certificates of deposit"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AllowanceForCreditLossesShort-TermCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AllowanceForCreditLossesShort-TermCertificatesOfDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses short-term certificates of deposit",
        "label": "Allowance For Credit Losses Short-Term Certificates Of Deposit",
        "documentation": "Allowance for credit losses short-term certificates of deposit."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Deferred Financing Costs Amortization",
        "negatedLabel": "Deferred Financing Costs Amortization",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r472",
      "r1287",
      "r1460"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r424",
      "r431",
      "r1069"
     ]
    },
    "gyre_AmortizationOfLandUseRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AmortizationOfLandUseRights",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of land use rights",
        "label": "Amortization Of Land Use Rights",
        "documentation": "Amortization of\u00a0land use rights."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AmountToBeReceivedUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AmountToBeReceivedUnderAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be received under agreement.",
        "label": "Amount To Be Received Under Agreement",
        "terseLabel": "Amount to be received under agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "gyre_AppropriationOfStatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AppropriationOfStatutoryReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Appropriation of statutory reserve",
        "documentation": "Appropriation of statutory reserve"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AppropriationsToStatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "AppropriationsToStatutoryReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Appropriations to statutory reserve",
        "label": "Appropriations To Statutory Reserve",
        "documentation": "Appropriations to statutory reserve."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r1445"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r1445"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureF351AssetAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "F351 Asset Acquisition",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets",
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r170",
      "r216",
      "r251",
      "r302",
      "r310",
      "r335",
      "r339",
      "r387",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r651",
      "r656",
      "r709",
      "r846",
      "r962",
      "r1060",
      "r1061",
      "r1105",
      "r1134",
      "r1339",
      "r1340",
      "r1466"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets:",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r227",
      "r251",
      "r387",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r651",
      "r656",
      "r709",
      "r1105",
      "r1339",
      "r1340",
      "r1466"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets at fair value",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r1093"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1140",
      "r1163"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1140",
      "r1163"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1140",
      "r1163"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r1247"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r405",
      "r845"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r405",
      "r685",
      "r830",
      "r1093",
      "r1097",
      "r1311",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1221"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1222"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "gyre_BCTwoThousandTwentyOneStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BCTwoThousandTwentyOneStockIncentivePlanMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BC 2021 Stock Incentive Plan",
        "label": "B C Two Thousand Twenty One Stock Incentive Plan [Member]",
        "documentation": "B C two thousand twenty one stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BadDebtExpenseAndOtherNonCashItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BadDebtExpenseAndOtherNonCashItems",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense and other non-cash items",
        "label": "Bad Debt Expense And Other Non-cash Items",
        "documentation": "Bad debt expense and other non-cash items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BeijingContinentPharmaceuticalsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BeijingContinentPharmaceuticalsCoLtdMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BC",
        "label": "Beijing Continent Pharmaceuticals Co., Ltd [Member]",
        "documentation": "Beijing continent pharmaceuticals Co., Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r638",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r638",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiplied by the fair value per share of Catalyst stock",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination agreement.",
        "label": "Business Combination Agreement [Member]",
        "terseLabel": "Business Combination Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total Purchase price",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r15"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR merger payable",
        "label": "Business Combination, Contingent Consideration, Liability",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r151",
      "r643",
      "r687",
      "r688",
      "r689"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GNI USA Contributions under the Business Combination Agreement",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r639"
     ]
    },
    "gyre_BusinessCombinationExcessClosingCashPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationExcessClosingCashPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "CVR excess closing cash payable",
        "label": "Business Combination Excess Closing Cash Payable",
        "documentation": "Business combination excess closing cash payable."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails": {
       "parentTag": "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Fair Value",
        "documentation": "Business combination fair value.",
        "totalLabel": "Fair value of Catalyst"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationFairValueOfCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationFairValueOfCommonShares",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails": {
       "parentTag": "gyre_BusinessCombinationFairValue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common shares to be owned by Catalyst's stockholders",
        "label": "Business Combination Fair Value of Common Shares",
        "documentation": "Business combination fair value of common shares."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationFairValueOfPreferredShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationFairValueOfPreferredShares",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails": {
       "parentTag": "gyre_BusinessCombinationFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of preferred shares to be owned by Catalyst's stockholders",
        "label": "Business Combination Fair Value of Preferred Shares",
        "documentation": "Business combination fair value of preferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued expenses and other current liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses and Other Current Liabilities",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advance payment received from GNI",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Advance Payment Received",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed advance payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, CVR Derivative Liability, noncurrent",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, CVR derivative liability, noncurrent.",
        "negatedLabel": "CVR derivative liability, noncurrent",
        "terseLabel": "CVR derivative liability, noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed In-Process Research and Development",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed in-process research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets acquired",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71"
     ]
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term receivable from GCBP",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Long-term Receivable",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed long-term receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated acquisition-date fair value of Catalyst",
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, noncurrent",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables from GNI",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Receivables Current",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, other receivables current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "CA",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CPIContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CPIContributionMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CPI Contribution",
        "label": "C P I Contribution [Member]",
        "documentation": "CPI contribution."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CVRDerivativeLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CVRDerivativeLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR derivative liability",
        "label": "C V R Derivative Liability Current",
        "documentation": "C V R derivative liability current."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CVRDerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CVRDerivativeLiabilityMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVR derivative liability.",
        "label": "C V R Derivative Liability [Member]",
        "terseLabel": "CVR Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CVRDerivativeLiabilityNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CVRDerivativeLiabilityNonCurrentMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C V R derivative liability non current member.",
        "label": "C V R Derivative Liability Non Current [Member]",
        "terseLabel": "CVR Derivative Liability non current"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CVRDerivativeLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CVRDerivativeLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CVR derivative liability",
        "terseLabel": "CVR derivative liability, noncurrent",
        "label": "C V R Derivative Liability Noncurrent",
        "documentation": "CVR derivative liability noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CVRMergerClosingPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CVRMergerClosingPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "C V R Merger Closing Payable",
        "documentation": "CVR merger closing payable.",
        "terseLabel": "CVR merger closing payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalAdditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalAdditionsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Capital Addition Purchase Commitments [Member]",
        "documentation": "Contractual obligation to increase property, plant and equipment either through construction or future purchases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r850",
      "r933",
      "r956",
      "r1105",
      "r1134",
      "r1270"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents acquired in connection with the GNI USA Contributions",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r210",
      "r1041"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "gyre_CashAndCashEquivalentsReportingCurrencyDenominatedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CashAndCashEquivalentsReportingCurrencyDenominatedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents denominated in RMB",
        "label": "Cash and Cash Equivalents Reporting Currency Denominated Value",
        "documentation": "Cash and cash equivalents reporting currency denominated value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r125",
      "r248"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net (decrease) increase in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r125"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1270",
      "r1479"
     ]
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CashPaidForAcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CashPaidForAcquisitionCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments made for acquisition costs",
        "label": "Cash Paid For Acquisition Costs",
        "documentation": "Cash paid for acquisition costs."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CatalystMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CatalystMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Catalyst",
        "label": "Catalyst [Member]",
        "documentation": "Catalyst."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r204",
      "r261",
      "r348",
      "r388",
      "r389",
      "r390",
      "r396",
      "r397",
      "r438",
      "r443",
      "r620",
      "r629",
      "r630",
      "r640",
      "r641",
      "r644",
      "r660",
      "r661",
      "r673",
      "r674",
      "r707",
      "r708",
      "r722",
      "r739",
      "r740",
      "r795",
      "r796",
      "r895",
      "r896"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r204",
      "r348",
      "r388",
      "r389",
      "r390",
      "r396",
      "r397",
      "r398",
      "r438",
      "r443",
      "r620",
      "r629",
      "r630",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r659",
      "r660",
      "r661",
      "r662",
      "r673",
      "r674",
      "r675",
      "r678",
      "r707",
      "r708",
      "r722",
      "r739",
      "r740",
      "r795",
      "r796",
      "r895",
      "r896",
      "r1257"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r275",
      "r393"
     ]
    },
    "gyre_ChangeInFairValueOfDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ChangeInFairValueOfDerivativeLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of derivative liabilities.",
        "label": "Change In Fair Value Of Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ChangeInFairValueOfLongTermReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ChangeInFairValueOfLongTermReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of long-term receivables.",
        "label": "Change In Fair Value Of Long Term Receivables",
        "negatedLabel": "Change in fair value of receivables from GCBP"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ChangeInFairValueOfReceivablesFromGCBiophrarmaCorp",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value Of Receivables From G C Biophrarma Corp",
        "documentation": "Change in fair value of receivables from GC biophrarma corp.",
        "negatedLabel": "Change in fair value of receivables from GCBP"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1196"
     ]
    },
    "gyre_ChangesOfValuationAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ChangesOfValuationAllowances",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes of valuation allowances",
        "label": "Changes of Valuation Allowances",
        "documentation": "Changes of valuation allowances.",
        "negatedLabel": "Changes of valuation allowances"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ChargesRelatedToWriteOffOfPrepaidManufacturingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges related to write off of prepaid manufacturing costs.",
        "label": "Charges Related To Write Off Of Prepaid Manufacturing Cost",
        "terseLabel": "Charges related to write off of prepaid manufacturing cost"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ChinaResourcesPharmaceuticalGroupLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ChinaResourcesPharmaceuticalGroupLimitedMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China Resources Pharmaceutical Group Ltd",
        "label": "China Resources Pharmaceutical Group Limited [Member]",
        "documentation": "China Resources Pharmaceutical Group Limited."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1193"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r217",
      "r218",
      "r219",
      "r251",
      "r281",
      "r285",
      "r294",
      "r296",
      "r304",
      "r305",
      "r387",
      "r460",
      "r462",
      "r463",
      "r464",
      "r467",
      "r468",
      "r475",
      "r476",
      "r479",
      "r482",
      "r490",
      "r709",
      "r911",
      "r912",
      "r913",
      "r914",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r934",
      "r948",
      "r971",
      "r993",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1249",
      "r1288",
      "r1298"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r304",
      "r475",
      "r476",
      "r477",
      "r479",
      "r482",
      "r488",
      "r490",
      "r911",
      "r912",
      "r913",
      "r914",
      "r1072",
      "r1249",
      "r1288"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrants exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issued shares",
        "label": "Class Of Warrants Or Rights Warrants Issued During Period Shares",
        "documentation": "Class of warrants or rights warrants issued during period shares."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "gyre_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue member.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration",
        "verboseLabel": "Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Combined square meter area for manufacturing facilities under lease",
        "label": "Combined Square Meter Area For Manufacturing Facilities Under Lease",
        "documentation": "Combined square meter area for manufacturing facilities under lease."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CommissionsAndOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CommissionsAndOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commissions And Offering Costs",
        "documentation": "Commissions and offering costs.",
        "terseLabel": "Commissions and offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 13)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r159",
      "r849",
      "r947"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "gyre_CommittedToAllocate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CommittedToAllocate",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Committed to allocate",
        "label": "Committed To Allocate",
        "documentation": "Committed to allocate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total Common Stock reserved",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividends paid per common share",
        "verboseLabel": "Common stock, cash dividend paid",
        "label": "Dividend declared",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared, unpaid, per common share",
        "verboseLabel": "Common stock, cash dividend declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1124",
      "r1125",
      "r1126",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1293",
      "r1294",
      "r1297",
      "r1447",
      "r1511",
      "r1514"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r948"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares sold",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Catalyst common stock outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r98",
      "r948",
      "r968",
      "r1514",
      "r1515"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 400,000,000 shares authorized; 86,307,544 shares and 76,595,616 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r851",
      "r1105"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1200"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to common stockholders",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r231",
      "r233",
      "r241",
      "r836",
      "r868",
      "r870"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income attributable to noncontrolling interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r75",
      "r79",
      "r231",
      "r233",
      "r240",
      "r835",
      "r868",
      "r869"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss) from operations",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r152",
      "r231",
      "r233",
      "r239",
      "r834",
      "r868"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computer Software",
        "terseLabel": "Computer software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1039",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1329",
      "r1331",
      "r1332"
     ]
    },
    "gyre_ConcentrationOfCustomerRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ConcentrationOfCustomerRiskPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Customer Risk",
        "label": "Concentration of Customer Risk [Policy Text Block]",
        "documentation": "Concentration of customer risk."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r82",
      "r83",
      "r347",
      "r1021"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r82",
      "r83",
      "r347",
      "r908",
      "r1021"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r82",
      "r83",
      "r347",
      "r1021",
      "r1256"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r187"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Concentration risk percentage",
        "terseLabel": "Concentration of customer risk",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r82",
      "r83",
      "r347"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r82",
      "r83",
      "r347",
      "r1021"
     ]
    },
    "srt_CondensedCashFlowStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedCashFlowStatementTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Cash Flow Statement [Table]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r1251"
     ]
    },
    "srt_CondensedCashFlowStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedCashFlowStatementsCaptionsLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Cash Flow Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r1251"
     ]
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Statements Schedule I Financial Information of Parent Company",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r1251"
     ]
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r1251"
     ]
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r1251"
     ]
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r1251"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r651",
      "r652",
      "r656",
      "r657",
      "r753",
      "r1026",
      "r1338",
      "r1341",
      "r1342"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r651",
      "r652",
      "r656",
      "r657",
      "r753",
      "r1026",
      "r1338",
      "r1341",
      "r1342"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ContinentPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ContinentPharmaceuticalsIncMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CPI",
        "label": "Continent Pharmaceuticals Inc [Member]",
        "documentation": "Continent pharmaceuticals inc."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ContingentValueRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ContingentValueRightsAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights Agreement.",
        "label": "Contingent Value Rights Agreement [Member]",
        "terseLabel": "Contingent Value Rights Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ContingentValueRightsDerivativeLiabilityNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ContingentValueRightsDerivativeLiabilityNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights derivative liability non current.",
        "label": "Contingent Value Rights Derivative Liability Non Current",
        "terseLabel": "CVR derivative liability, noncurrent",
        "verboseLabel": "Long-term CVR derivative liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r495",
      "r514"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "terseLabel": "Contract liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r514"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r514"
     ]
    },
    "gyre_ContributionsClosingPayableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ContributionsClosingPayableAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions closing payable amount",
        "label": "Contributions Closing Payable Amount",
        "documentation": "Contributions closing payable amount."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ConversionOfOutstandingPreferredStockRedeemedForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ConversionOfOutstandingPreferredStockRedeemedForCash",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of outstanding preferred stock redeemed for cash.",
        "label": "Conversion Of Outstanding Preferred Stock Redeemed For Cash",
        "terseLabel": "Conversion of outstanding preferred stock redeemed for cash"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ConvertiblePreferredStockConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ConvertiblePreferredStockConversion",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Conversion",
        "documentation": "Convertible preferred stock conversion.",
        "terseLabel": "Convertible preferred stock conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Issued and Outstanding",
        "verboseLabel": "Convertible Preferred stock (as converted)",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r479",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "gyre_ConvertiblePreferredStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ConvertiblePreferredStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock, Policy [Policy Text Block]",
        "documentation": "Convertible preferred stock, policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued upon conversion",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Preferred stock, shares issued upon conversion of common stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r55",
      "r97",
      "r140",
      "r485"
     ]
    },
    "gyre_CostOfCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CostOfCollaborationMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of collaboration.",
        "label": "Cost Of Collaboration [Member]",
        "terseLabel": "Cost of collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenues",
        "label": "Cost of Goods and Services Sold",
        "totalLabel": "Cost of Goods and Services Sold, Total",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r793"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "verboseLabel": "Cost of Revenues",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenue",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r469",
      "r477",
      "r751",
      "r771",
      "r844",
      "r1045",
      "r1047"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CpUSSharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CpUSSharePurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CP U.S. Share Purchase Agreement.",
        "terseLabel": "CP U.S. Share Purchase Agreement",
        "label": "CP U.S. SHARE PURCHASE AGREEMENT [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CumulativeAmountOfStatutoryReserveFund": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CumulativeAmountOfStatutoryReserveFund",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative amount of statutory reserve fund",
        "label": "Cumulative Amount Of Statutory Reserve Fund",
        "documentation": "Cumulative amount of statutory reserve fund."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current tax provision:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1259",
      "r1290",
      "r1444"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign - PRC",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1259",
      "r1290"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax provision:",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1290"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax provision:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1259",
      "r1290",
      "r1444"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r347"
     ]
    },
    "gyre_CvrExcessClosingCashPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CvrExcessClosingCashPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR excess closing cash payable",
        "label": "CVR Excess Closing Cash Payable",
        "documentation": "CVR excess closing cash payable."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CvrLiabilitySettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "CvrLiabilitySettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CVR Liability settlement",
        "documentation": "CVR liability settlement.",
        "terseLabel": "CVR Liability settlement"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1148",
      "r1237"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1148",
      "r1237"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1239"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1239"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1152",
      "r1241"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1239"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1143",
      "r1232"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1233"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1233"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1231"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1231"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1231"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1234"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1147",
      "r1236"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1147",
      "r1236"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1148",
      "r1237"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1151",
      "r1240"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1238"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1146",
      "r1235"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Deemed Issuance Of Common Stock And Convertible Preferred Stock To Former Stockholders",
        "documentation": "Deemed issuance of common stock and convertible preferred stock to former stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1443",
      "r1444"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign - PRC",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1443"
     ]
    },
    "gyre_DeferredGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred government grants",
        "label": "Deferred Government Grants",
        "documentation": "Deferred government grants."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredGovernmentGrantsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail": {
       "parentTag": "gyre_DeferredGovernmentGrantsCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current deferred government grants",
        "label": "Deferred Government Grants Current",
        "documentation": "Deferred government grants current."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredGovernmentGrantsCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred government grants",
        "label": "Deferred Government Grants Current And Noncurrent",
        "documentation": "Deferred government grants current and noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredGovernmentGrantsLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Government Grants [Line Items]",
        "documentation": "Deferred government grants."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredGovernmentGrantsNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail": {
       "parentTag": "gyre_DeferredGovernmentGrantsCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current deferred government grants",
        "label": "Deferred Government Grants Non current",
        "documentation": "Deferred government grants non current."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredGovernmentGrantsTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Government Grants [Table]",
        "documentation": "Deferred government grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r592"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax provision:",
        "terseLabel": "Deferred income taxes, net",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r192",
      "r1290"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax provision:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredIncomeTaxExpenseBenefitNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredIncomeTaxExpenseBenefitNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes, net",
        "label": "Deferred Income Tax Expense Benefit Net",
        "documentation": "Deferred income tax expense benefit net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Current, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1274"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred government grants",
        "label": "Deferred Revenue, Noncurrent",
        "totalLabel": "Deferred Revenue, Noncurrent, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1443",
      "r1444"
     ]
    },
    "gyre_DeferredTaxAssetsCapitalizedTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized transaction costs",
        "label": "Deferred Tax Assets Capitalized Transaction Costs",
        "documentation": "Deferred tax assets capitalized transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredTaxAssetsContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredTaxAssetsContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Deferred Tax Assets, Contract Liabilities",
        "documentation": "Deferred tax assets, contract liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredTaxAssetsFixedAssetsAndIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets fixed assets and intangibles.",
        "label": "Deferred Tax Assets Fixed Assets And Intangibles",
        "terseLabel": "Fixed and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred income tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredTaxAssetsImpactFromForeignCorporations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredTaxAssetsImpactFromForeignCorporations",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact from foreign corporations",
        "label": "Deferred Tax Assets Impact From Foreign Corporations",
        "documentation": "Deferred tax assets impact from foreign corporations"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets Lease Liabilities",
        "documentation": "Deferred tax assets lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1438"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry forwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1441"
     ]
    },
    "gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredTaxAssetsStateNetOperatingLossCarryForwards",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets state net operating loss carry forwards.",
        "label": "Deferred Tax Assets State Net Operating Loss Carry Forwards",
        "terseLabel": "Net operating loss carryforward, derecognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carry forwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1441"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1441"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodEndLabel": "Balance at the end of the year",
        "periodEndLabel": "Balance at the end of the year",
        "periodStartLabel": "Balance at the beginning of the year",
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedPeriodStartLabel": "Balance at the beginning of the year",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax liability",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1438"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liability - Fixed assets",
        "verboseLabel": "Deferred Tax Liability - Fixed Assets",
        "terseLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1441"
     ]
    },
    "gyre_DeferredTaxLiabilityRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DeferredTaxLiabilityRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liability - ROU assets",
        "terseLabel": "Deferred Tax Liability - ROU Assets",
        "label": "Deferred Tax Liability Right Of Use Assets",
        "documentation": "Deferred tax liability right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions for employee benefits",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r519",
      "r526",
      "r1080",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlans1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Defined Benefit Plan [Text Block]",
        "documentation": "The entire disclosure for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r789",
      "r1082"
     ]
    },
    "gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DepositsInLicensedBanksProtectedByDepositInsuranceSystem",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits in licensed banks protected by DIS",
        "label": "Deposits In Licensed Banks Protected By Deposit Insurance System",
        "documentation": "Deposits in licensed banks protected by deposit insurance system."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r302",
      "r315",
      "r339",
      "r1060",
      "r1061"
     ]
    },
    "us-gaap_DerivativeAssetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetMeasurementInput",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset measurement input",
        "label": "Derivative Asset, Measurement Input",
        "documentation": "Value of input used to measure derivative asset."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689",
      "r1097"
     ]
    },
    "gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liabilities estimated fair value increase decrease.",
        "label": "Derivative Liabilities Estimated Fair Value Increase Decrease",
        "terseLabel": "Change in the estimated fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability, noncurrent",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability measurement input",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689"
     ]
    },
    "us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesMethodsOfAccountingHedgingDerivatives",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r1446"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Sales by Product Categories",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r541",
      "r572",
      "r573",
      "r575",
      "r1087"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DisposalConsiderationInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DisposalConsiderationInOtherReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal consideration in other receivables.",
        "terseLabel": "Disposal consideration in other receivables from GNI",
        "label": "Disposal Consideration In Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Total consideration for sales agreements",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DistributionFromAssetSaleProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DistributionFromAssetSaleProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution from asset sale proceeds.",
        "label": "Distribution From Asset Sale Proceeds",
        "terseLabel": "Distribution to CVR holders from asset sale proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DistributionsToHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DistributionsToHolders",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions To Holders",
        "documentation": "Distributions to holders.",
        "terseLabel": "Distributions to holders"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DistributionsToHoldersPerCVR": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DistributionsToHoldersPerCVR",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions To Holders Per CVR",
        "documentation": "Distributions to holders per CVR.",
        "terseLabel": "Distributions to holders per CVR"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DivestitureLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DivestitureLossesMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestiture Losses",
        "label": "Divestiture Losses [Member]",
        "documentation": "Divestiture losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPayableAmountPerShare",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable, Amount Per Share",
        "terseLabel": "Cash dividends payable per common share",
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPayableDateOfRecordDayMonthAndYear",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable, Date of Record",
        "terseLabel": "Common stock, dividend payable, date of record",
        "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1140",
      "r1163"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1140",
      "r1163",
      "r1206"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal Income Tax",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "gyre_DrenBioIncAndCopiaScientificLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "DrenBioIncAndCopiaScientificLLCMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dren Bio, Inc. and Copia Scientific, LLC.",
        "label": "Dren Bio Inc And Copia Scientific L L C [Member]",
        "terseLabel": "Dren Bio, Inc. and Copia Scientific, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1195"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (loss) income per share, Basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Net income (loss) per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r278",
      "r281",
      "r294",
      "r295",
      "r296",
      "r301",
      "r636",
      "r648",
      "r682",
      "r683",
      "r837",
      "r871",
      "r1052"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (loss) income per share, Diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Net income (loss) per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r281",
      "r294",
      "r295",
      "r296",
      "r301",
      "r636",
      "r648",
      "r682",
      "r683",
      "r837",
      "r871",
      "r1052"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) Per Share (\"EPS\") Attributable to Common Stockholders",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r298"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEps"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EPS",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r297",
      "r299",
      "r300"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1459"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r1090"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax computed at federal statutory rate",
        "negatedLabel": "Tax computed at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r594",
      "r623",
      "r1090"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance change",
        "negatedLabel": "Valuation allowance change",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r1090",
      "r1291",
      "r1434"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESOP",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Employee Stock Ownership Plan Dividend, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r1291",
      "r1434",
      "r1435"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate difference due to different jurisdiction",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r597",
      "r1090",
      "r1291",
      "r1434"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible Expense - Operating",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r600",
      "r1291",
      "r1434"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "negatedLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1291",
      "r1434",
      "r1436"
     ]
    },
    "gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expense - acquisition related",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Related To Acquisition",
        "documentation": "Effective income tax rate reconciliation nondeductible expense related to acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "R&amp;D Super-deduction",
        "terseLabel": "R&amp;D Super-deduction",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1291",
      "r1434",
      "r1436"
     ]
    },
    "gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferential income tax rate for HNTE",
        "label": "Effective Income Tax Rate Reconciliation Preferential Income Tax Rate For HNTE",
        "documentation": "Effective income tax rate reconciliation preferential income tax rate for HNTE."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized employee stock based compensation expense, period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized employee stock based compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1432"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1246"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1248"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1189"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1242"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1242"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1242"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r201",
      "r235",
      "r236",
      "r237",
      "r258",
      "r259",
      "r260",
      "r263",
      "r270",
      "r272",
      "r274",
      "r303",
      "r392",
      "r399",
      "r439",
      "r492",
      "r618",
      "r619",
      "r632",
      "r633",
      "r634",
      "r637",
      "r647",
      "r648",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r681",
      "r711",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r722",
      "r725",
      "r744",
      "r866",
      "r897",
      "r898",
      "r899",
      "r922",
      "r993"
     ]
    },
    "gyre_EquityGainLossOfUnconsolidatedAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "EquityGainLossOfUnconsolidatedAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Gain Loss of Unconsolidated Affiliates",
        "documentation": "Equity gain loss of unconsolidated affiliates.",
        "negatedLabel": "Equity loss of unconsolidated affiliates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityIssuedInBusinessCombinationFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Issued in Business Combination, Fair Value Disclosure",
        "totalLabel": "Fair value of consideration issued",
        "documentation": "Fair value of equity issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686"
     ]
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Other-than-Temporary Impairment",
        "terseLabel": "Impairment charge",
        "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments",
        "terseLabel": "Total investment",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r320",
      "r339",
      "r386",
      "r1271",
      "r1319"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1156",
      "r1167",
      "r1177",
      "r1210"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1153",
      "r1164",
      "r1174",
      "r1207"
     ]
    },
    "gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess amount retained from net proceeds related to disposition of assets.",
        "label": "Excess Amount Retained From Net Proceeds Related To Disposition Of Assets",
        "terseLabel": "Excess amount retained from net proceeds related to disposition of assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "gyre_FCContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "FCContributionMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FC contribution.",
        "terseLabel": "FC Contribution",
        "label": "F C Contribution [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_FThreeFiveOneAssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "FThreeFiveOneAssetPurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "F351 asset purchase agreement.",
        "label": "F Three Five One Asset Purchase Agreement [Member]",
        "terseLabel": "F351 Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_FThreeFiveOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "FThreeFiveOneMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "F three five one.",
        "label": "F Three Five One [Member]",
        "terseLabel": "F351"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Less: Change in fair value of warrant liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11"
     ]
    },
    "gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement transfer between Level 1 and Level 2",
        "label": "Fair Value Assets and Liabilities Level1 To Level2 Transfers Amount",
        "documentation": "Fair value assets and liabilities level1 to level2 transfers amount."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "FairValueAssetsAndLiabilitiesLevel3TransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement transfer Level 3",
        "label": "Fair Value Assets and Liabilities Level3 Transfers Amount",
        "documentation": "Fair value assets and liabilities level3 transfers amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r699",
      "r1093"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r699",
      "r1093"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689",
      "r1097"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689",
      "r1097"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r1097"
     ]
    },
    "gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1449",
      "r1450"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r700",
      "r1095"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r695",
      "r700",
      "r1095"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r700",
      "r1095"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r684",
      "r686",
      "r687",
      "r688",
      "r689",
      "r698",
      "r699",
      "r701",
      "r758",
      "r759",
      "r760",
      "r1070",
      "r1071",
      "r1080",
      "r1081",
      "r1082",
      "r1093",
      "r1097"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements and Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r696",
      "r697",
      "r698",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r829",
      "r1093",
      "r1098"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r519",
      "r524",
      "r686",
      "r699",
      "r758",
      "r1080",
      "r1081",
      "r1082",
      "r1093"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r519",
      "r524",
      "r686",
      "r687",
      "r699",
      "r759",
      "r1070",
      "r1071",
      "r1080",
      "r1081",
      "r1082",
      "r1093"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r686",
      "r687",
      "r688",
      "r689",
      "r699",
      "r760",
      "r1070",
      "r1071",
      "r1080",
      "r1081",
      "r1082",
      "r1093",
      "r1097"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1454",
      "r1456"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions in the period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r700",
      "r1095"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r700",
      "r1095"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1454",
      "r1456"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions in the period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r700"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r700"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r684",
      "r686",
      "r687",
      "r688",
      "r689",
      "r698",
      "r699",
      "r701",
      "r758",
      "r759",
      "r760",
      "r1070",
      "r1071",
      "r1080",
      "r1081",
      "r1082",
      "r1093",
      "r1097"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FinanceReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceReceivablesMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable [Member]",
        "terseLabel": "Long-term Receivable from GCBP",
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r473",
      "r488",
      "r671",
      "r706",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r867",
      "r1067",
      "r1093",
      "r1095",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1106",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1448",
      "r1451",
      "r1452",
      "r1453",
      "r1455",
      "r1457"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life of finite lived intangible assets",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r412",
      "r430",
      "r1069"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1330",
      "r1516"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r1035",
      "r1069"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r1035",
      "r1069"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r1035",
      "r1069"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r1035",
      "r1069"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r1035",
      "r1069"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r433",
      "r434",
      "r794",
      "r798",
      "r1035"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r430",
      "r798",
      "r1069"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets with finite lives:",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r430",
      "r433",
      "r434",
      "r436",
      "r794",
      "r1035",
      "r1069"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r433",
      "r434",
      "r1035"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible assets, net",
        "terseLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r1329"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible assets, Weighted average amortization period",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "gyre_ForeignCurrencyRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ForeignCurrencyRiskPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Risk",
        "label": "Foreign Currency Risk [Policy Text Block]",
        "documentation": "Foreign currency risk."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation and Remeasurement",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1171",
      "r1181",
      "r1214"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1171",
      "r1181",
      "r1214"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1171",
      "r1181",
      "r1214"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1171",
      "r1181",
      "r1214"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1171",
      "r1181",
      "r1214"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1194"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GCBiopharmaCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "GCBiopharmaCorpMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GC Biopharma Corp.",
        "label": "G C Biopharma Corp [Member]",
        "terseLabel": "GC Biopharma Corp"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "GCBiophrarmaCorpAssetPurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GC Biophrarma Corp asset purchase agreement member.",
        "label": "G C Biophrarma Corp Asset Purchase Agreement [Member]",
        "terseLabel": "GCBP Asset Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GNIGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "GNIGroupMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GNI Group [Member]",
        "documentation": "GNI group.",
        "terseLabel": "GNI Group"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GNIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "GNIMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GNI",
        "label": "G N I [Member]",
        "terseLabel": "GNI"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GNIUSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "GNIUSAMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GNI USA",
        "label": "G N I U S A [Member]",
        "documentation": "GNI USA."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of property and equipment",
        "negatedLabel": "Divestiture losses",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Net gain on disposal of assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Divestiture losses",
        "negatedTerseLabel": "Loss on divestiture of subsidiary",
        "negatedLabel": "Divestiture losses",
        "terseLabel": "Loss on divestiture of subsidiary",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r1287"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property and equipment",
        "terseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total",
        "verboseLabel": "Loss on disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r973"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "gyre_GeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "GeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "label": "General and Administrative Expenses [Policy Text Block]",
        "documentation": "General and administrative expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grants",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720"
     ]
    },
    "gyre_GovernmentGrantIncomeWithinOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "GovernmentGrantIncomeWithinOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grant income",
        "label": "Government Grant Income Within Other Income",
        "documentation": "Government grant income within other income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r115",
      "r169",
      "r251",
      "r387",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r709",
      "r1054",
      "r1060",
      "r1300",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1339"
     ]
    },
    "gyre_GyreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "GyreMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gyre",
        "label": "Gyre [Member]",
        "documentation": "Gyre."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GyrePharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "GyrePharmaceuticalsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gyre Pharmaceuticals",
        "label": "Gyre Pharmaceuticals [Member]",
        "documentation": "Gyre Pharmaceuticals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due in one to five years",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r179",
      "r383",
      "r842"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five",
        "terseLabel": "Due in one to five years",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r840"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date",
        "totalLabel": "Total",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1312",
      "r1476"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r177",
      "r1313",
      "r1477"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r178",
      "r382",
      "r841"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfFairValueAndAmortizedCostOfHeldtomaturityDebtSecuritiesAndRedemptionDateDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r839"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1140",
      "r1163"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r49",
      "r134",
      "r1094"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r135"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired IPR&amp;D",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "terseLabel": "Loss before equity in (loss) income of subsidinaries",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r165",
      "r169",
      "r838",
      "r862",
      "r1054",
      "r1060",
      "r1300",
      "r1302",
      "r1303",
      "r1304",
      "r1305"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (loss) income from operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income (loss)",
        "terseLabel": "Net income (loss) from operations",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r169",
      "r251",
      "r262",
      "r270",
      "r387",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r636",
      "r648",
      "r683",
      "r709",
      "r862",
      "r1054",
      "r1300",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1339"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity loss (income) of subsidiaries",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity (income) loss of subsidiaries",
        "terseLabel": "Equity in income (loss) of subsidiaries",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r112",
      "r164",
      "r302",
      "r317",
      "r339",
      "r386",
      "r861"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r442",
      "r448",
      "r691",
      "r695",
      "r700",
      "r892",
      "r894",
      "r978",
      "r1035",
      "r1096",
      "r1482"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r448",
      "r691",
      "r695",
      "r700",
      "r892",
      "r894",
      "r978",
      "r1035",
      "r1096",
      "r1482"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r594",
      "r595",
      "r604",
      "r614",
      "r1090",
      "r1440"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r594",
      "r595",
      "r604",
      "r614",
      "r1090",
      "r1440"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r1440"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r1440"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r587",
      "r594",
      "r601",
      "r602",
      "r603",
      "r607",
      "r612",
      "r624",
      "r626",
      "r627",
      "r628",
      "r916",
      "r1090"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Tax-related penalties or interest recognized",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1437"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Total income tax provision:",
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r195",
      "r273",
      "r274",
      "r302",
      "r318",
      "r339",
      "r593",
      "r594",
      "r625",
      "r872",
      "r1090"
     ]
    },
    "gyre_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax.",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r589",
      "r590",
      "r607",
      "r608",
      "r611",
      "r616",
      "r910"
     ]
    },
    "gyre_IncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "IncomeTaxTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "totalLabel": "Income Taxes Paid, Net, Total",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r247",
      "r613",
      "r614"
     ]
    },
    "gyre_IncreaseDecreaseInAccountsAndNotesReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "IncreaseDecreaseInAccountsAndNotesReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts and note receivables",
        "label": "Increase Decrease In Accounts And Notes Receivables",
        "documentation": "Increase decrease in accounts and notes receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 39.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Increase (Decrease) in Due to Related Parties",
        "totalLabel": "Increase (Decrease) in Due to Related Parties, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 38.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes."
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInNotesReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInNotesReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Notes Receivable, Current",
        "negatedLabel": "Notes receivable",
        "documentation": "The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInNotesReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInNotesReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes receivable",
        "label": "Increase (Decrease) in Notes Receivables",
        "documentation": "The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1258",
      "r1286"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables from GNI",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 37.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average of Convertible Preferred Stock (as converted)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r296"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average of common stock options",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r296",
      "r540"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1171",
      "r1181",
      "r1205",
      "r1214",
      "r1218",
      "r1226"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1224"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r1141",
      "r1230"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1141",
      "r1230"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1141",
      "r1230"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r435",
      "r437",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r792",
      "r794",
      "r1048",
      "r1322"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest Income (Expense), Operating",
        "totalLabel": "Interest Income (Expense), Net, Total",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r1302"
     ]
    },
    "gyre_InterestIncomePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "InterestIncomePolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Income",
        "label": "Interest Income [Policy Text Block]",
        "documentation": "Interest income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1277"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 9.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventories, net",
        "terseLabel": "Inventories, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r1042",
      "r1105"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, Net",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r209",
      "r224",
      "r409",
      "r410",
      "r411",
      "r788",
      "r1049"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1279"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserves",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1280"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "gyre_InvestmentSubscriptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "InvestmentSubscriptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Subscription Amount",
        "documentation": "Investment subscription amount.",
        "terseLabel": "Investment obligation amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Fair Value and Amortized Cost of Held-to-maturity Debt Securities and Redemption Date",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in subsidiaries",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "totalLabel": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "gyre_LandUseRightsNetAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LandUseRightsNetAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land use rights, net assets",
        "label": "Land Use Rights, Net Assets",
        "documentation": "Land use rights, net assets."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LandUseRightsNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LandUseRightsNetNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land use rights, net",
        "label": "Land Use Rights Net Noncurrent",
        "documentation": "Land use rights net noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LandUseRightsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LandUseRightsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land Use Rights, Net",
        "label": "Land Use Rights [Policy Text Block]",
        "documentation": "Land use rights."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration month and year"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LeaseLabAndOfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LeaseLabAndOfficeSpaceMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease lab and office space.",
        "label": "Lease Lab And Office Space [Member]",
        "terseLabel": "Lease Lab And Office Space"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LeaseRenewedMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LeaseRenewedMonthAndYear",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Renewed Month And Year",
        "documentation": "Lease renewed month and year.",
        "terseLabel": "Lease renewed month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leasehold Improvement",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r737"
     ]
    },
    "gyre_LegalExpensesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LegalExpensesIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal expenses incurred.",
        "label": "Legal Expenses Incurred",
        "terseLabel": "Legal expenses incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal expense",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r738"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r738"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1462"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Undiscounted future payment",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r251",
      "r387",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r652",
      "r656",
      "r657",
      "r709",
      "r946",
      "r1053",
      "r1134",
      "r1339",
      "r1466",
      "r1467"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock, and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r161",
      "r856",
      "r1105",
      "r1289",
      "r1320",
      "r1458"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, convertible preferred stock, and equity",
        "verboseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities:",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r208",
      "r251",
      "r387",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r652",
      "r656",
      "r657",
      "r709",
      "r1105",
      "r1339",
      "r1466",
      "r1467"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial liabilities at fair value",
        "negatedLabel": "Liabilities, fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities, fair value",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r1449"
     ]
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "verboseLabel": "Uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License of Intellectual Property",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1345"
     ]
    },
    "us-gaap_LiquidationBasisOfAccountingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiquidationBasisOfAccountingTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidation Basis of Accounting [Text Block]",
        "terseLabel": "Liquidity",
        "documentation": "The entire disclosure for the liquidation basis of accounting."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "gyre_LiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LiquidityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LiquidityLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Line Items]",
        "terseLabel": "Liquidity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LiquidityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LiquidityTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Table]",
        "terseLabel": "Liquidity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_Long-TermCertificatesOfDepositMaturityDateRangeEnd": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "Long-TermCertificatesOfDepositMaturityDateRangeEnd",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "long-term certificates of deposit Maturity Date Range end",
        "documentation": "long-term certificates of deposit Maturity Date Range end.",
        "terseLabel": "long-term certificates of deposit maturity period end"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_Long-TermCertificatesOfDepositMaturityDateRangeStart": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "Long-TermCertificatesOfDepositMaturityDateRangeStart",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "long-term certificates of deposit maturity period start",
        "label": "long-term certificates of deposit Maturity Date Range Start",
        "documentation": "long-term certificates of deposit Maturity Date Range Start."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermAccountsNotesAndLoansReceivableNetNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term receivable from GCBP",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "totalLabel": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent, Total",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r1306"
     ]
    },
    "gyre_LongTermCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LongTermCertificatesOfDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term certificates of deposit",
        "label": "Long Term Certificates Of Deposit",
        "documentation": "Long Term Certificates Of Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LongTermCertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LongTermCertificatesOfDepositMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Certificates Of Deposit [Member]",
        "documentation": "Long-term certificates of deposit.",
        "terseLabel": "Long-term Certificates of Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LongTermCertificatesOfDepositPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LongTermCertificatesOfDepositPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Certificates of Deposit",
        "label": "Long Term Certificates of Deposit [Policy Text Block]",
        "documentation": "Long term certificates of deposit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Investments, Total",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "gyre_LongTermInvestmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "LongTermInvestmentsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Investments [Policy Text Block]",
        "documentation": "Long term investments.",
        "terseLabel": "Long-term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_MachineryAndElectronicDevicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "MachineryAndElectronicDevicesMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and Electronic Devices",
        "label": "Machinery and Electronic Devices [Member]",
        "documentation": "Machinery and electronic devices."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_MainlandChinaContributionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "MainlandChinaContributionPlanMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mainland China Contribution Plan",
        "label": "Mainland China Contribution Plan [Member]",
        "documentation": "Mainland China Contribution Plan."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r1075",
      "r1116",
      "r1121",
      "r1344",
      "r1481",
      "r1483",
      "r1484",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510"
     ]
    },
    "gyre_MaximumAmountOfTaxOffsetPerYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "MaximumAmountOfTaxOffsetPerYear",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of tax offset per year.",
        "label": "Maximum Amount Of Tax Offset Per Year",
        "terseLabel": "Maximum amount of tax offset per year"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r530",
      "r582",
      "r689",
      "r787",
      "r891",
      "r893",
      "r907",
      "r938",
      "r939",
      "r1001",
      "r1003",
      "r1005",
      "r1006",
      "r1008",
      "r1032",
      "r1033",
      "r1066",
      "r1072",
      "r1086",
      "r1097",
      "r1098",
      "r1102",
      "r1103",
      "r1117",
      "r1343",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "gyre_MeasurementInputCurrentlyEstimatedDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "MeasurementInputCurrentlyEstimatedDiscountRateMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currently Estimated Discount Rate",
        "label": "Measurement Input, Currently Estimated Discount Rate [Member]",
        "documentation": "Measurement input, currently estimated discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Volatility",
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-Free Interest",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689",
      "r1097"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689",
      "r1097"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r530",
      "r582",
      "r689",
      "r787",
      "r891",
      "r893",
      "r907",
      "r938",
      "r939",
      "r1001",
      "r1003",
      "r1005",
      "r1006",
      "r1008",
      "r1032",
      "r1033",
      "r1066",
      "r1072",
      "r1086",
      "r1097",
      "r1098",
      "r1102",
      "r1117",
      "r1343",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473"
     ]
    },
    "gyre_MinorityHolderContributionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "MinorityHolderContributionsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority Holder Contributions",
        "label": "Minority Holder Contributions [Member]",
        "documentation": "Minority holder contributions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, Attributable to Noncontrolling Interest, Ending Balance",
        "periodStartLabel": "Equity, Attributable to Noncontrolling Interest, Beginning Balance",
        "totalLabel": "Equity, Attributable to Noncontrolling Interest, Total",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r160",
      "r251",
      "r387",
      "r460",
      "r462",
      "r463",
      "r464",
      "r467",
      "r468",
      "r709",
      "r855",
      "r950"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of minority interest",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r142",
      "r153"
     ]
    },
    "gyre_MinorityInterestDecreaseFromRedemptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "MinorityInterestDecreaseFromRedemptionsShares",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of minority interest (in shares)",
        "label": "Minority Interest Decrease From Redemptions Shares",
        "documentation": "Minority interest decrease from redemptions shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority interest",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "gyre_MotorVehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "MotorVehiclesMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor Vehicles",
        "label": "Motor Vehicles [Member]",
        "documentation": "Motor vehicles."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "gyre_NDAPassesTheNMPAsReviewAndInspectionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "NDAPassesTheNMPAsReviewAndInspectionMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NDA Passes the NMPA's Review and Inspection",
        "label": "N D A Passes the N M P A's Review and Inspection [Member]",
        "documentation": "N D A Passes the N M P A's Review and Inspection."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_NMPAsApprovalOfTheNDAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "NMPAsApprovalOfTheNDAMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NMPA's Approval of the NDA",
        "label": "N M P A's Approval of the N D A [Member]",
        "documentation": "N M P A's Approval of the N D A."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r1075",
      "r1116",
      "r1121",
      "r1344",
      "r1481",
      "r1483",
      "r1484",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "gyre_NassimUsmanPhdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "NassimUsmanPhdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nassim Usman PhD.",
        "label": "Nassim Usman PhD [Member]",
        "terseLabel": "Nassim Usman, Ph.D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Nature of Operations",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r196"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "negatedTotalLabel": "Net cash flows (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financing Activities",
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investing Activities",
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used) provided by operating activities",
        "terseLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Activities",
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net (loss) income",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r127",
      "r166",
      "r206",
      "r229",
      "r232",
      "r237",
      "r251",
      "r262",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r292",
      "r387",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r636",
      "r648",
      "r683",
      "r709",
      "r865",
      "r970",
      "r991",
      "r992",
      "r1132",
      "r1339"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income attributable to noncontrolling interest",
        "label": "Less: Allocation of undistributed earnings to noncontrolling interest",
        "verboseLabel": "Net income attributable to noncontrolling interest",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r154",
      "r229",
      "r232",
      "r270",
      "r273",
      "r274",
      "r864",
      "r1285"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income attributable to common stockholders - basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income (loss) attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r266",
      "r267",
      "r268",
      "r269",
      "r278",
      "r279",
      "r293",
      "r296",
      "r648"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income attributable to common stockholders - diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r280",
      "r286",
      "r287",
      "r288",
      "r289",
      "r293",
      "r296"
     ]
    },
    "gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements - Issued But Not Yet Adopted",
        "label": "New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]",
        "documentation": "New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1171",
      "r1181",
      "r1205",
      "r1214"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1188"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1187"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of Non-Cash Financing and Investing Activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash lease expense",
        "label": "Noncash Lease Expense",
        "documentation": "Noncash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r492",
      "r1293",
      "r1294",
      "r1295",
      "r1297",
      "r1514"
     ]
    },
    "gyre_NoncontrollingInterestPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "NoncontrollingInterestPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest, Policy [Policy Text Block]",
        "documentation": "Noncontrolling interest, policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NontradeReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from GCBP",
        "label": "Nontrade Receivables, Current",
        "totalLabel": "Nontrade Receivables, Current, Total",
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "us-gaap_NotesAndLoansReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesAndLoansReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail": {
       "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable",
        "label": "Financing Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r1043",
      "r1321"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Financing Receivable, after Allowance for Credit Loss, Current, Total",
        "terseLabel": "Notes receivable",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1306"
     ]
    },
    "gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock issuable upon exercise and conversion of warrants",
        "label": "Number of Common Stock Shares Issuable Upon Exercise and Conversion Of Warrants",
        "documentation": "Number of common stock shares issuable upon exercise and conversion of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1301"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1065",
      "r1301"
     ]
    },
    "gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock issuable upon conversion of the outstanding shares",
        "label": "Number Of Shares Of Common Stock Issuable Upon Conversion Of The Outstanding Shares",
        "documentation": "Number of shares of common stock issuable upon conversion of the outstanding shares."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ObligationToPayInExchangeForTheIntellectualPropertyRights",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation to pay in exchange for the intellectual property rights",
        "documentation": "Obligation to pay in exchange for the intellectual property rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Tax Year",
        "terseLabel": "Tax year remains open to examination",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expense",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses excluding cost of revenues",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses excluding cost of revenues:",
        "verboseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (Loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r1054",
      "r1300",
      "r1302",
      "r1303",
      "r1304",
      "r1305"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1461"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "negatedLabel": "Less current portion of lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, noncurrent",
        "verboseLabel": "Lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating lease",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r732"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r1104"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r1104"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "gyre_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OperatingLossCarryforwardsWithIndefiniteLife": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "OperatingLossCarryforwardsWithIndefiniteLife",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards with indefinite life.",
        "label": "Operating Loss Carryforwards With Indefinite Life",
        "terseLabel": "Net operating loss carryforwards having indefinite life"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options Issued and Outstanding",
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options To Purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OrganizationAndNatureOfOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "OrganizationAndNatureOfOperationsLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and nature of operations.",
        "label": "Organization And Nature Of Operations [Line Items]",
        "terseLabel": "Organization and Nature of Operations [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OrganizationAndNatureOfOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "OrganizationAndNatureOfOperationsTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and Nature of Operations [Table]",
        "label": "Organization And Nature Of Operations [Table]",
        "terseLabel": "Organization And Nature Of Operations [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other accrued liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "totalLabel": "Total other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r1105"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments attributable to noncontrolling interest",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r16",
      "r152"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r16",
      "r152"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency translation loss",
        "verboseLabel": "Foreign currency translation adjustments",
        "terseLabel": "Foreign currency translation loss",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r866"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive (loss) income, net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r23",
      "r230",
      "r233",
      "r238",
      "r270",
      "r711",
      "r712",
      "r717",
      "r833",
      "r866",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OtherDirectorOrOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "OtherDirectorOrOfficerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other director or officer.",
        "label": "Other Director or Officer [Member]",
        "terseLabel": "Other Director or Officer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Income, net",
        "label": "Other Income [Member]",
        "documentation": "Primary financial statement caption encompassing other revenue."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Other Liabilities",
        "totalLabel": "Other Liabilities, Total",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r847",
      "r942",
      "r943",
      "r1134",
      "r1478",
      "r1512"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1105"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other expense",
        "negatedLabel": "Other expenses",
        "terseLabel": "Other Expense",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Income",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net:",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r957",
      "r1061",
      "r1480"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables from GNI",
        "label": "Other Receivables, Net, Current",
        "totalLabel": "Other Receivables, Net, Current, Total",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1158",
      "r1169",
      "r1179",
      "r1212"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1161",
      "r1172",
      "r1182",
      "r1215"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1161",
      "r1172",
      "r1182",
      "r1215"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent Company",
        "label": "Parent Company [Member]"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent",
        "verboseLabel": "Total Gyre Stockholders' Equity (Deficit)",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PatentsAndTechnologicalKnowHowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PatentsAndTechnologicalKnowHowMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PatentsAndTechnologicalKnowHowMember",
        "label": "Patents and Technological Know How [Member]",
        "documentation": "Patents and Technological Know-how"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1329",
      "r1331",
      "r1332"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1186"
     ]
    },
    "gyre_PayableToPropertyPlantAndEquipmentSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PayableToPropertyPlantAndEquipmentSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable To Property, Plant, And Equipment Suppliers",
        "documentation": "Payable to property, plant, and equipment suppliers.",
        "terseLabel": "Payable to PPE suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PayableToSellingExpenseSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PayableToSellingExpenseSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable to selling expense suppliers",
        "label": "Payable To Selling Expense Suppliers",
        "documentation": "Payable to selling expense suppliers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR merger payable, amount distributed",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "gyre_PaymentForResearchAndDevelopmentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PaymentForResearchAndDevelopmentFees",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Research and Development Fees",
        "documentation": "Payment for research and development fees."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PaymentOfDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PaymentOfDeferredOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred offering costs",
        "label": "Payment Of Deferred Offering Costs",
        "documentation": "Payment of deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PaymentOfDisposalOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PaymentOfDisposalOfSubsidiary",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash balance in a disposed subsidiary",
        "label": "Payment of Disposal of Subsidiary",
        "documentation": "Payment of disposal of subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PaymentsForExchangeForIntellectualPropertyRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PaymentsForExchangeForIntellectualPropertyRights",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for exchange of intellectual property rights",
        "label": "Payments For Exchange For Intellectual Property Rights",
        "documentation": "Payments for exchange for intellectual property rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Ordinary Dividends, Common Stock",
        "terseLabel": "Aggregate amount of special dividend payment",
        "verboseLabel": "Aggregate amount of special dividend payment",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Financing Costs",
        "totalLabel": "Payments of Financing Costs, Total",
        "terseLabel": "Deferred financing costs",
        "negatedLabel": "Deferred financing costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equity method investment",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "terseLabel": "Payment to acquire",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireRestrictedCertificatesOfDeposit",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of certificates of deposit",
        "label": "Payments to Acquire Restricted Certificates of Deposit",
        "documentation": "The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1196"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1196"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1188"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1187"
     ]
    },
    "gyre_PercentageOfAmountReceivedOnAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfAmountReceivedOnAgreement",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of amount received on agreement.",
        "label": "Percentage Of Amount Received On Agreement",
        "terseLabel": "Percentage of amount received on agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Cash and Cash Equivalents Reporting Currency Denominated",
        "documentation": "Percentage of cash and cash equivalents reporting currency denominated.",
        "terseLabel": "Percentage of cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfCommissionForSharesSold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfCommissionForSharesSold",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Commission for shares sold.",
        "label": "Percentage Of Commission For Shares Sold",
        "terseLabel": "Percentage of commission for shares sold"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfEquityInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfEquityInterest",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Equity Interest",
        "documentation": "Percentage of equity interest.",
        "terseLabel": "Percentage of equity interest"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfExcessCashOnDispositionsNet": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfExcessCashOnDispositionsNet",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of excess cash on dispositions net.",
        "label": "Percentage Of Excess Cash On Dispositions Net",
        "terseLabel": "Percentage of excess cash on dispositions net"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfExcessPreapprovedCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfExcessPreapprovedCosts",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of excess preapproved costs.",
        "label": "Percentage Of Excess Preapproved Costs",
        "terseLabel": "Percentage of excess preapproved costs"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfIndirectOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfIndirectOwnershipInterest",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indirect ownership interest",
        "label": "Percentage Of Indirect Ownership Interest",
        "documentation": "Percentage of indirect ownership interest."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority holders owned outstanding shares of common stock",
        "label": "Percentage Of Minority Holders Owned Outstanding Shares Of Common Stock",
        "documentation": "Percentage of minority holders owned outstanding shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority interest ownership directly and indirectly holds",
        "label": "Percentage Of Minority Interest Ownership Directly And Indirectly Holds",
        "documentation": "Percentage of minority interest ownership directly and indirectly holds."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfMinorityInterestOwnershipIndirectlyHolds",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority interest ownership indirectly holds",
        "label": "Percentage Of Minority Interest Ownership Indirectly Holds",
        "documentation": "Percentage of minority interest ownership indirectly holds."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfOutstandingSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfOutstandingSharesOfCommonStock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding shares of common stock",
        "label": "Percentage Of Outstanding Shares Of Common Stock",
        "documentation": "Percentage of outstanding shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfRestrictedNetAssetsExceedNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfRestrictedNetAssetsExceedNetAssets",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of restricted net assets of consolidated subsidiaries of consolidated net assets",
        "label": "Percentage of Restricted Net Assets Exceed Net Assets",
        "documentation": "Percentage of restricted net assets exceed net assets."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfRevenueAccountedSalesToDistributors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfRevenueAccountedSalesToDistributors",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of revenue accounted sales to distributors",
        "documentation": "Percentage of revenue accounted sales to distributors."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Short-Term Bank Deposits and Long-Term Certificates of Deposit Reporting Currency Denominated",
        "documentation": "Percentage of short-term bank deposits and long-term certificates of deposit reporting currency denominated.",
        "terseLabel": "Percentage of short-term bank deposits and long-term certificates of deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1189"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1188"
     ]
    },
    "gyre_PostClosingIndemnificationObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PostClosingIndemnificationObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post closing indemnification obligation.",
        "label": "Post Closing Indemnification Obligation",
        "terseLabel": "Post closing indemnification obligation"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PreMergerStockOptionsAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PreMergerStockOptionsAssumed",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails": {
       "parentTag": "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-GNI USA Contributions Catalyst stock options assumed by CPI",
        "label": "Pre Merger Stock Options Assumed",
        "documentation": "Pre merger stock options assumed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r475"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r948"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r475"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r948",
      "r968",
      "r1514",
      "r1515"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "gyre_PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PreferredStockWarrantsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Warrants Issued and Outstanding",
        "verboseLabel": "Preferred Stock Warrants (as converted)",
        "terseLabel": "Preferred Stock Warrants",
        "documentation": "Preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PreferredStockWarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PreferredStockWarrantsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock Warrants",
        "label": "Preferred Stock Warrants [Policy Text Block]",
        "documentation": "Preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PrepaidAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PrepaidAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid assets",
        "label": "Prepaid Assets Current",
        "documentation": "Prepaid assets current."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PrivatePlacementAndSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement and Securities Purchase Agreement",
        "label": "Private Placement and Securities Purchase Agreement [Member]",
        "documentation": "Private placement and securities purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of stock options included in other receivable.",
        "terseLabel": "Proceeds from the exercise of stock options included in other receivable",
        "label": "Proceeds From Exercise Of Stock Options Included In Other Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ProceedsFromGovernmentGrantsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ProceedsFromGovernmentGrantsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grants received",
        "label": "Proceeds From Government Grants Received",
        "documentation": "Proceeds from government grants received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock in ATM program",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of Convertible Preferred Stock and Preferred Stock Warrants under the Private Placement",
        "terseLabel": "Proceeeds from issuance of aggregate gross sales",
        "label": "Proceeds from Issuance or Sale of Equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r911"
     ]
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Proceeds from the sale of complement portfolio to Vertex",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equipment",
        "label": "Proceeds from Sale of Productive Assets",
        "totalLabel": "Proceeds from Sale of Productive Assets, Total",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options",
        "verboseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r20"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ETUARY",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of Pharmaceutical Products",
        "verboseLabel": "ETUARY",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r343",
      "r793",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r1037",
      "r1073",
      "r1115",
      "r1117",
      "r1118",
      "r1122",
      "r1123",
      "r1336",
      "r1337",
      "r1344",
      "r1481",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r343",
      "r793",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r1037",
      "r1073",
      "r1115",
      "r1117",
      "r1118",
      "r1122",
      "r1123",
      "r1336",
      "r1337",
      "r1344",
      "r1481",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "verboseLabel": "Net income (loss)",
        "terseLabel": "Net income (loss) from operations",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r229",
      "r232",
      "r245",
      "r251",
      "r262",
      "r270",
      "r273",
      "r274",
      "r387",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r636",
      "r648",
      "r650",
      "r653",
      "r654",
      "r683",
      "r709",
      "r838",
      "r863",
      "r921",
      "r970",
      "r991",
      "r992",
      "r1091",
      "r1092",
      "r1133",
      "r1285",
      "r1339"
     ]
    },
    "gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property And Equipment, Included In Accrued Expenses And Other Current Liabilities",
        "label": "Property And Equipment, Included In Accrued Expenses And Other Current Liabilities [Member]",
        "documentation": "Property and equipment, included in accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r737"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r212",
      "r860"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment",
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r737",
      "r843",
      "r860",
      "r1105"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r188",
      "r191",
      "r858"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r737"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1333"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1186"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1186"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r518",
      "r530",
      "r567",
      "r568",
      "r569",
      "r582",
      "r689",
      "r761",
      "r770",
      "r787",
      "r891",
      "r893",
      "r907",
      "r938",
      "r939",
      "r1001",
      "r1003",
      "r1005",
      "r1006",
      "r1008",
      "r1032",
      "r1033",
      "r1066",
      "r1072",
      "r1086",
      "r1097",
      "r1098",
      "r1102",
      "r1103",
      "r1117",
      "r1126",
      "r1334",
      "r1343",
      "r1452",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r518",
      "r530",
      "r567",
      "r568",
      "r569",
      "r582",
      "r689",
      "r761",
      "r770",
      "r787",
      "r891",
      "r893",
      "r907",
      "r938",
      "r939",
      "r1001",
      "r1003",
      "r1005",
      "r1006",
      "r1008",
      "r1032",
      "r1033",
      "r1066",
      "r1072",
      "r1086",
      "r1097",
      "r1098",
      "r1102",
      "r1103",
      "r1117",
      "r1126",
      "r1334",
      "r1343",
      "r1452",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r105"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party receivables",
        "label": "Receivables, Net, Current",
        "totalLabel": "Receivables, Net, Current, Total",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r1308"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1153",
      "r1164",
      "r1174",
      "r1207"
     ]
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "verboseLabel": "Redeemable Convertible Preferred Stock",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r525",
      "r748",
      "r749",
      "r848",
      "r857",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r967",
      "r969",
      "r1000"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "GNI",
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r748",
      "r749",
      "r750",
      "r751",
      "r848",
      "r857",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r967",
      "r969",
      "r1000"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r974",
      "r975",
      "r978"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r525",
      "r748",
      "r749",
      "r848",
      "r857",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r967",
      "r969",
      "r1000",
      "r1465"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r746",
      "r747",
      "r749",
      "r752",
      "r917",
      "r918",
      "r919",
      "r976",
      "r977",
      "r978",
      "r997",
      "r999"
     ]
    },
    "gyre_RemainingNumberOfFullTimeEmployees": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "RemainingNumberOfFullTimeEmployees",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining number of full time employees.",
        "label": "Remaining Number Of Full Time Employees",
        "terseLabel": "Remaining number of full time employees"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_RemainingOutstandingBalanceOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "RemainingOutstandingBalanceOfAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining outstanding balance",
        "label": "Remaining Outstanding Balance of Agreement",
        "documentation": "Remaining outstanding balance of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r469",
      "r477",
      "r751",
      "r771",
      "r844",
      "r1046",
      "r1047"
     ]
    },
    "gyre_RequiredMinimumTaxableIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "RequiredMinimumTaxableIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum taxable income required to support realizing the company's.",
        "label": "Required Minimum Taxable Income",
        "terseLabel": "Required Minimum Taxable Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Arrangement [Member]",
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development fees",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r1035",
      "r1060",
      "r1474"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1433"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit carry forwards derecognized.",
        "label": "Research And Development Tax Credit Carry Forwards Derecognized",
        "terseLabel": "Gross federal R&amp;D credit-related deferred tax assets derecognized"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1154",
      "r1165",
      "r1175",
      "r1208"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1155",
      "r1166",
      "r1176",
      "r1209"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1173",
      "r1183",
      "r1216"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r447",
      "r450",
      "r455"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of employees terminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Total restructuring charges",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r451",
      "r452",
      "r1335"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost And Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454"
     ]
    },
    "gyre_RestructuringLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "RestructuringLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring liability.",
        "label": "Restructuring Liability",
        "terseLabel": "Restructuring liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r142",
      "r854",
      "r901",
      "r906",
      "r915",
      "r949",
      "r1105"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r258",
      "r259",
      "r260",
      "r263",
      "r270",
      "r272",
      "r274",
      "r392",
      "r399",
      "r439",
      "r618",
      "r619",
      "r632",
      "r633",
      "r634",
      "r637",
      "r647",
      "r648",
      "r663",
      "r666",
      "r667",
      "r670",
      "r681",
      "r722",
      "r725",
      "r897",
      "r899",
      "r922",
      "r1514"
     ]
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r1086",
      "r1253",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r1086",
      "r1253",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r302",
      "r311",
      "r312",
      "r333",
      "r339",
      "r343",
      "r345",
      "r347",
      "r512",
      "r513",
      "r793"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from sales",
        "terseLabel": "Total",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r302",
      "r311",
      "r312",
      "r333",
      "r339",
      "r343",
      "r345",
      "r347",
      "r512",
      "r513",
      "r793"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Contract Liabilities",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r1036"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales",
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r1255"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r515"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1036",
      "r1050"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use asset obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset and lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r1104"
     ]
    },
    "gyre_RisksAndUncertainitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "RisksAndUncertainitiesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainities",
        "label": "Risks And Uncertainities [Policy Text Block]",
        "documentation": "Risks And Uncertainities [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r1254"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r1296"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r535",
      "r1250",
      "r1296"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts and Note Receivable, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r105"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Anti-dilutive Security not Included in Diluted per Share Calculations",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r638"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Purchase Price",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash Equivalents and Held-to-maturity Debt Securities",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock, Reserved for Future Issuance",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "documentation": "Schedule of common stock reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Provision for Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1442"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r1251"
     ]
    },
    "gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ScheduleOfDeferredGovernmentGrantsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Government Grants",
        "label": "Schedule Of Deferred Government Grants Table [Text Block]",
        "documentation": "Schedule of deferred government grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of the Company's Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1438"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r59",
      "r60",
      "r61",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted EPS Attributable to Common Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r1090",
      "r1434"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Recognized",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r430",
      "r433",
      "r434",
      "r436",
      "r794",
      "r1035",
      "r1069"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Carrying Amounts and Accumulated Amortization of intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1328"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories, Net of Reserves",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r106",
      "r107",
      "r108"
     ]
    },
    "gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives of Assets",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Life [Table Text Block]",
        "documentation": "Schedule of property plant and equipment estimated useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r737"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r974",
      "r975",
      "r978"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "terseLabel": "Schedule Of Restructuring And Related Costs [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r539",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r145"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r137",
      "r139",
      "r141",
      "r142",
      "r217",
      "r218",
      "r219",
      "r304",
      "r475",
      "r476",
      "r477",
      "r479",
      "r482",
      "r488",
      "r490",
      "r911",
      "r912",
      "r913",
      "r914",
      "r1072",
      "r1249",
      "r1288"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r1089"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1330"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposits",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r302",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r347",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r436",
      "r449",
      "r454",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r1057",
      "r1060",
      "r1061",
      "r1068",
      "r1120",
      "r1481",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510"
     ]
    },
    "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentExpenditureAdditionToLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Segment, Expenditure, Addition to Long-Lived Assets",
        "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r321",
      "r339",
      "r1060",
      "r1061"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r935",
      "r936",
      "r937",
      "r1002",
      "r1004",
      "r1007",
      "r1009",
      "r1020",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1038",
      "r1074",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1119",
      "r1126",
      "r1344",
      "r1481",
      "r1483",
      "r1484",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r302",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r322",
      "r324",
      "r325",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r347",
      "r1055",
      "r1058",
      "r1059",
      "r1060",
      "r1062",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r342",
      "r345",
      "r1056",
      "r1057",
      "r1063"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and marketing",
        "label": "Selling and Marketing Expense",
        "totalLabel": "Selling and Marketing Expense, Total",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Selling and Marketing",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "gyre_SellingAndMarketingExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SellingAndMarketingExpensesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and Marketing Expenses",
        "label": "Selling and Marketing Expenses [Policy Text Block]",
        "documentation": "Selling and marketing expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GNI USA Contributions",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "gyre_SeveranceAndOtherCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SeveranceAndOtherCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance and other costs.",
        "label": "Severance And Other Costs",
        "terseLabel": "Severance and other charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Severance costs and expenses",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ShanghaiPharmaceuticalsHoldingCompanyLimitedMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai Pharmaceuticals Holding Co., Ltd",
        "label": "Shanghai Pharmaceuticals Holding Company Limited [Member]",
        "documentation": "Shanghai Pharmaceuticals Holding Company Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of all equity awards that vested during the periods",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r539",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares Underlying Outstanding Options, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Deemed Issuance Of Options To Former Stockholders",
        "documentation": "Share based compensation arrangement by share based payment award options deemed issuance of options to former stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Options exercisable for shares",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Vested and exercisable- December 31, 2024",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested and exercisable - December 31, 2024",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options Forfeited and Cancelled",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options Forfeited and Cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options granted",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares Underlying Outstanding Options, Issuance of options to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Issuance Of Options To Former Stockholders",
        "documentation": "Share based compensation arrangement by share based payment award options issuance of options to former stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning Balance",
        "terseLabel": "Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r547"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares Underlying Outstanding Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted- Average Exercise Price, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r547"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Share Price",
        "documentation": "Share based compensation arrangement by share based payment award weighted average share price.",
        "terseLabel": "Weighted average share price of the Company (USD per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Option, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Deemed Issuance Of Options To Former Stockholders In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangements by share based payment award options deemed issuance of options to former stockholders in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Options Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options Forfeited and Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Option, Issuance of options to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Issuance Of Options To Former Stockholders In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangements by share based payment award options issuance of options to former stockholders in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r545",
      "r564",
      "r565",
      "r566",
      "r567",
      "r570",
      "r576",
      "r577",
      "r578",
      "r579"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplemental Disclosure of stock-based compensation expense",
        "terseLabel": "Supplemental Disclosure of stock-based compensation expense included in General and administrative expenses above:",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average share price of the Company (USD per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Expected option life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable - December 31, 2024",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and exercisable - December 31, 2024",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Outstanding Balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Estimated Fair Value of Option Awards Based on Black-scholes Model",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r144"
     ]
    },
    "gyre_SharesForAggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SharesForAggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares for aggregate purchase price",
        "label": "Shares for Aggregate Purchase Price",
        "documentation": "Shares for aggregate purchase price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_Short-TermBankDepositsMaturityDateRangeStart": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "Short-TermBankDepositsMaturityDateRangeStart",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Bank Deposits Maturity Date Range Start",
        "documentation": "Short-term bank deposits maturity date range start.",
        "terseLabel": "Short-term bank deposits maturity date range start"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_Short-TermBankDepositsMaturityPeriodEnd": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "Short-TermBankDepositsMaturityPeriodEnd",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term bank deposits maturity period end",
        "label": "Short-Term Bank Deposits Maturity Period End",
        "documentation": "Short-term bank deposits maturity period end."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ShortTermBankDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ShortTermBankDepositsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Bank Deposits [Member]",
        "documentation": "Short-term bank deposits.",
        "terseLabel": "Short-term Bank Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ShortTermBankDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ShortTermBankDepositsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Bank Deposits",
        "label": "Short Term Bank Deposits [Policy Text Block]",
        "documentation": "Short term bank deposits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "totalLabel": "Short-Term Investments, Total",
        "terseLabel": "Short-term bank deposits",
        "verboseLabel": "Short-term bank deposits",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r1281"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-Term Investments",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1011",
      "r1012",
      "r1040"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease expenses",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r1104"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r249"
     ]
    },
    "gyre_SinopharmGroupCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SinopharmGroupCompanyLimitedMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sinopharm Group Co., Ltd.",
        "label": "Sinopharm Group Company Limited [Member]",
        "documentation": "Sinopharm Group Company Limited."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SoftwareMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software [Member]",
        "documentation": "Software."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SquareMeterAreaForLaboratoryCenterUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SquareMeterAreaForLaboratoryCenterUnderLease",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square meter area for laboratory center under lease",
        "label": "Square Meter Area For Laboratory Center Under Lease",
        "documentation": "Square meter area for laboratory center under lease."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SquareMeterAreaForOfficeSpaceUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SquareMeterAreaForOfficeSpaceUnderLease",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square meter area for office space under lease",
        "label": "Square Meter Area For Office Space Under Lease",
        "documentation": "Square meter area for office space under lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAdministrationOfTaxationChinaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAdministrationOfTaxationChinaMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Administration of Taxation, China [Member]",
        "terseLabel": "PRC Tax",
        "documentation": "Designated tax department of the government of China."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State Income Tax",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r205",
      "r302",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r347",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r436",
      "r441",
      "r449",
      "r454",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r1057",
      "r1060",
      "r1061",
      "r1068",
      "r1120",
      "r1481",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "verboseLabel": "Series X Redeemable Convertible Preferred Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r217",
      "r218",
      "r219",
      "r251",
      "r281",
      "r285",
      "r294",
      "r296",
      "r304",
      "r305",
      "r387",
      "r460",
      "r462",
      "r463",
      "r464",
      "r467",
      "r468",
      "r475",
      "r476",
      "r479",
      "r482",
      "r490",
      "r709",
      "r911",
      "r912",
      "r913",
      "r914",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r934",
      "r948",
      "r971",
      "r993",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1249",
      "r1288",
      "r1298"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r98",
      "r102",
      "r103",
      "r201",
      "r235",
      "r236",
      "r237",
      "r258",
      "r259",
      "r260",
      "r263",
      "r270",
      "r272",
      "r274",
      "r303",
      "r392",
      "r399",
      "r439",
      "r492",
      "r618",
      "r619",
      "r632",
      "r633",
      "r634",
      "r637",
      "r647",
      "r648",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r681",
      "r711",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r722",
      "r725",
      "r744",
      "r866",
      "r897",
      "r898",
      "r899",
      "r922",
      "r993"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r935",
      "r936",
      "r937",
      "r1002",
      "r1004",
      "r1007",
      "r1009",
      "r1020",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1038",
      "r1074",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1119",
      "r1126",
      "r1344",
      "r1481",
      "r1483",
      "r1484",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r303",
      "r725",
      "r793",
      "r909",
      "r934",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r948",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r958",
      "r959",
      "r960",
      "r961",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r969",
      "r972",
      "r973",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r993",
      "r1127"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r535",
      "r1250",
      "r1252",
      "r1296"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r303",
      "r350",
      "r725",
      "r793",
      "r909",
      "r934",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r948",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r958",
      "r959",
      "r960",
      "r961",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r969",
      "r972",
      "r973",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r993",
      "r1127"
     ]
    },
    "gyre_StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statute Of Limitation Due To Computational Errors Made By Taxpayer Or Withholding Agent",
        "documentation": "Statute of limitation due to computational errors made by taxpayer or withholding agent.",
        "terseLabel": "Statute of limitations due to errors made by taxpayer or withholding agent"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StatuteOfLimitationDueToTaxEvasion": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "StatuteOfLimitationDueToTaxEvasion",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statute Of Limitation Due To Tax Evasion",
        "documentation": "Statute of limitation due to tax evasion.",
        "terseLabel": "Statute of limitations due to tax evasion"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StatuteOfLimitationDueToTransferPricingIssues": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "StatuteOfLimitationDueToTransferPricingIssues",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statute Of Limitation Due To Transfer Pricing Issues",
        "documentation": "Statute of limitation due to transfer pricing issues.",
        "terseLabel": "Statute of limitations due to transfer pricing issues"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "StatutoryReserve",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve",
        "label": "Statutory Reserve",
        "documentation": "Statutory reserve."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StatutoryReserveFund": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "StatutoryReserveFund",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve fund",
        "label": "Statutory Reserve Fund",
        "documentation": "Statutory reserve fund."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StatutoryReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "StatutoryReserveMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory Reserve",
        "label": "Statutory Reserve [Member]",
        "documentation": "Statutory Reserve."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1157",
      "r1168",
      "r1178",
      "r1211"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Assets acquisition, shares issued",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r142"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of stock shares, issued",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r55",
      "r98",
      "r102",
      "r142",
      "r471"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Common Stock upon ATM program (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r97",
      "r98",
      "r142",
      "r911",
      "r993",
      "r1014"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options exercised (in shares)",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Option exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r97",
      "r98",
      "r142",
      "r551"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "verboseLabel": "Issuance of common stock upon acquisition of F351 Assets",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r98",
      "r102",
      "r103",
      "r142"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock upon ATM program",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r97",
      "r98",
      "r142",
      "r922",
      "r993",
      "r1014",
      "r1133"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options exercised",
        "terseLabel": "Issuance of common stock from option exercises",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r98",
      "r102",
      "r103",
      "r142"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Gyre stockholders' equity (deficit)",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r102",
      "r103",
      "r131",
      "r950",
      "r968",
      "r994",
      "r995",
      "r1105",
      "r1134",
      "r1289",
      "r1320",
      "r1458",
      "r1514"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity:",
        "verboseLabel": "Stockholders (deficit) equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StockholdersEquityDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "StockholdersEquityDisclosureLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity disclosure.",
        "label": "Stockholders Equity Disclosure [Line Items]",
        "terseLabel": "Stockholders Equity Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StockholdersEquityDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "StockholdersEquityDisclosureTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity disclosure.",
        "label": "Stockholders Equity Disclosure [Table]",
        "terseLabel": "Stockholders Equity Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r77",
      "r201",
      "r202",
      "r236",
      "r258",
      "r259",
      "r260",
      "r263",
      "r270",
      "r272",
      "r392",
      "r399",
      "r439",
      "r492",
      "r618",
      "r619",
      "r632",
      "r633",
      "r634",
      "r637",
      "r647",
      "r648",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r681",
      "r711",
      "r713",
      "r717",
      "r723",
      "r744",
      "r898",
      "r899",
      "r920",
      "r950",
      "r968",
      "r994",
      "r995",
      "r1018",
      "r1133",
      "r1289",
      "r1320",
      "r1458",
      "r1514"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r250",
      "r474",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r489",
      "r492",
      "r672",
      "r996",
      "r998",
      "r1019"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split ratio",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "gyre_SubleaseArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SubleaseArrangementMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease arrangement.",
        "label": "Sublease Arrangement [Member]",
        "terseLabel": "Sublease Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SubmissionOfTheNewDrugApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SubmissionOfTheNewDrugApplicationMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Submission of the New Drug Application",
        "label": "Submission of the New Drug Application [Member]",
        "documentation": "Submission of the New Drug Application."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r754"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r754"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r754"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r754"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r754"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries",
        "label": "Subsidiaries [Member]"
       }
      }
     },
     "auth_ref": [
      "r1391",
      "r1463",
      "r1464",
      "r1465"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Present Value Assumptions used in Calculating Present Value of Lease Payments",
        "documentation": "Summary of present value assumptions of lease payments.",
        "label": "Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1439"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1269"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards available to offset future federal tax liabilities",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "gyre_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Credit carryforward, expire year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technological know-how",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1329",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary Equity, Balance",
        "periodStartLabel": "Temporary equity, Balance",
        "terseLabel": "Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r462",
      "r463",
      "r464",
      "r467",
      "r468",
      "r580",
      "r852"
     ]
    },
    "gyre_TemporaryEquityConvertiblePreferredStockConversionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TemporaryEquityConvertiblePreferredStockConversionShares",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Convertible Preferred Stock Conversion, Shares",
        "documentation": "Temporary equity, convertible preferred stock conversion, shares.",
        "terseLabel": "Temporary Equity, Convertible preferred stock conversion (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TemporaryEquityConvertiblePreferredStockConversionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TemporaryEquityConvertiblePreferredStockConversionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Convertible Preferred Stock Conversion, Value",
        "documentation": "Temporary equity, convertible preferred stock conversion, value",
        "terseLabel": "Temporary Equity, Convertible preferred stock conversion"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TemporaryEquityIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)",
        "documentation": "Temporary equity issued during period shares acquisitions.",
        "label": "Temporary Equity Issued During Period Shares Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TemporaryEquityIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions",
        "documentation": "Temporary equity issued during period value acquisitions.",
        "label": "Temporary Equity Issued During Period Value Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, par value",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r52"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Temporary equity, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20241231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary Equity, Balance (in shares)",
        "periodStartLabel": "Temporary equity, Balance (in shares)",
        "terseLabel": "Temporary equity, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Preferred Stock upon Private Placement (in shares)",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Preferred Stock upon Private Placement",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1196"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts and Note Receivables, Net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r1307",
      "r1309",
      "r1310"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1224"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r473",
      "r488",
      "r671",
      "r706",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r867",
      "r1093",
      "r1095",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1106",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1448",
      "r1451",
      "r1452",
      "r1453",
      "r1455",
      "r1457"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1227"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1229"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1227"
     ]
    },
    "gyre_TwoThousandEighteenOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TwoThousandEighteenOmnibusIncentivePlanMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen omnibus incentive plan.",
        "label": "Two Thousand Eighteen Omnibus Incentive Plan [Member]",
        "terseLabel": "2018 Omnibus Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TwoThousandTwentyFourATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TwoThousandTwentyFourATMProgramMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four A T M Program [Member]",
        "documentation": "Two thousand twenty four atm program.",
        "terseLabel": "2024 ATM Program"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TwoThousandTwentyOneATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TwoThousandTwentyOneATMProgramMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one ATM program.",
        "label": "Two Thousand Twenty One A T M Program [Member]",
        "terseLabel": "2021 ATM Program"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "TwoThousandTwentyThreeOmnibusIncentivePlanMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Incentive Plan",
        "label": "Two Thousand Twenty Three Omnibus Incentive Plan [member]",
        "documentation": "Two thousand twenty three omnibus incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r262",
      "r263",
      "r264",
      "r265",
      "r276",
      "r348",
      "r349",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r438",
      "r439",
      "r443",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r707",
      "r708",
      "r721",
      "r722",
      "r723",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r795",
      "r796",
      "r797",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsAndHeldtomaturityDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1080",
      "r1475"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1223"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Unrecognized tax benefit",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r605",
      "r1089"
     ]
    },
    "gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increase (decrease) resulting from tax positions.",
        "label": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Increase/(Decrease) of unrecognized tax benefits taken in prior years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase as a result of the GNI USA Contributions on October 30, 2023",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase/(Decrease) of unrecognized tax benefits related to current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r1089"
     ]
    },
    "gyre_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r185",
      "r186",
      "r189",
      "r190"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "totalLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "gyre_ValueOfAssetsExceedingDepositInsuranceSystemLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "ValueOfAssetsExceedingDepositInsuranceSystemLimit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value Of Assets Exceeding Deposit Insurance System Limit",
        "documentation": "Value of assets exceeding deposit insurance system limit.",
        "terseLabel": "Cash and cash equivalents, short-term bank deposits and long-term certificates of deposits exceeding China DIS coverage"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_VertexAssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "VertexAssetPurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex Asset Purchase Agreement.",
        "label": "Vertex Asset Purchase Agreement [Member]",
        "terseLabel": "Vertex Asset Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_VertexPharmaceuticalsIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "VertexPharmaceuticalsIncorporatedMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex pharmaceuticals incorporated.",
        "label": "Vertex Pharmaceuticals Incorporated [Member]",
        "terseLabel": "Vertex Pharmaceuticals Incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1192"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.gyretx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "verboseLabel": "Warrant Liability, Noncurrent",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1124",
      "r1125",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term (years)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "gyre_WarrantsSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "WarrantsSharePrice",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Share Price",
        "documentation": "Warrants share price.",
        "terseLabel": "Warrants share price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted",
        "verboseLabel": "Total average shares used in net (loss) income per common share, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r296"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r296"
     ]
    },
    "gyre_WeightedAverageOfPreferredStockWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20241231",
     "localname": "WeightedAverageOfPreferredStockWarrant",
     "calculation": {
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20241231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Of Preferred Stock Warrant",
        "documentation": "Weighted average of preferred stock warrant",
        "terseLabel": "Weighted average of Preferred Stock Warrants (as converted)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1190"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-24"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-30/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-20/tableOfContent"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEEE",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEEE"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "715",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477317/912-715-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "25",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480270/815-25-40-8A"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>128
<FILENAME>0000950170-25-040279-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-040279-xbrl.zip
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MA/TC *S<SE[_LOR6@<Z\;'>Z+D_^F#1#V 6_Y^.0VZ6V6692<D4]42)!RR2
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M"Q"=NU]^0A5GN^LU"GCDH%=YMI'/__RH W(T1/6B_^ZHQ3?BRB,+)KCUODO
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M&?9@(;>]:^H5X]:UQ.JA:"..*I>R C$H4 Q:$4D(\'1M@3-%FTORU4Y-S3;
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MPO_(1%S0F106;9'*JBRKBR]??]6LC<?#QQ>,5]XGI0B+P1$IT-E!]:7"?::
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M>Z/N)"\3+/=M2E7+95(9>+A3E,B4(PDA6<(5+$ICM<R^NG7YQ0KL.C1S'X\
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MW'K, # KCF>62%8>TW-[#IR 4N)$X9X%ID*N5IWY9L\4*^"26IB0F<6:GA%
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M/@*_Q[Q]TF;RKO4G/UYH"33DXKO_LG,R&7=_^:'SHXYT("7+[.<_<Z\4;X^
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M:!_92-VU2EV@TX/)41Z<9M\.\BCE]!ERO<3;/P*K,@DAC1,D9H'N0YCSSI1
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MO!E\ASJ:^7' !=\ZTQ^ TP!ZG6 >EG5CUJS!9U"4N^^WULAL,-0'ZV& 6A(
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M3;3W)1 +!WUAK8,+">,KAK"7?1&PO?.V;L!KQ>"U.7ZM&;PV4=Z7P"LN#A2
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M",RC4\BH@U"E^"W&3%\MLDJ&C'F8Z^C]A7%.6X6>2J^LP-N3?E7R]II3HGU
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MS6_A@N29BLB#C=G*:QJ[DNMF]!$<KWD>(XXG#FO;1;F9ED]VN+AI/+K&@WJ
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M[0479T:%@RC@[<79W:OMC5K&#0@VWJV%PCX2!ZREK8=)N-4--#+;]\5/#];
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M3UITT9S_0X^Q5/"09F#DJ]>5*J3JBR2[HEM>F5I8XSO3 )I.-5OX-&EKX5M
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M9 ")X@9HK0?IT#S(26]P;.#"  @M^O%C'7ZZ+X&!#3K].[#%!@7)OPQL,>S
M%AW8XEXJGU6DQU:-_ZTH78L->0.B:DNH_"OF\X 5:CB.]5*T[="G.OZA(3$4
M2&A ^;L06.=#?UN<_9M+7PJ_0&6)3[FN*?%N&#=K8SK9>[BS_],O*2(W.JO
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M'Y/-%.*XI5/#]O'JPLX/+M/QX^-&7U#!;.5O)1>J%UK^@C+LFMN5RZYA>6(
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M*S&$HJ,$Q3==S#/3Z#N4W_08]U,W]KZT]Q)RZGD<;=$I*7$]_D).<;JMIKL
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M<TO89<[,FF9R++:]G+3(,0^&[HCM!\>."_>&F\:>22WEV_4I]_D1](2M=_4
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M1[_I@W>^\8B)C'$^;K7W(:P7W_WT,L2P@'));F0IP)@S4=W[\R.GX=."')Q
M9?9I0T6?DTUL =27NIN8G(<3=+>_>A-&Y\,>F%<-\TSI^X?RE1(RJS7C?*QZ
ME]D\WRW6SGN^N?")H(R.<T]:K&#8=J5(3R+H4IG0=Z$0+DT#2$E"=)]W#5@[
M7^^P(,^9IN2DU#RO\VJ_4XR0)LS(RD=9NI'>+H3/%HD!]MG/L\L=F&3IB>'W
M;VB1UHS5MQ]()V5-41N_K7\2)+C[+0;TX=<)]/;)':A8P)JZ7G ^6-B03Y[=
MA';S=;EKFQ-K2:U:*L911<$N#CTU^"D$$3-<%$(?@=:;@EF=<2M. $L6) 2&
M6<$\:[6#@C,N;".3@+P2P>3[QC+BZ^ ](_&GT&X:VY"_PY!;:BV&&KCO?WR>
M@MM_88!M@'W)!HK099%A:7E+CJ;-(I&5-&U'BO8P;FEISB!FZ?DOGS_SH4E_
MO5)'<6@PO04@"Y#(I7ZF-S'\FMT"0.I(?)/$%6!01W*S0Z 5LI7EY\XJ_/IJ
M%Z5E70(<XI>X<KQ.;)NGP=A!,PM3""S&I9-%8$STX[*,;QC8#$:JO@TDZ5(B
M-WSM1^H30^(-Y7="=&@X*/I2)5<(N_J4<S+^7@H&\J5C[LAF0?KN/'O9; X7
M0\H,U?E G9UKS]!"A>[VAIN$A%_I.>(E%"R^X>;!%']P<NC M(NRII6V;B.8
M%,YF6?<1C24_FQP"Z5?CWR]B>'@1IHZ![^HB@->#>[3N^TZ'H@=SY7:7X-K[
MNL)!5TTNJX;B#%OD-B]1PTB36I XX9XD_^KQO(,6-/G(0@MTQEL%G;;W8YLF
M BJ 0^ \>U;K(K,8F?GGMBULAP:3XNV,XKT*ZXI^)Q']BI^J?Z:A-<2*@T%L
M XJ!*,$;-A7>"?@UY4=FE? &- Z9(>9"RF:8SWHR53XY4R5P"]DFL.!</MR(
MVHY'G02_O6G'\8F)+^!&U$P[BR,J1OWEX&O&.V<<7^>RH2228:+3#A3]4TJ0
MQHYN4@F3R:^E(HA]6I*"C6B"Z&>8CU4/'<[K6+U34T,"JQQ/SBIW?8%6IUOX
MUD4J%L#@A/Y-.;**,U0=;]T"5<?<ZZBAMV^U3++N_E.:"@XS'UV17"K]&2E+
M"DO4C?U> *\%/7QSGOW<2,:27D$]$*TH,9><Q^ ]RVMKQQ<FO/*;LJI\BY+X
M+>7930N9#W(KZ,K$+)%F6]9B1.1HV'UQX=C[SXAMZOCE8P'X)4$ ;F*UA(FO
M<UY06GJER_?;RQ3PX6A>W[Z*GQ[!7;FJ<'&+,F;5"/3)NDA^9]O]%DW+>4FM
M*"S<LF1B4MAX6T FFKY#SS<N>;$RJYL23&B<I][;E7Q4QB</O6&3OWT1-\GU
MDPL#_L 0S*MA)! M'_JM,4\(6FQ:RH\FY/PG'+>K:HCBO69CE^.#42UST 6)
MI!*?TD*# @Q6%SJN/N_Z+=H(FBIF  D+\C!8TXY"B+^_>CYPN 6'H][TV[AE
M_$4B94&I;(0S88Z1*BQ;E?^.H3*=TP:<H":A6P0KOU2=AL:5OKDE.0?#4.AP
M;:6=#$<@O)EA2E=\Q6 -%&A7*HPTQYY0"VFN0T"7!Y$O@2?=N)VR"D<Q6QJL
MI,5F_L@ HF:&DP1([1MARN4:JF"7,!@Y'E ]XHIA11"1@%TE5?9R3=2<P2*Q
MWM\\XG5[6XQ\-^L,Q@;$LQ??CA1;1.4:\8NJ5^,Q:_/R/ >'U=GS.EIOM<,7
M;#NBW'G[NQ.2I3PI&0D0,4R7;V9Q*'7!A:['W[]U\0QD9^06V9;.&=5>C!H_
MXN'TCV^<=*\I_\_!Q@^6D.P ;P_!0N<1[!!)E,!F(FV5W%B9(_OY483LDY:\
M40^<+)^C.L[(P0]*X0Z."583P5#S11!)6>+ =W:"?G[V V_;;3\G=8CR[,XE
MEBX=/Y-/K_@V:")BK4!.X,U,_>LGX.)O RX^FH"+'PUP\=-2!3^,%M1QIW=/
MDQ$,1S9BT!M*32N8(MNUI,2T"!N1E&O75OD6$8BY4Z)T5PQ9-4YXG4_,&XR!
MAH_/'S_^\K/AK$Y@S?Z,?#AW%KC_M7%-IL25"'-*K3+V:(GZ JECX+X)PIFT
M'_J%'!/<216$KQ,E0;QR.Q@J#/'@0%LMIK[8SQ*<9<)]]EMF6=%T))S)XJG0
MX1X$2?F\:]JM<G.2!T6;I^PV0]9.]V;1.AMXEI5+H/2X11JG_=!+',X%>8K\
M3+Y4%+S-NR[UDXY:2B/[A=]SR27E7W]Y?O_A@T]D"TUG:O1,7;SE3%GHA7N0
M<-:STF93>G)HRVZ-6(:^ES*=Y=[OY) %YMTJ:6!U^ %JE0PW/6G%7%]"<:X^
MOD4#:-\O]E%%M:^A#GX''UI7V+'U-4D667<'AU2HY.B,(H$M7TYG:#I#O_,,
M/?@M9XA36_2+T5,TLU;(%0=;5@X<?]NU6E_PX'"<#D '\)89!73 DC"2JY<[
MT.Q<S7VV&*K"X11DA@Q=,7X,H_,[<B(#/^4!50(,08Y]TJD_F],,:!V%F[!R
M@Z%F=GPM*NJ+!.-PD*4!C3-[,,@=C!U\4@FK/P4S28<%06/KR.NCUV,@L'>'
MMPZ"G4E<&"48B+LN6_%_8*0M,\RYZ;LA^JE9+/KV/%,K=J9_7,A.5QDRRCV%
MY/T\;M'>]=Q)%^U%]A: XQBW*$,(%4RA$-98SC><9T_[%N%7S#?DX/7\>,P<
M,\H*Y %?:4K:':(X8E);.HB@G<4CKUHT=4RPB#GX4969/_=0O$'N(^<^)QPV
M?R.P#)&2?8VFP=L=X^K$AF?I<9Z])&.A@EGLH^\+-NS')A\5?8T]2,G,O5&0
M7+J:Q;'[<A>"^QW;Z2/!>\59R',D3O(8&XW2-'%I<T(BC.+L9:CN!MI@[AR:
M/W?-@IF89)"^]BS]MN-0\,U"4WV: =P@N/!:?)X4I2?$4)P! ](-<:G5X4D)
MQ=[#R#K29)9E0*>R51N!.%-H9 #W?=(RZ]-.^UXFTF>Q;AI (<E!MO-D%6HS
MP1A*NBH/32)2C&L,+^,LW0B!^<T:Q^G8"&5WD!KU)2UTB("/3,ZK*0WR\@U:
M>I.33UYH_2D MKK]T^N$7TU^*^4>0Y:J@N0Y%W]DOV+*"H,^,FEMB#XZ\43(
M]]Q4,F5JD%'D++ON@/H\2I>-D9X+_(Y>3]\EF4+@=P4#HITBL7AB(QI=.'\3
MVF($60W8]$*FF;9W268LK1;?(FI)',67'R0G1UGV'*G411<(9?CW>#;ATMX*
M6F[A"A")#YJ='.0OF;_;-%W(P#('"&D^+"^M'$U$W 46_)".GO=;GM0ZXC(4
MD;G[ H.(*0R,63BWZ017'/V@=K 8\E:3M4,L ^T'O/N\T[XGO ":/>?)!$G.
MH..\+<81["<@R2>3^^1"V2^'(/.? S;W:<"%G6PATPEHZ&E7?V"SQ)HX!F=K
M0.CD*^>'I3-);ZD8+_:.,B0NCSFH"$JKDL2==442!I',+91C,\J<Q!SAW:[=
M#[J6!18F;GJI@/C0@&P,M0-/[5T@*3W@BF,_0M4_I*\2-1KY(R'=,6F53^_\
M_8/M5X]#*MM%OY&2PFY00L &M*!$8[/2^>++;%FV9/)*ZH^W7/Q#061FW0;&
MO;7SGC&8OI:&=SD??(0[^ A64B5*8SVZ=R]S)!*:O7-)S,-_R*=AN2RK4CP/
M.3EB.HDIRH@U_Q-8A,F=?7]QX3Z3V:YSJ>!2\-JZW*K!#K(;,H8/KBJ%?F[X
ML9U_CGA@4*E]O1%;WO<RY- M"X'! !(I@6AHBS,<_O<>4HQ,;15U"*9,WD]H
M[@%IV2W:DM.J S8 6Q<N^+OF>H<MWE'AT)Q/P;'B)$6%M6-#&IV0.7/#G:5X
MWTZ=AMB/,5&9:V=>",O1-'*@^O5B$)Z,31;8UG]XR/(O\B3HE(76.6G1U*K-
MF=#OX&'YZ;3UR<[5"I?<M8ZW^^BLY"AHEF[I;NQ9+N[=FY$ X*>]+HM>.99'
M/&M0%<:/UCI9= !)NZ9F9T>B5M'AXSY#W-12JV*@8992R\)O"1TR^ZW6N(1N
M6:JUK$G3HNEV!YIB L_=.?#<XPD\-X'G)D/MKAAJEF'0*%PG.E6Q'/LL,#>K
M5Z#YJL=:2ZI()JO3#Q4 71*TU,K'+Q_"!T(!;UR1&>519!0K0DG(RP,0Y&;M
M5%$/-'L7*9[*$_AR?&Z+:W>AV>ZU\P;<JT@=J\_CS1FN*XX\M3Q8")+9LF6!
MVEQRHE*CUC093AS.#J9I 6>XDC$,7RNEQFXLDXPO&#PWJ?0F-HRLLTC@$V ?
MCZ?<(1T6S_<71%L'"XXQ^=>*E%MJ"9$-Q5P$:D.=%?2[]5O7EDW>5:L434FB
MTS>+6#618:(/H/TSL2-HE<G4_*EA6I#%.NE9R6[MQN6U\4K)Y:&^ 851S.+4
MA;@LAVMI8'LT20=WNW1D/+Q2\FW;LN$8JHRN['Q1#^AW3*(KW]@D_&WMS29/
MJZD%;H$>U0T_U7TFF-UHI^B@8J%W)0Q/-,Z+=R['>O.6NUR/%B6'_GRP/(N"
ML_ (5D<\%;Y">6\PL7(X.ZOD9J>C+5?<_7&BP;KMA[Y%!?.MR*#0E58D9A E
M(:W-[H/EMMGS'^=0E_8 ,7*I[!(6HT'BG.D3M!!NX)ZJDUB&$GXF?=$D54HB
MI,=3L8DQIWL[6J3V_4^#+ VGK2*V=)^"IT/;[;2VT3>M3;%9*D-\U-*0DT81
M=>G% 3 5\W<M^F\'%+P5,C"=ZT_N7-L)8]/#;*>R3:P(1NR R5:J7Q$+$LI;
MX4"*E(B1K"1X&(87RUD.@RR:'OPLRH&V<3Z"L^II/'2*9HZRDG^ZV?2UUWC@
M[9HI3YSTZ]9/T/NITC,:MCDPDH@F!2HM-&ENRX7"E'T=0.B-8&#0EJPC?*\Q
M%4TF@ $80-*-46KNFJ8ZA>#X">RB,J(R9OMU*?"'(=0@)V%^[2J)C G([+"!
M3,9$._1V :9=[^7]\9!@X;L1_A?:LP7(_$P&SHZ,Q4Q M%B. 6@)S. -*/"2
MR+'(S#*OXT;G'3LD#'/WE["*$;,/W<(5J.M3.3#-)$@L!>&%5O?R_CSF_W1K
M/AISD_O,?>KI 7!#'RN,H&4&>P/RSVRY]+:=NG]CG7H8Z+/S=F=G:YU>CV;G
M"G<$$&:3OQ9S4N QIW $)NUQ<JB#5X/HP!/=+AF76\6$-!/PX*Z^XSNT0'^"
M'/A%8AW"B=8L#^)AAZRN/RML'3 YSFD>D)O&4+L#N$*$*'M;SZHR3M+"M&-F
M/E7' @2HW X1/-;(/LY&=T.\S^FWDAL=7)'W9"N!F%OP>:Y=2+-:0Q".N#TQ
M4QYG^^:#ITY+R6+@ ?@&C\PNJM)I^EVECM^ ADVC49%)*]W9$VM7HEY @(20
MC&%)FO9@HM[OE<R8!FP&ROP\>X:%:+K!A-;YM5,\N<1H$A2'WSF^D9F1"EGP
MT-OENIL&'N&Q%YU&\DS_%R'4J%";=7(?6;^;AJW[$/P2"XI71Y:7_% GQE58
M*>-4/\^^NZ:GE7TP> (NS1J+EX:GHMU?@I:^$OI<F!Q%A)N-S:>B<9I@%G8]
M/4 >->MYC.(RJ<ET^>2D]K, UE4[6Y(F6OA6[GBG<96M[3$QQB/!Q'L(B&03
M"/YRDRL[M==W;1Y=-R/OA:<HM>\D/_)>!AQI0V R-"#"DL''&\K,8V8Q<)=+
MW5%,KP[?*Y(T0OW%"9U0/.CO%&'JR*N^=B1E.'*T1:57OF&'1IG$DDG+@$%%
MJ,_,_C13EQJH)?@TL?)+_'/SV\672?WQO,Y7PNVV<8MU7I?=)AD(@0=CPT")
MDO6X0'$G0RT4(F.,\P9V$3^.=DZ>\J 'OO/!BL7ZMG/NM5957VO#1]E/]C82
M?>DW'Q.2%B95(]W/KUIG9B^:(RXC+T0YQ2&3^5HLRBK00?G=['>L[W+$>7?-
M/$0[-C4Q;#B)A7KA[4M %^2U;P)0T5/HZX/;?CJ(JTJ)PT%UP"2?3UL^WX[;
M\10EH:_:?/&:O$J/N9IEEXN%J[BPNL@N_<E\;GF_%[R_9@FB*[J>-]ZWP*A8
ML<<K;AVQSY[KV9K037<=W?3EA&Z:T$V3+C@!6_T_%OU3]'#:KZ?F6[YB9 /;
MOH[95MBN];Y2# 5?NVIK 3M?>!K!J\ETARD.9TT1#1OG(FI8C6:0N6]( DZ"
MA6LP"[+)5TP"!3\ULIH26#X[-GM%01QBU2V;RT[,TIT!OD03KHUF(3"S<:EJ
MX<@=E':H ]<J B;U-<JU)?E;<>N_T%3"CWE^;,8<]0DNC5 :IMVSS NMK47$
M07 Q0LJ7#$ 1X@AQKQ2!8O!'=M)L91.@810,]-4#H:B "T6BA_#3BN@["O&K
M4GJ&=!\D?J<4)N1'UB;U0WUT,A2\H$;%)P4E@AP5?_M@6L,QQZ9BGTX"W'%S
M(XO)'L W%=_H.3IL!:.<:+=8NZ(/S=D.PH+N8([1;<(#,AY1$OX"Y7S+5;(]
M1Q!"?C(>,,E%$F'?Z/2Y[TJ]#TENW_5ZV"G2-TSCJJ<N#=?'$>+;%Y23=KAM
M$V'@FDXFS;1I3\VDN8Q!FHD],<!30^2+)A6@CT!\I'<8&0Q=9$HD9@/K"@M+
MSK(;!L%XWKD,JHW-&_0BV/"O-MJ0PUCPVD''"A6V?-L-8_B+,E_5#:=I6XO*
M>H";%>-Q2E8!3*(50YATR.64DY;;;#FT*9&<.!B*/H%]NP@62IH('H=%F741
MBA!'%QFQU-1H5*S^Q[I)?Z>D&@L%WITEFM <MRGHI&_+P".("*<%<9J('*3L
M(&[X@K<X3"0[ZH!!]U8QRD[H:[!<Y,4UB3J0OH&O,W-O2LF8>&G6J0/"A=9L
MM-H^#\DH97]W #+*T^RL*L4G@)H!>L4CVS&S=W&8>F;1A!3*%I#+A6I=(O$E
MNKXE+U@H3XMM4]9AF7UQ,K*NKYV0/-+K)D]M%S,&*F6I0'*'DT_N5K,C"QHH
MKNKW(Z2WEIZL6*6.6R>#YKO4\C!!%;]S<M%=28VU4"RML"YOFG9>%EK[0/_
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M\;QJ%J\C-*'8>J4TT0V]8<)R<82/XVMDF.X\7V_G7:YXG+>\KV [?TA3[L0
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M+QXP=&T3P5B_>B'=#0%3YT;IC:S<_JVK-M.B R1L,VZV<"T$U0<.@K?WA9.
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M(\;,/@>Q'IMSTH1=T)FY2'U5#S_DN\7Z[-?\#:U<=HG>X2SZ3&-D^4:C3!*
MNKJ<T53J%7>#\#UEB['PU$HW=E2BFVL? JYHHGG(5Q&*Q1N+$: SU#?]+#TY
M!@8FM$&_0P5SH^7. Q+'>"*SB,49O0<!0A-2*OXB.K&^?B[&8)M2O?SYB5>J
M'J0",W9_GOUCVPQF0 N;M'P=J7>S.4:,2WJKB-V*2]>@GVA@>DE68*;WY\G:
M]6-KJDG86OK/"EQ(-P/O#Z[%0R!$@;W^:5_\^"18$,*MA?0P'2@4L,7T6WYR
M-%+K2Q,2-R!^&]"C3#_$)%RRQ+;"]GL] VH(\2EY%=WQN^B.WWFZ[FYFBZ.0
MRF/;_Y>6R\R^;9K7OF#O^7K?E8LR5T]';0=:ERXTYACRCHT_.&BP=.</GKOC
MBO^]5!J6M'_S>=19@Q9\P-U)YP'NB;>:K)U,9 IAKG6_<2TJ,]<NKVBE2E@O
M29M)OPNC0K]!;>([GLL SM+ELJS#,T2L'\G3XJ4U4JS'VZYRQ<IH##KME>)*
M3UP0=YO>VKO@;*%P7IV?.')KTMH?O=8.#(]']&<**TUY[U@;D#3>E94P"(J"
M@0!05F3TD&KJK:CXF#$D$A#,7^/>;%%T85&5J\NX84\8;(GR,V%T@\>%=D_#
M43F)A <DJ<)!)5: B[7;* /WCFFP22B!B:/3\FXN9QHEU?'P6GM>6X<Y6NR
M&B6I Y'5X,HI/)*71M',^[JR3LA1UQ[I_\.QG5+LAIQLHS:G^V_7V;/_S9*2
M@S2BP(&?[;E]N[6VG;NJN?EB%IC[F&%'=9;9"?G>S 2NP4[:0/2MSG#95#24
M&4MD&:TDT&O=HP9TU5?*5^U?F3)>^]>&LOKHO26,2;Z3O &E.@7[\T_CLG=^
MCY:_3HH*D!4,]$3SLM&B<FV<W.*C6 $H=E9IP&]<&_>LG@L,.,0-=>FLG <8
M8M]/+(%7C_18$D)#?OXS/'_R['Z!H(>4L:F+:PKS4?,GMH^B"D,Q]!HVNX$@
MGF6D0)6*O$!4PV(7L[1A6<SV-&FD22.=?CPB457J/UXETM&J5Q_<RWZBR]8@
M^MU/N/0[CDM_<&_"I4^X]$F4WQGG8B2 !$-/F*8]R(O]=+=K9ORE%F$>%F,C
MH)/:VJ@MR]2Y4,8 D"<HBQZ3*24FG(\41-U0\FSCR*EG,[7OHC2LL#[\NG:U
MM_R#+0C#OSNPH./)S0;6(W?R"0\CQOS>3$CN9B)4A9((W^MS=1;'"DDH"W#Y
M"%NM]*0^ .3IQ)<2:^!Q>#TPN#RO5,$E#.H89?"<6O?7.?>ZE :M8OA/9N(D
M6VZ;RB[UAWT &EZ0'0WNE(@-7-9+['WUABO2]47D4 T9P_3(V<GADV?MHNQ#
M:59-9Z'D6MB^5J@'1S^8YI,;7+W-A^?V"*F4"'T9UKC>9GPX(8N\9]9<[<A)
M53(]OI!&B&6=FQV<>)5BNFAQKS8-\E35V'Q8[)KH] +*KZL 4WR$1Q]Z(&D0
M;]'XP=M7+1*90QG+21".1'0HP*=G0,))O?)WC_BS@GE4HP!!SV#Z6@$\/&,?
M%Y)FS2J921_@^>/6&Z^.CX@@S Z*A9SR'3>(LU?D-RKK143#P=W+E<2L%YW-
M]7V?3>:ATXOVPOB-M,79PT=9P?VF?3EWP@KYEI6$/8W29<GP:)_3SJLX+IR1
M/67;)0HA<M!,^S'0C<AWV\!WZV:#4!HK:'Z*&2 ;.[4B]!M[%FD!:PR\JB23
MI];PF**H\NNFY<.K*YSNSP^H\>XNL^FD T\N5/+HWJ//YU]\?O'%.'#C]I=O
MVC,?V&[BQJAY19*]YK $1.EZ2/['2FW3%%ZR<S@ZZ@'$1DBO9!H>W?<. $1,
M-6C9^Q3%$+(3ZBI*JO^ED@6%W>P+B:Y(U1Y^C7X*KLXYG@_#(F^]?CB2YQ(]
MS>482F0?=*9,11)%I"TJ!_+8#G3P.F9$V1&\O)CC%1%WI]1&1MRA[;=\UF&F
M:8>!52- A=1+2\TF#"1X$3:=6L@9S,Q;8M[F"@L41@#;O"<V$W4(CN.843=.
MLMLKIO5A. UO@.-=B;NLXT93O)&XN07]IG*KT.C".K(J([[2*RO_;>W47=9F
MHX86H%GX3%#49'18_:^O)W() FS;,V ;397EWCHMS-'NM;ZI^KPMBU69=C75
MUKV:*0W,-(.)S*P1%^IZ,",E!?:%Q&,')WCZ2/BD$V?KT1*Q]HB<%UJ@APFW
MH.7]5U52,-> B\I;2(""QSCX='>E-XXL7IU90NYH#)(ILR7=L,<NU,,_LN\F
MI.DGIWI>-9H7WSGK@)V/R.Y!S*S::Y<-.W9!9LK>.^K/_UDAN.%]1B)P-BCC
M Y,'/@@EWJ"MW:#53^J]1S8<YBA-PTEB<X#A#W/,9Q&0@U[CV2%H(^2:AY@+
MT3Z'<8<1Y,7,YCBR: <QSGBF79@HB;B97<].W#O=4F#M?7/)41<8/N/LG8[H
MG^=NON4<3-'6272?OJ<9X[B_>[.3\OS;7[1IIWSP,@"(LW^<OSR?:0!1_:>R
MBRS(YJ9V @8C#>^N.?;-L";57&R=<^-:*(5^*V@H@.@$1N6UDVXT*P@S#TZ_
MWV$WME%50=Y)#[RZ"[WX0CQ1?E^!V;T0=B"S#"+"1]_<^!7G$JKF1A"/T0A^
M6MPD<+]5WX?^?V$$RX@KN[-U7FGKYY);H^QNR-">J6(!EXNI&>]696S;BU?Z
M[.<G@F+ONCY\$3U.L.N3&8EQ/O,HF0B%&(W.[OF6]/S!!"5/.[C(!OLY#B/P
M-_;V-OD;KJQ+T)"RC#RZ63;2=QHF0F + 8,"O=DZ+C6(TB8E1_LEP."4^@/5
M;IR1+; XY,VOQ!?F^S6@G(]?68AUAZ4RI">RJ32=^P\-'FENFZU6RCG2HY'Q
M+ZA6 7I1;Q)A8WDQE)ZD #2Q:E9)-1]:(,<]F<*,N-:XYG;.J/'3?+=/[4:I
MZUG(;/,)XM0V3)PXY[T\8,-2+WSN3MSFF,!;=PZ\=7\";TW@K3MIT[#\+;0M
MP@#A[2V(2&T@#3U7M;J3KBIHGK"S^,=X,A-.(_FGG:1M?["V]S<NKCC0:@3H
MYW##N5ODW+AW.5-]P>7@,V:OU@HN]\:UY)RZ5!O&9L[.2=NY[5I[LR8DU]QT
M1DV?9&"QTC1S'&FYPN5%)?1T![_VZY&NA3<%(Z #X_IO,/%H%!AOW3(I.$E[
M7[SD>"?ZJG'%"J*@Z%5!VRO[)SUQ5Q@_)!UT9H<=M]X\!VP4!AXI9MDXQ'/+
MSJ!G2K AG0?;C*L]4&-?KYS6$< &;=U:N]AI4^6F\_8;S.=/VHTX@1C#:;O;
M3\IN08X*$XPMLRO+-[Q"OB%[%O)1$VYABA&<VN%^:1!?U/\>INS(WSL+K8@L
MN3P[WIU).SOA/#B?(DP'CE.TY_'YD-9SV@0\=I^T1I<TQ%9SWC-3C<NT^FRF
MMR"3T2A8_-=-TJ<JYT9//B\YG&(G>;U-7CBM)!\FKV,*&M)R,52:<YD-7;2R
MQ]$*0;U0JIQEG/(P52K^KY(?\^BIA#D<!-%LN58=]X)6<B^1??\2T'U^ RJ=
MA98%2C!@=].H+QW\;G.FPQSLOGR;<\\<T2B$KN=X>FE5]\B=^EZR<4:>[K?"
M9$+%MO2:CSQFH8% 2>EAL]BIR^J)2ZC;4<#"^0]#+?N!.0H6.(4_&H'!5>BS
M,W5@O?6'/H& >%U"++]D+K!9AEIK9@F4OH5,;6CM(X1-PSC2TNZJU[DT+%?R
MLIGR9C"JIH$X5RH;[8;H'9<$-1UP*N8A,?M84()7'#P2@?V3 ZA#^R?*/TIZ
M#M=>EPOG"Z^+<D!FPP?CB8/RLG2I'!,>YX<>Z"L;)/O\Y*U4=[XZM32LI E^
M62X5"/Y,VD@:$U=>?3$[]B;^CE-"5QDOSI-?_AYXDFKAR+PN"_2-Y:LOZ:"U
MM4.KKF5I[7$UQTW7QLTO_49<(2A=JS_^-(Y*='GEN%66T?SQY1XF]E='!EBN
MWC;'.[PFMEY[H1$71V/HNK-EF_<2H,GG, P.Z95>-@M862_=HN=>7Y>&$%F2
M#>-CZ<CGS]0L**_SQ7YD)-W(SSPGS?.F]8QZF,)E2K('*BM;ZA^>/;^\3!:[
MH[-7Y6W$@#.3RC84]6\X\#19()^<VN"R#66HO,0&_^]R\7J>+UZS"@&O@U''
M=N/]M1G 1$)<PE@&ON'4%0SA$JTL>?^AWD<XG.AT<QX)SL^>_]LU)"9+:YS"
M52#7AHXBBZ:OG5%*2%*EVEMQDOR+U /H?>7CA?[-V)U%WJWEM]GK$G@>4CTE
M@%U./VW=KF\EO+KMVP5Y7L(<[/0/#L+KQ/(6*"+\P^=SY1(G%_"8?('U&P5S
M.0,C1071W<K-O&\[=AX$=&R*;Q:TGH\'VIM9!\O/>PN28)3$<UBA *,LH5MI
M_S#JMVWRHMK+PS/["6;'KQ S!0V89BS']\#HH#[,BC]X990%U-*W Q+1M)TI
M]DN-D>M""9F%Q(J^F_EE5:]6 >$M=U3-5WHYUI^7R?<E;XW<#K%DJ4WU_,M1
ME!DP8KIQ.X>'IWPH#+@%U%HH &.CB?<R_:PCB1YJG0;#)V-B(FCI4V<U+0QY
M@WM]1(RZL-RR-I%.7U\<V 7R;B4+/7>\])P="#LX(OZ:1;M7SQ ]B%(1CC Q
M+UIZEMIX<?99T;"!QFUAEWN#//J'Y#T<'I$T;6A8N7%NYY&!"1VL%H*U]-!X
M?7$<?>0]#7(!T>U"O>(F?RU 9$-JD^BAPY65%8.](^[#T8V,D$RW<[EV,>5K
MF+I'"R3#+I;RQ#F:?C)'GI"!YXRN.YOOSQAE-Z?E[O#__MM>"A?XK7(J TM
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M)+W925&J3-;!Z:J.0*F9O?"HXLDBN.NO=4*SW'DTRZ,)S3*A6>ZDTGUVB&:
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MQ.W :JGI@G]V^YK^TY6=#U1=/G\6_,42#N$U.2'E2NZ];M@7( .;IN'J#MX
M/[*WD/QC\U.W/";V0>&  " '+I@2^%V1MS!1CMH>Z@AU^9)FW#9SVH+DW] .
M:,(+<?5UV3:U!/1H:DODA(IJ[X-C:8*1_<$50FY^B=0*T>1/MVM:F":PFSC,
MIN[HVE5+VE;+*;#VZ4F:*Q,9$4AKTCJ?YEY _&(,**%8%>"M -#P/]FU);EL
MHE,&Z032&0AFD?+B>!MD7M&WK)E$-D(N^X%BI,::_J^*[\)H$@3(R,-#2$7B
M+,?GR5[DLEGTD+'D;X[^4C/3^]G@:3#574/O0/W0@^\;KG>!'QO2T@BTJ/(D
M;W=55JPF$H4L%YN"4$S-NYYDP]"?+NNV#MD7>N$,?TD<5:3C6>]UAGD;O)X9
M0I]57["Z3Z=CCU@BI,1:1@-PHN^VVTC5 !$C>6G^B.90[56]ZF#Y+I=4D\?.
MF%% 7K._LR!Y&.ETG;=ET[,>S#O&.S%BCZ;+4.2@H)N6GJ)R !^LG,8.]"T@
M(!"'>6DZ95WT# 5"G"MY:A\<B#$\!D^B9Z5GNW%5=?:Z;F[H,1=DUI R]G"F
MLJ;I[/IPT6 Y+>07@[BP5/.VR=F\04@2V$=\NRY7:[\?6-G[^&WZ.HZ\UN@N
MD]8^;4E].RALK]A?\>9\$L)JSY+]=?OK.&V>$U'SXFV*?ND&FN4M6N5 908=
M^1[:(\R$%0@F1P]?%BI4)2''VU4\)@7!S??9Y^47+!D-9;:@"2S*3G,W)0++
MT$'^!J2B$8D5\<F:"5<W_8YM$GD2%RN+OMK1@WY>TGW:<@4/L1MH3OJ.O@PX
M<(!L:](!ZW(K=ZC[C>/KUDVWQ1GN-+(]JN4DU1@ '2T]E2F;S\OK+UAKG)G6
M<&_(F97\VX^B'/$,>"9@V,GA)W<0JJQRA<:C!2#"U-QE??A*FV,;PRMMPQ/V
M=?FO/LUQ)N%\M@D9#3A(_GFHH*0*]4%+P?9%L8%F3KOZFG'3!YJ/,28;9!;B
METM&%WVU6+!1MJKV0ZTX8?+N'";O;Q,F;\+D37;%QV24!HC??P+AOIW)#U'>
MTY8^K2W])^5A.%B0+4MRXV&R*@ZU!+1GSE409&R*Q;I8Y_7*G6>_KLO* 4$1
MZA7S'9M#$N@/F"\.5WC(F(_D,]X@M9QF,'/)SLRZO-+<B<R$(QP6 MD/S#P!
M^ZA!RC$E V3T:@)'E8MB:[/%S_B/)2WQ.#Q7[%1ZF_O(6+5ZSINF?<U9F5 ,
M)78B0^88M61)FR[?P!(M%+W4*>8)*R4/9VBI(]:DC(8Z+L>E8?!($"?\)_U^
MD,W"[/.:02L:3J/%&OP&:S<OFPCAX:_"F[)X%?890&86'XKC0K-LA3@IYVPR
M6DFR\IU%F#3X%/_\/+O$&@X?"]N%7D" 34O=+*^EU.09(ALQP9NRLK?CI+"5
MWZQ[4W:\T@'#PI_CK05H"]]KD^]IK](0SM)MC&64&L(>T+@IQO3)R;Y?0OUT
M!X>5)E\J -%9:#<4-V(;P3W7TZS@SJZD>>1MG'%4WX\<04W.*J9RAGMHV)S.
M#0K-3-:25^>VDGLEM]_"L73OI6.J"G,*O8_-$D&]50L+0WX 3FMB#.[V-0AM
M:$@K$V^&(D:@I/!!R2_-\=^<$^+L*4<#X0!)^I7\"O(I2%V@P5,I<005C%XT
M6R&K@NH&5;>S) P!I"Q_J&"WPS ^IC/'Y/!57/ZJ_/9#92&?JV3E-X>P=U8T
MTQG_Y,YXQ*D@6YH.3-T[3UX@NB4<_L)M7>U+/<WFB#3],6M&PW@I^'&&O0C(
M1?09PT"DQ)2W.]T*EI*@/3$YTL")-HR"79[MH6EWRZ8"> 2Q-C6V9A U".-<
M.Q%CD0H-)T3C9ZHZ&:+""M _SDQ8)@HQ2"*H.BG5'6P?':RL16#0.R>]V@KZ
M$Q*03#$\^6[7THE7TX!_2O9!U]1:\DMB3.I_(VLD*=<BHZZI:U?-PKV2G%($
M0O$_R/DG]/0AV11GTC9-X<0*$H&2/LF8:)E$QFF+C-MQE)^'LXL=]#^Z(Q7)
M.CG^TRZ_@R#M9_79#TS@DD*TG^8+Q1Y\.$Z":1M/V_@W%$DF^W7I]ZO@3\M=
MK_Q$O@DM5QWD]>K?ZZ:?93^XN2LE;$0&W"S&G<3XV[W+6W#A%*XX("UZP$."
MO6B6W;]W[S.X8W$3!X0Z2*)G-WD7S1:&D)AC8Q.+'D22QF]]3,G7JFDE)H_F
M%E%.5[)K*>$P=*)02X<#-+>_?:8S<]N"TPR8GSSR;I+UT[X]-5G_ZR#?H,!;
M]HC-*2P[<F?)+52.D+C606H1I"!^2\)/ #=PW;4H(V4\3'C4(']'ZB@%Q-K4
M$B-SH;S4XG'>^60XHX W@BS^^:?GEZ":N__E-UTBDX$R]2#)L1MOR).FI^JL
MQ!N45A$=)!P3+<.(<4R,>"T=W']Z'0;L;?,;((\=XW[*&LF# &UR(4Q@-:6*
M[97(813)T,+W4&BB8YF_+Q7Q<[=$R6WK*I 53-KGDSO%Y#LO:.OR-C[B.$^;
MX5/9#$;RX7GRV&A5?EHKJJ#'DYRCSZHZPUHB!9/(+Q-Q:>F[47R"S\2YG1:K
M_ZLO6\5=DKB&1$)V6"SDD7+!-F[_,9362CK%*?#Q^7A@8,YY5E5$,.@9_1^D
MM/"%6*4<],FN1W0XY]0/R6NW[:V08?B 047,8EW0T?R=2F&+1$L59>OJU6ZM
MJ1NA,&!=N4F C*5J/V/AF&5+YXIYOGAM%(W_ZJ$IFKK.2Z4^9/57TZ;9N5C?
M3!+_8SKDO]-X_['!42H7G;*G5R6;3I/[\6=NXS\0]3C!C>\BW/CAO0EN/,&-
M3TV%_#8[$4=*;,0FJ[P602D%0VM6K5.+3MD:RK;@FA6.HC[OVZZ'B:><27G;
M L\HYM+A:(HD;#N/*2Q,4^E/Q*OGN()85[3&%3OJ-7G9V^AV;!A&%B>SGPF&
M,F=W.&6PP.S,MB,K$9P'&@5^VS3'1@(8KFK@MN<]#+KY7@VZVJWH97.I3.&C
MW&4KPUF+"<SCX(Z)L4HKV"U=B_7C8M19UM?^3_X68(50+&5+^!Y/@S+GJLR!
M)0IUTSRE$C$=J4'F$$.ZG/Q2)3J4[ZV,.%Q"FW53]LQIM7( ;@9FCV7+ @@X
MUW8U<5=]7(+F=Z=%K^F/9C)/IYU[TBH2XK3T>]777S(2C+L3290C"DY :C;M
M:S+!SI@;FZ/%'0G'LR6ZU2(6PXHG^[QU6Z"[:XX%<T=Z 8[9SRP"S*$0I$CS
M:RBQ)F"KFF1V@-*"8:AKA%46U >5!/6Y[,"#MYAVL/,C1"$-R&Q$O3E:U/9;
M*1/]54T$,1",X6%@%;2. ?VD"E0QD[KN$0WAP@/460[;Q. S'P.WX"4^/ $-
M\8&017=%[)PVT.HEMAA($#U6&?&/"&-Y^PLXR>W;5MZ0Y!Z,]=)70X5-\\KE
MF\D$F;;RJ9D@E^,=W6:J_;4_W%A]'R?2U[G'J#/EH^;1']SSX"S ROL=$B,H
M4XO)(S;6X-7(\ .&"\?IZ#W+N/)GZ#O[K)1):C-GI! E@KL;V\:N<CN[>]G*
M8[C"9GH"UL)T)&X1LZ(,V5*?P;4,8OC2)K>:KY3.I'N-ZA3%DAS=PUR5MN$P
M2XAMC7-L!<JOM%HJ5S9SWN"NYCB)7A+2C6 PRSWI6)H=[;22='^>_8=20(M<
MB^S!XZ]"T\29E79F>9 ,FT9(3.FXN5H!FBBX2TA@!EE<OJ\"*G%Y7$I,QWVY
ME+A3MQ8P"[=NL$43>K.H$@:3CN[&R5W)#+=2_S>=^$_NQ#]M=&<5*'JJ6$WE
MK67VTSRZK]N,]GGG7*:=2!D;=O'-R9MZWXVT=SVQ!H;:T54FB!B#Y!^G\_DQ
MG<_?N7TO3;X_-_E^\B=N<JX^IGW[&WKIKO..RWD/31(.3PJLV2?3-&PZ9FO%
MO701?KIV,8&KT- +.,S5J>G8ND6SJDM_TWG+0. ;,IBD-?P&+"YFT!JSWGR?
MN:)?" ]>T3#J37!BG((;YSR@.WSWZA^7+_Z/&(_R4X-\QQVWA(6Q;-F%DQ+H
MF':%G_* J\8LN!%/;CC[M:NV0H.#;*2&HI=EA9KK>BV92+\ I--EUJ8.;324
M9(,_4$AL9)T,B3Y+&[AY!H0A^>_:Y=5NC6Z7<:HT:D1DO#<,YH,GF_!/,G&D
M4@O:TN;B8P@U#3\IC2'&<51/;E05V!F.KI"K)P7Z,0FBWZF-Q@+8)SO9275^
M3#OVM^W/1D$RPFP!#**GK_!*1/J[023&]$ :5=$(7XR \9P\LX$J.V!3UT@$
M0Y$.IG0\"BDM9Q1XA-JEF'9$,3N"<_$PF/>,M!QVSHDX>,9"1= %I6]MX]6Q
M6"!0EVI4W/YNFX[8!XYZ@"\/\#<^*?1?)MACS)YT#^)Z9+#<;;454MV _AD\
M;4+,8ST5I+KBP"(S?JHB/CA%[[0+;-=82U <D82U!J2%M5.6J+[NI%70O.]*
MMM8.VR+&MSC/+G>!R<\_6%X40C$7SR8<80Z4"K^V#1J8AYA=IS/K.6Y3FD9Z
M-<9XGCVKC2]LIA'9D<Q#JZR R8QX_5N'J*Z$-^G)[^#AG)#KGSIR_?Z$7)^0
MZQ\K*$C9I++G+=I K2;ZJ,G>.WE[[U?T9W_M!&<)7H,>=,#H!H*<;RAL10C,
M&DB6VKR#:5 [Z_\>K";-_$J;+$\=NDVYUH(WLFBZ7> <K9FVE$'_KEVX$OR?
M"(&YV&6:1<S+FN(-#5P"371%'W:+?.O8]H+HEZ)7FSQS*6A/%N7?X:1QSN$R
M7V01%PF+ TA&*M,E(UL?M0D9I*BMOU?L949.I98QM*[<S/NV<]KN3<D0E6_1
M;AQC"[0O"T]_"VY&O 9MT1:11<IU["$N*IHF8G]&<0&;US^%/*XE-FUD+/=!
MGU5Q6 =]PUX[MT4'O4*"PD=6%ZY"?LUM3&T =]U4UP,RV*B5J#)(;Y5EHVIX
M$G[60B_MF;[9IS"*[PAHY(M"5DTN$(T(_&,/K-!EG\=-?'-N\LIJ7Z+7 "Y4
M!C..$4I/N6<M9XOO9/X7.^B7A.E$'^WK[/L]'8[G*51$'^M%>'DOXEK\<+G^
M\!>.,V#7O(@.%.B%U1&RZ$QZ'SJ[<HYTF.?\OH;=QD]$GFI^^@XZ9Y,F_:./
MT\]&5_LB$?%/0-S]([GWM[]<TQ[YP)PYJ& %O#62C[7MDFT_K](FGK[0L5FU
MB@]T]&0^RHM^"XC%<6$L,YO$^TP#5MN^77 _.=%SB*HQG;K'Y^D\?G[QY$>S
MY;@E+D+ ZZ3\TK?$M4:ZI/7)>6X]3_[([+4VB7UHOMD_^W8?%WZR@@53#--^
M^<_!_J7T^- 84;,*C@=([%$Q>HC4%7C;_D&R#MH_N[AW_TN^@^9QDSX520VR
MOQ#F@JX(APJ!1I1IX 'H%F@N'%75\D6TOMD<7>X]6A-M!1!*_7M>]^#N%_#D
M([$1EGW+JG"R%8[:"K&%(.:!-&K!KY[$W9L#R:WL)=19X-V,W__$K(7LY%^S
MUV$_Z<%^%@YVN>L&JNUEXKW8\3BQ13__RQ29F6R%.VA/OKIISI[5UPW4^,M]
MMW-3\=BT;T_.QOVE#C4C%X]A]MQ_+ &]'P+D[0780S?DQ&\VY6[GG%E3I$!V
M\.W[>E%6]B%9!3( KJ%1O4Z2 5G7/.699\^KO.; #H_,^,/L<URJUM7//SR]
M4A?]"QG3#Q99%3QB/,4NMO@L["6P"4\W.+!2\QX,J@*R^&=#-B8"HUV'Q#$&
MN2K;!9>7T+C/Z&,+1OF6Y_C@EVU96RNJJ[QM]Q*"$C/W4!JP6<[>9<S-*?#$
MY^)<1%H\8%H^9W2*T,8FU49?A-@N8Q([M5A1"=<C^)661!R6*AV9)],&>+^'
M(V]3\.QV#&+>+C'NCZ^Y34WSF\)LV:M&F/'W/L[;N7 FH\ ]PSTB9$?1;!40
M0C>KW%F5[]V@39)T&>)Q$S3&S;I1U!D-!&K,,939H(WZ@6\?=5:\&H/$H%&;
MJU>HD.OZ^5GRG:')) (-N+='I-F)O2'7EJ$Y4>]/364 W'/T;$Z!RX])8?].
M479%_VFYWQB) L<1GN=*&LZ=+:*O_S?0,^[L6R:9C=5.*C:FW?01[*;W!$$P
MGQY7]:*!\+M3B-Q1!4),9.1["T[MER(Y:3:KF+">3(LX![R(-NM.]K(1X(?6
M \@5POQ!R:<1$&A-M]9@B.V%>_DJ#>6TYMPR9YZ/WDDLS9M23-/Q)6&$HV_B
MR]T,YTA'5\V-Q#I9RWAJ/Z]G1E=-$;UO6SMY]GE9:!I?8IQO6:T%;:\%-PV-
MDL_T!=L9;&.2JI$[1"T5FWBVUGHU9/8UP:Z9?'J<N1L=1OL2]Y5VPT&3'*Z^
MK7?:S!J?KAMK%JQ([(7V+%"ZIR+.UM[^*9U$T\G%V5[D-V1 *ZV:F,]&_#X%
M#:<M?O+:-X(YF<4?.A=H%:GZU?\C! 8N;''R ^'4D"\ZLS)[!T(10[-',O=(
M;P3&J:.=0+\-GP[ 5SRDOQ:9LT#_@1YK45^U5GK3Z!7A8[F*E$&YK88P_U?L
M 8ZAYSU+8> O1(50>\TZ? G_L':B:Y<EZCJ!DCHQOW=XI"<(_)V#P%],$/@)
M G\GE8M)= ZE:86A^"RM-%*'.,U;H: BT8U]B-\M2WAHJUFBCE"U2#M1Y"W4
MR]OT4=3_S5@#A!/V_,3E\PEOD(E']H,OQ_<A/31 P [(EDY_N3[MS?+G[HTX
M=1C%R6CV) .%Q$,3&VZFH1<)^ "YMM)HD\GB6=P <V:-('TYAM &7J,D-;*P
M#QJ2#8FT)>9"MZ+%>9VO>,2.)#59(3,FEFD+5 7PYU4.QA:]IY28T[0+>MQ=
MV<F5PJ8<)U]FH4!$G  A1K0R$?SID8Q,7E-*,[2(PISK(?K6Z@$.N&;^+WMO
MVQRWD60+_Q7$QIUXI B0*\GVV!['_<"A)%N[EL4KRNNXGVZ@T=5-6&B@!R^D
M>G[]DR<SZPT-4+0LDTT1$1L[%KN[4%6HRM>3)Y4T,%<LX<+5>2!HU,K8$A73
M$)B1S$N]\-2A+GEGMS%X82!DP;N1LN=!^^8,*BYG=X0;PUGVFV&IB4TR^P<%
MAX-.-G*SYDBK4EH<J$$!2"IE+9'W)C4]=JJ3A3ECM1!!2<^01D#;HDAE!RIY
MR..#QJ9A.*1'3X;'Q\7ERCJ?2=B5SBJ-F\^-.@Y=[MU57:7V0$B";/F)OP=W
MOW_SH;E=92E"&;G\'<OI4$ NZN5 <2K2W0*,JJ4#"(70(P<$.C/UMC2NG_,I
MR?#&)7%B@)*0:'$]6(+"2.@OE8896C+A'QXA'_W6C6\%NJV;%(WGM;H^&#VF
MM2ZR,4L#?50WGNZK: 561!9 EKRL:\E[,+KC9*E3$UC.(XW_G;Y\?C(!A5)<
MU22&:@"ANFY" %RE'@T</X&A8.>&E#26/YQG],AS-]=91SS(ZX[SSS&#,6-H
MGVPI:O++U[3?@DS1 ODF\M(IJI$WQK4T=?R!9-H(--!?Y\&(<KL'AQA3D7X/
M@<?GKN#YR>NW\[%^V,?ZIU,K*O.+PD2\D.Z@1T!8=H:NZW:P;+(5V^\.81ER
M3:)\>I<Z/P-9?$40\)=2=^1=:T0KO.4+2H $[;9+6L%SAM/+ZQJ(4!DZ6@S#
M:0>EXW!Z6V,L@K2V^,FPW'V??TUJWM5%<8RC-%(-@J@YR7_GB[[S2W5^,L:*
MYVZ&!A0\TMJR"J3<#:Q5WEQ;S!0?1EO^-%:U&.J,K$6W-OENIFK!V :=#MD+
M$S"X)BA[3!GH;J]G1BJGX+NS7QF:9^1+U>O>*&OP;L AX>HTHPMOQT&^KVX1
M@Y %!].PEU_$330=V+9[JUD4G%32UO10D>&N!O6BX08%SY\OZF%?U#M"XWQF
MS/O=[_=\R.X:VSS@%K&<7<%Q.OA*DP-(E,SG^-9Q75$E''O#CLTI]&^-.!-9
M[(=>Y_%F;7(%;#$P558S&V_Z.]=761!J_;7%3 >,_YHF"!Y]:::R65/=TD.O
M.K0U_$+$D/ \#7&W@,'3;<>VY"3/:RU5J]TDQN)C/V=74>QIXCL^!";SX6:T
M&)LI/F!221P,Z^2&[2[;8H ^X\Q,!SBU*SA<%MFZJLEFY/8 /9U16$CH)" O
M@CMZ 3!AMRIF!Q,"LEVKB3!Z(V1+YJX[D0RX,)(AQ! :I_/=%1*FIM#?I#3K
M3-N7+6OY3QB&M,^,TA@TCQ=T'ST4$4A&X(G9F5^ >QI':B]5%YP9.5I3;\,Z
MH%%M9&@;!(694V,P!M#U =0BS-*LL4U-MC$@*7$;>^/+(R>4T2JM8%0ZGP_#
MSEX6RQY(8JGD<H? )V=]\BWE;82O(*E!^=O'K\/$U&9DS*RT#LYR^:6NCDYM
M&Y.W 5HL.:F*#?WMG< 3[IT)-N-P[QT.]ZL9ASOC< ]-KMX757K' =X_D&M3
M5!(2)F:O@Q9 Q("2Q=E";W])Y%*@9UI*N*PWT%&YQ8>=]4W;!_UZ3V+_XS79
M[Z@2Y8%0Z.]ZAL)V^Q&)^I^E7P;RF6?*YLO?AK)T,PZ^=-[UR\($L("Q4+<4
MI X>5X4C.K!VG%_)F[IMHQS-H$:6*:)- \Y!9WGS++A],;?I:-8.5;',D*(:
MI$IO,(^05M>E?Y?D>RS9LS(,B\NJ\$?8AG\Y$#DV@7.U7?9^I.IV? IH;L?]
MUMC%:/MX5BY>7S?KK%)\'0+]T3E,_7 N)94&"60.J)-94 8->%S:2P!X82.3
M:*+[MCZX'6Z1 _<3S:6#<T9.DA]_/AO<1UMSK2P]6IHL%VS%S?7$=7/<(@%=
M"[O&-$PKKK%R<&! )A1?&,FRLN>I9.$8V)VH*[,@#6\\4H9.8;%$;HG1D_G%
MX#+345]!O'"O[ -(GLS:\ ZUX4#E1)&1*M0<XF2IYIA25/035DM.%Z$-)O=&
M9VJGTH[BCNHU S$DS1U<T4S[\Q$"JG=<#_HJ)J"B'2ZVC,D6]H MR![HOK47
MF5Q6 6,'03%T2I-NIL8L%2)0^D=FP>1I,&0V"]?\/>"NJNPW'_CE^F)OUR=J
MLA.+\P\HXMBTLRKZG5 'T*G#FA&./'SU_,6^Y'GU'UW]KP[/>)WGPF'UMX&7
M)#KD+XS8I]*7#Q]&#AE;6I[3S)G&S%_8!LX". +0VJ:*VMFT'7J5H'FR[=)L
M5BN 5 !GPTJED(=KG**A![, 7 ;= 6'=!:4UTOV&!U[:_)S%Q9B*QL\C;G96
MM$YT1-X?;XL*DS =%>*&?CP]"Y#8KD26O5MDB]: QCYP!?:@5S]B'5Y_K6VY
M=AM=&L5N9C8SZ#-_B[YCEL&R(+.,Z^C^D3PJ'@M;*[H3['."^OHRS0QKHZ*+
MNH0D4DBI1>C!E7>U=:X%YX9&]#=I( -^H!G0%")\7]:V=5YP:5]C+@LT*UW9
M%*7YD!?;0MPX1M%I1:,C*:$1\0&-BF%1#[GLE?_*DH#Q;L*(7!;RC/5^ROHX
M^76K)%^E"4(R>V&(=+BB9(/>!@M7=!^8NX%4PG"9EYI["'C]*M;)X^'?H<R3
M#7[URW/I7."+3O11I\]?T!Q6(&L)V@L/!?"#OF^SM/&4Q:.$SN(2JMT,QU*C
M;7I$G74](#26FVG)BY\;Q::&^?QLD,<7F67QJ29^CCOPK7_."#Y5GC,?Z8>[
M>E:@587CJ^JF2LZUX._,HIOU5$^=93KF^WK6MH!I6<FM"H5M39U32\*HNB02
M[HZ04BBZ.4XR5 W![VE?(>.+-C2C,U!O'=6K54)*OS%EF0V>O616 'J@\ QD
ML*H7.R1$UV;DJR-XJ^$VGG#''GQA:N/.8O4Z=+&=<$@M&.SO3\CVW;7*/,-[
MD.=FRQA\*Y &"I.]%-H.E^A0#+W]MK<;5L;F7)PB99)F1X0ST-E60_/[HLEE
MO"&> 8 MF=C%H'5W-9UVO!DN3@7*:C5X)MP.Z;FN')I9M2.MOQ;SCA[ZKQX)
MJEK:=(HX]AJ=E/@LSQ[NZB'/SII":B;?BB5\W9UCP?7:6>PGH<5^;=S6RK>\
MS!HKWICV?Y6UW1%)KOP]Z5G0B!3M)D TNADYF;+L797)OET;DM."+O<R*THF
MU6 /OZ(!^%:(;N<9;(SI.)D"QO6<]@$F_@%<B1F<=M=1T+>NF<4K)+A=]>1K
M$$T>G3* ::B$OM0MG$7IQPM)!L"/&Q^:Y,>>##7 QJZ3H,*6U)?KK(N3T2F'
M]OR3F ?U2/!U$S%+=OG)5"%CD[Z<5:;N6W+]-?^U9[E$G91EX#;I6RN%N2WB
MA.5RG/QV890#*'@XBBI9)-LUWGP-(10D'8[+<8Q!_X_I@#)]>&@XA!E&>M]A
MI%_/,-(91GHO%=B?*:?Y&/9C-+EP3%^W=4+E+MT/2"](+UI5]^/I&4KLWQNI
MK$*\'QJDKPI01G 5?*A!ML(1AKHKADME$D]Y=?K3$8W$\QWJB3*[VN?<<RF&
MOA(NIZ*ZK,M+7[IS<\7U$5T(H(H@)+LL0<'\I>T9_,<>LQ?!ST;\I D=*FVN
ML/>Z3/0%*>DEDE5S5?M=B(J]0B(2_JT WW;JP06H.,QL.-N6W"_I+*US^LQV
MTZ<=S;BA'YM<8\=C]A._)"GYB7XB'Y[!T0S/TMUOUWQ&;E>3[L>Z_QB4ID=>
MV-/*JH".<MX.=OSJE^=[46C:$+B+1<T%R$%R=B3&[//>HB!,8_,7>PGC H"5
MC?UW$+TG%=8YY-M0P/L'A+^/.X6V* MV(?EXA%G&/KC[LU=#,T@5C4G<5\'A
M.M/SF#)*?W@@Y2H-$/UB$%HT1<!+X$,*I@-O\N#Z[%T2Q?7;_KG!K&P_.A>3
MN,$*!+\67VT_&XQDXRWF*)J*9L"X@0[MZX7FP*X7*IP'I!\U2Z$ND&_[QSB@
M&5G=_^H'$D+A0<ZRQ@2'N!<;9U_5Z&-WU&^C#5(P"6.%BJ9UO4K=8TW5U*6&
MB_RLN%G/GL J)"MFI[(,=P15$F%2<'\;QD2J9N&0,#4?8+4'DG'EO^MFZ]9@
M25.GID0'PVCI1CKY7J1XI*?;FW&Q#WDN- LRK6?Y^"7)QT]G,6JER^8P*\X-
M6NL-M['THL'F?F<H^GRZ#TW[_UGK>4]'YRB$;:4ZE2]*\C1-GJ7)5WPYOG9V
M ?=X6Q0U0A8D?27$I!IFOX\>ZEJS'.GBENF!?:3%1AQ\W6??;.O6Q(TX$EVQ
M#78!.6Z9R8<%GHX@QT-"H8)L$5.\WM2"=L<^])TA/.[6S:C_-.S_K($>W!W]
M0U7ND?:QYOM;=Y(#JCT^G>],?F$980#_0"<8C_FPS490GU<O+;/2B,,:EF>H
M'14@0"PLNDT>A=SZC_=3BMD.V4S<W\"99LRY7Q1 )"#2BG2K=E >_Z("5#BY
M)P7J1<5["5.PVVVY 3/]3_+*_R83I/6EJ:1##4DD-")(WIM=TF8K ^99U"IS
MBG3*#><-PR\ZM\W^1^$&TP\XX12X+72BN-3<]<+A"0YF>&'*9?C"\*SA2_,Q
M 2EP+ZIRYX2?&RWP!QB2%_)@N2]QK$2K  (<_9;E_+-0M@?##2L&Y-M?Z;?3
MO2DH_D[H=X."A2!JSE'WH$:)<<,Z"N./B_;]$,ZIS93<1@8[Z>CCW%_8=?#'
M)6OM^4#D6WX_"^(O21!_HL5\G@%!K#5FI^1H&XG]_<2$?S^2\, -?FM;+-W]
M[LU'YLZ+P 84 1-')4P$NSI\@5&F8W&CJ<HN*<?0^/5DF464HZSJH*-::[.*
MK/GCS.B>Z>^Y5#QB*>):Y[6N=:VN\Q@2GVZLB(D&*K[NNZ#KW/@0OESL./FI
MOD*1@+;'84;08BND,HXBDKV 55%J6(\D.G?=P\<[WA_AW]1W,/%,Z5O'_*+.
M%$%+"5NG-3 *K!X\.#Z6N[^@LU2ZW5?^IDK^JZ_$-7_R[*N4C>?7(J28]>:<
MB[*-=Q'@%.]"F10")*-J<[G_;_O2^#*,20EXG0 ,"Z]_^O'MZ!-\!;:P_N2
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M.LQ%F/$@$5$W.W:Z&?RQ9H;=0C3=6K8!F-F$\$2LD6P.04MVTFU*_BV-%0Y
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MSLS1SI#T?I4#_]!=P?MW;=DJN^CCY/5?OLX]UAV_T*!?I70;\6],+4'W/C"
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M2V#(!+] W[.PC1FB I*!1<4)H_(R5;?8F[QA3@(?!'"#;L&Q;L/KD_,5%^7
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MJ$.C#O[3MNQ1$;:6'Y>HY^IJIRM#?:NN$ !5(^.,_P@A'H"B=/.BYQR3R]A
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MO)0-(QD&CU-KN V;N'8FV\@T:'[_-I*/*&M(#=-L@&A06CL?NI2(R\?LCI7
M*1T3G6L0 2+\A@Z> XE=7;#ASS'(B4/%;>S ;\/XR> TWO 0:C!+#(1]L(%Z
M&[[Q*W?P0]@R51<#M=4,L^C KM,6ME/&-7/6+(O1"F?+XI<M0&AH#11&;77:
M#BB\<M6?N'*P>OJ]SEMP7JR]YOD7#R!F-<<6#L]KL+?7D3S(<1YQ"I@]T?*\
M3=0^\<$U7 2+,RO()&O'APD.VL?W$/)Z7?MR591:Y;IW<MO ZQC/-H0'W_%S
MH.H?[! 8;$EV4\)&E)7"$H86.7%4!Y=[-$+@FHUNS' -+"1W4O_--=-A892;
M[83/-#W9?JO/!.TEFD\+KI=%G(-]A0Q][7'R,BO*B>HLW=2@EAR$7]( !B_F
M*N/S)%O-E<3*K.#P?;RYKE+-U[7CI(0T('=_XV8Q<V_BWS@\[[(/6<A_/Q^<
M@SPXMW).?(H]>561C#$X'0=/VG8 L<GYZ-Y].[[1P[O'U?;BU;N0GLWA]@8E
M8%POEJJY;YVS"'(2V?WCSW[DG^F?)]Z)&!4=X]-1Z6U)G)Y]\S<H=YI([HB4
MHG*=)]_99G#"?6[)P >@]%SYLG=AE%8<2O8W=68C*[..F(<*PNB9*'L/JA:X
M4G#ZF[8FT'Z=3:/,SH,];[;]7*& ]YWMC&+JMSD_-$NA.Z_D02G@=VER93QK
M?1:VRO:L;?\TQ>^<DN6Z'5=JD24_%:@2H\N#37CG&R(&(L7*D9]^>??""9*(
M#]]5$X;/1M?$(-Y6PN&HS)5<VV=/GCV#/"A:]]?PMX ;=:4FM'NMG$7S">:T
M@Y=9<=U;(=*N(VEG1=A3$F&R-$O)M%(/"U$^+:C!XS$HZJ$Y^50*5;*+UV $
MK)>#B#WCJM' $TY@5[32GKR*LTX8?I8*AVUASOL1[\<O=77DE'!(/F#=LN2D
M :NB^;/L4 _E[<XZ\'8%W/."6?.6;?*(,02[QX[!M>ZE1KM8%EDSJ'$5N[UH
M$I]@:"]J)BQMI$C2!C\'8 AK.U[4Y5+J,9T"&O"A/GWRM]1F19820VW[_(*>
M:&>,H9ETWQJ=@B>N#&>)Q$*%11O7P#>)LU8Y0#@Z\UU4N@*S&Y3^$Q/G&2,@
MN##.JJ?'F ]FLV5JPX&W$W,]X6$!+PD&Y').;=[,.^-E2'N<_ 1,^G_C_W'K
MD.$W9.%(B)5,2(VW=9%UGFY#E/LW\7(P"$DKO[D<044VACT0]4Z"VM>@5E:K
MJ1QQP! W[U):?N9C+ID/@U]57'M5F@P%LC13#2D'V&Q?(#"D &B]6[(@RX@,
M(B[P1W&4]43TUVZQQ\FOKKI6'<R/.);<VBJAWW OI,6.,>HCBVJ]!=EFKF(W
M7@LS84[YJ7_F^GS6@_N'CBB>*ULDF5OE0%XPN8-&YI<%9SL0F5^8[LJ8RFU3
M*Y%VHURN^#,7@",;&=S<IB YRT:LQ:0?HW'69ILL>^QP*QF%;;;C:?.)SJS$
MZFB^[4K04H-7<NT;D<6UT6/RK+2]S>DM")&SKM(]YC(KD;&WDP%#=I8[2);]
M&J=*E^Z?QLP)@0>GDG&^3JJJ[NEJA+0MTA/.&Y8Q/P#]WRN@%^(,P6_!Q:>C
M>4XZ72Y0$.:B?TV:L=9U/46J#.WGOOK6XZ9[U'E*HRR+GK2*HI"IJ!(=YV>2
M##^J5C;@]=^IAAI5((!#K)BL1;6F7EEWO52J\>6A-;&X2$.VFP-W+&?8XKV#
M+?Y]ABW.L,5[J6',!TMVE4EKDP6"A#XD9^T9%=:A]2@M'[Q=9AER8YP%/@E_
M%>"HA.D(8<H2M9V!8O$>BC3-Y088D0VE0CZPAZ]B_<;\7Z+CBL@\S]A GS*R
MZ0MTQX0%@6YH60;\$.%?V%9>%8WT5&036&"?*!J^-%*XG-?JH-!KO"SJ/N(4
M^$&LT/#[")WR;^1Y;$SS)NN+X26:TK8<Z="=<1$8U7@3]CNSM?@EW>5/C.+]
M#SR-(U(.=#C"-.;_G+@TYAR)G _RH2FEO:*GB:9K=(S#\,_U<1K-M;,C<051
M[]%_BYU//979U5Y_]W28#E>L)JFHGFET7,/L,+JSKNMEF\;$ 1S,:%MV;!JS
MS8K&0C(1B&07KP6[0XX92_R#2[CX3XBK=>C+Q*3%@NV77V,2K>L3KGX6.61.
M;_-<HAP_*=2UJ5!IRMG$N#L-;>RL/^9KYRPRRT,4<.2^+"K7&.Y&(8D3[HM@
MN:9%,YTXS?0VZT9C#,]<C &Q:EQXLHHX;":W@UM;XSJ.G7<;%J03'AB*&*3A
MQR$V^NW?> E/G_XMM624G#Y()<7@8J..VT/Z.\A=>?IW_?63P:^/P<B9F ^8
M%'WUNNED<<I=YP-6G _"#(-/#7<R"KZDG+[C7YF:Z^BLF&"FJ=M6 PUN@W5K
M;S#GIS>9\]-/F3,BU\%A&"4A?9TIH.KI=]*/#P0YY,+0"S8?%*L?Y%F$S13R
M#SY$U0)=;U,EP:-F^??@Y-\>NU44>:V2LYHL5TL8]=P8;3N&KT*FO#6,_]N7
M8=__U3)L2@K=3(9]);_^_K.)L+_?1!S\_5/$P5=_F0A[<I,Y/_F$.7\?2;#O
M1R78"5F5I<JP[S^?#/M^A#[ JW2Q!8<>8G3&W^()SPO4Z-#_-OV:C%);_DFS
MX>H?1:Q9HW>);_&7&OQX*3^FW^'$N@T*LV1@K ?,8)"TI%/I>8Y;F/1BJPO9
MY"R=#ULZ'U9QC&5'?Z'!SKDWWWS>#]X:0>YWHLND/<=[7E80"[%=]P17FYMB
MVZFL=5WI+16\ANNY!-7^S>4%QBKR]Y@:PW9[ECO1AD?8M(E^89]Q_:^"&H$Q
M-M!CVIR*5K\H$-]?-48A7Y> /MM:<UTL6TFV3L/V^J57N6G%0,I:)!:6XLQJ
ML,6U0M_;$<Y!9+F?M04/N<>EM&NN4??$U&Q?$[(E#)!4*#>-IZ3HE"*DJ2[K
MS/(?AZS)485MW+()KT=#7XX0V0&1SD]>OK"\">!&B.B'L0"'A0<.9GD)CW]6
MO0].%-V\QS>BIIE\=4]8G9NND[ALFIR+XP-0HMR9=/^>J=1J SMP>(>]$!OM
M8.0!;7J*+0577Y8 =]&><\0U# 1_]%JTPE_.5>@U."<P8XXLK_3J2LK.D\&2
MJ2 >1]#C>E_.HNMXP,";[7^EO<JVVC=[OH3S)0Q=.>W$EYR+H[2S#'.O-D(M
MO_:.W0WL"(YOB/8)VY#AB%JB"8?0-1]H;96H3AIL69JQF[P>=J]QW ][6DY0
ME1).WK=O]J9NDSX+TLKYA6L'$%!I:"+'A!"PB;G!@1W.Q]U(7OY\\>:+%UX\
M"?K9ZV85X>"^\8]J)D\7GJ1K="/W'U3;\$347)ONF^K&THP BJ]?5ZVHH!G
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M%W2^H+=Q04]="@@%\V$<-X"XE:9:=Q>"LT5TBXUS1V0A$2'-O$%+.LM<;D(
M2 DS0E)\!'TU+#"&FL9T6BW@C[)3/BE_9_8UIF<V$L3KC*.F5/X< UV=Y;MK
M4HJVES9-M5TIX^6@$,J[1+,DF"7!;8';ZFI=<Z&+9L6YPR?T'2?/N2HB0\!6
M;,_&,)#EO=F!3QP5=I>: ^,/\Z8ONI1;K7EA0,;L%NFP]CUZ=TN<VC"W%IBO
MYJ,^'_7;J9&5\IPNJ];%D EUL\W0TC:U6=^)$J21BB6;"QHK.YJ/]GRT;^%H
MOZZ7CL^?#0UMGNT)*44."Y]XP&P<M&G5JC84;X'8LNQ"LFG._07I>@?2X6$]
M, N1$O1(GH7Z?/)O$3(<^1^<44!3[\8ER0MA)C?:C)D-=I3'>DY.WZQOM./\
M+,GG\WQK&3:+29FL2T:+XX4QU7A0;6%25'?0P2W-+(;G8WM+$5^.M(;GL*AR
ME$\&' EYC;81W,5(+.S P$8PE2N;^D59Y+X!A$4>Q8W\%%_)ILK27-:=B5#%
M@#8ZIIO"<]2%#-V-[[)Q[12FKM !EUW>!G7*/:*/OXWM&.W<\M(YBZ?.6>3V
M\XK(?1O0*]W]=LZUYP?'4_#G2D^_E*+3^48<XHWX:ZP(Z9"Z*$BCYQ<5:/MW
M5A'S81'VF8I.OX*8P.0OL*:@)>>@7T9X)5RUXR2J0]U(>0#9 9R4XEHK?J[.
MP$0(\='?<))J.!7&C2 4WA6E*Q8U68/.!%Q6ALF&&3EU ":1U[:!L2U]BZ3"
MGD3@OO&CU]9&[%W=NK9>"&]NZXF&2TRQU40VO<9$3AJZ@<;/Y'HQH.^6O!_?
M?W_\U=]X%[[_[OC[O]GE=344H@6HT2R>/7GV-7^-_N.KN,>$2S *YEZ;R0V>
MNF>.,@Z&.Z]&IB+J?H(&*GOSD$*:S&8;CY,3;[ZFC #B!JM:YF*G,=R5X<2T
M"XEE,QIK([97\3@:E+Z'4O(S(IWG$H-[66+P="XQ^&)*#!Z6A1+U"N>R\J@_
M([ H?2N= )@PGSX%CKWA)K,+TA7D^2WQYVHM1>;>S$FE0BSC1IK<JM*J?SLH
MC?^^JJ^.+I3E<=5P;^9.46:51 LKVED/=15SIX%%@"Z>T'"P$Z"-+= %5%8.
M1\H^P''R2PU@WD[6B#HT!@JYTDZ7/P)KQ'"-1973)00\CD9=%63\&#\X]HU#
M,:VVHMT6S<I4Q1(6%1858'(==X<SU;2JP)-W+-,0O<.QG #IZRR0:%R[*>,M
M4W,;6(K-2 7F<E@K>4W6$^P39NW2] /]N':+XMT*H3^.QIME,1N=:/I^ :*P
M9]SR#"1?V?)26I0.&ERQ84B&'O9-TAF\P\X^(8//V(Z_MDV\?6D!O;BK2=1R
MC9HG:Q%/(<B*Z1QQD&PHFF0OXR4M#W1H>?'4[1=+YAT1(^?W6N>'N=B'9,!T
MN[[BG3UCSGP+P5/Z^F"L+HTL^1A$I?0OLE2%'MK8?K_:"/?@V_[:=KXZ7[CX
M9^Z@HW6E+OZLV')\_,"::=R7;9:S\X_D%YNR/@6"&"B[I\=/6?T\QR6%2X+C
M>1)X@\^>/'TZ[_HG[?IK$0-OF$X!_$*6'^'4*X #W-IG3W\89T8^YI-"7P2B
MW$$XO3P+=2&3G'PP3<>4"5=9PZPQ;<L,-N+/99"X:_0L+\N(>CB.3K!WKAYA
MN;,^H>O\^9_>O9RC90\W6O9::;<U/<S7BWF4O1ZW99<#*]4U"T\]L700$T%P
MC90MJ'JL(9(Z(I0T "SCYU4/+#,W-D]]F61([<UA.VYY2F-P\\U62T,E4]('
M35SWE^/0=;;>R51KND(LJ"?)66 3PES0[N=76H_B[$*P$ME/F&Q5?BM7<@^X
M#79L.B(ASMS6E)D/A9#%^L:[;[1MF.W'SM9+T>9" ZY/2JVAF40A0I TN4FR
M745?RM^#/EU-Q A+S\035Z!H"9G&)6+/%/2P2=&N(\K!5FU=8F4:L9KV8G:V
MM\?@C=!<4!S+E;_RC?!31X#OK-2()8K[VY,5)\0X6%,Z^LI!5K'C?>8,L'0"
M]&6XOAMQ&+Z-6_V.]'!;U8%W<&7MZ3;;"$:(:3+0V3437\F&<X>E@Y.L('A%
M[.,-W@Y@'0Y$K>9W8TISB5<2P/Y]'7%43QTNY88UU:G$/"OE&"D1I[PL8-+W
M98?F0O%FQL0@;E.ZW=:("UK1;G.$4CU!H3\I-@7C7-D/6O'+E 7XB6@@V3Y^
MNCY"Q^3Z;'H-=$$KGWWR*_GX0*[:*CA3=A;^35JWB+:O:*WW9*M;!NVT[=SH
MWR"9#"LI9W7[0-3MH&.\BK,@L"'IIS@#Y$N40]V#/Y"0X @0ZQ3-C;AK1_H"
MDI/UJV^MH1U&/#.X-5D/WBT8(]D_D-?JVKL(_GFOH<1>!LU;5\BE(8FF4I"[
M8=GTF+7\27*A!3D'Q@*P]994<&Y](Q[1=LEJS(;Y*%PNT_\*Q6E*WXKJ\(9Q
M36Q7D$'DB-?V^&2Y7<T^[2L=HZ;?.H1W9,EQL1ND8K'H)697T&JL:+4B]U_D
M)[$^ \IK:;0J7=:$1$K/2OARJCX_M%F6IMT6"%S!IEK178C[C?65S5*J_20\
ME&)!A0%/Q25(WY8"KY*$R%@JC;YME,1.TJ4Y.VFS,W4?I/O=@'%F0MJ9D/:N
M;\@L%NZ&R4(PQDMI^Z:7U%]X']?@$MCQH$1H.2@51'2AQVY!P#(KO)(!!XS%
M/SFPBB@V%T0(,'6BXUH'$W07PE;C!TFA$>C1&-V5..3,5_F1"RHE"J%Q,<SB
M74>KY<GIO0#MMS3=RZPI:M!SV>YA;G?_,?>#^3P8@+G6850F<&9X[+)ZC->X
MXA5MB___[#M5M,^^>G(C[>OX:>&8?$P-_S 7_<P7X18N@L!4"A\AMF")6-PC
M[KG0UB4W.)HSB.]^@/B>S2"^+P;$-VN&63-\3N$PH*O,.J;S39,+Q.O$3Y%N
M6)8/R#1M756FI&5___5LO\RG]+8,^< 7-E53EZ7B!SR#M7./TR%E78I0VY4I
MT;UDX$D/HG/DEVJLW[=W&2./(Z<WDYPGPO_S99@OPZU=!NYCN.V&C(0VCC,?
MP_D8WI9,IB.SJIL-IS 7DCJ!^> CJW6SSJKBWYK.>*0 \-.W;UH%<SX.NDQQ
M5TQ!L'/@<J5)@F7/X%0&H'%V VYKQ3_(.F6.",$D L5':X*:]D>DN0)GI-_.
M56MA09V15*2 BM9-!/I!$1_W(2!9/]^J^5;=A3WNL8<X.,QF;28KC 4I9>N4
MK@GB/,A\V'Q5YZOZ6:^J3:QY#EW^AZH5FS\3^CJIU>HXNT@Z<HG*@KPQ'V^-
MH8IJVQ3DB#<[-[H2U 06H/G X*1+Q@S)DUN)ZS*TE;/[1;7"7X!!*EHV&6E@
MKD-3)7R%NOO+ J1D@@T8G;13V3>;LY;DL6(-5/SL-<VW]=9N:P3'%[Q)(7CX
MD/2CW<O]EUFEG!3Z/??SZYK2_#"S4,['^E:5D"TW"U11$,**H*DBGHM+B'@+
M-VU,L5GT3<L'<3Z]\^F]G;RT[9M5[C2*B_,4M,R*$]>^#H:6TR'R8!',#O\<
MY[#G<SR?X]LXQV%MB82AXDJ2\2*TV?2=3^?MG$[A5EO:BI,@J<7P4RY1+,OZ
M"J)U)*<0&<46.C<+U_GXWL[Q184[6[@>3HDX1D9:O\\[VUBX9R:+J O,/D6T
M(ZFVTCB"<$-*ET@M+"TF- 0_2]VIUCQ)[ (_F6_!? MNX19H,VP?>0O*_(+2
MTVQ!GMX])$)_V+SG?TT]S AUK.VL"@XW2U1ABY;IOZ6[G"U?YE0K"/K)$=.,
M*VJX.O18';"K7AG;1O4#R;6"BS1#+@O?RAT'V,4LP-<13U#I(URS=Z650&0C
M+H89B.6X ,8WCAZWO&VUBI2?"N<>DLN^>M5ME,8 H1/HI9BVHZUKM51&*&&9
M:9A<4:Y1'7;IM+UCV^/DGX8+C.U^5STM 74Q#1/28\2X,0[ICCHON.1<BGEC
MZH\1#99:EI1P'7F/VJ,2IAYB/4+R36]5]S_;H+1.F".$!<3V$#66?:72]MBI
M:],[SB'N:$0&/.$X1O_J20B;1OA1,B%N(OU4T+Z\S(K2*?&/#:8%PX:KMGDI
M=$KZ\>8K$E' ]Z5GW+ W=Y,AV9$+Q7\JK'O+J%S49W:F&6Q<$;2O8K:OIEZM
M#-(MO)&H_?(TQP$O<'("SCRH&UM+,KTD+7T'6XP<IEW=<Q>Q&E0H]&; FI(U
M_#YWTD/ODLXL)CK71!ZV#KBC4FEO.3.%05-?(7RQLLT5Q\^\+W84@]H=9A81
MVO*%;&AF#J+_K9:<&57.-*S3RGV1]RQ,P,OA M8D*S:M4"[AQ"^8CY,&)0%"
MPNV21 :^=IR\6N&)*_HWRP^I1!8F< .*(+W=T%I<#0:FFUS[S@AO <^&2T=I
M@&W==EO:KS1I<W# @Q^.I=]%5G9)6V_<M1P(^=\-4]4XKKE.1( P-]$SN9:A
M#<!.88^^3%7$W1_6^8;>?A.Q2('O63;7,;<YGL$X!$XG=%'4X^;"5"R2"W?E
MKAPQOU;+[,*VJOK3^SA<TW1A4#G)EL7 ''2ETW!Q[*S=TP>$PMT%M*"?Y6+W
M\3F0[4.B@X56;D":Y2Q/%B?0J->T=/#K'R$ FV@7#L/YZMIME5&'F>D;;2EX
M5V2[EA;R80F !YL9/>O:-<H6T:<[:YV/APA7,'$:;R1" CLSZ]"XA.;6!/>]
MJO&KN:KQBZEJ?%A*/R2Q"6+:UE1E_Q<!"?#O].J1:CSZ)I0ED.Y@VMJK@1J-
M&,!;)+707A1;Q[,98/2$\PBDBV;-8?22#._:N:X_U5=.Z'M%$TG^Y"/+%?)+
M;?YSZ(0-J6X\6%HX@")CJ4/B^J*YF(+P0]ONEZ04V*7AN,9@>>);-.+$3[&Y
M'"<O$$4HV.F1W=W?44?'9DI]'ZLZ[]N0L8U9KH,0X,"963?91NW*>,YB(XQ]
M>_9='IP8^^T"B>-!BPDNI4%])6/-PM"L%2+#3O2(KFH;"ALXZ)6>"8SJE<:S
M*GH,Z6.<<Z5SHNNG9$Y#T.;)N]=HSH"#*2+MOPQ'XNC1/_]\F@[C@#;FO"^;
MF&PR 'XB(EE708 "G1[[Q>]ZSS+F.C(B QS=D64&E>@'PK-UWS$-HXOP(5Q0
M#E>A4LZ35^6V-6DZWF%,_(*LO4A698T&Z1S1*>L%_=;0C^L-2W =A'?-LD=K
M!:WM+!E_"7U0VH[[E; 6,9!V IZU7[-"-4>,N7/"$^..<6G2OI8B0<D=\ML.
M;==&:0L;Z!&.X2NCPO3";%CT\CO@<\>-71RZ(0T3%:]6]&KI9,'SD2?@RWB"
M&SYDL(P;%I/X2RT))5<AY[7P+".B"SK1"L..".^@!&Y48+K6>"-9&O/!Y+UR
M;%Y_;5#.[&BC^6INMMS8U@;;)'PV;&*GW*G* SKL89>.G;DOJK'=+/K_W!;8
M5%:0DKL1&QWDI4MRC62K2,P4&UMYDDE5B5S9\%9J ?^T-;S??2KF".\YWQ?\
M0"C[K,"5<+5])/=\3A-Z,1?27A*#@UO\".(G%<TE%B$N$DO[?:J[=(2#>*:_
MFR$C?SG]7=UV>TU)0T)+2WE1-T.',:32AN,4^EC>Q:JG(X=:A6:3R8UON>Y\
MKDEOC_EQ9ZCL?&5N_\JX [L'P&CJ32U(Q)PL2EC306<..>I9Y>SWB>Q,93K:
MZ/<S?'8^TK=VI*M^LS!BN?@FH+3B7-7!GITFY/PFV?9-VYM9^LY'];:.JOCT
M3&2A&+451[0=(#L(0*>),&(HE$WLD*QIT+.7S79WCCD<VB(V4+07\W&>C_-M
M<;EPO(JKPP/<H5 JOC<,J\WDK$KS/40_6ZZ(!'(V%3(7:>L7M;"P9;N.CG$^
MT_.9OBT1K5U34BNA;>7NS$@WG\V[EK<VP<E]WP2Z[9#=$B5<&4WG^E!^/T5D
M USLJBZ+.LS-<&Q24//[9LHVVXGE,9Y0V&3O)3D1&B8*/4NY<Q"D>>X+B?$P
M9^0@,%]:CB%@7<4(XC6U)F ;,C:,(E/J>$8?(>T1DI[YKLYW]=8"+9I]6MG<
M(RZ78Z^SW7844AW$!^=#.A_2.PB@6VMG$!4<M&,,\DRAT@B0N\-6Q5.([!57
M7W&96J0GQN&W+/RMASMDMNJW0I'*8"ZAN8HCE],4*O-5FZ_:+5RUS5Y+5&N]
M_+F+,9_?^?S>FJI0U!@GD):% G:]\>]*6@,E8>4MMYMG+5.'[DJ_73/O)N/!
MZ$MS;Z8OK(KAZ[F*X8NI8IAURJQ3_AKW@UUDKI%@'[E6]*49P#:]NZ%>R\!5
MT=[. TZDF<5H/M*WBZ_!/W"*G1&O;0YL/E?['8"Y C%1>\"-KV'B:&;8Z6"F
M/)HICUX*W\1>?<=4H90-T"L:'M4F)!!S+1WW&$6ZMZUAOJ+I8@JQW5'-7[1-
MOY6_H22$_GP)-GV935PFP6W&'-3>%DWH=WZM&"9\WKG.'C2/<GF%PA'?FX;+
MMU6>7YBL)"F?-P5?%5$?U:H$Z<_"=%?&5,G;OFV+C(?[]3UMC!2!A5]U$WA=
M+)>E25YD;7><O.0RABXK2@ YUUGC4B%"7Q2 .Z5Y3JDU*?;!8<G=WO+2I#4F
MT>Y ^)^GSYR$^^L/UR=2I[SEA;_U"P>&_)\V2__&E^7X@L,#JX*_+SM]>@%$
MC]M(E!%U+C_@+J.O+EJYTQ84']7-'SV5+!\R35)\AOJ8 WKKSY[^H-0Y<0&&
MK=BUO-Q3Y:6.E8>SC5*5T:.JHXP8TP:U:?SR@"@LND%5X&XN(CIL=7TW[%1O
MZ3@.F%^E'(CT,P@PN084G$_"1<6:K*G[]44 #(SP@+C14KJT+,K>$L<PM]H%
M+<V@9@?%CDVA=SXXP2Q !@6J145_:"]&NMW,!_JP#_1?0>8DMH_U;Q3A,6E]
MVJ/*6!3E3,+YZJ3@OB;_I^D*".:E673!.4^C ^L8&?E$H_+3BEKE4&-MV!KF
MA @N"ZZ"! R ,*'G+K5<VQ?TF)5I0.5I:VR=G:Q*4<P_V]LI)"K4N3&!E"]0
MY3)45'27]#YHFC"2JN2UI'[.L04GZ\;P5?U$G<E;1I:!GI&VI^L;O.^_'W_[
M.5_X^>L#4^TCU>[RZF@;-@4J'W%X@H)UWQ7S_,6IS9])W3<2%N 83OHM_OM_
M??/D^ DH4$NMZ6\OR'1H1UDJZ16K+:^, .+:6,.#5'[59KG:!5U84:YI0)*E
MN9E%Z,,3H<\AZ1R_ Y.*>0X *>A/57*15XVB=BLP5$99B9:3X4^CT)^YWE8K
M!*QJMTB-($C09>])#&]-#N!UHJ<SE3K$#*X'Q-C %H%<QG3><\AU/_O72O%_
M7F;\RV5Q2<X[F2^6MG)/-8AQ8Q5#3+:3!C0\M U%QH*9'C!AZNQS^3B6 \MV
M&1@PH)SE359YCAAS'X?8TK%<?!U0$PFA',W29,+=N6[ _:PQO7:$L0'UT 'G
M)QK\LLI@QPLDMZTQ[Y7&V/+]:K #1+?:P\J'<R2  JX(L!)%X1D4=MLGI4+&
M*S0Z2I,G% GTQPVP]1B6H?O,/[VONS-+=T*7[3AYAS[PV!6HX:I&W+UO&,1@
MC8 A:_(^Y8BM.@?-,@=[0'A1&2R;C,KC46_-C6+9+1PQ2AU0=S/-<NRUC7!<
M./<MY+4(.()2Y;=()PA0A3/(O71_C/1[(9;OFH(SX7?VK2C%")D8IT;#,I("
MLZ8X<$UQ-]ZC"A)P&D?Q&T<J9 4MIQ]:2WBC+,5B'GO AKWZ,2V$&-T:R@B]
M2/$RQ5%DY2%6/"X128>-T83>VK"$='@[*0."+/H(64N@NJ2(:!"B"MAE'#MR
MV +3D6B(A@MV@$4 ]UTSS(=\%'P8=GQW\3A1 /,=/.P[^-<XO/:@X/ I>3C3
M%)$&7A7=5*N=U!L6(-V[Q!"N"&ZL6CYUE+DV!IRUG:J"7< ?Z#NFCR4-T\B>
MP3E_7]571Q>0#SCSG11'U(&E%=(C'B<GE;\X2^3;CVAHMDQ@CKB$47AAZF9\
M-"E)K5CGQJT@@CS^S! SI^/_R@L,YGVG1N";8*$)XO/B< 7GF-:[-HY*)H/.
ML*X76YN^LQS;^#/N=C[!MW&"RRQ_SU!Q=1#KP GZ_]E[UR:WK2MK^*^PGIH\
ME511/99DQ4[\29:L1$_B2"4[D_<K2!R2L$" QJ7;G%__[K4OYP* W2W9ZF9;
MJ)J:6-U- CC89Y]]67LMSMV2P&9LIX$H,&@S<.*!OT6@=C .RT1]#K&<RROU
M_"&4D_V!NIEAV'DH4:JZH?@Z[XYY=]S%[M@$:26M%2 <"2(IJ2RXS6MK Z&@
MY4/ PO%5R\;MZQ'*VDS[8Q^I,U"VP"*C?LO-=C[;^=W$,29=IOU:\OY&XQ7#
M8D^+>!GG5ZY91!7)H2E[TB13$B7:.=U5P3$^9I ">QAF[5Q9QO<R#VY\9.Y[
M?H,;S^;!C7EP8SZ.YN-HPM3(D@KZED!_'^GC39-O1"/@K4R^6B$KMS&-^!S+
M"P#T  &>H*G$%;9Z" +S,7-$S>9_MU+5(H0:I!\"RQDCCK_Z!K /+I9"\]$$
MR-POH*0DH[4H*U$BB504N7_#,%+ _[A]$=58]Z[9JE+QG(C,IG_7IJ^.F4<]
M&F=&3AL!=']09ZB/SJ8SRKIM[5?>2T\H01<3+3^5)<9'?5_3X]O1K9A-?C;Y
MNS#YV\J7,W.@ $NYJ"0-:?CN" \XY%GS\ND"8P58,+-XB7Y?C$^-4W0Z\W:8
MM\.=M]2\XFJBMNHC^[@)7N7_74<2)=$(#MR]<SJ.P-!="X)8QZ03^*$HIB1]
M9P:YH?2[V;1.@+C1IHS_6!KIK/O+?0L>'_]&;VK>.//&N8O0R8G!KS7B8=VQ
M2D;L((\&L%7698IV7!\U*T"N2[LM@%/IEZ61Z42$4 S;8-!L<D#$T"N%EOCM
MZ>.J*Q[K!:28@C"4Y4:@J8M3:@XS"NIWCX)ZHP./[/!'6$/#&(YA=B;\9D _
MR%1EK:HINGS&TYVW)=T/IA7&MJ,+P]):V! >;Y$+^22\U]%E#1D110;YXJ5;
M.VY=/7V\7#SYXLF7[/KH/Y[&JH,MK4-6,*A\MKGSMKE/,7'SH::C4R12?T <
M*?98HIN*+"TV3-'5H[-V(Z*@]".<IHU;_.7/%T__P-_YEV<7?_D#8W4^Y!X:
MQWDA1<(EG?W:M95:(T^CI*'UHJ7%QV /1A.8JIXE/3GVU<\*(SAF$ 5G'6E;
M=[<;[]!]A&(D5_\;3#R.MFJ*F5[\3]840'ZJ8N"0<B#^Z)22K*I31RJR0M7A
M?LF 4EU"[B>F3HA%7NG(RNF)A0-=23O<)5;(!FEP,[E3#+SH7%,ZLW6^KRUS
M>K%07 #/J^9HY;;:&$_@ZZF5?%\WKKXTZI9DO6QRIJ@V98]A5"9GN=1EP_.0
M=5==-(C8=M'<EG%HL39!=N4/VS:A-$GX1\Z>#D-I.R+^$64%^]Y3$4N0^P-X
M?]EBL W?2LBKGWY5]NA!>8:2\"I9O39>*B66=\WV*%3"M.,R[&-Z,_2_4M29
M9AP;,%TJ6EKXAX^WD*6E5USXP2>6[-71IT/61B_7L!HR8R:.8$W;L=[3]YW9
MC*Y-P?*.+.@%TFM<O-+MWPJ48SZ'S_L<OK_8;R.>N]F"&\V;.&"M$*2P@47,
M>--AI-,(HE7A=:FE$O7!(:/Y=AT?;W6VB6X/X!SI;\L PVR]YVV]GR@'_LU,
M\\-BP8O%\Y:/^UC$G9)HQJ+"0(5K34=KM'%P0SR'WPDV V07.+"\ANZAYK)3
M&*_=@^J()U2C6"LY@+3I;7?"X3#E6KAO4'Y@EH+^]X:(>Y?E"VVOI'M.N#?"
M0^*?C[_XP\7B=9@OYO-ZZAK+Q;,O+1#_^DL*Q&6%IO^:;N39%Q?/]*^?T7_Y
M8>".6:J%AQU'M$;YN96\\3=#T^"OJ4\:3AKC\P"TB */EC5K=XM-65]A=K-N
MXF'\::8N(0(8$W7Y6)=#_J/9DLQ;JVJ/_CC,"? ?($AEO@*.3(X3RT&Y1"X#
M[BPC>P =BA\]D,&R>&/D;I/)#38RH-WJ\+;%2J7D-2-*%IE4#0O"15*.H##N
MH%/=?9.VBD.L%FU;^C]=IJ#'/%QZO4V>?A/A(QLG[W;,KI9UDM&$VZS29YBZ
M:S&,,7_:?)Q\+L?):]%^\/"AG^K8-.E_#P  D;]M(VT5C#:$+50>)<<'@4&.
MBCW*JTGRC8#&<>X2E0!LEZB?R,BF<Q/3\EEV)NB]> _)%DIV"7L,CR=7GX'9
MN1:)314Q9O:!FD-K<I;F^)D\0Y/;PPI&/2NY1\+YM7>KX\-IF;B:L+&7::DZ
MI2.-)KW-$][@?,8UZQG7_N!P[7^><>V_&US[?%*>UTEYKS0H&W#N<8*0\C?7
MJ[:F"'7MHH%5<*]77=T4,[7.N=O4)TKF(PO@0<]BHH0NZ996C^MMP[PSK=L7
MCS:8B-M1<+.MZ]P'%M&/+/F]+ND=&*)DE. I0].I6_S7GR^>>CY"?.J_O@P_
M&":/']?ERHN< S(?A?E*M=W7<<%()"4%8OZN_2$K&F/%NBR @^?44 EY5JXL
MW*6SW$C::$S>=A 2661HW$SC!0H7VKGRP$4W!H/M315SCR[.1,S'/&J"/T.\
MIN&R"UJ *YF7E%H%9=[%GL-1^4;-TV)E0U.I6OJ\/1(O;X\MK0.S[F%Q4=*@
MH&#K6TM76>-V==\J4!-- *9-0RS/':41\<O8$W$/8%W6'''N:57IQXYK,1+A
M4T@,[-3X8_359;U=U?5[,V7Z7=3?0[4CCH-%?ZM-+?!H+R4AAC*J52N\),XT
M_<OUNF:G"W-4I0+A54-NT%<&^P@VMAET:+A#:6\/"5$H-XT2\YB[%;=1NDS)
MWFRH-7K/_-) 7E6(CG$B%^D?X-1CS@?$>1\0]Q-TO/:RVF2D3&*,,FHGFUA\
M)!B4I!0U58M+D]%0O!MI=IS*/6<[/"\[_ 1+\!_/"3:T,CI'Z4F*\F@>7UW;
M!!=9&KZH6/IR($1M/&%R^ %UT#,,M-YT.-JL-S;L=?#%Z6SB<@[$Y*.3K:N9
M=$-WQ0W1D!R6'/Q$BO6#ARZB0SV+6 L"CPT.@]P!0)&>WUQ=UXJ;D(7'GU&&
MU BGR 6E0H[VN$ZDMQ:(%EO^9#AUHS)9=(41,>U54Z!.O=DPF"9 =P9+..%=
MN$F#DW;PR2@LP]35H#LB?*9)[:_RU<'K?9CQ0>+:%D;I+8HF:-,<.;R35I?=
MX*4:1>B ,>5$>B5^+5/?XGY9.X>PKVLGOFUY8G'4=0;O*T8KC86;L1B_A03*
M[)O/TC??:V&"(:B>DC[N9'*KDX?E.7D;-=62]J*/@6=C.V]C^P1+<+MBPMB
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M$W)H_;%*F2I5HDT8^<W@*WW')CM O'ZVV-EB[\IB%31?:2U)VM3-UG56TZ1
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M>PM5<H5!_W)P5:L8T;6=SG7?@?9!HHV^TOEO+^#B)Z]EPFG3E\PRST/<T1A
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MY'[! B94>KZ<>K'X+L-!*D\^\92QXAH_H# RERR!PD$!=[;#OLUB6$S\\-P
M/_3-FD4N#I15;NIFK[Q=[UW,:8\<H93"+KT^^\RUM;%P^6N<!BMB\*N1UQ3!
M>ZYY33"1\-1F?(+$4:+ 0NZ-2TJ6,,OK'172?"SC03J2!M$G*F4AY]AFL@:7
MP9@!!!9Y06YI*8-:!%\0RKL&>B/M5.UO0*+HV[T:\[6F.!)JY[B"QMJ!&'V
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M_ZINW@N=TV]Y$U:2!A(."8N\>AZ$HL_LHV2([DG,B9(I"/&0.0*@@>P5QSI
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M&@V*DTV5W+?*>/0FZLB912/=J?CS7G8D4MFSCI4T1Q[M42R.NE?:ZW*'@BE
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M-[K+T)KF"@2=*IB+D>ZKV%13'RDPIQ2X:8!TVIL,L>A^TW]H]:C384$VHQ4
M3.S1O<A?K;R>8A?*B=_6J<[Y"=QL>)QX7C\\SAFX_3/JR)[QTY^/^JUY[24J
M6FL5NPC3#Y%P:#+CH$J7?J(U#*['<F&I Q_,W@_F[(-&G)&<-Q'-</2Q0W'
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MQ>!=M>BY7%'6EE3@'%Q1O,R'5T0-ZL^]F$GS];]>!DEK:&)(3C,^S;,5/;!
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M[H!>.R^>< ];H3&,%1H$,U8J-G3O-\A29^.?C?^.XI=H ).Q7TQQ>G'" !\
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M3**9MO \AQV.37*@S3;N?"U:^ANF/8*020G6D$SX'304/Y3N%\EZK@(,G(*
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MD!N*CE%/S#;WZI4LXW8T4K((*)O'KK/A<K,RB&RP>OAA^@)%6:'6"WY4G@&
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MONF0I2!/F:#K)G&T:WP/>2P5N"+@DY!5<*=):-SA+-15\'27SCMXY'Y*7S3
M1_DM;Q<C&'NMY+;'8K-?*'84WH^MC@A)\,5=D^A(W/"J4,.+M[5R5$2^,M9
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M6+]!>;?:.($X1)U3ZS."W,8V<06?.&.E!R'O+Z!.5E+7ND1=0Y=0M'(9?*D
M3D,"<Z2/2_7]I%B]BLWK_@P)"%X;ZSW[^MLO!\'?LR^__J+?4FPHD/(RP//F
M[E!+5S]^'6']J;ZQ0?;CH3HG]!13)_'I;_,/A)4*,=%*.@N/A919LD!3Y@7
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M: 7@57:H[Z1(.O<'$>SC=Z(T..WX:<??PX[7W;[RH973/FN$.HEK,^[91&>
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M)3=XF"QZWM%QY_;,9:(X;TLQ2U<5S FD3RSW)PA94;HUB=>]\'-+S\C$/T0
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MWJ!^A@",!0TC()35)>%Q"+#6FN,3>I7*./"./47HXTK:K,@<CN)J0YXI(4J
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M'UD0\"-X>EES]G(U<[00F[KR89F?]GXP"*]/T5=)A)<)-;(@(OV--EQE"6K
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MN +W>= -A77XO8,KR<ER>V&DS!+DP[%?LUL++C"Y#J^;)ADWK;*1&4Q,FE\
M"-%0>5I!/\U>?IEO_2LR.J@1<<]7<'\LG%LJ6S C_-$6+9Q847W,>OERQO=:
MW5B3S.JP!?V#7O+R2+@*GWQ<Q43"1CS[LH9H> #4Q'8BD(79#6*>%^6(/WR$
MMH=B19D76].D3>SBK3<']##YVE^U18\"8.-5)24%UNVCN="E/_+6;ESSTYGQ
MT9T9Z-N3E4JQIX]]T7+X[=,TJ1M7,78%9>.[-G %]CQJ::WGG2D]<[ M0E^9
MPN2/F9O1Q9IY!V?/36UQ2'0S9DE "L/''CY\(%L9.09ETUA>OJ!V;<BE[W7_
M3MOMM+?;R6#MB=H#_)UUM:Y[K/5)&D]42ZFOO<>Q<%7X"6MB4_3[Z<&]#NE?
M,UR<D_UAC8\@[79)>%22OA>;&)!>G,<OAC$A+1\?TO+K"6DY(2W_JB>/C:$,
MXD?<NN,&/T9/Q='TV#'"'Q9:5 :FKJ(T[:+8X9#PUM_'C=LV1C8CQ*X/[TY,
M/M3]6N%?QWIG;_95'JPQ>KA@.2@@#Z\_4AFDWQD4=IC]->+U#=0">C([93YW
MG SS[^0-P((F)6;%=C*N>.ZA@T!]8O6VYL];XF7#A][7\,>%?SMNAW\'%:<5
M,]O%EF.JIX>V)_\(DKD#4!D)0! M>1.S2-O*XE72EAXK.C3LX>%W.]"(&/MJ
MHL(B'JDU0RL66&@T4P5Y6TO]%_&:V0RM9L2'.N>W)TUF2C(DG#U1VM84S969
M!8D_OUPO& SW"N#:J7([&==3JMR.BJ.!<[/FW(CU&*)2:&O#O*Y/5F#D+Y -
M<02NZ7:4.,XQ0!8#7N2=-$LTT@=)B*"%5@RT2*',:TQ&#W7@E&R3$3[$?DDY
M<_\^_!V%@-&0!Z9,E&0PGOUXD52B\]FKGUZ\CG12A)9E WZ4"M1P+E#U@+RB
M@=W.A80&23;BM0QMD 61?S0B4Z<R>%VEWT7O:H_TU)51*L15@.*0U96"B$!*
M]&6XGNC:UGD+MZ3)]S<0: K^+O:2+37/HA_45L5\]G4MQ86WTSX_P1/[V(M,
M<A%:;[(LKKU2 X/;C5[(N(QAKS46/Z$=Y1>@:[GUQD@I9",G*!_,X5R.IWXX
MZJ,0W_%COARX!*+E+$E=^E]0)Z9N/QV8C=M(:LJ( DK?%3'T9MA'9OD8B[+V
M+K\11\1K'Q[3\\/;G,S2X@*!"=5MZ;D#;"^B;])&YV3<(^&^J-A8PLX#S0IN
M&'E9,]OS55=G[+4M>NKMBY]?O.1'^_GR91NJ8OT&'+B)1C%S59<E8Q#UE4(C
M*PIMJ$Y1JE3.Z\I_27+=['E2]2QYD\@9HKL#:3H1+R]J;YHR1&553?@VVJ,\
MP31O=WS/IM-%-14'\]&S'^9AJTA%*[]6V1Q:N%'#8[AKM17<D I+ZQ$;HM!W
M%$G04NU1@1DI37.TL[K/),^?C<3$2<=,F-/P*,G4R7$#T_(W59WD]3X^CY.?
M>%(NT]&DAVF[O(6*N9&D/YLA\D7$QO>2('E<OOG F/(/+0Q6E@RQ4A]2X3D?
M?'A/ZX?C*6D_@=NSTMNV,_$J,(G>*/Q/+\M)^;T?OCK_^LEWGZ19:/.VO_'S
M/9IP1F[T*=[L&=VQ_6&>M[2WW& -Q.GW-_ORVT\^^*)XFZ3C5^???OWDBV^_
M^^:K[Y]\^>U7WS[Y^I.GUQ0S(ZO[ YW0?JAEF"#) &.>;I@88?+\)L0D)A7,
M-_[B\\\_Z5WUA+:&/V$[IWX]MP+M10KSJJC%72C=?@\]OK 8T[SZM"BG1?E>
M%R7WM [Q0"&//2W%:2G>RU)L.^]-D]/,'?K+)K\>2[I,ZW%:C_>Z'L'IRA!/
M+3Z$^%12_-.:G-;DO:S)QJTHAVSRK;1$)1%2:D9X!G;_W<YD0$->,?D>$C^@
MZ 9G[[2,IV5\GUYGG[<Y[=6P&6%JIE6JZ$ $F4CK*E W9O>FU3RMYOMQ%!RT
MED5EJ#*%&>C,:<DLJI<M:)+\'Z?U.:W/>W$:> DZJ-*A92L/!&-+MVB<:79)
ME^($<OC+9^PO?'ACF".*ZHKJK>NH"E^6;NT]Q)"C1'&M],&Y"D+8[G3@(U.>
M"=*"5!9&T:4!55J[HR4H3,6XU!H,^'NBVUBSS@TS=4#_D\9YI!GM-DP85:3,
MB,I#C]QB7!0GK8U#:E/'!W743I1"3:&\!?V^&89_(\J^P2"WDG >U%VX&LMM
M$ ) <Q\5U\+\IYTS0F$["D>U/C^4B];2] T4^B>R[F8G4"B;;,V'PUV_7WW"
MB(N8&D<>?>/(-U/CR-0X,EGM4[3:[]@M,R+SQH!4OP^]JT300DKGK+PO0U@G
MX$L=]093+J<N9^BA_OG@?:27B9A92.O8M)"%DD8Y,@)'"4<S@Y@ 3TTR2E-_
MS&FOW?O1']SD[0S8:/JH!6NKZK8TCJ.>*^%6-+T=ED[(>",&>_TV2[VW+F='
MALF*WJ2EV3'=_1),A('9"[C(7F0C[GY _ FM8&A$B30J34>8P8Y9_?PYUQ8:
M_$#&6W"N:4/.DG&#+0D%1&(_>ARE+[1IVW2@8_%BZ]P;5@KEWIC >H"Y-6C)
MB,Q$^,>3YXZ]EFFG?Y0[G79+PSS+94WUV;B?. L@A0>_B3(1BXCX7*V<,4.E
M-P4QVQ&4\>Q7&92<K.E^HZC_%TCK@1T'IUX4LL^98$]:$S2ZMV!@8')O'ASW
M:A"%!OTL2[Y=D+TATJJE1=BJVB<HAP@A'4',69K\R6:."$1H.#U5DDCPA!8]
M]HN][<&T J>NY%O,08YN&,?4IUNF40_V['=O*8!@YI1,HG*\=(NBM6<^W8\(
MM.<%%SU)VRKG?H#(+:J3P[-N$*"!7VI4/XZN'6A+>Q!L7#S1+9$<V/ R@GX6
MQ0D2>F!R76/9$V)&C!G(Z*ZT#9$&/GWDT>R!M3(LJE965]L*/N4#;Y7,X]Z\
M!KHF,G7^-8HX13.CH93E9Y&Z1:G.G5]9:/EPM*S],,]G%RW^0-Y8IIW1= O*
M15WG34AA1:AC>!W)?/ T=-[2ESBE.7M(\1RGP_3G?&9B/Q=ZN<I=O^MF]D?B
MK%X018_?R8LWFEGTQ^&^1#8-VY(1FR#=BIP^*5]6?CQ-24?:.&56LMB8^RND
M8&U'")^X)60):#KW1),8$/>DJ$&%4:KR5]8U'N?\]!$<^3\\=3$WRPY-Z S+
M]R )H@E_7= <X&!.]ZED<)M4QQF+Q2Q2^"+R-K2-*VPJ[I?U>YGSH<+=0D]#
MG1C^5]194 0"(5KMI.8B\JMYV2D;G$S*4%'/C!*]#(XL2.@+F974H(1=#8$6
MHTY"#5/5[_5!I56O72,*)WV22F:SHYQ2< <CFUQP"*.XN]FI0@S5UZ /&LT=
MV3&_69P Z/.6*^3[7E^><D,) ZP0/$5-U:.QT>0\/?A#/Z#SU*=Z'PM&I.44
MU@7KN]H+K;#(9B?A5!KNT-F$[::]Y550U;2EHM'E&,]$UOZ1H(Q[)+4'CKO3
M^KVK_@O_IRM)P.S)%Z+NXOQ&IUOU'M :KFV^U,H3?O/KSIL1@:B\AM/H+_EZ
MT73>:B$/.'M>LM5XS7)#=)&+V!'I1W&QH-[$Z-K19?^17VM77JUW<-N=GVJT
M=S+M/&?%2>:B6N])[HAE0Z-ATW"UD"&T<0BV*5/UD+H=*:>JU<<K\R]O5O*1
MB#:VRTU1Y6=S47;7=R6:S>0^LZ!3_D8/?S*NJL\4.\FDJU)HWZG<O&^Z(%\;
MWH,MEAU: A^P&BN)XNA,-:@2L+>T@()32S@?=FSM</5Y )FPP\<1^\S-FXZ(
M]_UR^)*7 WYL7]NK.)Q+HN?GJ/13^JX0&UR^?G49Y'/I,7!G^@)$ 687Z:GS
M0H6K_$/_JM-M;OBK; T\WC_$,_&/]:,_6UK2C?J)S\P".C%F''PWO;R.:*CD
MYZ2X25)^C?_+EWXGT 2P Y5>)6UC9=I_H S9GZ"V3]&F2%THKKBNR54C'R@L
MJ]H^7*GJXBMLOJ4^8'A)FNNS2SAZ2F[F3>E&SU=>#/*/]W>_^4$T>>D:LQ5D
M&&1M#1YU.B8_NF/RB!%Y+7E =M72DX5<,7.V_%X72-.A&8S-QDLCR8D#1DR]
MFL[+GFP=W>G"[V0HBESTCH)W-#*7P<XGIJYWYSC2=S$W? 8640KQ^.6S(SN6
M70'>]>6!_>KPKY"L[5N#UIJ#=M9NO$,LV1]RC.?$DBH9DM&0OJX&TH%0'F2&
M56GF8W_!7T^D7\ LX+^&)6%'G(K^)2=PHI4>*8F1)@WO4J7/H_!ZC\P:!W#\
M=: G 1U02W OIAHCAEN$7?K1:BQU</15\#2NBJ;U4S['+6)S.F5Q4Y8@/Z<K
M,(CKH8[;DNI]/^=#>1,)/6.NF<.S\&.^$U:TMO4^3<7,.36>3 6X*WS4VY5K
M\&A2=OMW5^\HB?U?(T\91"/#:^5PSL_ +;-AHWT$F4LZ54\->#,A*!X]@N+;
M"4$Q(2@>I0OEQ[/K&.[ES]Q@<Y-TZ,]^D502KM/FDR1_%$/FPH;)(O?C&(UW
M;W(QF&F"&0;;1+$L;V](NP_K ,=@IY;?68]Y<Y"G[@G[CHM\1]@+36>8$'Z*
M-CZZK?)\-?NT^ S%%.\?D>(U>[E,VL0E=2GR6^4\!*U$71:JZFW"M].&\H_*
M-6;^/OY&AJ&%_."DFIB-%5,XEXP_^0OP4+DD*#*0M/+9-80G-CHTJIF$D25@
M@\PP['85QA4OZ+^V!>Q'JU;^]5:D6A#J5LJ[>:<;:UW!AUT,T/969$$GVA+^
M)'F.?&.W#.4?2D&%O+JJ+%+K90!]2U2! #&D\LF#'*7^6NG\Q8<=2*ZD?#DC
M5/!C0B[9K9UVF_Q* K.EHTA$/'BB3EN\(>49KAK4W;ZE:,D;/63.,A$;*C71
M,FK>2+Y+TK1<8*X;:_-TY@Q&1%WVFY#Z)E>LUEZ]=*TUAKM-QO/C,Y[]^CTG
MD;'(1@H<*80K+=@=JY/)8DWQ5R+!*V@.MZ=5NRF@UMOK+\$&44;/@&O"AV8;
MH<)B-PTC*Y+6$%B&]#?IH):.& OP7-[(^<!_ORDG6;R3WQ8/A^7=)2C<@.VS
MB[]H_;I>;\I#2- OXX';!]98?D5Q&N+9)48]9(]&^4'5I@^H4Z4P-5'A/ZJE
M_8$ @'=;MT=Y6\V!8"A<>56'PFDV\\<")?Y8=#>F(XE8-J5 [1'1&_IYOR7I
MGI*2C]RJ@F(B9)X4L]%47B(]FR.YW+7M+8&G9=57CUYECKJF40Y>8DVN* X?
MXF<S N9J&>#^\I?O:+&$8[Y'.6]*N:_&^?)/+#&K=/@8X( .GZ(.8EIU0K*-
M5>;6AQC;Y8+LHUH[51.J?4R8I^Z.5#[; +UC)3FCL,FH5"RDXS=#!MUZ+W-[
M<Y0E)(%S<'G3*@)C*/(>M$#OL'\)BM*1/[7V<YE*73)X*L#<E>;:HMGM:.4J
M8]?@=F,<90K)HG#1S]TR@HE#S-5G#OTH#YN)M>(=$\43:\4X1Y#@RI86%\_H
M54E@Z+DU$?U,2_)>EN32^6&U+'M!LAP!WXL0G.C15UV92!W4S:V1C E:)DZ@
M:2G?&R=0KX"F@<'<5<Y_M54'2L3HN*N'O4]$%E<^*-' @L2/*5\L*S]&-59
M "&-19D?L]H?I??T\87J_09/[BTB,0YIK! 'P%^L/,RNBK5?;^ GDIXN6E.
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MVZ V/T<LI3V(ZV[E%I(QD*3)LF\!785XG/@Q)!=T7LY@]H;MR1'CO<G=C->
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M/$)44DDU=[O1!9OY113L2S2AF=5\9C">R:Q]/[E.'\D6%,XF<IV:*XPN!!7
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MU&J(RK',.O (0*\!'[23"S?R_8'A(W0&;+L5;X4X_H00QX<UN005G;%TL=>
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M:K745&([^R(9]2_D19/ING>F:PM%,NBE&,C @A<@:M3O8H#8T Y%BD.FBG$
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MJCTV\NW3.<ZBS,[JIEMA=5,3G#'* 9I$.?VB^T63+?UC@L%N,V*A1\:[I%O
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M<_ ]%Z+PN_X5$= 1P O.].HVE]X_!\88RJV$.<7GC;]%Y:BZU$*=B;I@R@M
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M "F:SO^+7$#P0<.W0YIF.@1WZQ#<CK)],Q=^$)"7K 7?7'C!6 LC>T9W'CY
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M$00W?854>YP?=C62\N'$4!^5G&%8(J7[(HZC0J851QY2>5R2>B-M=M)H;$,
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MQ)A^T@>EOY;\3)3&#AE<N ?7,0,:H2%9DVVY&[@:J&9GZ_';X2;Y._I;LM,
M66#*7L -H/\7<[;P%^Q[T$MN>X))*]X[K?AW9Z>;XQAQL>B;JLU:Z/C(;#D0
MFV<!##-<X_,/A#\'*L#;#\051T$Y7.0@?_H\)$>YUS"@/ !!O&YZK5Q]"R^%
MBZ=;E7^DNXS^'^+/$2S-_>)9\J=--?NGP"1%@^!LY@XA1!W3MM,M0B5XIJLH
MABIY9$J9FC;3LXX4<A3N$,AGTCH[KG5N#P_K=5'>8]0>6(#BX[YLO7DOE]F
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MJ-(ST',(>*E<.TP,V2RXF8 QII:B?#A/6$/;;#($\Y+F.&ZHTY@ DZQV2)U
M$_YFYB3D[R,'(.Y2DU#-[%7,&XJO2U(D8T2BFTGW"<QE'QH76V(*[J][+_9?
M/#OXBP9_X'?_]<7^PZ?/_C)<W==SZ_TI^5]_ZFM03##'^C<OX_/Y;S2/9]7=
MCN][/00'M(@?_+"?_/K+R:O3MS_=8CKA6NO]GU<OD]/W1Z]?)\=O?_[YU2_O
M3[>>A%L7BIT]+O<"^_B+_^.D)2EM\I__7_D1OOE+#RYWCMKJ]6_Y_/DL.SAX
MLI<_?)'O/7[T=+:7S9YD>P=%_B)[_O"1>_'PT9\P%O!/>>+F_^M/Q[\]F3TY
M?/K\V>'>[/GS)_X[,[?W_'!>[#U^=O#X>>[F![,73_Z4U-D"7OZZ^&O410?=
M6C\K0NB=E!=?-^T1UC;]\[UA%\;_\Z@N\,/^G^_/ 1S9O??K^*%J\@]_2ER7
M9TLXY&WO_J2US.)H==T'^^W YGMN75?@*_&2LOCM(/\M:LC>>>-QO)\<_^.'
M5R>GKXY_/7GS_A_VT.U\1NWK'K=[IF+_#N"!%BH76+V;>R<;YPWVK0GWB1GA
MW/\!2'U2Z=6G1$/M5HAQP([]HCS#:I;R!1!-#P(>L.]'9_1]<EP$5ABQ%R<E
MN@ELK$X98HRW 9H"XK=918P3AOLCM=033+4@?:41=PCP*>!Y=536<31I$),5
M@' ;<D<,B%P,I8(4">%;NH4;DP_P*LKDQ40H:^;Z@#IU701(HU8I76$@'3"H
MZ*PF_ HA2U*-'R5(1](PHG;"%Q1&MT>T1DU.K( X\("(T1@6<HT'U5#3H,6&
MX^AK&4BA+XE)/OQ3M_A/C* N?"1L$&$\I8OO(XP;V'N%S0(,(VM=Z=_@F-_[
M><?F3^-&]N'3+)MEAX_V#I\^]K;H^=,7>R_<XX.]P^=Y\;1X=I@?/'O\U8WL
M>YA- A.:UV\E<^:M*=M69M((YK?*SOZ4T$OR-NCCRI_RCZ[80].Z,[KF:$63
M3(!6R5M^8)+U$OO-7EOQ.'_\XMG3^=Z+9X^RO<=/#F9[+XJGS_8.GF4/YT^?
M%T^RQU__M07?*+S 5P1_NQLO28>7"FX,%6*-^#U4*4T-X&5"1&8T0F</*>2W
MJ FUK=$[^L]=:[M_P.#O-^\%#B_8/L(_$<#6 NE_YETYY=::=TCHZUK]OI#L
M8>H;VH$80WI\7KIY\EI336^I>V;_CNR4'./!0"*=/7A=T1&891'Q;RB#Q\IE
M"X/NK.AKL/\_4DM10B^@W=_4*L*M]:GA26&M)8/*%EYNL[KL%C)2JL$G,W1<
M:2!M,R12HT999A$B2R$"H=AX 0$7^T:I$A@J%FJ$7\W_[:*OX+%#%Q1A3AA(
M381U;P2)2RA)0 \7%R!E_"E:N=_H/**K0M2I(:7C^Z/_X07W0X1U\::W\7[+
MBN"DF53:O.\ 9P3W8-E498YLR0MNAX:G._/[^F_)_WN'I\]7V+5@MQ?:/ SU
MF+_J.;AAL,HT/-9R52[X4M:EJQW0!_HU(EXT&HNY(2%;12,\:-?,5TIB*<XO
MII-K+\4H"?Z^\)"F0YY$7&"O@%XGL(^%Y'EOZ*S!7#=0GY#GADG&$4G>ODY,
MMW,W)B?' R>=[D,7>&?(:Q][S883V[_JI;_MH*.3H=4R1XL5H[3M$!+:2UK9
M29<G,-.TTBHBBZ->$7)68>HXE0,D;1!\5]VP!><.!O1FZ,Y&G03^DOZ;,$AV
MI;6-%24<I#$3^0;9@RQ;,].,AJ*A>M=")+X85U^4;5,C!?DM!XA32'S#%;DM
M)AKLD?3!==SH6JTEN*,OO=*AQ_HE[#N(R^$J]K&@;[5D(R> S@_SU?)$2"_+
MV]P2L:6D(KKDS?NH>8'.,H %#A]BIQV:#SS')9;*=(U;HD'4<-$J9>:Q^$$Y
M*$.L0F9=\G.9MPVHV.18?WW*@=XK:-IP#H8;P\L857]CFDQ]AO".&&5[BDRB
MD&Y@],' AP"VU'&G!CFGRDX& <(H)27^#*.4H!N:9@+]WMW;-6\OPIL-'5/!
MGTWXSSN'_WST<,)__F'PGU(?XB(*4QY=NT(4%U+NA9$?&BE* '_23 S,RK6M
MB*0N/W&]'QI,OL^3EQ%GRF?Z#UN"W1$7@DFX:G#@!PS2?LU5HZWY%)<:K!%Y
M(-([/L^ DI][03'/C?0@58)J#^TG^=2&7&#>9@L'E8/]Y+2LF7=]II0 _ *\
M45G9_O^0$P>@I0$VF1SWA[JYK >/R]& C1H&1-^0WO$KW<JDC0%[QMWC I0R
M8S9PP"\,MN;]0'>'QB%1M#?FPL$5<>Z/7UT%F7B:9J58U752E1\<N9@;]P1"
M*,-Y'KD6S7 #V&7DM94X9SOONXXP89"G3-ZD"94#CU+)<5ER3F5!(#YN>#OG
M/)J*/ST-7*&!*[Q1]SMHW(I9*++'S^;SY\_W7)$_]A:I\ [#P8NG>P>/GSV=
M/\GR%[.Y^^IY>=2L;^>J5[6HL@V0<-\,XOM1\Y.2EO01525SVF1\_:+TAA.F
M*?C30KSP >(]9W:)!=!6;9J-.88%<$QQ#!JSO(0<JL'!IJ23O1KXMTNURDEG
MDY-$DEEEW#G9M6]657HV>Y$]?NI=J8/YXVSO\7S^=,\[LL^\3#YY?) _/WST
MY/G3;R.]Q[+G;]O3?J9OX"1X!J^;]AIRO4,"=P1,.(D^F$GW2]@-;&D5*%?,
M48<N[2)(*(C>#,HKE'JGB<)4:2&!!DM!)9A1'^B.E%V^F40?/'WV_-&SAX=[
M\WGV=.]Q=C#?>_[DR8N]YX^>/WOZ_"F$#(=?7:*Y=.TEEHH__OGOB9 #:Z#S
M+D:G>?%^20,_-GRV8<;>Y(ML;DT1\IBU!A<(NT30%QXP>D&";'1LQE>1I+F;
M/2J>/IYY(7H"%?=\YH7HJ=MSS^>/#EYDC^;/BZ]OV4<D*13AW[:Z[YV1H>NB
M$*_S0!@\[XBX)<&*,_T BYJ(&,J$D0>)2X<RNB5\@'+."@8H(1NE],51)]LG
MU.@UM.N7R.!(QN/.O32[1?9Y_O.3N=>QK]P$<?GNP39WJVU H<"'NP[]/81!
MP6_?O3IY_^;5U(?Q1^C#N G1V5JF?(>TL8!/N?T-FZ3DYNOF@34<4H/_ZK-V
M)5S?99V<^G6^+-U9DR;'_BF\MU:7&01]T'M^B9,9?02/N**/Y8*(Q Y2'X$D
M,+ <6T8[N*9+YDB^,&?BZ02?D%+X= UJV\NIY?X78)X#!,P!<<4^DEQAV3J%
M)F.BN<@T\__H^>H\@>GR29Y5/NCT?OK"/^JY35%C0A/+7)OW8"P/E(!S2O!'
M(SUABA7BO&F]D *9$;RJ0EP]ICTA3\)H+QQ * ,%D5]-V0R C&QJ)MWQ\W9C
M6GE+\6=2S/=#4+Z0+>?M)4!6)R&Y(T)R0\H#4ZN5C$%J,;7/(*Z<T@F0Y[]L
M8#1$[BK$/%64M$I.S_MZ77IS3P2(:?*#*_^)R,YW)\=H@(^S^NS?YTV?)G]S
M,U="_O^BQ-GN\ F%5IV= 6?O"GA&5L@%FL%MGCY-GSQY(>[ PFDR;-:7%=8D
MFTN8LGQ>+C>7C$>,1QR@==V\V5D+,Y+G50,6GN]Y>)@>/!W<<__*DCON#4WV
MQ1'"6 Y7=^B*'8&A*K<OCM,9W#E%_1.-6YXT]1V1DIO2U!A&=%Y%6;5F)S0=
M(<;_*F7EOUN1=(5+I,G!0^)?YB'?%' QHNG@,/J;-A\4D(:G'HE)B^U4'DT3
MDX]V.([!Q*0/H']Z]>/13Y">/'[UZN6;7WZ<\I.31MQ&8H#]!=C"#@T9@ W,
M$NI*Q>8@PY]&4S@0;.) 0(!D''LG@!(/<)C^OVD8R(*SA&AZ*$'E-K[O[UUV
MAB?ZD[/=3W &1:7$["NX1VJGE<(L'N*5#ZWTH6.I[V087>'F, "<ILJYU8JI
MS)FFKRBQ3DY,D:;H9Z99Z+038C%'W.<&5,[T.<XS@051X;"EN4$S@&,".J=O
M,^000*3D/+MH6DQ1\3.&N0TRVW(R#SNEQM0\/-YU\_!X/_GYS2^ODM.CUZ_>
M_R-Y^>;T^*>WI[^>3$6LR4AL(Q-;&>[)H91,'4QWKX/I8.I@^L-T,'W+AQ;1
M1>L&3N%O9;G#]NW=T<G[7>?P3-Z\N4%C,JY[_M@&=,@I^.0W8A/^;=ZTOP7N
M].XWFM3TF_M7O\,RC3Y;\L0[;4<G__WJ??+Z[4ER\NK'-Z?O3XY^><\9J%,D
MA'W[2_+J___US?M_I/X3/QV]1[;8M\?__;>W/[U\=>(O\/[]JY/3Y.B7E\F;
MT]-?_:_>_7JRZ^?E^&]'IZ].D[>O^=D29EJ\"G2UH^K_+AZCW16,GXDBW#(@
M087JF,:OG<+XM4D^[E6<,D*1]Z;.]Y$#"P83%H)8HF%ZR3$/D&-)"LV9W7KA
M15=Z,W_\Q\FK86/BCCSQ<)K8_4X"W4,E^#=_<4>4*9/BN[>*[P@%P*NQ_#QY
MAB#*)RGGF"_A_V)<Z./'"0XG/0^RT[J\H?[5X013H1A8X)!T'L1QGK7$ZA/-
M.H5"PKFKL(60II!W)O]=UG[75CV/.(7$]WE6S7'$N5E,NCFU%@:A+JA+%7X&
MA5WW"!@=?!?2[WY=Q/5+A(<X30D?C3\S9<WON<)\60*EEY?*=\BT."G*>Z4H
MW];)?V5U#R7&@T-"FZ/&668E#"&B"=J%B A0FT2:\\_/]I\F?A45!!L/?+#Q
MYX?[AX^!RY)TXG="K6'UXJ::S3J!RN<X5<G_$'@RP@J?"!S^C?]=7[NPW *A
M@;,>%-V?'^T_D35)%WCKYA7R:>!@NQSX/0E&AV@]N/'_N-:_J.0]<,!G.5%5
M(BV)7^S>+ -MOH#)W=('65#_(W\-"[" SZ^1K!8'.('F;2^(8B=0I:^RC\HF
M@J 8INLQFW*<>96^[E:1 \-[--B*B$3X^'].$G9_A#=X/_$O^*@_ X[5PZ?X
MG<<;&S9XI0>'F^_T\4-\I]0>> :%WXNLZAG'^9T\@UD L0%I$1U)\ MJ5^#6
MA$K(-5V&<MHA=XTWJBGN&(W;VJ1E*1JJR >.SF6V)NZB=2RM.CDNLLDRM*R!
MU^-H=!BN8S_!T?:T)AG+SKW2#4[C0EQ ? >I02\R8"TE/@L@P_%/R;5R? #A
MPC!, V;0N9EB5F677!#'*Q-'P>8$/*!J93I5(AVBZK\RRJ0Z"MR.0$N3,Z:,
MTAW5"W6;A?DM2T<L0^'< GK%W446,YI.+L0]="'>]=[/SIC7\I47N-5:N+<!
M.LA4VV^ZKF?JX*,YC-U#H@'Y;GN3Z-/)\[A]SV,:R'4+E9^GOW6.'*'?U)K\
M!GSO.ZQ=J-[S=)R':9<6^G]._A][;][<-I+EB_[]O@6BKFO&O@&Q15(4)?O-
MC5#)=I5ZO&@DN1W](EY4)(&DB#((L+%(9G_Z>Y;,1(*+=I&@F!/W=ED2ELR#
MD[^SG_/A_,/9/SZ\__\W+0[SA&%XEP"SF0DP'9< L^$G;T$"S-K3%"O)T_^S
MRAK._U0-0^$;_@F_!6,WRO\<-ET&]3'EX,O1[Q]PT*S),\!TT6_GYR=?OU >
M 5SPZ9_G)Q2?;[K ^GCRY>C+\<G1)^_XZY?W)Q=Z#R#'OGVZH"U@.Y<C_,-*
M<PNV4E=KGHK^S[3T\I&:ZRY"Y3B)X_0:'2[5&6:'ESK'VNFQP%NA.LPM<%AX
M17HIR?F@YL" G8AMQ&ICU&<FQ>M6=4E:5$.70D_&N>0N(.3J@04=<6NQ,^J/
MC<Z4CSAGI[V[\]_8YJ-J7VSF,?(8)I$5N9G9N/P9Y!1#E]8PS:Y%%N[$:?H#
MZ6,/O<<2!E7XH=J?425THOHZLR<P+P.<86/?J&@)"A Z=5)R&6$3-E\U ['F
M/Y*+C7[D21<B*$IR #&YN<=P& V',K/;/ZM9'^AUK75QYEC1\CVU="MGWIQJ
MN"Q*;D!"XZ[(O4BS0'%C_&H>"ZD^%O>X1K<:NO3B:!QQ,V9_R8)P.(?VJ]%7
MX9;GV!D\*G"HUX).TSI/P;.8.8!78CN6:<76VH4J*!Z''M8OP%;>T2"%%7Y4
M5/BDJ'!NJ* ?CA]@P<OUG]6Z[\1.0*]+\I FG'\!)$]"JXMY-0=TN.P#S'QZ
M=%\N^^[27!7*/(!/AI%""2?<P7VSX7X5^@'V1KV*Y/7]J;+_<-NH>6)0E00*
MJVL2FCZ7TAM$J=5'50]VY X0U(-")C@]+?AAY1-8\JP,: :=&I^G!S!4;R&#
MQLO'<&!WQFDL@Y(Z9Q<1Z/3#6(SA.*?95$E?^.TP&F0I#>3+RDLX]T!D25/]
M:& >PBE5=F. )2BIS# '(4+M+! 2J <57DC/P3Z<WD?S1'5OE5( .XSQ!2 H
M07S!SY-THB;TJ6E25J_N,AG+PAO3E$8<\RQ#+;1()N9,W E8ZKXWQCF9BL!Z
M3!\]D/X U^ ;1VA&MKSOHRB6*K&#Y BVM$S+O!9P0RIPLXXZE0I*C)NJD70R
MQZY@43Y2$R8!X)%'<7Q<&&9Z0(:'_XFQ&SE]#I'IQ5!8!,78 ,14B97M1)1J
M<B,VEXX+GP<(<!FFH?/]#]ACO _-.V&HK^BQU1[/]:/>*SKRI4^*4@/L>9.S
M)T9H!>'#Q;>CLW\"K/?WWGFO)U$VE$D4PBHH7 GJDU*:4@_[IX&1K.9$JO M
MS;KDD0V3:"+1K<%]PY/TBLM<\9!AQ6H843_<EG=:O8-CQ\,HRXL%1Y,CKA1#
M!FXX.?V(&_N[@!7Q?1^^\7^_):00D;IA#7XY/3NF.7""H<$ST$#/5KKF*!I$
MI'EB\F:"VARKYA>_?]SYC__5Z73?M7WOHAS# K[(@-A0:2WPY\.]WCM[)*EF
M5-U%FK$'"3U.0SSTJ8KX4J&Q+LA5VX0SB-OD[S'S):JN$IH46W\6%K;D4 >
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M R" QA8 4!04'7WZM5G</F@==G_5J?%VFQ)5 :A?.B_1%ZYH\6;\A0OUT8H
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M2LKB_5"N]Q6L<QSE 0ARD<BT5*6"?(T3YEMW6L\ESV)&YOALLO-FY7A#%ML
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M&_%5UG4*'/9OV ERV/_DV-]QV+\*SL76+@[HU\KR#B(<1#0<(KH.(C9'%PR
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M$--I=1!CPK3$+G]K%)V;E&[[..)NHQ1M^_N'^XWA\FT1I<Z <3C<$/YT.-P
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M#BII6P3<\#7*PAU*\M=ZN\[@R')V8HJ\DB%6 =2E2%0VNM$Q*K(*/'6V=K'
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M76L<C^K+R+&A,1XZL?0\37V:>D$A="XEQ<"@0@-AR8DAR@D+!1;-M6AYO\E
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M.WO=@=PYZ S#G;U^>^\@D,/VX+#WBY< =/S7+Z&,WA[A/M+L"_RB.0SU._5
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M-,_7S\X7SKZ16)_&?(?H=9-*6ZD%V"B)'S4^[_P"[=3\O^1],/-:-;52>*G
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MIN2WH2,5#"I#*ABDUA%2L_HN#%+0V<KIC*RUOF9Z: B-;/ V @ZL@!6P E;
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M2*TKI&;UT5P*1+9B(B-;K3\SU#J#H$KNOS(N?Q?C+< *6 $K8 6L@!6P E;
M"E@!*V#5):R04UY_Y,U9\Y%87:3;K2&SI:24+=TQO/I$+%/7'=NU_)T[$>L?
M;TT<_V5,$S3;8&2ON:T0Y4A$=<);/N&I5ZT]QPR.W4'%L.84,VAL!VEL(QEF
M4-H.4MJ:#\L"C>T@C=TSZ4!M2"]O%># "E@!*V %K( 5L )6P I8 2M@U26L
MD%[>1'IYO27+7:3;K2&SI:27;5-W[]++ONG;VYA>/AJD=.4LO;RLO/'!^')<
M5IIE;*C>&.RU@U(<N6#0&'+!H+1N4!IRP:"Q5=,8F6G]F9$&:D,N>*L !U;
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M2@PJ1Q8:I-8-4C.0A :1K9K(R+;LS^Q*A N0@]XJP($5L )6P I8 2M@!:R
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M'_DA-+7%H:G5*S7$6Y22%TK&6];E@4%/*2X+%?3!7ASP>[,'MJF8C%I+HGK
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MB.RR%G3E./QG$_'IR;?*(-A W&K_',>7+</7F,\FU<J'A8M0:G%.H\UR&NQ
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MCSV'N7ILQD%H<&LY36OFY/%7*8X/YZ7Q<4;"67PFD?Q%5%^3<WZ[;)/*[-'
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MTFSIV@U;Z6/S<ZJ#H+ ! =(/JBBJ*,+X:&",](NX[2-ND7Z/'<:XN;R2.X+
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MR,\(XR'"&.D7<=M'W"+](HP' &.D7\1M'W&+](LP'@",D7X1MWW$+=(OPG@
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M&["$B^9T&R.D;S:5;1T=<)^^%#C_C<&,&H0:A+!%!X P'AJ,D7T1MCV$+3J
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M8?"SB[K@=TU9\.8B3V;QW:<BX9.K&N%7:?4ZOW,?[UZUORP?4'[Z5OF^Y%C
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M1##*(\HCRB/*(\KCE^6QV0(CC <M39$Z$Q5XD31P*I37-A#-Q59#ULQ-%C%
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MDWQ^^;W;ET*:Q1_/YLM)^]Z+-'6KR8=42.)C,_+-P%WQQ<==:]<^@7(G6+R
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MS9G(51#Z#^K?:^RRQ@/^4;\Q<)"-/^HO'1[<U^%3<O"H\*/2KX.VWMPYU0%
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MY6N,->35$Q!J9%*.E5B,T>\]+T@QU6,VF;!Y65V;F\RWNN @!L BEM7B'&0
M;*8R%39+Q)+(WB@B:I3(8F'$3SU3HM X>A";N(+F0O.<NJA/O'?=$YM[82(S
ME%FX8-X87^#-8"7Q[UDY:Z6#60$4.^;9\-LV@8/#+J:7Y?@2/?K-/GX;>9/%
M&.;2K#!F7L,2F0>:'V9C\\8+=(6>.&X?*+<?!N2^B^+ ,Y7$O%XI:$<D R62
M1YC_1P1[0DTXR/PP&:TC)O4-9"B"0B-GQV5M/C8D\VD!& LA5*<31AX,'G"7
M07_P!9:YZB!DF)O'1RNPV5)@>_\2NQKYA7WJ?ZW*Q<S[;2Z72!>__@\&Z]=>
M;D:'W_Z]!!']G_B?WXI)@>/NW_/W_^QN &@W:T</HKQ5A T6M()VKL:@0>8+
M"Q81J5Y[QOU7P]\%[#(L?M<8!K$B+% Q-:Z93A;#A0JTRK7W]VM9E=-"PEX8
MP8U.-Q-9:O6O8G,+&C7(_#D#,8 JY+K6BZE1RP1&5H*&FYM\?;BZO%"H1@ \
M=U/\_?3+WY<+R"S2-:6C)_A<( ,V%N6%>;1F<YC-N( K6DWE_80N2SR:!>5Z
M/?(V-LFLS?(%MG89P.8IZN6+.Z_=N!2MF8&O^*1*T% F8RY]77N?U6S!<828
M(W0!FK^;WJ?/9^W+G1H;JH0ZC!J[&:@Z8ADHL1Q G>$)F9$]1E[?3#<C[T8M
MAH+N='$.2^!%_A;-=O/#.TW4*;H_OIRN>72:;Y<BMU-\]N/?_W/D?<&JKQ>L
M\'Y5TW+2<TTUS_CR:^M\LI;24L*OO;E[]E*9_N>*$N@:H9=5/>H_5#&4_ELN
M6PY<@ )@!<8?R>*RD* 60&WA?:/EC;\7T[(J0$_\'82'JG8->V5,:_?4*X#@
MS)PJHE;]M&)VUFM^LT_O.[WB ?U\%/,2R6?KIK[5V@[$0S993K YJUYVBO=^
M,N:Q-@X^8QS_W-K%JGN&&65+FZQI.F_CM&R4E#D9K6#V:'H6AGCA2EC(7U3Q
M3_QN]QS/RI-1 YMDB9?REAYA8,9,W[QC9._X>4F!6ZY;+M9[[),WG=IH+DM.
M&^LPLH!@@I8LJ'T@NUGKT<-K5]>SA6%K3U@N4<.,!< ()"EC+,_-;4L/)MPS
MPC\K!#72NBH71B# 96PQOP"*^0MA%$Q+&<>=>5PYF:"7#HNRC# \SKMDXX7R
M!N:N^[=MX_F^ESU%SD@F5)3& 0EE%!(:ZX2P1' B-,N3*)5Q&&;KD049TWZ>
MIISP0.>$9DJ1/*<^B>*8*C_-PS 2ZY$%9V;33"&=3ZSZ6)FP"_E?N'&?5/4%
M-W@UM'>*-H&YJOZH3TTP!'N#!_55W5R]#/=]_^'=+?&^_HGO!SOC?0=",1Z
M;TOKZ\<52.]F[3JI::H7'P6%9;XOJ A2$H0)4$M")<E9P$DH= +4$E"6L'4*
M8S1/?!9+PB,,*P&R))D),J=YIG5*:<2S&RC,$$A]V@F0%<JRPN3[R"?P_9%O
M_S]X(FJ$)4CMXR"/C 9)(&!O4TPER,.(,.7'A,I4QSJ/?2["=?*(6!)D,I"$
MB=@G-)0YR6.@$;!]0^'3*,^2C52"QR0/>G3D,;!1C1JDA9#JX53[P_8@.@VB
MA^=Y3J),@"!2H0]J*V8D]C/MLXA&DHEU2DN2@#&> )'YN2944Z#.#!XAJ61
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M*%!Z>2Z%RG44/Z@WDE'8*S'V'_590[88P7[$N72'2$_07KMX+O[_^=#&=_>
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M[#_M_:YX !;<_N_?Y\:RV>(H,*RP*I&1DO!R G*V7#27V&T.?/_$_[&]'@U
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M#+8,FQD-]5</9+*JND8N8Q/TX;9-!"TCPO09+L 8]A/7[<3[;S.R&@@"43"
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MRTN.,W2D+@W#8XYW48G%!#AUBH58U+>BGC<,7"_.SU4]7Q:]N5%[8<7XF:G
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M [CKY^0Q:^DS!YP03O'LM7(+N7DHP0TU$%MPP-_MKIWX<]L\_2UG;^]S\#*
MTAV<ND.,#O;(VD?D;'[/)RZ[[H\+#E0H]6+NS+P_9HU:R)AC?B+(<6^Y[TK(
MKH&C328^4?9J%3^N GY8[J;L+)]:+%S^8<@5_./=&RO+P8B;^*3+\+ N/-/?
M#-+3#=&R3?R<R^)2*_<&&SRMYXNE, DK" G5 V7"M6\.:'S3,E?5B" $KIK:
M#:GVW?S"=-:5F5KA?M?U)3#TV3+SMI?+?D:UMDE<LRZ]>]B8KUM&Y/UQZX??
M^M?T>U?E$9#>34#W98" TLL>Z-WO,SU?S&QZ=:^^^R$YD_JRMM?YWY>%GMZQ
MTUB^TNF.X4F*7_*/?CR[=LD8@_Z;6VDKW+BJ&2[SNU<SFU?VXU7 OA.276$_
MBMF#PJF'X5%>1W59ZYTGLX.42SY)_.# 0=[,9JYTM_$EV+98-K"3)G3""H-X
M G0]2-T4;9^7HH:9W#W_6V^OTL/BT#[52.*'V/H[+7S2T\Q*18\V:Y*Z'_/I
MBKBL%;XF.^NI@GT!S5VYG&IGTWX8T(8:EHHLIEV7L,44*&'BR'^YAE4?[39Z
MZGRZY\F/_?.'3]B64];9>O;2/L?+4_DG&RKWWYPY>]OU2[)5:BZYX&P("EM.
M M\ULUIO]$;ZN)AP$.*APJD-$T5]<GH]F#7O&=IFD8FK#QDRI#;X3VP?F.O5
MMRW:]>Y5OO;%I^*Y]E,=6UIE<*M&JPO_N,*V99I;9\)&;O <M_[AHF_Z%WH/
M.]IQ+8)<5?X2:0&;/G5-@E;0JBNDO-&KPE>*L3HAYQ,F'3=91]K%Y2+4GBTO
M7CKZNM3$1LK%;)F<R=NVD;4?Q=(E(3D_3LC\VK[XT )C.8%XIEM;0*9\!,F[
ME%1?C=737ZCB6N5#EG?9WSK1"U!4G7_056<M?^H,A.<LA=<;9W7 ]FJ<DRQ\
MXD"NZK4V']:?[$X6^#"?>;^IZSO?E<Z$Y&'7U;L+^_DAU%U_\<[AY\<$39L5
M)-UV^T= R$&OOJ#'=1G+0SW4N_V<91K&TL(;? VM5<W@<6ZP2=>K[] H$%TI
MAVI->2P%D"E5E<Y*BBBVXXML[V*>5PI)F1<5YY)K278Q6KL+_OP#2+LS'5U]
MX&]ZOH>Z1RI%27*ID)9<(4J+%+$JIXB7%4Y+E7)5XO5ME1EALDA+9'(!\"@J
MC)B$#698%*;2,J^RXLFV=;3ECC[L8VF@G\%Q5!6.(UM?7W Y:C=BK+B\I>)2
M49[K@@B$<\YMG;E!59H91 G.E&)8T&*#S3XB-^8G4$:WL:;[U6'>9=%CS_(\
M3'Y-!_MAY5I4!4>*(GO8_[;SO[$=[F":TB#EQ-F3O2T)QHBQ&2/#*IM!ML'
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MSQIH5.W1#6@ -)/+Q>5VRK$X7IO! R^X&A!=>$QW23.K 51\LGSY4B?W(PY
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M/#ME6[[=XT[PX=EW=[1,5"HQP<:@3.("46(JQ J&45:: E>8%DS07<C%GVU
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M*6(P!BT2ZZ*RJB30+RD%TD3J0A22\F(CNGMOFK^_B/N[57UVU-6['+^4&VW
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MX+Z@S,$N=/=W3Y8N=#G P[O![BST'?>]P0,K7C;/#'WL-@ZW>[UOS+%.:Y8
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M'7#W[,L&]+-![6^K)Q,7S.B[@MO"XJ4#PLU=[K,TUZ_>79ICL;LTQW(]S3&
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M-QIX1B'T3(30P<I/XARZN\ZA>V0_CM@%/'8!/Y5\D%/H GXRSL78&#NRXY$
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MD83U-K.KQM[5NA6Z[,CRNW9@44B+?>XN^UJ@K[\ N_HO6W@5MW\O)BJI+^$
MYFYWW<X!)\UB8NK)9+BY\^2U\O?SR>3:;[75$Z^Q=^L'C=TY6?VF7H0>?9/K
M;B.P;WCS41C0.D]%5G*.\DHQ1#$NP!@N#,*&4L9RC G=Z$DJ2R(*P5,D*%5@
M0(/YS7":H4R494J*O,C81F?LI8QQ1O2O2RI[:Q%TQ6"^<O'9$(]%9&@\TUOB
ML?EY>G,MY$B(]-N7@*O70#$+2V*6*H! +#WID2UTA3@!I]?9\E=$Q(T"X3-O
MX0>P3>"E+M@6^+43#Z $R_K*TX_SHWA^TG,:8 [_]&QER7,L'8MN)7:1_3H
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MI\:%Q@?)YZ11W) DRS&3HC($D<PFO%9*(8Z)1JHDVI2D,IG<F"'S$+_SU[0
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ME_OJMZM#U<1)KA:'#])L%-I,\O2E#G"HNZBF9W'U# "%6RO+3S*2M=-F-H?
M<:I&(*ID_0*!3BHXN3[/5^\8@/,1\5L-@AJ=YGN&Q8E79PRJSW![>Y[!+1\=
M;G\'V^8#WD4?SUUL*D9.*HHI[YX1?F$G5=W"\W27F5Y=M(E^?#H":8=\A>N7
MK>J1'Y_'0?5NUN2'S"=>P+NW51QE^7SO=OG8M^-S&/R+?)=8?X$3ENK7$YWX
MPTW/\[";[:-BC9@(,"Y0I%$B;IQ&SA&#-/8<@G,KU";_NW""@J=%D=-:Y'U,
M$6F: N**<.UC(LZ(=?[W9NQC#.TOS?C\^KZDCXOAN]5WDFN^D[C#=\(#<ZOC
MU!/%J. 2PSP"69][]FQ'HK1&LT2B04GGBGNM(C(\.L2=,L%;@[T4UY666,QQ
M@L.=DQY451%D/*BO2HH3SCUAG!U*:<G@]BK+GBC&I=)NH,-)QJQ)]+G)^O#B
MJ>:\;Z]]IR<, <*_P;^5']JVS0'8:42+R"D_(]P!M#@?L'B9?Z(:Y/'M%6*O
MTS!^0Z%N8C?BK^ U9^>CUZ%N)T-[\2I_NQ&6#00$9OEAEVMO\.?"'5H^=7<B
M J&_GHS;NKMR$X<V#P^$=-^RE/)K7T9WWW8=PEUE*7HRJ+^@GFD9E6MJU@58
ME\IU=KG>NI!Q/1K6(WBVJ6VFK^QL.GZ]_@4,_?SCN2YVBZXVP1"\LL.O]J)]
M_<._7FKM36F#3L=6U/2:NO5$JQZ6<[UYT*[?[DEA\JHQ>!1PSM$NWZ,>S>PJ
MW/$0J>0!"0J8QZWB2$>K4.)!6G#&>##B;V3'\NY?T+427O1L/A^'%V5UX!Q;
M@IP'AY]39D&M2$3242<-X_#'QF:5![O^USRGW[J8[[_JZ5D]ZJJ'YA]LS?D_
M'C^J./^/=?XQ5RDE@KCT&EQ^29"E/B#MK"%.6DZP?K+SOU>U)8/;*]QZHAJ7
M:CM.MR5RJJ^=>!952(O/X._LW.?<52Z7L].8ERK@GWQZEU4:3V+3@=V\A@G.
M@I<YBZ,6/(OE57X<CMOV3]<"C;Y):-49>*(/<!5D+%O[0'2+D]"(N5Q&X8Q'
M'9&,E2%8FY>MV$;IQ8--]2=_%L-L&-^GVSAD/G==_. 6/PW'_N\_5!'4?0*G
M3YM9?''NQZ?9.3QOYWZX.!Q_K6P3[TZB]DQK;X_*JQ^[N3N>P75#^Z=71YW<
M?[RCOSJMEVN!W5+@M: LAR/SJ&L]^,\OEP]'$-*/9XM#YC<B& _P'Y?'PPL.
M[:2-K]HXL6 1XU)(W?+[_+P?;JK"_5*W=;<.??%J>8U;RFOGMY5J8.0?5X.V
MQ=O.H[9__<ZI9+^GL0'G^[WC@.G]WI .*-WA'7>PP?C&J7>_<NY2KO7P HXB
ML^_(#/0U?]OYVT^5WX-V%RVET=^TZ481Q+:]A9TJ\WWVV_1B. XY!8IQ/QI#
M563V!.-.BW'?AW'/T5\QZKU0_6(NBKDX G/!BKDXM.J7K=F]VYK]ZT;F-]?U
M3IJ\T#&]Z/*K\1^S>E'56X_\<);KH^K1)>587S=UO_C9]J+X8I[KKKI"''/[
MVKKPECCI.:(41\0UH\C89)$C)E$G';?,75]GU$)8HBU'.FB/N'0)62L8$L8H
M$4,*B>)[=:C8[B:Z'K0I>MFL,64W=T&=@CH%=>Y&'>^)UUII)#0'!(E)(<.#
M0]%;1047"B#F.NIX*B467B!L7$#<&(YL$@&IP*G"7 =YK:)K/ZC3@_9(+QMU
M#D:IW;U^KID?35^!R+<5(*^6E^3+KMX&7R]Y>0[A\V(^?J>2J@2^S]0%Z0VA
M3,^D6GAD=AKS!L(TC139:"CB2N:>O,HCX53"W&MJ!=U93]YG'O.^/-*8$O46
MR'F1ZED@YP%;F(2S*B=*?2($<<\-<I1Q%"5-B2@=N7H2==E+#GA?'N24->#>
M!;$/60,NX>PS]2UZDE'OF4Q+(GUW?@5C*7(7&?)6YE#60U@:F4%8)V&H5L*E
MC5!62Q$8]1C)1'+R'0=DO*4(>V,I]S91'^[E5_P^'FTYFJ6Z9[[%2TNFEV"V
M ,X+5,X"./<%'.*5SAE2Q")CB"<:D75<H! TMPZ0(\H-+@[IH\=YM5=IB0&D
MJ ; R0NYGFJB6*(XNL, #B6L ,X1AK)E];8W@2_,2>3+"FX)>8L'4CR0O7@@
M.%"9NU Q2\ #(<$B;11'# ?/!3/,;X:\6UN]+2%OF=,EY.V->A; *8"S^RZ(
MF <LA4!)9#)>!@BB&</(&H8YBSH @.QL[;:$O,]N3I?5V]X%L9_'4SLLX>O+
M\R9Z4PWV7'=!E;*P[Q*R1W -%)<H..\0QSHBPXQ%Q#JL>'#.^(W=M]NN1'XS
M"N!D^.WVLSSIN$)ZY6:\O#*Q$MD6+"I85+#H?EBDL"(Q$HRTQA9QDB#"Q<XB
M&9*E+ :K@MUUB?(NL(B*@D2'1J(;&ROWILWP(9M(]9A8?Q]=E3_<0I(UBM,B
MI4LI[;33B(Y"8U!+Q(R68/>E0DXYC# 8<6T,&'ZVD=Y\2*>168M.K9V\6@[U
MAZ'M#/W/R]$N[47NG M=.YVZS;UT%@V7TW@X''^%:_:L:\<!;>GS:-8AS, \
MMD'$@.RY>X8<R#TW%AF8?;_A3AN$](C1?8#)0\A:EQ_-]7]Q=LE:[U*Z+S'K
M<E?#CP?*]>Y5[_[J]?$V MG>(%W&ROT=IN,CA^XMG+Q$@U=DN;\. 04\>MQH
MI(!&,3O%[!2SL^>&)<7L]-I7?6H9Y%SX3ZB$[(N5VV=YY$^S>IA?^N%UD/<7
M=\&5)V#T4]:F^R+>WE2=[$QG2Z7)?,61)T:UY@D%93WB045D)6?(&VV,(1Q[
MMT&&9Y35TB2+L# 2<1LL@J-EWHFAA>3481?OO>+X:S-NVVV5.NH3H[= B?=\
M)G+_3&+!G((Y!7->-.88+ZWS(B#, '@X]PHP1R1D-;&<4B^(WJBT3W &#U&B
MQ*)%W!..=-YX'IBTA$?A#0F'P1QZ0K4IF',D6_>>RE938M;'=!49C]II,UO8
M@%&F8CUM8EM"V.).'+L5*E[$H;R(%)(CS#K$2*8"\$DBBYE$2K$@F%+4A8V^
M928R"'<#1\YB#.=$@325 E$J6,)8.BOX0;P(2FEQ(5[ Y"TX4U3U2%2UX,QB
M3X;31CA/D4H2<$9 T&E]8  <EC*?HHM^@^/,!FI3(A11$17BA!+DI LH:BVD
M9(Y2R0Z",^I$JRVTJ2K3MRRP/M=@]2_6G]6CV"SV_@RCGS;C4>UAFGVI?2Q!
M:W$FCMT:%6?B4,Y$T(J2$#D25'/$(TW()0_Q:*#!$N.XQ&EC@V=41&9^56VP
M1MQR@0R&2U"?K&>>Q&C309P)<\)Y"5M?PO0M2%-4]4A4M2#-'&F\P@8P1B*L
ME46<0QRJM;0H:4LTCPDSJC;HS)@Q<(I 7$6'>)()F20<LE%[IR$(]LH<!&GD
MB3!;X.8NT[>LL3[7L/67&1PTG36Q"UL33"/XO02KQ84X=AM47(B#=?>@4G@>
M')(\-\H.X#T8[ ,2DB4FA05,#M=="&QXT,)+%+G0>54V(!N80D1X)W@(@@5W
M&!=B&]1S9?+V?O(6G"FJ>B2J6G!F40],?0Q2YBI@"S@C:&8N318%;YWR/AII
M-E98#2!15SELB(#PUBJ-3%08N:@5I]%SJP^$,U@6G#F20+6LKQYB?74\'3?5
MEWA6^V$)4)^CX_!(DH3G:YUVJLQ/IZ1XT<Y'8D;B+N<M\NHJBPQI$C'"CC@>
MF(Y8L^O.1W22<$D#(I)1Q'4PR"IFD8XQ!9>,QQ0?: -L+]9C'TW$44Q P;."
M9R];F0N>/0G/F+*)2J>18B'DC;(,F:0I<CX%;)4D1/B-"B,J@U.2(I\KE;DW
MN2!))T2-4)X93J6_/X7\=O&L%\7*!<]ZM3+<2: >!7C.^8UV&8&ODM9W-UN]
M^V+DGE> ?EOO@],\L8M_\_S\F[Z(MW^2+(G^K?HFSE(?-$Y(& R^"25I3AQE
MN.,8PO!$_&9-V@-:;.YWRZXYX:H0?[R$^5N@IJCJD:AJ@9K+\F<I)':(<)\[
MJ?&4UY05\IZ;H+G'/C,]/+Z#YGZA1IV(4KYT-%%N658^0-3ZY]BVKZHWWL_.
M9T.;N_.%"'?QM<USI3\&NO@2)2U_>%F_L+3\/@W1C\OAZ9=#Y @37'&!'.40
M1U,9X3=-430>ZZ 84W'#(7I,[+UB@=^M&&#X?1CS+^ CO3D?@]+]L_O\5O]I
M2ZZ3.!&F%T'Z,:TA[(B*]T\%A0L*%Q0N*/QR45A(E4*P'MD@!.*88F23=B@E
MGQDL U'2;",MT3,4YB=4EI7\GJ-P6=)_<4OZHS@M/MES]\GH@&8S%\8S-XR]
M\\J>5=N/1PN^'P[:X?TC@I-6>9V&!<<0AVLC%VU 5#KO$L%<8;W3"H'?X[9\
M'LI.=#^:47U7*WOG]O3/_!9\*_A6\*W@VU;B?Q\MS^"$(\3_E-/,Z@D@EZ(S
M3A$5:-QI6<)6\8WJ7I"R%7R[(YJ'WRT(X]^7@_7[[!SNY>'O4'\YM$F\?9Y=
M/<GW;GY_@56KLCJNEWZ2HJQF *OX;1)';:R^VK;ZPZU)TGL_Q3YB F,2"]$B
M$5U 7'F)C,<"Z6BQ\R+RSK^_MJ/)"2JUHLAI#7:6N8@T3?ELPK6/B3BSL:-I
M54RWVDBY9B/%7?N7!K=7;?5$.2JXQ# +.Z>&>O9LQZ&?F"I-)>'(=>V0 W7(
M*9.[A$"\:J*FU,OK^DDLYCCSJSHG/6BE(J#3H*DJ*4YXWK7'-QJ$[$0_;P]0
M>Z(#E_H)+U)%Z\^J<:JF9[&ZB+9IJS@*,53OHH_G+C85(R<5Q91WV@R_L).J
MB>TDPJM]B<.+P0,1@- [P&='(/!UGG)WXV%XC&"[N[VJI_ @_B$E=&-PCS['
MYKSZ;?0EMM/L+U9_B;:=-2#COX*DFRH[DM,+^'1Z-@Z'Q-.]*N&FJ[7+U_V?
M63NMTT6//(CWH^K_S4:QHGH^O4ZJ7R^:6'TXLV!<?)QU?GJ>C!#9@:K4H^FX
MLM7$-M-1;-JS>E+9TR;&3J' [[#5L#ZO<XWFXI#J:SV%B0W3NH&3L^Z-86[G
M.5RWU=B!5+J*3KCJQ%X<B=OBL$J2@(G7+E+$!0O(R.B1"=Z#2^,DM1OLF58F
M#D8K(6D3 5C0X+9HJI&7/,E(3*2,+&'A%$;@U=5$_31SK6_J2;>Z>SZ>?6?M
M]F$8P0>W<XKT1#W7, *>Z"CT@W/A+;BOV3O-7;!)0)I+AER2BCGL>?0;7; ?
MK!\?8I/S+?8TOD]ST_U;-T?;=>V8@(6_5 ]$5_6#W[E%?V!Z[^3^L6?/TZW!
M HS6B\'(39&S3[-B,0?5AUG3SBQ83#![U[Z\,J<W6^*3&ZWL2=6>V>&P&HVG
MW4>UKR=@5_/-[>BBRD/WI9[6 %--'"X-;KXSX!5H4&>]%\Y7?>4@N%E;CV+;
M#JK_&'^-7_)M;@2'<[#<=C(9UQD#JO.YO[:X@0U?ZG;<7("ZG\,C3V-<WFA-
M(F_:_/&&LW?2'?EV? Z#>_%_6K@H>#ZKC]CAT88( 5WR9]XVS06,6/7%#F>7
M]UU<[5_^MZ9$O6ZK8?:-IMDW6KLN' L(95.JA^"8QY,*U A<U!Q<UR,_G(4.
M#:M\&8I?O^\ SK9MG,(0@8;X6=/ A;JOR>NE%C@[M",?8;1BA $^GDB=*^D(
MH0Q1R2SBT1*DK1'($((S^[.#@&@;JW=S2S;W0:\0\/;=5@\-BE3?[=DEX/7L
MN?*<.@Y5E0S U]"$%!,I\\<"\'IKD Y6<VXM5WRC$,]I(;"G!B5PWQ#'$/)K
MB-.1A_B?T<",Q?:ZJN:8*H=4NU#3VXEF>Z(.2S7]3A">WR"?4(]F=O$*.2?]
MOZJJ]Q'EXQ/1&^%D?MTN%;^6GU\&$DG+:+!#0K.<7TJY*P]CR"IB@^8D!;41
M2#PF_PF>H1V=UFX8WW0(]:YN_7"<@__/<.&?AF/_]Q^J"+HZ@9.FS6RQ4 4C
M%\.;Z7V?]&]D413X;]V:Q$TU>78V'2\7=?)P9'G"Z.7#T=!>C&>+0^:B)1@/
M\!^7QX.V#^VDC:_:"& /D+S4@OFR3W?>LBIQI<81W(_: 89/+UXMKW!5O+BR
M<C6_I1P0G>_X+6M&?KK%T(*J?7O]P[_>>IYA TWO/G%EZ68[99@W:O9-K[>V
M,%>/[K\$=_"%]0?DTK9AV<3@EG6W(LR'"_/*\%1SRW.S;*^FQ>5ZYM&(Z0$(
M\LCD[=KBYJU88KPC48)[38/+C<E%R"L0 E%GI)?,J:#L-K#DDS^+83:,[],O
M-3@[\<^ _.$ZP'S.@WA?;+G/DV=L>6&9V<\0+W;$;%=QK.VR?_/TJ5W9#V]7
M-GS<%N;65U-Q'J;.,[,AYM"W'G6(/82Q;'." :[1,X?S]G6@ZFO,K=%:\*F'
MP_'7MOJQ"[;',[A/:/_TZJAS^ULJB;BY.N3&3Q<.:^6'H"89ZDXC6O?8?NBL
MT/+]_MEMK_CV"K'7:1B_H5 WL0M9LKLU.Q^]#G4[ =_N5?YV Q,' E QO\+2
M!X(_%X)<ODMW(HJC\'HR;NONRET2"W1UU=^Z+!7ZMFN4O2ISZ\G<^ 7U;+)2
MM:9\<V5;*M=9<RTRJ$?#>@3/-K7-PHU?_P*&?O[Q7!<[Y]<F&()7=OC57K0+
M]WI5*=?+T+*.K:CI-77KB5;U+&Y=,P:=Q[$:RS\@?NV0>V5H'J9S/]QVZ_LZ
M#9?.^Z%#TOL'I3>$EX(,C+E'7'K#J>21I[$!,0I?_??8ZSSRM,&>[\<&6*D]
MOR*_3ZIANT,J=OF..]AF>J,%W+2:=Y8B]RA(O]E]./A^#AB-_.W__8'@'YXL
MPKO)#'KMH^TD%[(1P3RXGGY+(W!9-__B%+T8J.,<MW4#18M]VH5]^O6F7%.Q
M4;W97%DL1+$0A[40;VY).1<C48S$T4BM&(F]+?E>ED,^@HNHF(B#Q#K?)3C_
M?K')0\;RO YA&(^L0F(GLV.^"INZI?3Y^NNKO9FO&^3RLN;(5JQ/D6*18A^=
MDR+1HI=%BGV28IG=12][)L7#, /?DZWLQ48)GZ,_&\']3K,PJK^/QE_1V?CK
M8V;"4\BW#B[DK<GSX91Z3^;3*[1X"PJ=J'PR0B"#J4%<<H^<L1X9PR6.A,0D
M-BB>@I&<!$^1AP,0#Y8A0X-%FCI"DO."I72]+/T[Q>C;[-?'Z1::]1W?O.P!
MIA\=8/35.3HRU2N04%JU;!N30F1"28((S?ABO$>6F8"BI=9+IZ0R&U2M6\:D
ME:74U6XM6T(IAE\D2O6FN5F!JP)7!:Z>203CM4R>9GA(>:>))1#!6)D0=E@R
M23"7.X]@MD?M3>@6^E8<WZSL=3;MJ4W%CQ%M]NF%YIW0,[!?53M.TZ^VB?M6
M^(.7"1UQ2/\4J18$FR-8HHYK&0*R*3C$G7/(1881"1Q'KB2U>H,1*PE-F6,!
M2?@><48-,HXH ,$HF0N.DL0/E(.C:@N]*?;0;;),ZJ. HN<8^!3$><F(4U)\
M?TN66\P4()<7&'%%,8)P+2".M700OG%A-]B0M@QYNTWQ$;J%KLO/$P1+&K"@
M84'#@H:] 2/NE*9.2&1,;@THN,ZM !RR4EON*)6"XQV#T18SB.+P:TL]!9Y>
M9QFW4+/7O7ZFT1HM[K(]=%ME9.HNO7JOQ2 ]KZSDYT4K@VO[@78SE6X?A/OT
M?7T^/MS.EM&>)N "E'.@9$)&1JQ&7'.(V@RSR$27$#,N$J.,Y6PK72;VE*A4
MF.P)*A^I?B\ +'<WL?LQ:8\W7BN85#"II#+O 8I80/S(/ (,#(A3;Y -.B(7
M**!D<-+JC2:T6P;%W:8R.=W7>MX1PN3S26;VPZ 4O#QVU2UXV>L83CF/O8@$
M"1$ KKB0R"4OD.>!*>7@?TEW#%?;2W92M:]DYQ%"TP'2G0=K#W38#G)S[3IR
M!OM]<YTKOF<Z=R7W>T,Z,'N^XP%>4>V2([_'?- #3!Y"9+'\:#YM%V>_.#:+
M^Q'9/U"T=Z]S]T?XO2*X9P_VE+8W,I=^47_&YIG1O#R6#/+&,;[=^SW$^/6R
M+NHN\JC]6+5>$"8] YK\?5FZ7HS7P>?.KARL(MUBF?ICF;9&SU^,4S%.ST6Z
MQ3CUPSAMJ2U ,4V]CAAWTC[@2"/&9]56H !2@?LBW9<NW6(EBAX7Z1;I%BO1
M#TD7Z?8J^GGJ%LNY\)]6JO@2HY\MM4O8%/]#]R7W4_@'K+R]OT8_WD*]Z&I;
MI["F#!/$<28:E88AYWU"6G >B6,L;6X.H1X;'X)%GF0Z B8L<H9CY".GS/DD
M!1&':J_ MD!/^GSF<3]\B><!2#UVUIZ#JA;(V0_DE V1?R.).",H01H[A[@A
M '>$)V1<8();IZ38V&&R9<S;[89(:@H*]G$+9('# H<%#GL%AX='(XJ3"1+0
M2$@):$0T0YH2BTBDUCD3-.9IQVBT17(W7I#G6 C=GMHVXCFAV7&UDWCZ!.GG
MGJ3C3F'LLNCO12-DA#"-"<(0-A@0TB>.=+(11<R8TA8[J3<:*#$%WT$<A#Q/
M$O&8*+(R*:0988%:@IVR!\I1$K4%5K>=FH"#;GX[;B/0?ZA[IH%;0;2":"4%
M>N\.MC)Y[0!#F1< CS8D9'B4*$8G@G!!"[H1=&X94G?<W@++ K*]2#F5-&E!
MVX*V+Q=M#P]V05NF4V8\)0: *PB5LZ4>P()036WTEH0=@]WV,JQR"VV;7A:N
M]3H)NYV2SRTWUKASY$JWC<=VV[COU'L:EVA?IMX1KF+N0/ %AQ<]%9,/43*+
M&'81<%@Q9*UVB%&X)02C7HN-H%,QJKW$"B7A>*Y/)4A[HQ C3B83O3!,'BB/
M*[?1G6/']N"E@O'^8\M^3/*C#C<+YA7,*YG>+8.N-S$X N&K9,HAGIA 1BD/
M>(JYT8I823=:8FT9='>;Z65FCYG>YP+#SS_7VP\#5/#XN:IZP>.CC$&]]8EC
M;I'();=<&(&L3B8#HQ0:8\FTW3$<;K&["-YC,OBY0-\!TL%[Z3KR/[-V6J>+
MQ[K \X>A6VM#4JT)!I0T?U6/9G:AI:'^<@3RN-Z69<LD:[:)'1-TG1E7IV!V
MVFDUC"U\<0L5:V5'H:K/)[9NSN&B)U6=*CN9#&&>PF5/NJ^G9W']G/AM$D=M
MK.JV:J+/DQ6N,:K&D]C  :/3Y0'MH/H,Y\[I&_.-P0+8TVL7@Y/J<<AVJ;O1
M1D8<_JG&J;K.Y<]OBHX..!99&+<&;/>^WR7*_#X[AP_\ F0$43)2DY#"(A>L
MXKQX* 4*UBA-G2:!;A:L;K>%U<=X;NLLAM6(ZT,W=F0-5>!-_*LP:RZB;?HS
M5?@ 7VK,OZZ)^-_[IDA9<.V@;T^U:GU?EI5]P:_^YB:K_]7>;.D.^)Q_>+KE
MW4.H8)6.1E&+;(H>\< C,LX:I+E(TCO,5=HH&Q%.4*D514[KO#'/1:1I"H@K
MPK6/W<;SZU9\==3>I^N&?#-4N H0\%VI,7T"TKDU1.B)-G1.2\^>Z3@TU%E/
M+'$,>8U-W@;JD'40V]+ .$XQ6"O\=0TE%L-W,B'G)&BU4@09#[JJDN*$<T\8
M9T_5T$4P*]>"67&'LN+![<NI/=&*"BXQ7&F(T)?'RLYXM/XL.][9*>]<DBJ.
MLJ._X8C/@X35]EH]>8T3B$[:2821_Q*'%X,UDW"SGRV%<Q:+A*+W+NL_&.<H
M-,(R44>9=5)OQ4)_\F<QS(9QG+[C<?\RF\Z:N#I5?IXC\.<<FGV&)_AI./9_
M_Z&*,#TF</5I,XOSIX.P.(8WT_N^TM](?UR.GVP+2@86:4X5CC)5>+@A*KP,
M/.?A8<]4[X9)DN=1! ?OO(O!4S>XMX;5\%)I/!R.O[;5CQ!93\_&,WB.T/[I
MU1U!3/910_WE*='G:E[E ?,"E.A1ND=WG++KGU>]&E \CUZZ6@P4W7<C5OH<
M&K'>HR+W(>2Y+W%#R@WLS@O]GR]'W+ZYX<'BO7O?1"^(B@_:5^?G2XQ;RQXL
M?)?[K";=-GH;*S_;'+_+B_=B!%\>U?235[(/7@FPVS$#)U(\>"GVB9MR#B[2
M Q97/'F/72F0F,<.QEK'/=,HY64K+AA'CN.(#,4Q>1LBWRS2W_+:U0TQ].]P
ML\]?X_!+_ O<^6Q;)?S"/+U^XO@F;:^!Z:FL9 68[@0F671\YS66!8^VM6E,
M1D^\Y8A@FA"GDN>5"XMH"M+KI(7G&PT*=H]'_QUM\_GKN,!0_Z=HB8]Z"D.J
MZ'B!H6.!(2JE#<H$)"/'B#.=NP<(@)0H;*+<4HH/!4-G38S; J(MU).725KB
MH>,"(EUTO #1L0!1X#0(+"-B+FK$-4"2)HRA1(P%<&&>*W48(/IE/&NVM;%)
M%1SJ&0Z5@&CG.&2*CA<<.A8<XC;)B*U&6-&(N!(AUQ$3))40@1M)E=K82+LG
M'()CMX5#6Z"6*'.TQ$-'A$.?SR+(,X%AV[>FWUVM]7SGPN[PZD$U<"\:T81E
M06@#$":L1=Q%BK2@!I&(E5(NLA#B_A'M39Z*6X8U?OCPZCZE?<]WNI<0K)?0
MESE^=S,1GL;H<W"Y][^P[VD"+A"X: NC;-*12A2DD@"!)"*;C$4B,:D= 0R\
MH=/:=B%PB^Q(BNT)YIY*C?0R@.Z2!>DV-J!;/H?3_ZW[_@F;W?*NM>]<OC^;
M<&[>O_9X&J:-X5F5YN:&6D9P9,XCJG(O8D5S6RA+$%:)&PD_G#';V%#[,7Z)
MHUG\I1F?OX6+Y=GY7_7T[.VL!?'%YMZ;9>_QN'FS[/^:S_!#[]F[[XZ]C2UP
M<D#NLWENXSS#!OH>^_Q6)ND^MLX=Z<:Y@^[2DH-;+&P1YL.%N; ^-TOT:C(<
MDK7O@ #QPG9W9\:[W)';CB[^Y7]K2M3KMIHTXS#STZJ9*TI;?8U-K#*AVO"B
M.HVCS)N720$ OCJ>@!:\T\QJ\//GO[[Y^-^#ZA/\W5Y]D-G\P'9VIXR;+=#.
M[2$24"PXJB$(, YKQ"$L0$Z)B&*PU$<=5"3TNB?@<1+8)XR"PN )"*Z0=HXB
M:BB1)-#@=;SN"0#\YXBKZ3RRCW7[]P^QR1_8TTC6XH#)K(F7@0"BJY' 78&
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M' #'L![%#1E=O1,?"*;^N',:P4[0WQ7NXD%6?+B_QSB!9QJ^7DJB'N6709U
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M0_O7)AJF+$%E!,[@EF)D5-3(:NJ9A2^5>#A+)3C]O0X?FYW\+4R/FVW<D@5
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MG;J\[KW>65%J%:4R$BJC)X@0(\'F=PIIBD%1LJ6EEE-E^-JL@ >V8WP\14G
M_TNVA2G&.Q8,SU55RM[P_BQP1KI^DW-&N@<B'3=1*>H-,M1XQ%D(R$K*$',B
M2LK3M,@UC_@#>^X^$M)1>50J0#K>BZA]1KKO. 4.:?C(-H=E];TCI]IFL\DE
M'SVP9!R/IZ/4U[D11;]]_D/*,BK,0001#,)(:Q!+,6@4<6F452"B'*C=7\^&
M+X9F=/)__Q!&Z/=/O7FYAW>^W^KCO&NGKW]OA,4M[OD(,,0TV$O:6:1+PQ#G
MF"+8;J !P5Q)+$TI8==A2 DKF*$.,:43M908&2$5(J4TE&FIB0IKP]D2D/R2
MFHRG9LEA5#=C/XY3><9).(,G_.7RZI /YC)]=?S%3'R7V/+F:YBXJDZ2ZK>F
MW?F#84H>,<R/E-[LN.X'.17C+K4G7"U!TTKWJL.[6VJW>U3 P[E36!V O>$E
M7'[#@<67, G%%#:@[FIFJE'3S3IMW+6F[JDU=M(20/I-OXPG_RP^!W<Z@B4Y
MN2S^5IVE+OWM!)?VRN<@)0KCX8W2^&PS'4_FUTM-38KW9Z/*SNH"&"7UWKX(
MQ:>911_22>F]7IU6HS0V^(-)$%^=IP*>J_[92^+KOQ8S45>ZDS>#"/L'9ELE
MBH."L_V,HDJ-O(KCS[^F@>PG$W.6AVD]K?T]E-790>OP]Z/BM_%%V^,4K*UN
M1OM?+D&>?SX-<.<P \E9'R4).R@:*[L1[R#%X?G? _P6OYK)/\.T^&0 3(Y/
M)J'!X.*G)*-33PN*7R;66?S2?$=>_MS.&OKO$ $R*EC O_WMU<I)Z7HUG+9\
MBJF+NOG:I*^/BO/9)%F:TP0J+58M(TT:4#).EV]R6.LP'!X5<3(^*Z:P8^F4
M]&\"F\EX=M*>NG33HTUS3]H928L)]B>3<3U_K//)V(7@FW-FYYM&C.1)2M_1
M)"D6E 5E$,:I!H'IB'0, GE,G56$:A/7QJ<$55)&RH"<E@+Q&"S8'4RA$*@U
MC#%OUNOO/W3;]1:(8NZS>#])-/ ^MN,VMS2SOL2#FV:']8HT>CJT?L&>20^<
M(F!2=-8*G(:UDU)ZWJ+RFLCIT'HN/=KQ+7/A\ 7>MC@WE]?9OC"-:EO5=:+'
M;_)Q[_C&68JC-P(95EK$P1I#6G*-RH#+Z*DO@])KN4'<:1M#2 >!U48$04H"
MWSBAA(Q.8H'=RBR3#V ZP$. !&ZGF;0K]7;<#MVJ/P%TKW -R.BKX5J(+O,-
M_0[;L+[SS(\]>YZY;=1BTC(:)9+O\*P>ST<9S7D!-@/@/ %T-[FH.K. K*%O
MZ'6=59.)ET:!&C WP]?D"H"?JI&;S6U0.'446@YI4+N:PNN'R47EX,#98N;H
MBGYRE*XPG"4?;L?[AP&:C@OFK?0(EZQ$W,N C-0>,<^(55@X*^Q#0+-A_K^!
MSC-\TRWUNVZEUT'R]L,U"2LW#-;L%>4UI#9,+[],:&OTE8@IS:BUPZH^;=3@
MCB&7X&A0O)XUL)6^OPQF4EP-N#4-KRX/'>@4\F6U-O'O8>!1P)A0SDMD7$E2
M3Z2(%.,1E5@3;[W1#*_-?A4,#M8Z]5Y*'9<L#4B9P% P/M@2H(J2M3%XC5[^
MKBE7:]<6,*H:^Q:0P#!K?JH?[N;#1U3(WI/J!K.E%7=+A-B-5&ZFU/EB!!K5
M,F#T[*T.0P9KJAC50B!FFB9@T2$K*%@O);/,XK)D;*UX^CX$?Z/ALCQ;;DMV
M"Q[LP*7]+,R6H\+$:4@#4?W,-<-'KZR*NJVIG9LO;EQ/,\O=NW<.,=(H !4?
M&$;<>(4LUQ8)IH-CC@6VWJOO+BS7J#U7=DY]//+ONYU[E3;NEIS&OS](>'-/
MOIX01$]9[9D/1'U>_NK6_ -A^4TMYYK*/1]5?0;\O>(S3L=-PDD;6JR:<*:9
MMOYK^.,M,&SQ";'BI[?5,!2_C0<%V$0H83R3/\^CHU^6I_DF;[9KXI#=/-]/
M;UZE2UWYV.E<I6_T?;C[, TN3ZI7?0ZGSL! G9V?#]N'B%4:)KPP+=8NUCGL
M!SWCR'W'4S)']BN^]A%LXDGE$IW_!F;&<5V':9U7K,<<M$?A\7LCP3]\?%4,
MS9>Z,U)/9L-&0-==;/(#2/\S>)Q9D[F9>M6 V+3_  ':.C!;>FMT[7&3"@*[
MF'R$[C0E"347=<E'BMJ<SL*9^G21P%(ONP#A<N<@VD$8N\;_DD*5Z?3?!Y\&
M;8Y*-Q"^=:F:=L!Q.LTG6*GL;!J*8)H7K^>8<[LK-A.MDVMVV.;%#(I7R=\&
M)Z;565J4-+<>CKAY:9H7N%P:0P]?_/+?"4B&EZFQ3X+0Y!<USLW.9@LTBLUW
M"=JFZ>*CUJ$*!\&"->.V&U1*#Y*^FXT:&Z=I$F0F?FW;!L7Q63JH7NQ-<[TF
MNPT>K_(H>=/:I.+FW#8#R$QGT_'D<EZ(V,#]32_9,_SK2&$1(C;=N\/3+[W^
M\NNNO^I<O9B$\_35*)V1%J6]5KI4\MB81I3.O8R@3(2+I-H +]25KTP36!^-
MX;@+4PT7Z5X+RFP<EREWZS!LO5)%43)"P%J+!/&8:M^)-*ATCFGA2DS86H;A
M74JZ&EOO>+YM'<6^CU?PU:6]@PWX:;YA7?+[;>W [WE<!!_T/NHUMP,;RCT,
MRL%6*Z>P!GI1 7$?@(9XD"A*+R+EV 6WWM'_#B42F7+N2#DW!SH:BDJ)G4=)
M#IZWIM3P,MLW_:EUN#%']M^*XC_AWP*LX+I.=3<GH=.LFJ>$V\ ;I .Z%_A7
M4Y7_]05B+^,P?$6^FK1AM!>PJ[.ST4M J/.AN7R1?ETKQ1F4U:AYXGGC"?BS
M6ZGYHS<G(E!W7IZ/ZZJY<F-I SF]M..O:9W2NR\J>K[NND+G85,A=T##;U'/
MF"K-)%DBLR;U>D%<IXMF(]T:5Z,AZ*1@7IG)](4!>?IR]0?8^O;KEA:;CB.-
M1_Z%&7XQE_7+'_YC0;4W5HLE&ELBTVODUA.JNEM5[B,(AV5A<"]=H 7P=(]J
M-#/+L63AL.!>(\6$1IQ%CY2D'H72$T:H]2S*/\B.U[M_UO)QW3@1Z]EPD6M@
M[/@BK-C 1YW!B1J;+U8C,. JL#P6WDZX"!@!5X8&&&.?W&GP,S 8WF7_>E_I
M:3^^J84"6W0:;*:/GM+'#MY_D_=M$OZ<59,V?[!N'!.5!U$T+8;!U-/#2%<J
M14I*(B3EOH+!YXA&AGB)/!=4@!$HF5W+WBAM204 $;)*E0!+-B!% 9NX)%RY
M$(G5JZ'DZ^;?V]EH:_FRI/=Y=#\NO(U)%T-3\W79UWBCTZ^(L$)%<C .FP,Z
M+V6*L5WYPKYQ)JA^ &7?*Z'M"0D&$[F+0$0T*HHX-A)IQ^$_TGC-8HQ"K67,
MW9D$7RU6L'54O(^[),KR$(AR4IR-)V%.G&U(N*ETZIRT1T75Y% ?)?G6D%63
M2KS1:YO4J>_X78'>FZC#PC$_*(ZGRXF>S4!@^;).I[E)2"<=K=4WF>%P[!H?
M<W$^GDR[FH5U[K*I&#K%0C9Z[%-%U]*MS#4^REK@,T+Y5/H7VLC 08A-*226
M'@=4$F,0%R$F)S]#5FIMN(G"E&L%8W<6F\?GP$SGDZJ-:'T>7Q>:M_3CBA5Y
M"6ODDLQ,W5#!^-KX@DP0H1R!IPOPL)$%I$542&"AX;TYO/U:,SMB,,=11&2M
M<'"B)( E\*HR2DXXJ#>,LSV\X&A\ Q[T&R *L[(R712W#E=Q2;^:TE]W.?V;
M'=R#ZS[599?'DB/E "3M%AU(6W =7?FF.]:)LJ28!1 &CH)L4 XXGI4E4EP0
M'DUIJ%H+_=Q%-ESE9'<#8YM$M,]PL5^&329V "XYAP.GDUGH^AW_9],GZ::^
MM8W/<M5UGC8M'8Z&YG(\ZPYIEY-@/, _SH\'#AF:\SJ\J,.YF8!2,-_\MA55
M<]Z\X?)2^^:+JJ[:K(47\RM<]65>ZJ;5WE(,B/IQV=O9;6?K[OR/C>=I-E#T
M^R<NM9/:SJ"H&ZGYIM=;<?]6H]NW!>OQ.*@U!]$VI"$AJ\+KJAE87LV[K^:K
M\:A9FR0/KLV<OGF5KSCD4=JM]2W$\+P4\7>C*QT"U 9Z5+PR8(Y>UM.K\6Q+
MB48;BDCZIZ]+AK'F%EE-2*I554BG) N,@V>TE)39M4)U2KR6E%H4K&7IG!+4
M6:Q0:8ECW'LCTCG?PN2V'K"M$WQX$V9ZQ'CO71LK:?(;!4U2:/_RV[OBOTUZ
MZJ2BIK_^^O]L*G%]RTK29O$6Q^[/6=7&0HN?ZI"RY($.2=.&@="7CUC3=,]H
MQOO)B1E5_VI#C>G5?S.IA6E:L??GH2T+Z%M^X57M0;+04[)?^',&/PTO5YJP
M=;OZ^Z?CM)'OW73<B1&6G3G/"T.6]_ZHJ,[.@@=;-J1@,&C\XR]SV]4-QW7Z
MO&C9-UKX*^M5WV.'/@>!-B+@:)4%XX])C#@)&*D@!6*:@_Y9"H;#FG=(,&D#
M401IXS18C<RF$D&+>.2JE,$P[-;Z(^\0;10A3P1JDH@]"*H),D90-0PJF6C\
M;AXI7%)4:N5P),Y$MQ8-#(R7UC"-F,4<\;+TR 2LD1#"*Z\L8]:O==5..7/O
MX_^8U,!T^G[R,1D9;6/2]_%3<+,)H&NH7YGA,/A?+KOCZN[ [W4U^%[_C4,@
MK.LD-%^"98"[JOO[,*DNDB[\80A/EY);!JF0KTB69A/7& (8MDO2!%06.@L[
M')WEK:DFQ=_-<!:*7X.I05WIDGB M]XNLGO>C>KI9-;\DO'^>>']585H _AS
M)CF?C%.LT:?09.7"O!IIJ3.O:R5W$]T\""GM!5&AU!@%DM!9"XL,=PHI&6*4
MRFBWWO),NE)X0A6*:0@BQP&LSQ"2J XE!A$OG+UARL\"TC;#_._GXU%[8&H5
M\' 3DQV1LO_B^5:X/RC>&#!8FF._IR*DBFJW]'O;;32%8+["PC1JZT'0IL0Z
M)!)$4E'0.QWHG5HIH#C#2\D8!6U@3>]DU)C26(] ^P2MPS*%3+0">6FIB,:K
M*&@?:!,TFL%!]4):[E<^*-Z/BO\VHUE*<KBJR%^J($UB,=4]MI@*%VR5AWK)
M,MI(OJ_2#[%RG4/N=:@!)SIMXS#HMC1EC,XCH%(*=,L9,I((1+CDDF 1G!37
MZ39:&I6($@D+9,Y!)B.#X3\N2"F9TI0XNQ)L7FBXS0ZM-"]J.AK!RJZ2[/OX
M^32\GTV;C!5XLT\=U3[4LCJ20AXQUO_N*YO:$2<?4&>.+RO$YXG:9R!SW6()
MUX+.-Q;R'(!^N.60\R/$3^;W7<2X;PY6XQ 5<1RC2 *(?\8(LJ1Q=VL72V6(
M%VL5KO<)5K^NZN3K <NAX;S%%(V/;3N2IK/1VA"->E-0N^B2%X(_GM[V+5*M
M1HZ%YUCX84=O"<VQ\.VM9@MHC<@IEJ52+P+AV;5Q$-5)&\8"I9% V0G64TK9
M30;SI@E1S72HY&-H7 JI]ZV]7*15+)+N5QOQC(KCV0F\9'O-IKF-249>>W(J
MBEJ<:,=FDKI[%FU1^QA.7QY,\$OZ>3'0Y'I<MOC><]O@TDRMJSYSXZLK,'QT
MRZNT_8+JZ]Z_QHHXI($'%FOF+4F=SGEJ[B)L&A1"D!:2!$F=T7Y-79986F%"
M1(R*".>H-%R$*-!005D-08<@^S#C6QXI7AYQO7GR:4\X;=-,N,0DS9"-I&NG
M: MH/,/+U/0)%-)ZT2!Q&&JX8SK[I^KGPZ Z+9DB&GN$P9Q!7&..K, 4!1Z"
M\"R4S-'K5,>MT#*6&BC54S")2H6T$0R9*#%1T@<MV,8Q&VM>C\V]GA]2J-5W
M2OMQ[GV;CE/?K%'C04K?C:_69Q,UCD?+R?CUHFCP/#5 ;TY,2Y9*H=J>_(EZ
M?ZJ (AL72GV6HJ^3I5MN(OJ5AFD=B?_2(D([$C%6$[B[;T93%:DT$;Y)V]7>
MU@: V%&3@G'EH>QJ!U:\EHO) -?;F2ZX[8K3YL,8KS]\5[W@CYHDPJOXZ$$P
M8<F$=,Z%Y",'T4^;V0+,(!&8#E%+&>7:N N-2^T#L!YFG*:D#H>L)10)%;EP
M*D1O[/Y%/SM25!])=4C)A>O30.?$U7!2TWAWM1:RZI9K*7+_#8WET +8N>/2
MWGOCY(Y+W^VXQ'+'I4,OAU@6!IM:)]W2'7\O+SY]=AV7DFV]E#7;!B]F9_ .
M<*]ZKFZ>M_GDR49/[8#A]-0095$D>A63V]32=C&K.\7TTN]+?X/.YTZ39G<%
MP,TA*RC<! !3A^%AF+<%6,OI??'XL'H5"-MZI:?RS%M>6L2B3P7/U #!.H)P
ML,J9F,JDPS:"9_/66%WP>FT4?:,L=L/FCSL*^)SHY-M%H=L+A6EYSTC8[6-A
M-T2U*!F4E-PB'G;#N?<\C>*!+/6CWI(,A'S<&\H!*1]W6<D LT>^HQI(=IM8
MZD&_)![L\H9+X>+'"1AO#G(.,%F/<\(O-P4YYU^UXJ@[M5=:W&[B,4NQXG8A
M84/2KXVC[M:+NCEXO-")YR;<^32-CJQ\,5>;;ESY&U:IOU;:3J+0ORW\9*VG
MIV@F4@POD^ZVY(DM.H3_YI[N=A];WL6LQSNY=Z[:P@[DU<TRJ^<RZW^:BP:/
MCF&MS4DHWGP-$U?533F4"UE&]9J+LHS*,NH9RJB/X<Q43;"S<4H9-YV98?$Y
M3,Z*G_XW=5'[.<NM7G-6EEM9;CU]N;48ZU2\2Z[S45VYKOCZI^GI> ;7]%E2
M]9>7=N 6N[4'[,;W/BRWV&U9;QL;N>Q=F3=CN-Y"E=V3TY:??#2^:2/N"%)[
MV(M^8/MMB/K^@'\E0':YNLW=[[B\CY%96K(R1F(0+LN4SVP\4AP;%%3I1!D%
M47&M\O8N8PH7$<P;XY;'J:W*2=-+Y)?+M>J_XR]FXCN?YQ*CMM[2A^<[JR.J
M\%')U<:LM\SP/6;XL\K[8>CS6NY=GW_:I+HJ';>VKO^>0:IO(.6<(J74'"DC
M61JV()!.-3@ 0LQ+@:U=;Z>W9Y":NYXZS]/<.=[XQE>G&HS2H/4T^" 561PW
MV47F=<I^F;3U\(O:"GRGP4P#KC.N95S+N)9)-</9'99W4Z:G+6-@RB):1H 3
M,)208H!#RE#%K2-:D >-PUF!(/M]"+)WAJ!%[&,I])$B'W1]>(Z?35)MV#W]
M,K>B33'0"\*\7FV2.;_WG)]!ZIF#5#:^>H%6CV%\,6T X9+E%%,)*RG!^*(4
M1<&\C]1XK=>0;\_&UR)JU@3--@Z18RM#Y-AW+"K.^1'1FQM0/D,AT.MXFHL1
M1_?0>%JS JE"<-3=:)<!MN7ZF^9FRW?'U^O+GD3\K2LQ.TGMU8//O-0CU23C
MZ%9Q%%,6RC2:@91>(AY+ABQ *Y*68<>],H2OX>B]:@4?B*-_:28=O!M]@(49
M^[],QO7#6]X*A8_D-QK>9G[O,;]G6R_;>MG6>Q88%6/"(A41"3$B[H5&!C."
M,%7!\BB5BMNI9_\>1M5W JF]!]N C#;W3GJ&$J-_LC>#VXZSPI^L5-[[^N<U
M/[0UST(E"Y4G3>!YS0^H)"2[L!_%A1TZJV-W3NS^P\KA2+ [KF4_)-ACDO5/
M&WLR[]5#870I+4ZAY#*E OL8D0V^1"K-*92*,^'+K7@HYF/A@G\]2TT46T]#
MVY]GN=W>W-FPA8G;DA\Q^HC5*/V7)SOR/-ZW=C;K_ME;GKWE/0'#_6,1CQ23
M4I2("0Q81$V)K"@#HB6S.A+IA8R]\);/,:HW#G,Z("S[RY^!WOP<X2V[M@Y!
MO<AKWI\UST(E"Y4G3>!YS7/*=_:7K_K+P4"((5D7S;PNER9S#8=[20&_9Y^Z
M;"?<2^(]O"M@]L#OT^OA+8]>1H=8U"7BM.3(,(61$\&9("@U@?0AC_UM*U]F
MDRNWQX-=]/H(JUXX+N[=G/'I.$2S$_\ %.)#=<AE)_YS<>)K1B0MI4?:I4F#
MECL$B.12E18.7EH9W-I4W[TX\6_ LWV[\8D84-X'..R+V.B? ,X(EUUNA^?^
M>:YP>.!KGH5*%BI/FL#SFA]0WGL>A;#U40B\7ZZN[)W/WOE^>1-<U,J4#*.2
MI0)ZR00R):7(L)(I+4K!V5J3%Q:9BMP[Y(A.(QB(0=IHBHB-H=12:1[508Q3
MP%(>*=&+MM.'Y!\_'+&1]?OL%L]N\6<!9(QJAATE*;9K$=<D(&TC126Q7G(<
MRM*NC5S8,Y#MW1L^D&4?L*\OPJ)_8C?C6L:U R?5IPAG&T8N$*HDIE$BFP;^
M\!@DTBH:Y$NI)!A:FCNSM<CL<QBYD <N'"[?9XAZYA"53:]>8-5C-(H66LM(
M+7*!E&EX@D=6,INZ16.LB%#&Z9Z97CL9N$ T/F(R#UQX7@,7<M3N3AOY]U#/
M2VBZ!E3&#D./ WAT0),SWH]GZ3ES"&_7(;P[K'<&X!:  6@M)BJ I<DMXE@I
MI*DQ2 &,:JDII]3W 8#?7#'\MH)X\HB7ZDC@7J#N-PDYA_&R+;GO!3Y4-3+;
MDL\%RC1G02I6(B6B1ESB@(RR8%5J2SF)@9 TB*]74+;_,!Y_Q!Z,_1<6_1.[
M&=<RKATXJ3Y%.-L0QHNE+#$S$06F'  /9LA8[9$JI<$^&*$-[4,8;S,$;0KC
MD;V$\<H\.?V0.3^#U#,'J6Q\]0*M'L/X(F5@1D1$&4V]Z@U)9IA")9=>!^DE
MIGQKQM=VD&\UD$>V%<E3^@B7N5/ ?B-Y\#EM\6[?]1^S>EK%R]MCRM7MOW7'
M!ZW'=2W)5Q=[683;BIR;E^1!5/+Y-!1?.JT6F5:M;8>N%]Y,0Q%--2DN$L\7
MXUB,5Z>R%U],7=S4C&R/+_3O-SW/W6[V()F_^NH;R\&("Y*G<=^$!,2=]TAK
M$.Y&:R*\!<G.UE(Y]C_S^YKYT_SX&JCD+1#)#0D>NW'#R0'=G$W?$R)LPNX]
M>Z8M,,9CC/'!E)#H.2)$&,1Q*9'!WJ*@"65*:THCOLX8Q&".(ZA3U@H'[" )
MT@Y81$;)">>.,,Z> 6.4 ]Y_QC@/DZ()0*=W*:: /LDM4A=AY %/UK)2&D:"
M#^RHF(3Z/,!+783AY:!OK[6L5AR %K5EQ?+YJ4SFY&023I*"5,T-HW4M:3'X
MK_#-I+ [D/L3U:P> T"$M-QI@JA,A?86P #4)8R4-9A%&:SBC].V[ZZC=SZ/
MIV9XRWQ9L6)EE]]K3CL0O<<%N,00GJMOCY7X\3#HGAN@5684PJX$Q8F!6:$X
M_&D,<X%'K;5:"^CO0W%Z1+K' W(H=+]!O<GJQ/-0)U:]+&8X+,*?LVIZ69C$
M.34H#F9:7+09W4NZQ'G#0+?4)@Y#C%'"@\0@B'")*>*4!62B$4AJJPC55.$0
M]@K?;YJ->3>JIY-9TYWW/>S$Y/.I&74"KDV\7Y%N&\S !PBV_AMZG6 [( 25
M4GH?0XF8L0)Q[SPRGI0(&XFCYTZR<K\(V@?2XX=#>AE3GRVFOC+U*>R^"[#U
MOHB3\5F#EW.#?-E(3]!HSL\GXZ] X%,@E&QVWT=X$F49LP)$9J :<2,,?%(,
M2<I+[:R23&ZE)\.'R=B%X.NWL*??G[9^?SE'!IO;U?6$,++-_&"BY98IJR4J
M>:KGDBH55!N&O"24*!+*DJQ-++H/XF^+:,7W],+>D^Q6G/[SV'VZ;C6:F>Y-
M4_3^WXKB/^'?P@U-7:<<D9. NFJQ](KP@$ +Z8!N+?[53-3[^@*QEW$8OB)?
M34*S<G#QX>QL]-)7]?G07+Y(OZZEC0S*:M2\Z[S^&?[LP'#^TLV)"%[TY?FX
MKIHK3\+0I#=Z:<=?TR*G55M4M'W==<[)5>)53VCB+>H9D;+56N@F*61!7*>+
MFO=NC:O1L!K!LTW-9/K"S*;CEZL_P-:W7[>TV!2^FPA;\,(,OYC+^N4/_[&@
MVALSFQ*-+9'I-7+K"57=+5WT$5)[EH7!]^'G^JU;P%B6+_,6'"$JXCA&D00"
M*@LCR)(T'LAK%TMEB!?\#[KCQ>YA*E6/S8LVNPEX8>CO(S*:N[VHP)2NW!V6
M*-G<+>$<U_7LK,7[&U=L>= K6->,_7C],7M$,]DJ?:"G-[E\S.BR"/!PR=[T
MC3JTZO^MDXJXEFLWJ^=NWU^&QOT3?7*GXR$L1GL<.I]42;UI%,39T#0ZE"G2
M.</0'=-ZDUMKU[C30?$:[C<=%]6T+H;563-R%V D7*3LO],*'B,EI@Q3(J Y
M:NZ\_O3IW(MQ@IYA\E?#R]858$YZ$E.,FN8#Z94BZ*/C27U45",WG/GYF\Q:
M6SQ]7+H(?./2C29-QY+SF076:[\95:$>%)\;4S[IA6GYPN3LIM3$&0!FJVLV
M'O#W9Z/*SNKBW2@I0("3Q8>A&1TUOG8X&^C G19_SH!TXF5AZJ9/"L4O0?>K
M1K S(S"U3/,=>=GDL'QZ\ZKX-#4Q%L?.C6<)*$Z*7V;#88!/!<$27K4&W3T]
M'J@!OFARK O8A/1(=75V#G>JX)NS,#T=)Z]^LQ5+B]QT:I$O-V[-9;L0DZK^
M)XJ3 )^:=(1Z]4Z751CZ)JA0_#[X!*>  E+/)I=%'=QLDE;[2S4]A5^;=6RV
MKT[DVGZ=KM N;+H97'N)4-.=0K//9^/)%+C%IR> +8,-O.B6?I+"&*"@P!N'
MR47EKD(6W:ZW\8VC;OWADB=A%":P*9<M421"@UNT9]WLPGO.\O-VVLU=.FL*
MI8QW2$@B0:FA)5*R%(A;JYVCH:2QW$KTQ9T&/QN&]_%F3_>RD;Q TB4@_9PD
MPV=XAE^&<. /((^<.8?K3R>SL!_EJU<!Q #297P)(N%F)$DNSRL)?H4K<3P<
MCK^DO]8RPLW5VK_HF;EV:+EW6U2[Y_4;3?G&3?*P,3Q7_1_IG=+A:&@NQ[/N
MD/9N!.,!_G%^O$L)J>=U>%&'!,73,%^;MD*F.>^'FYK!78#$MPV2OYA?8T.7
MM_:V)1N0DORX;+AV[]Q:KO_QC7/)@(E[GGG/T_1 8_ZHMZ0#]MBO2-4N7W$'
ML[]N9,);MQ;,E;C;J\3-:WGOR8_B6Y,?MU9Y.U^#_CJ9USPVV]B(_PUF4KQ9
M"SALA\H/<3>>V/3'C  9 0YU+6\W^_<11S4^4XQX0!_DW0\@[,7V[)U5=@7)
M6>QDL;-'L<.RV.FKV.F[KIIG'BPV\LT\*+@43/SIQY^S'GN8@-)?>;3_U%53
M$D=L,$BRH!!W+" =O4*4<1R9E='QM19BRL48;,1P>#2(&V:1$8$ASXRA3.C2
M$;&U8I5%X<E2V&[.GW]?L.=',PV_5J/J;':VD@-[/EOJ@H'H<A8L_TX2K.(#
MLMU$V&UPSXU)COLG(T)UC*04B/)$1EQ(I(.10!)4<2QPU#H>"AF9KULF([:9
MC+*[,%M^&:C[3[7[E[ A.B6B8TB+5&,2:.KU23QBI56B)%9:O%95:DUIC"]+
M1)S5B+/@4E-L$,W>!$!WZH7&3P*HOR%A,U"OZGM4<&-X0*3T":@)3G7Q&DD5
MTUC(@/UZ>X^^DE$&ZJ<*U#N8#YE]);O9R(^+O.$J45&HIVT"<?:79#7L":IA
MA#A/L?5("I.F7&F.E-,&":.=CK),3==[9^@F'GT++/JNX] =*&%L(#:W7\\Z
MV H-":H=(<8B$E5$7!B#;&DQHB7!S&..25QKVMQ/&MJN!L8'E&8%K#^PDCTE
M&:(/$*(QMD0JK!!A@B5Y&9&Q\,DR:H,DE'N[)E[W;N(^"D2KS>(U0_0*#96,
M:NLC1U@["VI># C EZ&(N6;&@9X7UB9T]Y.&M@W1<FN3NY^ L#L\'TG.)]EG
M/DE7/S^L8BA^JD9M^Z+L)\E*V.,J81NJMK''26\B2$E/$)?<(\7!+C64BI)C
M2FRYWL9,^Q!+*E(;,PFV+(=/4CL4HXL:.^T=O;EQZ7W&R7TK-K#/>:E769<W
MSTL]).5JTY!=)J25$B-E,.RS,B+-TPF(4AJYCYXQYJ[3ABN%("PR)#BCH!!)
MA[0U%FF"B6%2"2-N]ED\'=H0J77\-VDC*TW9KY$AM?]4>S^Q::F2TAJ)I)$*
M<:++U,[6@$7I#=&FE*59:T.O-',E91AY$P&&54F0$=8C0[!20924RIOMR*<C
M-LL!?OJ0B@-WECJ'I Q $5%9I'0@B&"CL=!">+<&J590)K@42 19(LZ90D9J
MCB*FI>4F$$7DDZ<-E2&U1S"P@UR-6[L<;C-;//LAUOT0OKJH?!CYKJW;_7,U
M;K,!V3'Q (TTCR+?Q4IN(M7[R_XKN;S+U6WNOD\)TC23I)F8GR Q9[F;2?5
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MT!PL@'OA9Y/+8";]$8=L0.@"#*[C8;_(OV?/D_:Q'EP?X))^KT8STPF0I%&
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MD'\Y7'F'Z. ?Y'[Q.KKC]>Z?XW#)S.D9/W\!DZY!1]N"<16K)EDR.2)"0CT
MP4:S;CT(]70R:]\CP?CRR9-P4M6MMMS <@+)3V]>I>L,JR8W):$G8'#CP6@\
MC9<)A$_-Z"0,LA?]^3##NU'QW[-12 81.[JRM>(LZ7:MDN@7OO6%V_::@[:S
MPS:9<)F@GA=!O0UV,C.3R^M$58^'8+U/%P[[23(&0/\/C10"_;51 I*&?S(Q
M9XFX_O+JEP^#XA@4_V19S(;3U9Q0G[HZ578V[6@T^1C:^,)5)*%S1RP"#>F2
M':768+9N2J';XPH>AC?8.R&4%Q%I9TK$381/PEDDF:#88T9<5&L92Z66Q!.*
ML" $<:4MTI@QY)4GP48B>:E6W!&OYQM<I?N/SQHG[R?8MKDO>$O^7GPXJ:9]
M>ZP. A(\_+4)_#56^I< RHAI^"\QM0<&[MF#'P:7,48QT\FE':1%W&*!C X$
ME=C;Z .QI21K2;A,,8:=0DZ2@'@,%!FN(PHB.EDZ6^)TSA*77:55-%D5;5+%
M:WC%B\9.^UL7][K\;3QZU4;&MI;A76:VN]]C#<?)[ Z3LX;S_&*S%E'*RU;%
M!]:,LR:#P"_)TKGW/H7J4^3CGW,__B(7O47-*V]YV<#P364:C?'1(GWC'C23
MR67"\XLF0Z>[T<:'_ )"HF=K>QB2(1(:C;8<&086/O<.-A(KC:(P+&@5"0OA
MNF2()1.$28:DTRFE7P>D;)1(28N)LU$9C%<EP]\_WBP'W%;E0'DXX=:^/59B
MOIX]TV'PCRX%E4YY0$D&O,"Q12I@C[!T@3O)"75BK>(5^^@%**PB&D#CF'#9
M4HJ$I-1:$@4HP/O@'SZ0F7_N]UCC41?4&C6]LQJOAC7#%&XJZM,0ID?SF!;L
MX/!R4,!FM<EM368A.YS,PK>FFG1IL[\&D^H^KC*RWU8C>./*#(MW"Z]B[W Y
MZ3,IWI#(&YZT&K4\D5AZ$D[,I,W&^I:RD5[UFOT_Z-E+%ME7]GQ\9>]'Q7LW
M'3?:-#[JE.CEO)BUI.95_]>2=7T8H!N(LIS+ (CI-.(84%1[P4%S-64@P@H3
MUT#7A2A9:D@A@TU=))E&2@6--)$D<N\EUG'-G)T;.O6K-B?N@[E,F09MZM;6
MD@0W-Y?H"8'U%7433<^3;[NDQ7E>>%,U.#L'DIG_,C<AE[=U4+R>3>;R/E:3
M>EK\.3,3,(C3X>O= Q86K>F"&DUJV;4P1GJJE-][TH!*&U5+:9&S$Y <!17S
MM@35=,7SW.3;?&TJM8>7?0/-PY +7%M6"C!'F:<"<8,9LA$,4S!P*5%IGB;G
MU^6"%Z4IN0TH"-#=.?<BR9* 7,DIDYS'8,N-SN3Z\[CS5FY+&-"!R-+@?H_U
M$RAV/7NFPV ;SQDW6@7 0H81%X"I)@#OE-I8H84N)5NK&M\2VWP($Q"7J\PS
M2AE[GZ8@!^N4)9V2W<SK5&X]J9NN#@O6PG=)%,4#WG_OT'E8*15I?9]-3?K/
M-T1(!L6GF:W#G[-PI>9UL?6CM6C*J;E8\LBF\I0)G%G5\'K70'-#'5R",?AV
M$IKDRX,@;!$\QD1+)#!30-BR1$:HB S#U'.@;&S6<IWO[-S\&,Y,E9[P_6R:
M$DR3_?A+:_H#^=Z8U+\9'\1Z8Q&@Y%2>7X?1#_\U&O>>A,=7J[ 2*ZAS^D9?
M3=+]5&'_;:$B-Z+E;^'$#(M?S124[_I %NX).F[V^.J?E^L:ZZ*>V7]T-0!=
M]4 BDV%#)EUB#EPRU0H; *=)58=Y'O\X^?!2XI ;SR9M^S;;%:HER'2GQ5E+
M9@V25:,$:J,I&%VS45<W<+2$=@X6QZ9J@^($3$,#3QO:>S:WFDW=^*RY17KL
M^NKB;2(EG)BD>U-H8"[&J4[A<H'DW;LV\=7N>I-0CX>+V.J-ETRYF0V8F_0U
MK'&:3^<O0GK3$&-:LL;N7;K%HL1YQ3\=%][:.BE;C;-VWT(Z<UY/I?6'-ATS
MH?I2'Y8#6;)G3"V/0QR3,5@N763D#5@5Y[F+RI.AB;MB]Q+87/5K6G*1+A*[
M >#.EPDGS FGL<B2?9."J+-I@WB7(?E9X[#M=5G=$&Z]"<Z*+V&#K9J=0M^Q
MG2W1E,I D.-<(BZ%!K/9"&2DP80P'"2E:XFYC@7&P=Y63D>PG0E\HMBBX$M9
MRN1+*M=:"7[HB@$^CX\=$, DS(7)!S"AI\<COY G6XNW;)Z[U1,*Z:N'U7PC
M=:_AM&O-:%>*>H%GX>)%:JZ9M<PG]NKWS25A)<E:PI.@@-L6]7P*Y]-6>H#D
MP$?%7RY!;%SOO+'2H@.>'/X-PP3]L];V;W6&>6N.=Q\6;3GF[0"6^G[\E!2%
M[LA$;\7G^3$+W^SB]*;(\2^_O2O^VZ0%2V)MWD@ Y%XJ.?IR.DX5;>,OJ1=3
M/;-UY2LSJ6!+EN^3+O&7R7AV/K_RH#AV;MRE%K76_X9GV; BIL5&/V_<,)S5
M*2>I"0TTS<)!G_KKI9^,1Y5/4O;=A_:W.JE*R3\];#IF@A V<]=&=S*\6!OX
M'L?T(/-L[Y/AV*8\KL5UUM81?FI3_!<OF5GY^;#R[XLHT49";GN3-;7 "[):
MI9P-Q%Z!FF&'R3G<60SFLEBP5-;F[Y4Q57I/F"8H,*<0IUPA&[U#OE1>4LFP
MQ^ZZ-F\P"X$$A2+E LYQ#%E)/5+$R)(1B0WQ*Y&P]^VFP5T_CT&M?S=ZTVW_
MV_$$#,1W2U)\KN2W=+"U_.6<.W'/QVH\QH!G9U5=+Q7V-.R:)-3KR>RD.#X_
M'Z9. NF 93CX[?7Q%0*/BU<-?#<LWYSV)H6QS7*]T&^F2[[]-?C$\@60@Y^Y
MU(+7PR.FJ.$-=_GUP]5MN@M]^/BJ=]T7#D,@1"\#MJ5 U"3SGH2 E'86.2-8
M\$$Z+-?K?B1WLE0&>9WF ^! D2HC05X8);UWKO2N5P*!Y'K<>YOZJ6-/RZRO
MCP&!Z[IKRSMGP\;%M\3J;\=CWZB6#<]_#!<5B(WT][M16_<P'BU.&X]0DW?2
M]A?I>+U:'+>J+9RWLN$HURC=E]>-))I@@'S@4HZX<ACXUFJ$K0G".V&Q7$N7
MCJ57P98<"2TUXI$%I&T0R"M#C J.JS2VIT>\+@8Z\_H#P'^%K]O>?P#,<\!^
M?;RQ</=H.>\L45%;6M-EG+6=A (8H>$;+-P[EB$61TTL0Z54#G%O)< C,$\D
M1D2'.0#D6DHD(UHXAQDHU9$AKIE,V<=P"6II<+@LHUS-')N[OH%#EICE+IQR
MQ1_O?GM[\*ECB[Y #>6T5&/\XS62>LC$D^9)MCK.,7N*EQ;C8ZB#F;C35L,(
M%V$X;D.%']HN/_O.1,B^I\=U(\\+.%>\J5W'IZ--<:KKDT#G(>K.S62ZH<)9
MR;Q7[8UBLA3<HN@U0=R$$H'2:1%1-#!G)29V+5Y,2A(8C0X1)P Q XM(4XX1
M5BX*7'J+/;]6D]?MU^?Q? 3TEM1'B@>L]P#94_UQ.D[3-.<-8B;+HMHOB>JT
MJ!?-W(O&P+LPDVH\J^=<FU,/OS]K,C=ZSHV>']3H6>1&ST^IT?/]E($?'M0?
MNN>-GO>3'?T.:/ALU/997AF!LV^[I"^@]KQ>_5V;GCI*"N?PABJ454.D@:VZ
M2W99$$Y;$U)UA'59C%,U2JLY70VW6$P2:X\^,Y=7E3#P.*/.G][DM9CE(4[%
MTF5 19LW\+E2T0;%N];U-W^"*LQG>329?LTXD'^F(I1ZYE('AC@;MG4Z:YU'
M4GO!Q7"I:I535E<B/7_3-W">[))F_U5GMEF_=.!P7+=30.JU*[7%/"=A%";-
M0)&E\J&YI@F:Z712=4.LFF*B-!W$=)T@;DIA#E_/F]'65T6QRPVIFTR%V>B?
MH_&75"+D3,K"J=*F78R'%Z&>URTM]@;>+3FTX HFM5V_/LEMJ<MB2GM>^$]3
M[O.5-ZSX/&Y&<ZU;L^G8<U/YIFZHNS?L<W/J\IKZ$,.H/:JCAJ7T[*K)&5H5
M9^.%;[]G8]%[Y(-9>>GF8=,J@IJ,^$!R_>-"Q6Z&E_-!R=B/UY]N+S/CM2%6
M$A.1<)@BKK5'UI44B2A)R950FJ[UAKW/S/AWHU0I]]E\O?O$^-L\8IX8GR?&
M/ZK'?S<3XWF>&+]-/:PIS@69<Y\!\;T0XCU"N(=:G&O(HQP3G$6!#+6QS4O0
ME#$DE>'4.6^,6YL$>Q_D^>1.@Y\-P_N8M"5X9U#=WL<%'KUI9TG^ JHCK,#G
M1 6;@.FY&3*?FR*[^9I=M5!;U9*;67KU/'&G:IENFIAND<F3JGY27G\JA-_<
M^KLIZ*N:7/16&0;(''])2?,_->HQ*/%P:/WSBQM-RV6H?W36?-@FW=]!5*RJ
MH/U0@&ZO MVD!*D!UOP6:M -YY)[GL8&A#)\];_[7N>>IPV$>+KONZ1U/H[>
MN5E7&F"RKB[!+S?I2O.O6O+N3NV5KWDW(+^D<K8+"1N2?FT"JK=>U+/*^V&X
M:5T7GOMYH.F\F>A4^6(N/&]<^1M6J;^QI)THL_\+$%J\64/0;^[=;O>KY5',
M>KQC^^2>+/B>B."C6?#M4_ E$R%+N;Y*N6WM0!8[6>ST3>RP+';Z*G;NIUPY
M6-'HLG*U7\[JIC\N>0JO7(@O'E,V9M9Z=$3/JYOUI5[K2YEJLTPX#&7FFYZB
M6^LMRU%N4#]OU@6VI-PLQZ+2O9;OC7<1K'N(ZK.5"H#@4SKB/;EJ^=E&XYLV
M8G.J1U_@876UM[:P_[Z%)=U$W7=<U!LERRZ7N;G[/JFZFU7ZC*FZ'ZA[&V+.
M"N26%OA0234+X"R GQY5]UHQ_Z:7,2OF?5#,F_&"F7]ZA*]/"@R^L[R/T8XC
M<E4ZPU$H0TPS/3U2.!@DL<2,:B4E6Q_?<(_<ZLZ7W_#3\<C_;0P[MY93O;%'
M!UOIT<&^UZ-C8X..S,$]YN!L@CQS$Z1_*YG!9JM@HSW'RF*+M,8 -H9SI!73
MR$<J!>:88&'6>C\9^"&*B*P5#B!&$J0=P(Z,DA/.'6&<[1-L-K<2SQS<+W,K
MQT%Z;VZ]'4]@"T<%2AW;]\!']TR">[J<ME.L?'C*X;-&4X>9CE%I!#A($8_"
M(*6E0U: $>9D=%JO3:U_@.G6\>;.</2(4=P'++UWKF66 MFXZY]QER$M0]K!
M0!I@5AEIB,@+!_ D!$L3*))S4EA#+"VY6ILV\P #<<>0IH_@UAG2>BD%]AFQ
MVZ7)^ 2-PL_C:>J.^(UB@)VQU&TK<NB )I[RXUGJJ-$W8#W U(X=+'S&V!9C
M2V(\D1@#5%*P'1W12-.(422"!L( @CW;HMFXH7W2%JW&1PSWW9,LGRO(9KNQ
M/PN< 2X#W#,!. "C,G".'%,!<4T9,H$*%$P46EAJ);-;-")W"W#)AMP\L+ O
M\N"Y MPF*S*WZ^DO7.8ZT/TK)GEU^[NZ629DJCT\JGWVJYL;W1QNHYO7(89)
M&KJ2.]WTDK>RY#K8U<W:3*;:PZ/:9[^Z.</[J69XYTXWAQ>L.,ARI]QHX0DZ
MW'-$N3\+?*BDF@5P%L!/CZI[K9CG3C>]5\QSIYN^X6L&@PP&3YZ8LS;^S+7Q
M_JUDEKM9[O:;F+-W_(DJX;G_2<\X+1>+]P%8?IIO3[\*#9AG3BDN40D?$+>,
M(2MT^C.6CI8DQK"5!BSS]*!..CRXX*"&B\"G[U0>D".,>]%)\Y"JUW?D6_XY
M6V!/SP++8)O!-H/M;<$61\X)91+%$OL$G!)I %FD S/"ZA"$\MNHZML/V"K&
M,]3V&VISQYB#,:/;CC'^6UGU?:N@[1GB'V".Q).MJ,_@_P=1WKN26^0BX#YG
M7"##7(F"+7%092P)60/_AUC:3]/$?BK%_=G(SD9V!MT,NAET=]M'QV%J7>0(
M>\8!0!U# ,,2>6]D<!:7WO!M6MQ/T=3.D/N8QO9V(MS9V+Z'L9UM[+[P5(;[
M@^Q:IY@E 9<6B4@ .3T'M.54(/A28T!<9TJU#1-WM^WJRL>=XO%4X+5_=E8V
M9+,AFY$M(]LVTJ2"XM9*CX@H#>)68F2EX,A8K@+'3DJ-MV%'[A;9U%%)RHQL
M/46V97L1/AM8C-V^ZS]F];2*E[<'GZO;[W))6O+\;78&EW+PMZ\N_NL_X3\;
M5N([C[+@Z.Z"'4,'YUA91H.(-Q'43AR1PMXB&K!A 3,JU1I#WT=5_>1.@Y\-
MP_OX)L8 #'<1%CS^T4S#QP#W<-6P,HD7/Z=-_PQW_&4X=O_\H0C YN=PM>ED
M%G9,^!N(X;:R=0>D\?DT%).5Y2G&L9C"M[%MP +/:*:SZ7ARN6RZ3V!5B^FX
M.?#5^ S>Y;(IZI OZR+,]^#J2!"8S:&7P4S@@)$/OG@=7#BS85(P<E103'EA
M1CY]8(69A,+4<-9P./Y2K_2U.P!6O7['!_#I7% U<NJF8@<#.S,7].D)TRW@
MG=+A:&@NQ[/ND/9N!(-\_W%^/%#=T)S7X44=SDW:IOG:M%#0G/?#3;ZUY+2Q
M0"[3RQ?S:VQPFK6W%6*@E4SW_9J6+#UC]\ZP#5]?_O ?WSB7B %0U3W/'0AQ
MSS/+ 6&WNNL._(_W[::YWDQL@_/Q.=I:BU9W[.96=W?IQ/;]#-%>M&7;:Z?2
M_P5)7[Q9$_2/Z,;/;/1(+HO,.MMEG:0+[6L3%F9A)NY,W#LB;G8 G<G[# */
M&K,%"PZ,OO/9%(#<3&\P"B?WZ09T%Z[J!<_LWSDJ?(E5&2/RP1C$A0W(&D\0
M]D*47)?*X'(;OI3;>%".IUUWUD]S,E@Y>,61>CZ;A(4G%=%E5RK_CB>5D@'>
M'"/<%TO\N%-JS[B;)<0])80E)%HF<9ID)Q'G@0.WERD>XI171 D3MC+.+DN(
M^TJ(;.7V3L%)U%CX"DAZ$D8./LX:O_;\FVGQC]FDJGW54%:68KN78D%*3H50
MR)N0TIN<0L91AX2TS'EJ2>#NL?2<ZZ6]Z8C7<\JH0 !M28RQ@9*'(\6RGO.<
M]9S')$'4SWH'KXR/..*4?!D0QXXA;8A$2E$F+;$>M*?'4K2V**)N5Q5!!YP=
MCJS*+J7>:5P?)F%!G6LI!2E1X*^_?7Z3Y>@SD*.8&.ZP-LFEQ4&.*H=TX#1]
MDJ[T6-I('J+JG5Q.PJV$Z#))KAP&TO6OHSN9J[<3HGK U>$(T:SP/6>%;_]R
MHC1:2&XH*IE2B=-!=R(<(T(LJ%W"&U[&A^A;^Y 3W[$'B3X<\9"]6KW3L7X;
MCX":_ PH)R4.AC;/O6A2-,G+XOUY &T+KI*EUR-(KY+Y$)U%5CN7JN,I:#F@
MP!B+N>:$RDBWTI+F-@(,Z.**++KJAVT)+3$0F^OE>R>TLD[SG'6:;'S]H8Q7
M#I<8\< LXJ4)(&RP1D)Q7XI24L'"8SFQ'BB6;F=SB0$]()LK.ZX.3:DR[L]9
M55<-BTW"$(C</WU!V@,Y1I+#77#$RB@0=[Y$1E.08\&[J"W!]&'QPEL;AS<)
ML8\M'7P>'U\1Q[;T+7Q0J0]9W\KZUC/7M\#8L\R@(+A$H&,I9(D@"#,AJ*>,
M8L$>Q8FU SEUR\@A'1!Q.!(KN[5ZIX%]_#_F[/SEZ^+3[#Q,YKK8<TC+RO+S
M#RM8B7$PB$I*P6C5$1F0IPC4.^<B-[ST>I]NM(^A#F;B3H]'_G6X",/Q^1F\
MSO8B CPK>UG9.PAAM7]9H:F2@DJ-&/>@-W'&D4DM\JP11%)1^D#-/GU;#Y85
MM^P:/^";&Q'U3FADCU?O]*V_F^&L[0EC4B<6DQ+DW:D9G>2*O\?0>(S&!$>*
M2H4QXM$9I(0ND:,B<D=)H'(KC3YO(\5>-;O^;C1OP0T''==UF-8+$CF>4\@6
MDR .*-$TJSS/6>7)]MD?2H.$HC@@ZIA"W%N0064,"*RV$+DL#<#T8^E<NY%6
MMU.Z^( =4"U/=G+U3NEZ\^G]AZ<O,?<OL"P+WG%J$%>IVRR3255*A=.EQ8Z5
M8"CZM02(7:E7K^>NS/K-V?EP?!G"I^G8_?/]EU&8U*?5^8>A&;VN+BH?1K[>
MEH)%LH*5%:P#$1=9P?JCE-0*'<'^XY$CKCU#-GB?2@]C:4KC%=[*E*5]RJO;
MJ5AX4&:_5E:Q[K]7[Z>G89);P?5!JA%="E5&C)Q(&I42)=+88L2<!QEEI SA
MT;2PFUSU#:EL,65K\Q37W@FNW&NRQUK9@0B8K+?]8;EA)F*!O$[SNF0 0"?:
M(V$BE<*"S#)KB0N/&8R\JX2[K8XF<Z[7/76TAJLJV*G1] 7P]3UTMN41 >D*
MRU?L./QI:71OUF9./*+TO7G44R_D[_[%GPQ"L\@PBMS3-HIIO>$H.%#3 M&2
M^K6\U^TI>*_@NM5H!L_>U;R"R;JUYH-TH,GAR+C=$_Y"H>L%Z3\Q%:_'0B8K
M>7^(,O TH@X9H1CBG!.0<DJCR((WF JX&=V=DO= *7?+;#)\4.+NT0>]W<W,
MW/GHJ TCWF[\%I:IF?WFAJ:ND\0Z^?_9>]?F-I(C7?C[_HJ..?:&)H+%K7M7
M:=[="(TT,T?GC$>*T?@X]I.CKF+;()I& Y2XO_ZMZ@9(D"!%$L2E&TCO6B8)
M]"T[ZWGR5ID!W1XJ]=VMX7#_T]J27U\C]D,<A:_(5Y/0JD.>!S4['__@J^9B
M9*Y>YT]7H.U4)'#+S[&PKM.O\]%;BP=J#T1A['^XJ+O=**_;+95)\9=G,ETC
MY-=^ ]\6YK;]?"\0[O&&<M7#DO)URK90KK/)'<^D&H^J<;JWJ9G,)XW=_B"]
M^N[/G2ZV;I6)Z16\-J,OYJJ9C^!:5LK;TS.SCBVIZ1UUZXE6]0XREL"@)3K7
M$8M9KJTVQ);$1"0=3O:\ULGW=8(B&4LBN))*4_+W>=NV=&CP;Z9//HSN9_SB
MGF=Q;GKJIHJ!<FH<\E8EG\F;$FDE/"+*EY$&I<LH-SMU<Z7.ZLW8_UJ9=D9@
M%1H8N+GT_C^EVZIB<@#&TW:R2OKN>-HLAF[>G:7IYY)MPQJFE6V>C%G'GJ'_
MMZ9YIF\U53.]GBO:3O5,9RQ>5>/TEWJ6KNB;[V',YZ;&?&J]ERF?ZA2O/6]S
MS<-RC;C42__9[>77GR\Z@.?M44R\&TK^M#!X7^:9[SW\=#WQ5-X_\?1>H;XD
MX7BOY <5H.K#)-3G+8*7)=[[^\;VN7H ^ X$^"@ W^#FV +*[3M%]<PW + #
ML-,WV'EPPC# SKZ72H^JX8=H7.TRM?IN-?;X>I<(" MHY[P-T@6KJ-=6$6@M
M8,(P3)9OQH.>;)W<^]Q@LCST(M\X-YF94=,F'R<A'7X9FC57S?*=CNO[!-])
M8#BRWYB8_[0!D3ZDS<\4ZKW(L4TQMU?O7YF]+[FB%'/D:,D0QT0B2RE!PG K
MO"NI(2N[C%AD*N8.B8[HW/>"&*2-IHC8&(0N<T<?=;?H8Z74(_VP^-M2=\.\
M[MZ,_6(]WBI&_>NG=]>UJ&RY%!6QQWKKX(=;ZQSAZNZ'=?&410V&\H8$/%15
M!2(Z&B(27)6.,!1*BQ$W/E<?LA)1RJBWSFNG5]J4E(PJ)W&)HK <<:D)4BY1
M$B-61AV<T$SVBHCHB2(/[X4XPO7=:U?LF]%C<,6V0WEY3U)>&,7HIA 8%DB/
M3 G@O8WR7K3)_R)>("=8'JI(+=)E(K^26HU#J534Y4L<L':^SPKI+5;94K7]
MABB.B(>; \+Z[?'Z!5_KR'VM_DD2J&:C5$-C27DD 2E!\Q:M()#66"),>3)^
MJ3-AE6J>XV+MFFJ8!J89B"L%6:T]N%*_A6E1=XT=QI^+4=TTA3.3R55>55_,
MQ&_/K^J_+3$<LEL_[7[49&<X+3V)% 6,+>(Z]X]R9?J'"*>%-XPRO)7$UH?%
MBOLU+;BW>;TMEMNFLEGDI"1\=]0'BWEOEBLX6:"JP#N#XAUE ]5$*<1TGB'I
ME<D=,3B2D7!EC!'*^:WDL;;/._A$RAVZ7+"8(7LU-)<KK<;"I5593<'5 LH[
M$LJC3E*;W"SD@F.(.YDH3PF*O&?$J"!C\JFV54/XMEUL6Z&[$RYWF,J"=0Q>
M5N\$#*H*E--+RO&!>NJ%0:$D$G'L/#+>280M5E27/ABV,C5V4]6"0#F'MHXA
MIS48!^OGZFOP[3:M:CPUX\]Y(,U\DSGD?@? =U"ZL1;?<5LZ2U1,=X%#<K&X
M0(ICE5C,,AFM%U&OS EX>95@N]BN._.^OUYPFZL5/&'JX9&<L)![O)#[;SP,
MVL<"507.V3/G.*5#&:+-#?<UXBPJI*,,";Y+J:T5PM&5?O O+Q?<!>>PAZ>I
MPD+NEY,%6:P].%GOSR_R#JPXJ<_S8DHO:)S6^>2BGL^(@L4"K'>HK">BHLY&
M@AP5$7&%;68PC(PVT4MG.2[%YCVM;L7]G!;<S]UZ>[NTW#;$?.JD%#LL&X2U
M#,Y6[P0,J@JTTTO:B5X$3XA&I<O;@'4ID Y*(!)5),1S(GW8O+.U"]KA)T)C
MH)V!^%N0U-I'SPMS44W3K?Q/;IH\26>80X.K&TAK >L=+NLYY1.O)?*RWF4&
MDQI9S02R(F_=(H$XL8WF%S?+[8^;U?8V+[9-<1X#QAOD.@9'"QRMGDD2*&>C
ME*.ID]))CP2EB3ZPH$A[YY#PC!*I8O*IMI#5VC[E2*& <@;B9$%2:P].UJ_!
M-&'/7077',YUN.MGJSSX\E%H1\V4@D=CB4ZHQ:- G 6?&T=95,I@'*/68_*B
M;5WW,V6[3#??*XJJ7M#CV@/@  + :^N?UP9\!GPV&#XSVF**E4-2F;QGS%ND
M"7?(,*9,L-$9_*+.'#OE,PUTUD\$@+3;8#S"ZT&EU=C5YV%I7FEA0ZY[+"[-
M:-8FPPLS&M5?S-@%B*D,FD.!(;_!D(%%*K'7B#"=&))$AU3I+/)*>A6(<-:N
MQ$8WTLCCETG=;(H92W(B--0Y#G+=@B,'Z;>>21(H9L,;F8DDB4Z0#;G.T0>:
M'2J3G# OA?7:!&.WTKACDQ0CU8F44.$Q%.<*TFW[=*ZR5[7(NET5__Z_%"7D
MA^+W#W_==MN._AL3PV&[0;:IVJ6ZOUH(OU]TJRDW0EJ&;.0Z>71*(8.3LX:=
MH"'Y9D&1E:F:+\GA+0*=5[_G%_(A_K4)'?UN*HVG)?3'VOIXW._[8S>#BW=H
M.ML_20+I'1;I.2=<X-HAQ11!/%T'F;RKSEAME*+8BO B'W/7I$?P#I-]_0>0
M79,>9/0.Q>F<-X\$MQ,8&!AXJZ6C4E)-3$0DMA,!3$ J1H)T2;4JM531Q TG
M$I=*;#Y.\M3#Z=7'D1E/WXS]3_^:51?GZ7XWE6&$X6O@@X(/.F"=[9\D@0$/
MBP$QE2%ZBE$,P2 >"4/*2(D85Y$*89THU8;SG#MD0 4,.#B'%+*@>]ETV#2O
M=UI&^O!R@<T:NZ3G06_6  +_>\FU,)AHI(E*!.YU0-81@5C /OJ 2Z$W[<)V
M0>/_MP"+-PNLV%B'@!.)=SAM8:VUT;MM(^#>@GL+# L,"PR[<1=9:RU9=HRI
ML(B[Q)M*"(;*1+W8,NR#6)EIM)%2X.TQ+#LIRUX,\ .&A7SN ;C/M_*Y7=[V
MI!B'Z=Y7%#VE>4GY>I;G#_:-W;>THO[4 YI_AN#[0?3[YUDI=&#:E*@,+";.
MY!XI1AU*<":M5+8T@FW%D_TM;"K>G#Q7HOO'JW>4L7?,>@A6?E]D>10N*] :
MT-I0:(VIY#=J25!TI<GC"0VRP4BD22A+DA@OR!>U\]D!K?$3J7L8D 5:6_$3
MT\\F">._%B_KM]EYNI9+O_OJ<KL2^,>LF5;QZNE\='/Y;UWQ)5)*S_S  S_R
M:J[7\EQ^BZ4L;'26Y)EK$B.NHD9*1X)PM)@I;JTD[NY2%E90J4J*K%*Y.Z4-
M2-'H$2\)5RY$8K6XNY0_S<Z3H*\^Q-4(T!_IS#^.:O?/[XJ0UO)%.FHZF84M
M:_<#[_:IZ/EDN3_]9?]Q%HKS^C+D8I&FJ&,Q/;NW#5)A)NF_3<*W_)>F>%6-
MTU?K6;JH;[Y_O:PMQ[4X%H#1XL7B?N9/D,'LM9E-ZP7@YCO,ETC/E+^.1N:J
MGLV_TEU-ZU/\Y\77DUZ,S$437C?APDS,-"Q$TR%R>]AW]X6V+JNFZFKA7R_.
M\4#,JKNJ+$]E6>;K?LT2R[<X?^3T%K[^\-U_?.-8LN9A_)13OMM+)@;;[07I
MJ5)ZBY?<0FCSWJ7TA'AG,@V>%M<\1E\N"3Y_^I_?T>\6]S1?XIU!]W JZP'9
MOB1+=H^PMOE";IR6=2CO2Z?)MA[YS;TQBBE_BM7]T#M:L9 W^9:N3]Z+][3W
MI;/EY0)H!&BT?S1B@$:]1Z/]5&&_+(>\]Z#M=E_8CV;4^:;3UFVU(=UH/FKA
MQUX%,WEV=.V%'=KV+O(]QLE?7*_8CU@WU&K]7952!DPHLI@)Q#$+R$BO$(^L
MU)HJ5_(734T;;JT6P,/:%<TOAH=C--9!!X&B]DM1;3<5>@Q:VFM/XJ4%J>!)
M?..%O3TSX\^A38#=D_QZ?O.@K6\L.=S5\5(%WE PZDC O:?^AZ ^X-PGGAB2
MO Z5W C-HD)$4B(=-H31\B45 FU+O_FBOZ\\8&.M_$X4HSMR.EX6W]L[P(-C
M<B2."= >T![0WOWMVZ.AS#J*8C EXEX:9 4FB#)%(I<B!+_2A( 8S'&4$5DK
M72*[DB#M$@&6L>2$<T<89[NFO9T&VX#W>MD_"/S-IV>NPMCO,V?UE+T)>W\A
M0PX:/D7 0,(](6$NC8M*:!2DE8A389"2CB,616F""D;A[4S%['TGH&W"S#$1
M,CBBO7!$@1"!$($0'R?$1&G)B=0*:2HXXHPXI'VID#$A6,F=P^7*4#$H!@%"
M7,]#A:V7>]Y,M\?=B#^:)B1/>-QZPN;25*-V5UUM_Q'2"KU,CO)EY4-VG--W
MW@47SFV8%(R<%'E+QTE[V-OZ/#W,55I'20[C>EK8,*I".K::%E53G->34(RJ
M?X;15?IZ>NK\E?1#^G#:Y%Y#"4=6FA 57ZK1*)VHF(0DNO]I;RH!3/'73^V7
M+F:3B[H)S6GQQKFTIM-SCJYNW\V9:8J+29UOWQ>FB+-TOGNW67XVU;CY]LW<
M]^S=[9Q^.KU]0_<1RA[?;S&P?:(;-EV/:S&_:<LI[EFE)B9C+ML+35H-DVX%
MI&^Z1)M)^=/B/*^F[5^;XE43<EUW6AW?WUU/:1E=I!7U-3'Z-"_F/SUH/#WY
MV7;1!)$1;A17")-D4'%!!++<<R2LH8:0X#%?36P'Y8.V#&&?9PO(()(E9A0*
MZ=M"6A<Q=G=MJ0\7K63'GW^MF^:MF4RN$D!\,1/_<(A?WC*AQ&.9;<U.'YX*
MT!,5+-(I1EGX,61-&Q5F[ >B*,:PTCHF$96Y L(3C:Q1$5&2-$3%0#TU=Q4E
ML*B=:8=0R) [?P6DTE=1H,Y;:FVP6;EVK2CL].%67GW3DR8!3VB)MU[(I1@E
MP11N63+%JUP32?$/OWWXM?V)_/#]DKDRK9.=X&>)S>-L.DOF1J+D]H-J[.KS
M4*1'<V<G1163@&?)X#E9F!>?<U.%N@A?+ZI)_G;Q<DU]H .'%S(I6((A%O+
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M%UV9YNCJMON1_;9TMN#JS^/V>;,'TRZ_]/-]%8Y55P':_B7&=-)<--E&(-O
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MCI/;7%<[2>>9=-=)MU%]*W?RK01''FEF%I'W='?S8I)%5#S9H?GFNE3 ];$
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M;4C1E=&M.C)?<JW1,)Q?(Y)1)PU&@D61&XHJI&P9$",F,.*<L7IE%(:D4=-
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M^&EE0]-FUL%:[^O;TW%[\<;VOGH B38^D!@X>6AO#U;"MCB9 B?ODY-OC3,
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MM0%]X].WJF::1_]=KMO>&>)+_674P4Q&[9^H>S<0%5AYF\OA2,=Z K;W1KZ
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M%KP^MMBUJ?H=K$X4X7TP06#I L< QQRBH@XQYG,<(4Y0Y2-098!AT-VAZB[
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M]<I;0=:2W3?J.GC/K?E]!8V_C^UD_O,5- [MY$A:Q79?G]'8);5C!@ !:W'
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M*3U&)*WG.$42E!'[2>EL1+4"1J\!ZH#1@=&!T8'1@=&?NI&L="$Q:Q"A,N:
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M&2(42&[<>7(CU#-75<_,(,6Q4K,!/@$^ <. 9/FJZ03JF??-< "5 )6. 94
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M#S:RS;7]@8B5C8C8&_=FI?%M_VJ7J;4WLFCLO/DI^GCNXJQA9-103'E_4/[
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MO2J]C4V%#N"VHPY<X)]LEFHN..4\AZQ:28JXRUZ'D5$@8?/?,@0B^""+VC<
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MJ6BY2]%PI^2F\GV4 "?M^-H 'OIG5R_V$9V,/YGL\X@I()CM&=))?J !ZE?
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MKFS88FW]?H/R45)R#Z'6&17!6$N_QA_::GD&MG9<7.>+6S\-C]O-)B'7;IB
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MMBKIGS.?9TN\JO"K6F(ZB,Z$.!-\/6S"..)A1>R%AJ ( &?1@I@<2,RS0@7
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MNLCR-;"[69A'E<9[EC]NG^?\+T']C:O,R(. ^:M.&G;734Y@UVC0Z^RVBI&
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ME<B"@,K&2&FP.8B$XQ',\F68,GD5/P)W\,Z2T%2>(4GIAVU9TWEP,)=(1?Q
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M E("'@UA#.8Y8YY(W7)_65?W)_OCV8[B9 OK4#^1U"*"(FHQ 9QVIE/Z%.8
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M64,MUM/@(L.H[.O[!4EN*&E4O@?M@J[/[<5YG&U6.9BY+K)\0\/0F&=AE?=
M?>]WJC^ :8]C0W*<,69;4/LJFRMYM(;Q-!DLJU53(Z&TA.EK.8\-(:Z<X"V$
MYJLT2[(EF$;_(\U>?\E>U1O%JMYT\-9UL="*PM,+Z#[?0=B%AOFQJ3E@=!Q%
M"+S/40B!%R\L<99T]YAK>30.X5F+*$P!1/+.%K6C@S%<UJJN7VFJ2[9C386)
M ;M0PRFDU!.Q&0HM*OLAE-SK*<!! +]8X',)Z@&4+'"O%(H'>5F/_LHD/QY)
M:RBXGIH856.U">PM;JNO3?E,;HD(@"51>$'<JE6NU=YD_44=<E0IRJ[2V&4F
M6O^W,KC 5,NC.D&;\LB0P\&FKG,$>!+156(6$)0 "E!L;=$).&\K^1*[[+R&
MZA-U?Y:-[7 Z_N3W%=Q4E;<709&/TWF\P0*6R@'T+,HVI3KTJ ?% =)TJ/-K
M*(^:337OSDV[JRS_@O=/7H9Q2@(^6-2:WF_1NKK_8P=/)UZ  E\1]9="5EH5
MM^Z,[ 2NUD_K39+M$+>N*1P2$](-8FJM(3>H)8Y(6QV"9ARWY]H*%J?9!IR\
ML0R_W4"?PG1W$Z]C+<:A12U_;E;@KD8\0PT^%9*"WCJ]K[4R^NQTJ#B!0\=-
MP'<9OOAOLC!5&(/MCU5WBAZCKNFER9X[U=#V2KE6.^5H$\8TH$:78D%:;C+'
MPJ#.4Q;WKE?M9M4VU1HU/JW"O_^,LF4>;E:@ME8$^*G+^G.]LWE_[S+B7X8B
M$FI0$&AO\7=X@_%-\Y^HK%]G$<].Y;4W2ML>=1W,D+$C@]J/K-*^6W9U1]WH
M58(D&EDI3^FN*>C:L3><K^*4^D!]2M"\S+,TGE\BV$D:K89--6\[Y@O("-RA
M6'5J]@IY! LA^FR&-P6YV2LCC!(B35=E8AF([/!,[>HZWOI73_AG=!6_H%FJ
M<5F7%9N$:E][\TD*#J2D$9RF+=R/+&KY8Z,JQ!W14X$[/ZNX*'TEWYB,Y V_
M,63)EI<=T"0M]6X%1%&=!N\!_Y.#$I+#JERB-%N#2Y4\,F;8!B<@[\JPK\YW
MPE]V>GQ+,A.P_G5,Y"$F1>#XSR#CS/'Z_9H! @\H5(D.(T[C]7;=R2 ]2 <\
M8Y#748RF6%M5<>>&M@(?11!5T@)?LY3EN4Z) T2M?E$E7+:JZD?,?<174YC'
MF4G$;93[MHX@?SD?VF'1X[4[DGLSU[M]^CHG9C;P?I=X.4N+#1>#0]2:]5D@
M(;\,#ET>,",_:3TINKXR]&JM-GR+;:U1+PK,>^R[]U[ )*-\ RP]; PE?)-]
M7>\:R\JY$W^@FX)$^R^RG*BI;%U#%;6]APF(H%(TW%2?[\5<SY^3XE[LEFIM
MVN4FH]<'5<D5GDH.H-C9[*4AX#I@X.[ZR^.9)B! _'UB >=FR 2YJY9*O>VV
MD>GYCX/]2'LKV-3T&&7#.%51B:##?U>6]XFV1\'/,6^(-CF:TTV%/R>(0P0*
M.([*Y5",V!EY?VAXG)NN!3ZC;XJ^CD=7TTKOB!E2(@R*7^FE7LO*GH7XZ@4F
M^<$JQS&.?'&Y)<!*1*NME>Z[T'E[DJDTR^L>B!OY$="XJLWL6DX]L!=>LWT(
M"0GUP/W2LJZM$&@9)IS5O*9A,%)ML+S@J#+=;?@5E'Q*BV_S=X\V)D@:- <X
MMG2)'R!F2JH#?.V1Y \BY=U%5P4@:'#-559SON5#X&Y3](JBVRPM@<.%FUB^
MZQ5E_<N1M&MPT\T67PKJD6&2*:5U/%Z&&\S"P5T>)CP>_CI=9/DZM,"BMJWM
M,XU)_93!V>6)+:RM!%TH^!-B]T"N+@$?2QDEH2KMD>?#1P+NF^LUB=-=&],$
MZ6JXQPYX <LJ404SI1VY(*G-W\)?H".%*;P=YF?"*ZXYJ. %^Y=VJRB+3R&W
MTJ\9/ G2W NFTOXE:4&U6%1?_A+C=RZ?KW9:=5 W&OXB), 41%PLPE0P"0&\
MK#;2R5S/\26U%Q8+J-\HNB0L*Y7'J"%1\(Z0750'4/&G\-+XY\O+N'X7B'6S
MF"WJ%-W<.BB=7&WYJ4$M2](]JK:Z/0''"U!SU%E1-(QF6$2.J:^$2J:PKNNX
MSQ(@K>K6@VADSAV0L'99Q[L1&-<OA+EY0.*P>:B  -04] NRU;[LZ!S>H5?R
MD]H68%79GR-YFE?!$$_A5^8+H/0H5Y1^>[K1&DF6H04*.GQK3(TAVGQSED['
M-DWOL-O@NT/@P)?$J43PK*L#U*TS#?2C.>F]P,$46IXJ;0:FQQ;ITHKCQQA<
M(8!+K[ (R*)8"/1V%4=-F',5)RB_8%F?)5YYLE*N_3WP?_:RH&F</Y2%I^?<
M8'@NS/5<2QZ_/MRB?(E7L@%**14Z%$7]BFV"!*G5$B@*3PB-%5]L-,ES_SR\
MCH@/+[#4P;77$:#8+>*PBD9EGGX .2::E,"!&47[;NN:X/HQFO4I<],'$83/
M*B'A4R9H^M@^T.OQN]-Q#8E2Q=\(38+/6OZ"(LP276T!-X2GH-/F4.Y/;Z3G
MENV>*\S9APFH"-1)T91%_:MNV;%I'!>FBHUF<-1PUZFY&U\S.?^3 (_>& +Q
MW+8Q/6[ +AK8NKI'W;;L_=":4K15INDQ]B6-&,X/BB@<L#:YT&&T?.:PR+GY
MG=Z8% ^SP2A0\V-!(+.:]D>EBV _JE.!%+T/\UE.?'6IX<(0!6U;>V*ZL$Y*
MK"$#HJ_Q\<#7>%GEKE<PO!TJ>KQ3EF%RA=2&\.IW][)=#=-?W3Q*-&V[.A/;
ML?8^I;-M60!:)WUM,'M0Q/,A?5C5[4T"+4-$M#[?B;]H@A4Z$)A,E!-=CCJ\
MO%.$DZ+RD,@K77.AV%<>58GX@)8DEU):*F)[I<5<:QQ0_%^ 5T'4Z< P-[6$
M%]E-J<';[%#;>V2EH-PP&0\46_\02H.X05R+5F@.2&( -["LZ6V92*X6+,>I
MT0?%$O[DN"WL9D##!:07F+-'M-2EC]54F)JC%9G@@URM&C4G@'-CY$P*%6MB
M!X#3E_YD7)=-BA5U^5&?RD]KE"]Q/_ ^>RU7#-=9^6+*2_MCM[(4[6[#_'=4
M7FW32.\_JRCLVXI?9[_>1\346^HU]2:3/$E_XZE*>^O^7JP??U^HUD@0J4"U
M.U<,JAN-@>!6:&8,@LI+@AEE7(NRK/.P@_4Z9D&Y:51Q=?-FP)G2[FM?>VHQ
M>@3%ERU_E1GB4Q++4?)Z$IM(")EPFH709(/?02<2?E74N'^7B/Y[G>)N/66"
M[D'M7&57UY\O XN?Y^RS]AE5%'Y[JKD.@( T%MBUKJY[!UR;O<NPW.+".V::
MUF3_D)><BH%$X;M,)M?D]WP0J2F$7%DFFM/5\)@@8UDE]HM(/C;N<OR4@>[D
M)GY!D98+[D)A>K;W+P5:;).;>*$2B&UJ^AS6'*&HN,JS-7=B:;BZJ =EJ#<=
MY'=C(F%=#?]^,<2 4-P UM8'?52IIH:W8?R"DN@INX5L37 E4R!.8/G1<\F^
M!;>X18G9X10]K?)LNUR!%0*<DPH2R97G.V"@=3X2KEL929C3>!N:J@S4P\K5
MG7@9X(EI1Z5=R4$D#R8SDH[L,IMO"9<+_HDY\ DEA 8^0(\1N.XIE'S=ZDZ7
M=U8J6VVPDCY]1?D\+M!]'BLC*\;L@3_Y2D"4 R\1*S6?H9)GU((X3*Y3T%20
M]5"_DJK2'C.CD 32G%G4R[J*PG[/Z[-9U'PVNX7LG90'!!$)S. ,BI9MF( !
M\Z/NW([<DPE'!!@27P\=&6!J?C)&,3N?8U,M?]YTS*S/G5QJ[32/1<,W=8FJ
MWR-M5-"AU ;1 H'3 F1SI7"H6QI]@26"D,8!?\KS+"]NPPAA,2?\N@EWF"G.
M?XO+%41F  ^\5.QSE^3]N5#0,&A AXW6^'8JB-SWPD.!M8^(7=TI.?$<? \Q
M.8.69'E%V3!Q>:(VUO(\?OKBSZ2PQIW*X<!3CR%!9P6R*6075T:MV]7U:!-[
M0>D6L=4C4,I65[^YGL>,9-S>2'16%=,C6.B*%L]C@FCH270*6S?GR7U:&]%N
MR0\BY=?%07#K,T)H:2H,&,/  V_M A?V2@_/:%NX%EO4FI@"_+<PEWE;6%::
M&FJ0"6BM<W6G*KOY+J)CPQ_J(>$__GZQPUNC8+F;0"__D(%?X6V8AE0R5=U'
M'2O[TR;Q &G\QC^&X/0J*J[KOU1Z)=OJ/E- @#Z=X 7@6S\VXAQI*DS68U;,
MY\V =';:P'*'A%T+D(<Z0.QI?JBL+U$6#]6*XWFP00FB$:8@R(!*5"B&3^,O
M:2OZWAU=_PYB-K*RHK!/IR\ZE=8PV[H:4\/.XVYIH#;<)C#MP)LP[I0^X[AT
MY6ZH&+$CXA,"PS'!ZJDK>,9!PYP\2U8)1W^6 J#I7AYWXE\:@XL9R_/>_$(H
M6:'V<*'L<YYM-Z!9!O  >&XQR\<.K'IW3*!C'I4@7.H#SQ"M+EA:U)^ZL_(?
MP-)W#(::N:7JWJ:F__1HVE"D9B'?+G)5WG,;E/YN=:?G%G<P&,U@O.V>)PU]
MW<$N$:<LY1A\(>/:+&MZS2B2HQ7FLBK.$EQN%N"%<SCX6U^J4TFFI;TA9$6'
M=JUBK@B$R:K!#XA^V,JG2E=_NOY']C 7.L^?![S)&"RZ:Q_^PSLR2'87"F,D
M]*:):/2 (E"@@G4(>"IYP-4!=$:%9[\ +.:TX.G!M8^ZN;S'1U"<44MG?D.E
MP6 1E0_OIZ*,UV"IJOW2N\ C]J#KW\>:7JP2)$ "_?<ES9XA5@9Z31-6-Q0V
MUBE;';4R@>F*_FM+L[,:327Z.KZ-VD2/P9S3@*&[P%W$%TM>R:6P9/C_\/CJ
MS=R=*(T.PTWC326>S:TBDQ&2[+-AVM3TZ*3:0SU"=6OMD%.VI41%#%7.*)U?
M1^W$5$^U01EH6WLR+IB&\2B+^W0XCTM$?$'VO>!%'WGNVP7A.A"@ X$Z:J?T
M@RGZ Z=@SQ^<.I(X3^#.P8M4,59CM<EXTECZSTQ ?3A;5&$-W'YA-!E85'4M
M$4(VLS &(4WPPU!J#'3%_1L/:WQXD^50*.EX0L_F\WR+N!-I!U=_NXIO3PMC
M#V#@6NW2H66?;BRPZI5!V 2'I"[O,RJ:JDZ$,*XJ*3:6WD/H'D,!FZ7)SI[]
M=D%Y> !(X=D!!N_SQ7F<;58Y('%>9/E&>HUVIS*J8/>X0DEB@GEK%/)]@ "7
M$@O!)$X$D*JM3I&JT@34((=GDZ@RB3VA^2J-_[%%A97+V#AMC[J-\?W(XT'F
M-$.?7EFA*N\W?Y31L;%9R-\[D(1%46G@9CF1)+3^#+H:_L^@P(77<<DLQL!T
MAK1U1ST#[$ZK5%@DTFZ?/S86?P/9HW1XBUVIO-G8;69(A-%91DQ_T''=(_=D
M,GGZ3&^ENOP$7,F9HWO!LA]"2"EE=X3WO*,3^0$DI^*C84Q_K"H^555SIQ!)
M6R*CVN:95>4SRI9YN%E!J@(IFZ O.S*X3YW7[@I_(WM 526G9"#")_=QA5]V
MN&^OTQ=$S:9*]#)[ OX&R41I(;P'BR/S>(.OJ>JK1]!E R34ETT4EN@LRL@C
M)<EDZ(RL:[W#YLLC#4JQS[MBK.,Z24Q'"=+*-T&%^3Q<8ZYGY8)<P.#4B)O0
M9,F1E1L^R%806<3T=[(>=J@]23O@'-_/6Q(Q+QKP#C#_*0CYCH4L2'80DAH$
M'P<F@*;+6K,(N')B!($&DJL72<>[ED/@7*"<J690,5M<8A&U:"6KL:@P 19=
M$0T%GI\,O+ C@]Z9X)28DK&CC?XYXHKX(3"S>;*2'JU)13E;0,RY)3*(IH)W
MN"1!1:"Y:U6E_0&GAU\O,/<44^Q:YHNN1<G5U1A)4+N $,L<A1=9)$U/+O[L
M$QZHOC3$JZ1]=302VBFF_6!RDW10VD]M>8"S4HO$!!Y[>$"NDNSU<;O!TB/-
M-%U;JKNJXKI1\_?ZV.9W<IC:285X1)73F &L<*- Z1='<9CO&W(L*CCNW=WM
M_5EQMMGDV0LT]+1"=Y=G:BE15]RW#5Z$UV/@><)7>E.\H:Y'; ?0"F?Y[@ZI
MP1R$(OX["H)KL0)X]ZR%I&XH[!F80 ]><E9>(7B_DBK-3*.PRE/9 67W07@L
M9RW1G- W3)[27(/B?P 5Q^.H)ND&<Z\ 02M5&DE*30W$C.JLQ)A&^KF,GT7D
M*Z77;B^BCA?E5]P"^MHU0[=%+?>'H$Z,@N>&V:4 34TO]G6M[<\K.5^&*5,-
M O.-^Q71ZR:-[O'6 ,Z-=K]R%:D<P$U&2S>T1Q+,;C"-Y'Z5I>I8L581UX'R
M@*?,-.O%4_8+]?7 !_7BUP?9_M*6GU0PL"#[*/:*J98_KA$_8%&<;.&YJB_$
M3U]!BD41M5Q7Z-^SQ7[,D>K5<4[>WP2QC!+X:(1Q=)TR= ;5>!6EO2O!W.0N
MX":8,5#!Q=9<1\MOG]=Q01D"$-[0ZV6^76*!+F$NIYKTBI95?8+%<&^ZR_@E
MQG,>5<>)!PXIE;@65?T#_#$4A7*GT>8J"D_#. C;'8QYM='."$UM7]__^EAB
MB:N*>STYQ@36!IZP&PV?T4)<"FIR)OH<2X9:[H/XN(7_<YX5!9A7*2S2YS!.
MS]$BR\D)5Z(DR^[O_D3]^\2?[\[#!.#Z'E<(E<3L "'"&APLJZJ3@<ENHELS
M[PZ:88$X$*GNR*YDAE%Q%[AY#IJ /P)>6I(@XF#-,72HGDBC];:G,0'32@O
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MT>#QYP[P.P(N5:FGT*T] :1.$Y\/?@*VD]2<IN=J\8,[ NF-6T\7NNU8#^U
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MF#8U))W[1DL=U0QT,Z/<=/Z \\CH9]8 A)D>*8S:[@1R68SG<\@WA#C===G
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M\73QQAR/7YMC;23 Z.+,JXXHETM>-]D<VS54&Z_Z>R4+G7+_9UUE=9K)ZNC
M9?2]HNEPQUF.U%CYZ$*5=5_M+!GSN\QU*CKXO/4-Q4[81?8-#*8H#?]"(>Y\
MRVG$L$>OMA#':7$8&'$GC8C#YS!P@/DK:XG/\U<+(4.#MVJH/"M%+$D1"S\L
MK3W62NO6+!&80OM'LK4@A\C^<H+"O@'?3SE&>BGF>=0CWX[5#V#LG=<MC!V&
M'GK(D./!^14%P.IYE6'*N@]I"4D<*?^@)34T84D 3,ZQA&)EN"XB+'K7/#Y6
MN$&H WQM9_I*GD)Q30([XAI8:,5?\LHSJU.K9 GI;"7\SDDMWIBU4@P_@)H_
MPFSD[8F0ZH#DVDK\EAKQX:9ULML/-!%MGXS7SHC0+U)<L9=UO>;I&7;KH*XP
MQ&IK4Z(KTO+O;K?IWC-W#@6\(H=/8W+9!H3<?3V9=ABH@IB^\PV6(*\;L>A%
M2N7(LHY+L<%K_0.>D=Z+W_0LJ;%@FRX:\/#GR8T"X]3P:+M@WSH^%S3<[[3E
MCV>3P)A47YH//XWN@3MUC]I$T0#&Z4UT\,EPLM._]R#^55S3,L!I3=^),&CG
MZ )E?_X\8K_\_,O_#/_BKGE2S9^ -I@_\[Q$CXM,C_1R+BO)1 YL9.OLSU@^
MY@ 06QW)7L4Y0'CN=[X+8,CFUM"V=;KXFOQG64W6=2,>\Y57!UPE)'BS6^KU
M\%+.GLIU+2;L'%BV."^FRR)[6$/['XAW/W-P<_;"_RMTL48J8UQJ8R6I X\+
MZ6,KH3!PAXN0J.4Z EJEA"DM3*IA6@]ZD>-P00=%[=;X??Y_=R -^[@E\FA5
M0D*NM6EQ]U16#;B'3Y/B#]FO>^^GO>2GUN02,GHW+1BJ8=BN&Q0QI6FPD-N/
M> E=<TC(FI82'JU"'74J?P#HLCUYZ!R)@-@=O]8;P-DV\#@-L'4S$Z\+I]V9
M)5J7]5Y ."0;+22A&\9V&#.SY-NDXFG6(!_RA60H/N,FC]"_NZ\Q<5++AH,P
M^QQ5$SLRT_3(J:4]>!?@*'/2MMO'+7L6@K:DDCBRF5+*;*T?8BKL_?^E F[L
MA<PKN?V79+GZCS.Y*4XJV5\@M?,R9!IK&F%6P%:^A1>OEU4%GND,TG $0+L9
M>.@SRW/T#O]F-X2@N_%KV935K_PIF^=]-)!!<4S)._:1YUV#CF-R]S#ZUOE/
M*)ZER&#'.= ]G$G-%UEQURR;\ZJ"[$AQ=F#BG0=CA1)LD;_H-FT,U3"CA_T.
MFH(;(U]X :>F.*['Z3(K@+, DZNE=\+/+R&%XYV=..('!BO?QN/*C>5*ZAF7
M<XM^E,6RTW+>7K%(A MWZ]4JQR\]R>V&FE:GRYZ:XN56/TW3]G'(^)0-9*E@
M+DZG7VC$]#%D>+\N"]VFA1[C/7R-Q!W/U1X-V)@A#);<AF%+U;0H4G#PD'_/
M:V0=+N\ %^ET.=/U&9#B4J17I;"R^R)W:=GPT3CS0X!1EIBI&L'L'"@D!2T'
M87?I;$3W58RK$A9BOADO%LB4-ZUNQ:NI+)*'?'.5_<'SS:QL_]0M?\0+K@C1
M@LXH8VI,T'#.C(K1L(#=:.MGF1E:U!/Z8ET562,N!K&1+K)O\*L]'R2N::OE
MXN91DH>#)G\-1K3 ;W]XG HC)37H&Q?H8NN:\@EO>9-D!74:N.8--FOD:2U[
M6\Y*89^@@QR[#_1"+TO:95XAJZ1^ZM4 3 HK.02F_%_BHTS-*" 1(C#E["$F
M2;GV:7)(+5-Z&2A&KF&E6O>;GY7,T@YIJQ'HB"//C1,QZ&OW!+<%LCJ12;0(
M_98_\V+-??+N79'$38U"8Z7=_T8Y .E8W"C)H\QMFBXH+XDR#+%GM\\"*QTL
M(27 [K L59HM*TW&TU#1YBV@4C[;2O0B';(/>F0;KD@HTTUV[Q6 BX8_0A."
MU,./V&F;*55,ZV)&621GHE M#.5]"I(DLBW:3-5I'-Y6-\0(]%XFS>,%^RI1
MJ ?B2(_-_8'OI(BEZK/C'?@.GF-9-(?79JD;B@5._OC'.J-;>%+6C3A0SL1U
M6%K=V#/_LA6C0]P;0@EDV:=KW'K*(%B1IM"9+@' NBDN[T8Z/*#Y-D84+LX+
M)L2#T:OLWYNP&-N>'6EP3;RXP[0/1TH;L4D<:KQ^4'2V:ZQ(Y$ 06-?8SL6(
M=B?9##6V<>G'].#R(TGK.4/!PX&4M]&@Q)%K(,<E6I3E'EZ'MZ%8G"?U$UOD
MY4OMW,6*0W,8T/(V*ED8KN0%O8!4ONAE<97-P>V=0A8IT(LTZ.@]W<B?N"SJ
M=871O4W=\*7?J4<ZX<[-I59,)ZW!_T!ZH=;K[/+N0V#/6[#%-:P48N9TS;1*
M=KI1>=1,:V6D]D/,1<OB?.]6D'G&XL?4G-2H/GBIM'+(@7^NSZ)8[8G$<XL*
MI*.7 /<.KL669"$$LCM5U H^FMHN"1\<3O<]ZR*-CI(:OXHK_9$;O_%O5=;P
MZ6(Q78C;?Y5DZ=>D6"^2>8,ES/ <\&WS2PIM1_$+Z!2P%P!]16K9TM9+;ZW
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M@OOPSS^/V"\___+GCS(Q\INPU:%/1BG$%@ T75HEI1A92J-VLI ])82A?UD
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M,]\JWY(@9.Y'\-/PB[ 3(+%H6I 3\71="V-_[Q;39_ 4:I# 1R80'3V _TT
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M\K\1DTD"H'Y/$%Q!#\H'I3N,>&7?FCXEL1)MB<P7^__!7%V5<WJI^55BR@8
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MGY$3Z5A&<_.FRN9>5>N_\>SQ"9G6GWF5/'*J1&0KD N73O/$-8GVI_N[,Z@
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M_7@E=A77W/ RH:<^6_._B6<8UI!Z):N.F'%THJJ1;IPJOMBF9 _"?$NR=,1
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MIU_+HH%0&SPN]KZ*A#@FY3$4R(1$?$$- L>6;0!X*HEGB7A@939"=&@#H1]
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MTCN?W&K<.9#ERQEWD!_R\<IY&G# X :54,X8-;PMD9&Q(6<#+5W&^,M3+ZG
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MG(3>"]@Z5<NI&EG6*@77M[W/J?0&")[KBR2^;*)Y5*RR#O)F\$$B!;GG(>"
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M[_]M$'UD_J93EWF?:<_HJ76M6%/DWN;K7_$!I/PY9E$U[E)382M( 6>R\$#
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MQN>B0"WX >P\A)ZB-S0POW2@NO0+90G^E-I6K#4J&X1FBFARM%46''^]]"'
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M0Y,27 !K9*$EBZ-1V/0D;B%V""D^,5V:G:W..Q,VNW=8%$'ZJE'ZDPL\B<G
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M(FYP*@L4DZ# ^@A_'48X\!+^K3BTET>CSJF^IL_5T'#@S1:Q0+S-Y>3_":(
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M08.J@F8:=,>$IUB-N%#H:0.C7#2,U<")A\YT2B0(Q*@X 1L]KJ5SO? "29S
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MIZP #F=^<5ZYF.^[-D ZISCV[2_+@RSK+J;15Z; C?VMQ4%'6<T\W(_P.6L
MG)\+\KZ].&B-.=;?_FZ( 76&US:<<);/9W<BNL"42013;-*QS-S/O30W8:O$
MC35KU7K5,2)36W!LQWFM3*Z'"X\IDF4M,:X%S4V2P"C&-<N#CQ8O=[7T8JL#
M9^9GS4IJ;EH7^[7\ T.Q@U@=[S3?Z9F#/J;8JO5L*;373Q+!5IH![N+ Z@,U
MR59Q[)935.,US&BSK/WB^T"LKO5KQV:QY0P[2^,N:^=X+I9)JIW2K[&E!&/W
M;%5Q\$\0!7ERJ*OD@8_\7-5TB:'7;_X>!$4$-MNK3SAY1#[W2?H&UWM>UP5!
M]MQ^<F/HBRGK3:Z[>5>'),W#_X+@)LER?$9H<62RPVA;\$/\";(<$S*:)*1>
M1,OYJ35;=JRJQ #:%MF#O[<YK$([(CVU+>O\MEW]U!MDW9LMB4DA0TQ&_A,S
M9%7I)_15"DEB<'KRTN\@OR_B@!WH2FFL.4ZW R@C@I766G'4^)7O%X<B0JE'
M7](D@^(*%.<BQ-.^P)V^!MLDA:?C)YW7DZ+#QP^J>)7$2HKTG!Q6<V-NM+8H
MTN9M@C<9M;MBZ)GU%>E;(-+-L'06)C.:) 5M]$*^OGU)/D$:8^ZR Y#?],F!
MN2CA[MH6V)SDEG3#7!*C@QENT4$R?,?](RT93Q(:D>1>9()F/UQ^[KYA)2"8
MVNZQGT*,[11:H$A_5H?N#%!]+@.>"$*G$Z!Q1.XV4&J)UPET!U]%JC0/JP-#
MIN:J?,7("7@'\E5)VG<"2N6B*5W%M3JH99:3+Z27KS K$%N%,B#L?H=F:HC%
M[1A.O&P]-=PLJ\I\ 1P+<2LW[Z6<PP?BH&-FV6Q9CF943@T$H'QI!;W4=GL6
M2!;A=7;",XEV\#VI']3K"B[5;^%/SR"_\=+TA"KNX;>F.2L?.ZKA<*!8EC#>
MQ.!?P$LO5C$*$\[0A@-S9A4JZ.-R-,.7W]F\9O;JZ.$\I.% 7&WAU0<G_;Y/
MDV*WOP\_\?PO3_PH;,2_LE"XU) 0?W3#X7F#&QF!]J.OPG%0"C^P.)#44 ]K
M7#.TAG$>L-$"D!,F<T5BHCSP/%%K19\O?(U$O<5'G$![#GY"V"LG3.W:^(B$
M1+INQ!0L14#&78&?\@2(2=&3>$Y,BYF:G?B9POE\D&NT/+=?0[])#L<DQJ;G
M( C+!3[$VR0]X$\N,D.I?L_]PD_<C].\;*@U]2:&PYZ:%U-> 4K/H\9B,SIH
M6T2;L%X!#LL1KW,OV%E?&'!-+:P4H5XCM9/-TKPU4?C3>9+PAV^OZ!T88F!R
M_Z^S3NO)^QD>B@-U8MV_SX\8(7^F^S>-KPG@4_#BI?">8K\E<-%P5AROMEN<
M-@R"NSBGO53#:&@$PMCA#3D,RGU&98O.?V%D6$D,H#@GYB5-? ""[!Y*4^?
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MC<RIID#F,W^\7O/>2G "$$I_\!75[:]7E)23%;AJ85],M--(+BX8=-YVH]_
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MDYI:5<=V.-?(>X7,;:P..=^3 [KCFB]]HG2?S+)<,F8%+=\AR@(@'ARQ+##
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M# _OE-;]_XHTS((0NUL%9'5Z+\6\D@[<W<]C6.H*_P)>?[9R?6>;\Q]AOG^
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MR_<^.]O=<^L3YWNHJZ?VE$L55>7NV*<.FH0DCBE2 Y*R-;_^ " I\8(K"1
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MX-\7V#_.9&>,=GC):@\@F>A0)(F";58FR.T5-R!&Y$X)Y1546]6UNMU:S P
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M4B#(RRY*7N@.LKS9JI"SJ $.?:S5*-*;M&^>NBGN @B/<;HAC=TXX9_BN?9
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M?,J0"(Z?6J"5#87'F@VA/YS9$/K+'ZK;ZI=.K>_BI*6T1+;K!Y56:&W\.K:
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MG]*<C;3:UZ:Z)@.DQ7G9)0HE9MFF4[^J+8VKL31O9:5Q-5%J'THENC#?<B:
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MKU.C);BBUL >(\AR2.94C 4R@@Z'Q$^9X"(C.'!#W*1&)'E3.>!<-(!5ALU
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M&;A*"@ER7)>#5 1MB;(U7XD0K[D+]G$1)+AW6I6O(^"TDY>U9V1+R+H@.H.
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M]=]79&M$MFRIH#/^?[[B?[#^PP_,GN^0RA^GFZI7?9=#_/3+%6L:.?,!#CL
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MGW<85_S\U[\ !3][IU, ZBO^)'^(HCCC(_#?\"<6<G7U3X%?\[W#<7@*CH$
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M(*WNO!Z)3$^)6;Z'P9X/LXE!.5M$2ME?6-/^BL$7#$"%#5CU[U)]7'TE3:R
MW:%^C>MY\(*&OPM38GCYCN/)B\[:H@EC,$DRBV:F_SV#:0.)#C7<5^8#-^#,
MO6Y+'HA$CSG<HJ5UZ\:\\4O(7;)%!3^M;-3(@K<!)7E>2M_Q"K8QDQ5W><"
MV//+'5>(BG+S!J?K98.0U19'6TP; 9&B\6$KS/?*(VO\/?SQU+-8[Z>$*HC)
M'@4L1>_(*.):9 /QR@-07N4W?0<9+;E7#WKVM@=@J<D9/>$HS25Q%&Q!G($=
MTDR8M0$ER;-6<9I)U\\B@MM9Q+SP'(%2QBTMW%:P9!;8HH9P?LQ#[J00_JYV
M6H3:U\@6FJBON)6M)AOC8?0;=^W",$&C'^LP'"K"?7_>XKD9_ZO^0O*<7C-X
MD8<J*MTCY[>KTFI\E3-[Q2:Q^B4&=NCG6WY%2A6X;#6C=$T:DJQM/R91?M/,
M<*Y;E4U/G=D7VL8:IH;=5K D^4[K!L [C\&"M:/EBB8KQLO#!M69]7_V?@3'
M_%B( D#D<K?#*K8L48,*>\'(B$MCFA<7NKK"X<L];PE-AO[QV<3MKCLVD%1V
MN@7=12D^$:CT2Z.5M^$IF87MCW3I,R"D/=%<S6[F'3%=BTAX21JVAX<?<&D'
MNOQE4M]%UBQ2KSXGQ*IEU&E*;'@N!N)2.;W]^0 VI7OO9>%>7DII? 7@KF&(
M2JEOIUT"TIFA%;KIJ3N\[85]*NE+0 S\592REF']=WGV$F=_!PG<CT]P\ U!
MT9>/0]8R_1QG<?(K.P3;L&77TSTB*:>WZF^.X7U?S?5N*:S)\E-)47_*IB?%
M,!R2^Z!654%T<Y:+JZV[T("X/I.^3GBN4M5$EHMN*MAF")++U+0<-R((#$])
MDF+T#HD;P'"?#,4B>WN O,CC&XHXAT6D!/W"C<A2C7(\$,DAMCO_]?69)7N6
MU/.)E,P0_6,J\O2HDG"*C:/:S /:E+:0W)D-]3;A?2EY:"3HEX*4-0C_NHO'
M"$KS!E)M'!C(Q 4#K(I7)/WHC"$&0(<.\YJA%0" R_H6JG/0])0,@1:&GZ[B
M.,(@\E Y@*W!U1F@4T;GSO/OV7LF?4G%HJ%)TDL/M>@T&TB75OE",QH]P][O
MP*17=<[C]>"PJ^H:/B3P ]AHY972#41FCUJP6JNZ,ZTXTL%HZI20B PM*B5S
MM\CVC)U #2J##219->'2A/$!IOQKY:@/>F5M7Y&(X]99K*5S"@W6_O#V/6-&
M(6KVKGL[# >N!XCL65,S\8O;#H/UX-.*^S/:AKF/AL]&@)(NF7_P$ Y=._WE
M7_Y]=.&8-J8[:FVEGZ:B&Q]KM?;M!"&S!2SBF- BP?QV_89G+\IWGLQS?O2V
M<FW;I1\N&J+)10B4@Z@9*D#C@>7%/]!8_@&J/*_G<0)5$)=;"B/W+(J/:-AA
M>G/'B%%H6D)>[F<K#_.=,??U>34#(CX"]LD]ONF)\7#@NC%[" 9) S?ZQ,R)
MW=WE=\?ATK0?K. KA85ZP[:'* [C/28V_D\4?_X2?S;Z)EO!DEQNF7V'/_(D
M.QFP%9X?X%N.>#:+3A@8M-OP%X_")3D-G9Y@@\ X#(>L_-B(VA/B[_<@.P1"
MUA,_E$YC2V@R(H%%#TQ9MT46O>3<!XZR&M?:"4*4?RD7,C?E-BVY*,-V[>"A
MM_X-7D)3*&@7>P,AKV1YI:;0]'I6T;(CT1TZ4M]>%F_K6:N+G?(;R5L /I&_
MJ_7AM5])?GK9LK=E--4](6<7O9NW.ADL(R9JKD1XYN&X8)WF1A>R@5@D5Z[+
M66[C4'?)T/"X.22,/<*RP#K5UU+[B.2"S3^2LC38FF69>%Z:!PQ/R7!OFX*
M:G&;;RQBB1?"33[SX69&ES^_O1I1E?W@[FS3(K&_77U!]^0&/L6KV'6TM0H:
MBFLG#,W3%W/.+@9:[N9YFH'"D71XTH9@D-72K *<_UFR.,R]"5#3Q&H,.^ L
M&0C0N_)D#L,A-Q5__0O.1+H]L*/W7_\/4$L#!!0    ( .R!<5HK/]-U,#8
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MC@A,7N-K''68T;KMS$N%(4<(;P#;ZS*^&K6(<WQ826:N !.<=I15=&Q8$+P
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MHX*BR8_N9";:7P,?G<^"1$G$0J?.\DB+>ER-;&3/#L@UKQA?6MNVZK[&+,P
M#A],2X2-7+0/F(C6BKU!83.;^>4V,2\O F<=^\)E<0T3IU?V\?!F64U-66>
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MK7R,>W6UY.S5N&?K+/\"4$L#!!0    ( .R!<5I@?T2W;PD  #M$   /
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M5O0/Z"].O/^A?^#^5L7_ %!+ P04    " #L@7%:Q00"%:H&  #!(@  #P
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M!8+2^FE#L9,+R/!2CQ=\XN+9098)[( ?&9+'WG[Q+YW+MR"('O>?$'>*SB.
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M-) NTU64U_AH%54Z&DM<4YY*>"T^3+>/?P?BP]6!_>F/&AALHF :*HM454;
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M$^=Z2;:[U]UL'N4%F .IG#(!-[$9JN9V[MUX-2)!QL/X('L/I- '+1^B,^6
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M<)-MSI72R(9TY.PM^: &&Z?#QN8LQ.A?9&E8H)\C&;ZCU=*5Y(99BUT@?ZA
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MRJT7L15JGU&H;>A(2%TN%AXWV402])_[K;V_9=POPKC8\7+@/OPX .-1)M,
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M<4 T.\*>+I1)G./FV?<);LJ!B[C)G<4!C?1AEF0 '@YHJ*YMBQ'"O1B 'B=
MPM(.H&Q'T7Q __Z\=D*;6_'*]'"*1KM+E\3=>FCL>;ITS3.J6VA7H=2D)@(P
MW_FR/6!?/G"RI 2P=R.3)K1//W0*OO7)E' #9<'Z%0UFZ@*]W*3C![PHFT?8
M[Q%"VT53.11P/ K!A1A22U J^H2O[SS+S)FF8:3209?K+J8JH'@>4JWX)M8M
MA0OBB6DG5_>&&:X2L55[PA,EP65^-[XY82FLXP[7)?IU CO.QFH;7+WX_8&-
M[>V/P6\-#E=XG%\0>U]3N5 .]73H>E4R."!N+M_Q6G#AZ8='2&RN][:\8V[L
ML<G>I89/Z'L7Y"0E,L^6*DR\^G);D>!O?>E)CF*(>3/T+!?,AKF)9<$!??E,
MV *C#G% R[?,F$88-I\3!V0FRP$]CYR'<$!Z_5O#4P/L8_A]1V;4J,$1NIDY
MH+2@M/GK[%GZ@WBLOY'&Z$X0KV_NGQU"&:0'+6:)X<-\R%#7<0Q%;K*$K&)=
MHJR7FD:QBK 1=/YHONC6[1TNP4 T\# %ZWL=BQHYH&X.: K&,*<5I78HS:"T
M:VF,>NG>Q)TBWIE51PG54@KX^%IN7"F5(.(Z XAVPMU>^^6N33D//LB]<KUL
M8E0M_&&+>3@2 \Z^U'ADL4UIH_;#/5,E4=E?^Z6EI"[B:[>5C,4=[!>[QE.N
M6\FNKX58#-E8.]ZMI!.[['J4B8F&V><$C$_$)O4L/6U41>8Z5-IEB^0T+)'L
ML_2$(0VO2B6G+GSUX8#^,\U*_A9HD4M8#NCP,@O7IDE/HD ZH6+,<QVTW22V
MUL"#.7"IC1 *-L&$425/G)W<MR%I/T(D;6/$7($+J\M71C)7FW)O=LCAQXZ?
M_E">B+ GLT>^$O##S-/^C#A6$5H?:4:!$6W R+0%1#Q;;J@%TX436IE BY,U
MH<*K+7>3ROS<+S:UT\9SDC0K.2#^E4+AO!LS&"I,2%KTBHC\Y :JL798+S4^
MWJ)#\L2.JD"XVG-74^WC"X_[O2P:)?GE^'8\W37<9)QUQNO"!3/O R\N6^CX
M?7U>&;Q0G$"*"GHJ;*!Z(4[P5&GRGPMV7*<)*VJ4FCHXN/LJV+7_/N:&,KA#
M)MG:#_YX4'TO8<2SXCD@O[0I&\OW^+DT!"_>YK"/C"RA>30L[93+VBR8GOI8
M"^=7U]9B,M$\;W,*R+,8W8E(G?WJ$@!U:*L;@]Y^,W:AOJE0B;\W>E%QN[89
M?'2AO%?P21_26SP^+ST6I>J6Y2'?U_VVS[1:43TF_T[^G<P\*XWUD65J:(U2
MYWC6<?< D@Z<;AM2DMB[=%.QVUS!I+\ _B;7SDJG23B,#(>4%_U'X93_6PL1
M.6%.9GN51,BV]1T8X#W 1:%\(NL.%;H'648 8;V8;UN,_5M<],%S/WJY&G87
M',<!":AP0#Y@:(\>!]2+2RGD'\>G 0Z(PT4;: E:&G'N5XGE^(:Y]5T@<-H5
M,K6'36FS"6<,^(N%\Q,V8&?W5I=F!VSBR)V8_\0_IX$.;G9G* '<"/4VV;^&
M6<6RLBH7IZGO[O>>L,[R-I+Y8VE"&W)X,7/^_-B9%!ROB7;\@^2SF9[2)4+I
MYN=3_XP0"#ZL.'IC.#0!&_VNKWP)^0&K0)'O#_%U<LI\]?'5;F9>0.,,S!;V
MH]!+4/U2,[?C% ?[DO\'AC:<PTT@W5YV7; H"[R%8^IY$KX_W$O\VT^F_0VU
M^AYA EG%'<>,Z/[& 5&*H!S0TGT.Z)9.$CO^^R1;6FV.V<:Z^N.!R&Q]F?:_
MCTT'4Y5OP@$9,]<XH)//-]GNZ)=_4VC_'@'0;B/_'@BP"6ON=!2SP[ECNLZE
MF-!_Y+FU[2#& =9O'1+L<;C<QJT*U)5)@] 2&YKZO%$3W;C+?'[0\F?RR[%P
MEM:,0RX_3$"UF5(D8#B;NN')FSMW/>-:NY?O03^!]%*=>JF<Z&]MTJX/H/$A
M)E>27I51TA>WLM8<L5=$GA++-NVJ!-=K]J214G-/0Z4<E&4DC8:D'[TN>5(8
ME!J#J"O5([<51$)#\JL_387K_0WA_5LJP@L8<N&0P7K3 4/*=6$$V&"FP(1!
MZ'R:I'_+9+P&6,"WXQS-L#J'@8O/!E8'JFLJJ)'\17S.+GU8U^GN*N#U"5'3
MC@ZMEJA8UO@.*[;]ST=!3,$U1M]XA^X:ICZPB':N6Y!YAS:;Q).H23BN54)!
M:LR 3WZJ.DI&9/1,ZFT;'<JXVI9-U5<R= 0+#MR.J*B:=F@GY6;A!ZN<!Z T
MMJ::4.F3^2_C75=*KSLHW*YSL#]AG6+CY8A,T%&PC54DM%8H/E6+M0FQLC1V
M2%UX>"76>4&G@DSJS[\X+G).^S[)NLJP6OY&;I'*K9O8_?[@LL_+8+1"K_TL
M-RQ_<'[;Y:C:3,&SL,=%]4[K^W3^!>TX]D4?A#3Z#'H\UZP3(L.\5$N7(Q:M
M-Z.D7[O[+_4O4-C%6EE&">QS$]LLK<XPQ&D_(_WQ-J')B!#S!\_@KZI]YQ&B
ML-M%B;,*K'JT''MPKA[\SB9)X!,2L7_.MH'&DX8RIRTXTYUB&EPV^;_DMLXB
MEWO=1>F.);0F"WQ;Z]B+[>;/]"K:0Z>6N\\TF7L+YOZN2#\TA/K)S%*>@K^2
MJ3;NG521<V>;5C@ )=T@>BB9-KS,+ ^E*KSU.%MP[/*LP]G%(T9M5X$YOHK7
MS37H-8?"D_D7&^C?J^BJ97JQKB9\UIEWOON'V.86'#-W3"9;Y*=GI/G^<.YO
M>7<3/B 8#8#XPO !U"6@@$MP]413.A00)Z"4V32LZQ<CU:0>O:)IY>I2LH:T
M9V<N(4%#?\-BPLV4N#$AL(KP)R^T-Q;N22(OI)JNL-4QG7J8>W-3^^\>Y9 V
MGW+3&=H&FP\0O%$[NK,1>9V>0RP2[Z;,?+*V]%$^2Y?.>=QVFVIE0QSYZ(IP
MGJX>PGMY^N7D3&BE7\_1SAZQG)%J_55NQ]T5S#.P-O?5X.V]+%;H' .QWAB]
MU[L)B]@OQ& ^ @VZLJD+2)9WGGBW[5[AVZ%[IH$=Y<V&I73M7 :DE;6\^=!P
M.)(RQAC^P1QSH\\Q!5H7S+KFH@GU'% /0L"W\ +=#EE)@AO &B!$PDD_ M^V
M502E\#$5+/[%2)KV44:([OB&?I #NDQW;Z;FN?GQWKO05-=,;HBR6)J-BKH7
M!D#Y4)/T4(8TD$--FS&F!JV/[U]D\@"5PKMQ3I;CRATRP"YI[@0^302PO])"
M&WK\>ABS@)$$$-V/TKI8JOU+NXZFY!I$3X[(FDS)JR];JX+^=>T5E"[HR3<U
M)5V+'Z%V*1+.TW@Z%-JO\+Y8ZNC95,BI-8MJ'6L!.YS%*R6=2+Y,.;Z1RC['
MI(JI1%1$S(V]'EC"RGBE_3'K5&G/>O.):N4 ON=/^=*QNEUVBZ5V@J7#&\5P
MP5)%B[#5\@?<S/O!JGV)Z<5*X%(0Q-1N#_L@$$&/IHA4SP\+,6^,;30$@2X'
M5P,VCB-MMI5NB)5ICY7IB*?;)S".M*+I^?;Q[;>X^;<3\U%JFOSF.V?\@_0L
MHJ+AW!BVQW1>;C,L1JZ1<IO61ZBM41#*GTX90"ZRS62>?R:GD;Q=KEG9BN-?
M:312:1YC1OJ>B.WB@$J1IX=)V=_<NQ^6=BNM9HM./&"EOP.B))"/ZCII]WP]
MR$AX.O'STT)9Q:<9R(=OY2<LJO[22N8WTZ-W<\T4>X+_Q+KG![O>4GQ^-_M"
M+BY?ES)3MEKJKN@ZEO>JX.IK^28K7:;B<O@_J;&/BOZMR(8._O^WRGXI83E0
MTO;D+D&8ZHM<;PQ!UN0$,.^Y(^>2_S)]#BBGZ)^005OV:UHO2_ %F"W^C0-B
M>X-W,A((7S %& I9F@,:&)[9G(I@\TUR#3L*).T;,Z5IT&2"#W@CC0^H[,T5
M2<+Y8FBO.XYQ<3&(#%6]&J$U%SC:(?EA5:O#(WCYEKO+1SGG1?M!)/1OB74$
M0X[+_AI81;#U<J0W!V1Y!-7J>I^2*O$P3A$<7Z?-.T^[E"QC_^MB,A:A9I^>
M-KY>*LNKH(&3Y2V;?MIT!TA*$$'$Y@Z'QNIZJM$S)[Q3EC)O&ZO>3\II:DUV
M7:+F-;@NC5I;<T#_P"'A>]QI.3S!^LV(!SW>--? G??>% RU,)IB\WCNV!V@
MH)5B6DJQ@KFUQUL7,MS@LU?IWK%M5EY(3'V5EY;6".:N2)OBA78!M1GQ0JO.
M[]9'.VXG4?[,604PWD,5=Y[SX24K'0O$Y.V=PSXOVKT2SEA#/\Y9^FC_8D%^
M_OX4.VBCLOF;7G.'7H'F^LI0U<>R-;Q0L;4U8\5C\N\<^#=AXU2*NLZ*AMU%
M/,74+4YN:.X?1NXO()Z>I>&Z"7S,<_0T(F'Z(.3(2L=/K1,H_]< YO+[N[2E
M>DH[A#@KT_0,CQ%%_F*@E[+8G9P;_K7D87CEBI,>?&67 Y)FWN!&(PH]!3N:
M0URFRKTK$O3Y!M13I2!\;0K>6+]"+E274C$RKBLV59TOD:$6M+0$S4^6KJDN
MO%B%JI4'37!^=_BGE6A[-KFAN3XIB<?XU^"(Z#X@@B<AY=$'WU_JCV.5.ST]
M$6"^<$7BZOB7GE??%1Q*'89R\PT+KEGFN>FK.;R=X??%^"U_>'VZQ$Q RIU'
M_<]@I+DM3J$KD_W&M*I8YE'FJKUM7LQWBNP GK7VH^N+1+0.-PZXB7./,$5\
MAZ.K+T#>L3R[9H\^V>NU'C,P]J(B#@(]DU=;QV)@O]B<OCR/$0+2=XEJ;@.A
M_OY')A-4PF:<"&UU9-)<8!N^*:>,AF.>WF4PZ$U$2TA2AS@KK\VM' FQ'Y5T
M)\MEW**Y%U#=;*Y]N!.W;TT[R6614,A<;]31F0(5%0,UC1;\JUIWWV>?9FR.
MUP7MP,"&L09.XTCUU7%_ T-EF]H_6+'7K]IE%%LW0>L+[N0&9MY9RK#J&12K
M0DCKD8G*-B(&)GH6[19\C<$;Q2:-6;ZC2\LI%\@6KU[^/NVK7_CBAS&U$V7)
MRD#+ $KL8Q3:(4;#F_&V(#D2X2E&W. V;9,T?;2DW">^,UO"+-Z+_O$!V6?/
MU4@2SPTV;@K'N)/<!LJ1:;9X%97YU!YI6A)Z:V%R_<""E3TCF@;K!$^%SL.Z
M6?KN$US%1SC)A#?3(KKG$N8.A4-%_!_0!S'>5(CH"AP7S0P*I8B%N4QYU+OI
M7RYRQ--O[C[Y=I4V5!"@4IKK*:5]4/?M\#G*WJF4>Z.Q%A_R<0K$4:Q!896"
MIY>"8PRD/F;5+/N5IWS(/OF^M?:T S!HHK,LONC;G^KB+E3[/=O;O?K:W;%%
M)QZQGLRE]E<EHH/6UI>6=G\I(YO_C4S]>RSN> CT[1]&3Q+JEXE6H@L\/3:/
M9R_08,3!D+7K==$NA#&4>F0XULV/9K 7WI3(A)6LY18EHD0-)XA^%526Y%6?
M';DDBRQ[^UQ)7<-X1CXK*;Q=CA$'6-*@C#! @$ZVIHN2$#%&Q^CN!?.X!/9Y
MP&W!1A2(MA^;<XYVHH=)Y'1M"JQU"-(XH&AO*PW7/E@"WDTDX+R+'SSU#1:(
MM/1W]IS0D3F87_[Z%H)OLA0N-E5E)25B;G_"RHM>J@RO<%2K"_.$G\0JIK^J
M66WQSVHK5$_QE!@J\R)E^MEFGX:"G43SB +:J5G7* 5ZUDY^E:6R/'(0G_6*
MT-;2T1]?:4)M[?^,[H3@Y]9;RP#,+6"!YN1&0Z=1"SS 8)]'^&P\!2*QDI/+
M&HL0O/4E"#,//06\'!UP)L2-KKKI6Q&R)W9OI$XLKA<7_)*)]5^  A>@&Y-<
MFRF,5CJLNZB>C2]#FG7-RJ1U%\KZH%QH:PYT:'R;'LTR;*^Q:=Y*LD<B/G6[
MU=_26340#VE"!A[3:'6QG$DQU7>^][50PAD"+C P=(B>G[04M;M9FR4".1]&
M=_"4[[I)V[JQ6&VGGG]&WCXD/7-!)"/=VET]]>8:&5FCY'"QUD%-XQ.*8@.V
MMLU<T*,M+94>NR*8GF4B]K;'SGHDX%':C\+U@7U/=#_D)#<9<$]@;R DW)$U
M(XVQG;EI^_GQ.1),&HXLL7V_&58@!W\RW-ETS)^BHX$[Z=.4K7<+(^ >%^U,
MF SL[_8[LIJ9A67NU20?->L2SY;0:=,^^3DP>=5#0<X@!QK33'N;^Q;>E$1L
M\G),'D-,/[5;]4P9TL%"29;\"</UL8X:7QS\Q!OU@A=)E!4/W\C^#G9_@U2.
MN5O8WS(3IW;T"(SF2 #DM1\;>,U_4NHB-/ P'.*J::*,('I9,0]3$??$:<Z'
M#DU#'V(:THN2-*':=D#00PW$]*SLI*:5Y?K]/IDB3P;NS4ICXX-3+M-$(!IA
MB^8BPK<;'3*8J1IV+P>TQ^5*Q[Y4$*4TW@#.JC)_C,G&]%K<N&5]*-LNUO5@
M3"FD<JI?,=0VP%TQQ.+CT*+162K/XVZKY69B?K"83H^->D^SZ:4XE3Z%R,A2
M.;'F\^O?/2.G7%:A/ZA5!EJ4ZO^-9X7\#UA@5/,"!I##,@65*-I)F+MS,02A
MC@OL#WLVI,UIFTZ9 Y-,M0H?;02?)N[ 2DMOZG*\25V\PSE*F]%/C74(@;[/
M24B5S<^I/<XR 5<](A-0&6Y<,(+YB[B#6#7;B*/F=!YJ[\8A+F[\"D31B)3L
MQ/G>$164 G7S"/"UM]/H;#3)2&E44_JTF_&UL2H#*)4<6>->)+;B+DG[-%CP
M9TY31(M#QJHVYIR9).63@[4]91W';]U4%^9'!2*/Q)? 4USO7=I-P,+#A.6N
MI"I6ZW@HZO9.F?J%N.;XKRI2=+[FY<8]?$[U,K_IX$L)_>CUJ.&U?9>E1+EU
MIE*D";Q&YC27[\#\J!31P3LHU@_7("X;[2[Z@&64 A"Z?B?L*%N6*4F_D$B7
MHUZN1QQ ^ENWOD>YSJIF,[Z'?0AHD';J;.'J9\,KWY0F4R77Y#6U6LFH+[)C
MM_%QR#L9]0"7ZAU>9=7#O.<.^&$$V<HHH0[:[F,-_7UI=<3D]K X2I?^REVZ
M?>Q58UP/3. #(-DC(SO&-)3N[MY(>?UQ3<M1J^]AE*?O^;[02'^ACM4!Y%$;
MWNQ#,9*]:X\M^=.;4JS1@P:R%1Q0@SNV^2_U_ EH,/!.6[CS1F4!6:HLNK^
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M.OZC!"9V.TW0]P:0Z^;R+F,U-W:PH[ .N=I+?,#(C>GSQ&A6S_#Z?^*  M(
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M3H5E'K=!]'O;LXH-MD7AIC[/ L<=[LH0D=;Z1"[/L)<&&AQ*G6(J2F*%IMF
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M;@-T454GH%0(H'BIW5^WR5\E&4YU8'N9<A 23.7)$+^N)+@?CW!S3#,CDK"
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M%>VA#Z-1@H2-[))M!:*!2,,<[DE+[\X4H_(,J^3L9[]W6D.CE$:+)8Q%*DU
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MQK?K@/W'%T=L9(B?N$U4JK7\+*S;G##JI"T#[12QB@5["26Z*9Q).P-&B'>
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M?SZ[^Y=[+JHW+4]>R]-]?N>-7V9TI%%3\.#KB2V\G'B\5@9C$]E>>Y2-J]5
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MM)E,XG/6E@<G2&-?6CXZ644P:8+IN7KHI\D?I.V=!T$J#JS06EP2;W\K<1J
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MDOO0K0IUDK=JH;C#):X:<15:CGMN&A[S2C]1,QCTJ%[N__$U57'J(,33Z"J
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MM^]Y6VSI/KCA1>F11!]WTND-6WP<O;;$?K-WCP5O?\.%EF7[CBX46"(CH X
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MFF]-?NR/&\I]X1(V4_MMDN\/^B%*L+R*5O-"^F+D-_2;+Z])677T%)$I>S4
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M%M7FN>4MTE06[R[=>=T]^ ?_>+7T,GTQ93VRFI8*6@B7 SY(%C3\<W=$KM)
MX/A8*D76R.K#4S&K<OT#?-:K3#SWO0QS>Q"G>=-]\-'B5\_GD6-71_]>:?^\
M?J@M]W/\VYS]5W-.Q[7:NGT.;OAW<,!A;_S9:6'NA3#G(^5W_ZP+O3T5^"\6
M"<9P3%!C)%E)0M9[MCZE+&5+$T(\&PT$*]3OR[*1JW(^6;/B="GZ$^*IEB:3
M3 %?)=,8,=;N0!@*,'F8V4A>](I5+-[=1S$=B)$O^QKF2:C6R*7^L+"M$_$\
M8NBVJ1[1(O8"X&?]7S@:71=9"'T ,D)33ZY$P_4IPM6L\A;AMTB:@K=P+$_*
MP=:R-C>#5=;I M*C6)MLWKW-X^$NT*.\MG0^S71/A6MI<0A]K"W(JN_;HZ5L
MW+*)'=C_D*#KS]54Y 1Y8 2S,!*L*9R3VP)"I4); Z$YD'QQ]<MB2,!>G!.&
M.P.&;A_J2$J]DRQ^H&RM\_**_J'EKLL?W>K T]U(MQ9 %L).8ONE7RKW7"(M
M\DE22-.J1H/#YT"<+(H-LKF%LASR[4OYN>Y$VAFER<*CG<PIG@FM).;O//9-
MC\R8R+4%/Y?'1+]L+-[4D-DK#$ZP9CA[KO@4)O.6P?VWRQO")NR[X[0Q]3,9
MG*3X@*F!F")T )$V4LC(6YB(+=ZGYEVE$L$(TE)@)^(/UZMRT\[BPU]MK4F$
M.0HY[J"<%/V7IY:[TR[:.R-4)=<(>T&RNH-XW^$8+6([LQ+QX2 "Q^X.H0&P
M(U:;R&L[<__5T9@:<!L0C##/ZP)8.=I5.2V8F_X:E4&^*J--;%9(5R!MVF/Z
MBHUL#U:H@MP2YB#I1MC49>QNT3PTXA%*Z3VK\58=[+_B]N9EY4^PJ(EICH@#
M(;;H[E&&%TW\-Y^UIE=TBK*:_2]8%=4R:?7>GHH\UOD"IDB16K38\2[;&@\'
MVN7AKV!>)N!QRUHD.[3^#BM'4K>@[-'[T<C[.?=#7 L23[KP:+(B(^JD\P&5
M=$(/V:K?Y=]]+[=C&P&KD>Z2]]:;P]^'T%JXJ<,F2-:]][6Y9O[S6X9S(M0F
MUD?XW:>B4M<5Y25N*;IUN"3;\]S.'XC']6]>_YQ/"WL[>2:LNC9LY<W ^HF"
M'&W^J8I/->EN.8G>9T^S+QS]O ,SBE+SC!&==CT2<UZAWZSRR"QF1=&1$FC:
MC9D.FE=@FV-#[&9PJ$H?=H'NE2LG%Z-AU=W5^<QTZA*!^_W1A' [)$+U1[7N
MT#.(<K/XB'1)@L?F7:*BFQSEI"D"-GO9YR@YBZ-#J*D^[G<.A\:$6*<)?.\=
MB:ZSSRP=V/G7D=&ZO3GWFN*.E1T.V9YNPB\H$'A .\M7[BM>-_=X3<;IJ\>'
M9!E!I3_+#IUJ]V,/+1FL9S)J-#*EW[*#B_2+$#L#84U]LX$P@P=Z3V9P,>>B
M_&.@ %<GIT7ZW?P+SB/.!H)]K3[I@8%0^O=T#.ZGN8B#@7"W1,W-,! ^[A/@
M&7$LACKUX\$1_GNZI8'PIH15CS5W@>_OETL9\A)T WWZ VEVC\]S]%<#89G(
M ^A64V4>@V)ZM6D*9.L/W1A>6\='W-7D; /!$O SY=O_*3(!%I:,&2OE<^^&
M?)\7V85P)50+G^ XE8OG]B[N(6BZX=9-A<B*D1!RHZ)L8#2/<U"W%65!:1IO
MB*2D:TP4+IZ2/)Q^R"SGW; \M5IJ/3!ZRW[=XR[W<K!:-LBX%>+QF#?J(;L1
MTR+QL!DNB^5($JYS\H3&T'<@PI0C&S8S."1M/[J9/''#Q\%VIVH;])H5J/X<
ME9KP1[D#L(WR;>C].[5AV36\TYMS:W=C7W8M1;#;Z&8^<;B$^:3_'0V]9R T
M?0>>(J4=LO\:,5-4[.UN+/RJ%XS\V\=:&>WJ-O2\&#E%ML3:[3?"&R\$W=$/
M_=4G"*H8\][ZM.?4RMP'!W*_[:P>"K/>4+M&/>^#;/3\J:&AZB=[GCFT)PX,
MV]2+,GRD.^OHT ?I*^9 KC8="M8<@4*;N79L^QCV^DZ!@]I8:G4D)B_AZD1U
M@;?DET#%Y/)Q;%&/;+9[1Q_J=\]OY2POC5RYT43(.]LU^E'6_LNM6K+[7?MI
M>KOG1)8+=T*L6XMWP,- 8(;Y2XSN(B0<PPV$:-I OO8^O+?<E$N487-0EKX8
MC;_'HK<.N_3$Q6E6U3Y&HN#Q0&CA%=>HJL>I_4%=:*C:^&Z&..CZY[U3A4MP
MGT-?R6X>=M7?SYO\'C'#3;O#E](B,539#I4TQ8>1%*^4+V*I)2#TT"W)6VN"
M6,"4X<D?NLQUS>U0@OB<30M/+#(?I(_:.R&<DGLWDX[]*LL8S=UL([UEG?'N
M]#UY0V3,?4>7@IP_7\?I!]P3#]NY)T05_QH86-^J*:<G.LL[7,AE4Y9W #:4
M< 7O#SV=6G4P.U\5+8B':I5E8FI&X=>]E1-3U5#!2)IPPSB;\A+PC2JA[W@D
M?724X9' ->4_<\]/'%I(>UQ;4]=5V+:O)[+P@RWI-&\$IZ6$5.%7+"=M!QX-
MI2R2]M>>:FLD26$@O (5'NG4%!\'%5$C78"ZP_9R6<2^7I_Y2N?=IRJGY$;O
MZY*$1<<>@<TKBI];<92:P+ >ET>/SK8D=,=1F)UL(]3E2YK.J\2_.)'%"<J1
MA"^ G#3!*B;B-))&97*O=N%ZCZ%J8"C(5P1K\.<O$F4*UPPCM^0AD'^34M40
MA2>X,;NI>.R"?RI@ @VV7*B\6!H2$^([I#8[=*OV:EA#25S@SB+*C[SVRHJP
M^B-K)[2F?O<JZ-<<XSX7WQW&+KA6E+X#]R\+5OAG8"1TN?Y/ R'NB- ,:\ES
M2D;G0#J5]82#[@=$JKV/;(.N)X:24_-\"JVJH7-<B*PZQ5/XFK[U<5:2[<9#
M;E6H>,9'D.OMM.I^@*Y4GH^[O[8DZF[H\"M J60.X):Z6?HJ&#-:H3O$(HH3
M9JTU#DDP"3/**AFCVUJWV*_KH:R.I>#4D C-*&>R*+9'$<[!WDE>CO)$F4*T
M+%:X,E-96C+(<J)UVQ@S3,R'5J\:[8WA_]TP^(R2$+>5_,]GWY')Z;>][NP[
M=PH:WCW+"]S+$]8Q:F:/?"9U:M-57)(<I<'RRWQ.2G\(42PB1MN;] BLX4C!
M,67%7JG*E%]I]PNK5GR-Y?J"CNP!R-2+!D+55(1K6463/E_EV/_R_<=;W>3?
M?Y5;"JDL;WSZL]D$@ J[YJL8FBAM%I+[$'"&_%ZD1)6^'LT+OG*6FQ;NAN2?
M.:]ZP#>)^K[N<2=W&^3*BYG?>BVRDN[!.UT6^KS,/\J]0\]5<C1*E=R.15(M
M1*T8$CF1+S=G!0<_UE\3*0I_9PA=H+.U'MA&*$V<=$!%;LMR4O5G EOC(Q,B
M$J,>(5'*^)G,Z7;C0>_+=4^>/@ZLCS]?M/-4F8K43'I%5]1J$O$(N]5I(/S\
MC&*+1.R'.6W$Y4@Q:(RZPE=#"KFP;:/60'A2V[IH2IZ);>K>Z!ZT2]XB=#P_
M'>;Q3[NJM>Z4SSY5(-,L]H>P\;HW6SV,>J^?"P!.!_T3X+VGJBRZ,M1W]4Q,
M><7/'\37F+QF6<"Y>W<'$[KCAS_H'&:MBD6%-"/467^=&NW"P!8S80OM%+@(
M=QLVF F[4V3IXQRI(J8+UU)(< )NX:BL V(;U\<ZKW%PGKM1O*0',X^QP:UJ
M&<G\K-R>M>B]5VXF>OX^(S<XM^Y6:7$;([(1DX)$/'].4J^2H*!\\J"W?S^0
M]!"IQ8P\85H+=>D4<5GL\->=2B2['2[3_H(U/T/*2D9#"@M(61L%?B6TNZP2
MB;T-_'-PW=K'O.?,!PPOLWI^AO&)L0:799^Y]9-G1WZ8J;#^Y\-48)[V^GM7
MOXK!3N?1(7I0?/B%LTEGL5N,//A>F<K%N@ES[@,<E.-T:Q8O !I^]@"):LZ5
M]13:/H$]1!'WC@Y%8Z1Z>$F(_Q7'EQ736=N=D[SBCOL:AR1Y>*<*PIQ_V)1Y
M!,PEIA]B.R">.B^LAULUV7R^FFG"[@A?CL-#&T)3B#($3FI:IKT'L@/*4<HG
MI/!<);-Y\@H^0F*[':JTRVZB92RN0MK$M :.P^<*E!47F$L0MFYO]UF.?6S=
M3NVYNEV/'X3YS91-[( ^A2&.NK-(OE*;CMN'5Y^T%R!:!C52QUO.*M'^J,_!
MW-$PY(%R% VXB^Z&ACE*8G99LXUH0@X%*].:=>WZ#9\DF#%L6L2X[YE.69T/
MFK[(.XBRE_?PO8\=%-PX'_?DE&:@IJ]0DU<WIAJNR>2G*B,3Y8&5N8<R^T/+
M8D[F3/?3^LB_T6T )YT?8(TP8'&C:HR\!/T>*LQ5)=J:?-?H'F>N^N!@7Z&L
M^-7Y2-2E00G%NF]5CX^WRGA-WHZ(BI@$[:E!Q4^^%T3N5,4-,3@A5>?7+SW0
M7,?1@+JX,<K<G>_^97E]TI8AY:[Y:V]OF*Q]VO7APXNBI&-G(D\G1/I8!SHV
MM*_ZJ-8[5WS]NFB%[^OC\O* :XXG^D_TOTY:#]5]V.)CG/JXZIDT@W\Q_^*O
M>W?E*/M>^Y3_\=OQY:L(<;+TCY/#':]QCL,%X'=)SA@BQ"72["?>__(K[Z=8
MWK 43)].>O$*P'EQ";@F]G^]AUJ-S\ =RDT# :"#'Y,B@T?DFCFZ7<!YH?ZN
MP$&W$GL>0FO^@[+^-;"A'IF$$U23K9K-+>%DY#04I?RS<"US 6MM$^Y +%K"
MY\">$BH)V ?[<:Y4 -02D01,J]N;<H?E+RE<*^CEWW9Q\:$FW1K"9GCJMY_E
M#_S?2_\W]MXTK(FL:Q=.BX*($)5)0(@#2BMB'$ 4,&FU%9'&- X@(*0=D$F,
M"DB4D%(9PB"F6Q04A;0@H#)$95*&1.96&I%9@Y!)9395 J$@E<HIWN>=VGY.
MOWW.=8;O^Z[O!S_8J:3V7NN^U[K7WKMVR>^2QS7:^+)$&4K)4NPC3*L-4B?K
M)U4XB^X/Q#I ()2_4*:A\Y@=Y2K<J(F($+4!3I0#[>A">EDUN9@8/0X8P\?E
M9^#G(G9<QN9BL#M1&RN[&8>DZ=1Z3 ?[@4_[K'93] =L.08.U"P3;?<:YIJG
MD'57JF<C:YR;[S!'<0[]G;J(*KE!,H8^/Z== $-><,!BY&P.O5'LWH!G&3<B
M:QI8'AD]$G:4-2TN8Q98F@?M%.=DEJMSS=@8!Y(X5QV6%1P11+*=NFBG/UL=
MO=4>3'M7!K1X\_.&"%@-^U?69A""9IZS5?Y<0HSM,X5+[B%[(&*"@Z&4;8A7
M8U@#&@Q]>%1*U$..0@O @K*DS\MA4W"R1JAM \11EU@GV=>4+1HV;HE'%V%R
MB;FX=6D;P\F FW^XE^Y>]SC :Y)3QAE)SD$,0.ZHUD/D1%LH-YJY$?I85M.\
MHD[ 954&Y/B\0_8][PC;9H+J=R<@*P!Q!6!,UVUT2_O,?@"''P13KSG8BT>!
MW9"YIKC7B_*TZW/PJ57K*E!2!I/3KC9*&-T"#."S :&A$.$X_F=O<ENJ(N00
M3)%0+G.,2*L1/6AWTCH^>* >JV$!MH,5I, *^6*-%Z/N+])4N(0)MN8JSG'(
M4/RI CPME7)C4NO,ED"',@I$S=\C%I5MR.ZR\M/W@LXS[ 2Q1<??PE'R+\J;
M#"+D-BGZ5 99_E@*^?PB!;09&R"="AK8+FG(!=DU9%WDF'6(F!)K9@LKLV'C
M21'E,KH2CJ_<)?XM%&"AZV!V)ER#]M<QS8K+6GWZO=N.56)C(X,,/GD]J1UM
M9Z&7IMV54*0*]W+\*T_"0?)N95;E484-'"&_V%6Y[*C84@9[\DOZ1R9 W?IS
M])KN@\^+VQWP$+7^W$#&MUW6K+:)9HT1G^7M^2LV#4S'9J_+NN_QVMC;<7?'
M4;,?FV&%8C\&!FU^ .$M)JPOMURVP:HB9CO'D&=)UY!8?93UA'E'[&AUP"OL
M$0I<EMD+[Y/N@;1C8F\_](93J^U\K]TC560/RY,'D@,WEZ:<3_WB->06FQ&1
M73%,@PGL\QI]*IS@C KWAK!7A>,1^5,D]G]V'I8Z3.0R90IS!;*[G;28[BS9
MG'>!2V?7F:T$4Z\X['J($.'G8DXT1\_!0_2QDU/OHP_;0\)ZL]FMO+F(+[3Y
M,H&%.&Y^B.$[AK.@DIHGJ!9S="DK;R76IO6\#9EYFOO*SV@#:0%$B6.LE. 3
M)S>[9\R#,X3JO.5!3Q@;8/X#!@D^ "TKL;)P? +V-Q 3+M(N$4E&B)GQI^S"
M00.>81?)@EY6<U$CT1C5 %\_S/O><]>_(?&G2)DR%Z_\9IRKD"A4N.2!/_AN
M B(W<'MZY(>5'(?C>71=";L.OR!@>C)FW-2BGKI@G<-JD"5UK,/4+&,Y6%IA
M_8L_:@'W2_DQ0KR#KXAVF632L3Q6ZEK6S5L/)U8;._NGI/*6VA[?^;2B8QD4
M-5-O8-H*JI4_5G(JMXF .&.L"/?#1Z<0%EGSXTD;X)T*Q[>( 63=G8&'69+$
MYPPGJ=)"Y),M%FIBBI(Z*XL>T>!FUQ]?P"2^I?81HE+039W60<U62?83I3*
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M)'()'DOY H+\MR+E=:8A3)6?@0@)I*7(S*S0&O82Y+LNYC+$ PJ/LJ&J$>(
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M/NFBO)UY/<&[MR!HN%38-2T\0]8@&6(CVC0S 7*%,PL0I:20%D&V+\CZ");
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M<FU:SD-ISX9<+6!QH%TJJSC=<@>?!\V_F-3\*2DG8-J[[NGA=SW;"7=@FCP
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M2NDC0,0ZMIX7^AK08"Z[;U@F@)ZV3[B$U^.#'@[9!OOU.Y\QT["\N;+J9MI
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MR?;!%_]F.-&G0O9\9\(TZ>[9&0<1T6,6_R=(,P[\:3R$KSN"AZ,R%@.MALF
MZ)$0>39._&/<&/A38*F48_@(9Z:0QR.W2&?P@1&+\/_D$)L;(#1PV)43:&!\
MLRHE86QP,J7LS?VN[F9=YP [BO&KAP\:1DT< I>8Q]4[S1LZ4UL!"/P:KXWT
M.X'7O&]?6VMSUS?>PJ@[OH&R)&U*D! ?N9EWLSV@"<-#L#\WH7J2K_Q&K](,
M?&5_YN0/5:L/_0_QEH+LX[<5H6RV"<9,-SP62ROYI!$ FCMSJ%>F+2;LJ\.
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M+WLC@8!7K/D( 1R7;86'P?!.5)W9:+ 1-L465L&^8)-L2UL966Z#!,*%]^E
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M/W@%\.02/Z$/_LRF;_PV+4SD=]JA^\V\2Y&GE\MR_DH#0K8Y?+*[E!#'G-?
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M,L;5W@F9G_"+_3\'L%-/)[ZDAP"^8\WA]GG#<9@79:D!(Y[VB%VR&M#W\"4
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M1+H/ E9,%M$DO5&21'"8"DOWBAY[E6Y#]:@;1I._"N3]_L"E?>G.'_Z11]U
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M68"?O\?>XC>F&94+;PNZ$NV=HSR<0^YU:6U-2&TZ5#3:VB8L'7VCE4BJ'=F
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MV4NHPQO -EFS(FT,4TP5^ RTK9H[S9RB72WW"O VX,*!W?CI]#/FCK3SX1Y
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MFW075]'.,35A8N2# *9)TT=DW8WV+=UMEZN\ER6:.ZG([7=EJ+H[FDF5N&E
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MF5/1 AHAB?\5%YR5P1H!WC=BBE50RE2M0U4P%>1]Q?U2\7]4N/@E ;;D'LQ
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MFU/)"]?G#>_U/0>5R? UW0%RC,=V^ I]B3'CL)/B<7.+#(/LL+WU1I9"^G5
M@\U&=P[H,#T@C1NCI)5XP]J\P7$N[IVOOB''6TEAW!.>X6FRFM 5*B[@C[]1
M8LY:A;X.Z;N)&$/D.JX.X#.Z@O4K 8]:H,VZ6,1'6H>VS^!'M*"N&N'RKNHM
M5.9F(93XE 9.U71&94GQB[J9VZEQMF[LXM'%[^!D\1%5"AP&DGMY513V",B5
MNE7A(R5+!+JV@Z\Q?"<1F&20&TXB% Z-F-$>]VB!GQ*RX4M)[KZ?_$\86L4[
M9M_IN5+G8$J4LH?[E+L1;5!0T0M@6O8%28NY#J3&>I>60N0(TBKF%M#A*I,H
MLTL9<BVL>"XN)TN=\8[-03&CYMTCEEFM%I8;GO,OE]Q-,]GH1!9]%$A"/*VH
ME\80+%)'TJ#(3R7*'4Q_U7UT/K(4ED#5]=REUG38I+Z>THFOTQ4NQV():HP:
M1RAW ^UDDHA1*\)2A !Q(DD;$!>('2\P@?7)-Y*7/H7F'BD".V$!<=&;AXBI
MT090-_+^^TJ94^H!:GB(PTU4BXG%T=<]_1*%Q?@1 K2N3_$4)D('&A17"^%Z
MB%LKU$;,Y/$.U=2BT2C!)H9'K2VENOO\!Z8M?%H6/Y=:F/C&FAQAM!QFI7W9
M;+W["'EU%R/E:*GG$6(;(8I;9#K<!5*KTLQ 0J6D8[P7J +FPF-.KYB7>D51
MW$7(_%[*8L9KS[V';?<C6*71R&(MLX/0BJ1.IQU)C)F*5/FI@9J.;[S>_2.W
M0HV+O 2.CPCFMPJE<T%O!:=*Z=2%C\(:#\;U _YP\)E'/H^D;PXTO"RAGAY'
MC'T!:;^\D>X_L<@*OEA\S-DR\':M*\[#_VZI1>)C15,@)<?K)4L7L8"F:HCQ
M[GJ(SOI>>BT0#ZPJWPXVR"58D(ZQM!48:ZSSTH7KY6I<%%>'M!7Y%G:0&UJ3
M=)D&P$V6-F3*1LU\?G"46M#K,:9]MK%<2TY?RLBM30:JGE\0%N> %#;3,WWP
MBH6<&N^%(3TTM]>M6M+Y]6B-K<,UH/?!#'=X%,374'6$/KQ8ZF+F&:4GAF:<
MJE2RS#2&?+Z?[,^-='>+$6R"'61X-C/4IH:"&R#K^>N<@J9BC>'UEWH)NK09
M3HRU<#E\6WB1>51IAXK07?!Y[GRF/[B]=_0&2ZO>/M@%,QU*-7$^@RU-/E7]
MT#FW^H>TN6W%3D)-<\BOQ$;_YP#+.QN<O[[".Q[Y*\_,\2$J$LZQYD3\Q)S3
MABYDKFTCS7,?V&&KQ:MT=I#RPHF"Y1X^(6>;W@^46A&T/@>>9!HN3<AYOW>)
MPC8P9%M'I_.*'[NJ#3*>[*(FMB.Z:<G4MA%:-B$>6"+8CNPKA,^ HLK;L% 1
M"W)B2*N!2C=[/7!]/;H8?@1MH\1Z68#>44'XN0[R:<%2_,T9C;CRXSRT6;CD
MJ"/D%?=H0+ 13LCW\R();?*E!"/?QD%4)[9]*4VQ$^+6X1>@C>1"%@^RD=77
M"&-M\2/'R74>&&@U4;6$?H0UK$9JD</(V9]@G5KRBHG5Y7N4VQ"JL/&3*@K9
M+[70K"J]^YF;C8I(6NWVJ[-I[ONX6L@9.:U_LFNCFT)9Q<6A\V%\);H,#L4,
M7K*H?'4OGEV*&&T&\=>036 ?QG- X!KBXK][I*TDQGZM-'7]@:(FIC6OJ]O/
M/?Y7_;JX<^<>UNY6#3>]-T\Z6OP/5/.WDZ'9A.7V+A!'VC=[,/1+JA[S(E%<
MQUV)"27E):9ZMV0?VRQEPM;Z6/M+Z?VZ)%-Q7688??X(W!;D]/1*\!(W&Z.S
M39F/O+/+R-64L3!><&&CG1KGZ38IGJ1N1QN%%UK5.+H$-F6%/_1X91,QT:VI
MJ(+C_)HI?L^V(,[@:#5O#L9T$L*2??1E?<<X+[DZJ+E%>!>%T.%OW';N]JXY
M#NPQ&\5V6$OIA3E6\+ :AV.]W>;#+0*J11UN-=1B4P[BP&-^QY'EU(SJHHTE
M7BMA7^5%1KWL9DZF#[! *#W(\)!BUHM09'@=AA.J76%6FRF?W69U8?:M'](L
M^,U!6B%F8>M:9G0P)^KT-5R2RS2$+'IXN3!FD'-99@.$E8B6S%!G..J3W;MB
MXC*86,O2;[U?<9U!++>6\]CH%H@:8=WU]?JTA9,T?_HWSXO%5IXFBBXAZ'VM
M?"4HKVY/TX:O]&*>@H&O2M2SS?K(B;)?+5695J%&A67MDQ[= >ZEQ4V!=DZ&
M.SK[W-HG+1Q.M)E&=1@+V^BC09K/$C\/7GE@<1FSK,V;)>%SQ[B*Y3 '%$L?
M",'C>!WD""2\CFA)M>9B#E'Y%<W+I!VAR[0,JF=T[TJ'@"A@ :OKD=]4<EM;
M?NJSQ%OUVYQW-^27^3->G7\MK@>*)J.>2NGOBM!%#C(JWE=,TD.;,#A.'-(7
M#X_?]TL\XF/;<T]IR;P ]8U\@RX'W]L>R/_!&C\L@<_R] Q=Q?LY--\>PR<M
MEO'\5XW+!RD=^<$*;14;<P'+E9C/C1&>H78<K:'J!NV^P$@Y J<7H"+"0CX0
MG<R.69&)7T9E='T+1M;'7)Q\<N9&O&O882?09>'SUP6[YV),9IX5D8!XPL:0
M1XV^X-$&8(Y!?:?H>OGJ>9==X!"*$6.HVJSW!!+Z^& C*9W$DU+F#+)L05[4
M\,AG_^)?\@5KX5CEM\^$PI+&ON:XW3N:7UT9+$"*/6B#&ORF_2N_^H^?]'X@
MZ (?[B N:ERAOURDVF\=@ACQ^M?7>*U1XR+JJ]/6@YPN<I%0NAG\7"$5C>"+
M5$7#A*YDYT_W%*+"*PJAGY+868X%4*ILB:CCXQ7P\[C>& ]='8#F<)%G +(V
MK^_K?&_E\_$?\\/Z<[T4</*P8M.Q"+T*,\\RGY[VX7MCGBLG<Y!M?2H*>?J"
M&@?O=?CGFZ.3YA1D1HU[-:#&C9V>C"6+U+C;#6K<+9)3AJ 8<PJGU+A'?6J<
M!1=39Y\_WL\DFJ)AP(<)-6YZRTPM 2M_=4Z-^X5KW$1U!ZHM@=9Q-2X1>V.$
MU>_OPIQTU#B2<"P$0/X1]CT'*_]0B%V4V_V\?+(TB3QX18UK\%;CJO1_?T?*
MPA@!ESJ]FXQ^0WKJ,(VU^20P9OHJT*V="S9P)^W5N(]%:IQ4B_#[NR,U:IR(
MAZ1AC38AG,C$*,BTN7!:YT.IV1 %/B>:20/&.C _&\7YW<VC[X$^,4JAJ'$)
M^#P7%$ 2J4C,WXO3H?4I>7Q(C3/-P43!;M^HQI%1)R*Z;]HR=J;EGP:-Y\Y6
M:(Y?F.@2PNY=0+%5_O:C8UA+%X@25)EGYH_>$J(ZVI^ND("[G_PIV[$HV\+F
M@K:]-<,C65?0,V'4<_O< 3[F?-Q*[B1]NC4MW\^*!JKG 6UNF)STU+AJ3&K7
MR8.Y6/?CL)?&.Q0^0H0W@%\+&%,(89J0.N'6ST:V.*B. \A3 -F:B:Y:CSX6
MHB>$Z*JFX<< 44X87_K_SJI,[I/##?Y?]Z&ZSUB5#X;TLT7PGDN?U+ASOL$A
M2;?*4!V=CZK,80$EA8_PMO\Z]J'K8\GMWVFF]0_5;JG3IT/IHWOH0QN^>=P2
M_R*+UM/I.-+/#?A[;>$-GN!.3V*JTH(I\JO_,8:_-P:EWD%5 L /\M_NA(D
MDQ+:W'HA#VLCO)\I,1U)VNHQ+7!#-ER:3J/>$S:,KY?$EXGMV#F.RKD7@BFP
M^_2[X1?8<WJK.P^^)4NW[7QK>U;E9\K.7W G_7R;N$(CY_4W#]MRS,9>*\9H
MXP>1X0SAOM^;! &L)$P>QR16BW6N+K/C&$JM(W]RLP]%\0CG[8S9Q-Y_5C0U
M;HFV&G><JL:98]<2'\5Q<A+$F6;_=?6V.,H[RW:[7&\!G+[[S6V*CF>7!V.7
M^6?O9VY'K;9XOI*%OALY?WO+*\/JCNX-EOOBZ5N.&AB]SAE#S9#JM-UJG :Z
MC_J4',/:X*G&^3%"G!Q:20:^K\SJ'TF<-@#O0FK^<2]P1/> @]+/:W2[Q#?V
MB('6T,-%^5DOE*2<&8,37OI@.[M7A:> ?6PKV*J"X'1UCZ\O;J?+[68G\QO?
M)+P7K?4MN'C>.TT6?"4[^%;'S9&@KRVW.I;Q52>O6$8Y=Y>\WY@1FSY_A<M7
M\YEJ'&2*.G"T ?$'8,:)3OW*[<_9YDAT@_"E&C?Q\!]B6 ].^O#6*'9CP?@=
M["6XO[K^+QZYN&<:P[;Y&*6*:$ -/91G,?W74:4K1+";/J8F:EP'MU.(A3.1
MV/ L$F/Z)/T!TRD=U 3 :D8>Q0J3%$D=*&58PE?Q5/B1E9-I+TR'>?AA_\?.
M,FVP%:V%6&^GCM"^:#8[B:X@='23"&5>FCNMSM[NH6L0<&S=2[[:9:]RKCCF
MK#_\W=$)C.KP1_BU=T?*]2X'_^!$"_8-6A&L*W85:Q<?[7J_9W/YT3U6AZ&&
M%=%-KPRVV18^U1@_U((N_(@QCJ["MO/EX0KO%D!J\!RR2MN:(IV'B92UW1-]
M,\:X>;+]XZ2N*NDBNNZ-<I>A>&&1BH.NI+^;E\G@+W'<E!.::Y=+4_D7/,1'
M$M&5S WPM#(0K61IJ=+0C8@W[*BT\9. CMRX3G9U]U$I(1KQ!TMD)B_ (X1X
M0F$FPZRJO<<:JKLC-& 1!I)F[$NU6I,+;CUDV,F8.VS#!#^GK6^Q&+5>=9%9
M2L"0Q9"EAYC"^>#-+D44W">K(/<Z('I<Q1'5STP-.7TUTQDZ7P$=[NO5X]@'
M*+<PNESAXW)NC)M[)J-:1F0;D6.]-H+Y4XA)Z3-^$(]QZ(35[A#_KZLVE%#[
MOZ=?$VJ:PO52#D<D/9@D$X6S5C&2>L513)<%N05=>Q\@5A 076XF$RZ#OR=H
M>?C=8AP^P>./SH.]%+L/#7W-=7_B;'[2M_1N5F2W*E_\CT'J4[?AACR@BJK*
M!%M&"& :JSEMOHK'Q'1F95+-0H /^'"BA.!U3&M60II31F9QP^1W0C"?N1*+
M@--2%.2Y?M@]M -\H\8I;N8K)AO*W,G)+8F2Y,/=NP_DI96.3/.:^_KJ<L'Z
M.BI? UDA5'3"NV6B3IHB%PX%STA+7A+>)=7:VE23KPD-F:?!T,,)M5[;7Z@>
M2%LGR^@Z#,L^"B2.Z+DD[29Y^M6_-#(%XY/B<XJ:]>H;X6S15TT7\@3V<##4
M)<?7"-^-*[3@W7+R32I_JI80BVY190 7".R0O@BAMX%P$6RCN*EZR-)FO0)6
MD+8PS8J U:SF4C6NEGOM,J9@@?1%[B>8%A"AEARK[Q"_#HZ7#_V2V3@A#\J#
M<XZU9:)LYNPFS$F1 DOF07@HG>$]3%[)LF1X2_O"!6L9.4KO&CTJ^!,C0'HL
MS2+II7NPPO!3[B7I&U/E?"1 EJ@\'_/ MV0F1Y%MG9N_[Z1O50OF79?-;KRF
MQIT!EL,:+PE++=&5-/T#X6"N3*]&%,O5LN;,1[S@+G!<1KY:'@0EU1AMA,BU
MNZE5U%7V\R%"-: ;:$ WI!EM@]:DK6T,'#7P@"\KJF8L5@V890QT>G'/[JR8
M&6H;[J1]=N*7YW6+&BBO3DT?11==DW-B+TLP%MU[GU#$N5F 6N^5$JZR=L'S
M'R-V(#""AQY+%#=@'C@CD1.KKI1[RLA+_,BK);4]]I!&K+V--9KB+2,L&4@S
MASC1?*'6_@*J[]-!_\S4S>UBA:W 'UZD_!)]2RY$^1"QACH'7>4KQ%L+;P0+
M]-M(&_WT646R^"-T YJ73F%KGA5/FQ9>8_N)M[(^YO/1$VUT>T?9V9N[@3KW
MNO1@'D/H(K9^]:'58&"S[TF:BC:&8!"U?]H/"P^V_']B$L%.473/XA;6!F0W
M)*FN.$/H,-H-TF,0O<>ZG#=S#T,'8L+2>Q)6GQW?ZA^VMJ,B^(Q!TBX"IV<%
MO!8ZH\C'PL&SR'Q5ZNE6^ZW2T7AA$5 K[.B22FJ?(_ZA!0.E3/>^X9-0R<LQ
MQEN?LRWENW+]L@$C!OFE;L]64*/3BN9D2'."@"AB3GE+8+QCT"JA_\:<C9OL
M*GX^Y?XYA1(Z0/,=K#PD,7E0GHR,SH3\[%U#7]H#"Z6C''O3[ ;:@DP99P$C
ML[J4*199N7[;,Q1BK$BA67Q(!$^)#/,"WM=-X>?S:UXMO'QST2ES_^F.7LS2
M9;Q(YB;,V.XT\O'+F*3D4<621ED+B?C*^S%\TXFN_99;&!Q'FI<$7QB'C_1X
M?J\C&[G<XJ(E8S"-,+IQTR& <48_>7_FFYGX_;N^WN9;T9;/\SV N2^36"3B
M07,)3Y8,A).^@$3#EQXB%-4#P(]@"(N/-5$J>9TVBDT@,/PH-&O -BT7S_&W
M'+%WA-*&:F?N_+0C7I?CG4W!5"0FF>ENJ"JHN/)PQR,:LR3D>&JYKEB/NYR)
M$<WK9YA[P 45H-Y7K<+S(M@X^/HP20/NJG17\)7'D&VJ-,3F(=I$UIT@1DT]
M>=_?0 =;:LE?Y)7O MUD>O&LZJP>!D]V.!(2R8QRI/E^$I<V1"^GR\O/=7D_
MH6S%L=)O_7?PG86"0Y[TML"B\;;XPX>&2JG7'<DO@DJ':.]@S$2'A?+1.>Y
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M0B?_2]:8G#RNC(#"U#_VZ0AAY*4,DBG?"7%OP@F :;2OG9PC)*89CUDM834
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M44H=9.2BPJ'Q,->"P:UH+867?52D--*2<.Q"[=9<,43=8&8K>0GIHJU=-W
M$LC;6DOW2/=9>?>Z9'RJ=(H_KK".MQ-2UO=&J5Q\\C:S7M6FW77MP1:^E]"#
M';O>58X(Q[RT3P2A]SGX*<VPS2RFFJOEXF:ADAW_<9IN"OC*Z)E4_7K:;=:J
MB>7'CM]"N$=ZT, 9^^2IB<@/*XM&8L-2JSS7!OL<SM&WH.5^-B]Y]F'/@@7:
M?+X+RTL6UD),8CM!]NE\0^!;J(3CX<\#=E(MV8M&JP4+L^730JVY@I1:24R5
M+&AK]A?3FX=MNJ?N1 'QMUF[Q,T5 #EGK0"Y*%F8ML&M$#O+;J?,1XH4S'1;
M*C2=4JG*PB.7[1&LR=85L9?SKI"JVL;3%+P!.^5T4_"I8*:P$W77YDA;8DA$
M]B)TB[:@WCPZU#7-)=ZGE:*'' !#94.'&F./OYK-.ML.G*W5=('?E;JWYJ_N
M$L@X''(33K&(7)G>4UXZ:1'?Z0CJC9!A=WF55"BU0<ZJSR,,N76=01AFS-0/
MOR&V6ENB<*1,[X6XF>?B\FB-MEORNT=8U.986=63+^XW;!'7W*/=#X[":%^3
M E'+V4XP[ [<9W@746.<&9V#Z9?Y&R+XJY'18M0 WI59C-(1ZR*$*V_!2A1$
MJW K,,W#YS8=\#EV)XCQ3)8K78Z0FO*M:ON!.%BO45S-MH-BDEWBOJX+8MZ>
M8DIBU(Q."CF"7O&F3K,#,.AB>XX]DK07 (9]_ V(OB_2\* E/N(T&+KV.M3_
MD9[2&GLEYH99C7\U+Z+@]QJS&V+S+[*3+6U &VP1RUWA09I+#2->BL'9!=]Y
ME$+1<JFR>Q0[F-C,<N$E<HV=.0;V":BWYBMV=XAK)W\-:T=;(">IM-X8GB=O
M4"5Y>/T2.<UV@;Q272:(0L&@V_E<15VIWI':C'W,/#"</A\]!S_/AG6$IV[T
M)K)$KXEK6 ;*"DGZ;/(S*$,F& ?O\QI5IB@5HDV<A@KW=PK".9;L/H&1AY&B
MCID>8@_K-6D7MBD6\L(@:T5-<CU=EI:-&06ID@-)R8"],G3][^-U6*RC&R/>
MK:[4>(3$%U3$3,S3$0STCL$W-)@1&?D:E!_ NNCFV)P+]$'IH(X ?0\VW15_
MVP7*-TBU&05XO-$1F!<$$5C3P%WP^,0'L#IZQ:="!W6XMH@J+XAF2D)]9G>/
M8(8Z A)&ES#:Z!5<KHZPF(2N)D$_@4VF<L%\) 4S)CEH]+_&/PEJ:/@?C_#(
MY_F& 89BSS5>ZM=2"9I!-]$F3(+XY(9HJRDV2%LCWPWBUS U#" 2N544&8L;
MCH?_;1:YE3(7:8\/51+GLS+D.@)GRF"5M)'MF5#Y\?0Q11!U\5AM=8FLX?SS
M*.N6ZD"7\?[U%SZDC!?"']K4WR'/-!=8^HJVISK"X*K!_4B>!D0/()DRT(CE
MH"9IRRCK  ]8+Z'>7TY,REF8H<@@IM$-^$N1^T\K1CZ^<UMVKR+$BU?O=T/-
M.7NFZZL=V?%E,^XSHXBJY-.<F;$8^)K<("79(TC)4*5S#<;K+64VX &(EU4?
M'*/D+ U"0AO9Z[JFK.-)_I T(_I3U=?=]5MYH[$-KXNOWQF9:1G*+PR],Q3T
MXN5@RUF/ ZXK86-UD?8FQ3 R[&ND0K,+6(30'V0R=D)=W9150# "RO+VLCC-
M-^P.0>\OGO3P4=AL5FD8])Z : /S/1_X0_>._! 3.A\R6L/61]FYBC8\FI[@
M(NO)XRD1&D=V/\4)J8&]U+6XU@MZZCH\%]%3,DW0#3"MB9M&-V%;HMNZ/2X4
MH*'EE:2E4\[=E6GD#< .F0VU64PWK]2&[NJ/*L56# \>J1K3]BFE UK4!S;'
MEDPK,@_)<ADS)2W, ?%3P;)Z X6#CI#\]K  N5:P4[,5*1 =@NR37.(RK>(X
M%J,'D%K%<+]&:.796AB>;Y=OL7'#KI)5#N;,X].3L4-4GZ W_+!/$]/LL)>@
MA> D?>"0FBUVEBY"3VAO\0U1"OQ&4-)XEW5(GE6G%!!Y.)_:%G=><OXF$U+)
M78HFQ,V<U)SBJGLKNYT-C)]BYN(IKB'#T993\(+^[DQ;.*J:2- <)(\_T:Q"
M#VCO57+FO@2^IJ5@2[M0>A%"#.J+9B9-A_PO]MXTK(FT6QM-.Z&B1F52$-*.
MJ(AH Z(04ZV(M**FG4! 2-N(#!&C+4B$F%(9PFBZM8466M**@,H0952!E! @
MKXW(# )"IE9 B%0)A()4*E^Q?YS3;_<^Y]WG7-^^KOU]W_[!114D3ZUG/6O=
M][V2JO5\Z7/1O6FLWMK)HRV,H8?R3L+^-7[>"9%HF,ULWX_=H3^Z^5W.=&$7
MNIJ,)LM[;97%%G-1K;Q\A$<QLZ=T_82;X[6E8.D'");* ZJ%\0(3JI'"YIJ@
M,/RE>;B"EGB/39":ZJZ&BGF@;DK^_"!C8V.N/1H@M^D"U/?:*_1 YF,T_:7(
MLAB]JS3WJ,J8HRTD$N%^=[!T!21+912OQDQA:1+-LH^S!STX78^S3<1]>M,[
M?AQ7VA@->J7&5Y@IG(R;J<L?!'F(-K>-?&AV8-S=*'5-]SBAO.U?Y'G_)Z,-
MV[):?A]"-&K5'W-*4E69FJ\Y-NA/<'@55.HZ_$AN<QU?B$XHKSC)&6)I$C@;
M#'P.!0J^""2*)LXN/_"*3#H3.UJ"V%21NR;J?.?=DA0&I4981E>X9++]ZOJ6
M"6I:!B.,RW,#34PKHV]J>B4J'NQ:E6&"3"2+=G*<4;IF!QNH I9CQ^'O>VI!
M8ZX3QZ"%8ZLP]Q.# 9',7\8U=(O>05^S]O%?LC)<T$B%)E]?04O:5 "455CG
M6/50=:0YG OH706]9^*H]E?1#(X1.E-#GTXW"^T#XI2-]B.9RO[A2211S8 %
M5ZEDC2.JV8M6!<E'],6(1 PLXH0HI7&^ ,*/IEK+K2WJ7W*7=8Y=,?NFW;XW
MO,84OQ[:<]2A,6,;&J2TF<L>/8G>>SQ *06J&$M0IOJ-M@QS@5O525H!&*#U
M4_\(Z@>!2V_)_;-*HY0Z4E<$)9IB4L% K.0V$G,S%\C'4I$J'IE=&RZW=JXZ
MZ!>"F%09BS:EC!X-#]9Z7*&FNED[B.YZ[*TZ!PE'L3N:&&5C-UEF6=W(<PRO
MH\1+S?#%V';4-6]=XKI;B)M$L+1BN9S,<[S/OFGT#!X:['- %I7DL,^,VP^%
M>XZYE[:]-WVPJ?#MG:98QXC4.D%4FD-U/ZK,XWBB 5D<(_[7I<A)@<FXC3GJ
M)9'_P/:"]W1DK 7C3+SR? U\9@P&7,LO26F/O;L];;51_3P#H/$^QT3[VYC-
M%V#5-D(Q91)Z@( 5Z6S,Z(FV$+-7GM8F3)^3V812YHDK7964&\5#@BC0=+7V
M9WP+9JX55H3)&IP4.5<K=A0XU-#U4+/I?=]P2\P0(=<^HEI:H9$O4RF+5[=,
M]0"Q%MO1"QI3S"Y]%^JDV?.Q;QY"O.YHC8ZT G-6\/D44IYH![=9H%\Q6V'M
M+*%9/]4^P&PT9MP&< Z7+%B \FL9A@9N[<5@](2.- OSR,=6 0;V-N;L(;DZ
M-RPKV-&59V*K"K&99(JZ2_)+^WHHG>-:L$I;4*A]K"/YJ]QD6JE*/X?; GQA
M3[[JQ6GM86 7"E$Q_'E(IKU=FS\5Y/&M#^8657.$O;F;&7+DF[$N1;JW:ZRV
MY8V+=^R)-\-@,>7E/M'B,M5L<AU!?5]ALWQ6T1<[U*'X6O96?'%!U,*>$P?S
MRVJR.OA1<WXR^FS_<]I/'3%I/KG>Q=7??0ON?$&O)L>9I$I+^#6@.>I$U/ZE
M3?;"'J4Z<OIV<;Q)9(P:R!H<U-$P=<IA&)2#<[VXS<:4PHX8V,&[F;L%=:4C
M/L4$W5-]X$K1##1547<K:^A;)FX'GZ0LIIH_#I[:G"V$F>I;2/^P2LZG[),W
M)F:8-^'F8-6WKJJ5"GZ<8 [D7TZ/I10WUDFC<^36(['>ZO14M8WV 74F$JP/
M)/J244C!O,)PAZG0[,X:T5?PA'@9OA';@GKX(?-'JCK" VQ56L85]5"/YB6X
MA[*0NP';BC;(M+8*DZJ1N+Z9J%"V\.R[@F0E/U9D0Y18-RHHN?9W:U)2_0X@
M#C'CYD==H&UEA]U"?K!F^6\YZ;KF*]5/RUWKI,L EG019@F#JA"$Q-G6R?$F
M,#-<(I@OFM?=%^2[JKFXOC%>:B%:_TIF]4T%.4M'.N=RZAZ;69VQO%VTA6/9
M3-V%Z!]'%K:Y1V3G*M,O8SO.B69X(#9WP2H'SLRP3'8.08Y9AH*2NN?W.0%H
MIBSD3(_"575%9L.CS*Q@(BP?F"].MJHV)2P>HW<IJQA%#L//%4"LZ>GS05,V
M4>LZ:&O0A50Z8H8OT:<O]1*'9+KZ@?F7]:Y]B9!CP0 *NMY#_%XKJ'#2>*(\
M,526*O$>21(4%92=^DV?;X&9HLU*:#[VW<V%%/'4^ZQ&7L5%!1/LJE?0> KR
M')3ER3Q!#<L;*,4-'9-O"!TG-ZNR6L&=I9H)=U%O^,R!7+#'6YE:_3-:%:;Q
MY_[#,:>*\):U5D"]HG'MXKBA"Q&;X]ILT6*47ZTCZ6_JTY$D7%);Q<4\SDIT
MW@49/>E2=V1W<)\A')[ V<FZSQYQO7)D1.R[Y<4S6!JW*70(F TP!=V\6MP.
MM?9'!.IU($\P'PH,F3-R HU$ F3]=3W"[MV-+SM#Y,Y*X:)!H/A2?#:V#+W(
MA&^0#=%S5KGFA)(S0QQJZ;P+;(490\^77;W<7KJ J.W[^55"?;2?X(2P(1!=
M-_&2U:VPZ4K=J_V%Y@34C'1!:EF1-E.T!'_#W80V7[@H[^%?):I"T8Q L-0B
M-4PIG/4Q8_7MBO LMIK!\S(O&Y[(9*]3[BV!$GI.&%]B'95U7@MM,%/':>^T
MXO/:X9GJ/[0_JNSI%D-IG:K;<+J"+Q9VD^7T83>"3V,B>&)@J3#.KI+\4F"Z
MFG[M)N=8*W==V?5AFNE!S8J>QLR^=[L4YAXU'J-L"U!UV:@O;7PP?]RCJ.1N
MQ?.0_$]ZG_9>T[CBC196*%'-7,LP04=AOQJ!&=5RP83%!G3G;T3I2GN*T,7?
M>F^B7P3B:)2@;E5C8FA@2 O;XK*]^:JN59[W@Y;OB?..TCX&@NCHF2N6LAN/
MB(*$@:V#X.= D/ ZH;A_^C?%O1J$;X#52F0U&DEH; >-OB_>.=W2*Z 'D%M\
M'H-4'*U <]%-D@%N!D_SR4(>;1E>#1;RDZ'O!4D1$M5JC3WG6-LX@<@"0ZJK
M#$Q@+.0:8#;(.(]'6]?-V:W-&Z-W.TK%'> ",# %E3YB)TR]IUF@WI*IB23N
MEX)$@U>(WQXX2QVO.-U<>51=B'IK M'$*K#(J*Q6&R#G27S\=A'RY0:W+F-[
M":,K4?T#*H0_2J>[>U18*W.'&DW9 HDZ8STZI-GMXSLP=>"(ER\#O;^CPOP>
M^USUO/?M,2U]M?:)Y6!$3W;G(6U8))=TY;W&CMLB@)L=RU1;LZ9O?21\ V*V
M0I6]4MC5V$C,GX\O):,' /E\6'J=XTQXBG];&W,?K :T.=,G;W4DN<6H/434
M) %7,C4_C*BX+L)_O !4]9KO,1=$H'((@1W4*] @Q$W>.5R/2.L$,TJ8DSK2
M66_^+.P4@C^5A9#%%E^VC5!-X'H?[9TL](KY>RT_(6]U<W&C >=RT]G-K-5I
M^HV+@P8+SQ#57I>K\CU_^!5R2_T9-JGE7R-@W:7T'C*-[V@F8O827P5[# .:
MDYQOIY\1G\D65E/T[1::U!I3EHK,.,L1CVL!S?UMH>;'SU3P&>Q\:Y7%A_?W
MK_*V0T5E*A-0LWYZCM=C48\ZH$A/5:9D+4,UZB$40NCR2ZFP6$U%"786SL/V
MPV5QG"6PV!5^W\_#[<JNA>I(5]7&::)'\MXC[6%\ ^Q04ZC9K#('QXQ'03-7
M/[U24IJF$J6='9?2OYP$O< T36,YS9S;9_$%^HBE,6>+JW#3=DDUH\=4*L$M
MX,Y$S"6TFYQ0\0626<4U;ZOP(%=!*]"E![=]--MY:6@_;%GG8^G==@IA;HY2
MTF,?R>L/.M1LZUL;Y=V"#PE?5NI-;SX8 Y(@V2\$>XO6#*JG'%3SD-7X?)?'
MW#8+.SB'5W*"ZIJ-.55V$B7X7FXG(:YM6/G)N[>?:>(LD3<$$^MZ5UUROSXR
M^V/WFWM!*RC=[ADK'3S  FB.CA0H6,!A(I!JB<R:7$U92K7.XS8PC$-$9+1N
M1,(U+6TJYAL,I8I(,*LFUSQ2KATOS7]L#E:'9RQ'^J+L1?>NS$E^6%QXQWN?
MCV/_@3;[.7<G/F.WRC[H-7?_WUO=I!EK<W%:RO=4MN'2;X[#95'['UJN/%;&
MN_/$<>'KAFOU!K<8+=-]FE;JTZ<^ C\)__@>2L-_Q'8)3C,^\M3KPM/_D'KA
MTJE.M;M_4CU>- P\W<DKF\H*IO6\U03WU7=?C 281U/>?88^9*Q47O@%& 8?
M?X^<8 1I[ZEH^7&YSMT_7'&])>@Z1'U7T?+^ V1CE\\LURXA]( /HL%Y4JRD
M@DB6U^\I<+N4 @U<T9'JO:M [(W'FS&/40]LSR)"6M_O2820-6_ R6*L4\/<
MH2/=*PT@4!$5XEY7_D,C'29JDIE\8*!4,8+MLQ7@(6157C\>VR7 31309-"8
M*V8?+AF9HH"?.V"&CF3[,RCVX'"G>Q#J2-:LV3K2Z Z&4[/K7ZT!2HL$4V9G
M0)1!*,[W.<U_O?+AO]G&&7&A((NWC^*)YS;K2#6WB+E\:,*[WX #(7>(2)GN
MT98BV//WJ__5P-NCE89@S=?*QBGK9^4ZTM(#_3I2NO/_2K[Q\!*4N:KH*[9U
M#"*N2[R\NKN\<["5P")^*C-@UJ6.YG.T)9OPDTM6L2X%4<X-FO^: JP]O ^9
M,'=3*'VM;Y="2_H72;E;F-0W*5VBP$K;!5Y8+L4;%(?B[92Q8]#G?Z 7B?DF
M4^!>H,15:V2#%=)6$*:N9JQI/HJ++DBTQM/-[^*-63I20Q3>^T9'&KB81JR
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MNXS+=RM'DYJG/BPKF^R@Q1&6%J#:Z>;!N%>?/F'8#WPT>(0O':,1B9<O@_
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MGZ*:&W?8YV\H$$7YS\Z%OQGABGTMF \-I!"N[2>F/BH#VCZMT)'NA>,^2F+
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M%V24KE19OSA22_& <9XBY*AW,\T8J/)F+.;L)CC032&-$]*6[U-X2TT<8@G
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M 5T\6;_*X%Z0R$3[&SC]6*7 G&J;&>SGW4)U0OAR7I3(,M#+O= ZN\A4E/Z
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M+__/1MK-:L:_8?.<.V-31D(&@[WDZWU\G?,](^'S,;'^#[DR\)]_"?A_AO(
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M>C]V_VXD">:KHC(XI&C>(B_^#,"OO[@?H*H,>Y1RB<4>!;?5OI%6C"1\Q8U
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M0T&-2=42M5EC$JDE*39Q6,F0CM%2\GBVQ<++*EKJ-6JM?^>Y$F1&,GQHN_6
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MEWPEZAU)2D36VCTDI0UY(>L5FL-RE;^@7:H)FET;L0IQTW^.D%HC)?T\T\9
MF!'<@YHHFI(4'S@NB%2UH6 [SGX7T,W0^X>V0LP38F0UTIQS54V>P3#EZFGE
M3Z(_N@3T\*3 YX(.>\&:=8+"#>U[:U(.= FX"Y@+9:,;[D70I;>0I-8-OA'B
MZZ.[I)^MTN7>B<X_<Z_LE=GQ>#_'X!>N0NZPI36G4UPCU*RR/0_3P^JNJ+P2
MC81S9&M3B=9Y),(/_CPG$'K'4X535=RTQEBHYNMGWH-^K#E(P3[8HB(="$R
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M\7F8\T#6C,U6?(SM'0BE[VRPP^>DSXZ,'3NP(=Y\1TZX,(WNU]B8%[6KYGZ
M9PY_H$!3:,X[[:HG!V)$XQ&FF$XY?*7-#+$7J_0/6TY&F-PCMYY=J5^'P#$#
MV7ZF:]Z&?BA)_]#'RM,N?]G4:%W\[%G1;VX?6O?275[8##9XT4//14U'6HCU
M7CI*P"$2F.] !I)]>Z$O_G)[,AQ* -$5A< X2 R\(%UHS^5_TSE;K#G"BE $
MDDDT0"#-+(/'OR],4,CBP$#!!6= ?.C1_FO1+,D.9 )\4/XN;VBWG9_CI,%5
M.3<?AYUU]WTV]\#DY\MQQQN<.A"A9]MC\[EG\$V*/(2; !YHU*;ATY$F37L!
M3YM\4@%-\VMA09N1=41-8>"9^9*PWJW=RBGIWPHA"G6,*#-$$8Z^7_Y):#JM
MR\LS#'X4WO\>?$+OR0I%?V9(OY&I#VCYMH1K]:F1WV2S]V'+$(5]PJ6N;;XY
M:5TS\$T\<8ARL;U_W:[&SRT^*_(+'TQ8-VVRH7^:+Z-;Y1?6N)OZ@A</Z?E6
M 62R;+^?OCH/>ZQQQY<T<$S8TS$K!4SIA">)'%A%<DJM:[B\ICG-'YUP1E%C
MV,IV;AC("5%,N)=9O2\D:R_FI+ ^CS.1-"]A?,!]S'!7<7KH!N8&;$\V>[,V
M$SY,;W;Q1[,J@<259A&X"Z,]HM=108V%#3@+0J I[/&HM=+NIO*ZU4Y/[\I"
MQCF^9W%)_?R2DT=4N..^^Y_\9Z%;X\+M8_"(VZSLLC,.Z[7A:?*ATP^MT9S7
MQ$3DW! XXXAM'GQ>:,@*V7 % H*N^&R1&J1?5^[Q?W$+W1ES)^;8L8R6/=TY
M$'-"LJLTS.OV;P)]]YOX=]A)>4*OU?;1/UO-DO=Z?(\<2D.4:QL<0/W.4Y[J
M.*3?_9I+HM7S4VZM,8DEE6GMU4L4B[+JV?:!\YTM+M15V>9<V!I?^C,1P>$,
M2EJ%KZD?N^6,<KI%"_L;[1D=)70V5>JB]+X AU"EWNIKF!NB5)J6&80HH<1P
MZ)QH(2..87@ R>H%$'"]]DJX_30_]F(LY+AF*6N#K&*D)'_T88;Q<D8\9VIR
M>V^CK%Q@@IWUE5EL$M2@8L(DEH>,50]K<P9T%.EV]8T\C*]Q(5IHR_,QFXP]
M[.-HP56$7^H_$ZFJH,<Z'ZPYK2)F?/)NLAR');=#AD&G'MZ[TY4.8"69[#7<
M-;D-=H;R'M%$:,E&^-@ HSE7'8;(*G*82A67,X9M7,MQ85V1?GA5#IGE,6(X
MX]\2MB'JB,=2\<F@'-S]<>T--"D[-,(@\;+WMXR0%16N)T[<6^+<4F:8U<"9
MSK9NQ)T4-1.Z9%-HEL&<:>AGX4D%PQSS]D*\8U5L)R5]>I?IE5-DUC_ONN?F
M'Y\N?4JW:E+E&]#*1OIW-MDR[3\SEQ[Y?.?ZQX*8VHY^,JD_&>*GDSD[.IO&
M0-B\"I[TN&*H@L3;8-EY>/QGSG*V.\9$Z(K WFB-(7L6=D9)-<"&]B+7A\00
ME_A.^YMH(?:6H<_2JV@:0CR14T/*K J9/FNL_,IM)3!Q+P:5#YFF.Q(UB$AX
M"^OW0SX( T8L-%9!A"D2F @&J<[YZVMOL2&T12S3YUBSZ%OHXW'/!M$\W!V%
M>E3W,:Z<%^.ZZ1YN"VMO$ M9T17^B[$JDSM"-7^Z[4U4+\Y198B[\BJMRJ0%
M=]7 NUTK 0]6<KNJ#)SY#M-L02/*:KBT)?4<FSU!TL *"[ \?2+RYED :NWY
M=BF<&W8=K&JZEGXUG*F<;6N_54?YOC['U<TR<WQ*ZHAMWK$UFD*^/+6,%P./
M9\_=AVC:96(&A;T ,4FQ?2UEG*7-8CF)16.1V#3']W="GAUQ=93[N6RN>]!1
M^.O5HP>$3Q*S+E]=L+3*X6V3IJMU9.04M*M+KS]GGY(Z/<@9KH)C$?96E%D*
MQ>HH>53<5%+)G\!Q8'L@U@D/:198$1VQ$VA6=](6U>&F-]D;ZP\]D1 6_OAN
M[*(<_ 9?SC!E;=]5R]XWCK,HRK#,F4A4^$5L:IC3A7L[,,8-\C&;1&XIDP=.
M+_8$Q1H L^9R!P0S&.Q#*%!.CX.F?+Z-1IQ_$*[B^@@K2NCESC45M@RO/.[V
M!CM[O@),(&/%?&&JXDI=ON<NY3K/Y4WV;:&,=J?GLFDL;P5P)EP5#4QVA,?A
M?DTJW ,-*)7"8L'$8']CC*]8O6WU2ELZ@S1<=[5EJ%5E85NF2>(M=^@^=JEF
MNZB(M[E^F^*D266#&T_.;TY5'T6\8QR!;UA.ZBALKMQ^;-=(1.Q E&^I:!;F
MU;Y:K^Q:^L7V%DV)=YF9?Z:\U>;[O+?V8:K)7:E#TM38GJ-'.@IJ5:JC*H>G
M.4?M%EZ4V'=D=N45\--)GGHS"F^$R7IA71^L*&D?;;Q$3/:,0C/5&5BCQM5=
M,_LP8ZJ ,V$W>X7VANL^Q%H,32T>>Y^M7TM89_4:*P%]5D"Y&36&MM*710Y0
ME<@&YK&/UXGFLY?X C%"R['U;.N0NQ7*S(?M++WR=!=M-LV9\]+24'N+LQ+?
MARV(0!G$)-]V( F83AN#+\5:E<QFZ5 Y-"N?.K/3M,U.TB,066)I98!AWFP9
M]ZQZQ&*7_5@L84U*7O>KU5:5_5T<\WQ/2^5@O2*PIUGCS Y"K:.+#Z*\=M-2
M1@+-'HLX;J$BN80Q>POFW<ZP9"4_%UYD^'8=\\-<]J);8^YWI<]\QMN6E]=@
MQ5]?^#C%/B?T<V-%^;+?19M07_4B;#6J5-ZNJ0"3_*E8",I_G@J-&X#/);--
M,0&27::C3'==L# K$W<KPLYDL3YX*=1-#B>9/>F] RTV>HA0NE3&N3DA[\ZZ
MPQ/2BU9[U_AV9[EER+:>YJQE.V/UJ+WZ#+9,8\8V+<%R-&O8^QK9?BB@[DP6
MIR]"3*OBH$.+X,.JYB$U':O+9MMAD>AVA:S7#Q%L(\$U:OE;JGXW2!WDTL^<
M.GK['CND8=17XVT5R''_MM$]X,8-!(%!]F90Z4I'.!$R(FQ9Z4.E.HH0QHWH
MZN/(QWCV=,UAHLZTR8DV 5LGAZ1V'^4G$@/1B%+:<LS[+GL':G#GJKP;HGJ@
MR7MJPU3Q@*DK]9;G+9;F!TF82V_(YF=$,FT.40WFIE; $S$/LA:I8)P&QA$+
M,>KS%9\D_N,1>CD0XS\>Y9]C&X=GOM-1#GYRHLU 9.<'+#PV(.]'_'_=>CW+
M,[-YSXN _9P71^I\B<^\&?\8\ (^7T1!N<^I9SDVR#Q6+;Z),9Z5*O<^$RZ;
M9%^^H>@IS 3L8P<])W1OL'0(Z2[*%BLN'G 41QP_]A,3_W3KQ"J&=Y2)-C14
MZ],O4[D$#VF*)5>Q5>BZ,I$U%H&,)28OT/BRK)01HP\TLK=B*S21;'=43^RG
M5P:;NM+EX#FI2S.^ _.]@T5O1L$RAGY-)LM4\9FGO [^('J"VL*5U8#"K3JF
MY)7@+--USC:3A$Z!5**458*QKW24\0XEB&#T96X7#X27 /_(G[A&.?=^FH;>
MW"WG573SQF.^)/KS]#Z-C'1Q9B(ILG-LJ@(PQ$:&R@T_T6]V2M,O A>*Z4%0
M5J?P/$G:?7AE]N=&X%A\3WNKKYPKKJ:76:YN4KEZ*/F3NVB3D595+!ZD6+VV
MK\8+1O42'%RN+_=;47ZJ57TSZQW#/[BP(J=#6]V1>+VAOEA=6W@$*M-K/WY2
M:; >6U'&EP+3<HX\8$=%Z2@3/U]4UYCO"2H\<,WN>J!27_!XF%B8_ZCN3MJF
M)\*F=+6-W_(]2^=L[/7+L+9-22[@)Z87#0N>Z;T:Z=5&T!9KKQ=;M3.B97DU
MY8)HF.3NP8P$AJ&#&IN%O%+0!!H0]T=E%21I 'RPDR<?LG(KI;2K:.16[4V:
M+595Y:-.OH/ORGW[.2P&6QVNF.30^1Y9@_*B\W),MQ0VS= ,3"A.E5.?VY\!
M<S\DW,68[=:EC'/P.%>7!\&>#X)'R!J!:SD5"\GHNE:T85ZHM]?;XEF9APN<
MI,GKQX5&'1\GW/#MM)<[QOCG>]K8)425?+\H(_['?R/<?WIS</A'Z"!P>GXR
MJ0Y3?Q;JGDC!N><?T:+CM?0_OV#X\_ZGT-R:*+ZZ;=/E0'#GAQ&!^J'OV=>T
MG-[A*.&CD5:SMJJ62#-_27.?AGZ0GHY?%*;]^N,C5DW 8/%"4^,>;5;NR!O+
M%"BPYD7-B]Y]=OY'=_?_W))VQ:DD112AH\1Z86-UE+6FA!_-04?YD,3#2*G
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MSISH5V%DNQ4(?JUQRPG'@]3Z7!7'(9IOSC5#FK:I!T3I-6SA1KY3)&M;935
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M?.(3\ @;D <C61+Z"Z?5F%BFL *K6Y66/@DHM!1V[XUC+.))6\(<\P^!+TO
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MAU7V(B&E&'.;R+5 KK:8[O[E2F)Q8XQ*G$8Z8O/RT9\\7$J2MN@.@)OJXKJ
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MY3/IR6JRA^SII+&LD &V6I]F".>Y[^ZL%/4+].+J#B22#2@UT_B$>T&TB.5
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MWNPT'YQ4(2E5T\,RD1G@R$5+6+:$/X5]0D]E)N3(=X*]'P+!S#&8,H85S_<
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M:E_]%T;)'>--OA>'6- -'5?V*_0P[BAH9"[@M\UN9CCZC]?2TW0L!L]PI)N
M5$7EG%1&!>5H)IKMEOJR42='W/[7B/W@DZ'73<?]>#/GT\VO?"E&:P.YKQCJ
M!,)J-X77]+XQ?9OQQKB=_D1O_%E$=0VIL!M_HF:D*A]4CPM4%";MH,A#ZN0
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M,(94+U%1C$873L<Z-XZC-U07K8JR.=8"!>W#I)@,HDYMRM=Y'D_^&\A3B'+
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M<YQJDQ\EC!K^)MI _A/9VNBZR/@6M!C-LE>F0.II#IYID)<= W,L2YVXG[.
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M&ZFIV_[E=NO_*#WU_^'G-C?\OU!+ P04    " #L@7%:@&9@A;GA @!S6 ,
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M#C1T,IZ#Q>(&'B>F![K@!N+:C7\ %!?[\/1B[GIX($=QL A09:+^>#4:?KY
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M[UF')4_7I,DBS?Q[?JXWV+37OJ#&M^G,:U[XLB[$0>G$?,NJ9-Y.O,]\JP8
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M 64(_!@])YLEI7:F0X?AU9>*3K87^",U :NP)O#T1=VY#W4? \<! %@,S&D
MS@)B7;\U0$'Z?W/3L&@B+X5F,JH\O01DV\XJG%#2_*MN"GQQ<+H:\]*2NKMO
MXC3@&?)HU.]WL\UFBIL7YV4/>']M%.O_>0Y7M$MQIV=P5ZO^00J29@EK,>U'
M\$[*NUI%<O8TZ:BT8_"\=/;+I,)051SZ+-IN(+D^ 4I\DTL3)%)\*@S#9@GI
MJ(8JLX0>%/)+MR-GP;"H72K?-&M6<!&T!\5Y/.@HN!![GRTRP Q1#X0BI0VR
M%&+5/Z(<548*MNH6MFS?37I&PVPFM+:$WM,@%*X_SU[$-40>:G-(3C+7Y8&$
M2E%XXV?7E#+)*UH3Z^$T@CM8\P_5#;+UZ&;F8MS995B3]Z]AO-K6">=[P_3,
MJ0_KYIYA11 '2P[^8XQEJ@9"66GFB2\,Z=?;Z]?'3AK0E]S4D__:=K*&[0Z]
M/R_\5%DP;DX8!R=*E!Z,C:H*7B@QB56%@VF[9[57*M$<U2M$1 +.A@SY;#@W
M\UX_R>E)J]YK$][5>FO.4$2^*;SJ'[_NR_939#T<?')3V_FI5J<C+EF/]%;;
M;=O;PYG./(6U[>^.*;4M\SC6YV3[<'V,W/E@Q66/TB&E<NC1BIK*9Y4UZ?X9
MI:5IP9>'M?_.#3=T/$UL)U<K#S$'*9 _C8@W%5V>.)_L G,FXG! ZX9"TV)9
M>J@_;GEF^/G(8D:HJJC:;OY8XB8_B#@1$/IPI;.5.500L>BD[QC;_-,^SL^Y
MRS>S[9);<N+$O,5Q%.B8&C"G3RJ4*@Z3\./Q7_)\^K@O%'H)#15G9 F-,-T0
MV+9A1CK4A.FJ;E>I=K8=A#H:RC;YI&Q[& .:8)TN?>_-F67A,=:]D0S+Q'MC
M<1<"7XG9BY"D@_6J<>0HQ)&(&B93AK40$,II-'>XR%V";H;>WA+CDZ=O$_1G
MA!0B+$'=J@?G+S#9H;K9YP>-@[[8EUM1V\9+\A6S4NE7:?S? ")36.,6GF0V
M\2"O5Z9T5FA6T@5/7M9T6@D/KFW-(KKC]%Y+<1%)*Z/$<QY3R1N1"NF:<I+'
MN=6/HL_%)407AO6$Y1O7UG-Y>0>@Z4NO7AAB25W__B;;-U@9C)L?H@9PYG89
METJN7IA.NQ*'8;ZC QC)2Q-Z->"9V^F36Y0EIXDY%Z-;)9Z48[?<^HP_8]L0
MK_+/;W(MI^H.V)$"'6\J#[D4U+N0-OAYK0I#O?'Q6K >"L!=P'RK4 ,6H#@'
MVP9QY)/* $8LS.*S!WD*0VA$O@TJ;?F&=!R$SF?>IYJSFW@FS$Z_N)0S]09B
MHHY_^0O]\F(G@GZ$\P73R.E(_XGAI9$>?MW;P<2'G)%" 04*]&^C#(HP75<9
M\3J[@H(3@=!)82NF<T="U$4J992)$BDK UL"7T_F^*,[*Q)$J:_QOJ?5P#08
M((&L$*GF'O^R(PX:)_DE>^)+ H7-I>_>GWP_F&BA)& ?0.@H41@L)0B:?OQ#
MBWE7U$#*(=5=[C*ZO:SE-V8G3@M$(H#LHKK<C8L*_+<;]-4$Y!A7#[J>),OC
M(!X?V0=[Z@<V'_E,C%(&ED5D1)( #<6Z="Q&#HJE:N B;Q%/7,0#<.!A$RM'
M^(2K%!/4":9(?9K82<,_J4KJ]T1+"5>&YT*X5Y+KSA<ER(BZ#!#BI6&6E B1
MF3UJ=RXHL@3A_CV&S:WH*NZ?VE:V<:3)CUE"BQ%UA?S7,)_%86<QNAEI%JLH
MDIEFG'?H(FRQ*W-^S0#)#-9JG+6Y5F_[Q+^.%&E:)%$#B]Z-N1P?.W-SSUQI
MO^?]H:B-U.]?D!NX_16J!S^$]8664N4^%M^ %,YQD_@'G!II!DU9XFRB*2/Z
MX3BKTJ?%<X6XNB--J\&3TFSFX\=NZ,APON+4?^-\74^87^;7\-F8G-RXE*D>
ML8HUN[_@(EGOQ].3+/Y.; &+OX>Y,()B2#8/'UX+$;+(1"1[7-+:.GF195@U
M&$/(P+/)[O-H+072RHK1>RC_$IR0\,>7O9GEJZHV^WTL>]7P-48>ZC7@:$><
MW(]%L<2/>;KU>'.:)U/=)]G@@,E5Y525^0T=['+*FL?XL;SN/DJ$JF^>#*=8
MLD(2O8Y7=OK+W!0+?MU=B08BEN<VWXXMH7IWN<4EWON^:=RE*#5EBF TA*3.
MKH!HUT@;8+U&*Q-XYG)L.]@TO !N39D"%]/=FG(/2$?VPX04DF>QW[C?_!?%
M)R]J_B?VWBRNJ>O_]XYU $2,S )"5!!4Q+3*H(A)+0I:BG$$ 2&UB$QBJDP1
M0C:"S&*J5*A0B(B BB$R5PR)D "UB,Q3$#*U,D;VKABW)-D\.[_S/Z_S?\[K
MG/OGXKG(!5QD9ZW]'=Z?M;[KNSJ85>&^C06*T\FK&D?T_\3H?6NY#<4'W#[Z
M,*^AX!5O-$-LRD!]D"S<VQ&'Z,"!X()W0,OQ10$E-I=RYN6=*$>\#I7DD=L_
M);#:#1$J;<Q];CP4WDLL>BUHVNLWH_C<-,Q+Y1JK\WE1(MAAOI\6A [N1B1@
MNHRYL(R![2[5_^(% AIN'VAOHJ^!VR%9ZT>>\">H0%XJZ]YTJ#J\T#=+3N_>
MUM0ZL>69[?.ZNQ-9X'!-&<.(V@_<). :T:\3 JW'"%L1U.HWX+5RB.)"#163
M<^IH]NI[7,M.FW@ RPO'C=NW-?[L#>$5:="1%[>C7#KH1K#GU<<!T[AUV5Y
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MDF9C5$QT_)OI ^;+&/E935L)]:^J)!E3OA'9 =NWFN)6<+_VG_ON))L/$17
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MFZ"5/@-TDX!)&F7$6Z-!A%.=.O2ML\/.K9(:3N-MOWLC F8C3F4"B#]GHM/
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M1O/,_WRR3[ZPFV S#E->"<_X-E_*<VZ)9,&5GB6C*Y7I#WF_4F#;!9413S&
M(G,.4?Q\&5/'Z"3FX#9P=T:*:BBM!_$RK5?86R(+WL4>7?IKHI5<"F6@6M4,
MKA"1X&)P*]]K@+;_@DD6$"S)6<;H\*MA[+%AI\35@TY$HU$';E.(I$7W8_\
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MGP/H=-X/?1KN\CG.=\<O_F;OOEJO1]^"NA8'<8#(Z;S@A6S>\RE!L8?R-%R
MCGQ _01Q03I=\\N?FJ$XE,G%P63!1Y3NL-F24&'N@UFK-5!(29HD/5MWW]L,
M2<ZW^5D;;J/VDE %HD&[HI// _U(\+Z]DO>%7""=1=\*M![DVAZ*O[+!/X!:
M*2V8;V7-!NT>^*#5E?OM9'A<7DWRNZH.W4FGXM?GMF'4"/L-'MXU(C_VA-Y)
M!G] T59&27_/R>E\KG+@P!2P?B;+L?DIFOY['J/TK4.P$LW$*2 OI^[W&5+
M; ;9:C+-Y&0<_>U Y\9PTT4%#T,42W^*I8Q5*;;!L7':X%0'3M-^R@(<Z'!9
MYSEV6?7-$_CC^9$KU90FR_0^BNI A:"U_^S'D)N_RA(P]+M JPL0HH=76&H
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M88<L;7_D)%'\.^]YZ#P >:',JZ31QT0-:YHD6-AVY!4 VVME/UL$UBYCVEY
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M: D7"@=.9/!U0IQ2J#Y]GWR*=\^O(C\@-S3-;X$"9"(YH-0.%]6)YB7H]\:
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M$$\VH#JGKJ-CPWD-JY\RA"@^JIF\\(. !#L_I_28G2N-6-*!<.T]*ZD4ST"
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MBKSYU9E^M-\F7+1Z>#RCW/>&4U_?W!]]?;=W:Y5AH]G,X\1W>87L%G5;"^*
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MM*R?R\Z5<(V9#NMW.)$'1C;U\/A'4_6B?SQ5GK$=1\[QM00-*3 Q@7,>H^T
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M/(?D:+YYR<SZC/=2F:WJE,:3T3>M#.8OU?KU:H$+X)_OO*J@KNP'/RH<S(^
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MI>O.;0>W-:QO!"?S!X"S B-:IS#<M$<0$;,;6>_3 :3CAAOBF0136CI>ZP"
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M/@^2Y1&I;[07(*IBDX0\E'LD7XB85=%.]7FXWO=/*O524-/X3OW:CT!!LVU
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M]X=@NC/L3I]/S;^GC<_?+_#^1!NAN\?;Y<' QWR/O!"148H%M(:;PX=+7\)
M"%NADEX7[/F <GL6,+*R>O8X#AQ@5QDP72']*]LU.O3747_$O(]?P+3L1>WU
M$]!<PM->&@W2VK@ 9Z1JP.U=I^9HZ7_1%8#_$QO9BK*-$<LY*=A-KC)H/:M=
MP P)P Y!;5!S#)^,BT DJ*M_!<\)5*%S236:181F-8"?<LL=IG<:_&=R ]V#
MAFUI/;\\>CWQR^N)C58;S,Z<.>EEM]CKHZ7&!VR67][ZOTH=1&0VP_(J[J5
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M974?MRG4JZ^46SO@$0!VM!=:]?/V@IU*GV0G3:;.*;IP,QRJQ)L\EWL]?IT
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MS\CF#(M),GB3[@$7R%""1-,\&]V"= W4 BK12KC&MU;L02P'OIE46X0_?;"
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MN.<Q#6B9WP7?*H_.63=:\.UD:\[<>;)_V43$5(]7HI.!UQ[=7XC?"%;1$@/
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M:PTHFE#M3MT5@KUV#WP%M).7JE8[V;&6C%)"<O\';>\>UL2UQ@O'*J(@!D1
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M&"V8W'G09N""EUMJ\2C5<W^+O =>;4#:8N'Y8&RO= ?!G$C';$'Q@$G86]Z
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M_:2W?D(8<YLHSP^.OK0KLG=M0VY8^*6P5XX_1O1-.\?\N?[Q_I\I))"!$_
MZ]UCI<N?OC'_L>1_A9*=SJ0R'8;R][73(=LL?V7=45)U,O6%:5><_UQ"3B=6
M&H.8MHO4!E*("U1F)KBO&>),9S8FOP2[4.DLZD&BQQ-%8*217Z"\+3S5[$^$
MD,FF*<:@;$<OR>5$W"+7* .+T7\W;[F6/O0^$=H1$*^J8((D(VOVJ+NG\(S3
M-?LW#TPZL8"I6"/Z2F!/\G&_/-@7;,Z-WM1W")=+..M^%JG5Y].HQ7V'H4BT
M96^"JV9]6-F/JZ9C>3NG'C]RO](0<;VI.^M2F';W[1^&+-U#(J!SAA\C=8:2
M ,6*_:#&&-4F6Z"'DOJ@U1BOI$^Q%!PPEAX:Q&J*H#G!63BWA5CN%+7I7HG6
M4Y<7JU:P?!8^X6QKNOI6O+F@JG1YSKKJ_=^P.LHG'']YRAI,MM2!%HQ?+.>N
MH'NA!)I+7Z\@;6LI>TJ;@1"^>[J:#X2.FPFFFF6/$GZ%"A;$ZYY$QN]QW:&O
M<$DQ%0+D6,8M,?I0QQ15I$P*G=/W=C][N?<%ZU=:9AULE\C8*8;=="BH,[0V
M5Q;[^!%1910#.FJK_#/6]C+;K6:$2%-9S%A-"1PBBMK52=)UF/4.YY97K1*C
MNM/'D;:']^KCK;+Y>M&'&4Q+-MZ?!['12M,6:LVST:9]#*HBRU#(<VK>8>+-
MA**(4+5A)BC!6&H[8@T43+RXCT;8QQ)2M8:HEF9< >VT+2S=Q/^UG[-"L;;[
MYD2P;L&MD[DUI=G\AL:[3^R>U+M\4GT?UTYO5B0;A474*I!C1%R@3>"OBI7\
MP@K.] &Y42H(B"J">R;JI8MJ3C;ON);ZUG,XO[S]PIY+U3]B>SK9]<2M$4MC
M7]SEIL93[Y>#*8;M6S:U</KT*+Y#4&A8#*V^,ATFAI<6<,SR@.[QGZCG!OL:
MVAJH:9:X:#KXOMU[8"7V2!@+E";F@E&?M?WD-SXG4RKF@:3*_7S<JJ68M$&/
M0&UK!J.>U/,6B018]NEZWL+]SUG79? J<H?M)Z61?@>>(!R4:=_%JGAE]I:U
MMC*NTS.(@W\O4TO=1#G8UU*CH[1P*!2TH?Q"'SM0<YV,)AHO&EE.:>5AFVMS
MB"83'Z1?DVEX[@\K@6QK#[0L"1WA1%P_@6SR[!^_866#\VUP!!!B[ &E,5")
MFS%9:8.P&%G(L:N%6"#G%\#&HC2YQS''EFS,7@(%Y*(#;^C:#L8U-33<>]*\
M!_/RCDKH/1)P^<*_J-1EI>4MX"!^ T7:!'8C+"?*B0S%/50",>RSQ=3)L<,?
MME$^..O4F^![%=$WONOF!* )X5L[W_3^>N^'^.*^WSMFK/W7EN"35[Y.(O^]
MC^[?_<IT6F]'6>KO  E[7$!<U").2N,/.^FB+0HFZ+$(N^%56ERK*@]*U:M&
M#+,5H2\OO&TW+$[W\4W@;S^EWH\C9<UL$UO\E8B&0GM]EM[/:Z/<*M[_4BR;
MCI\/9=KN]E-SCIID94/A!*\07DQ&@9(:F@2S-4IW^,$'Y*;;S6"=]0-H#SB+
MM\#^HXGN_6145BUX_+I]R E$8TRWTAQM$U\\#C_Z4IC5XJ?R%%A2[_V%.5A$
M(W3!@,7[8Z<X]DG!;.Q) +PVD3S>V%M%JYKO>@.H#:-QG^M751$5CNV=[?\0
MN+/?Q!>_*3$4W?E-\4%3]_!%OG3?N>ZH@A+EP* %5N+V90I7 ^0(-N3@=5BA
M'..[0M$@/1O7MH5R&: 8XRT:E0[";,*^K-EK?1'E31R18[4I3@+-A5O*ZE&/
M=R^N3S%<G;9AH^:W3T"+=1E),Y13FZG'2GFH6N* M$5P_1-I@4(TA@$AYG<:
M$N*QEBQ0>IV,GPZ5BQ:>OPY\K3--P@G'8\$4M^L-KRAN55W.?"D^ALVK>!^7
ME9!)[!)H8W5:++SB3J^GGC_LU=JOQ+?GT:K R7;N\*1R'M5QW>HDFQ#@*T9@
MW^[FHT2C0*^(FF*(B^,?5--0\=0MRJ?]?W#V[E%-75O;>!0U(F+D&@4A]8H6
M$2V75 B)UEJD%*-2I4(AM:@04LQI%4EEDZW<PD7(:3W*$8]$!4$%C J8BC$!
M<J&M1R-&0$(AMU;E)GL?-:R2G<VW.>?]_?>>\1O?]T?&8+#&OLTUUYS/L_>:
MST3R9II0C%V('0["<O\"F]VW7DOJ<MQ>IU].PH??ZIXK;9'=$-447#3%&I/8
M0X=9BW O,$(KI2UDS*V#G$'R 9-21',??_V[4@9*3,$NB2 QB-*!1^1-<?G+
M4;ZH\=BX,/#>P9_BMAX^?G002@*SD #K>'U1HW SY@W8Z#E]QPG,?SUR2*GA
MB)B+0 DE'TM()S6CT857T*+R1@T1Y=WZQ^-Y3<,QO.M)9^.]?AWWPCR&AVA/
M<6_A<Z4WZYN@6!6K^67>>N82N*.+Y2Z/M+!."TF@WN)'PQ>LMNI<0;/E=_]Y
M%TRB/(67K*!%.A<836NDU\"+3KME]=UZU".Y-QA:2:VP/)7[\KY/.]1 @''L
MJ*,MC)-GH(\?: #UMDS0A_1UL)K9':QBI=<XBRL^[9TR/]^6B#[JRWOK&[7S
M8:P^BY*O8( .>W30V3]Z[#%P!/XX8$]^S!-&+%-2-^+SMPC_\S=/<C'/F2U?
MPI^5Y&G28>5)UIW']Q%II[*%",/]5=.D^%[%X@QE2]<I?"FT'X4+L9CKX$(2
M&@^D<0HYLN;\E?3JM2W*OB--C5G&A8*<+4K9K;RG'NO/1*]6#[Z0VF<).YGO
MM2(7*Q[8/?%?(@8K3\I76F@B?%YS#[%"*/E59Z7Y#++E95\MRLF# O@YIO[+
MR$0!Q"9\D!U0#-%KKE:7-[&*W[UXUG@S*>&9:Y>)E:\T-2ME[[H*8!Y_WBB\
MB'50[(X_H3DS785:EC?N-ICLPN^W=K3)C:T)ZB2ITQ (V(/0-?P!BKJ)H%'4
M8<,W&T&9F5W 2$95ME10AF9,O8E&(,5L)$5FX2]BU@S'$ $\R]$LC[$OXZ9$
M 9Z9W3^IY;0NJK3S09DM =28RF/-G#+%$J#O3*2+F,N2L<][UF,!]O>@#$>#
M@CHR4SP2D:Y8>F$+P=AX2*KM%U!>)Q,%3^#O ;::N4'?PEXLR-E.PDO>2@HY
M+F\I2V)0EX\ WQ1$[7H* K>#S."*4 D9Y,2A!9)%<GI.]G60W?Z!X)QNIR@1
MGION<^XR?"U=X<W37^9FRV39Q\,7LX^&BBUMDV/!=G?0T#FT%J&73)-2E?VI
M:N$"M$L=J"RK#D.$#^Q,:'4O(X@P1.DDDDO,,)%X&*QK@D^L,2A9'3C ?YNC
M],GHK12NNI<_&9_!ICWDE _Y$3XBPY],DWP9-&)%XTA"!]M#J%4L!,WV)&RC
MHQ%?+C!:7VIG>CGF=#-G ?X^QU\9VWDFG0^V&:GOH'D(NLP433K$;0(_VBS)
M1_K4+*_7ZQ6^KX1NZ+F&^D'LBZ?CH8,I-A:%R!TPERWF4)2F?_C0.QP>MEV.
M:GP]/J"<!Z=/E"D"P%5[7 H@PCP)8K(.1Z5%(]6R2U@P,E&('4(NJ!6;\RV*
MJXW!%7**-(/F]E8"HH7>_<D\V0E6V>OY_VIGY68J%F$K[_3B-,*:YC15&=L-
M6XT,-9B,A8D.V2DL9)X,>=CI,UY]MGY4Z ER;VBN7IW,9] ;GZ<G^E4T7!9\
METN/?;;^;>;[AM>]Z<=&0T650&G_0/A(V;+:6"#%F00)F</\D"-PVI6;U%ZI
MI.(>@&))-N:U[C_46A7'[DQ@ACX)NRZG7XL)._LW:4Y-U-F'#[F\E9^F#*T@
MDKF?0Q& ](W[V;="N: DR_X^ST?<*04K7JHF#"')0(]LL\+C-)1O.X)ZW^:C
ML/6SA%[FDAYYZ- :I+<5.92EFZ^Z,2!XV,&Z@U]''[)E/6&/O-F+B>"B57U2
M:9)4T) O:&#M"Z5]HW HQ?<>FM!.R6<M8:5Q3BIOUX\'U$"I(!?)40N75A'G
M:*&H>5)707Y'(&)73Y-:J=K809>$XL17B;WE5F5QE21/OHUUJM4U<4#-:386
M\;-T%%#4[C1E)]#-M\@;W..5(A#N))MT('&C8"ONWX$&X&ZY%.+_D-,:*:UX
M%<)(V62G8*MV@X_B3BQIE2%/,U9NSTU9^V[-'7IQ\Z+'R@O! QQ\@=2>-;-?
MT9<R-HKDF'5C?Z"Q&N4\ I&*2<)>HQ_S?<'?L4W@ %+?A0*)FAF$##4JO&$Q
MC.RB]/?AGM&=@^$3'4T;+J-K!M1P:^]5\P^6BT%9TMD_G_/> QK,+/!^)>9)
MM9UR7%>FT09JS/(?\%^-9'P^D5+*"(<W(='%N">HU$3(RF&NE"88L+)+66E2
M\;A%+%*Z,0*M%^!"ZA 9<0S)>&8^93^71H$.9:(AGR)B-64)05L6'XN,VO"0
M_1,)?\S[?_JB?(GR[V*_=6G8!0+]V5G3)+!J G] M]&E_VW@?UI9$&M%(I..
M-9LD)8J58+N%Y0_.#6B9SD1^A LYBS>$3I/RE;YA$[.Q,").Z!8!NH9%"9TH
M97F]I8@2)9W*HD1^^3%)L;\;>R&HZ5*$$$LM[")O+[SP^>A1065<3\L%/ZFO
MT*!LSE;IB)B#7,,2K+G?Z37'AP*0M#S&M@:NQ$41)*@TBT]"F:A/U!HV21!L
MD6J-"P'U"[ )$6OP,(Z;8)<@H9- *?)<<U!VRAFM8D[99[?N578QW>)X%HF7
M4#4CO*_EE'!D:850+!K0";O"AR8,/-LY H@1QPE2[.:_^4> $C3:S,Z'#[/[
M4SNJUXK-]>I<LI55]!78E&V1+($VHJR38:/28I:+<,6H]]3.DF]O"B*CGW 2
MNC$VO1[:340ZF'A*X3J@OY).6W:,Y8(_EK2\U$I%,WM,TH.+?"H[ XT>&+M'
MOM_D&FC>^4/.%>A]T$W6B%U?P8L8RZWW67G"V66:\)0 @J^SU>$Q.=9FD]$#
M['N9@CS2G3I)5RPE$.Q.5AJ[6.@%1);[#ZA68_YRA#;N:Z7U5W1MZ5,>9AN8
M+[5*-R*LQNY#M__CK]!:9,,/2+5=R_)8E4GMJ Y 126ATMGI*2M[<%\!>VOO
M.V/)\6H/?4OFGA?ZIV'*@4G;%]VA8M+(0RM_*:B"2W _<-W"=Q(DF/O:E6*E
M)[Z*=YSC)-]MYL^%OM;[FA-4G"+_]>#\58'27%G&2+V2[A^.>#>;HR*[F'[/
MM#+^=<'Q>8BLE'5;L1^<)1QR!I0ONL]M%.A-RM*W%UUL<G1RO!#9UJE<HCR<
MBN:WX\M0D9:U $RH.-[82E35Z3.AS0V)!0/FW#V<$O^5?8Q96>;5P,L2+#(T
M518.9:9JON4F5O%PO3T*[]P(N:"<=LZ2:"M%M.DWC :X]@1!P%Y$W$GKM[9/
MDYHG.QT)^QTWA.LA+R"=T5U R"=;O_^&,<LL=AJ"5E1N>WJ,OW@(8J,394'R
MCZLFQ(KU@DI-F[!)*JAU2B!(;1[!MD46\5@ETM>Y#W97K.S'^XVN\KUHM&F:
MI):0L%4$3ILH@I'3K\)3W!7Z#5B"A8 XE"0]%I#9J+*,QF1%2A?'U ><;#H0
MJZ0%B [T'(N_MEO/,M72FBLN(@/F@ KA<E ]I1VUI'701$I:ZV:F&[3)48M_
MB$4!&-%98B_ "PEF,O..]UAPOUTUR5F ^XQ2][597PU]".RFB;P?AKA,#U0A
M@VO3;?YST1H@%.6S#I3GF'LOV%TH\Z'D)[!YN:,<HUJ,A0;%;0N_L*WN=CVV
M"_!1\A;DL=B:Y!>P_:DB4)#!%@DWWKN/<(I:*8O %?M>4%;[ZEO5C>=&P%+3
M#+N2N49_B$U8A2Z068+;@YQL1WYR7">H(O3A;4<1P]F^;+ ?BW%(WDE+N(1]
MW &Y0_@^DJ7LFC@I7'K/<9G!0B;, >50*KGD,I]6#G?0/.5[&X:'EB#59PG(
M7*SPC%C=!$B.(!")&A-1G9H]$*NJ7I^O:N,7S@#/<MP7Y)ASV9_*GKWWX %2
M46\/Q'42OZRX> V=>N+F95[.C0$@MLA*FH)>MUR(\]8P(E.O)/Y2_^C: "?#
M4/GK-&F6XD-B66UEAF,LL-F^/WW(QW$A*_BD<EG23*/!%EK_$55G2N0393K+
M&7,&%Z^GO]P.\AMPO6(-T),[=8NA+4C7R; RN#0E",20Q_K,3>'?7^X14@5I
MEFKI]>$I3CD6]RZM8YK4/YH(XE&>K0IMK/[P"19GHAE"U$:*',+)DO;*JNP2
M:)V5OP#S ME(H%K,JE":-S\+A=U!I%KA"7:;'FR+09Z [$NC_CY]!]'/)X<V
MHOLN-@Y'I!4ITL$A^R+A$^5"!AVQVW()O/7-73T!XM@%4\H"W4F&BQG.3Y3E
MLS(NL$75I+YCXW ':T[6A.'^-F"J]GZ&>P__97B?_ZR>/[J5AY4+"=]/Z"S[
M4!YHH93(JE<I4&I%EHE2B['M:4(=DP+N,IUYBK7H"8$AF H"S"^:KG/A>8HP
M09DYNU#X'K9#/Q;&F2UPZ>(LPR*1-WO!2A/%%]Q0)2+J*7H!$<A=MJ"N_:A,
M]2IAIP?V$?)9XC2I!)K1"OV'\+%D,1:(4C39)X*[E/.VF5@&NI;5[%=Q2BK\
MIZ0E5U<N7$D<<:[)4K;Y/<(DR2O-49.GA6MV&(+S&6PKQ9V;,N>)/+H!"T>J
M\YM&E>[CC(#Z=,/51_5_PXX2%T@#,FMEEU^JA5,,IP=3."""8PBV<1TU$/4R
MP:7NMJ)42V7G!6*J[%TL,B/M.K0.[$=92<"<:=*)E&3%<C;R8VS#H$N'9$X+
MQ9N+KT=EI8S=C6! NS%E,)W:BJ^&.X+6"U>J;AIX_J$@V/(@X".'E)%K/P M
M1J3:X/Z_8U\A+!'C "KN5$0B?1KE?.PO2-%]5/+94SP<<#ZOM$07O].1D@4Q
MPKF$06T-A\S9%[Y OTS<5U<%R#W^[SL4RD,3SH"L,KK]@8I/8[NO""0?@S*+
M7PB!_9%HJT3#+C[>EM#IMS/*R=+45<KTGM&YM(A+F$X$M,JTE%Q"LL5GNA1>
MR"](6OF&]Q"X1'E''O/^<%%]Z32)/]&O-!M%<MI-Z-->!L_L*_'$-B&3VN34
M;4^9O@1Z"=-U2@NK W*NO944&WVA:'M$NG')S)<=D!G"K1JKL5268]Q:;-.Y
MAYU#FWHRH=1O:PG_G32P_^@:=[*3A-V*V7IEFG$!M @Y7&A-IG48*4KN!9KO
MH/ QS1ERM7^(?2C22/SPE8#>116ZZQ5SH14.)6SZQ]#JIXK%/]0.)EUT(O!D
MBV3<$\KDI_KU:08CU;#[\CM EO/N=8/=#3J!3A8&8W&U4 R(MF_$/G)<F28=
M%!<HF]GC7&2"  /S6X/+F7,0O-P4%=#5NU;9O*%AFN2RS?PQQU4>8W:$6";5
M%-?T*EEY2_#I:J<=WS"<<^BJICA&U,UHZU>4^C#*@-Z6J!=N4K9_#^588I7%
M^X982%KGX+XXFFE2^P">V02:BZ[LP#U0HTKL"I36\$)D8C>@FP:DQ=7+4%VA
MI)WN_S[Z6GS &L>+9WHACX:N6QI<8[<WVQP!%L4I:Z:'I?!E9[MQ<9BN<&@E
MFG8R*VK1IAQS0^Q,URB/I]^TNDS,VP_.J'VR;I9_M^+!L['0J%CUB<_;E**W
MN7Q[0K1<CO<CMGMU7PA/8%\Y2OG,9<)_PG?33BG< %NC],W2B9FKP7Z+))\P
MPQ]=*N4"0;Z97BYTA^8Y+BKF8\O04,(7;UMGVFO4<A9"7'L4B+6FU%M,[Z%A
MIW<_3#7#LP5=ZL0-$G*QXG?'>:;K(\3%%*T2%YZHN$TK@>(NI>M'F"STX+=_
M!A)PE[FA)QA+1=G:H9BB>2+<@U9,D,<2^:?+!3^8DG=_=>#OKYS^J?QZFE3.
M\<'#!-$61U?7A#,6@K#5P47&%JJ:77A4P#>'W[/PO03QL=U0Y"'SQ:1/FOE4
MT/P9\KK>ZGKX5X(5?M7+B*?FRUWK>=G'BVRJCK8Y[D&7[-[R2).D0P+B9;2E
M]=.D@C.X>S!(4BZ##J$7TFPL6S2VTHA4<H4^>MCL.^BX?@/FP01Z[HQZ"7^3
MJ1?VV73!]@T#8_A!W+J%]G\K3_X_+>>0ES-?]@_",Q_V"<@\\V6_<>_,)___
M;>#S6;:)4OER,\LOO5G U^)49.(T%'GT^]H1J@^YM"6.KHY8/SDU3YHJ?96@
MYR8^:/WCM*QJP_TZ;EOOF>^04,-Q:?WSD7U\US^NRKNK*@L8 8V"?)5P?0\6
M;!Y,T#!=DP]!RRW)L=OU?/E6\U[4KS8"+DY0G7CTJ*6MHJCM7:'<._'GIZ\S
M/[G.G1/>URE(_9AS1A$.?0G&ZX2]K&;6V#ND=-*\(=^L*Z6YX"PL$51:^,7X
M0E1<WGH_BFK*%L.'HQ9$D=L-V47,%5C4K?S/T91*5*).C!\YX>B]S#43!&^,
MX]54=)]O'IB8 [HLG'P)LDMB4'4IES:^8RV&9CUYJ^L7:S@MQG&ZG?[*8^@W
MS M)$(>6&?O_]=*Z3U0W]*H-OVW/$(@L 5IE,1[:QYPWDETIF7.,]OR-658,
MA5P2M-GCR]3"]YXPO3(4Z]"?R2.')L?>(.1X4)^&ZO8 7R1G%^BO7^]2CQU0
M@#33?67I\4!>G:(\XRZ\.*U[%9IY9X#K_LO5+>_U/-E6][-M4V'K\>*7 I[M
M*T>5?*D4^A1-R"=8EOB4P@.-UN8$#M*ME!)&&%+9'N'] .7L?'8S+/#!)RK+
MOMM7@;!O%]ISUM';W/#;D %<L7Z>-V+=^ZRN>O,J11L7_N"MF$#<Y4C?V.4&
MW( S[CG.RG--XB7"#MIB92:K4-F<IJJQTN;@3_S]Y$BE2!YH]6631_Q7HG0U
M:YG@J#5;Y:!^AMX]:X;+X"6AXKF0<YFYOF0\-$F&['QP")WM2YE[E#I-DAG'
M[R.CYB[U6W /T9O2BH2K!?PD1\$:A%:,968A7>9)4:O1!>\AJ/J&,F*]:V=4
M9N8Q*?AOK+MT,8-P2%?NOS(2)TXI-O%8;J'&10)IPOUGH3P.>20$"D,]4U:0
M')_TL0ZR^B.)+-])C%<2UKJ(;3-/G+HU?([ _6_]CIKJ59E)GX H_I5'5W][
MA4!!3R>PL&]3D2F_-=9MW1M"?Y:OGO?7<Q[I4U_>;?"LRJW9I@=BV_? R4HK
M47B!/LO$*2,9VXM6ME^?(YP/9!96D="EC[D&; ZJZ5E^E[T 3,9W;Y#O-?\N
M*_NRUW+J6/F^?V[WOWUCU8&$7?<]A)%0BN,JS+^-ZLR38Q-7L*_!K"O@OKEO
MO OQ;8?=F.L$D3;NC SG(N$*;#T812@6J?HBI=WGI<H1;ZOO>2>=)Y!UT*L7
M'D0;-V+Q/7V:\.IU(,8:%8POOI_T(+:CK>^>(,1F=%S*TE&QY:#L1A*VA#6;
M&2(<X"R9)GT=%VFJEIC$OHGX$WQ1KV*)H-[*SVO" S*,GJ^9@1Q!I-HC;*+]
M(D<K# ';R.V21<E@6SMS;=LS#TM1,UW5<)[QW:RIJ$,(Q;3O@C4WWG+X(I)D
M#A.I<_F:<_Y1O8KW]D.;D5QI^3MXV7 *I5?HSQ6&]C 2YI7[/[@F:(Y#R,78
M-A./XC9H?-2X'["2>Z$0_O?^93<X^]F7*1W2 N\A/Y1@]..X%Q2>W\GQ>B?V
M(-989:$9H1>M0";43;#VK]MY5K^C75,KN+PZ0=<7Z*'&Q4F""_&HU\V:'.G6
MA;M&S@Q&^ZS]L\;V*1A$*RV]^:B.H.N9?%.?"*>"2*MT?#-2WUY%+Y"OLSQR
M2>F&-MDWX]TT*N[QF\!J88NAW>C*I"?!=;W89E/N"LOD)]T0U3S@ZF[_K)>Q
M8VB%_#8:)2V0>_S)G]GD ,JM32&V!Q+;#R ?H5KA3IHS@>-W4\HG+. J&JUA
MS4HCV Q;[;_PWHP\[//86,";44#I]H\"M\U1!W%56]KI4"7U.;85T!'%Q)Y>
MN6]M=,Z<B)_+8O]"&0HNE) 5[M!"Y+0_":Q&9&9=AW&68<2GNBG3)"FLGH_H
M5!/S!T;:>@:,HQ'_\/=%SIVO3>_.\&E]>R=E)/MV?] CQV_BHUFKFB,W6T(E
M_=&VI"=AM-(V1:$]')K=G<6O,.RLOX3]I2=4DJ]<]'8\VKI&U/3+C=C&5THO
M_C?89E>=.BI@7V52[]5G;R>HL8W[C;\TC(BS%C;!QP]AOP/'-&FN$QA 5+8B
MA1[SI:HHWA )X8QGVX.%/RL7'VO@%/J'2C0&?ADK/2C:9"N$#)5=K*70=R#&
MG!FH/1%F[&(O$DCB$$HGW&^WG7O:US%$3;7 Q2<(-^$UIAO)4^)23FO?>+)9
M6<QIJ6XUTQW5ET&8_0-A_XS6]YL;A+]R*,)5&4H/(I8$6(UY\,',>'55N4B=
M2;?@(C-'E+(..=)J_X27>%-T[3<HB"".H":V.U3I8GSEO_1^Q80V\21Y.*&,
M28%6H>/2TD;HZ(R53X_)LTP/89%_>#.:EL<(L01REF",YGL]P4$,LJ4A-_4S
MN4C-7-AZOR^LH0%V&1G^_G+'T<:,,YJO[XQ0,^DA9E9_O>U;A)HGWXWTM1N;
M9WI@S8,B4,VIIW*>B>:,O8\$B" OJ^OZ8='V"'XI([#F5?@):O'Z1:=W_OC-
M.Y[+_:-U'E^EVM=M2OB=K>(;SM@,B#@/RJD5W+=2.N!BCK=B!7'.3UCIQGZ[
MZ? /]+'[*&]WWWJ(@M2]M.A.MW(6 ;C=0!VGU*<K-LLO= IGMY1UTE.8H,,>
M"8+-$P6<?2BMA" RGZ'>$K-QKL!(CR.X226NY[CA"S!:97L;.X\1A5[0)M+&
M6^N >!_!YPY)RSFMVRL:4 JQMOZ<)BU$KSP?ILUF'9ZH4*Q$ SJG2?,P-CH[
M17".7\)\'^A0FKGRY(;,]7(GV,KVS$BTG;&XG*3T)='Z6;;]3W$O:7L3G8AV
ML^HA-\[B+LL?8',JPC?WU'>VHE]&C#'7BM2CB,VH^@%\+"@*]DCJL*Q]=[G6
M]=.HX_.SLN[Y%'#_HA"E(5)SD81?8_@"^A#Q*Y>*Y'R",%;-;944,*(R^9>Q
M:/20L22,XHEMZ3:+=NYXJ_,%1"+0IFQ\@))+Q\ZYYNR_CW)*-F3YVL^W#NY^
MK0S$UPA[C*V2D^N%ZP2Q*D-7)\49U-B8CB+<2]BK]),JN5(7MI6S&#K8PTA.
M0ROL:L6L)]!V)$EKG(7-0NI4JC@D6,WT[\7#OQ!0+6E%7Q,7:I*N9[J5LSJ:
MN?@'CY]-DXYP#+($B65"$^P\S'*"0A">238>:?>#5LUP]@FS3ETV<7HH&(D>
MCT2Z;!'$'6:^ /EU6/(3>2"B[Y(L:I4:4A-_NOW@'DA J3O0U5)1(R,0-D\L
M3-9D6_VV.+U]_= F<$C>ZLID!%%9=!$),;V6H"_WZM.ZLUCE=SD+Y5Y<-'MW
M]^NF8Z.!36NF29;/?%8)/Y#KCWS3DKOF:8Y+>4;L_J9C#R*&=E0%!AXLBU1Q
M[A"@26]ZZ#L8TC%-:NYJURW@MIV[:GZ4MEN/A2%GVB.\RG&I::*X3:>ES!^1
MW:WBB,:_:IO9R,M7"Y>#J^:'P]8?1[>!LINC3+I^=2L:?CWWNNY//4JVG7'4
M,C:C@;8+"#SFN PB$]&;$OLQX&3V>R I:XV#+8J?E"YZVV(0B+[1GIA424^Q
M/*9)/%W_Y#:47MSR((ES7_:,0&B!749*TUNI<W@#N@WW8JEU/L\%=]G4/L??
MX'2= ;9.C%^M34F!4L#>;'LD!]<H%J.*9D1/\#$GPE^%XW@@U^BK^ !:C3[H
M+2/BD(*%Z$H@+TMRI*9ZK@!+,/.I6%!? /+ZXER9ZEG.8.SV2HNX]"0K.53G
M G@?]S"B;Z8/^3UI*>=IZ;9$:5EK><C,BPBVYTC5$?$!\WCD'M3_,H_O-70/
MKG_ELZ_R<G]*QM'D+Q-?3646G9_S0__^@0[_<6$8!]<K6Z9)[1)_N.,KQ0;L
M$Y1=P-P +76<@>CF:=(RR <$UF(A*/DDMCW5D]8,%RH"FLYV:6+%)2DA>DEG
M,WO-5;XU.8:YA'TL#!Z7+!G^<3CQ4)7 G54_(\!10?._ZJC!#A$YX'N4W,$N
M.?$W&HGI1]!B;R!":.:7IW'JJS;O0BM_J:"K_3M T0JI:*665OYF)$&6*,I_
MS=ANXA<G9I=B46G6J" H_BK]Y+$8;/&4KH04B/VWQM?_/SVQ_R\)RJ3C^TK-
M-.DTC8+/$9#W@DJ4OO?96^D"+K7*^]S+K8BD#,NU9"8DH3L?U &.RG\94G\2
MIZ4SUZ%]Y5"\A>TVZI-20MC21<!2G7A9G-6T9\J@B]-O2/OKZA.9 OIX$)+"
M,9!-D\5"[VC8%+CCW6!T9]_D/MA+N%B08-41H6ZQ0<#71+!*-C VH61S=-G-
MEOLL+Y#$B5L[/-D]S%R%B$J/75\CZ\6"+(-.7^H;I34D<RM_(-_&>X*YF92T
MC.I-Z*&[9U$7RSX9PNNLIM'F*<*_A'8J0*MYPEF@ZTJ4J&*-^?N,B^K _4O@
M=T%\NW] 3R-CDX4RAWM">^ON5'*=F O#%LY"P^@2SD*EZ1)\1TK8Q$M [:B>
MB\K*;[8JBPU=IQGKS.<9VQ%?VRF$)K(2,SQ%T.;Z"B8%U&OP*)!LELP'9*NT
MX*UROJ AO@]W F^^1(S:J) XA/#3+)-@//1^_^4WRB+.+6DQMO2 /:J^1/$A
MS3,%<G;<D&?:8_</G\C.ER?4 Q]]+)HV-DU"LTW;"<);.$1#N[24$GPM.(#8
M5366VFJZ?KT4RT5G/U;M;>EMH5&&F7[(X]8:KF+QXZ?3)%.UKFYXFK2@,=X:
M]!L;>6C#'%=91SY^MI[AZG<1KR4"62BMY6T@,O1KC#PY9U%YMJG&'ETR+L]>
M'Z$^\=N0RR?P7&ZL97;5VKG\4B6R1Y+_5#@C$_)2S>\?3>QAQ*%4,V7L,BJU
M_1T<HJB->2Q_:"ZBL]3E(UTJG]87$BM%A >A7?FXKR#;6JER9GQ4O30Y02V9
M*^=+N<V KU%X]*V7;T^K 0.=$2^NOV7G,>D"J5K9*M;P3]&G8-$51'P*/LSI
MOV!EGKEF2,S8#2JL&MI2Q7*AGF!IVXMJO@]O8IX//W6@'O)&6@QSF^Z*N=<,
M0\;1?V5$W+P^M_=BYE7A=P(^/O_-S5ARB5A#,T2KAL+ZL#B[FU!OO.W?C+H0
ML6IVV$6R12H^%FQ8$UQP[A9T$.C1X*YIDK\B&#1;Z@D76&C UAMO<KX<\:<A
ME:7O@MV2C>DS7X,]J=Z)]:_(*G:_T9*=KTR?CS,%-1;=22SNNJ#!=@"P$:IE
MFB0Z1LE7O(>45Q9C20A/2_/ DLW!Q;"KM)56GA(B,7>)@E>#A]8!FAO$0!DT
M[[#(5_I.#Z[$K>7PDW=_QSZ?]9 SL\F)E>J(5*=VZ@6373*?TPH6.(N<V?F
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MIQOF<9RQ.3TP]S[LS!7.Z\77\ZJ\&PY9&WX^"+;>3,>]:7/#?/G&J;5.)LE
M=#N^#B47*[]J1<1%!-?/"7;"!X2ST.#2#2T7Z4EH".!U1O [V!5M85V$[:YI
M_"]_6__J[E1%0RUW<FAEWY$]ST<2FPJHV8]RKFU9\V<@[MQD=Q'4; %>=E]L
MI^.2(@C7IP2@"1TL%QZ^!ARRTZ$O$0+D2V8)/&RY:%\9Q++22"-TP\Y\$WR2
MLY 9PHO07C!1E@AJ.@U1,NU$"<T]*4X/L:]S_G3GB0\U)N(]W5MH?V,A,;I^
MO9738>P7FPXWH&SKR_%@X1ULW9E/*VV)1-PG6%L'[@RV7Q\2G!SQ1E\-F\7]
M4K-QG.)]]?+^@;@Z;J_$'0\&FE7ZK O#K0UQ29_'!<3KX81K5TXN^'?%VHPX
M].\6I:F1,],7;A'K72\'B8N8B:+_;63FH#NLF9$SRID1(F'-#.WY]=\'_9>1
M?U]MYL>([**UB#O@HJD)->PJT&OAYP9C)SLO'N^6+&Y4FOW0E!J"5A&V:^#I
MO+Z(L]):AA.]WM4UW)GH2%E3AKN-N^?&:N(<YU^L*>I.&9[(+D3%MMM@.4(D
M]Y/,==!'O7)><"'S?8%(Q?0$1_G(J,FHA<N98:BD6)YZ*:-Z+?+Z!_-,!Z)Y
M0AJP6U(N9^>:'=2]/0>_D*](8+?>^BDS9FSP(]I)Y3?L(I:[G(U6VO[L880A
M;[J8R_6,5 (WG>IE+@7;=C_! J0CO<SW@3BX5,GU+5;0P)'7*O9/LCX&?[7B
M_I6=U9[Z56U]U7ZIGY[]9D&&=SF] F([KLHW6>$BSJU%5\VZ?);,]>G,_B'^
MF,.B/#V5.X%YE.$+G"^#?%6UWQW@BI[IB*B07A:D)CO.'S.Z0]M;GC+8U[A3
M1^X:78])J8K2MHJ+<,/JZ@LP]_N-Y%%=N]@0;^H;7U<#SB2 :$LN^W-)1R)
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M1">+UDM3*]4_<F>M=CL);3.)^Y5QH-FB P','[@'[ <%'--D(?R5T:#OK-Z
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MQ4:%XT__Q1\:6>OTYJ@MB>^&?>V0PERVP;@39*%L,[]#N13R<ES$9X-%>FN
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M*H\S'A!B%=LV,/!)7ZKHZ[=2%V[;KCRYHNRJ3;O*3,>L\U+W_T8YP[#]\L$
MW>4YMJC_SBK UBK*H\"ZJN*MR4*;R=U1.\@W(9^>O/I;=A3^5&I@[L2\JIMV
MV2LWG?SFMY-31 #]DOE<I3/F00>T4A+O!TT#^33F81#,8\@%;H!)\' 2[LQ-
ME-,W@I-KZD1LM9;A]"J(FCO>*%W,W32I=N8*#\-VH_TMF>XIDE4#38Y?<@**
M/V8+:FY>)9>)#YN7\E05(<@4\:5LP9B):2D3)^L89UQ,)V!K\2:]^C3+3ARF
M,^9N+CM^8E^R26KW-C9>-E#&.>4S_F7/\5?C6J2J^8)SXPF7W0NN#SU:)=13
MQM/-JZ#/T>]G2 X2;_PQI4&@,.9'17M>UA4)/:%0L )YW%GA]Q 9*;IUF%T6
MR*]!PPIHFVK9QY(R]S15OQ[JO'SC1ZC?Q:WJ[*79):LO;CN&O4U_1Q?O2;'O
MHS#GHEEOU:GPUL?X_)IW=/%?&0BZ.$LD]ZO_#&3Q&;,S!02ELV1RQCFL?V>8
M/>6'6:!.@P?+9_O^%=)6H*Q.NF\/H5Q@_H@K:#&44VPQ9V! ]U"ML/4$LS5<
ML?H$7#;$ANJBY+#;ZPH'D)U<BP6@M[B5G;R5XAYHBS8KQ"FEPK]7S*@:C=XQ
M,4,:<$9AI730#G<1%DK9+$=8)L.)UY]WPU(B=C>OL?!Q!\8$ VR#=4LDEBHC
MK&.8F=@'0QG8![/<%NGRC,)62A.1J4&&CJR9(<WW4&,?N/MO7=02;6D@T)]"
MQB(8\YL8RT?']+O2C7.YX?M0:X&<55@FE458=0H=)_P)W.#'O8=&J>I7=01J
MK,2K";+L?AA<D 5Z+D,H!9*5R71JGQX=D/_6T$40[;.GM=*)H0IWRP,X0>#"
MS=&RSAZG%D5GJ_+AY!!'O3"?;I\<Q5N.5E](UQ<SM-_7<]!/?+:FX.YWF=8I
M./EAWG2W63X2#"\<FXK*#,RO]W_RX?1+>286S>D,*L66L#MR#$^KT*RM$DOY
M/QK0%B4C!UY&7SE*#'#"^=5YL!LC*8:Q#*(@+7+J GDR$FQ0EV!1Z3>@U8BT
MT$>RF$LWC:H5L"UO [>\8ZBBUE"<J!,68<YZ^P,R-_6I^_3W"1:RJA+]E-+X
M2\4B2V6 ,*_U92=<Z!96S%O$S0D%"94O1BD-S-P @F]@'Z.E$W.TK 5^X-83
M+"P#-<2",?/'CV\!181N=II["-OY[&M]3\ /D-71@*OD+H]$4S4@ZV9(!%O9
M9;G9!'NX,\_05R)3N>((G= 9EE$-6R993L^Y^,OP>X@U_RS-FJT;E*SD"I7T
MD-ZF)XZ[$,:9XY3YH_0/45Y+?;(;E7_<(_Q@[_C7+X%09\2< W4N-0;-T *-
M/L180)LM5BYC+*<[08L Y4;-^$MS^',H'<THAHZ9-P[CSUI%9V@QR,=3CS)F
M2$LW0-D^%:4&.X$=^.N8+C$W(((9WO"L,2O$^S ZK_U:\\-)>,+=3#T$)1-/
M8,SAV: TBNTD)6_$!WBC=MJI?!VBH/L25\R!CICIW)>R"@9(GM>FS>NG^4,'
MM;E]-(^J5_@:I)U?2/.ZE2)95H$_WH&R\@(2[PULH/\5"1RW01>H#?7""3)Z
MP)2##)30,KPF=N@80ZS8'K$K0I_2J7+77)"Q[I4JA,_Q@4<5RWL"6.>$#I/U
MCGL>W$<GI0+-Y_WBW?J);=3&(C79_61J>E8L\V/2].]$U!8"2M5S;'=O$V69
M.H&-Y.B)(9A+<<![=%3WT&,Z0?X,R=5?=#9S0$[ T"^'I'SKR?'I-^5H@^[O
MOVM>1TY-[RGP*H@>4+A.'QPIT*_U+['YU-*,S^=>,##RZ-;<]=0"NA\*%XAW
MHV3Y)I 3 5B&6"M=2)-&!C='8V'9@88P@;_0!EL'^">U+TX\P3;= >$ZFR)\
M%;3U?O^7?2-,6WOW#CRX#_/Y0Z44/5]EL!%(O*"D7FBU.8(;]FB&9(4SL.,$
MPB=)\S6+TLF#HR\[*8Y\!7,0UV@WGY]W7L<YYX.VR4>6=?$\N#UR3<- CD]Z
ML=U>L.X.:/NTGYK^)&87.&U]Y4ES ?OWJ?$KYB#>H' AS'[,<>:V:)N_U]BG
M23;R>O"5 ^((U"9&N.\99*VC%([XH -%;X4.N+J!RS%- H$V(K!S9&4O!PJ\
MP2WQ<,3GR\U^(]S',GP%FE9IH+@"6.G2^@OL>(I>A:@Q)^^M%TS7+$WB^:C-
M9ZT 1L)-'S> @[K@\BM9IA3+M<8764KI$MZ*0;!_VEVT"#HB*:![@E'8813_
M"'DIEYZ=(<W%*5P;%KB&4N(>WD-99P(TSDF\E5UO<][.Y;V8(=T?A;Q046?]
M 95D)2(ZC;M#6Q&^3)U_21(,0M%*W92"-0>85?@*)#%/3-9IED%NJ$JN(6-'
MD)]'?"6@0$N,U$4C[+CW[O<$P';<NAUHT\7Q$?OVHCAZ/$HQS6\!IV_C/?0U
MS,)CKWBKP#"J,AVQ7*=3-"KM#Y-VK+.L)7!"B+?N%+)TP/^U>-]<*!QI;M,S
MSYI<)3Y=J\H?E0[$+>MOXI"3IG\KJE?5<)\^=N)U5&Q$]YQ&XP^">ZA<7K$:
M=*$B4['E6TD0=[A3\AX(J>5:Z?I*SIHIV%X09A#-@38C')F%HY]2<!8G+Q[+
M9,B&ZZD*N@]JHX1=4YAZD=L8?6UCCP[Y[3(17OAE?[%IXG5I&D_<TS('X_<"
M%9(1RC;FX_06Q/7,NWS[ BP.82H8<WVK4+X!+L08B$8W[S+JIWN9?]QH#1U
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M*7"9_H"WJ:W[S8;&[)5/V?,G+_NL;NIN',LHN':O>5=[B31(2GP<5[S'TVF
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M]*"Z@UI,(5\:&NF>(>WR>\X6#KG^E=?3M=5!Z?27'4Z+KY:LC=]UO9C[64F
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M2(3VZ9PS3&20MXD+=[J)Y-1%+*"69Q(1,O;#/Y31/AK^4>3GS,8*7^1&M+H
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M4]._26^-1G?6?)-^4Q/[^>/V_RF;\;^998EZ1%D$_[I.VAPV.\7NR'PWQ;Y
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M'>O'15?B,S[,GB'%<5"^+BR''@1M *>18_K5Q9V56F%!G&._F*+_: -G34_
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MH1$W@CH!MM.;:2_H^571?#?BB_O,;5HOA%#,>GZHP+$*O))$/ AKLC GK-.
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M*5/5_9E^VIM4*=D/6:TDIF#SD*=*O#UB)5%@1=!+<M8$E0"XP-O$PAF8U="
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MJ</^5^HZ:%\:<)D,F*)=I2]R;QM+\FN05;)3A5$46SZY[@ELVDCL<SA+3-[
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M]^M"!CXS?(6^D.2!.B!N.B_$6<E-,> B>4M0,L1H?A&E+S)F!^RU,2',D5P
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M7PX<4('(2N&(D:!]4]\.@ IBAN#+SBK9Q0AY8)8*-E7OTAV,B4,#D2-FR)4
MKRV(+"D.OJ<1> \Y.%QM=EAYM3'<%6F*4W%LF-X!D>.HB]+<_L8W26_BDB]9
M9$_;.$/[6\.SB8:66[QGL41MM?ZIP)&9*4]Y)Y234\[L>5H$-AC%((W2^Z(Q
MW )AZ+8B$SNA&K%F.N"F_QL8>_<X?SW,V\]'[&]5YRHH\^B8.<3)<'H] OC
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M4+]@!=A8A^AALX973&KC_FCN H$7,U1IFA7+ &SD-_QUIZL(LYCAP[LF. N
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M:#+6)> M$*]MR#$5>?:'@:7P2E[YL/1@5GD9;]@KMY_')D?(>M^+K!SF/ZR
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M'T0R:XZL-!O-.Y!YK!(QKC$2<G01<MKZI*D/1B/D2JD-0Z49+WD2]#:FX84
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MT+#4FT&UUBK]<@K$VKS0%T;U;?)0U7"L9Q-FR=PA1EMC+^3J?:#]X-R]P9?
MB]6B1>LQ>BE_/;B,NU ZO.ZUL$"V 90KK6N?(ZM1+5%N$N>_@VWVZ)R.RR"$
MBBA*SB)>SIL.YE;A7N#(=3WOKW-'5C9?Z= Y-@J6\-9\#MC'<'$QMV(JDC;]
M;3'H,06"UT0@]EJBGJ$M1 [VRMQY\BZH7JZ>X.AG4WKAW$I' CXK6XY\_JA;
MYC&;W5]3 [@=3!_"J,J.Z<P2YE),U7.4FH60)/0M$:E^/F(-! )L679R]\CO
MZ?;NX\VSQ0T6J69H'\R>K54FZ#_+[X>FG\H=:_ZU._[?6VC>>KH0_N,'W>":
MV;-C%TK^=7;L_*__F=CW;RW7Z/+A&W_^\[7Z)7>OE7W],6W.]Q$A--NUE;1K
M\V_(Y\)?,0;G*L7.\N.BHJ&-VA".>4^*V%YP_ Q45+D>1*"B$F@^15"X\ZP:
MN?V$/$'GHAOFS%MEJ;"N13Z;/:\IA^W;:+DM.+;"W?"F)-7JR'NK>C8:I,V9
ME#KEMSRL-.YC%L+Z>W(G,M#,!':F'T"U>3U(ZQAZ#^C,%*):;O/G)7E"EBH)
MT72>#,6D>=![OC.TQ.WQ**QL\R,7XD.YN&$/P3F7WI9LGCW(#H$Q05$7YK'Y
M!B'.0>C2H8.\4W^B#TQ[_S'5Q<$_9Q1Q%OB)!CXC3U JS1^%7<CW+:765?Q!
MP2*2H==<F&+#34",:]'&?$"$YY)G,#MQ+MNA 801C'#"F<?9U?MNAD8?(+_!
MCY<Q-Y0<Q+470O:D9Q^*RBD_+^ R!MP5WR*L[G1=?RCZM!'3](_I3^6:=UN?
M5:X4FVZ\\+N$O^F4NB<+EMY'[%%-_G2[Y2\9'C#&4;L;YY*>Q*E'F, &G*.P
M[0/\3;$O&8ANWVK0%*>WA7])5.;-F1:'\=-X+=9%]I)AUTJ?;C]6?A-S/6%3
MBT+]P5WB^F,70MCI!_G,)*A14]0(T<"G[,C;O"B1XK'H/9XVM._OX/+B)> /
MUF($%H43RL=KI[O!,<UCZU)!Q^>34+%@N9'<++$^UKE"^H- 2HRA 9>(QSMP
M:&+=O=#JUU9-$^3HQW7B&;&PKGJS+V"9LG")0N $ZE%6,;D9]8GOA!LAI=PQ
MZO:8V,$G@_(.((@AO(K3N7-H_(;GG&+Y GD*-.!ERJ,8M+[2&D!X*<YP<P1S
M9K-1^HVF:Z #-RID2RW7,J2%F>SM>)11*$C0+"']Y> ?>CJ(EMN3F_6ZHN:
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M5$SO*KK#>-,GGBUK"DH-XKE/*[>"L-O\I^(E\>"*><U!E3[*#A/U6_V&F<O
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M10XANX0F+D@Q!_#$[6)7?WI_O7X?XEBNDKT/W/7P^9.@91_P3M4?DM- _"=
M1]BVP_;D[#&<S+OI+!<_]FJ:6:N2UW'&^PV14I=1-^G9R;C _82DA/0FG+_L
M(Y<17IA$42K8#;[3ZQ8G>R[H9JX#$ ><-G#MQF![YKHA'O2E#(>+9:O)(!E.
M:99,_9WR3F:@-B04?>GS[N75:[-E#>NE^>G&W.;, G(UENK .L?\D&")6N?<
M'Q&[6#<?!+\85$,A+2V]_-5CL"-YFBXJ[Y*[_0HNU7!8]Y&H1J"1 JL:"R^<
M+R\,.9DB'8L^E?F,?Y2OL'X A->1,&KAI($NHT&L$A4W<9ITXX'$&FJYV%:!
M*4RLI!?RYXLQL? =JU^AKH"5K#SF(N)^6TVB^+W6X.K#9"S!R5F/,SI3O3I@
MNK0AF]LY=C?1:6S:\\KMUV>@<[+-K_E=0XQ9WDM&S)[QE,0J@I=9/1!'7-I!
M+\E2%R("1H%?K5>'*>O-.?)(A@!E%'C:XGUBE#L/,':V_M23OMUN9\_>]2\F
M)V+&*R07R",8QXF37+F^F68VJ^'ZV8W.14QO+<(UL.8)4GE5RA^1.4U]DS"(
M"(F39#^$^C.QWQL)G7YO=DF$=MS/S 4[9-Z\D@-$]%AD9"81. C_2'XUM I_
MW79?9'N-%X\VY;1Z8*+"(3]\J,1R%>.4Q)I*,$%A4+GI0NUI2J38/$)U"Q(]
MWWMNE*D%@HPCU=FB3O[R9^^D]8EES:E7U2_YKS.XS.JTTZ=/@A&*W59;[E(B
M<,#5=-[25ON[_+BX0-[05W\[&:I7*RW>'9Q%LF"P%9M2T',J8HJMKI9R)<?!
M:C\  @_U-CP6S.6YQS;V(%X8U^7@0 =\@;\Z-H7](>'ZLE'N>!5B38D<!!V?
M-MH?,DGPA/;:2#0PUQG5*C7G9VANLKD\.B;,D7W($V/'FD/.X"F=L!,9=Y(N
M2M<L)!>)37P\&10\UJN5E[@+J98V<DKXOCP?%+]UF9B+B@J0&(%!:H<$T*8-
M'?('C'8&[26YO2?$'_7)\MF*,E3RI<B?P)%;8Y S?R.OAH7;*AG+>;":/Z?O
M%EY:7MR:6GLHD4GG+" _([I*;R ?]MQH D?0Q,F1$ZT,_83G]..HY@?M1.8X
M3#G@TTZ[2,U"\%@1E"\Y3W&C4747;"<+0-+ 5F+K9UK9-I#'J\?>!;%4%!-W
M"G$DMD90P @YJ8[4 E'[-+?$!W$^?7N8O^(G3\]2T@?5C,OS&UC V_9\.B?7
M.L]RG1G ?US&M*&4.<>TDC!.5.._RCS(4R58N;)(#XZB\ORAM42@@N/&@^-
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M4N:Z1-DR7/[[Z__2H=&NUL_0^J6F=' :$Q<R/\)MVQDYE;:$5'5;DHM)SX=
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M<:."(1R8)[9#5M]&F"!^?8E>XY#$PM^TQ[:R/7+WX^'GW-11YUI7H_9[Z O
M'H]0!1L*XI>><2T("?9X\L.=&R,W7LXEW#A@ W=B]DO%LYY;+==DKDF<>GG.
M.TX^C$<*^L>LBU9CLWEQ9M2HE$*CE1\27A=JY4D3^S#7#J/]*-L3/,>QGHX!
MSYJCN$NGND.\I#&20SW3=^R+EEY_S5QD9[')(SAL@DDQVHY/*'R5GX/QYA (
MHR\DUX)J8CV79NVP,L'[.GNKYQA[^;,0!_@$?8#1):C/X25@&7*E="!\5S??
M.P*7Q.)M3<6U(3%T):M?M!-<&ZB5YC)JF8X_?T#D"6JC9S/LVE,9BMBF7#]-
M#F=!@]%V3&?O)\V9-N9OXKOS GH4L=J.UXL83ATW$*\7#=[9+ML97X"D*H4!
M7AY:S7/ZHX]KET3PI,JZ@:3/;[7<M:M-/:2?ZHS*)B/7M^!-Z--&K_.DK039
M1.2.#BW G]ZP>H/XFU'W7R7!#LAN;<4W3^X#>N1/1'B1I*=U]5UW*;T_"O,Y
M=2B5Z?5BTN8G&GFK1W!<,U@2 SG(G)+Y"P =;S)HBV=HJ9?EQSP.'0+G;@%.
M5^RQRWKO&=I+!<::B*KFS="4T!PJ<!D'O0TN=_">+E.0,#_]]7HM*CDO3WQ<
MHO$ S &MJJ^B/.>=M,C-08(RDD2FRY8;""6KL$EA06N\>0,9 *+, 10BSQ<<
MTQ3R5X!?J\";CPF=ZHJXB&D+-F,3+!5_+KA^A BBVR.^?9-CH@MNNW+Q0/3^
M(UR$]8J7A42@5QCTP[RQ3B/QOO9+'!I@S[-<A1,T^<VV>:U>^&,]JT,N9+O@
MMB7^(D_@K&#/ T?TX@7#GHL(;6%ZFR!42R:A/NZ*:4^QA,=55?Q6@LF7CKBI
M"]^EI/C$[^LF(Z4C4TT7!U*"S@=NX8E,IV<3;8IDRX 6,Y[3V9+[B?+V._.H
M06O"X *^G9:Y'FSSJ7JQ^B%K$9C:]]RW=3_Z]Z:2PWW8N?32Z+^%>=;=77LD
MYO,69QH_7#RXU?";&$UL=<5#OP"G$PAX'U!3X.Q'.-RI!F\[.+/?\J<>D;GS
M_P8U:HNL=L/-3\5<@W% H"_/(>U0]U,O&NQCNIJ;2N3)L"U(ZX2//< #VS7G
M+H+PF"O6I3.T>]8.^<IUEEOR)'N6J40<5J)((S,IDKM?T+%9QCC,R[++;\T-
M_0D4&72#5U3E;E%M X^#7@V.O$V6ILS#DEI?W@A_^XU/J_4<3V(Z;+G<^FWE
M<E&7KE[:+ET>KA>Y 0G&RG56P0NL$#@7LH9P5;N]F"H*23$8%_O6HN;&9]0E
MW3$YJZP-$R\=^:0GCK!IO,U)KFBTO)Y\]?;G9\/0>]8%8!\;3RAN9>!I**>
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ML[@]-=# [?2(,72);@Z-58C:+<$8]]Q])N/@2%!VV97;KT==!0[RIAY5='2
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MJ1$%R*32=-(8&J=3UP)=<TRE:9M!X@;YV2Z6(/AT+.[E43QB-32>2XN@YK\
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MQ/)M5C]"JZRS5U$'GADJ\QCX]KM![8)LW2-)-CX??=628M32A\$SS=7$5NW
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M/^$L',"9F*,PS* D 4!.@]*%Y?&2-^9^J5+%* P6M&J] ",2]*/M'M6)ZK]
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M37QK?1_?ATX50-X8V_*-K9SP!GLU!"O+T%B,;S9JSY,OSN0A9G=\=WWG1GE
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M)42]W%9=_A,OV^VD,-E$N.\\8CF0<I1PE&SGGZIK2,I?L?;]'T&M9:$M!\_
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M?S[#R\-=5Z67NW9Z<,!AC-$N;B4V8R$\_).>ZOOO9$Z-HX%WK4<(S:"G-#O
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M(JKWM9\Q,'SC1[\UN'RX_@5IXX-;Z5M5;<PY<(=VAMQ3Z(&JF[B+X9;HJ-P
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M.OG8LF\?XCN)S4'R#VHO/%B*J41PRR%9$SAHWDYVDX%X708\EW#I)1<(/?:
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M0,QA0WH#+[J_9LA''PV8.Q[CWS:@=/<5W\%^_34%29.YH-0\'_X%6=16*-^
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MB9BK" J3"NNV=2 />;L%"Y0FCKU0<J"'4[.DZZN^8^PA4TSEMG1?_D8^['_
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MC\#7E6P(-OWC7V7D_FW#R__GZ]/__)WB)16,/]4^\PA%P#\QWO0MZ7IYV:M
M<1;'3K8)>QL]"[&RBU$&WRAEM37>^"GZS[6N[Q!4"<6!MV9//O(RY"MAMXI7
MPQ@;3#ENSA,LA!:!<</3J#:MDVSUS9/7OOJQASV3@'%>GFQ#Q<N0W9<'FR2V
MK--F=DWSOE:T,N0IC6V^R@E:_=6OVO7!XF_]ZTY=^G6]?_X+-[>1"[Q9TX\0
M8[NTYR2/N.=)VRT'4U!U-L>)32=L*#QL'&5X"B74)UP#F?.B1TQ7@T4GIFAN
MHXKY[+E B2*%<E?"Y@D0WP''E'OQ)(+9.7$Z/&I?Y<20X$#?>.4%B;%^E=5O
M#6DF3\O5=VH1QUKNTJIGNE&4A]!8]@H[]H)1AJT\B$@!'-R_$:$7YMP0GC(V
MG>*VB3,YCI 'GB68/^HNR)3Y41CC57 'O#*I6MZ+,V7^E<(L3VXT9A+?V?\-
M.X@B*0'95K*I:Z+8=B\(.WU=F+X3!"::65R]-(NWD%Q'>&"J7+EU8M_[2P\N
M8'5H6);<@=B";<O$]S1=G1\R+&=M*(7"NXG] OU/K!WHR8EUY6HT]MN(T-<?
M4#L@SN7\H!I3X?D)HP:)E3 '[9+-*(56*NHP4:LZ7VOG!Z5A$N7;6'4I\0%0
M)F+]*/U\LOPC8EU5,C<N&V(#E6NAC+&I/%<6?RBE-"+>P'5NNI^J,8X5FSG"
MHG"0=Y//H"^YM@-(\1@]I\WHE6@:7H9_>R7Y/A$!/*V;-PHR2Y;5B</[QQ0_
M7,=N,6:R%RI=1;*0$Y+Y20_![JC8SM0ME<(\,^_EU556+^HLE^"9BI8\=5Z!
MCD6$]K#7)6H9QX@MU"$,RU<5X_P=P#K=_&$BN8;\R6N9^V(D'KC=B1,RS#9^
M@:Q 9C'UN36:@)(/"YGV*\1SX5\8,V7S;A.+.F5,W:HU)Z0#1OVN*BQ4[YG9
MUX 6'QELUMI"6\I \-8^R.>X5]V#).]6>]X(0B>\XX/*IG,]6XZ&E?F'W5U^
MM?#>Y/ _M](@MQM(DS]RB$X?<7^0D8RUMUZ]??$>9 ?*S?Y^17ER%MDQ'!)A
M93H-?BUQ%E.#SQIR\"F /P#G!"(%7;H4XV:.$QOTBID[]$.<1A?-YS$0)Z_9
M-!G\\+E9TB(8$.CB6\5@EU8%VS[N/<9>3OACTF:ZBW8?4*K8'CVOH7DZQ'%T
M>#V6?+G@'N"UU >5Z?W2FDE??&4EZF?;-NQ0WT$<OYWT9C\O6EBX>J)@Z1C[
MS,TSK+H]8!UF/"#(^&:T/K)2&@?-P /@]2#J'G_X0[RDIO(E_(%8K\HG'8N1
M??VI7/O84?9'/:]95KAM6TC@.[68*?OT?<&O-927>JK.\3L:F,Y=C=>-19G_
M1WM7'M;4N:=#42D"!D1! 4GKAHJ86V51C!PM*B)J5%1:%$XM5UDB1D4D2L@1
ME$V$5*U0L1(W1&5)9:T(.4)"TI9"V%.QD,VJ"#'G*(:O9)M#VYD[\TSG/O/'
M_#%SY^9YSE_?\YPWR6][?]_R?GZ&0% 4L SPFUQ^D9][3:,KI*[@3' W9Q$[
M'),+R1364^4/L1\!2S%O)N=]P)#X!S5Q<P14;"=(:LYL'O0 / 7%F5'H"*B/
M+P[5Z;H(ND:]:9S0B,69>@].^Q<LB>XL_HQG;?"YQRK0E75X0U,Y'9<8:'_
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M>_Y]Q[CCCC/N(N\8C%7>-><[YWSF\ZRU:!.T.>#$-4,30X"!@0%HI?\!M"E
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M5ZUOK!5[W1[XC,RZDJ(2^<=?8'&6T(H40_Y>:W:@ <@J&K"OB?Y3$ ZQHQ1
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M-Z+!\4+C4Z*+PES","OCPZC&NSUB+_TK7_R7:.(-$MNA)+W'W27JFQ*5XFF
MJQ(/Z8]!G4F&)\?-M+6.BT%9_*G2_55] \).YG+:_I7LF[MLI$4??_5JZO<9
MI7BQR0R-[$-VMB]@XCX6O7$43]+@42,D)<U!8[)E8M%:JS-<8V25DAP%*\OJ
MM 63BL%%V](\Q?ZHAU-O4M$!OEDYN47?2><.Y<DW2![%)/Q4)XQ>$_,F==/B
M9CKFN0=TN+^_5LX\$+H!YBR*W%K7]:\ZBN<_9Q'K/'_/TS+O(>;2CJ3/0]B[
M$6D6TV>F9):V[)CQR$7AXM:&I,@KU<ANA$7OWQ.])(,.SY)O$X;:86"2U2TZ
M/U7PMB.")FC 1[B^;J9AF&1?2FVNA4=:QP"+&[9_]*]QA?\21Y0B_XM8\2[X
MR)?/E-=K< 8PO6_JX[]H1+[MG9>F=^U;K7=[)N,/#2D-3KIHB$77WT(N_E_"
MB@=!_XJR#*L[(M-$F2/Y/Z\4C0'!U0K) 426F)TJ[@[UD-P6#^EO.?=<)NN*
MY9^47UN_\'-P#W4M<]?GZ&$,68R8459&:IK/Q1"%S)M&BC_$FHTM-+C.917%
M9\P%9_)R]4DZS3'&@R[Y;J_S,Q!<_J$%6)#V_HYKV?L@]Z5V&B#6?'GN@M^@
MN)CV!A<=_I5<#!^.*RW^E!EH"[_8NQ^2?9! 5^>!.!DZSNJTBK.1$@L],/1D
MP \:=6:[UHSLF/8J/L]6;W,2A]MN",<,Q"%NQ>XYYK[Z,PNBTMFRW^M0,W3C
M$5M&>GCZBHY@311V)U/O"^KGM"NW\GRYY''$EA?RDO..N'@"6$ #PT?R.*+B
MSVI--R77#IBC,A^*V*48B7CR3$N0!YXOL5_T'=L*\ -/!N+MTP\ODE XRGC/
M)00-Z&K,>)^YBU9+,\VKF[P"&<KQ.SN''EWH'=&#PO_MR50/E WIJ)1(92"E
MY@?%VE&*X.;X04GS!K[[O^O39H0KOQW35 XMN>\[;7ZM@BBY*TOJG5>*$Y<8
M]T-A';L@HB-U\ON5%7ZAUMY,ECY-&?>LZ/R0_\1Q?FYM]D,(?9$<NV!T?L05
M..<= 1=PHNMC;:MX/YV<=W4@ 7WI<:S_U0QK,=XKBOHX@>^&2UXG',5D_Y=U
M)>SHT>AQ9 <#F4[A"FN(L10JA@8L8'>\G^?5+'4.Q:&Y2+Y%04AZ6LRMZW>$
MW)IPSTY_F2EAYNX@*N<E/?DDJEJE"=[U]9'NSM\K,4 #F)!'G8*3K$1D-"/*
M=%-"N\?1$J.(KA(8S.0IS"CS4?\1\G]Y_"5I*QW:)+K=D_:/MS_\2G<[='YO
MK8EX&Y_9F8CB"3*:_]I H '&&5AAP\1'BJ?X_9C4PNM9\S\%MU-\C:*I;-1O
M$#:2]#S7J2G\>GT<5<+^)_8UW_T?/,V)K)*IG,\BC11_^?$ROO0R[MV$W:1[
M?0JN-0Y]/,L.OT+X%3]O)]2.4"143*_YN$/.?%(IG-*[ER5ZWI/GYPE19UXV
M+-O)"A0OLLV$>I($PI?4S^4)+4.D"+A1[^*:4P-89):;[/-U-^#VK_7SW.S=
MK<]%_\"L?Y@GZ$H7!,T:YA@3!5&.E<NWD>4U8YYI0;9B;$9,CT*^,7L?(_W1
M(V7AS*"=:*'O9W[X*5RV7J_R_%.C5W[W\^D3^O+GF(ZQGOY!@4\3YW<UZDFH
M.1IPW$W\&!%12JCT/AZ/J8Y)N*<7H]<P6Y=A-JO$#98,31/1Z(,KD6*)I;L^
M!!AJ!XE5LQCU1[$$.<^<4Y_VO7$G[?!VZH1$Y[-KCUS<J?L\]=?8GN:G,.PL
M"BSE,5.A0:#=<,*JASC+^-QW7.*Q7Q.18H-E/'M.\>%.FY%)I2Q,XV^^,1CP
MW_R/(= +OT5ZAT-&0CC01*O$G7NUKT]]XQHQ2=NZ>%C='9GI.VG4\)LMGP-]
MB;@72Q4BF5H0H0G^QGZ>'.;FJOBM>9T[O   F*I( >_9I,(9SJ+-2;V>\["I
MCE8J1][<>"='&",NID*ZJSZ>H_O;[)4O3RSU*AKUK)YL,>@]+1_HFROPF&7<
M1I%D+8L)>WC_H>=U*-*=@N&2%VU/#1:@4[R&1G:KSX_IRT,')FY)/A'E/SCL
M@)P<@8OD3_S.%GSM6;0LJ!+G65X^S]/%F]Q7."OS,\V-X1?F8^Q:TUS>)+)]
M[Y155,6&5!-Z:\KBN[?3K$_(<I/#8X<[BKL,=P"UKR92!^O\MX'_\UN__W_\
MQWA;6?$ 79>-_26\H?!+7S2E[TWJV'.!!T&GD[N+C[C9*/(!$@B2F>_.(IJV
MC:R@A4/5SN]!1(8W.#4STTY<>X][V9W3H.+2_UAN_>X7#8P+;.JC$:EB/LD<
MMY>L;D(5(1O6MV2(A/%9*'SZI9N64*E'^7W=R5B$].B+M-6*^Q;J.;AFKP.3
M;"]!^-&";^'R\D\ZOJ*3Z/%%I#_MCB'7PG4]RH)!N([YC2>&O[ZPE W#SL'E
M*9^DFREO=&\38O')L:!G< /Q_'[<\JG[;6%>$UN.+E(HC7'.<E:KZ0_,#Q@I
MMGK,_!9_#WZ-]= ;A$^QR'+WO91EK%T4R-<_\,F48XP4<]:K78 1)N8!8_!3
MFFK"QT9"SO?/5Y%,$-Q8&ZU4'$QZ+DV^^+2NHEJK,].7'LXK$ISOK.Q1NYVD
MX/DJ;"25IRH6S?)]^Q45W%NF+J[Z74'IAVF95BSWZ;0S$T^N/*I.Z?IL6-:
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M8R,E))BA70 ]T/@F_DC52-)(0O3)D]\3DF_;-O7$=OZ-<OY+0V" ;$)"X6A
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MV94>H[%:!;5VK&*BL_28=VES?>K"5;N.@<4["RG\#US.YX>'N1C V\H1/S[
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M1\)&U!7&5;DP7WN<*8)FENHI<I.56E(-\L[&RYXY"?8E3 '/4Y^@7GUGF/^
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M-XW)QM[V'E&8I$1.]4Q@#?6T37J5J)9B1OD>A=R5&^6]<T&:^N_]XF81CH$
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M@Y50KE8/*VR4R#<]V=SO7#WN><G_O<Y)6031K[G[3-L-MF%V]!R+Q$3^ 6$
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M-2:B<N2<W.3KXQC-.PO70]WD:K1G)C,B# AQ?DNOO"V<U#TEE,-,K8U4]G.
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M(J&QD<TWWY: Y$I#O"Q^&/G,39(K65-OLQ4\:30;$F_PAXE->QH9340'7CM
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MY/6=\$'_CQM.O,2LD!?=4^]XB<'1$P$X\"*L81DY?6]Q ;$M=;CNZ4IW!G"
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M,/C2@<@M#E9K&K?,3E1A"8*>8-75(L0QI*J<?PVA-RSQ>F3'X.A5=ISU@S,
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MW5U7U'>.>F-KR]?B\D/Q>M;G$$# VZOHAQJ!<VG[ K.Y?_W<"KR*!GU!F#-
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MYD_1 Z=CX\2&535@6['MA<)N==NNM.UG,/PVPDVM>%V?TR(PIYVG1(5^Z@P
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M=F_Y% \84<9L+[0LE&# $:)KV?0EOTU\%7YPKP0W!V5!!EF+Y?:W1/5< -G
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M^4VX._9U(5L:)- T4;'HG?T\1^12YXU/0U.XT L.O-;WF6")'1BU6!LO*)S
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M<^;96YJTOR+IDSLB!APO=F2_@:$7840=VZ7.X%/,%0"7>9ST_^8P]^\"X=8
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MX_O<CTC"J-ZJWOGZ%P\JI;3_5@[LZB(8#QN:G2\6?_NXH9\/"_^7=)*.$)+
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MV@V-5\'Q!/8KP/N5_0YT=9LZ9P<V=_]ZV><NG&C/%*&8S2WFI8\G Z[G-;&
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M/S\-X%+LMF._G964O1BWTYHP/BOZ#Q&,QC\%T1*I&^.=8&5U?"_V0I>G4\#
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MA"CD?];(0=F)H4:$VX7 J!WQ_)9)"1M_%D$GQW::^\)W'.P33,%U;23V_ZX
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MFD&, YOF2#H47R_F/,Y"VU/C5F[%E;/?=ASGZ2\!2BB]VK$_E#O7LJSU?\X
M3M"YO%=Q@].A<.8Y2KK43+2UC>9 @Y248;+3YK[%]4%;*S+OR,2P;X7!Q5[
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MI@1(9P+;6A),9Z15"":[OB78\J+4B6#G[SG'8;O81HCK8^;JD7KJ31$C#/=
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MI"OWLE0K0_=(0Y+;QEEZ[L\:-W 0:\MD59E6)$%/+[3Z?O##NT0!)_H>@&T
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MY0SP7:.8&J4+6%\[?WUW.2_3,G_R$Q@;5>4_WUS&37SN&6#P/MZ=>D4<0EP
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MF@\R\K/Z2ISDI?]8Z5!)'?U6B)\9>'34U@!^M6OOSD670,V6J$SBJ\@HIC/
MDF[]81$2,EMN]V55^B9:B"XQX[B&4;W[A:N*__L'3_;%:8Y>$ ._.C,OZ11
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M:Y@ "[@ESG'HKGQIBT.-H0;;F.&CZ2YNZ^,9\&"IA550N9+ER;,R__;KO$7
MWZR?KBLZ9*!M+U,'()OHU[8D6K_Q,X">0%4YV9L0/=YF<WN\SIPLB:6\L?RK
M93G(H-J$JHOP^MQ5JUGX-/95B!\M?_@')61]^U%5S<DHI=@A_>\.SY$#3_4T
M%TY6;I[A?6J/8W=GJ??'[XO&[[3YWDD_/*[*.(^CW+8TU%FJ'(>-P*2R3M W
MXKT!PZ;623YZ4]='&_=YM:/+>'43<Z_2E0HGZ7M2Q8A*R[LW8(;C,'G\RMC2
M4\)1)K:DU1!;!=*-NK7R&>GHGS%3::(JW4<M%7]G8D_;$AS2!GHY(6,S-S?H
MSEC;RSK-:,2YT.;$>?<E*W_!'9'XM@SB')0X1PCI59L$W[3VRU2?(,L4^NT@
M&)!7)9+03C_J78TM1"E?7UUR4!.8#98RH7F G:E2R3Q*PA=W2<XF8^2[5/2Z
M]=R+VLN=+=ZD?Q7SDOEC+A?6===#\=(9P-I+Z6L;2-CEBH+@(  >%M0RMQT^
MOLT<5"*Q?YF =J]<;%K>?S;=OH2/<>K$2)+%(]^F0F)ZL8$"$ZDOW?603$$1
M).7!'#N2Y ZY_"00$8XBY%[\'Q78(-@]@GO'&8!HB<"G.,H'@(ZJHFQV!K9U
MZ9#T2Q%6_%G1I_^R[4W?")IHZMWX0%<!.U<0M"/$,*QM-)B+B*S:#*!65ZTG
M8!UB])+-?B8M=S*I4BWH[+]?2H)\MO/:5@4Y_-=F"/_I9-(!\Y^H/$ $HYDE
MMR2*:E#U^)5\E9^3=>$/7R2ZOGK]WLZS_ HM\Z^;S8&(")1*ID'X(?4^,82S
M(.KUK2W9#ZS,.= _+KGG4?WO$EP$\:?J&V)=N#X3Z^KT;[QN4/&!**MIM>P'
MQ U66IH#3O)F7BR?UJL7IK#H55"0 X[!1Q1X+NMO6#/YOQZO"[.=ZH44>BXQ
M'2Y%\K/@Z:+J!R#1-C>3=I^,2U2]T-F2#>51]I IL1-3$[HG$P+.^^&,03TT
M$"2JX%ZIO!XYI 41&4016_4;RBIR'%]7OXVO6""?CVJP87*:_K<N[+[;VX3-
M+E!M5;N2)*N?\[ >:N+6E%VU8WV@3PY(')L>=?5_HNR]P]E\W[_QJ!8U2JD]
MHJ5H%;65D"ZKJJIJK[8VM8L@1*F]6HJB:&U54B/42NRMJ5TSDM1>B1%!Q./]
M>W[/.-Z_S_']/<\?UQ_W?1PYKOO.?9ZO\W6>UW6]SLH2?SN!Y8D63%M0[?1!
MQ!O!)U@[W>W74EOV9E%L\MW?[R=UB"%A__1O)RNW::B0^>U*R <]0 )\3W-B
M<TG?]%A#;VZ4H9B)._W=Y?=F6RM*QY,HLM#T-+K-!EA?W7CL]]DBI-G+^O6-
M92V1I_#:O=ZVGM>_Z>;^1ZG2D9S=T0B+IZB5K015_&P<591TD9)^:9=(;$Q[
MF3O+@78=R0_3T" ;E]F033OFP>0'\%^[:[E\(AL'["_XRU_&2BUM#[1_TQ'D
MNR,_Y&!:3AU!,5"TX>M((+'G;>W*/IC]CZ98!JP$,6)QTMA^UXQ5EOITN&\7
M$/0]Y=*"Z7M8.RNQAAJK ",;F8\V'-$99KTL?18Z[Y\**ZHTJT21= GU%+%0
MB<E0<6NQ$U6@_'W"UI9Q@?89GC3:%!RD2"3<;IMA@@4UGP*>D?6(J*X)N96R
M!3<8(Q.1%#!1/%FQS.5=U='+#L[Y).V=1%;TQ%96X3UC)B>SM#MD.&T@EMBM
MZ%, .XJUS<[3&>-<5V_(,:<K6G7'4^GNH*K0$]_/PPV\=1IW$DR 3#(!_B3M
MF8^FO<H3& Z%DW;/Q(S.LC:SC"?OD]O<]347;!/F;Y.#B4X=2D*WB(GH.,I5
MW$5+7;?X&>=K;I*3;75>KR(OFEXM$$XXUYHZ$F]V^"W3YEJ.N,5DW$9(M.:5
M9R"O_ZI+W?\<#6@AR*XNV1>[NE_ABN^MC8\TYB_,1,\E*0K45"W0V.@[$;5Q
MR;&"GA5[%;3M059Y"OY!M?(V\YL;]CN+B2+BE;\M1QK<7KF\'%]38SBH6W%;
MS*BU98$^)_Z*$%NYGKM]'#IE+W+P'DVMZJGNKV0MUJYX$Y3<)1,7=+TGMVZ>
MF\B2S]SRD>N 2YEU(P4T\E4C#)^[K_'M%LJ%E<7"+9>KT9,5LMRQ4QVCR%,E
M5?/A>, R3=#."] KZL7CQ(E[-<<\'U'TR"(JH;2Q-ML_M1=7/O1FIR[H\Z38
MO'K=[\KB'\2T-$SX/B2;19#">OU[R?'O6>&;:X'KX6IQ,,JM'#KL",OE+8IU
M6<,Y*;5[B!0G'P/>]V$QJ$UY@.IDZP!-\N?Q&YJI;JS$%A2I.)XUNJ S8_YZ
M8[)N_3LA<[.HS);PSLI.$G[,=$*)*,I6Z'+P' "^N0-^9\NXKR?URI8;TO+"
M.LA,OR4JVZ,--U+1=_X+#/_AAS+X6)B9Q@997@]:%E<\TC(*"PP5-$H_>?1C
M32*_I>K_D3" -IS!XC99_13 :+!0B?AZ"FBWQJ)X3PHZY>=/4.T'*+>Z9#]$
M=>!C,H_WXI;(\-@!O'3]_ZNF"SC.^O>9K(:\."$.#76R&P[#'$XS41O?HGSK
M+A 9B=\"3U=FQ0'(D]2+0SA-(OU&*I:'3RNX1<RR1771+&>XVDJG-UI=EK^G
M*\0M_W96M]FGO^>TU,_XP?YD%ZHZL8_L??PX=!A\<0O4!,%/PK W1S;MK%BO
M;=!!_=O+IZ75T44A'["'_K.@D$S?0]C1^E!R@\7<K^5M0X,J8L\F'/<W:UZ?
M#YQ]K,'\"+Q:V'77*BAR&K9@_(_.PGQ-"UF?&(&G;]]TM*X/8%NE2E1%N] 4
M9($Q/] 'CR=60L8FX)V>T16X[>EB,&,_7[#2&+@.;AXK;!G)?EYC<) MY ;,
M^1SF NPU*AS&]2Z*A=7"GV!3._/.NS0CL#[@SE^/]PUH@"4C^M*A:VUOZ6?\
MKY!1VVNG@+:'2!E7"V#8'NS=_.4,JB0L9E103JYBJ"CZW))3J^@-HQJ5XV(3
M^ANVIFM'B(SHO>PYHV>-43U/JM]N>7A4"HAZ=<:9SWTB7)$03?W-2)DGRY39
M4(=1O%!+XK%EN,Z&M'6M)\/4K!]B%'?=XNXEK\$ )_IMA9-/IB7B]J#K]#'?
MOB2[DV4))4\(X*@W0+J5CK[16K)_GQ>%G<["/*_./%YV,[V'TXB4.9YM1FC.
MR'K%B1CNR7!A$*A]7"Q.J_X'#+N7FS:GV$/22'#'JS0CGX[>7GN___P4\-:K
M9\:S# XB%PZ< AB$OG]O&LC_5KIFUH@'/D%%VG$[)M>0#%-\@C7-89EG27%-
M7IR4YUZ(E;87W+%)VK#13KA\^3>EO NB7A^Q;S"-QXG'4H*YODS8"(V(40<(
MHZH_S)4^]ZGN@8CA6CI>%^E4L=>)Z?"2^KAF)JPY_[%;=\! H:6T2IRR+RE3
M%[!P@49WHW*H>_IX?2&C?4Z\#<EYQJ+L$]ZT7)MZ9448:1"MJ5.K\;1+6FI)
M$!)\4E"N_F$G$RG;_]FKZC#OHFO601+* 9XP3=]I]F'+3_WZ.U.]I@'K9SU;
M?<SOSK'V#<>HM+Y,B0!6 YFHUU? /%":?$A/AS+L];"?FS>(78#.1L=Y]IS7
M2EM:]*M"TW;;>O'PO6-PM'_6QYOE-ZUO,LRD1K0)YWJCJ>I6< I'/:X6=8YZ
MU0*J-O$7 N4G D)J[N::G%-S-^0T,;O3PUZ6+(2[SGNKNYQ;5QPMF)S=,=1U
M? -8>L50,[#GR[\E#O_[,$/*$7.C"0<=RM2K1.ERM_R5],N']<J3*>>3%%?N
MJ.N* @I2= #L=[^P?#ML(D6<-#1S$VR?97?PW>*@W"5'UD82MF+:D+_FY/UN
M][?2>_ET"*<!EI!&Y*)C:ZCS26VS;L@";*KC_KA"WL7[5,V#V(_Q+HY&% .O
M/URE=T6OY2F&:11)UI%%SMPLKVIX+X8;YYE0B5"9<9N%!'2<G_K3VYI:%]B[
MZT&GAI.3NZM2Z&8PM1NZ0]K1>$WN.]:$'."7OF6!$RFV4IT!B=7 J%, JTB*
MP_N_0&E?7C%__))6*B"A4M74FQ!- I)[\&YNL!\0NT?D!UC2=/MQ)Z1I+-/
M)&E8:\R#SN1%!7I>\<B2T+, ?ZO!O.ID0-".5$"QM/:7B9A;1F:]4 VL_MS\
MSJF\2G%ZW+HBV9&WY;6"U6T7(X-OY+R3%M2<W=]30*0M01\3I<'2%&]&+)^G
MF!+E%K(Q''7'SU6$8S9]C%ZBYU('N^D8X-]N*1Q;W^R>[^^?YE=3>V/VM;X^
M0=3["P_C-Q7 )0#GJSCM6-74,FF7IAIB/*ZH,B.?.HKA']I#O2)LY<"'RJPD
MP!)R@!&[DQ*? MJQ5\CBD]A3@$,,]:I2'K$ YY\L )>>@@IBR]/$6)0FOUF#
MG!8#[0_-?1@ DI<>O3Y$+\AT_#P%N*&G\=W3T/<G!:U*\S)C4-.*06[9^;M.
M,T[.9LQL?V5%P'*>(FE#H:WYMUR_Q7$^?W$S :!^8Z[VPQYD< T!O<#<R'X@
MC-AUQQ $S\*]AOW-#)+TYT EKC/HKY2D<OK' >+F)Y@4)<_+MA?^_>YZQ6DR
M+OW?#5[[T.0;)1M'* :H=2GE[G"%[,(I@#_VVM@FSK!NP)3A5TJ2"L="U2G
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MS/5JB5\Z+];4<#,GE2%,W7D(H7@L">)>L93US+^'W0Z=(1QF'#CS2_:G %Z
M;WNB*$O]>[7"RHAOZG@NMM3U437O5I%QH)7$OJ-XY%/5U-\21XR[X,0\MEI4
M="[KA*<B*58Q\/MB[3 (M,4R,Z3@SF\]JW7II<YPMBN2)UTT["Y<?@1+;B"&
MKV]^^!YZ?GCI63$V#?F;^(/_H\?U.&7K=YOTQ9(IY"Y"[J3V&$B*4-)6;&V)
M4^YD^NJ@41-R/"7U6OOH\#9XO'ANJA6=GI(PKBF!DB_G?!;:-X"- \637%(-
M"<E=0";* Z))Y$VR;3?[O'/0I0:50_9%7IJ7D_RQSCO>*2,OL!:H)Z' L+H#
M]X2<-88C6F.8"WK*38M(OV$+(^ [TAV5"969@DL1"&5]4O;#6PPS"7URAZ66
M#9G)%KMY4W#\!7@<RFD&S(?17WI4Y^H9=,/M4UO27?I7(S?^B42F+1'EQPU&
M3LO[6\N;O,O ^HRX"]T%Q1"ML<.:<HGNV^:%?_"G ,'+P&,7<ULN#>;Y*>I0
MG;[CB#DYNR-]F)RJW1)]S<PI+/"3@)-WPNV9DY-H1$!0=(=YJ!H$C]7NY)V_
MLS>0J+$EJ*5H1:N8,_K0;.]XK3="\/R+X\G?0K>JN/F<<PS--\UTKB2$M_2,
M OL;7[I^\ YYHV+'_6M-*.)8G6)63UXDF+915>N-$]:5+DIU&BZ_-F5\[-O=
ML,;U_,.]K0M!@E#KLYQ_<K([VH[HB=7>;DZF)>?;E1QV4NJ4I:Y&W@5O/A Y
M2XPLCH)Q!W$@\X5M&E=5>'CSF5]>[(EY2=L[C)Q-#WVQ-3/[8E-@4Z#^WA#T
MV,3?J1*A;0LB3G>(CNI4/>#+"!1]\>T;G:[H'L#$*1)DG0]9OQ]A0=@J=ZI8
MV6V.93EY-Z# _NFO,\:M[&K8&X=>?!Q%X*0,[)J<F,<#N@?[0M%J1A'F6IK#
M=+$\[G]_U(<1[J9P'<X2&.3214!LDL-@IU/ = 3I"SF D'R/<-"!8K!=R[U4
M<ZS]QP-+:)Z,.=X2#925*V.)Y;NWF>!?]M/JI"X?)0+&(E#NMD=L?@:4:Y5@
M<MR_KZ7IUW,X#WE/ 2P5QZZG@-\1WV!83N\S[F[X'VYY@:U6X+UHLKOGC"GU
MG:#1&9R5)U.O)?_[1OS;HV7-4"U8AUOH-&I/>"V/K&D%(U[Y][45ZZ3J(0JW
MO!$/WF0B>JB;XK3C*Q5A419F2=;BK76RB.]:^!>FZ6L.[B.?MZ?I&%C"[LX"
ML:A_SY9!Y;<DC9\"OM(_/XOR-\]L,>8+ZSB&"6+PD* 1[9Y/#M"I^KT7_S+F
M]9OC-^$\.SY><0!>4)Z1Q?A_>F_3E8.->CR0AW*7S(15A_60Y%R0,BUQCBA$
MUE"%D))E+*<\!\!4HC1P_?/!%Z=OPYI76B7YNW.%D]M#6281#6:B%N[O#BH[
MPP!)2CX^$*K0?HVAM45'B)LB8E!VUG(P4>!'_]</8PF<+R#"$>$L@']V;9^O
M)!LX+;!.!1@0N=,2[;H.Y-:4GS6ZPVZ(.K](5A^[J1 Q[[AI:V>L#M3^02"E
MN12[F"A-.V8[L;>Y.SDQ=C'+EK;G7POCO+L N'US\3]4W?[=;,1T<Y<0?9<\
M3@C6'@9I$UFUR"YVGO '05EU/X>_R_76'3 (\R\F>%S3\FQ^(@(* #Z:[, 0
M3+/-M\&.:!91MCZU9*X9]JHRN^2J^=TN87414D,3V=B=R+201=&LGI3>SU2D
M0-SWH@RO!(3ZU<LO1O<U]:WFTIJ.*NX$;%80G+IA5Y!BT'/C(*E\W7(SB&=G
MGL>XHVY^@D7'LD7=CN!;#Q'?R+[#T+3]Q-O_73- [\Q$F/(AY;B)3*(\]B!6
M!LD#:9$967[V<X3[("#&\F"06UBTLJC:RW GX.OLD*W)\%V@$-3YI$I#$LI$
MAN.D-(X70BMPR='$9I%'DPI?)=R+%2\Y^)G;O7*8Y31(;[43SEI3!,\,M$]S
M;^ +H*_&*%(X?FM^HS%4-7XT_+['NXC!@5UAZ\S(5M%PB%H@O'CE"VN*QH53
M0)LNE(9X@"N.75#GZ @5_3&V[PGN^XE*FKV?^YS]\4S<HZ'^SKNMH ]6&3'@
MA0H,,T@-[FKQG,I!?)WZ9[;/3:2'I7+"WJ<P 3UZ#?DW/TS#C)QY"KC 3%!N
M/P5$G5$3J%,I.;A3V0*6)%7I\?T%(HGV%M/%F-L?%;Z<@XYWCP3QH8Z5J?.Y
M3"?%S8;?5T*%?OMMRBWKC=H:I>L_4>'D4WQSO[S:1*T:7]I#GW7TZHRJR%.!
M+ 0X-9*5!X;)MJ6";3*)RU1&W@7;J0.;,\NJA, Z5=\=3<1Z5K8>0;TX=1P#
M.0WK^U$JL@)XD0]#(0:: &@58?2?7WC& 5FH(A#T$\)!C/N;4P#MC*6U;9N?
MP#GS"3L)0S9S'=% _9Q./\XV"(S*.$?HZ+0@91?=PX*Y>M3W!_VKFM]/;YH$
M,%[L/)%SVWHD0?LW.2F/\,P6 #U'+JL@LUH2,+$R^^KBO;N5MT3J;Z.RS_M*
MC^R4>U6'^= +3U"3CX,@,N8GV?OH!,**Q0XD6'<LXW%6%SYBTU-$X2;OW0S'
MV5\M9D*LG'M=5VB(Z'9;\HTSO$P LBNPTKG8\!+5<[]^GXTW<VJ.^_,PX=Z=
M5S4<26JTSS6$86W&2'ZH&G$Y%B09@O7DM+)UMDC[E0&:(%KRS.LX.$^ERM/6
MIHG:TR:-DRJNT.STQ*$6ON9>("2W8LY3GC42SI#'81AJZNOGYN+"[!62+Q9N
M+N(K+!<)^-3'8]<F>'-R8^8X%").RB&_]<8"+ZWP43-A+.^R(O2_:9_K-!12
M$'Z=EN0KO/EG<K3V*7U;/89P!L("$*+'=XTK%%JB4E/IMJQV<*EHLB>M$TV1
MSM,$/_3V<]9MTP*HR4FRQRG -8\;PMUY"KA,>?#-14.P9GBS< Q*ZZ:\%540
MY0(+JC361B_62-RZ#ZV4S_JG9\D0 1.M@&9P5@V-S?_34>RB"I7T='/R:+*+
M4^1AI!^I+?TO]M_NJEN2H@A)$;C$X+NH9!N]$Z$E-9?IT8Z#^M\-P1"G"_;U
M<9K'-:57XWX(4W[>'%I-^YMW2?IJ#3F'6(GS.6^XGOZZ,X&@$,Q86IXJ_@I-
M42AY>P(R. 6\"ZTZ!?36PCH>08"C9Z]"UEX'4N*-_9*Y,:ZIRAE7:R/ M[PH
M)4)_?0Q6S?Q6M"_Z!:H)R'69KR0;$<0[K9EP^I'[\Q'J8\-F<_R2'YM__*Q.
MO]'\<W%Z&,T'GDU7HN>Y&L7R!H''U-0KYW'T_H6U&P*I60K3)+Z%CX'VPW/<
M0U?:XR1*)0Z;2*1&LK43X5D?5=I\/6">FSH5IBT4]MPJI*0_^^4=AT/_P\SE
M,LXM*J,;%\$C?-JB/^OECWJE<O!1&W=Z$VWP9K?;7U:R9 8EBW3FTG:*)=28
M!OAW)/<IH$^!D'$2+@7>>_24WN#?K3\EB7K8^6RB'99:CU4W]9EV-5F2E0LA
MBYY7\(&# P6->QH3B+:B$*-NU=R&A6!;5D@L%'X%\NQH67?,;O_#H\6WK?UU
M<PM)LL+=WK9>D^\I=T_2*=Q$CJ[)T.N-&98CBO%_\'I]M=8F;K*^BY5C+IR7
M>-.\OAS1/-[?F?5IG3!*:3PQH*]TZR(=)<?)U!K0KA@I\"W'>2 [!%8'+&9H
M&M?PO$ ?X3_+:IG>-H>G &;3!?@1#]3S%! IA29/?H8ZDGVQJ*E3@*Z>#/W<
M.C>,C>)V)8LEMZ#<U==&K^0/.SP8%#S#A#BWH^&^*:06;G441+FWG^61R*!X
MPSG9Z#?8Q?8MD'5/C95Y-53]=X7"YK7S5>$\'LQQL3R,= 0&C[Q@<74?7]-3
M +8JE DVK#F,VL;#B(I]+BA6J RA'/LDIGY:>QJ>I1@W,5XIFFS_4HMF6EL3
MD*(5H.@].5V1\PM+E^CBS*JE*^8(C-?17GW2DQ'5IX$(N*AF,UE=3TV#M1X5
MM%$5?B.%G;F.,-&*EM9.NC]OB335OE>5I6=6CQ$Y+^3FBCSC!?A[A![\%:10
MXX>7!$SBIZ'7EN\B3!,!DKF 79SAI&@SR&=\_T1W 7^[IFTBC7?OS&$B$OZ=
M-OXS;GS_\W6W%E\!07<EQZGB(=%4-OAY!6\WY-/LIQ/B]VZI/G^L855"?(QI
M+TGP<5--$WD$&OFC/V5%@HXJV[\@4H,FAXZ<.G@JW"DGVB:3BC,'O.D[IX#G
MV;[UI9I>\7OGJN$@91SKQ379M5 6HL;78NONF9G'8UM%3:-;+<\T7W7)_Y9C
MTU;$#JA\O6CA4BC]"L;EP@&AQ]-5V:FYCU",Q$FYV>*:W%<Y/<Z(,&1!17#'
M[9Y'H8W IL<GSDGGK.1HE$MR]$&61[W]42C<22*)-*@;GZ.TXE.MA:_G_]##
M#+YLY7!&'6*1E]]9"DH/X"[4PFX%D.IC[2"]X.7O/JRWZALOYR)V#]/U00^I
MB'<!CQ_\31U<\9FKZ;)?LP!3Q.;%?E,N<ZWR[4"V]Y]&Q-P2\5J&E7SJ+Z59
M8^(;&Z7<(#ZP-1*LCU38IJ<]!<@<(;]D)'TY!; _8!#^L1ZE@FN!86'M+6!L
M<;97U2RZW(T;O>S*U[+$?. 3]-GKF^H% 9J1=.,/XY'&MNQJ@H6NG #!&WL?
M$4<7[_WO7FG+<Q;F;S3SP\E 4B"1)3EF3UVOXV $4HQ[4S<N)5KWH4 I/4Y
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M6O^V)1\P%\4['ZI$=L#!."!)@15[UDKMYI46LZ69&1[G-'^^79*]^IQ=;K!
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MC*6#EBD"11@@W2&*91#7]<EPHCSN'88==*_ #!&5$J&=;*!SI;R2Q+#QW7]
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M%CK%/3CZ'![N?"_C+KLPG-%SZTY/I12J3<D19-*;@)\=A,VK@O,POF?Y<UU
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MFDM M]40XK. *DRHWO%5NZ"T>Z#KE9A;D#^I=$M; H_:/7 [C5A'X7?E_5O
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M8H7]S.N$TQ3.'J@$5KC$GW-UQ=RU<=>%D_IQ%%R2@S7ZEZ=WFDI0M5'KY=3
MV'*7-&9OTMW:*O"A7NCO!KB+<N.7BJS87\\(/VQ]3@:XM>!2KD37P 0YZHL@
MZO(-MQL6=RD!D8<K<#6'3OI'86O/U!XX;;1_2(P6B.QA\]["G&GF(WP.U(3S
M69R"V@8A25EK?P(<@_#D[W3DJ+)0CGF6PK7M,W@;;%9:"M[\;$*6P:S_;D^#
M&%K,IGXMM7][&(2UEL!;17 BZ:-J7Y0+Z+C?#%>IR9K'OVUOS:7Q7@UNNP5
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M^:/TF8CS,-CB^EZ8)I899;$NAT%#LUCCEHQ]1KUN/#:W?&,(6,6C<>&!Z%N
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MB74*3W]23_*^-)%&!NKHB[(C/G/UHBG>^$O!4ACS+6!@""ITAP@&MX ;2DZ
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MHVAO)KJ3\-\V0SH1Z(O&<+5W582G[B]S5-6WHVC#UV-&KU8"+:]YAIX.\'%
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MGYTO%_[5_SRVD[](?!CM;(DS?(YW<5YT[85E0QUC]-4</DV)2$BKY*J4ZX[
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M$W@(EE%UA7%7I%&XK)]6B-ZD)E^KGY>$- 5? P,=^/W,1F?B=I>$R+^^=N@
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M0\F,)KMSUD32US1_#8SQ_YSX*2I%<P=LJ3-R"ZB/[A$(O@60ME'L,&3U1!/
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MYZ3KNLM)J4C?UI-ZJSN3>W+TFM2BEUJ5A&Q8,)1=.DB)@$+Y2*?%"(W\?%/
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M<6&3+)RC[&]4^3A9XU<EJU-]X99,Q3Z2/.@ 1[V]MS8TI#HRSM$4KK_(V^M
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M/.]$KI'2+Z6?-X.:'K[\^52"4 Q@$LD?O%;BS7@@/, [GU3B*;^RFSQ!7^[
MT4>BO*\BVRW!#*"93D'/D./[YX3G$8GK?*ZKK6],>AR\AQ"DX1XU+&9L/Y;]
M<Y,*55MM-5BKRRC ?/HT>5C!NQI]K3\SKV$9M%_.*91]Z<=?BL=.P+T0<]\3
M&"XZ0M+=!FQI1?.=!67\)IASEBUXH>10VV94;GC0.?K2<XL&Q=]J"_N]*!"&
M%7PZB37)4S2O:@IF':8.$COV54IY?#"OU;#%3ICBC&9SF/<R5F?:$U,G#+=
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MFPU"(5-;$<OJ][16B I&IX],L5ABW>] O0]2P'M$5)$I;Y< !W:Q"D]XMN-
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M]WLF$,Z$X F]I<.2H&X*(\0'/)S$7J-M$HN1^A\G!^;LJ5JJ1 2&]753W:
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M),CB2H:/9-AK_#8C3D?-?Q7Q,;J69NYS32(A]<?^>\FJ=OT&FMS%RG8'"(9
M1>4?K$*3WZ%&,]:+#I_9HDU>S\V_;I*A[S\Y-%M\2Q[]6\; ]5KN $X8+:NY
MYO3XXERP83PWYW#W5KAY@BB<O8BH2=")^L,7)IGK>$@YNAU+M=$S&=#71->Y
M2@Y-4VN;14J<S1YYDKW5@#BZ)46\)DJJ)U ")(X2;Q3XYZTML[J08Q05)\N-
M)1LJ*X-GE2.3PI(D=-Y_(1>5^?R2%1\-.=_"O$.TBO7=LDS)NCJWR4X].S[\
M,77;[][H292D1'ET<KZIVC!ZZ#K'/+?#M1.R47\3)BOD3]A-(E,D,:*CD66R
M'OJW6CM?=%7V 7OESV_*.KPG/5^'\P%FX?(:]]-+L7",B TD#>#"%,CB('K1
M/.>"Q?<D"D(F"JRYR>_D_]XRTEQ_)%-O*[W=]N0FXQ8/YH/)NV:J#X?1K L1
M5P3)6K@*I(E E-?YD2#5\FC51%$.OGB%!R(#/-N?'IP,XYQ*(G6O5:%C:\!0
M$ X<]K2U"OW&G/-U3;0))J[__+> 5^X#X)//R2-;GP=7P2I8G&I,@>6:3_+Z
MT<_<?1"?Y.2WS?$\_@>+L#9#:9+4T7^9Y ]#!KA;A-8C#L'KSP(U;C)J*LCW
MKRR-L,)-]6GO,MZG6R7M<4!T^AY5MO,,P/AI<)^*Q>> _]_7>"MZ Q? Z_6=
M.;@8[_XKR9ZQ< /@(PDGW;?64R._XO"7!L*,2.UE1 =):#GPR57>C01,&PS=
M ?Y4'+:O5RPD** +$J)=3OTN/<LT79P65=.-:-X^H0\4Y>P<1.:4L8%44,#N
M''JLW+V#@6$?6?FG*FJD).24248D-::?V!7$ T$3;YI-MA]N?B("NGLK$[2"
MNP*KY;N%6 ([I4O/[KDH@1T*$T]!O+0_<9#JY=H)<[:(-E#Q^4+XQ5I9+PK/
MD_D!J/CF=QO5_AV N0V J>^X(NM-^556TOM0X7GNT1<^C<A\F6@.802%DNQZ
M&[CZ)BW0H0XC^0O+#7J!\?D!?<I/.UG^:W)R'[* !+(K67("'NM]@Q6(95K9
M!($\I]LXH#GK<X=CUT)8T1E/R,%_KI7UI#&REL#*(M)72(:@97/>KRK[/P7H
MXU$]9%6?JPV8SR:^^=KVJ#L?!D(#@R26'UR*8SQ)G+P[ZUQ]]HB_;RP*G+0?
MFUX*4*27O_R@,*9MCXF[?K!KSGV3"A-!%;Z>9=*<E17HNM"8VXS=JE"S^;ZL
MZ/P^)6L4ER7G"5,= +;3#ZY>10:B,Q"#F, -(#-6/J%[CM74-^R4<GC..[&D
MI/S0)&S 2O\25N67K0GP 2*/U\LX[O$_T!II^SK&$ V*OH7619@N<O\L4J&O
M>5F-Q).M<NQ^1*[AL=TZ=FXS6P.DAQE/E>7?).Q@WCUKT3'K7/=;IN^J.V&[
MU#,KX^A^K@I\[M#?)S^OT;/"C9+LT";!F( G;>LQWC(2R)4_UG5^!4*X-N)Q
MG(!;),:&_N^)C\1Y+2 @\'8PL(8.R7.M#HURR6U M58$>\C!C \D=8V^9N\_
MP!47P4ELI'%O?NHNNO,)CV+\X67[.?--!E;C6@Q#V',%C#JNR;ANU35+TPT[
MC2I(DHC*C0)8<MHI6E, **?2_[\2__]I^P0$@MCVVQ_>DD.K>XU9HSS7G]EJ
M5MD+G%ZK,MKXJ#TL_=OR;;SNHA_%86!1 4D%T8^?D5F^;S#1E-2N3SK:1WQF
MYTW4D'F$(_60>&.RC>LF'6N_T0Z?._\U?2ML#-X',6.4$ W<$QYE,B,>FJ9?
ME@99O9)3'S<'$AL^<H8; KP"4=J!08SMW:MX]R%!V>*6I($&]B=GJ9^;%+#"
M:(\T\AWEPY:_YWO2]VWJX,2WU?W?'=OEX7> <_FTC=ZYB!;+M3*MN:X<:IB,
M._4L8\_ :W?E>'K. KWXM]A=KWJ9K[$@@[V_O+C]6-QK#2A=#_AQ10!U#IWQ
M?ONC&L/'_ AF J(*04HQJ9!MZZ70QQ/A7""+T3Z.>?ZM,?C!.4\UYLS5>@-(
MZ$ )%5O_E<;I!H=4ID8YJUM^R,K##Q$D6'@IT-!'U/<\X[P)9="5$P47ZCR.
M9.7)N'V,.8TQ<L9J^]NE^OK/3 D]5>WJ S-UX@XQ+#9_Z@7X4REQ/?M?*M?]
MWV4&T^+79F#MQLJVNO#SOGWN8#](9$_B$-.#TOA\BZ_!"H3!9#JH_M!3;;S=
M/WNL+!,U-X1J0971W1JU&G8< KW?2NT>Q%9RKKFI293\GQOT?X?1X-^<OK".
MZ]T:NO2:1==4M1'#?Q/SX"9W( W!C[ ^O[!B**WF]3A]F>+3&\:1XW*+/T%C
MTG$*/ X4/S<1+_&2 )RPSRBQ]>.^=OC&1FK(QC+KJ$M$#K[X\^_XK0A!.+P*
M^6&H(Z6*@!Z6:/%GM",< &((F 13MCL"X?+:R8C2:JC)6GNH<^A5:J$WY+O$
MK_GW'7]]74B]?@4H1)GL4/ZX!JM,U-PSY[T)^RNSN+H,"W)8LXF4/F\R9V57
M$< J"7JDJ7BOA<CV0%135%H3XD-R0&T5']K)+OQP+MN/1YWO 21B8D =M;+_
MYW81__#MBX#1 -R;/-GG3?)Q'M:MPN'/TT,)_S97V] _H_YAY<6E]?Z+)%]'
MQ9O<(-!+]/1]! 9:!(:8/YP"L6(@;S'UB#)VO\*Y\EJ2-+^!9]XV].MZ I9Z
M^AQN>>Q$;N^=N5LES^UO_K007K^UEZR&NAY[( TTHZRG/5J5'U0X%@:M?!AV
MS _O),LD33&^>/H/# P8RR9#SX5@[7^H%%:$C<6RJ]9FZ7;_Z;;W\Z*)L=Z<
M]TYNG#XF2_%BV<6=+*J("6"Z_7L' /[GE0$CQG>N$TR?AY;O5FH)$SIU>?RJ
M#P(1QE@% 84?4$G-HQ_,7[KJP#[<M+;8HF36)2,%9!51DCUB&-J__P9JT;("
MZ/Q* ,X7*JK7B]]$WFWSP0W8F,<)%Z8-@HUO%W-(+#!"")>HJ]L\?X0V&31I
M'6)"66PD6T^@FOWZP\3B93YIUQU 4LM :J!L-;R]MKT+&,OZI'Z\Y<F&'XNE
M4</JEF&IKI) QJ/F1U7LF_AX._/_V1(PU^9!6J.,&1B ZQ6AE--(:R<;@ )+
MVYD+-'FCOKN"8*])\&<Y9N/EQ*%G26#M7IID4^P[%3_R&1=1;ION<A9R%7J+
M@Y<L,S0=&/>-XVX7>F.'"V-@@JQ<R:+=>9E_T9!ML=)3N$D15\&7$E@D@+-R
M([K[#A!>A^&[ RB!._^O\MXSJ*D&7!<-@J#T7J0J("A5JF"H"@@H37I5BI2
MH+10@R"]@X 5D"(U]-XA0$!4>M!0$T2D)](BA' 7[IE[Y\S^SCW?GG/OF3-S
M?F3X ;.2=SWOTU:RPBF(H-Q\"L*6DJ-*JZ@&@7//'0I&O=7!ZP"'P)R8&;M
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M='-+,TQ/*')GQ*LNR,"&H0'W%!@>IN73=9&PA=O &M0<642#G^9#4Q_<M<;
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MO<C;)@2I,QCCCK(&WV,<>-SXKG0W-T-:O1H 5OY(87,Q3RNOO:SAS[66S==
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MIZ.T ESJ"X(9JAFE+L\#7KM@WK^\WM)D_C4T9AF)W7DMTZ_Y&I07E3=OS_J
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M7Z_K<*59.U=D-:E\X@=J[S@.U1&L.W3IB&;P\;2/M/Z0/^ .0>:*,/@1LT8
ME2U"\JKMS[Y)P/V$UR>DUQ?^&?D3N[]TS+_C&N*3=52 4VRD4N#-]XX?T:T/
MM1M'9VU9?WF 6:YWEEQDN-#00F\8O#HYL&A<*^D%OFH)XG:M*TK\<<0D01@P
MI/[5IGJ\NKE;[:C.VI,=\91-,P3CYM9!!U6@<W:*6>[/NOA0R'RHM6]X3T74
M#A1&X\9ZX;?73:.E3W.(?67W#F].V7MKY2+>J<"CVO;/"Y8'/IKO$+^L=KG'
M= F\>W\70UT3-=)^2M17 ;]X+]SY?2=K^0E0,BUN_]L@",5(/[_7(23S$\9]
MA%.'OWH^M3Q_\(%7!NZC@LMP 2[^R_>R5QEG&!^>#[06W'.#OY[@)9J@6E(_
MZ\'FQ1=^13JNJ-UU%[P_ESLD,-UV7WVK[</:_2LXU:LA?I?\-N3PT0-0D=Z/
M(7_T'2*&N,FM<L:_K%8[!P&;*[7N?O-SR-'L#'#_[EC:(P^]ZT%'HS0_'E*-
MC"%M:%L+^UX^29G?+O3":P'&A7QB!UU)E,!U7W^9?[FWK288%S_;[51,W&&H
M];0BZ&AL=-V90:U09PIE>V/NR@.+[N,<PT1+*60M1R:,,KN$6PA?"MRSKL[7
MX(]RX.G!:J^_(+:#<2<*MK]PQ@KJHB+CRG<NZM?-%>A_*>"-;BC>GHBU^'3[
MGNWEQZ*T=#"=_UONDL[6AWXQM<.!D5MCKOVYU6E#E[:#];=B-:^0&_Q790/E
MKH_@\6KN#\B?"/K<EP#4(/1/T4^=86Z4K_EQ=(#ZG\) AU_3/(VMEAHS7EDY
M5RR.YYO/C%1^WO/+C3Q]J:KJ2<5?AJ12.YJ>^#&2\PSV&KF 2HA\@M\%MCX-
M CMY[,\&\GS8(RYQJ^AEF5<68_5-4X'XV85CY2<3!N7-J]XOP9J>[7S8(W0\
M84*?G!FBIUL>N.*M1!^L_3-\./!(Y*D<G/!@NT=K?W;5]TL%5(T'0X(!R3B#
M]32S9.MQW7JSW@K-W;&8EO;G%_,\LR1^Q@5#@O#I@DS3JIQ_/_3Y+QM]!_TJ
M^F]S790XW1\E(8L\T#4-?VL*K\M$P;D^Y/R1/N2R%,++%-NW(_\VORRCV'29
M7GA^")RPET+N$<K%*>?IRQ4P70\G3?%9P@X-#R?(/^8Q0)P<)K(&TR3Y8SX+
M[/DQ*63'\2(I)'"'%-)[C<4SEM$A X:$5H5<IHW2KTHAE]A_JUDOKG*U)5FI
M]$<.LHGNE<M)(1<VPB55T6<$[O^]7FOYSN1 5WRE=>F%2VO5RN-TMKU VI[:
MN\[9\<#!2K6MQ[]EWWI^=WZ=^PPZA=X0UD4:A0D^\G]G("_"AX,CJK7;=2T&
M"F1B;_2"7D85_N#SO\:X@S08:!O<Y+V//<:@03>'ZQYUPYM@YUL=.7>O7BU9
M>'>.0,\L/^Y;X+O;KGF8ZB1.-7CX>,6X9-&MPZQS,[5,/!@Q?NV'SLHM68E>
M6XF*+2W=:*$ B_0O'TD^6.]SXY1GO==*!&4**=+J$2Q1P1&^<AN[EC+?'3-A
M17XG,0K"\M(RZE5&B_^8<%1U+YM&*-8E['P4VS*N9%:8M7#JP\>3[RNZ(ZZX
M=$?L8;^#9\N*2@J)@*<TS0#=O-WA$^MO6H^;=:APR:H!HV  NJ6/&F#>?&%V
M%/'GE@9]'_>\>807>'O8OVJ7_K?35IF26?H%&&A4_@XV/.9>-[0LW@/?*O*Q
M=+989.H31K4BE+NKWL?)--;$G]T[X\\]O!2]YZEYOMVG?BOGJ(2WZ;"-DF$9
MI6DD"3VDD+:+R$L]ZV=73]"_(/0D/;6XJ2YL4T:]&4P_7+O1/Y9QRZ6K8K:Q
ML3%\T\8_WE]+,]PF8;<C=H0^/C!S[:?/$==M;=PH'+7;NF.0LO%J=$ZI>_&^
M4I2R70S0K8XXZ6@V46WG6E@80S#L"#:X]-59"MFR+B+]6=WJ(/#&89T\U/EL
M>^A;_)R)G571V5E6Y?HF_^J E_C9#Q:F=8"F%,+)(C?TI(NTN<C,41^&8P1#
MHLX268;%A #GT)O!HN QE$__2B%;GE:AU:+*M^CK<&0<C8*/7'P;45:;J>!+
M>F\KXTZG%L>NJYP>'1?I@'DUU<^]\]5WTJ%XMU@K\YXM>:=N+^*1YI\2M%=;
MDAN7/-?H'KL[^3=I]8+_B%%5U&&LQK4 QD:/HQJ^QS)W!F7HFI[6LG;R\MJJ
M (% UM3<Q";E[UP)]CTGP6?'9U^/[L M4R-Y7KL_-RJ:5[A4HSP/A*XT1Y5\
M7-0Y4A6^Y#[2V7LFH?YGT;AX!F=_U[07=X40ELP\HF1CJ1%ZE$V8+[MOY#Z>
M]/AFB5Z+_YZ?[RE+HZ!,2:\](7Z#V!NQ?^ZE:"\?FH2WB;J1&D'1#_('K8[7
M-=P=O-\=:;B_\D76Y3_WB<EN?LI)M^Y=A,UV"^1EB(W"JXASE\>1S'AQS2.^
M&:]>>6M&3=!,;7D:WC*JUOL8T'@W[L?KKS6(R OB4MH?MX#JI@]F*^^.3*[=
MN^4SYV:/2'FMP*#!/"J]37[K8\ 23! GL#[R81EX-V:]T2V*=S$Z_]1NF[UO
MULZ@-/5U?5_6>%*"Q[V<CZLL:I?2TK8!4VG7MYZ,ZBT-L/QX;LHTQ&HW2=W.
M\\7BKM-E ]>6GX^+P3-3/C?NT:CN3&0:019/#EH3[\"OR8FH =T[=3<]Y2[$
M.=-RPAJ;^V/-;EI,G=GZ]&YHSL6E<_?E=IY!;;W[^O4N&+-\_E_]"2B7D70.
M!:E*#Z5D-UL'&P(DAJ_(8S)1E^&9T=&4Y:"ZUKN G!QV0S'FX>_&U>H[LR>K
MRORJL-L_I.V@-V\8+-BGP?GNO+I&.79M3$^P8\0OQF1^^V4'V2XJF(CO$L/U
M$1^L&\ \KGLZN<Z'J??-[47^;_^=$Q9@;&ST#I72G^6]*XY:Q@\RJ3E8M9Q%
M'8I5ZIL\S3^X2Q_W&%"G&38?:G5\/VB:*+HT"ZX6N5S=%_C 1*<Y\,.G2N.%
MF'CJ4<:?@8NJ]WB5'J7>-[U#TYB_/C\V?OGE]Z1=](^LU@/.+Q_7\$_]:EA!
M, 'V?(80#J+/?(F50C;AUX)>SR((NM3& :ICY4SQQMYJ&S<M"2MNY.>R^(A9
M:$OCFVPKJ*71IK;TZX>WB0T@:^^R*7,2ZV%6N.FR//_W)/(S&6UQ\//SM[,N
M9PHGSN3=)XM;C=F\1 N[:Z4*2M=R#E#JUK_H%,=DNB:V9YI6F/_//YC^U\SL
M5XE@_@M\.Y^=ZN#^_6#_(M6N6>?/799=-\O8;/;?I][]46UM5W'Y_JW PY:>
M$P&18A_*5O ],'82)'$+6PU/-[BFG#.ZG<YL_&UY^WM@P%^(RY>R'RK-'O<H
M-AG7R,U9V:K/5.4^ED(4"P9+=P_C=M=;GIT9&W5 [-CT^+OKHQ?-]\=R?#L]
M,PO3#.]KO,W/8FXY\_DZ]?@Z]1R[U]<JCE^G[ZAT<?$X\QI[+QS(<WZS%+US
MM$ZTXUDKO0LF1\5R(T9XKUXE>@Y>C%*WUPE5O7,C0_? Q>-7-OEYR#ENCJ%8
M8M>(CJXE@4YZI-7$O%7,U-^LY62\!^?F\7TW!YZ,NK7[7;WR76NH-B]UW;7(
M*W^'F;(Q-A5_:[R!9ZAC0C\X[[]?DOUNU#DV</C/#SVQGS2$SY</SIH]D4*2
M]7@PL5*.%'+[M13RBT8"#].V2R%?7K!!/;@48C9+YYE>LQ5#D4M;'A.7J.C9
M,#79W28I!+X7)AJ(7O8Y+,-_6R9R55-/"I$/E4*^)YH","8&<4)D4=NCU!-K
MGED^^(<?TW<3QT[L9,)+D]\Y^GD,L_]>=W1"2XS/.Z.XURVN+:ZG V7JLE3\
M^,'$XI9;KY=N=-B&?BN<?]0YNVE#;1VZ(&+A2)_.Z8NUO\H"\L]!3,*K#EAD
MKYF%FLN)N\1%D:5-P*F"UV:[A Z!FXE3CU$U"@2,R$!<X.!5#=[K">0?NX)_
MI/TAK7O#6M7%"YX[SYV8W??QX^*OA]&9XDP@+HT'".Y&A.@JJ#KIGHOJW6R
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MHM&7X^+V;YY]Z*V;4?MP9+'*_&IQP(E$ EV;SKFUBFI#JLARVX:@#09P)/E
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M_OBCAX*W >\^F95"BI'0V%!0R)=543]_ IML%];NGCFAU8OD5,A(4[L4,A+
MHW2Z0R3=$_9@D]!A+HYX%<P HMN*U_'=[\3 U/ P\7/$;DS!(G,Y$GMD""[;
M56A7/#H%L3N"K6D=H)QX1"2_2J<\0$ D8^0ZZ,+1%R#6&=3FVTK4BXYVL"$(
M?<D P4"FE9+A/.U48CU" >_#=\_%:W)@6_^F[07(:9QZR03?EH'5G2$#V6SG
MR$E]N%![H8"5MKR ].B[NBB%K*6?U\<*1OGY*41.,;$1F2%QP&L!72)K2BY>
M#\NG=+(UD)PJ6#V%F:,GR*:#I!*PQ!LL%QX46?\#V*(3XGOX74)+D1K(YL@
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M(*LNP@Z G"W"E,.9[.R'LOA*S,.#50UV](N47^)\N#_SGHCV\>GIU$3^47^
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MJU7$2,$F0<H1F)%#.&(KY7S8!6(K<^A+ I##4&X^M!2!.4+6EE=0(*/"E4*
MTX:Z?/LV#\BB&W*LZYU*J_*,BV5CY/F,X$-]M3L+&,%[P2F4*S>,]54(2:;R
MS8#TSZ%-?>@&YG9U'KJ%U5$3G28(B=52=L(Q*E_D"$2)Y^N>AO$R0;+S3I"M
MO 2/J1P0(JP#5LO*\J"(9M^V!LXB!FTWAL$8G:I&B_7P;8@CPN8M[1QT;TK1
M6,"HV-?)U/ZAP8UO5VUA=&'\./N'I%_B"=^3 2DSE-GM3UC&UZ<9$_!1]'C?
M5+90HC<6G;L!L]J;_+642Q!>7EJ=P@PJH&7Q7UL\APA"I^#K=A[4@S6=O[Z
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MWX9IM^[2KU9=I:7A90_N]/#?KT\+M40=F&Z75EXH\_%^M^@?T363%INUQA=
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M1.QLIN!\3*GO^@#U=AK<>!TY$% '4]EV<Z;5_Y==O)67!0\04F5/*6LCH_
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MVXA8=R+M4291QM%F5#<=7#,(LU1[NZ<(<0*#=0F*XW"4W-_"GR[,G5,^^KO
M@2PMD("'./UKT<5Y8"QJRNI %]]B5._NFKH)NT,5PDO"0,A-MI!7O$[7(4^6
M^FMJ5@8[)B+HC%4BTZ <8QWQM?LR,KX-GG(M/C5BVG0?90E, &DE8;9$[3J3
M9FL MK*43,1+N6*5K'G\I.H00NI;!Z<_S#FB: P@PX'2 7?:FPCE*0A(LQ<)
M>DH0:\NT!T,KH/*$2;-&= U,D[?:3M>C9G#J4Y@J]-V?^E)KYL^. $_06N$M
M;!.3I<T- HY .XH'F0@IMW+G@-4BSKPQ"^IM%PG;V3]?3/,-D_1G7K$;].W5
MX57T1F;?J<XZ4$R_\ICJ9O3I$615?%3K/\Z12C2X?,P+4C J]=G#?N>-%J7Z
M^;><5_>JT7:@^J[6/V=X^+>A*\P"*??_^K8X_K\OB#(TN [L&V5<\/>>$L&Z
M[RQQS<GNT.GJW2P7EGB;MJ/MOP3+P5?B?PC3?P[<_4W0-_'?7+?WMR (KZS%
M7E!;*2' BB/P)4RNE>J;]AH<N\IB"V23>=U^T$]N<N-,3U3Y0O&8]S-&H%>W
M+!-=O/UABW'>DR])@5>NK,QR2%]SNG4-__ZO=>+&9@U.> ZH_Y?[(TGR89X&
MM]3QNF FZ.X<-:N#^K<)XN"&6!S4X'[)45\C@PJ&F0;WV,?MO[RZF] W881<
M!_ZKM_V7%_\_VP1#JY[>[ZV\I,ZQYR9AT7XU2,6L7D@W8F)8,IF_GND' >Q(
MG5/,0,BJV<(.@SQRC(+3^'90U-^O(*O$<UQJ7Y1?JU/S\1Y;NS=S=2H>,U@M
M[IUYU2]2?E[7X!+^Q@3XECQB('BFA:ZDSP-^M%C__(]"(9&HA Q>FN(BAB;*
M/S&XX<BT[^,[C %@-\&4* BE]T<T+6M5X/O-I)FBU@@Y<(M'3D2-V]$-- OG
M;CON==^E2?*Q<B,W&0#O8SDT%C(>TLQH]PWD%UKTNG'D+J7 &5.Z8L=GI] Z
M0N65W'5_^C/<*<\3=VB=FPY8UQ&8?/+O'8R!S\=W:OVQ/[8([#H*IQ0SYC7X
M9C:V+88I]00#8N4N,ZX9PZV.O[T;70V["M%5=U;UB<]?5X0'UW/Q]F3]4&7;
MM^8B?WC[[CL'AE+.0P]/4^22JLQZ%S=EDCJ3M!U9U6%J">%3:@E73-A+OBTZ
M ^B%OA 6AX 'K?5N6PY.W/(*WWS33>_E]W6K#?^P2/#TNK>DSZ8\X'1ER.?E
M3CT%EU^%>HH\<P[ZTQZ='<KA2#TIX-W)!_7EOUSK;[MBF[-RX+8&U[6Z^H;\
MU)!-TWX=HW^6K'R:;]+P^EG0$=+,@N3#5N]6.LY+?;12GQ_W4L'I?,/Z[@VG
M@E?IQLAFZ#SW">/0C[#+7GP'D)ST(Y^VLZ?6:7IO/3V\3.Y>0-M(M#U?D=%[
M+CGRI4$Q14?4,PNV#"I0[?L*Z@"QT2O7!4XZ4\H@*G_O*#>:LOE-:)M=A+AF
M#?E_8]#J4YT6J@S9TT[-26L.VI2L"N:]N!/["^8Y1FP#]M,</WWK&T;=?O1:
M.P@_,2X<"/I3OM%U@5';WH*=1;5[_SI1U' S4LD+"WE0].[87?TGGQ8S/^8Z
MJHB(LQJC7!>RWWC+@AL$[#$YE>TU9-19NSYJK*@ ]!:2XV::V5FTR25PEUOO
M ][+FXSW+5XO!=U3KV,=K%OI37ICICT%W_,#7&,+T9^L%@#<2^S/EQWV!9($
M(;L&)L6[Y&M^1GL[S/1S#\+ACX<(0[]D12?8%/B5GCE^_-(5N5E_KW1#NLJV
MXWX[^@]S!TR3DF^2=#M(!*8=6)8J;5L(7^[9_"-UWMZ*Y'?OQ/9'3;U/-:FR
M7_4S6UX/9&9]_7JVZW3KYI)_8I+_07;M4I2T;<D)\PG_QEQP<%=GP]MF ^I^
M"^:!]0YW_I+?^2LD9L/!&)Y+\>E)+EA]$R%*4W4HH"".N>LA["W,.FQ-?QP2
M8-&U^4?L^B8C#2[C<I6Q7GWX(JO/O]].N/TV>O/XJ1^&Q_: $Z\<-SK\.Q!>
M-1#^NFJ@IVHJ?/3#L?V&B_[?K@'T/SX_\^5N$P8:W&*5\D_U?2"8"KMJ<#P-
M3I;O[ )-!VAP-X6H/OX9T("QA,6[]H&V%4H*[*;!/2<"LM78W7S4@%IQ18,;
MN$I06BF#<_[%$,6%;Z5.>&U6MZ#"BH.N$H*9==S*X-D5NA.OP+3;T%R)C'N3
M;XN0(2O1"D1+KKN^):"=&8Z/LZ/K#<%IU$5C5RWR"\><W)(,/,+-CG?2QWEF
MUOTE7Q]D[<9'/^2O5Z=K<'3R-8!'C.<O]QN1Z+/T&#3%,(=OB 7@]]6J;3[,
M()":PB+"A-W0^GOT$K^/8?QE-SQ,FG[_,A(4'7X)GVB+K,CO]Q>W+>C<O]+S
M@!\G!5UL!7HV6&SQ-U!(1/1^H51RG3W^'0Q6_(Y$O%$7U%I&@62_7M96+(;*
MFZ]'2N8SMLL)MQ 7L,\-VO\7':SQ\-P+_1*[;:QQ8XE]B85^UY&,/I,Z0IZ=
M=RO!E!S&N4F>@Y ?8X ]%7*5<F[R==^"7<T$0WNJ&2Q06%R7^?M."OG++;31
MMSTDBQ"GC-Q(?**%>4\0E)L36,*XR1@6/OOB5/8:5'ETC2,41XY-6GH_JTU2
MJ=5 %*?(3&[P=V*X61+/6H,X0D/I2POSX;@&BPU@<THE;'MM6=B01;<]?1&-
MM*K]+$1,L+>O:6<>>R0>G;X34H-RGX1&;XM]V+L;YXC:(FOA8&A2EIE&6H*<
M [WB(!-9M(B[=-3"<'9YS.,\,9*N%^+[5X!_:\$_9_*SM///F/<DY ?95Q4\
M&G509CW.O!+\I%\\Z(I08.#D;.[RPH=H[S>&6R-%49X&@/O(8H'<X#0CHI&V
M,%].,$+?"?3LPQ^>FCIE$YZ[5AY./,1KXCWNWS^?8.:LG5<OYRX1XD5$[;$A
M/;;J<?D*=1X0+(G#]-.[GI[(K9 T"^:'DI>1])F>X$1? C-(YG&&\/>;%SGY
M+WEOGK^^+N=W3$T88'RR%W&4FV^2=_F 7P6%(S5#G)C@H@^^'T5S!I@D.$X*
M)*-:LZE["2P;#.5R2!;P=^$,-1E9H2 O#LO(DB0@%-F;BYW6:BO?CJC_C;DW
MC6IJZ]H%8XN(B-(*"%$14!&PH5&$Y!P1$#@0$>F"D*.(-!$Y*DB4D*A(#\8.
M.((0 0&1)B()*$TB28!7.1KI!80T*$@3V%L@;$E7X?WJJWMOU:UQOSOJ3_U8
M/W;&R&[66O.9S[/67'-BE2]2&3US0I/T^/A4XPNAE[8?"#5((F["K"+L)WPF
M ]@XX;4RPGL,+2Q-<@Y,D6T8%KOA>GRC!QO&%GLUL#HK$7YIBU$G(W6&XM+W
M5YGOSO=X]$>R<):^%W?8J3[1#8R]]08:!$I</0CP5.[F6>(;C!HNY3?P^NTB
MB,+,&R<)B"HXLDN/O2.?H@[%>[_NIZIM^:'7]U@O)ZLF_.:G?(=/!97AR_4%
MUZ*(99'7=6RU_41^6X+0G/WJ'4:P2_]YG,7O UR?^*<<]B5?]/ >2$ 2WL/K
M4MKU\R<M)O)]H"0@A+^4)OE=Z[O8<R OBY1F[; Z@?A'GX7A^+A+7\R(6X_7
MO(7I_2"E[$$ZI?B6/5)T79HOVRA[S]VX$'T'7C=P6RC3DY@ HT64J6!]P*2@
M"B+Y?FZVM4U;K.1NQ5ZG&R2R\]II%DDE(].-.24O.YY%' [X<=TO=ZG./Z*_
M;"I!QG?27*4@7:VK&"N<54'1KZI6879K$'H;S7O3EAH\"5:$GM>ZMC83<(>1
MUJ$J#05GO?N;@K,2=V" XXP%#&21(MGN'F9ZB -VL)9>O/_GO E4 3X\516(
M5;;A,C=L\+OZ+UO>7N*TZ-\Q!AO-?H[)-GKW\!@# LN?@#DAT*\RN1-1>URK
MA6&*M&V:>5O=>=2%&*'/S1&;!8^&<;\]5976Y9RK@PM1E0GG^H,[IH*''WT9
MJ'2$R(&E'S_._&*DZ%^[.HUE3!U/EP7^4$BA6L:4J1RV1PY;\NZ3PU+#Y#!O
MAJ1=<?E+>M(+TYF@20PA]J)D7G+8;)&"V7%DY<1?67+8W/SR_6)&SO*>E71+
M+\@2!?$?<93M)$L5X#ZO8(_<B<6=3D3S!:^591<OY"\%-C>F2!R1RP5RV+BM
M',;@_,<;E(CU9<7$GR0Y+%8-2B8N'I/#_HF6PXCDWJ1K,GV G(0W"(LOQ[FP
M$'"@AER!S5M*6]2'J_X8NIX21A2@-*<&;BIFA&,\MBP0W1I;@R,%,>C]-"$Z
MYJ$<YM='N;QH<%P@^#D>0?ZI(5,>EL.,Z]ARF,B=QI"Z210N(G;\_"LYS+=J
M\MK\T$'\UV:&>DOU1_,65!+G)W'&OAVG5I6 S<G>1Q_X(E81GVSHG)%68Z\.
M#4S$S=Q)WU,3TF8_WR:';:!KXG]OH?8VQP,L_D36HCZL6-$I;;*- #<M^A)S
M^S-J8W_,\*"0:7C&<5>4?:;>K'"_T$H<&*^O$AAO9G8RI(%:1[UCA@T,Q#W>
M?2IPF%FA>8!]:_<5Y_349_M>P#;6.JT[^LDK,_3H$:;DP=7+!^F2BB9GZ:7L
ME;B]E:!CV'^AK0&4_C<"[:PE(H53YW-K)]I(:8Q:3#(1B[I+. RE84OP&_JL
MN,J$;J1*C*4.E#/\;M0!.BA@:$;8!JN#E#3[K5&566N"^Q!;)?X>&P7]WGQQ
MQK^LB/I3,I.^V&U5^'5E-#*7"%R:F[D-QHM64@&$X0^!+AT4??Q)T)+-&-)!
M*<".W03?B)MODYF"ZU*8R$0@W'?9KQ65+-/\3!,Z_^Q@VB64WSF!,&[JIF(]
MK,TO@E9V!A_?D%C]7N]6257^^Z-QO^9 <2OA8#^15X0!4'"]24,-T*:2QUT+
MZ8B&ZL#<C)@1I3-T@'.W1N*W<AK4AJY- Q$M6*Q%]K.ON)P)]U[AP@;KP";7
MV"<+TQ#U^]N'G_@AT 0O;&9)0%*6_4,$G&(R> /I$MLQ!>N &TBL!=&IK\IO
MTX1&;>3-YLT!8E-"3[ RE/)2\MNMB/KEAN28CY%+[&7;9#S*-/UTCR?9NQ=O
M6XY1:RA+VHYYVWM*B>_W3FVP(QB SS0IQB:(VH-0@A);94<@%+CD!!+9E>ZH
ME+SZ) $YQ6.,,WA-5 A,M%ENP<F&'$R&?8 61KHU5WMRR#9SKMG#(+N^I'H:
M;9[S<N[%Q](= &;03J:8_%[0;?%AW,#8Q Q9?";RYADDX,:]1=Z Y!]5/#0;
M;!I+F& 14Y?#VAA9RXQTA 9$;F6H2)3&D&F&<% G;<'<V[6Q]SEFO7LQ=/,#
M\Q.W8[DCZ1F(3/;#R![]>*;V3J@FBH4Z0GAS@RDL&^1:B0\/8O 5Y(A7[6N'
M9(GCX?41C'4+*U$Q:BR,CNP38W6S4\V7LQB<-\M.E,13$5J^0SO?MJ!?VD5N
M1?<_*0[&1,C@;]Z2%@^+]H+9E"QB*.EV[@$H1!"6&-U\#.AI16P E9+IYA)C
MJ  (;,]#IDGT^0E&OX.J60.)B/V0>RO=].&' 9^ZMPT]$J>PTA%<"-L75$6Q
M[/KKGG^,)EKV4O^CD,Q',FU@YA%@*AJ3DND[9/_(8=2XQ"@)%F@2V.1<HND'
MO<=6A^O1ZG07D-MPCOX'.!:WQ]14ILPV5SS#'G"Q')SE_[0TIU [\X6(N5];
MI)G$2!0)#D1QA $KA3<.*N:@;%]?\\HRA:)'*)'HW!D7\3G,\+_HAM#*9JY5
M;J-2AH5N60:+H)OBW7<.KHDW-1XF)Q%,Z"3!Y@=:7!92[[U 2<:K')L;IHCT
MH95*?ENE^?9QX@.R+OJVH+C6X ,TL2>IYDMI%<(2NC;FON>R#HN\%;^J\NOP
M5SGL/*Z)%:>C[E#=D6V=7%E^-I*@#ZZ[5\TOB$9WS;U#O*4V41FT>L:KMPTM
MM2T-R;.??G:'ST9=%EJ$!%3/1M7L#$N.O\&/R=$MCKOG/Q*DFWW;Q@QZL1*:
M+!LF4_TD6WI$Q9\5PWR/#/A0-.I+Q8>@O,DJ)(^,J:^IW-Y/6(O0C/(UMSVA
M4)22WXE7[-&FM[WF%D9,IE']BWL7U08GVG2TZ8;]<XOP.Z,[@+#,9EMIY?]0
M]>??JTQKS\AA"BV0>!O)X\6OEW:>59!0NUL-GD8/ CM&3?.%FXS^"3ZGETX_
MFQ9W]OV#-Q])TR+&?3AD5*10B=L#%3TV]UJA3T09<RJ8&XRXB_C :-OLNO$1
M.0PNCIO#+ 8,BO\Q793^1X:@7#APNI"\3L;82LR]C?TYQ#A-Y)4Z(%2DA%UR
MF.7J@>^T!-] V7<7F8 X.90RU[Q5#MO]*7 Z4P[KE9SR$_JE>(_YB%+$MI/<
M382]T!J6WG;X>KKNE&POX-S8F#"7OEAMT]WI$83QZ;%ZQ,\*]"-[)#@4]6AC
M/0)=,X3OF+G:<9LM2(+J>(MR<*!#+YD&U+%MA&7AC0U,-55</).NW=15W&M>
M..8!\"[4)X2?C?0[+L)"AH%!Z&/$6G_,D(=#I?]SC9-9N)?JE)G>&PY]WM#]
M3,'3XL<)@^&+W>*.F)B)7Q[X@:D')8N8K_O/YK=]+D][7NZ]F>^\$%GA-%J:
M2W7]D-NA95(E:^BBK\=IB-(A$M@@N)R%%0R38!$RD]<]]D@^&?8[GZP*Y0?W
MSUY:$ W$ABJ0<#G!S*4[!II5_51I7EB<DY?UJ_?"G_LI^_-1]._-4>*=$7:Z
M4#F?H1H9O'L L0-WGLM$' 2<,QSZ$U=C#5>!GI52T@WLRZ&,T'F\$]]].LC9
MP<^G9Q&;H/WSRZ3?=9%O#^9].?J75KG043"-V@H-!R*4(4S"<[QC_#&N-D[)
M!_A45(E3.CTP<UE]'*Z9I79JH":L?N!;-MK]O7!QPPQE%BYLJ->8VH(>&>;A
MPD2)(#&1L.<]Z,<<4KHE0;[H+!^)L.1'J3'!\,*-4193ZYQ?1QDY-[YJB;TW
M=2S!]3+7)\HY<-K]6NR-*Y%9D5![SB'SGQ^=M]YU*#CJZNZ_+_C;."WNRM-0
M8ZU8D]G\])0"U"HVM=S614L/=PFAL>&5OQO-R,>M3*]039JO$6QAX5GU0A#A
M4ZWGY6,4['-4("VP@_N&DVO+;UM':^-_?UW+@+($"2I\-D$?Z!/E\[-<WMW'
MY;,1#KV7HJPQ6SBED8:F>J8I5.YFB/!)UCU297UHN:"/UZMM?H)V=TND_Y(<
M]CJ:A5P]Q=";)1A!I(XP)D;-"KD*:F)1^(G/3%-GK5"Z&%Q.VT)"Y*C8HZ5[
M=G'87:AJ];<E5?P1Z5KPOF\B,-PBT+-'%@9@A&O&,$H8W&A\UC%F\)%N^LXI
MM2J% J C/[NDXLU?8*LK;"H,WUC1FEZ'QVZSN/#8R.4O\U*7M)KJ&I/:'I/7
MH0,=9'6/4LFIKOW-YL#2;]T(,S1TL3.@Q_XP_PI_6E5[F)D;E]MX%7>=XTZO
M;TAVG: _G=)!_X,>^=[]"RM*E=!VB(Z,7BR(9_9F]STN*'49<K6E5NM56_C%
MFMG,:6F(CZ7U13 #\@L-6*O6'3G"K'J,#9W3]_+T$-O5:(+=Z6="=9TIIL<\
M"^R0)R CT77(> RS*@C'8N4B=>T3KF/80UF?$GFJ[OP@3JI$M7@X$GW74/LU
MF))DW2D]'-R[*'5'U3[D&P&]5UDU7P.#G4H"66O\4?$]^(/25"NR)J3&RF.D
M34!I.JGXL*C*D:%(/76<!8=5N/KV5L'GCBPKU):I4[AR_Z:WV=JSRQTLIPNW
M"X/T;EPR[,7:8@Y+CDE+:')8<IYO05B1Q ZR3:B:A$?*/H!T"B#KQ^A_R?_[
M6UJP ]&SI<=0@+V0YY,\+AJ=&C\Y4M2<-[7IA/DDF::450PL$."@WUV9CL13
M.[?Q^RRI"O\'X-&0'EN]KOGWORQC]1-VQ351J<E=--6EKM^OA<34-KF$Y70+
M]^\W5^[N""XN]^V*U<A\WEO^/B*<EAFE+5C\=M6M^_3 D_-_V?M\3$O6V%[B
M)!BSL\9Z6A^$^WUG6YSLR"NP0%_+5HX$?E9LN]J7=#E 3%P':J?<X).W8 OU
M>]$ZO?;(JDBT\?RP%>GR0)[/3+^M^9K.[8>:S:TVGX_8F>Y\O'3,V=C9P>/*
ML9&SJ&N[F*_/>NS_:=[2TE+:V/RIVZXU(D+3IOY5\OE=#?7)9KA3^_]JVQ[Y
M8B?E]^ /RTUFM.+HFI3!WUV/[XMRBSSH_=#W]$/W)Z5Q%T:&_*ZCSXH'_J?$
M'WJO\"5".>SAH( H-A[BRDH)RI3!QE]/>Z2S&%ZY'/:<G PN21[[$&=T5!17
M!XK3S3XA]N^A9"!Y!1AJG$+68,E?<D4QTN?TW1'!6EWVU\"X=UY0.3O/[\[^
MV 1;YG6[Q*GETMLICK4#-([ZM'8_P2/S#R/&0.Q12?^#K-;C+_YFO'81C@!*
M(A)T*1:E)B$"86U(=9PI+Y<IA]V#JTLB^"OQA-J,,,HZKN0H1"G!D=% =!M*
M!=(9LUY*I4F-WA7NJ@?\,AY$,?@(<(23M(A4Q1(,000MBA+1X'OP5L*P$WZG
M0 W:ZS=S6W&SC7@C\"[!"LH?TT?>0V[8SPA72UG)MB4^1.C%Z!%V!^$W]Q;U
MF/00S'%U?%.F92+"%BH'.'S1\]AX_:!C;1@->P.^JJ$<=CH^:U_W;)1G^W+W
ML#,&VC,P$V?;%IU,7BLY"+K[0T4@7""'L=12,/IT> 1\#7TK'@O]>CZ-64<P
MPS'8B-4 IMV,H8O74I 4!1>/XSMU9-A;OHPPW &1!,2MX:.J@*-[<3!N# W,
MD@5$U: I'CS:"Y/-: @3=H :/$NAI5A-U@E7KAYP I%"]S'2-DHZ?1<N5W12
M6DZ,F%.&XEH-58'ZDA=.Q>%HS+OJ$/[L([4,>Q>!\:M$#(BH!7=->T![>2\L
M9$9X)^ $?0,]D:V-<!@C06;P9)DVH8=8U\%2Q7;(-* *H%PPE_4?X8&;F[V(
MP"-1H+2,1LH<"FM#?>D4#+1:PB ,C\0BWZ6K]1'V2TY U0+..L<Q;NIUS+;F
M*%YT2O!.8(*T7[(F 8QNS8.SD,E#GF^W_P:OC_&;:%\IZ>LA38DI@/,N4Z)!
M3%NAY5OI\TLRL[,2;2!.,1%NP:EQ;7/IP8>:(8T7N!!WJ(^?",3SPYBH;2M5
M/T@$#0RNR3U#8,HB:T.VOX-SB=V=;7YZ2\DS4<VJ8Q'-R)XI..#%^3+O!M%T
M6K-<! 0&5N +%93AM[P%8\CKZ4?AM_5<VD?.MP_-_P&9"RR'KB#T;6>X?'*F
M3IS.4%S*&!0D@*</A=WKR(KU,'MG^<PTB^:!9"WM@/_EA=&"HF4;=<3&N ;!
M:"Z .0ZE".+)&E"BP#*=H ;YM34HAMQN$K,:CP6OM6H33%O :"9C%:$GKX'E
M#A]D*)P!'E&H!+;5E/-02GC??HEW="4.WIYG%.$2 .2F7K+B;@1($JTXT?%N
MA"K>$AP@(9 H$(W1P"L#2QURF [^#TA5O(/0?VVE4B<S*C:VY!Q8*<A-;$;R
MB??RN#-/@+I $LO0K-<J7PX;0G8LFU?=1-VU#ZEH2+.DSBGC[HG_@$E=BRLF
MEY.2J\^%O)STJ\_+R:T8"HS4NUYR[IKJ]R1ITK>]5R+B0^,N_PP<00<%OM\N
M&MAR$N!L2MOO^:\/[&<JC_]O.1VUV'@7,+B%1UP[+3,#.EA(?4G(0 PVW+2'
MKH<_PH"B2Z'AMJN=\5%8X\+;1#!.H,9DI&@/V+Q"690>@\H%2LE50Q\^C!_#
M5F8YS<Q8B&_>$8P/=5OG3 E4P@OCL1<>"OSY6371E\_7U37X/<A&QS>]Y]'J
M4S5V+QUV6NOV\U_IK B3X=?H>I%[T_:0O:[.>S^<CCR8Z7WU<?YK5_/ Z!,Y
MU3]('\FW%;."M%62 +4J#&HT48&&4BFM>>=+B0Y4Q&?<)6YO]ADC;I&U;H5<
M^$KI>"\>1@GO^2J?'<57&\YO-]P'>CY0NH5/X*/41T<D^P *^U@JOW?8K>'U
M6X6H*'J.GHYD %[N!KYRF,!ZX!UR4$7T3EHET\<;@Y:9]EO'&%GP55;P09E:
MRF?<-)]>4A&!5)<8\(+,QJ*%&D"(H+Q=Z/?.KB;W1M&T'W<574^" L9+!>(@
M%'_N+HVKCG?Z;._.-]?_B/Q3ET<2M2ED2*?5HQ,9ML(^('G#DV].ZAPY;-,Z
M\2ZG;^W^MW[^>O >GO,VX<=DUH=W^-_%QV1=9)@<%AK]Q9;/F?$2N\M&E\D2
MC7A1H?1!E#5'%>]$I39*"ZRX661=*_+::4.[!BJXU(I<1>A:*>9J/0FG6K*(
M0ZN-E$CVEC7XC5" @*R'+3QZ"'^HH3>&FY9G2T+ DV)'$GY0PI#?R++5<ECG
MQX0)KARFCXPF#2X)E.X0P]12Z&N@56"8:!Y 230Q/,Z_4Z0!&*8YDN?[I!AB
M\ ;N2LQXN1!)B9V!'*H;P\Q\+PO?BOD!UUSX"#\%>-8>AAJ[999;<7'LPNU=
ML5G[!.^D!8"1("X+81)N]UQV4)HKLR)T1CT+&IRT0R;)#D]CZH)KB363S/=!
ML?#-"H"V)GR&4Y52+E$S5E>66U-2K4F;I["'U&HG#W]):D1R_))FB)%<A5#G
M2+9JHT@8N!P6;GF+2\UI 1)E&S,J<"Q!<C; $.$ VP[3;AYH^XX*('(5R)]$
MU&&$P77PYD!PK4 MQ9(W:._$GR;=)NB P;DQG6O[$7H#GN67B%<LJ)9#8[P!
M5I8.2PY3PCLJ?-1P1H=2FUYSX5XP5Y@+-K4RZBP:GO]XA&:*[*YGQXMWRMZ-
M[@6"WRS'?KNX@3K,O2O3ZBVJ;\R;.P5>INT;#C@>%(?!/37)_GHA-TX[U[-^
M'G/3OE.4HI@?#Q4<K=#>'<QP?PM9BX]+T$#<3)OB@9MP3:(W$ T@LHBJBT28
MK).@"7JFR6'*C]$3;"Q<5W(&L&23]>MO UT7(,J8FAJ!@U$CV.!83.+F3^0:
M;*%!W1M0)XDJO58O5: YKTA!MU-F]@+3K?"M! >)9_>E\U E)9RP#3K*XVSB
MAB_/D62'L&A1!5]HL8&@"T71 N&0:XSPL$R]0.4TJ)/:+1IF(?2[K<U4I-$!
MM1E>/4X3\\-B)[PW=#@!S)>I9 ,HT1-IC8*\A$BQ[%$K:4&SMRTK4$AD/9+L
MEE85H2"3Z!D%O5%.F:D-K8;*F<%*$ ?L9-K5-$0KO)N19+_TL7TLL$9$ E/N
MT'?_R$LHH_'W$HPG#Y"Z+*$]M%+.BKN[UT_6)YA*5("&5LK0FF#(5*PSA.,P
MMT!$5 :;N'X6?P[DBB+ :!)AW63CUWHO['6$-E">=>E9CP4>\:BUG$/D)QR:
M'?_7R)? YOV/EJ[^YP'C#CBT=[Q ;!U)-I##_LQ'#;%X?A(K/^9AA>>Q<R<G
MRV' >QE"6B>1P[:8,@N.B34"%!/*%!CFH]HQ&D$*JST91H1<0X S]6BE@O&@
M*5^5JUFF?\LX! MII4S]H]AN9>5FC;TN'Y4(5U,P''W9,%$#H1N!I-G>57 $
M1CNRCCO3!PQTP#?$$I,0!HG\R[F@R[O@G:\S_%Y!&0(',Q9#">\^1E&+9&S$
M6PLHJX>^,I+-Z=NF,$JQEE]0.I+M0$<68B\>#C6\Y&+[9;NAO7*8RAK9UD!S
MQ#0JXT0ODG\!=WV893<AV:T]8!?4)QT8O&1NE.\F^]1+I>P2%KIS&H[[C@0(
M,(D('1#5'IV$V4Y3D1+@VI(=0$H;<1V$]:QK["D!A*)<,'V,W\=)J[$>=EUH
MRO*<.%7[B)]SQVKO)>N$0Z-]%HM77J"G+@K>5\&0AR37Q.&R_D:75L8]> ,A
M46EF[IQ8G\"1[8&^VZ8B-D$I[S#JUJ@ATW8Y;#WRHF4JXA"@U&Z9?M.EO=I(
M("(#XE;9[MYS"D:&U,<?A7QN "KMEA7A#W!QQT$XR<IR"]9V\AE8N .L;^$C
MA_7'1%E\C!K>K,\>!9K)-AX5(R4.P$0:W0RW<4E@D,LRN+DD4_963$(3$JC#
M'+(H$'#61FZ!\MUZ[2VC2T90YP11ADM>@&_+&%P5/95GO[R,M8OK+]RULIZ$
MMP;7MP@ZUT(?Q<?#X74#;&1J(Z.-E"J'U0ZD*/A:=X<H1L$$[+T$%9*$L2P7
MO[PQOM-<1Y8EB[N5OB,X$G$$(@$33.3V9FN@HP,MJQ,8"3#K(^W"TB0N95-T
MRDM".U%ED9B12]:=C9TS+$^W)(935LMZ3G_Y_27N1LPZ<$*!1H/=8M&%+NK?
MP@L M3$5R.+<FAOO6SRVO@\>D-_6J26M8826F(5O7B7Y)6O'4!GMF,&5XE,C
MZNUS?'LR54U8!.J+ODJ?(TP)GY$J#%XNMSY:Z%3M$0)DB/[&)!]V C/XIC,E
M8$@[4E-F!C':Z$9@@9!QAVZ*JQ2$,3GK)*90%%^JQF<W8C)I3>9Z\VW(\N#-
M4BKQ$C)S %/;<<=>%9AXQUAG'PU.L41T8KH>5Z@%P$6I )NNW\T(Y:3!-TM,
M^=PTV09(!508L!(887\8Y+!&C1!&0,=M^LY(A.X*;C%2$=I]BTCUJ3F>P;7?
MP(E&A;VUVM#U(;]WY/5X6R!_+$RH#'AW,%99T(^8LDCWY#"U1>+=FZ0V,\M-
MLBZBNI^@O(VQ"CN$8C,2B5OH*E!3:_!NT(>48IKQ!^C"-$#/NZQD'V NWR-5
M!."2F0F7Y[F2@V)+G#>+;J&0,IUSAI( D)$A6PU9CIG>6;#<(OD-3*"DTZ*W
M_0YRT( -8RP*VW$S:3PU-[>QFE[",S#&FX?RWTK,^=$JDW&V!'@WWG;][3"^
M]/ )F&0V&MK#83?!AS7>R6&J.\$PYLJY$,D5L3OT2!3=_)FN1?A KO>DJ+&F
MFPZ.236.]],8T!Y5'KQV+E6V>Q#':1TBD$!;$3ZE5:8]T*Q,K( R6'HHMIH^
M-GAS\EC;650R8A^ASU +VBN^"'%%J2!C1BAV"Z?KKY3\P9M#'CSDFBE&'8>$
M1Q9!P0IHB"#?*ES5U/L\0\%2J(RV2I5J6U:]H7&W@KY3?N^V(FWVX%FF(0RC
M]2+U)C(O]/9X]! 8W0Q>'F:S%6<[[C#[JN2&M"P6LTIB(2VV9@PE\DW?8>>T
M)=;UD"/0(R"GKQ"U;=#K!/,8S-U&%S9G&Q2'Z5<@7>-)"1(,$?BQW9'*CI6N
M<-88;^G>7IV&/N2?"EN<E\3TS,H.X*.1:@1[O,+NP6E?R#.7K$Q*M%<#O?E+
M;&0*6<,"[\HS.(^Y>U7BV9#803>"POC?0'**) A4:T?HWV&.^:'61!AN;&$$
M_H A_$".L$0<& %70APAC"ROA=>UI,Q$B9%0^5CFZ [HL "^"G^R#QE.UI=L
MD_XMVP%U*MSO_RX$31.ZD#2R,)__A!C-U9"H]<AA81LDNN+5O]&M>NUM0;-6
M\M9F1P&79+BM7IHCTY5]ULME5:NQ9080C9>EP=?)T)[W [/OD<%C?@"'W;):
MH!K8NNS$8;G;?+:6PS2Q] &!)62JQ,)LP8[N?X7*Y%)-;HL=\(Y01J7$'R*)
M#11\"Z.ZGQB&,L#-MQGN(W>,'NF-O5&#T R6X+HE#J"^8-UXR=@*7&U6Z.U.
M%F83/I8RC=B%, 8NEI3AR.R;ERN%HT;21XCM$/FD]-5"H!3;_GE(-FSG]"D+
M]'5W<#E^;XPE:L"LL5(;7'9%P.U']=^0W-XH%.WW>V4DP9%FOVV@?8-?M48$
M:G,&3.FNPEZ/K^2FEL/J4B1:&:(_Z) QV.#RL'^ C7:B9!+4)7_4]5P*!>=:
M.?J8B"M??P0?!OZIHZ_-V [Z0^6L9)&Y;1MZ4\.0UB+[>&#0\<Y?(L541JWD
M,U00/CAD@A0:ARCTP6^*7YNQU><J?U271<!?E0LQ-2-<#QXEG:$6J_]K@;P*
MTIYO1S>MB>./_#&<I<*_6%?IEENHT;_?DJZ,JUT0>A\'1O.CI7=_Z%E34JS,
M=5C]A\ZZASZ;U+N<%6;>T[YT&CUY_:\OP^^O FUK47^!OV4=;EM[D)J4[J1W
M/W$^3+9Q94/L%;1&(9B#I4\6R7>0VE75> =PS?&4T_VRM9*HU]W\%C"L=<Z0
M$ZW7]F)0]G,H*J2U48P.F!Q% G\,U(L,3;L$R?ZFW<VH$BB$G;=!:?*[EN2^
MXCNW,W@OD53+F0GQ\96RQ2NY2MZA3!7]&DE.00X6;I/F,,(M-2)U_.S4A Z\
MLKP@RU:][3*K/J,&C#9$8FO;A#-4FHDQYWH)NS,"Y;!5. '7'>+SQ2W(=DS_
M?RL$L!(%X$I:0$%'L3*5BO/<M_&DS3C'4UM,E7?9-/!<Z9]'@\_/;^C=^OZJ
M\4?V$_WFKT0,;27:P/+?T08_R)!YVTJT 7X/$/3O:(,P2'?GHVN7K\R/?#5X
MV8J\D?7FA()&_'O/1.E[AT2SO+R52&%COO/0DGI*+QG:BT+=D<,PJ8S.=[1?
M41B?'#GLK9<<]H:\?+U(/+>6^/YPSO(8<A&IJ;5L#H2P1W4!M9DKX+&VF^:<
M=&JT]A3"J!GHIU5%Y!'OSI:^[:^Q^I[!7+YT.E*4ZXDW,,BIOC14^\"Y(32>
M*%!>T-T1(?P6_2EOH4DMG;"SAZXU3=[P9UT7F866P]*$^( ;">8M\]@'D38Y
M(ILN5M35O'1_XT<F9&7<]QZ3ITUNOM\==Y5]2?>D[M1Z7>GI[??ZKTS*[AX/
M!VO71??:J; CRN-6!WJ-PC9<W+9OD??M<>2Y'_W>E;K.7H\C+3 WCKN6'VE;
M0+K;!Y9#T2=[D9?R+=-&]X,Y=?P7"_#!A>E&:0LI62W3@O>$9E/7LS =!7<$
MY+#DL::W3?$>)A_&H_:I!(8^L;0^:N)_V21ZB\*91M]=SDV+&3F+*^FX@C<%
M+=^U1 O&LZP^%KN,)9A,LQKHNBEG>A;?\+LH5AGB\*K%.6I[WH4#'N:?X_?,
MHLVL&'WV>?!A)<$NW".!3MKE9C-@X,PC010YR6I.X\<R(V4QP?VW'!;3)K?>
M)N=^1$.PT5^BY:QJ*1M-C9O'*">:H1.2<DW5ET3E4%J\P, O2/8!",VFR6%,
MJ2-?F\S/LG7IM9+#-D(A3+O\ ->K]K:E@=B#+3DEX_[,KJ]!09C?'MREBG?6
M4GN$ER!^2AMS2OU;\]YKZ"O?+UOM\7Z8>29A<&\KS6RP+<"8&#_^UR!R"[_D
MR*G*[;;4HKL^H:BM3J<?3X8>O;[1J^2XE;D;]>"1B _6CUORBS:?["'9,KX&
M2$REA5'V:B_Q%T 3"GA/+3FO(:-:LA,0'^\Q LX6.KQ]2^M6GT#WXAUC]Q_"
M7?DSRFW8[UY[]_#,Z=]#PM8^_!K\-6B_ZP\]S$P6,-HA4,O$&PDL=:%'[*LU
M^?R6.#[Y;K-Q!<Z,1; '"1D"K=[+IF]\P&\B.RUA1THUM6G^96# V< _1-?+
M_7 SJGUE#TS_8:C2D;A*/B.9AEI'V@QI= 2K]5GOH94!'>QH546WN9<,8K>R
M[]N4GKN<.Q3?<<WJX&\/E;^_N;W)S+SY ,J871?I)':%&J?;1DW W S%ES0(
M/$L$%QM&L*#*NW[$SE>?B^K6'SN&5-SK.3I2SR>+UK!\I$[O;O_2VA;A3!SZ
M>0_W?57%^3EK/5*NC_9X?H0=/N](69[7BY>(F(F/,3T1'72Z4FI+V3ZK@S2?
MW>5Z&K&3'KUW*A)Q_B^OEGK&3'F7HS2VA[H$J[/MLIA7'A?9!0^' *.6RI"M
MB/IYY<!_]&W\L>)6H-3DL^1*,>1F[G*FK@G<W!!AW$Y?)CRAU)>73>:>"AX)
MSVNX'5NPBXMNB#Z:M:"V=B]J3&EF#!AHY6ZVM,< 4H0%;FA4K;8TE^U@LL3/
MS4#H1$:KRV'L64&XY.!+14<%%47D7 N<LE&/M,O.0$<,M;R<'- (DA:/CD>;
M@$I"1Q#.[I(X9?C4 8_O2T[V2.#/,<,=Q9_J\]9G\S+$0I<3/<U'+RYGYE1$
MB J<9T;;:E@UTI='[8N]#JG0HH>BV_SHJ@-XG6*<&E_GMGFS5]GPI.'N_N9U
MO)/VMA1L7HQ;IS5-(EKZ.=E^K'7W*"[QC\3W\^/:\/,!&[NS]J,?A^+*IKRS
M3SROWEUQZN[3/#>/<N5!.K:RYLS3T&VEMP7;_$HQ0Z?OEF<P^]IZDL+%^WKY
MMSX BZ7HR"V4T\\CSX'[U'/K/2T?]%S)WO=8%EV<;O89P?[?W"[(_&_;!4G_
MD^T"R<JQ;\PTD8:9X8C-9!^XKVT5)! R]1,&\*7Q_/ZD,H4#H[156J8A 90P
MGJ]]UP+O_L+UVIBIG:6P-1X,.PT49H>\*"M)T,X"R%[@W?K^I:T1A5M[8]5V
M?2!R-BC<0@ZW?K1 K$YL/8+0QNFTUA=N@"H$Y,%C+(7/4SQJS[@"Y;?::Z@N
ML2B#IAV%AX 4$F&WQ*G;.DJ'/: ')S5C@ 8G@-*&21Y=U]VL)O# >"6@1(]Z
M%PN.6L0D' MJHLIJPI^IK:0BLA69@IB[Q*AH+7P\L#3S2QPHP4-PT$44#ND#
MUSP \HRI^"K4(+* '@!A;9BZW%2"L1QV;I)P &##Z^-F?!0H*R S*=MP+@+V
M/ [EF]\1O \,8\$U<7YLO="4Q)U=A)T8;-<2^57*S#F%?B)(JTN@C"MBATGD
M*OH6.8REP+PPSATT)IE*&=(/D)9&20Q XDEIA1R&I60RU G;3=M0::9NT/NQ
M]PLME@)NXJ(TL'UT-U":F[SH@ K,=0;&&ZI=^+_TU(;<]JSA889L>>5LKB%A
MF AXDC)&-0&.B,+BW-:;$Z)N@(%LY# "7JO0+K[# N2[)Q)=WGODZUAS7\[9
M 60]_N1TV0PP^J3*M3Q,F/?RRY<U,<B]=#W9/XSZI9D^\1G);NFS&63(G(8D
M"@A+(D:0((OR].8H/A<F"90^C2&E:1,W(Z/(0RQ>+ILSV- F6]5#WX/' $IW
M%J5A[4,Z=R[3LL)8A;M .>SVY68#7@91&YDZM[\Y(8J/2AZUE3U>B;4A#9:+
M3*3E]D?%482/7%HTFYAT$Y5H1=+"Y<LV%H%- DKB@ARV#:<?]$@4VX_$>KB+
M#E*AO4!'8&./]>1YL)RM&L8DKVWVJ\*C0"7F,%$+6N,*I2$S+^V78*IQA"76
MR@ I5<G>P^OMX:\[VDB0<5_*#/]E)%T#*A 'X5%08JELI M_"C)3?*8SI '&
MBU[WR6&7@MS;"?L ZSGV-F3$=>DSO*:]4Z7$N$NR[IE$:\!>K0HW? (@IP>.
M(;)X4I<SO7AKJ6[7;W#.TEWB1<5,ZWR'H97?I7$&R3P7H9,8_L.62VW(5-#S
M(1M=Y"7X':[!2O([';H2U"!HKP8=!9A[>!7 5J"6T8P!Q?RX#DZ&=OFGKAB%
M]7'KXF;:2G!^@NA[DB!X9O.U,36E"(K <ILD V"(U*75A(T$A5U&)U.C!]5$
MK5"L^)QDOS0+L1I_[+6TA'&.,YPKN@HXM)6S*7?1#21:"Y+'$"8 F+&P-@<U
MT16H",A@&>X O<B>H#F#Q1FV2/!C%EI!M\\]_V&HTFOUT8351NP;T5PU@52B
M*JA/(XJ)2AKR:V^)9\GV0N_+\': +QD,8X]JT+!P%5R&((B<O#!,-,#2]5XG
M(%WC'=;X@B=NELI(D<N^?_<O)[0U>Y0//K;IRO[1>^J_#X[Y=PN. _WXR%L(
M:\CT#!0/6K) G(*A5=7K1%VVM#8P]>ZQCMHE4D4IU%2RY/?BD<FAE;-G/OP1
M='^/'S"1;G^L8C)/=KMR"#UUT[DD+#Y:<_+'8]_8B-,4MU*]A<G^$E_U<M]L
M?^=2N\?C3\,VWG]XY:FQ]MB>]]:[AR)***M(':'^,R9A.2$' ZZ'Y K"QPYL
MDVS>5:.A?Z>-_]*Y'JYUM^U4@=T7O-/&5TEHZPI/K;V]F6'*SJZ'>23HNNV,
M@G6?((S)'"1RV*\]7$WBMS@YK'A #C,B2YYBI&?#)#ESR^0]<EA*"$&!S0LN
ML\@Q+D>!R%F@B\R%N&Q._'E4#GNO@->^=N+[RW)8Q4_Z4G$S:1&;@OSA^(C(
MKULGAWU ?59 D U.@>8N(6RRQ/-(?J>LC' 2,I(99(DUY+ N^!LYC$1$RMQL
MV^"_#.2P'PK(^=>$'&:J(X?YZ2H<0Y.L_,,2\0[F]<2[N<'NJ)MCO(G$&KR!
M;88YE0W>(+71K?IW@M<I90YC9#U<62<&W%QQ3J"6AN[D_H$/ !W/T-Y"*6-6
MZ4Q+;5Q^0(I[]UC=\NKT8;4'W]ZX?6:?.Y19IYI:_G%FF@]L4_31O!-3T4W=
MF;SORF[F[6[@X^*%*.3A(Z [^]/.SMJC"*( OCWLAN=!;_]FBHV@>>E@9ZU;
M5J1_NIG&G;:QZ7.5+WU^=%$\?,JM-_96]*7[[-2U)-.U9!]E2I C2!21H3Y^
MM5];W.A>:16>"(@%MNQ U:OBDV\!F8*_V2AP8IZ'2,'R*@-55?[HC1'NFV/"
M56/,77P3@_KP+G'(-(M%;.>Q:=5#\0Z&K!]Z>RAGH-_^5W&H"CB3J2CZ=6TJ
MI%"7ZT*DY%W O>H;6&!:1(+0C;FIC(L4DB\89%*J<!9M\])[4U$JP;D>9B^F
MX&KXP&NED_6CNVMOH>*??PV,D.W[O#/JFA,M>7K^D6Q#D>)V<5"';9MYO$Q9
M,93K @/G4N" %_Q6CSL?LP8WUF'[X#B99IH4\^;"VVX+\\7!<_6O0%NV)L <
MQ*)-TZIJ+'7&,'=&U;8/GHU$[$ID-Z!3%FTQJ4@ 38*,B+>1O!=(Y062'FZ-
M+XDW(1P ]$:16PB=<AC5DQ1/Y(^$N/=3S3V:/9[CUK0;[OA\'%O!:YK;4AF)
MUFXJI])W0(&"Z:(QHG(5$Z,!76N[!6_H]9M?49L(!4A]P/\F+6GV$<Q!)AR)
M)NJW-Y"MX@..2?-*6@!.FA5%HS6TB#1DY (DW7]T&B2G"*/P+;M0J=KHW;ZR
M/6!P-K^,S JV DJ_(740N@X#=RP66Y"MC.Z^_TMV>J(6,)#=A$SE:*CI(8[8
M#J>]J'LT\T0_YO73(O_Z?O4HQMTM6VJ^WX]^=UH.6XE7A[\ZIH*$CI7(5-:4
MW?J<01E4>7<S]_Z_?MW/4A(99->L:7SXLN/,H5TI9V+>^&;I;G4C8A;^'7'[
M<T)H)E8 -<N1M(X$>2#Y"K=]]S<H56%%;^4P92412:0@5CI2%RKJ=<(CL8ZL
M$*_H03FL$VZZQ# GLFB,*2IQ7&')P"SC])Z:1O\9GVW.!7;-K[)^A;SW&!*^
MG]YC,SM\D_%N";#W*OS^!HVSUS[VA?]B7FQ']&WM_2[*-O8E2,\ZN-V;?UHZ
MYSHD\G4U_A4MAVWNE\->*F3TWPI;9C4B^4/<131R?KN"(<5A*C05-"TBA#BQ
M)/,N58#$)\;B<)K"],/DL)P HAQV"*[@4( P>KD:_NL>4:+H%(-J.<RG1 X[
MJ "@E-CE!T[P(7_N2NF QY/$GZ_DL* W9%DR\5=HKAPVO_-__7@O:6F6'$;F
M_O)4_,%,[?]?3]<E?.*^MI3L0>I'$@XJ'$:B8AC#1+E)E&9K:8$<MH$LTGDD
M^AAXH@\Q+.) KK'DPYVRCI^(CR+_)6GYQ_F!]S^_BVW2S7*J([/'IWQRK89<
MFYSMS+4?N!*4DOZ^>.2?GBT@;FJ4NW6/\^;RNE(W\ [5SWB;=W+&RRRN+S-]
M3]6G'?_%&/?_:/1 2"H^/BHQ[36/06[Z,0H?B(W'J&*@X;:'4$9 +S7K,(N@
MG2PRT' *BS)U[I^SM*9HX]*OE>*('EM^:U IGUJZZOEJ\F=8AO1O!:O,A28%
M1'6<&7M4OZO96&" ]$@) GC=UIW"8 [[IKUWAL>?)*$#W/D-K3<FX\G"+V/J
MR5EV/?K.664C[?F-A;@1YV4ZN9_<1RHO;6WV"$RYLMW/?2\% 6>Z;66/'RS0
M\<RH"#Z"N]8M8OC759[.BSH=>:#"LZK:[:]\\?GT/2\1?_Y7"^C*B$3>&SC@
M'+NR"HT+9&*H'3,M%"+SL>+Z >$?[@70948*IK"&,@EJO?81ILG6VR2.)1);
MD)0^TZTR?'3_HK\Q PH5#&>P,:MQQ<O?/EHA] <DSFH9Q-9]"IG!8R3#=0CK
M)><AA5M>=Q"T329>X Y'BXRZ8YM00QF_0QGK&EAB^+9)@FJ?!BN.NT5BRI\,
MN"*HB$VSDBJUDS?CCT99]R)L>V=V [Z9>*2 HO9C.6YA ,,D2K;'*V!06?&B
M:811# V9BKQ$&2SY3?H488R+]H2(?/BZ"#E,Q=[PE62/]%GLM.6F07?S3TUC
M46%M0K7;]'W0O?[XIA$CC_Z:9@4,H]7611AN!@K3^&9I5J\OPF03U*@0-U";
M5(I+=&30^F(\KGG4]ELEG&X/??.ZEUKMV6\V@I!]BC$VH353"_4S;MS/?KAW
M:^]])K7R9[QL0Z* <J^1*]$P$IT'4H0.P+Q A\D94N'%)5%6M$C:Z$:H@)\0
MS1PU>]T(':T<A6Q;;U(_3^<1R"8-(0)&LK;A>C T)8W*%:H:!24&ZN3HT5^6
MSH5*74"3I@A^].;I49-><QJV4VWSC\:RIOB(9S^&RE-IG94>N]H3CH\/.P&R
M-&Q"-;:1"@PWHZ]G/0\(CLPK'7,,/8>]$F=_ZHW2SZ-B;05/(K8*N(!OAN4B
M.5QZ%V' _<6X=G%N/;'UZ/C/>OQPK;2H@; HAWD7D)N91 Q-AB.^IDBT]45J
M*;+-5U9R^A18"I"9UN1;2!I\I@L8%N&A@]4X(M^4/3RG"2T)OHL>B?5P[B@@
MD[ Z@SDI$+MG<+;@S4%/<EA\583VS9B?D]?7Z]<'.;K;PG_<^'_46OW_VN"/
M&0VHE9/]JE-#_8S2'\NRIF?X0'+KHTC;FXA'+Z<;T$II,H. R,98>NXU[6SL
MC6O1_(_QCGTAO?O/X9(***DQ69[\O[]&_M 9AP]>56"@3 7J+,:-"3;BQEC]
MAEN[[1TK(VRN!\/ Q=G*:N[7B+FB4?LAPA/^Y-PYH#VC/'+^[+1=]M>M$9BA
M./2ZQ[F8B&SS[U*(TL$9UC\]$(/1DYRF#E@8Q)(40\&D4X'GG6_0'@ 65<=X
MV]1%S6RRBKN"=TO^*6[W^E[(.XN+]-WJWQFQM?V*%Z$G'GN9/%$I(;@LQ"4_
M#<F_XNF!:EW:9*&B]'3TGNG1TKUR6&1OJUO9YJ2SUAN]D_XPR]ZONH?YO  1
M$0I%@IY:>6S'!0H?U3Z7+(?I5<<.4U(:^T;+%:C<)Z47U 1,*<@'_R,*]::I
M0>SS].%DX<X>:N=$77/:1>U<\'?C['_J&^X[_C4?\+5#I\I/0)Y9%RTH CM.
MMW25:LNTJ8#/C"$"FUG]_/-(D!GN^- AMY?3:_Q23KVMNS[2X)9Q-K/BL/-[
M\>F'+CM&])]G/+WL[*=KX'SFP8,''2UG=T]H#M4-= V__"F]3 @48#;PC\ S
MKWGJOQM7.*M+V__*WNN;G\CN\:\RWN[($O3M.?[TBF9!H/6&P>[LO31=SU,9
M/XK3ZWC,_^%4\/];V_OPR"G/DQUG85<6=>$8YJ/K?O%F]<N[LV<EMQ*T?E'$
M*-E L*&T (DE#VJT%EJ 5GJVB;*#7R2G $[J\[>-_C$?]1;/?\:T#K57U0B.
MF$\,N$<H$X_Z\[#=!MEQ6Y</KN,^S=AGY[[VY>[D<+>3#T]\?9[^H<W0YO3&
MDYD^K6M7?1;:69]SRXKHJ=CHGWJTZ^GDIZTO2L"K1]OW1<5^&Z_EH+2.5[OU
M5O3>G3J5E^1__*^GS[Z'Z5@KN[8>F^1\X$:AOM6)%)B:>)V*2H0#?YDJQ,WP
MPV'637/&3,*S\$.$;N1:>]O+.>!@.)DZT:8_@G'NEVAL)DVT[^PBZ$U?EUE#
MU?S:LB_#/V3:*6SBQA@#&_,A^^_(&KM*\W_^*G&UKW54WQN6XZJUZ\RV7X6N
M!U)7V3_\TN'8.S NAPD=%5CN*7U$O*A!+)DFV#5 &6,_HDIM&*HR7==H011N
M9!_<@NO?N__Y(R= X+K7)X*&'8[+LK5KW7DJNWZ-Y3^'SWKL-PRXW18"^EPH
MV;CMYN$"YWPW[P9+EGZYR9 K]MIV0FCN=US$V.'M%_77)96'VD'IG\L]#^6R
MM(<95O7IKO4+-$[W2S/H)$0&2:(V:;',)G@EZ5<,<CV4[TKBR]Z6PM>,A+\*
M#H*BWP5O![[.OP_CO[A<WV%3&7'ST2B1&9"P:;7*Y-SL'[?-N]?!ORC-W!![
M0^ZB1DB+Q\DTU'H091&K$M-C'\J?WV4]D80/+7?9I#>;E*"+N(15G9V<*0_U
M:>P9;WA+NDIW^0*&I?QB*/]YZ"M+YW2RQ3V;?86'IZXF86:JF!X?"H,R8Z;.
M7*&<)IG[VVYS&O42VQ+-F%]C<Z_XVAYJ/?<*RMS]ZO0XDZ-=L&?\;Z?PWO9S
M#L_WEGL^G=-U.HH(#N!R71.BG7;NB%T^/=!*_NN_5!GZO]"TOG/591OQ9A S
M[SC>'?!]()B;4;;XUL7UTO'Z6$Y;=C3@W1%\&.^_8O!AN'7B>+>5YV?V=]OV
M*@?G=%7%*SNK4P]N0R^^^I+NT>@#+(8YTVQZ,OZJ]/1ZJI]QY?(AC[+^C^14
M(A63B-B&6R^'==AAD@EZ.*Q3MQ5*<S)X \!(GJ/R7PZSJCC\%GC;Z'XHNR)@
M:AZ31HDML)AS!'+O?"=_2N:<[&EVC0^O7T*7?NCH);8ZX.->XHB"Y";@PZ<V
M,I-NTV4I\12A8QM_/\?G;,']%=!J0A'Y'P\,")ANC.VC/[JQVZLH]]3KSV/[
MA@MRA>2A8Z)3M=!BY8^;4E)FC;U:Y:3(HRSRIV-QX/3UPIVU=P+*NV2#6//9
MPO/T+I.6/NT/BQ<?R#I?CJ(;-0\^A@QV]#,NC%P37""KR79^F5I"^W2DX TJ
MH<*E=T.A;9_J!)U_!P;EM^II:DP?'IY<]DM<""CN;PZJ*!DYBYF^.9M5_/>E
MYUT7(VX,7:GXM'!G>JJ>)I[\V<-9QN[B'"%FX@^05_UY0*LN&/G1['0^KM'_
MWA\($]U[A@?_*<_ORW+:UGOWS(2GM5Z.J8'?]$;-R/.1+J)/Z9"CR$9:)G$$
M[Z&T<98"Z_'<*V,)6SH$JNIBCQYOIQ0TD-V5_"DFRL'B<K'>O=LO95.B\- S
MA9UGNK]MV9WVU]Q20K3V\T>!AW]-I.*(5OQ+$P;W)XX0*R\>3?#O87N?]MG1
M.\FLWD=]Z3)2X4S3>SS5G0<560UY3BKFS^&VC?]G,O/_;'J?7ASZ1S/V/>_/
MV*,2)^>!K7O_/!OZV^X_)YZ&K-'=_>W/S2UUB20U:1'"QA$P>O<0:B7 \<Y0
M224J?O,COARV!F\!M''2[;TH6)T_\^,O)!ODY 6E)QT*GM:K_EA3$+*1^OI?
M)\]$=V!2]8@2[6,BUIN'7#?4!@)3(2FB74]21:!!325X?);IO/-BW^+'0_K3
ME8%DXPS7T.=EA:_^T4+TLN<,DX-RFV-/O!0 -Q+TQ5\R@P+V.)D\\DK:%VMV
MIK#A5+FGQW.QX?5S?S=K(F,3V\:F&<G)VE8] Q&>I3<?1WC?&?SDH]Y<G#,Q
MV]\PAMJ N[B;S"[< RRE%-_GPX/Z8T9V^B\P"XZ/?]4H9)$CVWL(9O@#_9=]
M.2Y0!B_(5_A)?< #C$N9JSF[O%N[,?-U [WOR#2&4T96\-?UAK;YXK QDC *
M5.G0^\Y^\/7LU\"(J$JEIYE?2S XED]_V!.32V3K'0TQ(4EGKP39U,EAZT')
M1O=KEG<)Q_!G@/&J5/N,AAZ\=>RV-ZM(?POZ1YF3.SCF!BW_G([:YD<INH%:
MWR:V;8->9A<_K+#;?C2CT #EWJY1F5YTVC4N^XAM;"EI\U&*EL?1CJ0?QW66
MC+R/L>+]#*P?EKN5'FF(>Q[I88;W7"8Z5L2N33<\NJ:HW6#5A1T_]6_>:4)=
M_.0P%31YWW;SS=@.0^G!N:=^/Q\).)"II40+)?)_&!0H"I46VP>!IJRA<X>&
M)H/UP?&BTNG5QO"KQ'6X\3&?SS7#?PKTW;_[P?<]H^Q0R/P[>0H0/TM8>SB<
MJ"G9T3.";D3K,]*(JVCY[L]^C5VG\6^84YM&M?(_965>.->PY5IPJ9K:OHO4
M,;\47&[*M:0]Y?NM+\4<PK<_BK 5OKKQ^,6@L^A1N6]5-%!/LV_\FK#I]=5R
M,B BYAQID/6XK['G6!845+MKW?)Y^FW)JV#?U=F<"N+Y=XG=]QLSOXT9W!R;
MG\1T*#Q=:SPCRLQYRPB$XFTZW/XJC3[ 9VP;/'DA=D^9$YG]P$7_Y+O[;V P
MV'L>;H*M!NV7PR2::]K[_6Q\N>K-RL!X.YB>05Z%V]AN[KPNX9UQ62UE-')N
MU8_BZ-WO'QJ<W9HG.F"XX<KLA8&^5X/N97,W%6[<?R.UXGG-=^^I1:RG64S+
ML&NE:4(S/CKKK.JM.]F1ORC41]^3E!Z%3/I46'XO%_[HOILW'1%.NQDMU22V
M>C&B%5_!@.'M<]_YY:VO!</:N%MBC!L S^+W#FT*#CMB\BT8-_43I\5>OG#(
M?VV/E1!]8FO'R^#CM<JZNU78_L36RW+8G[]D!DZ"CXX=AGM[\#[2@HFODH.(
MK?V7)5<,RXPV#9T]V+:JJV;@H_&N7B3M=%O1\%_=SG=?R.SQ?F,H'<D)T&$N
M2[8#QPH&ES)IIJZ6$I2@)3@J[DS3@0\F]U9=.:QUY\.N@UI9+W\/@Q_[<ST=
MRA?U00=K)O\:QO6(D- 5RA2:0 I['I%7VC+8\P_Y8D.Z3O[IP/@CG6FE6:5F
MRO.KZYD=%=)@N,L_VG"S#T7IY4\N!N2+L@_;>WIA+%FG(Z]Z%FP@1J &/35+
M9O>6O<U[_-3OD/N\SEB[K=:3<<J:3>N5UJSSW+8?$8&"^U*:]#VK_>Z4>S&]
ML[_/2/.^>UA$6%\3JGKS.&PD9*9=!'J+BL&1FK> V%W[/N0M(@""Q(1S?,NU
M/Y9.?PV:*C2Z!],YU0BNF[[1^+P^4^MB4/W#3M7BH[\L.^ :R.CH+XY^GV7J
M ;(O-^GDLBD]@YS:XLGK>E.X8><>JO[;B09J7E\SZEGDDMV%??T]SOW7&Y94
M+H?\E-3>,NNK8O"JZ;M[9*NA);YG%C#5T:HWSBBQ2>('N;0V*$<7_;AN G^]
M/C[^@>A?]([P3P]**P]Y[/'%[)GC9,E8F->F=XE8SD;99_H.<([=<IKK!SD"
M$Z?Z)=;\2K/!R];]3=H-0X]OTL:X3_Z,5DLHZQ*.4^^<E'0./GV;:?!Q 7?I
MH;U#]K@6;MBB$_BJ\_#\7OZAS#+ZQGL)::1^8[>L?9_;*YQ//3;K2T)/MGL]
M]@GV[W"F7RR[XIUZS;Z>M":D;E.<7MA?N,P!*V9(V"/^/K?M/3F&,::;483'
MQNZ;'QL=]<G>4S_LG#!W3[93]OG $T8X!MHCAV7$&MCP TB)"V9RF%8:!=XY
M*DHK^E%/T/R<\:\S[17QNS\7=<#T^/;&MC-:?/^PNNB->&\HM\:SP4/$T,4N
MV[(8FUC[(X7T60%S-F[]GZ69=>Z[7ZMK\O.M!5RX%?=N;J&UGLX,M0$M2H2W
M,C9@X]!SF9=C3_HBTVJ' ^';H,L=;@VOL".H4V_>/!BC-KCN>AV8.KOZ;'5S
MY,0'B:MX-]0_Y_0:5)WLMP^J/HL>^C](>\^@IM8H;!0K2A607J(B(%VD23$Y
MBH" @" =(0>0$D(1 0D0$@7I[2A-08C2(B44:8*! *$HB$B7("6)@C3940A;
M".'B-]^=N6WF?G/OC_4CF<QDO_M=ZUG/6K.*ELS)]HPYVL*03/Y.7I+"V&:Z
M]IA51O_-#,ED6@HP"^_W+*@I11RG=+>( SJ6#]-O/O>YZ(07 2XK:5V.*A0S
M?GNM2%W@49F4,<),S_STDJW%D_96G.XZ6G;3EY&5$>KT+]A1#N_^$B%!;,4)
M#@H43M0:F^28>5[4TU$65@K-MJL@KUY.L;MPS=+@W73,NL<!*]<"9Z@S,; #
MS\B[B4V$BH P_$SY<TZRLC0?V?5SN*K\,9TAD1+" "$F4BM).OU[==UQ']6F
MU(NZ^QR>F3,[JTRKO5+M#1EG%&;) N1GN#K$0^71ET9_EHVK;IZ0>\O/F4K4
MD**:,O&)I?D/=+H<W$R-(\9215L>XM[S)XJZB#RG\4N !P#2DP]+6 \,<U/O
MU9=__IJ8.S([%*+:5XC%+Q_6TF$8#"*DNY+S+T]0'.R7BGX%"Z,>S/DVXYS'
M_LW7;+Y1]BY#\=1_)XZ=O]#YWU7I0T=/10IO.\G(+'Q2I_JSIL.E>*5^\TU>
MRJ]<]BQQ?_&=2ZRBUJ^5H55V3-^^_,^*B>70KT]F&(%^.Y#<#1?2A(H6(>':
M/4 04D6-CW@OHXA;P"1LV=Y*#-75EV-H)4*X/%EFL2VU6O0",TX:-:5.]:H?
M0KL!&>GTS$3HA5%#5ZIEU"?)/767D>!SQ.:W"<8.3M]_/<^GK-NG?'7^6AUQ
M\4;MZ?H$E\V4?0X]_MCY1MU>TB.73H9NIW5JD2S N_M)3<T#8-:IH:]4#IR
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M;@/$N<)JEA[#  Z$/VXP^&KQ3@)3Z*=VK_(\\:FSG4EUO<)";?=&&@PHAL)
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M%N614CFZYB\?)PMCM:#"[(FV^;4_P$;?DCNH_')ZAN7'@"2Q+ #RK;K&B;-
M;D/MRLY0;F8$E==K_=>=.W? V]V4P)[D<@OO\P)8'X3FCV4OO^T';UK4J21*
M52_N"/3D](&M;'1;\W15H*U&#"UHUHDN94L)06'S)Y#0$Y/:W*U$WTID&S_S
M16WE5R=K J(9*N.D+1DVH5KC85$>*RWBK-9Q#6M&XE2D L\J&#+Z6AKH*QDT
ME!V.E\&K[IV]X*!8^>7MY*#B,.?MBQE\[3>+<^6URO+'F,(7H12Q:I4JC![_
M,=:U0I=QKVP/-W/Q9E&Y;*\7WIK,9RR+EX7Z@OBT%R&GN@V-+R\*7VBMYIEP
M\HQY\=K1[B! ] 5K:UL>LL1IKE<<K2*W@M.F.K@G@RB34VL5Q4Y@2Z^^]L2+
M?YZ<OMT57#(SP]T^I/A$YIKS-_E6=7'6/89)(K!-U4TE:!,NG3!T!>@];.7)
M+;/&79.,R+ -7K^V&AP6>1K7^N@(?/A!(-TDP^.-IGCR ]Q@L"#FLXR^]:-\
MTS6S2I;<YT:2D'JBH1Y>;N]GG(%Q#)7W^I>6^"UIS6X<Q<P08SBI[2,:H9_6
M,H0?9):.KWOFLG\AD58XFOJZ!1V7H8GB7Y I &Z3=4A";%X4G:S+5OBL3E0/
MK5SN[W47"UY7YP&QW5 9]DACGM6(>IAD.%2AI9684YV'2?>9$JGGO793;K,8
M"%0);/@Z%WY/[$Z#0!+Y-C7H?*[ZJGBS[LF'W=\V@?GIHLF::"D'G7C]/UJ>
MC$W'YJQB>F*/?I3Z4=:U8)XYYX?IAFX!WDKV945W!Q+K.ZE5M%4?H6K&W"=Q
MUU>)5?K.::5U.1*/[>V5&K/W.:+ZKQI'JG<.)X^B/4!7:C#DZX]15+3M1/&X
MRA:!SS32)*_VASZ!^:AFFJR2+/5TQKAR.<]STDS@+C(4DG_T5>=6Y=[&D?3N
M1924B/>CRJJ%!AYY2>FX6K$!#4)\[TB"++^]24@:K=*FXN3K3QKYMHW%^0B,
M6PK9L8L6(F9X4UK%2K ]0.=<5D@6WCW>S+;*<D#-)DCX[(46\<O--04N!U3;
MS>3_-NWD?XCP'^RN&K;+HM&:XLKLWGL)\P;9IV=1FMU%''%]V]B&^;X/AH%\
M[:68L6;28>@%-Q;W7@7.&&@%FI/F^+&/2.+G@:5X^VJ6!7U070(AH]# D!*=
M@^A,21AS8%[:N)^,W+5G#U(B^G8ATP6W]DHQAYW8H_HO;(;*V<,M.#&,C LK
M>/QLWC^XWA!++Z 8*Z"0J4;+ZIYL@<IEW- Z*;#)';F5HV"58)$#;E.M6<+!
M3!=P_8 A_BP!2'2%M9% :N9C>)-C"LP7DDP9[H50L-3Y1S^]1@SE@-_]<UIO
MP2? RB!Y<OY4XSZ'A!DMN4,2'+0#HZG6IY X_G5#1Z"@DR34H01+"TL 8RI!
M_84CF\R4W_W@.Z#8 );@\A@GQ)8Q]6!4_B);@;IHMC9 F6:YC&M;<ZU@],=4
M,.)WFDO/,KXOEBP4"CDSTN-KXW'V1;^[VTSP-,FPK!MU;<34WC#<3#]3:HH8
M3H?$4R#KSW<5D7 AJ/0,./>;QDEN5V F@4:OP=7.21P/C82C&4^EH65]Z2</
M_!#/# N::#&^R"#N3.*\1.//C=5^F\KO4OG)\R_$801>N,_!L<^Q4(&K5^]7
MGX:12<V!2^N<P-]%;%V04^"4.QBCGL169?F#%E0W6/><YEBXF^T5A<XY;<;I
MCDM9!P8$IA) ES%+1CXH3KP:43GS(W\V9Z)AQ25T9B4/?@.<8=;OY6(DT I
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MN+&1@!7'"+%[H'(,FPZ E(#U<S-B%C.L2#3^!(GAAX;_,J=TID8P0Y#ZQ2?
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MI[]-32A<^'% OU[N<YS&+GP=+!1ENH&9(L^IRIF4"!ID70X@WSJ W5@T@O_
MK 7!V!O$:#J<HM %.1SFVL[%'.ZF# UG:/&?_$)9%O4U!]:)%Z_NY.US'/T
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MC*%5<TSP]([Z7R_+FW"#I;>B0X<5WBT&XD,T?\?NRD7."18!49]L)WOG<[@
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M")5^XQ(\:^>7+[M.M18/7PRJMGVD+[Y0S^ @^62>,L^$;[Z.E(07W0-F2**
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MOH-KYLB),!;4IBRT(-BR -4=#]U&+\$N4:=0OU7)EVB@+]^HJ?N/TQ0=3M-
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MR2]ODI&.,[W(=V0]@G)?1_-+ZY4(N6V)VN:1O:ZJ#'CK>$7%"[T:U&W@:.I
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MU*G,J/FM9VOU?3&8JAFAJIC%I+/#]Q4_*G?MO%-'^3.,S?4>&L%5-OT)VO8
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MKT/X.3U_Y&\:R$N?Z/E[FMO_6@ #A_3P%:B+'/TX!GUW;=>V?2$F_FA815'
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M]V)3\F,1O/.OP2))ND3I348 C"O)\C<8K3[9,+POHZX7S/RXX4U=QL0Q'<B
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MQ<3E9,@JWH4/6$O\;!&]YT(,Z8>RHY3HCO3T RW;P8(TT),<KF,JG-X(#OX
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M"8^)MX'<$%;7!5IW_:-7P?;V?DG1U.XOO:J3-FW,L8HXV:SN&:<.^>I$UMO
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M$]ZS#D:]N7BR\0+JF!C%#L1JN9P#XAXW(!.Y^?$M>> 4W5C47NRKHDU/#XL
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M-@KVYBB709]7BN/"QDVF?PV6I:I?7+YP"\O5"^-[#&]J7_@&P"^7/Z4LZ#P
MN/3H>Y[;ESR05)'D5OO7*O5S@.\X(A*>X7_)CT'+.F\D;CAIVPB@[MR:)U4-
M6!0-H12C%/VGUWIQPW^[[<L+WUX+8)YX9+0$<#F:7-4;>2\'9","_S:[+WO2
M@>'ZLJ 9&Z!_D 3SJJ'H9&!BB_6?^'Q:GTU;Y>"W>!A:_#HQ"&^.(@F_L SA
M-4MS0-9)"+.'A=;1!MRJ^&;/^6A/3SKNWG79ON$M/_3],;CNURUEOO(D969]
M2R[5_]'^[3W1?S\:IID)L+B?GTOY?RM@+L <'U;8X/D1Q*BDC*EHGUS@P:K
MZ5,*S+\%\&=4-E'<-?)UQ#%?:BAWDU'A'A$[%M7=$^:D,>NOLM*=-9"FX$NQ
M38;5]A"95<X!Z,X3! W>,T E8^E(E&6A",;7F%C>,6Y_44]Z=B,([\"QN,_C
M>U(M8II'0(!EPPVSDL]!%QA;F5^%E%8-LO><4K0AY7GNUNS?X+N(Y8TO;%_+
M>SU;R=="-QA.BB@^D%+/ :_U6,BC"SQFU1NO1YH%W?EG=[U&5_2,GY/6I$]
M7<#+SM"JJ%@BS1+#;H@VZJ3-OS+9_8G%2!W?Y.1I]VS&9Z:'"GXL)PQA2@S?
MB+*8KL0HHGQA6X&+S#/>R 7*&<#MWBV]8F6W3H@L>+\3 L##[1 \F'[$0[QV
MR?2I]Q-W.$VQ%*$ %/#ILE;2]LC[ARI<4VZ0RUE6DT3*Y0P5'J(,N2<97)VQ
MUS5_W#+%KI.@-\_+%]GEA:0CR[J2Q4B?I&V9P-MD)CIY]!C W:)WW*&>[BV
M\0:8&F*@'&^(H8JRQVKL,@2@@1&0&^-*;$OUU;$?CZ<]W',FZ$S4U1GYWG*]
M8W@K3-%>VXBH(-#@P]L9P?YFL9T6NC]*E./2/$I1Y>&1B2"P^TK2(^Y%-&A6
M6!T#CY6&7G,A,V&!T<<AEV?8]R%M@.!']@QK*; GIZ-4NT,H%ZD6H$T=9OVC
M1_!MJ)*?)_J2QQ76.OJVI[K7!U67,CW;8+1;@?[=#/%LDPIJ ]7^:;4N[MY2
ME$\)[N]GXA>IPH3?3S2SET,[*#?/GBI0[N.0L]^3CH[K5-Z> [1Z[7*=X/(7
M65I E,5"GV.!77HW\/0S(VO*&FJU87MN:;>B)_139T)"*V!D6<AP!QK8!F1R
MY;Z98H A+82C9]V9 CK>!%S[0C6C@<FL"4*SDZD@HV0^K$S--]>30/&/U31/
M*QM'2Q>6V%&/.-BHZ2<$ODFCN=DPZ3''L&EXSX$56-OTYYBT)["M6 VN_:;]
M%8T6Y]M;*Y?&_E*-0X1(A?F8O8(BYQE@:+/:LF(V_8*@M&69PHV[X8+U[_O5
M3P W0VW\"4\@8XVIDZWG@*O@.M1X^7=<(PY^15*'J2B-$;E6]U*OCY>QMH&!
M'1]NW(2MB"]5@B@YT;6\-_I[!*(U[V5F^_,*P)HCD>8^[\\M7\[['!,5HZ1,
M8 )[" _1NO9!"_ #XGL^*[5.V7?-8SUFXY(22!L46_N,D+&T&;$RMJ@CY-5M
M\CVL3LL'_[/"1/C3,K%L3H"7,-/5_9<Z@>+M0S$0(!Z)^N*[SV!5/;':;_A$
M:#=M0?\D+PD:$?58>%DTJ"/-0J_'DQ6<TDG5PP&-(AJZ>!9M*I2',\^N*%[=
M#M!7-P[=;&PY!^#$,7P0!KQ;2!$=QSG@:8KU6 %29B:ELOX.IN*.,OO[7N9+
M1[?_-X=P;KR_=EQ 3Y-ZA4F!8#JX"(2(@+\UNQ00'V(8TAD^'M^*FPS\T"+R
M3?E6T/'Z3+.D.>8<T#GT8898-V$C/R;N^QN0:5:^<GBG95E.>"I$N+W;L?X-
M14R9L+=B@'7VEV#1YVJG+#OE(8>#>G)#6B^N7O\MD.=MRP7M>()?7C[86+B)
MN1NN.K8GDNGN_V+KS5>F@IM_5U[[;ENIC<&8(-?=9!42LM"S\W;DX=@%E[/P
M@"3K1/2K#:]1%KFOZ]<C/M^5]?!_?6:=JD%A4?<P!BF&<%I$52:,_6A+]WNG
M[(;NQE<M[\_\T=PA,KQ;8,*L9=-Z%LT[W>R5-VR\!YK?/B[7T,"> Q+(EUQY
M#?1NV("C.C!:/&-2\8_V)0KW,_*4G_@65WQ%/3A^I96_L_I]9['8Z*=QB;HN
M-;$)EBO?2J5$7TW+#;YS<EP1Z]FLAF7#%>GH66(F*L0C@RGM>9]<,>GIJV^^
M<WDVL<9K 8@_15=,UYF,K$X>]\$8\?1[&Y;S92.GZ:Q/J*Y*;N8TE!1_1;G8
MW8WZ6B;H7AAW-[3$X.L/-6L-*._&P,-Q"##89%))](&$\\*]P>("$$;C'6BB
M77E(U$85BVR'/\4*X#YXH6=.TGB_UV\)9Z1">,CCINE(%JG= "E/>K#KGGFS
M9,&3GIGF[^\.8"84MTZZ@G00!4[8/E1(>0GS*_ZFN P>BJL+JV!?WKH[9!;<
M*;^+[JV<IR2]4#17K3%FK\]Z^#"+^W/,E&=@VL&@I6)&V=XE33N[4J16^*<I
M)8%RX>.N>_=\*_%&N<MBIHU*HR8C2<%JQ9L&J:QG'W08^;P.Z1F6W-9'/7 2
MUC-_FASJTGO?!L;GAYZ9CD*9?-8/W(^9A6BAO/;E#$]LY+&6ZG4UF3W&'W_4
M%H46/ H0RS9+F"^A?0KAB!V&J:4:K[8(; 4A=SC/ 7= G-#)%>#9]0IO_%!/
MNR=+8$BDWJK-;0+5,H&M>^H< *L''=VT06$K@)@BHCGLC*KW') [>>AH?P[@
MA1$"($['*A3DISCR-C%Q,,3N9%<_NG=.J_S2\0PE)(K<A^"PC016M2+K8_\T
M-L67%\RWS<V#Z%-/=Y<6Z:SPLU9_I=S<V[6G&<W3DYGM!3 5(]#H%&V4;90"
M,(HB,C7/;#J*,RP!6@"9U2=X.FG_)3*5G#46F_Z"KH#G#FLZ1Y[M9O#9]4,*
M,Y[<GTV:G$A60EQ=4G;;&O^>#)(N#DQ^%U3%V76&Q*DGW7U^?8WSA5-AT"0C
MQ@TU/MD%BZXU>5'N/J$3MW_"0O507N7+$M BO$>ALV[F\^]KSLLJ5H_\3\KV
MWR\P84'=)*@)1N^#KR0JF^G/')V]06PT7'Z-SZ,M47II_32F[VWB:4$E3DD\
M+<2;*0MO7P(RD*+A%!70KAG=X9:IK8E^%<=[M;VH1V[?0E3H.YOCM?!B^_?"
MAWZ+J O* G(49[;>MKDYZ;E2/PI=WM9&U@<LY8#0\@+A<9E'YP#\\QK8K&'7
M9"-_4ND0"DFQF5;9,J*6FGG@R!47GIV+Q9NBF"7[5<2^;K7-=TV7UX&"BT.+
MH[SBTN*M5=)4^FH1M2V]M?4Q2_2% G2)'D).]3&WXI(5NL-+Y%N!T16#34.T
M6[#+TK'S]FTS [NUWPHT:]$S+C/.GHQZ0D8Y<OO6W?%>:."L1XCZV;9I5L<"
MPPB.+U"G)#4 /ILFUKK.OFGVRILH)A2WU7X26V7MX6XI7O+8*PZ7W!@B$E+I
M[D^YY5F7)C]*P,J].C/0"_!TX3Y=2[AU#D *1P#+(/[3\]O J@)B#B^F$.Z'
MJQU],R95DI%IYO&)BQOIDZAO71#U_GAH)JM=%L2D9%AA93$5D QU<F;]]045
M)KVE297LW+&.M]+E-MZ</YB7GM1IK[4V234;S4FO@>GHU:%S%#]V=/%H1>7E
M7;V:US#F7IIJ@0:[G[Q5FJ2!#2*5B,I812M2^CXO8K2\W!=VW3K=O#JK@392
MWNO@E\2&9,R6KVUXYE 7C%(#*]M-YFEH1B"X7RL85P\PR[Q-.?B^=+ROE0.-
MS&';UO>/063[S'GWE1C^*-:[0-;6B8WVGYY_^QQIT\D5;BN)7VRUN8,D_0P&
MHA5#A- ZU!/C$VZKMO-Y]M_*:7!0?$IIL @^_AN8[<68TWBS>(6DVBM<LHV;
MYOO?UCUX2,TQ:P'6NV-&K]-=L4U6EEYZ=N6A*OUBZF?_@4#P<VNN/W'"H^F-
MB^A&%AW3OJVQ,-/@,I#&V%[Z7HR%ZDA:B_=OZO\JG_)?QHVX<//&P:A7:.6'
MZ[KC(J_&1)P>)\_.==_F8@QO Y:Y##\"?K6M7B0R_>@Q#QJZ0>3+EBKIR !V
M3(K&!C"0'MJ?Z-G00<"-8 (N $OF<D5<QUK'A7^]]>43&.>K$HG\GC?2W+-L
MNW.XY#E#T3&4C^]1BSFA.)&M?)]^XR;Q&4D-$&Q-$+]@AD9O?.W=4/NQM9N%
M-DR\4;;5ABN]4P%Y>+UW\\)'BD\F??:9-OW.TE*#Z+_!Y^XG"\?ZT\?!OUTQ
M78[:!5T0ZD4LLHVO:8(HE(P?:L.&K;1G--;8XD;QGWU^#P2 =DX(%L&/29DU
MP?B@%\G;ZHNQ953Z(G]K&7BI/K_QVGT$1$J9#MA6:>P.8TYP<;5A@\(UF),8
M\DZF*"'"4;G??3AJVU;K[P6SB"H W"W,,<+.?,[$P&8DEU<6&982V\DLL03M
MGL#,G9I:U7I+86B?*>ZHW&+\VV/Z HW7,7%6V4FC1#L\ 541+B,1KZZ.F!"[
M*BH5^URZ<W?*_N>0M\WUXNU%3A69ITXY:\ H&W90R[-<^?H,4./N%$G8$(5L
M$P9=J<0ZQ7O8=JH\:+!]J)W5LUB9Z#"DVVRR5U%AY3JHZIYV>FIO V#!PV]Z
M_6D7T VOVEQ<"U&W_4SP'Q#'4WWNQ0!U[R(FT4A&5UG:!_V3>Y=AQFT__A)9
MFX:=V"! ;,_':I(J:+S7RV]4';3$-UDX;!MS#B@/^%6TU5URM!&2^>?MH%(Y
ME?2W8%W\/.9 [R@VBP'H$K[V:5 IZVL@O]S01 MOVV*MYP??H"F?(18+&["
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M4\Q!3NUSSY6 4[M'SUK/ELO\T0Y[/]S\BQR,/&4-OZL4D,)!*S3+GF>$\'/
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M=3S4FH(*Q_8ML+'E,C=#:]\K": </HP0E2>41*&$WFKMIGB1RA6Y)ZFO=L-
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M]<N<:NX<;4.,QP#0@"VZ('AW8G1M8S\C&/I,J#'DY[59N1<_'C!#C DBKGK
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M(O.OK=<GH@Y;X^M #GA;)@WI7Q'N(&W^*034]!T/SFB0R;.\I6.N9:@4I)K
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M2%R16_E= S CP<T0MQ\\-8IL_E::#B]>+_1(*Y3.@KE<_:6[/2=B)O/_'BC
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MJ8EFZM@]-RO'+(2$)1 3//Y>!DU-W-WL8II1"A_"_0[5J3.)OV"]@)MXNC1
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M5S&9Y00),G-U\Y8[E G57,N\BFKM'Y"<Z;#.ZA$50 T>"V76N\^?\^D^E0X
MX/UPBB2##U'J+QC.?4X"V$E&BQE78%7WB'(8\Q97O[Q639U)R]#T8G"D4UK$
M\7@'E)/TX-Q#@W\MGIQ\Y&:95G/G2 C._OB;\I<:98'$]2<T?M4^$5)0 >*?
M@\[113Q?M>@YTT:U^9QV?I19B14E:95DT?[.7ET6&<E?'?J^/L\N5@&>[,?H
MU6'7$&IY&U4^.>42IW&VS!O,'[3+GO^Y=LSG0+E%US9B$&LE\Y4\#.(:!3'
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M9\JJ^6 WR+FH(H3^TMI;]'5BZHG16B. \)N/86B/#MKISP][X>MFG]E^;6N
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M</$A:%!5DI))Y7#BF0VN*"_W9N@W<'4(^*P\:'=;5W(-#("A!X) L$&[)R>
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M/5X/5RR:<K4*M/@_6'&AZ<QB'$9>)^D](RPUO7;;C=5B=?>\\*)P<(^;+PI
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M>IR&RMTBF6:=2M[<@*<G@!^G8?<B"&L#L:.&;=P[ 9PQ(HO0'&*I?X@P\@G
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M"(M9H@Z/S]4\:D+&> @V+&",3]6^;JHR3+DK&RMJ)2TZBAXWSJG5*(IN,^K
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M]$0I7C 7)#"VAJ#9&J_!^VY7(#Y.=%O\;H]JK>[;J&'M3<=!A]\H!Q%DZ;8
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M0@U7T!V8P0"(>O)-K(YHJ^*YY.@\<_'L+Q85W3DQ;^@02)=-J3): KZWR(B
MO#W@M.0F[025#,AD9 LI% OD/AS\I_9':1;J\D:_1&CZFSWF45=(GCCFT!J=
M>VCX5V?%T@;D:$B&.4!>&".S\NZCNLM'HD0'D(FDW>'/'"&CC3Y?6EXM%O.
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M8+C+3O,VDK]F?B_ LAQ>U;-B4DBW@5CT'%S)BSJT6_D_]Y<ZA<ZGY^4%^?B
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M[NTLBZH@!(8U#?MOK+UG6%-;U"X:!"G21)IT!02E2F^!@$@7J=*+TB$"(BU
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MEX G!.R3/XOZHQ^<9YYD@1:,^_U?I;>4X2:1KJ,1XFRBW0'U4R6M:D;>)#8
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M7*IX6V-TV#31>I=?O,+E)RW]I,X^/)]0V/M16<@7_D=6EXCQ&L#0SH<;.DW
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M(ZKQ2EBAVA*<%4JF+EXF4R+I;@2]4?<Z-D34KS=0604 W:FZZC_-:&CGC=?
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MN*:T8-31UBRNR*]BWOF >=E2V6V"K93[74MRWJA9^O8AN9Q/IK/^XT]V+?6
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ML;%==W00.GT2S75FQ&_Z!'3U4<V$8_/WYC 5ATMY;\K6KH(@<<&:(=6]GCM
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MX>(>/Y#GRP/4W'1Q\?9\#*D!X7('S9J_L'3O3FHZWZVX<<\=>O4M<260U\1
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M?Q1?*].%&#VH.I6]P(M2@-%(RW0NQMV$&78EV1C.GZ3_@)<0K(>3'F0:/5_
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MU=MUT)24:X389JE?KCIW%N<7+ A/G%I6YIQR_%5HA:=4>MZGFH5/SY;_X+=
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MDZHU:Z3:)FPW"6\+Y__2KYDF'ODCMUOX?(;4/"X=;Z88KX-.CE.P1;KO:,O
MMD:II"G*HW&&5!DHIES'/<ML:K@\U+PN3+N#,SLS2'<'#J581U1_'UD5RTK
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M^28G>)OJ,M!.37J/=]P]SC>H&%LQN*$+5FSHX%IP0L#-^QRH0E^9?0@UG4K
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MW1LBT%G&4/*D2\#>)+Q7G;$6KR0>STA@Q_;5G-<50_)*Z'E88YM/0!-4SFN
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ML"896TL'(13D-B'S]_4GL[AYB8'6!+?VP#YCH(0W;7+2U/.D,H0 ]LVJ,:U
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MR2.W/:,'ZB+D'LOC:',0)1]+05R:)P:7H=4+:YW[;K'+6NLK!!F<;=J*34'
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M_9 =4=(CU=A"7VV$].VVML$E2GP!)Z$&-F;DQC.+H]CY7R@;0Q*T379$1TI
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M0]*(VA^JNXPTA^$B+WA,&KYI>:\H!#:VOBR_MT,VPUSV ,J>(@T(3646D1C
M>P3P7D;_&_R56ZQ!"K?I)C G2K- E#Z1(Z(/4'0^F%.95.!./(M@_A3I] ![
M= >H<M)82T=V ?XD14MU>"/7>7AI2HH*M<:9DB<,-/^K5X^20?OA",$/:G@[
MZSI!.<4K\68W, M?C_?09EF>BUC3,3HJUX2[F]+02X%R8'Z<V!^F7FG<ZEV4
MNTC)IZWDV%F*QADYD^JT:VHT]" JU/)G,- (W<SZN<Q#,:N5XW?'Z^I(ENP'
MD&(>T9?%06KTMNF0I98VC]NOIB2Z$-1 4X(O@:-Y5\6!7/6@>P*]53 C.!0Y
M-V3=:DA;8E5&NP_[\!J9L%*KE*9X2M;4O X^QUT]@$JEF>(E2,B=W]^.7?>/
M:@H<+],KKT%Q#)40G]M Q.);]#. :- ##TV)J(\YV/IBMUH@Y]MP-EKNTC;%
M< )J&10&MJXO,2=ZVYX^:HW *08E[TJ@[VEZQ3E2P@GDMSAAVYN:JCW]7XU'
M!^WBA]>3\)K1(2A=+8IH9N12%H-QP!70/IC@.+94N:"?<02F6T]'T/$%H.L[
MHDU>.V/=F[Z1FA/L'F]I$*))NV$E 7UJ@X%Y!3Q5L'LYFJ&D#YBB#S'=NVO;
M4/RV:<#RD O@/ZKA<_G7@#C!0)*>;(#@5-.K']"Q!',TMP^TQU=LA8-T]&S1
M%.EJK?(0.#N8_)23* KS%<YX@^WJ/9M00W<\D_/X\!M49=Y7]-X45=B^ZY&P
M#M"H<T-;-@F,5E%M27XSHZ:VPOP/=*U"IS3<+D:9IN^4Q!5GH75'T<)'Z'DM
M]3H&Q*>4L]NT@SG:L=FH\F#GP3U$?]YM;E6MN7FV:&U]IS<2\%M^P8UGEY*_
MG6;YLNM_%_NDHT/7.5':,1([5!X3A)PKMMS6TF>QSQ]%6%DB1A6#060/.UEZ
M^51?9<49RK$>/V&BK[HROC8B$#C98W@_]CP86M&MNC2X0?!0^#UTEOZ7/Z@J
MQ#O:]2#^#'#JM/FCKH6!;E#C<RJ0NC:K.:Z&/B"4?,.NE@?>C)]<AIJU@C9^
MFJ?[#^*BG=K:FI>(4JY(Y]K Z^]^DQA<*8EW?J8+\FFXU^?^S6I> E?US'=5
MU8M3_W ]LG/5SSNVK72=.7_KS"4+?A1J4J50+9'T!:.X?2@,&GY"8O6A!@M"
M-:6_M!1Q3F@I&<1T/YVK%\Q@CYJN=8%QT4DZWHVV%H\P.AKQ<)!9!,!YH@?,
MR\]OZFP#S$+R</LQ[5_GYBD9)WM/U(DGAUK4=N!9*!.LC< <6:9IZ$WS&;P?
MK'I_[SR1D?L[L5!SR#N0Q%VC1H/DDQ-\S+[BG<KCC4N^>$5W<&@IRM1YB'X>
M+MC1@*R52GV1]<J]7>-TAV':RAZO/BKKW0RSSP,H'W#%!R,##7JK6A81_A;V
M#--U2_4)%(#;I8P7$X;1Y_BO@[;H3^8ME%GH\9XV%_4\+(3(-N=J.*S%TQ?9
M6UA:=R,Q]W+X)Z,N@$/-;9U'5,P//8[?T!YN+@C\O6G,V&#>$@E*@@'-U4T*
MN4 EU=\H)O*@GFR,T(&J#"G=4N_/>MVCGVAC$] DJ98V2WD.2AB[,46:+U[\
M;L%PT;1>4;*='U/;5VS^ G67XYOJ^C[Z1KOO0;[*R/D&2&L&FG;[HA=@A12Z
M =I &OXW["'M$+;03DMN 50N)MG?@AKUZFS<_RC^Y@/V!<)O%69$.**W&-/Q
M'P>M;KU9V,I:5%#\CE&SF[WC5RG]MIZ<.MX1^,6UMNV\;;=;G2=GYN^<(CTG
M6,^8*D(F6$2D0 +_"CA_7*"Z*?;!.QBNV+I2%)( -50CH($&!%M0IHO,P^[P
MJPN@ ^=32Q7F]^@U48><_9_H.M<D;DZ6%FVHM^Z-RE#=D4.\!R]7*;^+NL)]
M&@?431AR=0+5F)SQ@I?!72/7454/F\4>=4AHKMCM'=<6Y3\[S-X6UM!5C-B7
MTSY%;Q[3F/GID;,;SC\X.C!R"'?NY7S#U%VJ*,UZV-5_[TM++D-N8]@*!^HH
MAB;SEZ"D35#C(F'<4(L4<GZ.NNJ+T23 +G@:8J>?78TXM0A<,=9S;L?@>J0M
M8QS*+9KCMH>,Y+3&S.LS?+3X:N5R69XJCU\\4,;SE]\1EB7S/[,40F<4F9!#
MH@!=IC#.@+WPN<_,6_$W4$T=MM!&GT3 L.G< ; *D($JWQ;(!7=EATDHCAAU
M1272_B4L-*B+XVOSH>I7ZFJ"N^39!Q[J]NHZWC,[KT_UK_K.YZR:AN_([^L;
M)R+0EW#9%C172TF=G)"-\>I]Y%"FVUZBGI.UYX1ZNOTPM* QH9@=XRV0J91I
MG 67GFS3L1SC:1[I>0E)![IJV@<V+UMQ),"VHC.5H?#!' >D@(?5;OW3)&SA
MJ$XA&QN(,C7T<CWPGP!X/R-'0!8OP'^9CT4DH;/6W'W.V9BP2M?36N!<63)*
M6Z[D>-\_PK[V\T0S8']!Z,1F:<=2@[]Z(->[,QP&1R=VO!_X?8J$K@*:%1DF
M-?QU'>84VD99!)T%5=M,E^#\5G(:98F/2/F1I=J.+8/YUQJ_@MNV=AH^4G@,
M.U'N[I\WKY,44%HW?Q&^7J&K2[TOOLO]E#%R:#*Q^4;TL81SS4"9\!H@"FUF
MJ0)E:@^.!QS;!L)WV7Q3//KL"<<1[2\#":I")8,MBQ!@5Z7HE8@\SR*4QWAT
M&H)#3<F^ _%0;:-WHI!]F;&N/?50WI>W_"<=H*N@*[82%1<1P##U-LBD9P"U
M9<9$\T:FP"KHB.3H0J5"GJ :E-WST89>PR(0]RVPDA>P,6#L>L0D*WV,$X_X
M;FGJV5NH_8B"R;K<0,G%VHNJ7'-\X.76I_7IO!Y*'<-(-S,YH*4,T'P/5;^T
M//97]/.T?/D8N@*X"C#MQES."&H!&1WUH?-H@7@7;2G>48OT$9BHQH?H3FF,
M10&6 ^:6&(^7.;)-H9*PS8%2E6WJ 0A9\^S)3A/NWBTD :*YO@14Q^=\@YS7
M#;527P=N[Z.MY78/SK0($\=L.4=0$:R76@]Y2P?XV9O^R-*#LU"JK"V\,^$]
M_@GG2]3%O'F$X3P.S?V\"<YX@C"E7!L(%O!+.O./UB"GH7+Z\\V08=;_Z6WP
MW]W:97W'M&^*9'W)Y/YLBG3I6^M+)CC\W[12:.N(GCG$<2'NY&MLQQ2IU\AD
M"'O_FJ$'_MJ;) '-H609RQ+3]V_^!O_CG@;@9ZHA@S&!R$F'C1#ZH1QO]@Q
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MY +)TNNI.)&BS?QGY$X.7Y%5G<)1Y[+%#;="?R+5N<TJ&G?I_X6:$(1644[
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M_*HN\?X5QON54AUR![X5A9J4\;H DS.,9=PGB0G:-D)ZVR5KT!6#:O?L#_2
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ML +T0I3IX [$;R9PA'RDWVLF*)@)I^D*LDMZ14^3S,2>G_:D?HTQ#Q,R1 @
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M-S5?%V0X%$=9B5W04+-2( =PEUH7W,JRGAT6V*(;NUB,M?&-6Y/5Y!4HGXD
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M?=XY2;I/G5,?7:*/Z3\R-A#TZ;Y0W*7K-'P+;A.HI5-\M7+(1/^Q4<3; JY
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MW(BX3&?-5)S5C 6SS'\=K(-')H:AEDW26&=6%@4^RKR"H(-:-C<%-^-KIU>
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M6"IN:T+2^WVR:[#U1HD#?T/M'.7J/Z5*>H86/XXQ5,\1XQO]$]\D#'@,CI<
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M5O3W'\*"ION3RLO'N/; 39H0OOQ*QY&&SO+X7\9NO!YE/]=3P5JV1ND]9?,
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MLC_+"W#IUKK_<>ZK>?C '$5JO(N]!^((A\UU X8: 8D$)6:&;]].LTCS;6,
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M?2>6 B$3;D!$-A-J%!8NUO@6D&N8A7PM'GRG^ZYGCG*2-="O3IAZID06QM1
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M\KH8=GF=G_C/F46<DM$=U%?FJIDIXWV@(,!&983Y0?URW,Z0)K$ENN@6D**
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M&S.V5+86Z>&(9YM^>*W=18&*%&!EG-YDI/';2*70CR,N,8CI,M^!WREJH%_
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MHKW:SR*5OT:%+SFK\=%W8) A#W600EEP_:IH:]/WC!6@4K.CR?@IM_^1+U7
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MD\<B]EJ,F?X;;U,BZ$&.D-1'*%8$UL3I<XV!N 7&P3\0.1!+\76%<LEL+,U
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M@$,:NG6";X/D=L*BW$H6*"1LH_:AC]GL4O\<'PJ_,)25PS?'FYKX<E\+Z<3
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M7!VYJ#Y9L^[^\&V/U%K44"17I!]:[!._>6O'=*0]83JS48&[69!VLAW4B>=
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M''.P@#J#]>XF@?O7[<A-;>6GWG@M&/8T,,OM5UX?XL+J%B.###;)[G6MMTG
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MVU4NB81S4YA K*(XA%N3TVK1%7AO7,W6X@(%)=+6Y(N.[/$T=-#3Z6\5%>Y
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MOZ\FQ#XNTK(2NW[[.LE 7SDAJ0&NBF<=N'-C6%'I-5[-%@PZO;.][,=VR=+
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MPNY@W),;A,""C.*5:] PT]&#5:FK_NS6QA4?CG#JW)M\)T5=<E6GG.THC''
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M0_E,=$>EENTTW DR]3O.:Z&Y0+XI.^4&HCG.^X0EG=Z%.W->[924C[<-1#U
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MCY$&F70)R*D>I%T6<1=*4('BLJO/A[5-FYKC&B7G4H3Q&*%2)Q9P]Y.]89:
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MB.4X.4\2<TVD"-K3AL]'*86C]-DCWB>1=GV@<LX;[_/X(UJA1X^W_XOA>KI
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M T*@D7[*M0A>:JNH&GSC77_5)KP^;+D@3.^EF#-\Q('*IL>/'IW=);SS?YZ
M^*\#@'O_?1>M?PM;_EW+Q_^NYN$_B^D8N%..U1/O)A-K6@1K2[U%1A.BPCU]
M!<97Q$-,!PRTW4" 7^0G,+F%B?"YP<C3/WYLU)RBBN>!*OE*#M^XI=4?^H:S
M(_*0(B[B8.KUERN^A+*)=R-G@D"A,=.Z'N_6U(HQ5T<]P1OY3.1G3K3E:UMC
M"/DTY%O'!ILD,W1BL%8Z;U>,;M\CE/R"RM1#I#>\Q7_E7\Z"'E!]]^I]CV+"
MP>$#WQ;]AA'/=(+@([*Y,(LT4&$9)5Y>YN1&=QY6\C53X508!&3*E"?)TVBA
M(](5R!VI;R\O@KL$U""'].<%)R2;=,Z3%5E\A8TL5U_6R*LN!^Q$0\W'@T.*
MG.;^V?/^Q>CC$9;SJK%Q/2'/T\P7>_ 9VZP;HJQ;\-;R %!(K$,V2+ N3-74
MN#15<,SZ!M-2-!>?R;)&XZH:SN-6?%9M?D=L#[17?+Q\ENU6P'/:/%:Y?^]A
M4'>SVY"4:R!/?QWO6;?J?.;UM-(DCX8':.9;(>;9C<] ]1,.1*#$W#1ZH;$=
M42FR2'G294_O@D!]6(N)T5H:5I_D+FQ+FJ3:W:/KE$0?%>U,:[B0=:2I(K8Z
MI5.S[H8F^/)-S<XTMX%-;-8R85_6DLG 8+L![2,N&]R.>:B:R34DXVYK(MY*
M)M3I&V6N<!;^"?=C<-FZ%N^)ATS^2+>^5:F0(2V_OHMY6*J+;F%/&N'YJS"O
M@_HEH[&LQ"XL4I][,T%:2>&_-VUJ+??IWI]Q_"9*1K8PP:)2$XRR+5=LE;PE
MN!)&-L>&-9-KE4482S2$/X61;<P7%?C,Z=#>[0^0T]WJ@?ZO\1YHJF2O(4:R
M]BYX]UEW4+J9-I_#UY&.&3/(!>&*%6MOL(ZP6"Z/Z!;1.@=H$1G91@(+^:8$
M K(6V?CP_@'EB55,9!M]-A9D.\M=;5V&]PH_J"6I140PNS=6PMVM-RT=I<RF
M$R:>I_&JI7AA*[O2[[SE,O64.4F +_.^45'1K^E?)XJ7Z1X/5!](3Y8QKY&1
MSQDO!/HX8ZF6J8YHLU?7?TO/A>\'-UFCN%]V8HSK7!* K)]Q,VRW:0M3AER1
M"Q=OIS82?^:'AW/CP5,TKL4O%)QX>H<9-;6]Q7FEK'PN_N24CRF^:^2KGK@8
MI/UMI/LD['*8T7Y^^%^$ZO*P-/M19\(@HFQ%-%_> ',ZI+VN\>"RT&XBD+8U
MQ5DN@8/(5K,E!RUM+:;'=TJVZ,RG:5- 7E!#,<T_A>?^"/5HJZI<IW4^.+"E
M\_T2R>7-\@0T_^INW0&&W@N; UD> (9]9B=Q'U_>+Q,.3B'.*PW\8N@;#5CB
MV")0!UHNJ$(H'W("6W _1)AG)F[MI*<KGNZ1UV"?]6%NV?JGDV5J90ES;:<I
MA.6DG,LYU=;FNYD\*SKHM[XCL*KX?Y=**.9O;&S>5>LB8+;([47&2=R0YS3[
MT5D4,>!^CLC?/-HPTYGKBTY6U.-SP8J[\<&YAO3LMG&5_/&^7JZCCFY,&+"R
M)AP^5-YZO2)UINF02\V>0[,.M=M6;UE#;B7HCC\^?;+U(U['5EZST!W67M+<
M@Q4OI$M3">>YA=+_D+NU5SJ74V2Y!JP9.O.)+%[EG9&AI:CCJ1"2.^%+]IW1
ML:>GQK>=T0U4,]M*XS=?=/EQJU-V<9I:/9X2G K)9-)98)C0])=9Y%9*O],7
M]1(4QCS9EF_MXUB9[7[S'O1MB^T) (U#_B"'T)[)&..".GJ7<P_=F?N9U"DW
MH;:U_GAZA63\QPOKQ^>RH7IO$$H0E)_@>]<U]76O,/?-8Y:<YW7,@05_=3-J
M",-Y4@U$>L_'07P+(_>]QB&U=)Q\;%3@Q>2N0-X^VJ.U+59&U:&>N=JFL*1\
MC>G0XNO!H[[K]:\G(XZ$D9ZW]W.1$0Q$>TV#?$$P;J6.202#C7@_\P'=J+-^
M\(9YWZ/])/2M,#_ 0&FCY$%S#K/8[IN245J'CNLMS?U#K*ABSF:0"R7,55=3
M=R_JU13=Z!O=JZ)(5M\8@5Q?,VN8)L@@Z*_"70I5=?07/@2:]=*SU0:%<*;D
M(+)2>][<TK3I:Y0A^*:W3N@%\L=)DX1\[P-U.G9ATN(-H46QR>T[X%FC=*\
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M6)?P^IGU[3);YH[&KO=F]]?E83WX#.X:E73)(!:,_AS_A[B ZE'-78OD\Z^
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MV(.S8&![/;)9S$:LC%7Q&<_RT ]B5_5BZ5XG0IUWQ.X;K$T/V]ESQV==V?
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MR6//.BRW0:+URW]0_5IK$O>C7FHZA9  <3^E0+J4LV]$;B]:RSN$AL4\\'-
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M*A<%-UVTV/>YVB6>MA#0!G95_@P_NF I'PS3*O)D'FAEQRXE5.T7V8L(<QB
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M49%?F^:N]6E\*3D/WGG;<$;B4W KN7)ZV%QT;^Y&!)[D9M#@?4(AK8:502+
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M2(J<NJ5+93G\^;P<4M$6D%QRXO64GB6L96<"ED"\N:F9KJ/-PRK9I8]PYV]
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M;TC14NW4:$B;S /QRIB\R5K(8[=Y+D+F9DT][JOQ.=ZN^EMI.->0=>,;YY#
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MF)^G80U0M>O)Q5L84* 5JAF^#,9VJ*H KG4L1D=F*+K@IEM>6O$EYH#N.;B
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MK:[)JD#HS<QEL%B!A[<V<+.9B^/,4WMHLWGZIN(BN>@*8.=+6Q@_]"E^&V,
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MJ\S3^\PCS2>!C!F*2F;_K_W=<P$<:X!<T2*"2OR1 M0HA%*G,J)#MB1;+MB
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MU9W<43<6T5<M&1',K>_ZJO#-^^#LMN*_^NY6O!YX^QWZ?$>5,KPUP*L7K)[
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M_JOD8_^XFGR9E/!')" Q[HQF[Z2DD:TY0<Z"\I!'@JRD[J2^-!&+]/I$4MG
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M1@Q=YOC\'-<;[8ON2XLIOG_K#LE%7%4T4GNJI&+ *VO&8L!%3KD"-R1)CDF
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M<F#L*\6;^+^$WSR[(/IR]M_7VFG?2< G+I@CS_#*W+H).V.Z1U,)B'!F3I6
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MGMV!"?&6#2'60=V^UN[,;3U[<6>T-+OX15=.QM.X"KA83C!D2YKJJM(:#V1
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M2$MS'QU../%\Y67<+?MV;5*@\!?).R0).PP?JCVCGJ%T&8=[H00$K.87F#<
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MH#D&VRS(I7]K$'-;DV\HN;(!.%&0]377G7!(!B?4GV,V,M%2WIHA1'V=,6>
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M:>W\1?<&4L>W-I3^BY!+^<[]XEHWY=2!(3HG-3EJS'V%</= W6N1:$7)F/8
MZWD"17064M>PK 7<:^(MW]L8+ED+N#$WR<Q_]\I9*EAAM-:,VU;]4S/N/D,9
M#\0_%B'CZO_NE9?_R]'U?ZCB:/BO,^^4-&O+*3+>MAS]I^64,&'VU/3_VZI*
M9>W:X2@S95B^08YRP)JI#D%>[ <@H!:4FP8M-Z D:@'-GHY3M53WI*BYYS3R
M0OX<@=33^3XXERK"@]''Y17LJ/3IJZV;DDG Z8[8T,@MVCG0< !Y*GO<I$(W
M,?-8"\E5S8'KO7&G-&UDESQ3&6GP-?L /2\>I5X46USW@"J4)!&7?^1]!HJT
M,30I?_V3UF2U:OXX?PU(U@KGX9O:4%E!C;%U.6U8=&S.1+--04J;KSCXS#3O
MQ[-0*0*\A;CC"U*!?VR.B.+WL<1,*0>LL-$_NL&E:RXVJ84V^#K2L[X@>O@.
M:)U(1W7EBL*+=@PQWN6.Z%YT(YG-]![1W'57DU-O11_@NFJ:<@U! 5KW;2G5
M+*?@+K?8!E<2S#V#2,$P]Q'<\<FDBHRRWUJ*=1BY<L+N45)(8GL_!]<T\A&.
MUK43*2R1&P:Q] 9!7K/-A3HQ-1]>VI!LT\U$XW><B?E0:]XM:/^:%^/V1Z=W
M]NLYU\9CW\$&%5.1FRDP@^4(J:\*&U]DD"M6R;HOQ!?[F)C@DGG=8\D22Y%D
M*;^'U4"5"I5S:?E9*\ A#;)TF)O9P_<%[K?QH*>MO:$]T]G?K6Q":ZLNLJ3*
M5:75KZXTE70,IAB.ZG8\G>+;PQUKK1/*<B#KEC03OHJ@0^B_QL/)M2G;=AMI
MW^HG6LA5GC'.*U!ELQ8'N;KBOB]?$Y[/.JX[#P:Q*PZ2\7#>$;F@O=\P:?MY
M6U?$4!,L6;S+YJ]7V$9B7K%Y'[>?F%=J=H [ E(0&B%OG*$L@X]R"A$'Q@KP
MICLJ)U_BU8V61SS!W77&O-@U@[Y!7G71^.IF+)VH90AUOA^ZS_,7OO72Y5^C
MFV"/;DO-HNC?8D[%RP3@'9%AHP92IIFZP0VS%\_:X7@3[Q0X;HX')#YVG[@-
M=VPGG2,Y1"OJ$0W#6OC"ZW5'L%^1V9/)7IHF09"_5F[[G#46*,P7T^>#5U\%
M!1^JK<RL&@6GB2%IE[*8Y!ZU8ZMG_ST&2/7V]CGP0HLL(&'8A>>M9N6Q9DU^
M!*NOJ<1P#G\][[B"I9'E0$>?.\E*CK011;7<2WQ[GJ-%R' FJ=H=M+!WJ-:E
M)@6>5\"R25RH;/M!B>0U!!][$3&T[JKY,[C#PUJY S616YNF>RW"?#1-68QY
M_!%2/6Y$GEWK%%2.<LOW@VJUBJ:*!O]RTLY0%H(MXYV!:>>/\6A'U@G\'_<&
M:)U[&F[)_CA@R=G!+I;4$QDU_L$!GX?EI?1^*MN=/V0RAC=_V_G:OJMQ(.5O
MI9+HU!A^OW2H[?Y/H4TM#=_4F/K+-_LEOGO9]=;L-TZ$[7)S,%\)W^?HSZ@Y
MP]=,<@5RE+4X2?C65WZT+-6<H!"SWT/LT^CP:+4H$_?],8%P;P45WEW/O3]-
M U=76AKO^(=H@E?)I38[W%C?"-)-PS?QQY@ =U00=H7F /Q+"R+ G2)U OWN
M.',0W!&*)VMI^3,4QQHDZ?ELG1,ODERY5?BG]P?\.+E*>4<NPRU!J3H;E!P/
M)]:,-4MRV)A=7^?CQW^-="I7FJZE';D^IJPBWU_Y"[E=/X!B<KN\P#E21CQK
M(FP=S#3^XQF*DX26=(6,-]#(1@W+L!YC]\#.QM8#F@/\=Q.G W);XW2<_/6
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M(^G_+ROQ$QHRB!^ .[JB%%*A-:1_01(?0;.\6SC,DK$:9=(1>@Y-7,X5F%B
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M'4F %\PY-XTF4*S>Y%0O!HU>222 0F.!7H,^#?^6J=Y 3N+H28K%1[4@C;$
M;$B<I,QLPY8#< 9XJO$:>)(L2F[D6)NF@%7\UK($/4FJSGN*OD^J7G",".?7
M@_".472ERTBXAMHWVC!A[/;$V8^V&U9BT]L_*6=N-7P>8##E.:'@$0T@F+!/
M78UYJT=G4C/.*JVQ0]HD6_?4I+6$&QE-)V/&Z87W/3UGR_?^LL)4RQDQ;JRL
M0;,,-OR&(GTZZFWXG&@%S,'CX:Z$!0OQ5)GJ1 ^X+!9J>*1$P]3,J_%"@<(;
MX\%OJ\@I+4!J/]S0>B<=^&B@'ZZH#C]:=Z@&SLY1"TW0'<T#8T^@'9.4:":Z
M6MS(N@"6,S%;EST=A!W&)&-\Y"CY[%ZB\V%^6Z/7;U><EW?REV%[\&=23_;
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M#@10EQ#,.U@UV$R_#,$_@&J2^C7TX0\(5Z)=!'\#-DB-I1%/)N>5KX^/"!:
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M3N?@,'5%&_E\+-GK0_,_5$66<$'U]P,.X/0A1?Z#LN(8K]H*(O]N6/BF8N6
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M_M@$]1]0=%6G%JE='?-8MGZ6TAMQ[AO)YTVM$_<6Z2]T0BHEB*X:;8A-U.]
MFXXB;5JJ[KCA"[2L#IHU!EX8\*A GR&! 55(0H-;"#E&O&6J_C9SERL^G*)-
MZV\]?!\QJR<NR3.X,B.<H?^XY45(><'V2<H/BA4FL+W>R+GV<A^Q+(V]A]N,
MVPNH*TW&<N &JZI&\C54.WY+@&%/#,,2_ZX<G(MYHMZP=G./=!Y:I$_L83@Y
MA;'@@9*'Z"DU8S%*WRO7B4<K2OT: Q,\KHQS9M&@??]<@_POAI?=X_A_L\*D
M_*47)LEH@?_ZSE\L>_YO2=6_+#KO0;]-IU5YXOV>1"5MQ/"_+#KY[L1K)?PW
M%F9%T^]#N\F,T:?5#NI.^4Q'!.JS9?8"+$%M COJ\Y -KRO.E1N<#GC[:6@S
ML'F(?4K%PAZ'K/SZ'SH\:C=W\T97%AVZE[V!$.<0YL$&ZR RL\GT!EC> L[F
M;<)O2LSNA+,'7- ;<#]+CL6OON&4_^:JZ,S]]PPK^.V-)*V3:^/9',6#?$XQ
M%SST.DX7XA?XH[AB.)8>%##Z%>9&CMUAL,%ZDD+M(N\I!51[DF \S-B.1MF7
M1X-O@L?PS!_)7_DUD="I10]]\!$OH;$)JJMSPLL,3%")Z(H:?,\0LXO10A),
M:9&"4KA%?PANN2 UB^"YHYD&'VYF& Q<]/$U;%*\#SW)WUB-NFI&IT9$5^^Z
ML:Q27,S;&E $G[K#L?%BW+G_Y$JKFEVZ=/L4DH1@&Y'Q5+XKCT%68^KT\' E
MUUO#O(1Y:"$S)? NM$"0=$XMMH_J"24$">?N#A_(=FB^<>;,@QB[LJ"BF.SU
MYU.^O=HSGOV:M>":^#C03-.!Q6!]@)1N[/E]<?=[R(2QFFBG+2 6,(U]_7*:
MF I/_5?X-R!':,'_$:I27L&./N%:; L<5?@=1)@9S"KI<NQO\#K?OQ_HB7!X
M_=C#N_2H9O6U1_XEA[<HWKR"?^=D@O ^L2*X@09O E,'5N+YS&B.XDP+-%\2
M9.#V$B2UM6:LX[?SS=$S<*3^(;JL2 DV^!>C>772SY#4,BW-AL<0:F;?M,R^
MIHYUU!(O-!;SR_%UC=F*JLQE,/UJ7&!G(07\NCP$R3(LQL+)N[A U($5;5F8
MFR$0VX872NWX+P>6XAE2#PQ . )(=1^ ]]!Z1_43^#W,1,NZQ)B#N&24&X]C
M3I,Z\US1G"+>640L>W9$G?C*M8D,IV5J:W7>FXCP,WMKY2/7E5NKX+;!^V"%
MO:X&7F>T#3_,5_#GXG<A54G!VM>3E!A1?YB:<PD+1,+T]?@=8AKWC#X!+V+8
M8<&([Z_G]9=45-1%>(&@8PDUJ/>]?-.@ZTJ_GM5/XH8!R^AQ 0"/&0;(4N*F
M_H+Z:<M=Z"H5764<G*QP/IDA%_#"X$Z-4 <BD?HMZ"'8I&&UR)*I^HY914V6
M3N?Q<*%/^,.H9VP'82-'J"RSE5S'-N/W7!!+76E;!K:R,*+U-OKUN!HW] 5H
M+#T-C%78#42HGZ3@9<;$#L([E'UA^F-HOR$6XZ#!2*)^40\S2FR#BO3GT5+8
MD3"K,D3P.YES)?9:93J3&A_NV2BRXL5KWIQI<)[W \JFROH<-9[)T@5H2V@E
M\JNV4;JR_5BW.VN$;AWU!6V@U!8U(R>$+7K#$/F>88&7$A1^G_/J6N1!H6$#
MCRN4@68?B&7\;K#,4Q=BV,/U4P^FGXP/?"B=Q^]BN.'?^YS1C+'2G4V[R@-O
M>HTW)C$;"E8B![O%3=F"X_>B[!0G;AK&_X>CSW_(/(R<W.+=)&5#R#^/3VUD
MCC\GH>+_<!'^,U7]M?>%QS]V=_[:*>@?Q/[W?.,A#W+(>),4V3FCH06DNLZW
M19\9/$A$IC0X]Z,T?7J[L8?T7&[D)J/QC;8A8'WZZ5+NYM86R(X_GW7G)3P1
M&]A8'2%<?GVUY(C:D!6AV3"RV/-OAU^Q/:_R2.AR<271!CZ58W8FQ$PE0@[,
M;P8'7A#,D=FB L2P%W\@ =4DAU:X:OV3L46<!QBC\R3#:8#GAW"$6 A"\T/9
ML?'QI>C5-O_<P3UPEQ?^][*&5P]?'9W:#W[U[6Y3V,@Y%N*Y#%<TC##O1L((
MLV3X0'NPWJA='\2^P+]C1@.9V0KG<K<GQ((A< ;OC"8_0?]#=U/ZM=6/3_'.
M%7'7?FSVS-E2>+5FV=]#;:\\?^/GEB562E?!X\VCZ/(<S$ZK?X 7NC%5(EH%
M1R> +?1MY.6F8TMQ47Q;'TW-ST+6]ZMZRN#^'3 S>0RXS)QSOX<7I*99\&S1
MXP\/<[]N.U@CEVP%CZA;?1U\S7]O<#J@W(FPAX!JD0DY):"G12/]AD#>,?P9
MPY+?5FV? D9SA-5%&16B#*8=AQ>,6#1[Z9\]Y XV[D7%S5919R,V( GI[K0I
MFS1!YX//E?1BS X?^M%S-@<JK?J=O'[JZ*!*'II@(VI<P#R93F*'49(HF<2S
M>CGZBW!14WXB8;% -/<(_GW<Z$6^!T)-)^,KU8JEGO=A3$A%V;(!FYN\_;#8
M_^K QX *9# UKE5$B3G/+QCW.G%[@KV(]H(&[Z9> DC0>6P4=148&V1-=X65
M(VSDAOXI?I-O0_P4X8KGC$H=^"]%9B,,5UXH7L!8^-ZAZ$H\=3:V"0;KP]<F
M344DS)(H8C7'<F!X@!:=(YOP%:=_"26ZIDM<"MFBKF4V4S"O%@.-D$/6S"-B
M=$.+_KY0_P6JAAF=A#FSA$N-,"Y<'/4-J_,LX[^NZN%/[^*((I"V-+X%U\$I
M>#<\GL5?\@8M,K#VPW4=IWSVXZ7WT=3!W2]ZW'_\!,UE [OY'=!S0?,-%1WU
MN&XD\&4A32;%Q"N1'109(/78JAJ]5.!J2*BC4ZMDXLLN+;]C>X1;X$$%PRY*
M)QX:CVRVXCZ-.N!_L./#KG)^_W'Z33R>G,R-(4UTU$6@2S=L1D%B]K=HM$IX
M26DK<=&P%$QM9!W=D?_S>4&&9(V&*9#.QV]_4J9&+"0ICW@(L,0 3:*3O2QB
M_3-D1OY]SU1M=<=8>OGT'H]:Y_Y#72=UJW/]A B+Q&DB70423,R<Y6-/9JFK
M> T4"9KS95"YLIYFSCM.SJP\?0(X+5IJFKF]G6%_B%W-N?C)R>MC(S#W*]3D
MP5;U_+$P4:9T3;O$0G4\9WM[7.NO)$BX$!!;!)XNWVV*@$?O$:^9<) Q<. P
M>BIH1<:ILJ)*5V&<;8O1?.UH.E@F;P;[6E2Q@F91"N$-,YO<Z$V*70+8:,MY
M-?LTM2'6OLX+NC)@Z<]"7%+C+;S#/)""JNB[$4,0G-FFV66BG_GG,GR/J,Q%
M]VR2,L/ !;10/<L)K>S4Q^'?0&RV*)-@5,"[7FBA%.54WCG$M5&Y@+$(I9(0
MEW#I[1N63H,'K_!6<K3A5)G706'C>B2P-.P<WSKWP\M/ACRACB!YX%*,Y-/3
M-+A8RN"22.<:Z@IWDOR>*O 2Z38BPRJ1<)(2Z2VT1P,/H4=4-&&I2FG'O:1A
M7BEE.'&K&B=V75-3K46.3FO#9X\WYD8\<@]!J&F?>I!=T)$BY4"XW,5@3?P,
M64O7\^4T>&=?!:>OC+! F&G0T3=ANQ!6IB3< *(U*G $-[CR6[,55$$<- N]
M)P-F>%C0^_8.-HG*72[['/#QIJ:<E#IS71N9LXH0ETN@>DYUMT<20V;@ V0I
M.O-OED7_-^YO?V$]_^\OV[_NL_BO)8G_T QT33'@$6&(JXI3S[HR[CRS!I7!
MH)K3E"E.Y:]ZBHS*,D7I !5ST=8(!8171Q^P$RFZN!S9=NW12S7++OKGM![G
M):]#90?+CAVHDEQYN*2KY'>ET3+R6V-CMOK#$K*.32-O((5.QN.7Q$L]5&&*
MT3GHP8%(!=&I"7>10?"E24K#4S):Y_IDB12BD^1/.83=@GZ)L(Q\@R'EB.:9
M*D%KOCG/$96SU8FT*Y 9?SXO[#G,S/PD3&.8EZ%Y*J8YJI?7$[ZOIVDW(U"*
M#MM?&/,4!9LF%E97._BGQWU;WA/7?F9#6>WEH.4? K6"D1(#G>C\)LH.*A>-
M*$G2=+D2OE]U XU0:@5_*H_L%L*_3&3X.=]9GVPOY'F+6^ZU@DX2LW/+OZ]L
MB_MF<UG9X^WVO\8>)<S=\!OD##H*YV!6XX3-J(*I7HE?BZ<KB@A[(;:*YCK"
M["/6=_.<)BDS73!7)KIYJ2$D'[]E[.IEYH^ML@#I;08:MD3\&_Z(51P/]3OJ
MM\+R9E=:7W\C6,$<T:J-*Y#[))WNNG6JB"J2L&??1#+W='D\M!K<]O09>AS4
M<'W8">=*P@*<FF^Q.7<#?+'9UQ7WGSW]:@HBUKT@'W\%S-'%:P'4);5"#3EP
M(U6""\8^CL()S^985_6N=/C2#CFV1#MJ.:2?6/8MTR+.8$&U0^G;T'-W\IQH
M(VO>]$<YKWQ:5?["X(7&WA&TYGQHNP24L49^,VR,"AU/(2>;^ )M&HDV(YM"
MK_7P]JB5EP!SB1D,;4:6/^U)_U+QI/8^=\FFUY_PHWO9\SI^5,;8C=MO:[?J
M;?WUX:9K6DC1KP]&PYYPAV5,:S!:W/=1+4]GV*. /]+2"%'142U3)IPY+)J-
MV6L<#;[T+Q#P:KEH#O<&"X)S4L9>L?9T?M+1 +GN$^X2#$G+RI[7%&C>SE26
M/4.5,+ /W6/?DK5.,]Z ^ZOB"&?0?A.2V])"V-2@>SPO:Y1ON07TM.R)\H(Y
M-V3M?WS-Z;EQT"OF9))\"?M+DZ9R#NHR/N*H[E_R  7UR_!KY6X;4(,?^OBD
M.Z>O2C5PZQA_!7KLC<@2"UA?&3'KHHEVE)J_&1OBKR$Y>,/6^WG]T-.8]9.4
MZ#RP>!@J$XZ,:829!7;X;9\@F*9J2Y/Z<)U_"O>L!QP]E"G$S&YB-9>YJZ!G
MHIE-M>!M[W+W%L[G\G]BNP4'EV7+ WIB%UZ7[Y%6<?\>DF#F<BT:A'<+>X,;
MH5F$"_85S-()#6Z\S2@;C@S(/(C>T=(IQ&O(5')(+38)BU@CV)[9Q%_<P6,S
MDM5Y6><_-3T8"M X!0<*]W4]<1O1%9X[O@<PX1F;+P_PS/$24)7/G ?%*GLG
M.M7*=&(1]AE<6?PD1ED6HC,S^&/3<)$D1'7K"%)*DM0XU[8LPJU+<D[#(ODR
M/)BA[1BCS46]PY"!9W>C(UR?5EUL[M_765AKB+UM^AY,99X0]K74,\CP;!#-
MX+<9G0B7P#6:7<4:RS,:NHPSB[<27IZLHM'8$6ZI%J MV]D#/GOSMH*;T.15
ME'Z[LO)2HT-J31'P9OCS_GKG0H^?MCJ(/>X1S:+GIH(X6DJ!K5'Y6618/Q0Q
M#YVOZ8=H/))Y"^%UZM1;MS$GI.<./SYLDN* K6H?D=!GB&!#4U7U':^;RC1L
M&><^V][SUX$@[OBTEX<^)^2T&3P+PT;>8OP.&9B94-GXB(Y\'"1E!)^$#Q.?
MHP9X@':Y4KH2J4IY+-G,\U!3KU17/KO#==5,SWCI\2O?&9F=?+8GPK5#9Q_6
ML>1Z@WI!(B@3ID]2+/EK4&]_-!W.U-"2I9_QF,@LM].WN8/JELPXZ@*N]^'D
M!<T?AXCE</.=1U'5WZ]0W0LXGN3E>K$P>=INTV]X7^"9S*/"3)K52>DZ7C!^
M@WD"3 ?GN2M'VD9&,Y1S&--X;DA.8QYU9/^^=J))*Y[+#=F+;!7K=RQ>?NO7
MF&MX\OX#\I_,*?HV)]2B#K+AT31T@<B:9Z]FIDDI"#_G]%UN5=V -_G8-*/&
M)=F:*:<^"4G*T&AW/C6S]%W"CJF_'(PY&[+^!F7:M<^G0B3E< +K.5!LTAF]
M$G\*?C5)Z>TGS&P?$KWVRF=0NF3E;:ZAY3RH@V"M2G8X%.WT"P)DBL=26S0%
MCM<^M^_T*SE86I"C$5I)7 +9F2]TV1\&EHP#,DY_J[Y SHP2]=:H/)N5?=ZJ
MT1'U$WX';3IC)6\'*E9!ML0OD(GD$%*EML_D62=IMG^B3N?:JV?DQ-Y%Y=J>
M:X^&)BQ3:YZ@XVHBQ3.5+#U/8NRDB_.V5L,I'<,7:+MYZ\B0/T?4 =-Y1PMY
M6U!/PVQ^B]*,OS!JY^A=[K!:--(&A]7QU[0/?#%-6,@5-0R8=U34^MZGF+(#
MAP(OF%A1Q \D;)5P.K8#%J9A4Q#[!L8\9/P"=O2>$DUH&C!#GB07<DL:&)_!
M1+&)XOUY^S3,\XD"&%*\%3Y4O%Q60=PJ[@L_%/'%J&6CU;:_%_U.U\\BOU$G
MB4 J<AI&[;$OT-]*,5O\BD>6IUZ,B@VNF \<T@0J@NM>%?,.]Q#S M3;F96\
M^60Q!%)R0@M*GAQ&G__43\S14;<CTP=N>8<VX:4/ T#SHG><1I$B4L]!/32.
MG)D8@-_FS\16(N&CER1;D=EM,IH5WY5+K1M85 .;7EY4,-A4L+&RG<<21Y__
MEI@-U]:6_IU8C+@?:+L[]$T_:W5AXLEO?OQIRLU2XB7PO"A=:H_25,)TY@F@
M[V,C;3HQ[WWU@5JX7SV["CZJ;BZ!(?6'%W>6WW-.?XS2ZNP)QQ_@HLMCX0Z^
MP($@USVOX_(L7FWT\-T:NSR%<VI++224&L7&I8\Q)F+?1+M,IKBEZ"4U,UV#
M5#6\2F@9,(&KKL2+4@O67:C[$N'(\.!&KP/W$E5*ZX;8TBNAXP*7SOB#KR33
M5[?<=%:Z($I=B\$&<^O"+.]B0?A3YG%($-K6B)MN14)DX2XM8#FU@3/S/3@'
MHVO\'-"$QH(93Q'3S#B#V&[(RQ TIST^:ZJ;'ZM[Y[-,Q_36)TE^&G$+<)$Y
ME3>'L9S'05M@L4HI.W/FR G&0FP_FJ*F"0IF>IY_Y),;_A !,BN2:)L\O;X]
M_:-^3A+T2K+]36G/U@,+3?(0\4B980T9Q)F%V)=H%IEE3(TG\TJIF[HPU[O8
M'C([T@0#GZ&9][E :*>'K_5!>"!'&YL@DQ/+.C\YA6WK&<M?$MRN\]@09\#7
MA72-K"[]K1RJS@CU_/]> %^PT? %OY\Q%VX;"4(2]'7X39\@@S?161V9+'$[
M5X+ZD0 V]0[J!P^J@/2QL*#@71T?1L8@A7>8?+74!MTL#S(D'O[ES?"$7G34
MXQ>[B543!3<8A9:?G-B$@DRJ,F$RS43JSN^"G, 3XKXGM"OD  O2'R]'VG2.
M\/-6]9O1-(])BOD[YR7=G\A$9>M1FR C;%%18710<4HGQE)'GW+7)>XP.+_X
M"NH;U_]<1PM_1/Y[N'^W[?XOS!_-F/IP'H7\-VM*7>&3R/H"#YC3"%I$\3>B
MYS3*6=R/]0R7IYG[8?D5WGQQ=,0*N"HM[D7K3 \W:J.7TQO]C9*#._=?#LFV
M3[#[W?;+ZPL6Q'7]*;N89C%)^;X+5("0ZAYH:!X>GS!N!B:#'W.%!M8X9L.9
MI'#?_&MIYM]?IO^E6:SXO_CC?#$== 4J0AJA?BIAOI\$FSFHB+S\8]3;<(@7
M@9, [/AHGX7*\Q)C#78>&1_1ELA4)&BTUI(9,>&X*I:SI9WGBGSVYGXWS_;V
MNTK1G#C'%3TO#[2+ I!]TH4=/KNJJP1'R6 9"P0N@)5*H]__4UI5D@"SM2?,
MSB!*U7@]I*@"T&@V?$8+-;0I F4#GW4;89_"I/X\+S3V07HQMR@8GIY=I.50
MN8)-3]MYOI18EP!)TDXTL.%$ZW[XISZVK%&U@"D#^\A[2#%,/4ST5I\M-)Q'
M6\EH2AX%CP%7"MS01(U8<51#RQB;I/2#JJJ6<-?ZB"72#J5,-&<$\Y(U#CAL
M*P\KZJ;SCMZQ7,_.7PO,0@'9^(!S[0L$>-LRXD@^F]_P(C*&T.6#F/6HIDJW
MS&#-[YBD.$(GE [<1VVJR*9)"KH";&(J_.IR!9GQU+2!Y6@Q8K*K2AX'I#J\
MO4>.RQ6F%6_1_>CJKZ/GHN.:V2_@UAVU7>YA0LMW.6N_*Y_1 ^WA3S=VP 55
MA7Q?--.PB]^IA/?0^DW555F$.[87SV$LXK]B3F>>@/KN[4-?J#F],O46AAL\
M4'I?IGT5N0LY7B%,\P$TF26EN^!7#]E2LY[XH!E.B4"N4W#CYO[Z"3"%ST7D
MQFT[O1AA8G- O?%\<D0O;Q->< 3%X1#-^&4)J!';#W#+-#M!TS%+QTVHC/SJ
M:9[9 S2Y&@TZK0TLW17DV!0:7U'N)93AGW6/;> <R=8[;E?5_D Q.&HAS,Y1
MZYE,QBYM+E.5IRR38]:#S:(*5A-M!K82W8.<V84P4PAOU%^M%-R'H:MCL5;*
M)@5T]8.$H_I.X@L;9,3T#@^P/'HB%RUK<A!G87[+;ZA+O6757\6$A/Y\XZW(
M 52] !TZM7(= $-Z!_(.CF/[\1?2>?^'O3</:^IL]T;CB(@8$04!(75 5,14
M!6DQ9M41E6)4JB@(JTJ524Q;0:+$+!4A#&)JK? JKT1%142, X-ER"(DD/:E
MBHR1H&1J1828M:J&IV1E<5:ZW_WM;W^[[SG[_'6^[[K.'XOKXF+(LY[[?N[[
M]WONB92-7%0*D41NWDBXTM;M:_P2EIO>ZM*QLY,XH(,SI!-P44;=&CTCKT9S
MYI"_WV'U*"T8:WHJUGO4IWV>YN$W-=3C"ZP_ZT-KB=2%D@2;7 [FD0[!EC74
M-QL#8&?^LL? &X\Q?P(0"PND-JH%C_2E@L5[>!V-ETVG U8'AW57A(@GJ'E;
M>AO?18*$/Y9(#O&_N?VF/=3O>NOUR/D7-MLU_IFZ:)M?M]V6RWI67$U9Y],)
MQ#?6G"5(K @L'*7EU:W#8?W. F/D5?Y^;HYMG+9"D[4K(C,/]]@#EMG)0STB
M,;N\NR9CP)7P\&=&P9R(W7MZ^B)YD>NE'8>'*CPCO\!WVU'Z#CY)_ SGBI O
M)1,%RE': [$MZ^0/5'L5?80JD+.(@S]E_/C;,%<YX@["E=#4>W5AUQ.AR43J
M#=[(TXZ&"+^"3")<:TU;!_)PEW[]W]TY&7/:*SW#Y35,T3[WG=('OT(S$*TD
M'*J4$,YVY&2MQATZ:%*/,P=9KR+[W#AR2(1.9$\CNXY/3,=7!8MW= _IVS[0
M,]!*GTRI:V+-P<*E]]1;ZV-N)WQ'+, YF<SWN4?3MS[&8X7$IH*V8?AA/S&M
MD%KY0SLCA:S'7\)MK36S43H1CJTRTZR7H3AZ!C23R^>DZ>N=]04*9C;JR65[
M\\01>/@I@A&KH[#EKH[&"Z!#[VW\Y?C!2MQY*_HL>7Y.(]TX6,:IT'P%+.2D
M1Y8=H*P1Q> \.@<W-<PZ/$K3WHE>C$W]T;+ZYS2]..M\+PCJ:*P.ZE2?0=RB
MZ1FIT\%Q_8'.+UWBM5F".4WSYE\_5MYX[6MZ.,X@9IH4R$0V Y%]8FO:U[/.
M#($?+5S!\U%:)7WH&PPU#&>R[8'0G(MQ3]^K6X$=[M#]=E8M/"MEDIT,9U;@
MQ L2('WU+J1KR2BM:BGA7*PT)'$_[S*98+GK2+[P^AOT%GH_W'@$#S-7@R.&
M4-A0,)2$&\QS (JU*$<*Y*@'L1"TENQ-..Y5>J(DHG<O,U?J2$0]:O/GV!&)
M(!%94GT\191'S.-Z_C \$M5;_J#]\'N_R#W$)7"1VN,?K(^E;KP6TMY@@05R
M!G4,#CSQ,'=;SR/[.1,$"LBESMFRZ3GQ11=Z$,HM&D-Y@ DW7Y7NTT.9QS=>
MQ+?^P_(9?J#Y46G<]:2),B+X$#_ [[W4U7V"^8*>T2X""T1#<LN7MD8-=)+)
MNV!^;2U=BL9SU!X&4S-C&K$'GWI)5YZF5 L;H),C&TMF'QT)E*$]O1M !F^D
M68@-KME94WLFST/NF,SU._3V_;%[R9G='T[2#6'F1]:';+<!,1;.!(NY<J0W
MEW2@4V8[V)HM=>/[XZI31DH>G#&"GVR90*N"=5%KWPXW= \7??P,U=$Q:;H!
M<>1Q.1UO)YY*N=6[7FK_H+:^N_+3^=(?+KU=@E)6\DL(+%8J.<]KR4DP]L[<
M01W:G$3!2NN-.DKJAID:N:G'#=)Y8Y[]3:*\/B?\T0FQ]NE%W*>YN^9MJ8YZ
MW\$.^+47JPX79O%C[@ZR?3$T\_V><,7*D?ZLH>OM)F0+M)]R+YHF"FC\6_5S
ME/6N=-$@/(F_$^.:WW>23J@<M7L=5)!=B;H,C 2>9JW6>SHWN:<V>8Y3L">T
ML9CQ4^_4_&-#?/PUWH5F%U7WP=\"QL5-;F*^<BD<I4T<)(YV0]HB305S:([!
M-B9L;++56491?4?$_-36;R'!*3Y(I6BUXS'E?DNOUMA*/=4>#8+%(%67YT;X
MW!M0GY,DZD5TWA:F6]Q*M3@G('3/=7SCI2^EKMTTMM)ZF3HU==6H$^E#A%O%
M:#R]!Y*CCZJ5&@?!+\@T) $^(_4 QRPQQ'3K/8$;_RM,+/<<%];-A[7-E.K"
M(5&!#>+IR:7^M56/,8K]"RM;SF!F<2FXNX7B%F-![BN.K9-Z"SKS,!1KZH'-
M3_!68KK(X'H2V0^+D.G)S#/1GUB+J;,;SSRCKO,:@S=7&B!G7O@3S$?NRYT:
M0:P#A=JT343@-\OP_K/)HM-!WF]_=+FF*X>,*YJNPR#W&7J0 ^:[&O-N\&UM
MDYD&KEP$YL%#B@*Q+8NI]30RE3T+D06.TF(DCKSE#%?^6E"F]>3*AAE.@H6"
M9^AT]N3=1!JV0'2SZE$JUR>=[9PX;I/*/SL9I/Q$@;:'*8GPK'=>MC$R#+*+
MM!6WT\E?&%A(+ST+>O0+Q*"X2316(")VZBVM+OS-(BUYK3@.FL5'\(F_]\I'
M",C^'BL^I?3G8E[9UJHJX7: W(R0EC@.+>^3Q\]VK:8QKL/5=L0,B?EOUK\+
M A(8=BCE3WS@LTC<DWF-B/U-(#%H1&(7P6I>L-G?6KC$L"QZ;P1OG,[4C.2P
M[7!.!GLAL3DR9+<IH'7*ZVKWX^!P^XA#_=8_#@U56O)<?Z?<.C$SE7(A5?UG
M4>U+6+W"_"V>VBSNL>@T1LB21&TP@M=J7UW$5WW1/L1?WS<>=TTGO/7T,<1&
M>%RBB]=L<$4+*D.BME!6',6^&WB26!H7].3>M52=<;IE6WU[N33SSV*'LW"E
MLDD"%@F;-+T>LE0$VRH2(0[23_G>@(LIM[;;AK,C=@)O(AD/'^+SZ=?C+^]\
M*[$$$,LZ#@AUDBQF0&A$XRBM^9OHP:*%("UE(JKW?9[5"-*WX>(GMMOJ=&24
MQF6D0_<+*/O:()Y,?DS^5&+NMIT"\CGJC,;#$_?R^@8-4TLM_F!X+1#JV^[E
MC5.X2X2$G<Z4=3FEZZ[[P0P_8^8E[>/V@U$AFSOJ-M_R[1W,&6/-WKXGR,YL
M,KODVJYAS1QBOJ8G*)68#S]G'"(;R9>6V1 %.IZC:@C_F/R9?&8)-J?VHAUL
MY:_6DN'>P8B3D_]J+.P_Z_G^2T+V20BY_<^^ /_^@'%_=D+],W$O'^DY*>AA
MC#Q%G6Y3WVZE_GH)JKU,H3[& Y1\))%?_LNI8**_'/UUE8Z^_N=G^/XA^[,B
M+^\((FOS"K**7P$9O@4^V2W&/J]?I:P2C[\)3NE_9CM%@ 'R(W#P9R*>B_5\
M.*)]SMIM3G56!V;IV\)W)\;?.MDWZT8R]_4(ZI9,:6IL<RT=+$5R$.VM#EZQ
M+I$_407M7P7U/.QHW)XH6,+-?0#>4%!Q@72DO/DT.8DSL>3,DZ)"5L@)5]&M
M;L<6A7#M[DNOSHY[E\ %GW(,3TLL0?P4ZQV"PM3C<T&Y07Q2\U"II-RCE_4Z
MN3A2T#E*<_"'[$#P>JPZF[5"9X2:V'8/NEF.=(4F>\3:2LS_&@;5C6I(OCI0
MSAY;6?AY01BX>"+^R-UH'C+$G$59HZ_K]N#CS#]@IB&*MHS_W9I.SA7T">9U
ML&G$?.LM0= ;-:+DGH$>64MDIDS(W9]#YTEDZ@.YQ*8T*YW"-<ZWL)(<?[\(
M[MA>4"#?UL(NCS\0H_=]/$1L.*&SM9>V-:_;8RWEVU(,TBD1B@0-0:A(0'M!
MQ%COLU?SOP8WL0Y%#3=',#<4:UU'2451GZA[6WQM#^C?4P/"8_575NRN2&^,
MR$GH'K%+9X4>&/^HQZ_HFN#[K>;G\%1$>Q[&PCC/6\R96+#1R3*.X%JS*UZF
MZ35#\9:E@E\855 FY9[I_$-X>&8%?9;@*4G# N5_(YE\6C7@)NI\6V<G.%X#
MT<<J5M/U ?TG_?]@.N+=W;^QMI4TTABNB&P5=5@?06Z(K:F,-]S$4;\S'#Z%
MB\WW<->SD/:>8(7U[_[TR?Q4H-.?<%4BCGQ/@X4^)>KU\=DCH[2<9$ZN*B)4
M+,_/>=O)_[2CW%B1%FEYLM;!<T?#_.]?C-(VB6?:C$$9)B<G[[/X41)9Y:%;
MV%U@_@$P\".&%?P8]FKRB9<]G'%TI$F&#8 3H[1)4:.4=&+VNF_5&$4@]#UC
M"(52S='%O^WG-";YDHZOK.4:TIZ!J\Q>.-/H@"T8-!=V0]PGL%D-5N-'.)7X
M=?Z*[LJ0H]B+"'_(J2(?VR"]J<T+4TQ3\W*&(]KK BD3-$+/D"Q]WQNU$IFA
M#O95FGT:Z< '(F;Z*A$L3-+#)"?/M/#XL=8L_IX2PL5:)%A.N.'<1K2G3,Z8
MQ?<N 4=-RIKP[/?E*_MEPXC3>]-T#?$YQRGD[IY!KV7=K+"[1$#UL^A/_1$'
ML-3<[2+M_.Q3XSC2P6!93\3 7L0A*W64M=]!%:AQGV4"$03*[O 7=D'Q2(;&
ME>VUE_\E?K!$5Q_&>49PROF^UG-^%8ZP7JB(FMJZH].XH(-;(7&*E*T\JPHJ
MR+J)W1C96EL2S[YFV4_M;_(]MH.@TUT\E&'Q$_S#15S1V@R-X2_!JIO0/ =*
MKJ5@M64B+UC7G&NPVFW%&:=8WHGWR&='G6%0K!<\N/E&'?6T3,L9\IO\3O[U
MF_QO$P(/+2&V2#V!2J;!@IE@2>"0#BO4^Q#.*G.@]3%%N=/%&$?LQ4^RS<U+
M-7RH1Y6:*;;IW^S)P*.)_+B=.*"'Q_)7U6%+1N#&LNRKA9S"C4G'"([.""OR
M1YI1Q.N:]J>43?ZAS&>CM$,B,*=5Z1EL[L9CC5<L/@ B[6LM87W\6+ "L^A$
MS<PS&BR<<8;M YY<?4TN Z$Z/X9,.AVT8:KF/B<,.<O:QMJG7^TL'PFH5CA"
MVZO;G:,?BZ(Z/S@FAM=W5ZS37J7?^J !GS#,\38+O \$DI,#=)I,9!J?<Y?X
M#%R+M03Q..;H]!W/DM@+8$''N\3 X][]C1Y7CJ]$VY+*EV2*C^E/Z9_?O?=K
M';8JOJ8)S3Q7?2>2%RVE/T,.BWL']1+"M82T+\40<QZ8@+\ST^ZK1FFQ'#44
M 826971UJESL3H[E[XY$)O,WHUCL.==(L*;\.<'&^^IUECS/CSKOLF!M^0J%
MU+[K;H6RTG+P2FKQFV%H+9]#+=B='P>R;9= F.M0*:-9U*-J9%0%-B+JX#76
M1Z0[]09K+/[$,NO?D8,B1^);K*NKU1QXRDAZ$';@F+9G/N99+;SW*_:R57$E
MK'%$I;@2L[WZ/BZHOY60W^W"MJ_H!GMLZ8/4)Y7;R@Y/%PN:(6R[IK?$P!CR
MO:.TL E?T(/)%9I)%/%XZ6!(S4P63=D#5'(ILZUNV6W@L0N(;X+<2'#^-N\<
M9>V>)4@#'^-''V!O6AJW#[0-],UH9ZV=_[CN1QIY_G^X*RW]KS+<_VW*Y5_\
MX.JX?Y'[GF@: ?\W/_M/?M@7LR.GGONS4NJ%9OB09N0Y\LCXS^"[I^>?EW0_
MHF][4-LE7:R:9B7_[-&#CH.2Q(!)EYN>]Y*35V#!YBEBK4\616FYS8'0Q$-0
M'$/M&X+??)NMX_0@VX'%X*N91"Q_@)\[Q9"+I@V,U-4TKBM)?"<M-D@F;+R\
M\4&B>6*G:<Z/5;D4 3,U:](9CRAT\0H(\7Z]24X_'4VKEE:T]^.M31H&+TQ7
MG:[M-!&:^P,=O,+FB*K<ZTTGTGY]8@X)KH_,%2^&%P3^WDOS$F_@[1)9MI._
M],T!JVX+GHW8&6=BOGNMXO=_.WPX #YW'&IJ%8Z(92^7]_U#[Q'R\P=Z=E7T
M1V+9KJ_547LC>_>V'"EO_FXO9\KRAYL7^\+ UQ(L:(4JBC)*>27F9(!CL093
M9G+BA_9*Q(D_$US3BG*.NUR\PSKX54>*']R@?E5;\EQ3\=$_JE+#G?;Z?_G3
MO,4K/F-<&J55!!(>%,<;+[3>(0-XHS2S$/QAF4_W(O:!XKM->KHGJ"..66\1
M'P>\C/9D*[><&P)I,M2-6*5+\O?+O!)[..E]GC.GDNOS),X]WOM[SOTDRH1>
M83Q8*K;, X7FZ<_06&0\+\2\';^523(H8\T9%R(!4UL5^4="2_9&:1*C%V.'
M'UT#INWXTIOL"R6A9:!QL&DZKWIW?M?\KH#:YGB'$5<A=*CU.05-(9</C)-L
M)VL9<K!U!G&TS53IMR(<^.I:SXD=/K3F'H^^67RE1BJ^37S2P0I+,7AX&!?B
MI1%[7[?MW5VTM#BK6T5IG;K$_*7UTC[,JC3.LP03$ZQB/V)/P&]H1@G0X.DZ
M4V,6/^2;DKO,VVMT?_"/Z?W&!%RZNT/_TC2WX_)OQGQ>Q($UBUUH?X0;Q,3T
M>:2]RK*)EZ@-SB"9@J?N@GJ[H2?:)!]=08/)Z37D)/V86 7.:SE"M5=.D5=[
MG0<7C]6A"J8]?ULWL3K^YKQ&_U9GGCRB*O^5:7MG[.84/\[VVIKW1CO2OL4R
ME1=KWM()[0OU,,>"F"3+@H3NP/P(B>Q816WYNL^Z#DH[YW:]4E6N#M]>7XMO
MO698^"$W;?7^5F7X\?=]*SHJ3ZP*Z?*W'J=0<TC'6[_'J)IK[E:QIP&3V:V-
MG!Z'/!IN8@C%E6AS(5U8TZ^ W 3=R"0IO2I;:]WXC\8T^G3"%5/EF,Y=LVP&
MHK 3FSVV8N&-I1]$TU[,6G)5]'E^;W0HO,D\2LM%JJJ'DC"[9G>NO/6<IE(R
MU(*%*4>:*J^\.J_EYB*V_JF?X)EE\;<YYD2'<@H2+L.C\\KA2'CO**VXIS7Q
MP)+P%>0;EV/L"-H?J6:8,A#+$=DR)$8(S@<VT'L\&HJ\:D"M=I4F0^S$))(D
M%%]2E0*1+K_TUH;B1,94\1= 8V!DU606:J..;*ZJZ*BD*$2<*NAH^KV>Y_'=
M(_490\=/?"_[E3V-.L)IB/:<=-QC[+?A#&B_Q&'@>$FZU(<7HQ^EG0EH!M=P
MPS:<GL%*TAIWF/8^XV36;;C#_Z)>Y<^8M*X\^DG9&X9C<OG:#EU5;>G-*V2]
MSF_+(.=^?F^=];8-KJ'W4<J][R5;T0?]S5!.D4L;/Q97;<5WE=_EO4&R&7;O
MN9DH[?U+NGRE8!'V<EAIC6V"G)(=PW7&$D6+[^MYX,B1E.M[>\'UC>'WO]\4
M-=M:CQ>:'UHO4I;.E^[P1ES!-#(M$&'7P3KLPW;H%*S@'P IF%3>I%=[I!5>
MT*6U>@#1NFI54WW]R[OOKBP.01=[%![[2GUAXR]C?D>-8;9IJ;9IF*1:/(-A
MX!@]+0'QT<M 6:INN_;$$:67.\C TW0+?C0P)BU>,QEP]11@L&-_Q!O+S%*O
MC8A0#_Q\P/"8OV%R_,HJ==#M=J.N(A06P=AFBH,$&Y=A1[2:!N@L]+!$;DS4
MQ0Z]<ZRL;C#2&X>+_ !<QE]<41VRX7NEC+T2A.NA"6!P;<>'3P\M8:98'*#I
M-\79 2$.GK!B6L+QFU<J7\#1/)6AM4&3J9ER':AP5P/4**(1[H6<]I0X@1]0
MZ9EG6'[8/Z)\HW,65:S>RO0:O-PDS/BJX\/?8D]'+?@0$)9TN\E_QYZ?E_^4
M@:XFQU.X9R?+SC;0=;/ 1R!#I[!\= QWWC@9XV')Z5%: C19T-DW#K04\][)
M1FG3*\2S!HM<V_8]XZ_6M=)Y.Y)F5@R&X[,O;- ; _71M4E\]9&&FO43CW[_
M8MQ@:X^'>;$U'_ERE):QG9AA_9X]A0=K)7*1,?&*8'CC,^_NE"1.M,HTY[3Z
M1&J38"F^JU3":VEV[WE8\:BCN(L(TSO&;$\/>7"_7?MC+N=!197P3=#O@_1S
MC F5<+9T"?"]2< @JI3_%>8J7,*/,8C/5'E!V)5^A8:"BV&1&SOX8?K6,;UO
MVGEE<NGL3A>RZ6[*DY@MCSJ6=IN?];[<M'2?IB$>K0H>RKA+N.-TH]L-01?\
MZ&B9A<T+V1E$SR%7Q:.SI;,T?'?LZ>/JD5T_)'.G$1187R^U;TO9?B>Q9L'E
M9&/(WJHZUY&G%P_NLVPLCI_=P-BT'<X]KB)<YC4@=@0T2IO@ HHM6_;P:5BX
MK/5Y;5/$QESLGDG',>9:('X,*+6LC4QDTW%&CG_H=(.N7)CSW@$],TJ;P3_,
M"@PBV" *'[>MG16FEP3N$ 574$AK%;NV]%N&!ZJM16@L'TIQWP);I&VRM:AN
MQ56R3>H!<O$0+=0HF48L?@3:M)*IH$5GERT-4,8>^48GSBD@)]T'/^_3P5G2
M\0\[E]P+T A5W7C"=(^_[?S@R7;;__B[<<-;<S#3&$&'^%%L$YPE6 DV8*CY
M#/#$Y^E1^3H*SX!]6F8N>RPN5$"T@'*L8VEX<]]DS(S>!A<:;VEV'.CH=W][
MZ<M]TGWQ"WI^.E???!*B(5JI^%T&8HLW.E\8I:5Y_Q.Y_,4PVO^$>OY'A\*_
M:B9H"V->&Z7]?@4!@>'D[[^-TNX>TU[^BX$>?_G\J[^V13<7(D0)3#I2)+SN
M1V30B[?@+RY&_E=P9J_[9R/$'-3DA(XHBU;^>R-$'O+GTO42BX)++3WO]CAJ
M[;ETM<K,[ABE):$@R*-9;/>!J6:82ZR7RN\BVLL"9_PJR+#,X4>D:UN;?'_T
MY\X>4'\+$H:;"KS<\*^.@.#M[AW1"36!YOT!+\E+-_8ZW)8J=L!&=@Z-7(X>
MD#Q_JC+/H=9RB>6(B=9:;T )J#JJ$@7>&A$KB:Y@]GKH7T >[/GQX362)E^C
M.S0U7NI=B6G2)Z#IR>^N;;C]_/7^UE^$.SH_%(JKQ=6+UQ #>XAY($TG.8U6
M2(9N6@Z3SPPZR/A!0G84^18HQ(^.BBAE3$74Z>1D.SQ<J6X5?=E-..,>YN/6
M^TO9R_@KI-WO1:XWPB^CF3>JP"EMN>/[8\2&DCV>R!;<?.6(0?)A__63T"DT
M!YF&[!.?8F!1IBRVK:JC K@8]&(YT]:*S@\Z\ 122%< @\4_ 9G]'II$P#5M
M[)FO?P=R [/1) R*53+I(%C1-[=S?G?RPH O1,U%;M@H+:^RJ2T9<0OQ-A?>
MA8EWNO*8/<"6\;G(>I/XIDSP4V#1<FOF*"W.!'Q_[0NR_IWEB0\'6Z\O$3@3
MDZS?\=>=N,4KD#,J[,X1$RQLT-H@=JI;AT5N[*X++(E7T].3 JXP91']9]_.
MZ5HZ!S^KJEE9H!>]=6U$,(H#I0NFVFIN;-T*3HOBB[S!)4A)ST7'$H$6B'>A
ML7JD->,FV!FC;75X(V!T55@YZYX9";=$_2#7^<DWNMH9=?4H_O3FS<U3JA.G
MYG+G?_>SW8N*,:0 ?F"7*9@B:(.Q2-%TWKK&W_GCK+>D=G_.K^7P-[85<<?:
M[B_"S+:V3LRF:V"4MAFAK].)3Z/.\_$ED/-[:J>$C0*7G Y]\[4[B4$;7J&Z
MLA.,M9U^[TT3=O?N/B8:@B7D+Y=="0\_RL0LMXK]X3&OO<98ZTD[PA\_7&")
MC0_73 C@T/A[JQ]TH7$<)PZ6NQ6(<+OMV.%S?4%1/AN%.^^W^7_*#Y-H>$L_
M65IA*0]<%Y(UO=_J\OHJ73M(0<6%HG0Q ]5F(K9B696N3L"V!9!?(]AFIA">
M,O1!X\'_2$6R^ [@F&7K&\U4;>=X=+K XW61"SA3<%R<4Q=P1!?"F5)O.K,@
M*6Q;Q]T4SY4>Y[6>T12ZL]K&+3L!D3D>'VZ4J,OTJ4.Q%CI/:%YNS1?,$71*
MEW5+IR>,"//(^2]X8>9K'<8*B^=*DSD#<#&.\OC6[!O\L5APEI\QN9Z^"4L]
M>7<>]ERX/G3&S8NJ,[V;.Y"C"Z_2=>_,7UO/(+IJVR1Z"(ORH(-#DMY6\UK*
MZZ4:3"==Q4E6(12'@&U!PG.H;CXF**?W".:^&*4USM&W@LU#[QE#W$#YMD,/
MR!;QSNZO7D*]#UQ[-;.E#*3Q%J4Z0D2;Q7! =8$4 EE!SE0->5O6\^:1+LPF
M=#KU/P[@'"6,Y1(LW#98USY5P74]D1M*83:QTFNNQ=5<G4,9GB$+PW@BX2T%
M28?R2>0'<9??C#%D%#R)G&L[401E)L9KJ9VZSE]FO8'&QO$C*6'3K%>A!$@M
M:80?*',_T'M2F[U8>*N(^&)8ZDX=IY/)XI.C-*\O,7HV:Y4NQ"0L6MWML1VO
MSDS6N(+PW=][1BQD;,1GJK+>MZQ>9W;8;BWPT*<2,XI)QV9K(<+E"G?!SI7E
M$&E_3%](SX.GD(LC0^^I$]C+,88\%-E3^8RR3*ZJZBKI8A339/E'+>$)M^+C
M+U==NL-+W_B]87ME#>TC\E=*A]Z]QF<SL-#6'KKY>^H=>H@ ZFNMX&D-^X'E
M,^(@KLGRMI[T8X5;/@42?2+H-R<]Q@2U6E//.QGC07?E-5[87DS3.#A*F]C[
MDK="YGZH;R:.G.S'T.?^]"F>W! ;FG;-M##/0H]^+;+ENZU$9$XV(G==X\IF
M"WZ&/*23@%@942T7B]@!UGQ_C7K8S /V)8F7/W2I9)0;[8$GU'V+/X][N!EK
MX =A&KD]:X-.[+27_\EC["UZ(V%D_<J:C243),,M&VB(N*01=GT3O83Z(#=$
MEG:K$JS 7(.QSX.>BGV$4$)K3VH#["J@\R=:[U?N,;W?IX=G\X)UK@IYC,XT
M)4'@6N3AX9FZ$W!TG'$\AW!A1-O[)Y#\>[FNES-ML+[:V$')N4<5BG$(IUP#
MK&"J.3NL(O9RD$C:YV*%<L94TH]L%S_@"M%##. C5B0M[=<]+4Q#,*YBE(9=
MB 1%*EUP<V)G39=/-S^R!+B&=]["O!Y=C]@=I1YD%G/)#W%7Z3(F6#FL<&_-
MAK27+WM^H+3NI1;IJ=[(R8-<]V%)HL:7@09ZIG0F 6,/NI?<J@ #6&^#9C;%
MUY1%X[$2A<- RCBZL"\T<+WXB_;*4"08Z\_XLELL/QYN2OJWG*1I3/+(]G^"
MAKQ1FLGCWQWMA%':TP3(UL9X.VHUI/R+$?9_-<+K7[5'^(]R!;Q$ 8&%*L)9
MI7/-8ZW!>O5*H\;B1GP,LG6^31UU.[6,+*323L:8P.N0!Z7WRGCY[(]L@8!O
M;B5>#C"H]_9&^=TKCDE:%?EBS2?K9CQX=*( [O_M@)8S&QA(A_/4F2O-E<'8
M1LUI#18N[)#.)6:<6+<!-.'%YJ-@%;U!\2,6U=B;<-E1J1RE30+W--$%REMN
MY0&3^!_GA^WVR4AB[(QO?]NP?HQUD/@4%&#]!OKI9'HV;,]"M.(<>"I_3Z+?
M<$8=@O4W1;CF$<[ZR(5+W_K_8?*GS^0='*6%/:LLW,T=>CMT\W&'Y.W^<V^[
M]3TO#Y[^(AHVP-0'4O3H46JZD?Q(\(SA0GKQW; -_5D5G$D]H$P?GNL/V[U.
M+5J(>\HCXXY/N'6M_&5/[\L$]0_G6[WKS]*]9965]?7)(;X>/^K(Y%':(52=
M:) ,F8Y1AL=D/0?%,K,TE(?4YA=(/P'.=_B[0(F%89M9__#P(VI;[*P28B8_
M7T])6Z>4<<_ D]EC>/WF5,;D.E^]W.#!<"'@[GLL7Y_< ,= &&><]B_?I9&/
MO,R_]@<#CR4GEUOV$]0+GH8$[4'*9FMD T5DV('DSRBV"\Y$'FT0*CAY%#%M
M* Q-;"(='G9])&VO-&51[XLH)/9$"-B)#1M<"FXC\3=^!URY^ZY2;;YHZ\-V
MB2KZ?E> <=LXR]UV]DJ^FXI<R"O0"M)QKNY<-5XB$S Z^)$&QAGW8!'?MY2_
M#1-GI(@?C-)B0*%"2GO4=0L_F*&SAEN".>23[I30!:I0J25%W'/X@.4+#VL0
M>HG1LR4< 4$.Y.0#*U9^Q04^_4._^:ZDM503B\Q^)\>>??"4-JYJ61/_#^S/
M1+5DGHITM%*OF2WH+5H #-82"X<_&;19/N-Q=+!" W8A=D/4#KI0UOLT*PPS
MA&+-8DJ1HL48V:%[6VV]=$"2\,Q:IA X=YFX M6K!-? ;V5)\S]BJ/)F$IF$
MM_6^+;97.4S,B%UK%4GI K7 'GAH%T':0N@!;(PQ2%QY8O/7(!0/A#OXF_6C
MM*E\WVYRT0O@L!:>RHON,\"@^"ZX8PA!.3-YYPPR<C+VP5P>F,[W/7#W5O:1
MF_Q>RQI$%F'+E6%XH0GB7M-GUN^)6,L7_ 58X% \GMNLH;'I_"762ZCVAVJD
MFIDN\.<-Z_*,1,19386H^>5:U1<JZ=060VAXJ"BDLH/E>&M=:9Q@&NXHSBI8
M5]N9/,XG]R3T>(OOKYKG' .WJ54=:%YC%4L#"#X(U",]PX98D=0K_G)!$YS>
M]['MY#J5 Q]E_HJ7<7W>E"*>X30O+%K\+/E$\!<=AP/0*0/DG'<!O+J TH&)
M(VF7>MYZC_SC/SJF_&\>=%U<5'Q[8(0M/E&6H.H^'GWQ9L_+A*"BDMLOUQPH
M&5"?^(%^).W$B;1O\<B(/>K(#=Y-75V*\S+N>.Z2>^>+/_XQ>I5E/?(S2ARA
MCN@J/'"4MJW\\$F6CTR,[6@%/DP%,N-UD1V%UQ"!@F3ADFSN]7;B4\KU3*08
M]MBZ[7KQM(0C_3]W5'#HKP4L:5=EY,!]?EF(P^:W\V4];C))E2]1AAY ,Z,=
MK:6(]FRTF_6BU);'.!V*9Y[35(W2% R7Q&ZO";8)4;PCYJ2VND LG5,G-)P@
MJZH[R.ZR;Y*.K$;/\+V3OM&N#M^(;WA5H(N3:,5KNU(\(E=-^CMU!BEOQN&H
M0\Q/[]L(!C_YS_D@".@=I3GXZE1#2EM(P7J!]5FR:(AA__)$B:%<>89-CT.=
M^0CU*UZP_0 Z@Z!PDOW6VE)>P;;6L_S@M/$:-7(H*/3BLSR_!NB8U)>?  *Q
M>?)N]E*@PQ-U!3+)Y(2BC]H)GUL\L;Y:Q/+#WLG5HIQ*^2=MK("8<E[MSK;W
MO>BTQ(GJ7^./!]3_<OG<U:1^E_R.63=Z!RZ2)T9I52(CU[)6T(-@ZQ^3\\EV
M>!JDBP&J1HHJG8!TKL(4"=C <J+V>8C"8V-4*;Y<>UZ:955#M <FO9!JO3#A
M0SN2"._>.UA 'C9R=M0EYUTPAQM2C?:4D=T$*+ \H<Q:"FFOH _%QFO8L#D:
MK--JGE?KT.9R'X7T8^O?2 ;_&.YZDL5!RGA!O=LZI8R!D2O*='AG-[$=*1^E
MQ28\Y'-PG[PZ[ZM D+0QR4'&O'=EY3"'1A:]EF@-%!O:P0!+PQ64:H8W:<"B
M^7"U70-GW!/+5'ZXBG0%U0W'.4/GM5PG<,%<52@;I3G5S;G.NQ %Q ;/A+>J
M1HU#T@3AN60K,[B-[4"LP%X^+3]P_45?%$B7U]PJ]6R^,B*R! LTXFJ5,=)B
MRXA<#7T)/R\S,.2CM.>I34B%:FB9SM3;8> :W>[RO;%^I3%17L/(\H]L[I"Z
M$G[@".X?R8,43O)[ \/+!@N.GQTH>Q%_.>/6M9CR.)]&=;-8OXW^9FP."?62
MDV]2^S4>Q%MF(;(C@LG$+H!2.^]*JB%LRZ<L>[N32.(H;1S?%PO.>*_)+G(#
MI8L>8YFH'DIW[\[3TX67.>>2:Z/&17"G[>YY'2YP^IU8$W-S]YZ7+\"W'&=>
MYKT\RV%$%@7%2G+%V'I)GKB"8Q1AJ0910RM8]/8!)M%5*Y">XD;&0U6Z8-8
M-.4P.8?/PA9<N\GKV !NU3RMQ%V;V;X_7FC:0?F;5)\O,-?3R:;I/2_B1QCR
M2\2BTHB!X]/LS#,W(!.02H1P"2,G+Z,\@TYB9%@2B)G6^G)R*6^5=MBXN&\F
MII3!/;VD?:V!F05AG$U2MX%1VC1_=*)H C_8B@J6\QE@I_Y$B'Y*U<BK F;6
M8=(-=(_20CL_?.K_*T@KV_NZ;TEZ."8>A(SO_HSYKB-"_VVFWNFC B7T #+2
MM6A/JUQ<Q1W*P(/U@=F53 :?@4%-5U;(^N9V5(1R%4?[H([W+R/7L^=WUX7K
M_.BAWS,=>-OK$J_SZ%^H,BXJSRZI/+'8M]<!HP]4Y9 1+.J$3PBTWD:TA4BE
M*S$CTBRPUK(_99P33,?"AYQT:"_3O  4EE)(:3M6-:A0H^DL_Z*QH PSK_;0
M]6<DY[%-VW"N,G2CKVC*:^E\*;ZR7/?$[O.<OBA.>$7GKM\H](EH_Y8*56XM
MMTP@?RE:;*UBS^'@*\R%^+!\]3P]U.0H,#1&VV.LFA23PJ6P:821?@M3R363
MP0JY^XG^4\2RNW'2&5V.MX2SJ]VE%Y C1U)/S+_UYC-ZW>W_8R*,=^DS08F\
M;Z+-5R;JC=%*.3D#RTR_RRM6J,VEWWC>*KS.0S[K>!L0%;NK<^G- SGJEJT=
MY4NY2TO.7YQ[VO5\ULX%U38.5X8QAKZA!/85M<)'MOY(V YZ;Z#.)W.4]F4M
M<A+&OF!F!RG/Y148)]SF(QUH@B^')O@'R>P<8D]XK;%_6^>I>Q*NTPACL%^E
MTW)#L5]'S"4LKX^Z/ZJ_H A-TO66\:Z/%)COV2I98S4V##^]EYSTP1)%/J.(
M]F+!+QIGTHO7"V.4QS4NI7S:VPS+?O(?J ,4!PO5T4+J7#2762()!KY3]JQ\
M#B@N![&A.*<Q[\@NK#^[&%/V?B@L;/&XLHQYK] BN7X2>BJ414"R5A$#"Y'T
M2I4&DUP"=L)CB$"+@'#!"RA.?Q7%MIIZ8O35.7_.WC[+7M;^'IYYKP2WZ)$A
M+@[OQE1G*B6G&?2^+]K8B^58;2/IC+E4G]"WT@9&H-,?%O$#;@U&S[%0H@V[
M0T2!$KVMB['D%'H@+]"<""R&U4?,+MW)] P-%@8_?Z>5*+@]MK'$SM*5?;RP
M+]K9L_A+\1+Y6KZ39?5N(N+AX]HJW%N2S7;F<=85-(R<*RSW3&R2+DHZ:.[]
MC.R_3<F(X:*Y;\JC*!WR@#FTT^(B>!IAHN2CE9+CK->D+M4YF:<L0<0Z+-48
MBJ7KAT^3/F^") HH"W8E/WD3;?_L[2$I(_X;.'XD+Z.J7&]R>LVVJZYY-O_"
MFC;.R0^KUS6B$LK!,;-M%7D]8:2#R!+!IU3BM)KP:6,=LP3P]UM_D#J 5/,<
M7-6$]@PJH I8)C9R)\5)9U>!4LS2Z#ZQ4 MGJ6,SI=ZAADFLS67*%';AU9=Q
M^<?SS))C1Z[%]ZUJO]6)5MD:6S+QT[Q%),4 9941$CG]N;)9<Q]JE-CF!>[\
MH)E!?&S]>QV"']$'-C.FQ?79XW9YQ*>E\47^0=5-'FGP=!"Y%5Q@#4L_Z6"Y
M3O%9UU$>\/A#DLNKD=:](19)/L*5G(7LB30<)1TDVE8W8CEPM/@+GJ4&_AE!
MH1-,G#/D9@D1J!E5/L80;:M08-<U%],HDUP-(@6#,2B>A![@9G(.Z%[Z- 4%
MY@K<@9V<G(1QSDR]J#_V2P';#>/DI2#OC]HT#='3,] #HC-]7A3>_'*4EB3N
M]=4*Y2]A\Z['UORZ[5J&VJ#79*.QO<S<:#=\_@@D$TWFA6EWG<)+-C]CT?7&
M6&6L_+X\,0D;W(I/S9:\B*^*8-\,S/0[_;KF0H2%0<QT^ PKD3,!9:Z5IK.4
MD& E=(;QR'6H!<\U1X+5^RP>Q)?6FY1F+$=DZP7C08&LR!-;FIV(TW6N)^M\
MTLHVQ& BI?FXGE<24?^PZMFOW2GEC+TUCXH<QVJ:@US$>I/)G$,;I7V2M$X'
M":5V@B8QM@'.T50D,RJ09@3,KY:AO:WFDWA!LP=3S32'<C*/^PBEL_GK"QL?
M$C/Q:HJKQ7(=^=NM)97E86;!!<4[_HX:+$F9F[*(241=Y=T:EG=+IX8@'B!:
MI8!OP5BPQHG\2?")[7H-.B3)@N]+&M=A(O-7@&*YX]]C/KELKPA;]W1^L&4U
MST?Y71^O5_LA_R:^0E<BAYQY1V2JX\@I5OCM^'=YT.Y'F$B8K'%*4 LJ[\IB
M6*K4H*)KUN*VSQC-)F+V=KTH"[7= ??::;G$#+HV4/CARKIF1F7U4(%E"Z5N
M_G6[I2Z5'.,UG-Y<Y"96((_@K+LE?_>^U.UOR@J\GS#]V/<_W^9<![/7E/0D
M, _Y"5]MD RM,B ]*K,44&N<./"<ARB.5P\-6W82QZV9T&'Q3 J0HO6=_B]C
M=$Q9ZZD:!5JU\4HYO3HWBHUX\K\$B^R(>=T?RV['F9</5.U*.G)H/]95B%Q_
M,F,,X1?)'].!QIT((:>:01H7$ZX#37HKU'0Y-IN<SMOX3E83?+8R;Y4^5<AV
MXG]3T.@^+'_)W'9?6J343[PPO\ )<+9C0]M OD/+A?AK6Y:^;7<3[+!>9R79
M^BQ2NQTAF, +,R=@K:??<Z8!AOFL-4\Z4_#\>&R&P/D-P[XR3:,._QQ[>BD6
M=X$9,)K!\O91,-RC!@J"**SY40_,NU@Y*4+=4[?9^[>SW=WBUS<WT)!YY'+K
M)2B6VT/YKF#*8(2!1/,>, ^K-1_'3"*4,B=J*!1O3L<H:FEW,ID[RT=(^.+3
MHU9LP]D%NA8/![]4A:]W?3',*PD[W:^H09_[R\K>J%INQ>M[1[3_'\W'^G]Z
M_E]&Q/X]&>A?/+: %[4K)3 Y=?$HK6XCQ12]>.I_ZP/U7X-:?]$;]%\]T%^6
M&8;_BQN\OXS[_7<Y]/^\^9+32"P'^,3*.#T7S!76A] A\1A0K,^7X)!9VTE,
MN$.$/ZN+*@<4DVX0>#T&*25O(HYFB>G^]1XR=[NLY+\=OMJUE+$3GLXK;I*P
M2ATB-N_/&?#IZ]QF]YO02*UV_'> ;MDO:-,X(HF)HCR(.LQ/+.N(0&R"IA&V
MI:,]9"K=!(X\4;-F,C,@S7H4%@K\:R_(HQ>F/MM84O9FV#=-%Z:#G?T+\,U+
MT24U/IDWV@31, @,-GM46PO)3\F6($2!J!^VZDJ4&K6< L:N.9*WTD4@L,EK
M53M[/@\FUXRX9!LX'I079TM*P5KM;Q_B"3ZY$B<E7[?WO?%:7302__8K*T;)
M()!U@%IR/7#5B\!"NIRB75X9.,.<!2+Q=S+2[B'@&CS'Z6*;)K&6884&S>GD
MK,/7GQ&?XKVR5+9[USUB7_'KAYS$M-A;\>ZCM,SDP;R0#1A9?$>=$%CC=^89
MR>>UD([?6]-9,5Q+"(@E76.-_3HX75-!H9J4UNQH'^O?"5<+YR4/,:=A<)-C
MZI[VRA\%\WF0CA_M6+A)5;>GY$7\Q[UQO_/W7]!7G2_977<4&["S^,I-%%K;
M\,4VNU?*(9QZ@2JKF()*(O4=KMK24/0Q:"KC;RDT;P;;+>YLH5XSC4>I;H-<
M)Y09(5D--S/EMPY_1%@S5<I*.V%WZGV!*F6=/D8W6'HXP*6#8-Z:7]6FYO]F
MH51=-@DYR! A[FQ_XA"&&.TMWPI^&A$; V)CN18.<#"SK-?G @B3F'-K*K.'
MWJ8@.5('% L^^U%G0%+BIB++!GR"4FABK9I:N>\N^#[2<JP2FLD3;^^B7/'"
MJW0OJU@ZEN]C+6 [\%=:B\B)O"T=#:B]P)D7K6STFHA5WGQB_'W@\@;1I3F)
MY2%A/]9U!22%;:LK&ORB.^7*CM]-8=T!B;TO.=MK'M?7%L6:W?^7\/7_U@U]
M7]7%ZI(@)9N.PZ=3XB5^[R6S>(E16%7)-R6;QP>=<4>R_&O+%Y@3W0XGO35>
MK\M1OPVN_%[?_F;\E>TWJR]_W%8=LH'&CZ)$;[5F"*;_62=S0#+65F\UKFX#
M[M$$.Y*,A.AE7?Y17'V51'?E2/-PN-=*_*#$X+DS(#2DT6L:MC+=?^5(467*
MQ**J(O>'O+OSJG->A=2>^?X-?!%)$(.YK4,_6W8)5)<#C0]*^=%6"3F.B*4@
M/]*(9(DL?N2SFM:&EPQ#JCQTU;9,G.^$;[7(+_OW?5KP65U5=75[0 @\EJ=J
M$)4.5.4[IBU1YQ>6)*P42U+^:+-\C<CVH%HQBE%$=QK/KE%3A2A-("QB6&'U
MB% 1CA0]G2PQP K(^&2>7%5U_.B#5+,D YK*.A)[Z\2YW\EVQKS=CSO>'F9I
MEG>[Z<^%?T8O2*:#CP*'5NA,P =5,,""2NDC_/=W6I]S O\$Q.M]Z_1H8BT&
M0"W6J_=[:<Y.NYG IN%YHE-+DA\;B27)OHE14Z%9(+8Y,-"E.G!0OZIU6LC7
M"T1]MJ)"X!TL$_>DF:](K1)_- ^II#=S\FI:AU"MJ"=8(9@/1FGXO$9TVEO^
M3JUD;#1/8.'@)=D?<KFVR06'?\37[13+C_I$XQ1'S#[0SCU3O9$^=4]M(W9,
MF&%C""BV1>Q%..-"HP/VSGR^NRX%DS3 ,T@78A8>77V-/]9:[&>J0+-0MX-=
M<P%R+6^<@F'_/O2HV>_@:OKN*Q\B'=F#6QZM](TYDN95?OOUR-'BX:)3%$-[
MRO:QWN$G69SC$"='DW$5-JC+S*-0(CRE4$:R*I(\=&@6T_\*M EWYC4/-YK[
M:&A@^.57!?9M%:TSHP?-S8,GNB^._WIOW4>,28!#3KIH6<Q;1=J;_JS.79G<
MFL6HF$TI&Q3/S!+X@0*#>*8&2'0*U,6_/+4YVALKR$D)X=@/5E&R].,S8F[(
M;O,"0S(;'6,:+AM_W75$H_P&26%5#;O4CM(J8,*IVGS0>JT.LOC.$G@+.F":
M8#G9K)E:P3R#CD<21#UB_9."1JYZ72C@%H.#+8W515-QN[-)=7/*>#&*(-?L
M)4OXQF\;33+?\:GNHJPYSYS7=K!"]7ZKOK#&4U;>BT_AD_%KK'G$!,M,L@-]
ML#%/PN>A;<BALMKR6'.^]1I_#\[8BE<;U^$Q3:FI^:GM/+E",YT?J?.+_>Q'
MU8[$S=&SA*<*UN;T[U15;FA#JBJ-D3MJWZ,Y,+;9U-.B-PDA[16I"\[)E2Y?
M=Y/:H!5$"#;<!(US#<'M3ETK:$Y%'>M6Z"23XZJ06936R\LW,J8-J$:X&7<9
M$4+9?=[$M,*RW/Y'/]X_O=O/B&Y][4,KXKEII_/>CYLO_M)^]>UQ?RAQ.\+#
MV>*8J+$C?01/XRT;;'=%[^&>:F7?(G&SU-5Z)1E1EX[2=)OY+OAJ5>Z2NLB4
M,F(%2+L#Z#O; B)+[QWZ[4$P^)G>)'F@O/TFHD]LAMRV%BT4OF^Q94\F\1UQ
M5R-B\2;5U5)?('%M@I[W:E4Y;#O^LF=^*:V3?.36U$:!'V8NT96';,-?70P\
M14'14OW")2F1V8?N$:OU$H>!!R]O+.?<>-$H&5^DI/Y5#P5RDDPTGH0B[OWZ
M$Q1K=L!BFQ@>A*<J()0K\UJ!S6\#_3IC5WE)]J&DY-;9<=&,+N82XU?UE;]_
MF+1$W7/C^\A/(SS7/AUYJGH31",C46T9C&VEJ[GD9%OTR\MZGF5OX#X?I36.
MTNC(?D9/N-)1CWH)>HZ+E)IQ"2/]1E>L6A$1*!?/ G+MS((&R=1"1G;1C.H?
M\=;,MW5>U7T+W>^)%LMN _GGG163#N^01Y/%Q7ESU^?,WZ3/<_G$D+=V?MS)
MQ7/GGKR3<W7QG9,S:#1:V.O_TT;4D[L(YBC-CL;?C0D)%[E!2#A;S+D@"2NC
MMNT!FLG^F >;O\7LC,ZZEW;*($Y6W1P<U<.G.YH9=A7TLX)%W:P4/7W\BSW\
MT!I;NA"QZ/J]"SKZI-72$L?,\I3C-4MS]?9E(S<DO[9HQ83S=)59;K7E?!B8
MZ4@50\8\VS?#6H@FF!B"GPK@*>R%K3K'U(;SH&BX(7HV2+^M-)A.HM.(G;I$
MC3W(W0L0_8KBT&^0&[V\LG55^0/^G)GQQ\_EW>T;<-5Z7A03KAJ]JHD!EM)E
MHS3@HVI ,F'' .[S1TV"U: 4"U9 C#H*0'JV&+A>_'W 4\MP!H7Z-_S9>*A(
M]!X9_[../H%7RO+3%N;6KVL0>+M?Z:JJ+1U05ZB/2JZW'AA),L!@J8B8GJC3
M&,<=LWP,Y.8NP+W!C^I@Q>S#+!%5[JZ*)%L[!7[2[?K.CP'<Q)CM+YD \^F8
M]$'BD1CD0%D/$.J7%B[(N+T;'E!KS"<^7.RJ@\YK7"!M83CC83\QDTM.\L0,
MYA#@@"=P>B+-N\%.RU80ULQP\8?&))(+,55Z@&@&ST>101FF"_J-0ET&%BTR
MB+($"SOOI=3V&OEQ^2/#62F;8]HK'B=YJ;8*<1\Y9*/2ZB/:@B$C;B+MY;C!
MG$ IXELBGEH.*O+R<8?E%!1A[ 9.E)]<P#$Z%?,DS9?A+,('CVV"*F)M#1<E
M.93%=OC@=KW-_R57H1:=O89/+=6]Y(9@%]Y, [M^?3/"/742*M%0:)F8O<$R
MW]:W >'"IZ$'XB8WOZ\PLOYF8DVK\5,\2@MNOR.?N@0)S_B/TIR)>9<[9%(7
M .G-X#%[7OU(Q"]2.]4];^PNKR#Z7%OU7&OBGYZ%BVKS-0\UBBMA.D:S1ET=
MC&D4='H<Z::JB[H&$)VHV92]C><0@I^-V$NZ%^K9M9A<5W*V;A6F/[%#$]GV
MMO@^WEVN,ZYUB KCU-16GNY[:\_X741.CL32S7DV+:249@YD%.E$/;"YT%HJ
M=2/E?310ALD-K>G(P2=>''6,X55Z&0_5]J>SG*Y%AR3NNT&L+M"[M][>\^;W
M!/$TZ'Z=Z_4W!1&KC61)"6_KB<2-[8>A3T9I"2\I/CL/]V@68WL8F45SK><A
M[0WVQ&YRU<\X^QT%\+E#'I;Y9 LR%:) -61//TFL2=)!+F0W6CE>.J8.H-2A
MBRXN#HU)D?!9'>RY"8C+O13/\ B0HD/H]9HL)I^N^X[^VI6<;+L//H0\?Q1)
MR1<&2ITXAQ)=4HPYWEH%Q:T>UPC-$*SDK^],<3!-BH-H'Z[,DT?/':5E7-'2
M9[^.AC!QAO_?-/*1%S5-U3FL346+L;8.\DER\L]S^PY8PLV4N$Y?(V4,;-L>
M]MQ>\B>H0G1&P-00/OG>.'G>)<\ CT^L<?Q[Z_QM@RU7^9LQ97IE>63CMZTS
M\MM R[K[G76+O-76\RD7OET?_ ?7>AV-I:O;-69'BJY^%;;9F@W%<41] =9\
M<@'ABPN5T"D7\92 K+H].C]?&=L+R^CJ%N)+-<J( T(AZ1;ZV^N.^)I#XIF'
M"=]KP7<B>N-5Q\\5V172JWF0%K;EID_8;.L-(-",TJH8IZ&O6M7AI/TH#2M4
MBK$MG&SX?GAZ"M3KH.O@3P;E>+A!J(@\6K@17UJBW?Z-OJP$2\W<Q2L_7 ?K
M+-;]?1[TR2#^HR[&KMJ"]<].0@D"BM3)>(CV/#H+B@MA]'!UK<9:K$.!N@<@
M+LQ3?*A8>8V_J8/OJ9>X/KF][L8 R<!2FU[&RH)2*=LTZXW[J](CW%L@ 7(
M[W;!,^"]:Q)U_9W]^?[<!=;SB/8FXFGKX9PEQB*0\3PE![AJHU:0]CUXN(+2
M2&_]3\0B?'E2D"&XO<X;9T16X3Y*A]50<_2B;F+GU,)4G>?*P0BAKDBDB]IH
MVN)^LTI4W%+Z8O<DY.^(,^%IO0?%B8!W^)"MOFP]QB6FB\TUP-NRG? ";=I9
M@CED.[D*!%P'J\S! (9.$DC98+2_]2IA9PE6#Q[/O&@H/]*D/HJN_HTH<LAO
MV:,2[\ K(B:62.9'^ EST!#D@"D#KN .]5N^HC:I@4'C?V-9(N@XWGW!$A^'
M3F=#Q%CK=2( DVS'Z4-6@^-*9@:;_2"WH1IV\K=8?MH/)'K'2.71(*Z0-6$?
M]RXO=X>T_</C#QZA<XH[)MX9,Y)K@1#9+G(<SYFT%V(,\Y"U%DF$>IXZ>BB[
MW>O/E>.(CI$N70DB=1(%<^9N7DN3^]AXR(Z<06S&=EVRK.6=(Y^VK,E?';(%
MSFQ+#%P>-V+*]DOVA:8$SU3 D603C&U'GXO)R=XZT0Q0;?:G8+P.R;L,GS(E
M6^AN/?$CG-RZ>7K)Y-"[GNOC'H+<!G1:W2H=PR.NVUW7'K#O6D*-4&A\_R1N
M(.*[=M/2)QFJBT0VL<J:AQ[BGD$P#@P":\WB3B0&%:$N*M*^"1<:E&?1>.YS
MS><@J4Q-MN>K715(COJF*H,XIF.>]F)68:HL8KM>/-%S:F]D.Y_5[+=C<Z7$
M\8VY^SM>/+%.,H ^2R6<U^F52EA=8"ZQWD<2N&Z(+. ]_#Q<*\I)%F<*)H-0
M6Y-?]-%O)3(.6"A4OH37MB=U-(?#C&CFC,3 80:=-6=U1I%8Z^NX43XD.<#^
M/IGKE!C\>9?Q_7UZ[_'_Z6KJ_\](_T\9Z?^=%5(/_2\'OG7]=:.QO[P2_&_?
M6OS5UO^K=_VK(7+A?]F_[+_>AH[[ZZ#JO[S@^.]?G)QDC_['M:2A@W0HC+=L
MU""RKQ%M[E'QPYW5#2&M:A<N3=#1@NE[S6*A,IPQ]J;4RZOVQ#X^0I=O0#Q^
M_HJULJ8E/F9-V,<JU99 ^/78URJS*^Q'?&[-10XB9Z&*U :NNE<?*(?!)C0.
MZOF^I:D&:1BE93&POU%'?M,H[<R"5F70B>8"_=\0W8QG=3MO4;!+K,YW#9]V
MK&@IUH?Z%5QZ-= :OWQ^SAA"3\D!9B]&9&%0+ /,/V +^<33;>EP% Q51_2;
M]<#I&B^M"<$^Y\P2M,$.A!\DJS\<XA&?C#@G2EF=R1 C1+\:WBM45)'S.H8.
M%S:JR-FY\F_\E_=YCXB8H, "O1FE53*(V3];(O@>]ZT2*43^1/E*:E</\[WK
MNNM"+!_S6F3BJ8)/>:]:0KH$'M%T1UZ8/C"'[VOPC&U<F>^*'L27HB>T)Y:J
M%-7=[IL[?+H/^:]Z$N';^B;&?,\J0F,YO8CN$#0!26 ($>R1U*T7R.7LU4(Y
MC.6#05D::X]VL%3""BQ##A$L// ,\9FF1[6BQ>=YY,ZDE?]7>^<>U=25[_'X
MI( 8>2L(45&P18T/'J-@CM8B8RE&VBJ*XM%2# \QU_H@2LQ1G@I2ZC#*B".I
M4HTV6E0"&7DDA 30<90BR"M*7EY?D.&<$<,N.3F9'3ISY]ZK7>W\==N[NE8.
M:T%"SM[[_'Z__?V<\]O[]U)PQQQVZ<''_,MFJ#85GM!/3B/5Z2JY-_F)180D
MVE(IP5F"WLBBX\QCX1PQ&-3WG;@2J:L8NZ5W"]C1U?@W7D++R'366'F5V2TD
M?63XR'9<<S38,F<PB#TEI?1BT26T^^%A;+:O+=4]4Z!64F^=,Z_=]$Q3'=",
MN(&G)MMS#$62\ 93H5%[KP!']#Y+])%-6&:IQ_7$W>5%TWD0!@\^R?N&OR;T
M1$K4'GV@,39F$:]V1<?0YOFK7ZZ/PJ2W1VP)I?3[2(JF)\M6"F$;I@BI>QO^
MS=WRS3S)()@[:-Q-A R;3EBDX9L-AV8QBVKF7RT3XH,Q!5II ^+^K'1#20(>
MV-CW3F>PNA;+DWGAG67*QM(3[9([3NR/\3J9']XG,A= &E?XR[5E!RL&3NJ8
MW5O1'K&R!ANHT!9Y/L.FA"-XI5*V )S41?C^!C>2O66G]8]2FV53B8LG"->F
MK3-#V^N;16*>N*GFP9.:QME=B1T)TB-^P^S>%M-"2PFVBYO]$>E@N<)R @D&
MI/&[?8$^*>H5Q/B:>V>P\ZFE.Y>H-Z52[@0G=U\TO9E%[]+>J)6URZ7A@7HG
MQH;BJ([@^0LVM[17>?>G'J8_'MX$+ICW4+>%$A'IOHJRWXV[4@YL S/?BY&%
M;+/2Q@F^U8R'&I>M'C8PLLEHPV!/B2'@J& &&8:?$N,5S8B$)4TM3XI;*R82
ME'TL659#;%FXI&T[+I!CN"$&IXH3W:NE8E!2!P?\/7ZB1<1Z:W1C 5?J#E*-
M%LFU(N%;K+ED@N4L^1&6BB\Q-8/G.KK:;$JW?%FW1AL]-[57WE1T!'H'*^OJ
M\\](9F?:4#<CO@9G9Y,S]>RQWK,?\,/$O$[-Q[7XA:O#0W2<3=F[PKBKMI2Q
M)O&W680R=\%MQ&FO/ >1.%VK!#U?@O-<-_*#!]3<..7N] R1PH!,Y[,)S^/\
M U<CSJ6$=AV4YGKTJ_X2'GCEX9HK8(^9^?&L@8"!T_ ["V$GTBFE9@J[">L1
MFG:WUSD3_@CL4..8"T"M$DZAF/QX@I$;/N73E]Z- OL.V6)R!<B",@L)N.M6
M$YOE_6YE:>^FJW..&46ETVA(B95VV$KSPK3E# 9TJ4)-U24PW\P!XK66\D&Y
M]BKFQG(&'VT!]>8/N\D04$_8Z2*.RZ864].$IIW 3-2B=?<%'OS5G<<S!W4#
M(</KXKHW)O?-N7%__JSBF--S++8U-M/(@^ RQQQ//<!N!+18:;9*;Q%\.L%1
M,ASK7(DMU"T47X=,>Z:16)XJC<NK,MB3^I$I @=*[7%0Y36HTHQ+]:H?V+\'
M9&S"Z3F2B?&K?ML1[OTU+S,ML"DZ<>0I@W2!ZO4>PJ$?$]Y8KAE0Z@ZEFC)@
M6U$58SJYS[9;2E\@*-97UX):_>X=-2T0[(!4)0MZP-^M19VC?'Z_<%,\<%7)
MO.)G=6[NC_<-<TR+BLGOK[=\ 8?DC/PZ>V#F)="_!:*#W4;^<H*MNB4YP_7E
M&3810E51OM YG"UZ%G-4<LCO0U! 9#6SEA/*I&4IL]]M7Y&G<DZZ5E4OOGHX
M(VK'T7%_]?KGI/L#J:3BT<2@-R:9TMZ<9?J/NSYO?.?UQY/_N\K5/R2"723V
M9P=D%]=<S;7L1'I,_UW%5.C$E'V!>:;@ 8I_C  >UL2T961L0[0PRHSEHSAJ
M&K;M*:EC0VRB'@B6RD#$N22!3^VUKKH%^X2YU*R.7<(-]_<67-TM>8HW%^NY
M3LFNSSQ"2M??Z)Z0D3OB: J%[0>"^\*QLHE;>+&FO^%V>:QE+S250M+M"0/X
MBXQOFS\":%,:#L J9>G-LI8&VS8 Q_CV(G)9UQ V3>W$5I8%M==ML#U<?UB8
MEJA;<_=L9[W>L7,;?6!M/LFT99Q54]Z6T[+E@CYDLK_E;'@,$:ICDJX:TR;
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M"'LQDPZ$F2/(A<36RX3(%-'.7V*0]TA-?0##-^L#C&MTW"G/1E9?WTZHXXB
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M23WLJ!IELI^T O+7X]?CU^-G>2#6GK\#4$L#!!0    ( .R!<5JGZQ@\9 @
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M3]%Q6KE7D7]Q\8+/_P!02P$"% ,4    " #L@7%:Z+#PGVPU!@#5IU, $0
M            @ $     9WER92TR,#(T,3(S,2YH=&U02P$"% ,4    " #L
M@7%:CZR ZQ^' @"?R"4 $0              @ &;-08 9WER92TR,#(T,3(S
M,2YX<V102P$"% ,4    " #L@7%:*S_3=3 V  "ST $ #P
M@ 'IO @ 9WER92UE>#$Y7S$N:'1M4$L! A0#%     @ [(%Q6DV _EE,!
MN"<   \              ( !1O,( &=Y<F4M97@R,5\Q+FAT;5!+ 0(4 Q0
M   ( .R!<5JA(EB0B ,  &X1   /              "  ;_W" !G>7)E+65X
M,C-?,2YH=&U02P$"% ,4    " #L@7%:8']$MV\)   [1   #P
M    @ %T^P@ 9WER92UE>#,Q7S$N:'1M4$L! A0#%     @ [(%Q6C^E)WEA
M"0  LD(   \              ( !$ 4) &=Y<F4M97@S,5\R+FAT;5!+ 0(4
M Q0    ( .R!<5K%! (5J@8  ,$B   /              "  9X."0!G>7)E
M+65X,S)?,2YH=&U02P$"% ,4    " #L@7%:[JIA1Z\&  #S(0  #P
M        @ %U%0D 9WER92UE>#,R7S(N:'1M4$L! A0#%     @ [(%Q6L*O
M:__#'@  <ZL   X              ( !41P) &=Y<F4M97@T7S$N:'1M4$L!
M A0#%     @ [(%Q6JZ5=CGF*@, +Q$$ !$              ( !0#L) &EM
M9SDY.#0T.38W7S N:G!G4$L! A0#%     @ [(%Q6H!F8(6YX0( <U@# !$
M             ( !568, &EM9SDY.#0T.38W7S$N:G!G4$L! A0#%     @
M[(%Q6L129%J<.P( WE\" !$              ( !/4@/ &EM9SDY.#0T.38W
M7S(N:G!G4$L! A0#%     @ [(%Q6NX[#B79 P$ ,A0! !$
M ( !"(01 &EM9SDY.#0T.38W7S,N:G!G4$L! A0#%     @ [(%Q6FYI=3-+
MFP$ @K,! !$              ( !$(@2 &EM9SDY.#0T.38W7S0N:G!G4$L!
M A0#%     @ [(%Q6FA(PK9#: , ]!L$ !$              ( !BB,4 &EM
M9SDY.#0T.38W7S4N:G!G4$L! A0#%     @ [(%Q6J?K&#QD"   "PD  !$
M             ( !_(L7 &EM9SDY.#0T.38W7S8N:G!G4$L%!@     1 !$
*'@0  (^4%P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>gyre-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:gyre="http://www.gyretx.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gyre-20241231.xsd" xlink:type="simple"/>
    <context id="C_8004e979-5c0a-4003-aa51-99ebad904782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_80b233b8-8d6b-4b3a-b077-9d160ffc37ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_838330c8-c71e-4fe2-a49f-e6fc75cb5071">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="C_8437179e-663a-4744-b86d-fca26b0fe052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_845d0f12-d806-4911-8fda-490329d00ecd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_84e691d1-e698-40d8-a277-167dedf7a361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_855a18a4-8d8c-46bf-aa53-59975edfdf20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gyre:PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_865d32c0-6f1c-4e0d-9ca2-0c9a24caf2cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_86b63a2c-389d-4950-a678-157a2397918e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_893c5230-daf1-4851-a6bd-a1088e652270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8af0977b-b1f9-48ee-9940-3554e079223c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_8b6f77fc-9f62-4a56-a8a3-60296e884fd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8d6b27d0-681a-4b5e-86bf-4e37f3785874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8dc9cab1-3dbb-40a8-840c-8dd98ff4680f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAdministrationOfTaxationChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8e5cc978-0a42-4ec0-af0d-d74c36ee2dfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8e78646b-8c6e-48a2-bf10-a036ec1e9f6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f07b256-5b55-40cd-a1f0-534daf47f47f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8ff20dd2-fe0c-4bf5-810a-2ce783d0f15b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9059de58-0342-483c-bb12-68f46c8efdab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_90682bfe-2026-4fd0-87b6-43c6bb28213c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_90704b89-2d95-4695-898f-ba265baa62ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_94da0217-feba-4fbb-a5dc-d987be18247a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_96a600bd-711e-4434-a24c-a2180e74b33f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_97a869fa-0596-4ada-9896-83385642b0be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_981aaa53-b42e-4ad1-b13e-8a794b24f312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_98731e29-6638-4818-bfa3-de1d42eaf704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_990c44c7-915a-4a78-9e70-be8742ec4a8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9a91ad18-5e8c-4f49-bb3b-55e76625715d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9e3328d4-ba00-4ce5-8265-2253f006ba54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e8aff93-d025-49b6-9cc2-947107b8f15e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9f12cb44-8040-49a1-9b9e-a0f0137410fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a03ee1e8-f246-42c3-b72d-81a753170a1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:SubmissionOfTheNewDrugApplicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a06a4417-252f-4ba9-b828-689df30eb019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a0d10ade-3d48-49d5-bdd7-851689590754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a1ccaa34-a6d8-421c-aded-31248ab461e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a29cbd02-6a5c-4fdb-aff1-44deb722af3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:GCBiopharmaCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a34646ab-b257-4cc5-aaa5-c6130d624d7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a4960a5d-b308-445f-8714-9498ff7443b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_a56d2451-275e-4c7f-95db-b89dd45a7915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityNonCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a614a706-e7b1-4b3a-a6dd-8a447fd08d76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a6c79814-e564-4a3d-b0f2-8073710a53e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a6f4023f-6af1-478e-8828-c64f6e19e231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_a75bd85a-71ec-47ee-b069-04337603dd4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a8369019-ac43-4387-8220-f7bb3505e614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a8d02e48-8b97-4471-b7d2-9b754e3a60ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a90606c8-9443-4792-8781-57608b6e4e3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_aaa537e5-aadd-401c-b660-aedaa53b9b03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ab0e6ad3-77e4-40d2-a914-3a959c431d3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAdministrationOfTaxationChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ad2aff12-25e7-4121-b6bd-e885663b2263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ad700354-24cd-4e94-bf85-24453ba4377c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:GCBiopharmaCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_adc4bb81-abd5-4674-adb5-54f33ef3d80c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ae06bf9f-4849-4d7c-b764-bdd92fb5df72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_afb0500b-16d2-4911-ab34-f347a18f0103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b069b7f9-1d2e-4765-80cb-c51aa4c12c6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-26</startDate>
            <endDate>2022-12-26</endDate>
        </period>
    </context>
    <context id="C_b0da0539-7026-4894-ad23-631ed2889b06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b2bd78e9-9849-479f-8eb7-41ba287f57e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b35aebfe-1f39-4446-b3d0-8ed57d7c18ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b489322b-84cd-4fef-81ee-6ac40fe1d795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b4a86beb-1787-4bb4-bd49-dbe2b1f05f54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b5f0da22-de98-4ff9-8f08-36e85ba3bc7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b6236476-6e75-4438-a794-f025b4ae1817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b7908f32-a52a-47b5-a0f7-73f8bc7e1786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b8550c29-f99b-4014-8343-c78232d39a0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b931a2e4-4754-474d-9b6e-f1c8f4585e49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAdministrationOfTaxationChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bd730111-0947-4496-be1e-82bb97c3ba65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bfd51d7b-b349-4540-8451-b38e1a4adc25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c0f50cf0-d705-4547-8bb2-292161d2dc8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c26605c5-09bd-4994-af5d-7d427048d643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gyre:PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c2f5674d-e5bd-447a-8b4d-85feed272f13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c3036813-c367-4137-83bc-d3111a243c9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c44dd11e-3d19-4a70-8872-8c9259134b11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c4c9bfee-5e03-4161-8738-c6867fc7060c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-27</instant>
        </period>
    </context>
    <context id="C_c554efd0-8c25-49d5-887a-c4fae5255da6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c56613f3-6432-437c-9bab-9101a3786a66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c664e54d-79f7-479e-871b-a1086f9e1e55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c66f706c-79f5-4c3c-a4d4-6383b9abf3ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c72b6ba0-b44d-464c-8103-3b7702656381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c7af3ec1-7037-4691-9c1c-8e9ff94d139a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cc77e3d6-0b6d-4809-98bc-ba50dc57d0e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ce07c61e-a68b-4a21-856c-80d6f63dc861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cef73343-7eb4-4d39-88e9-9171f4dd709f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <context id="C_cf4603e2-2534-444f-a961-287cb64533d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d1aaf22a-2bdd-4556-a9b8-d529d34aef04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d274c80b-8c06-41ed-bb58-3a6d5311414f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d4414f45-2440-4efe-b9f6-4316754c428f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d65a54be-e60b-44d6-9d6e-c5423744feb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-26</startDate>
            <endDate>2024-08-26</endDate>
        </period>
    </context>
    <context id="C_d8c5083e-baaa-4ff7-ae97-3c6730697288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d9641dc2-ce11-4da3-92da-82b11fbc53ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_daacc8f9-d9a7-49ef-b6a0-b9c3726581cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_dbedf524-e39b-431f-b9b5-51f72b11b2b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc02e0a2-17b6-4879-92cf-e5b95666c954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e345ba39-3b04-455d-ae09-666d8d8b33bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="C_e3f9ca20-fe6e-464e-88fe-e2cdb2bbeb47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e4d869fa-260f-4c9f-9cf3-79a75bfecf47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e528bfc1-0b49-4dd0-ae39-ee76c0228232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e5513b2b-c8d0-4816-81a6-d83601aee525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e7855790-0097-47bb-9146-f38e022e4521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_e852315e-c976-4feb-af38-ee2ba333da3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="C_e87f13d9-462c-4972-9cd3-8231e00d9d31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e9706bd6-a8ea-4e15-9d5b-2d51ea3a4538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e9ca2ac7-674d-4810-a3f7-5cf959925a7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e9d4eda1-e8b4-4878-b3ba-046acdcd7131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ea5bb34e-9257-4104-825f-20adf13f8344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_eb61462d-1632-48d9-a73a-8eefdbf9c020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_eb7ac400-9cc8-4292-a3f3-4243436fc055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eca554e0-e672-4d9d-8689-890225dec430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ecfde2db-6b97-4952-8c3e-f7202cd08598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ed398fbe-2209-4cef-89f5-4af5eb6bb183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eeacae0c-b05c-49e6-aa94-3ba172e663e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ChinaResourcesPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f0a09c76-9e8a-4c61-b540-701ad6b7648e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_f0bc705e-b8c5-4374-a7bb-91203f55f706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f1739194-98a6-4fa5-9476-50a472bbd7b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f461bd8b-ec0e-46ff-8dbd-7d23531e4b91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ChinaResourcesPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f5133705-2d68-4e8e-84cd-45bc68a7fcf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f5361373-7c92-419e-8bf7-87b01cbf8a00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f5823b3d-6762-4329-9b17-efe63bdb21f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f5d8eb54-6979-4f3e-9be6-d8a1a8ec48fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:NMPAsApprovalOfTheNDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f6130ae2-a2e5-45e6-a4ed-5c019bfa760e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:CPIContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-26</instant>
        </period>
    </context>
    <context id="C_f655bd73-1357-4906-aaa2-0388e4dae1b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f74c758a-d9fd-40e2-85f1-d6a87ddcc5dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:NDAPassesTheNMPAsReviewAndInspectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f824d5e7-e950-4dec-bbd8-25ddc7864eac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f9d872ab-6ad9-4e1a-9bab-df2b883d5c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="C_fabc4de6-f3ea-4c14-8ab7-d36a14e5c91d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fb2f86f7-6be0-48e5-a0e5-ce77738921cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="C_fce1ab14-263e-4f06-8e6c-95e2226660e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="C_fe14599d-907f-447e-be99-9689d7f34472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ff4a65f5-6aee-43bc-ae21-205a10de9f61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:CPIContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_003c57ab-d9dd-422e-bacb-9a242555faac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:VertexAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_02538a53-cecd-41e8-aa82-e8efb664750a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_062c6dd6-59a4-4c32-8566-83e073df4f7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0694c0b0-9199-4cf1-86b8-378fc929e7fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_081e2763-6f98-4757-9d8d-5f31041f2742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_094d85c6-e458-4cfd-ad37-15cb54dd53db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_10dfd633-6fab-4fb0-bb22-6722bb1f66cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1152de71-ba52-48e2-80b9-f500c5502e72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_11e97b2b-d131-4b0d-a65f-f76a30c9fe74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_12c92d66-d545-47dd-8492-bf82d190b61c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_1388f67a-7e9b-4efe-996e-61341927c0bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_151e32fc-1c63-4e3f-9240-08cf605db0d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1550867e-92d1-4406-a92b-c15392d1f1b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_18a964f8-b880-42dd-8893-8c908e72943e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_18bc2358-95e4-46d2-9214-ce5de90d7258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_18ff54a5-54d5-42f4-81e9-6aa9f1a79af5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-26</startDate>
            <endDate>2022-12-26</endDate>
        </period>
    </context>
    <context id="C_196fe3c5-bc8a-4a5f-a84e-6cbf8da6bc14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gyre:LongTermCertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1999c1fd-3379-456f-aa61-90fe81f796d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_19def526-bb67-4646-b79c-ffcf90c9dc23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1a040f6f-bb6c-4771-9c85-7f74144c1343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1c9a63af-c293-421c-835a-b808c5bda6ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_1da1795e-730c-42e1-9de0-0fedc96400d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1dbb5718-381d-43cd-a699-edd659f1f0ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1e426f09-37bb-440e-a20a-2c6caa2e0a48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2105308e-fcfa-4236-bc88-d64b4d792f06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_21ad98a8-a7b0-4600-a53d-9f79dd8b3cbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:CPIContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_21d9722b-ebb3-4d75-9c08-5b1c34dda6b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_22f0fc96-1e38-40b1-9a23-4191cce058e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_254f82e6-b517-47d8-aa5e-0e78e7d7e7fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2552ff66-c519-4434-b8ac-87bd1b2941d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_25e32d74-d3e2-425b-866e-4b5bc29838fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-26</instant>
        </period>
    </context>
    <context id="C_27a7a081-3cd9-44fb-b829-bbe0a51e1049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_27c77b10-4086-4da2-b416-c9b80579f835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_28b79e15-5ce4-4bf9-8af0-0a1821e83289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_29261f54-503a-4613-b9da-f1c82b1b0e73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_29facfe6-6ed6-43d0-af3e-0188d8bb96fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2b54e9bb-fda5-4585-863a-b3bcf1e6972a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_2c09cdda-c1e5-435a-b940-ce423bcf6515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2d08f24c-1345-467d-96a2-4553b687c2fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <context id="C_2f70b255-6cf8-4fea-a0c2-53d777ed397c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-12-31</instant>
        </period>
    </context>
    <context id="C_3196cc03-d5f3-4937-bff3-52b2ec055f70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_33998465-47eb-4f6f-9f5b-ae8cb85bcc79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_33eee6f7-6eb9-4629-b3ef-0ea7887030bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_34a9e2bf-ec9e-4a2f-8f4f-2c7daaad7f85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_37337290-c4f6-4ef2-a6f7-8313d2a10b7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3a618d1d-ac50-42d9-955f-3512c0439863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_3b4e1000-5f70-49f3-a666-01af6c7cbdd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3bcf2b7f-ee59-442c-b6bd-34c12861eac8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3c2ac92b-d05c-4dcb-8edc-d7dc05708e32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="C_3c6a57d9-a896-48da-8a44-7f1b76f85732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_3cc0872f-8c3c-4dc7-ae6b-0b2043d6351e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3e003906-a6c6-4531-9eea-29f5b509e2c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:PatentsAndTechnologicalKnowHowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3ea2f2ca-4eb5-48e9-9b14-30c3e9e2d1ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3f38f4dc-c197-451a-9a92-1bfe597894f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_40f2813c-6dc2-4685-8c1e-588ca60a93fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_40f3484c-5a7d-4fad-9c74-3ddeb2ee3ca3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_47d1b610-ca09-4556-921e-9413b69cf697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_49141630-2e23-47e6-b10b-c4c4722c6d0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_491b859c-be4c-4cea-81be-c2b01d95cd3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_49f4dab9-8bd1-4577-b767-6356a5621a2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4b697f59-a7d2-4358-9a63-af70187de963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4cb4b16d-4b5f-4f2a-9fb0-59f281280fc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:FCContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-26</instant>
        </period>
    </context>
    <context id="C_4cf85ce7-378e-4422-9fd7-e7d329e19a16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-26</startDate>
            <endDate>2022-12-26</endDate>
        </period>
    </context>
    <context id="C_502e4c1c-95d6-4ae7-893a-2eda77e87309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">gyre:MainlandChinaContributionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5037ba80-7341-4533-b5cb-88a46c19f3b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_51a6c503-e72b-48c6-951e-f9d61b0aaa75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_524073ba-1001-4b0c-892e-803d6f0180eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_526db762-c121-4c94-bd8f-2957c39426c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_534c0221-d2f9-4713-8a7c-b850a4689dc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_54965d21-2615-4d08-a3c4-08ca451112ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_55596a3f-d3e4-4c79-87e1-e28ba063d3f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:CPIContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_55971d12-0611-489b-9033-d8d1ebf17458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="C_55af4e33-6cc0-4324-9605-d23cf73d489e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_56859774-ba75-4d74-b1b3-78de98856e4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_56cfb1ae-ec72-4d17-82fc-1198e04d1a30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_583140f7-2f5b-432a-a839-befb410b9e87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:ContinentPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-26</startDate>
            <endDate>2022-12-26</endDate>
        </period>
    </context>
    <context id="C_59171fe1-a910-4f9d-acea-66214546eade">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5b26b6c7-7509-44ec-b688-6724fcb64480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:PatentsAndTechnologicalKnowHowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5b526872-b885-43be-82fd-47148cef1b95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5c3e3497-8c9f-4117-820b-ed5757b69655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5e5fdd9a-b6de-418c-9820-744eb3b5f73c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5e716a13-8908-4a45-90e4-2cfac3c1eeaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5e72f9e3-7599-472f-92ab-fa429b264f71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_625ba7b4-bbf9-4cd1-b581-60e547a6e52a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gyre:ShortTermBankDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_62f49f26-9563-408b-b7c2-7c3b1be23119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_62f92e1d-e5a8-4fa2-9000-93f2a1b15be5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_637be181-9ac9-483b-8aeb-4f4857ea30c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="C_63ac599f-e0eb-4b2e-8ae3-eadeb59bf215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_641c5278-93b2-409e-a72b-833546eaec22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_650b198d-ed03-434f-8873-424e5a2b6569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_661aab60-409f-4f43-a899-d4da1611a236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <context id="C_6644aae0-eb2b-4676-83a9-ae38663b37d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_67cc03b4-d2c1-416e-b1f7-03b4721d045e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6846f876-7997-4227-a1ac-8419c302881e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_68a0f639-5b32-411d-b8ae-3d27cfa51531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6b620358-0d22-4e17-b10f-f5fdca4687e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6c54312b-5d11-479d-8137-af33dda8c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6cec0878-7860-4728-9cc5-0c28173f20eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6d30a83a-d0f3-4ca4-b55e-76c959f4075c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6d9205fa-fd4f-4d6d-be1a-9d6b1b8e9900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6e3414eb-e1eb-461f-b6f5-48348df952e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6e5dc256-5a04-41b0-a879-49f3fee0883f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyrePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6e8538d1-cf76-4d30-a57e-b5a4624ea831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_707b6aef-326f-458f-9f18-b11e1ee9ee78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_70a89060-d74f-4aad-a20a-b03e7164f4ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_72587811-89ac-4abd-97ba-a8887f54ccab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gyre:LongTermCertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7328c607-f5b4-4691-8c97-31b6f9ec5936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_75e8697e-8557-4795-a758-27f2b4bd196b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_761f52b8-1b53-40ce-8a99-390c026c9793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_77b7dffb-7a31-4205-a9eb-98bee99e2a4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_78e3aca5-80d5-40ae-9cf1-a3aa92d7c78c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_7a06ddc6-8a57-4cf2-a967-1f3297552aa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="C_7c56d128-f56c-40e8-9eed-aee500526cb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="C_7cf186e1-972c-4665-8d9c-1bfd52550fc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7ddd47da-42c9-45c5-8866-0c39c6994ea9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">gyre:MainlandChinaContributionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="U_sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>gyre:Segment</measure>
    </unit>
    <unit id="U_CNY">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_4293ce05-fd4b-46d8-a238-462aef780712">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_047c914f-8763-40d0-b33f-f0cb7afa03e2">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_36aeb3ff-d827-4e70-8e7c-5e38a92e3ff4">0001124105</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      id="F_e5069514-7ffc-45f8-813c-6fba7eae2521"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      id="F_3448db62-d53f-481f-8d69-743602ddb884"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_67cc03b4-d2c1-416e-b1f7-03b4721d045e"
      id="F_df845163-9662-4f0f-9d15-2572001b1a8c">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_1dbb5718-381d-43cd-a699-edd659f1f0ad"
      id="F_e144250a-53d1-44d0-abc4-0e596d38ecb8">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <gyre:LeaseExpirationMonthAndYear
      contextRef="C_2b54e9bb-fda5-4585-863a-b3bcf1e6972a"
      id="F_a5e3a326-17c6-4924-b500-780170a688d9">2027-03</gyre:LeaseExpirationMonthAndYear>
    <gyre:StatuteOfLimitationDueToTaxEvasion
      contextRef="C_ab0e6ad3-77e4-40d2-a914-3a959c431d3b"
      id="F_89458a30-1f4b-4bab-95ce-8c2641b3664a">P0Y</gyre:StatuteOfLimitationDueToTaxEvasion>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      id="F_64b29595-72b7-4d1e-a2ef-bcc1f661c31b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      id="F_7ff33148-e75c-4492-acae-7ea4bfe94b76"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_64cfc3bc-e6d1-4ed7-89c8-10257ca7a0d5">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_5b3aa47b-ba5b-4aae-9222-b1550983770a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_4d334793-ce3c-462b-87fb-55d4f20e42b6">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_5991a5ed-a303-4b97-9640-17383190b789">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_c9e2b185-8d10-45b9-a57b-dbb85414f656">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_5bffcfea-1268-433f-bfa5-04eae65b366e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_2950d5fc-cc1a-49c4-a5c8-37662c9a51c4">000-51173</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ae3ada45-10cb-4e77-8df2-0b5de899a827">Gyre Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_730fac0c-62d5-494d-ab73-269b07a0db4e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_5c21b1e9-5975-4d54-aa74-ec8e8f9ca71b">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_015f7805-f74e-4307-88c1-a88dedd76bd4">12770 High Bluff Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_60dea690-fa84-4b85-9ce4-0198dc0464cc">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_e0a8ae6e-d3ab-4674-a93f-5f3b6c17936c">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_74207a89-ecac-470c-ab7e-d9c439c84663">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_939089ad-3ed2-4f96-9dc1-fe0dc3ee289d">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_c3d111f1-1f44-4994-bd17-d9a877696466">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_a351a5c5-988a-4314-83c0-533a51fe5a05">949-3681</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_1c5f14b0-f96c-4b47-8952-881b5d93ba3c">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_186aa108-2f64-45b6-a3bb-00dff863a0d2">GYRE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_d57066ca-db1e-40f1-ae6d-f44c54975e63">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_6f23f133-df61-49af-87b3-35be3521994e">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_737b0aa6-b3a0-4703-87af-64301c7be3d2">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_32679977-66da-4092-b0ee-23ffbc68e7e5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_9ce4b3aa-49b5-4632-81d0-ebc58d9741a2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ae0f78a3-0009-431a-a2f5-226636d823fd">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_9ea26764-a940-43de-a7c4-4322c5d2940a">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_2ce8fa1e-3ebf-48ab-a4d4-ec861402c8a7">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_64cae1fb-7994-45fa-a19b-fc854ce50401">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_8949bdf9-9ce9-4853-80a6-28b2b609afdf">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_146ff0a7-29a9-4c16-9f0d-2bb7d99db9c6">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_78e3aca5-80d5-40ae-9cf1-a3aa92d7c78c"
      decimals="-5"
      id="F_ebc4e969-1b63-46d1-a6bc-566f99d38dfd"
      unitRef="U_USD">83300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_f9d872ab-6ad9-4e1a-9bab-df2b883d5c99"
      decimals="INF"
      id="F_301ea622-feb7-44f6-9597-56db3673a1e1"
      unitRef="U_shares">93612442</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_e3e5a98d-dff2-4ae3-9167-5eef0b7c748e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#x2019;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2025 (the &#x201c;Proxy Statement&#x201d;), which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_cf8ba115-c09c-436b-ab5a-1dc9a803e903">&lt;p id="item_1c_cybersecurity" style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Item 1C. CYBERSECURITY.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;We strive to safeguard our important data, hardware, and internal network from digital attacks, theft and damage. In the ordinary course of our business, we collect, use, store, and digitally transmit confidential, sensitive, proprietary, and personal information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy. To this end, we have implemented processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;At Gyre Therapeutics, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;these processes are managed and monitored by a third-party information technology&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;IT&#x201d;) consulting company (the &#x201c;Managed Service Provider&#x201d;) and are overseen by our Chief Financial Officer.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; At Gyre Pharmaceuticals, these processes are managed and monitored by a dedicated Information Security team, which is led by the General Manager. Gyre Therapeutics&#x2019; and Gyre Pharmaceuticals&#x2019; processes include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data. In the process of advancing the systematic development of information security, we seek to maintain a robust approach that encompasses policy formulation, organizational structuring, technological application enhancement, process optimization, and personnel training. For example, Gyre Therapeutics and Gyre Pharmaceuticals maintain software and hardware inventories, perform security monitoring and alerting, and complete ongoing risk assessments. Gyre Therapeutics and Gyre Pharmaceuticals also conduct regular employee trainings on cyber and information security, among other topics. In addition, both companies consult with outside advisors and experts on a regular basis to assist with assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the Company&#x2019;s risk environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Our Chief Financial Officer, who reports directly to our Chief Executive Officer, is responsible for assessing and managing Gyre Therapeutics&#x2019; cybersecurity risks with support from the Managed Service Provider, which employs IT consultants with over 20 years of experience managing information technology and cybersecurity matters and are certified as Microsoft Certified Systems Engineers. Our Gyre Pharmaceuticals information security team, who reports to the Secretary of the General Manager at Gyre Pharmaceuticals, comprises of three employees with an average of 20 years of experience managing information technology and cyber&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;security matters. The Secretary of the General Manager reports to the General Manager at Gyre Pharmaceuticals, and the General Manager reports to the Board of Directors and is responsible for assessing and managing Gyre Pharmaceuticals&#x2019; cybersecurity risks. We consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework. Since the beginning of the last fiscal year, we have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#x201c;Risk Factors,&#x201d; under the heading &#x201c;Breach, failure or disruption in or to our information system could compromise sensitive information related to our business and expose us to liability or reputational harm, and our ability to effectively manage our business operations could be adversely affected.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our management team.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_06aaba23-264c-4869-9e41-28cd6d72c174">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_d4c4976f-973a-451b-9d67-17a0f68d5a44">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_da47ff88-edc4-43de-b196-1476f5ac9bfe">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our management team.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_7b9a469c-1f4a-4ff6-add7-43541c823586">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_16783702-ffa6-4a1f-8559-8387686436b2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our management team.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_feb3d64b-4a5a-45cb-836e-e8f319a3f8de">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <dei:AuditorName
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_bc60d274-70f9-4153-a90a-7d0fe6cb7d2a">Grant Thornton Zhitong Certified Public Accountants LLP</dei:AuditorName>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_56859774-ba75-4d74-b1b3-78de98856e4c"
      id="F_8c6da38b-171e-442f-bb85-32b77793ca0c">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_56859774-ba75-4d74-b1b3-78de98856e4c"
      id="F_06d47d55-cbe9-4f1d-8970-8bb2b8d52d3e">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_56859774-ba75-4d74-b1b3-78de98856e4c"
      id="F_73f2a3d4-6485-40d3-83a5-5daa15c2d98e">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_56859774-ba75-4d74-b1b3-78de98856e4c"
      id="F_b7df9b72-ba7a-4e69-88ca-b0371b6e4c4a">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_9c405263-42c3-4ae0-a8a0-494d7cfaa1d0">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_d3c5f891-b2d5-4c84-860f-f7b83bb471ce">1487</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_54d7311d-5e89-43cc-ae40-0fb5248db7f4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Opinion on the financial statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Gyre Therapeutics, Inc. (a Delaware corporation) and subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2024 and 2023, the related consolidated statements of comprehensive income (loss), consolidated statements of convertible preferred stock and equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes and the financial statements schedule included in Schedule I (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;), the Company&#x2019;s internal control over financial reporting as of December 31, 2024, based on criteria established in the 2013 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control&#x2014;Integrated Framework &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#x201c;COSO&#x201d;), and our report dated March 17, 2025 expressed an unqualified opinion.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorLocation
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_bc727a24-3d30-45ed-b466-319b8ade9a7b">Beijing, China</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_589a5522-9336-429f-9bf9-31a8f75bf61b"
      unitRef="U_USD">11813000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_d31a212c-5df7-4139-9fec-1eb916e44cea"
      unitRef="U_USD">33509000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_49e356f4-c866-4860-9144-f18da6c13407"
      unitRef="U_USD">14858000</us-gaap:ShortTermInvestments>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_c4e7974c-432b-415a-9291-1eaf131b5e54"
      unitRef="U_USD">4373000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_edde70ac-7d40-4f93-b611-ec5a08b3840e"
      unitRef="U_USD">389000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_8ac6b665-e029-49cd-9d5c-1db802b6cb15"
      unitRef="U_USD">19589000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_0b6c6b04-74e2-4bbc-be69-a407f7c681f5"
      unitRef="U_USD">15163000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_081e2763-6f98-4757-9d8d-5f31041f2742"
      decimals="-3"
      id="F_59275fda-78b2-42fc-946c-b2c1ca5e088e"
      unitRef="U_USD">230000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_c2f5674d-e5bd-447a-8b4d-85feed272f13"
      decimals="-3"
      id="F_b9c94083-5943-42ce-807e-68c2e7476e2e"
      unitRef="U_USD">1287000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_d3a838e5-5d8d-4e95-bf79-21f278b2ec13"
      unitRef="U_USD">6337000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_1e838e0a-e046-41a9-aaeb-b29e9afae333"
      unitRef="U_USD">4281000</us-gaap:InventoryNet>
    <gyre:PrepaidAssetsCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_6be2f987-4139-4a15-a228-7785d4ddc134"
      unitRef="U_USD">1189000</gyre:PrepaidAssetsCurrent>
    <gyre:PrepaidAssetsCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_e9eecefa-4f2e-4abb-8e1d-e45788843fad"
      unitRef="U_USD">1547000</gyre:PrepaidAssetsCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="C_ad700354-24cd-4e94-bf85-24453ba4377c"
      decimals="-3"
      id="F_bc8d4865-35c7-49af-9501-db3f99799d08"
      unitRef="U_USD">4961000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_78f9ae34-841c-4a7e-a50b-342a58a5cfaa"
      unitRef="U_USD">1436000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_15d5502e-fa94-424f-8505-98e54128ddaf"
      unitRef="U_USD">1045000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_2103dc33-d796-4481-b3f5-807181c1242e"
      unitRef="U_USD">64786000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_a2de8997-cad6-42be-a374-09feb63490f4"
      unitRef="U_USD">57221000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_7c238c5a-2ca6-4fd3-b88e-30993d333cb0"
      unitRef="U_USD">23880000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_53beb134-3406-41f0-9531-d0e87023100f"
      unitRef="U_USD">23288000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="C_a29cbd02-6a5c-4fdb-aff1-44deb722af3d"
      decimals="-3"
      id="F_f9e6eed7-5bff-42ac-be7a-092dc951a2f0"
      unitRef="U_USD">4722000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_c03aa718-51b9-4ebf-b95a-92285fb4b34c"
      unitRef="U_USD">273000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_facb4a47-c6ce-45d9-b971-360547b4111c"
      unitRef="U_USD">205000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_f463d2e6-e563-4617-acda-04c2359b883d"
      unitRef="U_USD">1818000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_b32e139d-13b0-4721-8a4a-97d80eb0b594"
      unitRef="U_USD">489000</us-gaap:OperatingLeaseRightOfUseAsset>
    <gyre:LandUseRightsNetNoncurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_cf69dcd4-e563-4a43-96d0-80f1971fac83"
      unitRef="U_USD">1432000</gyre:LandUseRightsNetNoncurrent>
    <gyre:LandUseRightsNetNoncurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_abf36086-062d-41a0-9d38-6adcef6d9e00"
      unitRef="U_USD">1493000</gyre:LandUseRightsNetNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_421c7242-454d-43d7-bf1c-a8fca081b290"
      unitRef="U_USD">5619000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_223c37b0-b04f-4ee6-ae22-bb2e54a5a8d8"
      unitRef="U_USD">4695000</us-gaap:DeferredIncomeTaxAssetsNet>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_5928e424-d348-463b-8d81-7d771717e9af"
      unitRef="U_USD">24568000</gyre:LongTermCertificatesOfDeposit>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_94497a9f-5e0d-4fbd-ac55-d6d8996b5cd4"
      unitRef="U_USD">23431000</gyre:LongTermCertificatesOfDeposit>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_25f0ee93-cba8-48f1-b8a9-69b103cad8e3"
      unitRef="U_USD">3030000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_7461734b-da04-4ddf-930d-e768e858a750"
      unitRef="U_USD">995000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_e5cad52c-de75-4dd5-b9ac-34413279ed3f"
      unitRef="U_USD">125406000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_3229480b-4ea7-4dcc-9c53-f31f7f666416"
      unitRef="U_USD">116539000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_869ddb53-9449-4301-b55c-d79e5292b1d7"
      unitRef="U_USD">108000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_fd090a2f-6333-4c12-b9ac-beaea98f3dcc"
      unitRef="U_USD">355000</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_79a33ecb-6e43-4ae3-a4b8-e26b61d75b91"
      unitRef="U_USD">61000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_4573a1f9-9231-4455-853e-2197f0252b5b"
      unitRef="U_USD">39000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_8e5bd08b-4309-4e75-ae36-dd1467424810"
      unitRef="U_USD">227000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_3659ade7-5d0e-4a96-9bed-561c1b6e743e"
      unitRef="U_USD">1369000</us-gaap:OtherLiabilitiesCurrent>
    <gyre:CvrExcessClosingCashPayable
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_afae975d-396b-4264-9c40-a7ae636ac4eb"
      unitRef="U_USD">1085000</gyre:CvrExcessClosingCashPayable>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_f0475f11-e0fe-4a71-a695-511947691e75"
      unitRef="U_USD">10615000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_b7fbabc6-a687-4e44-9f61-98c0960e86b7"
      unitRef="U_USD">11935000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_7c442e40-36c5-43e7-99d5-5562adc65e3b"
      unitRef="U_USD">2831000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_ced0b897-a172-491a-8bfa-0af58a046151"
      unitRef="U_USD">5054000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_288d6f31-472c-49bc-b27d-7e10bb7567be"
      unitRef="U_USD">713000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_e4cd6cb3-ff5e-4adb-ae6d-efdf862ebf27"
      unitRef="U_USD">210000</us-gaap:OperatingLeaseLiabilityCurrent>
    <gyre:CVRDerivativeLiabilityCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_7bd73ef3-be3b-4d0a-9775-db9fa0a8738c"
      unitRef="U_USD">4961000</gyre:CVRDerivativeLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_af44a45c-4f32-4d26-8d28-f25992c492a0"
      unitRef="U_USD">19516000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_2b707806-9f76-475c-a2e5-af020d76516b"
      unitRef="U_USD">20047000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_7f7e4ccf-5da7-4a8a-89bf-24badb28fca4"
      unitRef="U_USD">885000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_2bf551d5-e2eb-4d6e-b3e3-c308a797919f"
      unitRef="U_USD">199000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_e50996a3-41d4-437c-a338-5da90a8541f4"
      unitRef="U_USD">928000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_e63df01c-c959-4883-b9e3-3d489cbdaabd"
      unitRef="U_USD">213000</us-gaap:DeferredRevenueNoncurrent>
    <gyre:CVRDerivativeLiabilityNoncurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_bdf1410a-69bc-4ca1-8a5a-fb3fabdbabe5"
      unitRef="U_USD">4722000</gyre:CVRDerivativeLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_0d9fa434-6544-4fee-958e-a18e4227f3ca"
      unitRef="U_USD">5668000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_2e8ab186-5b42-4db5-978f-8e1affe35bfd"
      unitRef="U_USD">12835000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_d63fd580-960c-4af3-b767-7c9cf3fa9faf"
      unitRef="U_USD">7000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_5cb74eca-de7c-453c-b9d5-a30db5622be9"
      unitRef="U_USD">49000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_d5304823-a826-4d53-b59b-31331d279a4b"
      unitRef="U_USD">27004000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_03690da9-ff34-480c-83f7-ed4974a12735"
      unitRef="U_USD">38065000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62"
      decimals="INF"
      id="F_5f683379-95b2-478b-a878-2205b120de3d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a"
      decimals="INF"
      id="F_8d636a94-5cca-4fd8-92dd-a23fcd9bb9b9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62"
      decimals="INF"
      id="F_441dc8bc-0866-4099-847c-36dbea3f04dd"
      unitRef="U_shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a"
      decimals="INF"
      id="F_749950dd-43ba-4397-b9f0-9632d664005c"
      unitRef="U_shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62"
      decimals="INF"
      id="F_bc55fe80-4b21-4aff-8c7f-3386870a5162"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62"
      decimals="INF"
      id="F_11e614c5-bca9-4088-96b2-978b850d524a"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a"
      decimals="INF"
      id="F_151928ae-6b15-4b99-865b-6463141953cb"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a"
      decimals="INF"
      id="F_2bd2fbb7-6da3-43a2-a1ca-7fa8fc7183c8"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a"
      decimals="-3"
      id="F_b62a0001-bca7-456f-b5e7-9d8c426a6a1a"
      unitRef="U_USD">64525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_24209542-b945-4616-b9ce-ab91b85c03b6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_39333e5d-340e-42c5-b4c7-c188e2da0071"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_1c7b6e95-b2e4-4d15-85b1-cffadda11f2a"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_8a6b1aac-db64-4d11-8245-eef600b514f5"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_a5cff3e0-4f9d-482e-b18f-ded9a92bcc93"
      unitRef="U_shares">86307544</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_6afeac9f-dbd1-41d6-9f42-0775d35feab9"
      unitRef="U_shares">86307544</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_8b103a05-49c4-4fe6-94aa-fa848e51f310"
      unitRef="U_shares">76595616</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_af9597b5-6f09-495c-90de-69165a1429d9"
      unitRef="U_shares">76595616</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_c6cd9edd-351a-4952-905b-555cc3c6f579"
      unitRef="U_USD">86000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_ca655226-9e40-4ebf-a023-5248e8ad1c5f"
      unitRef="U_USD">77000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_d3cf2f5d-e422-47a4-a4de-1c4d18ec6056"
      unitRef="U_USD">136185000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_1e6aba98-dffd-4039-8af4-738065f84053"
      unitRef="U_USD">68179000</us-gaap:AdditionalPaidInCapital>
    <gyre:StatutoryReserve
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_f909335e-5cda-49a8-946d-5edcd0538ec7"
      unitRef="U_USD">3098000</gyre:StatutoryReserve>
    <gyre:StatutoryReserve
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_3ba2dcf2-b130-49c1-8a36-d0c2e78bb2a6"
      unitRef="U_USD">3098000</gyre:StatutoryReserve>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_fc21ec7f-cd27-4a82-be76-d14f068409a0"
      unitRef="U_USD">-73453000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_fe912cb6-4ea6-4f90-8beb-ea850c5dcea7"
      unitRef="U_USD">-85538000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_e0b861cb-e69f-48d5-ad75-60d2d9b1a393"
      unitRef="U_USD">-2597000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_2e853340-8ace-4575-8e80-f2045344481c"
      unitRef="U_USD">-1644000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_4f75a31f-4fd4-4312-ae31-ba227cfe01c7"
      unitRef="U_USD">63319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_afde1cd3-a4c6-407b-b7ce-1340b718ec99"
      unitRef="U_USD">-15828000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_2cf07c15-aac5-4538-81ac-148c981e5f59"
      unitRef="U_USD">35083000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_eec4cab1-afbe-4a43-bc59-93a248aa6eac"
      unitRef="U_USD">29777000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_34884ad5-27d5-4002-be96-e36c64bdbac9"
      unitRef="U_USD">98402000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_a9db5a80-3509-45c1-8011-baa8b65a3cea"
      unitRef="U_USD">13949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_2fbc786f-c14c-4191-9fbd-02bebdf78cb3"
      unitRef="U_USD">125406000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_8efa17cd-580f-4072-a1b8-72fde09e7353"
      unitRef="U_USD">116539000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_7a482f91-cf2a-4f09-bad1-c8d51996d24a"
      unitRef="U_USD">105757000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_c9e03913-a068-45bb-9186-0d66a86fb03b"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_e5122719-d6df-4bea-8ed9-4c4294f96e90"
      unitRef="U_USD">3884000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_79f94d59-fb69-499c-85bc-dc93c4a1b617"
      unitRef="U_USD">4636000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_83e56e80-8db0-4d4f-8765-51597b271283"
      unitRef="U_USD">57511000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_87da24a1-7929-41bd-8c25-69e0f0f563ac"
      unitRef="U_USD">61159000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_a838e5a0-0420-4f5a-9594-78a74cf147be"
      unitRef="U_USD">12024000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_eba6e293-047b-473e-a3ce-b1ec72e5c1fd"
      unitRef="U_USD">13780000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_d6f2b18a-0356-424b-8e4d-f72600297e98"
      unitRef="U_USD">16109000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_c0bf2c38-4c67-40d2-9dfb-db7dfe1925b3"
      unitRef="U_USD">14662000</us-gaap:GeneralAndAdministrativeExpense>
    <gyre:AcquiredInProcessResearchAndDevelopment
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_3d87d0b6-2666-4c52-9a63-296ffe2db06b"
      unitRef="U_USD">83104000</gyre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_37cd8c73-c63a-4880-9a9d-77cdbe9d8ba8"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_0f826cf5-d8ff-4a36-b781-0b85e24256e8"
      unitRef="U_USD">-66000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_39027330-9221-4e83-a59b-e1be67ab7187"
      unitRef="U_USD">-628000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:CostsAndExpenses
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_0300f231-868d-4727-b07f-19e6b08efa97"
      unitRef="U_USD">89594000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_261c4efa-2c7f-4548-af0f-d080c68299fe"
      unitRef="U_USD">180680000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_1360edd2-c3e6-4ef4-8158-75abd5c59d63"
      unitRef="U_USD">16163000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_43930c47-c738-4cfb-a487-f038e1bb30db"
      unitRef="U_USD">-67230000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_2b897ba8-c207-40b0-8ca5-7f6cc03cec40"
      unitRef="U_USD">1547000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_255a3eec-4bba-4ffe-a624-cea59c00dbf5"
      unitRef="U_USD">1044000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_7923be3f-f891-4fe9-ae3b-7872e3598fe2"
      unitRef="U_USD">-1659000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_269cf636-e37f-4ceb-8afc-b788e8adc757"
      unitRef="U_USD">-1518000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_674f2681-6e6d-4841-b2b6-016b4b5b1d04"
      unitRef="U_USD">-7167000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_260a39cb-ae3d-4e59-8fcf-585705848ca7"
      unitRef="U_USD">9261000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_7df95b8c-49bb-46c7-91a3-19c6b3f01381"
      unitRef="U_USD">23218000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_401343f9-d751-43ab-bfc8-43e5eda87a67"
      unitRef="U_USD">-76965000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_f3591768-d17d-4572-a0f7-9634309905c0"
      unitRef="U_USD">5320000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_27ff8dd5-8f68-4ce1-b677-04ae0a1a110d"
      unitRef="U_USD">8515000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_6c308a6d-7091-4962-aa34-35e9af0f626c"
      unitRef="U_USD">17898000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_e78ce140-4811-4767-a5ab-c182bd48e90f"
      unitRef="U_USD">-85480000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_8982faf0-2728-49d2-9b61-83b533875768"
      unitRef="U_USD">5813000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_1f863750-54ee-4fc0-ba9b-28df46d895dd"
      unitRef="U_USD">7453000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_e08efddb-e459-4010-8bf3-1fd12925932b"
      unitRef="U_USD">12085000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_6f8189ac-f56d-4e63-86fc-53594dbb9f78"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_c4983a70-00c7-4283-863f-154bfdfc60b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="2"
      id="F_9671cbff-afb8-41ac-98dc-a16ca82aa836"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_49af914e-8cdf-4793-a43f-fa829a6c96a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="2"
      id="F_b9730931-a21d-41c8-8442-f0d03b9b5ac7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="0"
      id="F_3e8cdb51-4c18-4304-ad60-9e300eb16d1f"
      unitRef="U_shares">85094948</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="0"
      id="F_d63278c1-128a-4145-aa96-20f81a66656c"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="0"
      id="F_5f304801-75d1-42b4-8400-7ae6ad20c854"
      unitRef="U_shares">102293526</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="0"
      id="F_7bac29d6-3ad3-47f8-a79f-24bbc598cbf8"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_e86e3f05-571e-4080-819b-4a900da1cb8d"
      unitRef="U_USD">17898000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_7686994d-abb4-4552-9213-f9977aac12be"
      unitRef="U_USD">-85480000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_da81b943-b8e9-4d29-902a-83d09ab87477"
      unitRef="U_USD">-1460000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_4a2d7f20-c0b0-4b19-9013-9cf1f0a13b71"
      unitRef="U_USD">-1484000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_3dd80aea-dcd3-4ed7-a06b-720877940661"
      unitRef="U_USD">16438000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_22735d29-7be0-4124-b2ff-e7d5de8edcd9"
      unitRef="U_USD">-86964000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_70c60514-0717-42f6-8c71-479406b1985b"
      unitRef="U_USD">5813000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_60d7f994-f5ab-43fa-adf7-37efd913d4bc"
      unitRef="U_USD">7453000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_2baf38b1-7475-4b80-9d59-8147a73fdb27"
      unitRef="U_USD">-507000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_d365304d-91b8-4cc2-a656-7db41d7c8cbb"
      unitRef="U_USD">-647000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_89f22e60-fd17-42be-8577-dd346175f4e6"
      unitRef="U_USD">5306000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_74438ab4-d998-4f61-8dfb-25fd200bdb18"
      unitRef="U_USD">6806000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_5e3c975f-6b51-499c-a8ff-3debb2a63a55"
      unitRef="U_USD">11132000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_3970d897-b759-48de-950a-ac57218f6be0"
      unitRef="U_USD">-93770000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_62f49f26-9563-408b-b7c2-7c3b1be23119"
      decimals="INF"
      id="F_fe41e59f-fbf6-47e3-889e-e074653c6212"
      unitRef="U_shares">63588119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_62f49f26-9563-408b-b7c2-7c3b1be23119"
      decimals="-3"
      id="F_da09cb4f-118c-4601-b8a7-70218a91d08d"
      unitRef="U_USD">64000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_641c5278-93b2-409e-a72b-833546eaec22"
      decimals="-3"
      id="F_ee662f43-c48b-4a73-8d64-8be7c641bd5f"
      unitRef="U_USD">32795000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_29261f54-503a-4613-b9da-f1c82b1b0e73"
      decimals="-3"
      id="F_ff2f8d7a-f454-4e4e-b6f0-a92f0792cea4"
      unitRef="U_USD">2660000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_29facfe6-6ed6-43d0-af3e-0188d8bb96fe"
      decimals="-3"
      id="F_13412589-7691-4489-8c0b-db0c931f2fcd"
      unitRef="U_USD">7395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_59171fe1-a910-4f9d-acea-66214546eade"
      decimals="-3"
      id="F_0f26accb-6a60-4628-8808-4d1f71c4de80"
      unitRef="U_USD">-392000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_afb0500b-16d2-4911-ab34-f347a18f0103"
      decimals="-3"
      id="F_90d29daa-a533-4752-b3ee-7f208504e402"
      unitRef="U_USD">42522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c66f706c-79f5-4c3c-a4d4-6383b9abf3ef"
      decimals="-3"
      id="F_d857bc29-e7a8-48ee-a6f7-4f80b2b9c5ea"
      unitRef="U_USD">29695000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf"
      decimals="-3"
      id="F_189a3f75-a7f8-4d3a-b930-66aa8a0efeb2"
      unitRef="U_USD">72217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <gyre:TemporaryEquityIssuedDuringPeriodSharesAcquisitions
      contextRef="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23"
      decimals="INF"
      id="F_d035b0c6-8a61-43c6-a11a-1f765c49a003"
      unitRef="U_shares">12340</gyre:TemporaryEquityIssuedDuringPeriodSharesAcquisitions>
    <gyre:TemporaryEquityIssuedDuringPeriodValueAcquisitions
      contextRef="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23"
      decimals="-3"
      id="F_cf408c83-94aa-4d00-a7f4-65fd2c126493"
      unitRef="U_USD">63099000</gyre:TemporaryEquityIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706"
      decimals="INF"
      id="F_ba3990a8-1c9b-4147-8e28-ae1e1d35eda8"
      unitRef="U_shares">2531851</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706"
      decimals="-3"
      id="F_078eb0b7-b2fa-490f-ab88-ef2c5be5f606"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02"
      decimals="-3"
      id="F_e24db3dc-4c76-4bb7-8482-774cffbc6987"
      unitRef="U_USD">21246000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a"
      decimals="-3"
      id="F_44dd2bad-388c-4673-ac41-0b25e971d291"
      unitRef="U_USD">21249000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_a17ee9e4-6ae2-4da0-9688-9f9f48230a7f"
      unitRef="U_USD">21249000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <gyre:MinorityInterestDecreaseFromRedemptionsShares
      contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706"
      decimals="INF"
      id="F_fa0d9264-c402-4027-a206-dfc139f88064"
      unitRef="U_shares">10463627</gyre:MinorityInterestDecreaseFromRedemptionsShares>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706"
      decimals="-3"
      id="F_fdec5e13-73a8-48dd-beab-8c50c66b7eb9"
      unitRef="U_USD">-10000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02"
      decimals="-3"
      id="F_529f10db-f6d6-4c2b-a3f7-a8aacf74c723"
      unitRef="U_USD">-7845000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_a75bd85a-71ec-47ee-b069-04337603dd4a"
      decimals="-3"
      id="F_c19ba779-bb1f-43f6-81c0-69736108f5f5"
      unitRef="U_USD">-438000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_1da1795e-730c-42e1-9de0-0fedc96400d9"
      decimals="-3"
      id="F_ddaec7bb-f458-415a-b4b2-2f67a4227b13"
      unitRef="U_USD">415000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a"
      decimals="-3"
      id="F_6e91fed4-cf01-459c-b665-ed2416980aaf"
      unitRef="U_USD">-7878000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea"
      decimals="-3"
      id="F_efa57573-2b6a-4c66-9d2f-7cb81f5fe751"
      unitRef="U_USD">7878000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <gyre:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23"
      decimals="INF"
      id="F_818c1858-2c5a-4679-8afe-d0401aab7eb5"
      unitRef="U_shares">811</gyre:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0122c949-dbe8-4f4c-bfb6-a822c6db7b23"
      decimals="-3"
      id="F_f3fb1f93-876a-49b7-8590-879e462d9e22"
      unitRef="U_USD">1426000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02"
      decimals="-3"
      id="F_c5b2093c-8242-4ad6-b3c6-d2af797e55db"
      unitRef="U_USD">6127000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a"
      decimals="-3"
      id="F_1d776285-7ab8-414f-9dd5-55433c765383"
      unitRef="U_USD">6127000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea"
      decimals="-3"
      id="F_b7f66202-7386-42c8-8fa6-1a073acda3bf"
      unitRef="U_USD">1154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_9344d66d-1b2f-4a8b-8e0e-0e9658360020"
      unitRef="U_USD">7281000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f0bc705e-b8c5-4374-a7bb-91203f55f706"
      decimals="INF"
      id="F_07a07032-cf3e-4c1d-9fa7-a385cde7dd3f"
      unitRef="U_shares">12019</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ee506da1-60eb-4b22-850e-6a2d6ddc8a02"
      decimals="-3"
      id="F_56252254-35f7-4dd2-bcaf-99c690446276"
      unitRef="U_USD">166000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a"
      decimals="-3"
      id="F_80347059-bed3-41bf-8f10-3c47895396bb"
      unitRef="U_USD">166000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_de58b3d3-5a9f-425d-8710-0abf601ca583"
      unitRef="U_USD">166000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_1da1795e-730c-42e1-9de0-0fedc96400d9"
      decimals="-3"
      id="F_605eb16f-85f6-46af-8343-c79494e33523"
      unitRef="U_USD">-837000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a"
      decimals="-3"
      id="F_2f11ee3a-cd6a-492e-a720-37828938c655"
      unitRef="U_USD">-837000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea"
      decimals="-3"
      id="F_cf65909d-65d8-4b34-aa9b-6da6dcbda1a4"
      unitRef="U_USD">-647000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_ad4979ac-252d-44d3-a2a2-f73ab2bcb486"
      unitRef="U_USD">-1484000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_47d1b610-ca09-4556-921e-9413b69cf697"
      decimals="-3"
      id="F_468de409-2c11-44cb-9f85-1673f2e5477e"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7dd209e8-4aa7-4b9c-8135-83292d3faa5a"
      decimals="-3"
      id="F_ed9a7a45-59fe-4450-bb5f-3966954bf1e4"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ec7589b5-a2ce-49be-8182-3b1713c6bcea"
      decimals="-3"
      id="F_cbc06887-edf9-4539-893f-0bfe52fc8d27"
      unitRef="U_USD">7453000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_ab0dafbe-e4bc-40d3-899a-b085022d9dec"
      unitRef="U_USD">-85480000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a"
      decimals="INF"
      id="F_03beecbe-be89-4ba2-90bb-1c5cc52862a8"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a"
      decimals="-3"
      id="F_135cd1cd-dbbb-44ed-997d-e08e8feefefc"
      unitRef="U_USD">64525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_a6c79814-e564-4a3d-b0f2-8073710a53e4"
      decimals="INF"
      id="F_dfa4da1e-d828-439e-87d8-19b339fdec04"
      unitRef="U_shares">76595616</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a6c79814-e564-4a3d-b0f2-8073710a53e4"
      decimals="-3"
      id="F_3015c29a-0831-4aa7-ba0f-f793fb6d429d"
      unitRef="U_USD">77000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_56cfb1ae-ec72-4d17-82fc-1198e04d1a30"
      decimals="-3"
      id="F_29f9bd68-ff15-4576-8069-5bb3612d8e3d"
      unitRef="U_USD">68179000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1e426f09-37bb-440e-a20a-2c6caa2e0a48"
      decimals="-3"
      id="F_ac46dadc-299a-4b25-aa03-ed7857e11c23"
      unitRef="U_USD">3098000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d1aaf22a-2bdd-4556-a9b8-d529d34aef04"
      decimals="-3"
      id="F_09672b9d-ec62-4c5d-b9cc-3388eb4fdc7b"
      unitRef="U_USD">-85538000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_54965d21-2615-4d08-a3c4-08ca451112ae"
      decimals="-3"
      id="F_ab998662-1d31-4221-bc40-0fff54feaf8c"
      unitRef="U_USD">-1644000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8e5cc978-0a42-4ec0-af0d-d74c36ee2dfd"
      decimals="-3"
      id="F_7439f823-0134-4fbd-9fbf-d7bb7ab3db71"
      unitRef="U_USD">-15828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1550867e-92d1-4406-a92b-c15392d1f1b0"
      decimals="-3"
      id="F_6af6e60f-5270-4e92-b2b2-8d4f08d54971"
      unitRef="U_USD">29777000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_ac5e0c79-be58-4945-a7d1-022a980219d7"
      unitRef="U_USD">13949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055"
      decimals="-3"
      id="F_93e9cf81-cfda-48a5-91ff-123f6a965891"
      unitRef="U_USD">831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621"
      decimals="-3"
      id="F_e8c2ac0a-ea58-4b45-af66-d1e0cffb4eaf"
      unitRef="U_USD">831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_b3915dd6-058c-4af2-866f-7935377ad41c"
      unitRef="U_USD">831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e"
      decimals="INF"
      id="F_49d2defe-58d1-410e-a05b-8484de87bc32"
      unitRef="U_shares">874328</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e"
      decimals="-3"
      id="F_eba93654-24c5-4b47-a7c0-484ff1b22c10"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055"
      decimals="-3"
      id="F_4dfefde5-41fd-4586-aa1c-c9fe7b780119"
      unitRef="U_USD">1864000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621"
      decimals="-3"
      id="F_0797a1f3-aa92-4789-9edf-b7bc950635b8"
      unitRef="U_USD">1865000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_b6dc1cc4-68fb-4ec4-a1a5-1c4eee9d1910"
      unitRef="U_USD">1865000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <gyre:TemporaryEquityConvertiblePreferredStockConversionShares
      contextRef="C_34a9e2bf-ec9e-4a2f-8f4f-2c7daaad7f85"
      decimals="0"
      id="F_cfd0f1c5-8449-4aa2-97a2-c4311beae953"
      unitRef="U_shares">-13151</gyre:TemporaryEquityConvertiblePreferredStockConversionShares>
    <gyre:TemporaryEquityConvertiblePreferredStockConversionValue
      contextRef="C_34a9e2bf-ec9e-4a2f-8f4f-2c7daaad7f85"
      decimals="-3"
      id="F_d8f18499-58d2-4c33-bdd9-43a783451eea"
      unitRef="U_USD">-64525000</gyre:TemporaryEquityConvertiblePreferredStockConversionValue>
    <gyre:TemporaryEquityConvertiblePreferredStockConversionShares
      contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e"
      decimals="INF"
      id="F_a06bff46-bcc0-4acf-92b8-1280a014d31a"
      unitRef="U_shares">8767333</gyre:TemporaryEquityConvertiblePreferredStockConversionShares>
    <gyre:TemporaryEquityConvertiblePreferredStockConversionValue
      contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e"
      decimals="-3"
      id="F_ec4e5183-2772-44d0-ad9a-2710362f6118"
      unitRef="U_USD">8000</gyre:TemporaryEquityConvertiblePreferredStockConversionValue>
    <gyre:TemporaryEquityConvertiblePreferredStockConversionValue
      contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055"
      decimals="-3"
      id="F_024463b6-3d41-47a4-ae37-a152158e9b83"
      unitRef="U_USD">64517000</gyre:TemporaryEquityConvertiblePreferredStockConversionValue>
    <gyre:TemporaryEquityConvertiblePreferredStockConversionValue
      contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621"
      decimals="-3"
      id="F_a0a1e064-0db5-47df-a2ca-92c38023994a"
      unitRef="U_USD">64525000</gyre:TemporaryEquityConvertiblePreferredStockConversionValue>
    <gyre:TemporaryEquityConvertiblePreferredStockConversionValue
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_13045f89-6577-4835-b81a-80e5a939e680"
      unitRef="U_USD">64525000</gyre:TemporaryEquityConvertiblePreferredStockConversionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_341155ec-1a4c-45f2-bc54-4d21d6ed9c6e"
      decimals="INF"
      id="F_38b7a0c5-89f7-4596-93d1-fab392fbcfaf"
      unitRef="U_shares">70267</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055"
      decimals="-3"
      id="F_7a876715-6b11-449f-8202-bee02240e9fa"
      unitRef="U_USD">773000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621"
      decimals="-3"
      id="F_b9e82b51-a692-46f8-9034-bcc845b148c8"
      unitRef="U_USD">773000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_9a02cfd8-1e9f-4e2b-b5f7-69925a53dc7d"
      unitRef="U_USD">773000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <gyre:CvrLiabilitySettlement
      contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055"
      decimals="-3"
      id="F_22f193cb-7830-4e85-ba47-cd0999e10fd6"
      unitRef="U_USD">30000</gyre:CvrLiabilitySettlement>
    <gyre:CvrLiabilitySettlement
      contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621"
      decimals="-3"
      id="F_f3533c90-12d3-4951-940d-332c550168fe"
      unitRef="U_USD">30000</gyre:CvrLiabilitySettlement>
    <gyre:CvrLiabilitySettlement
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_8ddcf795-2074-4d42-8a52-9f98788809a7"
      unitRef="U_USD">30000</gyre:CvrLiabilitySettlement>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_eb7ac400-9cc8-4292-a3f3-4243436fc055"
      decimals="-3"
      id="F_9ea55d88-93de-4707-9952-630ba7c16da9"
      unitRef="U_USD">9000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621"
      decimals="-3"
      id="F_0d68c54b-2ed6-4dc4-8f23-4273a9be3dbb"
      unitRef="U_USD">9000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_68f929df-acff-4ef2-9221-3aa82c90d451"
      unitRef="U_USD">9000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_94da0217-feba-4fbb-a5dc-d987be18247a"
      decimals="-3"
      id="F_6c2fd7ae-aff7-4b76-bd19-35a115c9ba65"
      unitRef="U_USD">-953000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621"
      decimals="-3"
      id="F_4ef4699d-bfa0-4455-891e-443ec799050b"
      unitRef="U_USD">-953000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_3b4e1000-5f70-49f3-a666-01af6c7cbdd7"
      decimals="-3"
      id="F_941a7995-47d7-48e6-875e-94814e7ce00d"
      unitRef="U_USD">-507000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_b8385a38-c349-4666-9353-df19beed6fd9"
      unitRef="U_USD">-1460000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_8f07b256-5b55-40cd-a1f0-534daf47f47f"
      decimals="-3"
      id="F_5c28307e-840e-4780-96c6-fe40df954788"
      unitRef="U_USD">12085000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_70d02eb6-3ab0-4cbb-b037-b0422ecee621"
      decimals="-3"
      id="F_0d33bc77-1d79-4eb8-a26d-6c419d07db86"
      unitRef="U_USD">12085000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3b4e1000-5f70-49f3-a666-01af6c7cbdd7"
      decimals="-3"
      id="F_f1c2e5be-19ed-4b73-8e01-5c82fbe08330"
      unitRef="U_USD">5813000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_7f4a848c-797c-4395-b538-b7c445fdd3fb"
      unitRef="U_USD">17898000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_1999c1fd-3379-456f-aa61-90fe81f796d6"
      decimals="INF"
      id="F_07c118bf-0e48-49dc-af3a-0b3384c08436"
      unitRef="U_shares">86307544</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1999c1fd-3379-456f-aa61-90fe81f796d6"
      decimals="-3"
      id="F_ec953cf6-bde1-41db-9111-f6732b7a4ab6"
      unitRef="U_USD">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_adc4bb81-abd5-4674-adb5-54f33ef3d80c"
      decimals="-3"
      id="F_2ba2a0e4-3f4e-474a-a8cc-32caca3c277d"
      unitRef="U_USD">136185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_84e691d1-e698-40d8-a277-167dedf7a361"
      decimals="-3"
      id="F_62f8cedc-e83d-45d0-97a0-0f6f3f0bc70d"
      unitRef="U_USD">3098000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e528bfc1-0b49-4dd0-ae39-ee76c0228232"
      decimals="-3"
      id="F_97f99dfa-938f-4274-b858-2e489753a632"
      unitRef="U_USD">-73453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_55af4e33-6cc0-4324-9605-d23cf73d489e"
      decimals="-3"
      id="F_8d20260c-4313-4ecc-86a0-3c57456580d1"
      unitRef="U_USD">-2597000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_eca554e0-e672-4d9d-8689-890225dec430"
      decimals="-3"
      id="F_459c8638-8a2f-4549-9fe1-3c8117857cc3"
      unitRef="U_USD">63319000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_40f2813c-6dc2-4685-8c1e-588ca60a93fa"
      decimals="-3"
      id="F_6a4b4bbd-02b8-4677-8363-2099bfa2532a"
      unitRef="U_USD">35083000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_6732b48b-7582-48d6-b4e7-3146b79c0734"
      unitRef="U_USD">98402000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_2d5ddc6b-061e-4cee-875e-6ab0163a8aff"
      unitRef="U_USD">17898000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_7425b275-6c25-4160-8918-b89480204351"
      unitRef="U_USD">-85480000</us-gaap:ProfitLoss>
    <gyre:AcquiredInProcessResearchAndDevelopment
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_f1243883-2fbc-45c4-a58e-52ac4530dbb9"
      unitRef="U_USD">83104000</gyre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:ShareBasedCompensation
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_a1a0ec51-90db-439e-b442-7a7c69ec8aec"
      unitRef="U_USD">831000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_7ef9a054-477b-43ee-94e8-1cdb504a0d4b"
      unitRef="U_USD">7281000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_b625d2b2-1dfe-46c6-b5e9-b686acbe13a0"
      unitRef="U_USD">1549000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_7972c778-410b-4bdb-80df-b4c4776e2612"
      unitRef="U_USD">1074000</us-gaap:DepreciationDepletionAndAmortization>
    <gyre:NoncashLeaseExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_3c1f0898-e787-4211-ab74-7ff1f1514f12"
      unitRef="U_USD">672000</gyre:NoncashLeaseExpense>
    <gyre:NoncashLeaseExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_ebad3b30-bc81-4b19-83c4-ce17544db7c0"
      unitRef="U_USD">355000</gyre:NoncashLeaseExpense>
    <gyre:AmortizationOfLandUseRights
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_c44b5269-a985-4872-9689-99d20c4f045e"
      unitRef="U_USD">39000</gyre:AmortizationOfLandUseRights>
    <gyre:AmortizationOfLandUseRights
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_0ef126d4-a2f6-4296-84ab-873046171b55"
      unitRef="U_USD">40000</gyre:AmortizationOfLandUseRights>
    <gyre:DeferredIncomeTaxExpenseBenefitNet
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_a2705b94-166a-4cd0-a4c2-ee27b898a5e4"
      unitRef="U_USD">-1002000</gyre:DeferredIncomeTaxExpenseBenefitNet>
    <gyre:DeferredIncomeTaxExpenseBenefitNet
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_ffca3d86-f6f8-4ac4-90fc-705ac4c29a51"
      unitRef="U_USD">-1160000</gyre:DeferredIncomeTaxExpenseBenefitNet>
    <gyre:BadDebtExpenseAndOtherNonCashItems
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_a40d4a28-f0ef-44e9-9289-34c705969d19"
      unitRef="U_USD">170000</gyre:BadDebtExpenseAndOtherNonCashItems>
    <gyre:BadDebtExpenseAndOtherNonCashItems
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_d3c3c9ca-6517-4eeb-91d7-8e3d6878f624"
      unitRef="U_USD">-61000</gyre:BadDebtExpenseAndOtherNonCashItems>
    <gyre:AccruedInterestOnBankDeposit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_df6176f7-0a68-4dce-a461-63d58814fffd"
      unitRef="U_USD">1046000</gyre:AccruedInterestOnBankDeposit>
    <gyre:AccruedInterestOnBankDeposit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_dcf4b10f-c0bf-4e07-80f7-3076c9108e54"
      unitRef="U_USD">633000</gyre:AccruedInterestOnBankDeposit>
    <gyre:ChangeInFairValueOfLongTermReceivables
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_f7d9136b-8271-4ad5-80f5-fee19d481343"
      unitRef="U_USD">239000</gyre:ChangeInFairValueOfLongTermReceivables>
    <gyre:ChangeInFairValueOfLongTermReceivables
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_01268efa-1b62-4bdb-8a9e-600edd95fc21"
      unitRef="U_USD">39000</gyre:ChangeInFairValueOfLongTermReceivables>
    <gyre:ChangeInFairValueOfDerivativeLiabilities
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_69d95ea9-f4c7-4041-a632-09f14fce39b8"
      unitRef="U_USD">239000</gyre:ChangeInFairValueOfDerivativeLiabilities>
    <gyre:ChangeInFairValueOfDerivativeLiabilities
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_1d86c8b7-6500-4510-8cf1-c49934d6a34f"
      unitRef="U_USD">39000</gyre:ChangeInFairValueOfDerivativeLiabilities>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_9c698895-316e-4317-b459-f08ae84c462f"
      unitRef="U_USD">-7167000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_e1f698d7-9458-4a07-843b-0aafce67a4bf"
      unitRef="U_USD">9261000</us-gaap:FairValueAdjustmentOfWarrants>
    <gyre:EquityGainLossOfUnconsolidatedAffiliates
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_877b91f1-e02c-437a-a1fa-79ddf04fba83"
      unitRef="U_USD">-37000</gyre:EquityGainLossOfUnconsolidatedAffiliates>
    <gyre:EquityGainLossOfUnconsolidatedAffiliates
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_7a50537c-4665-4bf6-9a98-5e51c532207a"
      unitRef="U_USD">-1314000</gyre:EquityGainLossOfUnconsolidatedAffiliates>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_fc734f53-f382-4bc0-ba84-b851da0e7f1b"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_1f55d4f8-680b-4b8a-bbe9-ce00ce57f40a"
      unitRef="U_USD">-66000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_76c2e75d-cf40-46c1-9d10-7b8bebd0eed9"
      unitRef="U_USD">-628000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInNotesReceivables
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_66b8af29-145f-4c24-aa90-bcb1a5252732"
      unitRef="U_USD">4028000</us-gaap:IncreaseDecreaseInNotesReceivables>
    <us-gaap:IncreaseDecreaseInNotesReceivables
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_d892d265-563b-4148-a561-8a5cccaa924d"
      unitRef="U_USD">-1113000</us-gaap:IncreaseDecreaseInNotesReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_db21d03d-dfd5-40bb-bf81-8d024acbfb7d"
      unitRef="U_USD">5257000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_d27abe46-c8ae-4801-a081-eb64586cdf9b"
      unitRef="U_USD">-285000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_b12f5a21-8f2f-483f-b7d3-65664eae158c"
      unitRef="U_USD">96000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_e4a00c82-23fa-4944-bb5e-28cb00b1d601"
      unitRef="U_USD">2139000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_95a5d0b6-d9ee-4be4-b3ef-cc2512ea4fb1"
      unitRef="U_USD">-1747000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_f802b516-7c8c-49e0-bb19-3f46a2b51ec0"
      unitRef="U_USD">-520000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_32ea3674-9935-49ba-a7a7-38423a953274"
      unitRef="U_USD">82000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_9b849ca8-68fe-451c-a61f-35829178a2e3"
      unitRef="U_USD">-2166000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_f1bde380-35f4-4a21-87fc-4b1abd2bea77"
      unitRef="U_USD">3003000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_e97e25ea-31b3-4365-8f8a-c14f990d8a1d"
      unitRef="U_USD">-245000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_f849bca2-036b-42b6-8da6-91e315dd351c"
      unitRef="U_USD">192000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_1b0e7c4a-3b52-4219-bb24-b74bb520d89c"
      unitRef="U_USD">23000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_c6d1107d-926a-4e2b-9004-4799c07b06ed"
      unitRef="U_USD">-102000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_8f4dc31e-ea62-4944-90bb-39eba2e754f0"
      unitRef="U_USD">-83000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_dcd3b6f3-4c20-4185-8fc5-0a9ff5b87736"
      unitRef="U_USD">425000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_ea86c3c5-57a5-4a51-860c-204db42ae4b8"
      unitRef="U_USD">-1497000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_8e577e1a-0c2d-49c6-9094-7bfe5e28956a"
      unitRef="U_USD">1446000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_0a90d1cf-9959-4605-8554-dee11e64554e"
      unitRef="U_USD">-816000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_96ad4359-68cb-4dcd-93ea-728b6a502331"
      unitRef="U_USD">-473000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_972fb665-433d-4d00-a140-61064ca098d1"
      unitRef="U_USD">-3641000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_034d3983-172a-4018-b82b-e22619393b79"
      unitRef="U_USD">25892000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_a9541388-9b88-46b9-bf14-a7829f86696c"
      unitRef="U_USD">813000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_a7384830-4bf6-4854-b09d-c343db83f234"
      unitRef="U_USD">69000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_e9f7420d-eaf3-4997-b169-5e4a441a7ca3"
      unitRef="U_USD">15471000</us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit>
    <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_8d013c55-ec8a-43b9-8775-92afad3d3e1d"
      unitRef="U_USD">15735000</us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_256e7b7d-a6e9-4093-a338-253827eb0496"
      unitRef="U_USD">2315000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_a7c58cf1-7b11-4642-8df7-88f22e3f06a6"
      unitRef="U_USD">8517000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_a89bc96e-de75-4379-94ed-f738e222ba06"
      unitRef="U_USD">401000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_4759baa3-ba72-4fce-88bc-bc6942b9b44b"
      unitRef="U_USD">664000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_ded52038-42a0-4e51-9cc6-3d57377642ad"
      unitRef="U_USD">1686000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_c1ec078b-8da6-4624-868b-3e7931a049a6"
      unitRef="U_USD">1000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_210c7b70-6e85-4e05-a78f-8da6f82db664"
      unitRef="U_USD">5587000</us-gaap:CashAcquiredFromAcquisition>
    <gyre:CashPaidForAcquisitionCosts
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_7ae42da8-0a42-4bd0-8b12-547f6d4a4498"
      unitRef="U_USD">124000</gyre:CashPaidForAcquisitionCosts>
    <gyre:PaymentOfDisposalOfSubsidiary
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_994b53c2-7240-4e44-be88-3249ac9e1209"
      unitRef="U_USD">566000</gyre:PaymentOfDisposalOfSubsidiary>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_5123d3dd-261f-424b-b8a8-0dd92af53380"
      unitRef="U_USD">-19884000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_3f16f510-ccf5-4b8c-93fa-274f1dedf0ce"
      unitRef="U_USD">-19760000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <gyre:PaymentOfDeferredOfferingCosts
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_c168bd7b-f988-480d-a209-8eb2e60a3719"
      unitRef="U_USD">536000</gyre:PaymentOfDeferredOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_42e3d390-01ed-42b4-be30-75ed0751138d"
      unitRef="U_USD">773000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_deab8d91-ac20-4871-86c5-f0064fd9083f"
      unitRef="U_USD">1865000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_2109caae-8e0d-4c71-9215-197bc6ce1e82"
      unitRef="U_USD">2500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_648ff37d-b9c6-4bc5-93dd-11b924a65533"
      unitRef="U_USD">2102000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_585260ac-1846-4965-88cc-3d5330c49a3c"
      unitRef="U_USD">2500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_09472ecc-23d6-48f6-ba24-33496bad608c"
      unitRef="U_USD">-273000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_8e326bb4-8cae-4366-a387-414d563765cb"
      unitRef="U_USD">-298000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_072b113b-14d3-471d-852a-158926b81a43"
      unitRef="U_USD">-21696000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_07de216b-5729-418a-9cdf-2ff7863324ed"
      unitRef="U_USD">8334000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_0ef3506a-dc70-4e6b-a9c1-4e8569fcf986"
      unitRef="U_USD">33509000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf"
      decimals="-3"
      id="F_8b3b04a6-7d28-4993-afea-0ed150b0cefd"
      unitRef="U_USD">25175000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_b371b179-8d8b-4add-8183-bd24086ba50b"
      unitRef="U_USD">11813000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_33f221ec-fcf5-4462-bc10-fa551f6f0a17"
      unitRef="U_USD">33509000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <gyre:DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_3b55a94e-d8a1-4dc1-9700-ab084972ecb3"
      unitRef="U_USD">84348000</gyre:DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders>
    <gyre:AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_ea97a878-d32b-4ad3-8c7b-bb441389f9cc"
      unitRef="U_USD">2500000</gyre:AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions>
    <gyre:DisposalConsiderationInOtherReceivables
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_88ea521a-aba2-4f56-9d06-f8897062286e"
      unitRef="U_USD">768000</gyre:DisposalConsiderationInOtherReceivables>
    <gyre:AcquisitionCostsInDueToRelatedParties
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_abd88644-a5e0-482c-8822-52b3a09edcc9"
      unitRef="U_USD">535000</gyre:AcquisitionCostsInDueToRelatedParties>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_e41a54d1-c8c1-4f04-968b-e3469b4f59fe"
      unitRef="U_USD">2017000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_84778b81-dc3e-421f-a02c-bb137c61e3e3"
      unitRef="U_USD">277000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <gyre:ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_03fd29cd-71ed-4e15-be48-aba9e919d686"
      unitRef="U_USD">166000</gyre:ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable>
    <gyre:ConvertiblePreferredStockConversion
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_ab3b48c2-d8fc-4b6a-97fe-41721c79e73b"
      unitRef="U_USD">64525000</gyre:ConvertiblePreferredStockConversion>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_da019e26-581c-4c15-846a-30ffc663fa49"
      unitRef="U_USD">8518000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_82d00b16-4ab4-4714-9fd5-65f9ca2084e4"
      unitRef="U_USD">6346000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_94f47330-9c08-429d-884d-7420ebf064fe">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Therapeutics, Inc. (the &#x201c;Company,&#x201d; &#x201c;Gyre,&#x201d; or the &#x201c;combined company&#x201d;), formerly known as Catalyst Biosciences, Inc. (&#x201c;Catalyst&#x201d;), is a biopharmaceutical company originally incorporated in Delaware on March 7, 1997 under the name Targacept, Inc. Catalyst was a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, Catalyst had several protease assets that were designed to address unmet medical needs in disorders of the complement or coagulation systems.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;After completion of the transactions under the Business Combination Agreement as described below, Gyre became a commercial-stage pharmaceutical company with a proven track record of financial success developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs and involves a complex, multi-stage process with multiple pathways.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;F351 Asset Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;On December 26, 2022, Catalyst executed and closed an Asset Purchase Agreement, which was amended on March 29, 2023 (the &#x201c;F351 Agreement&#x201d;), with GNI Group Ltd. (&#x201c;GNI Japan&#x201d;) and GNI Hong Kong Limited (&#x201c;GNI HK&#x201d;) to purchase all of the assets and intellectual property rights primarily related to a clinical-stage proprietary Hydronidone compound for the treatment of metabolic dysfunction-associated steatohepatitis (&#x201c;MASH&#x201d;), a severe form of nonalcoholic fatty liver disease (collectively, the &#x201c;F351 Assets&#x201d;), other than such assets and intellectual property rights located in the People&#x2019;s Republic of China (&#x201c;PRC&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business Combination Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;On December 26, 2022, Catalyst entered into a Business Combination Agreement, as amended on March 29, 2023 and August 30, 2023 (the &#x201c;Business Combination Agreement&#x201d;) with GNI USA, Inc. (&#x201c;GNI USA&#x201d;), GNI Japan, GNI HK, Shanghai Genomics, Inc. (&#x201c;SG&#x201d; and collectively with GNI USA, GNI Japan and GNI HK, the &#x201c;Contributors,&#x201d; and each a &#x201c;Contributor&#x201d;), certain individuals (each, a &#x201c;Minority Holder&#x201d; and collectively, the &#x201c;Minority Holders&#x201d;) and Continent Pharmaceuticals Inc. (&#x201c;CPI&#x201d;). On October 30, 2023 (the &#x201c;Effective Time&#x201d;), the Contributions (as defined below) became effective and Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (doing business as Gyre Pharmaceuticals Co,, Ltd.) (&#x201c;Gyre Pharmaceuticals&#x201d;). In connection with the Contributions, and immediately prior to the Effective Time of the Contributions, Catalyst amended its certificate of incorporation, increased the number of authorized shares of its common stock, par value &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; per share (the &#x201c;Common Stock&#x201d;) from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, effected a&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;1-for-15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Reverse Stock Split&#x201d;) and changed its name to Gyre Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Shares of Catalyst Common Stock were previously listed on The Nasdaq Capital Market under the symbol &#x201c;CBIO.&#x201d; Catalyst had filed a listing application for the combined company with the Nasdaq Stock Market Inc. (&#x201c;Nasdaq&#x201d;). On October 31, 2023, Gyre&#x2019;s Common Stock commenced trading on the Nasdaq Capital Market under the symbol &#x201c;GYRE&#x201d;, on a post-reverse stock split adjusted basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Business Combination Agreement, at the Effective Time of the Contributions, and after giving effect to the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;1-for-15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; reverse stock spli&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;t,&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;GNI USA contributed all of its ordinary shares in the capital of CPI to Catalyst in exchange for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,923,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Gyre Common Stock (the &#x201c;CPI Contribution&#x201d;), &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;GNI USA contributed its interest in Further Challenger International Limited (&#x201c;Further Challenger&#x201d;) for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,664,779&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Gyre Common Stock (the &#x201c;FC Contribution&#x201d; and together with the CPI Contribution, the &#x201c;GNI USA Contributions&#x201d;), and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;c)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;each Minority Holder contributed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of the interest he or she held in his or her respective entity in exchange for an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,463,627&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Gyre Common Stock (the &#x201c;Minority Holder Contributions&#x201d; and together with the GNI USA Contributions, the &#x201c;Contributions&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As a result of the GNI USA Contributions, Gyre directly and indirectly holds &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of CPI&#x2019;s shares. Through Gyre&#x2019;s ownership of CPI, prior to the Minority Holder Contributions, Gyre held a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; indirect interest in Gyre Pharmaceuticals. Upon completion of the Minority Holder Contributions, Gyre obtained additional indirect interests in Gyre Pharmaceuticals and holds, in aggregate, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; indirect interest in Gyre Pharmaceuticals.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Immediately after the closing of the Contributions, excluding potentially dilutive securities, GNI USA owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of the outstanding shares of Gyre Common Stock, Catalyst&#x2019;s existing stockholders, excluding GNI USA, owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of the outstanding Gyre Common Stock, and the Minority Holders owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of the outstanding shares of Gyre Common Stock. The Convertible Preferred Stock remained outstanding after the closing of the Contributions and is not included in the above ownership percentages.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;At the Effective Time, Gyre Pharmaceuticals terminated its 2021 Stock Incentive Plan (the &#x201c;2021 Plan&#x201d;) and the options (the &#x201c;Gyre Pharmaceuticals Options&#x201d;) outstanding under the 2021 Plan were terminated and replaced with options granted under a subplan for Chinese participants under the Gyre 2023 Omnibus Incentive Plan (the &#x201c;2023 Omnibus Incentive Plan&#x201d;) that are substantially similar in all material respects to the Gyre Pharmaceuticals Options previously outstanding under the 2021 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remained issued and outstanding, and such shares and options were unaffected by the Contributions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company registered and established in the PRC in 2002. Gyre Pharmaceuticals is committed to the research and development of new drugs as well as manufacturing and commercialization of ETUARY (pirfenidone capsule) for the treatment of idiopathic pulmonary fibrosis and other pharmaceutical products. The registered office of Gyre Pharmaceuticals is located at 60 Shunkang Road, Shunyi District, Beijing, PRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The immediate holding company of Gyre Pharmaceuticals is BJContinent Pharmaceuticals Limited (&#x201c;BJC&#x201d;). The intermediate holding company of Gyre Pharmaceuticals is CPI. Immediately following the Contributions, the immediate holding company of CPI is Gyre. The immediate holding Company of Gyre is GNI USA and the ultimate holding company of Gyre is GNI Japan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The GNI USA Contributions were treated as an asset acquisition under U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), with CPI treated as the accounting acquirer and presented as the predecessor for the post-acquisition SEC reporting purposes. Since Catalyst is the legal acquirer, the GNI USA Contributions were accounted for as a reverse asset acquisition. This determination was based upon the terms of the Business Combination Agreement and other factors including that, immediately following the GNI USA Contributions: (i) GNI USA (as the parent company of CPI immediately prior to the GNI USA Contributions) owns a substantial majority of the voting power of the combined company; (ii) CPI, through GNI USA, has the ability to control the board of directors of the combined company; and (iii) senior management of Gyre Pharmaceuticals and GNI USA holds a majority of the key positions in senior management of the combined company. Immediately prior to the closing of the Contributions, Catalyst did not meet the definition of a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;business because Catalyst did not have an organized workforce that significantly contributed to its ability to create output, and substantially all of its fair value was concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of the closing date of the GNI USA Contributions, the net assets of Catalyst were recorded at their acquisition-date relative fair values in the accompanying consolidated financial statements of the Company and the reported operating results prior to the GNI USA Contributions are those of CPI.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in Gyre Pharmaceuticals.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingent Value Rights Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Concurrent with the signing of the Business Combination Agreement on December 26, 2022, Catalyst and the Rights Agent (as defined in the CVR Agreement) executed a contingent value rights agreement (the &#x201c;CVR Agreement&#x201d;), as amended on March 29, 2023, pursuant to which each holder of Catalyst Common Stock as of January 5, 2023 (the &#x201c;CVR Holder&#x201d;), excluding GNI, received one contractual contingent value right (a &#x201c;CVR&#x201d;) for each share of Catalyst Common Stock held by such holder. Each CVR entitles the holder thereof to receive certain cash payments in the future. For additional information, see Note 13 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;On October 30, 2023, the Company effected a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;1-for-15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; immediately prior to the Effective Time of the Contributions. The par value of the Catalyst Common Stock following the Reverse Stock Split was not adjusted and remains at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; per share. All of the Catalyst&#x2019;s issued and outstanding common stock and options have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding, which resulted in a proportional decrease in the number of shares of the Company&#x2019;s Common Stock reserved for issuance upon exercise or vesting of such stock options, warrants, and in the case of stock options and warrants, a proportional decrease in the exercise price of such stock options and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;No fractional shares were issued in connection with the Reverse Stock Split and stockholders who would otherwise be entitled to a fraction of one share received a proportional cash payment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, the Company had a net income of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, while net cash used in operating activities was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2024, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and cash and cash equivalents of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. Based on the Company&#x2019;s current operating plan, management believes that existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund the Company&#x2019;s operating activities and obligations for at least 12 months following the issuance of these consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_8af0977b-b1f9-48ee-9940-3554e079223c"
      decimals="INF"
      id="F_d8ce3751-2d32-45f6-a6cb-cfa9637d5228"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a4960a5d-b308-445f-8714-9498ff7443b8"
      decimals="INF"
      id="F_800c4c17-1269-464d-9a1b-2cf6e0714a6a"
      unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3a618d1d-ac50-42d9-955f-3512c0439863"
      decimals="INF"
      id="F_884161c4-97b4-4923-ae05-4d7f5f950bc2"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_661aab60-409f-4f43-a899-d4da1611a236"
      id="F_f64db999-38c9-4e20-995a-508f0a343dac"> 1-for-15 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_18ff54a5-54d5-42f4-81e9-6aa9f1a79af5"
      id="F_da33e611-41df-4c16-979f-6b57fafd3148">1-for-15 reverse stock spli</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f6130ae2-a2e5-45e6-a4ed-5c019bfa760e"
      decimals="INF"
      id="F_2c043b80-9b58-4103-b7ca-ac65640a854b"
      unitRef="U_shares">45923340</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4cb4b16d-4b5f-4f2a-9fb0-59f281280fc0"
      decimals="INF"
      id="F_4576dade-bfd0-4e00-8a52-38dcbbd4216f"
      unitRef="U_shares">17664779</us-gaap:CommonStockSharesIssued>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_25e32d74-d3e2-425b-866e-4b5bc29838fb"
      decimals="2"
      id="F_51ee594f-735f-4268-bdb4-7d953e66ed93"
      unitRef="U_pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_25e32d74-d3e2-425b-866e-4b5bc29838fb"
      decimals="INF"
      id="F_f4ed83a5-5ea8-4c3f-9dcc-112cd54eeadb"
      unitRef="U_shares">10463627</us-gaap:CommonStockSharesIssued>
    <gyre:PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds
      contextRef="C_4cf85ce7-378e-4422-9fd7-e7d329e19a16"
      decimals="2"
      id="F_661b1400-ab85-4548-97ff-6ab42b9301c6"
      unitRef="U_pure">1</gyre:PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds>
    <gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds
      contextRef="C_583140f7-2f5b-432a-a839-befb410b9e87"
      decimals="3"
      id="F_f625e9c3-8fb9-49d6-8284-e89cb6f63b89"
      unitRef="U_pure">0.56</gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds>
    <gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds
      contextRef="C_b069b7f9-1d2e-4765-80cb-c51aa4c12c6f"
      decimals="3"
      id="F_dfdc8296-e4b6-49d1-82ef-fb636a935028"
      unitRef="U_pure">0.652</gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds>
    <gyre:PercentageOfOutstandingSharesOfCommonStock
      contextRef="C_8437179e-663a-4744-b86d-fca26b0fe052"
      decimals="3"
      id="F_4a26c41d-8a73-48ba-8fd6-b6235f06b296"
      unitRef="U_pure">0.836</gyre:PercentageOfOutstandingSharesOfCommonStock>
    <gyre:PercentageOfOutstandingSharesOfCommonStock
      contextRef="C_6e8538d1-cf76-4d30-a57e-b5a4624ea831"
      decimals="3"
      id="F_79051165-9989-418b-aa5b-12f5ea607890"
      unitRef="U_pure">0.028</gyre:PercentageOfOutstandingSharesOfCommonStock>
    <gyre:PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="3"
      id="F_497a5351-d036-4a58-96e7-4d85ddc22d97"
      unitRef="U_pure">0.137</gyre:PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_661aab60-409f-4f43-a899-d4da1611a236"
      id="F_d6d909ae-c091-4e0a-bfca-3b3c0f7f5fd7">1-for-15 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1999c1fd-3379-456f-aa61-90fe81f796d6"
      decimals="3"
      id="F_0c5029b7-f6ee-4b6e-bd54-fe7b70309369"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:NetIncomeLoss
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_ff27ff39-a4a5-48aa-ba35-6df808d1ed24"
      unitRef="U_USD">17900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_7bc2c1fb-50cf-4d97-b848-0ee24156bf1e"
      unitRef="U_USD">-3600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_4cddb08b-27a4-4dd8-a679-1a2a5ef3cc8b"
      unitRef="U_USD">-73500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_4e2aada6-c32d-44c4-94fa-e41ea0cd875e"
      unitRef="U_USD">11800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_b03b7e15-1bd0-4f81-997d-33368a87f46d">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Noncontrolling Interest&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company reports noncontrolling interest (&#x201c;NCI&#x201d;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The measure of segment profit or loss is reported on the income statement as consolidated net income (loss). The CODM uses net income (loss) to evaluate income generated from segment assets in deciding whether to reinvest profits and monitor budget versus actual results in assessing performance of the segment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s CODM, as a group, includes Gyre&#x2019;s Chief of Executive Officer (&#x201c;CEO&#x201d;), Gyre Pharmaceuticals&#x2019;  General Manager, Gyre's Chief Operating Officer, and the Chairman of Gyre&#x2019;s Board of Directors (&#x201c;Gyre&#x2019;s Board&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The Company has determined that it operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; distinct operating segments and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; reportable segments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;f Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, note receivable, long-term certificates of deposits, and short-term bank deposits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In May 2015, a new Deposit Insurance System (&#x201c;DIS&#x201d;) managed by the People&#x2019;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#x201c;RMB&#x201d;) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company had cash and cash equivalents of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; millio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;n, and long-term certificates of deposit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; millio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;n, respectively. In addition, the Company had short-term bank deposits of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2024. For the years ended December&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; 31, 2024 and 2023, cash and cash equivalents, short-term bank deposits and long-term certificates of deposits exceeded the PRC DIS coverage by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Ac&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Customer Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, one customer, Sinopharm Group Co., Ltd., accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of accounts receivable, respectively. For the year ended December 31, 2024, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of total revenue respectively. For the year ended December 31, 2023, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of total revenue respectively. All customers are located in the PRC.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash equivalents includes cash on hand, demand deposits and money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;and Note 13 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for additional information regarding the CVR derivative liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase shares of the Convertible Preferred Stock (&#x201c;Preferred Stock Warrants&#x201d;) are freestanding financial instruments classified as warrant liability on the Company&#x2019;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#x2019;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, to account for the Convertible Preferred Stock. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long-term Certificates of Deposit&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The long-term certificates of deposit will mature between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;J&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;anuary&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;effective interest method. The Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; allowance for credit losses associated with the certificates of deposit as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and 2023.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short-term Bank Deposits&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The short-term bank deposits will mature between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;January 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. Short-term bank deposits consist of bank deposits with original maturities of one year or less, and long-term deposits that have a remaining maturity of less than one year. These deposits are recorded at amortized cost. Interest income from these deposits is recognized and reported within interest income. The Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; allowance for credit losses associated with the short-term certificates of deposit as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long-Term Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#x201c;GCBP&#x201d;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for additional information regarding the long-term receivable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long-term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise more than minor influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC Topic 323, Investments&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Method and Joint Ventures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 323&#x201d;). Under the equity method, the Company initially records its investments at fair value. The Company subsequently adjusts the carrying amount of the investment to recognize the Company&#x2019;s proportionate share of the equity investee&#x2019;s net income or loss after the date of investment. The Company evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; impairment charge was recognized for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts and Note Receivables, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#x2019;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#x2019;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:61.012%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.463%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Note receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts and note receivables, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes in the allowance for credit losses as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:61.012%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:18.462999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.203000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Provision for allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Recoveries collected and write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inventories, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:58.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_df845163-9662-4f0f-9d15-2572001b1a8c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of the estimated useful life or the term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;
        &lt;table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:58.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents, technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Nonrefundable advance payments for intangible assets are capitalized in &#x201c;other assets, noncurrent&#x201d; and will be recognized as intangible assets when the Company obtains the control of the underlying asset. As of December 31, 2024, the Company had paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million to obtain the drug registration certificate for nintedanib and the advance payment was included in &#x201c;other assets, noncurrent&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patents and Technological Know-How&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Computer Software&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_e144250a-53d1-44d0-abc4-0e596d38ecb8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#x2019;s leases do not contain any residual value guarantees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Land Use Rights, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair valu&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;t record any impairment of long-lived assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Tax Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company records revenue in accordance with ASC Topic 606 (&#x201c;ASC 606&#x201d;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#x2019;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sale of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer upon delivery of the underlying products.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;t recognize any contract assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities are recognized when the payments are received from customers before the Company transfers the related goods or services. Contract liabilities are recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the Company&#x2019;s Contract liability balance was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. Contract liability balance was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2023 which has been recognized as revenue during the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cost of Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#x2019;s assumptions regarding a number of variables including the fair value of its Common Stock, its expected Common Stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;amp;D with no alternative future use is&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;charged to expense at the acquisition date. Refer to Note 7 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;GNI USA Contributions under the Business Combination Agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for a more detailed description.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Selling and Marketing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Advertising Cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Advertising costs are expensed when incurred. Such costs approximated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; for the 2024 and 2023 fiscal years, respectively. Advertising costs are included in selling expenses on the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Government Grants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying amount of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interest Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Income (Loss) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Per Share (&#x201c;EPS&#x201d;) Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 260&#x201d;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#x2019;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#x2019;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;EPS &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for more information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Translation and Remeasurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of Gyre Pharmaceuticals is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Matters&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The Company uses the U.S. Dollar as its reporting currency.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive income (loss). During the years ended December 31, 2024 and December 31, 2023, the Company had translation loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of operations and comprehensive income (loss). The foreign currency transaction gains or losses for the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;were immaterial.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#x2019;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of the Company&#x2019;s cash and cash equivalents, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of the Company&#x2019;s short-term bank deposits and long-term certificates of deposit as of December 31, 2024 in the amount of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, respectively, were denominated in RMB.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures (Topic 280)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; this standard as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The adoption of this ASU did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;not &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;have any material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#x2019;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. ASU 2023-06 modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. Because of the variety of Topics amended, a broad range of entities may be affected by one or more of those amendments. Many of the amendments allow users to more easily compare entities subject to the SEC&#x2019;s existing disclosures with those entities that were not previously subject to the SEC&#x2019;s requirements. Also, the amendments align the requirements in the Codification with the SEC&#x2019;s regulations. For entities subject to the SEC&#x2019;s existing disclosure requirements and for entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. The amendments in this update should be applied prospectively. For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is currently evaluating the potential impact this standard will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of Income Statement Expenses (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The ASU requires the disaggregated disclosure of specific expense categories, including purchases of inventory, employee compensation, depreciation, and amortization, within relevant income&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;statement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;captions. This ASU also requires disclosure of the total amount of selling expenses along with the definition of selling expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU can either be applied prospectively to consolidated financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the consolidated financial statements. Early adoption is also permitted. This ASU will likely result in the required additional disclosures being included in our consolidated financial statements, once adopted. The Company is currently evaluating the provisions of this ASU.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_030db12f-17da-4915-a59a-c0f596ab7ccb">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_e04f6feb-4a99-4af7-b8b5-84ab484c72a6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <gyre:NoncontrollingInterestPolicyPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_3351fc13-a6aa-41a0-b1ef-35efe92a058c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Noncontrolling Interest&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company reports noncontrolling interest (&#x201c;NCI&#x201d;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;</gyre:NoncontrollingInterestPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_f9bd2e32-35ec-4f6e-adba-baea0acbde77">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The measure of segment profit or loss is reported on the income statement as consolidated net income (loss). The CODM uses net income (loss) to evaluate income generated from segment assets in deciding whether to reinvest profits and monitor budget versus actual results in assessing performance of the segment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s CODM, as a group, includes Gyre&#x2019;s Chief of Executive Officer (&#x201c;CEO&#x201d;), Gyre Pharmaceuticals&#x2019;  General Manager, Gyre's Chief Operating Officer, and the Chairman of Gyre&#x2019;s Board of Directors (&#x201c;Gyre&#x2019;s Board&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The Company has determined that it operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; distinct operating segments and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; reportable segments.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="INF"
      id="F_a8e1a674-a162-4298-886d-7899f5a598dc"
      unitRef="U_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="INF"
      id="F_c9d1ac29-51fc-4ff3-98c2-c5fb65703489"
      unitRef="U_Segment">2</us-gaap:NumberOfReportableSegments>
    <gyre:RisksAndUncertainitiesPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_b203af37-0b9a-4e2d-b07c-2ff125f30315">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.&lt;/span&gt;&lt;/p&gt;</gyre:RisksAndUncertainitiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_2863e381-0ee8-4cb7-a68b-fb0156121bd3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;f Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, note receivable, long-term certificates of deposits, and short-term bank deposits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In May 2015, a new Deposit Insurance System (&#x201c;DIS&#x201d;) managed by the People&#x2019;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#x201c;RMB&#x201d;) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company had cash and cash equivalents of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; millio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;n, and long-term certificates of deposit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; millio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;n, respectively. In addition, the Company had short-term bank deposits of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2024. For the years ended December&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; 31, 2024 and 2023, cash and cash equivalents, short-term bank deposits and long-term certificates of deposits exceeded the PRC DIS coverage by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Ac&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <gyre:DepositsInLicensedBanksProtectedByDepositInsuranceSystem
      contextRef="C_3c2ac92b-d05c-4dcb-8edc-d7dc05708e32"
      decimals="0"
      id="F_1926a929-9950-465f-94a9-7c49cb654d04"
      unitRef="U_CNY">500000</gyre:DepositsInLicensedBanksProtectedByDepositInsuranceSystem>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_daabf9a2-d031-407f-97cb-490f9af585aa"
      unitRef="U_USD">11800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-5"
      id="F_22d43133-6dc6-403f-b4a5-c8b8dcc3eab5"
      unitRef="U_USD">33500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_677f13e6-9703-4fdf-9768-d6c427a9d2a7"
      unitRef="U_USD">24600000</gyre:LongTermCertificatesOfDeposit>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-5"
      id="F_4b1b4250-5a80-41f9-b028-386f7fc8854e"
      unitRef="U_USD">23400000</gyre:LongTermCertificatesOfDeposit>
    <us-gaap:ShortTermInvestments
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_5d76a5f2-a366-41c8-b3f5-d1ab3d550766"
      unitRef="U_USD">14900000</us-gaap:ShortTermInvestments>
    <gyre:ValueOfAssetsExceedingDepositInsuranceSystemLimit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_f67df5a9-82a0-4fa7-8a79-4c6676b4118e"
      unitRef="U_USD">46300000</gyre:ValueOfAssetsExceedingDepositInsuranceSystemLimit>
    <gyre:ValueOfAssetsExceedingDepositInsuranceSystemLimit
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-5"
      id="F_2970d9b7-0f0b-4417-b095-0ea943fb58e0"
      unitRef="U_USD">49400000</gyre:ValueOfAssetsExceedingDepositInsuranceSystemLimit>
    <gyre:ConcentrationOfCustomerRiskPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_52b7d5e6-2c72-4cad-b46e-de99dce9f35d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Customer Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, one customer, Sinopharm Group Co., Ltd., accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of accounts receivable, respectively. For the year ended December 31, 2024, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of total revenue respectively. For the year ended December 31, 2023, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of total revenue respectively. All customers are located in the PRC.&lt;/span&gt;&lt;/p&gt;</gyre:ConcentrationOfCustomerRiskPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_33eee6f7-6eb9-4629-b3ef-0ea7887030bf"
      decimals="3"
      id="F_919c4626-b660-491a-b41f-f996d8c0e853"
      unitRef="U_pure">0.543</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_9f12cb44-8040-49a1-9b9e-a0f0137410fb"
      decimals="3"
      id="F_bfbf1723-1313-4e28-a92c-c19c36a1b0fb"
      unitRef="U_pure">0.505</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_a8369019-ac43-4387-8220-f7bb3505e614"
      decimals="3"
      id="F_34e98bf7-83a1-4056-8cda-d5af973f848f"
      unitRef="U_pure">0.485</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_eeacae0c-b05c-49e6-aa94-3ba172e663e7"
      decimals="3"
      id="F_1955eaa6-6f5d-436a-be0c-8aa306f6c69d"
      unitRef="U_pure">0.136</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_5e5fdd9a-b6de-418c-9820-744eb3b5f73c"
      decimals="3"
      id="F_69b9b503-32f5-4003-ae3f-f9c7718d33a0"
      unitRef="U_pure">0.106</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_b35aebfe-1f39-4446-b3d0-8ed57d7c18ed"
      decimals="3"
      id="F_59cc14c0-c92d-4b19-8acd-c35d94f0d147"
      unitRef="U_pure">0.501</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_f461bd8b-ec0e-46ff-8dbd-7d23531e4b91"
      decimals="3"
      id="F_0d09dd4f-d0da-41be-a006-8efb3d10822f"
      unitRef="U_pure">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_534c0221-d2f9-4713-8a7c-b850a4689dc4"
      decimals="3"
      id="F_af9faea2-7da8-488f-b89b-86b496abd1e5"
      unitRef="U_pure">0.112</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_14745b4e-6568-4337-8fd7-ba7b507540df">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash equivalents includes cash on hand, demand deposits and money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_bab91892-5c57-4668-93aa-1130901360d1">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_a720e31c-8f38-4976-b78b-3411e77e7d91">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;and Note 13 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for additional information regarding the CVR derivative liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives>
    <gyre:PreferredStockWarrantsPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_4c795b02-a29c-4b40-8004-63735e09ba06">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase shares of the Convertible Preferred Stock (&#x201c;Preferred Stock Warrants&#x201d;) are freestanding financial instruments classified as warrant liability on the Company&#x2019;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#x2019;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</gyre:PreferredStockWarrantsPolicyTextBlock>
    <gyre:ConvertiblePreferredStockPolicyPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_dc406a2f-27d8-4d93-a7bb-0e9355ef2fdb">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, to account for the Convertible Preferred Stock. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</gyre:ConvertiblePreferredStockPolicyPolicyTextBlock>
    <gyre:LongTermCertificatesOfDepositPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_37839fee-ef40-4ac9-865a-ef18aa96c2b9">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long-term Certificates of Deposit&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The long-term certificates of deposit will mature between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;J&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;anuary&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;effective interest method. The Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; allowance for credit losses associated with the certificates of deposit as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and 2023.&lt;/span&gt;&lt;/p&gt;</gyre:LongTermCertificatesOfDepositPolicyTextBlock>
    <gyre:Long-TermCertificatesOfDepositMaturityDateRangeStart
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ccf9684e-a6e4-4213-b55f-9f18f4778c41">2026-01</gyre:Long-TermCertificatesOfDepositMaturityDateRangeStart>
    <gyre:Long-TermCertificatesOfDepositMaturityDateRangeEnd
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ba75ac6b-26b1-4b04-b947-027516df8c44">2027-04</gyre:Long-TermCertificatesOfDepositMaturityDateRangeEnd>
    <gyre:AllowanceForCreditLossesCertificatesOfDeposit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_146839d9-6d85-4f84-bac6-f299e7024730"
      unitRef="U_USD">0</gyre:AllowanceForCreditLossesCertificatesOfDeposit>
    <gyre:AllowanceForCreditLossesCertificatesOfDeposit
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_9782ac43-6dbc-4f78-ba63-48dcdf12fb43"
      unitRef="U_USD">0</gyre:AllowanceForCreditLossesCertificatesOfDeposit>
    <gyre:ShortTermBankDepositsPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_c43f1780-9f65-4abe-a399-21fb7ad086e5">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short-term Bank Deposits&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The short-term bank deposits will mature between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;January 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. Short-term bank deposits consist of bank deposits with original maturities of one year or less, and long-term deposits that have a remaining maturity of less than one year. These deposits are recorded at amortized cost. Interest income from these deposits is recognized and reported within interest income. The Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; allowance for credit losses associated with the short-term certificates of deposit as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</gyre:ShortTermBankDepositsPolicyTextBlock>
    <gyre:Short-TermBankDepositsMaturityDateRangeStart
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_fa450738-7a1d-4b7e-bc5b-64fc138d762c">2025-01</gyre:Short-TermBankDepositsMaturityDateRangeStart>
    <gyre:Short-TermBankDepositsMaturityPeriodEnd
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_58facf9d-4b54-4386-960b-986e539eb80d">2025-12</gyre:Short-TermBankDepositsMaturityPeriodEnd>
    <gyre:AllowanceForCreditLossesShort-TermCertificatesOfDeposit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_e3c0bac2-ceef-4fc4-b15c-37f508484ed5"
      unitRef="U_USD">0</gyre:AllowanceForCreditLossesShort-TermCertificatesOfDeposit>
    <gyre:AllowanceForCreditLossesShort-TermCertificatesOfDeposit
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_c7f3ba5d-a5e1-45d0-bc58-d447fe53376d"
      unitRef="U_USD">0</gyre:AllowanceForCreditLossesShort-TermCertificatesOfDeposit>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_3bbe23ea-c6ca-4801-8b38-0f8af4d49438">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long-Term Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#x201c;GCBP&#x201d;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for additional information regarding the long-term receivable.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <gyre:LongTermInvestmentsPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ef181d53-1b2c-4545-908a-ac556fb7c948">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long-term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise more than minor influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC Topic 323, Investments&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Method and Joint Ventures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 323&#x201d;). Under the equity method, the Company initially records its investments at fair value. The Company subsequently adjusts the carrying amount of the investment to recognize the Company&#x2019;s proportionate share of the equity investee&#x2019;s net income or loss after the date of investment. The Company evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; impairment charge was recognized for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</gyre:LongTermInvestmentsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="INF"
      id="F_80046989-beb5-45c4-92e0-374745270a57"
      unitRef="U_USD">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="INF"
      id="F_199ad78c-ffea-4069-ae20-887f473e2d27"
      unitRef="U_USD">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_b877b63d-b045-4e22-a582-9778de7bdb95">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts and Note Receivables, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#x2019;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#x2019;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:61.012%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.463%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Note receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts and note receivables, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes in the allowance for credit losses as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:61.012%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:18.462999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.203000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Provision for allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Recoveries collected and write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ff2b2e02-3955-4ef9-b537-2b2f6782d537">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:61.012%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.463%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Note receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts and note receivables, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_91aa1224-94bf-4d9e-a5f7-9163488d84ec"
      unitRef="U_USD">19798000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_8a858bf4-0209-4a40-942f-b3e39ee93211"
      unitRef="U_USD">15204000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_abb4f2cc-8ef3-41f0-baaf-65e89abf4416"
      unitRef="U_USD">4373000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_28ab2262-aad9-4184-971a-c6e90f0cfd41"
      unitRef="U_USD">389000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_f10e3457-55bb-483c-8d8c-67c73194ec7a"
      unitRef="U_USD">209000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_b59df5af-7678-4866-bd40-a20f7b9aac96"
      unitRef="U_USD">41000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_3eae3b02-e470-4632-8c06-929c29d8e4f1"
      unitRef="U_USD">23962000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_96cea72a-b05a-4f4d-bf1d-eae7ad0ae482"
      unitRef="U_USD">15552000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_61536b80-58ef-48cb-ade7-b3184586d632">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes in the allowance for credit losses as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:61.012%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:18.462999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.203000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Provision for allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Recoveries collected and write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_5b902f76-74b9-4960-bf60-9a6e909718fe"
      unitRef="U_USD">41000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf"
      decimals="-3"
      id="F_8932fd5d-0eeb-41b8-8346-89b9968bd8e2"
      unitRef="U_USD">124000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <gyre:AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_5603cb3c-4f4a-480b-b816-8a27193c52e1"
      unitRef="U_USD">177000</gyre:AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_dfc53bf8-575e-48f8-8887-653759a0d32a"
      unitRef="U_USD">7000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_be49fbf3-46e3-4a6a-88c8-ecaed20a6d9e"
      unitRef="U_USD">82000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_868a8d55-a0df-48f0-ae50-63ff89bf2afc"
      unitRef="U_USD">2000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_aaa9e725-2586-4546-ad01-5a150ba84e0a"
      unitRef="U_USD">1000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_1f284843-b305-4718-b7ab-f39070b0ada1"
      unitRef="U_USD">209000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_5703e978-7faf-4b51-83b6-99ee2be1583d"
      unitRef="U_USD">41000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_d71b6ad2-e633-45ca-9300-7cfe89c8de21">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inventories, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_360861cf-69fd-4c36-8f7b-7c20ba3fae4c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:58.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_df845163-9662-4f0f-9d15-2572001b1a8c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of the estimated useful life or the term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;
        &lt;table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:58.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_1fe4d6c7-08d0-4e6e-a7f7-8be9d5e87fcb">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:58.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_df845163-9662-4f0f-9d15-2572001b1a8c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of the estimated useful life or the term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;
        &lt;table style="margin-left:5.204%;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:58.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_bd730111-0947-4496-be1e-82bb97c3ba65"
      id="F_19072842-fdd0-40c0-9160-19e2f3dfcd65">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_8004e979-5c0a-4003-aa51-99ebad904782"
      id="F_82006d65-a365-4fc9-bd46-c4635f567efa">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_6b620358-0d22-4e17-b10f-f5fdca4687e7"
      id="F_61b7bd86-535c-4f71-9d43-7e2d5263b7db">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f824d5e7-e950-4dec-bbd8-25ddc7864eac"
      id="F_d33af5a4-3af3-4591-a49e-5a1195b15b09">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_845d0f12-d806-4911-8fda-490329d00ecd"
      id="F_e91b36bf-124c-48f9-b724-81113272bda7">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_3cc0872f-8c3c-4dc7-ae6b-0b2043d6351e"
      id="F_684bbdb1-617a-4eee-bd3b-d07cc40755f2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_75e8697e-8557-4795-a758-27f2b4bd196b"
      id="F_fd749efc-4973-4193-b1dd-5603eb9545a1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f5133705-2d68-4e8e-84cd-45bc68a7fcf0"
      id="F_a74413ed-53b6-46fe-8019-ae9d22631635">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_30397301-6cf0-445b-a407-78a6f158aa72">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents, technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Nonrefundable advance payments for intangible assets are capitalized in &#x201c;other assets, noncurrent&#x201d; and will be recognized as intangible assets when the Company obtains the control of the underlying asset. As of December 31, 2024, the Company had paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million to obtain the drug registration certificate for nintedanib and the advance payment was included in &#x201c;other assets, noncurrent&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patents and Technological Know-How&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Computer Software&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_e144250a-53d1-44d0-abc4-0e596d38ecb8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_633ddd1f-a039-4123-9114-cccec8ff95e8"
      unitRef="U_USD">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_5b26b6c7-7509-44ec-b688-6724fcb64480"
      id="F_5163b8ea-25ec-4372-aee0-a30c4ad4680f">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_3e003906-a6c6-4531-9eea-29f5b509e2c5"
      id="F_321a6041-97b1-4167-b7fb-766c1885690d">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_981aaa53-b42e-4ad1-b13e-8a794b24f312"
      id="F_5caa1626-a280-4726-87c0-46ea2b5fcc77">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_01e5312a-15f5-4c24-adef-1da4d9d4a0f3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#x2019;s leases do not contain any residual value guarantees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <gyre:LandUseRightsPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_524d3452-da8d-4ad7-99e5-4bd6fd2d6186">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Land Use Rights, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.&lt;/span&gt;&lt;/p&gt;</gyre:LandUseRightsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_d2874ed6-a912-426b-850d-79661073e2f5">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair valu&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;t record any impairment of long-lived assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="INF"
      id="F_63759f48-2605-456b-ae96-00ba486c0ed6"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="INF"
      id="F_24612923-57a6-4df1-8556-18b6cc9b6ffd"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_59bb2782-f2cb-458f-bead-c93aa8f507a9">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Tax Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_3f6e4247-d87d-4f8c-89bb-ebe32de996eb">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company records revenue in accordance with ASC Topic 606 (&#x201c;ASC 606&#x201d;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#x2019;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sale of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer upon delivery of the underlying products.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;t recognize any contract assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_04d9e374-4180-45f5-a59d-cc569aacaec2"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_4cb725cd-ecad-4460-8954-a79107d0ad71"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_d4a5e62b-15aa-456f-903f-4213dd81b462">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities are recognized when the payments are received from customers before the Company transfers the related goods or services. Contract liabilities are recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the Company&#x2019;s Contract liability balance was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. Contract liability balance was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2023 which has been recognized as revenue during the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="0"
      id="F_5f05d883-5bcd-47c8-bede-7cc79514a821"
      unitRef="U_USD">61000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="0"
      id="F_dcc86c59-081c-43ce-b89e-066c4fddb992"
      unitRef="U_USD">39000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_d244fde1-7ade-41d1-99d6-3ddf1c4cdf76">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cost of Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_8c2b188e-ebdb-45f3-acb8-27abc3c70301">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#x2019;s assumptions regarding a number of variables including the fair value of its Common Stock, its expected Common Stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_9f06b436-a54e-448b-9251-281a04c8f5ab">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;amp;D with no alternative future use is&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;charged to expense at the acquisition date. Refer to Note 7 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;GNI USA Contributions under the Business Combination Agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for a more detailed description.&lt;/span&gt;&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_19613377-14f2-449d-80dc-20dba9606b2d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <gyre:SellingAndMarketingExpensesPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_8c82a61c-d096-4ae4-9e5a-a46d5865e4ac">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Selling and Marketing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</gyre:SellingAndMarketingExpensesPolicyTextBlock>
    <gyre:GeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_7256902b-fc28-4758-a032-0632882198bf">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.&lt;/span&gt;&lt;/p&gt;</gyre:GeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_c5d25d99-b08a-46b2-adbe-56128bf889e7">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Advertising Cost&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Advertising costs are expensed when incurred. Such costs approximated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; for the 2024 and 2023 fiscal years, respectively. Advertising costs are included in selling expenses on the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_229efdee-ce2e-4330-a246-b89520dc8452"
      unitRef="U_USD">10700000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_2f75d96d-c1e9-4440-8c6b-c8f993f32675"
      unitRef="U_USD">10500000</us-gaap:AdvertisingExpense>
    <us-gaap:GovernmentAssistancePolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_d0c121ff-3c16-42f9-8681-37f6191468b4">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Government Grants&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying amount of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <gyre:InterestIncomePolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_e28e8471-41ce-4d93-b0dc-ef7888e1d527">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interest Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.&lt;/span&gt;&lt;/p&gt;</gyre:InterestIncomePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_679215b5-aedc-470c-8ec6-4eed44175686">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_541be587-e6c9-409d-a41d-3403c86671af">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Income (Loss) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Per Share (&#x201c;EPS&#x201d;) Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 260&#x201d;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#x2019;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#x2019;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;EPS &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for more information.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_07cd173b-40e6-4825-877f-48193e6d91bf">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Translation and Remeasurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of Gyre Pharmaceuticals is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Matters&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The Company uses the U.S. Dollar as its reporting currency.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive income (loss). During the years ended December 31, 2024 and December 31, 2023, the Company had translation loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of operations and comprehensive income (loss). The foreign currency transaction gains or losses for the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;were immaterial.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_2b93c6b5-759e-43c7-8f27-435e036edb7e"
      unitRef="U_USD">-1500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_5a44826b-8b15-4358-812b-7d7f8a8f3100"
      unitRef="U_USD">-1500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <gyre:ForeignCurrencyRiskPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_94c89ae7-0bb2-45d5-acd4-95379e2d12db">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#x2019;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of the Company&#x2019;s cash and cash equivalents, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of the Company&#x2019;s short-term bank deposits and long-term certificates of deposit as of December 31, 2024 in the amount of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, respectively, were denominated in RMB.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</gyre:ForeignCurrencyRiskPolicyTextBlock>
    <gyre:PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="3"
      id="F_47d9df1d-0a7e-4ddc-a06f-19caeee4bcff"
      unitRef="U_pure">0.624</gyre:PercentageOfCashAndCashEquivalentsReportingCurrencyDenominated>
    <gyre:PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="3"
      id="F_65dd12a9-3199-40aa-b9c0-3e3b81a10efc"
      unitRef="U_pure">1</gyre:PercentageOfShortTermBankDepositsAndLongTermCertificatesOfDepositReportingCurrencyDenominated>
    <gyre:CashAndCashEquivalentsReportingCurrencyDenominatedValue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_dd2f11b2-1e69-45da-927b-e2ce6b6c4a6e"
      unitRef="U_USD">7400000</gyre:CashAndCashEquivalentsReportingCurrencyDenominatedValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_9aefe8fa-1936-4e04-9a6f-69354bd85a37"
      unitRef="U_USD">14900000</us-gaap:ShortTermInvestments>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_38c0a103-7d26-465e-8e72-01ae863ed954"
      unitRef="U_USD">24600000</gyre:LongTermCertificatesOfDeposit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_2766eb95-7edd-4ec8-bacb-3b92e4ab4d87">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures (Topic 280)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; this standard as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The adoption of this ASU did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;not &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;have any material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_650b198d-ed03-434f-8873-424e5a2b6569"
      id="F_861ba113-7ddc-46c9-8565-833c94e573a4">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_650b198d-ed03-434f-8873-424e5a2b6569"
      id="F_03a71367-7883-47d1-aa9c-f13a4e980f0c">2024-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_650b198d-ed03-434f-8873-424e5a2b6569"
      id="F_4f702f53-9561-4893-b1f9-051d59a63503">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <gyre:NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_fcf2b118-e921-4be5-b269-14bb43b41c39">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#x2019;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. ASU 2023-06 modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. Because of the variety of Topics amended, a broad range of entities may be affected by one or more of those amendments. Many of the amendments allow users to more easily compare entities subject to the SEC&#x2019;s existing disclosures with those entities that were not previously subject to the SEC&#x2019;s requirements. Also, the amendments align the requirements in the Codification with the SEC&#x2019;s regulations. For entities subject to the SEC&#x2019;s existing disclosure requirements and for entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. The amendments in this update should be applied prospectively. For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is currently evaluating the potential impact this standard will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of Income Statement Expenses (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The ASU requires the disaggregated disclosure of specific expense categories, including purchases of inventory, employee compensation, depreciation, and amortization, within relevant income&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;statement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;captions. This ASU also requires disclosure of the total amount of selling expenses along with the definition of selling expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU can either be applied prospectively to consolidated financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the consolidated financial statements. Early adoption is also permitted. This ASU will likely result in the required additional disclosures being included in our consolidated financial statements, once adopted. The Company is currently evaluating the provisions of this ASU.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;</gyre:NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_1b13f7e5-42a7-45a3-89f1-5f25cf679d1a">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;For a description of the fair value hierarchy and fair value methodology, see Note 2 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2024, the Company&#x2019;s highly liquid money market funds are included within cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Warrant liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Warrant liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The carrying amounts of cash, accounts and note receivables, net, other receivables, accounts payable, due to related parties, CVR excess closing cash payable, and accrued liabilities approximate their fair values due to their short maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024 and 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; transfers of fair value measurement between Level 1 and Level 2 and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; transfers into or out of Level 3 for both financial assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Receivable from GCBP and CVR Derivative Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The receivable from GCBP and the corresponding CVR derivative liability relate to the asset purchase agreement with GCBP. The fair value of this receivable and derivative liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;These unobservable inputs include the probability of GCBP meeting its contractual payment obligations, the timing of cash flows, and the expected recovery rate of the receivable. The estimation process incorporates GCBP&#x2019;s financial condition and market conditions that could impact its ability to fulfill obligations. Additionally, the selection of the discount rate (currently estimated at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%) may fluctuate over time&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The estimated fair value of the receivable from GCBP and CVR derivative liability was determined based on the anticipated amount and timing of projected cash flows to be received from GCBP pursuant to the GCBP asset purchase agreement discounted to their present values using an estimated discount rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2024, the Company expects to receive a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; hold-back payment from GCBP in the first quarter of 2025, which will be distributed, net of expenses, to the CVR Holders. The change in fair value of the receivable from GCBP and the corresponding CVR derivative liability was recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In October 2023, Catalyst entered into a Securities Purchase Agreement for a private placement with GNI USA (the &#x201c;Private Placement&#x201d;). The Private Placement closed immediately following the Contributions on October 30, 2023. Upon closing of the Private Placement, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Convertible Preferred Stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; Preferred Stock Warrants to purchase shares of Convertible Preferred Stock t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;o GNI for an aggregate purchase price of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The Preferred Stock Warrants are immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,915.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; per share of Convertible Preferred Stock and expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;October 30, 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;he number of shares of Common Stock issuable upon exercise and conversion of the Preferred Stock Warrants is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The Company accounted for the Private Placement as a non-arm's length transaction. The Preferred Stock Warrants were initially recognized at fair value upon issuance and the remaining proceeds from the Private Placement were allocated to the Convertible Preferred Stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Preferred Stock Warrants are freestanding financial instruments classified as a warrant liability on the Company&#x2019;s consolidated balance sheet. The fair value of the Preferred Stock Warrants is subject to uncertainty due to unobservable inputs, including the expected volatility of the Company&#x2019;s stock price, the likelihood of warrant exercise, and the estimated term of the warrants. Since there is limited market activity for the Preferred Stock Warrants, their fair value is determined using an option pricing model, which incorporates subjective inputs such as the Company&#x2019;s stock price volatility, derived from historical and peer company data, as well as management&#x2019;s expectations regarding future performance. As these assumptions evolve due to market conditions or company specific factors, the warrant liability may experience fluctuations. The Preferred Stock Warrants are revalued each reporting period with the change in fair value recorded as change in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The fair value of the warrant liability is estimated based on th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;e Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.620000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,915.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level 3 financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.625%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Additions in the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and held-to-maturity debt securities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Money market funds  (cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Short-term bank deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Short-term bank deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.951%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.318%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.438%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.778%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.118%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Money market funds  (cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The fair value and amortized cost of the Company's held-to-maturity debt securities and redemption date were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Due in one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Due in one to five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest income from the short-term bank deposits is recognized on an accrual basis over the term of the deposits. The accrued interest income for the periods ended December 31, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest income from the long-term certificates of deposit is recognized on an accrual basis over the term of the deposits. The accrued interest income for the periods ended December 31, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_e8e50f0e-0dfb-46f5-abb5-1ab8233f7a91">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Warrant liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-family:'Aptos',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Warrant liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8b6f77fc-9f62-4a56-a8a3-60296e884fd5"
      decimals="-3"
      id="F_dff57515-4ec1-4c6d-a74d-b8260899ca74"
      unitRef="U_USD">3300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a90606c8-9443-4792-8781-57608b6e4e3e"
      decimals="-3"
      id="F_0cd5dd56-b36a-4418-98f9-f68c6f07ae41"
      unitRef="U_USD">3300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b4a86beb-1787-4bb4-bd49-dbe2b1f05f54"
      decimals="-3"
      id="F_928d0d09-a913-44f3-b5b9-b82f42ece371"
      unitRef="U_USD">4961000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6d30a83a-d0f3-4ca4-b55e-76c959f4075c"
      decimals="-3"
      id="F_f0c068a4-1a80-40e9-be02-eb106d35d7f9"
      unitRef="U_USD">4961000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e9706bd6-a8ea-4e15-9d5b-2d51ea3a4538"
      decimals="-3"
      id="F_381e9a79-f9de-4145-9b77-4421b09fe309"
      unitRef="U_USD">3300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b0da0539-7026-4894-ad23-631ed2889b06"
      decimals="-3"
      id="F_f741d829-9914-4635-bfc5-62c9af5b1cc0"
      unitRef="U_USD">4961000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_8fd378d0-8c64-4b11-a672-03e92ce0f898"
      unitRef="U_USD">8261000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_ae06bf9f-4849-4d7c-b764-bdd92fb5df72"
      decimals="-3"
      id="F_b984e886-2e9c-4155-9c8f-46e93ed8fc8b"
      unitRef="U_USD">4961000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_6d9205fa-fd4f-4d6d-be1a-9d6b1b8e9900"
      decimals="-3"
      id="F_f12b0598-35bf-49a5-9281-6bf2ec846a6e"
      unitRef="U_USD">4961000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_68a0f639-5b32-411d-b8ae-3d27cfa51531"
      decimals="-3"
      id="F_06026020-a383-4d14-9c89-ccb9f09d0aa3"
      unitRef="U_USD">5668000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_3bcf2b7f-ee59-442c-b6bd-34c12861eac8"
      decimals="-3"
      id="F_afe9dff5-a14f-4d94-b05d-8a6a25116fe1"
      unitRef="U_USD">5668000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_b0da0539-7026-4894-ad23-631ed2889b06"
      decimals="-3"
      id="F_131d89ac-5a3b-433f-b9eb-0fc796b3a740"
      unitRef="U_USD">10629000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_e90b621a-10e4-4343-9f3c-a7e4a52d4662"
      unitRef="U_USD">10629000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a34646ab-b257-4cc5-aaa5-c6130d624d7f"
      decimals="-3"
      id="F_663fdca3-38c0-48b4-8ee3-3c286855998b"
      unitRef="U_USD">5860000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_90704b89-2d95-4695-898f-ba265baa62ee"
      decimals="-3"
      id="F_14a49538-f42e-4f2b-b92e-6ef1dbdfc000"
      unitRef="U_USD">5860000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f1739194-98a6-4fa5-9476-50a472bbd7b0"
      decimals="-3"
      id="F_215fd13c-3c2d-4785-aa5a-ff296a4c62cd"
      unitRef="U_USD">4722000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d4414f45-2440-4efe-b9f6-4316754c428f"
      decimals="-3"
      id="F_78561435-641b-45ee-aca0-d2df3fdc29b4"
      unitRef="U_USD">4722000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5e72f9e3-7599-472f-92ab-fa429b264f71"
      decimals="-3"
      id="F_723bfe9f-e311-4240-95a2-d5600e71f8ae"
      unitRef="U_USD">5860000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_77b7dffb-7a31-4205-a9eb-98bee99e2a4b"
      decimals="-3"
      id="F_5193e3eb-c2f4-403d-ba76-84e6bcfce396"
      unitRef="U_USD">4722000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_cd5f8916-aa25-41f1-9525-188212146ae8"
      unitRef="U_USD">10582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_e9d4eda1-e8b4-4878-b3ba-046acdcd7131"
      decimals="-3"
      id="F_f50acf29-4ed5-4df0-be52-30ef0433f35e"
      unitRef="U_USD">4722000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_8d6b27d0-681a-4b5e-86bf-4e37f3785874"
      decimals="-3"
      id="F_46e10bbf-4aba-494a-8d5a-37dc2ac24661"
      unitRef="U_USD">4722000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_d274c80b-8c06-41ed-bb58-3a6d5311414f"
      decimals="-3"
      id="F_5cf0d455-b9d9-40a3-9002-3b29f9c02232"
      unitRef="U_USD">12835000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_ecfde2db-6b97-4952-8c3e-f7202cd08598"
      decimals="-3"
      id="F_b7fa37ef-dfe8-4ca5-976c-49baef604f2f"
      unitRef="U_USD">12835000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_77b7dffb-7a31-4205-a9eb-98bee99e2a4b"
      decimals="-3"
      id="F_e305647c-e796-4ad5-8e98-c567796d0ad9"
      unitRef="U_USD">17557000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_6553ac65-6017-4ddc-9e61-61894a2ca1d6"
      unitRef="U_USD">17557000</us-gaap:LiabilitiesFairValueDisclosure>
    <gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_6cd1d25f-3914-465b-b512-661493fee8ee"
      unitRef="U_USD">0</gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount>
    <gyre:FairValueAssetsAndLiabilitiesLevel3TransfersAmount
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_c6e2c04c-6c0a-462d-90e1-8be2a691c5fd"
      unitRef="U_USD">0</gyre:FairValueAssetsAndLiabilitiesLevel3TransfersAmount>
    <us-gaap:DerivativeAssetMeasurementInput
      contextRef="C_c72b6ba0-b44d-464c-8103-3b7702656381"
      decimals="4"
      id="F_e50b37aa-59d8-4116-8c6f-1f4488511241"
      unitRef="U_pure">0.0505</us-gaap:DerivativeAssetMeasurementInput>
    <us-gaap:DerivativeAssetMeasurementInput
      contextRef="C_c72b6ba0-b44d-464c-8103-3b7702656381"
      decimals="4"
      id="F_bc9f3f6b-a178-4f9c-b7bf-2545313072a3"
      unitRef="U_pure">0.0505</us-gaap:DerivativeAssetMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_a56d2451-275e-4c7f-95db-b89dd45a7915"
      decimals="4"
      id="F_a863672b-a8f5-4e55-9411-e6c8ef6bf9e5"
      unitRef="U_pure">0.0505</us-gaap:DerivativeLiabilityMeasurementInput>
    <gyre:AmountToBeReceivedUnderAgreement
      contextRef="C_a8d02e48-8b97-4471-b7d2-9b754e3a60ee"
      decimals="-5"
      id="F_c9b2e25d-1d11-4e86-9001-05c71f10caeb"
      unitRef="U_USD">5000000</gyre:AmountToBeReceivedUnderAgreement>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f0a09c76-9e8a-4c61-b540-701ad6b7648e"
      decimals="INF"
      id="F_daebdc22-0116-4113-8bbe-ebe700319eac"
      unitRef="U_shares">811</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_12c92d66-d545-47dd-8492-bf82d190b61c"
      decimals="0"
      id="F_d7afc566-4507-47e4-bd5a-34a380b2f4b1"
      unitRef="U_shares">811</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_ea5bb34e-9257-4104-825f-20adf13f8344"
      decimals="-5"
      id="F_40550603-ecdb-433e-8d34-41927f3fa056"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_12c92d66-d545-47dd-8492-bf82d190b61c"
      decimals="2"
      id="F_35619202-6534-4bba-ba9a-67fb62e0d15c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4915</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_12c92d66-d545-47dd-8492-bf82d190b61c"
      id="F_dc85b8f5-bb6a-488f-9858-6372befb145a">2033-10-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <gyre:NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants
      contextRef="C_12c92d66-d545-47dd-8492-bf82d190b61c"
      decimals="INF"
      id="F_d17a89b4-7f0d-45c8-80ba-325594d18af5"
      unitRef="U_shares">540666</gyre:NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_192f5052-5bbe-4f8e-9fee-788ff093daeb">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The fair value of the warrant liability is estimated based on th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;e Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.620000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,915.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <gyre:WarrantsSharePrice
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="1"
      id="F_7b9c83dd-9942-4e76-8e87-54db97ab66c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.1</gyre:WarrantsSharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="2"
      id="F_7c018188-25de-4bab-bd5b-bd074f688015"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4915</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_02538a53-cecd-41e8-aa82-e8efb664750a"
      decimals="2"
      id="F_4a286995-1ef3-443f-ab4d-9f8da0c9ad8e"
      unitRef="U_pure">4.54</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      id="F_a18cb9f2-2385-49dd-a12e-d72ef729f3cd">P8Y9M29D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_ed398fbe-2209-4cef-89f5-4af5eb6bb183"
      decimals="2"
      id="F_d3864886-c38c-4e20-950e-a21b47fd3e9a"
      unitRef="U_pure">83</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_72de72cf-487f-499a-8700-4ebe8c8aed85">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level 3 financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.625%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Additions in the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="C_3ea2f2ca-4eb5-48e9-9b14-30c3e9e2d1ef"
      decimals="-3"
      id="F_6a086b1d-0666-4b79-8f51-284c28c50ac1"
      unitRef="U_USD">4683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="C_254f82e6-b517-47d8-aa5e-0e78e7d7e7fe"
      decimals="-3"
      id="F_ebd868d3-d928-4220-a3d4-cc8182caebe6"
      unitRef="U_USD">4683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="C_5037ba80-7341-4533-b5cb-88a46c19f3b0"
      decimals="-3"
      id="F_8e5f2e03-193e-4e7b-8869-e828a02c9168"
      unitRef="U_USD">3574000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="C_3ea2f2ca-4eb5-48e9-9b14-30c3e9e2d1ef"
      decimals="-3"
      id="F_4a8323a9-5c21-4fcf-8a32-b000c85691c2"
      unitRef="U_USD">39000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_254f82e6-b517-47d8-aa5e-0e78e7d7e7fe"
      decimals="-3"
      id="F_289372f0-7c7e-4618-bd80-cb8292af369c"
      unitRef="U_USD">39000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_5037ba80-7341-4533-b5cb-88a46c19f3b0"
      decimals="-3"
      id="F_fed4ca6b-0250-4c08-a786-9a39fd706bb0"
      unitRef="U_USD">9261000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_d4414f45-2440-4efe-b9f6-4316754c428f"
      decimals="-3"
      id="F_c4a4352b-4ad1-47f5-baef-a1c8da8bce43"
      unitRef="U_USD">4722000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_8d6b27d0-681a-4b5e-86bf-4e37f3785874"
      decimals="-3"
      id="F_c250b83f-7b03-450d-b08f-f5f444a1dd2a"
      unitRef="U_USD">4722000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_ecfde2db-6b97-4952-8c3e-f7202cd08598"
      decimals="-3"
      id="F_9a97a15f-9291-4feb-8abc-4dfea89e519f"
      unitRef="U_USD">12835000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="C_6c54312b-5d11-479d-8137-af33dda8c109"
      decimals="-3"
      id="F_efff157a-ec7b-48d3-8a3c-5b821ed99af0"
      unitRef="U_USD">239000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_c44dd11e-3d19-4a70-8872-8c9259134b11"
      decimals="-3"
      id="F_8dd9fbb1-2bf8-45f3-a793-591ccb4b26a9"
      unitRef="U_USD">239000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_6e3414eb-e1eb-461f-b6f5-48348df952e9"
      decimals="-3"
      id="F_830944d5-c8b6-46fa-95d6-db3c2e20987b"
      unitRef="U_USD">-7167000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_6d30a83a-d0f3-4ca4-b55e-76c959f4075c"
      decimals="-3"
      id="F_20d5ea71-e115-4cb7-b2b8-1e2515172178"
      unitRef="U_USD">4961000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_6d9205fa-fd4f-4d6d-be1a-9d6b1b8e9900"
      decimals="-3"
      id="F_35e7f0f6-76ed-4c5a-83ef-764225303423"
      unitRef="U_USD">4961000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_3bcf2b7f-ee59-442c-b6bd-34c12861eac8"
      decimals="-3"
      id="F_923213ba-536d-4c04-be3a-b834fc2afdc0"
      unitRef="U_USD">5668000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_051312fa-60c3-4cde-b8e8-db758a0763c8">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and held-to-maturity debt securities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Money market funds  (cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Short-term bank deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Short-term bank deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.951%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.318%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.438%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.778%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.118%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Money market funds  (cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c664e54d-79f7-479e-871b-a1086f9e1e55"
      decimals="-3"
      id="F_fbe451da-c42d-4876-b12b-686e3e6db255"
      unitRef="U_USD">3300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c664e54d-79f7-479e-871b-a1086f9e1e55"
      decimals="-3"
      id="F_4d514dd2-c944-4a2c-8cad-d19e67afa32c"
      unitRef="U_USD">3300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_625ba7b4-bbf9-4cd1-b581-60e547a6e52a"
      decimals="-3"
      id="F_28e6ea82-35fd-4856-bb21-05d2b526f747"
      unitRef="U_USD">14858000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_625ba7b4-bbf9-4cd1-b581-60e547a6e52a"
      decimals="-3"
      id="F_57e394ee-dc6e-4d07-8830-0c088f9fcf9f"
      unitRef="U_USD">14858000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_196fe3c5-bc8a-4a5f-a84e-6cbf8da6bc14"
      decimals="-3"
      id="F_9b0cd26b-1a1b-4ca6-9ad0-268e7c3cef5d"
      unitRef="U_USD">24568000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_196fe3c5-bc8a-4a5f-a84e-6cbf8da6bc14"
      decimals="-3"
      id="F_1e655cf9-196d-47b0-93f7-af5ab2be2017"
      unitRef="U_USD">24568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_a0699a27-0572-4dbe-8ee5-bfd4b234383c"
      unitRef="U_USD">42726000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_973f9e78-3ba3-440a-8626-fc0dea14bd26"
      unitRef="U_USD">42726000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8ff20dd2-fe0c-4bf5-810a-2ce783d0f15b"
      decimals="-3"
      id="F_02acb80e-44bf-4758-a9b0-3f37e789ebab"
      unitRef="U_USD">3300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_625ba7b4-bbf9-4cd1-b581-60e547a6e52a"
      decimals="-3"
      id="F_c72bfa44-d2d3-4877-82ef-d5db269ccc41"
      unitRef="U_USD">14858000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_196fe3c5-bc8a-4a5f-a84e-6cbf8da6bc14"
      decimals="-3"
      id="F_27b5c5d0-e374-4fd7-bbd6-fba7c574f1fb"
      unitRef="U_USD">24568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_fe651238-f246-436c-ad27-a9e664c59f25"
      unitRef="U_USD">42726000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_dbedf524-e39b-431f-b9b5-51f72b11b2b3"
      decimals="-3"
      id="F_9f6de45f-2178-49bb-8f44-c2f8b0c3b796"
      unitRef="U_USD">5860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_dbedf524-e39b-431f-b9b5-51f72b11b2b3"
      decimals="-3"
      id="F_4d1a51d0-e2b8-4256-bb13-9d7160a22781"
      unitRef="U_USD">5860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_72587811-89ac-4abd-97ba-a8887f54ccab"
      decimals="-3"
      id="F_650e7e84-eae6-4abb-a408-db06f98e41db"
      unitRef="U_USD">23431000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_72587811-89ac-4abd-97ba-a8887f54ccab"
      decimals="-3"
      id="F_29f9b5c1-626d-4442-8fd9-fca6ba79c921"
      unitRef="U_USD">23431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_72610c01-f8f8-47d4-9abd-3a2c697c7624"
      unitRef="U_USD">29291000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_f0194d45-3378-4b09-8ac0-f1a1ba3bd1d2"
      unitRef="U_USD">29291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_90682bfe-2026-4fd0-87b6-43c6bb28213c"
      decimals="-3"
      id="F_2f30a127-dc9b-46e9-bd18-c4cae8b0620f"
      unitRef="U_USD">5860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_72587811-89ac-4abd-97ba-a8887f54ccab"
      decimals="-3"
      id="F_2cc7465f-9a53-4f23-a71d-4cafce46c894"
      unitRef="U_USD">23431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_adec12d4-11b7-4684-8916-1d01d0c3d950"
      unitRef="U_USD">29291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_f92a98f5-4aa0-49c2-97f0-20fb2f8d9921">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The fair value and amortized cost of the Company's held-to-maturity debt securities and redemption date were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Due in one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Due in one to five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_489443db-15fb-4f6f-a27c-54baa96c908a"
      unitRef="U_USD">14858000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_dc63a0e3-746f-41f3-8050-7830c507923f"
      unitRef="U_USD">14858000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_6f0e7c77-fa85-47c4-b3cc-d737aa5dace7"
      unitRef="U_USD">24568000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_47fc98d5-cf98-4f98-806b-011decdeb6e9"
      unitRef="U_USD">24568000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_3bbe9ba9-568d-4152-8fae-cd032d4a4b69"
      unitRef="U_USD">39426000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_f4a0a67f-a0aa-4747-86af-ec28010ea01b"
      unitRef="U_USD">39426000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue>
    <gyre:AccruedInterestIncomeOnShortTermBankDeposits
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_947db538-8e15-4c81-ab7c-72e95c4cd833"
      unitRef="U_USD">400000</gyre:AccruedInterestIncomeOnShortTermBankDeposits>
    <gyre:AccruedInterestIncomeOnShortTermBankDeposits
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-6"
      id="F_df5b95f8-7d5a-4623-b10f-3f499030f326"
      unitRef="U_USD">0</gyre:AccruedInterestIncomeOnShortTermBankDeposits>
    <gyre:AccruedInterestIncomeOnLongTermCertificatesOfDeposit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_f8f0141a-3b1e-443d-9617-73d5cfbfca33"
      unitRef="U_USD">600000</gyre:AccruedInterestIncomeOnLongTermCertificatesOfDeposit>
    <gyre:AccruedInterestIncomeOnLongTermCertificatesOfDeposit
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-5"
      id="F_f111e8c1-f278-4fe3-ba75-56089af0c00c"
      unitRef="U_USD">600000</gyre:AccruedInterestIncomeOnLongTermCertificatesOfDeposit>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_84de264d-52e9-4a74-8ea7-f4d6a5b54d95">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Inventories, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Inventories, net of reserves of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2024 and 2023, respectively, consisted of the following components (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The provision for inventory and write-downs for the years ended December 31, 2024 and 2023 were immaterial.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.280000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and welfare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Payable to PPE suppliers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses - general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued sales discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Payable to selling expense suppliers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Employee reimbursement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses - research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred government grants represent funds provided by the government for research and development, construction of new facilities, or improvement of existing production facilities. The amount of deferred government grants as of December 31, 2024 and 2023, is net of the amount recognized as government grant income. During the years ended December 31, 2024 and 2023, the Company received &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million government grants, respectively. During the years ended December 31, 2024 and 2023, the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million of government grant income within other income in the consolidated statements of operations and comprehensive income (loss), respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Summarized below are deferred government grants as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Government grants for property and equipment, included in accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Current deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Government grants for property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Non-current deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million for each of the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long-Term Investment Measured Under Equity Method&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;On June 28, 2024, Gyre Pharmaceuticals entered into a partnership agreement as a limited partner with other investors and is obligated to pay $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million for an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; equity interest in the partnership. Pursuant to the partnership agreement, Gyre Pharmaceuticals, as a limited partner, shall not participate in any activities related to the management of the investment business. However, Gyre Pharmaceuticals may appoint a member to the advisory committee of the partnership. As of December 31, 2024, the Company's total investment into the partnership and the carrying value of the Company&#x2019;s long-term investment in this affiliate, which was included in &#x201c;Other assets, noncurrent&#x201d; in the balance sheet, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_f4a7d302-5e44-45ad-a98f-fbf1f40a738e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Inventories, net of reserves of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2024 and 2023, respectively, consisted of the following components (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="0"
      id="F_eb5a9493-d72e-4e31-a923-c70a0a1a9230"
      unitRef="U_USD">4000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="0"
      id="F_1960ef30-d1ee-4243-a643-61e9bf2ab2cb"
      unitRef="U_USD">46000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryRawMaterials
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_dcd396d1-d4c4-4b08-bd0e-feffc756b6d9"
      unitRef="U_USD">794000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_c270704f-f728-4ed7-91be-6036e23cdc09"
      unitRef="U_USD">919000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_8ead9634-9c39-4d2f-9185-99ea3026f031"
      unitRef="U_USD">2929000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_8a012755-feb1-485a-8cf1-2f3eb081783c"
      unitRef="U_USD">1997000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_0e49eb53-2a9f-4f09-b657-4b190219560e"
      unitRef="U_USD">2614000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_dcf2f766-e2a3-49a3-989f-cd79ead2b419"
      unitRef="U_USD">1365000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_35fd2f82-1365-40c4-98d4-bd77b9452738"
      unitRef="U_USD">6337000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_314eb9a0-4533-4bb5-bf57-b0af94ae0f87"
      unitRef="U_USD">4281000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_d3405402-544c-4725-b931-3b023683e948">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.280000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and welfare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Payable to PPE suppliers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses - general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued sales discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Payable to selling expense suppliers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Employee reimbursement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses - research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <gyre:AccruedPayrollAndWelfare
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_e3615bf5-2844-49a9-b8e8-c7877dd0465b"
      unitRef="U_USD">4765000</gyre:AccruedPayrollAndWelfare>
    <gyre:AccruedPayrollAndWelfare
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_390f7190-ab26-4ab2-9389-5ecd06802e7a"
      unitRef="U_USD">5790000</gyre:AccruedPayrollAndWelfare>
    <gyre:PayableToPropertyPlantAndEquipmentSuppliers
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_c1702929-b1bc-440e-9f0b-92a4bac8b162"
      unitRef="U_USD">1219000</gyre:PayableToPropertyPlantAndEquipmentSuppliers>
    <gyre:PayableToPropertyPlantAndEquipmentSuppliers
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_f876fdb7-6cab-4f36-a633-3dcede6df453"
      unitRef="U_USD">1336000</gyre:PayableToPropertyPlantAndEquipmentSuppliers>
    <gyre:AccruedExpensesGeneralAndAdministrative
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_3d238287-78ae-4a9c-a8ff-100c98acdf92"
      unitRef="U_USD">1005000</gyre:AccruedExpensesGeneralAndAdministrative>
    <gyre:AccruedExpensesGeneralAndAdministrative
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_1a9dfc40-e8c1-442a-a6a6-1d671022e673"
      unitRef="U_USD">1190000</gyre:AccruedExpensesGeneralAndAdministrative>
    <gyre:AccruedSalesDiscount
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_700d4d14-125a-4690-a828-e051cf410f2f"
      unitRef="U_USD">908000</gyre:AccruedSalesDiscount>
    <gyre:AccruedSalesDiscount
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_36525e1b-3ffb-4cc5-82d5-1a452189d25f"
      unitRef="U_USD">903000</gyre:AccruedSalesDiscount>
    <gyre:PayableToSellingExpenseSuppliers
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_082594c0-972e-4d5a-a00b-0e308cea20a2"
      unitRef="U_USD">900000</gyre:PayableToSellingExpenseSuppliers>
    <gyre:PayableToSellingExpenseSuppliers
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_00805867-67f3-43c8-a437-6cb2add4b6fc"
      unitRef="U_USD">820000</gyre:PayableToSellingExpenseSuppliers>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_f6360f68-cfdb-4ac3-9bda-7c250e8eda7e"
      unitRef="U_USD">737000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_56e656bd-90ef-4264-8675-0bf183a6ab99"
      unitRef="U_USD">648000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_dd91dcb0-f569-41ac-8ece-b5e59f9c4df9"
      unitRef="U_USD">667000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_32892775-ce13-4ad2-a8e0-3a20d1a9e466"
      unitRef="U_USD">837000</us-gaap:AccruedProfessionalFeesCurrent>
    <gyre:DeferredGovernmentGrants
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_8b55699c-b678-47a0-a353-df621ebda4a6"
      unitRef="U_USD">95000</gyre:DeferredGovernmentGrants>
    <gyre:DeferredGovernmentGrants
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_4e5eacaf-bd8d-43bc-8b29-fdb8b47c16b4"
      unitRef="U_USD">40000</gyre:DeferredGovernmentGrants>
    <gyre:AccruedExpensesResearchAndDevelopment
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_8bedad5a-a56f-42f0-9a37-a4d82399d4f7"
      unitRef="U_USD">57000</gyre:AccruedExpensesResearchAndDevelopment>
    <gyre:AccruedExpensesResearchAndDevelopment
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_87762dd6-6c5d-4801-8121-b144315af7d0"
      unitRef="U_USD">161000</gyre:AccruedExpensesResearchAndDevelopment>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_6a3b2453-eaa8-4073-ba41-958d4705dcdc"
      unitRef="U_USD">262000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_22afb842-1055-4dfe-be34-42fdc2feb7cc"
      unitRef="U_USD">210000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_994f862c-bcb5-4200-bab7-f1b5a1238fd3"
      unitRef="U_USD">10615000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_debc9069-12e7-4303-9687-c0233a41c081"
      unitRef="U_USD">11935000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <gyre:ProceedsFromGovernmentGrantsReceived
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_819ef035-e2e6-49b8-bb19-80c494fa57fc"
      unitRef="U_USD">900000</gyre:ProceedsFromGovernmentGrantsReceived>
    <gyre:ProceedsFromGovernmentGrantsReceived
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_8983f1e9-f86f-487e-94eb-4b79dca90c65"
      unitRef="U_USD">1100000</gyre:ProceedsFromGovernmentGrantsReceived>
    <gyre:GovernmentGrantIncomeWithinOtherIncome
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_a8d440a1-bc19-423a-8e1e-6b2b69348e10"
      unitRef="U_USD">100000</gyre:GovernmentGrantIncomeWithinOtherIncome>
    <gyre:GovernmentGrantIncomeWithinOtherIncome
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_8047fff1-46c8-4b61-a2cd-8ba91b6a4108"
      unitRef="U_USD">1000000</gyre:GovernmentGrantIncomeWithinOtherIncome>
    <gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_f4eb0f58-3b97-4b9c-acaf-a6ddaac59333">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Summarized below are deferred government grants as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Government grants for property and equipment, included in accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Current deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Government grants for property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Non-current deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock>
    <gyre:DeferredGovernmentGrantsCurrent
      contextRef="C_855a18a4-8d8c-46bf-aa53-59975edfdf20"
      decimals="-3"
      id="F_5ca1b6c4-220e-4832-9afa-b19f2b6b4a3b"
      unitRef="U_USD">95000</gyre:DeferredGovernmentGrantsCurrent>
    <gyre:DeferredGovernmentGrantsCurrent
      contextRef="C_c26605c5-09bd-4994-af5d-7d427048d643"
      decimals="-3"
      id="F_cc1c8878-584c-4ef7-94db-eca725457855"
      unitRef="U_USD">40000</gyre:DeferredGovernmentGrantsCurrent>
    <gyre:DeferredGovernmentGrantsCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_5d1382e2-ae92-4760-a37c-5b7f04c82a52"
      unitRef="U_USD">95000</gyre:DeferredGovernmentGrantsCurrent>
    <gyre:DeferredGovernmentGrantsCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_85ba76bf-cf11-4c49-b234-e62ff178e471"
      unitRef="U_USD">40000</gyre:DeferredGovernmentGrantsCurrent>
    <gyre:DeferredGovernmentGrantsNonCurrent
      contextRef="C_865d32c0-6f1c-4e0d-9ca2-0c9a24caf2cd"
      decimals="-3"
      id="F_33fe4be3-ca62-47ca-9e39-08f592875bf2"
      unitRef="U_USD">928000</gyre:DeferredGovernmentGrantsNonCurrent>
    <gyre:DeferredGovernmentGrantsNonCurrent
      contextRef="C_6cec0878-7860-4728-9cc5-0c28173f20eb"
      decimals="-3"
      id="F_1c78c82a-3e33-4f2e-ab45-dd84ab2cde68"
      unitRef="U_USD">213000</gyre:DeferredGovernmentGrantsNonCurrent>
    <gyre:DeferredGovernmentGrantsNonCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_10d26ab7-3a13-41da-8974-30dc45393cf2"
      unitRef="U_USD">928000</gyre:DeferredGovernmentGrantsNonCurrent>
    <gyre:DeferredGovernmentGrantsNonCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_904d0655-f5e9-4397-8330-a93043e8d978"
      unitRef="U_USD">213000</gyre:DeferredGovernmentGrantsNonCurrent>
    <gyre:DeferredGovernmentGrantsCurrentAndNoncurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_ae469746-dbcb-408e-939a-1ab074dbb9cb"
      unitRef="U_USD">1023000</gyre:DeferredGovernmentGrantsCurrentAndNoncurrent>
    <gyre:DeferredGovernmentGrantsCurrentAndNoncurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_7071ee10-880a-41f0-a0ba-6dfa23eda7da"
      unitRef="U_USD">253000</gyre:DeferredGovernmentGrantsCurrentAndNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_8e580160-3986-4167-b7b0-031b899eda38">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_97a869fa-0596-4ada-9896-83385642b0be"
      decimals="-3"
      id="F_4f32884f-d7ac-4d7e-a643-c98999140cb1"
      unitRef="U_USD">18980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fabc4de6-f3ea-4c14-8ab7-d36a14e5c91d"
      decimals="-3"
      id="F_9c6abc5d-034f-44c7-a65f-a81a422c518b"
      unitRef="U_USD">12289000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9e3328d4-ba00-4ce5-8265-2253f006ba54"
      decimals="-3"
      id="F_fdfb13ab-31e9-4cf6-a036-773d53772bd5"
      unitRef="U_USD">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ad2aff12-25e7-4121-b6bd-e885663b2263"
      decimals="-3"
      id="F_8b895bc2-7f69-45b7-acd3-82a23cfebec2"
      unitRef="U_USD">7875000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5e716a13-8908-4a45-90e4-2cfac3c1eeaf"
      decimals="-3"
      id="F_d8721de4-5284-4e2f-bfc4-bd2da19b460f"
      unitRef="U_USD">9442000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_33998465-47eb-4f6f-9f5b-ae8cb85bcc79"
      decimals="-3"
      id="F_c7092846-087a-44e7-886a-f8a184ef0327"
      unitRef="U_USD">6598000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_094d85c6-e458-4cfd-ad37-15cb54dd53db"
      decimals="-3"
      id="F_1265c4db-6411-4d6a-90cd-563f365a598d"
      unitRef="U_USD">653000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_990c44c7-915a-4a78-9e70-be8742ec4a8b"
      decimals="-3"
      id="F_92ced667-a6a1-4521-8cfa-dcab7cce9692"
      unitRef="U_USD">606000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_eb61462d-1632-48d9-a73a-8eefdbf9c020"
      decimals="-3"
      id="F_f3960465-4508-43e3-81e0-0b1b4d38e083"
      unitRef="U_USD">182000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_526db762-c121-4c94-bd8f-2957c39426c5"
      decimals="-3"
      id="F_37af26b8-73dd-4c13-9f82-bcfd0a76115c"
      unitRef="U_USD">185000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_ba2cd80f-590d-421f-9896-94b40960f1c7"
      unitRef="U_USD">29479000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_c706560b-14c6-414f-8cf7-cc49d84c0c54"
      unitRef="U_USD">27553000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_b1354745-b247-426e-b282-e9c08d7337e4"
      unitRef="U_USD">5599000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_567fddac-ad55-4020-af8b-ffc4cf6d1769"
      unitRef="U_USD">4265000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_10f87cf7-3db3-4ace-bead-26bcbf104708"
      unitRef="U_USD">23880000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_56cea492-10e5-4242-890e-bfeb9b717d2e"
      unitRef="U_USD">23288000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_199f3dea-5ebd-47c6-9c05-8ea0bc5e44f8"
      unitRef="U_USD">1300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_02782614-b596-4d2b-b797-ac1049e822c6"
      unitRef="U_USD">1000000</us-gaap:Depreciation>
    <gyre:InvestmentSubscriptionAmount
      contextRef="C_a6f4023f-6af1-478e-8828-c64f6e19e231"
      decimals="-5"
      id="F_b07f616f-8be2-453d-96ec-9dcc199b62ad"
      unitRef="U_USD">4200000</gyre:InvestmentSubscriptionAmount>
    <gyre:PercentageOfEquityInterest
      contextRef="C_a6f4023f-6af1-478e-8828-c64f6e19e231"
      decimals="4"
      id="F_445cac5e-43bf-441d-8463-bf673b0c4ecb"
      unitRef="U_pure">0.1893</gyre:PercentageOfEquityInterest>
    <us-gaap:EquityMethodInvestments
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_476b1123-263a-4ea1-8a95-9110b54db104"
      unitRef="U_USD">1700000</us-gaap:EquityMethodInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_b8550c29-f99b-4014-8343-c78232d39a0a"
      decimals="-5"
      id="F_63cac92f-735f-4a73-bca9-8da844aa4749"
      unitRef="U_USD">1600000</us-gaap:LongTermInvestments>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_bf86e90b-5836-4dff-9f33-a71ad841fd7d">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The gross carrying amounts and accumulated amortization of the Company&#x2019;s intangible assets with determinable lives as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.99%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.197000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.157%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Technological know-how&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Technological know-how&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets are carried at cost less accumulated amortization and impairment, if applicable, and the amortization expense is recorded in operating expenses. The weighted average amortization period for the intangible assets as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;4.04&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Amortization expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; for each of the years ended December 31, 2024, and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, respectively. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Based on finite-lived intangible assets recorded as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the estimated future amortization expense is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:85.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Estimated Amortization Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_9cb1e692-2db7-415d-bb65-2b96c63b7d7a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The gross carrying amounts and accumulated amortization of the Company&#x2019;s intangible assets with determinable lives as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.99%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.197000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.157%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Technological know-how&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Technological know-how&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_d9641dc2-ce11-4da3-92da-82b11fbc53ff"
      decimals="-3"
      id="F_0e7cf955-9029-464c-b9ac-99460e11ef58"
      unitRef="U_USD">423000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_d9641dc2-ce11-4da3-92da-82b11fbc53ff"
      decimals="-3"
      id="F_0de35761-1211-49cc-a39d-ea2ac6b7679e"
      unitRef="U_USD">303000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_d9641dc2-ce11-4da3-92da-82b11fbc53ff"
      decimals="-3"
      id="F_c86fc29d-efb7-4a1c-ba6f-0b0636104658"
      unitRef="U_USD">120000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_f5823b3d-6762-4329-9b17-efe63bdb21f4"
      decimals="-3"
      id="F_f2b486dd-afdb-4bbb-be30-1d40e4762a89"
      unitRef="U_USD">278000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_f5823b3d-6762-4329-9b17-efe63bdb21f4"
      decimals="-3"
      id="F_fa4a0372-4c50-4720-b06d-4086bba645aa"
      unitRef="U_USD">125000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_f5823b3d-6762-4329-9b17-efe63bdb21f4"
      decimals="-3"
      id="F_4b782b56-99e5-4548-bf6b-a68a4b226540"
      unitRef="U_USD">153000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_356e31a8-4840-493a-9ebf-39be1979a434"
      unitRef="U_USD">701000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_305b783c-be1d-42c9-ad8e-bd2840db6a86"
      unitRef="U_USD">428000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_7bc0c5e1-55dd-4456-bfc5-c4d377b77b62"
      unitRef="U_USD">273000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_2c09cdda-c1e5-435a-b940-ce423bcf6515"
      decimals="-3"
      id="F_b7082301-4011-4693-bccf-8544e1b33f86"
      unitRef="U_USD">430000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_2c09cdda-c1e5-435a-b940-ce423bcf6515"
      decimals="-3"
      id="F_1f1b9521-80bb-491f-814f-9bd354ab7652"
      unitRef="U_USD">290000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_2c09cdda-c1e5-435a-b940-ce423bcf6515"
      decimals="-3"
      id="F_20f9d621-566b-4183-821a-1e2abb9d804f"
      unitRef="U_USD">140000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_37337290-c4f6-4ef2-a6f7-8313d2a10b7a"
      decimals="-3"
      id="F_e0bb3513-090b-4cf4-8fae-e03378a0b688"
      unitRef="U_USD">171000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_37337290-c4f6-4ef2-a6f7-8313d2a10b7a"
      decimals="-3"
      id="F_06fc8bae-3c56-4adf-94e6-eeb5d5bd852f"
      unitRef="U_USD">106000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_37337290-c4f6-4ef2-a6f7-8313d2a10b7a"
      decimals="-3"
      id="F_d8a38f8e-b196-4d57-b94c-de1282aeca1d"
      unitRef="U_USD">65000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_ffcde63a-30be-4d73-aa8b-32000baec85f"
      unitRef="U_USD">601000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_c9edb1f2-637b-4f35-977c-f5049871a624"
      unitRef="U_USD">396000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_cacf404a-5621-4595-a8f9-4f365800638a"
      unitRef="U_USD">205000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      id="F_5176e29f-705b-4c02-a665-da9782b81d28">P4Y14D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="0"
      id="F_a78e972a-afec-4d4e-9ba9-845f6cb047fd"
      unitRef="U_USD">38000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_bac1a1b3-c809-435b-ab4a-2d340fedaa5c"
      unitRef="U_USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_65bba05f-eccb-4359-8e58-06f2b23ab68d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Based on finite-lived intangible assets recorded as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the estimated future amortization expense is as follows (in thousands):&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:85.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Estimated Amortization Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_9aab4c38-fc02-4534-b40e-920efcade45f"
      unitRef="U_USD">59000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_f6ec1ca4-102f-4264-bb6a-2fd6c8f85c46"
      unitRef="U_USD">59000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_266ad79d-6e40-4381-8052-1e5af24a2206"
      unitRef="U_USD">55000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_d42d506e-3be8-489d-8133-f19aa923c477"
      unitRef="U_USD">27000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_4af6e0a8-072e-475d-9c81-6755d496277a"
      unitRef="U_USD">26000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_5a3d5891-65aa-4be2-8529-1e0777be3dde"
      unitRef="U_USD">47000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_07af8e26-d676-4b1e-af9a-5f368b1be388"
      unitRef="U_USD">273000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_6310e3bc-276b-472f-94a1-07f4967f4b99">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s product revenues were mainly generated from the sale of ETUARY. Sales of ETUARY accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of total revenue for the years ended on December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sales of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company generates revenue mostly through sales of ETUARY and certain generic drugs. The distributors were the Company&#x2019;s direct customers, and sales to distributors accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of revenue from ETUARY. The distributors sell ETUARY to outlets, including hospitals and other medical institutions, as well as pharmacies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Product &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;returns to date have not been significant and the Company has not considered it necessary to record a reserve for product returns. The Company&#x2019;s product revenues were recognized at a point in time when the underlying product was delivered to the customer, which was when the customer obtained control of the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;product. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Revenue from sales of pharmaceutical products was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 2023, respectively. All sales are generated in the PRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s sales by product categories for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.008%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:27.705%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:27.225%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Sales of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_c0f50cf0-d705-4547-8bb2-292161d2dc8e"
      decimals="3"
      id="F_73db2876-9b08-4af8-b75e-eda2ce8d7e12"
      unitRef="U_pure">0.993</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_51a6c503-e72b-48c6-951e-f9d61b0aaa75"
      decimals="3"
      id="F_bef25dea-a0fe-480e-b80b-176e5bbd5639"
      unitRef="U_pure">0.989</us-gaap:ConcentrationRiskPercentage1>
    <gyre:PercentageOfRevenueAccountedSalesToDistributors
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="3"
      id="F_8617e88c-d6c7-451e-8f00-4a5cd04f6650"
      unitRef="U_pure">1</gyre:PercentageOfRevenueAccountedSalesToDistributors>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e4d869fa-260f-4c9f-9cf3-79a75bfecf47"
      decimals="-5"
      id="F_1f65a25e-7a97-4ca9-8bb8-2302b54e7d0f"
      unitRef="U_USD">105800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_1152de71-ba52-48e2-80b9-f500c5502e72"
      decimals="-5"
      id="F_0ef19e5b-eec3-4b44-9925-205dcd4c967b"
      unitRef="U_USD">113500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_de6e5ab2-4080-45db-896e-ffa6234a0118">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s sales by product categories for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.008%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:27.705%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:27.225%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Sales of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e4d869fa-260f-4c9f-9cf3-79a75bfecf47"
      decimals="-3"
      id="F_1488b479-cf03-40b9-8055-99f88bbe41d3"
      unitRef="U_USD">105757000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_1152de71-ba52-48e2-80b9-f500c5502e72"
      decimals="-3"
      id="F_49d613b8-4550-4711-bd59-1d98806dea54"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_11d4f5ae-a000-431e-aec8-5f1325352a78"
      unitRef="U_USD">105757000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_b1b309da-b63e-4833-b3d2-b5789eaae21b"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_b384e3e3-6ea7-4b69-8f43-40d90d957dcb">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;GNI USA Contributions under the Business Combination Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The GNI USA Contributions under the Business Combination Agreement (see Note 1) was treated as a reverse asset acquisition, with CPI as the accounting acquirer and Catalyst as the legal acquirer. Under U.S. GAAP, a company must evaluate if an integrated set of assets and activities qualifies as a business acquisition or an asset acquisition by assessing if the gross assets&#x2019; fair value is primarily concentrated in a single asset or a group of similar assets. If this criterion is met, the acquired operations are not considered a business. Catalyst did not meet the business definition as its fair value was concentrated in one IPR&amp;amp;D asset, it lacked an organized workforce contributing significantly to output creation, and no substantive processes were acquired. As such, the GNI USA Contributions was treated as an asset acquisition. In an asset acquisition, goodwill is not recognized, and the cost allocated to the acquired IPR&amp;amp;D with no alternative future use is expensed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Catalyst Common Stock outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Multiplied by the fair value per share of Catalyst stock (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value of common shares to be owned by Catalyst&#x2019;s stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value of preferred shares to be owned by Catalyst&#x2019;s stockholders (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value of Catalyst&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value of consideration issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;This amount is calculated based on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;666.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:84%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:14%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:84.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other receivables from GNI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Prepaid assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other assets, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Advance payment received from GNI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR excess closing cash payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR derivative liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in Gyre Pharmaceuticals&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_584f911e-1088-4345-80e2-624d7e9057c0">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Catalyst Common Stock outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Multiplied by the fair value per share of Catalyst stock (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value of common shares to be owned by Catalyst&#x2019;s stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value of preferred shares to be owned by Catalyst&#x2019;s stockholders (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value of Catalyst&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fair value of consideration issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;This amount is calculated based on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;666.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:84%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:14%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e7855790-0097-47bb-9146-f38e022e4521"
      decimals="INF"
      id="F_70ca9fae-9d69-46d1-a1b2-6e2f1ee83069"
      unitRef="U_shares">2532</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_e7855790-0097-47bb-9146-f38e022e4521"
      decimals="2"
      id="F_481558c6-a609-452f-b345-dd372cf841c3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.67</us-gaap:BusinessAcquisitionSharePrice>
    <gyre:BusinessCombinationFairValueOfCommonShares
      contextRef="C_e7855790-0097-47bb-9146-f38e022e4521"
      decimals="-3"
      id="F_97d12e1b-a27e-481f-add4-89111f801799"
      unitRef="U_USD">19420000</gyre:BusinessCombinationFairValueOfCommonShares>
    <gyre:BusinessCombinationFairValueOfPreferredShares
      contextRef="C_e7855790-0097-47bb-9146-f38e022e4521"
      decimals="-3"
      id="F_5c3010dd-bd13-4c9a-85c6-7eba53b7f240"
      unitRef="U_USD">63099000</gyre:BusinessCombinationFairValueOfPreferredShares>
    <gyre:BusinessCombinationFairValue
      contextRef="C_e7855790-0097-47bb-9146-f38e022e4521"
      decimals="-3"
      id="F_347f5d2b-afd9-4a13-bb61-0cf306e23d67"
      unitRef="U_USD">82519000</gyre:BusinessCombinationFairValue>
    <gyre:PreMergerStockOptionsAssumed
      contextRef="C_e7855790-0097-47bb-9146-f38e022e4521"
      decimals="-3"
      id="F_0a8e41ac-d9eb-4a0a-9c5a-a87ff2956e73"
      unitRef="U_USD">1829000</gyre:PreMergerStockOptionsAssumed>
    <us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure
      contextRef="C_e7855790-0097-47bb-9146-f38e022e4521"
      decimals="-3"
      id="F_7fe8c611-9573-4ec7-bcd1-aae2fd1eb3ab"
      unitRef="U_USD">84348000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="C_e7855790-0097-47bb-9146-f38e022e4521"
      decimals="-3"
      id="F_7442f9ea-2a40-4595-8e84-9eb66252a950"
      unitRef="U_USD">659000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_2d08f24c-1345-467d-96a2-4553b687c2fb"
      decimals="-3"
      id="F_b010ebc3-0fe5-4724-ba35-18adf118ce4e"
      unitRef="U_USD">85007000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_daacc8f9-d9a7-49ef-b6a0-b9c3726581cc"
      decimals="INF"
      id="F_39d4b8d7-f324-44e5-ae23-0a0e2fc368bf"
      unitRef="U_shares">12340</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_daacc8f9-d9a7-49ef-b6a0-b9c3726581cc"
      decimals="INF"
      id="F_8edcaf29-df9e-4a4d-b687-72b121ba5794"
      unitRef="U_shares">666.67</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ec175c4c-56e4-436f-84d5-b5ba30f7f13e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:84%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:14%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_47abff85-a3ea-4232-9ee3-57283680d7ea">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_38a776db-bb7d-4601-88ba-94f26e9c6816"
      unitRef="U_pure">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_25d0acc4-8f5d-465c-bcd3-eeaf51aebcf6"
      unitRef="U_pure">0.0365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_7fec32f8-5a13-4cc2-9178-468fe1671d48">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:84.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other receivables from GNI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Prepaid assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other assets, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Advance payment received from GNI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR excess closing cash payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;CVR derivative liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_f411facd-6d5a-427d-8fa4-fb2d964ffa50"
      unitRef="U_USD">5587000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_bbaf9e7b-cd0e-45dd-ad14-6d85deddb747"
      unitRef="U_USD">423000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_2f7c31b2-6aa9-4ae9-bad9-de662b6d0846"
      unitRef="U_USD">1097000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_0dc37157-d931-4dd3-93ff-25e39e0c646c"
      unitRef="U_USD">41000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_908781ad-e0f0-4461-914b-29156f258dfe"
      unitRef="U_USD">4683000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_19b30c2b-2fb3-4cc0-ad43-e19ec26914f7"
      unitRef="U_USD">168000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_1627c7cb-22ac-4cdf-adcb-18229d087975"
      unitRef="U_USD">83104000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_c6f1a3dd-0962-4e03-87b1-0091c9025c90"
      unitRef="U_USD">44000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_3b947fd4-133a-400e-8f07-cee2530c883f"
      unitRef="U_USD">2500000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_c362e0e6-2f3c-4001-b009-81d05f290417"
      unitRef="U_USD">1784000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities>
    <gyre:BusinessCombinationExcessClosingCashPayable
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_2a175cfc-f4ca-4adf-94e8-4925a30ff75e"
      unitRef="U_USD">1085000</gyre:BusinessCombinationExcessClosingCashPayable>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_34bc20f8-46d8-4226-99b9-2b980586a677"
      unitRef="U_USD">4683000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="C_3c6a57d9-a896-48da-8a44-7f1b76f85732"
      decimals="-3"
      id="F_e96c3e63-d09d-43ba-b35c-434503748e11"
      unitRef="U_USD">85007000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_3408262f-9279-4eb9-b906-3cba309f4ca2">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;8.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Restructuring&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Prior to the Contributions, CPI entered into a CP&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; U.S. Share Purchase Agreement with GNI USA and divested almost all of its assets other than its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; indirect ownership interest in Gyre Pharmaceuticals. GNI USA is the parent company of Gyre. In connection with the transaction, the Company recorded a receivable in the amount of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million included in other receivables from GNI on the consolidated balance sheet as of December 31, 2023 and recognized a loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; during the year ended December 31, 2023, included in divestiture losses of the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <gyre:PercentageOfIndirectOwnershipInterest
      contextRef="C_96a600bd-711e-4434-a24c-a2180e74b33f"
      decimals="3"
      id="F_16823d9b-9382-4375-860a-a4b24d70a920"
      unitRef="U_pure">0.56</gyre:PercentageOfIndirectOwnershipInterest>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_49141630-2e23-47e6-b10b-c4c4722c6d0e"
      decimals="-5"
      id="F_431d1948-d6f0-4a60-892d-a1bb4b1188dd"
      unitRef="U_USD">800000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_b5f0da22-de98-4ff9-8f08-36e85ba3bc7e"
      decimals="-5"
      id="F_074e2eb1-c3b1-470e-b757-86dbbdb864ba"
      unitRef="U_USD">-2700000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ae2d7493-3012-4ce3-b659-1c755d832cdd">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;9.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In April 2024, Gyre Pharmaceuticals entered into a lease arrangement for its new corporate headquarters, an approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; square meter office space in Beijing, PRC, which lease is set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;June 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. In 2022, Gyre Pharmaceuticals secured a lease for an office space of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; square meters in Zhengzhou, PRC, which was renewed in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;July 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and is set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;August 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. In November 2024, Gyre Pharmaceuticals secured a new lease for an office space of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; square meters in Shanghai, China, with the lease set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. In November 2023, the Company secured a lease for its U&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.S. headquarters in San Diego, California, with the lease set to expire in the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_a5e3a326-17c6-4924-b500-780170a688d9;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;first quarter of 2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company also has multiple short-term leased properties used as offices and employee dormitories. The Company recorded a total of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; short-term rent expenses during the years ended December 31, 2024 and 2023, respectively. The short-term rent expense amounts are recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company recorded an aggregate ROU asset of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and an aggregate lease liability of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Rent expense related to operating leases was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024, and 2023, respectively. Variable lease payments for the years ended December 31, 2024 and 2023 were immaterial.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Supplemental cash flow information related to operating leases was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The present value assumptions used in calculating the present value of the lease payments were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.687%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, undiscounted future minimum payments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:83%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Less: current portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company is required to maintain security deposits of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; in connection with various leases, which amounts are included in other assets, noncurrent on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Land use rights&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company held land use rights for two land parcels in Beijing&#x2019;s Shunyi District, expiring in 2053, and in Cangzhou, Hebei Province, expiring from 2067 to 2071. These parcels, with a combined area of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,559&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; square meters, are utilized as manufacturing facilities. As of December 31, 2024, the aggregate recorded land use rights, net assets for these parcels was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <gyre:SquareMeterAreaForOfficeSpaceUnderLease
      contextRef="C_7a06ddc6-8a57-4cf2-a967-1f3297552aa6"
      decimals="INF"
      id="F_1b99528d-50dc-4d50-b150-f87983b03241"
      unitRef="U_sqm">2130</gyre:SquareMeterAreaForOfficeSpaceUnderLease>
    <gyre:LeaseExpirationMonthAndYear
      contextRef="C_761f52b8-1b53-40ce-8a99-390c026c9793"
      id="F_24997a32-4a5b-4930-86f7-f9c5700a1c7a">2027-06</gyre:LeaseExpirationMonthAndYear>
    <gyre:SquareMeterAreaForLaboratoryCenterUnderLease
      contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf"
      decimals="INF"
      id="F_56f64288-7207-4f28-b230-1158a3fda502"
      unitRef="U_sqm">180</gyre:SquareMeterAreaForLaboratoryCenterUnderLease>
    <gyre:LeaseRenewedMonthAndYear
      contextRef="C_2552ff66-c519-4434-b8ac-87bd1b2941d2"
      id="F_c46f1833-ee01-4c87-bc4e-2413b411d516">2024-07</gyre:LeaseRenewedMonthAndYear>
    <gyre:LeaseExpirationMonthAndYear
      contextRef="C_2552ff66-c519-4434-b8ac-87bd1b2941d2"
      id="F_0f0ca66c-782e-4e68-ba86-70a1102b5dab">2026-08</gyre:LeaseExpirationMonthAndYear>
    <gyre:SquareMeterAreaForLaboratoryCenterUnderLease
      contextRef="C_fce1ab14-263e-4f06-8e6c-95e2226660e4"
      decimals="INF"
      id="F_89e07186-922d-4e83-8f59-c9aaa1ee9177"
      unitRef="U_sqm">224</gyre:SquareMeterAreaForLaboratoryCenterUnderLease>
    <gyre:LeaseExpirationMonthAndYear
      contextRef="C_1c9a63af-c293-421c-835a-b808c5bda6ff"
      id="F_b72d39e1-35ad-4d92-967b-49394541bd5a">2026-12</gyre:LeaseExpirationMonthAndYear>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="0"
      id="F_0fd997bb-2e60-40f7-b8e0-87efcdb37e44"
      unitRef="U_USD">68000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="0"
      id="F_701d8a77-7d44-45ff-b2d7-9955314e2b5e"
      unitRef="U_USD">89000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_6d0c77df-0f4d-4a9d-a53a-f332ee187760"
      unitRef="U_USD">1800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_875762c9-5c36-4e84-a8dd-717ec86f4f97"
      unitRef="U_USD">1600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_a4382d10-7908-4912-83ae-c41f2e874f90"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_789bec90-9477-4e54-a09a-dc35d7142a22"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_9a635ec8-88b2-44d2-a3fa-b15cb58d74cc">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Supplemental cash flow information related to operating leases was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_7cc3dacd-b522-4d26-8b79-3ca58ae3e4cf"
      unitRef="U_USD">872000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_2f0edd95-4597-42ea-88c0-a1bc51fb12a7"
      unitRef="U_USD">573000</us-gaap:OperatingLeasePayments>
    <gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_1920f69c-e437-4798-86e7-593144caa927">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The present value assumptions used in calculating the present value of the lease payments were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.687%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      id="F_42206722-e60f-4e5f-b103-222b77be99b3">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      id="F_36b331d6-3af1-458d-8221-8f2e53dc2a0e">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="4"
      id="F_d1740976-b6c7-44e4-a717-d01ed1f7023e"
      unitRef="U_pure">0.0476</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="4"
      id="F_438a1794-e702-4472-95c6-a99572a0f608"
      unitRef="U_pure">0.0478</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_404557b4-ccfb-4f4f-aa34-276deada1169">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, undiscounted future minimum payments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:83%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Less: current portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_29cd39e5-8ee2-4351-a147-b9767b6787e7"
      unitRef="U_USD">782000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_cf0f0788-398c-465e-b238-f2cecabf9aca"
      unitRef="U_USD">631000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_a3f5d538-0711-4e93-84a4-08d855df49e4"
      unitRef="U_USD">279000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_ba9d29dc-4269-44bf-b227-3c42c4343779"
      unitRef="U_USD">1692000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_934fc1ff-0b56-4279-a8b7-0a93f3878ed9"
      unitRef="U_USD">94000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_f93cd17a-c651-4a60-a29a-bc10b09d6b72"
      unitRef="U_USD">1598000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_b0bed329-1c28-4da8-9aec-50cded469884"
      unitRef="U_USD">713000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_1c3730de-5554-4c6b-95cb-7126a7b26b60"
      unitRef="U_USD">885000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SecurityDeposit
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_beddf837-d156-4851-824b-530da5bf02df"
      unitRef="U_USD">300000</us-gaap:SecurityDeposit>
    <gyre:CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="0"
      id="F_0a3afba3-eb62-4ea7-a6a8-9fb386b84d4a"
      unitRef="U_sqm">66559</gyre:CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease>
    <gyre:LandUseRightsNetAssets
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_9afa38b1-5f1a-4b20-a8f9-b92d3b5f186a"
      unitRef="U_USD">1400000</gyre:LandUseRightsNetAssets>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_e6c064d9-8369-43fd-872d-e5d1312bd3f7">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;10.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Under the Company&#x2019;s amended and restated certificate of incorporation, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Common Stock authorized for issuance with a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; par value per share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#x2019;s stock who are entitled to vote. The holders of Common Stock have voting rights equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;one vote&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; per share of Common Stock held. The holders of Common Stock are entitled to receive dividends when and as declared or paid by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Convertible Preferred Stock issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock Warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,077,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;[1]&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total Common Stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,618,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,588,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;[1]&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Includes &lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,304,898&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; options exercisable for shares of common stock, which underlying shares of common stock were transferred in the name of the Company to Futu Network Technology Limited, the stock plan administrator of the 2023 Omnibus Incentive Sub-Plan for Chinese Participants.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2024 ATM Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;On November 27, 2024, Gyre Therapeutics, Inc. entered into an Open Market Sale Agreement (the &#x201c;ATM Agreement&#x201d;) with Jefferies LLC (the &#x201c;Sales Agent&#x201d;) as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of Common Stock with aggregate gross sales proceeds of up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; through an at-the-market offering program (the &#x201c;ATM Program&#x201d;). The Company will pay the Sales Agent a commission of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; of the gross proceeds of any shares sold. The Company also agreed to reimburse &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;the Sales Agent for certain expenses incurred in connection with its services under the ATM Agreement, including up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; for legal expenses in connection with the establishment of the ATM Program. During the year ended and as of December 31, 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,267&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Common Stock under ATM Program and received net proceeds of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;, after deducting commissions and offering costs of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.02&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Sales of shares of Common Stock under the ATM Program may be made pursuant to the registration statement on Form S-3 (File No. 333-283237), which was declared effective by the SEC on November 22, 2024, and a related prospectus supplement filed with the SEC on November 27, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Net Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Under PRC laws and regulations, Gyre Pharmaceuticals is subject to restrictions on foreign exchange and cross-border cash transfers, including to parent companies and U.S. stockholders. The ability to distribute earnings to the parent companies and U.S. stockholders is also limited. Current PRC regulations permit Gyre Pharmaceuticals to pay dividends to BJC only out of its accumulated profits as determined in accordance with PRC accounting standards and regulations. Amounts restricted include paid-in capital and the statutory reserves of Gyre Pharmaceuticals&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. The aggregate amounts of restricted capital and statutory reserves, which represented the amount of net assets of the relevant subsidiaries not available for distribution were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As a result of the above restrictions, parent-only financial statements are presented in Schedule I.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Statutory Reserve&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals is required to set aside at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;% of its after-tax profits as the statutory reserve fund until the cumulative amount of the statutory reserve fund reaches &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;% or more of its registered capital, if any, to fund its statutory reserves, which are not available for distribution as cash dividends. At the Company&#x2019;s discretion, the Company may allocate a portion of after-tax profits based on PRC accounting standards to a discretionary reserve fund.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; appropriations to these reserves during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="0"
      id="F_0d83cd10-61d6-421b-b645-d4a48ac94c3c"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="0"
      id="F_33ac202e-54e0-4b89-9e82-646534a1a4fd"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="3"
      id="F_159673c0-d4ac-409f-8a6d-a2c43b9f8415"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="3"
      id="F_aa2ba5ed-1c60-458e-b5d6-48b7916e54c3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ad8c8b58-2dd2-4ff8-b51a-3ae2b87f22ec">one vote</us-gaap:CommonStockVotingRights>
    <gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_e604aa26-ba81-41c6-b688-a1bd578c4b1a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Convertible Preferred Stock issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock Warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,077,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;[1]&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total Common Stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,618,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,588,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;[1]&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Includes &lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,304,898&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; options exercisable for shares of common stock, which underlying shares of common stock were transferred in the name of the Company to Futu Network Technology Limited, the stock plan administrator of the 2023 Omnibus Incentive Sub-Plan for Chinese Participants.&lt;/span&gt;&lt;/p&gt;</gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7d4b6a2b-a70c-49dd-8ace-2e25b256643a"
      decimals="INF"
      id="F_2ba7e61f-e0c9-453f-b1eb-4d582812e893"
      unitRef="U_shares">8767332</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fe14599d-907f-447e-be99-9689d7f34472"
      decimals="INF"
      id="F_0eeaeac0-861b-4818-bfaa-f4faa85ff36f"
      unitRef="U_shares">540666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_40f3484c-5a7d-4fad-9c74-3ddeb2ee3ca3"
      decimals="INF"
      id="F_e5a42831-1aef-4278-a58e-d9f2ebedea08"
      unitRef="U_shares">540666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0694c0b0-9199-4cf1-86b8-378fc929e7fa"
      decimals="INF"
      id="F_7bc06cc7-be2c-4203-b87b-21235f95744e"
      unitRef="U_shares">18077869</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ce07c61e-a68b-4a21-856c-80d6f63dc861"
      decimals="INF"
      id="F_9d4afb78-6534-445b-b894-aef5ac38b7ff"
      unitRef="U_shares">18280548</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_5f127fd1-11a7-4cc8-9204-ab5b2b428a47"
      unitRef="U_shares">18618535</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_4af882da-a2ad-43ee-b723-3c6f7242067e"
      unitRef="U_shares">27588546</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_86b63a2c-389d-4950-a678-157a2397918e"
      decimals="INF"
      id="F_3951a9cb-95a3-4402-8a2d-463c51b29c74"
      unitRef="U_shares">7304898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_e852315e-c976-4feb-af38-ee2ba333da3a"
      decimals="-5"
      id="F_20623e8a-00ef-439f-9fe6-d02cb8129afc"
      unitRef="U_USD">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <gyre:PercentageOfCommissionForSharesSold
      contextRef="C_c4c9bfee-5e03-4161-8738-c6867fc7060c"
      decimals="2"
      id="F_cb20fda6-a35b-41a9-9749-5e05fd2d5e89"
      unitRef="U_pure">0.03</gyre:PercentageOfCommissionForSharesSold>
    <gyre:LegalExpensesIncurred
      contextRef="C_e852315e-c976-4feb-af38-ee2ba333da3a"
      decimals="0"
      id="F_c463db7d-0535-4d7e-a79d-3d31b806cb6b"
      unitRef="U_USD">135000</gyre:LegalExpensesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_63ac599f-e0eb-4b2e-8ae3-eadeb59bf215"
      decimals="INF"
      id="F_e0012445-ac51-49df-834f-5091dbda930d"
      unitRef="U_shares">70267</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_63ac599f-e0eb-4b2e-8ae3-eadeb59bf215"
      decimals="-5"
      id="F_92832966-3a0c-49fc-b62f-953b3b055338"
      unitRef="U_USD">800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <gyre:CommissionsAndOfferingCosts
      contextRef="C_63ac599f-e0eb-4b2e-8ae3-eadeb59bf215"
      decimals="-4"
      id="F_01a7a84f-de30-4ad8-b49b-639ec3c3e393"
      unitRef="U_USD">20000.00</gyre:CommissionsAndOfferingCosts>
    <gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_58f65311-8af1-4f5b-b17a-5cc396c50134"
      unitRef="U_USD">64300000</gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves>
    <gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-5"
      id="F_0b98c809-b18e-4de1-84e7-f7d6f240cec3"
      unitRef="U_USD">64300000</gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves>
    <gyre:StatutoryReserveFund
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_56dbda11-c684-4c19-a1d7-d4626f5b73b8"
      unitRef="U_pure">0.10</gyre:StatutoryReserveFund>
    <gyre:CumulativeAmountOfStatutoryReserveFund
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_eaf4cfbe-2f82-40a7-9c47-97ad93fff68d"
      unitRef="U_pure">0.50</gyre:CumulativeAmountOfStatutoryReserveFund>
    <gyre:AppropriationsToStatutoryReserve
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-6"
      id="F_76707d0e-51aa-46ef-9a93-b799a4af6a5c"
      unitRef="U_USD">0</gyre:AppropriationsToStatutoryReserve>
    <gyre:AppropriationsToStatutoryReserve
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-6"
      id="F_736168c1-47e5-4f3e-96f8-6069d0e407d7"
      unitRef="U_USD">0</gyre:AppropriationsToStatutoryReserve>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_f75203e3-bc2a-48c2-b355-84614fa5a283">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;11.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In December 2022, Catalyst issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Convertible Preferred Stock to GNI Japan and GNI HK in connection with the F351 Asset Acquisition (see Note 1 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;), which were subsequently transferred to GNI USA in October 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In October 2023, immediately following the closing of the Contributions, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Convertible Preferred Stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; Preferred Stock Warrants to GNI USA under the Private Placement. For additional information, see Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In November 2023, GNI USA provided notice to the Company to convert its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,151&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Convertible Preferred Stock. Each share of Convertible Preferred Stock was convertible into approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;666.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of common stock. On January 22, 2024, subject to the terms and conditions of the Convertible Preferred Stock Certificate of Designation, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of Common Stock were issued to GNI USA upon such conversion.&lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_21d9722b-ebb3-4d75-9c08-5b1c34dda6b9"
      decimals="INF"
      id="F_7730094b-b911-4d78-95b4-00ed325723b9"
      unitRef="U_shares">12340</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_637be181-9ac9-483b-8aeb-4f4857ea30c6"
      decimals="INF"
      id="F_6e0fb8ba-4370-41e0-8e76-394add5630ec"
      unitRef="U_shares">811</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_e345ba39-3b04-455d-ae09-666d8d8b33bd"
      decimals="0"
      id="F_e7ffebba-5361-47ed-8052-598c0f1cafc8"
      unitRef="U_shares">811</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_7c56d128-f56c-40e8-9eed-aee500526cb8"
      decimals="INF"
      id="F_d618e590-e1eb-496b-a4c8-87eff78a9c89"
      unitRef="U_shares">13151</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_32aa5abd-be11-4b38-afb6-d7b26fad8f62"
      decimals="INF"
      id="F_709e78a9-7820-4ce0-988c-4a45733233bc"
      unitRef="U_shares">666.67</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares
      contextRef="C_fb2f86f7-6be0-48e5-a0e5-ce77738921cb"
      decimals="INF"
      id="F_75a5ffcd-5732-4c43-a716-14747106ec76"
      unitRef="U_shares">8767332</gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_0ef81c40-f1e1-4331-b1b3-4d9cf58a1d64">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;12.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Stock Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2023 Omnibus Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The 2023 Omnibus Incentive Plan was approved by Catalyst&#x2019;s stockholders in August 2023 and ratified by Gyre&#x2019;s board of directors (the &#x201c;Board&#x201d;) in October 2023. The 2023 Omnibus Incentive Plan became effective on October 30, 2023. The 2023 Omnibus Incentive Plan permits the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,845,496&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of common stock and will automatically increase by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;% of the total number of outstanding shares of common stock on December 31st of the preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board on the first day of each fiscal year beginning on January 1, 2024. On January 1, 2024, pursuant to the automatic increase in the number of shares reserved, an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,829,780&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were reserved and made available for issuance under the 2023 Omnibus Incentive Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes stock option activity considering the conversion of Gyre Pharmaceuticals options to Gyre options to purchase shares of Gyre common stock upon completion of the Contributions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:21.521%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.759%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.67%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.151%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.738%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Number of Shares Underlying Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2014; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;444,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;680,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;874,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options forfeited and cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2014; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,077,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Vested and exercisable &#x2014; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,458,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value of options granted was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;7.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; per share for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The fair value of all equity awards that vested during the periods ended December 31, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash received from the exercise of options was approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Valuation Assumptions&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited relevant historical data, the Company estimated its volatility considering a number of factors, including the use of the volatility of comparable public companies. The expected term of options granted under the 2023 Omnibus Incentive Plan, all of which qualify as &#x201c;plain vanilla&#x201d; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#x2019;s limited relevant history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The fair value of employee stock options granted was estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.151%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.284%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected volatility (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected option life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted average share price of the Company (USD per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation recognized was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had an unrecognized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;3.12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_707b6aef-326f-458f-9f18-b11e1ee9ee78"
      decimals="INF"
      id="F_b093db1e-a747-456b-9fe1-9671e72ca9d4"
      unitRef="U_shares">17845496</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <gyre:PercentageOfOutstandingSharesOfCommonStock
      contextRef="C_4b697f59-a7d2-4358-9a63-af70187de963"
      decimals="2"
      id="F_9738190d-09cf-4904-b602-e4ee6d3e53c2"
      unitRef="U_pure">0.05</gyre:PercentageOfOutstandingSharesOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9059de58-0342-483c-bb12-68f46c8efdab"
      decimals="INF"
      id="F_5367ccce-4b37-42df-833a-6e39ef977f7b"
      unitRef="U_shares">3829780</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_8d3db45b-3fdc-472a-b1c1-0eb8caf0e40e">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:21.521%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.759%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.67%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.151%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.738%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Number of Shares Underlying Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2014; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;444,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;680,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;874,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options forfeited and cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2014; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,077,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Vested and exercisable &#x2014; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,458,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_9535ff1a-0557-45ad-840a-e85c65f618f6"
      unitRef="U_shares">18280548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="2"
      id="F_cc815794-8a73-46e6-9b1e-c603d760bbec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      id="F_8b5fe38b-25f4-445a-83e6-8a284bc19617">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_c39a4bc7-31f2-4815-9b22-f63ddf2ad997"
      unitRef="U_USD">444197000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="INF"
      id="F_023e5e09-15d7-4f53-b39a-7b30c4d8a147"
      unitRef="U_shares">680732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_ff30c48f-1eff-4d69-a031-028eb4f788fe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="INF"
      id="F_a957b097-3573-4dff-bed5-8d8f678436d5"
      unitRef="U_shares">874328</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_4f201565-3603-42a5-b65e-253b9f17d67f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="INF"
      id="F_db4fd7fc-3f95-4254-a380-c6ecae622ae1"
      unitRef="U_shares">9083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_9317257d-9cb3-4b4c-8cec-15d0ed7b7ecb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_cf98a530-53ff-4736-a522-a35389656437"
      unitRef="U_shares">18077869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="2"
      id="F_32930c21-a38b-491e-9bf2-51bd740e55bc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_128702f7-b6e6-4fe7-98fa-d5787cf994ca">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_06997f2b-ce15-469d-b73b-b39008168ac9"
      unitRef="U_USD">190377000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_b39b018e-d54b-4088-92aa-88949792422d"
      unitRef="U_shares">17458607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="2"
      id="F_943e7835-86f9-470e-a8b5-49b241fe1136"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_f57503af-e38c-4903-ab9d-857a0dea69a2">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_915e3a6f-2323-4da1-86f8-547d9e7d7024"
      unitRef="U_USD">189054000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_c1ce74d7-411e-4cdd-99dc-a9916db9a939"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="2"
      id="F_a0211fd4-116a-4057-a0db-e912389922f0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_a67b4c91-27ff-4b71-8850-8ba03f7eb84b"
      unitRef="U_USD">9600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_4a1483a8-0c5a-431e-84a8-aa3ce4f99986"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_214e7071-0502-423e-afa6-79b8129280ee"
      unitRef="U_USD">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_777ddfe5-3ab6-4dcd-ad15-0a70fd4c7356"
      unitRef="U_USD">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_18b33b6d-ae29-4a6a-ae83-72459cb8737a"
      unitRef="U_USD">1900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-6"
      id="F_14b38b97-544b-478d-b7a3-d712181e5511"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_12688adc-6717-4d25-8756-4bb9cc2e52f5">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The fair value of employee stock options granted was estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.151%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.284%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected volatility (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected option life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted average share price of the Company (USD per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16"
      decimals="4"
      id="F_a51c1bea-73e8-4c3e-9fd8-2340f3b7fc44"
      unitRef="U_pure">0.841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16"
      decimals="4"
      id="F_129ff156-24e8-4467-9ea7-d3284060f99f"
      unitRef="U_pure">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690"
      decimals="4"
      id="F_efc86fc3-964b-4e21-861d-35b8651b7b06"
      unitRef="U_pure">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690"
      decimals="4"
      id="F_a264aa4e-15d8-4410-afa9-78f0699e0d86"
      unitRef="U_pure">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16"
      decimals="4"
      id="F_11cd20bd-76a5-4994-8c9a-6a9c9f757d70"
      unitRef="U_pure">0.0364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16"
      decimals="4"
      id="F_629c11ab-1f8f-46aa-b5b0-25103d0401f9"
      unitRef="U_pure">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690"
      decimals="4"
      id="F_00b17808-1363-4cff-ab63-b32be7124db9"
      unitRef="U_pure">0.0382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690"
      decimals="4"
      id="F_5329bdf4-09cb-49fe-bf03-f0493ac757ed"
      unitRef="U_pure">0.0477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_19def526-bb67-4646-b79c-ffcf90c9dc23"
      id="F_0d078081-87d1-474d-84b0-a22654021b51">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c56613f3-6432-437c-9bab-9101a3786a66"
      id="F_f367b770-8a07-48a6-a0de-222f4dfd333c">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_893c5230-daf1-4851-a6bd-a1088e652270"
      id="F_b2877ba7-7a78-4195-ae8a-49da19a575ae">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b6236476-6e75-4438-a794-f025b4ae1817"
      id="F_0e4cb2cc-77ea-4f8b-89e1-10a906966dcc">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice
      contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16"
      decimals="2"
      id="F_4f1d7b76-7a61-4900-a99f-c7d18a4c52c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10</gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice>
    <gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice
      contextRef="C_ba5aad55-1cb9-43ec-8577-9dae0f32d690"
      decimals="2"
      id="F_a770a051-5a62-4bf4-b5aa-5b6b06e5c47c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.93</gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_c4254ba8-3ffa-445c-b614-ae686447539d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation recognized was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e5513b2b-c8d0-4816-81a6-d83601aee525"
      decimals="-3"
      id="F_b667b7d7-7c03-443b-a473-fcc56d9a0272"
      unitRef="U_USD">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c3036813-c367-4137-83bc-d3111a243c9e"
      decimals="-3"
      id="F_a59b5f84-b15f-4fd8-a812-6f4faffacabc"
      unitRef="U_USD">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_49f4dab9-8bd1-4577-b767-6356a5621a2b"
      decimals="-3"
      id="F_aefbca92-1eaa-4530-9e68-2858176f0693"
      unitRef="U_USD">481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cc77e3d6-0b6d-4809-98bc-ba50dc57d0e8"
      decimals="-3"
      id="F_1098d157-d10c-4dca-a6d1-b3a030147347"
      unitRef="U_USD">831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_28b79e15-5ce4-4bf9-8af0-0a1821e83289"
      decimals="-3"
      id="F_d4694084-8504-4df9-970e-e258c9c96b6f"
      unitRef="U_USD">6404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_465710c7-8529-4c45-aba0-695b69af3585"
      unitRef="U_USD">831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_564dbf4b-bad9-4343-ae31-89493baaed0f"
      unitRef="U_USD">7281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_27c77b10-4086-4da2-b416-c9b80579f835"
      decimals="-5"
      id="F_28760abc-8b9c-41db-99c2-887240964609"
      unitRef="U_USD">4200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_8cffebf0-4cfa-4a3b-a6e3-d3aa23695c16"
      id="F_889f6ba6-94d2-4120-b82c-332bd3c190fa">P3Y1M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_69411f87-1fd0-4d3b-b6ac-ff22a180d76d">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;13.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingent Value Rights Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Each CVR under the CVR Agreement (see Note 1 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;) entitles the holder to receive (i) certain cash payments from the net proceeds related to the disposition of Catalyst&#x2019;s legacy assets, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by the Company in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million as of the closing date of the transactions under the Business Combination Agreement, (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;% of the amount actually received by the Company, net of expenses, pursuant to an asset purchase agreement Catalyst entered into with Vertex Pharmaceuticals Inc. (&#x201c;Vertex&#x201d;) in May 2022 and (iv) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;of the excess amount, by which the preapproved costs to manage, negotiate, settle and finalize certain third party claims exceed the costs actually incurred with respect to such claims. The CVRs are not transferable, except in certain limited circumstances as provided for in the CVR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Agreement, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In June 2023, Catalyst fully settled the CVR payments related to the Vertex asset purchase agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In February 2023, Catalyst sold its legacy rare bleeding disorder program to GCBP. As a result, the Company distributed the net cash proceeds received from the GCBP asset sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; to the CVR Holders as well as recorded a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; long-term CVR derivative liability for the future distribution of the hold-back amount to be received in May 2025. As of December 31, 2024 and 2023, the carrying value of the CVR derivative liability was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; on the consolidated balance sheet, respectively. Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for additional information regarding the CVR derivative liability and GCBP asset sale.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;On October 30, 2023, pursuant to the CVR Agreement, the Company recorded a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; CVR excess closing cash payable upon closing of the Contributions. During the first quarter of 2024, the Company received a settlement related to the CVR litigation, and on August 26, 2024, it distributed approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; (or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; per contingent value right) to the CVR Holders. Subsequent to the payment, the CVR Holders have received all requisite cash payable under the CVR Agreement and there are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; outstanding distributions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Litigation and Legal Matters&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Purchasing Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s commitments related to purchase of property and equipment contracted but not yet reflected in the consolidated financial statements were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2024 and were expected to be incurred within one year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;F351&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In September 2020, Gyre Pharmaceuticals entered into an intellectual property (&#x201c;IP&#x201d;) transfer agreement (the &#x201c;F351 Transfer Agreement&#x201d;) with GNI Japan and certain of its wholly owned subsidiaries (the &#x201c;GNI Group&#x201d;). According to the F351 Transfer Agreement, Gyre Pharmaceuticals acquired the exclusive right to use Hydronidone IP rights in mainland China and the right of first offer for the global IP rights (the &#x201c;F351 IP Rights&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Under the F351 Transfer Agreement, in exchange for the F351 IP Rights, Gyre Pharmaceuticals is obligated to pay GNI Group &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; upon submission of the F351 New Drug Application (the &#x201c;NDA&#x201d;) to Center for Drug Evaluation of the National Medical Products Administration (the &#x201c;NMPA&#x201d;) of the PRC, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; after the NDA passes the NMPA&#x2019;s Center for Food and Drug Review and Inspection&#x2019;s on-site registration inspection for the F351 product, and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; upon NMPA&#x2019;s approval of the NDA. As of December 31, 2024, the payment conditions have not been met, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; payments have been made.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Programs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In addition to the F351 program, as of December 31, 2024, the Company has committed to allocate &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; toward future research and development activities for various programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, the Company may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <gyre:PercentageOfExcessCashOnDispositionsNet
      contextRef="C_b7908f32-a52a-47b5-a0f7-73f8bc7e1786"
      decimals="2"
      id="F_983de2ce-22c3-4198-ad48-d12e6adefc73"
      unitRef="U_pure">1</gyre:PercentageOfExcessCashOnDispositionsNet>
    <gyre:ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets
      contextRef="C_b7908f32-a52a-47b5-a0f7-73f8bc7e1786"
      decimals="-5"
      id="F_ed5ec1ff-baa8-4595-9ce8-8d5d801d2f2f"
      unitRef="U_USD">1000000</gyre:ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets>
    <gyre:PercentageOfAmountReceivedOnAgreement
      contextRef="C_003c57ab-d9dd-422e-bacb-9a242555faac"
      decimals="2"
      id="F_d240cf6e-116a-48b0-bd5a-be0b113b9357"
      unitRef="U_pure">1</gyre:PercentageOfAmountReceivedOnAgreement>
    <gyre:PercentageOfExcessPreapprovedCosts
      contextRef="C_b7908f32-a52a-47b5-a0f7-73f8bc7e1786"
      decimals="2"
      id="F_b72160ac-4339-4972-8c1a-6682281ae6b7"
      unitRef="U_pure">1</gyre:PercentageOfExcessPreapprovedCosts>
    <gyre:DistributionFromAssetSaleProceeds
      contextRef="C_55971d12-0611-489b-9033-d8d1ebf17458"
      decimals="-5"
      id="F_dc668d6f-9ca5-4aff-96cb-73620d031cf8"
      unitRef="U_USD">200000</gyre:DistributionFromAssetSaleProceeds>
    <gyre:ContingentValueRightsDerivativeLiabilityNonCurrent
      contextRef="C_838330c8-c71e-4fe2-a49f-e6fc75cb5071"
      decimals="-5"
      id="F_332039b0-be7b-4b06-a9e1-50dbfde1b571"
      unitRef="U_USD">4500000</gyre:ContingentValueRightsDerivativeLiabilityNonCurrent>
    <gyre:CVRDerivativeLiabilityNoncurrent
      contextRef="C_f5361373-7c92-419e-8bf7-87b01cbf8a00"
      decimals="-5"
      id="F_f12fa9b4-a387-4dcd-b089-f6a3e98f13ee"
      unitRef="U_USD">5000000</gyre:CVRDerivativeLiabilityNoncurrent>
    <gyre:CVRDerivativeLiabilityNoncurrent
      contextRef="C_10dfd633-6fab-4fb0-bb22-6722bb1f66cb"
      decimals="-5"
      id="F_95627c8d-c732-440b-8e0d-07ce4c7412c6"
      unitRef="U_USD">4700000</gyre:CVRDerivativeLiabilityNoncurrent>
    <gyre:ContributionsClosingPayableAmount
      contextRef="C_cef73343-7eb4-4d39-88e9-9171f4dd709f"
      decimals="-5"
      id="F_e18b447e-67c9-40ab-9d64-b0a5e16b6af6"
      unitRef="U_USD">1100000</gyre:ContributionsClosingPayableAmount>
    <gyre:DistributionsToHolders
      contextRef="C_d65a54be-e60b-44d6-9d6e-c5423744feb5"
      decimals="-5"
      id="F_49b3569e-3d26-4a03-bff7-a9b218111a44"
      unitRef="U_USD">12600000</gyre:DistributionsToHolders>
    <gyre:DistributionsToHoldersPerCVR
      contextRef="C_d65a54be-e60b-44d6-9d6e-c5423744feb5"
      decimals="2"
      id="F_d434a98e-9130-46c9-ae03-59ab6969573d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.4</gyre:DistributionsToHoldersPerCVR>
    <gyre:RemainingOutstandingBalanceOfAgreement
      contextRef="C_f5361373-7c92-419e-8bf7-87b01cbf8a00"
      decimals="-6"
      id="F_6ed00197-6038-4675-a68f-a302d49690a7"
      unitRef="U_USD">0</gyre:RemainingOutstandingBalanceOfAgreement>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_5c3e3497-8c9f-4117-820b-ed5757b69655"
      decimals="-5"
      id="F_b19227e1-c447-4769-a3a6-a7a01130e722"
      unitRef="U_USD">1400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights
      contextRef="C_a03ee1e8-f246-42c3-b72d-81a753170a1d"
      decimals="-5"
      id="F_e5dd1391-e3c8-4248-bfdc-d58d72730d0c"
      unitRef="U_USD">4600000</gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights>
    <gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights
      contextRef="C_f74c758a-d9fd-40e2-85f1-d6a87ddcc5dc"
      decimals="-5"
      id="F_fd7e0b56-2a47-41ee-89cb-ca63ede7c07e"
      unitRef="U_USD">1200000</gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights>
    <gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights
      contextRef="C_f5d8eb54-6979-4f3e-9be6-d8a1a8ec48fa"
      decimals="-5"
      id="F_a7191048-87d4-48c0-85b9-0bae6dc6b076"
      unitRef="U_USD">6900000</gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights>
    <gyre:PaymentsForExchangeForIntellectualPropertyRights
      contextRef="C_3196cc03-d5f3-4937-bff3-52b2ec055f70"
      decimals="INF"
      id="F_1b0f91b3-578c-4db7-89d4-f1a6fc04e7cd"
      unitRef="U_USD">0</gyre:PaymentsForExchangeForIntellectualPropertyRights>
    <gyre:CommittedToAllocate
      contextRef="C_151e32fc-1c63-4e3f-9240-08cf605db0d4"
      decimals="-5"
      id="F_4837564b-fd91-4ae5-910b-182e3cb701b2"
      unitRef="U_USD">20300000</gyre:CommittedToAllocate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_9a1b71af-6c02-499d-bc52-6f7154868921">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;14.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The components of the Company&#x2019;s provision for income taxes for the years ended December 31, 2024 and 2023 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.094%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Current income tax provision:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign - PRC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total current income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax provision:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign - PRC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total deferred income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate for the years ended December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.987%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.217%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.137%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Rate difference due to different jurisdiction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Preferential income tax rate for HNTE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Non-deductible expense &#x2013; Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Non-deductible expense &#x2013; acquisition related&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D Super-deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;ESOP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.02&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets as of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; December 31, 2024 and 2023 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.066%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.136999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.136999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Tax credit carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fixed and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Impact from foreign corporations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Capitalized transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liability &#x2013; ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liability &#x2013; Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The movements of the valuation allowance are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.677%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.424%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.889%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes of valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Based on the available objective evidence on December 31, 2024, the Company does not believe it is more likely than not that its net deferred tax assets will be realizable for US tax purposes. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets on December 31, 2024 for U.S. tax purposes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, after consideration of certain limitations (see below), the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million federal and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million state net operating loss carryforwards (&#x201c;NOL&#x201d;) available to reduce future taxable income which, if unused, will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; for federal and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; for state tax purposes. The federal net operating loss carryforward includes $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million that have an indefinite life.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; for federal and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million for state. If unused, the federal credit will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and the state tax credit does not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;If the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company&#x2019;s stock immediately before such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes under Section 382 occurred on December 31, 2007, August 20, 2015, April 13, 2017, February 15, 2018, February 18, 2020, and December 26, 2022. Approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;of the NOLs will expire&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;unutilized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;for federal and California state income tax purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; for federal and California state income tax purposes, respectively through the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;All of the federal R&amp;amp;D credits could expire unutilized, whereas none of the California R&amp;amp;D credits are subject to expiration. Approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million of gross federal R&amp;amp;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and credit carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company had approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized tax benefits as of December 31, 2024. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Beginning Balance on January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase related to business combination on October 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Ending Balance on December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Ending Balance on December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#x2019;s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;t recognized any tax-related penalties or interest in its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company files income tax returns in the United States federal, California, and Florida for tax year 2023. The Company filed an initial return in 2022 in Florida and final returns in 2021 in Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2024 and 2023, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; uncertain tax positions which affected its financial position as its results of operations or its cash flow for US tax purposes, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;According to the PRC Tax Administration and Collection Law, the statute of limitations is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitations is extended to five years under special circumstances where the underpayment of taxes is more than RMB100 thousand. In the case of transfer pricing issues, the statute of limitations is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; years. There is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_89458a30-1f4b-4bab-95ce-8c2641b3664a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; statute of limitations in the case of tax evasion. The income tax returns of the Company&#x2019;s PRC subsidiaries for the years from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; are open to examination by the PRC tax authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;APB 23&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Generally, a taxable outside basis difference associated with a foreign subsidiary may not be recognized if the indefinite reversal criterion of ASC paragraph 740-30-25-17 (APB Opinion No. 23, Accounting for Income Taxes &#x2013; Special Areas (&#x201c;APB 23&#x201d;)) is met. A deferred tax liability is recognized when an entity no longer meets the indefinite reversal criterion. ASC paragraph 740-30-25-17 provides a presumption that all undistributed earnings will be transferred to the parent entity may be overcome, and no income taxes shall be accrued by the parent entity, if sufficient evidence shows that the subsidiary has invested or will invest the undistributed earnings indefinitely or that the earnings will be remitted in a tax-free liquidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company does not have a plan of repatriation of earnings from non-US subsidiaries to the Company. However, to the extent the Company will not permanently reinvest in its PRC business, a deferred tax liability of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024 related to PRC withholding taxes on repatriation of Gyre Pharmaceuticals&#x2019; earnings (i.e., the Company&#x2019;s primary operating subsidiary in the PRC) would need to be recorded.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_8c3643f6-a2bf-48c0-9233-78a42ccdaacf">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The components of the Company&#x2019;s provision for income taxes for the years ended December 31, 2024 and 2023 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.094%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Current income tax provision:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign - PRC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total current income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax provision:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign - PRC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total deferred income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_4f485ca4-e5ef-46cd-80ea-707032987732"
      unitRef="U_USD">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_9d408b0b-990f-4a44-9839-df276040106a"
      unitRef="U_USD">6000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_c039ff89-4142-4f6a-897c-b68cec7fc997"
      unitRef="U_USD">6320000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_fc95f2ef-d6c5-4663-85b4-e56ba1b2548e"
      unitRef="U_USD">9343000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_51ad1700-4729-4c19-92f0-f162e13fc9d3"
      unitRef="U_USD">6322000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_5b955e44-c38e-4923-ae26-eaf696b2b73b"
      unitRef="U_USD">9349000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_3d3c8847-5d3c-4b33-b697-5df5c251ffe7"
      unitRef="U_USD">-1002000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_0f441237-f50d-43b7-9c25-9e3a6b9ee68d"
      unitRef="U_USD">-834000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_18ddc54b-cfb7-4346-a3c5-eb50e85f511d"
      unitRef="U_USD">-1002000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_5c02bcf4-0d34-43c3-8dd7-dda7ecb05da4"
      unitRef="U_USD">-834000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_83b1e05b-6f1c-4d43-8426-1e090da7ca58"
      unitRef="U_USD">5320000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_3e84bb7d-165a-4b70-b764-ab48e40c7790"
      unitRef="U_USD">8515000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ecc355fa-1daf-430f-80db-2e0a3e032780">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate for the years ended December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.987%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.217%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.137%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Rate difference due to different jurisdiction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Preferential income tax rate for HNTE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Non-deductible expense &#x2013; Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Non-deductible expense &#x2013; acquisition related&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D Super-deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;ESOP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.02&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_6d5085ff-deaa-46be-bad1-0d6654958a05"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_b11fb370-4927-44e4-8251-9cc8d8186aeb"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_e7742668-daec-4dc8-ac2c-67b3cd2b1e4c"
      unitRef="U_pure">0.0387</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_d8adf0f0-4d4e-40c3-9a17-88237b1bd7f7"
      unitRef="U_pure">-0.0243</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_01a4c09a-dea4-408c-9e42-4087c5d07bf1"
      unitRef="U_pure">-0.0948</gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte>
    <gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_5a9674a2-5388-4711-9140-11ba176da45f"
      unitRef="U_pure">0.0319</gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_553defcb-b9cc-43c2-9e72-ab0494127f2d"
      unitRef="U_pure">0.0664</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_8ad8c050-4e3b-45ae-b809-684d5657263e"
      unitRef="U_pure">-0.0628</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_811bd764-35f6-4cd5-a929-6edcf9b1024c"
      unitRef="U_pure">0</gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition>
    <gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_8a941b3a-e647-4d58-b161-03662d232063"
      unitRef="U_pure">-0.2216</gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToAcquisition>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_b63500ea-2722-4e9f-a1b3-24cccf4a45d9"
      unitRef="U_pure">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_92876279-34dc-4434-a426-ba617265de2a"
      unitRef="U_pure">-0.0145</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_ba9010f2-5800-4fca-8695-c26f4c21e278"
      unitRef="U_pure">0.0313</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_894fc20e-2c38-4db2-b5fe-350ef475a0fc"
      unitRef="U_pure">-0.0437</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_b3edc42a-485a-437e-8227-45b0c35172de"
      unitRef="U_pure">0.0113</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_572b69f5-c4f4-49d3-bedd-9a1f5a5ad804"
      unitRef="U_pure">-0.0055</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_195685f0-c685-4865-90b0-3cdf74a77eee"
      unitRef="U_pure">0.0002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_b4a3af06-d91c-47ed-b19d-6af276b714a9"
      unitRef="U_pure">-0.0076</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="4"
      id="F_7e693f30-f4d2-4fca-bda4-ec1b9e1972d3"
      unitRef="U_pure">0.2291</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="4"
      id="F_65e4e40c-a683-4441-bd89-f3eda026ace2"
      unitRef="U_pure">-0.1091</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_8fe242ac-db8d-4da7-985d-18d7f2e897f6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets as of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; December 31, 2024 and 2023 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.066%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.136999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.136999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Tax credit carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Fixed and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Impact from foreign corporations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Capitalized transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liability &#x2013; ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liability &#x2013; Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_d7482204-c273-4016-b221-5a4b5dc72a19"
      unitRef="U_USD">407000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_d5487c13-e7b0-4ad7-9837-2232dbcd9c94"
      unitRef="U_USD">2811000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <gyre:DeferredTaxAssetsContractLiabilities
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_fb8221d5-c530-4e2b-97d7-72b90e788f97"
      unitRef="U_USD">153000</gyre:DeferredTaxAssetsContractLiabilities>
    <gyre:DeferredTaxAssetsContractLiabilities
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_2f724f1e-852d-47e5-9906-024bac2cae97"
      unitRef="U_USD">39000</gyre:DeferredTaxAssetsContractLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_a427d1f2-e00b-49ca-bc7a-b15c95da3230"
      unitRef="U_USD">41714000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_8be29188-39dc-4d8a-82f4-6f148aaa58cd"
      unitRef="U_USD">40669000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_2c62be00-cec3-4c6a-8852-dd31a8e6ff4d"
      unitRef="U_USD">4463000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_de2d2d5a-e716-40cd-adc6-0b08297dea3c"
      unitRef="U_USD">4463000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <gyre:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_4b7cb18f-fa0e-4c45-8408-46b36fbd5f92"
      unitRef="U_USD">15385000</gyre:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <gyre:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_c89e7efb-bc59-43f8-9f6e-de769bb55c26"
      unitRef="U_USD">15332000</gyre:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <gyre:DeferredTaxAssetsImpactFromForeignCorporations
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_5f82cbf1-c25f-480b-8c90-a9afd6cb4075"
      unitRef="U_USD">8754000</gyre:DeferredTaxAssetsImpactFromForeignCorporations>
    <gyre:DeferredTaxAssetsImpactFromForeignCorporations
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_fd5ed119-7c30-4975-9e85-1f8f11d416de"
      unitRef="U_USD">4590000</gyre:DeferredTaxAssetsImpactFromForeignCorporations>
    <gyre:DeferredTaxAssetsCapitalizedTransactionCosts
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_c8d6deb4-bdc4-4669-b935-b5d1f21e1c57"
      unitRef="U_USD">430000</gyre:DeferredTaxAssetsCapitalizedTransactionCosts>
    <gyre:DeferredTaxAssetsCapitalizedTransactionCosts
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_92c66c6d-5227-4052-9dcc-5d32168f3286"
      unitRef="U_USD">658000</gyre:DeferredTaxAssetsCapitalizedTransactionCosts>
    <gyre:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_54fab19d-c4f5-43ed-852b-76eac32bd01d"
      unitRef="U_USD">288000</gyre:DeferredTaxAssetsLeaseLiabilities>
    <gyre:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_a9b0208c-68a6-40db-914c-a338aebfca0d"
      unitRef="U_USD">98000</gyre:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_e3f260d9-1396-41fc-87cb-d86d8e15cbb6"
      unitRef="U_USD">71594000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_4b16186d-be30-4de2-8c9a-a3d65bd9aeab"
      unitRef="U_USD">68660000</us-gaap:DeferredTaxAssetsGross>
    <gyre:DeferredTaxLiabilityRightOfUseAssets
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_924a56b3-bf49-4188-a0dc-0c52e894e814"
      unitRef="U_USD">296000</gyre:DeferredTaxLiabilityRightOfUseAssets>
    <gyre:DeferredTaxLiabilityRightOfUseAssets
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_cc5ce49c-8381-4000-ac30-ab9a8820b5eb"
      unitRef="U_USD">108000</gyre:DeferredTaxLiabilityRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_566291af-1fc3-4cae-8ff1-972987968faf"
      unitRef="U_USD">74000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_026efd20-feea-4f13-8a66-348f255bc578"
      unitRef="U_USD">84000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_7495a019-918a-4d9e-bc15-3e0dfde0759f"
      unitRef="U_USD">65605000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_09996313-825b-4cdc-8553-77490b30de52"
      unitRef="U_USD">63773000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_659e39a7-7e3f-464d-832c-fff6b68b7a53"
      unitRef="U_USD">5619000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_38825961-fc7a-43fa-bea6-91e771e39e6d"
      unitRef="U_USD">4695000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_35bfcb11-c260-48f9-89f1-0fb0384bb61c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The movements of the valuation allowance are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.677%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.424%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.889%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes of valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_8766e012-b035-403e-a6d8-4f379928c746"
      unitRef="U_USD">63773000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <gyre:ChangesOfValuationAllowances
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_52de0c9a-1a18-4897-93f8-16216c0a1327"
      unitRef="U_USD">1832000</gyre:ChangesOfValuationAllowances>
    <gyre:ChangesOfValuationAllowances
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_9fa23bc2-fea7-4d6a-b501-2381f465eedf"
      unitRef="U_USD">63773000</gyre:ChangesOfValuationAllowances>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_46acf859-e6b6-425a-86c4-3f57ae8ea806"
      unitRef="U_USD">65605000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_19713498-9254-431c-9d78-aaeeb64cc074"
      unitRef="U_USD">63773000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c"
      decimals="-5"
      id="F_0314a848-0198-4515-b4d4-5ba2a11ed047"
      unitRef="U_USD">193400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e3f9ca20-fe6e-464e-88fe-e2cdb2bbeb47"
      decimals="-5"
      id="F_aa37bc36-2618-4d19-ba8f-210478fe2d2a"
      unitRef="U_USD">13900000</us-gaap:OperatingLossCarryforwards>
    <gyre:OperatingLossCarryforwardsExpirationYear
      contextRef="C_18a964f8-b880-42dd-8893-8c908e72943e"
      id="F_d56aa348-3ec3-40ca-82de-15bf277e373f">2037</gyre:OperatingLossCarryforwardsExpirationYear>
    <gyre:OperatingLossCarryforwardsExpirationYear
      contextRef="C_aaa537e5-aadd-401c-b660-aedaa53b9b03"
      id="F_c3a0ab1c-d86f-48fa-b199-ede618c6ed78">2034</gyre:OperatingLossCarryforwardsExpirationYear>
    <gyre:OperatingLossCarryforwardsWithIndefiniteLife
      contextRef="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c"
      decimals="-5"
      id="F_b06f4e4d-71b2-4c83-a2f6-9aa04fbb5945"
      unitRef="U_USD">191900000</gyre:OperatingLossCarryforwardsWithIndefiniteLife>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c"
      decimals="0"
      id="F_791a4a6e-157a-42b0-ba03-8fa3e3d7a660"
      unitRef="U_USD">8000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_e3f9ca20-fe6e-464e-88fe-e2cdb2bbeb47"
      decimals="-5"
      id="F_f9d20303-a5b8-40da-9889-223e24ccbe5a"
      unitRef="U_USD">7500000</us-gaap:TaxCreditCarryforwardAmount>
    <gyre:TaxCreditCarryforwardExpirationYear
      contextRef="C_18a964f8-b880-42dd-8893-8c908e72943e"
      id="F_bbe667c5-33ce-4162-ae5f-45502060198d">2042</gyre:TaxCreditCarryforwardExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2f70b255-6cf8-4fea-a0c2-53d777ed397c"
      decimals="-5"
      id="F_b20cada1-da38-4ed1-825d-197596dc0ff5"
      unitRef="U_USD">156500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_c554efd0-8c25-49d5-887a-c4fae5255da6"
      decimals="-5"
      id="F_aa244039-102b-49a7-891d-98f569cd96ca"
      unitRef="U_USD">75200000</us-gaap:OperatingLossCarryforwards>
    <gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards
      contextRef="C_5e8de9b3-0dea-46e5-92a8-eed056bcf00c"
      decimals="-5"
      id="F_e199c988-26bb-4968-9cec-e32009d16d69"
      unitRef="U_USD">32900000</gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards>
    <gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards
      contextRef="C_c554efd0-8c25-49d5-887a-c4fae5255da6"
      decimals="-6"
      id="F_d09e81fe-d2bf-4da2-be68-83a271bd6354"
      unitRef="U_USD">0</gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards>
    <gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-5"
      id="F_753d5af9-5696-43da-b203-567acde83e21"
      unitRef="U_USD">26000000.0</gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_c2a725c1-f6d8-4137-ad15-f6be8c7bee3f"
      unitRef="U_USD">1900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ea879f49-858b-4df2-a42f-c31ba391b779">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Beginning Balance on January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase related to business combination on October 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Ending Balance on December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Ending Balance on December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_1388f67a-7e9b-4efe-996e-61341927c0bf"
      decimals="-3"
      id="F_5f05be56-e786-4398-82b2-646eceedd5c9"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_6cd2b021-a666-4f39-91a9-91080a50cb23"
      unitRef="U_USD">1883000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_bbaefe36-349f-4942-ab42-fb1f79306ec4"
      unitRef="U_USD">0</gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_92e4ec09-ae13-4ed4-8018-3bc1ddfe1900"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_2ef6e9f1-0719-41a4-8364-ee79dc217422"
      unitRef="U_USD">1883000</us-gaap:UnrecognizedTaxBenefits>
    <gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_0f88b742-642a-4cb2-ab28-098d64e1e15b"
      unitRef="U_USD">0</gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_c3045db3-620e-4f68-a6e2-c8cd39d2310e"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_406bc931-3862-43b1-9dff-f6abe00a46f3"
      unitRef="U_USD">1883000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_472adb57-69f4-4a21-b723-67e3cef933f2"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_69ff38e2-205f-4f3e-978e-90b7714e0047"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="INF"
      id="F_2883e4ca-7969-499a-b23e-d2e830eaa9c2"
      unitRef="U_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="INF"
      id="F_ba694843-3c9c-4b10-a4c7-1d8b094372df"
      unitRef="U_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <gyre:StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent
      contextRef="C_ab0e6ad3-77e4-40d2-a914-3a959c431d3b"
      id="F_b9614409-3933-42b6-8032-7d7e5868a019">P3Y</gyre:StatuteOfLimitationDueToComputationalErrorsMadeByTaxpayerOrWithholdingAgent>
    <gyre:StatuteOfLimitationDueToTransferPricingIssues
      contextRef="C_ab0e6ad3-77e4-40d2-a914-3a959c431d3b"
      id="F_342b65df-f41c-4ad2-9840-581e07a4f51e">P10Y</gyre:StatuteOfLimitationDueToTransferPricingIssues>
    <us-gaap:OpenTaxYear
      contextRef="C_b931a2e4-4754-474d-9b6e-f1c8f4585e49"
      id="F_75917b88-e989-4b23-841e-ffaf304c0e01">2019</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="C_8dc9cab1-3dbb-40a8-840c-8dd98ff4680f"
      id="F_7ef2aa57-1d1d-4f20-804e-856b23bd9b99">2024</us-gaap:OpenTaxYear>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-5"
      id="F_deff9164-4799-4ae4-aea2-3323b465ecd9"
      unitRef="U_USD">8300000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_de96861a-8acc-4cb8-b347-276a49a1b65f">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;15.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and development with GNI Group&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development fees paid to GNI Group during the year ended December 31, 2024 were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; research and development fees were paid to GNI Group d&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;uring the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company had a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million related parties payable due to GNI Group, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other receivables from GNI Group&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million in other receivables from GNI Group, of which &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; was from CPI&#x2019;s restructuring transaction (see Note 8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;). As of December 31, 2023, the Company had recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million in other receivables from GNI Group, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million was from CPI&#x2019;s restructuring transaction (see &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Note 8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;) and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million was from Gyre&#x2019;s cost sharing with GNI Group.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_62f92e1d-e5a8-4fa2-9000-93f2a1b15be5"
      decimals="-5"
      id="F_a51b66a0-53f5-41a8-8b7e-31ae31ccab94"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_dc02e0a2-17b6-4879-92cf-e5b95666c954"
      decimals="INF"
      id="F_c421633c-b717-4e4d-8a22-826eaba5a23f"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherLiabilities
      contextRef="C_c7af3ec1-7037-4691-9c1c-8e9ff94d139a"
      decimals="-5"
      id="F_e39659ce-3576-4724-8269-b83306b6a490"
      unitRef="U_USD">200000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="C_11e97b2b-d131-4b0d-a65f-f76a30c9fe74"
      decimals="-5"
      id="F_6e54a033-c6a1-4fdd-b49c-31f7b51cb0dd"
      unitRef="U_USD">1400000</us-gaap:OtherLiabilities>
    <us-gaap:OtherReceivables
      contextRef="C_a0d10ade-3d48-49d5-bdd7-851689590754"
      decimals="-5"
      id="F_bdc55e8b-758a-4aee-abd8-d71a89ad5e99"
      unitRef="U_USD">200000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_ff4a65f5-6aee-43bc-ae21-205a10de9f61"
      decimals="-5"
      id="F_499d5d7f-8a60-4a8c-8be0-f9fb400b3518"
      unitRef="U_USD">200000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_2105308e-fcfa-4236-bc88-d64b4d792f06"
      decimals="-5"
      id="F_30964851-1eb9-4e2f-a22d-da53b54fcc5c"
      unitRef="U_USD">1300000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_55596a3f-d3e4-4c79-87e1-e28ba063d3f2"
      decimals="-5"
      id="F_92183bbc-6483-43a6-b979-bc9dbfb372e6"
      unitRef="U_USD">800000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_062c6dd6-59a4-4c32-8566-83e073df4f7e"
      decimals="-5"
      id="F_e4c0d2cf-412c-4798-b8e8-ae698f70162a"
      unitRef="U_USD">500000</us-gaap:OtherReceivables>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_b19a3580-d82d-4c00-98a0-f443120640a8">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;16.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;EPS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The dilutive effect of outstanding stock options and warrants is calculated using the treasury stock method. Stock options and warrants are anti-dilutive and excluded from the diluted net income per share attributable to common stock calculation if the exercise price exceeds the average market price of the common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.540000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) attributable to common stockholders - basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Less:   Change in fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) attributable to common stockholders - diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Basic common shares outstanding:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,094,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,094,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,407,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Convertible Preferred Stock (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;528,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Preferred Stock Warrants (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,293,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) per share attributable to common stockholders:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;896,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Convertible Preferred stock (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock Warrants (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;896,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,588,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_f02a851f-60f7-45b6-9bb1-5c408f35e153">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.540000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) attributable to common stockholders - basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Less:   Change in fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) attributable to common stockholders - diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Basic common shares outstanding:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,094,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,094,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,407,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Convertible Preferred Stock (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;528,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of Preferred Stock Warrants (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares used in calculating net income (loss) per share attributable to common stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,293,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) per share attributable to common stockholders:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_70b6f8a1-0ec2-4bff-84bb-4c393898d5f7"
      unitRef="U_USD">17898000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_649e7a4d-5ae2-4152-b25d-f59d1bd4f504"
      unitRef="U_USD">-85480000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_f88cff84-f251-413a-822d-77e0cecbf1c3"
      unitRef="U_USD">5813000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_f4f1f634-c473-4c8a-b1b4-41e204b0518a"
      unitRef="U_USD">7453000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_3c224bf5-6859-4e61-aaeb-4e7504747994"
      unitRef="U_USD">12085000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_513987a9-e2ff-4b19-988d-555f1d1c0793"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_eae49253-60aa-4887-815c-260f0ad83aaa"
      unitRef="U_USD">-7167000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_468667be-3f8b-4747-bdfd-392c48b4555b"
      unitRef="U_USD">4918000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_538f36cb-dcb9-4b83-b9bc-337f520663d8"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="0"
      id="F_bc064e9f-94e9-408f-877f-ac9a12333d42"
      unitRef="U_shares">85094948</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="0"
      id="F_e600983a-e0a0-4b45-b7da-22ea8b05f86a"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="0"
      id="F_cc3c215a-076d-4513-ac65-24f2b096dc5d"
      unitRef="U_shares">85094948</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="0"
      id="F_903d9f3a-477f-43f4-9401-a778a4b2e689"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="INF"
      id="F_a04d4e65-ad4e-4899-b700-95fc65812a18"
      unitRef="U_shares">16407847</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="0"
      id="F_f0e51b8e-fd05-4a49-8a5a-5a0941b1a0a4"
      unitRef="U_shares">528442</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <gyre:WeightedAverageOfPreferredStockWarrant
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="0"
      id="F_f7a00484-f8cd-4238-aaf9-2d726ffd6fa6"
      unitRef="U_shares">262289</gyre:WeightedAverageOfPreferredStockWarrant>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="0"
      id="F_f1cd1ad2-5578-4b26-a9fd-26c9c646ad30"
      unitRef="U_shares">102293526</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="0"
      id="F_41472ea9-7bb3-4717-a5fd-a7d14b25a3e2"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_1d9081c3-c53d-446f-8f3a-faf28fef7201"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="2"
      id="F_6aa29583-12ee-4da2-9191-efea0bb924e5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="2"
      id="F_b67f08a6-6e55-4628-b547-ab2df81acb90"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="2"
      id="F_474dc95c-c3ce-40d7-a447-5dbf48799c2b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_ef0e52a4-1d68-491f-b818-38faa4252ab2">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;896,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Convertible Preferred stock (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock Warrants (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;896,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,588,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7cf186e1-972c-4665-8d9c-1bfd52550fc8"
      decimals="INF"
      id="F_7c21a15c-1007-4547-97cc-aa98e0b02f38"
      unitRef="U_shares">896960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a06a4417-252f-4ba9-b828-689df30eb019"
      decimals="0"
      id="F_6436289e-fff8-495e-8592-f7727115a78d"
      unitRef="U_shares">18280548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d8c5083e-baaa-4ff7-ae97-3c6730697288"
      decimals="0"
      id="F_2e495e25-7f06-4af4-8b5b-a41bb0981974"
      unitRef="U_shares">8767332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9a91ad18-5e8c-4f49-bb3b-55e76625715d"
      decimals="0"
      id="F_d508f7b6-309f-47ba-9b90-7de851f3c88c"
      unitRef="U_shares">540666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="INF"
      id="F_4dfd8ba2-32c1-49a0-a726-bb6d6ab5bb1a"
      unitRef="U_shares">896960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="0"
      id="F_f35a58f4-075b-4d81-934b-2666241fad21"
      unitRef="U_shares">27588546</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DefinedBenefitPlanTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_f7043259-2723-42d9-9434-3c9db4cfee11">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;17.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Mainland China Contribution Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Pursuant to relevant PRC regulations, the Company is required to make contributions to various defined contribution plans organized by municipal and provincial PRC governments. The contribution for each employee is based on a percentage of the employee&#x2019;s current compensation as required by the local&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;government. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme. The total contributions for such employee benefits were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024, and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Defined-Contribution Savings Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;In the U.S., the Company maintains a defined-contribution savings plan pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended. The plan is available to employees who meet the minimum age and length of service requirements. The contributions made during the year ended December 31, 2024 and 2023 were immaterial.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_7ddd47da-42c9-45c5-8866-0c39c6994ea9"
      decimals="-5"
      id="F_5759a3a9-70e7-4f4d-a7ba-721693977c86"
      unitRef="U_USD">5100000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_502e4c1c-95d6-4ae7-893a-2eda77e87309"
      decimals="-5"
      id="F_de1a1970-d1fd-4c17-a4a8-4b0d94948dd7"
      unitRef="U_USD">4300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_168d8495-2362-4808-b149-fe3ad00671e5">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;18.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The Company is a consolidated entity comprised of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; distinct operating segments: Gyre Pharmaceuticals &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;and Gyre after the Contributions. The Company&#x2019;s reportable segments are based upon internal organizational structure, the manner in which operations are managed, the criteria used by the CODM to evaluate segment performance, the availability of separate financial information, and overall materiality considerations. All Gyre&#x2019;s operations are within the U.S., while all of Gyre Pharmaceuticals&#x2019; operations are in mainland China.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre Pharmaceuticals&#x2019; product revenues are mainly generated from the sale of ETUARY and certain generic drugs. Gyre Pharmaceuticals primarily sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of MASH-associated liver fibrosis in the United States. Other than the IP associated with F351 in the U.S., Gyre has no other product candidates since the Company sold all of its legacy IP assets prior to the closing of the Contributions. Subsequent to the closing of the Contributions, Gyre has not generated any revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other represents the financial information from other subsidiaries, consisting of mainly CPI, GNI HK, and Continent Pharmaceuticals U.S., Inc. During the year ended December 31, 2023, prior to the Contributions, CPI divested almost all of its assets other than its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;% indirect ownership interest in Gyre Pharmaceuticals (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructuring&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Segment inform&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;ation for the years ended December 31, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.35%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.738000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross profit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Operating expenses excluding cost of revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Loss on disposal of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses excluding cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income (Loss) from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Supplemental Disclosure of stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.35%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.738000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross profit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Operating expenses excluding cost of revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Divestiture losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Loss on disposal of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses excluding cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income (Loss) from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Supplemental Disclosure of stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million represents legal expense recorded in CPI during the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million represents divestiture losses. See Note 8 for details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:'Aptos',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The table below presents total assets as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Purchase of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Purchase of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="INF"
      id="F_2240111a-500b-4282-b6d1-b48c47327c72"
      unitRef="U_Segment">2</us-gaap:NumberOfOperatingSegments>
    <gyre:PercentageOfIndirectOwnershipInterest
      contextRef="C_21ad98a8-a7b0-4600-a53d-9f79dd8b3cbd"
      decimals="3"
      id="F_10d0da9d-9c43-467a-a3c3-e17a95ce2737"
      unitRef="U_pure">0.56</gyre:PercentageOfIndirectOwnershipInterest>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_77c19da4-5efe-4ea5-a696-d985688f8ec6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Segment inform&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;ation for the years ended December 31, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.35%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.738000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross profit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Operating expenses excluding cost of revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Loss on disposal of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses excluding cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income (Loss) from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Supplemental Disclosure of stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.35%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.738000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.938%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gross profit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Operating expenses excluding cost of revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Divestiture losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Loss on disposal of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses excluding cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income (Loss) from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Interest income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Supplemental Disclosure of stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million represents legal expense recorded in CPI during the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; million represents divestiture losses. See Note 8 for details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The table below presents total assets as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Purchase of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Purchase of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_f0b8a713-798d-4979-b70f-52b2cd1dccbd"
      unitRef="U_USD">105757000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_d5745eb3-75c3-4edc-953d-cb02f37a6095"
      unitRef="U_USD">105757000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_4f0f8c78-cc4c-4e5c-b13e-b4c3d98679eb"
      unitRef="U_USD">3884000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_d10c6df9-e481-4261-a475-c00c293c20f4"
      unitRef="U_USD">3884000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_67235a47-8c78-4686-8e74-e2f40c06e2e2"
      unitRef="U_USD">101873000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_a6da9b44-1e86-43ce-9510-2cea3e88701f"
      unitRef="U_USD">101873000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_274e1dcc-1463-4fac-8f71-ce4715f12941"
      unitRef="U_USD">57511000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_aff79ed2-2273-40b2-8bb6-0215204b58d3"
      unitRef="U_USD">57511000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_3df59929-853c-4c30-ac89-53814b6403e0"
      unitRef="U_USD">11224000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_627f2d80-93ce-4c34-adaf-d4d24e53f280"
      unitRef="U_USD">800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_0c0163d9-dff4-4509-b539-3bb81812219b"
      unitRef="U_USD">12024000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_3fbb8d23-0669-43c2-87f4-cf6194e5b6b8"
      unitRef="U_USD">11051000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_ec4548fb-06f1-4ce7-887d-f9c399271130"
      unitRef="U_USD">5056000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25"
      decimals="-3"
      id="F_6e6254d8-6099-4904-9a76-52c446dab696"
      unitRef="U_USD">2000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_5e25b8c7-c531-4065-a078-cd9b25bd6de1"
      unitRef="U_USD">16109000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_66fbe23f-ac24-4059-b92b-e87399826734"
      unitRef="U_USD">-66000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_215ee5cd-0253-4274-aaad-b34dd2f8504c"
      unitRef="U_USD">-66000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingExpenses
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_ee597467-027d-43a1-9af6-6f09ccc4c912"
      unitRef="U_USD">79852000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_9e55e601-fcbf-41ce-8e6c-dfa517d54ee0"
      unitRef="U_USD">5856000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25"
      decimals="-3"
      id="F_aa5c3dd3-683e-4167-894d-557af0c0c153"
      unitRef="U_USD">2000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_8d20504e-9800-4d4b-a85d-fa81902af323"
      unitRef="U_USD">85710000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_c0489c76-ee7c-4293-be82-2114540fc56f"
      unitRef="U_USD">22021000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_8ac38036-3f65-41bb-8b20-59bf5acf548a"
      unitRef="U_USD">-5856000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25"
      decimals="-3"
      id="F_50ea9115-d9a9-4b6b-bb84-d3f14b70064a"
      unitRef="U_USD">-2000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_05c65eb0-8e1c-4239-8939-247df6acbf61"
      unitRef="U_USD">16163000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_25255eeb-e0f2-4e35-9514-fc1a88c75091"
      unitRef="U_USD">1321000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_7a0257f3-16d0-4bc3-96c9-616dbd96e546"
      unitRef="U_USD">232000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25"
      decimals="-3"
      id="F_b1fb2c63-3d1a-49d2-99cc-3553fdb3cc69"
      unitRef="U_USD">-6000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_f8b105cd-2b6a-4e27-9afa-0469242027f4"
      unitRef="U_USD">1547000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_2c1110a8-6dd5-470f-93f8-69468be77555"
      unitRef="U_USD">-1329000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_fb441f4c-83e1-4a8d-aa90-46b934e46795"
      unitRef="U_USD">-336000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25"
      decimals="-3"
      id="F_f38450b8-f7cf-4587-bddb-db605352bcb6"
      unitRef="U_USD">6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_5040d3c0-2bcf-4469-8949-b27da84c6123"
      unitRef="U_USD">-1659000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_d797daf3-4e2e-4af4-8d6c-64f8b5c1863a"
      unitRef="U_USD">-7167000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_e89c28e2-bca0-4e07-a96f-05a5ca888089"
      unitRef="U_USD">-7167000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_0c9e95c7-a2be-489f-9452-1175b7e39a5e"
      unitRef="U_USD">5318000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_1db12ea3-2bb8-42f1-9649-f53414143874"
      unitRef="U_USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_794cfacc-7af9-4b2b-89d1-156f7f6a1aef"
      unitRef="U_USD">5320000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_d8fde14a-1191-4d06-83b9-5919a5ca1816"
      unitRef="U_USD">16695000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_2c26c635-8baf-4ae2-b0dc-e7a66bc50147"
      unitRef="U_USD">1205000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bfd51d7b-b349-4540-8451-b38e1a4adc25"
      decimals="-3"
      id="F_db30e4ec-401d-4409-89a3-e15571ee6cca"
      unitRef="U_USD">-2000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_c5271396-1bf6-4a5f-bf6d-3421410c7f27"
      unitRef="U_USD">17898000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_22f0fc96-1e38-40b1-9a23-4191cce058e8"
      decimals="-3"
      id="F_2316d2bd-fbb4-416e-90d4-dafa6f147735"
      unitRef="U_USD">831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cc77e3d6-0b6d-4809-98bc-ba50dc57d0e8"
      decimals="-3"
      id="F_c98e5f57-e986-4c76-bc20-957ee224bda2"
      unitRef="U_USD">831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_034925ea-6bfd-4cea-8f3f-e8dacb6bf61c"
      unitRef="U_USD">831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_6c7db666-da67-47d1-9cfd-5af70416724b"
      unitRef="U_USD">831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_00336cc8-d657-4efe-b72c-841593f02e5f"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_592253d1-36af-4849-9a0e-7e4e0aee1c17"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_731589bc-bd0b-49d3-8db3-b3eb2030876a"
      unitRef="U_USD">4636000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_0adaa776-4b6e-461c-8a6e-50ad08c5af97"
      unitRef="U_USD">4636000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_3f783604-c945-4060-a2a0-53f6c5f64ea6"
      unitRef="U_USD">108814000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_8834ad1d-165a-4488-bf50-9d0b5082af10"
      unitRef="U_USD">108814000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_33a55c4c-b23a-40e4-86f4-8e9c821c50af"
      unitRef="U_USD">61159000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_3994432f-7e7d-4903-84a7-d19320af99d1"
      unitRef="U_USD">61159000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_140905c1-f4c1-4269-a165-dd6cb701b3d7"
      unitRef="U_USD">13698000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_bb416ea8-d6f4-4b62-bcce-88d4142a4219"
      unitRef="U_USD">82000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_e1f6a80b-d8ec-4f0b-88f4-005c7967701c"
      unitRef="U_USD">13780000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_bdf42420-64b9-4b7a-ae6a-9aaa682d73ef"
      unitRef="U_USD">8872000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_4c52bcf7-72d3-434e-ac34-01cedd222596"
      unitRef="U_USD">5214000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795"
      decimals="-3"
      id="F_41a46ffc-d8be-4647-b4b8-9a54d44df13a"
      unitRef="U_USD">576000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_de8487ba-c446-485f-9240-607a84d47e62"
      unitRef="U_USD">14662000</us-gaap:GeneralAndAdministrativeExpense>
    <gyre:AcquiredInProcessResearchAndDevelopment
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_255d3d3f-5972-4031-8b10-62df9895942a"
      unitRef="U_USD">83104000</gyre:AcquiredInProcessResearchAndDevelopment>
    <gyre:AcquiredInProcessResearchAndDevelopment
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_50d9539f-09dd-43fe-ab13-174463a33319"
      unitRef="U_USD">83104000</gyre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795"
      decimals="-3"
      id="F_149a77f7-ffed-436a-81d7-99f191445001"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_fbe96d6a-bd06-4120-bd08-5d232c6f2199"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_69555945-c376-4435-ab10-c2a2ac7ca51a"
      unitRef="U_USD">-628000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_bca352e3-aa05-41e4-b92e-2c9fac7aba9a"
      unitRef="U_USD">-628000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingExpenses
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_bbf5358b-6c50-4e5d-8ddd-8d4e0a4dc2c6"
      unitRef="U_USD">84357000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_dc205222-c793-4bf0-a6e9-c855f6c058af"
      unitRef="U_USD">88400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795"
      decimals="-3"
      id="F_15be67dc-280f-444c-a2ed-9af1c0655119"
      unitRef="U_USD">3287000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_b39cfc07-a68b-4a78-a538-6bacf3801554"
      unitRef="U_USD">176044000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_a8bdc2a7-c00a-4231-84b2-1feb82ed589f"
      unitRef="U_USD">24457000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_bd53ea85-b79f-47b0-beff-b4e1313ccb73"
      unitRef="U_USD">-88400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795"
      decimals="-3"
      id="F_8edf54ef-f93d-4adb-be58-5a6c7a27e29f"
      unitRef="U_USD">-3287000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_471c2433-c48c-43b3-8ea9-429de3a5f92e"
      unitRef="U_USD">-67230000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_c26c81cd-b321-4ee5-8a0e-daee52b1d698"
      unitRef="U_USD">1044000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_f71b78d1-aea0-4c45-b839-0d946b1b00cb"
      unitRef="U_USD">1044000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_5a4cd8e4-4764-416e-aa11-171e954e1280"
      unitRef="U_USD">-1246000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_205c0a2f-faf3-4079-bc7d-e8d5aae9f0fe"
      unitRef="U_USD">-272000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_d1249a10-2121-4832-9aad-ccb63e3df8ae"
      unitRef="U_USD">-1518000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_e55fe255-3758-471f-b7f9-35d4e07bf87e"
      unitRef="U_USD">9261000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_01762126-2558-4bf1-88ef-add3fb056850"
      unitRef="U_USD">9261000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_11d0786b-7012-418f-ac99-89b3cd8dabf2"
      unitRef="U_USD">8509000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_6c182280-3e1b-4c05-824d-f55ec769994d"
      unitRef="U_USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_4d7198fe-d66a-4d59-85bc-8c8178f646ae"
      unitRef="U_USD">8515000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_9dcc9459-ca9d-410a-a3d9-1a843450624f"
      unitRef="U_USD">15746000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_655f59d7-8471-4af3-9d39-23dfc0151c14"
      unitRef="U_USD">-97939000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b489322b-84cd-4fef-81ee-6ac40fe1d795"
      decimals="-3"
      id="F_52431f4d-f769-42a8-b972-954a61e916e7"
      unitRef="U_USD">-3287000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_f6bdf3a9-126e-4c2d-bfeb-b4a4a79a9f77"
      unitRef="U_USD">-85480000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_18bc2358-95e4-46d2-9214-ce5de90d7258"
      decimals="-3"
      id="F_faf2cf50-5e78-4117-8248-29ab3dc1cc4a"
      unitRef="U_USD">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e5513b2b-c8d0-4816-81a6-d83601aee525"
      decimals="-3"
      id="F_bd82c3c2-bf5b-4cec-888f-5335f205e262"
      unitRef="U_USD">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b2bd78e9-9849-479f-8eb7-41ba287f57e6"
      decimals="-3"
      id="F_0698a47b-b070-459d-a341-20ee3fe0afe1"
      unitRef="U_USD">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c3036813-c367-4137-83bc-d3111a243c9e"
      decimals="-3"
      id="F_699643b4-5ece-4ed4-af13-3756bcf61d36"
      unitRef="U_USD">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6846f876-7997-4227-a1ac-8419c302881e"
      decimals="-3"
      id="F_211632da-a6b3-43ec-a3df-3505a61cca74"
      unitRef="U_USD">481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_49f4dab9-8bd1-4577-b767-6356a5621a2b"
      decimals="-3"
      id="F_7959f6ac-d792-45d7-a169-143bc7842a17"
      unitRef="U_USD">481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f655bd73-1357-4906-aaa2-0388e4dae1b0"
      decimals="-3"
      id="F_d81132c6-e41c-43c8-87f9-bb357672f578"
      unitRef="U_USD">1916000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_80b233b8-8d6b-4b3a-b077-9d160ffc37ec"
      decimals="-3"
      id="F_04411ced-d72a-4b02-a69e-e43a87e886e5"
      unitRef="U_USD">4488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_28b79e15-5ce4-4bf9-8af0-0a1821e83289"
      decimals="-3"
      id="F_16d08413-9d0d-4e59-b98b-576cbbe774ab"
      unitRef="U_USD">6404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_70027150-590f-4d44-a130-34aeae58aa80"
      unitRef="U_USD">2793000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_491b859c-be4c-4cea-81be-c2b01d95cd3f"
      decimals="-3"
      id="F_90637eef-7ed4-4037-a3ef-9b953032a26d"
      unitRef="U_USD">4488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_ba37559b-cc86-46c6-88ea-78974f063ce1"
      unitRef="U_USD">7281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LegalFees
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_8743f915-a28f-4629-9d66-17cefbd55044"
      unitRef="U_USD">600000</us-gaap:LegalFees>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-5"
      id="F_f53e62a1-41f9-4544-b5d3-0f4dd093d2cb"
      unitRef="U_USD">-2700000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:Assets
      contextRef="C_6e5dc256-5a04-41b0-a879-49f3fee0883f"
      decimals="-3"
      id="F_4a1cde87-fad0-4901-ba07-5c77f557dad1"
      unitRef="U_USD">114248000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_6644aae0-eb2b-4676-83a9-ae38663b37d8"
      decimals="-3"
      id="F_1a79a8a1-fbae-47da-adb5-2474b48941b0"
      unitRef="U_USD">10790000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_e9ca2ac7-674d-4810-a3f7-5cf959925a7c"
      decimals="-3"
      id="F_e862cc8c-d1f5-4014-996c-c631a742278d"
      unitRef="U_USD">368000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_3f38f4dc-c197-451a-9a92-1bfe597894f8"
      decimals="-3"
      id="F_bceba1b5-fc46-4864-bf3e-83c1b54f55a2"
      unitRef="U_USD">125406000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_e87f13d9-462c-4972-9cd3-8231e00d9d31"
      decimals="-3"
      id="F_1ef395ac-41fe-4b2c-8f98-234df4051ae4"
      unitRef="U_USD">101761000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_a614a706-e7b1-4b3a-a6dd-8a447fd08d76"
      decimals="-3"
      id="F_1573bea2-e4f8-4b6f-8e7b-2a97164df236"
      unitRef="U_USD">13865000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_27a7a081-3cd9-44fb-b829-bbe0a51e1049"
      decimals="-3"
      id="F_c5ad7750-bb0d-4490-8e86-2901c46dc73a"
      unitRef="U_USD">913000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_7328c607-f5b4-4691-8c97-31b6f9ec5936"
      decimals="-3"
      id="F_05311238-9471-42dd-b2f1-3014622589ed"
      unitRef="U_USD">116539000</us-gaap:Assets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="C_31b7ce3d-98d0-4b88-bdaa-b6a31638f195"
      decimals="-3"
      id="F_7edfb146-a2f1-46f7-a550-549409760c2f"
      unitRef="U_USD">2301000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="C_c21eda5e-6bd9-4387-b2f8-69453d4c9e11"
      decimals="-3"
      id="F_660561dd-52cb-433a-83e7-94233fb4945f"
      unitRef="U_USD">14000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      decimals="-3"
      id="F_a0e0b58a-c344-4199-b9bb-0d56c09110d0"
      unitRef="U_USD">2315000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="C_ab3ef0f9-7b22-4702-9cec-8794f32be1b2"
      decimals="-3"
      id="F_7f3e835e-49d7-4ad4-aef0-ee91cbaf51c7"
      unitRef="U_USD">8517000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="C_1a040f6f-bb6c-4771-9c85-7f74144c1343"
      decimals="-3"
      id="F_a497632c-b55b-403e-af4f-48c62a55485f"
      unitRef="U_USD">8517000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock
      contextRef="C_5b526872-b885-43be-82fd-47148cef1b95"
      id="F_41ae00e0-1e15-40bc-8256-14e7804fc4f3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p id="schedulei" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(In thousands, except shares and per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Related party receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Investment in subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Liabilities, convertible preferred stock, and stockholders&#x2019; equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Current liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Due to related parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;"&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total current liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Convertible Preferred Stock, $&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;par value, &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;shares authorized; &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;shares and &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,151&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;shares issued and outstanding at December 31, 2024 and 2023, respectively&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Stockholders&#x2019; equity (deficit):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Common stock, $&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;par value, &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;shares authorized; &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,307,544&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;shares and &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,595,616&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;shares issued and outstanding at December 31, 2024 and 2023, respectively&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;"&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Additional paid-in capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Statutory reserve&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;"&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accumulated deficit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;"&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Total liabilities, convertible preferred stock, and stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;The accompanying notes are an integral part of these condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Condensed Consolidated Statements of Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Divestiture losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Loss before equity in income of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Equity in income (loss) of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Other comprehensive loss, net of tax of &lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_64b29595-72b7-4d1e-a2ef-bcc1f661c31b;"&gt;&lt;span style="-sec-ix-hidden:F_7ff33148-e75c-4492-acae-7ea4bfe94b76;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Comprehensive income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;The accompanying notes are an integral part of these condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Gyre Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:68.874%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:12.963000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:12.663%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Operating Activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Adjustments to reconcile net income (loss) to net cash used for operating activities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Equity (income) loss of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Divestiture losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Changes in operating assets and liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Due to related parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Effect of exchange rate changes on cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Net change in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents at beginning of the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;The accompanying notes are an integral part of these condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Notes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a pa&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;rent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; percent of consolidated net assets as of the end of the most recently completed fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries. CPI, the legal acquiree and accounting acquirer of the Contributions considered the &#x201c;registrant&#x201d; and presented as the parent company, Gyre Therapeutics, Inc. (&#x201c;Gyre&#x201d;) to supplement its condensed financial statement in Schedule I. The parent company records its investments in subsidiaries under the equity method of accounting as prescribed in ASC 323, Investments-Equity Method, and Joint Ventures. Such investments are presented on the Condensed Balance Sheets as &#x201c;Investment in subsidiaries&#x201d;. Ordinarily under the equity method, an investor in an equity method investee would cease to recognize its share of the losses of an investee once the carrying value of the investment has been reduced to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to reflect its share, based on its proportionate interest, of the losses of subsidiaries regardless of the carrying value of the investment even though the parent company is not obligated to provide continuing support or fund losses.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or redemption requirements of redeemable stocks or guarantees of the parent company.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_cf4603e2-2534-444f-a961-287cb64533d2"
      decimals="-3"
      id="F_dfee539c-c471-4ec5-bca7-31ad05f3fba6"
      unitRef="U_USD">768000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_8e78646b-8c6e-48a2-bf10-a036ec1e9f6e"
      decimals="-3"
      id="F_458c6249-5c9b-439a-902e-25b95a438d85"
      unitRef="U_USD">768000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_f866a708-0ee9-4ff5-9f0e-f783ae7a3d32"
      unitRef="U_USD">768000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_b438359d-75d2-48f4-b84c-31051753f15c"
      unitRef="U_USD">768000</us-gaap:AssetsCurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_95f67bf0-d67f-4a60-b7e4-c40ade986c4d"
      unitRef="U_USD">64313000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_fbd01e8b-416f-4328-bd44-91f316bf13b6"
      unitRef="U_USD">49709000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_793da66b-5818-49de-ab4b-df96b6a16214"
      unitRef="U_USD">65081000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_15881b22-20d2-4cfd-9dfd-317074dfe115"
      unitRef="U_USD">50477000</us-gaap:Assets>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_cf4603e2-2534-444f-a961-287cb64533d2"
      decimals="-3"
      id="F_58aa036b-6048-4661-bc80-9931e489dd64"
      unitRef="U_USD">538000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_8e78646b-8c6e-48a2-bf10-a036ec1e9f6e"
      decimals="-3"
      id="F_aa7598ad-b958-4489-a482-1a656a20cee7"
      unitRef="U_USD">538000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_6aeca817-826b-483d-b492-2444481e3090"
      unitRef="U_USD">1224000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_448a989e-705d-45ef-838d-5fff9a1157e0"
      unitRef="U_USD">1242000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_a60bd226-8b09-4506-94c5-04861d9cfce7"
      unitRef="U_USD">1762000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_05cc8573-3fd1-43ce-bc3b-a47c974a651f"
      unitRef="U_USD">1780000</us-gaap:LiabilitiesCurrent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_98731e29-6638-4818-bfa3-de1d42eaf704"
      decimals="INF"
      id="F_da9e24ae-d545-4855-b627-625b67b5c159"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7"
      decimals="INF"
      id="F_f71cd05d-692d-4ed1-8e7a-c642db9a5618"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_98731e29-6638-4818-bfa3-de1d42eaf704"
      decimals="INF"
      id="F_5603e56a-e7ff-43e4-a0a4-3a4a78f0d5b8"
      unitRef="U_shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7"
      decimals="INF"
      id="F_266f0958-22a9-401f-9702-96ff2049cd90"
      unitRef="U_shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_98731e29-6638-4818-bfa3-de1d42eaf704"
      decimals="INF"
      id="F_6981c9e1-bf54-484f-bfe4-baa31017746a"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_98731e29-6638-4818-bfa3-de1d42eaf704"
      decimals="INF"
      id="F_f9c28d35-3066-417e-9c9e-284d22d61905"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7"
      decimals="INF"
      id="F_606535b4-bf96-435e-878c-eff6f768783f"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7"
      decimals="INF"
      id="F_ce8f69a8-391f-4863-a28f-d03c9ad433ea"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_254cabe3-de28-4ec7-85e2-ac88794f8fe7"
      decimals="-3"
      id="F_fa23a4a1-373b-4bc2-a4c1-91c7a4d52583"
      unitRef="U_USD">64525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="INF"
      id="F_1832e9de-9bd1-4b2f-9360-c0b7c9726fcf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="INF"
      id="F_329aca45-0732-47b1-8b48-5619307fe83c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="INF"
      id="F_85d6fb31-8c5a-4e84-836b-87bf23e7b91a"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="INF"
      id="F_7aaadbcd-372c-4a70-9bb8-808987c89519"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="INF"
      id="F_aa504c57-560c-4989-82c7-069401a32235"
      unitRef="U_shares">86307544</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="INF"
      id="F_a5100ac2-17f6-4085-bdcc-e72114b27869"
      unitRef="U_shares">86307544</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="INF"
      id="F_ec86d371-9d6e-4819-b1c7-2869bb1b591b"
      unitRef="U_shares">76595616</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="INF"
      id="F_016e1c2b-ed1d-4d8d-94a8-c419820f99b6"
      unitRef="U_shares">76595616</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_7c83b440-083d-496b-9500-a65259d6a71c"
      unitRef="U_USD">86000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_335e9c7d-5ccc-4216-9698-ec3f3602502c"
      unitRef="U_USD">77000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_f542441c-8762-4b93-96e5-5a7626dd154f"
      unitRef="U_USD">136185000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_84f8a65a-a237-45b9-9681-4ec8734ccf05"
      unitRef="U_USD">68179000</us-gaap:AdditionalPaidInCapital>
    <gyre:StatutoryReserve
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_a721fec1-7af4-4126-9b1a-3f3cd2488d18"
      unitRef="U_USD">3098000</gyre:StatutoryReserve>
    <gyre:StatutoryReserve
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_982bba9e-5fbe-42cb-ac06-75275da9bdd2"
      unitRef="U_USD">3098000</gyre:StatutoryReserve>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_403b71c6-d49c-4116-9762-b8fba627684e"
      unitRef="U_USD">-73453000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_fab26b53-22bf-43ae-94dc-473a2c2abd6b"
      unitRef="U_USD">-85538000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_47a3461a-4967-485d-856a-c4ce1a9991eb"
      unitRef="U_USD">-2597000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_caa39233-645a-40cf-a61b-d0bb7cfe0c3e"
      unitRef="U_USD">-1644000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_4effec30-89dc-4340-8706-ce92dc5a09be"
      unitRef="U_USD">63319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_53682284-9867-4931-9091-ccab5a653517"
      unitRef="U_USD">-15828000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="-3"
      id="F_80b2de8c-2fa1-4445-9d9d-df1233bdf86e"
      unitRef="U_USD">65081000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_9e8aff93-d025-49b6-9cc2-947107b8f15e"
      decimals="-3"
      id="F_a926197c-8b44-4dc4-a47f-c81b7788b6a0"
      unitRef="U_USD">50477000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_955606ef-bb88-4303-80e3-356b6fac1d73"
      unitRef="U_USD">105000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_47549841-4b8b-4f0f-9877-3f4b3a5aae1c"
      unitRef="U_USD">605000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_2ae21d0e-201c-4c01-9ee5-6712277b44da"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_7ccffa07-6a73-4333-86dd-8019b0a42c4a"
      unitRef="U_USD">105000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_84295304-8987-4736-be0f-0bc7a3c1d460"
      unitRef="U_USD">3316000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_d9d7ccaf-1b82-4d05-8da4-24f3213526e3"
      unitRef="U_USD">12190000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_befcb390-09ce-4458-998e-33ecc83a4189"
      unitRef="U_USD">-89617000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_5bd66c0a-7541-4642-bda3-8518cc6c639b"
      unitRef="U_USD">12085000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_a1d8912a-b2b4-4224-835b-0168b43c85e1"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_1f3712f9-00fa-4cbd-8324-f45e2d01b8fa"
      unitRef="U_USD">-953000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_54137a36-534a-4c97-9540-6da42fb42a40"
      unitRef="U_USD">-837000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_2c2dd9ea-40d5-405d-8138-df22fb031f01"
      unitRef="U_USD">11132000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_b3b0f4fd-ac41-4e88-9abf-3bb0a011240d"
      unitRef="U_USD">-93770000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_2b54466a-248f-47db-ab34-1271f10529a1"
      unitRef="U_USD">12085000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_cad4f2cf-5155-49cf-8dc4-a529dff245b0"
      unitRef="U_USD">-92933000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_9633dbb1-516d-4c86-8f74-cc43b7753da3"
      unitRef="U_USD">12190000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_7831c33f-fa39-40b4-a292-5ce114b2e39f"
      unitRef="U_USD">-89617000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_bd8ec319-b7b2-4667-b1dd-d5b52e578192"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_01240fb9-d460-4333-923e-e23bbff1a6f5"
      unitRef="U_USD">533000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_6c5fbff1-1586-4d68-a050-1edd5e04e2bb"
      unitRef="U_USD">-105000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_7be8ff3a-0525-4601-988c-0ba961a3b0c1"
      unitRef="U_USD">-72000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_70a89060-d74f-4aad-a20a-b03e7164f4ee"
      decimals="-3"
      id="F_aa55deca-103d-48ae-b1b3-4ce81c9f2c03"
      unitRef="U_USD">105000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_524073ba-1001-4b0c-892e-803d6f0180eb"
      decimals="-3"
      id="F_f8ad263f-a8be-44b8-95f9-a3039857a208"
      unitRef="U_USD">72000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <gyre:PercentageOfRestrictedNetAssetsExceedNetAssets
      contextRef="C_a1ccaa34-a6d8-421c-aded-31248ab461e3"
      decimals="2"
      id="F_40065c22-bccf-4704-8832-346d2cd551f2"
      unitRef="U_pure">0.25</gyre:PercentageOfRestrictedNetAssetsExceedNetAssets>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_14a49538-f42e-4f2b-b92e-6ef1dbdfc000"
          xlink:label="F_14a49538-f42e-4f2b-b92e-6ef1dbdfc000"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_dff57515-4ec1-4c6d-a74d-b8260899ca74"
          xlink:label="F_dff57515-4ec1-4c6d-a74d-b8260899ca74"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0cd5dd56-b36a-4418-98f9-f68c6f07ae41"
          xlink:label="F_0cd5dd56-b36a-4418-98f9-f68c6f07ae41"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_663fdca3-38c0-48b4-8ee3-3c286855998b"
          xlink:label="F_663fdca3-38c0-48b4-8ee3-3c286855998b"
          xlink:type="locator"/>
        <link:footnote id="FNT_61d264df-69d6-495e-8eeb-41acb2cd480b" xlink:label="FNT_61d264df-69d6-495e-8eeb-41acb2cd480b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_14a49538-f42e-4f2b-b92e-6ef1dbdfc000"
          xlink:to="FNT_61d264df-69d6-495e-8eeb-41acb2cd480b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_dff57515-4ec1-4c6d-a74d-b8260899ca74"
          xlink:to="FNT_61d264df-69d6-495e-8eeb-41acb2cd480b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0cd5dd56-b36a-4418-98f9-f68c6f07ae41"
          xlink:to="FNT_61d264df-69d6-495e-8eeb-41acb2cd480b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_663fdca3-38c0-48b4-8ee3-3c286855998b"
          xlink:to="FNT_61d264df-69d6-495e-8eeb-41acb2cd480b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_481558c6-a609-452f-b345-dd372cf841c3"
          xlink:label="F_481558c6-a609-452f-b345-dd372cf841c3"
          xlink:type="locator"/>
        <link:footnote id="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878" xlink:label="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_481558c6-a609-452f-b345-dd372cf841c3"
          xlink:to="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_5c3010dd-bd13-4c9a-85c6-7eba53b7f240"
          xlink:label="F_5c3010dd-bd13-4c9a-85c6-7eba53b7f240"
          xlink:type="locator"/>
        <link:footnote id="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9" xlink:label="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This amount is calculated based on </xhtml:span><xhtml:span style="font-size:10pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,340</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </xhtml:span><xhtml:span style="font-size:10pt;font-family:'Aptos',sans-serif;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">666.67</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5c3010dd-bd13-4c9a-85c6-7eba53b7f240"
          xlink:to="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_0a8e41ac-d9eb-4a0a-9c5a-a87ff2956e73"
          xlink:label="F_0a8e41ac-d9eb-4a0a-9c5a-a87ff2956e73"
          xlink:type="locator"/>
        <link:footnote id="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9" xlink:label="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </xhtml:span><xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</xhtml:span></xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0a8e41ac-d9eb-4a0a-9c5a-a87ff2956e73"
          xlink:to="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_7bc06cc7-be2c-4203-b87b-21235f95744e"
          xlink:label="F_7bc06cc7-be2c-4203-b87b-21235f95744e"
          xlink:type="locator"/>
        <link:footnote id="FNT_775f804e-b10d-499a-afe9-f05a8b8a2ac7" xlink:label="FNT_775f804e-b10d-499a-afe9-f05a8b8a2ac7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Includes </xhtml:span><xhtml:span style="font-size:8pt;font-family:'Aptos',sans-serif;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,304,898</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> options exercisable for shares of common stock, which underlying shares of common stock were transferred in the name of the Company to Futu Network Technology Limited, the stock plan administrator of the 2023 Omnibus Incentive Sub-Plan for Chinese Participants.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7bc06cc7-be2c-4203-b87b-21235f95744e"
          xlink:to="FNT_775f804e-b10d-499a-afe9-f05a8b8a2ac7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
